{
  "41375035": {
    "paper_id": "41375035",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Relevant clinical data were then extracted from cBioPortal [18\u201320]",
      "KRAS -Mutant RCC vs. Classical PRCC (cases were obtained from the\nMSK-IMPACT cohort from cBioPortal); Supplementary Figure S3",
      "De Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:30.315312",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41375035.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "41291067": {
    "paper_id": "41291067",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal data\nDatasets from TCGA, METABRIC and MSKCC were searched for EGFR\nampli \ufb01cation, as well as mutations in PIK3CA, PIK3R1, PIK3R2, PIK3R3, PTEN,\nAKT1, AKT2, AKT3, RPS6KB1, RPS6KB2 and RPS6 in cBioPortal (cbioportal.org)[41\u201343]",
      "RESULTS\nIncidence of EGFR ampli \ufb01cation in breast cancer\nEGFR ampli \ufb01cation was observed in 1.2 \u20132.4% of cases in the TCGA,\nMETABRIC and MSKCC databases in cBioPortal [ 41\u201343], depending\non the dataset (Table 1)",
      "PI3K pathway mutations in EGFR ampli \ufb01ed breast cancer\nConsidering the co-incidence of mutations in PI3K signaling inthese EGFR ampli \ufb01ed cell lines, using cBioPortal we investigated\nthe incidence in patients",
      "The Caris dataset\ndoes not include alterations in the genes downstream of mTOR,\ncontributing to the difference comparing the sums of Caris andthe cBioPortal data",
      "DATA AVAILABILITY\nThe MSKCC, TCGA and METABRIC datasets analyzed in this study are available on\ncBioPortal.org [ 41\u201343]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative\nanalysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis\nand visualization of longitudinal genomic and clinical data from the AACR project\nGENIE biopharma collaborative in cBioPortal",
      "SL helped withconceptualization of the project, analyzed cBioPortal datasets, helped with dataanalysis and interpretation, and reviewed and edited the manuscript"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:33.404912",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41291067.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "41301734": {
    "paper_id": "41301734",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Clinical data of the GBM patients containing information about\ntheIDH1R132 mutation status, molecular subtypes, survival times and overall survival out-\ncomes were obtained from cBioPortal (https://www.cbioportal.org) [ 15\u201317] (accessed on\n2 July 2023 )",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:34.135566",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41301734.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41386847": {
    "paper_id": "41386847",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genetic, epigenetic, and \nimmune infiltration characteristics of these biomarkers were further \nvalidated using cBioPortal, UALCAN, and TIMER",
      "Validation of prognostic meta-DEGs via cBioPortal and UALCAN\nWe accessed the cBioPortal30\u201332(https://www.cbioportal.org/ ) to \nexamine the putative copy number alterations (CNAs) and mutations of \nprognostically significant meta-DEGs",
      "Validation of prognostic meta-DEGs via cBioPortal and UALCAN\nGenomic alterations in CLDN18 , CLDN2 , CYP4B1 , CYP4X1 , FAM83A , \nHLF, PLA2G1B were investigated across 584 tumor samples of TCGA- \nLUAD cohort",
      "Analysis and Visualization of \nLongitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma \nCollaborative in cBioPortal",
      "32.Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics \nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:35.123985",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41386847.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "41301029": {
    "paper_id": "41301029",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods: 359 tumor sam-\nples from 346 patients with angiosarcoma were identified from the AACR Project GENIE\nv18.0-public database using cBioPortal",
      "The data was accessed and collected on 13 August 2025 from\ncBioPortal (v18.0-public) software, which includes clinical and genomic data from 2017 and\nlater",
      "Cancers 2025 ,17, 3663 17 of 19\nData Availability Statement: The data was accessed and collected on 13 August 2025, from the\ncBioPortal (v18.0-public) software, which includes clinical and genomic data from 2017 onward",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:35.174535",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41301029.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "41369330": {
    "paper_id": "41369330",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In the first analysis, data from cBioPortal, which contains\ndata from 6709 individuals, was used to search if the mutations in the above-listed genes\noccur in AML blasts [ 45,46]",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:36.168784",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41369330.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41236806": {
    "paper_id": "41236806",
    "cbioportal_paper_citations": [
      "https://pubmed.ncbi.nlm.nih.gov/37668528/\n19",
      "https://pubmed.ncbi.nlm.nih.gov/23550210/\n20",
      "https://pubmed.ncbi.nlm.nih.gov/22588877/\n21"
    ],
    "cbioportal_platform_mentions": [
      "Material & Methods\ncBioPortal Database and Bioinformatics Analysis\nMutation, structural variant, and copy number alterations in the\nBRCA1 andBRCA2 genes were analyzed using data obtained\nfrom cBioPortal for Cancer Genomics (https://www",
      "cbioportal.org/, accessed on September 23, 2025).18\u201320A total\nof 12 361 tumor samples from 11 893 prostate cancer patients\nacross 18 comprehensive studies were included in the ana-\nlysis.21\u201340Raw data on mutation counts and alterationfrequencies were downloaded from cBioPortal and processed\nusing RStudio (version 2024.12.1 +563 for macOS)",
      "Clinical data from\npatients were similarly retrieved from cBioPortal and used forsurvival analysis",
      "Results\nWidespread Prevalence of BRCA1 and BRCA2\nMutations and Deep Deletions is Associated with aWorse Prognosis in Patients\nGenomic and clinical data were reanalyzed from 8676 tumor\nsamples across 8444 patients using publicly available datasets\nfrom cBioPortal",
      "To test whether\nDNA-PK expression correlates with overall survival (OS), we\nreanalyzed genomic and clinical data from 12 361 samples across1893 patients using publicly available cBioPortal datasets",
      "(A-B) Frequency of BRCA1 (A) and BRCA2 (B) Alterations,\nIncluding Mutations (red) and Deep Deletions (Blue), Across the cBioPortal for Cancer Genomics Database for Prostate Cancer",
      "(A) Frequency of PRKDC (DNA-PK)\nAlterations, Including Mutations (red), Ampli \ufb01cation (Green) and Deep Deletions (Blue), Across the CBioPortal Database for Prostate Cancer",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visu-\nalization of longitudinal genomic and clinical data from the\nAACR project GENIE biopharma collaborative in cBioPortal.Cancer Res [Internet]",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of com-\nplex cancer genomics and clinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {
      "28825054": [
        "https://pubmed.ncbi.nlm.nih.gov/28825054/\n31"
      ],
      "22722839": [
        "2012 Jul 12 [cited 2025 Jun 23];487(7406):239-243.https://pubmed.ncbi.nlm.nih.gov/22722839/\n24"
      ],
      "34667026": [
        "https://pubmed.ncbi.nlm.nih.gov/34667026/\n30"
      ],
      "35504881": [
        "https://pubmed.ncbi.nlm.nih.gov/35504881/\n39"
      ],
      "28927585": [
        "2018 Mar 1 [cited 2025 Jun 23];73(3):322-339.https://pubmed.ncbi.nlm.nih.gov/28927585/\n33"
      ],
      "20579941": [
        "https://pubmed.ncbi.nlm.nih.gov/20579941/26"
      ],
      "26544944": [
        "https://pubmed.ncbi.nlm.nih.gov/26544944/\n32"
      ],
      "26000489": [
        "https://pubmed.ncbi.nlm.nih.gov/26000489/\n2",
        "ncbi.nlm.nih.gov/26000489/Scherer et al 9\n\n12",
        "ncbi.nlm.nih.gov/26000489/\n29"
      ],
      "35617398": [
        "https://pubmed.ncbi.nlm.nih.gov/35617398/\n37"
      ],
      "28068672": [
        "2017 Jan 19 [cited 2025 Sep 26];541(7637):359-364.https://pubmed.ncbi.nlm.nih.gov/28068672/\n41"
      ],
      "32220891": [
        "https://pubmed.ncbi.nlm.nih.gov/32220891/\n25"
      ],
      "23622249": [
        "https://pubmed.ncbi.nlm.nih.gov/\n23622249/\n23"
      ],
      "32317181": [
        "https://pubmed.ncbi.nlm.nih.gov/32317181/\n27"
      ],
      "38488813": [
        "https://pubmed.ncbi.nlm.nih.gov/38488813/\n40"
      ],
      "35670774": [
        "ncbi.nlm.nih.gov/35670774/\n28"
      ],
      "30537516": [
        "gov/30537516/\n38"
      ],
      "29610475": [
        "gov/29610475/\n36"
      ],
      "31061129": [
        "2019 [cited 2025 Jun 23];166(23):11428-11436.https://pubmed.ncbi.nlm.nih.gov/31061129/\n35"
      ],
      "26855148": [
        "https://pubmed.ncbi.nlm.nih.gov/26855148/\n22"
      ],
      "26928463": [
        "ncbi.nlm.nih.gov/26928463/\n34"
      ]
    },
    "extraction_date": "2025-12-19T17:10:36.689510",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41236806.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 20
  },
  "41341921": {
    "paper_id": "41341921",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.2 Integrative analysis of EIF3M mutations \nand methylation\nThe cBio Cancer Genomics Portal (cBioPortal, https://\nwww.cbioportal.org ) integrates multi-omics data, including somatic \nmutations, copy number alterations (CNAs), expression profiles \nand clinical information, enabling comprehensive analysis of \nEIF3M mutation frequencies, CNAs, and other genomic alterations \nacross cancer contexts ( De\u00a0Bruijn  et al., 2023 )",
      "Abbreviation Full name Abbreviation Full name\nACC Adrenocortical carcinoma LUAD Lung adenocarcinoma\nBLCA Bladder Urothelial Carcinoma LUSC Lung squamous cell carcinoma\nBRCA Breast invasive carcinoma OV Ovarian serous cystadenocarcinoma\nCHOL Cholangiocarcinoma PAAD Pancreatic adenocarcinoma\nCOAD Colon adenocarcinoma PCPG Pheochromocytoma and Paraganglioma\nDLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma PRAD Prostate adenocarcinoma\nESCA Esophageal carcinoma READ Rectum adenocarcinoma\nGBM Glioblastoma multiforme SARC Sarcoma\nHNSC Head and Neck squamous cell carcinoma SKCM Skin Cutaneous Melanoma\nKICH Kidney Chromophobe STAD Stomach adenocarcinoma\nKIRC Kidney renal clear cell carcinoma TGCT Testicular Germ Cell Tumors\nKIRP Kidney renal papillary cell carcinoma THCA Thyroid carcinoma\nLAML Acute Myeloid Leukemia THYM Thymoma\nLGG Brain Lower Grade Glioma UCEC Uterine Corpus Endometrial Carcinoma\nLIHC Liver hepatocellular carcinoma UVM Uveal Melanoma\n3.4 The gene mutation and epigenetic \nmodification of EIF3M\nFirstly, utilizing the cBioPortal analysis platform, select pan-\ncancer whole genome data from TCGA and the International \nCancer Genome Consortium (ICGC) to construct the genetic \nalteration profile of EIF3M",
      "The mutation site sample information \nbased on the cBioPortal platform is summarized in Supplementary  \nTable S7",
      "Data availability statement\nAll data analyzed in this study are publicly available from \nTCGA ( https://portal.gdc.cancer.gov ), ICGC ( https://dcc.icgc.org ), \nGTEx ( https://gtexportal.org ), TIMER2.0, GEPIA2, UALCAN, \nHPA, cBioPortal, SMART, Pathway Commons, Enrichr, STRING, \nmiRDB, TargetScan, miRWalk, dbDEMC, and starBase",
      "Analysis and visualization of longitudinal genomic and clinical data \nfrom the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:37.888940",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41341921.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "41228349": {
    "paper_id": "41228349",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data Availability Statement: cBio Portal for Cancer Genomics: https://www.cbioportal.org/ (ac-\ncessed on 15 October 2025); UCSC Xena Functional Genomics Explorer: https://xenabrowser.net/\n(accessed on 15 October 2025); Kaplan\u2013Meier Plotter: https://kmplot.com/analysis/ (accessed on 15\nOctober 2025)",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "De Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:42.449702",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41228349.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41229797": {
    "paper_id": "41229797",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Characteristics of ANLN in LUAD\nThe mutation frequency of ANLN was obtained from \ncBioPortal ( https://www.cbioportal.org/ ) (21)",
      "J Thorac Dis 2025;17(10):7937-7954  | https://dx.doi.org/10.21037/jtd-2025-836Characteristics of ANLN in LUAD\nThe mutation frequency of ANLN  in LUAD is 6%, \nwith amplification mutations predominating according \nto the cBioPortal for Cancer Genomics ( Figure 4A )",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis \nand Visualization of Longitudinal Genomic and Clinical \nData from the AACR Project GENIE Biopharma \nCollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:42.714532",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41229797.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41362722": {
    "paper_id": "41362722",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Moreover,  data  from  cBioPortal  database  \n(https://www.cbioportal.org/)  reveals  that TOPK  \nmutations,  included  missense, fusion,  and insertions,  \nare present  in cancers  such  as renal  non- clear  cell \ncarcinoma,  ovarian  epithelial  tumor,  and glioblastoma  \n(Supplement  Figure  1A-B) [29-31]",
      "Gao J, Aksoy  BA, Dogrusoz  U, Dresdner G, Gross  B, Sumer SO, et al. \nIntegrative  analysis  of complex  cancer  genomics  and clinical profiles  using  the \ncBioPortal",
      "de Bruijn  I, Kundra  R, Mastrogiacomo B, Tran  TN, Sikina  L, Mazor  T, et al. \nAnalysis  and Visualization  of Longitudinal  Genomic  and Clinical Data  from  \nthe AACR  Project GENIE  Biopharma Collaborative  in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:45.307276",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41362722.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41235343": {
    "paper_id": "41235343",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The mutation frequency of GCKR in TCGA cohorts\nwas calculated using the cBioPortal database (https://www\n.cbioportal.org/) [18]",
      "GCKR mutation data were\nobtained from the cBioPortal website (http://www\n.cbioportal.org) [18]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:47.847525",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41235343.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41201200": {
    "paper_id": "41201200",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.5   |   Database Processing\nClinical and bulk RNA-  seq data from the TCGA OSCC and \nHNC cohorts were assessed via cBioPortal (Firehose Legacy) \nand UCSC Xena (GDC TCGA Head and Neck Cancer) [ 19\u201322 ]",
      "Mastrogiacomo, et\u00a0 al., \u201cAnalysis and \nVisualization of Longitudinal Genomic and Clinical Data From the \nAACR Project GENIE Biopharma Collaborative in cBioPortal,\u201d Cancer \nResearch  83, no",
      "Dogrusoz, et\u00a0 al., \u201cIntegrative Analysis of \nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d \nScience Signaling  6, no"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:51.709533",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41201200.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41153058": {
    "paper_id": "41153058",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Integrative analysis of complex cancer genomics and clinical \nprofiles using the cBioPortal",
      "de Bruijn I, et al. Analysis and visualization of longitudinal genomic and clini -\ncal data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:54.407662",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41153058.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41168197": {
    "paper_id": "41168197",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "OncoPrinter ( https://www.cbioportal.org/\noncoprinter )\n83\u201385and Adobe Acrobat were used\nto create this \ufb01gure.Gender \nAge TMB \nMSI SBS\nMSH6\nPMS2\nMSH2MLH1\nBRCA1\nSUFU\nNF1\nBUB1B\nCHR7 gainCHR10 lossEGFR\nCDKN2A\nTERT\nTP53\nPTEN\nPOLEMissense Promoter TruncatingAmpli\ufb01cation Deep Deletion Shallow Deletionfemale male\n19 77\n1.5 339\n0 48.2\nClock-like HRD Other POLE&dMMR Temozolomide\nPGV\nSplicePGV + somatic event 2 PGVsHMF007273 A\nHMF003436 A\nHMF005706 A\nHMF000729 A\nHMF001910A\nHMF002509 A\nHMF000788 A\nHMF003589AHMF001180AHMF003795A\nHMF002821\nA\nHMF006763A\nHMF003406 A\nHMF006895AHMF000649\nA\nHMF001434AHMF000842\nA\nHMF000655 A\nHMF001787AHMF000329A\nHMF006506\nA\nHMF007027A\nHMF001235 A\nHMF001701 A\nHMF000925AHMF007010Ahttps://doi.org/10.1038/s41525-025-00526-z Article\nnpj Genomic Medicine |           (2025) 10:70 6\n\nidenti \ufb01ed in individuals who do not meet current germline testing criteria\nand in cancers not traditionally associ ated with hereditary predisposition,\nparticularly those historically classi \ufb01ed as sporadic36,52\u201354",
      "et al. Analysis and visualization of longitudinal\ngenomic and clinical data from the AACR Project GENIE\nBiopharma Collaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:54.574923",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41168197.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41125532": {
    "paper_id": "41125532",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Puta-\ntive driver mutations were annotated using cBioPortal.23\nBinding predictions for shared mutations in human cSCC\nHuman leukocyte antigen (HLA) types were identified for \neach tumor from the Nassir et al dataset using Polysolver.24 \nBinding was predicted with NetMHCpan4.0 for patient- \nspecific HLA alleles for the Nassir et al dataset",
      "Mutations annotated as putative driver mutations in the cBioPortal are shown in red",
      "23 de Bruijn I, Kundra R, Mastrogiacomo B, et\u00a0al. Analysis and \nVisualization of Longitudinal Genomic and Clinical Data from the \nAACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:10:59.381298",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41125532.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41174249": {
    "paper_id": "41174249",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Results\nHotspots and multiple FGFR1 mutations are recurrent\nin brain tumors\nWe queried the GENIE database (de Bruijn et al, 2023 )(https://\ngenie.cbioportal.org/ )t od e \ufb01ne the spectrum of tumors harboringat least one of the two hotspot variants N546K and K656E",
      "Source data are available online for this \ufb01gure.Jacopo Boni et al The EMBO Journal\n\u00a9 The Author(s) The EMBO Journal Volume 44 | Issue 24 | December 2025 | 7513 \u20137540 7527\n\nReagent/resourceReference or\nsourceIdenti \ufb01er or catalog\nnumber\nProlong Gold Antifade Reagent\nwith DAPIInvitrogen #P36935\nMatrigel \u00ae Corning #354234\nT7 endonuclease I New England\nBiolabs#M0302S\nAZD4547 (Fexagratinib) Astra Zeneca 1035270-39-3\nSoftwareR software v4.3.3 https://www.r-\nproject.org/\nImageJ software https://imagej.net\n/ij/\nSAINTexpress v3.6.1 Teo et al, 2014\nAlphaFold 3 DeepMindSTAR v2.7.0alimma package version 1.8.2 BioconductorOtherTransBlot Turbo RTA Transfer\nKitBio-RAD #1704158\nClarity Western ECL Substrate\nKitBio-RAD #1705060\nBCA Protein Assay Kit ThermoScienti \ufb01c #23227\nRNeasy Kit Qiagen #74104SuperScript Reverse\nTranscriptase II KitInvitrogen #18064014\nPowerUp SYBR Green Master\nMixApplied Biosystems #A25776\nRNA 6000 Nano Assay Agilent #50671511\nTruSeq \u00aeStranded mRNA LT\nSample Prep KitIllumina #20020594\nReview of public tumor data\nPublic tumor data was interrogated using the GENIE/cBioportal\ndatabase (de Bruijn et al, 2023 )(https://genie.cbioportal.org/ ),\nselecting the GENIE Cohort v16.1 (last accessed in October 2024)\nand query for FGFR1 gene",
      "Brain\nPathol 3:283 \u2013295\nde Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa\nA, Zhao G, Lai B et al (2023) Analysis and visualization of longitudinal\ngenomic and clinical data from the AACR Project GENIE Biopharma\nCollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:00.392590",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41174249.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41089282": {
    "paper_id": "41089282",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.6 Comprehensive analysis of large-scale\nthyroid cancer genomics\nAn integrative analysis of mutations exceeding 10% prevalence\nin the PTC cohort, including BRAF ,TERT, RET, TP53, CDKN2A ,\nand NRAS , was performed using cBioPortal ( https://\nwww.cbioportal.org/ )(25)",
      "The mutual exclusivity and co-occurrence of these\nmutations and their correlation with survival time, were assessed\naccording to cBioPortal \u2019s instructions",
      "De Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACRproject GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:08.989826",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41089282.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41108004": {
    "paper_id": "41108004",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Utilizing the cBioPortal platform [ 52\u201354], we systemati -\ncally interrogated the genomic alterations of the CTRC  \ngene in several authoritative ovarian cancer datasets, \nnamely TCGA-OV, CPTAC, and MSK (data accessed: \nAugust 28, 2025)",
      "Leveraging the cBioPortal platform, \nwe conducted a comprehensive analysis of its genomic \nalterations across multiple authoritative cohorts, includ -\ning TCGA-OV, CPTAC, and MSK (data accessed on \nAugust 28, 2025)",
      "Overall, the table provides detailed information about cellular heterogeneity, cell type identification, differential gene \nexpression, and the state of biological function\n\nPage 14 of 20\nShi et al. Journal of Ovarian Research           (2025) 18:227 \nfrom the cBioPortal platform (encompassing 3,276 \nsamples / 2,654 patients), we discovered that the CTRC  \ngene exhibits significant genomic alterations in ovarian \ncancer",
      "Gao, et al. Integrative analysis of complex cancer genomics and clinical \nprofiles using the cBioPortal",
      "de Bruijn et al. Analysis and visualization of longitudinal genomic and clinical \ndata from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:09.098462",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41108004.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "41105760": {
    "paper_id": "41105760",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Clinical patient data\nThe patient data used in this study were taken from cBioPortal (73\u2013\n75) for Cancer Genomics, which has access to data from patients \nwith breast cancer retrieved from TCGA or using TIMER2.0 (76), \nwhich allows for the correlation of gene expression for patients with \nbasal- subtype breast cancer",
      "Schultz, Analysis and visualization of longitudinal genomic \nand clinical data from the AA cR Project Genie Biopharma c ollaborative in cBioPortal",
      "Schultz, i ntegrative analysis of complex \ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:11.406083",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41105760.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41089657": {
    "paper_id": "41089657",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The initial \u201cGENE \u201dlist was compiled from the\nPAGER ( Huang et al., 2012 ;Yue et al., 2018 ;2022 ), cBioPortal ( de\nBruijn et al., 2023 ), and COSMIC ( Tate et al., 2019 ) databases",
      "For the cBioPortal and COSMIC databases, thresholds were de \ufb01ned\nby identifying points where mu tational frequency no longer\ndemonstrated cancer-speci \ufb01cs i g n i \ufb01cance in prior studies",
      "From\ncBioPortal, 1,000 genes were selected using cutoffs of 8.2% for copynumber alterations (CNA) and 2.8% for mutational frequency",
      "Finally,candidate genes from PAGER, cBioPortal, and COSMIC wereaggregated to form the \u201cGl i s t \u201d, comprising 2,493 genes in total",
      "Mutationfrequency data was obtained from cBioPortal ( de Bruijn et al.,\n2023 ), while protein expression pro \ufb01les across tissues relevant to\ntherapeutic safety (e.g., brain, gastrointestinal tract, liver, and\nkidney) were sourced from the ProteinAtlas ( Uhl\u00e9n et al., 2015 )",
      "Mutation and CNA data were sourced\nfrom CBioPortal ( de Bruijn et al., 2023 ) using two cohorts: the\n\u201cPancreatic Cancer (UTSW, Nat Commun 2015) \u201dand \u201cPancreatic\nAdenocarcinoma (TCGA, PanCancer Atlas) \u201dstudies, both of which\nemployed whole-exome sequencing for all samples",
      "For example, multiple studies within\nCBioPortal, such as \u201cPancreatic Cancer (UTSW, Nat Commun\n2015) \u201dand \u201cPancreatic Adenocarci noma (TCGA, PanCancer\nAtlas), \u201dwere analyzed concurrently to increase the reliability of\nmutational frequency and CNA data",
      "Modality of ranking Weighted\nscore\nGT list score 0.329\nCNA(CBIOPORTAL UTSW NAT COMMUN 2015) 0.201\nExpression list score 0.088GET list score 0.085\nMutation frequency (cBioporta lTCGA PanCancerAtlas) 0.079\nCNA(CBIOPORTAL TCGA PANCANCERATLAS) 0.048\nMutation frequency (Cbioportal UTSW Nat Commun\n2015)\u22120.023\nBrain expression score \u22120.054\nKidney expression score \u22120.081\nGastrointestinal expression score \u22120.095\nLiver expression score \u22120.101\nFrontiers in Systems Biology frontiersin.org 07Gu and Chen 10.3389/fsysb.2025.1649758\n\nEGFR is the fourth highest-ranked gene, attributed to its high\nGET list and Expression list scores",
      "Gene RP\nscoreCHATGPT\nscoreGT list\nscoreMutation frequency\n(cBioportal TCGA\nPanCancer Atlas)RP-LIT\nscoreGPT-LIT\nscoreGET list\nscoreExpression list\nscore\nPIK3CA 34.8 310 58.7 2.8 0.199 1.771 96 97\nMYC 30.1 330 9.5 0.0 0.032 0.349 214 210\nSRC 20.0 320 0.0 1.1 0.044 0.711 143 144EGFR 18.2 320 2.4 0.6 0.010 0.171 134 133\nCDK1 15.9 305 15.3 65.4 0.134 2.563 30 7\nPRKCA 15.3 305 3.0 0.0 1.702 25.556 101 102TNF 12.1 270 2.4 0.0 0.013 0.292 83 86\nLCK 11.5 220 1.7 0.0 1.274 24.444 62 60\nJAK2 10.6 285 1.0 0.6 0.082 2.192 67 67MAPK1 10.3 305 11.6 3.4 0.139 4.122 7 7\nAURKB 9.1 295 0.0 0.6 0.008 0.246 70 70\nKRAS 8.7 220 1.7 1.7 0.335 8.462 48 47MAPK8 7.8 295 0.0 0.0 0.002 0.068 121 117\nMTOR 7.1 220 1.7 0.0 0.588 18.333 52 52\nITGA4 6.9 220 4.3 0.6 2.298 73.333 40 37TOP2A 6.9 310 10.2 1.1 0.215 9.688 0 0\nCHEK1 6.7 220 1.7 0.0 0.128 4.231 46 45\nBCL2 6.2 220 1.7 0.6 0.012 0.418 41 41PRKCB 6.0 250 1.4 0.6 1.004 41.667 60 58\nERBB4 5.5 220 3.4 0.6 0.184 7.333 81 83\nFrontiers in Systems Biology frontiersin.org 08Gu and Chen 10.3389/fsysb.2025.1649758\n\nITGA4 ranks 15th on our list",
      "Analysis and visualization of longitudinal genomic and clinical data from the\nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:14.102656",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41089657.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 10,
    "total_data_pmids_cited": 0
  },
  "41102416": {
    "paper_id": "41102416",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Somatic genomic alterations, including \nsingle-nucleotide variants, insertions and deletions, copy number \nalterations and select structural rearrangements, were detected as previously described35 and were anonymized and uploaded to cBio -\nPortal for Cancer Genomics36,37 for visualization and analysis under \nAACR Project GENIE (https://www.cbioportal.org/)",
      "Gao, J., et al. Integrative analysis of complex cancer genomics \nand clinical profiles using the cBioPortal",
      "et al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR Project GENIE \nBiopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:14.343365",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41102416.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41073135": {
    "paper_id": "41073135",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "49 Gao J, Aksoy BA, Dogrusoz U, et\u00a0al. Integrative analysis of complex \ncancer genomics and clinical profiles using the cBioPortal",
      "50 de Bruijn I, Kundra R, Mastrogiacomo B, et\u00a0al. Analysis and \nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:19.103218",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41073135.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41088330": {
    "paper_id": "41088330",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Materials and methods\nME2 correlation with genes in Serine metabolic pathway\nTranscriptomic analysis was performed on a subset of \nsamples (only TNBC) from the Breast Invasive Carci -\nnoma dataset generated by Ciriello et al. from cBioPortal \n[21\u201323], which was determined by a lack of estrogen and \nprogesterone receptor expression and clinically nega -\ntive HER2 expression",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:22.699419",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41088330.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41062612": {
    "paper_id": "41062612",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Scientific Reports  |        (2025) 15:35135 10 | https://doi.org/10.1038/s41598-025-19027-1www.nature.com/scientificreports/\n\nData availability\nThe datasets analysed during the current study are available from the following public resources: TCGA (The \nCancer Genome Atlas, https://portal.gdc .cancer.gov/ ), GEO ( https://www.ncbi .nlm.nih.gov/geo/ ), DEPMAP \n(https://depmap .org/portal/ ), cBioportal ( https://www",
      "cbioportal.org/ ), and ENCODE  (   h t t p s : / / w w w",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:25.334875",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41062612.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "41185627": {
    "paper_id": "41185627",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Z-scored bulk RNA sequencing data from the Oncology \nResearch Information Exchange Network (ORIEN) AVA -\nTAR program were obtained from cBioPortal [ 52\u201354]",
      "Validating the\u00a0Aggregate Interaction List \nas\u00a0a\u00a0Predictor of\u00a0Survival in\u00a0a\u00a0Separate Cohort \nof\u00a0ICI\u2011Treated Melanoma Patients\nAfter identifying a compilation of interactions that differen-\ntiated R pre-treatment, we examined the survival association \nof these interaction pairs in a separate set of 411 melanoma \npatients treated with ICI, for which bulk RNA-sequencing \ndata were available on CBioPortal [52]",
      "Gao, J., et\u00a0al. Integrative analysis of complex cancer genom-\nics and clinical profiles using the cBioPortal",
      "de Bruijn, I., et\u00a0al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR project GENIE biop-\nharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:25.540368",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41185627.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "41068948": {
    "paper_id": "41068948",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Transcription factor CREB1 mediates the upregulation of \nlncRNA RAB30-DT in HCC\ncBioPortal [ 49] analysis showed that while lncRNA \nRAB30-DT  is consistently upregulated in HCC, genomic \nalterations at its locus, including copy number and struc -\ntural variants, are rare (< 1% of patients) (Supplemen -\ntary Fig",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:26.334657",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41068948.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41051525": {
    "paper_id": "41051525",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "According to the MSK-IMPACT\u00ae \ndatabase from cBioPortal, STK11 mutations, including mis-\nsense, truncating, in-frame shift, splice, and fusion altera-\ntions, are detected in only 59 of 3116 (1.9%) breast cancer \npatients [52]",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, \nMazor T, Li X, Ochoa A, Zhao G, Lai B, Abeshouse A, Baiceanu \nD, Ciftci E, Dogrusoz U, Dufilie A, Erkoc Z, Garcia Lara E, Fu Z, \nGross B, Haynes C, Heath A, Higgins D, Jagannathan P, Kalletla \nK, Kumari P, Lindsay J, Lisman A, Leenknegt B, Lukasse P, Mad-\nela D, Madupuri R, van Nierop P, Plantalech O, Quach J, Resnick \nAC, Rodenburg SYA, Satravada BA, Schaeffer F, Sheridan R, \nSingh J, Sirohi R, Sumer SO, van Hagen S, Wang A, Wilson M, \nZhang H, Zhu K, Rusk N, Brown S, Lavery JA, Panageas KS, \nRudolph JE, LeNoue-Newton ML, Warner JL, Guo X, Hunter-\nZinck H, Yu TV, Pilai S, Nichols C, Gardos SM, Philip J, Kehl \nKL, Riely GJ, Schrag D, Lee J, Fiandalo MV, Sweeney SM, Pugh \nTJ, Sander C, Cerami E, Gao J, Schultz N (2023) Analysis and \nvisualization of longitudinal genomic and clinical data from the \nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:30.324133",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41051525.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41046136": {
    "paper_id": "41046136",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To understand \nthese seven proteins\u2019 clinical values and whether they could \nserve as biomarkers would require a prospective patient co-\nhort, which is not available to us currently [as of 6 May \n2024, according to cBioportal (de Bruijn et al. 2023 ) the only \nHNSCC dataset that has both CNA and RNA-seq is the \nTCGA dataset used in this work]",
      "de Bruijn I, Kundra R, Mastrogiacomo B et al. Analysis and visualiza -\ntion of longitudinal genomic and clinical data from the AACR proj-\nect GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:31.521193",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41046136.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41029863": {
    "paper_id": "41029863",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "g o v / ) [7], and the cBioPortal  (   h t t p s : / / w \nw w",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:39.237597",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41029863.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41044153": {
    "paper_id": "41044153",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We further investigated genetic alterations, DNA methylation, and drug sensitivity using cBioPortal, \nSMART, and GSCA databases",
      "html\nTIMER2.0Gene expression levels across \nvarious pan-cancersGene expression levels across different cancer types TCGA http://timer.cistrome.org/\nKaplan-Meier PlotterGene expression & patient\nprognosis dataSurvival Analysis TCGA https://kmplot.com/analysis/\nGEOquery (version 2.74.0) \nR packageExpression profiling by array Retrieving data from NCBI GEO GEO https://seandavi.github.io/GEOquery/\nDESeq2 (v1.46.0) R \nPackageExpression profiling by array Differential gene expression analysis GEOhttps://bioconductor.org/packages/\nDESeq2\nEnhancedVolcano R \npackage (v1.24.0)Differential gene expression data Visualization of differential expression results GEOhttps://bioconductor.org/packages/\nEnhancedVolcano\nDepMap Cancer cell line analysis Cell lines with gene effect scoresAchilles and \nSanger\u2019s SCORE \nprojectshttps://depmap.org/\nTCGAplot R package \n(v8.0.0)Gene expression Gene-gene correlation analysis TCGAhttps://github.com/tjhwangxiong/\nTCGAplot\nggplot2 R Package (v3.5.1)Breast cancer cell lines and gene \neffect score dataBarplot visualizing cancer line analysis results DepMap https://ggplot2.tidyverse.org/\nSMART Promoter DNA methylation DNA methylation analysis TCGA http://www.bioinfo-zs.com/smartapp/\ncBioPortal Genetic alterationFrequency of mutation, amplification, deep deletion \nand multiple alterations across various BRCA studiesTCGA https://www.cbioportal.org/\nAlphaFold Protein structure predictionsPredicting protein 3D structures from amino acid \nsequencesAlphaFold \nProtein Structure \nDatabasehttps://alphafold.com/\nTCGAplot R package \n(v8.0.0)Immune infiltration correlation \nand immune-related genes \ncorrelationGene expression Immune cell ratio, immune \nscore, chemokines, chemokine receptors, immune \ncheckpoint genes (ICGs), immune inhibitors, and \nimmune stimulators correlation analysisTCGAhttps://github.com/tjhwangxiong/\nTCGAplot\nggVennDiagram (v1.5.3) \nR packagePositively correlated immune-\nrelated genesVenn diagram visualizing common Positively \ncorrelated immune-related genesCorrelation \nanalysis resultshttps://gaospecial.github.io/\nggVennDiagram/\nSTRING Protein-protein interaction Protein-protein interaction network visualizationProteins and their \ninteractionshttps://string-db.org /\nclusterProfiler (v4.14.4) R \npackageGenomic data (gene expression, \ngene sets, pathways)Functional enrichment analysisKEGG, Reactome, \nGO h t t p s :   /  / y u l a  b - s m  u",
      "Investigation of genetic alteration within BRCA cohorts\nThe genetic alteration status of WNT2, WNT7B, and WNT11 in patients with BRCA across various cancer \ncohorts was analyzed using cBioPortal for Cancer Genomics ( https://www.cb ioportal.org/ )33",
      "This investigation \nfocused on breast cancer across 30 studies available on cBioPortal that evaluated alteration frequency, mutation \ntypes, mutations, structural variants, amplifications, deep deletions, multiple alterations, and copy number \nalterations (CNA)",
      "The WNT2, WNT7B, and WNT11 alteration frequencies and mutation types in TCGA \ntumors were examined using the \u201cCancer Types Summary\u201d module of cBioPortal",
      "Investigation of genetic alteration within BRCA cohorts\nInvestigation of the genetic alteration status of WNT2, WNT7B, and WNT11 in patients with BRCA across \nvarious cancer cohorts using cBioPortal has revealed notable insights",
      "The genetic alterations of WNT11 across the BRCA cohort were analysed by the cBioPortal database",
      "o r g / \n) , Shiny Methylation Analysis Resource Tool (SMART) App ( http://www.bioinfo-zs.com/smartapp /), cBioPortal \nweb database ( https://www.cbioportal.org /), STRING database ( https://string-db.org /), GDSC  d a t a b a s e (https://\nwww.cancerrxgene.org /), and CTRP database ( https://clinicaltrialsapi.cancer.gov /)",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:39.402819",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41044153.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 0
  },
  "41020834": {
    "paper_id": "41020834",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genomic Alterations and Modification Analysis\nThe cBioPortal for Cancer Genomics (http://www.cbioportal.org, accessed on 10 June\n2025) is an open-access database for the exploration, analysis, and visualization of mul-\ntidimensional cancer genomics data [ 15,16]",
      "Here, cBioPortal was used to investigate\nthe genomic alteration types and frequencies across different cancers",
      "Visualization\nof the genomic alteration rate was achieved by the cBioPortal web tool",
      "Data Availability Statement: The datasets utilized in this study can be accessed from the following\nsources: The Cancer Genome Atlas (https://cancergenome.nih.gov/, accessed on 6 June 2025), GTEx\n(https://www.gtexportal.org/, accessed on 6 June 2025), cBioPortal (http://www.cbioportal.org,\naccessed on 10 June 2025), GEPIA2 (http://gepia2.cancer-pku.cn/, accessed on 30 June 2025), UCSC\nXena database (https://xenabrowser.net/, accessed on 6 June 2025), Tumor Immunotherapy Gene\nExpression Resource (TIGER) database (http://tiger.canceromics.org/, accessed on 16 June 2025),\nand the Human Protein Atlas (https://www.proteinatlas.org/, accessed on 16 June 2025)",
      "Acknowledgments: We sincerely thank the researchers who collected and maintained the TCGA,\nGTEx, UCSC Xena, HPA, GEPIA2, cBioPortal and TIGER data, etc. Their high-quality work provides\nmassive help for our research",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:42.365909",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41020834.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "41011149": {
    "paper_id": "41011149",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genetic Alterations and Survival Analysis of These Therapeutic Targets in PCa Patients\nTo delve deeper into the molecular signatures associated with the 84 therapeutic targets\namong various cohorts of PCa patients, analyses of genetic alterations and survival were\nconducted utilizing cBioPortal",
      "Genetic Alteration Analysis\ncBioPortal (accessible at https://www.cbioportal.org/, with the latest update on\nAugust 21, 2023) is an online integrated data mining platform that was employed to\ninvestigate genetic modifications and conduct survival analysis concerning MGFD-related\ntargets in the context of prostate cancer treatment [ 65]",
      "This study included six prostate\ncancer cohorts from the cBioPortal database, primarily derived from multiple research\nprojects such as MSK, MCTP , Broad/Cornell and the SU2C/PCF Dream Team [ 19\u201324]",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:51.540884",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41011149.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "41023204": {
    "paper_id": "41023204",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Figures were generated in cBioPortal.org247 \u2013249with data from the MSK-IMPACT clinical cohort.250Histology\nannotations were obtained from clinical diagnosis, in the style of real word data (RWD)",
      "Figures were generated in cBioPortal.org.247 \u2013249X",
      "Figures were generated in cBioPortal.org247 \u2013249with data from the MSK-IMPACT clinical cohort.250Histology annotations were\nobtained from clinical diagnosis, in the style of RWD",
      "et al. Integrative analysis of complex cancer genomics and clinical pro-\n\ufb01les using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic and clinical\ndata from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:51.980354",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41023204.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "41009727": {
    "paper_id": "41009727",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In addition to the primary GEO datasets\nused for differential expression and machine learning modeling (GSE28799, GSE54388,\nGSE14407), the study incorporated several validated external platforms\u2014including GEPIA,\nTNMplot, Kaplan\u2013Meier Plotter, Human Protein Atlas, and cBioPortal\u2014for independent\nverification of expression levels, prognostic associations, protein localization, and genomic\nalterations",
      "Parallel analyses were conducted\nusing TNMplot, Kaplan\u2013Meier Plotter, Human Protein Atlas, and cBioPortal to ensure\ncross-platform reproducibility of transcriptomic, proteomic, and genomic features",
      "Protein expression data were extracted from the\nHuman Protein Atlas database (https://www.proteinatlas.org/, (accessed on 21 March\n2025)), while genetic alteration information was accessed through cBioPortal for Cancer\nGenomics [48]",
      "Analysis and\nvisualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:56.487573",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41009727.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "41029822": {
    "paper_id": "41029822",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The  M e t \na s t a t i c Breast Cancer (TMBC) dataset [ 57] was available \nthrough cBioPortal [ 58]",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:57.184575",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41029822.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41007704": {
    "paper_id": "41007704",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Materials and Methods\nWe utilized the AACR GENIE BPC NSCLC 2.0-public cohort, a publicly available\ndataset in cBioportal, to identify all NSCLC patients with KRAS mutations, SMARCA4\nmutations, or KRAS /SMARCA4 co-mutations [ 26,27]",
      "The dataset is publicly available through the AACR GENIE Data Commons\n(https://genie.cbioportal.org/)",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, H.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:11:58.646648",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41007704.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41003874": {
    "paper_id": "41003874",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "mRNA expression and protein abundance data from GBM tissue \nsamples were obtained via cBioPortal for Cancer Genomics (CPTAC, Cell 2021) from \ndatasets originally published by Wang et al. ( Cancer Cell  2021) [ 5\u20138]",
      "Data availability\nData used in this publication were generated by the National Cancer Institute Clinical Proteomic Tumor Analysis \nConsortium (CPTAC) and accessed via cBioPortal for Cancer Genomics ( https://www.cbioportal.org/study/summary",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualization of longitudinal genomic and clinical data from the \nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:01.102022",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41003874.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41009348": {
    "paper_id": "41009348",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Differential gene expression and mutational analyses were per-\nformed using public datasets (TCGA, TNMplot, GEPIA2, GSCA, PANDA, and cBioPortal)\nto assess the prevalence and clinical significance of BRAF, MEK, and PI3K alterations in\nCRC",
      "These results were analyzed\non cBioPortal for Cancer Genomics",
      "These pathways were analyzed in cBioPortal for Cancer Genomics version 6.3.6,\nwithin a p-value of 1.16 \u00d710\u22126",
      "Furthermore, the cBioPortal\n6.0 version for Cancer Genomics (https://www.cbioportal.org/, 24 April 2024) was used to\nexplore BRAF/MEK/PI3K genomic alterations, particularly driver mutations in CRC and\ntheir impact on the patient\u2019s overall survival [ 91\u201393]",
      "Furthermore, analysis of the biological processes impacted by the\ngenetic alterations of BRAF/MEK/PI3K in CRC was achieved on the Network Data\nExchange (NDEx Cancer Pathways) of the cBioPortal for Cancer Genomics web tool\n(https://www.cbioportal.org/, 29 April 2024) [ 91,92]",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:06.866922",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41009348.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "41000977": {
    "paper_id": "41000977",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The associated expression Z scores 94 \nwere downloaded from cBioPortal (24-26) (https://www.cbioportal.org/)",
      "Prior investigators found strong 216 \nassociations between IGF1R and \u03b21 integrin (17, 18, 33), so we began by searching for \u03b21 integrin 217 \nexpression, as well as its ligand fibronectin, in human breast cancers by mining the cancers by 218 \nmining the METABRIC dataset (22, 23) using cBioPortal (24-26)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and 559 \nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma 560 \nCollaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of 562 \ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:10.924412",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41000977.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "41006257": {
    "paper_id": "41006257",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The MSK-IMPACT NSCLC genomic data is\navailable on cBioPortal as part of the MSK-CHORD cohort at https://\nwww.cbioportal.org/study/summary?id=msk_chord_2024 .A l lc l i n i c a l\nannotations used for analyses in this paper are available at https://\ngithub.com/clinical-data-mining/variant-annotation to enable others\nto reproduce our \ufb01ndings and make additional discoveries",
      "et al. Analysis and Visualization of Longitudinal Genomic\nand Clinical Data from the AACR Project GENIE Biopharma Colla-borative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:11.785671",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41006257.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "41225146": {
    "paper_id": "41225146",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Co-expression analysis between EMP3 and S100A4 mRNA levels was\nperformed using mRNA expression da ta derived from the Illumina HT-12\nv3 microarray platform accessed through cBioPortal for CancerGenomics\n69\u201371",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR Project GENIE BiopharmaCollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:14.518129",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41225146.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40998903": {
    "paper_id": "40998903",
    "cbioportal_paper_citations": [
      "https://pu bmed.ncbi.nlm.nih.go v/23550210/\n 30",
      "https://pubmed.ncbi.nl m.nih.gov/37668528/\n 32"
    ],
    "cbioportal_platform_mentions": [
      "Additionally, we use cBioPortal, \nPhosphoNET, and AlphaFold to analyze the distribution of genetic alterations, phosphorylation \nsites, and pathogenic hotspots in C15ORF48",
      "Investigating the association between C15orf48  and tumor mutations using cBioPortal\nTo further explore the connection between C15orf48  gene and tumors, the cBioPortal platform was employed \nto explore the association between C15orf48  and gene mutations",
      "cBioPortal( https: //www.cbioportal.org/ ) is a \npowerful online tool that enables the mining, transformation, and visualization of cancer genomics datasets29\u201331",
      "Next, integrate phosphorylation sites from PhosphoNET \nand tumor hotspots from cBioPortal",
      "Additionally, analysis \nvia cBioPortal reveals that T38, T53, and T57 are mutation hotspots in tumors and overlap with regulatory \nphosphorylation sites, suggesting their potential significance",
      "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal - PubMed",
      "Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in \ncBioPortal - PubMed",
      "Acknowledgements\nWe are grateful to the public databases, including GEPIA, Timer2.0, Human Protein Atlas, cBioPortal, Phospho -\nNET, and AlphaFold, for providing open access"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:15.645771",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40998903.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "41000613": {
    "paper_id": "41000613",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We analyzed patient sequencing \ndata from The Cancer Genome Atlas ( TCGA ) and AACR Project GENIE  v18.0  via cBioportal  [26\u2013\n28], and stratified patients  into two groups: ARID1A /ARID 1B wild-type vs ARID1A /ARID 1B \nmutan ts (truncating, missense  or non -sense mutation s), and assessed  mutation burden",
      "De Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and \nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE \nBiopharma Collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis \nof complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:16.484532",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41000613.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40988915": {
    "paper_id": "40988915",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To validate the correlation between the shedding pAxl \nand EMT scores, we obtained an additional 110 LUAD \nRNA-seq data from the Clinical Proteomic Tumor Analysis \nConsortium (CPTAC) data set24by means of cBioPortal \n(https://www.cbioportal.org ),25\u201327including gene ex-\npressions quantified as reads per kilobase of transcript per \nmillion mapped reads, and subsequently transformed \nthem into Z-scores"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:21.381654",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40988915.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "40994935": {
    "paper_id": "40994935",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The gene\nampli \ufb01cation and mutation status of MGLL was obtained from\nthe cBioPortal ( http://www.cbioportal.org/ ) for Cancer Genomics\n(19)",
      "Analysis of the MGLL\ngene \u2019s OncoPrint pro \ufb01le in ccRCC patients using the cBioPortal\ndatabase revealed that trunca ting, deep deletion, and pro \ufb01led\nmutations in MGLL were present in less than 8% of\ncases ( Figure 1K )",
      "(J)Immunohistochemical staining of MGLL in ccRCC and normal tissues (scale bar, 200 mm).(K)cBioPortal\nOncoPrint graph showing the distribution of MGLL genomic changes in ccRCC patients",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the aacrproject genie biopharma collaborative in cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:21.505496",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40994935.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40977519": {
    "paper_id": "40977519",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Firstly, we assessed the benefit of cell line collections in sig -\nnal seeking PARP inhibitor studies by systematically analys -\ning cell lines from the Cancer Cell Line Encyclopedia (Broad, \n2019) [ 8\u201310 ], accessed via cBioPortal",
      "Data were \naccessed via cBioPortal",
      "Data Availability Statement\nThe data that support the findings of this study are available in the \nCancer Cell Line Encyclopedia, accessed via cBioPortal ( https:/ /  www",
      "Mastrogiacomo, et\u00a0al., \u201cAnalysis and Visu -\nalization of Longitudinal Genomic and Clinical Data From the AACR \nProject GENIE Biopharma Collaborative in cBioPortal,\u201d Cancer Re -\nsearch  83 (2023): 3861\u20133867",
      "Dogrusoz, et\u00a0 al., \u201cIntegrative Analysis of \nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d \nScience Signaling  6 (2013): pl1",
      "Driver annotations were based on OncoKB \nand Hotspots from cBioPortal",
      "Data were accessed via cBioPortal",
      "Data were accessed via \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:21.873714",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40977519.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "41188599": {
    "paper_id": "41188599",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Log2-normalized METABRIC gene expression data, as well as \nbatch-normalized gene expression from TCGA Illumina HiSeq_\nRNASeqV2 and all associated metadata, were downloaded from the \ncBioPortal",
      "et al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR Project GENIE \nBiopharma Collaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and \nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:22.595755",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41188599.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40944348": {
    "paper_id": "40944348",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Using cBioPortal, we included all pan-  cancer \nand nonuterine sarcoma studies, 10 and 16, respectively, and \nqueried for BCOR  alterations, obtaining seven cases of CCSA \nand DCSA",
      "This possibil -\nity is supported by the difference in the frequency of BCOR  ge-\nnetic alterations in our study versus the one identified during \nour search of cBioPortal, which included 361 cases of CCSA and \nDCSA with a frequency of 5% and 1.9%, respectively [ 25\u201327 ]",
      "Mastrogiacomo, et\u00a0al., \u201cAnalysis and Vi -\nsualization of Longitudinal Genomic and Clinical Data From the AACR \nProject GENIE Biopharma Collaborative in cBioPortal,\u201d Cancer Re -\nsearch  83, no",
      "Dogrusoz, et\u00a0 al., \u201cIntegrative Analysis of \nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d \nScience Signaling  6, no"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:27.626205",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40944348.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40955658": {
    "paper_id": "40955658",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Public gene expression data were \nacquired from the KM plotter (24, 25) (https://kmplot.com/analysis/), \ncBioPortal (58\u201360) (https://www .cbioportal.org/), or Tumor Immuno-\ntherapy Gene Expression Resource (http://tiger.canceromics.org/#/)",
      "Gao J, et al. Integrative analysis of complex \ncancer genomics and clinical profiles using the \ncBioPortal",
      "de Bruijn I, et al. Analysis and visualization of \nlongitudinal genomic and clinical data from the \nAACR Project GENIE biopharma collaborative \nin cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:28.630049",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40955658.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40904607": {
    "paper_id": "40904607",
    "cbioportal_paper_citations": [
      "PubMed ID:\n22588877\nde Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al., Schultz N",
      "PubMed ID: 37668528\nGao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al., Schultz N",
      "PubMed ID: 23550210\nGupta S, Jani J, Vijayasurya, Mochi J, Tabasum S, Sabarwal A, Pappachan A"
    ],
    "cbioportal_platform_mentions": [
      "mRNA expression values were retrieved through the expOmics platform (Li et al.,\n2024), while clinical survival data were collected via cBioPortal (Cerami et al. 2012; Gao et al., 2013; de Bruijn et al.,\n2023)",
      "Analysis and Visualization\nof Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Integrative analysis of complex\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:30.465206",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40904607.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40909996": {
    "paper_id": "40909996",
    "cbioportal_paper_citations": [
      "doi: 10.1158/2159-8290.CD-12-0095 [PubMed: 22588877] \n30",
      "doi: \n10.1158/0008-5472.CAN-23-0816 [PubMed: 37668528] \n31"
    ],
    "cbioportal_platform_mentions": [
      "Author Manuscript Author Manuscript Author Manuscript Author Manuscript\n\npatient sample was extracted from cBioPortal",
      "TCGA cohorts featured TMB and \nFGA values for patient tumor samples, which were obtained through cBioPortal ( 29\u201331)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis \nand visualization of longitudinal genomic and clinical data from the AACR project \nGENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of \ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {
      "29337640": [
        "doi: 10.1200/JCO.2017.75.3384 [PubMed: \n29337640] \n24"
      ],
      "30643254": [
        "doi: 10.1038/s41588-018-0312-8 [PubMed: 30643254] \n20"
      ]
    },
    "extraction_date": "2025-12-19T17:12:30.483826",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40909996.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 2
  },
  "40919994": {
    "paper_id": "40919994",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "RNA sequencing \nexpression data from 34,138 samples of patients with various malignancies \nwere obtained and downloaded from the Open Pediatric Cancer Project v15 \n(pedcbioportal.kidsfirstdrc.org), and 244 samples from the Pediatric Pre-\nclinical Testing Consortium [cbioportal.org; now referred to as the Pediatric \nPreclinical In Vivo Testing Consortium (PIVOT); https://preclinicalpivot",
      "de Bruijn I, Kundr a R, Mastr ogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from the \nAACR project GENIE Biopharma Collabor ative in cBioPortal",
      "24.Gao J, Akso y BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Inte-\ngrative analysis of comple x cancer genomics and clinical profiles using the \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:34.030887",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40919994.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40976930": {
    "paper_id": "40976930",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "\u201cAnalysis and \nVisualization of Longitudinal Genomic and Clinical Data From the \nAACR Project GENIE Biopharma Collaborative in cBioPortal.\u201d Cancer \nResearch  83, no"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:35.190532",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40976930.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "40869426": {
    "paper_id": "40869426",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis and\nvisualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:40.658801",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40869426.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "40874905": {
    "paper_id": "40874905",
    "cbioportal_paper_citations": [
      "doi:10.1158/2159-8290.Cd-12-0095 [PubMed: 22588877] Plagens et al. Page 18\nMol Cancer Res",
      "doi:10.1158/0008-5472.Can-23-0816 \n[PubMed: 37668528] \n40",
      "doi:10.1126/scisignal.2004088 \n[PubMed: 23550210] \n41"
    ],
    "cbioportal_platform_mentions": [
      "METABRIC cohort data accession\nThe mRNA expression z-scores relative to all samples (log microarray) of the gene names \nassociated with our 185 shared MS hits were downloaded for the METABRIC patients with \nmRNA data (cohort of 1505 ER+ BC patients with relapse-free survival information) from \ncBioPortal.org  using a z-score threshold of \u00b1 1.96 (accession date 02 Feb 2023) 37\u201342",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and Visualization of Longitudinal \nGenomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in \ncBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical \nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {
      "27161491": [
        "doi:10.1038/\nncomms11479 [PubMed: 27161491] \n42"
      ],
      "33212010": [
        "doi:10.1016/j.cell.2020.10.036 \n[PubMed: 33212010] Plagens et al. Page 20\nMol Cancer Res"
      ],
      "22522925": [
        "doi:10.1038/\nnature10983 [PubMed: 22522925] \n39"
      ],
      "30867590": [
        "doi:10.1038/\ns41586-019-1007-8 [PubMed: 30867590] \n43"
      ]
    },
    "extraction_date": "2025-12-19T17:12:41.673213",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40874905.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 4
  },
  "40868045": {
    "paper_id": "40868045",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Differential expression analysis was conducted using the cBioPortal platform (https:\n//www.cbioportal.org/) (accessed on 20 February 2025) based on log2-transformed RSEM-\nnormalized expression values",
      "Figure 2 was generated using log2-transformed RSEM expression values from cBioPortal v6.2",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:41.821394",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40868045.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "41062697": {
    "paper_id": "41062697",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et\u00a0al. Analysis and visualization of longitudinal genomic and clinical data  \nfrom the AACR project GENIE Biopharma Collaborative in cBioPortal",
      "Tumour mutations were obtained \nthrough cBioPortal (datasets from refs",
      "cbioportal.org/), intogen (intogen.org) and the GENIE synapse data \nportal (https://genie.synapse.org/) as described in Methods",
      "et\u00a0al. Integrative analysis of complex cancer genomics and clinical profiles using \nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:45.537233",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41062697.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40875132": {
    "paper_id": "40875132",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Inter -\nactive online portals such as the National Cancer Institute \nGenomic Data Commons (GDC), cBioPortal, and Kaplan-\nMeier Plotter are repositories of publicly available clinical, \ngenomic and transcriptomic data which can be combined \nwith library screening results in order to prioritise down -\nstream investigations [ 139\u2013146]",
      "Skipper et al.collaborative in Cbioportal",
      "Gao et al., Integrative analysis of complex cancer genomics \nand clinical profiles using the Cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:49.810038",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40875132.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40846695": {
    "paper_id": "40846695",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Access to the TCGA data was facilitated through cBioPortal [ 51\u201353]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative\nanalysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis\nand visualization of longitudinal genomic and clinical data from the AACR project\nGENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:49.813141",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40846695.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40894652": {
    "paper_id": "40894652",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "116  \nDifferential Gene Expression Analysis by cBioportal:  Data from the Lung Adenocarcinoma (TCGA, Pan C ancer 117  \nAtlas) Study in cBioportal  (26-28) was used for these analyses",
      "Once groups were created comparisons were 120  \nperformed within the cBioportal groups tab by selecting the desired sample groups",
      "Upon comparing the 121  \ndesired groups,  we navigated to the mRNA tab of the comparison which reports differentially expressed genes 122  \nand filtered the list to only significantly differentially expressed genes , q-value <0.05 de rived from a Benjamini - 123  \nHochberg procedure  within cBioportal",
      "We used GSEA on a pre -ranked gene list produced by the group comparison in cBioportal 127  \npreviously detailed",
      "We used CBioPortal to perform the differential expression 333  \nanalysis and found that there were thousands of genes that were differentially expressed between these 334  \ngroups ( Figure 4A )",
      "et al.  (2023) Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project 556  \nGENIE Biopharma Collaborative in cBioPortal",
      "et al.  (2013) Integrative analysis of complex cancer genomics and clinical profiles using the 559  \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:49.965383",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40894652.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "40849558": {
    "paper_id": "40849558",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We used tools such as Gene \nExpression Profiling Interactive Analysis 2, logistic regression, receiver operating \ncharacteristic analysis, Sieber algorithm for immune detection, immune checkpoint \ngene correlation, cBioPortal analysis, and genomic sensitivities of cancers from the \nGenomics of Drug Sensitivity in Cancer and Cancer Therapeutics Response Portal \nto evaluate the association of GOT1 with CRC",
      "2.6 Gene variant analysis\nThe cBioPortal database [ 25\u201327] (https://www.cbioportal.org/ ), a comprehensive \nresource for cancer genomic data, was used to assess the tumour mutation burden \n(TMB), copy number variation (CNV), and microsatellite instability (MSI) of GOT1",
      "9a) of GOT1 in 33 TCGA \ncancer types were obtained from the cBioPortal database",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic \nand clinical data from the AACR project GENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and \nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:50.320933",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40849558.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40849581": {
    "paper_id": "40849581",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "According to an open database\n(www.cbioportal.org ) containing the results of multiple cancer\nstudies, 122 genetic alterations of the BMF gene, predominantly\ndeep deletions and mutations, were detected in 23 cancer typesamong a total of 32 (10,953 patients)",
      "The frequency of BMF genetic alterations ( www.cbioportal.org )",
      "Selected studies contain structural variants, mutations, and copy number data (TCGA\nPanCancer Atlas Studies from www.cbioportal.org )[163 \u2013165].N.V",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative\nanalysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis\nand visualization of longitudinal genomic and clinical data from the AACR\nproject GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:51.735591",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40849581.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40839124": {
    "paper_id": "40839124",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "When \nVHL is mutated or inactivated, HIF accumulates and drives \nthe transcriptional upregulation of VEGF and other pro-angio -\ngenic factors, thereby promoting tumor vascularization and \nprogression.36\nTo further investigate whether VHL inactivation contributes \nto IL-8 upregulation in RCC, we examined the potential asso -\nciation between IL-8 expression levels and the genetic status \nof VHL through cBioportal ( www.cbioportal.org )",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex \ncancer genomics and clinical profiles using the cBioPortal",
      "Anal -\nysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:52.294540",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40839124.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40950237": {
    "paper_id": "40950237",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the 1548 \nAACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:53.028327",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40950237.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "40806338": {
    "paper_id": "40806338",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In this\nreport, we re-analyzed cancer genomes deposited in COSMIC [ 41] or cBioPortal [ 42,43]\nto identify driver mutations in other genes that co-occur with POLe mutations",
      "POLe Mutation Spectrum in Human Cancers\nComplete POLe mutation data from COSMIC and cBioPortal were first parsed into\ncoding and non-coding data",
      "Although most mutations reported by both sites are from sim-\nilar samples, there are some differences: (1) only COSMIC reports synonymous mutations,\n(2) only COSMIC reports mutation zygocity, and (3) cBioPortal reports more samples than\nCOSMIC",
      "Both COSMIC and\ncBioPortal report POLe mutations in nearly every cancer type (Figure 1B)",
      "cBioPortal\nalso reports more mutations in lung and skin than COSMIC",
      "This analysis showed that a higher percentage of coding mutations are\ncharacterized as driver in the COSMIC than the cBioPortal dataset (Figure 1C)",
      "POLe mutation types\nreported in COSMIC and cBioPortal",
      "Protein MutationTertiary Structure\nInteraction\nChangesElectrostatic\nSurface Potential\nChanges\u2206\u2206G Value\n(kcal/mol)\nPIK3CAR88Q Yes, decreased Neutral to negative \u22124.53\nE545K Yes, decreased Negative to neutral +0.08\nH1074R NoNegative to partial\nnegative\u22120.56\nCNOT R559Q Yes, increased No change \u22120.08\nFBXW7R465Q No No change \u22121.83\nR465H No No change \u22121.40\nR465C No No change +7.88\nCTNNB1 S45F No No change \u22121.87\nSF3B1R196Q No Positive to negative \u22120.23\nR315Q No Positive to neutral +0.54\nCHD4 R1338I No No change \u22122.31\nCHD8 R546C NoPositive to partial\npositive\u22120.37\nTo understand whether co-mutations between POLe and the genes identified here\nare likely to co-occur, we used the cBioPortal mutual exclusivity calculator",
      "Evidence of POLe-Specific Mutation Signatures from In Vivo Mutagenic Screens\nand Experiments\nAlthough the purpose of this report was to analyze colorectal data deposited in\nCOSMIC or cBioPortal, other studies have tested the impact of some of these mutations\nin human cells",
      "cBioPortal data was\naccessed using cBioPortal\u2019s public API (https://www.cbioportal.org/api/swagger-ui/\nindex.html?urls.primaryName=public (accessed on 7 July 2024)) and Python 3.13, and the\nmain website (https://www.cbioportal.org/ (accessed on 7 July 2024))",
      "Determination of Mutation Driver Potential\nUsing the/api/mutations/fetch function of the cBioPortal API and Python 3.13, the\nsamples from the selected cBioPortal datasets were filtered for those with POLe mutation(s)",
      "For this anal-\nysis, we used the cBioPortal repository",
      "Using the /api/mutations/fetch function of the\ncBioPortal API and Python 3.13, the patient samples from the selected cBioPortal datasets\nwere filtered for those with POLe mutation(s)",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:56.967418",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40806338.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 15,
    "total_data_pmids_cited": 0
  },
  "40806592": {
    "paper_id": "40806592",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The p.S9N variant is described in Li\u2013Fraumeni syndrome in the ClinVar database,\nand it has been reported in a melanoma patient in the cBioPortal database, while p.S15N\nlacks any reports in the ClinVar, cBioPortal, and COSMIC databases [ 27\u201329]",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis\nand visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:57.530662",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40806592.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40832239": {
    "paper_id": "40832239",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "MutationAssessor in cBioPortal \nYang Su1, Xiang Li2, Boris Reva3, Yevgeniy Antipin4, Nikolaus Schultz2, Ino de Bruijn2, Chris \nSander1,5,6,7 \n1 Department of Systems Biology, Harvard Medical School, Boston, MA, USA \n2 Memorial Sloan Kettering Cancer Center, New York, NY, USA \n3 Departments of Obstetrics/Gynecology & Reproductive Sciences, Icahn School of Medicine at \nMount Sinai, New York, NY, USA \n4 AlgoGenomics LLC, New York, NY, USA \n5 Broad Institute of Harvard and MIT, Cambridge, MA, USA \n6 CEDAR Center, Knight Cancer Center, OHSU, Portland, OR, USA \n7 Ludwig Center at Harvard; Dana-Farber/Harvard Cancer Center, Boston, MA, USA \n \nAbstract   \nMutationAssessor (MA) helps researchers evaluate the likely functional impact of somatic \nand germline mutations in cancer",
      "Functional impact \nof ~4 million somatic amino-acid changing mutations across more than 320K human \ntumor samples are now available in the widely used cBioPortal for Cancer Genomics",
      "The widely used cBioPortal for \nCancer Genomics makes these data available for cancer researchers (de Bruijn et al., 2023)",
      "cBioPortal is an open-access platform designed for visualizing, analyzing, and exploring \nlarge-scale cancer genomics datasets",
      "Widely used in \nprecision oncology and translational research, cBioPortal accelerates discoveries by making \ncomplex cancer genomics data accessible (e.g., for clinical interpretation of personalized variant \nprofiles) and actionable (for the design of experimental and computational cancer biology research \nprojects)",
      "One of the mutation effect tools in cBioPortal is MutationAssessor (Reva et al., 2011)",
      "Instead, MutationAssessor is based on evolutionary constraints on sequence variation in real \norganisms (Rochman et al., 2020), prioritizes scoring for real-world cancer mutations and makes \nthese predictions easily accessible through integration with the cBioPortal for Cancer Genomics",
      "We make available source code in the public domain, multiple sequence \nalignments for human proteins via Genome Nexus (de Bruijn et al., 2022), and detailed mutational \neffect scores in the user-friendly and widely used cBioPortal for Cancer Genomics (cbioportal.org)",
      "cBioPortal, originally developed in the context of The Cancer Genome Atlas now covers data from \nmore than 320K tumor samples and a suite of analysis tools and is used by more than 40K unique \nactive users as of early 2025",
      "The relevance of FIS \nfor predicting functional impact can be assessed by its ability to distinguish curated benign \nand pathogenic mutations from the ClinVar database, and to separate mutations observed \nin the general population (UK Biobank) from highly recurrent, cancer-tissue somatic \nmutations (extracted from cBioPortal, number of occurrences in cancer samples > 200)",
      "The updated functional impact scores and multiple \nsequence alignments are available through Genome Nexus (de Bruijn et al., 2022) and cBioPortal \n(de Bruijn et al., 2023) (Fig",
      "Access to MutationAssessor functional impact predictions in cBioPortal \nand Genome Nexus",
      "(A) In cBioPortal, go to the \u201cMutations\" tab (1), click the \u201cColumns\u201d \nbutton (2) and in the pop-up check the \u201cFunctional Impact\" checkbox (3) to show the \n\u201cFunctional Impact\u201d column in the mutations table",
      "Updates with better ClinVar benchmark score \nAs a strong motivation to update MA functional impact scores in cBioPortal for Cancer Genomics, \nwe found that MA r4 performs better than MA r3 at agreeing with the expert-curated clinical \nannotations of human disease-related AA-changing single substitution variants from the ClinVar \ndatabase (Landrum et al., 2014) (average AUC = 0.910 for MA r4 vs 0.877 for MA r3)",
      "(B) FIS and number of occurrences of somatic cancer mutations in \ncBioPortal",
      "Variants are binned by their total number of occurrences across all studies in cBioPortal",
      "We examined the somatic \nAA-changing mutations found in cancer patient samples in cBioPortal (Fig",
      "Applying these rules to the highly recurrent mutations in cBioPortal, we identified several putative \nswitch-of-function mutations in cancer (Table 3)",
      "Highly recurrent (\u2265 200 occurrences) mutations in cBioPortal that have high specificity \nscores and high conjugate specificity scores are predicted to be switch-of-function \nmutations",
      "Focus on effects in the human organism versus laboratory based assays \nIn the landscape of ongoing work about variant effect prediction for different biological questions \n(Gnad et al., 2013; Notin et al., 2023), the main advantages of this new version of \nMutationAssessor are its (1) straightforward interpretability in conjunction with (2) improved \nclassification performance for known effects, (3) focus on cancer mutations, and (4) availability of \nmutation effect predictions in the interactive, user-friendly cBioPortal for Cancer Genomics",
      "When \nprovided by research tools such as the cBioPortal for Cancer Genomics, FIS provides hypotheses \nthat can be useful as a first step in characterizing novel, functional variants and planning focused \nfurther experimental investigation on the highest rank candidates using techniques of cell biology \nincluding non-human pre-clinical experiments",
      "cBioPortal and COSMIC",
      "Cancer somatic mutations were obtained from cBioPortal for Cancer \nGenomics (including AACR Project GENIE data) and COSMIC Cancer Mutation Census v98",
      "Data and Code Availability \nThe updated functional impact score (FIS) for sequence variants in human proteins and the \nassociated multiple sequence alignments are available by entering the sequence variant at \nGenome Nexus and cBioPortal for Cancer Genomics, and as a file (DOI: \n10.5281/zenodo.15305085)",
      "Funding for cBioPortal: NCI ITCR 1U24CA274633",
      "Analysis and \nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE \nBiopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:12:58.999243",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40832239.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 26,
    "total_data_pmids_cited": 0
  },
  "41017066": {
    "paper_id": "41017066",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TheCancerGenomeAtlas(TCGA)melanomadataset31\nwasdownloadedfromcBioPortal( https://www.cbioportal",
      "Histology images reported in this paper\nwillbesharedbytheleadcontactuponrequest.External\ndatasets19,31,35\u201337wereaccessedfromtheirpublicationand\nfromotherdatarepositories( https://www.cbioportal.org/\nstudy/summary?id=skcm_tcga_pan_can_atlas_2018 )\nand https://github.com/ParkerICI/MORRISON-1-\npublic.32\u201334,38\nETHICS STATEMENT\nThe research was conducted in compliance with the\nDeclarationofHelsinkiandwasapprovedbytheSemmel-\nweis University Regional and Institutional Committee of\nScienceandResearchEthics(IRB,SETUKEB114/2012)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and\nvisualizationoflongitudinalgenomicandclinicaldatafromthe\nAACR project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:00.206242",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41017066.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40799741": {
    "paper_id": "40799741",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:00.499993",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40799741.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "40804718": {
    "paper_id": "40804718",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioportal database [ 7] was used to ana -\nlyze the somatic mutation information of B-LLPSI sig -\nnatures in renal clear cell carcinoma and non-clear cell \ncarcinoma",
      "Analysis and visualization of longitudinal genomic and clinical data from \n\nPage 18 of 18\nWang et al. BMC Cancer          (2025) 25:1314 \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:00.895856",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40804718.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40796942": {
    "paper_id": "40796942",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Protein quantification data were acquired from the cBioPortal \nFirehose generated by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) via mass spectrometry, \nand protein values represent normalized, relative abundance levels on a log2 scale",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:02.867359",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40796942.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40792276": {
    "paper_id": "40792276",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Transcriptomic\nand clinical data are publicly available and were downloaded from\nthe cBioPortal repository ( 23)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACRproject GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:02.989738",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40792276.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40779492": {
    "paper_id": "40779492",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1158/2159-8290.CD-12-0095  PMID: 22588877\n 5",
      "https://doi.org/10.1126/scisignal.2004088  PMID: 23550210\n 6",
      "https://doi.org/10.1158/0008-5472.CAN-\n23-0816  PMID: 37668528\n 7"
    ],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using \nthe cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data \nfrom the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {
      "36355783": [
        "https://doi.org/10.1158/2159-8290.CD-22-0405  PMID: 36355783\n 31"
      ]
    },
    "extraction_date": "2025-12-19T17:13:03.447840",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40779492.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 1
  },
  "40725190": {
    "paper_id": "40725190",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutational profiles were annotated and visualized using\nMutationMapper in the cBioPortal (version 6.3.3) [ 50\u201352]",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.E.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:07.764345",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40725190.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40746562": {
    "paper_id": "40746562",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "CBioPortal (http://www.cbioportal.org/ , v6.0.20) tool was applied to \nassess PCP4 alteration frequency, mutation type and CNA (copy \nnumber alteration) of prostate cancer samples (28\u201330)",
      "The Cancer \nGenome Atlas (TCGA, prad_tcga_pan_can_atlas_2018), the Stand \nUp To Cancer (SU2C, prad_su2c_2019), MSKCC (MSKCC cancer \ncell 2010), and prostate_dkfz_2018 datasets were downloaded from \nCBioPortal website",
      "A \nhigh frequency of PCP4 gene deletion was observed in different \nprostate adenocarcinoma studies based on cBioportal database",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Ngoc Tran T, Sikina L, Mazor T, et al. \nAnalysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR \nProject GENIE Biopharma Collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative \nanalysis of complex cancer genomics and clinical pro\ufb01 les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:08.931987",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40746562.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40775431": {
    "paper_id": "40775431",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Scientific Reports  |        (2025) 15:28934 4 | https://doi.org/10.1038/s41598-025-14342-zwww.nature.com/scientificreports/\n\nGenetic alteration and methylation status of ITGAV\nThe genetic alterations of ITGAV in pan-cancer were investigated using the cBioPortal",
      "Genetic alteration and DNA methylation analysis\nThe cBioPortal database V6.3.1 ( https://www.cb ioportal.org/ )30 was used to assess ITGAV genetic alteration \nwith 10,967 samples which obtained from 10,953 patients in 32 types of cancer from the 32 most recent TCGA \nstudies",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:09.540947",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40775431.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40789164": {
    "paper_id": "40789164",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Furthermore, wequeried whether PIWIL2 allelic loss correlates with patient survivalusing the cBioportal CNA tool; indeed, allelic loss of PIWIL2correlates with poorer patient survival compared to patients withoutan allelic loss ( Fig",
      "The results from the SWAN and cBioportal\nanalyses highlight the overall loss of regulation of the entire piRNAbiogenesis pathway in colon cancer and identify PIWIL2 as a topcandidate for the loss of the pathway \u2019s regulation",
      "(D) The cBioportal database was used to interrogate TCGA COAD\ndataset for overall survival of PIWIL2 allelic loss compared to unaltered\ntumors",
      "cBioportal\ncBioportal is another open-source web-based tool to visualizemultidimensional cancer genomics data sets, including data from TCGA PanCancer Atlas (Cerami et al., 2012; Gao et al., 2013; de Bruijn et al., 2023)",
      "This\ntool can be found at the following webpage: https://www.cbioportal.org .The\nTCGA COAD data set was selected and then queried for samples with shallow\ndeletion CNAs (loss of one allele; HETLOSS) of PIWIL2 and a plot of Overall\nSurvival was generated using the Comparison/Survival Tool",
      "Analysis and visualization of\nlongitudinal genomic and clinical data from the AACR project GENIE biopharmacollaborative in cBioPortal",
      "Integrative analysis of\ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:11.451410",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40789164.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "40774224": {
    "paper_id": "40774224",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "de Bruijn, et al., Analysis and visualization of longitudinal genomic and clinical \ndata from the AACR Project GENIE Biopharma Collaborative in cBioPortal, Cancer \nRes 83 (23) (2023) 3861 \u20133867",
      "Gao, et al., Integrative analysis of complex cancer genomics and clinical profiles \nusing the cBioPortal, Sci Signal 6 (269) (2013) pl1.A.T"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:11.550499",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40774224.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40723918": {
    "paper_id": "40723918",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In addition, analysis of TCGA using\ncBioPortal for Cancer Genomics (http://www.cbioportal.org) [50] revealed that PHF20L1\nexhibits diverse alteration frequencies and types across multiple cancers",
      "The data presented in the figure were obtained from open-access platforms\nand visualised, including the Human Protein Atlas (https://www.proteinatlas.org/), GEPIA 2\n(http://gepia2.cancer-pku.cn/#index, accessed on 25 April 2025), and cBioPortal (https://www",
      "cbioportal.org/)",
      "The alteration frequency of PHF20L1 in various cancers can be downloaded from the\ncBioPortal For Cancer Genomics (https://www.cbioportal.org/results/cancerTypesSummary?case_set_\nid=all&gene_list=PHF20L1&cancer_study_list=5c8a7d55e4b046111fee2296 , accessed on 25 April 2025)",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:12.541853",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40723918.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40691352": {
    "paper_id": "40691352",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:13.974401",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40691352.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "40722679": {
    "paper_id": "40722679",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The TCGA-LUAD dataset was sourced from The Cancer Genome Atlas (TCGA) project\nand downloaded from the cBioPortal database (https://www.cbioportal.org/ (accessed\non19 March 2025",
      "The OncoSG dataset was\nalso obtained from the cBioPortal database [ 30] and consists of RNA sequencing profiles\nand clinical data for 169 LUAD patients",
      "LUAD Patient Subgroups\nThe bulk RNA sequencing and clinical data of LUAD patients in the TCGA (The Cancer\nGenome Atlas) [ 23] project were downloaded from cBioPortal [ 36]",
      "The OncoSG\ndataset was also obtained from the cBioPortal database",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis\nand visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:14.712380",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40722679.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40704654": {
    "paper_id": "40704654",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Patient transcr iptomic data \nTranscriptome (n \u0089429) data from mCRPC biopsies, generated by the \nInternational Stand Up To Cancer (SU2C)/Prostate Cancer Foundation, \nwere downloaded from cBioPortal (23\u201325) and reanalyzed (26, 27)",
      "de Bruijn I, Kundr a R, Mastro giacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalys is and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collabor ative in cBioPortal",
      "25.Gao J, Akso y BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Inte-\ngrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:21.506153",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40704654.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40658067": {
    "paper_id": "40658067",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Finally, the cluster-\ningresultswerevisualizedusingtheDimplotfunction.TheGliomaLongi-\ntudinalAnalysisRNA-seqdatasets,whichwereanalyzedusingcBioPortal\n(https://www.cbioportal.org/ ).[36\u201339]\nSubpopulationAnalysisofNeuronCells :Di\ufb00erentiallyexpressedgenes\n(DEGs)ofthetargetcellpopulationwereidenti\ufb01edusingtheFindMarkers\nfunction"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:21.536761",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40658067.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "40721297": {
    "paper_id": "40721297",
    "cbioportal_paper_citations": [
      "doi:10.1158/2159-8290.CD-12-0095 [PubMed: 22588877] Pawar et al. Page 20\nGenes Dev",
      "doi:10.1158/0008-5472.CAN-23-0816 [PubMed: 37668528] \nde Fallois J, Sieckmann T, Sch\u00f6nauer R, Petzold F, M\u00fcnch J, Pauly M, Vasileiou G, Findeisen C, \nKampmeier A, Kuechler A, et al. 2024"
    ],
    "cbioportal_platform_mentions": [
      "Results\nPhf6 loss transforms Flt3-ITD -driven CMML into AML\nWe examined human patient mutational data from cBioPortal ( Welch et al. 2016 ; Tyner et al. \n2018 ; Bottomly et al. 2022 ) to identify genes comutated with PHF6  in AML and identified \nRUNX1 , FLT3 , and WT1  as the top-ranked genes (Fig",
      "The workflow included review of published functional \ndata, PubMed, ClinVar ( https://www.ncbi.nlm.nih.gov/clinvar ), gnomAD (v4.1), COSMIC \n(Forbes et al. 2017 ; Tate et al. 2019 ), cBioPortal ( Cerami et al. 2012 ; Gao et al. 2013 ; \nde Bruijn et al. 2023 ), OncoKB ( Chakravarty et al. 2017 ; Suehnholz et al. 2024 ), and \nVarSome ( Kopanos et al. 2019 ) to score and characterize variants into three tiers: (1) tier 1: \nFDA-approved therapy associated with the variant, (2) tier 1 or 2: potential significance of \npathogenicity, and (3) tier 3: variant of unknown significance (V oUS), with likely benign or \nbenign variants not reported",
      "Analysis and visualization of longitudinal genomic and clinical data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Integrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal",
      "Data were \nobtained from cBioPortal",
      "Data were obtained from cBioPortal"
    ],
    "data_publication_citations": {
      "27959731": [
        "doi:10.1056/NEJMoa1605949 \n[PubMed: 27959731] \nWendorff AA, Aidan Quinn S, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, Litzow MR, \nTallman MS, Paietta E, Paganin M, Basso G, et al. 2019"
      ],
      "27276561": [
        "doi:10.1056/NEJMoa1516192 [PubMed: 27276561] \nRam\u00edrez F, Ryan DP, Gr\u00fcning B, Bhardwaj V , Kilpert F, Richter AS, Heyne S, D\u00fcndar F, Manke T"
      ],
      "21909114": [
        "doi:10.1038/nature10496 [PubMed: 21909114] \nYuan S, Wang X, Hou S, Guo T, Lan Y , Yang S, Zhao F, Gao J, Wang Y , Chu Y , et al. 2022"
      ],
      "30333627": [
        "doi:10.1038/s41586-018-0623-z [PubMed: 30333627] \nVan Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De \nMoerloose B, Philipp\u00e9 J, Gonz\u00e1lez-Garc\u00eda S, Toribio ML, et al. 2010"
      ],
      "24030381": [
        "doi:10.1182/blood-2013-08-518886 \n[PubMed: 24030381] \nPapaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, \nThol F, Bolli N, et al. 2016"
      ],
      "35868306": [
        "doi:10.1016/j.ccell.2022.07.002 [PubMed: 35868306] \nThe Cancer Genome Atlas Research Network"
      ],
      "23634996": [
        "doi:10.1056/NEJMoa1301689 \n[PubMed: 23634996] \nCerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne \nCJ, Heuer ML, Larsson E, et al. 2012"
      ]
    },
    "extraction_date": "2025-12-19T17:13:21.890375",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40721297.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 7
  },
  "40721560": {
    "paper_id": "40721560",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "0 5 .H i e r a r c h i c a lc l u s t e r i n gh e a t m a p swere constructed with Euclidean distance based on z-score normal-isation of the data.Article https://doi.org/10.1038/s41467-025-61897-6\nNature Communications |         (2025) 16:6923 13\n\nAnalysis of TCGA datasets\nThe cBioPortal was used to download FH gene alteration data53\u201355,\nutilising the pan-cancer analysis of whole genomes dataset28.T h eX e n a\nplatform was used to generate survival curve data based on FH copy\nnumber ampli \ufb01cation56using the same dataset28",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project GENIE biopharma colla-borative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:23.140893",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40721560.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40667321": {
    "paper_id": "40667321",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Targeted sequencing data were obtained for 137 ESCC samples from cBioPortal \n[33\u201336], 142 CHNE and 66 ESCC samples from Yokoyama et al. [7], and 832 CHNE samples \nfrom Martincorena et al. [8]",
      "The datasets supporting the conclusions of \nthis article are available through cBioPortal (https://www.cbioportal.org/study/; ID \nescc_ucla_2014), Synapse (https://www.synapse.org/; ID syn33401857), and the supplementary \nmaterials of Martincorena et al. [8], Yokoyama et al. [7], Yuan et al. [30], and Liu et al. [32]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis \nof complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and \nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE \nBiopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:24.310356",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40667321.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40655141": {
    "paper_id": "40655141",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal\ndatabase helped explore potential MZF1 mutations across cancer types",
      "2.4 Mutation and genomic alterations of\nMZF1 in cancer\nGenomic alterations of the MZF1 gene across various cancer\ntypes were analyzed using the cBioPortal database ( https://\nwww.cbioportal.org/ )(22)",
      "A thorough examination of the genomic landscape was\nperformed, emphasizing genomic instability, with data sourced from the cBioPortal and GSCA databases to assess pan-cancer alterations, includingCNVs and DNA methylation patterns",
      "To explore the genomic\nalterations of the MZF1 gene across various cancer types, conducted\nan analysis using the cBioPortal database",
      "De Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the aacrproject genie biopharma collaborative in cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:25.510644",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40655141.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40649942": {
    "paper_id": "40649942",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Primary clinical data from patients\nwere retrieved from the TCGA database and analyzed using cBioPortal, stitch, string, R and\nPython",
      "Study Selection\nThe cBioportal repository of gene expression datasets, a reputable and widely utilized\nplatform, was searched on 12 January 2025, utilizing the keyword \u201crenal\u201d",
      "Additionally, in order to obtain a comprehensive\nand robust dataset, public genomic libraries and databases, including cBioportal, were\nextensively utilized to source patients\u2019 genomic primary clinical data, with a specific focus\non renal cancer",
      "KIRC and KIRP Survival Analysis\nSurvival analysis was performed using clinical patient data from the TCGA database\nvia cBioPortal",
      "This analysis was performed using the cBioportal for\ncancer genomics on primary data of patients",
      "Additionally, the cBioportal and R package\nwere also employed to carry out differential expression and functional analysis with VHL\nand TTN",
      "Data Availability Statement: The data presented in this study are openly available in the cBioportal\ncurated from the TCGA database at cBioPortal for Cancer Genomics",
      "De Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:29.494492",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40649942.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "40647516": {
    "paper_id": "40647516",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "CBioPortal was utilized [ 15\u201317]",
      "We excluded silent\nmutations from the analysis based on OncoKB annotations in cBioPortal [ 19,20]",
      "Information for patient samples and genes in-\ncluded in the MSK-IMPACT panel is available from cBioPortal at the following website [ 15\u201317]:\nhttps://www.cbioportal.org (accessed on 4 Ocotber 2023)",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:30.270412",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40647516.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40647542": {
    "paper_id": "40647542",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis\nand visualization of longitudinal genomic and clinical data from the AACR project genie biopharma collaborative in cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:30.477682",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40647542.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "40647442": {
    "paper_id": "40647442",
    "cbioportal_paper_citations": [
      "Available\nonline: https://pubmed.ncbi.nlm.nih.gov/23550210/ (accessed on 23 August 2024)",
      "Available online: https://pubmed.ncbi.nlm.nih.gov/22588877/ (accessed on 23 August 2024)"
    ],
    "cbioportal_platform_mentions": [
      "These analyses were performed\nusing TCGEx [15] and cBioportal [16\u201318]",
      "Additionally, co-expressed genes were extracted using cBioPortal [ 16\u201318], with\na focus on correlations between ENHO and key chemokines, human leukocyte antigens\n(HLAs), immune checkpoints, and immunostimulatory genes, and visualized",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.E.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:31.753536",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40647442.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40646641": {
    "paper_id": "40646641",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Further analysis of data from 1380 HCC patients across \n5 studies in cBioPortal [ 33] revealed that 6% of patients \nexhibited ASH1L-AS1  amplification and structural \nvariations (Fig",
      "(A) Analysis of 1,380 HCC patients from five studies in cBioPortal re -\nvealed that 6% of patients exhibited ASH1L-AS1  amplification or structural \nvariations",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:35.006183",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40646641.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40629868": {
    "paper_id": "40629868",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:35.932782",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40629868.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "40634697": {
    "paper_id": "40634697",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The\ntraining/test data set is available on the website cBioPortal for CancerGenomics\n48\u201350",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project GENIE biopharmacollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:37.789394",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40634697.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40626673": {
    "paper_id": "40626673",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A query of the cBioportal database for cancer \ngenomics 26-28 including 11 studies 5,11,12,29-36 revealed \nthat deep or shallow deletions (largely corresponding \nto homo- or heterozygous deletions) of the KDM6A \nlocus can be found in 1% (deep deletion) and 8% \n(shallow deletion) of female bladder cancer patients \nlacking truncating KDM6A mutations",
      "org/10.1158/2159-8290.CD-12-0095\n27 Gao J, Aksoy B A, Dogrusoz U, et al. Integrative analysis of com -\nplex cancer genomics and clinical profiles using the cBioPortal",
      "https://doi.org/10.1126/scisignal.2004088\n28 de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and Visual -\nization of Longitudinal Genomic and Clinical Data from the AACR \nProject GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:38.430107",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40626673.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40627234": {
    "paper_id": "40627234",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Number (7) Cross-referencing data analysis \nusing available CRC datasets from the TCGA on the cBioPortal plat -\nform",
      "Comparison and data analysis using the cancer \ngenome atlas program (TCGA) datasets on the \ncBioPortal for cancer genomics\nFor the potential PGVs and the lpVUSs prioritised after data \nanalysis through Ion Reporter and Franklin we performed \nan additional data analysis by making use of the publicly \navailable datasets from the Cancer Genome Atlas Program \n(TCGA) datasets on the cBioPortal site [ 13\u201315]",
      "The filtered data was inspected for the presence of the priori -\ntised variants of interest in our study to observe whether any \npatient in the cBioPortal datasets carried the same variants",
      "Co-occurrence of variants in two different genes provided in \nthe cbioPortal were also analysed to obtain additional evi -\ndence for their disease relevance",
      "Cross-reference of germline variants with somatic \ndata and variant frequency from the TCGA\nTo provide further evidence for the potential pathogenicity \nof the PGVs and lpVUSs identified in this study, we analysed \navailable CRC data from patients in the TCGA PanCancer \nAtlas on the cBioPortal cancer genomics database  (   h t t p s : / / \nw w w",
      "This analysis showed that none of the \nPGV or lpVUS cases identified in our study were present \nin the cBioPortal bowel cancer datasets with somatic data",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, \nMazor T et al (2023) Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR project GENIE bio -\npharma collaborative in cBioPortal",
      "He Y , Lei C, Wan C, Zeng S, Zhang T, Luo F et al (2024) A \ncomprehensive whole genome database of ethnic minority clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:41.114361",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40627234.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "40634509": {
    "paper_id": "40634509",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The top hits from the SNV/InDel analysis were further\nannotated with functional consequences using the cBioPortal Mutation-\nMapper tool to yield a list of variants more likely to impact the encodedprotein",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative\nanalysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis\nand visualization of longitudinal genomic and clinical data from the AACR projectGENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:43.512425",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40634509.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40610594": {
    "paper_id": "40610594",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project GENIE biopharmacollaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:51.943530",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40610594.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40615439": {
    "paper_id": "40615439",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The \ngenerated dataset is user-friendly, via a visual web application that allows users to navigate the integrated data and their distribution among the collected studies\n11.ReferenceNumber of \npatientsNumber of patients with available molecular features Sample number Data source (Identifier)\nBlateau et al. 953 SNV: 53 Pre-treatment: 53 Personal communication16\nCatalanotti et al.666SNV: 66\nCNA: 66Pre-treatment: 66 cBioPortal web browser28; cBioPortal data29\u201331\nHugo et al.1244 GEx: 36Pre-treatment: 14\nOn treatment: 12Progression: 10Clinical data: extracted from the article; GEO GSE65186\n32\nKwong et al.1322 GEx: 44Pre-treatment: 12\nProgression: 32Clinical data: extracted from the article; EGA EGA000010009233\nLong et al.149 GEx: 23Pre-treatment: 9\nProgression: 9Post-treatment: 5Clinical data: extracted from the article; GEO GSE61992\n34\nLouveau et al.824SNV: 24\nGEx: 24Pre-treatment: 24 Personal communication17\nRizos et al.1524 GEx: 51Pre-treatment: 21\nProgression: 24Post-treatment: 6Clinical data: extracted from the article; GEO GSE50509\n35\nVan Allen et al .545 SNV: 78Pre-treatment: 39\nProgression: 39cBioPortal web browser36\ncBioPortal data29\u201331\nYan  et al.7130 GEx: 72 Pre-treatment: 72Clinical data: extracted from the articleGEX: extracted from the article\nTotal 417SNV: 191\nCNA: 66GEx: 132Pre-treatment: 310On treatment: 12Progression: 66\nPost-treatment: 11MelanoDB\n18\nTable 1",
      "cbioportal",
      "https://www.cbioportal.org/study/summary?id= skcm_vanderbilt_mskcc_2015 Accessed: 2025-03-23 \n(2017)",
      "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma \nCollaborative in cBioPortal",
      "https://\nwww.cbioportal.org/study/summary?id=skcm_broad_brafresist_2012 Accessed: 2025-03-23 (2014)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:52.084933",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40615439.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "40624356": {
    "paper_id": "40624356",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Our interrogation\nof mutation data in the curated set of non-redundant studies(http://www.cbioportal.org/ ) (Cerami et al, 2012 ;d eB r u i j ne ta l ,\n2023 ; Gao et al, 2013 )s h o w st h a t RNPC3 is rarely mutated in\ncancer",
      "Oncogene 33:2717 \u20132727\nde Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa\nA, Zhao G, Lai B et al (2023) Analysis and visualization of longitudinalgenomic and clinical data from the AACR Project GENIE Biopharma\nCollaborative in cBioPortal",
      "J Clin Invest 102:184 \u2013193\nGao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen\nA, Sinha R, Larsson E et al (2013) Integrative analysis of complex cancer\ngenomics and clinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:54.058001",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40624356.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40598036": {
    "paper_id": "40598036",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal for Cancer Genomics is an open-access, \nopen-source resource for interactive exploration of mul -\ntidimensional cancer genomics datasets",
      "The in-silico \nevaluation of the frequency of RNA fusion mutations in \nCRC patients was performed using the Colorectal Cancer \n(MSK, JNC 2021) dataset, which is one of the CRC stud -\nies available in the cBioportal public database",
      "To evalu -\nate the incidence of ROS1  fusion and MAP2K1  mutation \nin CRCs, cBioportal data were searched",
      "We investigated ROS1  and RET  fusions and MAP2K1  \nmutations concerning mutation rates in the CRC (MSK, JNC 2021) study from the cBioPortal for cancer genom -\nics database",
      "According to the cBioPortal, \nROS1  and RET  fusion were present in only one case each \n(0.06%) in CRCs [ 23\u201326]",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:54.806902",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40598036.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "40613212": {
    "paper_id": "40613212",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To investigate \nstructural alterations in small GTPase genes in patients with glioma, a comprehensive analysis was performed utilizing data from Glioma (MSK, Clin Cancer Res 2019) and Merged Cohort of LGG and GBM (TCGA, Cell 2016) in cBioPortal (https://www.cbioportal.org) (33)",
      "Glioma (MSK, Clin Cancer Res 2019) and Merged Cohort of LGG and GBM (TCGA, Cell 2016) in cBioPortal (https://www.cbioportal.org) were selected for analysis, including mutations, structural alterations and putative copy\u2011number alterations from GISTIC of relevant genes",
      "de Bruijn I, Kundra  R, Mastrogiacomo B, Tran TN, Sikina  L, \nMazor T, Li X, Ochoa A, Zhao G, Lai B, et al : Analysis and \nvisualization of longitudinal genomic and clinical data from the AACR Project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:55.346725",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40613212.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40615396": {
    "paper_id": "40615396",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Using the TCGA online portal ( https://www.cbioportal.org/ ), we per-\nformed an NSUN6 -centered analysis",
      "eStatistical analysis of\ntranswell migration assays in d.fAnalysis of mRNA expression levels of NSUN6-\ntargeted genes in patients, comparing those with low ( \ufb01rst quartile, n= 36) and\nhigh (fourth quartile, n= 37) NSUN6 expression, was conducted using the TCGA\nonline portal ( https://www.cbioportal.org/ )",
      "et al. Analysis and Visualization of Longitudinal Genomic\nand Clinical Data from the AACR Project GENIE Biopharma Colla-borative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:57.579639",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40615396.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40587607": {
    "paper_id": "40587607",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:13:58.915888",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40587607.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "40628262": {
    "paper_id": "40628262",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:01.739682",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40628262.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "40572720": {
    "paper_id": "40572720",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Addition-\nally, the in silico evaluation of the frequency of ROS1 andRET RNA fusion mutations in\npatients with CRC was conducted by using the Colorectal Cancer (MSK, JNC 2021) dataset\nfrom the cBioPortal for Cancer Genomics public database [ 22\u201325] This was undertaken due\nto the unavailability of literature on the subject",
      "We investigated the ROS1 and RET fusions concerning mutation rates in the CRC\n(MSK, JNC 2021) study from the cBioPortal for cancer genomics database",
      "According to the\ncBioPortal database, ROS1 andRET fusion were present in only one case each (0.06%) in\nCRCs [ 22\u201325]",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:03.386672",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40572720.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40594069": {
    "paper_id": "40594069",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods\nThe genetic landscape of TCGA pan-cancer datasets\nTo have an overview of the expression of the ASCC family, structural variant, mutation, and copy number \nalteration (CNA) data were analyzed and therefore summarized in a bar chart by the corporeal for Cancer \nGenomics platform ( https://www.cbioportal.org/ )47\u201349",
      "All the pan-cancer datasets available on the \ncBioportal platform were selected for the analysis of ASCC1/2/3",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:04.657919",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40594069.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40591997": {
    "paper_id": "40591997",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "CX43 promotes a phenotypically stable E/M state in glioblastoma by \nmodulating key EMT/MET regulators\nCorrelation plots were generated using the Glioblastoma Multiforme \n(TCGA, GDC) dataset in cBioPortal [48\u201350] to understand the modula -\ntory role of Cx43 in regulating key EMT/MET factors",
      "Sumer, et al., \nIntegrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal, Sci",
      "Mazor, et al., \nAnalysis and visualization of longitudinal genomic and clinical data from the AACR \nproject GENIE biopharma collaborative in cBioPortal, Cancer Res"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:04.816007",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40591997.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40554389": {
    "paper_id": "40554389",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A query of the cBioportal database \n(05.06.2024) [17] including 2,565 prostate cancers with copy number \nprofiling from 24 studies revealed 33 (1.24 %) tumors with \u201cdeep \u201d \n(largely corresponding to a homozygous deletion) MTAP deletion",
      "de Bruijn, et al., Analysis and Visualization of Longitudinal Genomic and Clinical \nData from the AACR Project GENIE Biopharma Collaborative in cBioPortal, Cancer \nRes"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:08.002139",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40554389.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40542203": {
    "paper_id": "40542203",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data availability\nGenomic pro \ufb01ling data is available using cBioPortal ( https://www",
      "cbioportal.org/ ) for AACR GENIE and Nacev et al. datasets and from the\nsource data for the Gounder et al. dataset ( https://www.nature.com/articles/\ns41467-022-30496-0#data-availability )",
      "Transcriptomic data is available using cBioPortal\nfor Pleasance et al., Rotika et al., the TCGA, and the Cancer Cell Line\nEncyclopedia datasets",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project GENIE biopharma\ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:09.362179",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40542203.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40554764": {
    "paper_id": "40554764",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis and visualization of\nlongitudinal genomic and clinical data from the AACR Project GENIE BiopharmaCollaborative in cBioPortal",
      "Integrative analysis of\ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:14.662779",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40554764.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40535802": {
    "paper_id": "40535802",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "For a comprehensive \nunderstanding of mutations in DBF4B across \npan-cancer, we acquired data on DBF4B genetic \nalterations from the cBioPortal database (www",
      "cbioportal.org/)  [26]",
      "Genetic alteration of DBF4B in pan-cancer  \nWe retrieved data on DBF4B genetic alterations \nin pan -cancer from the cBioPortal database",
      "Genetic alterations of DBF4B in pan -cancer using the cBioPortal",
      "(A) DBF4B gene mutation type analysis in various cancers by cBioPortal",
      "Leveraging TCGA, GTEx, UALCAN, cBioportal, UCSC, and other databases, we investigated the \nmolecular features of DBF4B across 33 tumors",
      "https://www.jcancer.org/v16p2626s1.pdf  \nAcknowledgements  \nThe authors are grateful to the contribution of \nTIMER2.0, HPA, TISIDB, UCSC, cBioPortal, Cancer \nSEA, UALCA, MethSurv, GSCALite, STRING, Gene MANIA, GTEx and TCGA databases for sharing the pan cancer dataset as open access",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and Visualization of Longitudinal Genomic and Clinical Data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:15.083382",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40535802.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "40552140": {
    "paper_id": "40552140",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "For strati \ufb01-\ncation based on TP53 mutation status, data were obtained from the\nOregon Health & Science University (OHSU) AML cohort\n57, avail-\nable through cBioPortal53-55https://www.cbioportal.org/ .SLFN11\nexpression in different cytogenetic groups was obtained from the\nTCGA AML data set available through BloodSpot56https://servers",
      "Data were extracted from the OSHU\nAML cohort using the cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative ana lysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE\nbiopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:15.379638",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40552140.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40681687": {
    "paper_id": "40681687",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "bMutation pro \ufb01le and frequencies of\nSPRS model genes in LUAD from the cBioPortal database",
      "For comprehensive ana-lysis, RNA sequencing data, mutation data, and copy number alteration(CNA) data for TCGA-LUAD patients were retrieved from the cBioPortaldatabase ( http://www.cbioportal.org/ )\n70, which enabled us to construct a\ndetailed mutational landscap eo fS P R Sm o d e lg e n e si nL U A D",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project genie biopharmacollaborative in CBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:15.653603",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40681687.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40526350": {
    "paper_id": "40526350",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In contrast to cBioPortal \n[22, 23], which is mainly used to explore patient-unspecific \ngenomic profiles, the KC tailors its genomic information to \nthe given patient-specific molecular data [20]",
      "Unlike cBioPortal, an open-source \nplatform primarily focused on exploratory visualization and \nlarge-scale cancer genomics datasets, the KC operates at the \nindividual patient level, streamlining the identification of \ntailored treatment options",
      "Future cooperation or collaboration between the KC \nand cBioPortal seems beneficial to use the synergies and \nfull potential of both platforms as cBioPortal provides high-\nquality access to molecular profiles and clinical attributes \nfrom large-scale cancer genomics projects",
      "Bruijn I De, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, \nMazor T, et\u00a0al. Analysis and visualization of longitudinal genomic \nand clinical data from the AACR project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:17.084772",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40526350.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40537809": {
    "paper_id": "40537809",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data from \ntissue samples of 1,516 CRC patients, including genomic \nvariations from a targeted sequencing panel such as \nsomatic mutations, copy number alterations, rearrange -\nments, and fusions, indicate that 74% of CRCs carry TP53 mutations (cBioPortal, https:// www",
      "Figure 2 is extracted from cBioPortal (https:// www",
      "2 is extracted from cBioPortal (https:// www",
      "Analysis \nand visualization of longitudinal genomic and clinical data from the \nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:19.079035",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40537809.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40593803": {
    "paper_id": "40593803",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "hKaplan \u2013Meier survival curve of TCGA cancer patients\nwith or without FOXK1 ampli \ufb01cation (based on GISTIC score) with separate analysis\nfor male (number of patients without ampli \ufb01catio n= 3043, and with ampli \ufb01ca-\ntion= 49) and female patients (number of patients without ampli \ufb01catio n=2 5 0 0 ,\nand with ampli \ufb01catio n= 67) (data sourced from cBioportal)",
      "For survival curve, we generated\ngraph using custom made R script with survminer (v3.5.8) and survival\n(v0.5.0) library using survival data from cbioportal\n93\u201395.C h r o m o s o m a l\nFOXK1 ampli \ufb01cation compared to normal FOXK1 curve were gener-\nated using data from the ICGC/TCGA Pan-Cancer Analysis of WholeGenomes Consortium\n96",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR p roject GENIE biopharma colla-\nborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:21.350257",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40593803.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40522583": {
    "paper_id": "40522583",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To com -\nplement our analysis, the cBioportal database ( http://www.cbioportal.org/ ) was engaged \nto dissect DCAF5 \u2019s copy number variations and genetic mutations across various cancer \ntypes [ 40]",
      "Subsequently, we utilized the cBioPortal database to investigate genomic alterations \nassociated with DCAF5",
      "org), PROTTER [ 47], String [ 48), TIMER ( 33), BioGPS ( 49), TISIDB ( 41), TIDE ( 39) and cBioportal database [ 50, 51]",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic \nand clinical data from the AACR project GENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and \nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:24.385078",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40522583.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40518465": {
    "paper_id": "40518465",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioportal HMGA2 RNAseq data\nTwo datasets on Kidney Renal Clear Cell Carcinoma \n(TCGA, PanCancer Atlas, 512 samples) and Kidney \nRenal Clear Cell Carcinoma (TCGA, PanCancer Atlas, \n328 samples) [61\u2013 70] were selected for survival analy -\nsis according to HMGA2 expression on the cBioportal website ( https://  www",
      "cBioportal survival analysis of\u00a0HMGA2 expression\nThe Kaplan plots of clear cell and papillary renal cell car -\ncinomas are shown in Supplementary Fig",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, \nMazor T, Li X, Ochoa A, Zhao G, Lai B, Abeshouse A, Baiceanu \nD, Ciftci E, Dogrusoz U, Dufilie A, Erkoc Z, Garcia Lara E, Fu Z, Gross B, Haynes C, Heath A, Higgins D, Jagannathan P, Kalletla \nK, Kumari P, Lindsay J, Lisman A, Leenknegt B, Lukasse P, Mad-\nela D, Madupuri R, van Nierop P, Plantalech O, Quach J, Resnick \nAC, Rodenburg SYA, Satravada BA, Schaeffer F, Sheridan R, \nSingh J, Sirohi R, Sumer SO, van Hagen S, Wang A, Wilson M, \nZhang H, Zhu K, Rusk N, Brown S, Lavery JA, Panageas KS, \nRudolph JE, LeNoue-Newton ML, Warner JL, Guo X, Hunter-\nZinck H, Yu TV, Pilai S, Nichols C, Gardos SM, Philip J, Aacr \nProject Genie Bpc Core Team APGC, Kehl KL, Riely GJ, Schrag \nD, Lee J, Fiandalo MV, Sweeney SM, Pugh TJ, Sander C, Cerami \nE, Gao J, Schultz N (2023) Analysis and visualization of longitu-\ndinal genomic and clinical data from the AACR project GENIE \nbiopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, \nSun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, \nSchultz N (2013) Integrative analysis of complex cancer genomics \nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:27.182150",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40518465.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40496560": {
    "paper_id": "40496560",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "For ATC controls, data were obtained from the database of The\nCancer Genome Atlas Program (TGCA) as published on the\nwebsite ( https://www.cbioportal.org/study/summary?id=thyroid_\ngatci_2024 )(8\u201311) and selected by being at the bottom of the\ninsertion list in the database on February 25th,2025, in a ratio of one\nto one and matched by cases' age",
      "To perform a\nsurvival comparison, a control group of six patients was randomly\n(the latest insertion in the database) selected from the ATC-TGCA\npopulation (\"cBioPortal for Cancer Genomics,\" n.d.) and matched\nby age",
      "A group of 21 controls was\nobtained as before and age- and stage-matched with cases for OS\ncomparison (\"cBioPortal for Cancer Genomics,\" n.d.)",
      "doi: 10.1136/bmjopen-2019-030215\n8.cBioPortal for cancer genomics [WWW document]",
      "Available online at: https://\nwww.cbioportal.org/ (Accessed 2.21.25)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACRproject GENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative\nanalysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:27.895294",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40496560.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "40506726": {
    "paper_id": "40506726",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:29.046896",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40506726.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "40512859": {
    "paper_id": "40512859",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To \ninvestigate the expression levels of PLAC8 , NF- \u03baB, and BCL- xL in \npatients with prostate cancer, we retrieved data from TCGA Pro-\ngram datasets using cBioPortal (56) and extracted gene expression \nvalues from OncoDB (57)",
      "Schultz, Analysis and visualization of longitudinal genomic \nand clinical data from the AA cR project Genie biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:31.913093",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40512859.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40501689": {
    "paper_id": "40501689",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "121 \ncBioPortal data 122 105 and is also made available for use under a CC0 license",
      "; https://doi.org/10.1101/2025.06.03.657674doi: bioRxiv preprint \n\n7 \n \nDatasets from TCGA (Cell 2015), METABRIC (Nature 2012 and Nature Communications 2016) 123 \nand MSKCC (Cell 2018) were searched for EGFR amplification, as well as mutations in 124 \nPIK3CA, PIK3R1, PIK3R2, PIK3R3, PTEN, AKT1, AKT2, AKT3, RPS6KB1, RPS6KB2 and 125 \nRPS6 in cBioPortal (cbioportal.org) (41-43)",
      "; https://doi.org/10.1101/2025.06.03.657674doi: bioRxiv preprint \n\n11 \n \nResults 206 \nIncidence of EGFR amplification in breast cancer 207 \nEGFR amplification was observed in 1.2-2.4% of cases in the TCGA, METABRIC and 208 \nMSKCC databases in cBioPortal (41-43), depending on the dataset (Table 1)",
      "257 \n PI3K pathway mutations in EGFR amplified breast cancer 258 \nConsidering the co-incidence of mutations in PI3K signaling in these EGFR amplified 259 \ncell lines, using cBioPortal we investigated the incidence in patients",
      "The Caris dataset does not include 270 \nalterations in the genes downstream of mTOR, contributing to the difference comparing the sums 271 \nof Caris and the cBioPortal data",
      "SL analyzed cBioPortal datasets, helped with project conceptualization, data analysis 491 \nand interpretation, and manuscript editing",
      "501 \nData Availability Statement: The MSKCC, TCGA and METABRIC datasets analyzed in this 502 \nstudy are available on cBioPortal.org (41-43)",
      "798 \nFigure S2 Legend:  Patient data from cbioportal.org plotting varying mutations or amplifications 799 \nby gene in the PI3K pathway"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:31.966132",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40501689.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "40463905": {
    "paper_id": "40463905",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods: We identi \ufb01ed the ARID1A mutation as a potential prognostic marker in\nEGFR-mutant LUAD by analysing data from cBioPortal",
      "2 Materials and methods\n2.1 Bioinformatics analysis\nThe genomic data of 12862 LUAD patients from four large studies\n(MSK-CHORD, MSK-IMPACT Clinical Sequencing Cohort, ChinaPancancer, and MSK MetTropism) were extracted from cBioPortal(https://www.cbioportal.org/ )(de Bruijn et al., 2023 ), which were used\nto analyse the frequencies of EGFR and SWI/SNF family membermutations in LUAD",
      "Analysis and visualization of longitudinal genomic and clinical data from the\nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:36.042195",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40463905.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40517236": {
    "paper_id": "40517236",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A Lollipop plot of p53 mutations generated with cBioPortal \n(MSK-CHORD) [267\u2013270]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genom-\nics and clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudi-\nnal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:37.255917",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40517236.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40442732": {
    "paper_id": "40442732",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal retrieved information about genetic variants in HECW1 gene",
      "Table 1  Univariate and multivariate Cox regression analyses of the overall survival of GC\nCharacteristics Total( N) Univariate analysis Multivariate analysis\nHazard ratio (95% CI) P value Hazard ratio (95% CI) P value\nPathologic T stage 362\nT1&T2 96 Reference Reference\nT3 167 1.713 (1.103 - 2.660) 0.016 1.495 (0.817 - 2.736) 0.192\nT4 99 1.729 (1.061 - 2.819) 0.028 1.206 (0.584 - 2.488) 0.613\nPathologic N stage 352\nN0 107 Reference Reference\nN1 97 1.629 (1.001 - 2.649) 0.049 0.947 (0.483 - 1.856) 0.874\nN2 74 1.655 (0.979 - 2.797) 0.060 1.033 (0.519 - 2.055) 0.926\nN3 74 2.709 (1.669 - 4.396) < 0.001 1.746 (0.905 - 3.366) 0.096\nGender 370\nFemale 133 Reference\nMale 237 1.267 (0.891 - 1.804) 0.188\nRace 320\nAsian 73 Reference\nBlack or African American 11 1.949 (0.808 - 4.698) 0.137\nWhite 236 1.449 (0.873 - 2.405) 0.152\nAge 367\n<= 65 163 Reference Reference\n> 65 204 1.620 (1.154 - 2.276) 0.005 1.701 (1.068 - 2.710) 0.025\nHistologic grade 361\nG1 10 Reference\nG2 134 1.648 (0.400 - 6.787) 0.489\nG3 217 2.174 (0.535 - 8.832) 0.278\nReflux history 213\nNo 174 Reference Reference\nYes 39 0.582 (0.291 - 1.162) 0.125 0.602 (0.268 - 1.350) 0.218\nH pylori infection 162\nNo 144 Reference\nYes 18 0.650 (0.279 - 1.513) 0.317\nBarretts esophagus 207\nNo 192 Reference\nYes 15 0.892 (0.326 - 2.441) 0.824\nPathologic M stage 352\nM0 327 Reference Reference\nM1 25 2.254 (1.295 - 3.924) 0.004 2.040 (0.823 - 5.059) 0.124\nHECW1 370\nLow 185 Reference Reference\nHigh 185 1.489 (1.068 - 2.076) 0.019 1.649 (1.045 - 2.603) 0.032\n\nPage 6 of 16\nYang et al. World Journal of Surgical Oncology           (2025) 23:204 \nHECW1 gene alterations in GC\nComprehensive genomic profiling of HECW1 alterations \nwas performed through cBioPortal analysis platform \nusing 32 cancer cohorts from The Cancer Genome Atlas \n(TCGA) Pan-Cancer Atlas ( n = 10,967 tumor samples)",
      "Supplementary Material 1\nAcknowledgements\nWe are grateful for the open access to the following databases: the Tumor \nImmunoassay Resource (TIMER2.0) system, the Gene Expression Profiling \nInteraction Analysis (GEPIA2), the Kaplan-Meier-plotter, the cBioPortal, and \nthe STRING database",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa \nA, Zhao G, Lai B, et al. Analysis and visualization of longitudinal genomic \nand clinical data from the AACR project GENIE biopharma collaborative in \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:44.256999",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40442732.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40459297": {
    "paper_id": "40459297",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Materials and Methods: Pan-  cancer bioinformatics analysis (TCGA, GEPIA2, cBioPortal) assessed GABRP expression, sur -\nvival associations, and immune infiltration across 33 cancers",
      "2.5   |   cBioPortal Analysis\ncBioPortal [ 18] (https://  www",
      "We employed cBioPortal to analyze the mutation \nfrequency of GABRP in gliomas and visualize the details of \nGABRP mutations",
      "3.6   |   Mutation Analysis of GABRP in Pan-  Cancer\nUsing the cBioPortal database, we studied the mutation status of \nGABRP",
      "cBioPortal (18) ( https:/ /  www",
      "Mastrogiacomo, et\u00a0al., \u201cAnalysis and Vi -\nsualization of Longitudinal Genomic and Clinical Data From the AACR \nProject GENIE Biopharma Collaborative in cBioPortal,\u201d Cancer Re -\nsearch  83, no"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:45.451824",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40459297.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "40447619": {
    "paper_id": "40447619",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal \nhttps://www.cbioportal.org/ ; 11",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:48.429283",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40447619.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40460119": {
    "paper_id": "40460119",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(I) Oncoprint (generated by cBioPortal) showing homozygous deletions, shallow deletions, \nand mutations of BRCA2, CDT1, CDC6, and DBF4",
      "de Bruijn et al., Analysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE Biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:49.276708",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40460119.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40490560": {
    "paper_id": "40490560",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Source data are available online for this \ufb01gure.Mericka McCabe et al EMBO Molecular Medicine\n\u00a9 The Author(s) EMBO Molecular Medicine Volume 17 | July 2025 | 1716 \u20131755 1731\n\nReagent/resource Reference or source Identi \ufb01er or catalog number\nGoat anti-mouse\nAlexa Fluor 555Thermo Fisher\nScienti \ufb01cCat# A32727\nGoat anti-Rabbit\nAlexa Fluor 488Thermo Fisher\nScienti \ufb01cCat# A-11008\nAnti-rabbit IgG,\nHRP-linkedAntibody #7074Cell Signaling Cat# 7074\nOligonucleotides and other sequence-based reagents\nList of qPCR\nprimersThis study Appendix Table S3\nAHT mutant\nforward primerFisher Scienti \ufb01c\nCustom DNAOligonucleotides5\u2019-\nggtgcgcaaagggggccaggaaacct-3\u2019\nAHT mutant\nreverse primerFisher Scienti \ufb01c\nCustom DNA\nOligonucleotides5\u2019-ttctcaatgagctccccc-3 \u2019\nRAR\u03b1siRNA Origene Cat# SR303989A\nNCoR1 siRNA Origene Cat# SR423484A\nLAMP2A sgRNA\nforward primerFisher Scienti \ufb01c\nCustom DNA\nOligonucleotides5\u2019-caccgcaacttccttgtgcccatag-\n3\u2019\nLAMP2A sgRNA\nreverse primerFisher Scienti \ufb01c\nCustom DNAOligonucleotides5\u2019-\naaacctatgggcacaaggaagttgc-3 \u2019\nChemicals, enzymes and other reagents\nFITC-NCoR1 GenScript FITC-Ahx-\nRLITLADHICQIITQDFAR\nFITC-SRC GenScript FITC-Ahx-RHKILHRLLQEGSRecombinant RAR \u03b1\nLBDThis study N/A\nChemDiv screening\ncompoundsThis study Appendix Table S2\nBiotin-CIM7 This study N/A\nAll-trans retinoic\nacidSigma-Aldrich Cat# R2625\nAM580 Millipore Sigma Cat# A8843\nAmmonium\nchlorideSigma-Aldrich Cat# A9434\nLeupeptin Thermo Fisher Cat# BP2662\nHoechst Life Technologies Cat# 33342Paraformaldehyde\nsolution 4% in PBSSanta Cruz Cat# sc-281692\nDimethyl sulfoxide\n(DMSO)Sigma-Aldrich Cat# D2650\nEthanol Supelco Cat# EX0276\nPolyethylene glycol\n400 (PEG-400)\nNextal Biotechnologies Cat# 133086\nTween-80 Sigma-Aldrich Cat# P1754\nRPMI 1640 Thermo Fisher Cat# 11875119DMEM high\nglucoseSigma Cat# D5648\nDMEM/F-12 Thermo Fisher Cat# 11320033\nFetal Bovine Serum\n(FBS)Fisher Cat# 35010CVReagent/resource Reference or source Identi \ufb01er or catalog number\nNeonatal Calf\nSerum (NCS)Hyclone Cat# SH30401\nAntibiotic-\nAntimycoticGibco Cat# 15240096\nMyco-sniff\nTM\nmycoplasma PCR\ndetection kitMP Biomedical Cat# 093050201\nLipofectamine \u2122\n2000Invitrogen Cat# 11668027\nRneasy\u00aePlus Mini\nKitQiagen Cat# 74134\nQuantiTect\nReverse\nTranscription KitQiagen Cat# 205314\nCellTiter-Glo\u00ae\nLuminescent Cell\nViability AssayPromega Cat# G7570\nPureLink \u2122HiPure\nPlasmid MidiprepKitInvitrogen Cat# K210004\nQ5\n\u00aeSite-Directed\nMutagenesis KitNew England Biolabs\u00aeCat# E0554S\nImmPRESS \u00aeHRP\nHorse Anti-GoatPolymer Detection\nKit, PeroxidaseVector Laboratories Cat# MP-7405\nImmPRESS \u00aeHRP\nGoat Anti-Rat IgG,\nMouse adsorbedPolymer DetectionKit, PeroxidaseVector Laboratories Cat# MP-7444\nImmPRESS \u00aeHRP\nGoat Anti-RabbitIgG Polymer\nDetection Kit,\nPeroxidaseVector Laboratories Cat# MP-7451\nImmPRESS \u00aeHRP\nGoat Anti-MouseIgG PolymerDetection Kit,PeroxidaseVector Laboratories Cat# MP-7452\nDuolink In Situ PLA\nProbe Anti-RabbitSigma-Aldrich Cat# DUO92002\nDuolink In Situ PLA\nProbe Anti-MouseSigma-Aldrich Cat# DUO92004\nDeadEnd \u2122\nColorimetric\nTUNEL SystemPromega Cat# G7130\nWestern\nLightning\nTMPlus\nECLRevvity Cat# NEL103001\nSuperSignal \u2122\nWest FemtoMaximumSensitivitySubstrateThermo Fisher Cat# 34095\nSafetyScreen44\nPanel \u2013FREuro\ufb01ns Cat#PP241EMBO Molecular Medicine Mericka McCabe et al\n1732 EMBO Molecular Medicine Volume 17 | July 2025 | 1716 \u20131755 \u00a9 The Author(s)\n\nReagent/resource Reference or source Identi \ufb01er or catalog number\nProtein binding\n(plasma, mouse,CD-1) \u2013USEuro\ufb01ns Cat#2223\nSoftware\nImageJ v1.53r https://imagej.net/\nSchneider et al, 2012\n(Nature Methods)\nGraphPad Prism v9 https://\nwww.graphpad.com/\nGenevestigator \u00ae https://\ngenevestigator.com/\nSchr\u00f6dinger\nSoftware Suite\nReleases 2017-\n2023https://\nwww.schrodinger.com/\nmaestro\nPyMOL http://\nwww.pymol.org/\nMicrosoft Excel\n365 Version 2305www.microsoft.com\nColumbus Image\nData Storage andAnalysiswww.perkinelmer.com\nQuPath https://\nqupath.github.io/Bankhead et al, 2017\n(Scienti \ufb01c Reports)\nMicroCal PEAQ-\nITC analysis\nsoftwareMalvern Panalytical\nGeneSys Syngene\nImage Studio 6.0 LI-CORLeica Application\nSuite XLeica Microsystems\nBiorender https://\nwww.biorender.com/\nProteome\nDiscoverer v2.5ThermoFisher\ncBioPortal https://\nwww.cbioportal.org/\nOtherAxiolab 5\n\ufb02uorescent\nmicroscopeZeiss\nAxiovert 200\n\ufb02uorescence\nmicroscopeZeiss\nG-BOX Chemi XX6 SynGene\nOdyssey Fc Imager LI-CORQuantStudio\nTM5\nReal-Time 384-\nwell PCR systemApplied BiosystemsTM\nOperetta High\nContent ImagineSystemPerkin Elmer\nIn\ufb01nite F200 PRO Tecan\nMicroCal PEAQ-\nITCMalvern PanalyticalReagent/resource Reference or source Identi \ufb01er or catalog number\nSpark Tecan\nCytation 5 Cell\nImagingMultimode ReaderBioTek\nGenesis \u2122 Oxford Science\nHuman lung tumor\nand nontumormicroarraySanchez-Palencia et al,\n2011 (International\nJournal of Cancer)\nCell culture and knockdowns\nAll cell lines were obtained from the American Type Culture\nCollection (ATCC) and validated by Short Tandem Repeat (STR)\npro\ufb01ling",
      "RNA expression ofMericka McCabe et al EMBO Molecular Medicine\n\u00a9 The Author(s) EMBO Molecular Medicine Volume 17 | July 2025 | 1716 \u20131755 1733\n\nCMA network genes and oncogene mu tation status of cancers from\nthe TCGA PanCancer Atlas were acquired from CBioPortal\n(Cerami et al, 2012 ;d eB r u i j ne ta l , 2023 ; Gao et al, 2013 ;L i u\net al, 2018 )",
      "Int J Mol Sci 18:1279\nde Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa\nA, Zhao G, Lai B et al (2023) Analysis and visualization of longitudinal\ngenomic and clinical data from the AACR Project GENIE Biopharma\nCollaborative in cBioPortal",
      "J Med Chem 49:6177 \u20136196\nGao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen\nA, Sinha R, Larsson E et al (2013) Integrative analysis of complex cancergenomics and clinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:50.689163",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40490560.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40475606": {
    "paper_id": "40475606",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Furthermore, we queried 132  \nwhether PIWIL2 allelic loss correlates with  patient  survival using the cBioportal copy  number alteration 133  \n(CNA ) tool; indeed,  allelic loss of PIWIL2 correlates with  poorer patient survival compared to patients 134  \nwithout an allelic loss ( Fig",
      "The results from the SWAN  and cBioportal  analys es highlight the 135  \noverall loss of regulation of the entire  piRNA biogenesis  pathway in colon cancer and  identify  PIWIL2  136  \nas a top candidate for  the loss of  the pathway \u2019s regulation",
      "398  \n 399  \ncBioportal:  cBioportal is another  open -source web-based  tool to visualize  multidimensional cancer 400  \ngenomics data sets , including data from TCGA Pan Cancer  Atlas   (Cerami et al., 2012, Gao et al., 2013, 401  \nde Bruijn et al., 2023)",
      "This tool can be found at the following webpage: https://www.cbioportal.org",
      "691  \nAnalysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE 692  \nBiopharma Collaborative in cBioPortal",
      "Integrative analysis of complex cancer 719  \ngenomics and clinical pro\ufb01les using the cBioPortal",
      "D) The cBioportal  972  \ndatabase  was used to interrogate  TCGA COAD dataset for Overall survival of PIWIL2 allelic loss  973  \ncompared to  unaltered tumors"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:51.767302",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40475606.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "40440584": {
    "paper_id": "40440584",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Clinical data are obtained from cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al: Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Bio pharma Collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al: Integrative analysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal",
      "cBioPortal",
      "https://www.cbioportal.org/\n25"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:52.439884",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40440584.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40430098": {
    "paper_id": "40430098",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "This is an open access resource http://cbioportal.org accessed on 2 April\n2025) that allows for exploration of multidimensional cancer genomics datasets",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:53.137369",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40430098.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40400994": {
    "paper_id": "40400994",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We mined \nGenomic data from the SU2C-PCF Dream Team \ndataset on cBioPortal and found PPM1D altera -\ntions in 29/429 (7%) of metastatic castration-\nresistant prostate cancer patient samples [21-\n23]",
      "Genomic data from the SU2C-PCF Dream \nTeam dataset on cBioPortal found PPM1D altera -\ntions in 29/429 (7%) of metastatic castration-resis -\ntant prostate cancer patient samples",
      "Anal -\nysis and visualization of longitudinal genomic \nand clinical data from the AACR project GENIE \nbiopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:54.969506",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40400994.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40395657": {
    "paper_id": "40395657",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. \nIntegrative analysis of complex cancer genomics and clinical pro-\nfiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor \nT, et al. Analysis and visualization of longitudinal genomic and clin-\nical data from the AACR Project GENIE Biopharma Collaborative \nin cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:14:58.013968",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40395657.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40385985": {
    "paper_id": "40385985",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Another valuable platform is cBioPortal, which facilitates the\nvisualization of TCGA studies and additional cancer genomic data\n(Cerami et al., 2012 ;de Bruijn et al., 2023 )",
      "Moving forward, further integration of our pipelineinto platforms like cBioPortal could provide greater utility bystreamlining data accessibility a nd visualization",
      "Analysis and visualization of longitudinal genomic and clinical data from the\nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:00.023767",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40385985.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40404897": {
    "paper_id": "40404897",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gene alteration analysis\ncBioPortal ( https://www.cbioportal.org/ ) was used to identify modi \ufb01cations\nof the HDAC6 gene across cancers, and speci \ufb01cally in LUAD, based onTable 2 | Clinical characteristics of patients with LUAD from\nmultiple cohorts\nCharacteristics TCGA GSE68465 GSE50081\nN=492 (%) N=439 (%) N=128 (%)\nAge\nMedian 66 65 70.15Range 33-88 33-87 40.16-85.91\nGender\nFemale 264 (53.66) 218 (49.66) 63 (49.22)Male 228 (46.34) 221 (50.34) 65 (50.78)\nSmoking history\nYes 407 (82.72) 299 (68.11) 92 (71.88)NO 71 (14.43) 48 (10.93) 23 (17.97)NA 14 (2.85) 92 (20.96) 13 (10.15)\nTNM Stage\nI 266 (54.07) 275 (62.64) 92 (71.88)II 120 (24.39) 96 (21.87) 36 (28.12)III 80 (12.26) 68 (15.49) /IV 26 (5.28) / /\nOS Status\nDead 179 (36.38) 234 (53.30) 52 (40.63)Live 313 (63.62) 205 (46.70) 76 (59.37)\nNAnot available, OSoverall survival.https://doi.org/10.1038/s41698-025-00949-y Article\nnpj Precision Oncology |           (2025) 9:150 17\n\nTCGA data",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project GENIE biopharmacollaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:00.083883",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40404897.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40410408": {
    "paper_id": "40410408",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cbioportal.org/study/clini calData?id=brca_tcga_pub2015",
      "The publicly\navailable prostate cancer reports and clinical data can be found at https://\nwww.cbioportal.org/study/summary?id=prad_tcga_pub .T h eo p t i c a lc h a r -\nacter recognition processed reports are available at https://data.mendeley",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project GENIE BiopharmaCollaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:00.187718",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40410408.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40389618": {
    "paper_id": "40389618",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "GBM subtype data was obta ined from the cBioPortal database\n[16\u201318]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative\nanalysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis\nand Visualization of Longitudinal Genomic and Clinical Data from the AACR\nProject GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:00.673997",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40389618.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40391157": {
    "paper_id": "40391157",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Furthermore, analysis of 258 TNBC\ntumor samples from the cBioPortal ( 32\u201337) revealed no correlation\n(Spearman \u2019s rank correlation coef \ufb01cient = 0.13, p-value = 0.04;Crossman et al. 10.3389/fonc.2025.1579214\nFrontiers in Oncology frontiersin.org 10\n\nFIGURE 4\nTumors overexpressing MerTK are sensitive to immune checkpoint inhibition",
      "Data was obtained from the cBioportal (n=258 TNBC patients).(E)Correlation analysis of tumor-bound MerTK and stromal PD-L1 staining by mIF (n=101 TNBC patients)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR\nproject GENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative\nanalysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:02.229353",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40391157.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40405280": {
    "paper_id": "40405280",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "At 24 h intervals, monocytes were \ncounted, using the Countess automatic cell counter \n(ThermoFisher Scientific, C10281), and viability was \nmeasured using Trypan blue staining.Immune cell infiltration\nData analysis of immune cell infiltration into tumours \nin clinical samples was performed using publicly avail -\nable TCGA (The Cancer Genome Atlas) datasets [34\u2013\n36], which were accessed through cBioPortal [37\u201339]",
      "LMTK3 expression levels from RNA sequencing data \nwere taken from cBioPortal and separated into four quar -\ntiles based on levels of LMTK3 and the first (Q1) and last \n(Q4) quartiles were compared to assess immune cell infil -\ntration in tumours",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Inte -\ngrative analysis of complex cancer genomics and clinical profiles using \nthe cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and Visualization of Longitudinal Genomic and Clinical Data \nfrom the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:02.649669",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40405280.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40361362": {
    "paper_id": "40361362",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gene Expression Profiling\nThe cBioPortal was utilized as previously described to acquire full gene expression\nanalyses [ 25,26]",
      "Group differences in genomic alteration\nfrequencies, disease staging, MSI MANTIS scores, tumor mutation burden, median diag-\nnosis age, sex/race distribution, and relative expression of immunologically interesting\nmarkers were analyzed via cbioportal.org [ 25,26,31]",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the CBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in CBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:09.651556",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40361362.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40361444": {
    "paper_id": "40361444",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods : We used the\nskin cutaneous melanoma (SKCM) database, ICI-pretreated melanoma dataset, and other\nplatforms including cBioPortal, TIMER 2.0, TISIDB, and UALCAN for the analysis",
      "The Co-Expression Study Between the HDAC4 Gene and the T-Cell Inflamed TME\nSignature Genes\nThe study was conducted using the Skin Cutaneous Melanoma (SKCM) (TCGA, Fire-\nhose Legacy) dataset in cBioPortal (https://www.cbioportal.org/; accessed on 11 Novem-\nber 2024) [ 52\u201354]",
      "The Co-expression tab in cBioPortal was utilized to\ninvestigate the correlation between the mRNA expression (RNA Seq V2 RSEM) of HDAC4\nand T-cell inflamed TME gene signatures in the patient dataset (n = 287)",
      "To study the co-expression between HDAC4 and T-cell inflamed TME gene signatures\nusing a heat map and hierarchical clustering, mRNA expression z-scores relative to all\nsamples (log RNA Seq V2 RSEM) of HDAC4 and T-cell inflamed TME gene signatures were\nretrieved from the SKCM (TCGA, Firehose Legacy) dataset in cBioPortal (n = 472) (https:\n//www.cbioportal.org/; accessed on 11 November 2024) [ 52\u201354]",
      "The Transcription Analysis and the DNA Methylation Analysis of T-Cell Inflamed TME\nSignature Genes with Regard to HDAC4 Expression\nTo investigate the effect of HDAC4 expression on the mRNA expression and the\nDNA methylation levels of the T-cell inflamed TME gene signatures, we used the SKCM\n(TCGA, Firehose Legacy) dataset in cBioPortal (https://www.cbioportal.org/; accessed on\n11 November 2024) [ 52\u201354]",
      "The data for the transcription analysis and DNA methylation analysis were downloaded\nfrom the mRNA tab and the DNA methylation tab in the Comparison/Survival module of\ncBioPortal, respectively",
      "Survival Prognosis Analysis\nWe used the SKCM (TCGA, Firehose Legacy) dataset in cBioPortal (https://www",
      "cbioportal.org/; accessed on 11 November 2024) [ 52\u201354]",
      "The overall survival (OS) and disease-free survival\n(DFS) data were downloaded using the Survival tab in the Comparison/Survival module\nof cBioPortal",
      "The Effect of HDAC4 Expression in ICI-Pretreated Melanoma Patients\nWe used the melanoma (MSK, NEJM 2014) dataset from the immunogenomic studies\nsection of cBioPortal (https://www.cbioportal.org/; accessed on 10 April 2025) [ 52\u201354]",
      "To investigate the impact of\nHDAC4 expression on TIL status, HDAC4 mRNA expression data were obtained for the\nhigh and low CBSET T-cell CD8 groups as well as for the high and low ESTIMATE immune\nscore groups from the mRNA tab in the Comparison/Survival module of cBioPortal",
      "The analysis was conducted utilizing the SKCM (TCGA, Firehose Legacy)\ndataset in cBioPortal (n = 287)",
      "The data were acquired from the\nSKCM (TCGA, Firehose Legacy) dataset in cBioPortal",
      "The data were acquired \nfrom the SKCM (TCGA, Firehose Legacy) da taset in cBioPortal",
      "The difference in patient\nnumbers between Figure 6 compared to Figures 4 and 5 was due to the lack of survival\ndata for certain patients in the cBioPortal database",
      "The di \ufb00erence in patient \nnumbers between Figure 6 compared to Figures 4 and 5 was due to the lack of survival \ndata for certain patients in the cBioPortal da tabase",
      "To further investigate how HDAC4 can influence the TME in a cohort\nof melanoma patients who were pretreated with ICIs, we utilized the melanoma (MSK,\nNEJM 2014) dataset from cBioPortal",
      "Cancers 2025 ,17, 1518 13 of 20\nCancers 2025 , 17, x FOR PEER REVIEW 14 of 22 \n \n NEJM 2014) dataset from cBioPortal",
      "The datasets analyzed during the study are available in the following\nrepositories (https://www.cbioportal.org/; accessed on 11 November 2024 and on 10 April 2025),\n(http://timer.cistrome.org/; accessed on 3 December 2024), (http://cis.hku.hk/TISIDB/; accessed\non 3 December 2024 and on 9 April 2025), and (https://ualcan.path.uab.edu/index.html; accessed on\n11 November 2024)",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "De Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:09.867505",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40361444.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 21,
    "total_data_pmids_cited": 0
  },
  "40384867": {
    "paper_id": "40384867",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.6 Clinic al data acquisition and bioinformatics \nanalysis  \nWe conducted a comprehensive retrospective \nanalysis via cBioPortal [40] to assess the prevalence of \nTP53 mutations  in PCa, analyzing data from 7,678 \npatients across 19 studies, with follow -up data for 671 \npatients",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and Visualization of Longitudinal Genomic and Clinical Data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:10.026572",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40384867.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40361150": {
    "paper_id": "40361150",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Inte -\ngrative analysis of complex cancer genomics and clinical profiles using \nthe cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and Visualization of longitudinal genomic and clinical data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:12.272982",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40361150.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40378956": {
    "paper_id": "40378956",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Public database analyses\nGene expression and survival data for TCGA BRCA patients\nwas downloaded using cBioPortal ( 76\u201378)",
      "The list of DEGs(p-adj<0.05) between the high versus lowPAFAH1B1 quar-\ntiles was also downloaded from cBioPortal and \ufb01ltered for\ngenes associated with proliferation, identi \ufb01ed by Venet et al. (35,79)",
      "O.,\net al. (2013) Integrative analysis of complex cancer genomics and clinical\npro\ufb01les using the cBioPortal",
      "N., Sikina, L.,\nMazor, T., et al. (2023) Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project GENIE biopharma collaborative\nin cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:13.807960",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40378956.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40342733": {
    "paper_id": "40342733",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy  BA, Dogrusoz  U, et al. Integrative  analysis  of complex  cancer  genomics  and clinical  profiles  using  the cBioPortal",
      "Analysis \nand visualization  of longitudinal  genomic  and clinical  data from  the AACR  Project  GENIE  Biopharma  Collaborative  in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:16.261015",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40342733.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40330450": {
    "paper_id": "40330450",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Key words: cBioPortal, NF-\u03ba B, oxida-\ntive stress-related genes, inflamma-\ntion, immunomodulation, esophageal cancer",
      "Merging five datasets\nThrough the cBioPortal platform [26\u201328], the five data-\nsets were harmonized to extract genomic alterations in six genes of interest: HMGB1, ROS1, IL6, FGFR1, FGFR2, and \nTLR4",
      "According to the cBioPortal user documentation \nand data-loading guidelines, once already-processed and \nnormalized data are submitted, cBioPortal optionally com-\nputes per-gene Z-scores (mean of zero, standard deviation \nof one) across samples for visualization and outlier detec-\ntion, relying on the data to be analysis-ready (for example, \ntranscripts per million, reads per kilobase of transcript per \nmillion mapped reads, or variance stabilizing transforma-tion in differential expression sequencing 2 for RNA-seq, \nor robust multi-array average/quantile normalization for \nmicroarrays)",
      "cBioPortal also requires the data to be in \na single scale (e.g., log\n2) and consistent across all samples, \nand if a \u201cnormal\u201d subset of samples is specified, it can cal-\nculate Z-scores relative to those normal samples",
      "Finally, \nusers must provide these normalized values in specific file formats, thereby ensuring that the data is uniform, prop-erly scaled, and suitable for cBioPortal\u2019s visualization and analysis tools",
      "Query in the cBioPortal and two other independent co-\nhorts: ESCCdb (Sichuan) and GSE45670\nData mining was performed using the cBioPortal plat-\nform (accessed November 2024) and the ESCCdb from Sichuan and GSE45670 [25], which enabled the retrieval of specific genomic alterations and expression data for analysis",
      "A notable limitation is that survival analyses were conducted using cBioPortal, which only supports univari-ate Kaplan-Meier analyses and does not allow multivariate \nCox regression to adjust for potential confounders such as \ncancer stage",
      "The author would like to thank the cBioPortal, the ES-\nCCdb/Sichuan platforms, and the GSE45670 investiga-\ntors for providing free access to all the data used in this \nstudy, which would not have been possible without their generous openness in granting access to these sophis-\nticated analytic tools and resources",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visu-alization of longitudinal genomic and clinical data from the AACR project GENIE Biopharma Collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:17.653922",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40330450.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 10,
    "total_data_pmids_cited": 0
  },
  "40348904": {
    "paper_id": "40348904",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis of next-generation sequencing data\nBefore the analysis, we selected 399 patients with PTC from the THCA(TCGA, Firehose Legacy) dataset available on cBioPortal\n41,42",
      "et al. Analysis and Visualization of Longitudinal Genomic\nand Clinical Data from the AACR Project GENIE BiopharmaCollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:19.158547",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40348904.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40360478": {
    "paper_id": "40360478",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "For the validation datasets, we obtained the mutation calls of the\npanel sequencing data and their well-curated clinical data from 25,040tumor samples from the MSK-CHORD cohort ( https://www.cbioportal",
      "cbioportal.org/ )7",
      "Additionally, we downloaded somatic SNVs of\nwhole-exome sequencing data from 379 BRCA samples from themetastatic breast cancer genomics project ( https://www.cbioportal",
      "We downloaded the somatic mutations of panel\nsequencing data for the MSK-CHORD study from cBioPortal [ https://\nwww.cbioportal.org/study/summary?id=msk_chord_2024 ] (available\nunder the Creative Commons BY-NC-ND 4.0 licence), panel sequencingdata for the GENIE study [ https://www.synapse.org/Synapse:\nsyn27056172 ] and somatic mutations of WES data for the metastatic\nbreast cancer genomics pr oject from cBioPortal [ https://www",
      "cbioportal.org/study/clinicalData?id=brca_mbcproject_2022 ], dbGaP\naccession phs001709 [ https://www.ncbi.nlm.nih.gov/projects/gap/cgi-\nbin/study.cgi?study_id=phs001709.v2.p2 ]",
      "et al. Analysis and vis ualization of longitudinal genomic\nand clinical data from the AACR p roject GENIE biopharma colla-\nborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:20.406428",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40360478.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "40322427": {
    "paper_id": "40322427",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Joint analysis of genomic information and clinical information\nThe cBioPortal platform \n[16]\n (\nhttps://www.cbioportal.org\n) was utilized to comprehensively analyze mutation\nfrequency details in head and neck tumors and expose associations between mutations and clinical\nparameters by integrating patient clinical data",
      "The association between specific mutations and the survival prognosis of the TCGA\npatients is further disclosed with the help of cBioPortal's survival curve plotting capabilities",
      "For high-frequency mutated genes, the mutation type information is sourced from the cBioPortal website",
      "Additionally, the categorization of patient groups and the comparison of differences in gene expression\nlevels between groups were accomplished by using the mRNA analysis function in the \"Comparison/Survival\"\nsection of cBioPortal",
      "We then conducted a group analysis of TMB on the cBioPortal platform",
      "Subsequently, we compared the differences in the TMB between these two subgroups using\nthe cBioPortal platform to investigate the correlation between HPV infection status and tumor genomic\ninstability",
      "DOI 10.7759/cureus.81629\n2\n of \n15\n\nEnrichment analysis\nUtilizing the grouping comparison function of the cBioPortal platform, we separated the patients into two\ngroups: those with a COL11A1 gene mutation and those without",
      "Subsequently, we categorized the patient population\naccording to the median estimated score of each individual and conducted a comparative analysis of gene\nmutation frequencies between these groups using the cBioPortal platform",
      "We obtained the TMB-level data for both\ngroups from the cBioPortal website",
      "(C) Data from JAMA Oncol 2016, available on cBioPortal,\nconfirm the variations in TMB at different T stages",
      "Comparable results have been noted in third-party databases (Figure \n1C\n, data derived from the JAMA\nOncology dataset published in cBioPortal in 2016)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al.: \nAnalysis and visualization of longitudinal genomic and\nclinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:22.023926",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40322427.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 12,
    "total_data_pmids_cited": 0
  },
  "40294153": {
    "paper_id": "40294153",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1158/2159-8290.CD-12-0095  PMID: 22588877\n 33",
      "https://doi.org/10.1126/scisignal.2004088  PMID: 23550210\n 34",
      "https://doi.org/10.1158/0008-5472.CAN-23-\n0816  PMID: 37668528\n 35"
    ],
    "cbioportal_platform_mentions": [
      "The \nphosphorylation sites were predicted by cBioPortal and PhosphoNet",
      "Furthermore, \nvariations of FUNDC2 in cancers were investigated by cBioPortal",
      "STRING analysis revealed that FUNDC2 can interact with FUNDC1, \net al. Fifteen phosphorylation sites were predicted by PhosphoNet and cBioPortal, \nof which the S167 also overlapped with the mutation sites of FUNDC2",
      "TIMER 2.0, GEPIA, STRING, cBioPortal, and PhosphoNet databases were \nemployed in this study to analyze the expression and prognostic role of FUNDC2 in \npan-cancer, and the relationship between FUNDC2  expression and the degree of \nimmune infiltration was examined [ 10\u201313]",
      "Furthermore, Data availability statement : All relevant data \ncan be obtained from the TIMER 2.0 database \n(http://cistrome.org/TIMER/ ), GEPIA ( http://\ngepia.cancer-pku.cn/ ), STRING database \n(https://string-db.org/ ), cBioportal database \n(http://www.cbioportal.org ), Phosphonet web -\nsite ( http://www.phosphonet.ca/default.aspx ), \nAlphaFold ( https://alphafold.ebi.ac.uk/ ), Uniprot \ndatabase ( https://www.uniprot.org/ )",
      "Variations of FUNDC2 in pan-cancer\nThe cBioportal database ( http://www.cbioportal.org ), which contains somatic mutations, Copy number variants (CNVs), \nand cancer genomics information from the TCGA and GEO databases was used in this study",
      "The single nucleotide muta -\ntions of FUNDC2  in the pan-cancer cohort and mutation types were investigated by using the cBioPortal [ 31\u201335]",
      "In order to conduct a \nthorough examination of the genetic modifications of FUNDC2, cBioportal was utilized to evaluate a total of 10,953 cancer \nFig 1",
      "Variations of FUNDC2 in pan-cancer were studied by using cBioPortal",
      "(A) Different mutations types and frequencies were summarized by \ncBioPortal ( https://www.cbioportal.org/ )",
      "(B) The hotspots and variations of FUNDC2 in \nvarious cancers were studied by cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using \nthe cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:22.977086",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40294153.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 13,
    "total_data_pmids_cited": 0
  },
  "40346007": {
    "paper_id": "40346007",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Dogrusoz, et\u00a0 al., \u201cIntegrative Analysis of \nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d \nScience Signaling  6, no",
      "Mastrogiacomo, et\u00a0 al., \u201cAnalysis and \nVisualization of Longitudinal Genomic and Clinical Data From the \nAACR Project GENIE Biopharma Collaborative in cBioPortal,\u201d Cancer \nResearch  83, no"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:23.438554",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40346007.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40307896": {
    "paper_id": "40307896",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "CEBPA mutation status was also \nretrieved com cBioportal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer \ngenomics and clinical profiles using the cBioPortal",
      "Analysis and Visualization \nof Longitudinal Genomic and Clinical Data from the AACR Project GENIE \nBiopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:24.254653",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40307896.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40287951": {
    "paper_id": "40287951",
    "cbioportal_paper_citations": [
      "[PubMed: \n22588877] \n36",
      "[PubMed: 37668528] \n38"
    ],
    "cbioportal_platform_mentions": [
      "In Silico Expression Correlations\ncBioPortal patient-derived data sets were queried to visualize gene correlations between \nSTEAP1, AR, KLK2, KLK3, KLK15, NKX3\u20131,  and TMPRSS2",
      "Expression Analysis of STEAP1 and STEAP2 in mCRPC Patients\nTo examine clinical correlations between STEAP1  and AR, we queried primary prostate \nadenocarcinoma (TCGA, Firehose Legacy) and metastatic prostate adenocarcinoma \n(SU2C/PCF Dream Team) cohorts from cBioPortal",
      "Gao J, et al. , Integrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal",
      "de Bruijn I, et al. , Analysis and Visualization of Longitudinal Genomic and Clinical Data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {
      "31061129": [
        "[PubMed: 31061129] \n35"
      ]
    },
    "extraction_date": "2025-12-19T17:15:26.789460",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40287951.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 1
  },
  "40274768": {
    "paper_id": "40274768",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "BPearson correlation R values were\ncalculated for PAK1 and TRPM7 in PAAD dataset using cBioPortal website",
      "Theplatform cBioPortal [ 46\u201348] was used to retrieve mRNA expression from\nPAAD cohort to calculate Pearson correlation coef \ufb01cient (R value) and p-\nvalues for PAK1 and TRPM7",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis\nand visualization of longitudinal genomic and clinical data from the AACR project\nGENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative\nanalysis of complex cancer genomics and clinical pro \ufb01les using the cBioPortal",
      "All data from GEPIA and\ncbioportal are available and are based upon public data extracted from TCGA\nResearch Network"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:28.518662",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40274768.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40253353": {
    "paper_id": "40253353",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The \nclinical data for each patient (such as age at diagnosis, \nsurvival status, and follow-up duration) were obtained \nfrom Firehose Legacy, Pan-Cancer Atlas in Genomic \nData Commons, and cBioPortal [ 21, 22]",
      "Survival \ndata and other clinical data, including survival status and follow-up duration, \ncan be accessed via Firehose Legacy, Pan-Cancer Atlas in Genomic Data \nCommons, and cBioPortal ( https://www.cbioportal.org / )",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualization of lon -\ngitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:32.230662",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40253353.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40271221": {
    "paper_id": "40271221",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "( C ) A bar diagram  showing  the frequency  and type of alterations  in the \nXRCC1 gene among PCa patients  from different  cohorts was generated  using cBioportal  website  ( https://www.cbioportal.org  / )",
      "We also examined  cbioportal  ( https://www.cbioportal",
      "https:// doi.org/  10.1158/  2159- 8290.CD-  12- 0095 \n25.Gao J, Aksoy BA, Dogrusoz  U et al. Integrative  analysis  of \ncomplex  cancer genomics  and clinical profiles  using the cBioPortal",
      "https:// doi.org/  10.1126/  scisignal.2004088  \n26.de Bruijn I, Kundra  R, Mastrogiacomo  B et al. Analysis  and \nvisualization  of longitudinal  genomic  and clinical data from the \nAACR Project GENIE  Biopharma  Collaborative  in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:34.734956",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40271221.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40241258": {
    "paper_id": "40241258",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "50 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B,\nSumer SO, Sun Y, Jacobsen A, Sinha R, Larsson Eet al. (2013) Integrative analysis of complex cancer\ngenomics and clinical pro\ufb01les using the cBioPortal",
      "51 de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN,\nSikina L, Mazor T, Li X, Ochoa A, Zhao G, Lai Bet al. (2023) Analysis and visualization of longitudinal\ngenomic and clinical data from the AACR project\nGENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:35.889316",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40241258.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40233044": {
    "paper_id": "40233044",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1158/0008-5472.CAN-23-0816  PMID: \n37668528\n 28",
      "org/10.1126/scisignal.2004088  PMID: 23550210\n 29",
      "https://doi.org/10.1158/2159-8290.CD-12-0095  PMID: 22588877\n 30"
    ],
    "cbioportal_platform_mentions": [
      "Co-expression and gene set enrichment \nanalyses (GSEA) were carried out using cBioportal and enrichr, respectively",
      "Mutation analysis\nAlteration frequency of ANGPTL4 for all cancers along with alteration frequency of other \ngenes in altered and non-altered ANGPTL4 groups was retrieved from cBioportal [ 27\u201329]",
      "Co-expressed genes and functional enrichment analysis\nCo-expressed genes with their spearman\u2019s correlation coefficients were retrieved from \nthe cBioportal [ 27\u201329]",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization \nof longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in \ncBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex \ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:39.797443",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40233044.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40227503": {
    "paper_id": "40227503",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:41.916763",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40227503.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "40227722": {
    "paper_id": "40227722",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Supplementary Materials: The following supporting information can be downloaded at:\nhttps://www.mdpi.com/article/10.3390/cancers17071172/s1, Figure S1: Incidence of gene alter-\nations across various cancer types from PanCancer studies generated with cBioPortal software,\nhttps://www.cbioportal.org/; Table S1: Characterization of molecular alterations of the eight signifi-\ncant mutated genes in this cohort",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:42.209640",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40227722.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40241305": {
    "paper_id": "40241305",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Integrated cBioPortal forCancerGenomics and\nPeCananalyses\nComprehensive listsofsomaticmutations inH3-3BandH4C9\nwerecompiled throughintersecting searches ofcBioPortal for\nCancerGenomics andPeCan.71\u201373Through thecBioPortal web\nbrowser(https://www.cbioportal.org ),webuiltacustomcase\nsetinthemanualquerysectionthatincluded all255,345cases\nthatcomprise thedatasetasofApril3,2024.Becausequeries\narelimitedbygeneandsamplecount,wefirstcreatedauser-\ndefinedgenelistthatincluded H3-3B.Thesesearchesenabled\nustoexporttablesfromtheMutations tabwithalistofallre-\nportedsomaticvariantsinthesetwogenesacrossthe34cate-\ngoriesofdatasetscompiled incBioPortal (TableS3).Basedon\nthesesearches, wealsoexported thetablesfromtheCancerTypes\nSummary Tab(Figure6B).Theselistsofsomaticmutations were\nthenamended withnon-overlapping mutations aggregated in\nPeCan(https://pecan.stjude.cloud ),whichwerefoundinthe\nProteinPaint tabafterperforming asearchbasedongene.These\ncombined listsfacilitated thegeneration ofFigure6A",
      "Webresources\ncBioPortal: https://www.cbioportal.org\nGestaltMatcher Database: https://db.gestaltmatcher.org/\npublications?locale \u0088en\nSt.JudePeCanplatform: https://pecan.stjude.cloud\nReceived: February 26,2025\nAccepted: April10,2025\nReferences\n1.Luger,K.,M\u00e4der,A.W.,Richmond, R.K.,Sargent,D.F.,and\nRichmond, T.J.(1997).Crystalstructure ofthenucleosome\ncoreparticleat2.8Aresolution"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:43.178883",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40241305.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40369846": {
    "paper_id": "40369846",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.17   |   Analysis of Publicly Available Datasets\nFor analysis of The Cancer Genome Atlas (TCGA), RNA- \nSeq data from 33 cancers were downloaded from cBioPortal \n(RRID:SCR_014555 ) [37\u201339 ]",
      "Mastrogiacomo, et\u00a0 al., \u201cAnalysis and \nVisualization of Longitudinal Genomic and Clinical Data From the \nAACR Project GENIE Biopharma Collaborative in cBioPortal,\u201d Cancer \nResearch  83, no",
      "Dogrusoz, et\u00a0 al., \u201cIntegrative Analysis of \nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d \nScience Signaling  6, no"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:47.367123",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40369846.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40206332": {
    "paper_id": "40206332",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutation data was retrieved via \ncBioPortal for Cancer Genomics (Cerami et al. 2012 , Gao \net al. 2013 , de Bruijn et al. 2023 )",
      "1198/016214507000000211\nde Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualiza -\ntion of longitudinal genomic and clinical data from the AACR proj-\nect GENIE biopharma collaborative in cBioPortal",
      "https://doi.org/10.1007/ \ns11634-018-0329-yGao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex can-\ncer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:48.399589",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40206332.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40225855": {
    "paper_id": "40225855",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal  for Cancer  Genomics  is a \nmulti- function web- based  tool for performing  genetic  \nalteration  analyses [38]",
      "We utilized  this cBioPortal  to \naddress  information  about  the proportion of mutated  \nKRAS  and TP53  and their  impact  on the OS rate in the \nPAAD  cohort",
      "de Bruijn  I, Kundra  R, Mastrogiacomo B, Tran  TN, Sikina  L, Mazor  T, et al. \nAnalysis  and Visualization  of Longitudinal  Genomic  and Clinical Data  from  \nthe AACR  Project GENIE  Biopharma Collaborative  in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:50.700121",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40225855.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40196362": {
    "paper_id": "40196362",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2 Material and methods\n2.1 Analysis of NEU1 expression in\npublic databases\ncBioPortal can be used to explore, multidimensional cancer\ngenome data visualization and analysis ( de Bruijn et al., 2023 )",
      "3 Results\n3.1 NEU1 is upregulated in liver cancer and\nlinked to the prognosis of liver\ncancer patients\nWe analyzed the expression of NEU1 across various tumor\nsamples using a wide range of databases and analytical tools,including cBioPortal, GEPIA and GEO",
      "Data from the\ncBioPortal platform revealed that NEU1 was expressed inmultiple tumor tissues ( Supplementary Figure S1 )",
      "Analysis and visualization of longitudinal genomic and clinical data from the\nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:53.464104",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40196362.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40201310": {
    "paper_id": "40201310",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods:  We conducted  an extensive  analysis  of genomics,  transcriptomics,  and clinical  data  retrieved  from  public  \nrepositories,  including  cBioPortal",
      "METHODS\nSelection of genomic data set of tumor samples\nGenomic  data sets available  at the cBioPortal  repository  (https://www.cbioportal.org ; accessed  from  January  \nto April  2023) [17-19] were  systematically  screened  for a total  of 217.491  tumor  samples",
      "The \nformer,  consisting  of 65,970  patients  (from  69.340  distinct  samples),  was created  using  the tab \u201cCurated  set \non non-redundant  studies\u201d  at cBioPortal  and includes  the combination  of 214 independent  (TCGA  and \nnon-TCGA)  studies  with  no overlapping  samples,  encompassing  about  100 distinct  tumor  types  from  \nprimary  and metastatic  tumor  sites in adult  and pediatric  groups  [Supplementary  File 1]",
      "The latter  cohort  \nderives  from  the AACR  Project  GENIE  (Genomics  Evidence  Neoplasia  Information  Exchange)  v13.0-public  \n(available  on the cBioPortal  repository),  consisting  of 148.268  patients  (with  167.423  analyzed  tumor  \nsamples), covering more than 110 different tumor types [ Supplementary File 1 ]",
      "Tumors  were  selected  on a mutation  frequency  \ncutoff  of 5% from  the TCGA  and non-TCGA  datasets  in cBioPortal",
      "2025;8:14 https://dx.doi.org/10.20517/cdr.2024.213 Page 5 of 24\n(for the same  tumor  type)  available  on cBioportal  with  >100  patients  were  combined  together",
      "After  selecting  the gene  pairs,  systematic  analysis  to evaluate  mutual  exclusivity  or co-occurrence  \nfor each  tumor  of interest  was carried  out using  the tool implemented  in the cBioPortal  repository",
      "In these subgroups, and for each analyzed\ntumor type, we evaluated the survival and the statistically significant enrichment of specific clinical and\nmolecular features, possibly associated with the presence of BRAF  mutations, by using the \u201ccompare\u201d\nfunction implemented in cBioPortal",
      "As reported in cBioPortal, for the survival\nanalysis, the log-rank test was used to test the null hypothesis that there is no difference between the groups\nin the probability of an event at any time point",
      "Using  the \u201cmRNA\u201d  and \n\u201cProtein\u201d  tab function  of cBioportal,  which  include  mRNA  expression  data as RSEM  (Batch  normalized  \nfrom  Illumina  HiSeq_RNASeqV2)  and protein  expression,  measured  by reverse-phase  protein  array  \n(RPPA),  respectively,  we selected  only  gene  lists with  Benjamini-Hochberg  adjusted  P-values  (Q-value  < \n0.05)",
      "This cohort comes from the combination of 214 independent\n(TCGA and non-TCGA) studies from the manually curated set of the cBioPortal repository ( https://www",
      "cbioportal.org )",
      "Cohort #2 is the AACR Project GENIE v13.0-public - recently released and available on the\ncBioPortal repository - consisting of 148.268 patients (with 167.423 analyzed tumor samples), covering\nmore than 120 different tumor types [ Supplementary File 1 ]",
      "DECLARATIONS\nAuthors\u2019 contributions\nWriting of the manuscript: Costa V, Giovannetti E, Perfetto C, Aprile M\nReview of the manuscript: Costa V, Giovannetti E\nData analysis: Costa V, Perfetto C, Aprile M, Cataldi S\nFigure design: Costa V, Perfetto C, Aprile M\nAvailability of data and materials\nThe datasets  presented  in this study  are available  in the online  repository  cBioportal  (https://www",
      "Analysis and  \nvisualization  of longitudinal  genomic  and clinical  data from  the AACR  project  GENIE  biopharma  collaborative  in cBioPortal",
      "Gao J, Aksoy  BA, Dogrusoz  U, et al. Integrative  analysis  of complex  cancer  genomics  and clinical  profiles  using  the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:55.357924",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40201310.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 16,
    "total_data_pmids_cited": 0
  },
  "40192943": {
    "paper_id": "40192943",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data analysis was performed on mRNA expression z-scores relative to all samples (log microarray) \ndownloaded from http://www.cbioportal.org  [21\u201323]",
      "Data availability  Data analysis was performed on mRNA expression \nz-scores relative to all samples (log microarray) downloaded from \nhttp://www.cbioportal.org",
      "Bruijn et al., Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR project GENIE bio -\npharma collaborative in cBioPortal",
      "Gao et al., Integrative analysis of complex cancer genomics and \nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:55.456089",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40192943.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40251157": {
    "paper_id": "40251157",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "While resources\nsuch as cBioPortal ( https://www.cbioportal.org/ )18\u201320,U C S CX e n a( https://\nxena.ucsc.edu/ )21, and GEPIA2 ( https://gepia2.cancer-pku.cn/ )22,a r ew i d e l yused for cancer genomics research, M ammOnc-DB distinguishes itself\nthrough its comprehensive multi-om ics integration and subgroup-speci \ufb01c\nfocus",
      "et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR project GENIE biopharmacollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:15:57.132121",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40251157.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40186710": {
    "paper_id": "40186710",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal (https:// www",
      "E IF analysis of DLX4 in HEK293 and U2OS cell lines; green represents the target protein DLX4, \nand blue represents the nucleus (HPA database)\n\nVol.:(0123456789)Discover Oncology          (2025) 16:467  | https://doi.org/10.1007/s12672-025-02258-z \n \n Research\n3.3  Genetic variation of\u00a0DLX4\nThe cBioPortal platform was utilized to analyze the mutation profiles of DLX4 in 32 studies comprising 10,967 samples",
      "3  Genetic variation of LX4: A Amino acid mutation sites of DLX4 (cBioPortal database)",
      "B Types of DLX4 mutations in pan-cancer \n(cBioPortal database)",
      "C Protein structure of DLX4 obtained from the cBioPortal database",
      "org/), cBioPortal (https:// www",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa A, Zhao G, Lai B, et\u00a0al. Analysis and visualization of \nlongitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:03.223424",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40186710.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "40199338": {
    "paper_id": "40199338",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Furthermore, EPAS1 mutations were extremely rare across 33 human cancer types from the 212 studies avail-\nable on cBioPortal (5/69,045 tumor samples, 0.007%; ref",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. \nIntegrative analysis of complex cancer genomics and clinical profiles \nusing the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L,  \nMazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collabo-rative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:03.669532",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40199338.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40164800": {
    "paper_id": "40164800",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "HTAN data can be accessed through the \nHTAN Portal, explored in visualization tools\u2014including CellxGene, Minerva \nand cBioPortal\u2014and analyzed in the cloud through the NCI Cancer Research \nData Commons",
      "cBioPortal: an open-source visualization tool for exploring \nmultimodal cancer data",
      "Second, the portal integrates with cBioPortal for Cancer Genomics, \nan open-source tool for visualizing and analyzing cancer genomics \ndata11\u2013 13",
      "HTAN datasets including data from bulk sequencing and other \nmethods, such as imaging or single-cell sequencing, are deposited into \ncBioPortal (https://cbioportal.org)",
      "Our infrastructure roadmap includes \nimprovements to data ingestion (for example, additional data integrity \nchecking), data harmonization, the data-release process (increased \nautomation and improved data tracking), and dissemination through \nthe HTAN Portal (enhanced publication pages) and the broader cancer \ndata ecosystem, including streamlined releases to CRDC, CellxGene, \ncBioPortal and other repositories",
      "et al. Integrative analysis of complex cancer genomics and \nclinical profiles using the cBioPortal",
      "et al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR Project GENIE \nBiopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:05.361412",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40164800.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "40188944": {
    "paper_id": "40188944",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "O.,\net al. (2013) Integrative analysis of complex cancer genomics and clinical\npro\ufb01les using the cBioPortal",
      "(2023) Analysis and visualization of longitudinal\ngenomic and clinical data from the AACR project GENIE biopharma\ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:05.663933",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40188944.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40170512": {
    "paper_id": "40170512",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(A) Lollipop plot\nof ARID1A mutations with Cancer Hotspots, OncoKB, and post-translational modi\ufb01cation annotation downloaded from cbioportal [24,25,26] ;( B )\nARID1A mutation types; (C) Mutation types of the top 10 mutated genes; (D) Study design summarizing the generation of the different cell line\nmodels developed here and the subsequent analysis performed (color coded); (E) Representative Sanger sequencing result of UROtsa ARID1A\nKO #5, the PAM (Protospacer Adjacent Motif) is underlined and the difference highlighted in yellow; (F) Western blot imaging of potential\nUROtsa ARID1A knockout cells and wildtype control; clones indicated in red are knockout clones, which were selected for further studies",
      "Data accessibility\nMemorial Sloan Kettering (MSK) bladder cancer panel\ndata 2022 [23] were downloaded from cbioportal\n[24,25,26]",
      "https://doi.org/10.1158/2159-8290.CD-12-0095\n25 de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN,\nSikina L, Mazor T, et al. Analysis and visualization oflongitudinal genomic and clinical data from the AACRproject GENIE biopharma collaborative in cBioPortal.Cancer Res",
      "1158/0008-5472.CAN-23-0816\n26 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B,\nSumer SO, et al. Integrative analysis of complex cancergenomics and clinical pro\ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:08.503380",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40170512.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40184664": {
    "paper_id": "40184664",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Lai, et al., Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR project GENIE biopharma collaborative \nin cBioPortal, Cancer Res",
      "Larsson, et al., Integrative analysis of complex cancer \ngenomics and clinical profiles using the cBioPortal, Sci"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:09.064592",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40184664.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40196015": {
    "paper_id": "40196015",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To assess if high mRNA RECQL4 426 \nexpression relates to cancer genomic instability, we utilized pan -cancer data from the cBioPortal 427 \nthat examined copy number alterations and mutations",
      "454 \n(C) Quantification of RECQL4 amplifications and deep delet ion in the MSK Met Tropism cohort in cbioportal 455 \n43-46",
      "479 \n(B) The MSK Met Tropism cohort in cbioportal was analyzed for OS, which depends on RECQL4 480 \namplification from a pan -cancer cohort 43-46",
      "719 \nInformation on RECQL4 modifications in cancer was acquired by querying publicly 720 \navailable TCGA data using the cBioPortal for Cancer Genomics database 721 \n(https://www.cbioportal.org ) and extracting information on RECQL4 modifications in relev ant 722 \ncancer subtypes",
      "et al.  Integrative analysis of complex cancer genomics and clinic al profiles using the 1045  \ncBioPortal",
      "et al.  Analysis and Visualization of Longitudinal Genomic and  Clinical Data from the 1047  \nAACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:09.674432",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40196015.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "40141210": {
    "paper_id": "40141210",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "By design, this was an in silico diagnostic study,\nconducted using data from the cBioPortal database (accessed on 21 September 2024) and\nseveral data processing and machine learning Python libraries",
      "Data Preprocessing\nAfter data extraction from the cBioPortal database had been completed, data on sex,\nage at time of sequencing, and genetic variant presence for 665 genes across 21,016 patient\ntumor samples were selected (Supplemental Table S1)",
      "Data Curation\nThe data were extracted from cBioPortal (https://www.cbioportal.org/, accessed on\n21 September 2024), a comprehensive database for cancer genomics [ 25\u201327]",
      "cBioPortal\ncontains clinical and genomic data from the AACR Project GENIE\u00ae(Genomic Evidence\nNeoplasia Information Exchange)",
      "AACR Project GENIE (https://genie.cbioportal.org/,\naccessed on 21 September 2024) is a publicly accessible registry of real-world genomic data\ncreated through collaboration between 19 leading international cancer centers [ 28]",
      "Data filtering process in the cBioPortal system (created with Biorender.com)",
      "Data downloaded from the publicly available cBioPortal database does not\nrequire ethical approval",
      "Data Availability Statement: The data used in this study are publicly available as part of a virtual\nstudy in the cBioPortal system, available at the following link: https://genie.cbioportal.org/study",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "Integrative cBioPortal Analysis Revealed Molecular Mechanisms That Regulate\nEGFR-PI3K-AKT-mTOR Pathway in Diffuse Gliomas of the Brain",
      "De Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:11.050273",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40141210.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 11,
    "total_data_pmids_cited": 0
  },
  "40149548": {
    "paper_id": "40149548",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Visualization of Copy Number Alterations (CNAs) Across TCGA Pan-Cancer Cohorts\nTo visualize the CNAs of SLC19A1 on a pan-cancer scale, the cBioPortal platform was\nused to integrate the mutation data from the TCGA pan-cancer cohorts (https://www",
      "cbioportal.org/) (accessed on 10 June 2023) [ 60\u201362]",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:15.245380",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40149548.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40155851": {
    "paper_id": "40155851",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Materials and methods  This study integrated multiple public databases (TCGA, HCMDB, UALCAN, HPA, UniProt, \ncBioPortal, and GEO) to evaluate CDH3 expression, construct a prognostic model, and perform functional and \ntranslational analyses",
      "o r g /     ) [23], Universal Protein (UniProt) \ndatabase ( https://www.uniprot.org ) [24], Cancer  m e t a \ns t a s i s : Human Cancer Metastasis Database (HCMDB) \ndatabase ( https://hcmdb.i-sanger.com/ ) [25],  M u t a t i o \nn analysis: cBio Cancer Genomics Portal (cBioPortal) \ndatabase ( http://cbioportal.org ) [26], Protein  m o d i fi   c  a t \ni o n : Posttranslational modifications (qPTM)  (   h t t p : / / q p \nt m",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa \nA, Zhao G, Lai B, et al. Analysis and visualization of longitudinal genomic \nand clinical data from the AACR project GENIE biopharma collaborative in \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:15.388483",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40155851.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40144665": {
    "paper_id": "40144665",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Correlation of TRAF2 expression with mutationsand epigenetic in tumors was evaluated using the cBioPortal platform and the\nGSCA database",
      "2.3 TRAF2 mutation characterization and\nmethylation analysis\nTo examine the mutational characteristics of TRAF2 in various\ncancers, we queried the site, type, and number of TRAF2 mutations in\nthe \u201cMutation \u201dmodule on the cBioPortal platform ( De Bruijn et al.,\n2023)",
      "3.3 TRAF2 mutation and methylation\nin tumors\nWe used the cBioPortal platform for the mutation analysis of\nTRAF2",
      "(A)Mutation analysis of TRAF2 in the CBioPortal\ndatabase",
      "Analysis and visualization of longitudinal genomic and clinical data from the\nAACR project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:15.490266",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40144665.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40102028": {
    "paper_id": "40102028",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "METABRIC APP gene expression analysis\nMETABRIC (Molecular Taxonomy of Breast Cancer \nInternational Consortium) 34 35 gene expression values \nwere obtained from cBioPortal.36\u201338 ER- positive tumors \nwith messenger RNA expression were selected for anal-\nysis",
      "37 Gao J, Aksoy BA, Dogrusoz U, et\u00a0al. Integrative analysis of complex \ncancer genomics and clinical profiles using the cBioPortal",
      "38 de Bruijn I, Kundra R, Mastrogiacomo B, et\u00a0al. Analysis and \nVisualization of Longitudinal Genomic and Clinical Data from the \nAACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:21.323343",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40102028.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40102635": {
    "paper_id": "40102635",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:25.406189",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40102635.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "40101298": {
    "paper_id": "40101298",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Bulk mRNA sequencing datafrom head and neck squamous cell carcinoma (HNSCC)\nand cervical squamous cell carcinoma (cvSCC) tumors\nfrom The Cancer Genome Atlas (TCGA, RRID:SCR_\n003193 ) project were consulted using CBioPortal\n(RRID:SCR_014555 )[83\u201385]",
      "DEGs between groups\nwere computed using cBioPortal",
      "GSEA for gene lists unaccompa-\nnied by expression values (cBioPortal analyses) were per-\nformed using gPro\ufb01ler ( RRID:SCR_006809 )[87].G S E A\nof RNA-Seq data and generation of enrichment plotswere conducted using the\nGSEA desktop application soft-\nware (v4.3.3 RRID:SCR_003199 )[88]",
      "84 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B,\nSumer SO, et al. Integrative analysis of complex cancergenomics and clinical pro\ufb01les using the cBioPortal",
      "85 de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN,\nSikina L, Mazor T, et al. Analysis and visualization of\nlongitudinal genomic and clinical data from the AACR\nproject GENIE biopharma collaborative in cBioPortal.Cancer Res"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:27.526641",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40101298.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40141058": {
    "paper_id": "40141058",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In\na cBioPortal curated set of non-redundant samples, the IGF2BP2 gene was altered in 18%\nof ovarian cancers, 14% of cervical cancers, 9% of lung cancers, 8% of uterine cancers, 5%\nof esophageal and gastric cancers, 4% of head and neck cancers, 3% of prostate cancers,\n3% of bladder cancers, 2.8% of testicular cancers, 2.8% of skin cancers, 2.5% of breast\ncancers, 1.5% of colon cancers, 1.3% of soft tissue tumors, and 0.8% of pancreatic cancers\n(Figure 5A) [ 77\u201379]",
      "Data from the cBioPortal curated set of non-redundant studies [77\u201379]",
      "Patient data were derived from GEPIA2, Kaplan\u2013Meier\nPlotter, and cBioPortal",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal",
      "De Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:27.569790",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40141058.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40088749": {
    "paper_id": "40088749",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genetic alteration analysis\nThe cBioPortal [28\u201330] (https://www.cbioportal.org/ ) was utilized \nto compile genetic mutation data pertaining to APOA1 based on TCGA \nPan-Cancer Atlas data, including alteration frequency, mutation type, \nand copy number alteration (CNA)",
      "APOA1 genetic alteration and DNA methylation in pan-cancer\nThe results from the cBioPortal database showed that the APOA1 \ngene is altered in several cancers, and \"deep deletion\" had the highest \npercentage",
      "Furthermore, analysis of the cBioPortal database indicated that missense \nmutations were the predominant type of APOA1 gene mutation in can-\ncers (Fig",
      "The alteration frequencies and different mutation types of APOA1 in pan-cancer according to cBioPortal dataset",
      "Schultz, Integrative \nanalysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci",
      "Schultz, Analysis and visualization of \nlongitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal, Cancer Res"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:27.784483",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40088749.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "40084357": {
    "paper_id": "40084357",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genomic data was obtained from the Memorial \nSloan Kettering Cancer Center tumor registry \n(MSK-CHORD (MSK, Nature 2024)) through the \ncBioPortal database [25]",
      "Expression of PC mutant genes was \ndetermined using the cBioPortal, and a chi-\nsquared test was used to determine signifi -\ncance [30-32]",
      "Our analysis of genomic \ndata from the cBioPortal showed that Black \nmales had a higher frequency of expression  \nof KRAS and TP53 in comparison with Black \nfemales",
      "Analysis and visualization \nof longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collabora -\ntive in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:30.794363",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40084357.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40093208": {
    "paper_id": "40093208",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "; https://doi.org/10.1101/2025.03.05.25323443doi: medRxiv preprint \n\n \n the MSAR genes to those in which somatic mutations have been observed in targeted sequencing of 2,383 652 \nmyeloid and lymphoid neoplasms and their matched normals via MSK -IMPACT Heme panel on the cBioPortal 653 \nfor Cancer Genomics.10\u201312 We chose the most stringent % threshold of shared aut -mCAs that contained at least 654 \n1 hematologic malignancy driver gene for each mCA chromosome and type; the thresholds are reported in 655 \nSupplementary Table 3",
      "; https://doi.org/10.1101/2025.03.05.25323443doi: medRxiv preprint \n\n \n Project GENIE Biopharma Collaborative in cBioPortal",
      "et al.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:31.100980",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40093208.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40080912": {
    "paper_id": "40080912",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data from Dermawan et al. and Nguyen et al. were collected using cBioPortal\n[23\u201325]",
      "Data from Dermawan et al. and Nguyen\net al. were collected using cBioPortal ( https://www",
      "cbioportal.org/ )[23\u201325]",
      "24 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B,\nSumer SO, et al. Integrative analysis of complex cancergenomics and clinical pro\ufb01les using the cbioportal",
      "25 de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN,\nSikina L, Mazor T, et al. Analysis and visualization oflongitudinal genomic and clinical data from the AACRproject genie biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:31.693440",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40080912.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40084262": {
    "paper_id": "40084262",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genomic  alterations and genomic  instability  \nanalysis  \nThe mutation  frequency  of FUT1  across  cancers  \nwas analyzed  using  the cBioPortal  database  \n(https://www.cbioportal.org/),  with  a differential  \nmutation  frequency  plot generated",
      "The Cancer  Type  \nSummary  module  in cBioPortal  was employed  to \nevaluate  the frequencies  of three  genomic  alteration  \ntypes \u2014mutations,  amplifications,  and deep  \ndeletions \u2014across  multiple  cancer  type[18 \u201320]",
      "https://www.medsci.org/v22p1313s1.pdf  \nAcknowledgments  \nWe sincerely  thank  the public  databases,  \nincluding  CCLE,  UCSC  Xena,  TCGA,  GTEx,  \nTIMER2.0,  cBioPortal,  RM2Target,  CancerSEA,  \nMsigdb,  STRING,  GeneMANIA,  TIDE,  and CMap,  for providing  open  access  to their  invaluable  resources",
      "Data availability  \nThe data  used  in our study  were  obtained  from  \npublicly  available  databases  and are freely  accessible  \nat the following  URLs: CCLE:  https://  \nsites.broadinstitute.org/ccle;  UCSC Xena:  http:// \nxena.ucsc.edu/;  TCGA:  https://www.cancer.gov/ \ntcga;  GTEx:  https://commonfund.nih.gov/GTEx;  \ncBioPortal:  https://www.cbioportal.org/;  \nRM2Target:  http://rm2target.canceromics.org/#/ \nhome;  CancerSEA:  http://biocc.hrbmu.edu.cn/ \nCancerSEA/home.jsp;  Msigdb:  http://software  \n.broadinstitute.org/gsea/msigdb;  STRING:  https://  \nstring -preview.org/;  GeneMANIA:  http://  \ngenemania.org/;  TIDE:  http://tide.dfci.harvard.edu/  \ndownload/;  Connectivity  Map  (CMap):  \nhttps://portals.broadinstitute.org/cmap/",
      "de Bruijn  I, Kundra  R, Mastrogiacomo B, et al. Analysis  and Visualization  of \nLongitudinal  Genomic  and Clinical Data  from  the AACR  Project  GENIE  \nBiopharma Collaborative  in cBioPortal",
      "Gao J, Aksoy  BA, Dogrusoz  U, et al. Integrative  analysis  of complex  cancer  \ngenomics  and clinical profiles  using  the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:35.189922",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40084262.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "40065368": {
    "paper_id": "40065368",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "PDAC cohort\nThe gene expression profile and clinical data for 177 \nPDAC patients (TCGA-PAAD PanCancer Atlas data -\nset [ 38]) were obtained from The Cancer Genome Atlas \n(TCGA) via the cBioPortal website  (   h t t p s : / / w w w",
      "Hypoxia scores (Buffa [ 50], Winter [ 51], and Ragnum \n[52]) for PDAC patients (TCGA-PAAD dataset) were \nretrieved from the cBioPortal website [ 39\u201341]",
      "( A) Data from PDAC patients (TCGA-PAAD dataset; n = 177) were obtained \nfrom the cBioPortal website ( https://www.cbioportal.org/ )",
      "( A) Data from PDAC patients (TCGA-PAAD dataset; n = 177) were obtained from the \ncBioPortal website ( https://www.cbioportal.org/ )",
      "( A) Data from PDAC patients (TCGA-PAAD dataset; n = 177) were obtained from the cBio -\nPortal website ( https://www.cbioportal.org/ )",
      "(C,D) Data from PDAC patients (TCGA-PAAD dataset; n = 177) were obtained from \nthe cBioPortal website ( https://www.cbioportal.org/ )",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa \nA, Zhao G, Lai B, et al. Analysis and visualization of longitudinal genomic \nand clinical data from the AACR project GENIE biopharma collaborative in \ncBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen \nA, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics \nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:37.734525",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40065368.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "40072681": {
    "paper_id": "40072681",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "How to\u00a0recall a\u00a0dataset from\u00a0cBioPortal\nThe cBioPortal for Cancer Genomics was originally devel -\noped at the Memorial Sloan Kettering Cancer Center \n(MSK) to originally support The Cancer Genome Atlas \n(TCGA) dataset and other large-scale cancer genomic data \n[16]",
      "It is an open-access, open-source resource for inter -\nactive exploration of multidimensional cancer genomics \ndata sets.The principal aim of cBioPortal is to make complex \ngenomic data accessible and easier for cancer research, pro -\nviding an intuitive and user-friendly interface",
      "For these reasons, the cBioPortal may help researchers \nin the use of these complex dataset for the discovery of new \nbiological insights and the development of clinical applica -\ntions [ 16\u201318]",
      "To recall on Phantasus a dataset present on cBioPortal, go \nto cBioPortal ( https://  www",
      "7  Download a dataset from \ncBioPortal",
      "cBioPortal offers \nboth an interactive platform \nfor exploring cancer genomic \nand the capability to download \ndatasets for importing into \nPhantasus for more in-depth \nanalysis",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; \nSumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et\u00a0al. \nIntegrative analysis of complex cancer genomics and clinical pro -\nfiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:37.745424",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40072681.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "40074806": {
    "paper_id": "40074806",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The mutation and variation status of each gene were analyzed \nvia the cBioPortal platform ( https://www",
      "cbioportal.org/ )54",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:40.151877",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40074806.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40084259": {
    "paper_id": "40084259",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Moreover,  the somatic  mutation  profiles  and the copy  \nnumber  variation  (CNV)  profiles  of TCGA -LUAD  \nwere accessed  from  TCGA  portal  and cBioPortal  \n(https://www.cbioportal.org/),  respectively,  for \ngenomic characteristics  analysis  (11)",
      "The RNA -seq and WES  data  of \nthe TCGA -LUAD  dataset  are downloaded from  the \nGDC  Data  Portal  (https://portal.gdc.cancer.gov/)  \nand the cBioPortal  (https://www.cbioportal.org/)",
      "de Bruijn  I, Kundra  R, Mastrogiacomo B, Tran  TN, Sikina  L, Mazor  T, et al. \nAnalysis  and Visualization  of Longitudinal  Genomic  and Clinical Data  from  \nthe AACR  Project GENIE  Biopharma Collaborative  in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:40.912494",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40084259.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40113751": {
    "paper_id": "40113751",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Analysis and visualization of longitudinal genomic and clinical\ndata from the AACR Project GENIE biopharma collaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and clinical pro-\n\ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:43.248845",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40113751.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40061872": {
    "paper_id": "40061872",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Online bioinformatic databases including TCGA, UALCAN, Kaplan\u2013Meier plot-\nter, bc-GenExMiner, cBioPortal, STRING, Enrichr, and TIMER were utilized for analysis",
      "2.5 cBioPortal\nA comprehensive online repository for presenting and evalu -\nating multivariate cancer genomics data, cBioPortal (https:// \ncbioportal.org), serves as a vital resource",
      "Additionally, from the co- \nexpression module of cBioPortal, co-expressed genes related \nto each NTRK were retrieved; then, common genes between \nall NTRK family members were determined by Venn dia-\ngram, and the mutation percentage of co-expressed genes in \nBC was checked through the OncoPrint module of \ncBioPortal",
      "3.3 Genomic alterations and GO enrichment \nanalysis of NTRKs in BC patients\nThe cBioPortal database was employed to analyse genomic \nvariations of the NTRKs",
      "(A) Genomic alteration of NTRKs in BC patients (cBioPortal)",
      "Analysis and \nvisualization of longitudinal genomic and clinical data from the \nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:45.540903",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40061872.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "40063003": {
    "paper_id": "40063003",
    "cbioportal_paper_citations": [
      "[PubMed: \n22588877] \n122",
      "[PubMed: 37668528] \n123",
      "[PubMed: 23550210] Swett and Tothova Page 18\nInt J Cancer"
    ],
    "cbioportal_platform_mentions": [
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa A, Zhao G, \nLai B, Abeshouse A, Baiceanu D, et al. Analysis and Visualization of Longitudinal Genomic and \nClinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y , Jacobsen A, Sinha \nR, Larsson E, Cerami E, Sander C, et al. Integrative analysis of complex cancer genomics and \nclinical profiles using the cBioPortal",
      "Mutation frequency was stratified \nby both cohesin gene and type of mutation (driver mutation versus variant of uncertain \nsignificance [VUS] as determined by cBioPortal)121\u2013123",
      "Mutation was identified as a driver \nmutation by cBioPortal if it was annotated as a statistically significant hotspot mutation and \nwas a truncating or a splice site mutation; otherwise, mutations were labeled as VUS",
      "cBioPortal identified putative driver mutations only in STAG2  and RAD21  and \nnot other cohesin complex genes"
    ],
    "data_publication_citations": {
      "24120142": [
        "[PubMed: 24120142] Swett and Tothova Page 12\nInt J Cancer"
      ],
      "25186949": [
        "[PubMed: 25186949] \n23"
      ],
      "24030381": [
        "[PubMed: \n24030381] \n37"
      ],
      "23636398": [
        "[PubMed: 23636398] \n34"
      ],
      "24476821": [
        "[PubMed: 24476821] \n27"
      ],
      "23634996": [
        "[PubMed: \n23634996] \n40"
      ],
      "26091043": [
        "[PubMed: 26091043] \n35"
      ],
      "25223734": [
        "[PubMed: 25223734] \n25"
      ]
    },
    "extraction_date": "2025-12-19T17:16:48.131482",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40063003.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 8
  },
  "40063513": {
    "paper_id": "40063513",
    "cbioportal_paper_citations": [
      "[PubMed: \n22588877] \n36",
      "[PubMed: 37668528] \n40",
      "[PubMed: 23550210] \n41"
    ],
    "cbioportal_platform_mentions": [
      "NF1 TCGA-MPNST:\nThe RNA-Seq by Expectation-Maximization (RSEM) normalized counts matrix was \nobtained from the TCGA Sarcoma (Firehose) dataset using cBioPortal (RRID:SCR_014555)Mitchell et al. Page 5\nClin Cancer Res",
      "Author Manuscript Author Manuscript Author Manuscript Author Manuscript\n\n[35] (https://www.cbioportal.org/ )",
      "Cancer cell line RNA sequencing, DEGs and \ntreatment response data were obtained from the Cancer Cell Line Encyclopedia[ 38] using \ncBioPortal[ 35, 39, 40] (https://www.cbioportal.org/ )",
      "de Bruijn I., et al. , Analysis and Visualization of Longitudinal Genomic and Clinical Data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao J., et al. , Integrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal",
      "(B) Schematic adapted from \ncBioPortal depicting genes adjacent to CDKN2A  and MTAP  within the 9p21.3 locus"
    ],
    "data_publication_citations": {
      "32561749": [
        "[PubMed: 32561749] \n25"
      ],
      "25240281": [
        "[PubMed: 25240281] \n15"
      ],
      "31068700": [
        "[PubMed: 31068700] \n39"
      ]
    },
    "extraction_date": "2025-12-19T17:16:49.813281",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40063513.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 3
  },
  "40060625": {
    "paper_id": "40060625",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "RESULTS  \n \nCDK4/6 pathway is altered in  GBMs  \n To determine the frequency of CDK4/6 pathway alteration in GBM patients , we performed bioinformatic \nanalyses using cBioPortal  (31-33)",
      "Oncoprint of CDK4/6 pathway genomic alterations in GBM (IDH -WT) \npatients generated from cBioPortal GBM datasets (N=642)",
      "Kaplan -Meier analysis of GBM (IDH -\nWT) patients \u2019 OS and DFS with or without CDK4/6 pathway alterations from cBioPortal GBM datasets \n(N=642)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and \nvisualization of longitudinal genomic and clinical data from the AACR project GENIE \nbiopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative \nanalysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:53.164042",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40060625.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40060410": {
    "paper_id": "40060410",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Clinical Patient Data:  The patient data used in this study were taken from cBioPortal (72\u201374) for \nCancer Genomics, which has access to breast cancer patient data retrieved from The Cancer \nGenome Atlas Program (TCGA) , or using TIMER2.0 (75), which allows for correlation of gene \nexpression for basal -subtype breast cancer patients",
      "de Bruijn I, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data \nfrom the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:54.380404",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40060410.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40064867": {
    "paper_id": "40064867",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We searched cBioPortal\n105,d b G A P ,a n d\nthe Gene Expression Omnibus (GEO) for studies with ancestry andsubtype information",
      "Data for all TCGAsamples was accessed from cBioPortal ( www.cbioportal.org )i n\nDecember 2022",
      "Ancestry information for the TCGA cancer data wasobtained from Carrot-Zhang et al. 30.D a t a s e t su s e di nt h eB R C A\nexternal validation (Table 1) were downloaded from cBioPortal and\nGEO in April 2024",
      "et al. Analysis and visualization of longitudinal geno-\nmic and clinical data from the aacr project genie biopharma col-laborative in cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:54.801865",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40064867.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40029433": {
    "paper_id": "40029433",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DLBCL microbiome \ndata were sourced from the cBioPortal platform at https://  \nwww",
      "We acquired 1406 genus from \nthe DLBCL microenvironment through the cBioPortal plat -\nform (Supplementary Table\u00a0S1)",
      "Data availability The data used to identify the DLBCL intratumoral \nmicrobial genus were derived from the cBioPortal platform (https://  \nwww",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, \nMazor T, Li X, Ochoa A, Zhao G, Lai B et\u00a0al (2023) Analysis \nand visualization of longitudinal genomic and clinical data from \nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:16:59.548358",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40029433.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "40034437": {
    "paper_id": "40034437",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:02.095748",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40034437.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "40027618": {
    "paper_id": "40027618",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al.  Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR \nProject GENIE Biopharma Collaborative in cBioPortal",
      "et al.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:06.383973",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40027618.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40024979": {
    "paper_id": "40024979",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal for \nCancer Genomics display of A the percentage of ATM  genetic altera-\ntions and B the spectrum of ATM  mutations in the different protein domains within TCGA PanCancer Atlas, representing 32 combined \nstudies with 10,953 samples (https:// bit",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer \nSO, et\u00a0al. Integrative analysis of complex cancer genom-\nics and clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina \nL, Mazor T, et\u00a0 al. Analysis and visualization of longitu-\ndinal genomic and clinical data from the AACR Project \nGENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:06.729682",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40024979.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "40001942": {
    "paper_id": "40001942",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Raw data were\nextracted from the cBioPortal for Cancer Genomics, Memorial Sloan Kettering Cancer Center (MSK)\n(https://www.cbioportal.org, accessed on 29 October 2024) [142\u2013144]",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:08.701994",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40001942.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39980051": {
    "paper_id": "39980051",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To examine the correlation of top genome-wide hits \nassociated with response to letrozole with expression \nof ESR1  in the TCGA (Firehose Legacy) dataset, the \nTCGA data were accessed using cBioPortal [16\u201318] on \n9/12/2023; TCGA data were generated by the TCGA \nResearch Network (https:// www",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, \nOchoa A, Zhao G, Lai B, et al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR project GENIE biopharma col-\nlaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, \nJacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex \ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:13.802221",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39980051.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39997217": {
    "paper_id": "39997217",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "https:// doi.org/  10.1038/  s41420-  024- 02041- z \n59.de Bruijn I, Kundra  R, Mastrogiacomo  B et al. Analysis  and \nvisualization  of longitudinal  genomic  and clinical data from the \nAACR Project GENIE  Biopharma  Collaborative  in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:15.404360",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39997217.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "39990557": {
    "paper_id": "39990557",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "De Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and Visualization of Longitudinal \nGenomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in \ncBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative Analysis of Complex Cancer Genomics and \nClinical Profiles Using the cBioPortal",
      "The publicly available breast cancer reports and clinical data can be found at  \nhttps://www.cbioportal.org/study/clinicalData?id=brca_tcga_pub2015   \n \nThe publicly available prostate cancer reports and clinical data can be found at  \nhttps://www.cbioportal.org/study/summary?id=prad_tcga_pub  \n \nAnd the optical character recognition processed reports are available at \nhttps://data.mendeley.com/datasets/hyg5xkznpx/1  \nCode Availability"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:16.300627",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39990557.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39979869": {
    "paper_id": "39979869",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Additionally, we investigated the \nassociation of these mutations with different cancer types using the cBioPortal and canSAR databases",
      "Correlation of missense SNPs with cancer\nTo investigate the correlation between the 11 deleteri -\nous missense SNPs and various cancer types, we accessed \ncancer genomics data through cBioPortal [ 72\u201374] and \ncanSAR [ 75], both of which leverage data from The Can -\ncer Genome Atlas (TCGA)",
      "Page 11 of 18\nMehboob et al. BMC Cancer           (2025) 25:304 \nAssociation of missense SNPs with certain types of cancer\nBased on the mutation profiles from the cBioPortal and \ncanSAR databases, the G181S and R247W variants of \nCTRP6 were linked to colon adenocarcinoma (COAD) \nand uterine corpus endometrial carcinoma (UCEC), \nrespectively",
      "These three mutations are \nthe only ones identified to have a clear association with \ncancer in both the cBioPortal and canSAR databases",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:17.850612",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39979869.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "40004137": {
    "paper_id": "40004137",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Furthermore, to identify alterations in gene products that are\nS-palmitoylated, we utilized bioinformatic tools such as SwissPalm and analyzed rele-\nvant data from publicly available databases such as cBioportal",
      "The expression of zDHHC enzymes in skin cells and skin cancers was\nassessed using publicly available databases including cBioportal and Human Protein Atlas\n(HPA)",
      "cBioportal is a publicly available online tool for the analysis of genomic data pertaining\nto various cancer types that was accessed through https://www.cbioportal.org accessed on\n16 November 2024 [ 62\u201364]",
      "Expression of Skin Barrier Function Mediators, ErbB Family Members, and PLSCR Family\nMembers in Skin Cancers\nUsing cBioportal [ 62\u201364], we assessed the expression of skin barrier function mediators,\nEGFR family members, and PLSCR family members across a series of skin cancers including\nbasal cell carcinoma, cutaneous squamous cell carcinoma, acral melanoma, metastatic\nmelanoma, and skin cutaneous melanoma",
      "Our analyses derived from cBioportal [ 62\u201364]\nare shown in Supplementary File S8 (skin barrier function proteins), Supplementary File S9\n(ErbB family members), and Supplementary File S10 (PLSCR family members)",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:18.482541",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40004137.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "39955431": {
    "paper_id": "39955431",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Survival analyses, genetic alterations, and RNA modifications were \nassessed through the GEPIA2 and cBioPortal platforms",
      "2.3  Genetic alteration analysis\nThe cBioPortal tool (http:// www",
      "The cBioPortal tool (http:// www",
      "(P < 0.05)\n\nVol.:(0123456789)Discover Oncology          (2025) 16:190  | https://doi.org/10.1007/s12672-025-01965-x \n \n Analysis\ndisease-specific survival-were compared between tumors with and without ENOPH1 alterations using the \"Comparison\" \nfunction in the cBioPortal platform",
      "ENOPH1 mutation patterns in various cancers from the TCGA \ndatabase were analyzed using the cBioPortal platform",
      "D \nSurvival Correlation: The potential association between ENOPH1 mutation status and overall, disease-specific, disease-free, and progression-\nfree survival in UCEC was examined using cBioPortal\u25b8\n\nVol.:(0123456789)Discover Oncology          (2025) 16:190  | https://doi.org/10.1007/s12672-025-01965-x \n \n Analysis\n\n\nVol:.(1234567890)Analysis  \nDiscover Oncology          (2025) 16:190  | https://doi.org/10.1007/s12672-025-01965-x\nRNA modification-related genes, especially those involved in m1A, m5C, and m6A modifications",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa A, Zhao G, Lai B, et\u00a0al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR Project GENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et\u00a0al. Integrative analysis of complex cancer \ngenomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:19.712801",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39955431.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "39973357": {
    "paper_id": "39973357",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The advent of next-generation sequencing technolo-\ngies and the availability of large-scale datasets, such\nas those from The Cancer Genome Atlas (TCGA)and cBioPortal, have greatly improved our ability tocharacterise the molecular landscape of CRC",
      "Materials and methods\nData acquisition\nWe utilised data from the Pan Cancer Atlas project of\nTCGA, accessed via the cBioPortal platform [12\u201315]",
      "Data are publicly accessiblevia cBioPortal ( https://www.cbioportal.org )[16]",
      "Detailed instructions foraccessing these datasets are available via the respectiveplatforms (TCGA: https://www.cancer.gov/tcga ; cBio-\nPortal: https://www.cbioportal.org ); CCLE: https://\nsites.broadinstitute.org/ccle/",
      "12 de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN,\nSikina L, Mazor T, Li X, Ochoa A, Zhao G, Lai Bet al. (2023) Analysis and visualization of longitudinal\ngenomic and clinical data from the AACR projectGENIE biopharma collaborative in cBioPortal",
      "13 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B,\nSumer SO, Sun Y, Jacobsen A, Sinha R, Larsson Eet al. (2013) Integrative analysis of complex cancer\ngenomics and clinical pro\ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:19.813852",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39973357.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "39945880": {
    "paper_id": "39945880",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:26.467976",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39945880.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "39920793": {
    "paper_id": "39920793",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Results\nRIT1 alterations in NSCLC are associated with increased \nRIT1 protein expression\nTaking advantage of the cancer genomics data integrated \nby the cBioPortal platform (cbioportal.org), we analyzed \nthe alterations of KRAS , HRAS , NRAS , and RIT1  paralog \ngenes occurring in NSCLC samples [ 17\u201319]",
      "(A) Frequencies of \nvarious genomic alterations of KRAS , HRAS , NRAS , and RIT1 in NSCLC patients were analyzed with the cBioPortal platform  (   h t t p s : / / w  w w",
      "We next generated lollipop plot to demonstrate \nhotspots for RIT1 mutations in lung adenocarcinoma \npatients using cBioPortal",
      "Since our bioinformatic analysis unveiled the relatively \nhigh frequency of amplification changes in RIT1  gene, \nwe reexamined the correlations of RIT1  alterations with \nthose of its RAS  paralogs in lung adenocarcinoma using \ncBioPortal integrated analysis",
      "(A) Correlation \nanalysis of RIT1 alterations with those of its RAS paralogs in lung adenocarcinoma with cBioPortal platform ( https://www.cbioportal.org/ )",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen \nA, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics \nand clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa \nA, Zhao G, Lai B, et al. Analysis and visualization of longitudinal genomic \nand clinical data from the AACR Project GENIE Biopharma Collaborative in \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:27.176490",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39920793.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "39941725": {
    "paper_id": "39941725",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.E.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:27.557008",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39941725.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "39906575": {
    "paper_id": "39906575",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Publicly available databases \n(cBioPortal, ClinVar, dbSNP) were used for pathogenicity and \nknowledge status",
      "Dogrusoz, et\u00a0 al., \u201cIntegrative Analysis of \nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d \nScience Signaling  6, no",
      "Mastrogiacomo, et\u00a0 al., \u201cAnalysis and \nVisualization of Longitudinal Genomic and Clinical Data From the \nAACR Project GENIE Biopharma Collaborative in cBioPortal,\u201d Cancer \nResearch  83, no"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:29.044546",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39906575.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39906812": {
    "paper_id": "39906812",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Cbioportal\nThe cBioPortal platform (https://www.cbioportal.org ) provides a robust resource for exploring multi-dimensional cancer genomic \ndatasets, primarily derived from the TCGA [21]",
      "PAQR11 genetic alterations are prevalent across various tumor tissues\nAlterations in PAQR11 across various cancers were analyzed using cBioPortal",
      "A: The landscape of PAQR11 genetic alterations was \ngenerated utilizing the cBioPortal database",
      "Mazor, et al., Analysis and visualization of longitudinal genomic and clinical data from the \nAACR project GENIE biopharma collaborative in cBioPortal, Cancer Res"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:29.562336",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39906812.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "39905117": {
    "paper_id": "39905117",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:35.000153",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39905117.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "40045379": {
    "paper_id": "40045379",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Meanwhile, through the analy -\nsis based on the cBioPortal database (https:// www",
      "gov/ geo/), cBioportal (http:// \nwww",
      "Using the cBioPortal platform (https:// www",
      "For example, Rigiracciolo \net\u00a0al. collected FAK mRNA expression data from breast \ncancer patients from cBioportal, plotted Kaplan\u2013Meier \nsurvival curves based on subgroups and calculated the \nsignificance of differences to validate their prognostic \nvalue [68]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, \nJacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex \ncancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, \nOchoa A, Zhao G, Lai B, et al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR project GENIE biopharma \ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:35.115470",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40045379.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "39895803": {
    "paper_id": "39895803",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Multiple web platforms  and \nsoftware were used for data analysis,  including  R, Cytoscape,  HPA,  TISIDB,  UALCAN,  GEO,  cBioPortal,  \nSTRING,  GSCALite, and  CancerSEA",
      "Additionally,  we \ninvestigated  KANK2's  associations  with  cancer  \nsubtypes  using  the TISIDB  database  and explored  \ngenetic  alterations  via cBioPortal",
      "Genetic  alteration  analysis of KANK2  \nThe cBioPortal  (https://www.cbioportal.org/)  \nwas queried for data  on genetic  alterations  of KANK2,  \ncovering  all TCGA  Pan-Cancer  Atlas  Studies [8-10]",
      "Genetic  alteration  of KANK2   \nGenetic  mutations  affecting  KANK2  expression  \nwere analyzed  using  the cBioPortal  online  tool,  \nencompassing  all TCGA  Pan-Cancer  Atlas  studies  \nwith  13,863 samples",
      "de Bruijn  I, Kundra  R, Mastrogiacomo B, Tran  TN, Sikina  L, Mazor  T, et al. \nAnalysis  and Visualization  of Longitudinal  Genomic  and Clinical Data  from  \nthe AACR  Project GENIE  Biopharma Collaborative  in cBioPortal",
      "Gao J, Aksoy  BA, Dogrusoz  U, Dresdner G, Gross  B, Sumer SO, et al. \nIntegrative  analysis  of complex  cancer  genomics  and clinical profiles  using  the \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:37.198677",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39895803.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "39885513": {
    "paper_id": "39885513",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Subsequently, Tumor Mutation Burden (TMB) data \nwere downloaded from the cBioPortal database [42\u201344]",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, \nOchoa A, Zhao G, Lai B, et al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR project GENIE biopharma col-\nlaborative in cBioportal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, \nJacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex can-\ncer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:41.763611",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39885513.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39851286": {
    "paper_id": "39851286",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We accessed cBioportal to retrieve the information of \ufb01ltered and \nhigh-quality information about genetic events, including IDH1/2 , ATRX , TP53 , and TERT  promoter \nmutations, CDKN2A/B  homozygous deletion, EGFR  ampli \ufb01cation, 7 gain/10 loss chromosomal ab-\nnormalities, 1p/19q co-deletion, and MGMT  hypermethylation",
      "We accessed cBioportal to retrieve the information of filtered and\nhigh-quality information about genetic events, including IDH1/2 ,ATRX ,TP53 , and TERT promoter\nmutations, CDKN2A/B homozygous deletion, EGFR amplification, 7 gain/10 loss chromosomal\nabnormalities, 1p/19q co-deletion, and MGMT hypermethylation",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:44.363658",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39851286.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "39830769": {
    "paper_id": "39830769",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis \nand Visualization of Longitudinal Genomic and Clinical \nData from the AACR Project GENIE Biopharma \nCollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:46.496439",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39830769.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "39868467": {
    "paper_id": "39868467",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Expr ession analy sis of STING, RIG-I, and type I IFN(s ) acros s \nsolid tumors from TCGA \nProgression-free survival (PFS), overall survival (OS), RNA-seq \nby Expectation Maximization (RSEM)\u2013normalized STING1 \n(STING), RIGI (RIG-I), and type I IFN (IFNA1, IFNA7, and IFNA8) \nmRNA expression datasets for all solid tumor indications available \nwithin TCGA Pan-Cancer Atlas were retrieved from the cBioPortal \ndatabase (RRID:SCR_014555, www.cbioportal.org; refs",
      "The PFS, OS, \nand RNA-seq by RSEM-normalized STING, RIG-I, and type I IFN \nmRNA expression datasets were retrieved from the cBioPortal da-\ntabase (www.cbioportal.org; refs",
      "A, Percentage of patients exhibiting high \nSTING and RIG-I mRNA expression levels (defined as expression value higher than the 25th percentile for both genes among all TCGA Pan-Cancer Atlas expression \ndata) from the cBioPortal database, excluding those solid tumor indications with fewer than 100 patient samples",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from the \nAACR project GENIE biopharma collaborative in cBioPortal",
      "34.Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Inte-\ngrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:47.852360",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39868467.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "39814636": {
    "paper_id": "39814636",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Finally, we analysed promoter methylation level by UAL-CAN and mutation by cBioPortal of TPPP3 in HNSC.Results: TPPP3 was less expressed in OSCC",
      "cBioPortal analysis\ncBioPortal for Cancer Genomics is a resource for interactivelyexploring multidimensional cancer genomics data sets",
      "34\ncBioPortal provides rapid, intuitive, and high-quality accessto the molecular spectrum and clinical properties of large-scale cancer genomics projects",
      "35,36We used cBioPortal to\nexplore the mutation of TPPP3 in HNSC",
      "Besides, based on the\nsequencing data of HNSC patients in the TCGA database, weused cBioPortal to determine the frequency and type of TPPP3alterations in HNSC"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:48.517252",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39814636.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "39901189": {
    "paper_id": "39901189",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Z-score normalised expression data for the \nMETABRIC cohort [18, 19] was retrieved using the \ncBioPortal [40\u201342], along with paired clinical data",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Inte -\ngrative analysis of complex cancer genomics and clinical profiles using \nthe cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR Project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:50.900609",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39901189.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39829913": {
    "paper_id": "39829913",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis and Visualization of Longitudinal Genomic and Clinical \nData from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Integrative analysis of complex cancer genomics and clinical pro\ufb01les using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:51.060996",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39829913.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "39873147": {
    "paper_id": "39873147",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Patient data analy sis \nThe Cancer Genome Atlas (TCGA; RRID:SCR_003193) data \nused in the article are in whole or part based upon data generated by the TCGA Research Network (https://www.cancer.gov/tcga) \nand accessed through cBioPortal (https://www.cbioportal.org; \nRRID:SCR_014555) or https://xenabrowser.net/ (57)",
      "The figur e was adapted from cBioPortal",
      "79.Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Inte-\ngrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from the \nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:56.858681",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39873147.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "39802185": {
    "paper_id": "39802185",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The Affymetrix SNP 6.0\nmicroarrays and NGS data were obtained from the cBioPortal for Cancer Genomics\ndatabase (https:/ / www.cbioportal.org/ ) ( Gao et al., 2013 )",
      "A notion of the combined detection of the studied genes methylation was obtained using\nthe OncoPrinter tool (https:/ / www.cbioportal.org/ oncoprinter) ( Gao et al., 2013 )",
      "(A) Distribution and characteristics of muta-\ntions in the TP53 gene in DLBCL according to the results of next generation sequencing (NGS) analysis of\n1,295 samples presented in the cBioPortal for Cancer Genomics database ( Gao et al., 2013 ); (B) impaired\nmaturation of pri-miRNA to pre-miRNA in the case of mutations in codons 135, 175, 248 and 273, which\nare mutation hotspots in the TP53 gene",
      "In this regard, the data presented in\nthe cBioPortal for Cancer Genomics database are of great interest ( Gao et al., 2013 )",
      "(A) The\nfrequency of detected chromosomal abnormalities (monosomies and deletions of microRNA gene loci)\naccording to a classic cytogenetic study of 1,612 DLBCL samples with cytogenetic defects presented in\nthe Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer ( Mitelman Database of\nChromosome Aberrations and Gene Fusions in Cancer, 2024 ) (B) Cases with decrease in genome copy num-\nber in the loci of p53-responsive microRNA genes (rose color) presented in the cBioPortal for Cancer Ge-\nnomics database ( Gao et al., 2013 )",
      "Full-size\n DOI: 10.7717/peerj.18661/fig-2\nFurther, according to data, presented in the cBioPortal for Cancer Genomics database,\nthe reduction of genome copy number in the gene loci MIR-34B/C (chr11:111,383,663-\n111,384,240), MIR-129-1 (chr7:127,847,925-127,847,996), MIR-129-2 (chr11:43,602,944-\n43,603,0 33), MIR-203 (chr14:104,583,742-104,583,851), MIR-143 andMIR-145 genes\n(chr5:148,808,481-148,810,296), were observed in 5%, 13%, 16%, 14% and 12% of\nsamples, respectively (Fig",
      "3B, the combined loss of two or more genes of p53-responsive microRNAs\nVoropaeva et al. (2025), PeerJ, DOI 10.7717/peerj.18661 11/28\n\n \nFigure 3 Spectrum and frequency of detected aberrations in microRNA biogenesis genes according to\nthe analysis of 1295 DLBCL samples presented in the cBioPortal for Cancer Genomics database ( Gao et\nal., 2013 )",
      "However,\nVoropaeva et al. (2025), PeerJ, DOI 10.7717/peerj.18661 12/28\n\nTable 2 The analysis of the tested pairs among the genes losses by the OncoPrinter, according to the\ncBioPortal for Cancer Genomics database ( Navarro & Lieberman, 2015 )",
      "According to the analysis of high-throughput sequencing data of 1295 DLBCL samples\npresented in the cBioPortal for Cancer Genomics database, aberrations rarely detected\nin all genes except for three, namely MOV10, PRKRA andDDX5 (Mitelman Database of\nChromosome Aberrations and Gene Fusions in Cancer, 2024 )",
      "Analysis\nand visualization of longitudinal genomic and clinical data from the AACR project\nGENIE biopharma collaborative in cBioPortal",
      "Integrative analysis of\ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:58.816245",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39802185.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 11,
    "total_data_pmids_cited": 0
  },
  "39781045": {
    "paper_id": "39781045",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Cancer cell line encyclopedia, human protein atlas (HPA) \nand cBioPortal database analysis",
      "cBio \u2011\nPortal (https: //www.cbioportal.org /), an open\u2011source cancer \ngenomics data platform, was used to analyze the mutations, \ncopy\u2011number alterations and gene expression of PAXIP1 in \npatients with HCC (31,32)",
      "Liver studies were selected and \nthe keyword \u2018PAXIP1\u2019 was searched on the query page of the \ncBioPortal website  (33\u201142)",
      "To elucidate the relationship between \nPAXIP1  expression and HCC prognosis, PAXIP1 genomic \nalterations were first analyzed in HCC using the cBioPortal \nwebsite",
      "PAXIP1 genomic alterations in fourteen studies of liver carcinomas analyzed using the cBioPortal database",
      "de Bruijn I, Kundra  R, Mastrogiacomo B, Tran TN, Sikina L, \nMazor T, Li X, Ochoa A, Zhao G, Lai B , et al : Analysis and \nvisualization of longitudinal genomic and clinical data from the \nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:17:59.866570",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39781045.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "39769478": {
    "paper_id": "39769478",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data Availability Statement: The Genie data are available through The AACR Project GENIE\nConsortium at cBioportal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:02.987892",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39769478.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "39803512": {
    "paper_id": "39803512",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "483 \n 484 \nHuman cancer bioinformatics  485 \nBioinformatics analysis of human data was performed using cBioPortal",
      "cBioPortal was used to subset TCGA BRCA patients into four 488 \nclinical subtypes based on clinical expression data of markers",
      "de Bruijn  et al. , Analysis and Visualization of Longitudinal Genomic and Clinical Data 590 \nfrom the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao  et al. , Integrative analysis of complex cancer genomics and clinical profiles using 593 \nthe cBioPortal",
      "Samples are segregated by TP53 deletion, missense mutation, or \nwild-type in cBioPortal",
      "(E) cBioPortal data of SQLE and \nDHCR7 mevalonate pathway gene expression, RSEM batch normalized from Illumina HiSeq_RNASeqV2"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:07.634538",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39803512.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0
  },
  "39779848": {
    "paper_id": "39779848",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:10.103508",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39779848.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0
  },
  "39765674": {
    "paper_id": "39765674",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data so urce: The Cancer Genome Atlas (TCGA), PanCancer \nAtlas, and MSK, Nature Medicine 2022\u2014cBioPortal for Cancer Genomics",
      "Data source: The Cancer Genome Atlas (TCGA), PanCancer\nAtlas, and MSK, Nature Medicine 2022\u2014cBioPortal for Cancer Genomics",
      "Data source: MSK, Nature Medicine, 2022\u2014cBioPortal for Can-\ncer Genomics",
      "Data source: MSK, Nature Medicine, 2022\u2014cBioPortal for\nCancer Genomics",
      "According to the MSK cohort data reported in Nature Medicine (2022), available on \ncBioPortal for Cancer Genomics [48\u201350], whic h included 692 rectal cancer samples, 4% \nexhibited PTEN  alterations, primarily consisting of missense mutations, deletions, and \ntruncating mutations",
      "Biology 2024 ,13, 1007 9 of 24\nAccording to the MSK cohort data reported in Nature Medicine (2022), available\non cBioPortal for Cancer Genomics [ 48\u201350], which included 692 rectal cancer samples,\n4% exhibited PTEN alterations, primarily consisting of missense mutations, deletions, and\ntruncating mutations",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the CBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.; Ochoa, A.; Zhao, G.; Lai, B.; et al. Analysis and\nVisualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in CBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:15.695228",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39765674.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0
  },
  "39763776": {
    "paper_id": "39763776",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "tumors following our published protocols.21,39 Comprehensive descriptions of these PDXO lines \nand clinical annotations for the originating tumor samples are provided in Supplementary Table \nS1, and omic profiles of the originating patient tumor (when available), the PDX, and the \nmatching PDXO lines wer e imported into cBioPortal.40\u201342 Each of the organoid lines was \nfunctionally characterized for response to a subset of >100 anticancer therapies centering on \ntreatments approved for breast cancer and drugs available through the National Cancer \nInstitute\u2019s Cancer Therapy Evaluation Progra m",
      "Data processing for cBioPortal  \nFor clinical data variables, meta data for samples was integrated with institutional patient data \nextracted from the electronic medical record using custom Python scripts and made both \nrelative to the patient date of birth and formatted for cBioPortal (Doc kerized version V6.0.16) per \ndocumentation ( https://docs.cbioportal.org/file -formats )",
      "MAF files were compiled and formatted for cBioPortal using \nscripts available upon request",
      "Requisite z-score TPM values were calculated for all genes across \nsamples using scripts provided by cBioPortal.org",
      "All uploaded data passed cBioPortal integral \nvalidation sc ripts for expected formats and sample alignment",
      "All data used for model training is downloadable from \nthis repository or through cBioPortal (link to be provided upon acceptance for publication)",
      "AA and JW processed omic data for PDMCs and uploaded them \nto cBioportal",
      "AA and SDS processed metadata and developed a modified cBioportal instance",
      "KTV and AW provided oversight to PDMC omics data sharing and cBioportal structure",
      "et al.  Integrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal",
      "et al.  Analysis and visualization of longitudinal genomic and clinical data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "While natural log transformed IC50 \nvalues were used in the development of ScreenDL to facilitate the harmonization of PDXO and \ncell line drug response data, the calculation of GRaoc values for cBioPortal involved several \nmodifications to improve the stab ility of GR calculations and reduce bias in GRaoc values"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:20.131091",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39763776.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 12,
    "total_data_pmids_cited": 0
  },
  "39789388": {
    "paper_id": "39789388",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The \ufb02uorescence of single cells was quanti \ufb01ed using\na Attune NxT system and analyzed using FlowJo v10.8.1 software.Bioinformatics and statistical analysis\nThe TCGA ( n= 1084) and CPTAC ( n= 105) datasets (Data refs:\nBerger et al, 2018 ;M e r t i n se ta l , 2016 ) were accessed and analysed\nusing cBioportal in March 2022 (Cerami et al, 2012 ;d eB r u i j ne ta l ,\n2023 ;G a oe ta l , 2013 )",
      "Source data from GDC ( https://www.cbioportal.org/study",
      "Biochem Soc\nTrans 45:1125 \u20131136\nde Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa\nA, Zhao G, Lai B et al (2023) Analysis and visualization of longitudinal\ngenomic and clinical data from the AACR Project GENIE BiopharmaCollaborative in cBioPortal",
      "Nature 460:278 \u2013282\nGao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen\nA, Sinha R, Larsson E et al (2013) Integrative analysis of complex cancergenomics and clinical pro \ufb01les using the cBioPortal",
      "Source data from\nGDC ( https://www.cbioportal.org/study?id =breast_cptac_gdc )[ D A T A S E T ]\nMevissen TE, Hospenthal MK, Geurink PP, Elliott PR, Akutsu M, Arnaudo N,\nEkkebus R, Kulathu Y, Wauer T, El Oualid F et al (2013) OTU deubiquitinases\nreveal mechanisms of linkage speci \ufb01city and enable ubiquitin chain restriction\nanalysis"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:22.842503",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39789388.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "39735786": {
    "paper_id": "39735786",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Application Notes\npyBioPortal: a Python package for simplifying cBioPortal \ndata access in cancer research\nMatteo Valerio \n , MscEng1,\ufffd, Alessandro Inno, MD1, Stefania Gori, MD1 \n1Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Verona, Italy\n\ufffdCorresponding author: Matteo Valerio, MscEng, Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Via Don A",
      "cBioPortal is one of the most widely used platforms for accessing cancer genomic and clinical data",
      "The primary objective \nof this study was to develop a tool that simplifies programmatic interaction with cBioPortal\u2019s web service",
      "Materials and Methods: We developed the pyBioPortal Python package, which leverages the cBioPortal REST API to access genomic and clin-\nical data",
      "Results: pyBioPortal offers an efficient interface between the user and the cBioPortal database",
      "By simpli -\nfying the interaction with the cBioPortal API and providing data in Pandas DataFrame format, pyBioPortal allows users to focus more on the ana-\nlytical aspects rather than data extraction",
      "pyBioPortal is a newly developed Python tool designed to simplify \nthe process of retrieving data from cBioPortal, a widely used platforms for accessing cancer genomic and clinical data",
      "Key words: cBioPortal; cancer research; bioinformatics; Python",
      "However, directly using the \ndownloadable data from cBioPortal without significant \nprocessing, or specifically its available API, could be challenging for researchers and university students without \nspecific programming skills, as the data may be presented \nin complex, nested formats that require conversion into \nusable tables",
      "Objectives\nThe main objective that led to the development of pyBio -\nPortal is to simplify programmatic interaction with \ncBioPortal\u2019s public API and provide the retrieved data in a \nstandardized format, directly usable for analysis, with the \naim of improving the reproducibility of results in cancer \nresearch",
      "The package uses the REST API web services provided by \ncBioPortal to retrieve the data of interest, leveraging external \nlibraries such as Requests7and Pandas8for handling Hyper -\ntext Transfer Protocol (HTTP) requests9and processing the \nretrieved data",
      "The structure of the package is organized into modules, \neach of which is dedicated to a specific type of data, as \ndefined by the cBioPortal API described in the related docu -\nmentation (https://www.cbioportal.org/api/swagger-ui/index",
      "pyBioPortal manages the entire set of endpoints provided \nby the cBioPortal REST API, supporting HTTP requests with \nboth GET and POST methods",
      "The functions within each \nmodule are named according to a convention outlined in the \nAPI documentation, which identifies the type of request sent \nto the server: functions using the GET method are prefixed \nwith \u201cget,\u201d while those using the POST method are prefixed \nwith \u201cfetch.\u201d\nDatabase query and data retrieval\nTo specify and request which data you want to retrieve from \nthe cBioPortal database, it is necessary to define a query hav-\ning parameters whose type and meaning are described in the \nonline documentation provided by cBioPortal",
      "The installation of the package is straightforward and fol-\nlows the standard procedure for both platforms with the fol-\nlowing commands:\n#PyPIinst\nallation\npipinstal\nlpybiopor\ntal\n#Anaconda\ninstallat\nion\ncondainst\nall\ncmatteo.v\naleriopyb\nioportal\nExample of usage\npyBioPortal implements a simple and efficient interface \nbetween the user and the cBioPortal database",
      "To illustrate \nits usage, an example is provided for retrieving clinical data \non patient survival from a study available in cBioPortal",
      "The \nstudy considered is related to The Cancer Genome Atlas \nSerous Ovarian Cancer project,11identified by the code \n\u201cov_tcga_pub.\u201d\nFirst, import the module that handles the specific type of \ndata, in this case, \u201cclinical_data.\u201d Next, identify the appro -\npriate function from the module for the data to be retrieved, \nin this case, \u201cfetch_all_clinical_data_in_study.\u201d Then, specify \nthe variables to be acquired, according to the cBioPortal doc-\numentation",
      "io), which includes various application examples organized in \nJupyter Notebooks.13\nConfiguration for local instances of cBioPortal\nThe pyBioPortal package is designed to interact with the pub-\nlic API of cBioPortal, with the default Uniform Resource \nLocator (URL) set to https://www.cbioportal.org/api",
      "How -\never, the package also supports the use of local instances of \ncBioPortal, which can be implemented by institutions or com-\npanies that wish to maintain their data on private servers.To use a local instance instead of the public one, API base \nURL can be configured using the \u201cconfigure_base_url\u201d func-\ntion from the pyBioPortal configuration module (\u201c__con -\nfig\u201d)",
      "This allows HTTP requests to be sent to a specific \ncBioPortal instance, installed locally or on a private server, \nrather than to the public instance",
      "__configa\nsconf\nconf.conf\nigure_bas\ne_url(\"ht\ntps://loc\nal_instan\nce_url\")\nThis feature is particularly useful for users working with \nsensitive data or who require complete control over their \nanalysis environment, avoiding dependence on the public \ncBioPortal infrastructure",
      "Discussion\nThe pyBioPortal package was developed with the main goal \nof simplifying interaction with the public cBioPortal API, \nmaking biological and clinical data more accessible to \nresearchers or university students who are not familiar with \nadvanced programming",
      "From the official documentation of cBioPortal (https:// \ndocs.cbioportal.org/web-api-and-clients/), there are 2 main \nways to access the API using Python: the Bravado package, \nwhich allows direct interaction with the API, and the cbio_py \npackage, a wrapper for the API",
      "Schematic representation of the data flow from cBioPortal to the user through pyBioPortal.JAMIA Open, 2025, Vol",
      "In con-\ntrast, pyBioPortal handles the entire set of cBioPortal API \nendpoints, including both GET and POST methods, and pro-\nvides data directly in the user-friendly Pandas DataFrame for-\nmat",
      "Currently, pyBioPortal uses the Pandas library to convert \ndata obtained from cBioPortal into DataFrames, providing a \nfamiliar and versatile format for data analysis in Python",
      "Addition -\nally, the retrieval time of large datasets from the cBioPortal \nAPI could be lengthy, slowing down the execution of code \nthat depends on it",
      "Kaplan-Meier survival curves obtained using Lifelines package with the clinical data retrieved from cBioPortal.4                                                                                                                                                                                               JAMIA Open, 2025, Vol",
      "Given that cBioPortal is adopted by numerous institutions \nand companies with local installations, pyBioPortal includes \nfunctionality to configure the server URL for API interac -\ntions",
      "In the future, it is planned to implement new supporting \nfeatures that will enhance and improve usage, such as user \nauthorization support for local cBioPortal instances and the \ndevelopment of built-in analysis functions",
      "Conclusion\nIn this paper, we presented pyBioPortal, a Python package \nuseful for retrieving data from cBioPortal through its REST \nweb services, which provides quick and easy access to hetero -\ngeneous biological and clinical data",
      "The aim is to provide a significant contribution to the bio-\ninformatics community by offering a tool that facilitates pro-\ngrammatic access to cBioPortal data and enhances the \nreproducibility of the analyses in cancer research",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of com-\nplex cancer genomics and clinical profiles using the cBioPortal",
      "Analysis and visualization of longitudinal genomic and clinical \ndata from the AACR project GENIE biopharma collaborative in \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:23.105142",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39735786.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 34,
    "total_data_pmids_cited": 0
  },
  "39741346": {
    "paper_id": "39741346",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To further characterize KDM6A genetic alterations \nin PC, we took advantage of the online tool cBioPortal for cancer genomics [ 90\u201392] for searching genetic altera -\ntions across both prostate adenocarcinoma and meta -\nstatic prostate adenocarcinoma",
      "2C, the \nvariation frequency of KDM6A is about 8% (cBioPortal), \nfrequency that is comparable with two relevant genes in \nprostate cancer such as BRCA2 [ 93] and ATM [ 94]",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. \nAnalysis and visualization of longitudinal genomic and clinical data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Integrative analysis of \ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:27.831060",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39741346.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "39747580": {
    "paper_id": "39747580",
    "cbioportal_paper_citations": [
      "[PubMed: 22588877] \n43",
      "[PubMed: 37668528] \n44"
    ],
    "cbioportal_platform_mentions": [
      "Data from TCGA were access via \nthe NCI Genomic Data Commons ( https://gdc.cancer.gov/ )41 and cBioPortal ( https://www.cbioportal.org/ )42\u201344",
      "de Bruijn I et al. Analysis and visualization of longitudinal genomic and clinical data from \nthe AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Gao J et al. Integrative analysis of complex cancer genomics and clinical profiles using the \ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:28.997993",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39747580.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39720461": {
    "paper_id": "39720461",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "With respect to genetic alterations of MACF1 in brain tumors, specifically glioblastomas, cancer genome atlas cbioportal (https://www.cbioportal.org/) analyses revealed that 5% of pat ient sa mples consist e d of mut at ions or a mpl i ficat ions  (21\u201123)",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al : Integrative analysis \nof complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra  R, Mastrogiacomo B, Tran TN, Sikina  L, \nMazor T, Li X, Ochoa A, Zhao G, Lai B, et al : Analysis and \nvisualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:32.226790",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39720461.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39715959": {
    "paper_id": "39715959",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2  Materials and\u00a0methods\n2.1  Data collection\nThe RNA-seq dataset as well as genetic mutation and clinical information of TCGA [14] were downloaded from the \ncBioportal [16\u2013 18] in April 2024",
      "2.5  Data visualization\nHeatmaps, UMAP plots, and violin plots were created using the \u201cpheatmap\u201d[25] \u201cumap\u201d[21], and \u201cvioplot\u201d[26] pack -\nages in R [22]; Kaplan\u2013Meier plots were generated using cBioPortal [16\u2013 18]; and Bar plots were generated using \nMicrosoft Excel",
      "Data availability The results shown here are based upon data generated by cBioPortal and are available in a public repository from the https://  \nwww",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et\u00a0al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE \nbiopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et\u00a0al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:34.224198",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39715959.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0
  },
  "39727012": {
    "paper_id": "39727012",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(C) CYBC1 and \nNOXA1 mRNA expression correlation data derived from the cBioPortal database (n=141)",
      "Database analysis revealed a positive cor -\nrelation between CYBC1 and NOXA1 mRNA expression, as \nevidenced by data from TCGA sourced from the cBioPor -\ntal database (https:/ /www.cbioportal.org) (Fig",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer \nSO, et al. Integrative analysis of complex cancer genomics and \nclinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, \nMazor T, et al. Analysis and visualization of longitudinal \ngenomic and clinical data from the AACR Project GENIE Biop -\nharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:34.824622",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39727012.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0
  },
  "39715911": {
    "paper_id": "39715911",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods The expression levels, prognostic values, genetic mutations, and DNA promoter methylation of ZBTB11 across \ntumor types were explored via various online websites and databases, including TIMER2.0, GEPIA2, cBioPortal, UALCAN, \nGSCA, CancerSEA, and others",
      "Additionally, the cBioPortal [26\u2013 28] (https:// www",
      "We \nutilized the cBioPortal database to analyze the genetic variants of ZBTB11 in pan-cancer",
      "Furthermore, analysis of the cBioPortal database indi-\ncated that missense mutations were the predominant type of ZBTB11 gene mutation in cancers (Fig",
      "D Alteration frequencies of ZBTB11 in human pan-cancer by \nthe cBioPortal tool",
      "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "Analysis and visualization of longitudinal genomic and clinical data from the AACR project \nGENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:37.162379",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39715911.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0
  },
  "39715885": {
    "paper_id": "39715885",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioportal, originally developed at Memorial Sloan\nKettering Cancer Center, is an inclusi ve and continually updated database,\ncompiling datasets from TCGA, GDC, GENIE and others as well as newlypublished studies",
      "Another reason is\nthat the cBioportal database comes with built-in analysis tools, including\nsurvival rate displays",
      "The cBioportal database for \u201cbowels cancer \u201dincluded\n19 studies, with 7661 CRC samples from 7435 patients (as of Jan-Feb, 2024)",
      "0 5 ) .H o w e v e r ,a m o n g\nthe 42 SCGs, an association of a gene alteration with a race category wasfound for 29 genes, according to the cBioportal database, suggestingthat most (69.0%) of the white variant-pronounced SCGs may beinvolved in an ethnicity-speci \ufb01c role for survival (examples of race\ncategory changes for AAs are shown in Fig",
      "The clinical\nattributes are as de \ufb01ned in the cBioportal database",
      "For (2): With consultation of data i n the cBioportal bow el cancer (as of\n9/5/2024, 24 studies, total 8611 samples), HTR1F and FLCN did not meet\nour\u201csurvival-critical gene \u201dcriteria",
      "For example , as of Sept 10, 2024, the cBioportal\ndatabase carries 8625 bowel cancer samples, yet only 5 were identi \ufb01edas AIs",
      "CMScaller (available at https://github.com/\npeterawe/CMScaller ) provides CMS classi \ufb01cation of colorectal cancer pre-\nclinical models based on a \ufb01ltered set of cancer cell-intrinsic, subtype-\nenriched gene expression markers13.W ei n p u tt h eR N A s e qd a t a( f r o m\nprevious study8; original data deposited to Gene Expression Omnibus\n(GEO) (NIH, US) as GSE237684) into the CMScaller, which returned thedistribution of samples in the CMS groups.https://doi.org/10.1038/s41698-024-00782-9 Article\nnpj Precision Oncology |           (2024) 8:288 12\n\nSCG identi \ufb01cation\nFor each of the genes in the list (Supplementary Tables 1 \u20133), we consulted\ncBioportal ( www.cbioportal.com )9\u201311",
      "Based on the cBioportal algorism,\nCRCs with the gene of interest altered and unaltered were grouped, and thesurvival rate of patients, as well as vario us clinical attributes, were compared\nbetween gene-altered and gene-unaltered groups",
      "Gao et al. Integrative analysis of complex cancer genomics and\nclinical pro \ufb01les using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR Project GENIE biopharmacollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:44.750471",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39715885.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 11,
    "total_data_pmids_cited": 0
  },
  "39687985": {
    "paper_id": "39687985",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of com-\nplex cancer genomics and clinical pro\ufb01les using the cBioPortal.Sci"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:45.963803",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39687985.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "39688957": {
    "paper_id": "39688957",
    "cbioportal_paper_citations": [
      "1158/2159-8290.CD-12-0095, PMID: 22588877\nChen Q, He Z, Lan A, Shen X, Wen H, Wu CI",
      "DOI: https://doi.org/10.1158/0008-5472.CAN-23- \n0816, PMID: 37668528\nDeng S, Xing K, He X"
    ],
    "cbioportal_platform_mentions": [
      "Patient data were retrieved from the GENIE \ndatabase (https://genie-public-beta.cbioportal.org/) and stratified into three groups based on EGFR mutation profiles: Group 1 comprises patients with \nEGFR CDN mutations; group 2 includes patients with nonsynonymous mutations in EGFR that are not cancer- driving nucleotides (CDNs); the EGFRWT \ngroup consists of patients with no EGFR mutations (see \u2018Methods\u2019)",
      "Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE biopharma \ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:48.162169",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39688957.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0
  },
  "39762893": {
    "paper_id": "39762893",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Survival data validates gene expression and\u00a0prognosis\nData from the small cell lung cancer study [35] published \nin Nature in 2015 is downloaded from cBioPortal [36\u201338]",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex \ncancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualization \nof longitudinal genomic and clinical data from the AACR Project GENIE \nbiopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:49.539199",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39762893.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0
  },
  "39679742": {
    "paper_id": "39679742",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis and visualization of longitudinal\ngenomic and clinical data from the aacr project genie biopharma collaborative in\ncbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:18:55.825216",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39679742.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0
  },
  "39660144": {
    "paper_id": "39660144",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Spearman\u2019s or Pearson\u2019s correlation\nanalyseswereconductedinFigures1C,E,4,2B,aswellasinTables\nQueries of TCGA data via Cbioportal and 1\u20134",
      "The cBioPortal for Cancer Genomics provides aweb resource\nforintegrativeanalysis(23\u201325).Geneexpressioncorrelationswere\nResults\nexploredusingtheLiverHepatocellularCarcinomadataset(TCGA,\nPanCancer Atlas), with results displayed as scatter plots in Log2\nRPA1-ETAA1 association linked to PD-L1 in\nRSEM (normalized from RNASeqV2) (n=366)",
      "ETAA1 RNASeqV2 data were this end, we used a predicted functional PPI network, which\ncollected from the TCGA PanCancer Atlas cohort via cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:32:55.921517",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39660144.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.207861661911011,
      "cbioportal_papers": 0.0002129077911376953,
      "platform_mentions": 0.0016093254089355469,
      "data_citations": 0.3201942443847656,
      "num_data_pmids_checked": 380
    }
  },
  "39650068": {
    "paper_id": "39650068",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "canbefoundhere:https://www.cbioportal.org/study/summary?id=\nFutibatinib, an irreversible FGFR inhibitor, significantly inhibited breast_msk_2018"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:32:56.047885",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39650068.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.106158971786499,
      "cbioportal_papers": 0.0003409385681152344,
      "platform_mentions": 0.0035860538482666016,
      "data_citations": 0.5446441173553467,
      "num_data_pmids_checked": 380
    }
  },
  "39684873": {
    "paper_id": "39684873",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:00.246208",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39684873.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.620500087738037,
      "cbioportal_papers": 0.00030303001403808594,
      "platform_mentions": 0.0027458667755126953,
      "data_citations": 0.24259614944458008,
      "num_data_pmids_checked": 380
    }
  },
  "39671496": {
    "paper_id": "39671496",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "were downloaded from cBioPortal (59, 61)",
      "Schultz, Analysis and visualization of longitudinal genomic regulate endosomal Pi(4,5)P2 homeostasis via lipid transport to promote embryogenesis\nand clinical data from the AAcR project Genie biopharma collaborative in cBioPortal",
      "cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:02.238028",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39671496.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.991406917572021,
      "cbioportal_papers": 0.0005009174346923828,
      "platform_mentions": 0.0052988529205322266,
      "data_citations": 0.8246207237243652,
      "num_data_pmids_checked": 380
    }
  },
  "39652422": {
    "paper_id": "39652422",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "AACR Project GENIE: Powering Biopharma Collaborative in cBioPortal",
      "Protoc.Mol.Biol.109:21.29.1\u201321.29.9.https://doi.org/10.1002/0471142727 Jacobsen,R.Sinha,E.Larsson,etal.2013.Integrativeanalysisofcom-\n.mb2129s109 plex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:07.111660",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39652422.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.216119050979614,
      "cbioportal_papers": 0.0004930496215820312,
      "platform_mentions": 0.0039119720458984375,
      "data_citations": 0.41880202293395996,
      "num_data_pmids_checked": 380
    }
  },
  "39637338": {
    "paper_id": "39637338",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:08.295868",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39637338.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.281619310379028,
      "cbioportal_papers": 0.00017786026000976562,
      "platform_mentions": 0.0014750957489013672,
      "data_citations": 0.0909128189086914,
      "num_data_pmids_checked": 380
    }
  },
  "39580563": {
    "paper_id": "39580563",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:11.377983",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39580563.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.002770185470581,
      "cbioportal_papers": 0.00019788742065429688,
      "platform_mentions": 0.0004010200500488281,
      "data_citations": 0.11122822761535645,
      "num_data_pmids_checked": 380
    }
  },
  "39616148": {
    "paper_id": "39616148",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:12.411016",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39616148.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.117664098739624,
      "cbioportal_papers": 0.0002598762512207031,
      "platform_mentions": 0.0019490718841552734,
      "data_citations": 0.232072114944458,
      "num_data_pmids_checked": 380
    }
  },
  "39605676": {
    "paper_id": "39605676",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutation data for the TCGA KIRC cohort was downloaded from cBioPortal\n(https://www.cbioportal.org/study/summary?id=kirc_tcga_pan_can_atlas_2018)18,63\u201365",
      "Clinical data for TCGA KIRC was downloaded from cBioPortal\n(https://www.cbioportal.org/study/summary?id=kirc_tcga_pan_can_atlas_2018)18,63\u201365"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:14.912575",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39605676.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.424795150756836,
      "cbioportal_papers": 0.0002620220184326172,
      "platform_mentions": 0.0029129981994628906,
      "data_citations": 0.2382640838623047,
      "num_data_pmids_checked": 380
    }
  },
  "39579248": {
    "paper_id": "39579248",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "There was a statistically sig-\nT cells\nnificant positive correlation with high GR tumor cell expres-\nsion and higher percentages of FOXP3+ immune cells\nand BATF3+ immune cells (Table 2, FOXP3+ p = 0.046, Within the TCGA database via cBioportal [24\u201326], we\nBATF3+ p = 0.021), demonstrating increased infiltration found that NR3C1 mRNA expression was significantly cor-\nof regulatory T-cells and BATF3+ immune cells into the related to FOXP3 expression (Fig",
      "Verron\u00e8se E et al (2016) Immune cell dysfunctions in breast can-\ngenomics and clinical profiles using the cBioPortal\u201d",
      "Treilleux I et al (2004) Dendritic cell infiltration and prognosis\nbiopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:16.202564",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39579248.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.899858236312866,
      "cbioportal_papers": 0.00021791458129882812,
      "platform_mentions": 0.0019240379333496094,
      "data_citations": 0.1763298511505127,
      "num_data_pmids_checked": 380
    }
  },
  "39688960": {
    "paper_id": "39688960",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Additional mutation data was acquired from the AACR Project GENIE Consortium via cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:21.829458",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39688960.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 33.15993690490723,
      "cbioportal_papers": 0.0003409385681152344,
      "platform_mentions": 0.0029859542846679688,
      "data_citations": 0.28807806968688965,
      "num_data_pmids_checked": 380
    }
  },
  "39575998": {
    "paper_id": "39575998",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Clinical data was retrieved from\ncBioPortal database to compare overall survival between mutated POLE (POLEmut) and\n\u00a9 2025",
      "Relationship between POLE mutations and survival\nAnalysis of the relationship between the mutational status of the POLE gene and survival\nin patients with EC was conducted using data from studies registered for this cancer in the\nhttps://ejgo.org https://doi.org/10.3802/jgo.2025.36.e45 3/13\n\nPOLE: functions, interactions, and prognostic role\ncBioPortal for Cancer Genomics database (https://www.cbioportal.org/) [21]",
      "Relationship between POLE mutations and survival\ncBioPortal was used for visualization, analysis, and downloading of genomic datasets from\nstudies conducted on endometrial carcinoma and uterine corpus EC",
      "The overall survival of EC patients with POLEmut and POLEwt was evaluated using cBioPortal\n(Fig",
      "Analysis of the data extracted from the cBioPortal database",
      "DFS and OS of endometrial cancer patients according to the data recorded in cBioPortal for POLE mutation status and clinical data for this cancer",
      "In the present study,\nwe observed that analysis of the data retrieved from the cBioPortal database showed the same\ntrend (Fig",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization\nof longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:22.310037",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39575998.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.890811920166016,
      "cbioportal_papers": 0.00019407272338867188,
      "platform_mentions": 0.002276182174682617,
      "data_citations": 0.10269904136657715,
      "num_data_pmids_checked": 380
    }
  },
  "39575113": {
    "paper_id": "39575113",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis and visualization of longitudinal\ngenomic and clinical data from the aacr project genie biopharma collaborative in\ncbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:23.390053",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39575113.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.805458307266235,
      "cbioportal_papers": 0.00021195411682128906,
      "platform_mentions": 0.0017158985137939453,
      "data_citations": 0.20454096794128418,
      "num_data_pmids_checked": 380
    }
  },
  "39543667": {
    "paper_id": "39543667",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "h t m l\ncBioPortal for cancer genomics https://www.cbioportal.org\nGCD Data Portal https:/ /portal .gdc.ca ncer .gov/\nBBG Lab - Cancer Genome Interpreter/Cancer Biomarker Database https:/ /www.ca ncergen omei nterpreter.org/home and\nhttps:/ /www.ca ncergen omei nterpreter.org/biomarkers\nCaterogy 3 Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer https:/ /mitelm andatab ase",
      "MyCancerGenome also sup- OncoKB annotations are publicly accessible through\nports integration with applications outside its web inter- its website and are also integrated into the cBioPortal\nface, such as landscape analyses and interpretive reports for Cancer Genomics, enabling easy interpretation of\nfor pathologists, clinical trial planning, and molecular genomic alterations by researchers and clinicians [12\u2013\ntumor board reports [9]",
      "A recent update now includes functional and u ) is an online, interactive, open-access resource for col-\nmechanistic descriptions of how each gene contributes to laborative editing, maintenance, and sharing of clinical-\ndisease progression in terms of the key cancer hallmarks grade interpretations on cancer genes, connecting its\n\nGazola et al. Molecular Cytogenetics (2024) 17:28 Page 9 of 18\nvariants to tumor-specific and tissue-specific interpreta- cBioPortal\ntions [22]",
      "Key features of PMKB include support for all The cBioPortal for Cancer Genomics ( h t t p s : / / w w w",
      "Through cBioPortal, users\nscientific data and literature references, potentially can also access data from the AACR Project GENIE upon\nincluding treatment information",
      "cance into three tiers: The cBioPortal platform supports and stores diverse\ntypes of genomic data, including non-synonymous\n\u2022 Variants with strong evidence of clinical utility mutations, DNA copy-number variations, mRNA and\n(tier 1): Variants with strong evidence of clinical microRNA expression data, protein-level and phospho-\nactionability for the tumor type, including FDA- protein-level data, DNA methylation data, and de-iden-\napproved targeted therapies and prognostic tified clinical data [12, 13]",
      "Upon accessing cBioPortal,\nsignificance, as well as those recognized by WHO users can select from a list of cancer studies, with options\nguidelines",
      "When search-\n3): Variants with currently undetermined relevance, ing for a particular gene, cBioPortal provides a list of\nprovided for future potential clinical utility if new cancer cases containing mutations in that gene among\nevidence emerges",
      "cBioPortal provides\nPMKB is easy to navigate and a valuable resource for cli- access to processed clinical data from TCGA studies\nnicians and researchers, providing a dynamic platform and allows researchers to visualize mutations in 3D pro-\nfor cancer genomic data interpretation and informed tein structures by integrating data from the Protein Data\ndecision-making based on insights, with the option of Bank (PDB), which is valuable for studying the biological\ndownloading all data interpretations and variants",
      "changes undergo review by molecular pathologists and However, data on the clinical relevance of specific\noncologists, however, because information is being con- genomic alterations comes from cBioPortal\u2019s integration\nstantly added by specialists in \u201cinterpretation\u201d format, with the OncoKB platform",
      "Gazola et al. Molecular Cytogenetics (2024) 17:28 Page 10 of 18\nThis integration makes cBioPortal particularly useful While most data are publicly available, some raw data\nfor oncologists and researchers, allowing them to quickly from the TCGA and TARGET databases may require\nidentify similar cases already reported in the literature additional authorizations to access via dbGaP, which can\nand obtain clinically relevant information to support delay access to certain subsets of data for researchers",
      "to identify new tumor targets or mechanisms of drug-\nDifferently from PMKB, cBioPortal for Cancer Genom- variant associations, potentially leading to new clinical\nics, GDC Data Portal and BBG Lab - Cancer Genome studies",
      "Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid\nKnowledgebase by Weill Cornell of Medicine, Molecular Match Portal by biopsy: a step closer to transform diagnosis, prognosis and future of cancer\nMolecular Match, cBioPortal for Cancer Genomics by Center for Molecular treatments",
      "Analysis and visualization of longitudinal genomic and clinical data from\nthe AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:26.626300",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39543667.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 14,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.847047090530396,
      "cbioportal_papers": 0.00045228004455566406,
      "platform_mentions": 0.030614852905273438,
      "data_citations": 0.282742977142334,
      "num_data_pmids_checked": 380
    }
  },
  "39518911": {
    "paper_id": "39518911",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DatasetSelectionCriteria\nTo perform survival analysis, we searched the Gene Expression Omnibus (GEO)\n(accesseddate1October2021),cBioPortal(accesseddate1October2021),andtheGenomic\nData Commons Data Portal (accessed date 1 October 2021) to identify eligible datasets\nthat met the following criteria: (1) PCa cases with available gene expression data and\n(2)availableclinicopathologicalfeatureswith\u22655yearsoffollow-up"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:31.783833",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39518911.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.061021089553833,
      "cbioportal_papers": 0.0002970695495605469,
      "platform_mentions": 0.002305746078491211,
      "data_citations": 0.31616735458374023,
      "num_data_pmids_checked": 380
    }
  },
  "39519311": {
    "paper_id": "39519311",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TheCancerGenomeAtlasDatasetAnalysis\nThe clinical data and mRNA expression levels of PPARA, PPARG, and PPARD in\npatientswithovariancancerwereextractedfromtheTCGAovariancancerdataset(2011\nversion,n=489,andhttp://cbioportal.org,accessedon7May2024)[33,49]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:35.731990",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39519311.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.283926963806152,
      "cbioportal_papers": 0.00027298927307128906,
      "platform_mentions": 0.02762007713317871,
      "data_citations": 0.1917719841003418,
      "num_data_pmids_checked": 380
    }
  },
  "39677666": {
    "paper_id": "39677666",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:37.204912",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39677666.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 48.63098692893982,
      "cbioportal_papers": 0.00028586387634277344,
      "platform_mentions": 0.0022079944610595703,
      "data_citations": 0.18457508087158203,
      "num_data_pmids_checked": 380
    }
  },
  "39518098": {
    "paper_id": "39518098",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(A)EZH2gainstatusindifferent\ncancer types from the cBioPortal database"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:38.869320",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39518098.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.378615856170654,
      "cbioportal_papers": 0.0003108978271484375,
      "platform_mentions": 0.0023832321166992188,
      "data_citations": 0.4595170021057129,
      "num_data_pmids_checked": 380
    }
  },
  "39518051": {
    "paper_id": "39518051",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "AccesstoClinicalData\nRelevant clinical data and pathology reports were retrieved using cBioPortal [24\u201326]",
      "\u201chttps://www.cbioportal.org/study/clinicalData?id=ov_tcga(accessedon24October2024)\u201d"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:40.742997",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39518051.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.864647150039673,
      "cbioportal_papers": 0.00033783912658691406,
      "platform_mentions": 0.0034601688385009766,
      "data_citations": 0.24810385704040527,
      "num_data_pmids_checked": 380
    }
  },
  "39540840": {
    "paper_id": "39540840",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Public bulk RNA-seq data from ICB-treated cohorts were down-\nloaded from the cBioPortal (https://www.cbioportal.org/; refs",
      "D u W, Hua F, Li X, Zhang J, Li S, Wang W, et al. Loss of optineurin Integrative analysis of complex cancer genomics and clinical profiles\ndrives cancer immune evasion via palmitoylation-dependent IFNGR1 using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:42.361154",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39540840.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 27.095930814743042,
      "cbioportal_papers": 0.000530242919921875,
      "platform_mentions": 0.06162285804748535,
      "data_citations": 0.2903432846069336,
      "num_data_pmids_checked": 380
    }
  },
  "39519144": {
    "paper_id": "39519144",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:50.054434",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39519144.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 27.7364821434021,
      "cbioportal_papers": 0.0003509521484375,
      "platform_mentions": 0.002939939498901367,
      "data_citations": 0.41324806213378906,
      "num_data_pmids_checked": 380
    }
  },
  "39421280": {
    "paper_id": "39421280",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To determine how\ndefects in CC components impact cancers, we analyzed human gastrointestinal (GI) cancer patient tissue and clinical data from cBioPortal",
      "cBioPortal datasets were analyzed for CC factor alterations and patient outcomes in GI cancers (bowel, stomach, esophagus, pancreas, and\nliver)",
      "The cBioPortal for Cancer Genomics (cBioPortal.org) To establish driver gene cohorts, a free account was created\ndatabase is an open access, web-based platform that contains with cBioPortal for Cancer Genomics at www.cbioportal.org/",
      "curated genomics data of cancer tissues of major cancer types Bowel cancer non-redundant studies (17 studies) were cho-\nand corresponding patient outcomes.22-24 cBioPortal stores de- sen and queried for driver gene, for example, APC",
      "We therefore examined cBioPortal for CC factor changes with other driver genes were created: APC cohort (4393\nand patient survival outcomes especially focused on bowel and patients); KRAS cohort (2737 patients); TP53 cohort (4275\nother GI tract cancers of the stomach, esophagus, pancreas, patients); BRAF cohort (661 patients); and BRAF cohort from\nliver, and biliary tract",
      "Furthermore, we report on the use of cBioPortal gene CC factor changes (eg, APC CC factors) are desig-\ngene co-expression datasets to define the genes and molecular nated Altered Group",
      "tled Cancer Types Summary (Cancer Type Detailed), Mutual\nOur analysis and results highlight the use of the cBioPortal Exclusivity, Mutations, Comparison/Survival, and Clinical",
      "Selected the altered\nsamples (with alterations in the queried driver gene) by click-\nCBioPortal data analysis\ning the \u201cQuery\u201d next to the \u201cAltered Samples\u201d underneath the\nQueried dataset for bowel cancers simultaneously for 6 CC \u201cDownload\u201d tab",
      "Altered\ngroup in bar graph represents race profile of patients with alter- The versatility of cBioPortal is that curated data can be easily\nations in SF1, whereas Unaltered group represents race profile accessed and groups can be compared (Group Comparison)\nof patients without alterations in any of the 6 CC factors",
      "The log-rank test is\nCo-expression data and IPA\nused to compute significance of survival curves as indicated by\nUsing TCGA, PanCancer Atlas (Colorectal Adenocarcinoma) p < 0.05 or more importantly, q of < 0.05.22-24\ndataset, the co-expression data (RNA, protein, or both when Often the survival curves in cBioPortal compare unequal\navailable) of correlated genes was accessed for each CC factor: number of patients",
      "gene list for proteins that correlated with SF1 protein expres-\nsion was created by selecting: Find genes in Protein levels\nResult\n(mass spectrometry by CPTAC; 84 samples) that are corre-\nSelection of CC factors for cBioPortal query\nlated with SF1 in Protein levels (mass spectrometry by\nCPTAC; 84 samples)",
      "Only significantly co-expressed genes were ach, esophagus, pancreas, liver) datasets from cBioPortal were\n<\nretained for analysis (q-value 0.05)",
      "Incidence of CC factor alterations in GI cancers from cBioPortal",
      "All non-redundant studies in cBioPortal for each type of GI\nTo summarize, analysis of 17 different bowel cancer studies\ncancer were selected (eg, under bowel cancers, our query\nrevealed low rates of genetic changes of CC factors and with\nselected 17 non-redundant studies)",
      "Colon cancer were not monitored for survival, but both experimental results\npatients with alterations in CC factor genes have significantly in mice and human patient data from cBioPortal show that\nbetter progression-free survival (q = 3.05e-8) as well as overall genetic loss of SF1 engenders better outcomes",
      "bowel cancers\nThe Kaplan-Meier survival curves derived from cBioPortal\nExamination of the type of mutations in the 6 different CC\noften compare unequal number of patients in altered and unal-\nfactors indicated some hotspots for missense and truncation\ntered groups",
      "This proves that although sample\nsizes may be unequal, 19 out of 20 times the q-values derived\nfrom cBioPortal are reliable indication that survival of altered CC component expression in bowel cancers:\nand unaltered groups is significantly different",
      "TCGA PanCancer Atlas study\nOther clinical attributes are also significantly associated\ncBioPortal also reports changes in mRNA and protein levels in\nwith specific CC factor mutations",
      "We therefore used cBioPortal database to investigate how\nchanges in CC factors modulate the outcome of specific driver\nBRAF cohort\ngenes in colorectal cancer patients",
      "In the multi-step\n\nZhang et al 11\nmodel of colorectal cancer development, APC is genetically TCGA PanCancer Atlas database in cBioPortal was queried\naltered in early adenoma stage, KRAS alterations occur during for mRNAs (RNA-sequencing data) and proteins (mass spec-\nintermediate to late adenoma stages, whereas TP53 alterations troscopy data) whose expression levels correlate with each CC\noccur in subsequent adenocarcinoma stage.20 Our analysis factor (see Supplementary Methods 4)",
      "for cell survival, nutrition, biosynthesis, autophagy, cellular\nExperimental studies using crosslinking and immunoprecipita- movement (invasion), or immune surveillance, such as oxida-\ntion (CLIP) or RNA-Sequencing techniques have identified tive phosphorylation,39 E1F2 signaling,40 insulin secretion,41\npre-mRNA targets and pathways targeted by SF1 from HeLa microRNA biogenesis,42 growth factor receptor\u2013mediated\ncells and from C elegans.2,18 In this study, we used the co- signaling, and phagosome formation.43 Conversely, pathways\nexpression dataset in cBioPortal to obtain information regard- strongly downregulated include tumor suppressor pathways\ning splicing targets of the macromolecular CC spliceosome",
      "Other confounding factors in\n\nZhang et al 13\nanalyzing human cancer patient data from cBioPortal include trend toward better overall or progression-free survival rates",
      "However, it should be noted that the genetic profile of cells\nBowel cancer patients with APC and KRAS mutations, but not from human cancer patients in cBioPortal are complex and\nthose with TP53 and BRAF mutations, tended to harbor muta- many factors, in addition to the CC factor mutations, likely\ntions in more than 1 CC factor",
      "across 27 cancer types in 9070 patients derived from the By using the cBioPortal co-expression database, we have\nTCGA database.48 This study did not focus on different spli- been able to identify the likely targets and pathways of a large\nceosome complexes but screened across all the spliceosome and transient CC (E-complex)",
      "AM and YZ genomics and clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualization of\nlongitudinal genomic and clinical data from the AACR project GENIE bio-\nData availability pharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:56.045292",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39421280.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 26,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.397841215133667,
      "cbioportal_papers": 0.00032782554626464844,
      "platform_mentions": 0.003529071807861328,
      "data_citations": 0.2822842597961426,
      "num_data_pmids_checked": 380
    }
  },
  "39455949": {
    "paper_id": "39455949",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods TIMER, GEPIA, the human protein atlas, GEPIA, TISCH2, and cBioportal examined the gene expression,\nprotein expression, prognostic value, and genetic modification landscape of PTTG1 in 33 malignancies based on the\nTCGA cohort",
      "We discov- depicted based on TCGA pan-cancer atlas studies by\nered that PTTG1 is overexpressed in several tumours and cBioPortal (https://www.cbioportal.org/) [14]",
      "3B), with low\ncBioPortal was used to analyse genetic variations (muta- frequency in the other cancer types (Fig",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa\nA, Zhao G, Lai B, et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR Project GENIE Biopharma Collaborative in\nDeclarations cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:58.589836",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39455949.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.4666690826416,
      "cbioportal_papers": 0.00031495094299316406,
      "platform_mentions": 0.0038399696350097656,
      "data_citations": 0.20760607719421387,
      "num_data_pmids_checked": 380
    }
  },
  "39472543": {
    "paper_id": "39472543",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The external validation\ndatasetisavailableathttps://www.cbioportal.org/study/summary?id=sclc_\nExperimentsettings ucologne_2015"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:33:58.940041",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39472543.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.078089237213135,
      "cbioportal_papers": 0.0002567768096923828,
      "platform_mentions": 0.002410888671875,
      "data_citations": 0.10050415992736816,
      "num_data_pmids_checked": 380
    }
  },
  "39409174": {
    "paper_id": "39409174",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Figures were created and modified by using the MutationMap-\nTI\u2014transactivationinhibitorydomain.FigureswerecreatedandmodifiedbyusingtheMutation-\nper (https://www.cbioportal.org/mutation_mapper, accessed on 9 September 2024) [35]",
      "Mapper(https://www.cbioportal.org/mutation_mapper,accessedon9September2024)[35]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:03.440648",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39409174.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.266974925994873,
      "cbioportal_papers": 0.00020885467529296875,
      "platform_mentions": 0.002235889434814453,
      "data_citations": 0.11666083335876465,
      "num_data_pmids_checked": 380
    }
  },
  "39444988": {
    "paper_id": "39444988",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The upper aqueous phase was then gently\nqueried the cBioPortal (Gao et al. 2013; de Bruijn et al. transferred to fresh autoclaved microcentrifuge tubes",
      "The supernatant was removed, and the pel-\ncohort in cBioPortal and chose the same tumor samples used let was washed thrice with 75% ethanol and the centrifuged\ninitially for DEA",
      "2 Venn plot showing overlapping DEMRGs across (A) LUAD hose Legacy) cohort within cBioPortal for mutational analy-\nand (B) LUSC cohorts",
      "https://d oi.o rg/1 0.1 378/c hest.1 2-2 345 plex cancer genomics and clinical profiles using the cBioPortal",
      "https://\ncancer s1501 0057 doi.o rg/1 0.1 038/n rg.2 015.1 7\nde Bruijn I, Kundra R, Mastrogiacomo B et al (2023) Analysis and Klein JM, Busch JD, Potting C et al (2012) The mitochondrial ami-\nvisualization of longitudinal genomic and clinical data from the doxime-reducing component (mARC1) is a novel signal-anchored\nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:04.576865",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39444988.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.660948991775513,
      "cbioportal_papers": 0.00034880638122558594,
      "platform_mentions": 0.003000974655151367,
      "data_citations": 0.16940522193908691,
      "num_data_pmids_checked": 380
    }
  },
  "39396849": {
    "paper_id": "39396849",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In prostate cancer, as in many other\ncancers, the DNA repair mechanisms, particularly BRCA2 and other major HRR pathway\ngenes, can be mutated (Figure 2; source cBioportal, Cerami et al 2012, Gao et al, 2013 and\nde Bruijn et al. 2023 ), leading to increased reliance on alternative repair pathways, such as\nthe base excision repair pathway involving PARP (Morales et al., 2014)"
    ],
    "data_publication_citations": {
      "29610475": [
        "10.1038/s41588-018-0078-z [PubMed:\n29610475]\nInt Rev Cell Mol Biol"
      ]
    },
    "extraction_date": "2025-12-19T17:34:11.366592",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39396849.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.06193494796753,
      "cbioportal_papers": 0.00035500526428222656,
      "platform_mentions": 0.0027971267700195312,
      "data_citations": 0.36133503913879395,
      "num_data_pmids_checked": 380
    }
  },
  "39399052": {
    "paper_id": "39399052",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Survival analyses\nDataset selection criteria\nTo perform survival analysis, we searched Gene Expression Omnibus (GEO), cBioPortal and the\nGenomic Data Commons Data Portal to identify eligible datasets that met the following criteria:\n(1) PCa cases with available gene expression data and (2) available clinico-pathological features\nwith \u22655 years of follow-up",
      "NEPC patients samples dataset\nTo assess gene expression in NEPC samples, we downloaded the data from the Neuroendocrine\nProstate Cancer (Multi-Institute, Nat Med 2016) dataset published by Beltran et al. [12] from\ncBioPortal [47\u201349]",
      "Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.;\nJacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative Analysis of Complex Cancer\nGenomics and Clinical Profiles Using the cBioPortal",
      "de Bruijn, I.; Kundra, R.; Mastrogiacomo, B.; Tran, T.N.; Sikina, L.; Mazor, T.; Li, X.;\nOchoa, A.; Zhao, G.; Lai, B.; et al. Analysis and Visualization of Longitudinal Genomic\nand Clinical Data from the AACR Project GENIE Biopharma Collaborative in\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:15.064651",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39399052.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.214797258377075,
      "cbioportal_papers": 0.0003046989440917969,
      "platform_mentions": 0.0026559829711914062,
      "data_citations": 0.25692105293273926,
      "num_data_pmids_checked": 380
    }
  },
  "39379462": {
    "paper_id": "39379462",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma\nCollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:16.160227",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39379462.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.53036880493164,
      "cbioportal_papers": 0.0002200603485107422,
      "platform_mentions": 0.0022711753845214844,
      "data_citations": 0.1687779426574707,
      "num_data_pmids_checked": 380
    }
  },
  "39377535": {
    "paper_id": "39377535",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:22.255637",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39377535.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.38203001022339,
      "cbioportal_papers": 0.0004398822784423828,
      "platform_mentions": 0.0035042762756347656,
      "data_citations": 0.2680928707122803,
      "num_data_pmids_checked": 380
    }
  },
  "39345631": {
    "paper_id": "39345631",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:26.688843",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39345631.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.520002126693726,
      "cbioportal_papers": 0.00020694732666015625,
      "platform_mentions": 0.0002338886260986328,
      "data_citations": 0.07260394096374512,
      "num_data_pmids_checked": 380
    }
  },
  "39337357": {
    "paper_id": "39337357",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "However, the cBioportal data-\nbase did not include data on changes in the copy number or correlation of these changes with\nthe expression of IKBKG gens in STAD or CHUK, IKBKB, and IKBKG in READ",
      "GeneAlterationsandTheirInfluenceonIKKComplexGeneExpressionLevel\ncBioportal(https://www.cbioportal.org/,accessedbetween11\u201313September2023)is\nanonlinedatabaseusedtoevaluateputativecopynumberalterations,linearcopynumber\nvalues,andothergeneticaberrationsforselectedgenes[63\u201365].TheTCGAFirehoseLegacy\ndatabasewasusedforCOAD,ESCA,andSTAD,andMSKNatureMedicine2022wasused\nforREAD.AnoncoprintplotwasgeneratedforindividualIKKcomplexgenemembers"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:36.159234",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39337357.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.793140411376953,
      "cbioportal_papers": 0.00027871131896972656,
      "platform_mentions": 0.0028352737426757812,
      "data_citations": 0.20261025428771973,
      "num_data_pmids_checked": 380
    }
  },
  "39335176": {
    "paper_id": "39335176",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data analy-\nsis was performed on mRNA expression z-scores relative to all samples (log microar-\nray) downloaded from http://www.cbioportal.org [21\u201323]",
      "Dataanalysiswasperformed\nonmRNAexpressionz-scoresrelativetoalldiploids(logRNASeqV2RSEM)downloaded\nfromhttp://www.cbioportal.org",
      "DataAvailabilityStatement:ThemRNAexpressiondatapresentedinthisstudyareavailablefor\ndownload(http://www.cbioportal.org),withimmunohistochemistrydataavailableonrequest"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:39.589794",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39335176.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.056112051010132,
      "cbioportal_papers": 0.00022101402282714844,
      "platform_mentions": 0.002125978469848633,
      "data_citations": 0.2751271724700928,
      "num_data_pmids_checked": 380
    }
  },
  "39372744": {
    "paper_id": "39372744",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We next explored the mutational landscape in\nmetastatic patients using the publicly available MSK-MET-SKCM cohort31 and the cBioportal\nplatform32\u201334"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:50.318734",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39372744.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 38.38739728927612,
      "cbioportal_papers": 0.0004889965057373047,
      "platform_mentions": 0.003056764602661133,
      "data_citations": 0.5548248291015625,
      "num_data_pmids_checked": 380
    }
  },
  "39322779": {
    "paper_id": "39322779",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:52.245586",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39322779.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 25.202629804611206,
      "cbioportal_papers": 0.0004227161407470703,
      "platform_mentions": 0.004029035568237305,
      "data_citations": 0.3420112133026123,
      "num_data_pmids_checked": 380
    }
  },
  "39320351": {
    "paper_id": "39320351",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "sion (\u223c40 organoids) was loaded into a microsyringe (702RN- cBioPortal was used to access the 2,509 datasets, and samples\n7636-01; Hamilton)",
      "Ewald reported personal fees from BioNTech outside the\nJacobsen,R.Sinha,E.Larsson,etal.2013.Integrativeanalysisofcom-\nsubmittedwork;andhisspouseisanemployeeofImmunocore plex cancer genomics and clinical profiles using the cBioPortal",
      "nar/gkw377\nLi,A.Ochoa,G.Zhao,B.Lai,etal.2023.Analysisandvisualizationof Leal,A.S.,S.A.Misek,E.M.Lisabeth,R.R.Neubig,andK.T.Liby.2019.The\nlongitudinalgenomicandclinicaldatafromtheAACRprojectGENIE Rho/MRTFpathwayinhibitorCCG-222740reducesstellatecellactiva-\nbiopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:57.182880",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39320351.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.363609075546265,
      "cbioportal_papers": 0.00033783912658691406,
      "platform_mentions": 0.0027420520782470703,
      "data_citations": 0.22626423835754395,
      "num_data_pmids_checked": 380
    }
  },
  "39457707": {
    "paper_id": "39457707",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods: ThedatasetoflungcancerwasanalyzedutilizingtheTIMER2.0,UALCAN,TNMplot,\nMEXPRESS,cBioPortal,MethSurv,KMPlotter,STRING,andShinyGO0.80databases.Bloodsamples\nfrom50patientswereassessedusingthereal-timePCRmethod",
      "TheassociationbetweentheABCG2mRNAexpressionleveland\nmethylation beta-value (HM27 and HM450 merge) was analyzed using the cBioPortal\nplatform (https://www.cbioportal.org, accessed on 2 September 2024)",
      "cbioportal.org/;accessedon10September2024)[42,45,46]",
      "Correlation between the gene expression level and methylation of two ABCG2 regions in LUAD\nCorrelationbetweenthegeneexpressionlevelandmethylationoftwoABCG2regionsinLUAD\nsamples ((B) cg24207176 and (C) cg24352530 probes; cBioPortal)",
      "(D) The heat map showing twelve\nsamples((B)cg24207176and(C)cg24352530probes;cBioPortal).(D)Theheatmapshowingtwelve\nmethylatedCpGsitesofABCG2(1=fullymethylated/redcolor;0=fullyunmethylated/bluecolor;\nMethSurv).(E\u2013I)SurvivalcurvesbasedonselectedCpGmethylationsites(MethSurv)",
      "Analysis of ABCG2 Gene Mutations and Copy Number Variations in LUAD and LUSC\n\nBiomedicines 2024, 12, x FOR PEER REVIEW 12 of 22\nBiomedicines2024,12,2394 12of21\nABCG2 gene alterations were studied using the cBioPortal database utilizing the\nTCGA PanCancer Atlas set",
      "the ABCG2 gene for LUSC samples, using cBioPortal",
      "DataAvailabilityStatement: Inthecaseoftheinsilicoanalysis,dataarederivedfrompublicly\navailabledatasets(TIMER2.0,UALCAN,TNMplot,MEXPRESS,cBioPortal,MethSurv,KMPlot-\nter, STRING, ShinyGO 0.80)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:34:57.544247",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39457707.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 80.09315991401672,
      "cbioportal_papers": 0.0003809928894042969,
      "platform_mentions": 0.003798961639404297,
      "data_citations": 0.24181604385375977,
      "num_data_pmids_checked": 380
    }
  },
  "39310123": {
    "paper_id": "39310123",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The build-up of genetic alterations, gene lists and cBioPortal datasets of genes\nsuch as the activation of proto-oncogenes and from each cancer subtype that contained SNVs\nthe deactivation of tumor-suppressor genes, and CNAs [18-20]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:02.864021",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39310123.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.246197938919067,
      "cbioportal_papers": 0.000102996826171875,
      "platform_mentions": 0.0012218952178955078,
      "data_citations": 0.2687370777130127,
      "num_data_pmids_checked": 380
    }
  },
  "39312090": {
    "paper_id": "39312090",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "However, Institute\u2019s Patient-Derived Models Repository (NCI PDMR),\nless than half of the Phase I or II clinical trials reported race Genomics Data Commons (GDC), cBioPortal for Cancer\nand ethnicity data, indicating significant underrepresentation Genomics, American Association for Cancer Research\u2019s\nof NHB and Hispanic populations compared to their relative [AACR] Project GENIE v.16.0, International Cancer\nincidence rates of liver cancer [24]",
      "cBioPortal for Cancer Genomics, AACR Project GENIE,\nNCI\u2019s PDMR, ICGC Data Portal, HCCDB: Integrative\nMolecular Database of Hepatocellular Carcinoma and Liver\nMethods\nCancer Expression Resource (CancerLivER)",
      "The cBioPortal registry, includes 11 liver cancer studies,\nethnicity and racial data is provided for three studies: LIHC\n(TCGA, Firehouse Legacy), LIHC (TCGA, PanCancer\nAtlas), and HCC (MSK, JCO Precis Oncol 2023)",
      "cal profiles using the cBioPortal",
      "Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC,\nGENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:04.245971",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39312090.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.47029995918274,
      "cbioportal_papers": 0.0002541542053222656,
      "platform_mentions": 0.0023920536041259766,
      "data_citations": 0.34033989906311035,
      "num_data_pmids_checked": 380
    }
  },
  "39259513": {
    "paper_id": "39259513",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:06.271142",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39259513.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 3.171675205230713,
      "cbioportal_papers": 5.3882598876953125e-05,
      "platform_mentions": 0.0006041526794433594,
      "data_citations": 0.01812291145324707,
      "num_data_pmids_checked": 380
    }
  },
  "39322687": {
    "paper_id": "39322687",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "PishvaianMJ,BlaisEM,BrodyJR,LyonsE,DeArbeloaP,HendifarA,etal.Overall\nwww.cbioportal.org/.CRISPR-andRNAi-basedPIK3CAdependencyscoresandRPPA-\nsurvivalinpatientswithpancreaticcancerreceivingmatchedtherapiesfollowing\nbasedmeasurementsofphosphorylatedAKT(S473andT308)for38celllineswere molecularprofiling:aretrospectiveanalysisoftheKnowYourTumorregistrytrial"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:06.661095",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39322687.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 30.29464602470398,
      "cbioportal_papers": 0.00032401084899902344,
      "platform_mentions": 0.0033538341522216797,
      "data_citations": 0.1968371868133545,
      "num_data_pmids_checked": 380
    }
  },
  "39300184": {
    "paper_id": "39300184",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To further support our findings of the involvement of AGR2 in PD-L1 regulation, we screened the publicly\navailable cBioPortal database26\u201328",
      "In addition, we analysed other\navailable CRC datasets in cBioPortal",
      "(G)\nCorrelation analysis of AGR2 and PD-L1 expression in colorectal patient samples represented by Pearson and\nSpearman correlation coefficients extracted from the cBioPortal database",
      "Additionally, the positive\ncorrelation between AGR2 and PD-L1 in CRC is also supported by cohorts available in the cBioPortal database,\nindicating the overlap of our findings with data from CRC patient samples",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma\nCollaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:20.366157",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39300184.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 22.384295225143433,
      "cbioportal_papers": 0.00036597251892089844,
      "platform_mentions": 0.003331899642944336,
      "data_citations": 0.34334492683410645,
      "num_data_pmids_checked": 380
    }
  },
  "39242834": {
    "paper_id": "39242834",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:21.214780",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39242834.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.829554319381714,
      "cbioportal_papers": 0.0003151893615722656,
      "platform_mentions": 0.002228975296020508,
      "data_citations": 0.13657402992248535,
      "num_data_pmids_checked": 380
    }
  },
  "39304771": {
    "paper_id": "39304771",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:30.423109",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39304771.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 32.752370834350586,
      "cbioportal_papers": 0.0004031658172607422,
      "platform_mentions": 0.002794027328491211,
      "data_citations": 0.47257113456726074,
      "num_data_pmids_checked": 380
    }
  },
  "39202333": {
    "paper_id": "39202333",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:45.359622",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39202333.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 24.050514936447144,
      "cbioportal_papers": 0.00015997886657714844,
      "platform_mentions": 0.0012981891632080078,
      "data_citations": 0.08649921417236328,
      "num_data_pmids_checked": 380
    }
  },
  "39201599": {
    "paper_id": "39201599",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:45.478430",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39201599.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.895529985427856,
      "cbioportal_papers": 0.00019812583923339844,
      "platform_mentions": 0.0015151500701904297,
      "data_citations": 0.15793514251708984,
      "num_data_pmids_checked": 380
    }
  },
  "39400127": {
    "paper_id": "39400127",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Sample tissue for lung cancer brain\nThe Cancer Genome Atlas (TCGA) through the cBioPortal for Cancer Ge-\nmetastases was used to prepare a spectral library for unmixing the signals in\nnomics (32\u201334)",
      "GENIE biopharma collaborative in cBioPortal",
      "Sun L, Kienzler JC, Reynoso JG, Lee A, Shiuan E, Li S, et al. Immune checkpoint\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:35:53.158747",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39400127.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 116.79139518737793,
      "cbioportal_papers": 0.00041604042053222656,
      "platform_mentions": 0.003651857376098633,
      "data_citations": 0.31783509254455566,
      "num_data_pmids_checked": 380
    }
  },
  "39201428": {
    "paper_id": "39201428",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:09.114947",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39201428.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.420364141464233,
      "cbioportal_papers": 0.0003037452697753906,
      "platform_mentions": 0.0023889541625976562,
      "data_citations": 0.29965734481811523,
      "num_data_pmids_checked": 380
    }
  },
  "39200195": {
    "paper_id": "39200195",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "MutationCharacterAnalysis\nThecBioPortaldatabase[30\u201332](http://www.cbioportal.org/accessedon13June\n2024)wasused toanalyzethemutationcharacteristics ofDCTPP1inpan-cancers",
      "TofurtherelucidatetheDCTPP1up-regulationinseveralcancertypes,weexamined\nitsgeneticalterationfrequencyacrossdifferenttumorsusingdatafromtheTCGAdatabase,\nretrieved via cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:13.786166",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39200195.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.2458438873291,
      "cbioportal_papers": 0.0002639293670654297,
      "platform_mentions": 0.002694845199584961,
      "data_citations": 0.3784661293029785,
      "num_data_pmids_checked": 380
    }
  },
  "39506116": {
    "paper_id": "39506116",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "in cBioPortal, in this case a patient (P-0050196) with prostate adenocarcinoma\nRaw numbers are given in Supplementary Table 1",
      "MSK-CHORD is available\nously published cohorts14,18,19 and validated with MSK-BPC annotations through cBioPortal, allowing for additional visualization and cohort\n(Methods section NLP models)",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from Jowel Garcia1, Naveen Rachuri1, Kevin Boehm1, Mitchell Parker1, Henry Walch1,\nthe AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "MSK-CHORD is available under the Creative Commons BY-NC-ND 4.0\nlicence and can be accessed on cBioPortal (https://www.cbioportal.org/\nradLongformer",
      "Data from the GENIE BPC can\nas input the full text of CT chest, abdomen and pelvis (CAP) reports and be accessed on cBioPortal (https://genie.cbioportal.org/), with addi-\npredict binarized OS within 6 months, a clinically meaningful endpoint tional data available as previously described16 and further instructions\nand a time frame in which a single radiology report might meaningfully here: https://www.aacr.org/professionals/research/aacr-project-genie/\nprognosticate"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:15.722262",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39506116.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 163.2378077507019,
      "cbioportal_papers": 0.00042700767517089844,
      "platform_mentions": 0.005231142044067383,
      "data_citations": 0.6948275566101074,
      "num_data_pmids_checked": 380
    }
  },
  "39227586": {
    "paper_id": "39227586",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "CellDeathandDisease (2024) 15:646\n\n1.5\n1.0\n0.5\n0.0 QRICH1\nInaddition,weanalyzedQRICH1genemutationsintheCancer T-ALLpatientsfromtheGSE161895dataset(Fig.8B).Itisshownthat\nGenome Atlas (TCGA) PanCancer Atlas using the online tool theexpressionlevelofQRICH1remainedhighinnormallymphocytes\ncBioPortal [26]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:21.049716",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39227586.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 74.65618324279785,
      "cbioportal_papers": 0.0002486705780029297,
      "platform_mentions": 0.0020012855529785156,
      "data_citations": 0.09161710739135742,
      "num_data_pmids_checked": 380
    }
  },
  "39223638": {
    "paper_id": "39223638",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:24.271407",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39223638.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 63.6261510848999,
      "cbioportal_papers": 0.0002949237823486328,
      "platform_mentions": 0.00035500526428222656,
      "data_citations": 0.241682767868042,
      "num_data_pmids_checked": 380
    }
  },
  "39201394": {
    "paper_id": "39201394",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:24.433608",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39201394.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 38.793373107910156,
      "cbioportal_papers": 0.00030612945556640625,
      "platform_mentions": 0.002254962921142578,
      "data_citations": 0.1473081111907959,
      "num_data_pmids_checked": 380
    }
  },
  "39746898": {
    "paper_id": "39746898",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:35.471313",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39746898.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 226.80354022979736,
      "cbioportal_papers": 0.00043082237243652344,
      "platform_mentions": 0.003287076950073242,
      "data_citations": 0.30081796646118164,
      "num_data_pmids_checked": 380
    }
  },
  "39753968": {
    "paper_id": "39753968",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data availability\nGenomic and associated clinical data for all patients and tumor samples\nStatistics and reproducibility included in this study have been deposited in cBioPortal for Cancer\nEnrichment testing was performed using two-sided Fisher\u2019s exact tests Genomics and are publicly accessible and downloadable at https://\nwith multiple test correction by the FDR method where appropriate",
      "For www.cbioportal.org/study/summary?id=pdac_msk_2024",
      "Oncoprints were generated using cBioPortal com/oncokb/oncokb-annotator",
      "declares consulting activity from AstraZeneca,\nclinical profiles using the cBioPortal",
      "receives research funding from Agenus, Amgen, Genentech/\ngenomic and clinical data from the AACR Project GENIE Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI\nBiopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:36.059418",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39753968.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 227.33965396881104,
      "cbioportal_papers": 0.00043892860412597656,
      "platform_mentions": 0.0054819583892822266,
      "data_citations": 0.3506608009338379,
      "num_data_pmids_checked": 380
    }
  },
  "39127153": {
    "paper_id": "39127153",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:37.963253",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39127153.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.303643941879272,
      "cbioportal_papers": 0.0003399848937988281,
      "platform_mentions": 0.00045800209045410156,
      "data_citations": 0.21881699562072754,
      "num_data_pmids_checked": 380
    }
  },
  "39185156": {
    "paper_id": "39185156",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:38.830731",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39185156.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 24.59908699989319,
      "cbioportal_papers": 0.0003609657287597656,
      "platform_mentions": 0.00041794776916503906,
      "data_citations": 0.38982582092285156,
      "num_data_pmids_checked": 380
    }
  },
  "39139341": {
    "paper_id": "39139341",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In this study, we used several bioinformatics platforms, namely Tumor Immune Estimation\nResource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), University of Alabama at\nBirmingham Cancer Data Analysis Portal (UALCAN) databases, Kaplan-Meier plotter, and cBioPortal, to\nconduct a comprehensive analysis to highlight the expression of epithelial growth factor receptor (EGFR) in\npatients with GBM",
      "cBioPortal\nThe cBioPortal for Cancer Genomics is a useful resource for interactively exploring genetic alterations and\nmultidimensional cancer genomics data sets [10]",
      "In this work, we used cBioPortal to look into the genetic\nchanges of BMX across diverse cancer types",
      "DOI 10.7759/cureus.64506 8 of 13\n\nFIGURE 10: The correlation between the EGFR expression level and the\nsurvival outcomes of patients\nEGFR, epithelial growth factor receptor; GBM, glioblastoma multiforme; UALCAN, University of Alabama at\nBirmingham Cancer Data Analysis Portal\nGenetic variation of EGFR across various cancers\nUsing the cBioPortal platform, the genetic variation of EGFR across various cancers was analyzed",
      "DOI 10.7759/cureus.64506 9 of 13\n\nFIGURE 11: Genetic alteration analysis of EGFR using the cBioPortal\ndatabase\nEGGR, epithelial growth factor receptor\nFIGURE 12: Genetic alteration analysis of EGFR using the cBioPortal\ndatabase\nEGGR, epithelial growth factor receptor; log-rank P: p-value resulting from log-rank test\nCross-validation of EGFR using ggplot\nUsing public databases that were obtained from Gene Expression Omnibus (GEO), we validated the\nexpression of EGFR in GBM patients",
      "We used the cBioPortal platform to study the mutation of EGFR in patients with GBM, and we found that\nmost of the mutation was an amplification mutation (30.5%), followed by multiple alterations (12.67%)",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al.: Analysis and visualization of longitudinal genomic and\nclinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:39.107090",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39139341.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.790453910827637,
      "cbioportal_papers": 0.00010585784912109375,
      "platform_mentions": 0.001196146011352539,
      "data_citations": 0.025883197784423828,
      "num_data_pmids_checked": 380
    }
  },
  "39157351": {
    "paper_id": "39157351",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Correlation of the expressions of miR-338\u20135p, ETS1 and NOTCH1 was analyzed using the cBioPortal database (TCGA, Nature 2012)\n[38]",
      "de Bruijn, et al., Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE biopharma collaborative in cBioPortal,\nCancer Res"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:39.980628",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39157351.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.61635184288025,
      "cbioportal_papers": 0.00031685829162597656,
      "platform_mentions": 0.0028340816497802734,
      "data_citations": 0.29776477813720703,
      "num_data_pmids_checked": 380
    }
  },
  "39183755": {
    "paper_id": "39183755",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Anti-resorptive medications, such as bisphosphonates\nandreceptoractivatorofnuclearfactor-\u03baBligand(RANKL)inhibitors, PubliclyavailablebulkRNAsequencingandproteinexpressiondata\nare a mainstay of treatment for patients with bone metastases for of patient tumors from the Cancer Genome Atlas (TCGA) \u2013 Breast\nreducingmorbidityassociatedwithbonedestruction[4].However,bone Invasive Carcinoma cohort (n = 1053) was accessed and visualized\nmetastasisisconsideredtohavenocure[5],emphasizingtheimportance through cBioPortal[25\u201327]",
      "Additionally,furtherbulkRNAsequencingdatawasobtainedfromThe\nDespite the fundamental importance of Gli2 and noncanonical Metastatic Breast Cancer Project (https://www.mbcproject.org/)\nHedgehogsignalinginthegrowth ofbonemetastases,therehasbeen [32,33], also via cBioPortal, and Spearman\u2019s correlation of mRNA\nlittle work studying its role in the crosstalk between tumor cells and expressionofkeymyeloidlineagephenotypicmarkersandCSF1/CSF1R\nothercellsinthebonemicroenvironment.However,recentstudieshave versusGli2mRNAexpressionwascalculated.Finally,mRNAexpression\ndemonstrated the potential role of Gli2 in modulating the immune data of Gli2 and other Hedgehog signaling components in laboratory\nmicroenvironment",
      "Gli2-high tumorshaveincreased expressionof myeloidactivationanddifferentiation genesandcytokines importantinbone metastasis.(A)\nFlowchartofmethodsusedtoanalyzepatientdatafromprimarybreasttumorsfromTheCancerGenomeAtlas(TCGA)PanCancerAtlas(dataaccessedthrough\ncBioPortal).(B)VolcanoplotshowingmRNAexpressionofmyeloidactivationanddifferentiationgenesintumorswithhighGli2geneexpression(topquartile,n=\n271tumors)comparedtotumorswithlowGli2geneexpression(bottomquartile,n=270tumors).Top50mostsignificantdifferentiallyexpressedgenesfromthis\nlistshowninTableS4.(C)mRNAexpressionofcytokinesinGli2hightumorsandGli2lowtumors.Student\u2019sttestwithFDRcorrectionformultiplecomparisons.*q\n<0.05.SchematiccreatedinBiorender.com"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:40.114840",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39183755.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 24.287741899490356,
      "cbioportal_papers": 0.0003037452697753906,
      "platform_mentions": 0.0022470951080322266,
      "data_citations": 0.10215592384338379,
      "num_data_pmids_checked": 380
    }
  },
  "39057170": {
    "paper_id": "39057170",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:50.122079",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39057170.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.8908851146698,
      "cbioportal_papers": 9.274482727050781e-05,
      "platform_mentions": 0.001039266586303711,
      "data_citations": 0.08667516708374023,
      "num_data_pmids_checked": 380
    }
  },
  "39111833": {
    "paper_id": "39111833",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:52.789170",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39111833.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.2798490524292,
      "cbioportal_papers": 0.0003459453582763672,
      "platform_mentions": 0.0027480125427246094,
      "data_citations": 0.3961679935455322,
      "num_data_pmids_checked": 380
    }
  },
  "39078225": {
    "paper_id": "39078225",
    "cbioportal_paper_citations": [
      "Signal 6, pl1 10.1126/\nscisignal.2004088 [PubMed: 23550210]\n99",
      "Cancer\nDiscov 2, 401\u2013404 10.1158/2159-8290.CD-12-0095 [PubMed: 22588877]\n100",
      "Cancer Res 83, 3861\u20133867\n10.1158/0008-5472.CAN-23-0816 [PubMed: 37668528]\n101"
    ],
    "cbioportal_platform_mentions": [
      "Examining the mutational frequency PDAC cases in\nCBioPortal revealed a KMT mutation in 15.8%, which KMT2C and KMT2D mutations\nbeing the most common [98\u2013100]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. (2013) Integrative analysis\nof complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T et al. (2023) Analysis and visualization of longitudinal genomic and clinical data from the\nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {
      "24670651": [
        "Nature 509, 91\u201395 10.1038/nature13176 [PubMed: 24670651]\nBiochem J"
      ],
      "22820256": [
        "Nature\n488, 106\u2013110 10.1038/nature11329 [PubMed: 22820256]\n87"
      ],
      "21796119": [
        "Nature 476, 298\u2013303 10.1038/\nnature10351 [PubMed: 21796119]\n88"
      ]
    },
    "extraction_date": "2025-12-19T17:36:52.949155",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39078225.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 3,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.687058210372925,
      "cbioportal_papers": 0.004342794418334961,
      "platform_mentions": 0.04508209228515625,
      "data_citations": 0.23543500900268555,
      "num_data_pmids_checked": 380
    }
  },
  "39057174": {
    "paper_id": "39057174",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:53.589973",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39057174.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.47325086593628,
      "cbioportal_papers": 0.00020694732666015625,
      "platform_mentions": 0.001519918441772461,
      "data_citations": 0.07268714904785156,
      "num_data_pmids_checked": 380
    }
  },
  "39114029": {
    "paper_id": "39114029",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analyses using the cBioPortal tool, Shiny\nMethylation Analysis Resource Tool (SMART), and MethSurv provided insights into the\nmethylation and epigenetic alterations of RPL4",
      "Mutant personality analysis\nThe mutational profile of RPL4 in multiple cancers was assessed using the cBioPortal (http://www.cbioportal.org/) [16]",
      "Mastrogiacomo, et al., Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma\ncollaborative in cBioPortal, Cancer Res"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:36:56.492918",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39114029.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.89336395263672,
      "cbioportal_papers": 0.00024700164794921875,
      "platform_mentions": 0.0030527114868164062,
      "data_citations": 0.12477993965148926,
      "num_data_pmids_checked": 380
    }
  },
  "39062026": {
    "paper_id": "39062026",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Utilizing cBioPortal for Cancer Genomics [128\u2013130], an open access, open source\nresourcefacilitatinginteractiveexplorationofmultidimensionalcancergenomicsdatasets,\nweconductedananalysisofthegeneticalterationsofp53invarioustypesoflungcancer",
      "Utilizing cBioPortal for Cancer Genomics [128\u2013130], an open access, open source\nresource facilitating interactive exploration of multidimensional cancer genomics\ndatasets, we conducted an analysis of the genetic alterations of p53 in various types of\nlung cancer",
      "Genetic alterations of p53 in the different types of lung cancer from cBioPortal datasets",
      "TP53geneexpressioninLUSCpatientswasanalyzedwiththeexpressionofseveral\ngenes from cBioPortal datasets",
      "Furthermore, the\npatterns of TP53 mutations observed in cBioPortal data inform our understanding of\nprognosisandtherapeuticresponses,offeringpotentialavenuesfortargetedtreatments\nandpersonalizedmedicineapproachesinlungcancer[128,130,190,192\u2013196]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:02.800847",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39062026.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.199960231781006,
      "cbioportal_papers": 0.000431060791015625,
      "platform_mentions": 0.0033578872680664062,
      "data_citations": 0.47100019454956055,
      "num_data_pmids_checked": 380
    }
  },
  "39199616": {
    "paper_id": "39199616",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "SomaticMutationsandClinicalData\nSomatic mutation information and the related clinical data were retrieved from\nthe public repository cBioPortal for cancer genomics [15] using the pyBioPortal library,\nspecifically created in Python 3 to simplify and automate acquisition, integration, and\nprocessingoperations",
      "DataAvailabilityStatement:ThedatausedinthisresearchareavailableonlinefromthecBioPortal\nwebsite(https://www.cbioportal.org/).Additionally,thedatacanbeaccessedprogrammatically\nwithPython3usingthepyBioPortallibrary.Moreinformationanddocumentationcanbefoundat\nhttps://github.com/Matteo-Valerio/pyBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:03.348823",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39199616.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 53.94571900367737,
      "cbioportal_papers": 0.0003211498260498047,
      "platform_mentions": 0.003287076950073242,
      "data_citations": 0.21285581588745117,
      "num_data_pmids_checked": 380
    }
  },
  "38969020": {
    "paper_id": "38969020",
    "cbioportal_paper_citations": [
      "[PubMed:\n22588877]\n11",
      "[PubMed: 23550210]\n12",
      "[PubMed: 37668528]\n13"
    ],
    "cbioportal_platform_mentions": [
      "METHODS\nPatient\u2019s Data\nData were obtained from the PanCancer Study: Cancer Therapy and Clonal Hematopoiesis\nvia cBioportal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualization of longitudinal genomic\nand clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {
      "33106634": [
        "[PubMed: 33106634]\n10"
      ]
    },
    "extraction_date": "2025-12-19T17:37:03.373078",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38969020.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.541815042495728,
      "cbioportal_papers": 0.0019800662994384766,
      "platform_mentions": 0.0013642311096191406,
      "data_citations": 0.20762896537780762,
      "num_data_pmids_checked": 380
    }
  },
  "39070636": {
    "paper_id": "39070636",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutations were\n183 identified from cBioPortal 27-29 and COSMIC 30 (http://www.sanger.ac.uk/genetics/CGP/cosmic/)\n184\n185\nIn total, we analyzed mutations in eight amino acid residues and for R377, the most highly mutated\n186\nresidue in cancer, we included two distinct mutations of R377, the most highly mutated residue in\n187\ncancer, both of which (R377H and R377C) are equally represented in patients (Fig"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:03.762324",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39070636.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 24.778853178024292,
      "cbioportal_papers": 0.00020074844360351562,
      "platform_mentions": 0.01912212371826172,
      "data_citations": 0.11532211303710938,
      "num_data_pmids_checked": 380
    }
  },
  "39031010": {
    "paper_id": "39031010",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Pathological details, including histotypes (invasive Cancer International Consortium (METABRIC) dataset11\ncarcinoma of no special type (ductal), invasive lobular using the cBioPortal platform for Cancer Genomics.12 The\ncarcinoma, and mucinous carcinoma), overall tumor METABRIC trial collected patient characteristics, breast\ngrade, tumor size, nodal involvement, and tumors, tumor expression data, CNV profiles, and SNP geno-\nwere retrospectively assigned to either luminal A- or types",
      "Patient data were from the\nMETABRIC dataset assessable on the cBioPortal platform",
      "sualization of longitudinal genomic and clinical data from the\nAACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:03.819166",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39031010.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.77277421951294,
      "cbioportal_papers": 0.00020503997802734375,
      "platform_mentions": 0.0017900466918945312,
      "data_citations": 0.08261680603027344,
      "num_data_pmids_checked": 380
    }
  },
  "39043735": {
    "paper_id": "39043735",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data source\nThe expression data of CRGs in LGG patients and control group with was downloaded in Gene Expression Profil-\ning Interactive Analysis (GEPIA) (http://g epia.c ancer-p ku.c n/) and cBioPortal for Cancer Genomics (https://w ww",
      "Frequency of mutations in LGG based on CBioPortal",
      "Data availability\nData from GEPIA, TIMER 2.0, cBioPortal and CGDB is freely available and we have cited necessary papers\nas requested",
      "et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma\ncollaborative in cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:05.550470",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39043735.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.609498977661133,
      "cbioportal_papers": 0.0001819133758544922,
      "platform_mentions": 0.0017139911651611328,
      "data_citations": 0.11546802520751953,
      "num_data_pmids_checked": 380
    }
  },
  "39052387": {
    "paper_id": "39052387",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "28; MSK (29\u201332) data\nwas derived from cBioportal (81\u201383) lung adenocarcinoma studies",
      "The data downloaded from cBioportal (81, 83) were processed to annotate variants for MGA, MET,\nEGFR, and KRAS",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "de Bruijn I, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biophar-\nma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:06.003399",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39052387.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.613674879074097,
      "cbioportal_papers": 0.00036978721618652344,
      "platform_mentions": 0.0033740997314453125,
      "data_citations": 0.26375865936279297,
      "num_data_pmids_checked": 380
    }
  },
  "38948867": {
    "paper_id": "38948867",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:10.069127",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38948867.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.462975025177002,
      "cbioportal_papers": 0.00021505355834960938,
      "platform_mentions": 0.0002598762512207031,
      "data_citations": 0.11248493194580078,
      "num_data_pmids_checked": 380
    }
  },
  "38948009": {
    "paper_id": "38948009",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Meier plotter [KM plotter] (L\ufffdanczky and Gyo}rffy 2021),\nEach analysis tab contains several plots with adjustable cBioPortal (Cerami et al. 2012, Gao et al. 2013, de Bruijn\ngraphical inputs and buttons for downloading all plots and et al. 2023), Survival Genie (Dwivedi et al. 2022), GEPIA2\ndata",
      "Of the existing webtools, cBioPortal is the only one that\nSupplementary Fig",
      "Unlike\ning TCGA data, as well as being the only webtool that anno- cBioPortal, which shows summarized group information,\ntates gene expression over PCA plots",
      "We envisage Evergene will be a valuable ex- tion of longitudinal genomic and clinical data from the AACR proj-\nploratory tool for lay scientists in assisting the discovery of ect GENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex can-\nThe data used in Evergene are in whole based upon data gen-\ncer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:11.276983",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38948009.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.730420827865601,
      "cbioportal_papers": 0.00010228157043457031,
      "platform_mentions": 0.0011987686157226562,
      "data_citations": 0.17205214500427246,
      "num_data_pmids_checked": 380
    }
  },
  "38928223": {
    "paper_id": "38928223",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Thelattermutationisnot\nregisteredinanyofthedatabasesweexplored(COSMIC[10],cBioPortal[11],ClinVar[12],\nOncoKB[13],andJax-CKB[14])andisnotreportedintheliterature"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:11.556423",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38928223.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.729690074920654,
      "cbioportal_papers": 0.00015997886657714844,
      "platform_mentions": 0.0012359619140625,
      "data_citations": 0.06284809112548828,
      "num_data_pmids_checked": 380
    }
  },
  "38911024": {
    "paper_id": "38911024",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "51I.deBruijnetal.,\u201cAnalysisandvisualizationoflongitudinalgenomicandclini-\n25K.Hurleyetal.,\u201cReconstructedsingle-cellfatetrajectoriesdefinelineageplas- cal data from the AACR project GENIE biopharma collaborative in\nticitywindowsduring differentiationofhumanPSC-deriveddistallungpro- cBioPortal,\u201dCancerRes.83,3861\u20133867(2023)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:17.259969",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38911024.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.480583906173706,
      "cbioportal_papers": 0.0002942085266113281,
      "platform_mentions": 0.0020868778228759766,
      "data_citations": 0.19567584991455078,
      "num_data_pmids_checked": 380
    }
  },
  "38941002": {
    "paper_id": "38941002",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The FUT11 genetic variation information was retrieved using cBioPortal, and its drug sensitivity was analyzed\nusing CellMiner",
      "2.7 Genetic variation of FUT11 in GC\nFUT11 genetic alteration information was retrieved using cBioPortal (https://w ww.c biopo rtal.o rg/) [24, 25] and included\nall TCGA pan-cancer studies",
      "3.7 FUT11 genetic variation in GC\nFUT11 mutations in cancers were explored using the cBioPortal platform and TCGA data for mutation analysis",
      "7 Genetic mutations in FUT11 in the cBioPortal database",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR project\nGENIE biopharma collaborative in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:17.733449",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38941002.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.936289072036743,
      "cbioportal_papers": 0.00030612945556640625,
      "platform_mentions": 0.002586841583251953,
      "data_citations": 0.34255504608154297,
      "num_data_pmids_checked": 380
    }
  },
  "38927408": {
    "paper_id": "38927408",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal\u2013TCGABioinformaticAnalysis\nWelocatedthehumangenes(seeSupplementaryTableS1)encodingtheboneturnover\nmarkersstudiedusingtheNationalInstitutesofHealth(NIH)Genewebsite[17]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:19.208168",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38927408.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.278438806533813,
      "cbioportal_papers": 0.00024437904357910156,
      "platform_mentions": 0.0019059181213378906,
      "data_citations": 0.10827398300170898,
      "num_data_pmids_checked": 380
    }
  },
  "38948762": {
    "paper_id": "38948762",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To understand these seven proteins\u2019\nclinical values and whether they could serve as biomarkers would require a prospective patient\ncohort, which is not available to us currently (As of May 6, 2024, according to cBioportal (de\nBruijn et al., 2023), https://www.cbioportal.org/), the only HNSCC dataset that has both CNA\nand RNA-seq data available is from TCGA, which is used in this work)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:21.165741",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38948762.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.15850806236267,
      "cbioportal_papers": 0.0002307891845703125,
      "platform_mentions": 0.008791208267211914,
      "data_citations": 0.159498929977417,
      "num_data_pmids_checked": 380
    }
  },
  "38898487": {
    "paper_id": "38898487",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "METABRIC data was\ndownloaded from cbioportal (http://www.cbioportal",
      "Prolactin as a local growth promoter in patients with breast\ncancer genomics and clinical profiles using the cBioPortal",
      "Targeting HER2-positive breast cancer:\nCollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:26.981792",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38898487.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.571995973587036,
      "cbioportal_papers": 0.0003552436828613281,
      "platform_mentions": 0.0032548904418945312,
      "data_citations": 0.3366227149963379,
      "num_data_pmids_checked": 380
    }
  },
  "38895265": {
    "paper_id": "38895265",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "1 (\ud835\udc50 \u2212\ud835\udc50 )2\n\ud835\udc52\ud835\udc65\ud835\udc5d \ud835\udc5c\ud835\udc4f\ud835\udc60\n477 \ud835\udc45\ud835\udc40\ud835\udc46\ud835\udc45\ud835\udc38 = \u221a \u2217\u2211\n\ud835\udc5b \ud835\udc50 2\n\ud835\udc5c\ud835\udc4f\ud835\udc60\n478 The mitotic success rate (MSR) of each condition was computed as the ratio of M-to-G1 transition (P ) to the\nM,G1\n479 sum of the transition rates for M-to-G1 (P ) and M-to-multinucleated (P ):\nM,G1 M,Multi\n\ud835\udc43\n\ud835\udc40,\ud835\udc3a1\n480 \ud835\udc40\ud835\udc46\ud835\udc45 =\n\ud835\udc43 +\ud835\udc43\n\ud835\udc40,\ud835\udc3a1 \ud835\udc40,\ud835\udc40\ud835\udc62\ud835\udc59\ud835\udc61\ud835\udc56\n481\n482 The expected duration of G1, S/G2 and M cell cycle phases was calculated from the homotypic transition rates\n483 as[97]:\n1\n484 \ud835\udc39\ud835\udc5c\ud835\udc5f \ud835\udc56 ==\ud835\udc57: \ud835\udc38\ud835\udc65\ud835\udc5d\ud835\udc52\ud835\udc50\ud835\udc61\ud835\udc52\ud835\udc51\ud835\udc37\ud835\udc62\ud835\udc5f\ud835\udc4e\ud835\udc61\ud835\udc56\ud835\udc5c\ud835\udc5b =\n\ud835\udc56,\ud835\udc57 1\u2212\ud835\udc43\n\ud835\udc56,\ud835\udc57\n485\n486 Metabric survival and microarray analysis: The Metabric[48] microarray and patient metadata was accessed\n487 through cbioportal[98-100] and analyzed using R (v4.3.2) and the \u2018survival\u2019 package (v3.5.7)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:31.422323",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38895265.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.91415810585022,
      "cbioportal_papers": 0.0003180503845214844,
      "platform_mentions": 0.0024878978729248047,
      "data_citations": 0.22820305824279785,
      "num_data_pmids_checked": 380
    }
  },
  "39227583": {
    "paper_id": "39227583",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:32.693790",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39227583.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 145.74957990646362,
      "cbioportal_papers": 0.00040030479431152344,
      "platform_mentions": 0.0028238296508789062,
      "data_citations": 0.27974605560302734,
      "num_data_pmids_checked": 380
    }
  },
  "38879648": {
    "paper_id": "38879648",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:36.287601",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38879648.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.69788122177124,
      "cbioportal_papers": 0.0003216266632080078,
      "platform_mentions": 0.0003681182861328125,
      "data_citations": 0.42315006256103516,
      "num_data_pmids_checked": 380
    }
  },
  "38847368": {
    "paper_id": "38847368",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Changing the pathogenicity of a VUS requires a multi-\nmodal approach using existing literature, genomic data-\nbases (eg, cBioPortal and OncoKB), and computational\npredictive models.7,8,11 Commercial vendors employ a clas-\nsification algorithm to reclassify variants",
      "8\n800\n700\n38%\n600 25%\n500\n400 97%\n300\n75% 30%\n62%\n200\n33%\n32% 18%\n100 70% 37%\n67% 68% 63% 82%\n0 3%\nKRAS ATM BRCA2 BRCA1 MSH3 CHEK2 MEN1 MUTYH\n*Data obtained via cBioPortal using the TCGA PanCancer Atlas Studies and including a total of 10,967\nsamples across 32 studies",
      "Data obtained via\ncBioPortal using the TCGA PanCancer Atlas Studies and including a total of 10 967 samples across 32 studies",
      "Analy-\nthe APC gene has provided insight into what was previously sis and visualization of longitudinal genomic and clinical data from\nknown as an either \u201cattenuated\u201d or \u201cclassic\u201d phenotype of the aacr project genie biopharma collaborative in cbioportal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex\ncancer genomics and clinical profiles using the cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:37.088399",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38847368.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 4.319568872451782,
      "cbioportal_papers": 6.914138793945312e-05,
      "platform_mentions": 0.0007817745208740234,
      "data_citations": 0.042701005935668945,
      "num_data_pmids_checked": 380
    }
  },
  "38892296": {
    "paper_id": "38892296",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "ComparedtomCSPCgenomicdatafromthestudyconductedbyStopsacketal.(designated\nas the Memorial Sloan Kettering (MSK) patient cohort, n = 424 samples) available on\ncBioPortal[34],weobservedthatVCaPcellsweremorecloselyalignedwiththemutation\nratesofmCSPCpatientsthanLNCaPcells(Figure4D).Specifically,mutationratesforBCL2,\nMCL1,ATM,BRCA1,BRIP1,NBN,MDM2,TP53,PIK3CA,andPTENfromVCaPcellsmore\nInt",
      "Finally, we determined which cell lines best represent PCa populations using\nDepMap celligner and publicly available genomic data visualized by cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:43.945260",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38892296.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 32.162492752075195,
      "cbioportal_papers": 0.0003578662872314453,
      "platform_mentions": 0.002918243408203125,
      "data_citations": 0.22097492218017578,
      "num_data_pmids_checked": 380
    }
  },
  "38906885": {
    "paper_id": "38906885",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "4E), and increased bepronetoDSBformationduringBETitreatment.Nonetheless,these\nlavivruSfoytilibaborP\nG22-TMZ Resistant\n(LIG4 mutation)\n100 Control\nRT p=0.28\nTMZ p=0.0004\n50\n0\n0 100 200 300\nDays\nlavivruSfoytilibaborP\nDSBR (G22 PDX)\n20\n15\nControl\n10 RT p<0.0001\n5 TMZ p=0.58\n3\n2\n1\n0\nNHEJ HR MMEJ\n)%(noisserpxEretropeR\nA B C\np=0.049 G22\nG22-TMZ\np=0.023\np=0.0008\nG59\n100\n50\n0\n0 100 200 300\nDays\nlavivruSfoytilibaborP\nG59-TMZ Resistant\n(XRCC5 mutation)\n100\nControl\nRT p=0.0004\nTMZ p<0.0001\n50\n0\n0 100 200 300\nDays\nlavivruSfoytilibaborP\nD DSBR (G59 PDX) E F\n2.5\n2.0\n1.5\n1.0\nControl 0.5\nRT p=0.007\n0.15\n0.10 TMZ p=0.23\n0.05\n0.00\nNHEJ HR MMEJ\n)%(noisserpxEretropeR\np=0.034 G59\nG59-TMZ\np=0.13\np=0.017\nGBM GBM\n100 100 TRIP13 low\nTRIP13 high\np=0.009\n50 50 q=0.013\n0 0\n0 20 40 60 80 100 0 20 40 60 80 100\nMonths Months\nlavivruSfoytilibaborP\nArticle https://doi.org/10.1038/s41467-024-49316-8\nG\nGBM GBM\n100 100 POLQ low BRCA1 low SHLD1 high\nPOLQ high BRCA1 high SHLD1 low\np=0.68 p=0.09 p=0.008\n50 50 q=0.012\n0 0\n0 20 40 60 80 100 0 20 40 60 80 100\nMonths Months\nFig.3|TMZresistanceisassociatedwithalteredDSBR,especiallyenhancedHR cBioportal(n=46pergroup)31\u201333.In(A,D),dataarepresentedasthemeanofthree\nandMMEJ.AFM-DSBRanalysisofG22(parental)andG22-TMZ(acquiredTMZ independentexperiments,errorbarsshowSD,andp-valuesarefrommultiple\nresistance)PDXlines.B,CSurvivalanalysisofmice(n=8forG22andn=10forG22- unpairedtwo-tailedt-testswithHolm-\u0160id\u00e1kcorrectionformultipletesting.For\nTMZ)implantedintracraniallywiththeindicatedPDXlineandtreatedwithplacebo, (B,C,E,F)p-valuesarefromMantelCoxtest.In(G)p-valuesarefromLogranktest\nTMZ,orradiotherapy.DFM-DSBRanalysisofG59andG59-TMZacquiredresistant incBioPortalandq-values(alsofromcBioPortal)employBenjaminiHochberg\nline.E,FSurvivalanalysisofmiceimplantedwithG59(n=9)orG59-TMZ(n=10) proceduretocorrectforfalsediscovery.Sourcedataareprovidedasasource\nandtreatedasdescribedfor(B,C).GSurvivalofGBMpatientstreatedwith datafile",
      "2%milk\nLig4 Rabbit CST #14649 Westernblot 1:1000o/n\nPDXsamples 4\u00b0CinPBST\n2%milk\nPreviously reported PDX lines were derived from tumor specimens\nBLM Rabbit CST #2742 Westernblot 1:1000o/n\nobtainedfollowinginformedconsentfromadultGBMpatientswith 4\u00b0CinPBST\nthe approval of the Mayo Clinic Ethics Review Board (IRB# 07- 2%milk\n007623)69.Clinicalinformationaboutthepatientsfromwhichthese MSH2 Rabbit CST #2017 Westernblot 1:20002h\nroomtemp\nsampleswerederivedispubliclyavailableat(https://www.cbioportal",
      "Phosphopeptides were also labeled using TMT dataset wasanalyzed in cBioportal",
      "Genes thatwere expressed ata\n10plexreagentsandprocessedinthesamemannerasthewholepro- significantlyhigherlevelinTP53-mutantGBM(q<0.05incBioportal)\nteomesamples.Thepooledphosphopeptidesmultiplexwasfractio- wereidentifiedbycomparisonincBioPortalandthelistof2239sig-\nnated by high pH reversed phase chromatography (Thermo Fisher nificantly upregulated genes was downloaded from cBioPortal in\nScientific#84868)usinga12-stepgradientofincreasingacetonitrile",
      "Patients were stratified by median gene expression for the\n(bothThermoFisherScientific).Sampleswereinjectedontoa30cm, desired gene, and survival was plotted in cBioPortal with statistical\n100\u00b5m(internaldiameter)columnpackedwith2.4\u00b5mC18-AQresin, analysis done in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:47.296228",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38906885.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 40.76919102668762,
      "cbioportal_papers": 0.0004978179931640625,
      "platform_mentions": 0.0038039684295654297,
      "data_citations": 0.39690113067626953,
      "num_data_pmids_checked": 380
    }
  },
  "38888911": {
    "paper_id": "38888911",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We used cBioPortal (33\u201335) to analyze the two gene expression data sets,\nLive-cell imaging analysis for lipid accumulation and The Cancer Genomic Atlas (TCGA; ref",
      "In breast cancer [TCGA (36) and Metabric (37\u201339)] using cBioPortal (33\u201335)",
      "cBioPortal",
      "AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:47.405934",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38888911.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 29.918955087661743,
      "cbioportal_papers": 0.0003421306610107422,
      "platform_mentions": 0.0030410289764404297,
      "data_citations": 0.19838166236877441,
      "num_data_pmids_checked": 380
    }
  },
  "38862927": {
    "paper_id": "38862927",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "HER2 posi-\nlowing HER2 DPs by referring to cBioPortal [18]: RTK tivity was defined as IHC 3 + or IHC 2+/FISH positivity,\nsignalling (EGFR, ERBB2, ERBB3, ERBB4, FGFR1, and HER2 negativity was defined as IHC 2+/FISH nega-\nFGFR2, KDR, KIT, MET, PDGFRA and PDGFRB), RAS- tivity, IHC 1 + or 0, according to the ToGA study [8]",
      "de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. 4Department of Pathology, Niigata Cancer Center Hospital, 2-15-3 Analysis and visualization of longitudinal genomic and clinical data from\nKawagishi-cho, Chuo-ku, Niigata City, Niigata 951-8566, Japan the AACR Project GENIE Biopharma Collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:47.825832",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38862927.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.315909147262573,
      "cbioportal_papers": 0.0002779960632324219,
      "platform_mentions": 0.002413034439086914,
      "data_citations": 0.08477997779846191,
      "num_data_pmids_checked": 380
    }
  },
  "38831458": {
    "paper_id": "38831458",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Overall Survival (OS) and Relapse-Free Survival (RFS)\nanalysis of breast cancer patients were determined using\nDifferential expression profiling of the transcriptome cBioPortal software [20\u201322]",
      "Protein phosphatase 1 in tumori-\nGenomics and Clinical profiles using the cBioPortal",
      "Wu H, Qin W, Lu S, et al. Long noncoding RNA ZFAS1 promoting small\nCollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:55.481677",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38831458.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.81507110595703,
      "cbioportal_papers": 0.00032401084899902344,
      "platform_mentions": 0.0030050277709960938,
      "data_citations": 0.2857930660247803,
      "num_data_pmids_checked": 380
    }
  },
  "38791079": {
    "paper_id": "38791079",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:56.037405",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38791079.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.742777109146118,
      "cbioportal_papers": 0.0003688335418701172,
      "platform_mentions": 0.002972841262817383,
      "data_citations": 0.196486234664917,
      "num_data_pmids_checked": 380
    }
  },
  "38886591": {
    "paper_id": "38886591",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "breast cancer and warrant development and clinical investigation of\nDUSP6 inhibitors in combination withHER2-directedtherapies in the\ncBioPortal database analyses\npatients",
      "carcinoma samples and the relevant clinical information are\navailableattheTCGAdataportal,cBioPortalforCancerGenomics Statistical analysis\n(http://www.cbioportal.org/)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:57.079580",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38886591.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 39.07067680358887,
      "cbioportal_papers": 0.0004780292510986328,
      "platform_mentions": 0.004720926284790039,
      "data_citations": 0.2454991340637207,
      "num_data_pmids_checked": 380
    }
  },
  "38765019": {
    "paper_id": "38765019",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A CBioPortal, we identified the SBS DNA muta-\nsuperfamily that contains two or more of the 35 tions for each of the 35 candidate genes",
      "However, CbioPortal [13-15], a can-\nremains constant between proteins, is the cer genomics database, has the additional\nmain comparison between genes",
      "However, feature of focusing only on NSCLC amino acid\nanalysis of the common gene superfamilies mutations, so we also used CBioPortal to iden-\nmay yield unique insight into NSCLC because tify the amino acid substitutions for each of the\ncommon gene superfamilies encompass a set 35 candidate genes",
      "Despite are particularly valuable because of their pos-\nextensive investigation into CBioPortal and sible role as biomarkers for predictors of drug\nCOSMIC, no significant CD74 mutations or or therapy response [23]",
      "Expression of CD74, the receptor\nthe AACR Project GENIE biopharma collabora- for macrophage migration inhibitory factor, in\ntive in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:57.720069",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38765019.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.840687274932861,
      "cbioportal_papers": 0.00016880035400390625,
      "platform_mentions": 0.0014879703521728516,
      "data_citations": 0.05176496505737305,
      "num_data_pmids_checked": 380
    }
  },
  "38785549": {
    "paper_id": "38785549",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:37:57.978665",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38785549.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.525575876235962,
      "cbioportal_papers": 0.0003452301025390625,
      "platform_mentions": 0.0023970603942871094,
      "data_citations": 0.1539781093597412,
      "num_data_pmids_checked": 380
    }
  },
  "38766631": {
    "paper_id": "38766631",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Molecular docking was performed between\nMutation data for this study were collected from cBioPortal ABC transporters and mitoxantrone individually using LeDock\n(Ceramietal.,2012)developedatMemorialSloanKetteringCancer (Liu and Xu, 2019), and the complex structures were visualized\nCenter(MSKCC)whichhostsdatafromTheCancerGenomeAtlas for interactions in the 2D mode using LigPlus (Laskowski and\n(TCGA)(Weinsteinetal.,2013),NationalInstituteofHealth(NIH)",
      "(2023).Analysisandvisualizationoflongitudinalgenomicandclinicaldatafromthe\nMethods7(4),248\u2013249.doi:10.1038/nmeth0410-248 AACR Project GENIE biopharma collaborative in cBioPortal",
      "cBioPortal.Sci.Signal6(269),pl1.doi:10.1126/scisignal.2004088\nThecBiocancergenomicsportal:anopenplatformforexploringmultidimensional\ncancergenomicsdata.CancerDiscov.2(5),401\u2013404.doi:10.1158/2159-8290.CD-12- Garc\u00eda,M.,Mac\u00edas,R.M.,Cubero,J.J.,Ben\u00edtez,J.,Caravaca,F.,andGervasini,G"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:38:00.666949",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38766631.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.155757188796997,
      "cbioportal_papers": 0.0003097057342529297,
      "platform_mentions": 0.002462148666381836,
      "data_citations": 0.09038996696472168,
      "num_data_pmids_checked": 380
    }
  },
  "38740655": {
    "paper_id": "38740655",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:38:06.042014",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38740655.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.85700798034668,
      "cbioportal_papers": 0.0002281665802001953,
      "platform_mentions": 0.0003409385681152344,
      "data_citations": 0.08616375923156738,
      "num_data_pmids_checked": 380
    }
  },
  "38884271": {
    "paper_id": "38884271",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "For example, histone Web sites and database referencing\nacetylation ( 19\u201321 ) and ubiquitination ( 22 ,23 ) have been as- Mutation data were retrieved from the cBioPortal database\nsociated with increased chromatin accessibility upon UV ir- ( https://www.cbioportal.org; ( 33\u201335 )",
      "Sub- To investigate the impact of ASH1L on mutation rates in en-\nsequently, we used RF2NA ( 54 ), a machine learning approach, hancers, the cBioPortal database ( https://www.cbioportal.org )\nto obtain the predicted structure of the complex formed by this was queried for skin melanoma studies and all classes of\n440-amino acid ASH1L segment with DNA",
      "According to the cBioPortal resource for Cancer\nis challenging because the structure of the whole 333-kDa Genomics, ASH1L itself is commonly mutated in skin cancer,\nASH1L protein has not yet been experimentally determined",
      "clinical profiles using the cBioPortal",
      "and\nthe AACR project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:38:08.307896",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38884271.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 48.609986782073975,
      "cbioportal_papers": 0.0004181861877441406,
      "platform_mentions": 0.00525212287902832,
      "data_citations": 0.45418381690979004,
      "num_data_pmids_checked": 380
    }
  },
  "38786098": {
    "paper_id": "38786098",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:38:08.550747",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38786098.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 24.327249765396118,
      "cbioportal_papers": 0.00025916099548339844,
      "platform_mentions": 0.0020148754119873047,
      "data_citations": 0.15255093574523926,
      "num_data_pmids_checked": 380
    }
  },
  "38700982": {
    "paper_id": "38700982",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Survival analysis\u2014TCGA Breast Invasive Carcinoma patients copy number variation\ndata in Nature cohort44 was downloaded from cbioportal",
      "The\noncoprint was plotted for ER positive patients from the same dataset using Oncoprinter from\ncbioportal",
      "Signature activity score\u2014The transcriptomic data of breast cancer patients from TCGA\nand the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)\nbreast cancer cohorts was obtained from the cBioPortal (http://cbioportal.org).32,30,31 For the\nanalysis, only breast cancer patients with ER-positive status were included"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:38:09.209328",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38700982.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.191492080688477,
      "cbioportal_papers": 0.0003230571746826172,
      "platform_mentions": 0.0034911632537841797,
      "data_citations": 0.25342583656311035,
      "num_data_pmids_checked": 380
    }
  },
  "38662435": {
    "paper_id": "38662435",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We thank Ankona\ngenerated using GEPIA2 (53) or cBioportal (54\u201356)",
      "cBioPortal",
      "valine-bearing cargos to and through the Golgi com- cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:38:16.051605",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38662435.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.556111097335815,
      "cbioportal_papers": 0.0003750324249267578,
      "platform_mentions": 0.0033426284790039062,
      "data_citations": 1.8245611190795898,
      "num_data_pmids_checked": 380
    }
  },
  "38672585": {
    "paper_id": "38672585",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T17:38:16.947556",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38672585.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.615565061569214,
      "cbioportal_papers": 0.0003650188446044922,
      "platform_mentions": 0.00045371055603027344,
      "data_citations": 0.3523738384246826,
      "num_data_pmids_checked": 380
    }
  },
  "38610926": {
    "paper_id": "38610926",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:42.707550",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38610926.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 3.979994058609009,
      "cbioportal_papers": 0.0001499652862548828,
      "platform_mentions": 0.0012857913970947266,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "38555285": {
    "paper_id": "38555285",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "sideredsufficientforthenextstageofclinicaldevelopmentif\u226513/36 Specificrequestsforaccesstode-identifiedclinicaldatashouldbe\npatientshadaCRorPRincohort5,withtheexacttwo-sided95%CI senttothecorrespondingauthor.Thestudyprotocolisavailableasa\nranging from 20.8\u201353.8%, surpassing the minimum 20% ORR and SupplementaryNoteintheSupplementaryInformation.Thepublicly\ncontainingthetarget45%ORR.Conversely,thedatawouldbesuffi- available data of mRNA alteration of POLE and POLA1 used in this\ncientif\u226511/35patientsachievedCRorPRincohort6,withtheexact study are available in the cBioPortal database [https://www",
      "two-sided 95% CI ranging 16.9\u201349.3%, surpassing the minimum 15% cbioportal.org]82\u201384"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:46.816357",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38555285.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.085960149765015,
      "cbioportal_papers": 0.00034999847412109375,
      "platform_mentions": 0.0036988258361816406,
      "data_citations": 0.00012922286987304688,
      "num_data_pmids_checked": 1
    }
  },
  "38602182": {
    "paper_id": "38602182",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Department of Biotechnology,\nGovernment of India, Ramalingaswami KEYWORDS\nFellowship, Grant/Award Number: BT/ diagnosis by expression analysis, enzymes, metastasis- associated gene, oral cavity, prognostic\nRLF/Re- entry/21/2018; marker\nManipal Academy of Higher Education,\nGrant/Award Number: 00000676\nAbbreviations: ACTB, \u03b2- actin; cBioPortal, Cancer Genomics Portal; CI, confidence interval; DFS, disease- free survival; ENE, extranodal extension; GEPIA2, Gene Expression Profiling\nInteractive Analysis 2; GO, Gene Ontology; HIF- 1\u03b1, hypoxia- inducible factor 1- alpha; HPV, human papillomavirus; IEC, Institutional Ethics Committee; KEGG, Kyoto Encyclopedia of\nGenes and Genomes; NF- \u03baB, nuclear factor- kappa B; OS, overall survival; OSCC, oral squamous cell carcinoma; PON2, paraoxonase- 2; TCGA- HNSCC, The Cancer Genome Atlas\ndatasets for head and neck squamous cell carcinoma; TPM, transcripts per million",
      "The reverse transcriptase reactions consisted To investigate the role of PON2 in cancer, genes demonstrat-\nof 500 ng of RNA samples, 2 \u03bcL of 5\u00d7 PrimeScript Buffer (for Real ing positive correlations were identified by extracting data from\nTime), 0.5 \u03bcL of PrimeScript RT Enzyme Mix I, 4.5 \u03bcL RNase- free the cBioPortal (https:// www .cbiop ortal .org/ ).24,25 Subsequently,\nwater, and 1 \u03bcL of primers (0.5 \u03bcL oligodT primer and 0.5 \u03bcL of ran- gene enrichment analysis was undertaken using ShinyGO 0.80\ndom 6 mers)",
      "3.5 | Gene set enrichment analysis\n3.4 | Survival analysis Gene set enrichment analysis using cBioPortal identified a distinct\ncluster of 30 genes characterized by significant positive coexpression",
      "Rama TCGA database (https:// portal .gdc .cancer .gov), cBioPortal (https://\nRao Damerla: Conceptualization; funding acquisition; resources; www",
      "plex cancer genomics and clinical profiles using the cBioPortal",
      "doi:10.1016/j.biopha.2021.111729 project GENIE biopharma collaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:47.565101",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38602182.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.836958169937134,
      "cbioportal_papers": 0.00021314620971679688,
      "platform_mentions": 0.0018200874328613281,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "38730319": {
    "paper_id": "38730319",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "biopharma collaborative in cBioPortal",
      "Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:51.831751",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38730319.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.101297378540039,
      "cbioportal_papers": 0.00039386749267578125,
      "platform_mentions": 0.003973960876464844,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "38611046": {
    "paper_id": "38611046",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:54.074854",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38611046.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.230502128601074,
      "cbioportal_papers": 0.0003039836883544922,
      "platform_mentions": 0.0023941993713378906,
      "data_citations": 9.298324584960938e-06,
      "num_data_pmids_checked": 0
    }
  },
  "38752473": {
    "paper_id": "38752473",
    "cbioportal_paper_citations": [
      "Bioinformatics analysis\nData collection, preprocessing, and mapping of mutational data on PKC\u03b8\u2019s full protein\nsequence\nThe mutational datafor PKC\u03b8 were derived from TCGA PanCancer Atlas Study [PMID: 29288495], which was\nretrieved using the \u2018Quick Select\u2019 feature in the cBioPortal (v6.0.2) website [PMID:22588877]"
    ],
    "cbioportal_platform_mentions": [
      "Results\nA multitude of mutations have been identified in PKC\u03b8 across diverse cancers\nTo identify PKC\u03b8 mutations in human cancers, we utilized several online databases including the cBioPortal\nfor Cancer Genomics [48\u201350], The Cancer Genome Atlas (TCGA), the Dependency Map (DepMap) Portal\n[51\u201356], the Catalogue of Somatic Mutations in Cancer (COSMIC) [57], and the Mitelman Database of\nChromosome Aberrations and Gene Fusions in Cancer [58,59]",
      "Materials and methods\nIdentification of PKC\u03b8 cancer-associated mutations\nMutations in PKC\u03b8 were identified from the following online databases: the cBioPortal for Cancer Genomics\n[48\u201350], TCGA, the Dependency Map (DepMap) Portal [51\u201356], the COSMIC [57], and the Mitelman\nDatabase of Chromosome Aberrations and Gene Fusions in Cancer (https://mitelmandatabase.isb-cgc.org/)\n[58,59]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:54.186263",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38752473.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.22015905380249,
      "cbioportal_papers": 0.0028400421142578125,
      "platform_mentions": 0.017392873764038086,
      "data_citations": 0.00025200843811035156,
      "num_data_pmids_checked": 2
    }
  },
  "38542966": {
    "paper_id": "38542966",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "RFeisrusltt,s we directed our focus towards the investigation of genetic mutations in the cy-\nto2p.1l.aBsmioiincf odrommataicinA noafl CysTisLoAfG-4e naestsicoMciauttaetdio wnsiitnh tchaenCcyetro.p UlassminicgD caomncaeinr ogfeCnToLmAi-c4 datasets from\ncBioPortal [33\u201335], we identified a series of point mutations in the cytoplasmic domain of\nFirst, we directed our focus towards the investigation of genetic mutations in the\nCcTyLtoAp-l4a,s mdeictedcotemda iinn otufmCToLr Asa-4mapssleosc.i aTtehdeswe imthuctaantcioern.sU sspinagnnceandc verargieonuosm riecsiddautaesse,t nsotably\ninfcrolumdicnBgio SP1o8r5taYl, [K313\u20139315N],, wR1e9i3dIe, nSt1ifi94edI, Ta1s9e7rRie,s Go1f9p9oRin, Pt2m0u5tLa,t iEo2n0s8iKn, tahmeocnytgo optlahsemrsi c(Figure\n1Ado).m Taoin fuorftChTeLr Aco-4m,dperteehcteenddin thtuem porervsaamlepnlcees .aTnhde sdeismtruitbautitoinosns opfa nthneesdev maruiotuastiroensisd aucerso,ss dif-\nfenroetnatb lcyainnccelurds,i nwgeS 1c8o5nYd,Ku1c9te1Nd ,aRn1 9a3lIl,eSli1c9 4fIr,eTq1u9e7nRc,yG 1a9n9aRl,yPs2is0,5 Ld,rEa2w08inKg, admaotna gfroothmer sdiverse\n(Figure1A).Tofurthercomprehendtheprevalenceanddistributionofthesemutations\nsources, such as The Cancer Genome Atlas (TCGA) PanCancer Atlas and Memorial Sloan\nacrossdifferentcancers,weconductedanallelicfrequencyanalysis,drawingdatafrom\nKettering Cancer Center (MSK) [36,37]",
      "The length of the green lines shows the quantity level of the\ncBioPortal data sets for cancer genomics"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:56.167520",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38542966.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.43841528892517,
      "cbioportal_papers": 0.0002868175506591797,
      "platform_mentions": 0.002316713333129883,
      "data_citations": 0.0003101825714111328,
      "num_data_pmids_checked": 3
    }
  },
  "38539447": {
    "paper_id": "38539447",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:57.042719",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38539447.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.383819818496704,
      "cbioportal_papers": 0.0002129077911376953,
      "platform_mentions": 0.0016481876373291016,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "38540240": {
    "paper_id": "38540240",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:58.661453",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38540240.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.843201875686646,
      "cbioportal_papers": 0.0001971721649169922,
      "platform_mentions": 0.0014798641204833984,
      "data_citations": 7.200241088867188e-05,
      "num_data_pmids_checked": 1
    }
  },
  "38615020": {
    "paper_id": "38615020",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To further confirm the effect of\ntion, a positive correlation between the expression of COMP on CSCs, the expression of aldehyde dehydroge-\nCOMP and TGFB isoforms in ovarian serous cystade- nase (ALDH), a well-established ovarian CSCs marker\nnocarcinoma was observed using the online cBioPortal [38], was assessed",
      "Mechanistically, upon Notch activation, isoforms of TGFB (B1, B2, and B3) in Ovarian Serous Cystadenocarcinoma,\nextracted from cBioPortal database",
      "the AACR project GENIE biopharma collaborative in cBioPortal",
      "Nfonsam VN, Nfonsam LE, Chen D, Omesiete PN, Cruz A, Runyan RB, et al. grative analysis of complex cancer genomics and clinical profiles using COMP gene coexpresses with EMT genes and is associated with poor\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:26:58.844448",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38615020.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.114484786987305,
      "cbioportal_papers": 0.0003829002380371094,
      "platform_mentions": 0.00350189208984375,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "38496643": {
    "paper_id": "38496643",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Next, we analyzed two large breast cancer patient gene expression data sets (TCGA (Cancer\nGenome Atlas, 2012) and Metabric (Curtis et al., 2012; Pereira et al., 2016; Rueda et al., 2019))\nusing cBioPortal (Cerami et al., 2012; de Bruijn et al., 2023; Gao et al., 2013)",
      "Data analyzed using\ncBioPortal",
      "Data analyzed using cBioPortal",
      "Clinical data analysis of human breast cancer patients\nWe used cBioPortal (Cerami et al., 2012; de Bruijn et al., 2023; Gao et al., 2013) to analyze the\ntwo breast cancer patient gene expression data sets TCGA (Cancer Genome Atlas, 2012) and\nMetabric (Curtis et al., 2012; Pereira et al., 2016; Rueda et al., 2019)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:05.226807",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38496643.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.036625862121582,
      "cbioportal_papers": 0.0004000663757324219,
      "platform_mentions": 0.002886056900024414,
      "data_citations": 0.00045108795166015625,
      "num_data_pmids_checked": 4
    }
  },
  "38398101": {
    "paper_id": "38398101",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:09.523888",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38398101.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.453886270523071,
      "cbioportal_papers": 0.00033926963806152344,
      "platform_mentions": 0.0026090145111083984,
      "data_citations": 1.3113021850585938e-05,
      "num_data_pmids_checked": 0
    }
  },
  "38392627": {
    "paper_id": "38392627",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Geneexpressionanalyseswerebasedon82GCPCsamples,dividedinto69diffuse\nGC and 13 signet ring cell cases and constituting a subset of a larger cohort including\n415samples forwhich moleculardatais partof thestomachadenocarcinoma, Firehose\nLegacystudy,TCGA(cBioPortalathttps://www.cbioportal.org(accessedon28December\n2023)and240samplesfrompatientsdiagnosedwithdiffuseGCandrepresentingasubset\nof 875 patients reported by KM plotter at https://kmplot.com/analysis/index.php?p=\nservice&cancer=gastric(accessedon28December2023))",
      "Gene Expression Analysis\nWe performed a computational transcriptional analysis using the cBioPortal software\nand RNA-seq data from 82 GC PCs, which were divided into 69 diffuse-type GC cases and\n13 signet ring cell GC cases, all part of the Firehose Legacy GC series of TCGA (18)",
      "Transcriptional signatures associated\nwith the two PCGC KRT8-high and KRT8-low groups were established through the\ncBioPortal software [18]",
      "DataAvailabilityStatement: Datarepresentedoranalyzedinthisstudyareopenlyavailableas\nsuch or can be obtained by means of the software: Stomach Adenocarcinoma, Firehose Legacy\nStudyathttps://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/STAD/20160128/(ac-\ncessedon20December2023)andhttps://www.cbioportal.org/study/summary?id=stad_tcga(ac-\ncessedon20December2023);SubcellulaRVissoftware:Enrichmentvisualizationofproteinlocaliza-\ntionathttp://phenome.manchester.ac.uk/subcellular/(accessedon20December2023);KMplot-\nterathttps://kmplot.com/analysis/index.php?p=service&cancer=pancancer_rnaseq(accessedon\n20December2023);Enrichrathttps://maayanlab.cloud/Enrichr/(accessedon20December2023)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:11.564108",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38392627.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.68747067451477,
      "cbioportal_papers": 0.00023293495178222656,
      "platform_mentions": 0.014536857604980469,
      "data_citations": 5.0067901611328125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "38396649": {
    "paper_id": "38396649",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:12.265364",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38396649.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.602711915969849,
      "cbioportal_papers": 0.0003230571746826172,
      "platform_mentions": 0.0003807544708251953,
      "data_citations": 0.0003609657287597656,
      "num_data_pmids_checked": 3
    }
  },
  "38416404": {
    "paper_id": "38416404",
    "cbioportal_paper_citations": [
      "nlm.nih.gov/23550210/ 42"
    ],
    "cbioportal_platform_mentions": [
      "Data from The Cancer Genome Atlas\nFurthermore, early-phase trials of the PARPi, olaparib, in treating (TCGA)sampleswereacquiredfromthepan-cancerreleasefromthe\nadvanced castration-resistant prostate cancer (CRPC) indicated GDCdataportal(https://gdc.cancer.gov/about-data/publications/pan\npotential clinical benefit in ATM-mutant tumors, but these results canatlas).DataforadditionalsampleswereobtainedfromcBioPortalat\nwerenotvalidatedinsubsequentprospectiveandretrospectiveclinical www.cbioportal.org(24\u201326).Published,existingmutationalsignatures\nanalyses",
      "Molecular data for additional patient\nmembrane.After1hourofblockingatroomtemperaturewith5% samples were obtained from publicly available cohorts deposited\nskim milk, membrane was incubated with primary antibody on cBioPortal (www.cbioportal.org) and AACR Genie Project\npChk1ser345 (Cell Signaling Technology, no",
      "After cbioportal.org) as referenced (24, 26)",
      "Integrativeanalysisofcomplexcancergenomicsandclinicalprofilesusingthe TP53mutationsshowmutualexclusivitybutdistinctclinicalimpactinmantle\ncBioPortal\u2014PubMed.[cited2024Jan25].Availablefrom:https://pubmed.ncbi"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:12.661389",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38416404.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.46435832977295,
      "cbioportal_papers": 0.003573894500732422,
      "platform_mentions": 0.017277956008911133,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "38500596": {
    "paper_id": "38500596",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Integrative analysis of complex cancer genomics and clinical 34.Buchko,G .W., Daughdrill,G .W., de Lorimier,R ., Rao,B .K.,\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:14.509483",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38500596.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.424408674240112,
      "cbioportal_papers": 0.0004088878631591797,
      "platform_mentions": 0.003651142120361328,
      "data_citations": 0.00015401840209960938,
      "num_data_pmids_checked": 1
    }
  },
  "38540967": {
    "paper_id": "38540967",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DataAvailabilityStatement:Dataavailabilityislistedasbelow:GEPIA(GeneExpressionProfiling\nInteractiveAnalysis),http://gepia.cancer-pku.cn/(accessedon1February2024); cBioPortalfor\nCancerGenomics,https://www.cbioportal.org/(accessedon6February2024);L1000CDS2,https://\nmaayanlab.cloud/L1000CDS2/#/index(accessedon11January2024);ReactomePathwayDatabase,\nhttps://reactome.org/(accessedon1February2024)",
      "Data Availability Statement: Data availability is listed as below: GEPIA (Gene Expression Profiling\nJ.Pers.Med.2024,14,224 Interactive Analysis), http://gepia.cancer-pku.cn/ (accessed on 1 February 2024); cBioPortal for Can-12of22\ncer Genomics, https://www.cbioportal.org/ (accessed on 6 February 2024); L1000CDS2,\nhttps://maayanlab.cloud/L1000CDS2/#/index (accessed on 11 January 2024); Reactome Pathway Da-\ntabase, https://reactome.org/ (accessed on 1 February 2024)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:17.133709",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38540967.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 34.33380389213562,
      "cbioportal_papers": 0.00031113624572753906,
      "platform_mentions": 0.0034639835357666016,
      "data_citations": 0.00012183189392089844,
      "num_data_pmids_checked": 1
    }
  },
  "38318212": {
    "paper_id": "38318212",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Glioma] and Cell 2013 [Glioblastoma]) from cBioPortal (http://\ncbioportal.org), an open-access resource for interactive exploration\nFlowcytometry of multidimensional cancer genomics\ndatasets.77\u201379\nRNA Seq V2\nTransfectedA1207andU87cellswerewashedinphosphate-buffered RSEM-baseddatafromtheTCGAdataset(Cell2013[Glioblastoma])\nsaline (PBS) and harvested with an enzyme-free dissociation buffer wereusedtoanalyzethecorrelations.Themulti-geneprognosticin-\n(ThermoFisherScientific,Darmstadt,Germany).Thecellswereincu- dexforagroupofgenes(CSPG4,PDGFRA,PDGFRB,ITGB1)was\nbated with the indicated phycoerythrin (PE)-labeled antibodies for analyzedbyGBMmolecularsubtypeusingtheNationalCancerInsti-\n30 min at room temperature"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:21.037573",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38318212.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.466055870056152,
      "cbioportal_papers": 0.00029730796813964844,
      "platform_mentions": 0.003034830093383789,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "38229522": {
    "paper_id": "38229522",
    "cbioportal_paper_citations": [
      "[PubMed: 22588877] Erratum in: Cancer\nDiscov"
    ],
    "cbioportal_platform_mentions": [
      "Lastly,\nPER2 expression and genomic alterations were identified on data set from the skin cancer\nmutational landscape studies using the cBioPortal software (Pickering et al., 2104; Chang &\nShain, 2021; Bonilla et al., 2016; Cerami et al., 2012; Gao et al., 2013; Brujin et al., 2023",
      "Author\nManuscript\nAuthor\nManuscript\nAuthor\nManuscript\nAuthor\nManuscript\n\nYujra et al. Page 9\nde Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, Li X, Ochoa A, Zhao G, Lai\nB, Abeshouse A, Baiceanu D, Ciftci E, Dogrusoz U, Dufilie A, Erkoc Z, Garcia Lara E, Fu Z, Gross\nBE, Haynes CD, Heath A et al. Analysis and Visualization of Longitudinal Genomic and Clinical\nData from the AACR Project GENIE Biopharma Collaborative in cBioPortal",
      "Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {
      "25303977": [
        "10.1158/1078-0432.CCR-14-1768 [PubMed: 25303977]\nRodchenkov I, Babur O, Luna A, Aksoy BA, Wong JV, Fong D, Franz M, Siper MC, Cheung M,\nWrana M, Mistry H, Mosier L, Dlin J, Wen Q, O\u2019Callaghan C, Li W, Elder G, Smith PT,\nDallago C, Cerami E, Gross B, Dogrusoz U, Demir E, Bader GD, Sander C"
      ],
      "34272401": [
        "10.1038/s41525-021-00226-4 [PubMed: 34272401]\nChen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ and Chang JG (2005)"
      ],
      "26950094": [
        "10.1038/\nng.3525 [PubMed: 26950094]\nJ Cell Biochem"
      ]
    },
    "extraction_date": "2025-12-19T18:27:21.433567",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38229522.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 3,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.720132112503052,
      "cbioportal_papers": 0.0018360614776611328,
      "platform_mentions": 0.0018939971923828125,
      "data_citations": 0.021955013275146484,
      "num_data_pmids_checked": 3
    }
  },
  "38339265": {
    "paper_id": "38339265",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "AqueryoftheAmericanAssociationforCancerResearch\n(AACR)ProjectGENIEpublicdatabaseincBioportal[32]found299samplesfrom202cases\ndocumentedasPMF(https://genie.cbioportal.org/study?id=6562046bb01fff74fbb6c576\n(accessedon25November2023))",
      "Moredetails\ncanbefoundat:https://genie.cbioportal.org/study?id=6562046bb01fff74fbb6c576(needlogin)(accessedon25\nNovember2023).#Themutationsarenamedusingasingle-letteraminoacidcodeifthemostfrequentmutations\naredocumentedasaminoacidchanges.*Documentedat0.5%(1/199)inGENIE;prevalencewasadjustedbased\nonotherstudies[49]",
      "This is also confirmed by a query of the AACR GENIE public\ndatabasecomparingPMFtoPVandET(https://genie.cbioportal.org/study?id=65622d3\nbb01fff74fbb6c5cc(accessedon25November2023))"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:22.669486",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38339265.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.401188850402832,
      "cbioportal_papers": 0.00038695335388183594,
      "platform_mentions": 0.0037729740142822266,
      "data_citations": 1.430511474609375e-05,
      "num_data_pmids_checked": 0
    }
  },
  "38279653": {
    "paper_id": "38279653",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Moreover, this project has received\nP=8.005e\u22125),althoughnotinhighergradeglioblastomapatients\nfunding from the European Horizon\u2019s research and innovation\n(TCGA-GBM) (r =0.02, P =0.777) based on cbioportal.org [100\u2013\nprogram HORIZON-HLTH-2022-STAYHLTH-02 under agreement\n102].Byusingthe\u2018SearchGene/Geneset\u2019module,wefoundother\nNo101095679.FundedbytheEuropeanUnion.Viewsandopinions\ncluster5genesexpressedlikeCCND2(SupplementaryTable5B),\nexpressed are however those of the author(s) only and do\nwhichcanbefurthertestedinotherTCGAorclinicalcohorts",
      "Johnson NT,Dhroso A,Hughes KJ,Korkin D.Biological clas- and visualization of longitudinal genomic and clinical data\nsification with RNA-seq data: can alternatively spliced tran- from the AACR Project GENIE Biopharma Collaborative in\nscriptexpressionenhancemachinelearningclassifiers?RNA cBioPortal [published online ahead of print, 2023 Sep 5]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:23.013964",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38279653.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.353320837020874,
      "cbioportal_papers": 0.0002949237823486328,
      "platform_mentions": 0.0032591819763183594,
      "data_citations": 0.0002231597900390625,
      "num_data_pmids_checked": 2
    }
  },
  "38509063": {
    "paper_id": "38509063",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Elyada,E.etal.Cross-speciessingle-cellanalysisofpancreatic\nThehumanbulkRNA-sequencingdatawasqueriedusingcBioPortal ductaladenocarcinomarevealsantigen-presentingcancer-asso-\n(https://www.cbioportal.org/,cohortTCGASARC)andcanbedown- ciatedfibroblasts.CancerDiscov.9,1102\u20131123(2019)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:23.071164",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38509063.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 31.113569974899292,
      "cbioportal_papers": 0.00040411949157714844,
      "platform_mentions": 0.004091739654541016,
      "data_citations": 0.00014400482177734375,
      "num_data_pmids_checked": 1
    }
  },
  "38279263": {
    "paper_id": "38279263",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:23.437929",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38279263.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.137341022491455,
      "cbioportal_papers": 0.0003190040588378906,
      "platform_mentions": 0.003153085708618164,
      "data_citations": 0.0002357959747314453,
      "num_data_pmids_checked": 2
    }
  },
  "38136436": {
    "paper_id": "38136436",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "VariantClassification\nForthefunctionalinterpretationandclassificationofnon-synonymousvariantson\nDNA-level as well as gene fusions on RNA-level, the following databases were used:\n\nCancers2023,15,5892 4of20\nClinVar,VarSome,cbioPortal,MolecularTumorBoardPortal,LOVD3,MitelmanDatabase,\nandChimerDB3.0database[20\u201328]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:31.538864",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38136436.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.063880205154419,
      "cbioportal_papers": 0.0003178119659423828,
      "platform_mentions": 0.002354860305786133,
      "data_citations": 0.00021886825561523438,
      "num_data_pmids_checked": 2
    }
  },
  "38104870": {
    "paper_id": "38104870",
    "cbioportal_paper_citations": [
      "[PubMed:\n22588877]\n53",
      "[PubMed: 23550210]\n54"
    ],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal",
      "de Bruijn I, Kundra R, Mastrogiacomo B, et al. Analysis and Visualization of Longitudinal\nGenomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in\ncBioPortal"
    ],
    "data_publication_citations": {
      "25631445": [
        "[PubMed: 25631445]\n19"
      ]
    },
    "extraction_date": "2025-12-19T18:27:33.453339",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38104870.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.380813121795654,
      "cbioportal_papers": 0.0032210350036621094,
      "platform_mentions": 0.0027267932891845703,
      "data_citations": 0.0025348663330078125,
      "num_data_pmids_checked": 2
    }
  },
  "38195917": {
    "paper_id": "38195917",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:34.658855",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38195917.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.51211404800415,
      "cbioportal_papers": 0.00039696693420410156,
      "platform_mentions": 0.0004508495330810547,
      "data_citations": 0.00026798248291015625,
      "num_data_pmids_checked": 2
    }
  },
  "38201511": {
    "paper_id": "38201511",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:35.181186",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38201511.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.663355112075806,
      "cbioportal_papers": 0.0003762245178222656,
      "platform_mentions": 0.0005466938018798828,
      "data_citations": 0.0007789134979248047,
      "num_data_pmids_checked": 6
    }
  },
  "38097622": {
    "paper_id": "38097622",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "analysisof5989patientsamplesofhaematopoieticcancersusing\nHowever, it is noteworthy that NEDD4, WWP1, and WWP2, some the cBioPortal database showed no correlation between ARRDC3\noftheHECTE3ubiquitinligasesthoughttointeractphysicallywith mutation (loss/amplification) with either MYC amplification or\nARRDC3, are also thought to act as regulators of MDM2 and/or TP53 loss [50\u201352]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:40.737933",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38097622.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.66393494606018,
      "cbioportal_papers": 0.0002551078796386719,
      "platform_mentions": 0.0020270347595214844,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "37958652": {
    "paper_id": "37958652",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TheATCG\ndatabaseshowedthat10%ofcasesprofiledshowgeneamplificationforCERS2inbladder\ncancer (data obtained through cBioPortal [61]), and regarding gene transcription, the\nexpressionisslightlyhigherincancersamples(Log2foldchange0.2,withapvalueof0.025)\namong432samples(404tumorvs",
      "2023, 24, 15668 8 of 14\ndatabase showed that 10% of cases profiled show gene amplification for CERS2 in bladder\ncancer (data obtained through cBioPortal [61]), and regarding gene transcription, the ex-\npression is slightly higher in cancer samples (Log2 foldchange 0.2, with a p value of 0.025)\nInt.J.Mol.Sci.2023,24,15668 among 432 samples (404 tumor vs. 28 non-tumor, data obtained through GEPIA2 8[6of21]5)",
      "FiFgiugruer e4.4 C.CERERS2S 2exexppreressssiioonn iinn ddiiffffeerreenntt BBCC ddaattaasseettss..T Thheesseeg grraapphhssw wereerec ocnosntsrutrcutecdtefdro fmromex perxepsrseiosnsion\ndata available in the curatedBladderData package (in R repository), cBioPortal [61], as well as data\ndata available in the curatedBladderData package (in R repository), cBioPortal [61], as well as\nobtained from the following articles: GSE13507_eset in [63], GSE19915.GPL3883_eset in [64],\ndataobtainedfromthefollowingarticles: GSE13507_esetin[63],GSE19915.GPL3883_esetin[64],\nGSE32894_eset in [65], and GDS1479 in [66]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:49.103175",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/37958652.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.611747026443481,
      "cbioportal_papers": 0.00029397010803222656,
      "platform_mentions": 0.002279996871948242,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40518921": {
    "paper_id": "40518921",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Somatic muta-\nthe pathological basis of most cardiovascular diseases is\ntions of OLR1 were obtained from the cBioPortal for\natherosclerosis(AS),characterizedbytheformationoflipid\nCancerGenomicsdatabase(https://www.cbioportal.org/).11\ndeposits in the intima of medium and large arteries, which\nfurther develop into atherosclerotic plaques.4 Although\nmany lipid-lowering drugs have been applied in clinical Cells and treatment\npractice,impairedlipidmetabolismdoesnotimprovesatis-\nfactorily,andtheprogressofASisnotwellcontrolled,indi- AfricanGreenMonkeyKidneyCellCOS-7cellswerepur-\ncating the underlying mechanism isnot yet clear.5 chased from COBioer (Nanjing, China) and cultured in\nOxidizedlow-densitylipoproteinreceptor1(OLR1,also DMEM (Gibco, USA) with 10% fetal bovine serum\nknown as lectin-like oxidized low-density lipoprotein (FBS, Thermo Fisher, Germany) and 100U/ml penicillin-\nreceptor-1,fulllength1\u2013273aa)primarilyrecognizesmodi- streptomycin solution (Gibco, China) at 37\u00b0C in 5% CO\n2\nfied low-density lipoprotein (LDL) as its specific ligands, atmosphere",
      "Hum Mol\ncBioPortal.CancerRes2023;83:3861\u20133867"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:27:50.073306",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40518921.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.316635847091675,
      "cbioportal_papers": 0.0002181529998779297,
      "platform_mentions": 0.00226593017578125,
      "data_citations": 1.4066696166992188e-05,
      "num_data_pmids_checked": 0
    }
  },
  "38172915": {
    "paper_id": "38172915",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "For visualization, the from cBioportal 15 October 2023)",
      "cBioportal annotations were been implicated in basal-like breast cancer [17, 19, 20];\nconducted as previously described [60\u201362]",
      "cBioportal annotations of Notch muta\u2011\nline (left) and the 19 cell line (right) datasets"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:24.261142",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38172915.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 33.48307204246521,
      "cbioportal_papers": 0.00043582916259765625,
      "platform_mentions": 0.0038170814514160156,
      "data_citations": 0.00043702125549316406,
      "num_data_pmids_checked": 3
    }
  },
  "38066746": {
    "paper_id": "38066746",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "MutationCharacterandMethylationAnalysis\nThecBioPortaldatabase[37\u201339](http://www.cbioportal.org/accessedon26August\n2023)wasappliedtoanalyzethemutationcharacterofGLYATinpan-cancers",
      "However, mutation data from the cBioPortal Web tool\nrevealedaGLYATmutationrateofonly0.2%inKIRCcases(Figure4)",
      "However, mutation data from the cBioPortal Web tool re-\nvealed a GLYAT mutation rate of only 0.2% in KIRC cases (Figure 4)",
      ".BBararr rpplolto dtedpeipcitcintign ggegneenteict iacltaelrteartiaotniosn rsatreast eosf\noGfLGYALYTA Tini nddiiffffeerreenntt ttuummoorr tytyppesesf rofmromth ethTeC GTACGdaAt abdaastea,braester,i evreedtrifervoemd cfBrioomPo rctaBli,o(Photrttpasl:,\n(https://www.cbioportal.org/, accessed on 22 August 2023))",
      "Mutations are represented in green, de-\n//www.cbioportal.org/,accessedon22August2023)).Mutationsarerepresentedingreen,deletions\nletions in blue, amplification in red, and multiple alterations in gray"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:21.243776",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38066746.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 29.84231209754944,
      "cbioportal_papers": 0.00032806396484375,
      "platform_mentions": 0.0036580562591552734,
      "data_citations": 8.821487426757812e-06,
      "num_data_pmids_checked": 0
    }
  },
  "37958668": {
    "paper_id": "37958668",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "InSilicoAnalysis\nData from the TCGA database were extracted through the cBioportal portal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:09.501199",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/37958668.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.911418914794922,
      "cbioportal_papers": 0.0003559589385986328,
      "platform_mentions": 0.0027418136596679688,
      "data_citations": 1.4066696166992188e-05,
      "num_data_pmids_checked": 0
    }
  },
  "37903775": {
    "paper_id": "37903775",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genetic alteration analysis\nThe cBioportal database (https://w ww.c biopo rtal.o rg/)16 is a comprehensive platform that integrates research data\nfrom different tumor genomes, enabling the visualization and analysis of operational assumptions",
      "(A, B) The mutation features of KCNQ4 were analyzed\nby using the cBioPortal",
      "(C) The mutation site with the highest alteration frequency (R589L/R589Q/D593Tfs*23\nand R589W) in the 3D structure of KCNQ4 via cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:39.479727",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/37903775.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 30.83993124961853,
      "cbioportal_papers": 0.0002620220184326172,
      "platform_mentions": 0.0020971298217773438,
      "data_citations": 0.00019812583923339844,
      "num_data_pmids_checked": 2
    }
  },
  "41378029": {
    "paper_id": "41378029",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genomic alteration and mutational burden analyses\nThrough TIMER\u2019s computational algorithms, we evaluated\nThe cBioPortal resource (https://www.cbioportal.org), an MCRS1 transcriptional profiles in HCC and their\nonline cancer genomics interface consolidating TCGA and spatial correlations with six tumor-infiltrating leukocyte\nInternational Cancer Genome Consortium datasets (22), populations: neutrophils, DCs, CD8+ T lymphocytes,\nwas employed to retrieve somatic mutation profiles"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:32.442873",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41378029.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 22.85602593421936,
      "cbioportal_papers": 0.00046825408935546875,
      "platform_mentions": 0.031890869140625,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41378004": {
    "paper_id": "41378004",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Transl Cancer Res 2025;14(11):7881-7902 | https://dx.doi.org/10.21037/tcr-2025-1191\n\nTranslational Cancer Research, Vol 14, No 11 November 2025 7883\nDatabase tools Immune subtype\nconsensus clustering\n(unsupervised)\ncBioportal GEPIA2 TIMER\nIS1 IS2\nTrain cohort\nTCGA-ESCA TCGA-ESCA\nOverexpressed genes validation cohort\nGSE53625\nMutated genes\nImmune-subtype\nOS and PFS mutation characters\nAPCs correlation\nImmune-related\nmolecular signature\nImmune-landscape\nPotential tumor antigen\nin ESCA WGCNA\nImmune-Hub gene\nFigure 1 An overview of the study\u2019s work flow",
      "In the first part, we collected TCGA-ESCA datasets (n=150), and used database tools such\nas cBioportal and GEPIA2 to conduct mutation analysis and survival analysis, etc., to identify potential tumor antigens",
      "cn/static/public/tcr-2025-1191-2.xlsx provides detailed\nGene expression profiling interactive and cBioPortal\nclinicopathological information about the specimens in this\nanalyses\ncDNA microarray",
      "is first heated to 95 for approximately 1\u20132 minutes to\ncbioportal.org) (11), an open platform for researching denature the DNA strands, thereby separating the double-\n\u2103\nmulti-dimensional cancer genome datasets, was used to stranded molecules into single-stranded templates"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:41.541075",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41378004.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.16060185432434,
      "cbioportal_papers": 0.0003712177276611328,
      "platform_mentions": 0.004027128219604492,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41373739": {
    "paper_id": "41373739",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:55.791261",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41373739.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.29002857208252,
      "cbioportal_papers": 0.0002522468566894531,
      "platform_mentions": 0.00029277801513671875,
      "data_citations": 9.894371032714844e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41373636": {
    "paper_id": "41373636",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Moleculardatawere\nobtainedfromcBioPortal(https://www.cbioportal.org,lastaccessed29April2025)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:57.405830",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41373636.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.923825979232788,
      "cbioportal_papers": 0.00019407272338867188,
      "platform_mentions": 0.0019237995147705078,
      "data_citations": 9.775161743164062e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41377662": {
    "paper_id": "41377662",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Vieira Braga, F.A., Kar, G., Berg, M., Carpaij, O.A., Polanski, K., Simon, ysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:57.630457",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41377662.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 33.29511022567749,
      "cbioportal_papers": 0.00042176246643066406,
      "platform_mentions": 0.0041730403900146484,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41362743": {
    "paper_id": "41362743",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Given its relevance, we then examined\nrevealed significantly lower expression in the FAT1 mutations in pan-cancer datasets using\nresistant group compared to the sensitive ones (Figure cBioPortal, finding that FAT1 mutations occur in over\n4A)",
      "strides in BC treatment, particularly in triple-negative\nDatabase\nbreast cancer (TNBC), with promising agents such as\nimmune checkpoint inhibitors (ICIs), antibody-drug cBioportal (http://www.cbioportal.org/)\nconjugates (ADCs), and CAR T-cell therapies [50]",
      "We analyzed features of FAT1 across various\nHowever, persistent challenges limit widespread\noncologic cohorts using the cBioportal database [56]",
      "2022;7:168 the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:28:59.946938",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41362743.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.400454998016357,
      "cbioportal_papers": 0.0003619194030761719,
      "platform_mentions": 0.0044438838958740234,
      "data_citations": 0.00012302398681640625,
      "num_data_pmids_checked": 1
    }
  },
  "41357570": {
    "paper_id": "41357570",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "RRM2regulatesBcl-2inheadandneckandlungcancers:apotentialtargetforcancer IntegrationandanalysisofCPTACproteomicsdatainthecontextofcancergenomics\ntherapy.ClinCancerRes.(2013)19:3416\u201328.doi:10.1158/1078-0432.CCR-13-0073 in the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:07.565616",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41357570.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.896697759628296,
      "cbioportal_papers": 0.00022602081298828125,
      "platform_mentions": 0.0017199516296386719,
      "data_citations": 5.7220458984375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41348985": {
    "paper_id": "41348985",
    "cbioportal_paper_citations": [
      "[PubMed: 23550210]\n12"
    ],
    "cbioportal_platform_mentions": [
      "Driver gene mutations\nwere defined for each patient using cBioPortal and were limited to with greater than 5%\nfrequency in the cohort",
      "To confirm\nthis, we used cBioPortal to analyze a larger cohort of NSCLC patients and verified mutual\nexclusivity of RAS-MAPK alterations (Fig 4C, Fig S3A)",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of\ncomplex cancer genomics and clinical profiles using the cBioPortal",
      "(C) Mutual exclusivity analysis using the cBioPortal showing\nthat driver mutations in NF1 are mutually exclusive from KRAS (q < 0.007), and driver\nmutations in BRAF are mutually exclusive from KRAS (q < 0.001)"
    ],
    "data_publication_citations": {
      "34145282": [
        "[PubMed: 34145282]\n14"
      ]
    },
    "extraction_date": "2025-12-19T18:29:08.899790",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41348985.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.911686897277832,
      "cbioportal_papers": 0.0017039775848388672,
      "platform_mentions": 0.00189208984375,
      "data_citations": 0.01829814910888672,
      "num_data_pmids_checked": 1
    }
  },
  "41361777": {
    "paper_id": "41361777",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods We utilized TCGAplot R package (v8.0.0), Sangerbox3.0, GEPIA2, cBioPortal, UALCAN, TISIDB, BioGRID, and\nsingle-cell RNA sequencing (scRNA-seq) data to decipher the close association of BIRC5 with tumor occurrence\nand development as well as its involvement in gene mutations, methylation patterns, immune infiltration levels,\nfunctional aspects, and prognosis outcomes",
      "As a key component Analysis of genetic alterations and promoter methylation\nof chromosome passenger complex (CPC), BIRC5 plays BIRC5 genetic modifications were examined through the\nan essential role in ensuring accurate chromosome align- utilization of the cBioPortal database ( h t t p s : / / w w w",
      "Currently, extensive research has consistently shown number alterations (CNAs) and alteration frequency\nthat BIRC5 is significantly overexpressed in a range of across tumor types, was obtained from cBioPortal's Can-\ncancers, including breast [7, 8], liver [9], stomach [10], cer Types Summary",
      "across TCGA datasets using cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:10.334726",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41361777.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.518137216567993,
      "cbioportal_papers": 0.00024390220642089844,
      "platform_mentions": 0.0020771026611328125,
      "data_citations": 0.00010609626770019531,
      "num_data_pmids_checked": 1
    }
  },
  "41360825": {
    "paper_id": "41360825",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:17.260003",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41360825.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.824257135391235,
      "cbioportal_papers": 0.0001418590545654297,
      "platform_mentions": 0.0002079010009765625,
      "data_citations": 4.887580871582031e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41347086": {
    "paper_id": "41347086",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutational profiles, copy number\ndegradation without forming polyubiquitin chains, a feature that alterations (CNAs), and gene fusion events were analyzed using\nunderscoresitsdistinctroleinbothphysiologicalandpathological thecBioPortalplatform(https://www.cbioportal.org/)basedonthe\ncontexts(4)",
      "Quantitative measurements of target\n(CNA) for a pan - cancer analysis were obtained from the\ngene expression were normalized against the housekeeping gene\ncBioPortal website (17)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:18.668884",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41347086.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.053781986236572,
      "cbioportal_papers": 0.0003001689910888672,
      "platform_mentions": 0.0030868053436279297,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41342186": {
    "paper_id": "41342186",
    "cbioportal_paper_citations": [
      "[doi: 10.1158/2159-8290.CD-12-0095] [Medline:\n22588877]\n18",
      "[doi: 10.1126/scisignal.2004088] [Medline: 23550210]\n19"
    ],
    "cbioportal_platform_mentions": [
      "Invasive nonpapillary urothelial carcinomas can\nthe cBioPortal for Cancer Genomics [17,18]",
      "Hub\nobtained from cBioPortal",
      "Data Availability\nAll data collected and analyzed in this study are publicly available at cBioPortal [49,50]",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the\ncBioPortal",
      "cBioPortal",
      "URL: https://www.cbioportal.org/study/summary?id=blca_tcga_pub_\n2017 [Accessed 2025-11-10]\n50",
      "URL: https://www.cbioportal.org/study/summary?id=blca_tcga_pub\n[Accessed 2025-11-10]\nAbbreviations\nCMap: connectivity map\nGO: Gene Ontology\nKEGG: Kyoto Encyclopedia of Genes and Genomes\nPPI: protein-protein interaction\nRNA-seq: RNA sequencing\nTCGA: The Cancer Genome Atlas\nEdited by Tiffany Leung; peer-reviewed by Hiroshi Miyamoto, Xun Ding; submitted 29.Apr.2025; final revised version\nreceived 12.Oct.2025; accepted 25.Oct.2025; published 27.Nov.2025\nhttps://bioinform.jmir.org/2025/1/e76736 JMIR Bioinform Biotech2025 | vol"
    ],
    "data_publication_citations": {
      "28988769": [
        "[doi: 10.1016/j.cell.2017.09.007] [Medline: 28988769]\n16"
      ],
      "24476821": [
        "[doi: 10.1038/nature12965] [Medline: 24476821]\n17"
      ]
    },
    "extraction_date": "2025-12-19T18:29:21.804346",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41342186.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 2,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.833674192428589,
      "cbioportal_papers": 0.002623319625854492,
      "platform_mentions": 0.0030281543731689453,
      "data_citations": 0.029842138290405273,
      "num_data_pmids_checked": 2
    }
  },
  "38132155": {
    "paper_id": "38132155",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:49.386540",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/38132155.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 118.51419305801392,
      "cbioportal_papers": 0.00042128562927246094,
      "platform_mentions": 0.0032498836517333984,
      "data_citations": 1.5735626220703125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41321318": {
    "paper_id": "41321318",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "All analyses were done on cBioPortal",
      "Correlations were assessed in cBioPortal",
      "Funding acquisition: XY, MET, and\nperformed directly in cBioPortal using the Prostate Adenocarcinoma SPB",
      "of androgen receptor signaling inhibitor resis- cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:32.303160",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41321318.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.558789253234863,
      "cbioportal_papers": 0.00030994415283203125,
      "platform_mentions": 0.032488346099853516,
      "data_citations": 0.00022292137145996094,
      "num_data_pmids_checked": 2
    }
  },
  "41315241": {
    "paper_id": "41315241",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Cancer Genome Atlas (TCGA) via cBioPortal [46, 47] (http:// 18",
      "RosenEM,JosephA,JinL,YaoY,ChauMH,FuchsA,etal.Urinaryandtissue\nwww.cbioportal.org)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:35.780142",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41315241.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.537201881408691,
      "cbioportal_papers": 0.0002739429473876953,
      "platform_mentions": 0.0028839111328125,
      "data_citations": 0.00017905235290527344,
      "num_data_pmids_checked": 2
    }
  },
  "41321316": {
    "paper_id": "41321316",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "First, using at the proliferative phase in patients with endometriosis compared\ncBioportal analysis of The Cancer Genome Atlas (TGCA) data with normal samples (Figure 3C)",
      "(A) Summary plot showing ZMIZ1 mutation frequencies associated with tumors using cBioportal\nanalysis of TGCA cancer dataset (31, 32)",
      "Estrogen receptors: new cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:36.262745",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41321316.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.430386781692505,
      "cbioportal_papers": 0.0003750324249267578,
      "platform_mentions": 0.003453969955444336,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41332998": {
    "paper_id": "41332998",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal Cancer Genomics Database Analysis\nThe cBioPortal Cancer Genomics online database (http://www.cbioportal.org) has been recognized as a platform for\ninvestigating and assessing genomic data from various cancer datasets.26 cBioPortal has 147 distinct research areas across\n31 different kinds of cancer types",
      "The impacts of genomic alterations in ZHX factors, such as copy-number variance, gene\ndeletion, and mutations on OS in EC patient were detected using the cBioPortal database in the present study",
      "Association Between ZHX Genomic Alterations and Patient Survival\nWe next characterized the prognostic correlation between genomic alterations of ZHX factors and outcomes of EC\npatients using the cBioPortal database",
      "thyroid cancer metastasis of thyroid cancer through transcriptional inhibition of S100 calcium-binding protein A14.32\nAlthough these above observations suggest that ZHX2 may might act serve as a tumor suppressor in lung cancer, ZHX2\nexpression has been found observed to be upregulated in clear cell renal cell carcinoma and facilitate tumorigenesis of in\na hypoxia inducible factor-\u03b1 (HIF-\u03b1)-independent manner.33,34 These observations are consistent with relevant findings\nof ZHX2 as an oncogene in gastric cancer, including our previous report.20,35 In addition, it has been found that ZHX2\nmay promote HIF1\u03b1 oncogenic signaling in triple-negative breast cancer (TNBC) and hypoxia-induced phase separation\nInternational Journal of General Medicine 2025:18 https://doi.org/10.2147/IJGM.S554208 7 1 3 5\nPowered by TCPDF (www.tcpdf.org)\n\nFigure 7 Genomic alterations of ZHX genes and their corresponding associations with outcomes in EC patients using the cBioPortal online database",
      "(A) The proportion and distribution of samples with alterations in ZHX factors by\nOncoPrint in cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:39.078262",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41332998.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 21.809046030044556,
      "cbioportal_papers": 0.00020194053649902344,
      "platform_mentions": 0.0022840499877929688,
      "data_citations": 7.390975952148438e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41339360": {
    "paper_id": "41339360",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:40.011091",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41339360.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 29.606568098068237,
      "cbioportal_papers": 0.00045490264892578125,
      "platform_mentions": 0.0032470226287841797,
      "data_citations": 0.0001800060272216797,
      "num_data_pmids_checked": 1
    }
  },
  "41300966": {
    "paper_id": "41300966",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Forthisanalysis,weutilizedtwoindependentcohorts: aninternal\ninstitutionalseries(FMUcohort,n=299)andapubliclyaccessibledatasetobtainedfrom\ncBioPortal(AC-ICAMcohort,n=178)derivedfromwhole-exomesequencingdata[26,27]",
      "DataAvailabilityStatement:TheAC-ICAMdatasetusedinthisstudyisavailablefromcBioPortal\n(https://www.cbioportal.org/,accessedon28August2025)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:44.122437",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41300966.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.809694051742554,
      "cbioportal_papers": 0.0001800060272216797,
      "platform_mentions": 0.001699686050415039,
      "data_citations": 7.295608520507812e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41300765": {
    "paper_id": "41300765",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "InformationfromtheMolecularTaxonomyofBreastCancerInternationalCon-\nsortium(METABRIC)andtheCancerGenomeAtlas(TCGA)wasaccessedviacBioPortal\n(https://www.cbioportal.org/, accessed on 24 September 2022) [11,12]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:44.526817",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41300765.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 5.415329933166504,
      "cbioportal_papers": 0.00015020370483398438,
      "platform_mentions": 0.0014560222625732422,
      "data_citations": 5.5789947509765625e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41300276": {
    "paper_id": "41300276",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Themaindata\nsourcesareasfollows:\nGenomics information associated with gastric diseases was retrieved from online\ndatabasesincludinghttp://www.licpathway.net/ATACdb/(Chromosomestructure,ac-\ncessed on 5 August 2023), https://ngdc.cncb.ac.cn/methbank/ (DNA methylation),\nhttps://www.encodeproject.org/ (Histone modification, accessed on 10 October 2023),\nhttps://www.cbioportal.org/ (Copy number alteration genes, mutated genes, struc-\ntural variant genes, accessed on 12 November 2023), https://www.ncbi.nlm.nih.gov/\nsnp/ (Single-nucleotide polymorphisms, SNPs, accessed on 28 November 2023), and\nhttps://www.omim.org/(OnlineMendelianInheritanceinMan,OMIM,accessedon3\nDecember2023)[29\u201333]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:49.251085",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41300276.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.202254056930542,
      "cbioportal_papers": 0.0002701282501220703,
      "platform_mentions": 0.0026350021362304688,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41267139": {
    "paper_id": "41267139",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Co-expressed genes linked to SORCS2 were identi-\nunderlying OC carcinogenesis and progression are cru- fied utilizing the cBioPortal database, applying stringent\ncial for improving patient outcomes",
      "tified utilizing the cBioPortal database and subjected The PPI network suggested that SORCS2 is functionally\nto functional enrichment analysis via DAVID 6.8"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:57.651491",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41267139.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.085520029067993,
      "cbioportal_papers": 0.00028705596923828125,
      "platform_mentions": 0.0026679039001464844,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41265458": {
    "paper_id": "41265458",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "BRCA1 variant predictions: Variants were selected from ClinVar, gnomAD, TCGA/\ncBioPortal, LOVD, and a prospective MDA breast cancer patient cohort as previously\ndescribed.21 Collected BRCA1-BRCT variants assays were mined from the neXtProt\nserver, which classifies the effect of mutation as a phenotypic intensity for each assay.58\nTo determine if variants that moderately engaged chaperones exhibited partial functional\nactivity, the number of assays reporting a \u201cmild\u201d or \u201cmoderate\u201d effect for each variant was\ncalculated and expressed as a percentage relative to the total number of assays reported for\neach individual variant"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:29:59.860403",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41265458.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.590139865875244,
      "cbioportal_papers": 0.0003552436828613281,
      "platform_mentions": 0.0028667449951171875,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41301068": {
    "paper_id": "41301068",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "GeneticAlterationAnalysis\nThe cBioPortal platform integrates data from comprehensive tumor genome stud-\nies, including large projects like TCGA and ICGC, encompassing data from over\n28,000 samples [22]",
      "In this study, we utilized the cBioPortal database to investigate\nthemutationfrequencyandformsofRBPfamilymembers"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:03.771098",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41301068.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 27.963090896606445,
      "cbioportal_papers": 0.0002491474151611328,
      "platform_mentions": 0.027189970016479492,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41269529": {
    "paper_id": "41269529",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:05.904156",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41269529.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 21.762979984283447,
      "cbioportal_papers": 0.00039315223693847656,
      "platform_mentions": 0.0008029937744140625,
      "data_citations": 0.0005528926849365234,
      "num_data_pmids_checked": 4
    }
  },
  "41301809": {
    "paper_id": "41301809",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:06.735301",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41301809.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 34.42959785461426,
      "cbioportal_papers": 0.0002942085266113281,
      "platform_mentions": 0.0020139217376708984,
      "data_citations": 0.00010704994201660156,
      "num_data_pmids_checked": 1
    }
  },
  "41261171": {
    "paper_id": "41261171",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Cellviability andproliferation\nRKO,MIP-101,andthecorresponding5-FU,andCPT-11resistantcelllines\nMATERIALSANDMETHODS wereseededin96-wellplatesatadensityof1500\u20133000cellsperwellfor\nPatient cohortsand bioinformatic data analysis 24hfollowedbytreatmentwiththePD-1inhibitorNivolumab(Nivo)with\nPubliclyavailablegeneexpressiondatalinkedtoclinicalinformationwere andwithout5-FUorCPT-11for48h.Cellviabilitywasdeterminedbythe\nretrieved fromthree sources: (1) TCGA via the Genomic Data Commons MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-\n(GDC) application and cBioPortal [25, 26]; (2) The personalized OncoGe- phenyl)-2 H-tetrazolium, inner salt) viability assay (Promega) using a\nnomics (POG) program at BC Cancer; and (3) the GEO database",
      "were extracted from cBioPortal (https://www.cbioportal.org/)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:10.353025",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41261171.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.956109046936035,
      "cbioportal_papers": 0.0003581047058105469,
      "platform_mentions": 0.0036389827728271484,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41256460": {
    "paper_id": "41256460",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis\nof complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:10.706718",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41256460.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.820324897766113,
      "cbioportal_papers": 0.0002911090850830078,
      "platform_mentions": 0.0021588802337646484,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41255652": {
    "paper_id": "41255652",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Le et al.4 hypothesized that the patient who\nbioinformatics database cBioPortal (The cBioPortal for\nbenefited from PD-1 blockade might have microsatellite\nCancer Genomics)",
      "In gastric adenocarcinomas and head\npublic database cBioPortal.34,35 Next-generation sequencing\nand neck squamous cell carcinomas (SCC), the combined\nwas employed to evaluate approximately 25,755 patients\npositive score (CPS) should be \u22651% when using the SP22C3\nacross 50 tumor types from the MSK MetTropism dataset",
      "A comparison of BRAF V600E mutations and rearranged during transfection (RET), as well as neurotrophic tyrosine\nreceptor kinase (NTRK) 1, 2, and 3 fusions, was performed using the OncoPrints tool to visualize mutual exclusion and co-\noccurrence trends between gene pairs in the cBioPortal database.34,35 In the figure, genes are displayed in rows, while data points\nare represented in columns",
      "Precis Cancer Med\nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:15.203295",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41255652.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.443333148956299,
      "cbioportal_papers": 0.00021886825561523438,
      "platform_mentions": 0.0019078254699707031,
      "data_citations": 0.00010204315185546875,
      "num_data_pmids_checked": 1
    }
  },
  "41253923": {
    "paper_id": "41253923",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We generated the graph B via the cBioPortal 58,59",
      "Moreover, several studies revealed a high mutation rate for ARHGAP35, the gene that encodes p190A, ranging\nfrom 4% to over 8% of tumor samples (http://www.cbioportal.org) (Fig",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:20.853267",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41253923.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.93156099319458,
      "cbioportal_papers": 0.00033402442932128906,
      "platform_mentions": 0.004224061965942383,
      "data_citations": 0.00012612342834472656,
      "num_data_pmids_checked": 1
    }
  },
  "41237175": {
    "paper_id": "41237175",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genetic alteration analysis of HTR7\ncBioPortal (https://www.cbioportal.org/) is a web platform that provides a resource for exploring, visualizing, and analyzing\nmultidimensional cancer genomics data [18]",
      "https://doi.org/10.1371/journal.pone.0335398.g010\nPLOS One | https://doi.org/10.1371/journal.pone.0335398 November 14, 2025 15 / 22\n\nGenetic alteration analysis of HTR7\nTo explore HTR7 gene variants in pan-cancer, we utilised the cBioPortal platform, which revealed that the frequency of\nHTR7 gene variants was highest in UCEC and SKCM (\uff1e4%)",
      "We comprehensively explored the correlation between HTR7 and 33 cancers,\nincluding gene expression, diagnostic value, prognosis, clinical and pathological staging, TME, DNA methylation, cancer\npathways, and drug sensitivity, using databases including TCGA, GTEx, UALCAN, HPA, and cBioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:22.967039",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41237175.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.19597864151001,
      "cbioportal_papers": 0.00023412704467773438,
      "platform_mentions": 0.0027070045471191406,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41237160": {
    "paper_id": "41237160",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1158/2159-8290.CD-12-0095 PMID: 22588877\n31",
      "https://doi.org/10.1126/scisignal.2004088 PMID: 23550210\n32"
    ],
    "cbioportal_platform_mentions": [
      "Materials and methods\nCTC1 and STN1 gene expression analysis\nAnalysis of CST gene alterations was performed with cBioPortal using TCGA PanCancer Atlas Skin Cutaneous Melanoma\ndataset",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:23.493889",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41237160.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.13040566444397,
      "cbioportal_papers": 0.002565145492553711,
      "platform_mentions": 0.0019071102142333984,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41234433": {
    "paper_id": "41234433",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "These\nmechanisms range from poor drug absorption, rapid\nGene expression profiles and clinical data of patients with colon\nmetabolism, and treatment intolerance to specificities of\ncancer were downloaded from the cBioPortal website (https://\nthe tumor microenvironment, such as drug metabolism\nwww.cbioportal.org)",
      "3.1 Identification of differentially expressed\ngenes\n2.4 Weighted gene co-expression network For this study, the public database TCGA Firehose Legacy\nanalysis (COADREAD/20160128) and PanCancer Atlas available on\ncBioPortal were analyzed (Gao et al., 2013; Cerami et al., 2012),\nA co-expression network was built to investigate the correlation which included 1,232 patients with colon cancer",
      "Cancer 134 (3),\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:25.969091",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41234433.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.240307807922363,
      "cbioportal_papers": 0.00028896331787109375,
      "platform_mentions": 0.003442049026489258,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41220429": {
    "paper_id": "41220429",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Database Brief description Links\nTCGA(Weinsteinetal.,2013) Collectedmultipleomicsdataof33tumortypes,thelargesthumantumorsequencing https://www.cancergenome.nih.gov/\ndatabaseintheworld\nEGA(Lappalainenetal.,2015) Collectionofover800medicalstudiesofalltypesofsequencingdataandtypingdata https://ega-archive.org/\nCGHub(Wilksetal.,2014) Sequencingdataof25differenttypesofcancersfromTCGA,TARGET,andCCLE https://cghub.ucsc.edu/\nwerecollectedandorganized\nICGC(Consortiumetal.,2010) Collectingomicsdatafrommanydifferenttypesofcancers,andcomprehensively https://dcc.icgc.org/\ndescribedthegenomicchangesofmanycancer\nCOSMIC(Forbesetal.,2015) Collectingomicsdataonmanytypesofcancer,itistheworld\u2019slargestandmost https://cancer.sanger.ac.uk/cosmic\ncomprehensivedatabaseofsomaticmutations\ncBioPortal(Gaoetal.,2013) Collectsgenomicdataonmanydifferenttypesofcancer,providingvisualanalysis http://www.cbioportal.org/\ntoolsacrossgenes,samplesanddatatypes\nUCSCXena(NavarroGonzalezetal., Collectingdatafromseverallargecancerresearchprojects,andprovidesconvenient http://genome.ucsc.edu/\n2021) dataanalysisandvisualizationcapabilities\narrayMap(Caietal.,2015) Providepre-processedtumorgenomemicroarraydataandCNAatlas http://www.arraymap.org/\nBioMuta(Wuetal.,2014) 26differenttypesofcancerswerecollectedSNV-data https://hive.biochemistry.gwu.edu/home/\nGEO(Barrettetal.,2012) Collectionandorganizationofhigh-throughputgeneexpressiondatasubmittedby https://www.ncbi.nlm.nih.gov/geo/\nresearchinstitutionsaroundtheworld\nArrayExpress(Kolesnikovetal.,2015) Collectedandorganizedmicroarraychip-basedandhigh-throughputsequencingof https://www.ebi.ac.uk/arrayexpress/\nexperimentalgenomicsdata\nOncomiRDB(Wangetal.,2014) CollectionandannotationofexperimentallyvalidatedmiRNAswithpromotiveor http://www.oncomir.org/\ninhibitoryeffectsondifferentcancertypes\nmiRCancer(Xieetal.,2013) AcomprehensivecollectionofmiRNAexpressionprofilesinvarioushumancancers http://mircancer.ecu.edu/\nSomaMiR(Bhattacharyaetal.,2013) CollectingdataonmiRNAsandmutationsontheirtargets https://compbio.uthsc.edu/SomaMiR/\nChiTaRS(Frenkel-Morgensternetal., Cancergenomesequencebreakpointswerecollectedalongwithexpressionleveldata https://chitars.bioinfo.cnio.es/\n2015) ofthecorrespondingchimerictranscripts\nMethylCancer(Heetal.,2007) CollectedtumorDNAmethylation,cancer-relatedgenes,mutations,CpGislands,and http://methylcancer.psych.ac.cn/\ncancerinformation\nMethHC(Huangetal.,2015) OrganizedDNAmethylation,mRNA/miRNAgeneexpression,miRNAmethylation, http://methhc.mbc.nctu.edu.tw/\nandassociationbetweenmethylationandgeneexpressionlevelsfromTCGA\nCGC(Subramanianetal.,2021) NCI-fundedcloudplatformco-localizinglargedatasets,andcomputepowerfor https://www.cancergenomicscloud.org/\nsecure,collaborativemulti-omicsanalysis\nCPTAC(Mesrietal.,2024) CPTACprovidesarichsourceofpublicdata,servingasacriticalresourcefor https://cptac-data-portal.georgetown.edu/\nresearchersstudyingpan-cancerproteomics cptac/\nFrontiersinGenetics 04 frontiersin.org\n\nWangetal",
      "ic Ab c s a t n r c a e c r t\ncBioPortal.Sci.Signal.6,pl1.doi:10.1126/scisignal.2004088\nanalysisprogram.CancerRes.84,1852.doi:10.1158/1538-7445.am2024-1852\nHe, X., Chang,S., Zhang, J., Zhao, Q.,Xiang,H.,Kusonmano, K.,et al.(2007)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:35.834592",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41220429.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.856981039047241,
      "cbioportal_papers": 0.0004150867462158203,
      "platform_mentions": 0.003882884979248047,
      "data_citations": 8.821487426757812e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41208969": {
    "paper_id": "41208969",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "IPS from the TCIA database quantified\nexpressionmatrixrankedbylogFCusingtheMSigDBc2geneset tumor immunogenicity and were compared between subtypes\n(v2023.2.Hs).Parametersincludedseed=2020,genesetsize=10\u2013 (42)(https://tcia.at/home).TMB(43)(https://www.cbioportal.org/\n500,adjustedp<0.05,andFDR<0.25"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:36.958815",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41208969.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.961692810058594,
      "cbioportal_papers": 0.0002911090850830078,
      "platform_mentions": 0.0029592514038085938,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41226688": {
    "paper_id": "41226688",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:40.730519",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41226688.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.82563304901123,
      "cbioportal_papers": 0.0002651214599609375,
      "platform_mentions": 0.0019600391387939453,
      "data_citations": 8.916854858398438e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41218079": {
    "paper_id": "41218079",
    "cbioportal_paper_citations": [
      "GaoJ,AksoyBA,DogrusozU,DresdnerG,GrossB,SumerSO,etal.Integrativeanalysisofcomplexcancergenomicsandclinicalprofilesusing\nthecBioPortal.SciSignal.2013;6(269):pl1.https://doi.org/10.1126/scisignal.2004088PMID:23550210\n33"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "23000897": [
        "https://doi.org/10.1038/nature11412PMID:23000897\n26"
      ]
    },
    "extraction_date": "2025-12-19T18:30:41.122008",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41218079.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.58369207382202,
      "cbioportal_papers": 0.0017480850219726562,
      "platform_mentions": 0.0018258094787597656,
      "data_citations": 0.02873516082763672,
      "num_data_pmids_checked": 1
    }
  },
  "41199851": {
    "paper_id": "41199851",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TP: Validation,\nreported PBRM1 oncogenic alterations based on the cBioPortal Writing \u2013 review & editing"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:42.333100",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41199851.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.490370035171509,
      "cbioportal_papers": 0.00017189979553222656,
      "platform_mentions": 0.0012619495391845703,
      "data_citations": 0.0001163482666015625,
      "num_data_pmids_checked": 2
    }
  },
  "41257698": {
    "paper_id": "41257698",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Bioinformatics analysis\nThe applied principles to find appropriate articles and Mutation, gene expression, and dna methylation analysis\nmethods were continuously compared with the content To study Cancer Genomics, cBioPortal (v5.1.10; h t t p : / /\nof the PRISMA 2020 statement to ensure comprehensive w w w",
      "Additionally, cBioPortal was utilized to investigate\nwebsite (CRD42023455350, h t t p s : / / w w w",
      "Schwappacher and BID gene missense and splice mutations\ncolleagues investigated serum from advanced prostate To assess the mutational profile of BID across different\ncancer and COAD patients after a 12-week WB-EMS cancers, we downloaded the alteration profile of the BID\ntraining, a tolerable resistance exercise for physically gene from cBioPortal in the TCGA Pan-Cancer Atlas",
      "(A) Frequency of BID genetic alterations across various cancer types from cBioPortal",
      "Moreover, methylation and its expression profile, we analyzed data\nin the examination and comparison of the data retrieved from the cBioPortal database"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:42.858803",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41257698.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 45.149471282958984,
      "cbioportal_papers": 0.0003910064697265625,
      "platform_mentions": 0.0034308433532714844,
      "data_citations": 1.2159347534179688e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41231214": {
    "paper_id": "41231214",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:45.545867",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41231214.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 30.31377387046814,
      "cbioportal_papers": 0.00035309791564941406,
      "platform_mentions": 0.0027627944946289062,
      "data_citations": 0.0003771781921386719,
      "num_data_pmids_checked": 3
    }
  },
  "41184420": {
    "paper_id": "41184420",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "IGF axis activity associates with deregulated immune genes and immune infiltrating cells in\nPCa tissues\nTo test the clinical relevance of these findings we interrogated public RNA-seq data from the Prostate\nAdenocarcinoma Firehose Legacy dataset in cbioportal (www.cbioportal.org/study/summary?id=prad_tcga)30",
      "We accessed data from cbioportal on 110 ipilimumab\n-treated metastatic melanoma patients, of whom 40 had tumor transcriptional profiling43",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:51.141635",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41184420.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.79337191581726,
      "cbioportal_papers": 0.0002300739288330078,
      "platform_mentions": 0.0029447078704833984,
      "data_citations": 8.106231689453125e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41179319": {
    "paper_id": "41179319",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The results\n(n=1,084) (57) were downloaded from cBioPortal (58, 59) indicated that patients with high expression of both\non August 13, 2024",
      "(A\u2010D) Molecular Taxonomy of Breast Cancer International Consortium data were downloaded from cBioPortal",
      "(E\u2010H) The Cancer Genome Atlas Pan\u2010Cancer\nAtlas data was downloaded from cBioPortal",
      "(A\u2010H) The Cancer Genome Atlas Pan\u2010Cancer Atlas data was downloaded from\ncBioPortal",
      "METABRIC data was downloaded from cBioPortal",
      "TCGA Pan\u2010Cancer Atlas data was\ndownloaded from cBioPortal",
      "DOI: 10.1371/journal.pone.0235747\nDOI: 10.1158/2159\u20118290.CD\u201112\u20110095 67 Kasai T, Tamori S, Takasaki Y, Matsuoka I, Ozaki A, Matsuda\n58 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, C, Harada Y, Sasaki K, Ohno S, Akimoto K: High expression of\nSun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, PKC\u03bb and ALDH1A3 indicates a poor prognosis, and PKC\u03bb is\nSchultz N: Integrative analysis of complex cancer genomics required for the asymmetric cell division of ALDH1A3\u2011\nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:52.229595",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41179319.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.656430244445801,
      "cbioportal_papers": 0.00022912025451660156,
      "platform_mentions": 0.001974821090698242,
      "data_citations": 0.00023603439331054688,
      "num_data_pmids_checked": 3
    }
  },
  "41186627": {
    "paper_id": "41186627",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A web portal, cBio Cancer Genomics portal\n\nAnbarasu et al. Discover Oncology (2025) 16:2029 Page 5 of 19\n(http://cbioportal.org/), v6.3.5 is an interactive resource to explore the multidimensional\ncancer genomic data sets used to construct the Kaplan-Meier survival (KM-plot) plot for\nall the hub genes across the four cancers studied [28]",
      "2.8 Validation\nThe validation for the genes that were screened from the survival analysis was per-\nformed by analyzing their mutation profile for each of the genes in their appropriate\ncancer dataset in the cBioPortal [28]",
      "cBio Cancer Genomics portal (http://cbioportal.org/), v6.3.5 was used\nto perform survival analysis",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:55.080274",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41186627.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.339704990386963,
      "cbioportal_papers": 0.0003399848937988281,
      "platform_mentions": 0.003721952438354492,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41184341": {
    "paper_id": "41184341",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. \u201cIntegrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:30:59.663349",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41184341.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.795416116714478,
      "cbioportal_papers": 0.0003657341003417969,
      "platform_mentions": 0.003335237503051758,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41179310": {
    "paper_id": "41179310",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Aldehyde dehydrogenase 1 and The Cancer Genome Atlas (TCGA; n=1,084) (59)\n(ALDH1) is a detoxifying enzyme that converts aldehydes datasets were downloaded from cBioportal (60, 61) on\ninto carboxylic acids and is known as a CSC marker (16)",
      "(A\u2010H) The METABRIC dataset was downloaded from cBioPortal",
      "(A\u2010H) TCGA Pan\u2010Cancer dataset was downloaded from cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:05.022212",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41179310.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.877526998519897,
      "cbioportal_papers": 0.0002791881561279297,
      "platform_mentions": 0.002337932586669922,
      "data_citations": 0.00028634071350097656,
      "num_data_pmids_checked": 3
    }
  },
  "41172875": {
    "paper_id": "41172875",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Li, Application of weighted\ngenomics and clinical profiles using the cBioPortal, Sci"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:06.711814",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41172875.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.454973936080933,
      "cbioportal_papers": 0.00020694732666015625,
      "platform_mentions": 0.002298116683959961,
      "data_citations": 7.891654968261719e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41163069": {
    "paper_id": "41163069",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioportal tool [30, 31] to download mRNA expres-\nsion (similar to [5]), from the Open Pediatric Cancer Metabolomics\n(OpenPedCan) Project v15 as follows: for non-tumor Method conducted similar to [5]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:08.978949",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41163069.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.894613027572632,
      "cbioportal_papers": 0.0003898143768310547,
      "platform_mentions": 0.00345611572265625,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41159143": {
    "paper_id": "41159143",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Weusedthehumanbreastandprostatecancerdataset(TCGA,\nTheassayswereconductedinduplicate.Lungsweredissociated Firehose Legacy) from cBioPortal [53] (www.cbioportal.org) to\ninto single-cell suspensions using a gentle MACS Dissociator performSpearmancorrelationanalysistoidentifyco-expression\n(Miltenyi Biotech)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:17.686888",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41159143.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.909283876419067,
      "cbioportal_papers": 0.00033092498779296875,
      "platform_mentions": 0.0033860206604003906,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41193657": {
    "paper_id": "41193657",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In ATAC-seq data\nPublicly available gene expression data from a matched cohort estab- peak regions with Benjamini\u2013Hochberg corrected P < 0.05 and log\n2\nlished previously59 or mCRPC was downloaded from cBioportal (20 foldchange >0.5 or <0.5 were considered statistically significant",
      "and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:25.142327",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41193657.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 48.16509389877319,
      "cbioportal_papers": 0.0005500316619873047,
      "platform_mentions": 0.005287885665893555,
      "data_citations": 0.000598907470703125,
      "num_data_pmids_checked": 3
    }
  },
  "41154638": {
    "paper_id": "41154638",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Database Analysis Website(10June2025)\nPredictionofprotein,DNAandRNA\nAlphaFold3 structureandmodelingof https://alphafold.ebi.ac.uk/\nstructuralcomplexes\nAutoDockVina1.2.0 Protein\u2013liganddocking https://vina.scripps.edu/\nCB-Dock2 Protein\u2013ligandblinddocking https://cadd.labshare.cn/cb-dock2/\ncBioPortalfor\nMulti-omicscancergenomicsdata http://cbioportal.org/\nCancerGenomics\neVITTA Transcriptomefunctionalcharacterization https://tau.cmmt.ubc.ca/eVITTA/\ng:Profiler Functionalenrichmentanalysisatgenelevel https://biit.cs.ut.ee/gprofiler/gost\nGenefunctions,cellularprocessesand\nGO http://www.geneontology.org/\nsubcellularlocalizationofproteins\nGOtermannotationand\nGOnet https://tools.dice-database.org/GOnet/\nenrichmentanalysis\niDEP2.0 RNA-seqdataanalysis https://bioinformatics.sdstate.edu/idep/\nhumanlncRNAsintegrationwith\nLncBook2.0 https://ngdc.cncb.ac.cn/lncbook/\nmulti-omicsannotations\nLncRNA-ID lncRNAidentification https://github.com/zhangy72/LncRNA-ID\nmiRNAfunctionsandinteractionnetworks\nmiRNet2.0 withgenes,diseases,compounds, https://www.mirnet.ca/\ntranscriptionfactors"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:29.404326",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41154638.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.712632894515991,
      "cbioportal_papers": 0.00032711029052734375,
      "platform_mentions": 0.0029358863830566406,
      "data_citations": 0.0001220703125,
      "num_data_pmids_checked": 1
    }
  },
  "41155675": {
    "paper_id": "41155675",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DataAvailabilityStatement: Allthegenomicandclinicopathologicaldatautilizedforthisstudy\narefreelyavailableinthecBioPortalforCancerGenomicswebsite(https://www.cbioportal.org/,\naccessedon2August2025)andtheGenomeDataCommonsrepository(https://portal.gdc.cancer"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:31.255658",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41155675.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 22.26745915412903,
      "cbioportal_papers": 0.0002162456512451172,
      "platform_mentions": 0.002077817916870117,
      "data_citations": 0.00015497207641601562,
      "num_data_pmids_checked": 2
    }
  },
  "41162745": {
    "paper_id": "41162745",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:33.083491",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41162745.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 33.40503191947937,
      "cbioportal_papers": 0.00032520294189453125,
      "platform_mentions": 0.0024650096893310547,
      "data_citations": 0.00032830238342285156,
      "num_data_pmids_checked": 3
    }
  },
  "41162355": {
    "paper_id": "41162355",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "obtained from the cBioPortal for Cancer Genomics133,134, using the Mol.Biol.24,131\u2013139(2017)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:35.156830",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41162355.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 30.09677004814148,
      "cbioportal_papers": 0.0005390644073486328,
      "platform_mentions": 0.003648042678833008,
      "data_citations": 1.1920928955078125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41152458": {
    "paper_id": "41152458",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Brose,M.S.etal.BRAFandRASMutationsinHumanLungCancer\nGenomics Portal (cBioPortal)18,19",
      "search from fourteen datasets within cBioPortal that included either 3"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:36.434107",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41152458.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.0281102657318115,
      "cbioportal_papers": 0.0001838207244873047,
      "platform_mentions": 0.0013000965118408203,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41151853": {
    "paper_id": "41151853",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Significant genes\n(adjusted p<0.05) were subjected to GO and KEGG enrichment (EnrichR), mutational profiling (cBioPortal), and\nKaplan\u2011Meier survival analysis",
      "Pathway enrichment candidate genes were examined using TCGA datasets\nanalysis identifies biological pathways (e.g., KEGG, accessed via cBioPortal (https://www.cbioportal.org/)",
      "During the priming phase, CD4+T\nmentioned cancer types, survival analysis was conducted cells provide essential help signals to CD8+ T cells through\nusing TCGA data accessed via cBioPortal",
      "While analyzing TCGA datasets\nnucleus and intracellular membrane\u2011bounded organelle through cBioPortal, mutations were identified and\nwere the enriched Gene Ontology Cellular Component mapped along with their frequencies across various\n(GO\u2011CC) terms, while MAP kinase activity and protein cancer types (35)",
      "The figure was generated using cBioPortal,\nbased on data retrieved from The Cancer Genome Atlas (TCGA) datasets",
      "The figure was generated through the cBioPortal\nbased on The Cancer Genome Atlas (TCGA) datasets",
      "Cancer Center and cBioPortal datasets",
      "Science\u2019s STKE 2005(271): tr5, and clinical profiles using the cBioPortal",
      "Front Oncol and cBioPortal data"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:42.908279",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41151853.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.649199724197388,
      "cbioportal_papers": 0.0002701282501220703,
      "platform_mentions": 0.002959728240966797,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41153357": {
    "paper_id": "41153357",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "AnalysisofFAM72BGeneticMutations\nToobtaininformationonFAM72Bgenemutationtypes,sites,frequencies,andsur-\nvivaldifferences,the\u201cCancerTypesSummary\u201d,\u201cMutations\u201d,and\u201cComparison/Survival\u201d\nmoduleswereselectedfromthecBioPortal6.3.6database(https://www.cbioportal.org/)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:44.551577",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41153357.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.406245946884155,
      "cbioportal_papers": 0.0002732276916503906,
      "platform_mentions": 0.002306699752807617,
      "data_citations": 0.0001952648162841797,
      "num_data_pmids_checked": 2
    }
  },
  "41142627": {
    "paper_id": "41142627",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "UsingthemedianCLIC6mRNAexpressionasacutoff,TCGA\nThe \u201cOncoprint\u201d module of the cBioPortal database (15) pan-cancer samples were divided into high and low expression\n(http://www.cbioportal.org/) was used to detect genetic variations groups.The\u201cDESeq2\u201dand\u201cedgeR\u201dpackageswereusedtoanalyze\nin CLIC6 in the \u201cTCGA Pan-Cancer Atlas Studies\u201d dataset",
      "The CNV pie chart derived from this database\nCLIC6 could be a molecular therapy target, this study used the showedthatmostcancersexhibitedheterozygousamplificationand\ncBioPortal database to investigate CLIC6 genetic variation across deletion, and homozygous amplification, with rare homozygous\nvarious cancer types"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:46.572450",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41142627.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.344963788986206,
      "cbioportal_papers": 0.00030112266540527344,
      "platform_mentions": 0.002850055694580078,
      "data_citations": 5.7220458984375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41126177": {
    "paper_id": "41126177",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "These insights Genetic alteration analysis\nindicated that DLX4 facilitates transcriptional responses cBioPortal (http://cbioportal.org) provides the alteration\ncontributing to the progression and adverse prognosis frequency, mutation type, CNA (copy number altera-\nof CRC by utilizing its phase-separation capabilities to tion) and mutation site information of candidate proteins\nregulate the cell cycle protein ZC3HC1",
      "The results showed that DLX4 expression utilized the cBioPortal platform based on the TCGA\nwas upregulated in CRC compared with normal tis- database to conducted comprehensive analyses of copy\nsue",
      "2 Association of DLX4 with genomic alterations in CRC (A) Somatic mutations for DLX4 in CRC by cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:31:59.704326",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41126177.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.124207258224487,
      "cbioportal_papers": 0.0003108978271484375,
      "platform_mentions": 0.0035691261291503906,
      "data_citations": 1.5735626220703125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41136536": {
    "paper_id": "41136536",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "WeuseddatacontainedatcBioportal(www.cbioportal.org)(accessedin\nOctober2023)5,13toexplorethemutationsofthePBRM1geneinpatients Co-essentialityandgeneticinteractions\nwithanytypeofcancer.Weusedacombinationof32studiesthatcontained Asacomplementarysourceofphenotypicandmolecularinformation,we\n10,967samplesfrom10,953patients(TCGAdata).Thiswebresourcealso extracted genetic interactions from public resources and published\nprovidesmutatedvariantsmappedtogenomicdomains",
      "available in the (www.cbioportal.org; https://www.cancerrxgene.org; 20"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:00.763781",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41136536.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.755905866622925,
      "cbioportal_papers": 0.00012183189392089844,
      "platform_mentions": 0.001316070556640625,
      "data_citations": 5.0067901611328125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41125665": {
    "paper_id": "41125665",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "RNA-sequencing data stored in The Cancer Genome Atlas\n(TCGA)22,23 and in the GLASS database24,25 were used, and data was downloaded from cBioPortal",
      "16); these analyses accessed the TCGA database through cBioPortal",
      "8, 10, 11\nand 13\u201315, these analyses accessed the GLASS database through cBioPortal",
      "Genetic alterations in GBM PDX tumors were data-\nmined from The Brain Tumor PDX database (Mayo Clinic) curated through cBioPortal",
      "Data gathered from GLASS\ndatabase through cBioPortal and filtered for GBM tumors (247 patients with recurrent tumor information,\nof which 89 patients also had MGMT promoter methylation status data)",
      "On examining the relationship between high EGR1 expression and survival in recurrent GBM using\ncBioPortal to access the TCGA database, the survival curve for patients with high EGR1 expression was distinct\nand non-overlapping with the survival curve for patients with low EGR1 expression; however, the difference\nwas not significant, likely due to the small number of patients (SFig",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:06.947593",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41125665.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.344643115997314,
      "cbioportal_papers": 0.0004608631134033203,
      "platform_mentions": 0.004380941390991211,
      "data_citations": 0.0007929801940917969,
      "num_data_pmids_checked": 5
    }
  },
  "41122645": {
    "paper_id": "41122645",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The\u201cOncoPrint\u201dmoduleofthecBioPortaldatabase(September Gene Ontology (GO) and Kyoto Encyclopedia of Genes and\n11,2024; https://www.cbioportal.org)wasdeployedtoanalyzethe Genomes (KEGG) were utilized to investigate the biological roles\nCORO1Ageneticalterationslevelinthe\u201cTCGAPan-CancerAtlas andpredictedpathwaysofCORO1Aanditsassociatedproteins",
      "Consequently, we deployed the prevalentacrossmostcancers.Rarehomozygousamplificationsare\ncBioPortal database to determine the profile of CORO1A genetic mainlyobservedinBRCA,DLBC,LUAD,MESO,BLCA,andUCS,\nvariationinpan-cancer.AnalysisrevealedthatCORO1Amutations whilerarehomozygousdeletionsareprimarilyfoundinLAMLand\noccurred in 168 (1.5%) of the 10,967 pan-cancer samples, TGCT (Supplementary Figure S3A)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:11.766632",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41122645.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.009898900985718,
      "cbioportal_papers": 0.0003387928009033203,
      "platform_mentions": 0.002779245376586914,
      "data_citations": 8.821487426757812e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41112295": {
    "paper_id": "41112295",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Tumor mutation burden (TMB) data from enrichmentanalysiswasconductedusingdatafromtheReactome\ncBioPortal (https://www.cbioportal.org) (56, 57) and intratumor Knowledgebase(https://reactome.org)andtheKyotoEncyclopedia\nFrontiersinImmunology 04 frontiersin.org\n\nLiuetal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:13.737452",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41112295.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.956274032592773,
      "cbioportal_papers": 0.000370025634765625,
      "platform_mentions": 0.0036988258361816406,
      "data_citations": 0.0006539821624755859,
      "num_data_pmids_checked": 5
    }
  },
  "41111090": {
    "paper_id": "41111090",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:22.001502",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41111090.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.209360122680664,
      "cbioportal_papers": 0.00032830238342285156,
      "platform_mentions": 0.0004069805145263672,
      "data_citations": 0.00011682510375976562,
      "num_data_pmids_checked": 1
    }
  },
  "41109929": {
    "paper_id": "41109929",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We confirmed a critical role for Rac1 in BRAFi resistance\nas visualized by cBioportal [10, 11], cancer genome sequencing conferredbyVav1andidentifiedcomplex,pleiotropicmechanisms\nrevealsadditionalRAC1hotspotmutationsscatteredacrossmany by which Rac1 and Rac1 GEFs can drive BRAFi resistance in\ndifferent cancer types (Supplementary Table S1)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:25.303160",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41109929.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.562732696533203,
      "cbioportal_papers": 0.00032210350036621094,
      "platform_mentions": 0.002396821975708008,
      "data_citations": 0.0001251697540283203,
      "num_data_pmids_checked": 1
    }
  },
  "41105363": {
    "paper_id": "41105363",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.9 Genomic alteration analysis\nMutation data were retrieved via cBioPortal API (v2.2.0)",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analy-\nsis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:35.481764",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41105363.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.082077741622925,
      "cbioportal_papers": 0.00024080276489257812,
      "platform_mentions": 0.0022089481353759766,
      "data_citations": 8.606910705566406e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41111983": {
    "paper_id": "41111983",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genetic Alteration Analysis heat maps and association plots, which visualize the\nWe used the cBioPortal database to analyze the genetic correlation between DAPL1 expression and other\nalteration features of DAPL1, based on the cancer significant genes in BRCA",
      "We accessed cBioPortal at top 10 positively and negatively correlated genes with\nhttps://www.cbioportal.org/ (24, 25), searched for DAPL1, using a color scale representing Z-scores",
      "We then used the \u201cSurvival\u201d tab to We also analyzed the expression correlation between\ncompare the overall survival and disease/progression- DAPL1 and the selected genes, through the cBioPortal\nfree survival analyses between all TCGA cancer case database",
      "On the cBioPortal website, we selected the\ncases with and without DAPL1 alterations, generating BRCA dataset and searched for \u201cDAPL1\u201d along with\nKaplan-Meier curves for visualization",
      "doi:10.1007/s12017-015-8342-1 using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:37.270038",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41111983.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 30.304728984832764,
      "cbioportal_papers": 0.00023889541625976562,
      "platform_mentions": 0.003099203109741211,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41109905": {
    "paper_id": "41109905",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "divergent with chemotherapy plus immunotherapy being All analyses were performed in cBioCancer Genomics\nthe first line option in cholangiocarcinomas, while anti- Portal (cBioportal, assessed from www.c biopo rtal.o rg),\nangiogenic targeting with immunotherapy or combination which is an openly available cancer genomics site that\n\nJournal of Gastrointestinal Cancer (2025) 56:207 Page 3 of 22 207\nharbors openly available genomic data across cancer sub- in one or more of the 19 receptor tyrosine kinase pathway\ntypes [13, 14]",
      "cBioportal hosts curated data that can be genes examined (KRAS, NRAS, BRAF, PIK3CA, EGFR,\neasily summarized from the platform, and groups of inter- ERBB2, ERBB3, ERBB4, FGFR1, FGFR2, FGFR3, FGFR4,\nest within individual studies can be constructed for separate NTRK1, NTRK2, NTRK3, PTEN, AKT1, AKT2, AKT3)\nanalyses",
      "To view a profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:40.305095",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41109905.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.27567410469055,
      "cbioportal_papers": 0.0003628730773925781,
      "platform_mentions": 0.003025054931640625,
      "data_citations": 0.00036406517028808594,
      "num_data_pmids_checked": 3
    }
  },
  "41100766": {
    "paper_id": "41100766",
    "cbioportal_paper_citations": [
      "[doi: 10.1158/2159-8290.CD-12-0095] [Medline:\n22588877]\n23",
      "[doi: 10.1126/scisignal.2004088] [Medline: 23550210]\n24"
    ],
    "cbioportal_platform_mentions": [
      "and wgiere\nbased on 4 comparisons, we projected each cell type into a\nbased on the findings of SPeregbiriMiskSiIi et al [1P9]g ainMd S2 Sdatasets 4D latent space using a formula measuring similarity between\n[20,21] on cBioPortal [22,23]",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the\ncBioPortal"
    ],
    "data_publication_citations": {
      "35970919": [
        "[doi: 10.1038/s41591-022-01930-z] [Medline: 35970919]\n22"
      ],
      "32730818": [
        "[doi: 10.1053/j.gastro.2020.07.041] [Medline: 32730818]\n21"
      ]
    },
    "extraction_date": "2025-12-19T18:32:47.777363",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41100766.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 2,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.257179975509644,
      "cbioportal_papers": 0.002362966537475586,
      "platform_mentions": 0.0019631385803222656,
      "data_citations": 0.02073192596435547,
      "num_data_pmids_checked": 2
    }
  },
  "41089673": {
    "paper_id": "41089673",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "False discovery rate (FDR) correction\nmultiple bulk RNA-seq datasets, including The Cancer Genome was automatically applied within the FindAllMarkers function\nAtlas (TCGA) COAD and READ project (TCGA cohort) using the Benjamini\u2013Hochberg (BH) method, and adjusted p-\nfrom cBioPortal, the Siluo et al. cohort (silu_2022 cohort) values (p_val_adj) were used to determine statistical significance",
      "PNI annotations were extracted from\nbased on deconvolution for bulk RNA\npostoperative pathological reports provided by TCGA, which\ndatasets\nwere accessed via the cBioPortal platform (Gao et al., 2013)",
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:32:57.762879",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41089673.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.97588300704956,
      "cbioportal_papers": 0.00027179718017578125,
      "platform_mentions": 0.0023889541625976562,
      "data_citations": 9.894371032714844e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41083700": {
    "paper_id": "41083700",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We studied the pan-cancer role of KRT6A with the help of a variety of external public databases (mainly\nincluding TCGA, GTEx, HPA, TIMER2.0, UALCAN, TISIDB, GEPIA2, Kaplan-Meier Plotter, cBioPortal\nand TISCH2, etc.)",
      "In this study, we performed a comprehensive analysis of KRT6A in human pan-cancer using public\ndatabases such as TCGA, GTEx, HPA, TIMER2.0, UALCAN, TISIDB, GEPIA2, and cBioPortal, and explored\nthe differential expression of KRT6A in different tumors and its correlation with patient survival prognosis,\nclinical subtypes, DNA methylation, RNA methylation, protein phosphorylation, single-cell distribution,\nTMB, MSI, TSC, immune checkpoints, immune regulatory genes, immune infiltration, immunotherapy, and\ndrug sensitivity",
      "Genetic variation analysis of KRT6A\nThe cBio Cancer Genomics Portal (cBioPortal) (https://www.cbioportal.org)35\u201337 is a multidimensional cancer\ngenomics dataset that provides interactive retrieval, visualization, and analysis of multivariate genetic variation",
      "We used the \u201cTCGA PanCancer Atlas Studies\u201d in cBioPortal to obtain the genetic variations of KRT6A in\ndifferent tumors, and used the \u201cCancer Types Summary\u201d, \u201cMutations\u201d, \u201cPlots\u201d and \u201cComparison/Survival\u201d\nmodules to explore the genetic changes and mutation site information",
      "KRT6A gene alterations in pan-cancer\nIn order to study the mutation of KRT6A gene in pan-cancer, we used cBioPortal online platform to conduct\ncorrelation research based on TCGA database",
      "(A) Summary of genetic alterations of KRT6A in the TCGA pan-cancer dataset\nbased on cBioPortal database analysis"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:13.018893",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41083700.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.25219202041626,
      "cbioportal_papers": 0.0002999305725097656,
      "platform_mentions": 0.0033180713653564453,
      "data_citations": 1.5020370483398438e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41096603": {
    "paper_id": "41096603",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:17.621416",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41096603.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 37.27205419540405,
      "cbioportal_papers": 0.0002779960632324219,
      "platform_mentions": 0.0022771358489990234,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41082058": {
    "paper_id": "41082058",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods We conducted a comprehensive pan-cancer analysis integrating multi-\nomics data from public databases, including TIMER2.0, GEPIA2, TISIDB, and cBioPortal,\nto evaluate EME1 expression, genetic alterations, and their association with clinical\noutcomes, immune infiltration, and molecular pathways",
      "In this investiga-\ntion, we analyzed the genetic changes in the EME1 gene in tumor specimens by using\nthe cBioPortal database to ascertain the landscape of these modifications ( h t t p s : / / w w w",
      "A Bar Chart: EME1 expression level\nrelationship with tumor grade; B Box Plot: Positive connection between EME1 expression level and tumor grade; C\nBar Chart: EME1 expression level link with tumor stage; D Violin Plot: Positive connection between EME1 expression\nlevel and tumor stage\n3.4 EME1 Genetic alterations: implications for patient outcome across common human\ncancers\nAnalysis of the cBioPortal database revealed genetic abnormalities in the EME1 gene\nacross various cancer types, including BRCA, pleural mesothelioma (MESO), and endo-\nmetrial cancer, among others",
      "5 Mutation Analysis of EME1 with cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:25.842874",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41082058.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.809958934783936,
      "cbioportal_papers": 0.00021123886108398438,
      "platform_mentions": 0.0020008087158203125,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41080584": {
    "paper_id": "41080584",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "This discovery spurred were obtained from the cBioPortal database (19) for subsequent\nfurther investigations into the mechanisms underlying UVR- analysis.Relevantclinicaland pathological informationforthe30\ninduced immunosuppression"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:32.548073",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41080584.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.923480749130249,
      "cbioportal_papers": 0.0002970695495605469,
      "platform_mentions": 0.0021140575408935547,
      "data_citations": 0.0006258487701416016,
      "num_data_pmids_checked": 6
    }
  },
  "41098933": {
    "paper_id": "41098933",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The raw data of RNA\nsequence data (counts) were extracted, and a data table was created using R (version 4.2.3) [10], and clinical\ndata corresponding to the TCGA-HNSC cohort were downloaded from cBioportal\n(https://www.cbioportal.org/) [11,12]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:33.583262",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41098933.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 56.23905873298645,
      "cbioportal_papers": 0.00032782554626464844,
      "platform_mentions": 0.003112316131591797,
      "data_citations": 0.00011801719665527344,
      "num_data_pmids_checked": 1
    }
  },
  "41137179": {
    "paper_id": "41137179",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal database and Lei-\nand the data were preprocessed following Genome Anal- den Open Variation Database were used to identify addi-\nysis Toolkit (GATK) 4 best practices [24, 25]",
      "To explore ple and complex chromosomal rearrangements involv-\nwhether similar mutations occur in other tumor types, ing 6p21.31 (HMGA1) and/or 12q14.3 (HMGA2) in\nwe searched the cBioPortal database and identified 17 of 23 (74%) polyps (Fig",
      "Mehine M, Kaasinen E, M\u00e4kinen N, Katainen R, K\u00e4mpj\u00e4rvi K, Pitk\u00e4nen\ngrative analysis of complex cancer genomics and clinical profiles using E, et al. Characterization of uterine leiomyomas by whole-genome\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:34.340815",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41137179.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 117.87218594551086,
      "cbioportal_papers": 0.00036215782165527344,
      "platform_mentions": 0.003303050994873047,
      "data_citations": 0.018676042556762695,
      "num_data_pmids_checked": 5
    }
  },
  "41079989": {
    "paper_id": "41079989",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Driver mutations were defined according\nand previous studies to provide a broader perspective of its early to well-known hotspot mutations in COSMIC [18] and cBioportal\nmolecular driving events",
      "Biomed\nplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:37.639443",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41079989.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.793711185455322,
      "cbioportal_papers": 0.000270843505859375,
      "platform_mentions": 0.0023310184478759766,
      "data_citations": 0.00010085105895996094,
      "num_data_pmids_checked": 1
    }
  },
  "41066315": {
    "paper_id": "41066315",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1158/2159-8290.CD-12-0095 PMID: 22588877\n37",
      "https://doi.org/10.1126/scisignal.2004088 PMID: 23550210\n38"
    ],
    "cbioportal_platform_mentions": [
      "For example, for adrenal\ngland, 28% of samples show ATM mutations, 0% ATR, 16% BRCA1, etc. cBioPortal exclusivity analysis\nCo-occurrence or exclusivity between PRMT5 and DSB repair genes was calculated using the cBioPortal calculator\n(https://www.cbioportal.org) [36,37]",
      "To investigate this, we used the cBioPortal mutual exclusivity calculator which generates statistical signif-\nicance of co-occurrence (probability value)",
      "Probability of mutation co-occurrence using the cBioPortal exclusivity calculator",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using\nthe cBioPortal"
    ],
    "data_publication_citations": {
      "22722201": [
        "https://doi.org/10.1038/nature11017 PMID: 22722201\n45"
      ]
    },
    "extraction_date": "2025-12-19T18:33:48.222995",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41066315.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.853984117507935,
      "cbioportal_papers": 0.00308990478515625,
      "platform_mentions": 0.022569894790649414,
      "data_citations": 0.002393007278442383,
      "num_data_pmids_checked": 1
    }
  },
  "41071836": {
    "paper_id": "41071836",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1126/scisignal.2004088 PMID: 23550210\n40"
    ],
    "cbioportal_platform_mentions": [
      "Fig 3 summarizes the genomic alter-\nations analysis of DPP4 in Cancer using the TCGA [35,36] database and cBioportal [36]",
      "All patient data were sourced from TCGA PanCancer Atlas Studies [38] and ana-\nlyzed using cBioPortal [39]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:48.460021",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41071836.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.743788957595825,
      "cbioportal_papers": 0.0026869773864746094,
      "platform_mentions": 0.04996991157531738,
      "data_citations": 1.1920928955078125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41071812": {
    "paper_id": "41071812",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:52.181697",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41071812.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.576135873794556,
      "cbioportal_papers": 0.0003352165222167969,
      "platform_mentions": 0.002604961395263672,
      "data_citations": 8.344650268554688e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41058670": {
    "paper_id": "41058670",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "For GEPIA2-based expression analysis, the parameters\nwere set as follows: Log2FC cutoff = 1, p-value cutoff = 0.01, For Cancer Genomics, cBioPortal (https://cbioportal.org) is an\njitter size = 0.4",
      "Gene expression values were log-transformed interactive web platform designed for the exploration,\n36940 | RSCAdv.,2025,15,36938\u201336968 \u00a92025TheAuthor(s).PublishedbytheRoyalSocietyofChemistry\n.MA\n40:31:8\n5202/91/21\nno\ndedaolnwoD\n.5202\nrebotcO\n60\nno\ndehsilbuP\n.elcitrA\nsseccA\nnepO\n.ecneciL\ndetropnU\n0.3\nlaicremmoCnoN-noitubirttA\nsnommoC\nevitaerC\na\nrednu\ndesnecil\nsi\nelcitra\nsihT\nView Article Online\n\nPaper RSCAdvances\nvisualization, and analysis of multidimensional cancer 2.7 Machinelearning(ML)applicationtopredictbioactivity\ngenomics data.42 In this study, the genetic alteration pro\ue103les (pIC )\n50\nofCDK2wereexaminedusingthepublicdatabase,cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:56.334965",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41058670.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.670660734176636,
      "cbioportal_papers": 0.00031685829162597656,
      "platform_mentions": 0.01891803741455078,
      "data_citations": 0.0001239776611328125,
      "num_data_pmids_checked": 1
    }
  },
  "41056281": {
    "paper_id": "41056281",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1158/2159-8290.CD-12-0095 PMID: 22588877\n33",
      "https://doi.org/10.1126/scisignal.2004088 PMID: 23550210\n34"
    ],
    "cbioportal_platform_mentions": [
      "Clinical data were retrieved from the\ncBioPortal database [32,33]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:33:57.524123",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41056281.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.012109994888306,
      "cbioportal_papers": 0.002994060516357422,
      "platform_mentions": 0.002424955368041992,
      "data_citations": 8.821487426757812e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41057692": {
    "paper_id": "41057692",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:02.569109",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41057692.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.291479110717773,
      "cbioportal_papers": 0.0003581047058105469,
      "platform_mentions": 0.0004868507385253906,
      "data_citations": 0.0002510547637939453,
      "num_data_pmids_checked": 2
    }
  },
  "41142634": {
    "paper_id": "41142634",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Multiplex im-\nGenetic alteration analysis munofluorescent staining was performed utilizing the PANO 7-\ncBioPortal ( https://www.cbioportal.org/) is a website that can an- plex IHC kit (cat 0 004 100 100; Panovue, Beijing, China)",
      "( A ) Gene variation frequency of SKP2 in pan-cancer was analyzed\nusing the cBioPortal database",
      "CA Can- cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:04.531769",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41142634.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 151.4378581047058,
      "cbioportal_papers": 0.0003161430358886719,
      "platform_mentions": 0.00363922119140625,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41053414": {
    "paper_id": "41053414",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:04.839218",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41053414.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.263896942138672,
      "cbioportal_papers": 0.00021195411682128906,
      "platform_mentions": 0.0015711784362792969,
      "data_citations": 0.00015497207641601562,
      "num_data_pmids_checked": 2
    }
  },
  "41053077": {
    "paper_id": "41053077",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:15.954764",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41053077.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.281739950180054,
      "cbioportal_papers": 0.00023102760314941406,
      "platform_mentions": 0.08534693717956543,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41053870": {
    "paper_id": "41053870",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Integrative analysis of\nPrewett S, Wong HH, McDonald S, Tarpey P, et al. Introduction and impact complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:16.868467",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41053870.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.529190063476562,
      "cbioportal_papers": 0.0003757476806640625,
      "platform_mentions": 0.0035071372985839844,
      "data_citations": 0.0002503395080566406,
      "num_data_pmids_checked": 2
    }
  },
  "41048937": {
    "paper_id": "41048937",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Additionally, the economic burden imposed by cancer on 2.3 Genetic alteration test\nsocietyissubstantialandcannotbeoverlooked(4).Consequently,\nthe identification of effective cancer biomarkers holds critical The cBioPortal platform (https://www.cbioportal.org), as\nsignificance in improving prognostic outcomes for individuals described in detail elsewhere (12), was utilized to collect data\ndiagnosedwithcancerandalleviatingthesocietalburden",
      "2.8 Functional enrichment analysis\n3.2 Mutations in CGB5 across different\nThe present study utilized the Metascape database (http:// tumor types\nmetascape.org/gp/index.html#/main/step1) to perform functional\nenrichmentanalysisontheselectedoverlappinggenes(18),which To investigate the mutation status of the CGB5 gene across\nincluded Kyoto Encyclopedia of Genes and Genomes (KEGG) various malignancies, its mutation profile was analyzed using\npathways,GeneOntology(GO)terminologyandtissueenrichment the cBioPortal platform and TCGA data"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:18.392848",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41048937.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.827270030975342,
      "cbioportal_papers": 0.0002448558807373047,
      "platform_mentions": 0.002578258514404297,
      "data_citations": 9.584426879882812e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41044136": {
    "paper_id": "41044136",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We used databases such as cBioPortal, NCBI/\nClinvar, and the Catalogue of Somatic Mutations in Cancer (COSMIC) to identify relevant genomic coordinates",
      "et al. Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:19.199962",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41044136.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.31363296508789,
      "cbioportal_papers": 0.00020384788513183594,
      "platform_mentions": 0.0017840862274169922,
      "data_citations": 0.0003561973571777344,
      "num_data_pmids_checked": 5
    }
  },
  "41030644": {
    "paper_id": "41030644",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The datasets analyzed in the current study were downloaded\nThese data have selection bias and are not necessarily reflec- from cBioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:23.195390",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41030644.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.3106770515441895,
      "cbioportal_papers": 0.0002472400665283203,
      "platform_mentions": 0.0022988319396972656,
      "data_citations": 0.00025010108947753906,
      "num_data_pmids_checked": 3
    }
  },
  "41055979": {
    "paper_id": "41055979",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Further cohort details, includ- secondarily validate this relationship, contingency analyses were per-\ning demographic and clinical characteristics are reported in formed between SF3B1 and TP53 in cBioPortal in ER+ breast cancer,\nSI Appendix, Tables S3\u2013S6",
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:27.602432",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41055979.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 35.416744232177734,
      "cbioportal_papers": 0.0003478527069091797,
      "platform_mentions": 0.003256082534790039,
      "data_citations": 0.00024199485778808594,
      "num_data_pmids_checked": 2
    }
  },
  "41030312": {
    "paper_id": "41030312",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Wefurther integrateddata\nfrom multiple bioinformatics platforms, including TIMER2, UALCAN, GEPIA2, cBioPortal, R, GSCA, and\nLinkedOmics",
      "alterations (CNAs)\u2014were analyzed in the TCGA Pan-Cancer The cells were then transfected with either 10 nM of non-\nAtlas via cBioPortal (https://www.cbioportal.org/).13 HMOX1 targeting siRNA (siRNA-NC) or 10 nM of HMOX1-targeting\npromoter methylation patterns across tumor and matched siRNA (siRNA-HMOX1)",
      "Similarly, robust associations were\ncancer observed with C\u2013C Motif Chemokine Receptor 1 (CCR1) (r =\n0.392 and p = 2.2 \u00d7 10 \u221216), CXC chemokine receptor 3\ncBioPortal analysis revealed genomic alterations of HMOX1 (CXCR3)(r=0.361andp=1.93\u00d710 \u221218),andCXCR6(r=0.31\nacross multiple malignancies, with mutations representing and p = 3.02 \u00d7 10 \u221213) (Fig"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:28.077963",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41030312.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.682589054107666,
      "cbioportal_papers": 0.000186920166015625,
      "platform_mentions": 0.002178192138671875,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41030978": {
    "paper_id": "41030978",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao, J., et al., Integrative analysis of complex cancer genomics and clinical profiles using\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:29.011695",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41030978.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.04184079170227,
      "cbioportal_papers": 0.0002949237823486328,
      "platform_mentions": 0.0028252601623535156,
      "data_citations": 0.00020241737365722656,
      "num_data_pmids_checked": 2
    }
  },
  "41023871": {
    "paper_id": "41023871",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Preclinical and clinical studies have To investigate genetic alterations of ZNF703 in vari-\ndemonstrated that antibody-mediated CTLA-4 blockade ous cancers, we employed the cBioPortal database [23]",
      "The\nidentified three ICP genes (PD-L1, ICAM1, and CX3CL1) correlation between ZNF703 promoter methylation lev-\nwhose expression is directly regulated by ZNF703.Fur- els, including specific DNA methylation sites, and mRNA\nthermore, by analyzing protein-protein interaction net- expression was determined through the cBioPortal data-\nworks from the STRING database and cross-referencing base",
      "1A, ZNF703 expression was significantly elevated in\n\nShi et al. BMC Cancer (2025) 25:1437 Page 5 of 17\neight tumor types compared to their corresponding nor- Genetic alteration analysis of ZNF703\nmal tissues, including BRCA (breast invasive carcinoma), The mutation frequency of ZNF703 was analyzed using\nCHOL (cholangiocarcinoma), COAD (colon adenocar- the cBioPortal platform",
      "To systematically assess the prognostic significance of Through the cBioportal platform, we identified a sig-\nZNF703 across TCGA malignancies, we stratified tumor nificant negative correlation between ZNF703 mRNA\ncases into high- and low-expression cohorts based on levels and the methylation status of cg04553559 and\nZNF703 expression levels, subsequently investigating its cg18379495, located within the TSS1500 and 1stExon\ncorrelation with patient outcomes",
      "Ai L, et al. Research status and outlook of PD-1/PD-L1 inhibitors for Cancer\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:32.723776",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41023871.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.500767946243286,
      "cbioportal_papers": 0.0002930164337158203,
      "platform_mentions": 0.002599000930786133,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41021104": {
    "paper_id": "41021104",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.3 Genomic alteration analysis\nPan-cancer analyses of ILF2 genomic alterations, including mutation frequency, ampli-\nfication, and deep deletion across various cancer types, were conducted using the Sum-\nmary module in the cBioPortal database [21]",
      "2.4 Molecular alteration and splicing analysis\nGenomic data related to ILF2, including somatic mutations and DNA methylation, were\nretrieved, analyzed, and visualized using the cBioPortal platform ( h t t p : / / w w w",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and\nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:34.597238",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41021104.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.326954126358032,
      "cbioportal_papers": 0.00021195411682128906,
      "platform_mentions": 0.0017809867858886719,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41014556": {
    "paper_id": "41014556",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:35.265285",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41014556.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.652284860610962,
      "cbioportal_papers": 0.0003552436828613281,
      "platform_mentions": 0.0007758140563964844,
      "data_citations": 1.4066696166992188e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41011272": {
    "paper_id": "41011272",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:36.582495",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41011272.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.37903118133545,
      "cbioportal_papers": 0.00029587745666503906,
      "platform_mentions": 0.0021741390228271484,
      "data_citations": 0.00020599365234375,
      "num_data_pmids_checked": 2
    }
  },
  "41004667": {
    "paper_id": "41004667",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Additionally, 499 scanned slides from the PTC cohort in The Cancer Genome Atlas - Thyroid\nCarcinoma (TCGA-THCA) dataset were accessed via cBioPortal to assess the presence of TLSs and compare the clinical and\nmolecular characteristics of PTC cases with and without TLSs",
      "Analysis of PTC scanned images from cBioPortal revealed TLSs in 8.4% of cases, of which 62% harbored the BRAFV600E\nmutation, along with upregulation of immune cell markers and SLC5A5 (NIS) expression",
      "Mature TLSs (m-TLSs) are characterized \u2013 Thyroid Carcinoma (TCGA-THCA) dataset, accessed\nby organized structures with germinal centers from cBioPortal (https://www.cBioPortal.org), were\n(GCs), which are oval, clear areas enriched with B analyzed to study TLS morphology (13,14)",
      "the cBioPortal platform, possibly not representing\nThe morphological characteristics of TLSs observed in the entire tumor",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. easily accessible and cost-effective approach that Integrative analysis of complex cancer genomics and clinical profiles\nusing the cBioPortal",
      "doi: 10.1038/s43018-021-00232-6\nSUPPLEMENTARY MATERIAL\nPatients with PTC diagnosis\nPTC tissue TCGA-THCA\nsamples (cBioPortal)\n(archives) Digital Images\nPTC (TLS+) PTC (TLS+)\nTLS Maturation\nLocation in state of TLS\nPTC in PTC\nBRAFV600E_TLS+\nPeritumoral Intratumoral\n(invasive (tumor Mature TLS Immature TLS\nmargin) parenchyma) (with GC) (without GC) Molecular markers\nB and T cells;\nSLC5A5 (NIS)\nB cell identification\n(immunofluorescence)\nSupplementary Figure 1",
      "TCGA Thyroid Carcinoma (THCA) digital histological samples obtained from cBioPortal and clinical prognosis",
      "BRAF_TLS- (n=210) vs BRAFV600E_TLS+ (n=26) in TCGA Thyroid Cancer (THCA) - cBioPortal",
      "Data were obtained from the PTC cohort of The Cancer Genome Atlas \u2013 Thyroid Carcinoma (TCGA-\nTHCA), and the graphic was generated using the public dataset available at cBioPortal (www.cbioportal.org, accessed September 2024)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:45.443276",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41004667.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.176005840301514,
      "cbioportal_papers": 0.00010991096496582031,
      "platform_mentions": 0.0016829967498779297,
      "data_citations": 4.220008850097656e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41010015": {
    "paper_id": "41010015",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "AnalysisofGeneticModifications\nInthisstudy,\u201cTCGApan-cancermappingstudy\u201dwaschosenfromthe\u201cQuickSe-\nlection\u201d option on the cBioPortal website (https://www.cbioportal.org/, accessed on\n19May2025)[16], After that, enter JCHAIN into the \u201cQuery\u201d module to obtain the mu-\ntationlandscape,mutationtype,andprognosisforJCHAIN.Followingthat,theSparkle\ndatabasewasusedtocalculatethecorrelationoftheJCHAINexpressionwithscoressuch\nasaneuploidyandhomologousrecombinationdefects,andthefmsbpackagegenerated\naspiderwebgraphtoillustratethepan-cancercorrelationcoefficients[17]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:45.942179",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41010015.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.91024160385132,
      "cbioportal_papers": 0.00018024444580078125,
      "platform_mentions": 0.001711130142211914,
      "data_citations": 6.985664367675781e-05,
      "num_data_pmids_checked": 1
    }
  },
  "41007824": {
    "paper_id": "41007824",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data Availability Statement: The original data presented in the study are openly available in\nCBioPortal(https://www.cbioportal.org,accessedon23April2025)andtheGEOdatabase(https:\n//www.ncbi.nlm.nih.gov/geo/,accessedon17April2025)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:46.737778",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41007824.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.131431102752686,
      "cbioportal_papers": 0.0003037452697753906,
      "platform_mentions": 0.002997159957885742,
      "data_citations": 0.0001049041748046875,
      "num_data_pmids_checked": 1
    }
  },
  "41008787": {
    "paper_id": "41008787",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DataAvailabilityStatement:TheTCGAdatasetusedinthisstudyispubliclyavailablethroughthe\nmetaGXbreastRpackage[31](https://bioconductor.org/packages/release/data/experiment/html/\nMetaGxBreast.html,accessedon1January2022)andcBioPorta[15,16](https://www.cbioportal.org/\nstudy/summary?id=brca_tcga_pan_can_atlas_2018,accessedon17April2024).Otherpan-cancer\nandbreastcancerdatasetsarepubliclyavailablethroughthecBioPortal.Onrequest,theanalyzed\ndatageneratedduringthisstudycanbeprovidedbythecorrespondingauthors",
      "cBioPortalforCancerGenomics.Availableonline:https://www.cbioportal.org/study/summary?id=ilc_msk_2023(accessedon\n5September2025)",
      "Availableonline: https://www.cbioportal.org/study/summary?id=brca_mbcproject_2022\n(accessedon5September2025)",
      "cBioPortalforCancerGenomics.Availableonline:https://www.cbioportal.org/study/summary?id=breast_msk_2025(accessed\non5September2025)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:49.648180",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41008787.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.91417908668518,
      "cbioportal_papers": 0.0002589225769042969,
      "platform_mentions": 0.002634286880493164,
      "data_citations": 0.0009691715240478516,
      "num_data_pmids_checked": 11
    }
  },
  "41001838": {
    "paper_id": "41001838",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A pan- cancer analysis of TRNT1 was conducted using various online bioin-\nformatics tools, including GEPIA2, cBioPortal, TIMER2, Metascape, and UALCAN, combined with experimental validation",
      "Abbreviations: BC, breast cancer; BLCA, bladder urothelial carcinoma; cBioPortal, cancer genomics portal; CHOL, cholangiocarcinoma; COAD, colon\nadenocarcinoma; CPTAC, clinical proteomic tumour analysis consortium; ESCA, oesophageal carcinoma; ESCC, oesophageal squamous cell carcinoma; GEPIA2,\ngene expression profiling interactive analysis (version 2); GO, gene ontology; HNSC, head and neck squamous cell carcinoma; HPA, human protein atlas; IHC,\nimmunohistochemical; KEGG, Kyoto encyclopedia of genes and genomes; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal\npapillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; OC, ovarian cancer; OS, overall survival; PAAD, pancreatic\nadenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; RCC, renal cell carcinoma; READ, rectum adenocarcinoma;\nSARC, sarcoma; STAD, stomach adenocarcinoma; STRING, search tool for the retrieval of interacting genes/proteins; TCGA, the Cancer Genome Atlas; THCA,\nthyroid carcinoma; TIME, tumour immune microenvironment; TIMER2.0, tumour immune estimation resource (version 2.0); TISIDB, tumour immune single- cell\nexpression database; TLS, tertiary lymphoid structures; TMAs, tissue microarrays; UALCAN, University of Alabama at Birmingham Cancer Data Analysis Portal;\nUCEC, uterine corpus endometrial carcinoma",
      "A comparison of gene expression profiles\nbetween African American and Caucasian American colorec- We accessed the cBioPortal website (https:// www",
      "Using the cBioPortal database, we investigated the muta-\nlowed by the retina and bone marrow",
      "Dogrusoz, et al., \u201cIntegrative Analysis of\nauthors and contributors of the HPA, TIMER, UALCAN, cBioPortal, Complex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d\nTISIDB, and Kaplan\u2013Meier Plotter websites for providing valuable re- Science Signaling 6 (2013): pl1"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:53.555907",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41001838.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.5688111782073975,
      "cbioportal_papers": 0.0002727508544921875,
      "platform_mentions": 0.0025398731231689453,
      "data_citations": 1.3828277587890625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "41002590": {
    "paper_id": "41002590",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TCGADataProcessing\nForcomparativeanalysisbetweenthestudycohortandpubliclyavailabletranscriptomic\ndata,mRNAexpressionprofilesandclinicaldatawereobtainedfromTheCancerGenomeAtlas\n(TCGA)throughcBioPortalforCancerGenomics(https://www.cbioportal.org/)[12,13].The\ndatasetincludedprogression-freeandoverallsurvivalinformationfor109laryngealcancer\nsamples"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:34:54.246877",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41002590.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.769664764404297,
      "cbioportal_papers": 0.0002181529998779297,
      "platform_mentions": 0.002125978469848633,
      "data_citations": 5.0067901611328125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40998459": {
    "paper_id": "40998459",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data from cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:05.223850",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40998459.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.55075192451477,
      "cbioportal_papers": 0.0004527568817138672,
      "platform_mentions": 0.004704952239990234,
      "data_citations": 1.1920928955078125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40997327": {
    "paper_id": "40997327",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:05.861758",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40997327.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.286279201507568,
      "cbioportal_papers": 0.0003509521484375,
      "platform_mentions": 0.00040793418884277344,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40996701": {
    "paper_id": "40996701",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Drug development Systems biology Clinical research\nCategory Feature Genomics (gnomAD) (DrugBank) (reactome) (cBioPortal)\nData structure and Multi-omics data Variant-focused with Chemical-biological Pathway-focused with Multi-omics with\nstorage limited transcriptomic integration limited multi-omics clinical data\ndata\nUnstructured data Limited text mining Chemical literature Protocol Clinical notes\ndocumentation processing\nTemporal data support Static datasets Limited reaction Dynamic pathway Longitudinal patient\nkinetics simulation data\nQuery and Real-time filtering Population-scale Limited to subsets of Pathway-limited scope Sample-limited cohort\nvisualization of > 106 records variant filtering compound database selection\nInteractive Limited to genomic Drug-target-pathway Within pathway Genotype-phenotype\ncross-domain queries context connections boundaries correlations\n3D/spatial data Limited protein Molecular structure Network topology Limited anatomical\nvisualization structure viewers context\nAnalytics and Interactive statistical Population frequency Structure-activity Enrichment analysis Survival and\ninteractivity analysis tools analysis correlation analysis\nHypothesis testing Limited to constraint Virtual screening Pathway perturbation Biomarker association\nframework metrics testing\nMachine learning Variant pathogenicity Chemical similarity Limited predictive Outcome prediction\nintegration models\nCollaborative features Multi-user Single-user model Single-user model Single-user model Limited sharing\nsimultaneous capabilities\ninteraction\nVersion control of Download-only Limited project saving Export options Study groups\nanalyses\nUser annotation None Limited annotations None Basic study\nframeworks descriptions\nTechnical architecture API extensibility Comprehensive REST Basic REST endpoints Limited API access Comprehensive\nAPI programmatic access\nComputational Cloud-based Limited analytical Server-based Hybrid architecture\nscalability distributed computing capacity processing\nFAIR data principles Partial implementation Partial implementation Partial implementation Partial implementation\nimplementation\nThe table summarizes implemented features and highlights missing capabilities across representative platforms in genomics, drug development, systems\nbiology, and clinical research, in relation to the proposed interactive model",
      "https://doi.org/10.1038/s41587-019\nplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:08.088427",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40996701.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.809355974197388,
      "cbioportal_papers": 0.0002868175506591797,
      "platform_mentions": 0.0025060176849365234,
      "data_citations": 4.76837158203125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40989165": {
    "paper_id": "40989165",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "the COADREAD dataset was acquired from cBioPortal P-values were corrected using the Benjamini\u2013Hochberg\n(https://www.cbioportal.org/)[44]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:14.130776",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40989165.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.898313999176025,
      "cbioportal_papers": 0.00021505355834960938,
      "platform_mentions": 0.0021638870239257812,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40983794": {
    "paper_id": "40983794",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal website (https://www.cbioportal.org/) provided the M E T A B\nR I C [11] dataset (n = 1980 samples) for the corresponding patients ' survival and gene\nexpression profiles in external validation",
      "The cbioportal [20] provided the hypoxia scores",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analy-\nsis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:15.309708",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40983794.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.444908142089844,
      "cbioportal_papers": 0.00022602081298828125,
      "platform_mentions": 0.0026428699493408203,
      "data_citations": 5.7220458984375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40978058": {
    "paper_id": "40978058",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Subsequently, the ESTIMATE score, the\n2.2.2.1SLC7A11mutationsignaturebasedonthe immunescore,thestromalscore,andthetumorpurityoftheHCC\ncBioPortaldatabase tumorsamplesinTCGAwerecalculatedusingtheestimatepackage\nInformation on SLC7A11 was screened from cBioPortal (https://bioconductor.org/packages/release/bioc/html/\n(https://www.cbioportal.org/) (16), and the mutation information estimate.html) (22) in R4.1.2",
      "High 27.66\n3.2.2 SLC7A11 mutation in pan-cancer based on\nAFP(ng/ml)\nthe cBioPortal and GDC databases\n\u2265400 31.48 0.010 0.140 1.702 0.840\u20133.450 SLC7A11mutationsinmultipletypesofcancerswerescreenedin\n<400 50.48 the cBioPortal database"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:20.200370",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40978058.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.043982744216919,
      "cbioportal_papers": 0.00025916099548339844,
      "platform_mentions": 0.002621889114379883,
      "data_citations": 8.821487426757812e-06,
      "num_data_pmids_checked": 0
    }
  },
  "41004572": {
    "paper_id": "41004572",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Schultz, integrative analysis of complex GeO: GSe228251\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:21.991789",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/41004572.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 45.37712097167969,
      "cbioportal_papers": 0.0004360675811767578,
      "platform_mentions": 0.030679941177368164,
      "data_citations": 0.0004961490631103516,
      "num_data_pmids_checked": 3
    }
  },
  "40977743": {
    "paper_id": "40977743",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genomic\nthetermsoftheCreativeCommonsAttribution alterations were identified via the cBioPortal database",
      "Weanalyzedthegeneticalterationlandscape,frequencies,andsites\nof PIEZO1 in pan-cancer by using the cBioPortal database (https://\nThe diagnostic and survival analysis www.cbioportal.org)(19).WeprocessedandanalyzedtheMAFfile\nusing the R package maftools (20)",
      "To\naccountforthisconfoundingfactor,weadjustedfortheESTIMATE The cBioportal database indicated that PIEZO1 alterations\nScoreinmultivariateCoxproportionalhazardsregressionmodels"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:22.561589",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40977743.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.231936931610107,
      "cbioportal_papers": 0.00029206275939941406,
      "platform_mentions": 0.0029048919677734375,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40970322": {
    "paper_id": "40970322",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal (www",
      "cells were lysed and debris removed to obtain single\u2011cell cbioportal.org) (20,21) was used to analyze TCGA\u2011generated\nsuspensions",
      "Spearman's correlation coefficient (\u03c1) and the P\u2011value\nBiosciences), anti\u2011CD4 (BV 510; BioLegend), or anti\u2011CD8 were calculated using the cBioPortal webpage",
      "The cells were then fixed and curve analysis was performed using the cBioPortal webpage\npermeabilized using a Cytofix/Cytoperm Kit (BD Biosciences) tools",
      "Spearman's correlation\ncoefficients and equations were automatically generated using the cBioPortal webpage tool"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:35.359461",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40970322.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.103395700454712,
      "cbioportal_papers": 0.0004000663757324219,
      "platform_mentions": 0.005074977874755859,
      "data_citations": 0.02474498748779297,
      "num_data_pmids_checked": 3
    }
  },
  "40969301": {
    "paper_id": "40969301",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:36.594793",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40969301.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.594856023788452,
      "cbioportal_papers": 0.0004992485046386719,
      "platform_mentions": 0.0005948543548583984,
      "data_citations": 0.0003571510314941406,
      "num_data_pmids_checked": 2
    }
  },
  "40952541": {
    "paper_id": "40952541",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "According to data\nfrom cBioPortal, ZIC genes harbor copy number alterations in multiple cancer types,\nespecially homozygous deletions in pediatric leukemias and Wilms' tumor [8]",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:44.921299",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40952541.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.323531150817871,
      "cbioportal_papers": 0.0002071857452392578,
      "platform_mentions": 0.0019979476928710938,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40959096": {
    "paper_id": "40959096",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To genomic landscape of MCM4, including mutations\nmaintain genome replication and stability, tumor cells and copy number variations, was explored through\nrely on a large number of chromosomal the cBioPortal [16], where the relationship between\nstability-related proteins [6]",
      "Moreover, KM analysis indicated\nMCM4 in the cBioPortal database, including\nthat elevated SRF expression was associated with\nmutations, structural variations, amplifications, deep\nworse outcomes in SKCM patients (Figure 3D)",
      "Cancer\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:44.967137",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40959096.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.581893682479858,
      "cbioportal_papers": 0.00023603439331054688,
      "platform_mentions": 0.0020148754119873047,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40983636": {
    "paper_id": "40983636",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A final IHC staining index (SI) score for each\nspecimenwasdeterminedaspreviouslydescribed[11].Stainingintensity\nGenerationofgraphs andstatistical analysis\nandpercentageforKBTBD11,PTENandphospho-AKT(Ser473)stainingin\nAlltheTCGAPRADdatawasdownloadedincancerXenabrowser(https://\nhuman PCa tissues were graded 0 to 3 as follows: 0 no staining, 1 low\nxenabrowser.net/) and cBioPortal (https://www.cbioportal.org/) [13, 14]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:49.493878",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40983636.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 41.39497113227844,
      "cbioportal_papers": 0.0003268718719482422,
      "platform_mentions": 0.003186941146850586,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40950112": {
    "paper_id": "40950112",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "One popular tool,\ncBioPortal (1, 2), allows users to submit sets of genes for a cancer type of interest and query for\ngenomic and transcriptomic aberrations",
      "cBioPortal mainly focuses on gene mutation and copy\nnumber alterations (CNA) data and provides visualization highlighting mutation and CNA patterns\nand gene expression for specific genes",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis\nof complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:54.569576",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40950112.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.574923038482666,
      "cbioportal_papers": 0.00014901161193847656,
      "platform_mentions": 0.0012509822845458984,
      "data_citations": 3.814697265625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40950660": {
    "paper_id": "40950660",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal (40)\nwas utilized to examine FAM50A genomic alterations across\nvarious cancer types",
      "(D) Frequency of genetic alterations in FAM50A across various cancers, as evidenced\nby the cBioPortal database",
      "Produced by cBioPortal online tool",
      "The \u2018+\u2019 denotes corresponding data available in cBioPortal for the specified\ntumor type"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:35:59.477803",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40950660.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.51571273803711,
      "cbioportal_papers": 0.00035119056701660156,
      "platform_mentions": 0.0027921199798583984,
      "data_citations": 1.3828277587890625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40948768": {
    "paper_id": "40948768",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "scRNA-seq retrieved from cBioPortal; promoter and gene-body methylation\nanalysis was performed using the \u201cSeurat\u201d R package"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:03.379986",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40948768.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.794238090515137,
      "cbioportal_papers": 0.0003788471221923828,
      "platform_mentions": 0.0024099349975585938,
      "data_citations": 1.1205673217773438e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40950055": {
    "paper_id": "40950055",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In support of this hypothesis, mutation analysis in diverse human cancers using\n163 the cBioPortal platform for cancer genomics (www.cbioportal.org) showed that\n6\n\nbioRxiv preprint doi: https://doi.org/10.1101/2025.09.01.673523; this version posted September 2, 2025"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:04.075667",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40950055.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.572943925857544,
      "cbioportal_papers": 0.00020384788513183594,
      "platform_mentions": 0.0022232532501220703,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40940401": {
    "paper_id": "40940401",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Association of SDC2 and FN mRNA expression with nodal metastasis status and cancer\nstages\nWe investigated SDC2 and FN mRNA expression in breast cancer according to nodal metastasis status and\ncancer staging using the UALCAN and cBioPortal online databases",
      "mRNA expression level of SDC2 in breast carcinoma tissues compared with normal tissues based on\n(A) nodal status and (B) clinical stage, according to METABRIC (https://www.cbioportal.org/) (accessed on\n25 August 2024) and UALCAN database (http://ualcan.path.uab.edu/) (accessed on 25 August 2024)",
      "mRNA expression level of FN in breast carcinoma tissues compared with normal tissues based on\n(A) nodal status and (B) clinical stage according to METABRIC (https://www.cbioportal.org/) (accessed on\n13 June 2025) and UALCAN database (http://ualcan.path.uab.edu/) (accessed on 13 June 2025)",
      "Clinicopathological value of SDC2 and FN expression in breast cancer\nTo investigate the associations between the expression of SDC2 and FN and various breast cancer characteristics\nin the TCGA dataset, we utilized UALCAN and cBioPortal (https://www.cbioportal.org/) (accessed on 25 August\n2024)75 web tools",
      "It should be noted that the online datasets (STRING, DAVID, UALCAN, HPA, cBioPortal, Kaplan\u2013Meier\nPlotter, and ROC Plotter) do not allow filtering of the selection of breast cancer patients based on BMI",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:13.478215",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40940401.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.994789123535156,
      "cbioportal_papers": 0.0003871917724609375,
      "platform_mentions": 0.004853010177612305,
      "data_citations": 1.2159347534179688e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40934285": {
    "paper_id": "40934285",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:20.962997",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40934285.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.554346323013306,
      "cbioportal_papers": 0.0003299713134765625,
      "platform_mentions": 0.0003802776336669922,
      "data_citations": 0.0002307891845703125,
      "num_data_pmids_checked": 2
    }
  },
  "40962882": {
    "paper_id": "40962882",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:22.523346",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40962882.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 59.953876972198486,
      "cbioportal_papers": 0.0005950927734375,
      "platform_mentions": 0.004593849182128906,
      "data_citations": 0.0012068748474121094,
      "num_data_pmids_checked": 5
    }
  },
  "40928210": {
    "paper_id": "40928210",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:24.267834",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40928210.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.701918125152588,
      "cbioportal_papers": 0.0001850128173828125,
      "platform_mentions": 0.0014410018920898438,
      "data_citations": 5.0067901611328125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40932875": {
    "paper_id": "40932875",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:28.111652",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40932875.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 24.033010005950928,
      "cbioportal_papers": 0.0003032684326171875,
      "platform_mentions": 0.0024878978729248047,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40923330": {
    "paper_id": "40923330",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Clinical\nand normalized expression data were retrieved for the TCGA-BLCA 2.6 | Statisticalanalysis\ncohort by cBioPortal,33 for the UROMOL project by Lindskrog et al. (Source and Supporting Information),30 and for the Mariathasan et al. StatisticalanalysiswasperformedbytheIBMSPSSStatistics20soft-\ncohortbyKaplan\u2013Meierplotter(Tumortype:Urothelial).34 ware (IBM Corp., Armonk, NY)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:28.939375",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40923330.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.947028160095215,
      "cbioportal_papers": 0.00023984909057617188,
      "platform_mentions": 0.0020599365234375,
      "data_citations": 0.00016307830810546875,
      "num_data_pmids_checked": 2
    }
  },
  "40922695": {
    "paper_id": "40922695",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Next, the cBioPortal database and LAVA\ndatabase were screened to explore molecular profiling data",
      "Among the ERBB2-amplified samples from GC patients in\nthe cBioPortal database, TP53 missense mutations (51.1%) and CCNE1 amplifications\n(25.5%) were the most common co-mutations associated with ERBB2 amplification",
      "Next, we screened ERBB2-amplified GC patients from the cBioPortal for Cancer Genomics (cBioPortal\ndatabase, https://www.cbioportal.org/).21,22 The criteria for selecting the studies in cBioPortal database\nwere: (a) studies with sufficient sample sizes and containing GC patients; (b) studies with detailed NGS\nresults (containing copy number variations)",
      "Then, two pancancer studies were included, namely, the MSK-\nIMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017) and China Pan-cancer (OrigiMed, Nature\n2022), to explore co-mutations with ERBB2 amplification in ERBB2-amplified GC; In addition, three\npancancer studies from cBioPortal database, namely, the MSK-IMPACT Clinical Sequencing Cohort\n(MSK, Nat Med 2017), MetTropism (MSK, Cell 2021) and MSK-CHORD (MSK, Nature 2024) were\nscreened to analyse the overall survival probabilities of GC patients harboring co-mutations with ERBB2\namplification",
      "Additionally, a total of 94 ERBB2-amplified patients were obtained from\ntwo pancancer studies in the cBioPortal database to analyze co-mutations, including 25 patients from the\nMSK-IMPACT cohort and 69 patients from the OrigiMed cohort",
      "Genomic alterations cooccurred with ERBB2 amplification and survival analyses in the cBioPortal\ndatabase\nAmong the 94 ERBB2-amplified GC patients obtained from cBioPortal, the NGS results revealed that TP53\nmissense mutations and CCNE1 amplifications were the most common cooccurring mutations with ERBB2\namplification, with incidences of 51.1% (48/94) and 25.5% (24/94), respectively",
      "Molecular profiling and survival analysis of ERBB2-amplified GC patients in the cBioportal database",
      "Moreover, we chose pancancer studies from the cBioPortal database to investigate the prognostic\nroles of the abovementioned genes, and we selected the patients harboring ERBB2 L755S from the\nLAVA database to determine the distribution of this mutation in solid tumors",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:32.042239",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40922695.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.491674184799194,
      "cbioportal_papers": 0.0002410411834716797,
      "platform_mentions": 0.002933025360107422,
      "data_citations": 8.487701416015625e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40913834": {
    "paper_id": "40913834",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To evaluate ERBB2 mRNA expression across different tumor\nHER2 immunohistochemistry and fluorescent in situ types, we retrieved The Cancer Genome Atlas (TCGA) pan-\nhybridization cancer datasets from cBioPortal,20,21 which include data\nfrom 7563 patient samples across 12 cancer types",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex\npattern for advanced gastric cancer in Japan and factors associated\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:40.235563",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40913834.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.959381103515625,
      "cbioportal_papers": 0.00025773048400878906,
      "platform_mentions": 0.0017452239990234375,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40904601": {
    "paper_id": "40904601",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "36208ES60; Shanghai\n(GTEx), UALCAN, GEPIA2, Tumor Immune Estimation Yeasen Biotechnology Co., Ltd.) and imaged with the Bio\u2011Rad\nResource (TIMER)2.0, GSCA and cBioPortal",
      "RNA extraction and subsequent reverse Through modules such as \u2018Cancer Types Summary\u2019, \u2018Plots\u2019,\ntranscription were performed according to the protocols in \u2018Mutations\u2019 and \u2018Survival\u2019, cBioPortal was used to delineate\nthe PrimeScript\u2122 RT Master Mix (cat",
      "functional characterization was pursued through GO/KEGG\nThe cBioPortal platform (https://www.cbioportal.org/) inte\u2011 and GSEA analyses",
      "cancer types were analyzed using cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:43.197285",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40904601.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.223932027816772,
      "cbioportal_papers": 0.0002880096435546875,
      "platform_mentions": 0.003392934799194336,
      "data_citations": 9.989738464355469e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40906088": {
    "paper_id": "40906088",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Figure 2 illustrates the correlation between KRAS mutations and patient survival rates\n\nBiology2025,14,936 10of39\nacross select cancer types, based on publicly available datasets from cBioPortal [94,95],\nemphasizingtheclinicalimpactofspecificmutationhotspotssuchasglycine12(G12)and\nalanine59(A59)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:44.214529",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40906088.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.079424142837524,
      "cbioportal_papers": 0.000308990478515625,
      "platform_mentions": 0.0021140575408935547,
      "data_citations": 2.002716064453125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40900734": {
    "paper_id": "40900734",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Evidence from the\ndatabases and analytical tools such as The Cancer Genome TISIDB database revealed that SMC2 is positively associ\u2011\nAtlas, TIMER 2.0, TISIDB, cBioportal, Gene Ontology, Gene ated with immunosuppressive genes",
      "The cBioPortal treated overnight at 4\u02daC with the anti\u2011SMC2 rabbit/IgG\ndatabase was also employed to evaluate SMC2 mutations in primary antibodies (cat",
      "interval (PFI) in patients with cancer was performed, revealing\nMoreover, the distribution of SMC2 mutations in cancer were that the overexpression of SMC2 may negatively affect the\nanalyzed using three datasets of LUAD from the cBioPortal prognosis of patients with LUAD (Fig",
      "Consequently,\n(http://www.cbioportal.org/) platform (23, 24) (TCGA, LUAD was selected as the cancer of focus in the investigation",
      "To further assess the role of SMC2\ncBioPortal database",
      "(C) Summary of OncoPrint visualization of SMC2 changes (in the cBioPortal database)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:47.704416",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40900734.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.450055122375488,
      "cbioportal_papers": 0.0002849102020263672,
      "platform_mentions": 0.003482818603515625,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40899986": {
    "paper_id": "40899986",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Human clinical data analysis\nCBioPortal.org (RRID:SCR_014555) was used to construct an OncoPrint plotting the\nfrequency of alterations in AR, MYC, P53, PTEN, and RB1 in primary prostate cancer\npatients from The Cancer Genome Atlas (TCGA) dataset (39) and mCRPC patients from\na Stand Up to Cancer (SU2C) dataset (16), and generate a Kaplan-Meier survival curve of\nmCRPC patients harboring MYC, P53, and/or PTEN alterations from the SU2C dataset",
      "To analyze established immune signatures in prostate cancer patients with specific\ngenetic alterations, we obtained gene expression dataset from the SU2C dataset (16)\nand corresponding genomic mutation datasets (40,41) from cBioPortal.org",
      "Publicly available SU2C (16) and TCGA (39) RNA-\nseq and genomic datasets were obtained from cBioPortal.org"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:49.839973",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40899986.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.584528207778931,
      "cbioportal_papers": 0.0003399848937988281,
      "platform_mentions": 0.004071712493896484,
      "data_citations": 0.0006971359252929688,
      "num_data_pmids_checked": 6
    }
  },
  "40898423": {
    "paper_id": "40898423",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "of YRDC and Related Transcription Factors\nIdentification\n2.6 | Characterizing the Tumor- Infiltrating\nThe genetic alteration status of YRDC was assessed using Immune Cells\ncBioPortal (https://w ww.c biopo rtal.o rg/, based on TCGA Pan-\nCancer Atlas data) [25, 26]",
      "Complex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d\nScience Signaling 6, no"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:55.485966",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40898423.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.232731819152832,
      "cbioportal_papers": 0.00023102760314941406,
      "platform_mentions": 0.0020890235900878906,
      "data_citations": 0.0001590251922607422,
      "num_data_pmids_checked": 2
    }
  },
  "40904351": {
    "paper_id": "40904351",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "756 https://doi.org/10.2147/BCTT.S537429 B r e a s t C a n c e r : T a r g e t s a n d T h e r a p y 2 0 2 5 : 1 7\nPPoowweerreedd bbyy TTCCPPDDFF ((wwwwww..ttccppddff..oorrgg))\n\nAimaiti et al\nGenetic Variant Characterization of BYSL\ncBioPortal database,19 the \u201cOncoPrint\u201d module was used to investigate BYSL genetic variants in the \u201cTCGA Pan-Cancer\nAtlas Studies\u201d dataset, which included 10443 mutation data from 32 studies (n = 10,967)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:36:57.774910",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40904351.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 25.707010984420776,
      "cbioportal_papers": 0.00024080276489257812,
      "platform_mentions": 0.0018780231475830078,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40890493": {
    "paper_id": "40890493",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Biao Wang\nbiaowang@fjmu.edu.cn Methods Data from six databases, including UCSC Xena, TCGA, GTEx, TIMER2.0,\n1Department of Plastic Surgery, The\nGEPIA, and cBioPortal, were analyzed to assess ANGPT2 expression in pan-cancer",
      "For identifying the top 100 genes most correlated with ANGPT2,\nwe utilized the Gene Expression Profiling Interactive Analysis (GEPIA2) database using\ndata from TCGA [26], while genetic alterations were analyzed through cBioPortal [27]",
      "2.2 Genetic alteration analysis\nThe cBioPortal platform [29] (http://www.cbioportal.org) was used to analyze genetic\nalterations in ANGPT2",
      "3 Results\n3.1 Genetic alteration analysis of ANGPT2\nWe conducted a pan-cancer genetic alteration analysis of ANGPT2 using the cBioPortal\nplatform",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analy-\nsis of complex cancer genomics and clinical profiles using the cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:01.990394",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40890493.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.134071111679077,
      "cbioportal_papers": 0.00022912025451660156,
      "platform_mentions": 0.002827167510986328,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40896366": {
    "paper_id": "40896366",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Wilcoxon tests with\ntrols and immunocompromised mouse strains, such as NSG mice, Benjamini-Hochberg FDR corrections were automatically generated\nwe can further validate the mechanistic insights and therapeutic po- in cBioPortal to statistically compare CRC cases with FBXO7 shallow\ntential observed in vitro",
      "MATERIALS AND METHODS\nBioinformatic and statistical approaches siRNA-based gene silencing and western blot\nFBXO7 copy number losses data were extracted from TCGA Pan- Gene silencing was performed by transfecting ON-TARGETplus\nCancer Atlas23 using cBioPortal (www.cbioportal.org).24 Copy (Dharmacon) siRNA duplexes into cells using RNAiMax Transfec-\nnumber losses from 10 solid tumor types (bladder, breast, CRC, glio- tion Reagent (Life Technologies)",
      "33 September 2025\n\nwww.moleculartherapy.org\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:02.102398",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40896366.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.375549793243408,
      "cbioportal_papers": 0.0003101825714111328,
      "platform_mentions": 0.0035271644592285156,
      "data_citations": 0.0003209114074707031,
      "num_data_pmids_checked": 3
    }
  },
  "40888998": {
    "paper_id": "40888998",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Microsatellite Instability (MSI) data were obtained\nfrom cBioPortal [14] (https://www.cbioportal), and immune scores were calculated\nusing the Tumor Immune Dysfunction and Exclusion (TIDE) [15] website ( h t t p : / / t i d e"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:04.768412",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40888998.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.2582368850708,
      "cbioportal_papers": 0.00022912025451660156,
      "platform_mentions": 0.0019867420196533203,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40883027": {
    "paper_id": "40883027",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "This approach was particularly\nExpectation Maximization) values for TCGA\u2011BRCA and CGCI\u2011 benchmarked via assessments of MYCN amplification in\nBLGSP samples were obtained from cBioPortal for Cancer neuroblastoma (14)",
      "Survival input data for the sequencing read ratios) for the CGCI\u2011BLGSP FASLG\nTCGA\u2011BRCA (pancancer) and the CGCI\u2011BLGSP dataset were indicated a trend towards worse OS probabilities\nobtained and assessed using a Kaplan\u2011Meier web tool at associated with the higher level of FASLG CNs (Figure 1A;\ncBioPortal for Cancer Genomics (15, 16) and GDC, p=0.077)",
      "DOI:\n10.1007/s00262\u2011023\u201103366\u2011x\nData are available in the supporting online material\n2 Han Y, Liu D, Li L: PD\u20111/PD\u2011L1 pathway: Current researches\n(SOM) or publicly available at cbioportal.org or, via\nin cancer",
      "DOI: 10.1158/2159\u20118290.CD\u201120\u20110756\nSun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C,\nSchultz N: Integrative analysis of complex cancer genomics\nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:05.930712",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40883027.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 3.9270179271698,
      "cbioportal_papers": 9.894371032714844e-05,
      "platform_mentions": 0.0015032291412353516,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40885971": {
    "paper_id": "40885971",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:06.323815",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40885971.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.519222021102905,
      "cbioportal_papers": 0.0003151893615722656,
      "platform_mentions": 0.0027709007263183594,
      "data_citations": 0.0004391670227050781,
      "num_data_pmids_checked": 4
    }
  },
  "40873584": {
    "paper_id": "40873584",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cross-validation strategy for machine\nretrieved from GeneCards (https://www.genecards.org/) using the learning models: 10-fold cross-validation, repeated 3 times to\nkeyword\u201cmacrophage polarization.\u201dMutation statusofcandidate ensuremodelstability,usingthe\u201ccaret\u201dRpackage\ngenes was assessed using cBioPortal (https://www.cbioportal.org/)\n(32).Protein-levelexpressiondataofMPGsinnormalandtumor\n2.5 Construction and validation of the\ntissues were accessed from the Human Protein Atlas (https://\nmacrophage polarization signature\nwww.proteinatlas.org/) (33)",
      "10.3389/fimmu.2025.1639303\nGenomic profiling of MPGS genes using cBioPortal showed further validation"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:17.688105",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40873584.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.859543085098267,
      "cbioportal_papers": 0.0003311634063720703,
      "platform_mentions": 0.003186941146850586,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40869275": {
    "paper_id": "40869275",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "MatchingclinicopathologicaldatawereobtainedfromthecBioPortalforCancerGenomics\n\nInt.J.Mol.Sci.2025,26,7956 11of16\n(https://www.cbioportal.org/accessedon2January2025)[49]",
      "Int.J.Mol.Sci.2025,26,7956 14of16\nDataAvailabilityStatement:ThedatapresentedinthisstudyareopenlyavailablefromTheCancer\nGenomeAtlas(TCGA)repository,specificallytheTCGA-THCAdataset,accessibleviaplatforms\nsuchascBioPortalforCancerGenomics(https://www.cbioportal.org/accessedon2January2025)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:19.816726",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40869275.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.484622955322266,
      "cbioportal_papers": 0.0002467632293701172,
      "platform_mentions": 0.0024912357330322266,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40869231": {
    "paper_id": "40869231",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:23.578070",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40869231.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 5.88791298866272,
      "cbioportal_papers": 0.0001709461212158203,
      "platform_mentions": 0.0012848377227783203,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40882030": {
    "paper_id": "40882030",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:31.421061",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40882030.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 29.248209953308105,
      "cbioportal_papers": 0.0005459785461425781,
      "platform_mentions": 0.0049762725830078125,
      "data_citations": 8.106231689453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40872629": {
    "paper_id": "40872629",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The predictive capability of this\nsignaturewasvalidatedusingtheDKFZPCacohort(n=118;accessedviacBioPortal,\nhttps://www.cbioportal.org/,accessedon15November2024),yieldingAUCvaluesof\n0.700,0.659,and0.659for1-,3-,and5-yearpredictions(Figure3D).Moreover,multivari-\nateCoxregressionrevealedthatriskscore,Tstage,andGleasonscoreindependently\npredictedBCRinPCa(Figure3E).Basedonthesefindings,wedevelopedacomprehen-\nsivenomogramthatincorporatestheseclinicalparameterstopredictsurvivaloutcomes\nandassistinclinicaldecision-making(Figure3F)",
      "RNA-seqandclinicaldataforPCasamplesfromtheDKFZwereobtainedviacBioPortal\n(http://cbioportal.org,accessedon15November2024)[57]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:32.583655",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40872629.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 26.59464120864868,
      "cbioportal_papers": 0.00026488304138183594,
      "platform_mentions": 0.002637147903442383,
      "data_citations": 9.489059448242188e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40869130": {
    "paper_id": "40869130",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "WenextusedthecBioCancerGenomicsPortal(http://cbioportal.org)[53\u201355]\nto determine the expression levels of these genes in individual patient samples within\nTCGAPanCancerAtlas,BreastInvasiveCarcinomadataset[53\u201355]",
      "Anoncoprintdepictinggenesoverex-\npressedinbreastcancerpatientsamplesfromtheTCAGdataset[60]wasdeterminedusing\ncBioportal[61,62]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:35.873369",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40869130.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.039137840270996,
      "cbioportal_papers": 0.00025916099548339844,
      "platform_mentions": 0.002708911895751953,
      "data_citations": 0.00010085105895996094,
      "num_data_pmids_checked": 1
    }
  },
  "40867322": {
    "paper_id": "40867322",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:36.790728",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40867322.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 5.366637945175171,
      "cbioportal_papers": 0.00022912025451660156,
      "platform_mentions": 0.0025238990783691406,
      "data_citations": 1.2159347534179688e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40866630": {
    "paper_id": "40866630",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:39.026188",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40866630.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.415408134460449,
      "cbioportal_papers": 0.0003101825714111328,
      "platform_mentions": 0.0023360252380371094,
      "data_citations": 0.0003650188446044922,
      "num_data_pmids_checked": 3
    }
  },
  "40861812": {
    "paper_id": "40861812",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Clinical\nrelevance was evaluated through survival analyses on cBioPortal and KM plotter platforms, and immunotherapy\nresponses were assessed based on gene expression profiles",
      "Results include\nAll the sample based mutational analysis were key statistical metrics such as hazard ratios with 95%\nbased on the cBioPortal [14], an online server for confidence intervals, log-rank p-values, and the\nvisualization, and analysis of multidimensional number of patients at risk at various time points",
      "Kaplan-Meier survival curves were generated\nCell Proliferation and Migration Ability\nusing cBioPortal for the PTC cohort",
      "The efficiency of gene\ncBioPortal",
      "For the\nOncotreemap in cBioPortal was used to classify CCK-8 assay, cells were trypsinized, counted, and\nATC samples based on the presence or absence of plated into 96-well plates at 1,000 cells per well",
      "cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. https://www.jcancer.org/v16p3551s4.xlsx Integrative analysis of complex cancer genomics and clinical profiles using the\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:44.094288",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40861812.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.17105484008789,
      "cbioportal_papers": 0.0003070831298828125,
      "platform_mentions": 0.002489805221557617,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40861810": {
    "paper_id": "40861810",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Subsequently, we\nperformed KEGG and GO enrichment analyses on\nGenetic alteration analysis of SGO1\nthese proteins using the SRplot web platform\nThe cBioPortal web (https://www.cbioportal",
      "Additionally, we also the cBioPortal database was used to analyze genetic\nobserved that a high expression level of SGO1 is alterations of SGO1 in 10,967 tumor samples in\nmarkedly correlated with a poorer disease-free pan-cancer",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the\nThe animal experiment was approved by the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:44.294510",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40861810.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.500404119491577,
      "cbioportal_papers": 0.00035309791564941406,
      "platform_mentions": 0.0023376941680908203,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40860811": {
    "paper_id": "40860811",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TYPEOriginalResearch\nPUBLISHED08August2025\nDOI10.3389/fonc.2025.1608664\nfi\nDe ne a good prognosis of\nRNF43\ncodon 659-mutated and\nOPENACCESS\nconcomitant genomic signatures\nEDITEDBY\nTizianaVenesio,\nInstituteforCancerResearchandTreatment\nin CRC: an analysis of the\n(IRCC),Italy\nREVIEWEDBY\nGiulioFerrero, cBioPortal database\nUniversityofTurin,Italy\nHyundeokKang,\nFlowtrials,UnitedStates\nFeng Wang1\u2020, Li Lin2\u2020, Zhongkang Li3\u2020, Lei Qin3, Shuai Zhang4,\n*CORRESPONDENCE\nYingyingHuang Xueqing Hu4, Yunbo Zhao4 and Yingying Huang4*\nyinghh@hotmail.com\n1DepartmentofGastrointestinalSurgery,BeijingTsinghuaChanggungHospital,SchoolofClinical\n\u2020Theseauthorshavecontributed\nMedicine,TsinghuaUniversity,Beijing,China,2DepartmentofOncologyCenter,PekingUniversity\nequallytothiswork InternationalHospital,Beijing,China,3Geneplus-Beijing,Beijing,China,4DepartmentofOncology,\nBeijingHospital,NationalCenterofGerontology,Beijing,China\nRECEIVED09April2025\nACCEPTED18July2025\nPUBLISHED08August2025\nBackground: Heterogeneity of colorectal cancer (CRC) leads to significant\nCITATION\nWangF,LinL,LiZ,QinL,ZhangS,HuX, differences in Overall Survival (OS)",
      "COPYRIGHT\n\u00a92025Wang,Lin,Li,Qin,Zhang,Hu,Zhao\nandHuang.Thisisanopen-accessarticle Methods: The clinical characteristics, mutational characteristics, and survival\ndistributedunderthetermsoftheCreative data of CRC patients were obtained for RNF43-mutated analysis from\nCommonsAttributionLicense(CCBY).The\nuse,distributionorreproductioninother cBioPortal",
      "KEYWORDS\ncolorectal cancer (CRC), cbioportal database, RNF43-mutated, mutation\nanalysis,prognostic\n1 Introduction BRAFisthecoregeneoftheMitogen-ActivatedProteinKinase\n(MAPK) signaling pathway, which regulates cell proliferation and\nColorectal cancer (CRC) is the third most common cancer in apoptosis(14).TheincidenceofBRAF-mutatedCRCisabout10-\ntheworldandthesecondleadingcauseofcancer-relateddeath(1)",
      "It has been In this study, we explored prognostic biomarkers with\nsuggestedthatRNF43-mutatedcanbeusedasapredictivebiomarker predictive value based on clinicopathological and molecular\nof anti-BRAF/EGFR combination therapy response in microsatellite- characteristics of colorectal cancer patients in the cBioPortal\nstabilized (MSS) BRAF V600E metastatic colorectal cancer patients, database",
      "MSI-H directly used the downloaded label with\nThe clinical characteristics, mutational characteristics, and cBioPortal,andthetotalnumberofMSI-HandMSSpatientswas\nsurvival data of CRC patients were recruited for RNF43-mutated 296 and 2858, respectively",
      "Before analyzing this study, we\nanalysisfromtheCancerGenomeAtlas(TCGA)databaseusingthe calculated the mutation frequencies in 11 cohorts to better\ncBio Cancer Genomics Portal (cBioPortal), available at http:// understand the reproducibility and limitations of the research, as\nwww.cbioportal.org (Supplementary Tables 1, 2) (25)",
      "10.3389/fonc.2025.1608664\nGlossary\nCRC Colorectalcancer ARID1A AT-richinteractiondomain1A\nOS OverallSurvival CIC Capicuatranscriptionalrepressor\nPFS Progression-freesurvival PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic\nsubunitalpha\nICIs Immunecheckpointinhibitors\nPTPRS ProteintyrosinephosphatasereceptortypeS\nNCCN theNationalComprehensiveCancerNetwork\nAPC APCregulatorofWNTsignalingpathway\nRNF43 Ringfingerprotein43\nFAT1 FATatypicalcadherin1\nBRAF B-Rafproto-oncogene,serine/threoninekinase\nPOLE DNApolymeraseepsilon,catalyticsubunit\nMAPK theMitogen-ActivatedProteinKinase\nNOTCH3 Notchreceptor3\nMSI Microsatelliteinstability\nSPEN Spenfamilytranscriptionalrepressor\nMSS Microsatellitestable\nTP53 Tumorproteinp53\nTMB Tumormutationalburden\nKRAS KRASproto-oncogene,GTPase\nTNM TheTumor-Node-Metastasissystem\nFBXW7 F-boxandWDrepeatdomaincontaining7\nHR Hazardratio\nSMAD4 SMADfamilymember4\nCI Confidenceinterval\nTCF7L2 Transcriptionfactor7like2\nPI3K Phosphoinositol-3kinase\nSOX9 SRY-boxtranscriptionfactor9\nTCGA TheCancerGenomeAtlas\nPTCH1 Patched1\ncBioPortal cBioCancerGenomicsPortal\nSMARCA4 SWI/SNF related BAF chromatin remodeling complex\nGO GeneOntology\nsubunitATPase4\nKEGG KyotoEncyclopediaofGenesandGenomes\nFLT4 Fmsrelatedreceptortyrosinekinase4\nKM Kaplan-Meier\nFrontiersinOncology 18 frontiersin.org"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:37:57.510354",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40860811.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 18.44305682182312,
      "cbioportal_papers": 0.00030994415283203125,
      "platform_mentions": 0.0029649734497070312,
      "data_citations": 0.00021719932556152344,
      "num_data_pmids_checked": 2
    }
  },
  "40867349": {
    "paper_id": "40867349",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:00.175126",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40867349.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 36.5779550075531,
      "cbioportal_papers": 0.00030684471130371094,
      "platform_mentions": 0.002132892608642578,
      "data_citations": 0.0005290508270263672,
      "num_data_pmids_checked": 5
    }
  },
  "40857406": {
    "paper_id": "40857406",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:03.910439",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40857406.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.808836936950684,
      "cbioportal_papers": 0.0002989768981933594,
      "platform_mentions": 0.0003478527069091797,
      "data_citations": 0.00012803077697753906,
      "num_data_pmids_checked": 1
    }
  },
  "40849356": {
    "paper_id": "40849356",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Figure downloaded from cBioPortal, representing data from the TCGA PanCancer Atlas case series, excluding\ncases with mutations in EGFR, ERBB2, MET, KRAS, BRAF, or fusions of ALK, NTRK1-3, RET, ROS1 (any alterations reported for these genes are\nrepresentedexclusivelybyCNAs)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:05.594659",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40849356.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 21.195378065109253,
      "cbioportal_papers": 0.0004928112030029297,
      "platform_mentions": 0.004191875457763672,
      "data_citations": 0.0808420181274414,
      "num_data_pmids_checked": 13
    }
  },
  "40843374": {
    "paper_id": "40843374",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Riskscoresforeachpatientwerecalculatedusingamultivariate\nCoxregressionmodelbasedontheexpressionlevelsandcoefficients\noftheprognostic MRlncRNAs, followingthe formula: Genetic variations\nRiskscore(cid:1)(cid:1)iCoefficient(MRlncRNAsi)\u00d7Expression(MRlncRNAsi)\nThecBioPortaldatabase(http://www.cbioportal.org/)(Gaoetal.,\n2013)providesvisualizationtoolsforcancergenomicdataanalysis",
      "Additionally, survival analysis combining risk score with TMB\nGenetic alterations of MRlncRNAs were analyzed using the and MSI revealed that patients in the low TMB + low-risk score\ncBioPortal database"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:10.528957",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40843374.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.333949089050293,
      "cbioportal_papers": 0.00026988983154296875,
      "platform_mentions": 0.0026061534881591797,
      "data_citations": 8.106231689453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40846973": {
    "paper_id": "40846973",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "lines in terms of perturbed cancer pathways, we com- Figure 8 presents radar plots summarizing eight key indi-\npared the number of perturbed genes across 10 cancer ces: DLS_01, DLS_02, DLS_03, DLS_06, DLS_07, DLS_\npathways monitored by cBioPortal project [110] includ- cons, Ro5, and cRo5",
      "Modeling results showed that the\nwas generated based on data mined from cBioPortal [110] analogues indeed align with the pharmacophoric features"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:12.645800",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40846973.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.130841255187988,
      "cbioportal_papers": 0.0004496574401855469,
      "platform_mentions": 0.0040073394775390625,
      "data_citations": 1.1682510375976562e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40831628": {
    "paper_id": "40831628",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mateo J, Chakravarty D, Dienstmann R, Jezdic S, cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:15.374259",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40831628.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.742878198623657,
      "cbioportal_papers": 0.00030303001403808594,
      "platform_mentions": 0.002624988555908203,
      "data_citations": 0.00011992454528808594,
      "num_data_pmids_checked": 1
    }
  },
  "40828325": {
    "paper_id": "40828325",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN,\nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:32.009881",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40828325.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.610546827316284,
      "cbioportal_papers": 7.224082946777344e-05,
      "platform_mentions": 0.0008180141448974609,
      "data_citations": 7.295608520507812e-05,
      "num_data_pmids_checked": 3
    }
  },
  "40829174": {
    "paper_id": "40829174",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:34.682695",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40829174.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 22.027238130569458,
      "cbioportal_papers": 0.00035309791564941406,
      "platform_mentions": 0.003239870071411133,
      "data_citations": 0.00013399124145507812,
      "num_data_pmids_checked": 1
    }
  },
  "40835742": {
    "paper_id": "40835742",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Table2|Disease-relatedmutationsandpathogenicityscores\nvariant source REVEL DeMaskdelta EVE Alphamissense \u0394\u0394Gbinding-p5 \u0394\u0394Gbinding-p1\nfitness\nV161M ClinVar(1,VUS) 0.435 \u22120.201 Benign Ambiguous Neutral Neutral\nE163D ClinVar(1,VUS) 0.404 \u22120.264 Pathogenic Pathogenic Neutral Neutral\nL166V cBioPortal 0.378 \u22120.132 Benign Benign Potentiallydamaging Neutral\n(0.8\u20131.6kcal/mol)\nN169S cBioPortal 0.161 \u22120.010 Benign Benign Neutral Neutral\nN169T cBioPortal 0.227 \u22120.059 Uncertain Benign Neutral Neutral\nE175Q cBioPortalCOSMIC 0.309 \u22120.092 Pathogenic Benign PotentiallyNeutral Damaging(1.0\u20131.45kcal/mol)\n(0.2\u20131.3kcal/mol)\nD176Y cBioPortalCOSMIC 0.442 \u22120.317 Pathogenic Ambiguous PotentiallyNeutral PotentiallyDamaging\n(0.2\u20131.2kcal/mol) (0.9\u20131.6kcal/mol)\nF178V cBioPortal,COSMIC 0.58 \u22120.341 Pathogenic Pathogenic Damaging(3.0\u20134.5kcal/mol) Damaging(3.0\u20130.3.5kcal/mol)\nV179D ClinVar(1,VUS) 0.482 \u22120.389 Pathogenic Pathogenic Neutral Neutral\nA184D cBioPortal 0.245 \u22120.091 Benign Benign Neutral Neutral\nA184S cBioPortalCOSMIC 0.159 0.042 Benign Benign Neutral Neutral\nIfthesourceforthevariantisClinVar,wereportedthereviewstatusandtheclassification.DeMaskgenerallyclassifiesasloss-of-functionvariantswithafitnessscore<0andgain-of-function>0.Weusedas\nathresholdfordamagingvariantsaDeMaskscore<\u22120.3or>0.3todecreasethenumberoffalsepositives.AsimilarstrategyisappliedtotheREVELscore"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:39.921462",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40835742.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 35.999560832977295,
      "cbioportal_papers": 0.0005180835723876953,
      "platform_mentions": 0.0036687850952148438,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40826166": {
    "paper_id": "40826166",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:43.545768",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40826166.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.819863080978394,
      "cbioportal_papers": 0.00021719932556152344,
      "platform_mentions": 0.0016088485717773438,
      "data_citations": 0.00014710426330566406,
      "num_data_pmids_checked": 2
    }
  },
  "40826108": {
    "paper_id": "40826108",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In silico datasets\nPrimary and metastatic ER+ breast cancer datasets Results\nGene expression data was downloaded from The Cancer Genome-wide CRISPR/Cas9 screens identify JNK pathway\nGenome Atlas (TCGA) [32, 33] through cBioPortal [34, suppression as a driver of endocrine therapy and CDK4/6\n35] in January and December 2024"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:54.028955",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40826108.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.103085994720459,
      "cbioportal_papers": 0.0003921985626220703,
      "platform_mentions": 0.0034477710723876953,
      "data_citations": 0.00040721893310546875,
      "num_data_pmids_checked": 3
    }
  },
  "40826334": {
    "paper_id": "40826334",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(TCGA, Firehose Legacy) using the cBioPortal database",
      "E TOPK mutation frequency in multiple TCGA pan-cancer dataset in the cBioPortal database",
      "Mutation analysis\nThe cBioPortal database (https://www.cbioportal.org/) is\nConclusion\na user-friendly and powerful resource for exploring and\nIn summary, our findings demonstrate that TOPK analyzing diverse cancer genomics data, covering epi-\nupregulation is closely associated with poor progno- genetics, gene expression profiles and proteomics data\nsis and altered immune infiltration within the tumor [65, 66]",
      "Herein, we utilized cBioPortal to assess the\n\nZheng et al. BMC Cancer (2025) 25:1334 Page 19 of 22\nalterations in TOPK across 38 datasets, which collec- \u201cSeurat\u201d R package and subjected to principal component\ntively included 26,390 pan-cancer samples"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:38:55.238304",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40826334.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.16337823867798,
      "cbioportal_papers": 0.00031495094299316406,
      "platform_mentions": 0.0032889842987060547,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40824763": {
    "paper_id": "40824763",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "These findings suggest that dMMR/MSI colorectal can- Expression Omnibus (RRID: SCR_005012), cBioPortal (RRID: SCR_014555),\ncers represent a clinically heterogeneous population in terms of prognosis and or the Colorectal Cancer Subtyping Consortium synapse data portal (RRID:\ntherapeutic response, likely reflecting underlying molecular diversity",
      "Data availability\nS1; Supplementary Table S1), and we analyzed the expression of 188 glycosyl-\nThe data analyzed in this study were obtained from Gene Expression transferase genes included in 10 Kyoto Encyclopedia of Genes and Genomes\nOmnibus (http://www.ncbi.nlm.nih.gov/geo) or cBioPortal (http://www",
      "1A and Supplementary\ncbioportal.org/; ref",
      "Nat cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:00.396525",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40824763.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.757373094558716,
      "cbioportal_papers": 0.00035500526428222656,
      "platform_mentions": 0.003933906555175781,
      "data_citations": 0.000347137451171875,
      "num_data_pmids_checked": 3
    }
  },
  "40821770": {
    "paper_id": "40821770",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Drug sensitivity analysis was performed using the\nG6PC1 mutations and copy number variations (CNVs) were \u201cDrug\u201dmoduleofGSCA.TheWilcoxonrank-sumtestwasappliedto\nanalyzed using cBioPortal to assess their association with HCC assesshalf-maximalinhibitoryconcentrationvaluesbetweenG6PC1high\nprognosis(26).Mutationsubtypeswerefurthercharacterizedusing andG6PC1lowgroups.Furthermore,geneexpressionprofilesofrelevant\ntheCOSMICdatabase.DNAmethylationpatterns wereevaluated drugtargetswereanalyzedusingtheDrugBankdatabase(38)",
      "characterized G6PC1 genomic alterations, including mutational accounted for 46.92% of variants, while synonymous mutations\nprofiles and CNVs, across two datasets (n=866) from cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:01.973721",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40821770.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.732455015182495,
      "cbioportal_papers": 0.00033473968505859375,
      "platform_mentions": 0.002454996109008789,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40830225": {
    "paper_id": "40830225",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Overview of genomic alterations in cancer and RIN3 mutations\nA systematic analysis of four major genomic alterations (mutations, amplifications, deep deletions, and multiple\nalterations) in tumors was performed using the cancer type summary module of the cBioPortal database ( h t t p\ns : // w w w",
      "cBioPortal analysis identified\nCNVs as the most frequent alteration, with a positive correlation between RIN3 expression, CNVs, and DNA\nmethylation",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:05.473618",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40830225.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 54.941200256347656,
      "cbioportal_papers": 0.00030994415283203125,
      "platform_mentions": 0.0026929378509521484,
      "data_citations": 0.00031113624572753906,
      "num_data_pmids_checked": 3
    }
  },
  "40821099": {
    "paper_id": "40821099",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The mutational status of SDHA was examined using\ncBioPortal, and its relationship with immune infiltration and drug sensitivity was assessed",
      "ber variation (CNV) status of SDHA in breast\ncancer, we utilized the cBioPortal database\nPrognostic significance of SDHA (https://www.cbioportal.org/), which provides\ncomprehensive genomic data from various can-\nTo evaluate the prognostic significance of SDHA\ncer studies, including breast cancer",
      "The combined hazard ratio from the CNV analysis results of SDHA in breast can-\nfixed effect model was 1.75 (95% CI: 1.18- cer using the cBioPortal database"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:08.080472",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40821099.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.6375038623809814,
      "cbioportal_papers": 0.0003101825714111328,
      "platform_mentions": 0.0033957958221435547,
      "data_citations": 8.106231689453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40823663": {
    "paper_id": "40823663",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(A) Genetic alterations in EZH2 across mature B-cell neos, BLL, and acute myeloid\nleukemia (AML), analyzed using The Cancer Genome Atlas data from the Genomics Evidence Neoplasia Information Exchange (GENIE) cohort (version 16.1) on cBioPortal (B-cell\nneos, n = 6444; BLL, n = 911; AML, n = 3859)",
      "(B) Frequency of EZH2Y641F mutations across various cancer types, based on GENIE cohort (v16.1) data analyzed via cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:11.451943",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40823663.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.366318941116333,
      "cbioportal_papers": 0.000270843505859375,
      "platform_mentions": 0.002579927444458008,
      "data_citations": 9.608268737792969e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40820091": {
    "paper_id": "40820091",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "As a andNOX4versusACTA2,COL1A1,LOXL1andLOXL2inCCAtumours\nstandard, dropsof25\u03bcLofthemixture wereseededinto culture fromtherepositoryofTCGAwereanalysedthroughthecBioPortal\nplatesandincubatedfor30minat37\u00b0Cwithoutmediumtoallow database(https://www.cbioportal.org/)andrepresentedasSpear-\nthe matrix solidification"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:31.702405",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40820091.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 26.17884612083435,
      "cbioportal_papers": 0.0004730224609375,
      "platform_mentions": 0.005076885223388672,
      "data_citations": 0.00656580924987793,
      "num_data_pmids_checked": 1
    }
  },
  "40819060": {
    "paper_id": "40819060",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "werecollected fromGDC (TCGA-COAD), cBioPortal [31] (Rectal_MSK2022\nStatistical analyses were performed to evaluate differences in P65\n[32]),andGEO(GSE33113[33])databases.Survivalanalysiswasperformed\nenrichmentattheTRIM31promoter"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:32.363302",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40819060.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 24.2794668674469,
      "cbioportal_papers": 0.0003609657287597656,
      "platform_mentions": 0.002501964569091797,
      "data_citations": 0.00032401084899902344,
      "num_data_pmids_checked": 3
    }
  },
  "40805206": {
    "paper_id": "40805206",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "SurvivalAnalysis\nTCGA melanoma cohort was downloaded through cBioportal [26,27]",
      "DataAvailabilityStatement:Thedatasupportingthefindingsofthisstudyareavailablefromthe\ncorrespondingauthoruponreasonablerequest.Publiclyarchiveddatasets(Vesiclepedia,HisgAtlas,\nHCMDB,cRFPRepository,CBioportal)wereanalyzedduringthisstudy"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:38.524714",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40805206.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.819496154785156,
      "cbioportal_papers": 0.00032591819763183594,
      "platform_mentions": 0.002290964126586914,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40799645": {
    "paper_id": "40799645",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:43.949812",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40799645.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 5.374722957611084,
      "cbioportal_papers": 0.00026702880859375,
      "platform_mentions": 0.0020689964294433594,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40799237": {
    "paper_id": "40799237",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Functional enrichment analyses revealed the We first analyzed the frequency and types ofSHCBP1 via the\ncorrelation of SHCBP1 with the cell cycle and DNA damage cBioPortal database using the TCGA-BRCA database, containing\npathways.Subsequently,wedemonstratedthatSHCBP1positively 963BCsampleswithmutationandcopynumberalteration(CNA)\nregulated TNBC cell proliferation and migration in vitro",
      "Eight TNBC samples in GSE161529 were ThecBioPortaldatabase(36)(https://www.cbioportal.org/)was\nincluded in our study"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:49.568962",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40799237.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 5.594851732254028,
      "cbioportal_papers": 0.00023818016052246094,
      "platform_mentions": 0.0023810863494873047,
      "data_citations": 1.1682510375976562e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40802750": {
    "paper_id": "40802750",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "log- rank tests were conducted in cBioportal [in (e) and (F)]",
      "cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:49.905158",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40802750.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.492751836776733,
      "cbioportal_papers": 0.0004298686981201172,
      "platform_mentions": 0.004373788833618164,
      "data_citations": 0.00015616416931152344,
      "num_data_pmids_checked": 1
    }
  },
  "40814001": {
    "paper_id": "40814001",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Both datasets were\ncluster ORA analysis on the TCR-T and PC-CAR targets, downloaded from cBioPortal [117, 118]",
      "Correction for multiple hypothesis was\nues) was obtained from cBioPortal [117, 118] for the\nobtained using the BH method setting the threshold for\ngenes of interest",
      "in soft tissue sarcomas was obtained by integrating data Then, for each gene pair we assessed co-expression in\nin the \u201cdata_sv.txt\u201d file obtained from cBioPortal for normal cells and tissues, with the caveat that genes for\nthe MSK-IMPACT cohort, data from the study from an ideal target pair of an \u201cAND\u201d logic-gated CAR would\nGao et al. [123] on recurrent gene fusions in TCGA have mutually exclusive expression across all normal cells\ntumor samples, and from a search through the Mitel- and tissues"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:52.164216",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40814001.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 40.706413984298706,
      "cbioportal_papers": 0.0004677772521972656,
      "platform_mentions": 0.004569292068481445,
      "data_citations": 0.0006420612335205078,
      "num_data_pmids_checked": 4
    }
  },
  "40796116": {
    "paper_id": "40796116",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:53.084646",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40796116.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 3.4964818954467773,
      "cbioportal_papers": 0.00017213821411132812,
      "platform_mentions": 0.0015301704406738281,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40794953": {
    "paper_id": "40794953",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Furthermore, we did not use the so-called\n\nTowardsmachinelearningfairnessinclassifyingmulticategorycausesofdeath | 13\nfairnessmetrics,butthetraditionalgroupversusgroupcompari- Data availability\nsonforrobuststatisticalinference.Themainreasonisthatthose\nThedatasetsusedand/oranalyzedinthisstudyareavailableon\nAIfairnessmetricsaremostlydebatableorattributabletoasingle\nthecBioPortalwebsite(ColorectalCancer:www.cbioportal.org/stu\nsource [18,42].Indeed,one group appears to prefer established\ndy/summary?id=coadread_tcga_pan_can_atlas_2018; Lung Can-\n(balanced) accuracy as the performance metrics over fairness\ncer:https://www.cbioportal.org/study/summary?id=luad_tcga_pa\nmetrics [43]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:39:59.389444",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40794953.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.205531120300293,
      "cbioportal_papers": 0.00029587745666503906,
      "platform_mentions": 0.018604040145874023,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40792149": {
    "paper_id": "40792149",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The \u201cSimilar Gene Detection\u201d module (19) of\nTo explore genetic variation in HNRNPA2B1, this work\nGEPIA2 (http://gepia2.cancer-pku.cn/#survival) was used\nutilized the cBioPortal (24) (https://www.cbioportal.org/)\nto screen the top 100 HNRNPA2B1-correlated target\ntool for analyzing the HNRNPA2B1 mutation signature in\ngenes by comparing cancer samples and healthy samples",
      "We analyzed the HNRNPA2B1\nmutational signature of TCGA tumors via the cBioPortal tool",
      "We also analyzed\npotential correlations between mutation status and progression-free, disease specific, overall KIRC (D) using the cBioPortal tool"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:05.170415",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40792149.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.05870008468628,
      "cbioportal_papers": 0.0004401206970214844,
      "platform_mentions": 0.004586935043334961,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40788260": {
    "paper_id": "40788260",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:05.943963",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40788260.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.5332019329071045,
      "cbioportal_papers": 0.00033783912658691406,
      "platform_mentions": 0.0005419254302978516,
      "data_citations": 0.00035834312438964844,
      "num_data_pmids_checked": 3
    }
  },
  "40531993": {
    "paper_id": "40531993",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "S1A) re- ported on the cBioPortal platform (45)",
      "S1A), the mutation fre- performed using FASTQC tool (92), followed by reads trimming to\nquencies for 18,736 protein-c oding genes were extracted from the remove 10 bp from the external regions, and reads with a quality\nCCLE (44) database within the cBioPortal platform (45)",
      "Kao,\nlongitudinal genomic and clinical data from the AAcR Project Genie Biopharma h3K4 methylation at active genes mitigates transcription- replication conflicts during\ncollaborative in cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:47.304573",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40531993.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 790.1442382335663,
      "cbioportal_papers": 0.0006661415100097656,
      "platform_mentions": 0.04911494255065918,
      "data_citations": 0.00045108795166015625,
      "num_data_pmids_checked": 2
    }
  },
  "40820100": {
    "paper_id": "40820100",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:27.690011",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40820100.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 85.70604062080383,
      "cbioportal_papers": 0.0003209114074707031,
      "platform_mentions": 0.0031690597534179688,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40788171": {
    "paper_id": "40788171",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis of public datasets\nThe Cancer Genome Atlas (TCGA, RRID:SCR_003193) Prostate Adenocarcinoma (TCGA-\nPRAD) and SU2C/PCF Dream Team datasets were retrieved from the cBioPortal (http://\nwww.cbioportal.org/) for Cancer Genomics",
      "According to the above datasets, comparative\nexpression and survival analysis were performed with cBioPortal (RRID:SCR_014555),\nGene Expression Profiling Interactive Analysis (GEPIA, SCR_018294) and Prostate Cancer\nTranscriptome Atlas (PCTA) bioinformatic tools",
      "For public datasets analysis, TCGA-PRAD and SU2C/PCF\nDream Team datasets were retrieved from the cBioPortal (http://www.cbioportal.org/) for\nCancer Genomics",
      "There is no code used in this article, and the comparative expression\nand survival analysis were performed with cBioPortal, GEPIA and PCTA bioinformatic\ntools"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:28.862078",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40788171.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.65245795249939,
      "cbioportal_papers": 0.0003609657287597656,
      "platform_mentions": 0.004103899002075195,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40795068": {
    "paper_id": "40795068",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "5Division of Hematology/\n(\u223c1\u20134% of tumors, via cBioPortal; refs",
      "This finding indicates\nCBioPortal (16\u201318)]",
      "Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A,\ngrative analysis of complex cancer genomics and clinical profiles using the et al. Activated d16HER2 homodimers and SRC kinase mediate optimal effi-\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:29.242955",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40795068.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 39.30936121940613,
      "cbioportal_papers": 0.0003650188446044922,
      "platform_mentions": 0.0032520294189453125,
      "data_citations": 0.0002617835998535156,
      "num_data_pmids_checked": 2
    }
  },
  "40765578": {
    "paper_id": "40765578",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "FrontiersinGenetics 01 frontiersin.org\n\nJineshandGodwin 10.3389/fgene.2025.1569403\nMethods\ngroup patient IDs were fed into cBioPortal as groups, and the\nmutation data for driver mutations and variants of unknown\nTCGA skin cutaneous melanoma (SKCM) significance (VUS) were examined",
      "The RNA-Seq dataset was processed as cBioPortal: SKCM 450 k methylation\ndescribed previously (Jinesh et al., 2024a)",
      "Briefly, the\nFLG + FLG2 filaggrinHigh versus FLG + FLG2 filaggrinLow (n = 450 k methylation data of TCGA SKCM samples were accessed\n47 each) groups of equal size within sets to have equal statistical through cBioPortal (https://www.cbioportal.org/) (Cerami et al.,\npower.Furtherdetailsregardingthenumberofpatientspergroup 2012; Gao et al., 2013)",
      "TheC1-positionalsetenrichmentsweresortedbasedonNESs,\nandthetopupregulatedsignaturewasexaminedforfilaggrinsand\nassociated gene identities using GraphPad Prism v.7.04 (La Jolla,\ncBioPortal: SKCM FLG and FLG2 mutation CA, United States)",
      "analysis Rcode:\nSKCMmutationdataforFLGandFLG2wereobtainedthrough library(ggplot2)\ncBioPortal (https://www.cbioportal.org/) (Cerami et al., 2012; Gao ggplot(DFname, aes(x = Xgroup, y=YGeneset)) +\netal.,2013).Briefly,SKCMFLG+FLG2filaggrinHighandfilaggrinLow geom_point(aes(size =NegativeFRDqValue, color =NES)) +\nFrontiersinGenetics 02 frontiersin.org\n\nJineshandGodwin 10.3389/fgene.2025.1569403\nscale_color_gradientn(colors=c(\u201cmagenta,\u201d\u201csteelblue,\u201d\u201cblack,\u201d expression, genetics, microbes and immunity, and chemicals and\n\u201cwhite,\u201d \u201cbrown,\u201d \u201cred,\u201d\u201cyellow\u201d), drugs",
      "The p-values were based on cBioPortal\nThe dotplot and scale were composited in Adobe Photoshop analysis",
      "FrontiersinGenetics 03 frontiersin.org\n\nJineshandGodwin 10.3389/fgene.2025.1569403\nFIGURE1\nFilaggrin-basedexpressionprofilingrevealstheunderpinningsofthesignalingandimmunecontextoffilaggrinHighmelanomas.(A)Kaplan\u2013Meier\ncurvesofFLG(top)andFLG2(bottom)-basedclassificationsofmelanoma.(B)CorrelationanalysisofFLGandFLG2expressioninmelanomas.(C)\ncBioPortal-baseddriverandvariantsofunknownsignificance(*VUS)mutationsbetweenfilaggrinHigh/Lowgroupsofmelanomas.(D)Methylationversus\nmRNAexpressionvolcanoplotshowingFLGandFLG2(redellipsemarks)atthehighlymethylatedsubset.(E)GSEAoffilaggrinHigh/LowRNA-Seqdata",
      "Integrative analysis of complex cancer genomics and clinical profiles using the\nDermatology87(2),458\u2013460.doi:10.1016/j.jaad.2021.09.068 cBioPortal.Sci.Signal6(269),pl1.doi:10.1126/scisignal.2004088\nBachert,C.,Humbert,M.,Hanania,N.A.,Zhang,N.,Holgate,S.,Buhl,R.,etal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:32.514657",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40765578.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 3.2510669231414795,
      "cbioportal_papers": 0.0001590251922607422,
      "platform_mentions": 0.00156402587890625,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40777438": {
    "paper_id": "40777438",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data sources\nWe sourced clinicogenomic data from (i) eight published datasets hosted by cBioPortal\n[48\u201356], (ii) The Cancer Genome Atlas dataset hosted on Genomic Data Commons [57], and\n(iii) 108 samples sequenced at Yale University [58]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:34.659588",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40777438.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 28.7002592086792,
      "cbioportal_papers": 0.00020575523376464844,
      "platform_mentions": 0.0017049312591552734,
      "data_citations": 0.0007121562957763672,
      "num_data_pmids_checked": 10
    }
  },
  "40777024": {
    "paper_id": "40777024",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "downloaded alteration data including Copy number alteration\nTo date, the Consensus Molecular Subtypes (CMS) framework (CNA) and Somatic mutation counts from the cbioportal online\nclassifies CRC into four groups\u2014CMS1 (immune), CMS2 (canonical/ tool (https://www.cbioportal.org) (21)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:35.132092",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40777024.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.931296110153198,
      "cbioportal_papers": 0.0002818107604980469,
      "platform_mentions": 0.003183126449584961,
      "data_citations": 8.106231689453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40770093": {
    "paper_id": "40770093",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:36.188397",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40770093.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.46753978729248,
      "cbioportal_papers": 0.00036978721618652344,
      "platform_mentions": 0.0021419525146484375,
      "data_citations": 0.00015592575073242188,
      "num_data_pmids_checked": 1
    }
  },
  "40766638": {
    "paper_id": "40766638",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:37.121549",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40766638.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.256453275680542,
      "cbioportal_papers": 0.00031375885009765625,
      "platform_mentions": 0.0025358200073242188,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40760233": {
    "paper_id": "40760233",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "HO-3867's selective inhibition of mutant p53 and abil-\nity to induce apoptosis in ovarian cancer cells make it The TCGA PanCancer Atlas data were accessed and\na promising agent for targeting a broader patient popu- retrieved from cBioPortal (https://w ww.c biopo rtal.o rg/) [21,\nlation",
      "Patients with high TP53 expression (red line) exhib-\non TCGA \u201cCancer Type Detailed\u201d annotations using cBioPortal",
      "Analysis of The Cancer Genome Atlas\nProtein levels of phospho-p53 (Ser15), total p53, and the downstream (TCGA; cbioportal.com) data reveals significant variability\neffector p21 were assessed",
      "Raab M, Kostova I, Pena-Llopis S, Fietz D, Kressin M, Aberou- SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander\nmandi SM, Ullrich E, Becker S, Sanhaji M, Strebhardt K (2024) C, Schultz N (2013) Integrative analysis of complex cancer\nRescue of p53 functions by in vitro-transcribed mRNA impedes genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:40.430513",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40760233.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.912102937698364,
      "cbioportal_papers": 0.0003528594970703125,
      "platform_mentions": 0.0031828880310058594,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40744688": {
    "paper_id": "40744688",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Xie, et al., \u201cConstruction and Validation of a\nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d Ferroptosis- Related Prognostic Model for Gastric Cancer,\u201d Journal of\nScience Signaling 6 (2013): pl1"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:40.950728",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40744688.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 5.809478044509888,
      "cbioportal_papers": 0.00024700164794921875,
      "platform_mentions": 0.0021979808807373047,
      "data_citations": 2.7179718017578125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40738882": {
    "paper_id": "40738882",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:41.967219",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40738882.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 5.766394853591919,
      "cbioportal_papers": 0.0002968311309814453,
      "platform_mentions": 0.0021660327911376953,
      "data_citations": 0.00011324882507324219,
      "num_data_pmids_checked": 1
    }
  },
  "40723248": {
    "paper_id": "40723248",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Inthisstudy,weconductedananalysisutilizingdatafromTheCancerGenomeAtlas\n(TCGA)andemployedvarioustools,includingGeneOntology(GO),theKyotoEncyclope-\ndiaofGenesandGenomes(KEGG),andreceiveroperatingcharacteristic(ROC)curves,to\nidentifyandselectthetargetgene,namelyEnoyl-CoAHydrataseAnd3-HydroxyacylCoA\nDehydrogenase(EHHADH),ageneassociatedwithmetabolismthatexhibitsco-expression\nwithMICAinHCC.Subsequently,weutilizedgeneexpressionprofilinginteractionanalysis\n(GEPIA),thecBioCancerGenomicsPortal(cBioportal),andtheTumorImmuneEstimation\nResource(TIMER)toassesstheexpressionlevelsandprognosticsignificanceofEHHADH",
      "Furthermore,thecBioPortal(http://www.cbioportal.org/),afreelyaccessibledatabase\nthatconsolidatesresearchdatafromvarioussources,includingTCGA[23],wasutilized",
      "Cancers2025,17,2365 20of23\nAbbreviations\nAOD Averageopticaldensity\nBP Biologicalprocess\ncBioportal cBioCancerGenomicsPortal\nCC Cellularcomponent\nCEG Co-expressiongenes\nCNV Copynumbervariation\nDAB 3,3\u2032-diaminobenzidine\nDAP10 DNAX-ActivationProtein10\nDEG Differentiallyexpressedgene\nEHHADH Enoyl-CoAHydrataseAnd3-HydroxyacylCoADehydrogenase\nFAO Fattyacidoxidation\nFAS Fattyacidsynthesis\nFBS Fetalbovineserum\nFFA Freefattyacid\nGEPIA GeneExpressionProfilingInteractionAnalysis\nGO GeneOntology\nHCC Hepatocellularcarcinoma\nHPA TheHumanProteinAtlas\nIHC Immunohistochemistry\nIL Interleukin\nKEGG KyotoEncyclopediaofGenesandGenomes\nLPS Lipopolysaccharide\nMF Molecularfunction\nMHC Majorhistocompatibilitycomplex\nMICA MajorhistocompatibilitycomplexclassIpolypeptide-relatedsequenceA\nMRGs Metabolism-relatedgenes\nNC Negativecontrol\nNKG2D Naturalkillergroup2,memberD\nPCA Principalcomponentanalysis\nPCs Principalcomponents\nPMA Phorbol12-myristate13-acetate\nPPP Pentosephosphatepathway\nqRT-PCR Quantitativereal-timePCR\nROC Receiveroperatingcharacteristic\nscRNA-seq Single-cellRNAsequence\nTAM Tumor-associatedmacrophages\nTCA Tricarboxylicacidcycle\nTCGA TheCancerGenomeAtlas\nTIMER TumorIMmuneEstimationResource\nTME Tumormicroenvironment\nReferences\n1"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:43.696860",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40723248.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.565134048461914,
      "cbioportal_papers": 0.0002760887145996094,
      "platform_mentions": 0.0026700496673583984,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40723207": {
    "paper_id": "40723207",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:47.499488",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40723207.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.0559000968933105,
      "cbioportal_papers": 0.0002918243408203125,
      "platform_mentions": 0.002048015594482422,
      "data_citations": 0.0003020763397216797,
      "num_data_pmids_checked": 3
    }
  },
  "40719984": {
    "paper_id": "40719984",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "4.3 Genetic variation analysis\nThe cBio Cancer Genomics Portal (c-BioPortal) (https://www.cbioportal.org/) is a w e b - b\na s e d tool for genetic alteration analysis [25]",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:48.614401",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40719984.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 4.914396047592163,
      "cbioportal_papers": 0.00019693374633789062,
      "platform_mentions": 0.0023860931396484375,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40721593": {
    "paper_id": "40721593",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Co-occurrence and co-expression analysis\nThe examination of co-occurrence and mutual exclusivity was conducted utilizing cBioPortal platform (version\n1.3.2, developed by the Memorial Sloan Kettering Cancer Center in New York)43",
      "Copy number variation (CNV) analysis\nCopy number variation data for CDKN2A, CDKN2B, and TERT in the TCGA-LGG and TCGA-GBM cohorts\nwere obtained from cBioPortal or directly from the TCGA GDC data portal",
      "Co-occurrence and co-expression characteristics of CDKN2A, CDKN2B, and CDKN2B-AS1 in\nbrain cancer\nUsing cBioPortal, we compared the genetic alterations of CDKN2A, CDKN2B, and CDKN2B-AS1 in three\ncohorts: TCGA-LGG, TCGA-GBM, and CPTAC-Glioma"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:48.886259",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40721593.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 6.906458139419556,
      "cbioportal_papers": 0.00042176246643066406,
      "platform_mentions": 0.003493070602416992,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40703801": {
    "paper_id": "40703801",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "GBM\u201d made available by The Cancer Genome Atlas using As per our study, previous literature suggests a posi-\ncBioPortal.7 By selecting only samples with IDH1/2 mutations tive association between MRI enhancement and grade in\n\u00a9 The Author(s) 2025",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:49.093088",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40703801.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 1.5861842632293701,
      "cbioportal_papers": 4.482269287109375e-05,
      "platform_mentions": 0.0005049705505371094,
      "data_citations": 1.7881393432617188e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40722474": {
    "paper_id": "40722474",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A notable application of cBioPortal is the OncoPrint, a compact heatmap-like vi-\nsualisation tailored to summarise genetic alterations across patient cohorts [27]",
      "In a German case study, cBioPortal [29] was successfully integrated into hospital\ninformationsystems,enablingdirectaccesstoEHRsandlaboratorydatabases,effectively\ntransformingtheplatformintoaClinicalDecisionSupportSystem(CDSS)forprecision\noncology"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:40:49.581914",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40722474.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.604069948196411,
      "cbioportal_papers": 0.0002899169921875,
      "platform_mentions": 0.0020411014556884766,
      "data_citations": 9.775161743164062e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40704992": {
    "paper_id": "40704992",
    "cbioportal_paper_citations": [
      "1158/2159-8290.CD-12-0095, PMID: 22588877\nChandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce- Rodriguez I, Chakravarthi BVSK,\nVarambally S",
      "DOI: https://doi.org/10.1126/scisignal.2004088, PMID: 23550210\nGoswami CP, Nakshatri H"
    ],
    "cbioportal_platform_mentions": [
      "(A) YTHDF2- RNA complexes were identified by LC- MS/MS and collected from reference; YTHDF2 correlated genes were collected from\nTNMplot (https://tnmplot.com/analysis/), Gene: YTHDF2, Gene vs. all genes correlation: Genechip data, Tissue: Lung; STAT3 correlated genes were\ncollected from cBioPortal (http://www.cbioportal.org/), Lung cancer (SMC, cancer research 2016); n=22; Gene: STAT3",
      "Integrative analysis of complex cancer genomics and clinical profiles using the\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:33.292555",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40704992.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 45.964322090148926,
      "cbioportal_papers": 0.0031087398529052734,
      "platform_mentions": 0.004164934158325195,
      "data_citations": 5.507469177246094e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40702751": {
    "paper_id": "40702751",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Copy number alteration (CNA) data for PDL1 in ADC cell proliferation, we first assessed PDL1 expression in\ncancer patients were also retrieved from TCGA via cBioPortal",
      "(D) Distribution of PDL1 copy number alterations\u2013amplification,\nnormal, and deletion\u2013across multiple cancer types, based on cBioPortal data",
      "Dogrusoz, et al., \u201cIntegrative Analysis of\nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d 45"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:33.531165",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40702751.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 44.914236068725586,
      "cbioportal_papers": 0.0002219676971435547,
      "platform_mentions": 0.002076864242553711,
      "data_citations": 9.322166442871094e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40701956": {
    "paper_id": "40701956",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "investigated whether expression of CypD, the regulator of mPTP The hallmark features of EMT, including loss of E-cadherin\nopening,16affectssurvivalofmelanomapatients.AnalysisofRNA expression and the gain of expression of N-cadherin, vimentin,\nsequencing (RNA-seq) data from melanoma patients with Snail,andTwist,wereconfirmedinCypDKDcellsundernormoxic\nmetastases obtained from the cBioPortal database (http:// conditions (Fig",
      "Snail and Twist\nwww.cbioportal.org)20,21 revealed that patients with low expres- are key transcription factors that induce EMT by reducing cell\nsionofCypDintheprimary tumorhaveapoorer prognosis than adhesionandepithelium-maintainingsignalsthroughtheregula-\nthose with high expression (Fig",
      "3\nFig.1 CypDexpressionandmelanomametastasis.aCypDexpressionandoverallsurvivalofmelanomapatientswithmetastasis.DFCI86and\nTCGA87 data were downloaded from the cBioPortal database (http://www.cbioportal.org).20,21 Overall survival rates in the high CypD\nexpressiongroup(top25%ofpatients)andlowCypDexpressiongroup(bottom25%ofpatients)wereanalyzedandplottedasKaplan-Meier\ncurves.bExpressionofCypDinnon-metastatic(StageII)andmetastaticmelanomapatients(StageIII).TCGA88datawereobtainedfromthe\ncBioPortaldatabaseandcomparedwithrespecttoCypDexpression.cExpressionofmitochondrialchaperonesinmetastatictumors.Datasets\nfrompatientswithmetastatic(n=41)andnon-metastatic(n=40)skincancerwereobtainedfromtheGeneExpressionOmnibusdatabase84\n(GSE7553),andmRNAlevelsofmitochondrial chaperoneswerecompared.Theresultsarepresentedasdotplots.dImmunohistochemical\n(IHC)andhematoxylin&eosin(H&E)stainingofprimarytumortissuesfrommelanomapatients.H&EandIHCstainingusingaCypDantibody\nwereperformedonnon-metastatic(n=5)andmetastaticprimarytumors(n=12)(left).CypDexpressionwasquantifiedusingImageJ(right)",
      "Tumorallograft, xenograft, and metastasis models inmice GEO dataand statistical analyses\nAnimaltumorallograftandxenograftexperimentswereapprovedby Survivaldataforpatientswithmetastaticmelanomawereretrieved\ntheUNIST(UNISTIACUC-16-27,UNISTIACUC-20-02).ControlorCypD- from the cBioPortal database (http://www.cbioportal.org).20,21\noverexpressing B16F10 cells (100\u03bcL, 2\u00d7105 cells) were injected mRNA expression array data from human melanoma patients,\nsubcutaneously into the footpads of C57BL/6 mice"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:35.700036",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40701956.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 46.80884289741516,
      "cbioportal_papers": 0.0003809928894042969,
      "platform_mentions": 0.004093170166015625,
      "data_citations": 0.00027632713317871094,
      "num_data_pmids_checked": 2
    }
  },
  "40698865": {
    "paper_id": "40698865",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The TCGA pan cancer data comes tionsidentifyprognosticsubgroupsofmicrosatellitestablecol-\nfrom the TCGA database, and the validation set data comes orectalcancer.MolCancer2024;23:264.https://doi.org/10.1186/\nfrom literature search,DepMap,and cBioPortal data boxes.The s12943-024-02173-x"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:35.867464",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40698865.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 46.265995025634766,
      "cbioportal_papers": 0.00026106834411621094,
      "platform_mentions": 0.001983165740966797,
      "data_citations": 0.0001888275146484375,
      "num_data_pmids_checked": 2
    }
  },
  "40691172": {
    "paper_id": "40691172",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:38.737592",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40691172.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 2.8680601119995117,
      "cbioportal_papers": 0.00010800361633300781,
      "platform_mentions": 0.001107931137084961,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40699790": {
    "paper_id": "40699790",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortalGenomicProfiling\nThecBioPortalresource(https://www.cbioportal.org/accessedon4November2024),\ndesignedforcancergenomicsexploration[22],enabledananalysisoftheFBXO10genomic\nalterationsinHCCusingtheCLCA(Nature2024)dataset"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:39.080727",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40699790.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 49.9852831363678,
      "cbioportal_papers": 0.0002009868621826172,
      "platform_mentions": 0.0019850730895996094,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40694543": {
    "paper_id": "40694543",
    "cbioportal_paper_citations": [
      "2012;2(5):401\u20134.https://doi.org/10.1158/2159-8290.CD-12-0095PMID:22588877\n16",
      "https://doi.org/10.1126/scisignal.2004088PMID:23550210\n17",
      "https://doi.org/10.1126/scisignal.2004088PMID:23550210\n18"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:41.072554",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40694543.pdf",
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.522735118865967,
      "cbioportal_papers": 0.0016980171203613281,
      "platform_mentions": 0.0014510154724121094,
      "data_citations": 3.814697265625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40696096": {
    "paper_id": "40696096",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis of patient tumor gene expression data\nThe RNA sequencing (RNA\u2010seq) log V2 RSEM expression data for the Breast Invasive Carcinoma (Cell 2015)\n2\nfrom The Cancer Geneome Atlas (TCGA were accessed via cBioportal and patients were specifically identified\nfrom the clinical data28,29",
      "Gene array expression data from the Breast Cancer Molecular Taxonomy of Breast\nCancer International Consortium (METABRIC) dataset was also accessed via cBioportal and TNBC patients\nspecifically identified30",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:42.569048",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40696096.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.271167039871216,
      "cbioportal_papers": 0.00045108795166015625,
      "platform_mentions": 0.0041599273681640625,
      "data_citations": 0.00029587745666503906,
      "num_data_pmids_checked": 2
    }
  },
  "40694159": {
    "paper_id": "40694159",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal, with bar plots generated to display the altera- AutoDock software was then employed to obtain the PDBQT\ntion rates",
      "and TIMER2.0 database to explore the association between\nFor a further insight into the mutational characteristics DNAJB4 expression an immune cell infiltration in pan-can-\nof DNAJB4, we utilized the cBioportal database to exam- cer",
      "Gao J, et al. Integrative analysis of complex cancer genomics and patients with unresectable hepatocellular carcinoma: a randomised\nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:43.306974",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40694159.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 7.590227127075195,
      "cbioportal_papers": 0.00036787986755371094,
      "platform_mentions": 0.003381013870239258,
      "data_citations": 0.00014209747314453125,
      "num_data_pmids_checked": 1
    }
  },
  "40687655": {
    "paper_id": "40687655",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "from the cBioPortal database (16) (https://www.cbioportal",
      "Sun Z, Jing C, Xiao C, et al. An autophagy-related long cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:50.976229",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40687655.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.892416954040527,
      "cbioportal_papers": 0.0003032684326171875,
      "platform_mentions": 0.0024929046630859375,
      "data_citations": 0.00011110305786132812,
      "num_data_pmids_checked": 1
    }
  },
  "40678577": {
    "paper_id": "40678577",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "illustrated descriptively using an OncoPrint (generated by cBioPortal\nOncoPrinter) (Gao et al., 2013; Cerami et al., 2012)",
      "Integrative analysis of complex cancer\ngenomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:52.061431",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40678577.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.751129150390625,
      "cbioportal_papers": 0.00019311904907226562,
      "platform_mentions": 0.001811981201171875,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40682838": {
    "paper_id": "40682838",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The processing analyzed through cBioportal (39) including CCA (Fig"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:55.683931",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40682838.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.593515157699585,
      "cbioportal_papers": 0.0005269050598144531,
      "platform_mentions": 0.004685163497924805,
      "data_citations": 1.5974044799804688e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40679044": {
    "paper_id": "40679044",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Keywords: Glioma,EMTmarker,NOTCH1,SOX2,progression,WHOgrade,cBioPortal,GlioVis,quantitativereal-timepolymerase\nchainreaction,qRT-PCR",
      "The current reference version of the human genome utilized\nData from multiple studies available in the cBioPor- by cBioPortal is hg19/GRCh37",
      "The observed changes reported in cBioPortal were differencebetweenthecopynumberofthetumorgeneandthe\nvalidated through additional database searches and quanti- reference.NormalizedcontinuousCNAvalueswereprocessed\ntative real-time polymerase chain reaction (qRT-PCR)",
      "classifiedasdeepdeletions(indicatingahomozygousdeletion),\nwhilevaluesof\u22121representedshallowdeletions(indicatinga\nheterozygousdeletion).SampleswithacontinuousCNAvalue\nMaterialsandmethods of 0 were designated as diploid, with no gene copy number\ncBioPortal changes.Avalueof1indicatedalow-levelgain(afewadditional\nTheanalysisofselectedgenesingliomasofvariouspathohis- copies,oftenbroad),andamplificationswerecharacterizedby\ntologicaltypesandgradeswasconductedusingdatafromThe avalueof2,indicatinghigh-levelamplification(morecopies,\ncBioPortal for Cancer Genomics database [14,15]",
      "Specifically, Biosystems #4388950) was used to reverse-transcribe equal\nthe RNASeq V2 data in cBioPortal corresponds to the amountsofRNAafterithadbeentreatedwithDNaseI(Sigma-\nrsem.genes.normalized_resultsfilefromTCGA.Amoredetailed Aldrich#EN0521).EachsamplewassubjectedtoqRT-PCRanal-\nexplanation of RSEM output can be found at https://www",
      "Within cBioPortal, the extractedasdescribedinearlierstudies[27].Foreachsample,\nproteindatawereadditionallyprocessedandnormalizedwith 500ngoftotalRNAwastreatedwithDNaseI(Roche)at30\u00b0C\nthecalculationofthez-scoresandconvertedtothelogscale",
      "dendroglioma.Mutationswerepresentinonly0.24%and0.17%\nData retrieved from the publicly available cBioPortal of GBM and diffuse glioma, respectively",
      "comparingourqRT-PCRresultstobothdatabases,weobserved\nthat expressions were compatible for the majority of genes\n(Table2).CTNNB1roseinhighergrades,whichwascompatible\nwithdatafromGlioVis.BothNOTCH1andSOX2expressionfell\ninhighergrades,whichwascompatiblewithGlioVisandcBio-\nPortal.TJP1/ZO-1waslowinbothgroups,lowerthancontrols,\nand this was in accordance with both cBioPortal and GlioVis\nand was biologically logical",
      "VIM and TWIST1 qRT-PCR levels\nwere concordant with both GlioVis and cBioPortal",
      "Samples from the controls,whichwasdifferentfromGlioVis.However,ZEB2was\nGlioblastomaMultiformestudy(TCGA,FirehoseLegacy)wereobtainedby compatible with GBM high expression reported in cBioPor-\nnext-generationsequencingfromRNASeqV2RSEManddownloadedfrom\ntal.LEF1wasalsonotcompatiblewiththedatabases.qRT-PCR\ncBioPortal.TCGA:TheCancerGenomeAtlas"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:41:55.819922",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40679044.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 10,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.234567880630493,
      "cbioportal_papers": 0.0002827644348144531,
      "platform_mentions": 0.0020961761474609375,
      "data_citations": 0.0007660388946533203,
      "num_data_pmids_checked": 8
    }
  },
  "40673101": {
    "paper_id": "40673101",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Oweida A, Sharifi Z, Halabi H, et al. Differential cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:00.377820",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40673101.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.31396198272705,
      "cbioportal_papers": 0.000225067138671875,
      "platform_mentions": 0.001947164535522461,
      "data_citations": 8.797645568847656e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40690678": {
    "paper_id": "40690678",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:01.282596",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40690678.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 22.471731901168823,
      "cbioportal_papers": 0.0002932548522949219,
      "platform_mentions": 0.0027320384979248047,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40678154": {
    "paper_id": "40678154",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Cell culture\nTo further investigate the mutation status of gene OTUD6B-AS1 in The human breast cancer and normal cell lines were purchased from\ntumors, we utilized both database Cbioportal [27] and TCGA to analyze the Shanghai Institute of Biochemistry and Cell Biology, Chinese Acad-\nthe genomic alteration data of OTUD6B-AS1 in tumors, with a particular emy of Sciences (Shanghai, China)",
      "Dogrusoz, et al., Integrative analysis of complex cancer\ngenomics and clinical profiles using the cBioPortal, Sci"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:01.630249",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40678154.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.622381925582886,
      "cbioportal_papers": 0.00020122528076171875,
      "platform_mentions": 0.002006053924560547,
      "data_citations": 8.344650268554688e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40668891": {
    "paper_id": "40668891",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Processed data was downloaded from cbioportal.com (51) and plotted using GraphPad Prism\n9"
    ],
    "data_publication_citations": {
      "26909576": [
        "[PubMed: 26909576]\n24"
      ]
    },
    "extraction_date": "2025-12-19T18:42:03.943114",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40668891.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.228404998779297,
      "cbioportal_papers": 0.00034880638122558594,
      "platform_mentions": 0.0031290054321289062,
      "data_citations": 0.026801109313964844,
      "num_data_pmids_checked": 1
    }
  },
  "40668814": {
    "paper_id": "40668814",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1126/scisignal.2004088 PMID: 23550210\n22"
    ],
    "cbioportal_platform_mentions": [
      "ysis aids in developing combination and personalized therapies for diverse cancer\nproteinatlas.org), the cBioPortal database\nmodels [4,5]",
      "(https://www.cbioportal.org/), CancerSEA data-\nbase (http://biocc.hrbmu.edu.cn/CancerSEA/), Sterol Regulatory Element-Binding Transcription Factor 1 (SREBF1) is a specific\nand the GEPIA2.0 database (http://gepia2",
      "Genetic alteration analysis\nThe cBioPortal database (https://www.cbioportal.org/) was utilized to gather the data about the alteration frequency,\nmutation type, mutation site information, and threedimensional (3D) structure of SREBF1 in all TCGA databases [21]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:04.087265",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40668814.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.250770092010498,
      "cbioportal_papers": 0.001802206039428711,
      "platform_mentions": 0.0037708282470703125,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40658617": {
    "paper_id": "40658617",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We also\ncell carcinoma (RCC).2 Insertion, deletion, and nonsense perform a gene query analysis of FLCN PVs in TC on\nmutationsleadtoprematuretruncationandlossoffunction cBioPortal(www.cbioportal.org).Ourstudy\u2019sobjectives\nof the FLCN protein.3 Although the precise mechanism is were to report BHD and associated TC and hypothesize\nunclear, FLCN likely functions as a tumor suppressor gene thatFLCNmaybeanoncogenicdriverinTC.Thepatients\n(SupplementaryData).4\u20137 wereenrolledundertheNationalInstitutesofHealthInsti-\nTumors of other sites are rare in BHD; however, colo- tutional Review Board-approved research protocols\nrectal,lung,andbreastcancersandparotidoncocytomashave (77-DK-0096 and 10-DK-0102), and all patients signed\nbeen described.8 Thyroid cancer (TC),although reported,is informedconsent",
      "Biopsyofonepleuralnoduleconfirmedpoorlydifferentiated\nTC(PDTC)bearinghistopathologicalsimilaritytotheinitial FLCNasasomaticdriverinTC\nOTC.Systemictherapywitheverolimusandlenvatinibwas\nWe analyzed 2334 TC samples from 2285 patients with\ninitiated due to rapid disease progression, but everolimus\nPTC,PDTC,andanaplasticTC(ATC)oncBioPortal(www\nwasdiscontinuedduetopneumonitis.Heiscurrentlyunder-\n.cbioportal.org).FLCNPVswerefoundin2%ofalltheTC\ngoingevaluationforimmunecheckpointinhibitortherapy",
      "complex cancer genomics and clinical profiles using the\nCurrUrolRep2011;12(1):47\u201355;doi:10.1007/s11934-010- cBioPortal.2013.Availablefrom:http://www.cbioportal\n0156-y .org/results/oncoprint?gene_list=FLCN&cancer_study_list=\n6"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:04.811876",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40658617.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 3.164736032485962,
      "cbioportal_papers": 0.0001010894775390625,
      "platform_mentions": 0.0013861656188964844,
      "data_citations": 3.981590270996094e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40664642": {
    "paper_id": "40664642",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "GranditsAM,BrombergerS,HellerG,ReinoehlBA,TomasichE,SchossleitnerK,\ncbioportal.org) web portal [36, 37]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:11.742189",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40664642.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.436646223068237,
      "cbioportal_papers": 0.0003838539123535156,
      "platform_mentions": 0.004122018814086914,
      "data_citations": 0.00014209747314453125,
      "num_data_pmids_checked": 1
    }
  },
  "40654790": {
    "paper_id": "40654790",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Herein, we curated missense mutations\noccurring in core histone genes in breast cancers using data from MSK-IMPACT and cBioPortal\nto identify high frequency breast cancer-associated histone gene mutations",
      "We curated\nmissense mutations in core histone genes in breast cancers using the MSK-IMPACT clinical\nsequencing cohort [39] and several other published studies in cBioPortal [40]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:12.310236",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40654790.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.336503028869629,
      "cbioportal_papers": 0.00028204917907714844,
      "platform_mentions": 0.0024471282958984375,
      "data_citations": 0.00011205673217773438,
      "num_data_pmids_checked": 1
    }
  },
  "40654133": {
    "paper_id": "40654133",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "RESULTS\nSomatic mutations in IRE1\u03b1 that occur in NMSC modulate its RNase activity\nExamination of TCGA PanCancer Atlas with cBioPortal (Cerami et al., 2012; Gao et al.,\n2013) revealed that IRE1\u03b1 is altered in 3% of all human cancers with amplification being\nthe most frequent genomic change followed by somatic missense mutations that occur at\na frequency of 1.3% (Fig"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:13.191813",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40654133.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.376258134841919,
      "cbioportal_papers": 0.00036215782165527344,
      "platform_mentions": 0.0031168460845947266,
      "data_citations": 1.3828277587890625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40665008": {
    "paper_id": "40665008",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:14.908589",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40665008.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.50330376625061,
      "cbioportal_papers": 0.0003638267517089844,
      "platform_mentions": 0.0004801750183105469,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40654626": {
    "paper_id": "40654626",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:20.133818",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40654626.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.039108991622925,
      "cbioportal_papers": 0.00035881996154785156,
      "platform_mentions": 0.00043892860412597656,
      "data_citations": 0.00037598609924316406,
      "num_data_pmids_checked": 3
    }
  },
  "40653567": {
    "paper_id": "40653567",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "3.5 Immunohistochemical analysis and mutation prediction\nWe examined the incidence and kind of Hub gene mutations as well as how these mutations affected patient outcomes\nusing the cBioPortal (http://c biopo rtal.o rg)",
      "4.3 Mutational analysis of hub genes\nThe cBioPortal cancer meta-database was queried for the mutational expression study of ten protein-coding genes",
      "In our work, deep deletion, amplification\nand missense mutation was identified in ECA patients from CBioPortal tool",
      "CALML3 is another oncogenic gene found in ECA but our studies didn\u2019t find specific mutation from Cbioportal",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:23.132169",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40653567.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.383649826049805,
      "cbioportal_papers": 0.0002770423889160156,
      "platform_mentions": 0.002462148666381836,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40640880": {
    "paper_id": "40640880",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cer International Consortium (METABRIC, n = 320) via\nThe resulting dcc files from each AOI were further cBioPortal [15, 16], and the Sweden Cancerome Analysis\nimported and analysed using the GeoMxTools R pack- Network - Breast (SCAN-B, n = 333) dataset, available\nage (v3.8.0)",
      "Approval was granted by the Ethics Committee cBioPortal complementary data sources and analysis options"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:23.672726",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40640880.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.477046012878418,
      "cbioportal_papers": 0.0003039836883544922,
      "platform_mentions": 0.0026900768280029297,
      "data_citations": 0.00010585784912109375,
      "num_data_pmids_checked": 1
    }
  },
  "40640336": {
    "paper_id": "40640336",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "lines relevant to chemotherapy drug responses and cancers with\nFor analysis of TCGA datasets, the cBioPortal in-built Wilcoxon Test elevatedRNaseH2subunitlevels[29,32].mRNAexpressionofat\nwasused"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:25.525945",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40640336.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.569578170776367,
      "cbioportal_papers": 0.0003819465637207031,
      "platform_mentions": 0.0029840469360351562,
      "data_citations": 0.00014090538024902344,
      "num_data_pmids_checked": 1
    }
  },
  "40646089": {
    "paper_id": "40646089",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The mutation frequency of LAG3 in\nthe TCGA cohort was calculated using the cBioPortal database (https://www.cbioportal.org/)25",
      "The cBioPortal (http://www.cbioportal.org) website is a powerful tool from which to search for LAG3\nmutation frequencies, types, copy number alteration data, and genetically altered traits31",
      "Pan-cancer variants of the LAG3 gene were assessed using the\ncBioPortal (TCGA, Pan-Cancer Atlas) database"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:25.934939",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40646089.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.582313776016235,
      "cbioportal_papers": 0.0002429485321044922,
      "platform_mentions": 0.0027039051055908203,
      "data_citations": 0.00018095970153808594,
      "num_data_pmids_checked": 2
    }
  },
  "40636694": {
    "paper_id": "40636694",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.3 Genetic alteration analysis of ZNF433 2.5 Correlation analysis between ZNF433\nacross cancers expression and genomic features (TMB/\nMSI)\nWe logged into the cBioPortal website (https://\nwww.cBioPortal.org/) and selected \u201cTCGA PanCancer Atlas We analyzed the Spearman correlation between ZNF433\nStudies\u201d in the \u201cQuick Select\u201d section (27, 28)",
      "We further examined the mutation sites using the TMB levels are strongly associated with improved efficacy in\n\u201cMutations\u201d module in cBioPortal",
      "According to the analysis\nresults,itisshownthatinnormaltesticulartissue,ZNF433exhibits We assessed the genetic alteration status of the ZNF433 gene\nhighstainingintensity,whileinnormalliverandkidneytissue,its using the cBioPortal database, examining mutations, structural\nstaining level is moderate",
      "characterization of ZNF433 across various cancers, delineating its\nGenetic alteration analysis via cBioPortal identified ZNF433 potential in diagnostic, prognostic, and personalized treatment\nmutationsandamplificationsacrossmultiplecancers.Notably,OV applications",
      "Additionally, we thank the UCSC Xena, TheSupplementaryMaterialforthisarticlecanbefoundonline\nTCGA,GTEx,HPA,cBioPortal,TIMER2,GEPIA2,UALCAN,and at:https://www.frontiersin.org/articles/10.3389/fonc.2025.1584042/\nSTRINGdatabasesforprovidingvaluabledataresources"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:31.775946",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40636694.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.627317905426025,
      "cbioportal_papers": 0.0003211498260498047,
      "platform_mentions": 0.003284931182861328,
      "data_citations": 0.0002200603485107422,
      "num_data_pmids_checked": 2
    }
  },
  "40624624": {
    "paper_id": "40624624",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In addition, a time-dependent ROC curve\nexplored in cBioPortal (https://www.cbioportal.org/) was plotted using this web tool"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:34.419364",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40624624.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.883563041687012,
      "cbioportal_papers": 0.00026297569274902344,
      "platform_mentions": 0.0031299591064453125,
      "data_citations": 9.298324584960938e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40616171": {
    "paper_id": "40616171",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutation types and frequen-\nFor target gene selection, we applied thresholds of log cies were analyzed using cBioPortal (http:// www",
      "Through the cantly correlated with TMB in three types of tumors,\ncBioPortal platform, we analyzed the mutations of the including COAD, STAD and READ (Fig",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Inte- analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined\ngrative analysis of complex cancer genomics and clinical profiles using immunotherapy in patients with muscle-invasive bladder cancer: a multi-\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:42.541659",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40616171.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.743848085403442,
      "cbioportal_papers": 0.0002689361572265625,
      "platform_mentions": 0.002440929412841797,
      "data_citations": 0.00011277198791503906,
      "num_data_pmids_checked": 1
    }
  },
  "40612943": {
    "paper_id": "40612943",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Depth of anesthesia was\nconfirmedbylossofreflexesandslowedrespiration.Tumorvolume\nwasmeasuredeverythreedaysusingcalipersandcalculatedas0.5\u00d7\nGEPIA2, cBioPortal analysis\nlength\u00d7width\u00b2.Onday21,micewereeuthanizedviaCO inhalation\n2\n(30\u201350% chamber volume/min), followed by cervical dislocation to\nAcorrelativeprognosticanalysisofSNRPB2fromtheGEPIA2 confirmdeath.Tumorswereharvested,photographed,andweighed",
      "Randomization was performed using a random\ncbioportal.org) served as an open online resource for visualizing\nnumbertable.Blindingwasappliedduringtumormeasurementand\nmultidimensionalcancergenomicsdatasets(15)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:51.374142",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40612943.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.797970056533813,
      "cbioportal_papers": 0.0002658367156982422,
      "platform_mentions": 0.0025920867919921875,
      "data_citations": 5.0067901611328125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40626556": {
    "paper_id": "40626556",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Our study utilized disease-free survival (DFS) informa- cates that a gene is connected to less influential or weakening\ntion of 500 PRAD patients in the \u201cProstate Adenocarcinoma genes, possibly resulting in lower relative influence scores or\n(TCGA, Firehorse Legacy)\u201ddataset [ 15 ] with corresponding reduced significance in the network, such as ANXA1 , GNB3 ,\nclinicopathologic information available on cBioPortal ( https: POMC , GPER1 , and TIMP1 in tumor samples (Fig",
      "// www.cbioportal.org/ ) [ 15 , 16 ]",
      "Mol Oncol\ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:42:56.758418",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40626556.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 33.04096078872681,
      "cbioportal_papers": 0.0004982948303222656,
      "platform_mentions": 0.004083871841430664,
      "data_citations": 0.00014591217041015625,
      "num_data_pmids_checked": 1
    }
  },
  "40610434": {
    "paper_id": "40610434",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Efferocytosis sequesters apoptotic cells from Bioinformatics\nother immune cells, bypasses class II MHC processing and TCGA data were analyzed using cBioportal [33, 34] using the Cell 2013\ndegrades proteins more rapidly than phagocytosis, preventing RNAseqdataset[35].ChineseGliomaGenomeAtlas(CGGA)data[36]were\nantigen presentation [16]",
      "dataset (152 patients) using cBioportal showed significantly\nhigher expression in the mesenchymal subtype (Fig",
      "the following sources: cBioportal https://www.cbioportal.org/;\nTransglutaminase2-/-micerevealaphagocytosis-associatedcrosstalkbetween\nGliovis http://gliovis.bioinfo.cnio.es/; Broad Institute Single Cell\nmacrophagesandapoptoticcells.ProcNatlAcadSciUSA.2003;100:7812\u20137"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:00.043820",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40610434.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 8.659559965133667,
      "cbioportal_papers": 0.0003247261047363281,
      "platform_mentions": 0.0033211708068847656,
      "data_citations": 0.000125885009765625,
      "num_data_pmids_checked": 1
    }
  },
  "40748136": {
    "paper_id": "40748136",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "488 papillary thyroid cancer (PTC; THCA), 112 normal\nbreastand1,197breastcancer(BRCA)samplesfromThe Intriguingly, in addition to a Src-mediated\nCancer Genome Atlas (TCGA) were downloaded from phosphorylation site, PBF-Y174 is the key residue in a\nFireBrowse (http://firebrowse.org/) and cBioPortal tyrosine-basedsortingsignal(YXX\u03c6;Fig.1C)requiredfor\n(https://www.cbioportal.org/) (24, 25)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:18.252940",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40748136.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 163.56921672821045,
      "cbioportal_papers": 0.0003781318664550781,
      "platform_mentions": 0.02349400520324707,
      "data_citations": 0.00010704994201660156,
      "num_data_pmids_checked": 1
    }
  },
  "40607380": {
    "paper_id": "40607380",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "PABPN1 genomic alterations in six\nurogenital cancers\nMicrosatellite instability, neoantigen, and\nESTIMATE of the TME in human cancers The cBio Cancer Genomics Portal (c-BioPortal) (http://\ncbioportal.org) aggregated a multidimensional cancer genomics\nTheassociationbetweenPABPN1expressionandaspectsofthe dataset (30)",
      "The cBioPortal website was utilized to analyze genomic\nalterationsofPABPN1 in urogenitalcancers.Resultsindicatedthat\ngenomic alterations of PABPN1 occurred in 1.1% of patients Analysis of PABPN1 coexpression networks\n(Figure 6A and Supplementary Figure S7)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:23.019882",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40607380.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 26.100093841552734,
      "cbioportal_papers": 0.0003902912139892578,
      "platform_mentions": 0.003912925720214844,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40604275": {
    "paper_id": "40604275",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. ARID1A mutation plus CXCL13 expression act as combinatorial the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:24.027759",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40604275.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.97868299484253,
      "cbioportal_papers": 0.00048732757568359375,
      "platform_mentions": 0.004622697830200195,
      "data_citations": 8.106231689453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40619590": {
    "paper_id": "40619590",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TCGA website (https://www.cancer.gov/tcga.), cBioPortal (http://www",
      "cbioportal.org/),[50] and UCSC Xena (http://www.xena.ucsc.edu/).[51] [5] D.Hanahan,R.A.Weinberg,Cell2011,144,646"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:25.381024",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40619590.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 59.43527913093567,
      "cbioportal_papers": 0.00039887428283691406,
      "platform_mentions": 0.0038781166076660156,
      "data_citations": 0.00013899803161621094,
      "num_data_pmids_checked": 1
    }
  },
  "40604187": {
    "paper_id": "40604187",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The study participant performed a total of 30 tasks in three data portals30\u201332which had failure\nrates of 19.3% (cBioPortal), 2% (ENCODE), and 8.8% (HuBMAP) in our computational evaluation",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:34.069494",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40604187.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.813870191574097,
      "cbioportal_papers": 0.00024890899658203125,
      "platform_mentions": 0.002267122268676758,
      "data_citations": 3.814697265625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40597017": {
    "paper_id": "40597017",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "p\u2011values reflect the significance of each gene\u2019s correlation with overall survival in oral squamous cell carcinoma (OSCC)\npatients\nusing the cBioPortal database [26]",
      "A OncoPrint of IGF2BP2, HNRNPC, TRMT61B, and NAT10 using the cBioPortal database",
      "Oral cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:40.610623",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40597017.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.567903995513916,
      "cbioportal_papers": 0.00032830238342285156,
      "platform_mentions": 0.002959728240966797,
      "data_citations": 0.00011992454528808594,
      "num_data_pmids_checked": 1
    }
  },
  "40596315": {
    "paper_id": "40596315",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Survival and statistical analyses\nTwo prostate cancer datasets, TCGA (PanCancer Atlas)27 and MSKCC (MSK Cancer Cell, 2010)28were\ndownloaded from cBioPortal (https://www.cbioportal.org/ accessed on 28 June 2023)29,30 and respectively\ncontained 333 and 140 prostate cancers that had both mRNA expression data and disease-free survival status",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:44.741208",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40596315.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.33994221687317,
      "cbioportal_papers": 0.0002567768096923828,
      "platform_mentions": 0.003567218780517578,
      "data_citations": 0.00027489662170410156,
      "num_data_pmids_checked": 3
    }
  },
  "40591124": {
    "paper_id": "40591124",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:53.322056",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40591124.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 12.691159963607788,
      "cbioportal_papers": 0.00014901161193847656,
      "platform_mentions": 0.0014050006866455078,
      "data_citations": 5.0067901611328125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40600473": {
    "paper_id": "40600473",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Tools such as cBioPortal (254), Web- Pattern has released GenePattern Notebooks (279), which allow\nMeV (102), Xena (255), and recount (270) attempt to overcome this scientists to insert GenePattern analyses as cells in a Jupyter note-\nby centralizing analysis and preprocessing or public domain data",
      "The cBioPortal for Cancer Genomics (283) and Xena (255)\nplatforms each provide a collection of analysis methods for a variety provide these capabilities for cancer genomics data from TCGA and\nof cancer data modalities, as well as general AI approaches",
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:43:55.069615",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40600473.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 32.009605169296265,
      "cbioportal_papers": 0.0007460117340087891,
      "platform_mentions": 0.020904064178466797,
      "data_citations": 2.09808349609375e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40590989": {
    "paper_id": "40590989",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "https://d oi.o rg/1 0.1 038/n bt.4 195\nics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:00.728323",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40590989.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.976032018661499,
      "cbioportal_papers": 0.0004870891571044922,
      "platform_mentions": 0.0042378902435302734,
      "data_citations": 0.00017905235290527344,
      "num_data_pmids_checked": 1
    }
  },
  "40589937": {
    "paper_id": "40589937",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Information about the number-at-risk cases, were obtained from the online CBioPortal for Cancer\nmedian values of the mRNA expression level, HRs, 95% Genomics (http://www.cbioportal.org), which is an open\nCIs, and p-values can be found on the K-M Plotter web- resource tool for analysis and visualization of multiple\nsite",
      "Alteration frequency of MEF2 family members in NSCLC (cBioPortal)",
      "NSCLC\nRelationship Between MEF-2 Family Members and\nWe evaluated the genetic alterations of MEF-2 fam-\nImmune Cell Infiltration\nily members in NSCLC patients using cBioPortal",
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:09.482059",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40589937.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.155640840530396,
      "cbioportal_papers": 0.00032210350036621094,
      "platform_mentions": 0.0038580894470214844,
      "data_citations": 8.344650268554688e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40588515": {
    "paper_id": "40588515",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:14.814533",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40588515.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.737112998962402,
      "cbioportal_papers": 0.0004987716674804688,
      "platform_mentions": 0.0006809234619140625,
      "data_citations": 0.00019097328186035156,
      "num_data_pmids_checked": 1
    }
  },
  "40999053": {
    "paper_id": "40999053",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "parison of genomic annotations between SMAD4-altered and unaltered\nsamples, along with corresponding statistical analyses, were generated Data availability\nand visualized using the cBioPortal",
      "The accessed and analyzed using cBioPortal for cancer genomics (https://\ntumor and normal gene sets were then intersected to identify liver www.cbioportal.org)",
      "Spatiotemporal heterogeneity across and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:15.846705",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40999053.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 569.0522356033325,
      "cbioportal_papers": 0.0005390644073486328,
      "platform_mentions": 0.025798797607421875,
      "data_citations": 0.0004100799560546875,
      "num_data_pmids_checked": 2
    }
  },
  "40585842": {
    "paper_id": "40585842",
    "cbioportal_paper_citations": [
      "Sci Signal 2013; 6: pl1 [RCA] [PMID: 23550210\nDOI: 10.1126/scisignal.2004088] [FullText]\n31 Yao L, Tian F"
    ],
    "cbioportal_platform_mentions": [
      "Data analysis and statistics\nThe correlation between NOTCH1 and NT5E was explored using the GEPIA2 database[29] and cBioPortal database[30]",
      "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:23.260418",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40585842.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 22.501620054244995,
      "cbioportal_papers": 0.002232074737548828,
      "platform_mentions": 0.0023550987243652344,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40585243": {
    "paper_id": "40585243",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data availability statement\nGenetic alterations identi\u0000ed by MSK-IMPACT will be available on cBioPortal upon publication",
      "et al. Integrative analysis of complex cancer genomics and clinical pro\u0000les using the\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:29.075931",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40585243.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.404958963394165,
      "cbioportal_papers": 0.00010013580322265625,
      "platform_mentions": 0.0013129711151123047,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40574864": {
    "paper_id": "40574864",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.3 Evaluation of clinical efficacy\nTMBwasretrievedfromcBioPortal(https://www.cbioportal.org)\n(26, 27)",
      "We would like to thank the staff members of the TCGA\nResearch Network, the cBioPortal, the UCSC Xena data portal,\nEthics statement\ntheTISCHdataportal,andalltheauthorsformakingtheirvaluable\nresearchdatapublic.ThankstoDr.WeichaoDanforhisguidance\nEthicalapprovalwasnotrequiredforthestudiesonhumansin\nandassistanceintheselectionofcelllines"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:32.048329",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40574864.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.14641284942627,
      "cbioportal_papers": 0.0004291534423828125,
      "platform_mentions": 0.004446983337402344,
      "data_citations": 0.042922019958496094,
      "num_data_pmids_checked": 6
    }
  },
  "40573960": {
    "paper_id": "40573960",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:46.935001",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40573960.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.595540046691895,
      "cbioportal_papers": 0.000293731689453125,
      "platform_mentions": 0.0022852420806884766,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40571311": {
    "paper_id": "40571311",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The METABRIC dataset\nAtypical protein kinase C (aPKC) is a Ser/Thr kinase (n=2509) (38, 39) was downloaded from cBioPortal\nbelonging to the PKC subfamily and is insensitive to (https://www.cbioportal.org/) (40, 41) on March 29, 2022",
      "TCGA Pan\u2011 The dataset includes data on two different methods of\nCancer Atlas dataset (n=1,084) (42) was downloaded endocrine therapy, including the anti\u2011estrogen drug,\nfrom cBioPortal (https://www.cbioportal.org/) (40, 41) tamoxifen, and aromatase inhibitors (anastrazole,\non July 15, 2024",
      "(A\u2010C) METABRIC\ndata were downloaded from cBioPortal",
      "Cancer Cell 36(3): and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:47.455905",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40571311.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.3626229763031,
      "cbioportal_papers": 0.0002682209014892578,
      "platform_mentions": 0.002931833267211914,
      "data_citations": 0.0002658367156982422,
      "num_data_pmids_checked": 3
    }
  },
  "40573300": {
    "paper_id": "40573300",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DataAvailabilityStatement:Allthegenomicandclinicopathologicaldatautilizedforthisstudyare\nfreelyavailableinthecBioPortalfortheCancerGenomicswebsite(https://www.cbioportal.org/,\naccessedon25April2025),andtheGenomeDataCommonsrepository(https://portal.gdc.cancer"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:49.431464",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40573300.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.305551052093506,
      "cbioportal_papers": 0.0002288818359375,
      "platform_mentions": 0.03747820854187012,
      "data_citations": 0.00024390220642089844,
      "num_data_pmids_checked": 3
    }
  },
  "40593549": {
    "paper_id": "40593549",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Project GENIE (mbc_genie_2020) generativemoleculardesignwithreinforcementlearning.JACSAu\n[http://genie.cbioportal.org/study/summary?id=mbc_genie_2020]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:44:54.277470",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40593549.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 80.20323133468628,
      "cbioportal_papers": 0.00041604042053222656,
      "platform_mentions": 0.004145145416259766,
      "data_citations": 9.775161743164062e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40565018": {
    "paper_id": "40565018",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:04.535981",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40565018.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.963435888290405,
      "cbioportal_papers": 0.00025081634521484375,
      "platform_mentions": 0.00030112266540527344,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40565600": {
    "paper_id": "40565600",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Datasets\nThe most current information from the TCGA PanCancer Atlas studies [40] was\nobtained via API calls from cBioPortal [43]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:06.100928",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40565600.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.162968158721924,
      "cbioportal_papers": 0.00030493736267089844,
      "platform_mentions": 0.002153158187866211,
      "data_citations": 0.0003247261047363281,
      "num_data_pmids_checked": 3
    }
  },
  "40561160": {
    "paper_id": "40561160",
    "cbioportal_paper_citations": [
      "https://doi:10.1158/2159-8290.CD-12-0095 PMID: 22588877\n37",
      "https://doi.org/10.1126/scisignal.2004088 PMID: 23550210\n38"
    ],
    "cbioportal_platform_mentions": [
      "Mutation data for each patient were downloaded from cBioPortal (https://\nwww.cbioportal.org/) and analyzed (S1 Table) [36,37]",
      "This table shows the data sources, sample sizes, download URLs, raw data, and reference information\nfor 13 cancer types downloaded from cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using\nthe cBioPortal"
    ],
    "data_publication_citations": {
      "26544944": [
        "https://doi.org/10.1016/j.cell.2015.10.025 PMID: 26544944\n32"
      ],
      "26091043": [
        "https://doi.org/10.1016/j.cell.2015.05.044 PMID: 26091043\n33"
      ],
      "22810696": [
        "https://doi.org/10.1038/nature11252 PMID: 22810696\nPLOS One | https://doi.org/10.1371/journal.pone.0326071 June 25, 2025 13 / 14\n\n26"
      ],
      "22960745": [
        "https://doi.org/10.1038/nature11404 PMID: 22960745\n30"
      ],
      "28052061": [
        "https://doi.org/10.1038/nature20805 PMID: 28052061\n35"
      ],
      "28481359": [
        "https://doi.org/10.1038/nm.4333 PMID: 28481359\n8"
      ],
      "23636398": [
        "https://doi.org/10.1038/nature12113 PMID: 23636398\n36"
      ],
      "25079552": [
        "https://doi.org/10.1038/nature13385 PMID: 25079552\n29"
      ],
      "21720365": [
        "https://doi.org/10.1038/nature10166 PMID: 21720365\n31"
      ],
      "23792563": [
        "https://doi.org/10.1038/nature12222 PMID: 23792563\n28"
      ],
      "25631445": [
        "https://doi.org/10.1038/nature14129 PMID: 25631445\n27"
      ],
      "25079317": [
        "https://doi.org/10.1038/nature13480 PMID: 25079317\n34"
      ],
      "23000897": [
        "https://doi.org/10.1038/nature11412 PMID: 23000897\n25"
      ],
      "24476821": [
        "https://doi.org/10.1038/nature12965 PMID: 24476821\n24"
      ]
    },
    "extraction_date": "2025-12-19T18:45:11.035960",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40561160.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 14,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 16.569921016693115,
      "cbioportal_papers": 0.0021009445190429688,
      "platform_mentions": 0.0024518966674804688,
      "data_citations": 0.17129921913146973,
      "num_data_pmids_checked": 14
    }
  },
  "40558521": {
    "paper_id": "40558521",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:21.450248",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40558521.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.32245397567749,
      "cbioportal_papers": 0.00019478797912597656,
      "platform_mentions": 0.0014760494232177734,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40558540": {
    "paper_id": "40558540",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:26.816950",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40558540.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 22.22574210166931,
      "cbioportal_papers": 0.0003027915954589844,
      "platform_mentions": 0.0022389888763427734,
      "data_citations": 0.00011515617370605469,
      "num_data_pmids_checked": 1
    }
  },
  "40562609": {
    "paper_id": "40562609",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The Next Generation first, they were modified to overexpress LUC2 and gain\nSequence (NGS) data is available in the cBioportal blasticidin resistance",
      "Driver mutations were analysed using A total of 1 \u00d7 106 NCH93 cells in 5 mL of PBS were\nthe maftools package in R (version 4.2.0) and compared injected into the skull convexity of adult NSG mice\nwith online databases COSMIC v.99 and cBioPortal to (RRID: IMSR_JAX: 005557) using stereotaxic guidance\nidentify unique mutations.2 7,28 Significantly co- as previously described",
      "Next Generation\nslightly significant reduction of ANXA3 in NF2-Cluster\nSequence (NGS) data is available in the cBioportal (http://zadehportal2",
      "3 Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based 28 Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex\nclassification and grading system for meningioma: a multicentre, cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:27.870421",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40562609.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 38.41822075843811,
      "cbioportal_papers": 0.00035500526428222656,
      "platform_mentions": 0.0033369064331054688,
      "data_citations": 0.0001380443572998047,
      "num_data_pmids_checked": 1
    }
  },
  "40553452": {
    "paper_id": "40553452",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:34.493988",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40553452.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.372332096099854,
      "cbioportal_papers": 0.0002949237823486328,
      "platform_mentions": 0.0026030540466308594,
      "data_citations": 0.0002071857452392578,
      "num_data_pmids_checked": 2
    }
  },
  "40614202": {
    "paper_id": "40614202",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(A) cBioPortal (23) mutational profile of the TP53 gene locus in the\ntcGA (28), icGc (29), and QcMG (9) PdAc patient cohorts (total patients, n = 739; TP53- mutated patients, n = 396)",
      "TCGA (28), QCMG (9), and ICGC (29) were accessed via cBioPortal\n(23, 53)",
      "PDX-d erived primary cell\nLast, data were accessed via an internal KFO5002 cBioPortal plat- lines holding the nomenclature PDAC000T were cultured in serum-\nform",
      "cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:34.580532",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40614202.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 180.13097620010376,
      "cbioportal_papers": 0.0005590915679931641,
      "platform_mentions": 0.01689887046813965,
      "data_citations": 0.00037288665771484375,
      "num_data_pmids_checked": 2
    }
  },
  "40545636": {
    "paper_id": "40545636",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus\n(GDC) data portal (https://portal.gdc.cancer.gov) and\nbevacizumab versus capecitabine alone in patients with colorectal\ncBioPortal(https://www.cbioportal.org/).Sequencingdata\ncancer (QUASAR 2): an open-label, randomised phase 3 trial"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:41.106494",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40545636.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 14.285710096359253,
      "cbioportal_papers": 0.000308990478515625,
      "platform_mentions": 0.0031621456146240234,
      "data_citations": 0.00021696090698242188,
      "num_data_pmids_checked": 2
    }
  },
  "40547168": {
    "paper_id": "40547168",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "SPARC/SERPINE1 mutation in GC\nUsing TCGA-STAD data and analyzing it through the cBioPortal database (https://www.cbioportal.org), the study\nassessed the genetic variation of SPARC and SERPINE1[17]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:43.553607",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40547168.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 22.10041904449463,
      "cbioportal_papers": 0.0002338886260986328,
      "platform_mentions": 0.002501249313354492,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40535123": {
    "paper_id": "40535123",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The\nCOPYRIGHT genetic alteration status of FCHSD1 in human pan-cancer was studied using\n\u00a92025Liu,Ding,Tang,Liu,Mao,Wang,Zou the cBioPortal website",
      "The negative control used was the\ncBioPortal company\u2019s universal negative control",
      "mechanisms(27).RNAsequencinghasbecomeanindispensabletool We utilized the cBioPortal website to investigate the genetic\nincontemporarycancerresearch.Asoneoftheearliestresearchteams alterationsofFCHSD1inhumancancersandfoundthatthemajor\ninvolved in TCGA biomarker studies, the Liu laboratory has geneticalterationsofFCHSD1incancersaremutations,structural\nsubstantially advanced the field through developing different variations, amplifications, and deep deletions"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:44.525542",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40535123.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 9.918457984924316,
      "cbioportal_papers": 0.0003008842468261719,
      "platform_mentions": 0.002270936965942383,
      "data_citations": 0.0001239776611328125,
      "num_data_pmids_checked": 1
    }
  },
  "40535799": {
    "paper_id": "40535799",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We first examined the mutational landscape and\nVariable gene selection and scaling\ncopy number variations (CNVs) of these RA\nmetabolism-related genes in the bladder cancer cohort The expression data were scaled by identifying\nfrom TCGA using the CBioPortal tool [22]",
      "2014; 192:\nNGS data was obtained from the cBioPortal for 2953-8",
      "Journal of\nCancer Genomics (http://cbioportal.org), TCGA translational medicine",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:51.991917",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40535799.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 17.463945865631104,
      "cbioportal_papers": 0.00023603439331054688,
      "platform_mentions": 0.03355908393859863,
      "data_citations": 8.821487426757812e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40537745": {
    "paper_id": "40537745",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "20 \u00b5l transfection mixture was prepared accord-\nphosphorylated MAPK proteins were determined in ing to the manufacturer\u2019s protocol consisting of\nsubsets of TCGA samples (Table 1) by Reverse Phase OptiMEM (Gibco, Thermo Fisher Scientific), siPort\nProtein Arrays (RPPA) and assessed via cBioPortal [36, NeoFX transfection reagent (Thermo Fisher Scien-\n37]",
      "Program (TCGA) (www.cancer.gov/tcga) and cbioportal",
      "Circ-EIF3I promotes\nY, Jacobsen A, Sinha R, Larsson E et al.: Integrative analysis of complex cancer hepatocellular carcinoma progression through modulating miR-361-3p/\ngenomics and clinical profiles using the cBioPortal",
      "Increased expression of\nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:52.415989",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40537745.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 24.54176688194275,
      "cbioportal_papers": 0.0003631114959716797,
      "platform_mentions": 0.003281116485595703,
      "data_citations": 1.2874603271484375e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40535120": {
    "paper_id": "40535120",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "extended genes and 32 core genes (http://www.pharmaadme.org),\nwhichincludephaseIandIIdrug-metabolizingenzymes,modifiers, Additionally, information from the cBioPortal website database\nand transporters that influence hepatic drug clearance and (https://www.cbioportal.org/) (14) and Gene Expression Omnibus\nmetabolism(5\u20137)",
      "The hypoxia Variant landscape of ARGs in patients with\nscore of BC was acquired from the cBioPortal (https:// BC\nwww.cbioportal.org/)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:45:56.720637",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40535120.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.611406087875366,
      "cbioportal_papers": 0.0002276897430419922,
      "platform_mentions": 0.0022912025451660156,
      "data_citations": 8.20159912109375e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40535103": {
    "paper_id": "40535103",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:06.689568",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40535103.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 23.110902070999146,
      "cbioportal_papers": 0.00034809112548828125,
      "platform_mentions": 0.0004038810729980469,
      "data_citations": 0.00013375282287597656,
      "num_data_pmids_checked": 1
    }
  },
  "40530133": {
    "paper_id": "40530133",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods: To address this gap, we performed a comprehensive bioinformatics analysis using various tools\nand databases, including the The Cancer Genome Atlas (TCGA) dataset, R software, Kaplan-Meier Plotter,\ncBioPortal, LinkedOmics, Metascape, TIMER, receiver operating characteristic (ROC) curve, and nomogram",
      "examined in LIHC cohorts via cBioPortal (https://www",
      "Complementary analyses in R (version 4.2.1, package\ncbioportal.org/) (21)",
      "the cBioPortal online tool to analyze mutations in the\nMEX3B/C/D expressed more in higher tumor grade and MEX3 family genes"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:17.353510",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40530133.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 20.552093029022217,
      "cbioportal_papers": 0.0004398822784423828,
      "platform_mentions": 0.0626668930053711,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40581983": {
    "paper_id": "40581983",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(MSK) breast cancer datasets available through cBioPortal [45\u2013 PCDHA10, PRTG, and PRICKLE2 were identified as novel breast\n47]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:19.159805",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40581983.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 124.33088612556458,
      "cbioportal_papers": 0.0002989768981933594,
      "platform_mentions": 0.0022857189178466797,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40529021": {
    "paper_id": "40529021",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Some studies suggest that Tregs are capable retrieved from cBioPortal to validate the results (29,30)",
      "gdc.cancer.gov) and were downloaded from cBioPortal for The Kolmogorov-Smirnov test was used to analyze the\nfurther analysis",
      "MATH acquired comprehensive mutation and clinical data from\nvalue was independently associated with overall survival in cBioPortal and conducted an analysis to determine their\nthe ccRCC cohort (P=0.046, Figure 1E)",
      "Clonal Heterogeneity and\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:20.502213",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40529021.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.667773962020874,
      "cbioportal_papers": 0.0005109310150146484,
      "platform_mentions": 0.008711099624633789,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40521274": {
    "paper_id": "40521274",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Selective targeting of activating\nThe Cancer Genome Atlas (TCGA) bladder cancer cohort\nFGFR3alterationsrepresentsanattractivetherapeuticstrat-\n[7];and(6)113metastaticUCs(mUCs)fromamulticenter\negy,andFGFRinhibitorsarealreadyusedinclinicalpractice\ncohortofpatients treatedwithimmunecheckpointinhibi-\n[5].PathogenicactivatingFGFR3alterationsexhibitastage-\ntors(FOSMICcohort;[8]).FGFR3mutationalandgenefusion\ndependent frequency.Papillarynoninvasive UC andarele-\ndata were downloaded and adapted from the most recent\nvantproportionofstroma-invasiveUCtumorsmainlyarise\ndata set release of the TCGA bladder cancer cohort (BLCA,\nviaahyperplasiasequencedrivenbyactivatingFGFR3alter-\nPanCancer Atlas version) from the cBioPortal for cancer\nations.Bycontrast,themajorityofmuscle-invasiveUCsand\ngenomics [9,10]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:23.225505",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40521274.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 5.87006688117981,
      "cbioportal_papers": 0.00017905235290527344,
      "platform_mentions": 0.0015039443969726562,
      "data_citations": 6.198883056640625e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40518514": {
    "paper_id": "40518514",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "ECF-R cells\ncer Genome Atlas (TCGA) and the oncoSG [29] data- exhibited significantly increased invasive potential com-\nset using cBioPortal [30, 31]",
      "Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun YC,\nPublisher\u2019s note\nJacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer\ngenomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:32.834583",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40518514.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 13.66538691520691,
      "cbioportal_papers": 0.0003190040588378906,
      "platform_mentions": 0.002774953842163086,
      "data_citations": 0.00010609626770019531,
      "num_data_pmids_checked": 1
    }
  },
  "40517334": {
    "paper_id": "40517334",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutation data for CWH43 were sourced from the cBioPortal (http://c biopo rtal.o rg) [20]",
      "3.7 Impact of CWH43 genetic alterations on prognosis in ccRCC patients\nWe utilized the cBioPortal to assess how alterations in the CWH43 gene affect the prognosis of patients with ccRCC",
      "B Analysis of mutation frequency and (C) mutation sites via cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:36.240982",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40517334.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.735753059387207,
      "cbioportal_papers": 0.0002582073211669922,
      "platform_mentions": 0.002198934555053711,
      "data_citations": 0.00028395652770996094,
      "num_data_pmids_checked": 3
    }
  },
  "40512411": {
    "paper_id": "40512411",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Breast cancer datasets from TCGA and METABRIC were obtained from cBioPortal\n[22] and UCSC Xena [23]",
      "We used \u201cmaftools\u201d and cBioPortal to analyze gene mutations",
      "Hypoxia scores were obtained from cBioPortal, and drug sensi-\ntivities were predicted using \u201concoPredict\u201d [30]",
      "Two endometriosis datasets,\nGSE51981 and GSE35287, were obtained from the NCBI GEO, and Breast cancer datasets from TCGA and METABRIC were\nretrieved from cBioPortal and UCSC Xena",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and\nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:53.901828",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40512411.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 21.04235291481018,
      "cbioportal_papers": 0.0002760887145996094,
      "platform_mentions": 0.0026569366455078125,
      "data_citations": 1.7881393432617188e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40508075": {
    "paper_id": "40508075",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Publicdatasetswithclinicaldatafrom\nBarquilha,C.N.;Barbosa,I.C.;Lima, patients(TheHumanProteinAtlas,cBioPortal,SurvExpressandCamcAPP)wereusedto\nF.d.O.;Barbosa,G.O.;Carvalho,H.F.; validatethegeneandproteinexpressionofSLIT1,SLIT2,ROBO1,andROBO4,correlating\nDelella,F.K.;Felisbino,S.L",
      "WeperformedthegenesurvivalanalysisofSLIT1,-2,-3andROBO1,-2,-3,-4using\ncBioPortal for Cancer Genomics and SurvExpress Kaplan\u2013Meier curves, based on data\nfromtheMSKCCstudybyTayloretal.,2010[18]",
      "GeneexpressionpatternswereanalyzedusingtheSurvExpressdatabase[22],\nthe Cambridge Carcinoma of the Prostate App (CamcAPP) database developed by the\nCancer Research UK Cambridge Institute [20] (https://bioinformatics.cruk.cam.ac.uk/\napps/camcAPP/) (accessed on 4 March 2025), cBioPortal for Cancer Genomics [41,42]\n(https://www.cbioportal.org/)(accessedon4March2025),andTheCancerGenomeAtlas\n(TCGA)[19]",
      "uk/apps/camcAPP/)(accessedon4March2025)fromtheCancerResearchUKCambridgeInstitute,\ncBioPortal for Cancer Genomics database (https://www.cbioportal.org/) (accessed on 4 March\n2025),andHumanProteinAtlas(HPA)(https://www.proteinatlas.org/)(accessedon4March2025)\ndatabase"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:46:55.358756",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40508075.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 19.103219032287598,
      "cbioportal_papers": 0.00019097328186035156,
      "platform_mentions": 0.0018351078033447266,
      "data_citations": 7.224082946777344e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40530423": {
    "paper_id": "40530423",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Remarkably, an analysis of data from TCGA\nused the TFEA.ChIP tool to search for transcriptional regulators PanCancer Atlas (https://www.cancer.gov/tcga) using the cBio-\nthat preferentially targeted DE genes identified after overexpres- Portal for Cancer Genomics (https://www.cbioportal.org/)58,59\nsion of AurkB and/or INCENP.57This analysis further reinforced revealed that the percentage of cancer cases in which both\nthe idea that increased amounts of either AurkB or INCENP and AURKB and INCENP showed an elevated expression (mRNA\nthe simultaneous induction of both proteins have a profoundly expression Z score >2) is significantly smaller than that of tumors\ndifferent impact on global gene expression",
      "Integrative anal-\nniak, L.C.F., Wang, L., Audhya, A., Burkard, M.E., Roopra, A., and Weaver, ysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:47:02.755231",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40530423.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 70.68161010742188,
      "cbioportal_papers": 0.0004661083221435547,
      "platform_mentions": 0.005604982376098633,
      "data_citations": 1.2159347534179688e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40501869": {
    "paper_id": "40501869",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "97 Materials and Methods:\n98 CTC1 and STN1 gene expression analysis\n99 Analysis of CST gene alterations was performed with cBioPortal using TCGA PanCancer\n100 Atlas Skin Cutaneous Melanoma dataset"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:47:05.755910",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40501869.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 10.37862777709961,
      "cbioportal_papers": 0.00020384788513183594,
      "platform_mentions": 0.0017642974853515625,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40507905": {
    "paper_id": "40507905",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:47:20.664545",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40507905.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 26.667526960372925,
      "cbioportal_papers": 0.0005450248718261719,
      "platform_mentions": 0.04404807090759277,
      "data_citations": 1.2159347534179688e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40637234": {
    "paper_id": "40637234",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "ated with specific risk groups using the cBioPortal platform\nAt the pan-cancer level, we inferred four clusters of sam- [ 45 , 46 ], verifying that the overall survival of patients carrying\nples showing different prognoses ( Supplementary Fig",
      "complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:47:36.781150",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40637234.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 316.64273285865784,
      "cbioportal_papers": 0.00045871734619140625,
      "platform_mentions": 0.0038292407989501953,
      "data_citations": 0.00015616416931152344,
      "num_data_pmids_checked": 1
    }
  },
  "40514415": {
    "paper_id": "40514415",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:47:39.890866",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40514415.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 76.57518792152405,
      "cbioportal_papers": 0.00031304359436035156,
      "platform_mentions": 0.002179861068725586,
      "data_citations": 0.0002071857452392578,
      "num_data_pmids_checked": 2
    }
  },
  "40500270": {
    "paper_id": "40500270",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cbioportal.org/study/summary?id=hnsc_tcga] and TCGA CESC data- Cancer123,1302\u20131314(2020)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:47:56.263184",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40500270.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 35.5948588848114,
      "cbioportal_papers": 0.0003159046173095703,
      "platform_mentions": 0.0030269622802734375,
      "data_citations": 0.0002219676971435547,
      "num_data_pmids_checked": 2
    }
  },
  "40498073": {
    "paper_id": "40498073",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "63.Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of https:// doi.org/ 10.1016/ j.cell.2018.06.018\ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:48:02.185514",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40498073.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 25.36896324157715,
      "cbioportal_papers": 0.00040793418884277344,
      "platform_mentions": 0.003916025161743164,
      "data_citations": 0.00029206275939941406,
      "num_data_pmids_checked": 2
    }
  },
  "40484944": {
    "paper_id": "40484944",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:48:11.356698",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40484944.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 15.050657033920288,
      "cbioportal_papers": 0.00030517578125,
      "platform_mentions": 0.0003540515899658203,
      "data_citations": 1.0728836059570312e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40500731": {
    "paper_id": "40500731",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Endogenous peroxidase was quenched with\n(George et al. 2015) (Dataset in cBioportal (Gao et al. 3% H O for 10 min in both TMA and cells"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:48:11.750926",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40500731.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 65.9629979133606,
      "cbioportal_papers": 0.00033211708068847656,
      "platform_mentions": 0.0030777454376220703,
      "data_citations": 0.00011801719665527344,
      "num_data_pmids_checked": 1
    }
  },
  "40478518": {
    "paper_id": "40478518",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Then the results were checked using cBioPortal and GEO database",
      "Clinical information of\nthe Memorial Sloan Kettering Cancer Center were obtained from cBioPortal (http://w ww.c biopo rtal.o rg)",
      "2.5 Somatic copy\u2011number alteration (SCNA), mutation and DNA methylation analysis\ncBioPortal (http://w ww.c biopo rtal.o rg) offers various analytical capabilities, including mutation-related analysis and\nvisualization [16]",
      "After logging into cBioPortal, \u201cTCGA Pan Cancer Atlas Study\u201d [17, 18] were selected in \u201cQuick Selection\u201d\nsection and inputted \u201cSYTL4\u201d to investigate SYTL4-related gene mutations",
      "The cBioPortal database indicates that SYTL4 presents a certain frequency of genetic\nalterations in most cancers, mutation and amplification are the most common types of genetic alterations of SYTL4\n(Fig",
      "C Sites and case numbers with SYTL4 genetic alterations in pan-cancer from cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T18:48:13.503691",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40478518.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "_timing": {
      "pdf_extraction": 11.303473949432373,
      "cbioportal_papers": 0.0002589225769042969,
      "platform_mentions": 0.0021979808807373047,
      "data_citations": 4.76837158203125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40530418": {
    "cbioportal_paper_citations": [
      "To import human datasets of cancer collected in the cBioPortal76,77 we used the cBioPortalData R package.78 For each considered dataset, we then scored each tumor based on the RNA expression of the genes in our signature, as the sum of the normalised expression values. Each tumor was then assigned either to a Low or High expressing category, using the median value of the signature as cutoff. Survival curves were then computed using the survfit function of the R package survival. Differences in the resulting curves for the Low and High expressing categories were tested using a Log Rank test, via the survdiff function of the R package survival. Kaplan-Meier plots were drawn using the R package survminer."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "25409260": [
        "Among the available datasets, we considered only those containing transcriptomic data of at least 40 samples. These included a study from Snyder et al.,29 and the skin cutaneous melanoma dataset from the TCGA-Pan Cancer Atlas.30 The analysis of data from Snyder et al. revealed a significantly higher Overall Survival (OS) in patients with high expression of the combined signatures, as compared to patients with low expression (Figure 7A). In the case of the TCGA PanCancer Atlas dataset, the analysis also revealed a significantly higher OS, as well as a significantly higher Disease-Free Survival (DFS) in patients with high expression of our signature (Figure 7B).Figure 7Expression of the pDC killing signature positively correlate with a higher OS and DFS in cutaneous melanoma patient cohorts(A) Kaplan-Meier survival curves showing the overall survival (OS) for patients stratified by high (red) versus low (blue) expression (bulk-RNA-seq data) of the pDCs killing signature. Data from Snyder et al. 2014. Numbers of patients at risk over time per high or low signature and p-value (log rank test) are indicated.(B) Same as (A) but considering the TCGA cohort, including both OS and DFS (disease-free survival)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.09507107734680176,
    "data_pmids_checked": 2,
    "paper_id": "40530418",
    "extraction_date": "2025-12-19T19:46:32.625587",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40530418.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40531870": {
    "cbioportal_paper_citations": [
      "We first investigated whether UBR4-regulated protein homeostasis contributes to human cancer, based on previous findings suggesting dysregulated mitosis and cell growth in UBR4-mutant cells (27, 28). An unbiased analysis using The Cancer Genome Atlas (TCGA) datasets (31) revealed that UBR4 mRNA expression was significantly higher in LUAD tumor samples (N = 510) than that in normal lung tissue samples (N = 59; P = 0.0014 from unpaired and P = 0.0085 from paired Student t tests; Fig. 1A). UBR4 protein levels, which previously correlated with UBR4 mRNA levels, were also significantly elevated in LUAD tissues compared with those in normal controls (SI Appendix, Fig. S1 A and B). To better understand the functional signatures of UBR4 in LUAD, we performed gene set enrichment analysis (GSEA) using hallmark and gene ontology (GO) gene sets. GSEA of the hallmark gene sets identified that high UBR4 levels were associated with cell cycle\u2013related pathways such as G2/M checkpoints, whereas low UBR4 levels were associated with mitochondrial functions, including OXPHOS (Fig. 1B and SI Appendix, Fig. S1 C and D). In addition, UBR4 mRNA levels were positively correlated with CDK6 (Spearman\u2019s correlation; \u03c1 = 0.03, P = 0.0001) and antigen identified by monoclonal antibody Ki67 (MKI67) (\u03c1 = 0.347, P < 0.0001), and negatively correlated with CDKN1A (\u03c1 = 0.120, P = 0.0072) in patients with LUAD (Fig. 1C and SI Appendix, Fig. S1E). Transcripts of various chemotaxis-stimulating factors, glutathione peroxidases, and mitochondrial proteins were also significantly correlated with UBR4 expression (SI Appendix, Fig. S1D). Similarly, GO pathway enrichment using the DAVID database (32) revealed that UBR4 in LUAD tumors was strongly associated with cell cycle regulation and mitochondrial respiration (Fig. 1D). These findings indicate a pathophysiological association between UBR4 and LUAD."
    ],
    "cbioportal_platform_mentions": [
      "Identification of the pathological link between the UBR4 expression and LUAD. (A) Dot plots with mean and SD bars, comparing UBR4 mRNA expression levels between normal and tumor tissues in patients with LUAD. Data were obtained from cBioportal (https://www.cbioportal.org/). Left: Analysis of all LUAD data from TCGA (normal, n = 59; tumor, n = 510). Right: Comparison of paired samples (n = 56) was performed using a two-tailed unpaired or paired Student\u2019s t test. (B) GSEA showing DEG pathways in LUAD tissues with high (first quartile; Left) and low (fourth quartile; Right) UBR4 expression. Top hallmark pathways are displayed with NESs on the x-axis. Dot size indicates the \u201cgene ratio\u201d (k:n), where k is the number of core enrichment genes and n is the total number of genes in each set. Dot colors denote FDR-corrected P-values. (C) Scatter plot illustrated correlations between UBR4 expression and cell cycle-related mRNAs (CDKN1A/p21, CDK6, or MKI67) in LUAD patients. Solid lines depict regression lines, whereas dashed lines represent 95% CI (n = 510, \u03c1- and P-values from Spearman\u2019s correlation analysis). (D) GO enrichment analysis using the DAVID database, highlighting genes significantly coexpressed with UBR4. Bar plots displayed biological process (BP) terms ordered by fold enrichment (x-axis) with blue indicating negative and red indicating positive associations. (E) Volcano plot depicting differential expression analysis between A549 WT and \u0394UBR4 cells from bulk RNAseq analysis. Significantly upregulated and downregulated DEGs in \u0394UBR4 cells are shown in red and blue, respectively (P < 0.05, log2-fold change > 1.6). DEGs highlighted in bold indicate the genes identified from both RNAseq and TMT-MS analyses. (F) Heat map showing DEPs from TMT-MS, grouped by cell cycle- and mitochondrial function-related BPs. WCLs from samples were labeled with 6-plex isobaric tags, analyzed by LC-MS3. The color key indicates the Z-score (red: upregulation; blue: downregulation). (G) IB analysis validating the TMT-MS results using WCLs from WT and \u0394UBR4 cells. (H) Venn diagram representing the overlap of DEGs and DEPs upregulated in \u0394UBR4 cells, with known genes in cell cycle and senescence pathways. (I) qRT-PCR showing a significant increase in CDKN1A mRNA levels in \u0394UBR4 cells."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.013908147811889648,
    "data_pmids_checked": 0,
    "paper_id": "40531870",
    "extraction_date": "2025-12-19T19:46:32.544230",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40531870.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40457074": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "23000897": [
        "KDM4C is one of the most frequently mutated genes encoding HDMs in TNBC in The Cancer Genome Atlas (TCGA)22 and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)23 cohorts (Extended Data Fig. 1a). Within TNBC, KDM4C amplification is associated with the basal TNBC subtype, and KDM4C-amplified cell lines are also more commonly basal or triple-negative (Extended Data Fig. 1b\u2013e). KDM4C amplification correlates with mRNA and protein levels in patient-derived xenograft (PDX) models, primary TNBC tumors and cell lines (Extended Data Fig. 1f\u2013l). Based on these analyses, we selected four KDM4C-amplified basal breast cancer cell lines (SUM149, HCC1954, HCC38 and HCC70) and four KDM4C-non-amplified lines (HCC1806, HDQP1, HCC1143 and HCC1569) to assess the functional relevance of KDM4C in basal breast cancer (Extended Data Fig. 2a,b).",
        "To explore the potential clinical relevance of our findings, we generated KDM4C and GSH modulated gene signatures using DEGs associated with KDM4C knockdown in HCC1954 and SUM149 cell lines (n = 23 genes) and GSH-high versus GSH-low TNBC cell lines (n = 113 genes) defined in our previous study44, respectively (Supplementary Fig. 2a and Supplementary Table 7). Strong positive correlation between GSH and KDM4C signatures was also observed in basal primary tumors in both TCGA and METABRIC cohorts22,23 (Supplementary Fig. 2b), recapitulating our findings in cell line models. Furthermore, oxidative stress signature was inversely correlated with KDM4C signature (Supplementary Fig. 2c), in line with our experimental results of dampened mitochondrial respiration and increased ROS levels following KDM4C inhibition"
      ],
      "22522925": [
        "KDM4C is one of the most frequently mutated genes encoding HDMs in TNBC in The Cancer Genome Atlas (TCGA)22 and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)23 cohorts (Extended Data Fig. 1a). Within TNBC, KDM4C amplification is associated with the basal TNBC subtype, and KDM4C-amplified cell lines are also more commonly basal or triple-negative (Extended Data Fig. 1b\u2013e). KDM4C amplification correlates with mRNA and protein levels in patient-derived xenograft (PDX) models, primary TNBC tumors and cell lines (Extended Data Fig. 1f\u2013l). Based on these analyses, we selected four KDM4C-amplified basal breast cancer cell lines (SUM149, HCC1954, HCC38 and HCC70) and four KDM4C-non-amplified lines (HCC1806, HDQP1, HCC1143 and HCC1569) to assess the functional relevance of KDM4C in basal breast cancer (Extended Data Fig. 2a,b).",
        "To explore the potential clinical relevance of our findings, we generated KDM4C and GSH modulated gene signatures using DEGs associated with KDM4C knockdown in HCC1954 and SUM149 cell lines (n = 23 genes) and GSH-high versus GSH-low TNBC cell lines (n = 113 genes) defined in our previous study44, respectively (Supplementary Fig. 2a and Supplementary Table 7). Strong positive correlation between GSH and KDM4C signatures was also observed in basal primary tumors in both TCGA and METABRIC cohorts22,23 (Supplementary Fig. 2b), recapitulating our findings in cell line models. Furthermore, oxidative stress signature was inversely correlated with KDM4C signature (Supplementary Fig. 2c), in line with our experimental results of dampened mitochondrial respiration and increased ROS levels following KDM4C inhibition"
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2560150623321533,
    "data_pmids_checked": 3,
    "paper_id": "40457074",
    "extraction_date": "2025-12-19T19:46:32.823656",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40457074.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40460118": {
    "cbioportal_paper_citations": [
      "Finally, we analyzed the relationship between the Regnase-1 expression level and prognosis in colorectal adenocarcinoma cases using The Cancer Genome Atlas Program (TCGA) Firehose Legacy dataset on the cBioPortal platform (42, 43). Among 379 cases that had RNA-seq data of colon cancer tissues, 68 cases had a higher-than-average expression of both IL17A and IL17F. We divided these cases into two groups depending on whether their expression levels of Regnase-1 mRNA in colorectal cancer tissues were higher or lower than the average. Both overall survival and disease-free survival were significantly shorter in the group with low Regnase-1 expression (Fig. 7 E and F). This result indicates the protective role of Regnase-1 in human colorectal cancers."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.03675127029418945,
    "data_pmids_checked": 0,
    "paper_id": "40460118",
    "extraction_date": "2025-12-19T19:46:32.567591",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40460118.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40462930": {
    "cbioportal_paper_citations": [
      "We used 37,118 curated and labeled missense variants from 12,488 unique protein regions overlapping with the IDRome database. 20,831 variants from PrimateAI and 14,392 from ClinVar were used as benign labels35,36. For pathogenic variants, 1074 variants from ClinVar, 405 variants from cancer hotspots, and 416 variants from other data sources were collected46,56\u201358. For ClinVar, all used labels were selected with at least one-star non-conflict submits and were filtered to remove start-loss mutations at the first methionine residue. However, upon integrating these data with features extracted from Zoonomia MSAs, 3 Pathogenic and 416 Benign variants were dropped as a result of missing MSA information. Our final training and data analysis was performed on 36,696 variants of 12,303 IDRs."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.019243717193603516,
    "data_pmids_checked": 0,
    "paper_id": "40462930",
    "extraction_date": "2025-12-19T19:46:32.549801",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40462930.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40487451": {
    "cbioportal_paper_citations": [
      "In light of the penetrant anti-clonogenic effect of the SAEi on MYC-High cells, we asked whether ovarian cancer cell lines displayed differential sensitivity to the SAEi. While MYC is amplified in many cancers, HGSOC has the highest amplification frequency, at almost 40%.2,43 To do this, we assembled a panel of ten established ovarian cancer cell lines (Figure 2A), six of which bear the hallmarks of HGSOC, namely TP53 mutations and high chromosome instability scores, three reflect ovarian clear cell carcinoma, and one is more typical of the low-grade serous ovarian subtype.48,49 Importantly, MYC status \u2013 as determined by copy number variation, mRNA expression, protein expression, and MYC V1 target gene enrichment \u2013 varied across the panel (Figure 2A). SAEi sensitivity was measured using a short-term proliferation assay (Figure 2B) and a long-term clonogenic assay (Figure 2C), revealing five sensitive and five resistant cell lines (Figure 2D). Again, sensitivity correlated with the induction of polyploidy and apoptosis (Figure 2E), and cell fate profiling revealed an increase in abnormal cell divisions and post-mitotic apoptotic events (Figure 2F and S3). However, we observed no obvious correlation between sensitivity and MYC status. This could reflect several factors, for example, the small sample size, cell lines being derived from different disease subtypes, different cell culture media, and network adaptations due to extensive in vitro cell culture. To address these issues, we turned our attention to a larger panel of patient-derived ovarian cancer models.48,50,51,52Figure 2A subset of ovarian cancer cell lines is sensitive to the inhibition of SUMO signaling(A) (Left) Mutation profile of selected ovarian cancer cell lines.45,46 \u2217 = missense mutation of unknown significance. (Right) Expression of MYC and MYC Hallmark Genes V1 based on RNA-sequencing data,47 and Myc and Sae2 protein levels determined by LICOR immunoblotting.(B) Bar graph of ML-792 GI50 values derived from 96-h proliferation assays, showing mean \u00b1 s.e.m from three biological replicates.(C) Representative colony formation assays.(D) xy plot of mean GI50 values against colony area expressed as a percentage of untreated controls. r provides Pearson correlation value, \u2217\u2217p < 0.01.(E) DNA content histograms and (F) cell fate profiles comparing exemplar lines. ML-792 was used at 200 nM for all experiments, and cell fate profiles are as described in Figure 1E.See also Figure S3.",
      "(A) (Left) Mutation profile of selected ovarian cancer cell lines.45,46 \u2217 = missense mutation of unknown significance. (Right) Expression of MYC and MYC Hallmark Genes V1 based on RNA-sequencing data,47 and Myc and Sae2 protein levels determined by LICOR immunoblotting.",
      "The genetic background of the cell lines47 was visualised using the cBioPortal for Cancer Genomics (https://www.cbioportal.org/).45,46 Gene counts were downloaded from the Depmap data portal, release 24Q2. Hallmark MYC targets were downloaded from https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MYC_TARGETS_V1. Normalised gene expression for MYC target genes were z-scored and summed to give a single value for MYC target gene expression."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31068700": [
        "In light of the penetrant anti-clonogenic effect of the SAEi on MYC-High cells, we asked whether ovarian cancer cell lines displayed differential sensitivity to the SAEi. While MYC is amplified in many cancers, HGSOC has the highest amplification frequency, at almost 40%.2,43 To do this, we assembled a panel of ten established ovarian cancer cell lines (Figure 2A), six of which bear the hallmarks of HGSOC, namely TP53 mutations and high chromosome instability scores, three reflect ovarian clear cell carcinoma, and one is more typical of the low-grade serous ovarian subtype.48,49 Importantly, MYC status \u2013 as determined by copy number variation, mRNA expression, protein expression, and MYC V1 target gene enrichment \u2013 varied across the panel (Figure 2A). SAEi sensitivity was measured using a short-term proliferation assay (Figure 2B) and a long-term clonogenic assay (Figure 2C), revealing five sensitive and five resistant cell lines (Figure 2D). Again, sensitivity correlated with the induction of polyploidy and apoptosis (Figure 2E), and cell fate profiling revealed an increase in abnormal cell divisions and post-mitotic apoptotic events (Figure 2F and S3). However, we observed no obvious correlation between sensitivity and MYC status. This could reflect several factors, for example, the small sample size, cell lines being derived from different disease subtypes, different cell culture media, and network adaptations due to extensive in vitro cell culture. To address these issues, we turned our attention to a larger panel of patient-derived ovarian cancer models.48,50,51,52Figure 2A subset of ovarian cancer cell lines is sensitive to the inhibition of SUMO signaling(A) (Left) Mutation profile of selected ovarian cancer cell lines.45,46 \u2217 = missense mutation of unknown significance. (Right) Expression of MYC and MYC Hallmark Genes V1 based on RNA-sequencing data,47 and Myc and Sae2 protein levels determined by LICOR immunoblotting.(B) Bar graph of ML-792 GI50 values derived from 96-h proliferation assays, showing mean \u00b1 s.e.m from three biological replicates.(C) Representative colony formation assays.(D) xy plot of mean GI50 values against colony area expressed as a percentage of untreated controls. r provides Pearson correlation value, \u2217\u2217p < 0.01.(E) DNA content histograms and (F) cell fate profiles comparing exemplar lines. ML-792 was used at 200 nM for all experiments, and cell fate profiles are as described in Figure 1E.See also Figure S3.",
        "(A) (Left) Mutation profile of selected ovarian cancer cell lines.45,46 \u2217 = missense mutation of unknown significance. (Right) Expression of MYC and MYC Hallmark Genes V1 based on RNA-sequencing data,47 and Myc and Sae2 protein levels determined by LICOR immunoblotting.",
        "The genetic background of the cell lines47 was visualised using the cBioPortal for Cancer Genomics (https://www.cbioportal.org/).45,46 Gene counts were downloaded from the Depmap data portal, release 24Q2. Hallmark MYC targets were downloaded from https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MYC_TARGETS_V1. Normalised gene expression for MYC target genes were z-scored and summed to give a single value for MYC target gene expression."
      ],
      "21720365": [
        "Interestingly there was also no correlation between sensitivity to siSMAD2 and siSNIP1 (Figure 6D). One possible explanation for the data in Figure 6D is that these OCMs harbor several different vulnerabilities that when probed exacerbate proliferative deregulation, in turn explaining why different interventions yield a spectrum of OCM sensitivities with little correlation. This idea also draws on our recent experience with replication stress response (RSR) inhibitors. Despite most HGSOC suffering from replication stress62,63 our prior study found that sensitivity to ATR, CHK1, WEE1, and PARG inhibitors was not correlated, indicating RSR-targeting drugs were not interchangeable.51 And yet, 15 of the 16 OCMs analyzed were sensitive to a low-dose ATR-CHK1 inhibitor combination. This idea also draws on the observation that deregulating transcriptional regulators E2F1, MYB2L, and FOXM1 in the presence of TP53 mutation, leads to mitotic errors.64 Indeed, HGSOCs can overcome proliferative controls and acquire chromosome instability via multiple mechanisms,62,65,66 and our observations indicate that this genetic diversity manifests as phenotypic heterogeneity in turn leading to multiple, non-overlapping vulnerabilities.",
        "The SUMOylation inhibitor TAK-981 has entered early phase clinical trials, focusing on patients with advanced or metastatic solid tumors (non-squamous non-small cell lung cancer, cervical cancer, microsatellite stable colorectal cancer) or relapsed/refractory multiple myeloma.17 TAK-981 is also an apex SUMO inhibitor, targeting the SAE1/2 heterodimer via the same mechanism as ML-792.16 Although slightly less potent in vitro, TAK-981 shows more durable responses in pre-clinical tumor models. It also induces chromosome segregation errors and polyploidy in human pancreatic cancer cell lines.42 Our results show that a subset of patient-derived HGSOC models is sensitive to an apex SUMO inhibitor of this class. When exposed to ML-792 alone, while 18 of the 30 OCMs screened were largely resistant, five were particularly sensitive, and a further seven showed intermediate sensitivity. Of the 12 sensitive/intermediate OCMs, only two are sensitive to the PARP inhibitor Olaparib, while seven are resistant, and three have not yet been tested (to be described elsewhere). This suggests that SUMO inhibitors may have the potential to target HGSOC independent of homologous recombination (HR) status. Note that while PARP inhibitors are highly effective in cases of HR-deficient disease, \u223c60% of HGSOCs are HR-proficient,62,79,80 and therefore unlikely to respond to a PARP inhibitor. Because there are currently few treatment options for this patient subgroup, evaluating SUMOylation inhibitors in HR-proficient HGSOC should be a priority."
      ]
    },
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.09792590141296387,
    "data_pmids_checked": 2,
    "paper_id": "40487451",
    "extraction_date": "2025-12-19T19:46:32.629334",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40487451.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40501575": {
    "cbioportal_paper_citations": [
      "eIF3e and eIF3d RNA signatures were made by comparing the LFC of RNA in siCtrl cells compared to KD cells in hypoxia. Genes included in each signature had a log2 fold change <\u22121 or >1 and an adjusted p value <0.05. mRNA microarray data for 2509 primary breast tumor samples were downloaded from cBioPortal for Cancer Genomics84, 85 specifically from the METABRIC Breast Cancer study62, 63. Duplicate microarray data for patient entries were merged by taking the mean of the z-score for each gene. Patients with missing microarray data were removed. After preprocessing, we performed downstream analysis on the remaining 1980 patients."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "30867590": [
        "eIF3e and eIF3d RNA signatures were made by comparing the LFC of RNA in siCtrl cells compared to KD cells in hypoxia. Genes included in each signature had a log2 fold change <\u22121 or >1 and an adjusted p value <0.05. mRNA microarray data for 2509 primary breast tumor samples were downloaded from cBioPortal for Cancer Genomics84, 85 specifically from the METABRIC Breast Cancer study62, 63. Duplicate microarray data for patient entries were merged by taking the mean of the z-score for each gene. Patients with missing microarray data were removed. After preprocessing, we performed downstream analysis on the remaining 1980 patients."
      ],
      "27161491": [
        "Hypoxia is known to promote tumor progression and correlate with worse prognosis among breast cancer patients4, 55, 59. Since our data show that eIF3d and eIF3e promote the hypoxic response in breast cancer cells, we asked whether EIF3D or EIF3E were dysregulated in large breast cancer patient cohorts, such as METABRIC (1980 patients), in a manner correlated with survival. We found that 3% and 46% of patients exhibited gain/amplification in the EIF3D or EIF3E alleles (Fig. S3A), respectively. Interestingly, EIF3E gain/amplification significantly correlated with worse prognosis, while EIF3D gain/amplification did not (Fig. 4A\u2013B). However, since the chromosomal location of EIF3E (8q23) is very close to that of cMYC (8q24), which is amplified in ~70% of human malignancies and acts as a prominent oncogene60, the prognostic value of EIF3E may be driven by cMYC co-amplification. Therefore, we developed EIF3D and EIF3E signatures from RNA-seq in MCF7SIX1 cells with eIF3d or eIF3e KD in hypoxia (p < 0.05 and LFC > 1 or <\u22121), to identify a prognostic signature specific to EIF3D and EIF3E independent of cMYC. We stratified patients based on the enrichment of EIF3D and EIF3E RNA signatures. Enrichment of the EIF3E signature was associated with worsened survival compared to patients depleted of the EIF3E signature (Fig. 4C). The eIF3d signature did not correlate with overall survival (Fig. S3B). Next, we asked how a previously published 42-gene mRNA hypoxia signature conserved across breast cancer cell lines61 stratified patient survival. As expected, enrichment of the hypoxia signature was associated with worsened patient survival in the METABRIC dataset62\u201364 (Fig. 4D).",
        "eIF3e and eIF3d RNA signatures were made by comparing the LFC of RNA in siCtrl cells compared to KD cells in hypoxia. Genes included in each signature had a log2 fold change <\u22121 or >1 and an adjusted p value <0.05. mRNA microarray data for 2509 primary breast tumor samples were downloaded from cBioPortal for Cancer Genomics84, 85 specifically from the METABRIC Breast Cancer study62, 63. Duplicate microarray data for patient entries were merged by taking the mean of the z-score for each gene. Patients with missing microarray data were removed. After preprocessing, we performed downstream analysis on the remaining 1980 patients."
      ],
      "22522925": [
        "Hypoxia is known to promote tumor progression and correlate with worse prognosis among breast cancer patients4, 55, 59. Since our data show that eIF3d and eIF3e promote the hypoxic response in breast cancer cells, we asked whether EIF3D or EIF3E were dysregulated in large breast cancer patient cohorts, such as METABRIC (1980 patients), in a manner correlated with survival. We found that 3% and 46% of patients exhibited gain/amplification in the EIF3D or EIF3E alleles (Fig. S3A), respectively. Interestingly, EIF3E gain/amplification significantly correlated with worse prognosis, while EIF3D gain/amplification did not (Fig. 4A\u2013B). However, since the chromosomal location of EIF3E (8q23) is very close to that of cMYC (8q24), which is amplified in ~70% of human malignancies and acts as a prominent oncogene60, the prognostic value of EIF3E may be driven by cMYC co-amplification. Therefore, we developed EIF3D and EIF3E signatures from RNA-seq in MCF7SIX1 cells with eIF3d or eIF3e KD in hypoxia (p < 0.05 and LFC > 1 or <\u22121), to identify a prognostic signature specific to EIF3D and EIF3E independent of cMYC. We stratified patients based on the enrichment of EIF3D and EIF3E RNA signatures. Enrichment of the EIF3E signature was associated with worsened survival compared to patients depleted of the EIF3E signature (Fig. 4C). The eIF3d signature did not correlate with overall survival (Fig. S3B). Next, we asked how a previously published 42-gene mRNA hypoxia signature conserved across breast cancer cell lines61 stratified patient survival. As expected, enrichment of the hypoxia signature was associated with worsened patient survival in the METABRIC dataset62\u201364 (Fig. 4D)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1193699836730957,
    "data_pmids_checked": 3,
    "paper_id": "40501575",
    "extraction_date": "2025-12-19T19:46:32.650184",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40501575.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40453522": {
    "cbioportal_paper_citations": [
      "We identified TP53 mutant cases of AML, MDS, AML-MRC, and t-AML in the cBioPortal database, a public-facing repository that incorporates data from multiple studies,28,29 and in the Hematologic Malignancies Data Repository of the Dana-Farber Cancer Institute. From cBioPortal, we incorporated AML data sets from Oregon Health and Science University30 and the Cancer Genome Atlas3; MDS data sets from the University of Tokyo31 and Memorial Sloan-Kettering Cancer Center (MSKCC)30,32; and an MDS/AML data set from Washington University in St. Louis.33 All cases in both data sets were annotated with diagnostic classification and mutation(s) identified by next-generation sequencing, including nucleotide change, amino acid change, and VAF; additional information, including karyotype, treatment history, and clinical outcome, was available for a limited subset of cases. The data sets were not significantly different in terms of the ratios of missense to inactivating TP53 mutations within disease categories. The only exception was the Vanderbilt-Ingram Cancer Center (VICC) data set, which had fewer missense mutations in all disease categories but otherwise reflected the same trends seen in the other data sets. Duplicates within and between databases were manually filtered and removed, and only cases with TP53 mutations annotated as pathogenic or likely pathogenic were included in the analysis (ie, nonpathogenic variants were excluded). After filtering, there were a total of 1117 independent instances of TP53 mutations in myeloid neoplasms, representing 536, 349, 167, and 65 instances in AML, MDS, AML-MRC, and t-AML, respectively. We classified TP53 mutations as nonsense, frameshift, splice, in-frame indel, or missense, and calculated the frequency of each mutation type in each disease. Information on large deletions was not available. When samples from the same patient were sequenced multiple times, replicates were removed for cataloging p53 mutations but were retained for analyses involving VAF and comutations to capture evolving changes. For survival analysis of individuals with multiple TP53 mutations, the mutation with the highest VAF was considered."
    ],
    "cbioportal_platform_mentions": [
      "Data were obtained from cBioPortal using the cBioPortalData Bioconductor package in R version 4.1.3 from the previously identified studies. All comutation plots were created using the CoMut python package.",
      "In this study, we identified differences in TP53 mutations between myeloid neoplasms and solid tumors, as well as between subtypes of myeloid neoplasms, particularly between MDS and AML-MRC. These findings suggest discrete biological mechanisms for mutant p53 in hematologic malignancies, particularly in driving initiation and progression of myeloid neoplasia, and indicate that molecular and functional characterization of TP53 mutations, as opposed to p53 immunohistochemistry alone, may be required for optimal assessment of TP53-mutant myeloid neoplasms in clinical practice. Notably, our analyses took advantage of large consortia that pool data from multiple independent studies and institutions (eg, cBioPortal) to uncover associations between TP53 mutation types, functions, and disease categories. This approach has been fruitful in yielding both novel mechanistic insights and clinically useful correlations in solid tumors.40, 41, 42 However, data derived from such sources are, by nature, heterogeneous in their analytical methods and clinical treatment protocols. Future studies using cohorts derived from single institutions will be critical to ensure that the conclusions are not influenced by hidden confounding variables that can occur in both overly homogeneous or heterogeneous data sets; furthermore, these studies may uncover additional associations or determine impacts of other variables (eg, blast count or monoallelic vs biallelic mutation) on the correlation between individual mutations/mutation classes and clinical outcomes."
    ],
    "data_publication_citations": {
      "27959731": [
        "We identified TP53 mutant cases of AML, MDS, AML-MRC, and t-AML in the cBioPortal database, a public-facing repository that incorporates data from multiple studies,28,29 and in the Hematologic Malignancies Data Repository of the Dana-Farber Cancer Institute. From cBioPortal, we incorporated AML data sets from Oregon Health and Science University30 and the Cancer Genome Atlas3; MDS data sets from the University of Tokyo31 and Memorial Sloan-Kettering Cancer Center (MSKCC)30,32; and an MDS/AML data set from Washington University in St. Louis.33 All cases in both data sets were annotated with diagnostic classification and mutation(s) identified by next-generation sequencing, including nucleotide change, amino acid change, and VAF; additional information, including karyotype, treatment history, and clinical outcome, was available for a limited subset of cases. The data sets were not significantly different in terms of the ratios of missense to inactivating TP53 mutations within disease categories. The only exception was the Vanderbilt-Ingram Cancer Center (VICC) data set, which had fewer missense mutations in all disease categories but otherwise reflected the same trends seen in the other data sets. Duplicates within and between databases were manually filtered and removed, and only cases with TP53 mutations annotated as pathogenic or likely pathogenic were included in the analysis (ie, nonpathogenic variants were excluded). After filtering, there were a total of 1117 independent instances of TP53 mutations in myeloid neoplasms, representing 536, 349, 167, and 65 instances in AML, MDS, AML-MRC, and t-AML, respectively. We classified TP53 mutations as nonsense, frameshift, splice, in-frame indel, or missense, and calculated the frequency of each mutation type in each disease. Information on large deletions was not available. When samples from the same patient were sequenced multiple times, replicates were removed for cataloging p53 mutations but were retained for analyses involving VAF and comutations to capture evolving changes. For survival analysis of individuals with multiple TP53 mutations, the mutation with the highest VAF was considered."
      ],
      "24030381": [
        "The transcription factor p53, encoded by the TP53 gene, functions as a tumor suppressor in multiple tissues.1 TP53 is the most frequently mutated gene in human cancers, with mutation incidence exceeding 50% for many cancer types.2 In myeloid neoplasms, TP53 mutations occur in \u223c10% of cases,3,4 and, as for solid tumors, are strong and independent predictors of adverse prognosis, including failure of induction chemotherapy, relapse after hematopoietic stem cell transplantation, and reduced overall survival.5, 6, 7, 8",
        "Among myeloid neoplasms, MDS and AML-MRC showed the greatest differences in terms of their types, distributions, and predicted transcriptional activities of TP53 mutations. These findings suggest that distinct types of TP53 mutations mediate initiation of MDS and progression of MDS to AML. We find that R175H, G245S, and R282W were underrepresented in MDS and AML-MRC compared with AML; the R175H result is consistent with the study of Tashakori et al.20 Conversely, R273H mutations were more common in MDS and AML-MRC than in AML. We found that missense mutations, particularly those retaining higher levels of transcriptional activity, are overrepresented in MDS, whereas mutations resulting in complete loss of expression or transcriptional activity of p53 protein are relatively overrepresented in AML-MRC. This result suggests that p53 missense mutations may play a more active role in initiation of MDS, possibly by acquiring gain-of-function properties, whereas p53 inactivation is sufficient for progression to AML-MRC. The specific association of TP53 nonsense mutations with DNMT3A mutations in AML-MRC supports this hypothesis, because DNMT3A mutations (and, more broadly, mutations in genes that regulate chromatin accessibility and/or epigenetic control of gene expression) are common founder mutations in both MDS4 and clonal hematopoiesis of indeterminate potential.49 Notably, WT p53 protein can assume a \u201cpseudomutant\u201d conformation in hematopoietic stem cells, frequently in the presence of DNMT3A mutations, leading to mutant-like activation of downstream transcriptional pathways.50 Thus, in this setting, TP53 missense mutation may not provide additional selective advantage to preleukemic clones, whereas truncating mutations may be capable of promoting further leukemogenesis and driving progression to AML-MRC. Overall, these findings raise the intriguing possibility that specific identification of TP53 mutations in MDS may be useful in predicting which patients are likely to progress to AML. Tracking the evolution of TP53 mutations in individual patients during progression from MDS to AML-MRC will be instrumental in further evaluation of this question. It would also be of interest to analyze the distribution of TP53 mutations as a function of blast percentage in MDS, particularly in light of recent data indicating that the clinical impact of TP53 mutation is different in MDS with and without excess blasts.17 Although such analysis would require larger and more comprehensively annotated data sets than those used for this study, it might identify whether differences in the nature and distribution of mutations manifest at an even earlier stage than the transition from MDS to AML."
      ],
      "21909114": [
        "We identified TP53 mutant cases of AML, MDS, AML-MRC, and t-AML in the cBioPortal database, a public-facing repository that incorporates data from multiple studies,28,29 and in the Hematologic Malignancies Data Repository of the Dana-Farber Cancer Institute. From cBioPortal, we incorporated AML data sets from Oregon Health and Science University30 and the Cancer Genome Atlas3; MDS data sets from the University of Tokyo31 and Memorial Sloan-Kettering Cancer Center (MSKCC)30,32; and an MDS/AML data set from Washington University in St. Louis.33 All cases in both data sets were annotated with diagnostic classification and mutation(s) identified by next-generation sequencing, including nucleotide change, amino acid change, and VAF; additional information, including karyotype, treatment history, and clinical outcome, was available for a limited subset of cases. The data sets were not significantly different in terms of the ratios of missense to inactivating TP53 mutations within disease categories. The only exception was the Vanderbilt-Ingram Cancer Center (VICC) data set, which had fewer missense mutations in all disease categories but otherwise reflected the same trends seen in the other data sets. Duplicates within and between databases were manually filtered and removed, and only cases with TP53 mutations annotated as pathogenic or likely pathogenic were included in the analysis (ie, nonpathogenic variants were excluded). After filtering, there were a total of 1117 independent instances of TP53 mutations in myeloid neoplasms, representing 536, 349, 167, and 65 instances in AML, MDS, AML-MRC, and t-AML, respectively. We classified TP53 mutations as nonsense, frameshift, splice, in-frame indel, or missense, and calculated the frequency of each mutation type in each disease. Information on large deletions was not available. When samples from the same patient were sequenced multiple times, replicates were removed for cataloging p53 mutations but were retained for analyses involving VAF and comutations to capture evolving changes. For survival analysis of individuals with multiple TP53 mutations, the mutation with the highest VAF was considered."
      ],
      "27276561": [
        "We identified TP53 mutant cases of AML, MDS, AML-MRC, and t-AML in the cBioPortal database, a public-facing repository that incorporates data from multiple studies,28,29 and in the Hematologic Malignancies Data Repository of the Dana-Farber Cancer Institute. From cBioPortal, we incorporated AML data sets from Oregon Health and Science University30 and the Cancer Genome Atlas3; MDS data sets from the University of Tokyo31 and Memorial Sloan-Kettering Cancer Center (MSKCC)30,32; and an MDS/AML data set from Washington University in St. Louis.33 All cases in both data sets were annotated with diagnostic classification and mutation(s) identified by next-generation sequencing, including nucleotide change, amino acid change, and VAF; additional information, including karyotype, treatment history, and clinical outcome, was available for a limited subset of cases. The data sets were not significantly different in terms of the ratios of missense to inactivating TP53 mutations within disease categories. The only exception was the Vanderbilt-Ingram Cancer Center (VICC) data set, which had fewer missense mutations in all disease categories but otherwise reflected the same trends seen in the other data sets. Duplicates within and between databases were manually filtered and removed, and only cases with TP53 mutations annotated as pathogenic or likely pathogenic were included in the analysis (ie, nonpathogenic variants were excluded). After filtering, there were a total of 1117 independent instances of TP53 mutations in myeloid neoplasms, representing 536, 349, 167, and 65 instances in AML, MDS, AML-MRC, and t-AML, respectively. We classified TP53 mutations as nonsense, frameshift, splice, in-frame indel, or missense, and calculated the frequency of each mutation type in each disease. Information on large deletions was not available. When samples from the same patient were sequenced multiple times, replicates were removed for cataloging p53 mutations but were retained for analyses involving VAF and comutations to capture evolving changes. For survival analysis of individuals with multiple TP53 mutations, the mutation with the highest VAF was considered."
      ],
      "23634996": [
        "The transcription factor p53, encoded by the TP53 gene, functions as a tumor suppressor in multiple tissues.1 TP53 is the most frequently mutated gene in human cancers, with mutation incidence exceeding 50% for many cancer types.2 In myeloid neoplasms, TP53 mutations occur in \u223c10% of cases,3,4 and, as for solid tumors, are strong and independent predictors of adverse prognosis, including failure of induction chemotherapy, relapse after hematopoietic stem cell transplantation, and reduced overall survival.5, 6, 7, 8",
        "We identified TP53 mutant cases of AML, MDS, AML-MRC, and t-AML in the cBioPortal database, a public-facing repository that incorporates data from multiple studies,28,29 and in the Hematologic Malignancies Data Repository of the Dana-Farber Cancer Institute. From cBioPortal, we incorporated AML data sets from Oregon Health and Science University30 and the Cancer Genome Atlas3; MDS data sets from the University of Tokyo31 and Memorial Sloan-Kettering Cancer Center (MSKCC)30,32; and an MDS/AML data set from Washington University in St. Louis.33 All cases in both data sets were annotated with diagnostic classification and mutation(s) identified by next-generation sequencing, including nucleotide change, amino acid change, and VAF; additional information, including karyotype, treatment history, and clinical outcome, was available for a limited subset of cases. The data sets were not significantly different in terms of the ratios of missense to inactivating TP53 mutations within disease categories. The only exception was the Vanderbilt-Ingram Cancer Center (VICC) data set, which had fewer missense mutations in all disease categories but otherwise reflected the same trends seen in the other data sets. Duplicates within and between databases were manually filtered and removed, and only cases with TP53 mutations annotated as pathogenic or likely pathogenic were included in the analysis (ie, nonpathogenic variants were excluded). After filtering, there were a total of 1117 independent instances of TP53 mutations in myeloid neoplasms, representing 536, 349, 167, and 65 instances in AML, MDS, AML-MRC, and t-AML, respectively. We classified TP53 mutations as nonsense, frameshift, splice, in-frame indel, or missense, and calculated the frequency of each mutation type in each disease. Information on large deletions was not available. When samples from the same patient were sequenced multiple times, replicates were removed for cataloging p53 mutations but were retained for analyses involving VAF and comutations to capture evolving changes. For survival analysis of individuals with multiple TP53 mutations, the mutation with the highest VAF was considered.",
        "In the analyzed data sets, 6.9% to 23.5% myeloid neoplasia cases were TP53 mutant, consistent with previously reported statistics.3 In total, the analyzed data sets included 414 unique mutations; \u223c20% of samples contained multiple TP53 mutations, with <3% containing \u22653 mutations (Table 1). The distribution of VAFs was similar between disease categories except for MDS, which had significantly lower VAFs, consistent with expected lower blast counts (supplemental Figure 1A; supplemental Table 1). Patterns of single-nucleotide substitutions in TP53 were similar between diseases; C\u2192T mutations, which showed a coding strand bias, comprised approximately half of all single-nucleotide changes, consistent with mutations arising from DNA methylation (supplemental Figure 1B). In samples with multiple mutations, VAFs were generally within a twofold range, indicating that the mutations arose at similar points in disease progression (supplemental Figure 1C, region between gray lines).Table 1.Percentage of cases harboring the indicated number of distinct TP53 mutationsNumber of TP53 mutations1, % (n)2, % (n)\u22653, % (n)AML78.6 (338)19.1 (82)2.3 (10)MDS77.3 (214)20.6 (57)2.2 (6)AML-MRC79.5 (109)19.0 (26)1.5 (2)t-AML81.8 (45)18.2 (10)0 (0)Cases were stratified by disease type, and the percentage of cases with 1, 2, and \u22653 mutations was determined. For patients of whom multiple samples were sequenced, the largest number of distinct TP53 mutations identified in a single sample was considered."
      ],
      "30333627": [
        "We identified TP53 mutant cases of AML, MDS, AML-MRC, and t-AML in the cBioPortal database, a public-facing repository that incorporates data from multiple studies,28,29 and in the Hematologic Malignancies Data Repository of the Dana-Farber Cancer Institute. From cBioPortal, we incorporated AML data sets from Oregon Health and Science University30 and the Cancer Genome Atlas3; MDS data sets from the University of Tokyo31 and Memorial Sloan-Kettering Cancer Center (MSKCC)30,32; and an MDS/AML data set from Washington University in St. Louis.33 All cases in both data sets were annotated with diagnostic classification and mutation(s) identified by next-generation sequencing, including nucleotide change, amino acid change, and VAF; additional information, including karyotype, treatment history, and clinical outcome, was available for a limited subset of cases. The data sets were not significantly different in terms of the ratios of missense to inactivating TP53 mutations within disease categories. The only exception was the Vanderbilt-Ingram Cancer Center (VICC) data set, which had fewer missense mutations in all disease categories but otherwise reflected the same trends seen in the other data sets. Duplicates within and between databases were manually filtered and removed, and only cases with TP53 mutations annotated as pathogenic or likely pathogenic were included in the analysis (ie, nonpathogenic variants were excluded). After filtering, there were a total of 1117 independent instances of TP53 mutations in myeloid neoplasms, representing 536, 349, 167, and 65 instances in AML, MDS, AML-MRC, and t-AML, respectively. We classified TP53 mutations as nonsense, frameshift, splice, in-frame indel, or missense, and calculated the frequency of each mutation type in each disease. Information on large deletions was not available. When samples from the same patient were sequenced multiple times, replicates were removed for cataloging p53 mutations but were retained for analyses involving VAF and comutations to capture evolving changes. For survival analysis of individuals with multiple TP53 mutations, the mutation with the highest VAF was considered."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 6,
    "extraction_method": "jats_xml",
    "extraction_time": 0.54012131690979,
    "data_pmids_checked": 6,
    "paper_id": "40453522",
    "extraction_date": "2025-12-19T19:46:33.172226",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40453522.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40449847": {
    "cbioportal_paper_citations": [
      "As plectin was a critical component of HD and served as a cytoskeletal/structural cytolinker, we next expanded our analysis to include HD/HD-associated and DSM/DSM-associated component genes (referred to as plectin-associated genes), using the online available genomic landscape databases of 1640 SCCs, including 629 head and neck SCCs (HNSCCs), 487 lung SCCs (LSCCs), 297 cervical SCCs (CSCCs), and 227 ESCCs.44,45 Detailed analyses via cBioPortal showed that mutations of HD/HD-associated components (PLEC, DST, COL17A1, ITGA6, ITGB4, CD151, KRT14, KRT5, LAMA3, LAMB3, and LAMC2) and DSM/DSM-associated components (PLEC, DSP, DSG, DSC, JUP, and PKP1-3) were recurrently found in 1% to 8% of the SCC samples (Figure 2A and B). Notably, mutations in individual plectin or plectin-associated genes were rare events, but they were mutually exclusive. When combined with all mutations in plectin and plectin-associated genes, the total number of mutations was approximately 50% of the SCCs examined, suggesting that plectin and plectin-associated gene products could play important roles in ESCC/SCC carcinogenesis.Figure 2Genomic alterations of plectin/plectin-associated genes in human ESCC/SCC. (A) Schematic illustration of HD (left) and DSMs (right) structures in the stratified epithelium. (B) Somatic mutations of plectin/plectin-associated genes, including HD/HD-associated components and DSM/DSM-associated components in 7 SCC cohorts (1640 samples) including 629 HNSCCs, 487 LSCCs, 297 CSCCs, and 227 ESCCs using cBioPortal. (C) Amplification of plectin/plectin-associated genes, including HD/HD-associated components and DSM/DSM-associated components in 7 SCC cohorts (1640 samples) using cBioPortal. (D) PLEC mRNA levels in 102 pairs of ESCC and adjacent tissues by qRT-PCR assay. \u2217\u2217\u2217P < .001. (E) Plectin mRNA expression in 2 SCC cohorts (1010 samples) analyzed by cBioPortal.",
      "Somatic mutations and copy-number alterations of HD/HD-associated components (PLEC, DST, Col17A1, ITGB4, ITGA6, CD151, KRT14, KRT5, LAMA3, LAMB3, LAMC2), DSM components (DSP, DSG1, DSG2, DSG3, DSG4, DSC1, DSC2, DSC3, JUP, PKP1, PKP2, PKP3) in 1640 SCC samples including 629 HNSCCs, 487 LSCCs, 297 CSCCs and 227 ESCCs were analyzed using cBioPortal (cBio cancer genomics portal), available at (https://www.cbioportal.org/).44,45"
    ],
    "cbioportal_platform_mentions": [
      "Genomic alterations of plectin/plectin-associated genes in human ESCC/SCC. (A) Schematic illustration of HD (left) and DSMs (right) structures in the stratified epithelium. (B) Somatic mutations of plectin/plectin-associated genes, including HD/HD-associated components and DSM/DSM-associated components in 7 SCC cohorts (1640 samples) including 629 HNSCCs, 487 LSCCs, 297 CSCCs, and 227 ESCCs using cBioPortal. (C) Amplification of plectin/plectin-associated genes, including HD/HD-associated components and DSM/DSM-associated components in 7 SCC cohorts (1640 samples) using cBioPortal. (D) PLEC mRNA levels in 102 pairs of ESCC and adjacent tissues by qRT-PCR assay. \u2217\u2217\u2217P < .001. (E) Plectin mRNA expression in 2 SCC cohorts (1010 samples) analyzed by cBioPortal.",
      "Paradoxically, we also observed genomic amplifications in the plectin gene locus on chromosome 8q24 in 6% of these analyzed SCCs, which was consistent with previous reports (Figure 2C).16,19,46,47 Because some samples had plectin mutations, whereas others showed plectin amplifications in these SCC cohorts, we determined the mRNA expression levels of plectin in 102 paired ESCCs and their adjacent non-tumor tissues by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Our results showed that compared with controls, 6.9% of ESCCs had low plectin mRNA expression, whereas 45.1% of ESCCs had plectin mRNA overexpression (Figure 2D). The underexpression or overexpression of plectin mRNA was also detected in SCCs from 2 The Cancer Genome Atlas (TCGA) PanCancer Atlas databases using cBioPortal analysis (Figure 2E). These results indicated that the perturbations of plectin expression in human cancers were complex.",
      "The mRNA expression levels of plectin in 1010 SCCs including 523 HNSCCs and 487 LSCCs from 2 of TCGA PanCancer Atlas databases using cBioPortal analysis were assessed based on the mRNA expression z-score (threshold \u00b11.5) relative to normal samples (log RNA Seq V2 RSEM)."
    ],
    "data_publication_citations": {
      "31792460": [
        "Consistently, plectin is expressed in both basal and suprabasal cells in skin SSE, and its genetic alterations/abnormal protein expressions cause several human SSE-related diseases, including bullous pemphigoid (BP).32 Moreover, in addition to the low frequency of mutated plectin gene observed in ESSCs, high and frequent loss-of-function (LOF) mutations in the plectin gene are detected in liposarcoma and testicular germ cell tumors.28,33, 34, 35 Paradoxically, overexpression of plectin mRNA and protein is also found in many human tumors, including prostate cancer, bladder cancer, and pancreatic cancer, suggesting that the role(s) of plectin in carcinogenesis is complex.36, 37, 38, 39 In particular, plectin expression is controlled by the oncogenic transcription factor \u0394Np63 (referred to as p63), and the function(s) of the plectin protein is regulated by post-translational modifications, such as CDK, AKT, and/or PKC phosphorylation.40,41 In addition, the Drosophila plectin/spectraplakin ortholog, Shot, is a downstream effector modulated by Notch signaling during foregut development.42 However, it is unknown whether Shot is a direct transcriptional target of Notch proteins. Given that LOF mutations in the Notch gene family are commonly detected in \u223c20% of ESCCs, and that gene amplification and protein overexpression of p63 occur in over 50% of ESCCs, it is plausible that plectin dysfunction, abnormalities in plectin-associated or -dependent macromolecules and interactions, and/or deficiencies in plectin regulators may significantly contribute to the carcinogenesis of ESCC.15, 16, 17,20 In this study, we unravel the characteristics of the aberrant oncogenic cytolinker, plectin, in human ESCC."
      ],
      "24670651": [
        "ESCC, the dominant form of human esophageal cancer, is the 7th most common cancer and the 6th leading cause of cancer death worldwide.12 Epidemiologic and genetic studies have shown that the incidence, development, and progression of ESCC are influenced by both environmental factors and genetic alterations. Although the environmental factors associated with ESCC have been identified as poor diet, alcohol consumption, and smoking, recent large-scale genetic landscape analyses have identified cancer-driver gene mutations in ESCC.13, 14, 15, 16, 17, 18, 19 As in other squamous cell carcinomas (SCCs), an extremely high frequency of p53 gene mutations is observed in ESCC, indicating a significant disruption in genomic stability. Other frequently mutated genes involved in regulating cell stemness and lineage commitment (Sox2 and p63), cell proliferation (RTK-Ras-PI3K-AKT-MAPK-Myc), cell cycle progression (cyclin D1-Cdk4/6-p16-RB), cell polarity and differentiation (FAT1-4 and Notch/WNT/Hippo), epigenetics (KMT2/4 and KAD6), and redox metabolism homeostasis (NRF2).15, 16, 17, 18,20 Despite the advances in multi-omics analysis, the molecular mechanisms underlying ESCC carcinogenesis remain largely unknown. As ESCC is characterized by high heterogeneous, we note that \u201ca long tail\u201d of mutated genes with low frequency are recurrently detected in ESCC.17 However, the roles of these genes involved in ESCC carcinogenesis remain unclear. Among them, plectin, a cytolinker and a crucial component of the HD, has genomic alterations in \u223c5% of all ESCC samples analyzed (Figure 1A). Notably, we and others have recently found that mutations in the plectin gene are recurrently detected in 4-nitroquinoline-N-oxide (4NQO)- or N-nitroso-N-methylbenzylamine (NMBzA)-induced SCC/ESCC rodent models.21,22Figure 1PLEC mutations in human ESCC. (A) Rate of PLEC mutations in 5 human ESCC genomic sequencing data (n = 973). (B) PLEC mutations were detected in 8 human ESCC cell lines. (C) Enrichment of PLEC mutations in its protein functional domains in 465 ESCCs (4 cohorts).",
        "Consistently, plectin is expressed in both basal and suprabasal cells in skin SSE, and its genetic alterations/abnormal protein expressions cause several human SSE-related diseases, including bullous pemphigoid (BP).32 Moreover, in addition to the low frequency of mutated plectin gene observed in ESSCs, high and frequent loss-of-function (LOF) mutations in the plectin gene are detected in liposarcoma and testicular germ cell tumors.28,33, 34, 35 Paradoxically, overexpression of plectin mRNA and protein is also found in many human tumors, including prostate cancer, bladder cancer, and pancreatic cancer, suggesting that the role(s) of plectin in carcinogenesis is complex.36, 37, 38, 39 In particular, plectin expression is controlled by the oncogenic transcription factor \u0394Np63 (referred to as p63), and the function(s) of the plectin protein is regulated by post-translational modifications, such as CDK, AKT, and/or PKC phosphorylation.40,41 In addition, the Drosophila plectin/spectraplakin ortholog, Shot, is a downstream effector modulated by Notch signaling during foregut development.42 However, it is unknown whether Shot is a direct transcriptional target of Notch proteins. Given that LOF mutations in the Notch gene family are commonly detected in \u223c20% of ESCCs, and that gene amplification and protein overexpression of p63 occur in over 50% of ESCCs, it is plausible that plectin dysfunction, abnormalities in plectin-associated or -dependent macromolecules and interactions, and/or deficiencies in plectin regulators may significantly contribute to the carcinogenesis of ESCC.15, 16, 17,20 In this study, we unravel the characteristics of the aberrant oncogenic cytolinker, plectin, in human ESCC.",
        "We sought to determine plectin and plectin-associated genes (eg, HD, DSM, and cytoskeletal component genes) involved in the carcinogenesis of ESCC. To this end, we first manually analyzed the genomic sequencing data of 973 ESCC samples, including 639 whole-genome sequencing (WGS) datasets, 215 whole-exome sequencing (WES) datasets, and 119 targeted deep sequencing datasets from 5 published studies.15, 16, 17,19,20 The results revealed genomic alterations in the plectin gene, including missense mutations, nonsense mutations, and deletion mutations, occurring in approximately 5% of these ESCCs (Figure 1A). In addition, plectin gene mutations were also detected in 2 ESCC cell lines, EC109 and KYSE450, from our WGS data (Figure 1B; Supplementary Table 1) and 2 published studies (Figure 1B).19,43 Although no hotspot mutations were observed, the mutations were mainly located within the functional domains of the plectin protein, such as the C-terminal plectin repeat domains (PRDs), the rod coiled-coil domain, and the N-terminal plakin domain (Figure 1C), suggesting that they were likely to be LOF mutations, as previously reported.28,33, 34, 35 Taken together, these results indicated that, although the genomic alterations of the plectin gene were rare, they occurred recurrently in ESCCs.",
        "Paradoxically, we also observed genomic amplifications in the plectin gene locus on chromosome 8q24 in 6% of these analyzed SCCs, which was consistent with previous reports (Figure 2C).16,19,46,47 Because some samples had plectin mutations, whereas others showed plectin amplifications in these SCC cohorts, we determined the mRNA expression levels of plectin in 102 paired ESCCs and their adjacent non-tumor tissues by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Our results showed that compared with controls, 6.9% of ESCCs had low plectin mRNA expression, whereas 45.1% of ESCCs had plectin mRNA overexpression (Figure 2D). The underexpression or overexpression of plectin mRNA was also detected in SCCs from 2 The Cancer Genome Atlas (TCGA) PanCancer Atlas databases using cBioPortal analysis (Figure 2E). These results indicated that the perturbations of plectin expression in human cancers were complex.",
        "Genomic alteration rates of the plectin gene were calculated according to the genomic sequencing data of 973 ESCCs, including 639 WGS data, 215 WES data, and 119 targeted deep sequencing data from 5 published studies.15, 16, 17,19,20 Mutation data of the plectin gene in ESCC cell lines (KYSE30, KYSE150, KYSE180, KYSE410, KYES450, KYES510, EC109, and TE-1) were acquired from the published sequencing studies, Cancer Cell Line Encyclopedia (CCLE) database and our sequencing data (Supplementary Table 1).19,43,79 The clean data files of whole genome sequencing of EC109 have been deposited on GSA for humans (HRA008578, https://ngdc.cncb.ac.cn/gsa-human/browse/HRA008578).",
        "The organoids were processed into single cells as described previously.16 CUT&Tag library was performed according to the instructions of NovoNGS CUT&Tag 4.0 High-Sensitivity Kit (for Illumina) (Novoprotein). Briefly, the cells were fixed on the surface of ConA magnetic beads, and then the cell membrane was permeabilized by adding Digitonin. The primary antibody, secondary antibody, and transposon were incubated and cleaved in turn. The reaction products were extracted by DNA extraction and enriched by PCR to complete the construction of the next-generation sequencing library. The library preparations were sequenced on the Illumina Novaseq platform at Tianjin Novogene Bioinformatic Technology Co, Ltd, and 150 bp paired-end reads were generated. Raw data (raw reads) of fastq format were first processed using fastp (v 0.20.0) to obtain clean data. Index of the reference genome was built using BWA (v 0.7.12), and clean reads were aligned to the reference genome using BWA mem -k 32 -T 30 -t 4 -M. All peak calling was performed with MACS2 (v 2.1.0). Peaks were adjusted to the same size (500 bp) centered on peak summits, and motif discoveries of these loci sequences were performed using findMotifsGenome.pl program in HOMER (v 4.9.1) software. Peak-related genes were confirmed by ChIPseeker. The raw data files are available from the GSA database (CRA022955, https://ngdc.cncb.ac.cn/gsub/submit/gsa/subCRA029321/finishedOverview)."
      ],
      "21798897": [
        "Paradoxically, we also observed genomic amplifications in the plectin gene locus on chromosome 8q24 in 6% of these analyzed SCCs, which was consistent with previous reports (Figure 2C).16,19,46,47 Because some samples had plectin mutations, whereas others showed plectin amplifications in these SCC cohorts, we determined the mRNA expression levels of plectin in 102 paired ESCCs and their adjacent non-tumor tissues by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Our results showed that compared with controls, 6.9% of ESCCs had low plectin mRNA expression, whereas 45.1% of ESCCs had plectin mRNA overexpression (Figure 2D). The underexpression or overexpression of plectin mRNA was also detected in SCCs from 2 The Cancer Genome Atlas (TCGA) PanCancer Atlas databases using cBioPortal analysis (Figure 2E). These results indicated that the perturbations of plectin expression in human cancers were complex."
      ],
      "32025007": [
        "However, we also paradoxically observed that plectin is frequently overexpressed in ESCC samples, consistent with previous findings that plectin overexpression has been detected in various types of human cancers.36,39,57,58 Moreover, in addition to previous reports that plectin expression is regulated by the oncogenic transcription factor p63,40 we demonstrate that plectin is also a downstream target of Notch1, a frequently mutated tumor suppressor gene in ESCC. Although accumulating evidence supports the critical roles of p63 and Notch signaling involved in SSE tissue homeostasis and ESCC carcinogenesis, the precise downstream targets of p63 and Notch1 in esophageal SSE/ESCC have not been well-defined. Thus, genetic alterations, abnormal expressions, and transcriptional regulations of plectin, as well as aberrant plectin-associated HDs and DSMs in ESCC, led us to hypothesize that misexpression (either underexpression or overexpression) of plectin could disrupt its localization and function. These perturbations disrupt the functions of plectin-associated macromolecular structures, HDs and DSMs, ultimately leading to the dysfunctions of these structures and abnormalities in cell-ECM and cell-cell junctions, as well as signaling and mechanotransduction to drive/promote ESCC carcinogenesis."
      ],
      "24686850": [
        "ESCC, the dominant form of human esophageal cancer, is the 7th most common cancer and the 6th leading cause of cancer death worldwide.12 Epidemiologic and genetic studies have shown that the incidence, development, and progression of ESCC are influenced by both environmental factors and genetic alterations. Although the environmental factors associated with ESCC have been identified as poor diet, alcohol consumption, and smoking, recent large-scale genetic landscape analyses have identified cancer-driver gene mutations in ESCC.13, 14, 15, 16, 17, 18, 19 As in other squamous cell carcinomas (SCCs), an extremely high frequency of p53 gene mutations is observed in ESCC, indicating a significant disruption in genomic stability. Other frequently mutated genes involved in regulating cell stemness and lineage commitment (Sox2 and p63), cell proliferation (RTK-Ras-PI3K-AKT-MAPK-Myc), cell cycle progression (cyclin D1-Cdk4/6-p16-RB), cell polarity and differentiation (FAT1-4 and Notch/WNT/Hippo), epigenetics (KMT2/4 and KAD6), and redox metabolism homeostasis (NRF2).15, 16, 17, 18,20 Despite the advances in multi-omics analysis, the molecular mechanisms underlying ESCC carcinogenesis remain largely unknown. As ESCC is characterized by high heterogeneous, we note that \u201ca long tail\u201d of mutated genes with low frequency are recurrently detected in ESCC.17 However, the roles of these genes involved in ESCC carcinogenesis remain unclear. Among them, plectin, a cytolinker and a crucial component of the HD, has genomic alterations in \u223c5% of all ESCC samples analyzed (Figure 1A). Notably, we and others have recently found that mutations in the plectin gene are recurrently detected in 4-nitroquinoline-N-oxide (4NQO)- or N-nitroso-N-methylbenzylamine (NMBzA)-induced SCC/ESCC rodent models.21,22Figure 1PLEC mutations in human ESCC. (A) Rate of PLEC mutations in 5 human ESCC genomic sequencing data (n = 973). (B) PLEC mutations were detected in 8 human ESCC cell lines. (C) Enrichment of PLEC mutations in its protein functional domains in 465 ESCCs (4 cohorts).",
        "We sought to determine plectin and plectin-associated genes (eg, HD, DSM, and cytoskeletal component genes) involved in the carcinogenesis of ESCC. To this end, we first manually analyzed the genomic sequencing data of 973 ESCC samples, including 639 whole-genome sequencing (WGS) datasets, 215 whole-exome sequencing (WES) datasets, and 119 targeted deep sequencing datasets from 5 published studies.15, 16, 17,19,20 The results revealed genomic alterations in the plectin gene, including missense mutations, nonsense mutations, and deletion mutations, occurring in approximately 5% of these ESCCs (Figure 1A). In addition, plectin gene mutations were also detected in 2 ESCC cell lines, EC109 and KYSE450, from our WGS data (Figure 1B; Supplementary Table 1) and 2 published studies (Figure 1B).19,43 Although no hotspot mutations were observed, the mutations were mainly located within the functional domains of the plectin protein, such as the C-terminal plectin repeat domains (PRDs), the rod coiled-coil domain, and the N-terminal plakin domain (Figure 1C), suggesting that they were likely to be LOF mutations, as previously reported.28,33, 34, 35 Taken together, these results indicated that, although the genomic alterations of the plectin gene were rare, they occurred recurrently in ESCCs.",
        "Paradoxically, we also observed genomic amplifications in the plectin gene locus on chromosome 8q24 in 6% of these analyzed SCCs, which was consistent with previous reports (Figure 2C).16,19,46,47 Because some samples had plectin mutations, whereas others showed plectin amplifications in these SCC cohorts, we determined the mRNA expression levels of plectin in 102 paired ESCCs and their adjacent non-tumor tissues by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Our results showed that compared with controls, 6.9% of ESCCs had low plectin mRNA expression, whereas 45.1% of ESCCs had plectin mRNA overexpression (Figure 2D). The underexpression or overexpression of plectin mRNA was also detected in SCCs from 2 The Cancer Genome Atlas (TCGA) PanCancer Atlas databases using cBioPortal analysis (Figure 2E). These results indicated that the perturbations of plectin expression in human cancers were complex.",
        "Genomic alteration rates of the plectin gene were calculated according to the genomic sequencing data of 973 ESCCs, including 639 WGS data, 215 WES data, and 119 targeted deep sequencing data from 5 published studies.15, 16, 17,19,20 Mutation data of the plectin gene in ESCC cell lines (KYSE30, KYSE150, KYSE180, KYSE410, KYES450, KYES510, EC109, and TE-1) were acquired from the published sequencing studies, Cancer Cell Line Encyclopedia (CCLE) database and our sequencing data (Supplementary Table 1).19,43,79 The clean data files of whole genome sequencing of EC109 have been deposited on GSA for humans (HRA008578, https://ngdc.cncb.ac.cn/gsa-human/browse/HRA008578)."
      ],
      "21798893": [
        "Paradoxically, we also observed genomic amplifications in the plectin gene locus on chromosome 8q24 in 6% of these analyzed SCCs, which was consistent with previous reports (Figure 2C).16,19,46,47 Because some samples had plectin mutations, whereas others showed plectin amplifications in these SCC cohorts, we determined the mRNA expression levels of plectin in 102 paired ESCCs and their adjacent non-tumor tissues by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Our results showed that compared with controls, 6.9% of ESCCs had low plectin mRNA expression, whereas 45.1% of ESCCs had plectin mRNA overexpression (Figure 2D). The underexpression or overexpression of plectin mRNA was also detected in SCCs from 2 The Cancer Genome Atlas (TCGA) PanCancer Atlas databases using cBioPortal analysis (Figure 2E). These results indicated that the perturbations of plectin expression in human cancers were complex."
      ],
      "22460905": [
        "Genomic alteration rates of the plectin gene were calculated according to the genomic sequencing data of 973 ESCCs, including 639 WGS data, 215 WES data, and 119 targeted deep sequencing data from 5 published studies.15, 16, 17,19,20 Mutation data of the plectin gene in ESCC cell lines (KYSE30, KYSE150, KYSE180, KYSE410, KYES450, KYES510, EC109, and TE-1) were acquired from the published sequencing studies, Cancer Cell Line Encyclopedia (CCLE) database and our sequencing data (Supplementary Table 1).19,43,79 The clean data files of whole genome sequencing of EC109 have been deposited on GSA for humans (HRA008578, https://ngdc.cncb.ac.cn/gsa-human/browse/HRA008578)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 7,
    "extraction_method": "jats_xml",
    "extraction_time": 0.869074821472168,
    "data_pmids_checked": 7,
    "paper_id": "40449847",
    "extraction_date": "2025-12-19T19:46:33.519325",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40449847.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40458374": {
    "cbioportal_paper_citations": [
      "To explore molecular and clinical features associated with Stemness, we performed integrative analysis of genomic, transcriptomic, clinicopathologic, and outcome data using cBioPortal for Cancer Genomics (RRID:SCR_014555), which provides interactive access to multidimensional cancer genomics datasets and integrated visualization tools79. Specifically, we analyzed data from primary prostate cancer (Pri-PCa; TCGA-PRAD 2018, Pan-Cancer Atlas) and metastatic castration-resistant PCa (mCRPC; SU2C 2019) cohorts. Clinicopathologic variables (e.g., age, Gleason scores, PSA levels, tumor stage), genomic alterations (e.g., mutation frequency, TMB, fraction genome altered, CNAs, and SVs), and patient outcome data (e.g., overall survival, progression-free survival) were retrieved from cBioPortal (RRID:SCR_014555) as described in the \u201cPCa clinical datasets and data collection\u201d section. Transcriptomic data used for Stemness score calculation were obtained as described in the same section. For comparative analysis, mCRPC samples were stratified into top and bottom 33% by Stemness score. In TCGA, only treatment-na\u00efve Pri-PCa samples were used for a similar 33% stratification, excluding 70 patients who had received adjuvant (post-surgery) hormone therapy to reflect spontaneous disease progression. Differential expression analysis was conducted using DESeq280 (version 1.42.1; RRID:SCR_015687), and gene-level and genome-wide alteration frequencies were assessed across stratified groups and disease stages (e.g., Pri-PCa vs. mCRPC) using OncoPrint visualizations, bar plots, and correlation analysis. Associations with clinical outcomes were evaluated as described in the \u201cStatistical analysis\u201d section."
    ],
    "cbioportal_platform_mentions": [
      "cBioPortal for Cancer Genomics (RRID:SCR_014555; https://www.cbioportal.org/)",
      "TCGA PRAD 2015 and Pan-Cancer Atlas 2018: The Cancer Genome Atlas (TCGA) (https://www.cancer.gov/tcga) repository collected high-throughput molecular and clinical data from primary cancer and matched normal/benign samples spanning 33 human cancer types, including prostate adenocarcinoma (PRAD). For each cancer type, TCGA published an initial \u201cmarker papers\u201d summarizing analyses performed. Supplemental and associated data files supporting these \u201cmarker papers\u201d are available through the NCI Genomic Data Commons (GDC) website (https://gdc.cancer.gov/about-data/publications). For prostate cancer, TCGA PRAD 2015 (PMID: 26544944; ref. 18; DOI: 10.1016/j.cell.2015.10.025) is the marker paper on PCa published in 2015, which includes the dataset of 333 primary prostate adenocarcinomas (281 treatment-na\u00efve Pri-PCa, 49 PCa with post-surgery adjuvant ADT, and 52 matched normal/benign prostate tissue). Genomic data were obtained from cBioPortal for Cancer Genomics (RRID:SCR_014555; https://www.cbioportal.org), specifically the TCGA-PRAD Firehose Legacy study (https://www.cbioportal.org/study/summary?id=prad_tcga). RNAseq expression data was obtained from Zhang et al., 2020 (PMID: 32350277; ref. 16; DOI: 10.1038/s41467-020-15815-7).",
      "The expanded TCGA PRAD 2018 (Pan-Cancer Altas) cohort includes 494 patients with Pri-PCa (422 treatment-na\u00efve Pri-PCa, 70 PCa with post-surgery adjuvant hormone treatment, 2 PCa with chemotherapy) and 52 matched adjacent normal/benign prostate tissue. Clinicopathologic features (age, Gleason scores, PSA levels, tumor stages) and genomic alterations data (mutation frequency, copy number alterations [CNAs], structural variants [SVs], tumor mutation burden [TMB], fraction genome altered) were retrieved from cBioPortal for Cancer Genomics PRAD PanCancer Atlas study (https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018) and from the Pan-Cancer Atlas companion site (welcome to the Pan-Cancer Atlas webpage: https://www.cell.com/pb-assets/consortium/pancanceratlas/pancani3/index.html). Survival data were obtained from Liu et al., 201865 (PMID: 29625055; DOI: 10.1016/j.cell.2018.02.052). Normalized RNAseq data were downloaded via NCI GDC hub at UCSC Xena Functional Genomics Portal (https://gdc.xenahubs.net, version 2019-07-20; DOI: 10.1038/s41587-020-0546-8).",
      "Taylor 2010 (PMID: 20579941; DOI: 10.1016/j.ccr.2010.05.026)36: Transcriptomic profiles (Microarray) and clinicopathologic (recurrence-free survival) data of 29 adjacent benign prostate tissue, 131 Pri-PCa, and 19 mPCa were obtained from the GEO database (GSE21034) and the cBioPortal for Cancer Genomics PRAD MSKCC 2010 study (https://www.cbioportal.org/study/summary?id=prad_mskcc).",
      "SU2C 2015 (PMID: 26000489; DOI: 10.1016/j.cell.2015.05.001)10: Clinical and genomic data of 150 mCRPC samples were obtained from the cBioPortal for Cancer Genomics PRAD SU2C 2015 study (https://www.cbioportal.org/study/summary?id=prad_su2c_2015). RNAseq data of 98 mCRPC samples was retrieved from Zhang et al., 202016 (PMID: 32350277; DOI: 10.1038/s41467-020-15815-7; ref. 16).",
      "SU2C 2019 (PMID: 31061129; DOI: 10.1073/pnas.1902651116)41: This dataset includes clinicopathologic and genomic data for 444 mCRPC samples. RNAseq data of 266 mCRPC samples (prepared by using poly(A) enrichment for RNAseq library construction) were obtained from the cBioPortal for Cancer Genomics PRAD SU2C 2019 study (https://www.cbioportal.org/study/summary?id=prad_su2c_2019). In parallel with TCGA-PRAD, clinicopathologic features (age, Gleason scores, PSA levels), genomic alterations (mutation frequency, CNAs, SVs, TMB, fraction genome altered), and patient outcome data (overall survival) were also retrieved from cBioPortal (RRID:SCR_014555). These datasets were used for comparative analysis between Stemness-high and Stemness-low groups, and to explore genomic drivers and clinical associations as described in the Methods.",
      "Beltran 2016 (PMID: 26855148; DOI: 10.1038/nm.4045)28: RNAseq data of mCRPC samples, including 34 castration-resistant adenocarcinoma (mCRPC-Adeno) and 15 neuroendocrine histologies (mCRPC-NEPC) samples, was obtained from cBioPortal for the Cancer Genomics (https://www.cbioportal.org/study/summary?id=nepc_wcm_2016)."
    ],
    "data_publication_citations": {
      "26544944": [
        "To determine the global and dynamic changes of and inter-relationship between degree of malignancy (oncogenic dedifferentiation) and level of (luminal) differentiation during PCa development and progression (Supplementary Fig. S1A\u2013B), we employed two transcriptome-based algorithms to annotate 26 datasets of 3,102 bulk RNA-seq and 84,081 microarray samples encompassing the PCa continuum (Supplementary Fig. S1B; Supplementary Table S1). In our studies, we focused on and compared three progressive stages: from normal prostate to localized Pri-PCa, from low-grade to high-grade Pri-PCa, and from treatment-na\u00efve Pri-PCa to CRPC/mCRPC (Supplementary Fig. S1A). We defined \u201cprogression\u201d as stages beyond Pri-PCa and as disease entities that are more aggressive in a comparative manner. Specifically, we adapted the Stemness Index6 (mRNAsi; Stemness for short) (Supplementary Fig. S1C) to gauge the degree of malignancy (or aggressiveness) and employed the Z-score normalized canonical (pro-differentiation) AR activity or AR-A (Supplementary Fig. S1D) to measure the level of differentiation. Canonical AR-A can be determined by quantifying AR-regulated transcripts under intact androgen/AR signaling conditions, and there are several such AR-regulated gene lists14, 15, 16, 17, 18 (Supplementary Fig. S2A\u2013B). We validated the AR-A list based on their enrichment in prostatic epithelium differentiation, correlation of individual gene expression with AR-A signatures in clinical datasets, and overall consistency in correlation among the AR-A scores (Supplementary Fig. S2B\u2013D). Given that Bluemn\u2019s AR-A score14 correlated well with other scores (Supplementary Fig. S2E\u2013G) and the 10 genes in this signature consistently represented AR targets in multiple clinical datasets (Supplementary Fig. S2D; Supplementary Table S2), we decided to use this AR-regulated gene list for our AR-A quantification.",
        "In analyzing AR-A and Stemness in matched pairs of prostate tumor (T) and normal (N; tumor-adjacent benign) tissues in the TCGA-PRAD18 (n=51 pairs), Wyatt 201423 (n=12 pairs), and Long 202024 (n=10 pairs) cohorts, we observed concordantly increased AR-A and Stemness (Fig. 1A\u2013C). Accompanying elevated AR-A, AR mRNA levels were also increased in Pri-PCa compared to benign tissue (Fig. 1A\u2013C; note that the increase in AR mRNA levels in the Long 2020 cohort approached statistical significance). The paired T/N comparisons (Fig. 1A\u2013C) suggest that early PCa initiation and growth are characterized by concordantly increased Stemness and AR-A. To test whether AR-A might causally drive increased Stemness early during prostate tumorigenesis, we investigated 4 PCa nADT (i.e., ~2\u20136 months of ADT before prostatectomy or radiation) cohorts24, 25, 26. In the first 3 cohorts with matched pairs of pre- and post-nADT samples (from the same patients), nADT concordantly downregulated AR-A (without decreasing AR mRNA levels) as well as the Stemness (Fig. 1D\u2013F). In the Nastiuk cohort with non-paired post-nADT and no-nADT samples (i.e., from different patients but matched for ages and tumor grades and stages), nADT increased AR mRNA levels (Supplementary Fig. S4A) but reduced both AR-A and Stemness (Supplementary Fig. S4B\u2013C).",
        "TCGA PRAD 2015 and Pan-Cancer Atlas 2018: The Cancer Genome Atlas (TCGA) (https://www.cancer.gov/tcga) repository collected high-throughput molecular and clinical data from primary cancer and matched normal/benign samples spanning 33 human cancer types, including prostate adenocarcinoma (PRAD). For each cancer type, TCGA published an initial \u201cmarker papers\u201d summarizing analyses performed. Supplemental and associated data files supporting these \u201cmarker papers\u201d are available through the NCI Genomic Data Commons (GDC) website (https://gdc.cancer.gov/about-data/publications). For prostate cancer, TCGA PRAD 2015 (PMID: 26544944; ref. 18; DOI: 10.1016/j.cell.2015.10.025) is the marker paper on PCa published in 2015, which includes the dataset of 333 primary prostate adenocarcinomas (281 treatment-na\u00efve Pri-PCa, 49 PCa with post-surgery adjuvant ADT, and 52 matched normal/benign prostate tissue). Genomic data were obtained from cBioPortal for Cancer Genomics (RRID:SCR_014555; https://www.cbioportal.org), specifically the TCGA-PRAD Firehose Legacy study (https://www.cbioportal.org/study/summary?id=prad_tcga). RNAseq expression data was obtained from Zhang et al., 2020 (PMID: 32350277; ref. 16; DOI: 10.1038/s41467-020-15815-7).",
        "Bolis 2021 (PMID: 34857732; DOI: 10.1038/s41467-021-26840-5)27: RNAseq and clinicopathologic data of 1,223 clinical samples from an integrated cohort consisting of normal prostate specimens (n = 174), Pri-PCa (n = 714) and mCRPC (n = 335) was obtained from the Zenodo repository (Record ID: 5546618; https://zenodo.org/records/5546618). This resource of Prostate Cancer Transcriptome Atlas (https://prostatecanceratlas.org) was built and integrated from the following studies/datasets: (1) Genotype-Tissue Expression Database (GTEx; PMID: 23715323; ref. 29); (2) The Cancer Genome Atlas (TCGA, TCGA-PRAD; PMID: 26544944; ref. 18); (3) Atlas of RNA-sequencing profiles of normal human tissues68 (GSE120795; PMID: 31015567; ref. 68); (4) Integrative epigenetic taxonomy of PNPCa69 (GSE120741; PMID: 30464211; ref. 69); (5) Prognostic markers in locally advanced lymph node-negative prostate cancer (PRJNA477449); (6) The long noncoding RNA landscape of NEPC and its clinical implications70 (PRJEB21092; PMID: 29757368; ref. 70); (7) Integrative clinical sequencing analysis of metastatic CRPC reveals a high frequency of clinical actionability (PRJNA283922; dbGaP: phs000915; PMID: 26000489; ref. 10); (8) CSER\u2014exploring precision cancer medicine for sarcoma and rare cancers71 (PRJNA223419; dbGaP: phs000673; PMID: 28783718; ref. 71); (9) Molecular basis of NEPC (Beltran 2016; PRJNA282856; dbGaP: phs000909; PMID: 26855148; ref. 28); (10) Heterogeneity of androgen receptor splice variant-7 (AR-V7) protein expression and response to therapy in CRPC72 (GSE118435; PMID: 30334814; ref. 72); (11) RNAseq of human PCa cell lines and mCRPC tumor73, 74, 75 (GSE14750; PMIDs: 32460015; ref. 73; 33658518; ref. 74; 34244513; ref. 75 | GSE171729; PMID: 34244513; ref. 75); and (12) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic CRPC (PRJNA520923; GEO: GSE126078; PMID: 31361600; ref. 33)."
      ],
      "35617398": [
        "The aggressive PAM50-LumB molecular subtype42, 43, 44 was significantly more prevalent in Stemness-high PCa, accounting for 74% in Pri-PCa (compared to 15% in Stemness-low PCa; Fig. 5G) and 43% in mCRPC (compared to 4% in Stemness-low PCa; Fig. 5H). The PCS1 subtype45, 46, known for its association with ADT resistance and the highest risk of progression to advanced disease in comparison with PCS2 or PCS3, was predominantly enriched in both Stemness-high Pri-PCa and mCRPC (Fig. 5I\u2013L). Notably, the PAM50-Basal subtype42, 43 increased in Stemness-high mCRPC but not in Pri-PCa (Fig. 5G\u2013H), aligning with the characteristics of mCRPC, which involves lineage plasticity and acquisition of basal, mesenchymal, neural and stem-like phenotypes when developing ARPI resistance7, 44, 47. Consequently, Stemness-high samples remained largely AR-dependent48 in Pri-PCa (Fig. 5M) but transitioned to AR-independent NE subtype44 in mCRPC (Fig. 5N). Stemness-high PCa was also characterized by high proliferation as evidenced by their enrichment in a 31-gene cell-cycle progression signature44 (Fig. 5O\u2013P). Finally, we examined the association between Stemness and a signature of lineage plasticity risk after Enza treatment for mCRPC12 and found that Stemness-high tumors may be at risk for this virulent form of treatment resistance (Fig. 5Q\u2013R).",
        "What biological correlates do our Stemness metrics measure? First, it measures transcriptional features and relative abundance of stem cells and CSCs. Therefore, the NHP basal/stem cells display higher Stemness than luminal cells (consistent with literature19, 20, 21, 22); ARPI treatment, while shutting down AR signaling, enriches CSCs7, 34, 54, 55 and upregulates Stemness (this study); and PCa cell lines, xenografts and PDX, known to be clonally derived from cancer stem/progenitor cells, demonstrate the highest Stemness. Second, it measures cellular and lineage plasticity induced by treatment and genetic alterations. Thus, mCRPC, which harbor more abundant treatment-reprogrammed AR\u2212/lo cells and PCa cells with stem-like features or in an AR-indifferent state8, 12, 13, 14, 16, 33, 47, 48, manifests the highest Stemness. Our analysis further substantiates the aggressive nature of (AR\u2212/lo) CRPC-NEPC and DNPC compared to ARPC, as evidenced by their elevated PCa-Stem signature scores. This suggests a shift in the phenotypic landscape of mCRPC towards more stem-like and aggressive forms, particularly under the pressure of advanced therapies. Likewise, aggressive DKO and TKO murine prostate tumors have undergone lineage transformation and also exhibit higher Stemness than indolent SKO tumors. Third, the Stemness metric likely reports the high proliferative status of advanced PCa and mCRPC, as Stemness-high tumors in both Pri-PCa and mCRPC are enriched in \u201cCell-cycle progression\u201d signature and most genes in the 12-gene PCa-Stem Signature are involved in mitosis and cell-cycle progression. Finally, the Stemness score measures PCa aggressiveness as high Stemness correlates not only with more advanced and aggressive stages of PCa but also with aggressive PAM50-LumB and PCS1 molecular subtypes.",
        "In recent years, several studies27,57\u201360 have proposed stemness-based classifications or prognostic models using either single-cell RNA-seq (scRNA-seq), bulk RNA-seq or integrative analyses. These studies reinforce the biological relevance of stemness and highlight oncogenic pathways such as MYC activation, RB1/PTEN loss, and lineage plasticity in PCa progression. However, to our knowledge, none has established a quantitative, clinically validated stemness metric across a pan-cohort framework as comprehensive as ours. Of note, our 12-gene PCa-Stem signature, derived from bulk transcriptomic stratification, shows strong biological overlap with the lineage plasticity signature (LPSig) reported by Zhao et al. using scRNA-seq59. Among the shared genes, HMMR emerges as a critical node of convergence as it has been shown that HMMR promotes NE differentiation and aggressive behavior in CRPC models59. The presence of HMMR, along with DLGAP5, AURKB, and BIRC5 in our PCa-Stem signature, highlights the translational potential of this gene set in targeting NEPC and other plasticity-driven CRPC subtypes. Supporting this, Zheng et al. used multi-omics integration and machine learning to define three stemness-based PCa subtypes and constructed a nine-gene prognostic signature57 that also included HMMR and DLGAP5. KLK12, another PCa-Stem gene, was recently identified as a unique marker for SOX9High stem-like luminal epithelial cells enriched following androgen deprivation61. Additionally, our findings that MYC amplification, RB1 deletion, and PTEN loss are enriched in Stemness-high tumors are consistent with the previously reported chromatin accessibility (ATAC-seq) patterns48 and multi-omics spatial data61. It is worth noting that although our PCa-Stem signature was initially designed for risk stratification in mCRPC, the analytical framework is inherently flexible as the same platform can be extended to derive subtype-specific signatures (e.g., PCa-Stem-v2) tailored for distinct clinical phenotypes such as DNPC, ARPC, or NEPC. This scalability provides a foundation for personalized prognostication and therapy selection in PCa."
      ],
      "26000489": [
        "The level of malignancy of primary PCa (Pri-PCa) has been traditionally assessed by pathologists using a combined Gleason Score (GS), which gauges histopathological differentiation pattern of prostatic glands. The higher the GS, the more undifferentiated and more malignant the Pri-PCa is. The GS system, although clinically the \u2018gold\u2019 standard in pinpointing PCa diagnosis, is only semi-quantitative, can be subjective (to individual pathologist\u2019s assessment), and is generally not applicable to treatment-failed tumors and distant metastases (which have mostly lost differentiated glandular structures). Notably, whether more advanced Pri-PCa (GS8-10), treatment failure and metastatic dissemination are quantitatively associated with increased cancer stemness remains unknown. On the other hand, AR is the master regulator of normal prostatic epithelium differentiation and represents the therapeutic target of PCa treatments including androgen-deprivation therapy (ADT) and ARPIs. Inevitably, tumors develop resistance to ADT/ARPIs leading to the state of castration-resistant PCa (CRPC), which involves many mechanisms including genetic alterations of AR and key genes in AR pathway10, lineage plasticity8, 11, 12, and increased stemness8, 13. It is unclear how the global pro-differentiation AR signaling activity changes and evolves during the spectrum of PCa initiation and progression and during development of treatment resistance and metastasis. These discussions raise the need to quantify the AR signaling and stemness and closely track their dynamic evolution and inter-relationship during PCa progression.",
        "Next, we asked how clinical treatment and metastatic progression may impact the Stemness and AR-A by querying untreated Pri-PCa and Pri-PCa/ADT from TCGA and mCRPC in SU2C10 (Fig. 3A\u2013C). AR-A was elevated in Pri-PCa compared to adjacent benign tissue (N) but reduced in more aggressive Pri-PCa/ADT samples, while the Stemness, in contrast, continually and persistently increased from N \u2192 Pri-PCa \u2192 Pri-PCa/ADT (Fig. 3B\u2013C). Strikingly, mCRPC, despite markedly upregulating AR mRNA (Fig. 3A), showed the lowest AR-A but highest Stemness (Fig. 3B\u2013C), indicating a shift from a positive correlation between AR-A and Stemness in Pri-PCa to a negative association in mCRPC (Fig. 3D).",
        "Bolis 2021 (PMID: 34857732; DOI: 10.1038/s41467-021-26840-5)27: RNAseq and clinicopathologic data of 1,223 clinical samples from an integrated cohort consisting of normal prostate specimens (n = 174), Pri-PCa (n = 714) and mCRPC (n = 335) was obtained from the Zenodo repository (Record ID: 5546618; https://zenodo.org/records/5546618). This resource of Prostate Cancer Transcriptome Atlas (https://prostatecanceratlas.org) was built and integrated from the following studies/datasets: (1) Genotype-Tissue Expression Database (GTEx; PMID: 23715323; ref. 29); (2) The Cancer Genome Atlas (TCGA, TCGA-PRAD; PMID: 26544944; ref. 18); (3) Atlas of RNA-sequencing profiles of normal human tissues68 (GSE120795; PMID: 31015567; ref. 68); (4) Integrative epigenetic taxonomy of PNPCa69 (GSE120741; PMID: 30464211; ref. 69); (5) Prognostic markers in locally advanced lymph node-negative prostate cancer (PRJNA477449); (6) The long noncoding RNA landscape of NEPC and its clinical implications70 (PRJEB21092; PMID: 29757368; ref. 70); (7) Integrative clinical sequencing analysis of metastatic CRPC reveals a high frequency of clinical actionability (PRJNA283922; dbGaP: phs000915; PMID: 26000489; ref. 10); (8) CSER\u2014exploring precision cancer medicine for sarcoma and rare cancers71 (PRJNA223419; dbGaP: phs000673; PMID: 28783718; ref. 71); (9) Molecular basis of NEPC (Beltran 2016; PRJNA282856; dbGaP: phs000909; PMID: 26855148; ref. 28); (10) Heterogeneity of androgen receptor splice variant-7 (AR-V7) protein expression and response to therapy in CRPC72 (GSE118435; PMID: 30334814; ref. 72); (11) RNAseq of human PCa cell lines and mCRPC tumor73, 74, 75 (GSE14750; PMIDs: 32460015; ref. 73; 33658518; ref. 74; 34244513; ref. 75 | GSE171729; PMID: 34244513; ref. 75); and (12) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic CRPC (PRJNA520923; GEO: GSE126078; PMID: 31361600; ref. 33).",
        "SU2C 2015 (PMID: 26000489; DOI: 10.1016/j.cell.2015.05.001)10: Clinical and genomic data of 150 mCRPC samples were obtained from the cBioPortal for Cancer Genomics PRAD SU2C 2015 study (https://www.cbioportal.org/study/summary?id=prad_su2c_2015). RNAseq data of 98 mCRPC samples was retrieved from Zhang et al., 202016 (PMID: 32350277; DOI: 10.1038/s41467-020-15815-7; ref. 16)."
      ],
      "28783718": [
        "Bolis 2021 (PMID: 34857732; DOI: 10.1038/s41467-021-26840-5)27: RNAseq and clinicopathologic data of 1,223 clinical samples from an integrated cohort consisting of normal prostate specimens (n = 174), Pri-PCa (n = 714) and mCRPC (n = 335) was obtained from the Zenodo repository (Record ID: 5546618; https://zenodo.org/records/5546618). This resource of Prostate Cancer Transcriptome Atlas (https://prostatecanceratlas.org) was built and integrated from the following studies/datasets: (1) Genotype-Tissue Expression Database (GTEx; PMID: 23715323; ref. 29); (2) The Cancer Genome Atlas (TCGA, TCGA-PRAD; PMID: 26544944; ref. 18); (3) Atlas of RNA-sequencing profiles of normal human tissues68 (GSE120795; PMID: 31015567; ref. 68); (4) Integrative epigenetic taxonomy of PNPCa69 (GSE120741; PMID: 30464211; ref. 69); (5) Prognostic markers in locally advanced lymph node-negative prostate cancer (PRJNA477449); (6) The long noncoding RNA landscape of NEPC and its clinical implications70 (PRJEB21092; PMID: 29757368; ref. 70); (7) Integrative clinical sequencing analysis of metastatic CRPC reveals a high frequency of clinical actionability (PRJNA283922; dbGaP: phs000915; PMID: 26000489; ref. 10); (8) CSER\u2014exploring precision cancer medicine for sarcoma and rare cancers71 (PRJNA223419; dbGaP: phs000673; PMID: 28783718; ref. 71); (9) Molecular basis of NEPC (Beltran 2016; PRJNA282856; dbGaP: phs000909; PMID: 26855148; ref. 28); (10) Heterogeneity of androgen receptor splice variant-7 (AR-V7) protein expression and response to therapy in CRPC72 (GSE118435; PMID: 30334814; ref. 72); (11) RNAseq of human PCa cell lines and mCRPC tumor73, 74, 75 (GSE14750; PMIDs: 32460015; ref. 73; 33658518; ref. 74; 34244513; ref. 75 | GSE171729; PMID: 34244513; ref. 75); and (12) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic CRPC (PRJNA520923; GEO: GSE126078; PMID: 31361600; ref. 33)."
      ],
      "26855148": [
        "By employing normalized RNAseq data from the PCa transcriptome atlas (Bolis 2021), which included normal prostate specimens (n = 174), Pri-PCa (n = 714) and mCRPC (n = 335)27, we tracked the Stemness and AR-A across the PCa spectrum (Fig. 3E). AR-A increased from benign to Pri-PCa but declined in Pri-PCa/ADT and continued to decrease in mCRPC, reaching its lowest in mCRPC-NE28 as supported by J-T test (Fig. 3E). In contrast, the Stemness exhibited a continually increasing trajectory across the PCa spectrum encompassing Normal/Benign \u2192 treatment-na\u00efve Pri-PCa \u2192 Pri-PCa/ADT \u2192 (m)CRPC (P<0.0001, J-T Trend test; Fig. 3F; Supplementary Fig. S5A). Notably, the 3 subtypes of mCRPC, i.e., AR-positive (ARPC), CRPC-NEPC and AR\u2212/NE\u2212 double-negative PCa (DNPC) all showed higher Stemness than Pri-PCa and also displayed increasing Stemness among the 3 subtypes (Supplementary Fig. S5B). Unexpectedly, tumor-adjacent benign prostate tissues showed much higher Stemness than normal prostate in the Genotype-Tissue Expression Project (GTEx)29 (Fig. 3F; Supplementary Fig. S5A), which were all obtained from cancer-free organ donors. This surprising finding suggests that the transcriptomes of adjacent benign tissues have apparently skewed towards those of cancer samples, consistent with previous observations that adjacent benign tissues represent an intermediate state between healthy and tumor tissues30. Also of interest, the Cancer Cell Line Encyclopedia (CCLE)31, 32 cell lines including PCa cell lines, and PCa-derived PDX33 and xenografts34 exhibited the highest Stemness (Fig. 3F; Supplementary Fig. S5A), supporting that cancer cell lines and xenografts are clonally derived from and highly enriched in cancer stem cells (CSCs).",
        "Bolis 2021 (PMID: 34857732; DOI: 10.1038/s41467-021-26840-5)27: RNAseq and clinicopathologic data of 1,223 clinical samples from an integrated cohort consisting of normal prostate specimens (n = 174), Pri-PCa (n = 714) and mCRPC (n = 335) was obtained from the Zenodo repository (Record ID: 5546618; https://zenodo.org/records/5546618). This resource of Prostate Cancer Transcriptome Atlas (https://prostatecanceratlas.org) was built and integrated from the following studies/datasets: (1) Genotype-Tissue Expression Database (GTEx; PMID: 23715323; ref. 29); (2) The Cancer Genome Atlas (TCGA, TCGA-PRAD; PMID: 26544944; ref. 18); (3) Atlas of RNA-sequencing profiles of normal human tissues68 (GSE120795; PMID: 31015567; ref. 68); (4) Integrative epigenetic taxonomy of PNPCa69 (GSE120741; PMID: 30464211; ref. 69); (5) Prognostic markers in locally advanced lymph node-negative prostate cancer (PRJNA477449); (6) The long noncoding RNA landscape of NEPC and its clinical implications70 (PRJEB21092; PMID: 29757368; ref. 70); (7) Integrative clinical sequencing analysis of metastatic CRPC reveals a high frequency of clinical actionability (PRJNA283922; dbGaP: phs000915; PMID: 26000489; ref. 10); (8) CSER\u2014exploring precision cancer medicine for sarcoma and rare cancers71 (PRJNA223419; dbGaP: phs000673; PMID: 28783718; ref. 71); (9) Molecular basis of NEPC (Beltran 2016; PRJNA282856; dbGaP: phs000909; PMID: 26855148; ref. 28); (10) Heterogeneity of androgen receptor splice variant-7 (AR-V7) protein expression and response to therapy in CRPC72 (GSE118435; PMID: 30334814; ref. 72); (11) RNAseq of human PCa cell lines and mCRPC tumor73, 74, 75 (GSE14750; PMIDs: 32460015; ref. 73; 33658518; ref. 74; 34244513; ref. 75 | GSE171729; PMID: 34244513; ref. 75); and (12) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic CRPC (PRJNA520923; GEO: GSE126078; PMID: 31361600; ref. 33).",
        "Beltran 2016 (PMID: 26855148; DOI: 10.1038/nm.4045)28: RNAseq data of mCRPC samples, including 34 castration-resistant adenocarcinoma (mCRPC-Adeno) and 15 neuroendocrine histologies (mCRPC-NEPC) samples, was obtained from cBioPortal for the Cancer Genomics (https://www.cbioportal.org/study/summary?id=nepc_wcm_2016)."
      ],
      "29610475": [
        "Globally, both Pri-PCa and mCRPC exhibited mutations in more than a dozen genes although most of these alterations were <10% (Supplementary Fig. S8A; green symbols), consistent with reports that PCa is genomically heterogeneous with a broad spectrum of genomic alternations of low penetrance49, 50. On the other hand, homozygous deletion (HOMDEL) events, particularly, loss of PTEN and RB1, occurred frequently in both Pri-PCa and mCRPC (Supplementary Fig. S8A; blue symbols) whereas AMP events in oncogenes such as MYC were more prevalent in mCRPC (Supplementary Fig. S8A; red symbols). Nevertheless, PTEN and RB1 DEL represented among the most prevalent alterations in early-stage (GS6) PCa (Supplementary Fig. S8B\u2013C). Analysis of genetic alterations across the spectrum of PCa progression revealed that among the 3 tumor suppressors (RB1, PTEN and TP53), while homozygous RB1 DEL remained relatively constant at 13%, 6%, 10% and 10% in low-grade (GS6), high-grade (GS9/10), treated Pri-PCa and mCRPC, respectively, PTEN HOMDEL (9%, 23%, 30% and 26%) and TP53 MUT (0%, 21%, 27% and 37%) continued to increase along this progression (Supplementary Fig. S8B\u2013C). Among the 3 oncogenic events analyzed, while high levels of TMPRSS2 fusions (~40%) remained unchanged from low-grade to high-grade Pri-PCa to mCRPC, MYC (2%, 12%, 19% and 24%) and AR (0%, 1%, 6% and 49%) AMP continued to increase along the progression trajectory (Supplementary Fig. S8B\u2013C). In fact, prevalent AR MUT (11%) were observed only in the most aggressive and Stemness-highest mCRPC (Supplementary Fig. S8B\u2013C), suggesting potentially high noncanonical AR-A in mCRPC. Analyzing these major genomic alterations in association with PCa Stemness, we observed that RB1 DEL, FOXA1 (together with SPOP, IDH1, and CHD1) MUT, and especially MYC AMP were significantly associated with increased Stemness in Pri-PCa (Supplementary Fig. S8D). In mCRPC, only RB1 DEL exhibited a statistically significant association with higher Stemness (Supplementary Fig. S8E)."
      ],
      "20579941": [
        "As in our early dissection of the relationship between AR-A and Stemness during spontaneous Pri-PCa progression (Fig. 2F\u2013G), analysis of the Bolis 2021 PCa transcriptome atlas27 revealed a similar change from a positive correlation between AR-A and Stemness in Pri-PCa (blue line; Pearson\u2019s r=0.32, P<0.0001; Fig. 3G) to a negative correlation between the two in mCRPC (green line; Pearson\u2019s r=\u22120.15, P=0.005; Fig. 3G). We further extended our Stemness and AR-A interrogation to include microarray-derived transcriptomic datasets35, 36, allowing us to access data from PCa cohorts generated before the Next-generation sequencing (NGS) era. Analyzing the GRID database of over 82,000 prospectively collected biopsy samples of localized PCa from clinical use of the Veracyte Decipher test35, we systematically quantified the Stemness across the NCCN Risk Groups and observed increasing Stemness along the NCCN Risk trajectory (Fig. 3H). Likewise, in the Taylor dataset36, we observed that AR-A was the highest in Pri-PCa but significantly decreased in metastatic PCa (mPCa) (Fig. 3I) while the Stemness increased progressively from benign to Pri-PCa and reached the highest levels in mPCa (Fig. 3J). Linear regression analysis confirmed a gradual loss of positive correlation between AR-A and Stemness during PCa progression, as illustrated by distinct regression lines for each stage (Fig. 3K\u2013M).",
        "We investigated global Stemness and its prognostic significance, and observed that high Stemness consistently correlated with worse patient survival across various cohorts including the Spratt 201738 (P=0.001, log-rank; Fig. 4A), Tosoian 202039 (P=0.014, log-rank; Fig. 4B), CHAARTED 202140 (P=0.006, log-rank; Fig. 4C; P=0.149, log-rank; Supplementary Fig. S6A), and the mCRPC (SU2C 201941; P=0.06, log-rank; Supplementary Fig. S6B\u2013C) as well as Taylor 201036 (P=0.028, log-rank; Supplementary Fig. S6D\u2013E). Notably, the CHAARTED cohorts displayed the highest mean Stemness compared to Tosoian and Spratt cohorts, and the CHAARTED cohort showed the highest median Decipher Prostate Genomic Classifier38, 39, 40 among the three cohorts (Fig. 4D). Interestingly, like high Stemness, low AR-A was correlated with poor patient survival in the Taylor dataset (P=0.040, log-rank; Supplementary Fig. S6F).",
        "Taylor 2010 (PMID: 20579941; DOI: 10.1016/j.ccr.2010.05.026)36: Transcriptomic profiles (Microarray) and clinicopathologic (recurrence-free survival) data of 29 adjacent benign prostate tissue, 131 Pri-PCa, and 19 mPCa were obtained from the GEO database (GSE21034) and the cBioPortal for Cancer Genomics PRAD MSKCC 2010 study (https://www.cbioportal.org/study/summary?id=prad_mskcc)."
      ],
      "30537516": [
        "Gerhauser 2018 (PMID: 30537516; DOI: 10.1016/j.ccell.2018.10.016)67: RNAseq data of 118 primary tumor samples and 9 adjacent benign prostate tissue from early-onset PCa patients was obtained from the European Genome-Phenome Archive (EGA) (https://ega-archive.org), accession number EGAS00001002923."
      ],
      "29625055": [
        "The expanded TCGA PRAD 2018 (Pan-Cancer Altas) cohort includes 494 patients with Pri-PCa (422 treatment-na\u00efve Pri-PCa, 70 PCa with post-surgery adjuvant hormone treatment, 2 PCa with chemotherapy) and 52 matched adjacent normal/benign prostate tissue. Clinicopathologic features (age, Gleason scores, PSA levels, tumor stages) and genomic alterations data (mutation frequency, copy number alterations [CNAs], structural variants [SVs], tumor mutation burden [TMB], fraction genome altered) were retrieved from cBioPortal for Cancer Genomics PRAD PanCancer Atlas study (https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018) and from the Pan-Cancer Atlas companion site (welcome to the Pan-Cancer Atlas webpage: https://www.cell.com/pb-assets/consortium/pancanceratlas/pancani3/index.html). Survival data were obtained from Liu et al., 201865 (PMID: 29625055; DOI: 10.1016/j.cell.2018.02.052). Normalized RNAseq data were downloaded via NCI GDC hub at UCSC Xena Functional Genomics Portal (https://gdc.xenahubs.net, version 2019-07-20; DOI: 10.1038/s41587-020-0546-8)."
      ],
      "31068700": [
        "By employing normalized RNAseq data from the PCa transcriptome atlas (Bolis 2021), which included normal prostate specimens (n = 174), Pri-PCa (n = 714) and mCRPC (n = 335)27, we tracked the Stemness and AR-A across the PCa spectrum (Fig. 3E). AR-A increased from benign to Pri-PCa but declined in Pri-PCa/ADT and continued to decrease in mCRPC, reaching its lowest in mCRPC-NE28 as supported by J-T test (Fig. 3E). In contrast, the Stemness exhibited a continually increasing trajectory across the PCa spectrum encompassing Normal/Benign \u2192 treatment-na\u00efve Pri-PCa \u2192 Pri-PCa/ADT \u2192 (m)CRPC (P<0.0001, J-T Trend test; Fig. 3F; Supplementary Fig. S5A). Notably, the 3 subtypes of mCRPC, i.e., AR-positive (ARPC), CRPC-NEPC and AR\u2212/NE\u2212 double-negative PCa (DNPC) all showed higher Stemness than Pri-PCa and also displayed increasing Stemness among the 3 subtypes (Supplementary Fig. S5B). Unexpectedly, tumor-adjacent benign prostate tissues showed much higher Stemness than normal prostate in the Genotype-Tissue Expression Project (GTEx)29 (Fig. 3F; Supplementary Fig. S5A), which were all obtained from cancer-free organ donors. This surprising finding suggests that the transcriptomes of adjacent benign tissues have apparently skewed towards those of cancer samples, consistent with previous observations that adjacent benign tissues represent an intermediate state between healthy and tumor tissues30. Also of interest, the Cancer Cell Line Encyclopedia (CCLE)31, 32 cell lines including PCa cell lines, and PCa-derived PDX33 and xenografts34 exhibited the highest Stemness (Fig. 3F; Supplementary Fig. S5A), supporting that cancer cell lines and xenografts are clonally derived from and highly enriched in cancer stem cells (CSCs)."
      ],
      "22460905": [
        "By employing normalized RNAseq data from the PCa transcriptome atlas (Bolis 2021), which included normal prostate specimens (n = 174), Pri-PCa (n = 714) and mCRPC (n = 335)27, we tracked the Stemness and AR-A across the PCa spectrum (Fig. 3E). AR-A increased from benign to Pri-PCa but declined in Pri-PCa/ADT and continued to decrease in mCRPC, reaching its lowest in mCRPC-NE28 as supported by J-T test (Fig. 3E). In contrast, the Stemness exhibited a continually increasing trajectory across the PCa spectrum encompassing Normal/Benign \u2192 treatment-na\u00efve Pri-PCa \u2192 Pri-PCa/ADT \u2192 (m)CRPC (P<0.0001, J-T Trend test; Fig. 3F; Supplementary Fig. S5A). Notably, the 3 subtypes of mCRPC, i.e., AR-positive (ARPC), CRPC-NEPC and AR\u2212/NE\u2212 double-negative PCa (DNPC) all showed higher Stemness than Pri-PCa and also displayed increasing Stemness among the 3 subtypes (Supplementary Fig. S5B). Unexpectedly, tumor-adjacent benign prostate tissues showed much higher Stemness than normal prostate in the Genotype-Tissue Expression Project (GTEx)29 (Fig. 3F; Supplementary Fig. S5A), which were all obtained from cancer-free organ donors. This surprising finding suggests that the transcriptomes of adjacent benign tissues have apparently skewed towards those of cancer samples, consistent with previous observations that adjacent benign tissues represent an intermediate state between healthy and tumor tissues30. Also of interest, the Cancer Cell Line Encyclopedia (CCLE)31, 32 cell lines including PCa cell lines, and PCa-derived PDX33 and xenografts34 exhibited the highest Stemness (Fig. 3F; Supplementary Fig. S5A), supporting that cancer cell lines and xenografts are clonally derived from and highly enriched in cancer stem cells (CSCs).",
        "CCLE 2018 (PMID: 22460905; DOI: 10.1038/nature11003)31: RNAseq data of 1,019 human cell lines were obtained from the Xena Functional Genomics Portal76 (https://xenabrowser.net, version: 2018-05-30; ref. 76). Among them, eight prostate cancer cell lines \u2014 DU145 (RRID:CVCL_0105), LNCaP clone FGC (RRID:CVCL_1379), MDA PCa 2b (RRID:CVCL_4745), NCI-H660 (RRID:CVCL_0459), PC-3 (RRID:CVCL_0035), VCaP (RRID:CVCL_2235), 22Rv1 (RRID:CVCL_1045), and PRECLH (PrEC LH; RRID:CVCL_V626) \u2014 were included for analysis."
      ],
      "31061129": [
        "We investigated global Stemness and its prognostic significance, and observed that high Stemness consistently correlated with worse patient survival across various cohorts including the Spratt 201738 (P=0.001, log-rank; Fig. 4A), Tosoian 202039 (P=0.014, log-rank; Fig. 4B), CHAARTED 202140 (P=0.006, log-rank; Fig. 4C; P=0.149, log-rank; Supplementary Fig. S6A), and the mCRPC (SU2C 201941; P=0.06, log-rank; Supplementary Fig. S6B\u2013C) as well as Taylor 201036 (P=0.028, log-rank; Supplementary Fig. S6D\u2013E). Notably, the CHAARTED cohorts displayed the highest mean Stemness compared to Tosoian and Spratt cohorts, and the CHAARTED cohort showed the highest median Decipher Prostate Genomic Classifier38, 39, 40 among the three cohorts (Fig. 4D). Interestingly, like high Stemness, low AR-A was correlated with poor patient survival in the Taylor dataset (P=0.040, log-rank; Supplementary Fig. S6F).",
        "SU2C 2019 (PMID: 31061129; DOI: 10.1073/pnas.1902651116)41: This dataset includes clinicopathologic and genomic data for 444 mCRPC samples. RNAseq data of 266 mCRPC samples (prepared by using poly(A) enrichment for RNAseq library construction) were obtained from the cBioPortal for Cancer Genomics PRAD SU2C 2019 study (https://www.cbioportal.org/study/summary?id=prad_su2c_2019). In parallel with TCGA-PRAD, clinicopathologic features (age, Gleason scores, PSA levels), genomic alterations (mutation frequency, CNAs, SVs, TMB, fraction genome altered), and patient outcome data (overall survival) were also retrieved from cBioPortal (RRID:SCR_014555). These datasets were used for comparative analysis between Stemness-high and Stemness-low groups, and to explore genomic drivers and clinical associations as described in the Methods."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 12,
    "extraction_method": "jats_xml",
    "extraction_time": 1.0582799911499023,
    "data_pmids_checked": 12,
    "paper_id": "40458374",
    "extraction_date": "2025-12-19T19:46:33.610900",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40458374.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40437874": {
    "cbioportal_paper_citations": [
      "Patients at Memorial Sloan Kettering Cancer Center with alterations in MET were identified. Patients\u2019 tumours were sequenced using the MSK\u2010IMPACT next generation sequencing platform, which at the time covered up to 468 genes of interest, 34 , 35 as well as with the RNA\u2010based ARCHER fusion panel. 36 , 37 Liquid biopsies were performed using our institution's MSK\u2010ACCESS assay, which covers 169 genes and accounts for paired leukocyte sequencing. 38 Additional patients with MET alterations were identified from our clinical sequencing database, which amalgamates data on sequencing of tumours and/or ctDNA. 39 , 40 This study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "28481359": [
        "Patients at Memorial Sloan Kettering Cancer Center with alterations in MET were identified. Patients\u2019 tumours were sequenced using the MSK\u2010IMPACT next generation sequencing platform, which at the time covered up to 468 genes of interest, 34 , 35 as well as with the RNA\u2010based ARCHER fusion panel. 36 , 37 Liquid biopsies were performed using our institution's MSK\u2010ACCESS assay, which covers 169 genes and accounts for paired leukocyte sequencing. 38 Additional patients with MET alterations were identified from our clinical sequencing database, which amalgamates data on sequencing of tumours and/or ctDNA. 39 , 40 This study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.05417513847351074,
    "data_pmids_checked": 1,
    "paper_id": "40437874",
    "extraction_date": "2025-12-19T19:46:33.665341",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40437874.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40448998": {
    "cbioportal_paper_citations": [
      "RNA expression data from various Publicly available prostate cancer clinical cohorts were extracted from cBioPortal,74 Oncomine,76 CANCERTOOL75 and PCTA dataset,26. All the gene expression comparative analyses between different groups of patients, as well as correlations among selected groups of genes, were done using Cbioportal or CANCERTOOL. Kaplan-Meier survival curves (HR and 95% CI) were generated using CANCERTOOL, as mentioned accordingly."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26544944": [
        "We observed that high BCL2 mRNA expression is associated with low AR score, the AR-transcriptomic signature,21 in TCGA (primary),27 and PCF-SU2C (mCRPC)28 (Figure 1F). Additionally, in the TCGA dataset, we observed a strong negative association between BCL2 and AR protein expression (Figure S2H). It is important to note that PSA/KLK3 is a widely used, clinically relevant marker for AR activity in PC.29 In both primary27 and mCPRC28 samples, we observed a strong negative association between PSA/KLK3 and BCL2 mRNA expression (Figure S2I)."
      ],
      "26000489": [
        "Androgen-deprivation therapy (ADT) and androgen receptor (AR)-targeting therapies have demonstrated clinical benefits for prostate cancer (PC) patients, including the preservation of quality of life and the extension of survival.1\u20135 Although most prostate tumors initially respond to ADT, the duration of castration sensitivity varies, and relapse occurs as the disease transitions to lethal and incurable castration-resistant PC (CRPC).6 Despite advances in metastatic CRPC (mCRPC) therapies\u2013including AR-signaling inhibitors (ARSIs), docetaxel, radioligand therapy (RLT), PARP (poly(ADP-ribose) polymerase) inhibitors (for HRR [homologous recombintion repair]-deficient tumors), and immunotherapy (Sipuleucel-T), prolonged responsiveness is rarely observed.7 Furthermore, studies have shown that a significant proportion of mCRPCs exhibit alteration (amplification and mutation) of the AR gene8,9 and lineage plasticity (neuroendocrine PC [NEPC]).10 Notably, localized castration-sensitive PC (CSPC) rarely demonstrates AR alterations8 or lineage plasticity.11 These findings suggest that AR alterations and lineage plasticity/NEPC-like features likely arise as adaptations to systemic therapy rather than driving primary CSPC progression to aggressive disease, including mCRPC."
      ],
      "26855148": [
        "Our analysis revealed that BCL2 was strongly overexpressed in metastatic tumors compared to primary in the Grasso cohort30 (Figure S2J). Interestingly, we also observed that high-BCL2-expressing tumors in the mCRPC cohort displayed NEPC features (NE score31; Figure 1G). In the PCF-SU2C dataset, mCRPC tumors with high BCL2 (median) and low PSA (median) expression were predominantly neuroendocrine-like and had significantly lower AR activity compared to other BCL2-PSA subgroups (Figure 1H)."
      ],
      "28481359": [
        "BCL2 mRNA expression showed no association with Gleason score in the Taylor24 or The Cancer Genome Atlas (TCGA) PC cohorts, nor was it linked to biochemical recurrence (Figures S2E and S2F). Genomic BCL2 alterations were rare, with only two deletions among 727 cases in the MSKCC-IMPACT cohort (cBio-Portal).25 In the Prostate Cancer Transcriptome Atlas (PCTA) dataset,26 BCL2 mRNA levels were significantly higher (p < 0.001) in basal and luminal A subtypes compared to luminal B. (Figure S2G)."
      ],
      "25201530": [
        "While the pharmacological blockade of AR induces BCL2 expression in both mutant (LNCaP) and wild-type (LAPC4, VCaP, and 22RV1) full-length AR-expressing cells,24 our data indicate that the transient knockdown of mutant AR in LNCaP does not result in the induction of endogenous BCL2 expression. However, our findings also show that transient knockdown or overexpression of wild-type AR in PC cells is sufficient to alter AR protein or mRNA expression. Collectively, these results suggest that ADT or AR-targeted therapies may induce BCL2 expression in CSPC as well as in some CRPC cells (22RV1), depending on the status of AR in the cell. Although investigating the effects of AR alterations\u2013such as post-transcriptional and translational modifications, structural aberrations, or mutations\u2013on BCL2 expression and castration resistance is an intriguing avenue for future research, it is beyond the scope of our current study. Another major limitation is that most established CSPC cell lines used in this research are derived from metastatic sites and, as such, do not fully capture the heterogeneity and complexity of primary castration-sensitive tumors.47,70 Moreover, most of the patient-derived prostate organoids also originated from mCRPC and therefore do not respond to ADT.71\u201373 Therefore, future efforts to establish patient-derived CSPC organoids will help address the limitations associated with the lack of suitable experimental models, although this is also outside the scope of our study."
      ],
      "22722839": [
        "Our analysis revealed that BCL2 was strongly overexpressed in metastatic tumors compared to primary in the Grasso cohort30 (Figure S2J). Interestingly, we also observed that high-BCL2-expressing tumors in the mCRPC cohort displayed NEPC features (NE score31; Figure 1G). In the PCF-SU2C dataset, mCRPC tumors with high BCL2 (median) and low PSA (median) expression were predominantly neuroendocrine-like and had significantly lower AR activity compared to other BCL2-PSA subgroups (Figure 1H)."
      ],
      "31061129": [
        "We observed that high BCL2 mRNA expression is associated with low AR score, the AR-transcriptomic signature,21 in TCGA (primary),27 and PCF-SU2C (mCRPC)28 (Figure 1F). Additionally, in the TCGA dataset, we observed a strong negative association between BCL2 and AR protein expression (Figure S2H). It is important to note that PSA/KLK3 is a widely used, clinically relevant marker for AR activity in PC.29 In both primary27 and mCPRC28 samples, we observed a strong negative association between PSA/KLK3 and BCL2 mRNA expression (Figure S2I).",
        "Our subsequent investigation was aimed at determining whether exposure to abiraterone (ABI) or enzalutamide (ENZA) can lead to any changes in BCL2 mRNA expression in mCRPC patients. Surprisingly, our observations did not reveal any significant induction of BCL, BCLXL, or BCLW mRNA in mCRPC patients (SU2C cohort,28 who received first line of ARSI [ABI or ENZA] as compared to the patients receiving standard treatment (LHRH; Figure S2K). Similarly, exposure to a taxane did not alter BCL2 mRNA expression in mCRPC patients (Figure S2L). Our data provide direct clinical evidence of BCL2 expression upregulation in response to ADT only in CSPC as well as showing a strong negative association of BCL2 expression with the AR signaling pathway in PC cells."
      ],
      "35670774": [
        "Recently, we showed that loss of PIK3R1, the gene encoding the regulatory subunit of PI3-kinase, resulted in increased PC cell proliferation and AKT activity, including insulin-stimulated AKT activity.42"
      ],
      "20579941": [
        "BCL2 mRNA expression showed no association with Gleason score in the Taylor24 or The Cancer Genome Atlas (TCGA) PC cohorts, nor was it linked to biochemical recurrence (Figures S2E and S2F). Genomic BCL2 alterations were rare, with only two deletions among 727 cases in the MSKCC-IMPACT cohort (cBio-Portal).25 In the Prostate Cancer Transcriptome Atlas (PCTA) dataset,26 BCL2 mRNA levels were significantly higher (p < 0.001) in basal and luminal A subtypes compared to luminal B. (Figure S2G).",
        "While alterations in AR are drivers of most CRPC tumors, alternative-signaling pathways such as PI3K/AKT, primarily stemming from partial or complete loss of PTEN,24 are pivotal in ensuring PC cell survival and leading to disease progression. Previously, Carver and colleagues showed that PI3K pathway inhibition in PTEN-null PC cells (human and mouse) activates AR signaling, and AR inhibition by ENZA or ADT activates AKT signaling.15 Thus, these two oncogenic pathways cross-regulate each other by reciprocal feedback.15",
        "While the pharmacological blockade of AR induces BCL2 expression in both mutant (LNCaP) and wild-type (LAPC4, VCaP, and 22RV1) full-length AR-expressing cells,24 our data indicate that the transient knockdown of mutant AR in LNCaP does not result in the induction of endogenous BCL2 expression. However, our findings also show that transient knockdown or overexpression of wild-type AR in PC cells is sufficient to alter AR protein or mRNA expression. Collectively, these results suggest that ADT or AR-targeted therapies may induce BCL2 expression in CSPC as well as in some CRPC cells (22RV1), depending on the status of AR in the cell. Although investigating the effects of AR alterations\u2013such as post-transcriptional and translational modifications, structural aberrations, or mutations\u2013on BCL2 expression and castration resistance is an intriguing avenue for future research, it is beyond the scope of our current study. Another major limitation is that most established CSPC cell lines used in this research are derived from metastatic sites and, as such, do not fully capture the heterogeneity and complexity of primary castration-sensitive tumors.47,70 Moreover, most of the patient-derived prostate organoids also originated from mCRPC and therefore do not respond to ADT.71\u201373 Therefore, future efforts to establish patient-derived CSPC organoids will help address the limitations associated with the lack of suitable experimental models, although this is also outside the scope of our study."
      ],
      "22460905": [
        "Surprisingly, in contrast to CSPC cells, we observed that pharmacological inhibition of AKT kinase induces both BCL2 protein and mRNA expression in PTEN-null CRPC LNCaP-Abl36 and PC3M cells but not in PTEN wild-type DU145 cells47 (Figures 5I\u20135J and S6G). As BCL2 inhibits apoptosis, we tested whether its induction is a general response to cytotoxic drugs by treating LNCaP-Abl cells with talazoparib, a PARP inhibitor. Talazoparib modestly reduced BCL2 expression (Figure S6F), suggesting that BCL2 induction in these cells is specific to Akt inhibition and reflects a feedback loop between PI3K-Akt signaling and BCL2 in CRPC (Figure 5K).",
        "Our study has several limitations. While we have observed that inhibiting the AR pathway can upregulate BCL2, the molecular mechanism underlying this upregulation is not fully understood. Previous studies have shown that transcription factors such as the AR-interacting partner FOXA1 and the EMT factor SNAIL regulate BCL2 expression.33,34 However, in our experiments, we did not observe any impact of FOXA1 or SNAIL knockdown on BCL2 expression, suggesting that AR may directly regulate BCL2. A prior study indicated that AR could bind to the BCL2 promoter69; therefore, whether AR acts as a transcriptional suppressor of BCL2 in CSPC and some CRPC (22RV1) cells needs further investigation. Additionally, we found that ARSI fails to induce BCL2 expression in clinical samples and some CRPC cells (LNCaP-abl), indicating a potential alteration in the AR-binding site on the BCL2 promoter between CSPC and CRPC that requires further exploration. Furthermore, while our data strongly suggest that AR inhibition-mediated BCL2 upregulation is mostly specific to CSPC, we also showed that ENZA treatment can induce BCL2 expression in the 22RV1 cell line, a model of CRPC. It is noteworthy that 22RV1 exhibits castration resistance due to the presence of the AR splice variant ARV7 in addition to full-length wild-type AR.47 Importantly, our study showed that the introduction of ARV7 into PC cells does not affect BCL2 expression.",
        "While the pharmacological blockade of AR induces BCL2 expression in both mutant (LNCaP) and wild-type (LAPC4, VCaP, and 22RV1) full-length AR-expressing cells,24 our data indicate that the transient knockdown of mutant AR in LNCaP does not result in the induction of endogenous BCL2 expression. However, our findings also show that transient knockdown or overexpression of wild-type AR in PC cells is sufficient to alter AR protein or mRNA expression. Collectively, these results suggest that ADT or AR-targeted therapies may induce BCL2 expression in CSPC as well as in some CRPC cells (22RV1), depending on the status of AR in the cell. Although investigating the effects of AR alterations\u2013such as post-transcriptional and translational modifications, structural aberrations, or mutations\u2013on BCL2 expression and castration resistance is an intriguing avenue for future research, it is beyond the scope of our current study. Another major limitation is that most established CSPC cell lines used in this research are derived from metastatic sites and, as such, do not fully capture the heterogeneity and complexity of primary castration-sensitive tumors.47,70 Moreover, most of the patient-derived prostate organoids also originated from mCRPC and therefore do not respond to ADT.71\u201373 Therefore, future efforts to establish patient-derived CSPC organoids will help address the limitations associated with the lack of suitable experimental models, although this is also outside the scope of our study."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 10,
    "extraction_method": "jats_xml",
    "extraction_time": 0.8710939884185791,
    "data_pmids_checked": 12,
    "paper_id": "40448998",
    "extraction_date": "2025-12-19T19:46:33.694820",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40448998.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40452844": {
    "paper_id": "40452844",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:40.788596",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40452844.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 3.7748708724975586,
      "cbioportal_papers": 0.0002162456512451172,
      "pdf_extraction_pass2": 4.3802409172058105,
      "cbioportal_papers_pass2": 0.0002319812774658203,
      "used_full_extraction": true,
      "pdf_extraction": 8.15511178970337,
      "platform_mentions": 0.001867055892944336,
      "data_citations": 0.0001537799835205078,
      "num_data_pmids_checked": 2
    }
  },
  "40463876": {
    "paper_id": "40463876",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gene expression analysis\ncBioportal\nWedownloadedthegeneexpression RNAseq(FPKMformat)\nof 33 cancers from TCGA database using UCSC Xena (https://\nxena.ucsc.edu/) (15)",
      "cBioportal contains over\ntissue was extracted from Genotype-Tissue Expression(GTEx)\n200cancergenomicsstudiesfromtheTCGAdatabase.(19)Inthis\ndatabase (https://gtexportal.org/home/datasets) to supply normal\nstudy,aco-expressiongenedatasetoftheSERPINE2wereobtained\ntissue RNA-seq transcriptome data lacking in TCGA",
      "TodissectthegenenetworkofSERPINE2incolorectalcancer, During tumor progression and metastasis, complex\nwe obtained a set of genes related to SERPINE2 expression in communication networks between tumor cells and stromal cells\ncolorectal cancer through cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:43.191965",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40463876.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 4.847209215164185,
      "cbioportal_papers": 0.0002338886260986328,
      "pdf_extraction_pass2": 5.781942844390869,
      "cbioportal_papers_pass2": 0.0002262592315673828,
      "used_full_extraction": true,
      "pdf_extraction": 10.629152059555054,
      "platform_mentions": 0.02717900276184082,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40458731": {
    "paper_id": "40458731",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.8 OncoPrint visualization of top genomic\nalterations 3 Results\nTop gene mutations and copy number alterations were 3.1 NCI-MPACT agent activity across all\nidentified for PDX models responding to veliparib plus PDX models\ntemozolomide using cBioPortal (16, 17)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:43.506859",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40458731.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 4.968782901763916,
      "cbioportal_papers": 0.0003147125244140625,
      "pdf_extraction_pass2": 5.984983921051025,
      "cbioportal_papers_pass2": 0.0003199577331542969,
      "used_full_extraction": true,
      "pdf_extraction": 10.953766822814941,
      "platform_mentions": 0.0022819042205810547,
      "data_citations": 5.245208740234375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40447838": {
    "paper_id": "40447838",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:48.055897",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40447838.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.792220830917358,
      "cbioportal_papers": 0.00024819374084472656,
      "pdf_extraction_pass2": 6.079134225845337,
      "cbioportal_papers_pass2": 0.0002429485321044922,
      "used_full_extraction": true,
      "pdf_extraction": 14.871355056762695,
      "platform_mentions": 0.0023119449615478516,
      "data_citations": 8.893013000488281e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40433389": {
    "paper_id": "40433389",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To assess the\ndiscriminatory power of EXO1 expression levels (high or low) in The geneticalterationsofEXO1genewereanalyzedusingthe\ndistinguishing tumor samples from control samples, receiver cBioPortal (www.cbioportal.org/) and TIMER2.0 (http://\noperating characteristic (ROC) analysis was conducted using the timer.cistrome.org/) in databases of female-related cancers",
      "using cBioPortal to analyze the different prognostic significance\nbetweenEXO1alteredandunalteredgroupsamongvariousfemale-\nrelatedcancers(23)",
      "Additionally, the predictive After confirming the prognostic value of EXO1, we utilized\nperformance of EXO1 expression was assessed using time- cBioPortal and TIMER 2.0 to analyze the genetic alterations in\ndependent ROC curves",
      "Analysis using the\nPFI were 0.569, 0.596, and 0.640 at 1, 3, and 5 years, respectively cBioPortal online tool revealed the presence of two or more\n(Figures 4G)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:48.323224",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40433389.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.40996503829956,
      "cbioportal_papers": 0.0003437995910644531,
      "pdf_extraction_pass2": 5.2410218715667725,
      "cbioportal_papers_pass2": 0.0003712177276611328,
      "used_full_extraction": true,
      "pdf_extraction": 14.650986909866333,
      "platform_mentions": 0.0035338401794433594,
      "data_citations": 0.0001289844512939453,
      "num_data_pmids_checked": 1
    }
  },
  "40443402": {
    "paper_id": "40443402",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Radiotherapy-sensitive and resistant\namplifications, and deep deletions were performed HK1 cell lines were kindly provided by Prof. Jian Zhang\nutilizing the Cancer Type Summary module available in (Southern Medical University, China).[46, 47]\nthe cBioPortal database.[34] The processed SNV data were\nanalyzed using the \u201cmaftools\u201d R package, in order to Western blotting\nelucidate the mutational landscape of ELAVL1 across Cell lysates were prepared using RIPA lysis buffer to\npan-cancer datasets.[35] The processed CNV data were extract proteins, which were then separated by SDS-PAGE\nobtained from GSCA database and visualized using (Beyotime) and transferred onto PVDF membranes\n\u201cggplot2\u201d R package.[36] (Millipore)",
      "Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, et al. HER2\nIntegrative analysis of complex cancer genomics and clinical profiles expression, copy number variation and survival outcomes in HER2-low\nusing the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:50.552027",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40443402.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.252648830413818,
      "cbioportal_papers": 0.00030112266540527344,
      "pdf_extraction_pass2": 6.775836944580078,
      "cbioportal_papers_pass2": 0.00031280517578125,
      "used_full_extraction": true,
      "pdf_extraction": 17.028485774993896,
      "platform_mentions": 0.0025789737701416016,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40424933": {
    "cbioportal_paper_citations": [
      "Firstly, to investigate the genetic alterations of TRIM proteins in glioma, we utilized Cbioportal to analyze the occurrence of such alterations in the TCGA-LGG (Lower-grade glioma/514 patients) and TCGA-GBM (Glioblastoma/390 patients) cohorts, respectively [36,37]. The results show that the incidence of genetic modifications in patients diagnosed with LGG or GBM exhibits a similar pattern, with TRIM genes being altered in approximately 33 % of LGG patients (168 events among 514 patients) and 32 % of GBM patients (126 events among 390 patients). Among the TRIM genes examined, namely TRIM3(4 %), TRIM5(4 %), TRIM6(4 %), TRIM21(4 %), TRIM22(4 %), TRIM28(4 %), TRIM34(4 %), TRIM68(4 %), TRIML1(4 %), and TRIML2(4 %), the mutation rates were relatively higher in LGG patients (Figure S1), while in GBM patients, relatively higher mutation rates were observed in TRIM76(2.8 %), TRIM50(2.6 %), and TRIML1(2.6 %) (Figure S2). Notably, TRIM3 gene is located within the chromosomal locus 11p15.5, and approximately 20 % of human glioblastoma samples demonstrate loss of heterozygosity in this region [38,39]. Despite the presence of an intact 11p15.5 locus in many GBM samples, analysis has revealed a lower than anticipated expression of TRIM3, indicating the potential involvement of other mechanisms in the regulation of TRIM3 expression [40]. Given that the 11p15 region is also prone to frequent dysregulated DNA methylation and loss of imprinting [41], it is possible that DNA methylation may play a role in the low expression of TRIM3. Interestingly, The TRIM8 gene is located on chromosome 10q24.3, which also is a region that exhibits frequent deletion or loss of heterozygosity in GBM [42]. Despite its frequent hemizygous deletion in GBM, TRIM8 demonstrates similar expression levels in GBM samples as in normal brain tissue [43]. A plausible mechanism for this phenomenon is the activation of STAT3, which upregulates TRIM8 and thus enables the normalization of TRIM8 expression in the context of hemizygous gene deletion [43]. In addition, certain transcription factors linked to the aberrantly activated signaling pathways in glioma have the potential to regulate the expression of TRIM proteins. For instance, TRIM19 (PML) transcription is suppressed by transcription factor SOX2 in GBM cells [44]. Additionally, in EGFR/EGFRvIII-driven gliomas, the activation of STAT3 by EGFR/EGFRvIII enhances the transcription of TRIM2414. TRIM59 transcription is activated by EGFR/EGFRvIII through transcription factor SOX9 in GBM cells [45]. Similarly, our previous work has demonstrated that the transcription factor SP1 can directly bind to the \u221291 to \u221282 region of the TRIM56 promoter, resulting in the activation of TRIM56 transcription [46]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.03692293167114258,
    "data_pmids_checked": 0,
    "paper_id": "40424933",
    "extraction_date": "2025-12-19T19:46:50.593338",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40424933.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40423510": {
    "cbioportal_paper_citations": [
      "TCGA-THCA dataset was downloaded from the Cancer Genome Atlas (TCGA) (https://portal.gdc.cancer.gov/). We analyzed the raw-counts data with gene expression profile of 358 classical PTC (PTCcl); 37 tall cell PTC (PTCtc), and 58 solid tissue (NT) samples. Matching clinicopathological data were downloaded from cBioPortal for Cancer Genomics (https://www.cbioportal.org/) (Gao et al. 2013). Differential expression was reported as fold change \u2265|1.5| along with associated adjusted P values (FDR \u2264 0.05), computed according to Benjamini\u2013Hochberg (Benjamini & Cohen 2017). The quantification of RNA-seq data was obtained by the tool RNA-seq by expectation-maximization (RSEM) (Li & Dewey 2011)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.052845001220703125,
    "data_pmids_checked": 0,
    "paper_id": "40423510",
    "extraction_date": "2025-12-19T19:46:50.659530",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40423510.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40426992": {
    "paper_id": "40426992",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:53.385434",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40426992.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 2.8429582118988037,
      "cbioportal_papers": 9.393692016601562e-05,
      "pdf_extraction_pass2": 2.2178092002868652,
      "cbioportal_papers_pass2": 8.988380432128906e-05,
      "used_full_extraction": true,
      "pdf_extraction": 5.060767412185669,
      "platform_mentions": 0.0010180473327636719,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40430023": {
    "paper_id": "40430023",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Int.J.Mol.Sci.2025,26,4883 5of18\nThen,toexaminewhethertheimpactofG\u03b113onSOD2proteinexpressionmightbe\nmediated through SOD2 mRNA expression in prostate cancer tissue, we first analyzed\nthreeindependentRNAsequencingdatasetsfromTCGA-PRAD[42], theGermanCan-\ncerResearchCenter(DKFZ,early-onsetprostatecancer)[43]andtheSU2C-PCFproject\n(metastatic, castration-resistant prostate cancer) [44] on the cBioPortal website [37,45]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:57.606617",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40430023.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.566258907318115,
      "cbioportal_papers": 0.0003390312194824219,
      "pdf_extraction_pass2": 7.157004117965698,
      "cbioportal_papers_pass2": 0.0003299713134765625,
      "used_full_extraction": true,
      "pdf_extraction": 16.723263025283813,
      "platform_mentions": 0.002961874008178711,
      "data_citations": 0.0004420280456542969,
      "num_data_pmids_checked": 4
    }
  },
  "40427178": {
    "paper_id": "40427178",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:46:58.749839",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40427178.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 4.882453918457031,
      "cbioportal_papers": 0.0003361701965332031,
      "pdf_extraction_pass2": 5.793944835662842,
      "cbioportal_papers_pass2": 0.00038933753967285156,
      "used_full_extraction": true,
      "pdf_extraction": 10.676398754119873,
      "platform_mentions": 0.002959728240966797,
      "data_citations": 0.0006368160247802734,
      "num_data_pmids_checked": 5
    }
  },
  "40421219": {
    "paper_id": "40421219",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "soft-tissuesarcoma.Clin.CancerRes.24(21),5233\u20135238.doi:10.1158/1078-0432.CCR- Integrative analysis of complex cancer genomics and clinical profiles using the\n17-3766 cBioPortal.Sci.Signal6(269),pl1.doi:10.1126/scisignal.2004088\nChoi,B.,Lee,J.S.,Kim,S.J.,Hong,D.,Park,J.B.,andLee,K.Y.(2020).Anti-tumor Gao,X.,Ding,P.,Zhang,Z.,Li,Y.,Zhao,Q.,Wang,D.,etal.(2023).Analysisof\neffects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice recurrence and metastasis patterns and prognosis after complete resection of\nxenograftedwithdedifferentiatedliposarcoma.CancerLett.478,56\u201369.doi:10.1016/ retroperitonealliposarcoma.Front.Oncol.13,1273169.doi:10.3389/fonc.2023.1273169\nj.canlet.2020.02.042\nGhadimi,M.P.,Al-Zaid,T.,Madewell,J.,Peng,T.,Colombo,C.,Hoffman,A.,etal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:05.676429",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40421219.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.889434814453125,
      "cbioportal_papers": 0.00046324729919433594,
      "pdf_extraction_pass2": 6.396189212799072,
      "cbioportal_papers_pass2": 0.000492095947265625,
      "used_full_extraction": true,
      "pdf_extraction": 12.285624027252197,
      "platform_mentions": 0.004038095474243164,
      "data_citations": 0.00017189979553222656,
      "num_data_pmids_checked": 1
    }
  },
  "40409685": {
    "cbioportal_paper_citations": [
      "The UALCAN Database (http://ualcan.path.uab.edu) was used as detailed previously37 to investigate MYO5B mRNA in COAD. The UALCAN database provides comprehensive demographic information on patients including age, ethnicity, tumor characteristics, and survival metrics. Additionally, the TNMplot (https://tnmplot.com) and the GEPIA2 Database (http://gepia2.cancer-pku.cn) were used to enhance the depth of our analyses.38 Mutation frequency analysis of MYO5B in colorectal cancer samples was identified through COSMIC v95 (Catalogue of Somatic Mutations in Cancer https://cancer.sanger.ac.uk)39 and the TIMER2.0 database (https://cistrome.shinyapps.io/timer).40 MYO5B mutation patterns were gleaned from MEXPRESS (https://mexpress.be/) and cBioPortal v4.1.1 portal (https://www.cbioportal.org/) as previously described.40, 41, 42, 43, 44, 45, 46 Mutation type, frequency, and copy number variation (CNV) of colorectal cancer tumors from TCGA (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers) was observed in the MutationMapper module."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.0705420970916748,
    "data_pmids_checked": 0,
    "paper_id": "40409685",
    "extraction_date": "2025-12-19T19:47:05.764556",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40409685.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40422563": {
    "paper_id": "40422563",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In silico dataset: An RSEM (RNAseq by expectation-maximization) of 208 genes\n(SupplementaryTableS1)includingDSC3expressionwasevaluatedbymRNAlevels[15]\ninMIBCusingtheTCGAdatabase(2017)Thecellcancerstudy,availableatcBioPortal.org,\nRRID:SCR_014555forCancerGenomics(https://www.cbioportal.org/, accessedon12\nJune 2024 (cBioPortal, RRID:SCR_014555)) [16] as well as a supplement to the publica-\ntion [6]",
      "Additionally,geneswithamoderatetohighcorrelation(Spearman\u2019scorrelation\u22650.6)\nwith DSC3 expression in the TCGA-BLCA dataset were identified on cBioPortal and\nanalyzed for enrichment analysis (Supplementary Figure S3)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:07.776927",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40422563.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.785915851593018,
      "cbioportal_papers": 0.000247955322265625,
      "pdf_extraction_pass2": 8.32198691368103,
      "cbioportal_papers_pass2": 0.00024700164794921875,
      "used_full_extraction": true,
      "pdf_extraction": 17.107902765274048,
      "platform_mentions": 0.002566099166870117,
      "data_citations": 8.416175842285156e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40410601": {
    "paper_id": "40410601",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.3 Genetic alteration profiling\nThe mutation landscape of cuproptosis-related genes was characterized using TCGA-STAD and cBioPortal data, focus-\ning on samples with detectable genetic alterations [26]",
      "The alteration summary, derived from cBioPortal data,\nconfirmed CDKN2A\u2019s prominence in genetic alterations, evident through various mutation types such as amplification\nand deep deletion (Fig",
      "B Summary of genetic alterations across different studies of origin, highlighting the profiling for copy number alterations, mutations, and\nstructural variants, with data from cBioPortal website",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:13.114421",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40410601.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.879223823547363,
      "cbioportal_papers": 0.0002532005310058594,
      "pdf_extraction_pass2": 8.481990098953247,
      "cbioportal_papers_pass2": 0.0003139972686767578,
      "used_full_extraction": true,
      "pdf_extraction": 14.36121392250061,
      "platform_mentions": 0.0026099681854248047,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40427758": {
    "paper_id": "40427758",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DataAvailabilityStatement:Allthegenomicandclinicopathologicaldatautilisedforthisstudyare\nfreelyavailableinthecBioPortalforCancerGenomicswebsite(https://www.cbioportal.org/),and\ntheGenomeDataCommonsrepository(https://portal.gdc.cancer.gov/)",
      "Acknowledgments:TheauthorwishestoexpresshisgratitudetothePrinceSattamBinAbdulaziz\nUniversity, as well as to The Cancer Genome Atlas and the cBioPortal for Cancer Genomics for\nmakingthedatausedinthisstudypubliclyavailable"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:13.213955",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40427758.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 12.916022062301636,
      "cbioportal_papers": 0.00022912025451660156,
      "pdf_extraction_pass2": 16.77029299736023,
      "cbioportal_papers_pass2": 0.0002307891845703125,
      "used_full_extraction": true,
      "pdf_extraction": 29.686315059661865,
      "platform_mentions": 0.002209901809692383,
      "data_citations": 0.00015306472778320312,
      "num_data_pmids_checked": 2
    }
  },
  "40403210": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Patients in the MSK cohort were diagnosed and treated between 2000 and 2015 (follow-up until 2019), and their clinical and genomic data were made publicly available through cBioPortal for Cancer Genomics. For the METABRIC cohort, patient diagnoses occurred between 1995 and 2010 (follow-up until 2016), and this data set was also publicly accessible through cBioPortal after its initial publication in 2012.",
      "Clinical data, including age, tumor grade, stage, menopausal state, and survival outcomes, were obtained from electronic medical records and tumor registries within the MSK and METABRIC cohorts. Genomic data were acquired through NGS techniques used by both institutions.12-14 Data were accessed through the cBioPortal for Cancer Genomics, where both clinical and genomic data sets were publicly available."
    ],
    "data_publication_citations": {
      "30205045": [
        "This study aimed to investigate the prognostic significance of TP53mut and PI3K/AKT pathway alterations in BC leveraging data from two of the largest, well-characterized BC cohorts: the Memorial Sloan Kettering (MSK) Cancer Center13 and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC).12,14 By integrating clinical and genomic data, we seek to elucidate how these genetic alterations influence survival outcomes and to identify potential interactions between TP53 and the PI3K/AKT pathway across distinct BC subtypes.",
        "This study retrospective analysis integrated clinical and genomic data from 4,265 patients with BC in the MSK (n = 1,756)13 and METABRIC (n = 2,509)12,14 cohorts to investigate the impact of TP53mut and PI3K/AKT pathway alterations on clinicopathologic features and overall survival (OS) across BC subtypes and stages.",
        "In the MSK cohort, TP53mut was detected using targeted next-generation sequencing (NGS) panels, specifically the MSK-Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) assay.13 The METABRIC cohort used whole-exome sequencing (WES) to identify TP53mut.12,14 For our analysis, all types of pathogenic TP53mut were included. This comprehensive approach was chosen because different mutation types can have varying effects on the function of the p53 protein, potentially influencing tumor behavior and patient outcomes.35,36 Given that TP53mut can result in loss of function, dominant-negative effects, or gain of function, considering all mutation types provides a holistic view of their prognostic significance.",
        "In the MSK cohort, gene amplifications and mutations were identified using the MSK-IMPACT assay.13 Amplifications were defined as \u2265six copies. In the METABRIC cohort, WES and single nucleotide polymorphism arrays were used to detect amplifications (\u2265six copies) and mutations.12,14",
        "To our knowledge, this study is the first study to comprehensively evaluate the prognostic significance of TP53mut and PI3K/AKT pathway alterations across BC subtypes using data from the MSK13 and METABRIC cohorts.12,14 Our findings show that both TP53mut and PI3K/AKT alterations significantly worsen survival, independent of the BC subtype and other prognostic clinicopathologic features.",
        "This study has several strengths. First, it leverages a large, well-characterized data set from two cohorts, MSK13 and METABRIC,12,14 allowing for long-term follow-up and increasing the generalizability of findings. Second, the integration of clinical and genomic data enabled a detailed investigation of TP53mut, PI3K/AKT pathway alterations, and their interaction with BC subtypes. Third, the use of multivariable Cox proportional hazards models accounted for potential confounders such as age, tumor grade, stage, and BC subtype, enhancing the robustness of survival analyses.55,56"
      ],
      "23000897": [
        "Breast cancer (BC) is a highly heterogeneous disease, comprising various molecular subtypes with distinct prognoses and therapeutic responses.1-6 The genetic landscape of BC includes genomic alterations in several key genes that drive tumor development and progression.7-14 Among them, the TP53 gene plays a crucial role in cell cycle regulation, DNA repair, and apoptosis.15-17 Mutations in TP53 (TP53muts) are prevalent in various cancers, including BC, and are often associated with aggressive tumor characteristics and poor prognosis.18-20 Approximately 30% of patients with BC have TP53mut.20,21 The prognostic role of TP53mut in BC remains unclear. While most reports suggest poor clinical outcomes for patients with tumors harboring TP53mut, others have reported neutral or even beneficial outcomes.20 Despite the high prevalence of TP53mut in BC, they are not yet used routinely as predictive markers because their effects on outcomes vary because of different biological responses to treatments like DNA damage and hormone deprivation.20"
      ],
      "27161491": [
        "Breast cancer (BC) is a highly heterogeneous disease, comprising various molecular subtypes with distinct prognoses and therapeutic responses.1-6 The genetic landscape of BC includes genomic alterations in several key genes that drive tumor development and progression.7-14 Among them, the TP53 gene plays a crucial role in cell cycle regulation, DNA repair, and apoptosis.15-17 Mutations in TP53 (TP53muts) are prevalent in various cancers, including BC, and are often associated with aggressive tumor characteristics and poor prognosis.18-20 Approximately 30% of patients with BC have TP53mut.20,21 The prognostic role of TP53mut in BC remains unclear. While most reports suggest poor clinical outcomes for patients with tumors harboring TP53mut, others have reported neutral or even beneficial outcomes.20 Despite the high prevalence of TP53mut in BC, they are not yet used routinely as predictive markers because their effects on outcomes vary because of different biological responses to treatments like DNA damage and hormone deprivation.20",
        "This study aimed to investigate the prognostic significance of TP53mut and PI3K/AKT pathway alterations in BC leveraging data from two of the largest, well-characterized BC cohorts: the Memorial Sloan Kettering (MSK) Cancer Center13 and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC).12,14 By integrating clinical and genomic data, we seek to elucidate how these genetic alterations influence survival outcomes and to identify potential interactions between TP53 and the PI3K/AKT pathway across distinct BC subtypes.",
        "This study retrospective analysis integrated clinical and genomic data from 4,265 patients with BC in the MSK (n = 1,756)13 and METABRIC (n = 2,509)12,14 cohorts to investigate the impact of TP53mut and PI3K/AKT pathway alterations on clinicopathologic features and overall survival (OS) across BC subtypes and stages.",
        "In the MSK cohort, TP53mut was detected using targeted next-generation sequencing (NGS) panels, specifically the MSK-Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) assay.13 The METABRIC cohort used whole-exome sequencing (WES) to identify TP53mut.12,14 For our analysis, all types of pathogenic TP53mut were included. This comprehensive approach was chosen because different mutation types can have varying effects on the function of the p53 protein, potentially influencing tumor behavior and patient outcomes.35,36 Given that TP53mut can result in loss of function, dominant-negative effects, or gain of function, considering all mutation types provides a holistic view of their prognostic significance.",
        "In the MSK cohort, gene amplifications and mutations were identified using the MSK-IMPACT assay.13 Amplifications were defined as \u2265six copies. In the METABRIC cohort, WES and single nucleotide polymorphism arrays were used to detect amplifications (\u2265six copies) and mutations.12,14",
        "Clinical data, including age, tumor grade, stage, menopausal state, and survival outcomes, were obtained from electronic medical records and tumor registries within the MSK and METABRIC cohorts. Genomic data were acquired through NGS techniques used by both institutions.12-14 Data were accessed through the cBioPortal for Cancer Genomics, where both clinical and genomic data sets were publicly available.",
        "To our knowledge, this study is the first study to comprehensively evaluate the prognostic significance of TP53mut and PI3K/AKT pathway alterations across BC subtypes using data from the MSK13 and METABRIC cohorts.12,14 Our findings show that both TP53mut and PI3K/AKT alterations significantly worsen survival, independent of the BC subtype and other prognostic clinicopathologic features.",
        "This study has several strengths. First, it leverages a large, well-characterized data set from two cohorts, MSK13 and METABRIC,12,14 allowing for long-term follow-up and increasing the generalizability of findings. Second, the integration of clinical and genomic data enabled a detailed investigation of TP53mut, PI3K/AKT pathway alterations, and their interaction with BC subtypes. Third, the use of multivariable Cox proportional hazards models accounted for potential confounders such as age, tumor grade, stage, and BC subtype, enhancing the robustness of survival analyses.55,56"
      ],
      "22522925": [
        "This study aimed to investigate the prognostic significance of TP53mut and PI3K/AKT pathway alterations in BC leveraging data from two of the largest, well-characterized BC cohorts: the Memorial Sloan Kettering (MSK) Cancer Center13 and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC).12,14 By integrating clinical and genomic data, we seek to elucidate how these genetic alterations influence survival outcomes and to identify potential interactions between TP53 and the PI3K/AKT pathway across distinct BC subtypes.",
        "This study retrospective analysis integrated clinical and genomic data from 4,265 patients with BC in the MSK (n = 1,756)13 and METABRIC (n = 2,509)12,14 cohorts to investigate the impact of TP53mut and PI3K/AKT pathway alterations on clinicopathologic features and overall survival (OS) across BC subtypes and stages.",
        "In the MSK cohort, TP53mut was detected using targeted next-generation sequencing (NGS) panels, specifically the MSK-Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) assay.13 The METABRIC cohort used whole-exome sequencing (WES) to identify TP53mut.12,14 For our analysis, all types of pathogenic TP53mut were included. This comprehensive approach was chosen because different mutation types can have varying effects on the function of the p53 protein, potentially influencing tumor behavior and patient outcomes.35,36 Given that TP53mut can result in loss of function, dominant-negative effects, or gain of function, considering all mutation types provides a holistic view of their prognostic significance.",
        "In the MSK cohort, gene amplifications and mutations were identified using the MSK-IMPACT assay.13 Amplifications were defined as \u2265six copies. In the METABRIC cohort, WES and single nucleotide polymorphism arrays were used to detect amplifications (\u2265six copies) and mutations.12,14",
        "Clinical data, including age, tumor grade, stage, menopausal state, and survival outcomes, were obtained from electronic medical records and tumor registries within the MSK and METABRIC cohorts. Genomic data were acquired through NGS techniques used by both institutions.12-14 Data were accessed through the cBioPortal for Cancer Genomics, where both clinical and genomic data sets were publicly available.",
        "To our knowledge, this study is the first study to comprehensively evaluate the prognostic significance of TP53mut and PI3K/AKT pathway alterations across BC subtypes using data from the MSK13 and METABRIC cohorts.12,14 Our findings show that both TP53mut and PI3K/AKT alterations significantly worsen survival, independent of the BC subtype and other prognostic clinicopathologic features.",
        "This study has several strengths. First, it leverages a large, well-characterized data set from two cohorts, MSK13 and METABRIC,12,14 allowing for long-term follow-up and increasing the generalizability of findings. Second, the integration of clinical and genomic data enabled a detailed investigation of TP53mut, PI3K/AKT pathway alterations, and their interaction with BC subtypes. Third, the use of multivariable Cox proportional hazards models accounted for potential confounders such as age, tumor grade, stage, and BC subtype, enhancing the robustness of survival analyses.55,56"
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 1.2457489967346191,
    "data_pmids_checked": 4,
    "paper_id": "40403210",
    "extraction_date": "2025-12-19T19:47:14.368273",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40403210.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40406134": {
    "paper_id": "40406134",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "prognosis in individuals treated with immune checkpoint inhibitor (ICI)\nanalyzed via Cbioportal website",
      "by regulating the cell cycle, signaling pathways, and epithelial- ThecBioPortaldatabase[http://www.cbioportal.org/]wasaccessed\nmesenchymal transition (EMT)",
      "ARID1A mutated differential prognostic\nFurthermore, survival outcomes associated with ARID1AMut immune genes\nwere examined by reviewing immunotherapy cohorts in the\ncBioPortal database"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:17.664428",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40406134.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.673973083496094,
      "cbioportal_papers": 0.00026917457580566406,
      "pdf_extraction_pass2": 5.197945833206177,
      "cbioportal_papers_pass2": 0.0002720355987548828,
      "used_full_extraction": true,
      "pdf_extraction": 11.87191891670227,
      "platform_mentions": 0.002721071243286133,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40405009": {
    "paper_id": "40405009",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "RAP1GAP mutation frequencies across tumor types were retrieved from the cBioPortal website [25]",
      "Mutation frequency and types were retrieved from cBioPortal, revealing that\n\u201cmRNA High\u201d was the most prevalent alteration in nearly all tumors (Fig",
      "Integrative analysis of complex cancer genomics and clinical profiles\nusing the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:20.621761",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40405009.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.843638181686401,
      "cbioportal_papers": 0.0002067089080810547,
      "pdf_extraction_pass2": 5.98983907699585,
      "cbioportal_papers_pass2": 0.00021409988403320312,
      "used_full_extraction": true,
      "pdf_extraction": 12.833477258682251,
      "platform_mentions": 0.0018811225891113281,
      "data_citations": 0.00015091896057128906,
      "num_data_pmids_checked": 2
    }
  },
  "40395202": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In our previous work, we utilized data from TCGA and other sources to analyze the characteristics of the most prominent copy number amplification region, 20q, in colorectal cancer. We identified several oncogenes located within this region.6,7 The study of 20q and its relationship with colorectal cancer has gained increasing attention from researchers, and some studies have found that the presence of copy number amplification in 20q can divide colorectal cancer into two distinct subtypes. 8 However, it is surprising that large data visualization websites for colorectal cancer, such as Cbioportal 9 and COSMIC, 10 show that the frequency of deep deletion of copy number in the 16p13.3 region ranks first, significantly higher than 20q. Nevertheless, there is relatively limited comprehensive research on the relationship between the 16p13.3 region, the RBFOX1 gene located within it, and colorectal cancer. Therefore, in this article, we will utilize large-scale data and experimental analysis to investigate the CNV characteristics, copy number alterations, mRNA expression levels, and their correlation with clinical pathological data of the RBFOX1 gene in colorectal cancer. We will also employ experimental methods such as immunohistochemistry and immunofluorescence to analyze the expression of RBFOX1 protein in colorectal cancer cells and tissues. These studies will provide preliminary theoretical support for understanding the relationship between RBFOX1 and colorectal cancer.",
      "Two colorectal cancer datasets, namely Colorectal Adenocarcinoma (TCGA, Firehose Legacy) and Colon Cancer (CPTAC-2 Prospective, Cell 2019), were downloaded from The cBioPortal for Cancer Genomics official website. 9 These two large datasets include copy number data, mRNA expression data, and clinical information of colorectal cancer samples. Putative copy-number calls on colorectal cancer datasets were determined using GISTIC 2.0. The values assigned are as follows: \u22122 = homozygous deletion; \u22121 = hemizygous deletion; 0 = neutral / no change; 1 = gain; 2 = high level amplification. 11",
      "Copy Number Variation of RBFOX1 and Its Correlation with DFS and OS. A. Online Data from Cbioportal shows that RBFOX1 has the Highest Frequency of Copy Number Deletions in Colorectal Cancer. B And C. Analysis of RBFOX1 Copy Number Situation in Colorectal Adenocarcinoma (TCGA, Firehose Legacy) and Colon Cancer (CPTAC-2 Prospective, Cell 2019) Data. D. KM Survival Curve of Progression-Free Survival and Overall Survival Among the Four Groups."
    ],
    "data_publication_citations": {
      "22810696": [
        "In colorectal cancer, the RBFOX1 gene exhibits a high frequency of copy number deletions. Interestingly, the variation in the copy number of this gene in colorectal cancer tissues is diverse, with some tissues showing low levels of copy number deletions and amplifications. This feature is distinctly different from the copy number changes of other chromosomes. For instance, in colorectal cancer tissues, genes on 8q and 20q show significant copy number amplifications, which are singular and almost devoid of deletion mutations.25\u201327 Furthermore, when analyzing the correlation between RBFOX1 copy number changes and clinical information, we found that both copy number amplifications and deletions seem to lead to tumor progression. These findings suggest that although RBFOX1 exhibits significant copy number deletions in colorectal cancer, it may not be a typical tumor suppressor gene (TSG). Multiple studies have shown that RBFOX1 on chr-16 p region is often affected by heterozygous and homozygous deletions, but its homozygous deletion frequency is much lower than that of classical TSGs, and no somatic mutations have been observed in the RBFOX1 coding region, indicating that it is not a classical TSG.28,29"
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2555828094482422,
    "data_pmids_checked": 1,
    "paper_id": "40395202",
    "extraction_date": "2025-12-19T19:47:20.917406",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40395202.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40394232": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.19902396202087402,
    "data_pmids_checked": 0,
    "paper_id": "40394232",
    "extraction_date": "2025-12-19T19:47:21.116526",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40394232.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40396179": {
    "paper_id": "40396179",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "However, further patients were obtained from cBioPortal (24) (https://\nfunctional studies are required to confirm this hypothesis",
      "The high www.cbioportal.org/)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:29.883645",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40396179.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.0170958042144775,
      "cbioportal_papers": 0.00026297569274902344,
      "pdf_extraction_pass2": 6.179260969161987,
      "cbioportal_papers_pass2": 0.0002770423889160156,
      "used_full_extraction": true,
      "pdf_extraction": 12.196356773376465,
      "platform_mentions": 0.0026378631591796875,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40387385": {
    "cbioportal_paper_citations": [
      "FUT8 mRNA levels in the TCGA Firehouse Legacy cohort [62] and the Cancer Cell 2018 cohort [63] were analysed using cBioportal [64, 65] as described previously [58] (Figures S1A,B)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26544944": [
        "FUT8 mRNA levels in the TCGA Firehouse Legacy cohort [62] and the Cancer Cell 2018 cohort [63] were analysed using cBioportal [64, 65] as described previously [58] (Figures S1A,B).",
        "FUT8 has previously been identified as upregulated in prostate cancer tumours and linked with the development of high\u2010grade disease [49]. However, this study relied on cell lines and a relatively small number of clinical samples. Here, we monitor FUT8 expression at both the gene and protein level in 8 independent cohorts (comprising > 1500 clinical samples) and confirm upregulation of FUT8 in aggressive high grade prostate tumour tissue. Analysis of RNA sequencing data from The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA PRAD) cohort [62] revealed FUT8 levels are significantly higher in Gleason grade 7 and 8+ tumours, compared to Gleason grade 6 tumours (n = 595, p < 0.001, p < 0.01) (Figure S1A). Similarly, in the Cancer Cell 2018 cohort [63], FUT8 levels were significantly higher in Gleason 8+ tumours compared to Gleason 6/7 prostate tumours (n = 118, p < 0.05) (Figure S1B). Previous studies have suggested that FUT8 can be repressed by androgens [84, 85], and consistent with this, we detected an increase in FUT8 levels in clinical samples from patients treated with ADT and a decrease in FUT8 levels in prostate cancer cells stimulated with androgens (Figure S1C\u2013G). Real\u2010time quantitative PCR detected upregulation of the FUT8 gene in prostate cancer relative to benign prostate hyperplasia (BPH) gland (n = 12, p < 0.01) (Figure 1A) which was further validated in a larger independent patient cohort (n = 49, p < 0.01) (Figure 1B). In additional cohorts of patients with prostate cancer, FUT8 mRNA was upregulated in prostate cancers with a \u2018metastatic\u2019 signature compared to tumours with \u2018non\u2010metastatic\u2019 biology [67] (n20, p < 0.05) (Figure 1C) and in metastatic prostate tumours compared to localised disease (n = 20, p < 0.05) (Figure 1D). Next, to test if FUT8 is also upregulated at the protein level in high grade prostate tumours, we used immunohistochemistry (IHC) to monitor FUT8 protein levels in two previously published prostate cancer tissue microarrays (TMAs) [58, 61, 68, 69]. We confirmed the specificity of our FUT8 immunohistochemistry via detection of protein depletion in Formalin Fixed Paraffin embedded (FFPE) cell pellets (Figure S2). FUT8 protein levels were significantly higher in Gleason grade 7 and Gleason grade 8\u201310 (8+) tumours compared to Gleason grade 6 tumours (p < 0.01 and p < 0.0001) (Figure 1E) and in patients with metastasis compared to patients with localised disease (p = 0.0084) (Figure 1F). Taken together, our data suggest FUT8 is upregulated at both the gene and protein level in high grade prostate tumours and in patients with metastatic disease.",
        "The findings presented above suggested overexpression of FUT8 is linked to high grade prostate cancer and can promote an aggressive cell phenotype. Next, to search for signalling networks regulated by FUT8 target glycoproteins, we used RNA\u2010sequencing to identify genes that change with either knockdown or overexpression of FUT8. Bioinformatic analysis identified 381 significant differentially expressed genes when FUT8 is overexpressed in CWR22Rv1 cells and 3519 significant differentially expressed genes when. FUT8 was depleted in PC3 cells (adjusted p\u2010value < 0.05, Log2FC 0.58) (Figure 5A, Figure S6 and Tables S2 and S3). Interestingly, Gene Ontology analysis revealed CWR22Rv1 cells overexpressing FUT8 have enrichment in \u2018ossification\u2019, \u2018bone mineralisation\u2019 and \u2018regulation of osteoblast differentiation\u2019, whereas PC3 cells with knockdown of FUT8 have enrichment in pathways related to the \u2018immune system\u2019, \u2018cell migration\u2019 and \u2018adhesion\u2019 (Figure 5B,C, Figure S6 and Tables S4 and S5). Validation at the protein level in prostate cancer cells confirmed a correlation between FUT8 and levels of insulin\u2010like growth factor binding protein\u20105 (IGFBP5) (which is linked to prostate cancer progression [94]), interleukin 1 beta (IL1B) (a cytokine linked to an immune suppressive microenvironment [95]) and Prostaglandin E synthase 3 (PTGES3) (an AR regulator that promotes cell proliferation [96]) (Figure 5D\u2013F). Furthermore, analysis of the TCGA PRAD cohort [62] revealed a significant correlation between expression of FUT8 and genes for IGFBP5, IL1B and PTGES3 in clinical prostate cancer tissue (Figure 5G). These findings provide novel insights into molecular mechanisms important for prostate cancer progression and point towards targeting FUT8 and/or its associated glycoproteins as novel targets for prostate cancer therapeutics."
      ],
      "30537516": [
        "FUT8 mRNA levels in the TCGA Firehouse Legacy cohort [62] and the Cancer Cell 2018 cohort [63] were analysed using cBioportal [64, 65] as described previously [58] (Figures S1A,B).",
        "FUT8 has previously been identified as upregulated in prostate cancer tumours and linked with the development of high\u2010grade disease [49]. However, this study relied on cell lines and a relatively small number of clinical samples. Here, we monitor FUT8 expression at both the gene and protein level in 8 independent cohorts (comprising > 1500 clinical samples) and confirm upregulation of FUT8 in aggressive high grade prostate tumour tissue. Analysis of RNA sequencing data from The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA PRAD) cohort [62] revealed FUT8 levels are significantly higher in Gleason grade 7 and 8+ tumours, compared to Gleason grade 6 tumours (n = 595, p < 0.001, p < 0.01) (Figure S1A). Similarly, in the Cancer Cell 2018 cohort [63], FUT8 levels were significantly higher in Gleason 8+ tumours compared to Gleason 6/7 prostate tumours (n = 118, p < 0.05) (Figure S1B). Previous studies have suggested that FUT8 can be repressed by androgens [84, 85], and consistent with this, we detected an increase in FUT8 levels in clinical samples from patients treated with ADT and a decrease in FUT8 levels in prostate cancer cells stimulated with androgens (Figure S1C\u2013G). Real\u2010time quantitative PCR detected upregulation of the FUT8 gene in prostate cancer relative to benign prostate hyperplasia (BPH) gland (n = 12, p < 0.01) (Figure 1A) which was further validated in a larger independent patient cohort (n = 49, p < 0.01) (Figure 1B). In additional cohorts of patients with prostate cancer, FUT8 mRNA was upregulated in prostate cancers with a \u2018metastatic\u2019 signature compared to tumours with \u2018non\u2010metastatic\u2019 biology [67] (n20, p < 0.05) (Figure 1C) and in metastatic prostate tumours compared to localised disease (n = 20, p < 0.05) (Figure 1D). Next, to test if FUT8 is also upregulated at the protein level in high grade prostate tumours, we used immunohistochemistry (IHC) to monitor FUT8 protein levels in two previously published prostate cancer tissue microarrays (TMAs) [58, 61, 68, 69]. We confirmed the specificity of our FUT8 immunohistochemistry via detection of protein depletion in Formalin Fixed Paraffin embedded (FFPE) cell pellets (Figure S2). FUT8 protein levels were significantly higher in Gleason grade 7 and Gleason grade 8\u201310 (8+) tumours compared to Gleason grade 6 tumours (p < 0.01 and p < 0.0001) (Figure 1E) and in patients with metastasis compared to patients with localised disease (p = 0.0084) (Figure 1F). Taken together, our data suggest FUT8 is upregulated at both the gene and protein level in high grade prostate tumours and in patients with metastatic disease."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.09641027450561523,
    "data_pmids_checked": 2,
    "paper_id": "40387385",
    "extraction_date": "2025-12-19T19:47:29.986428",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40387385.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40397285": {
    "paper_id": "40397285",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.3.6 Association between gene expression and pathological staging\ncBioPortal for Cancer Genomics (http://c biopo rtal.o rg) is an open-access resource that provides an integrated view of\ncancer genomics datasets, allowing researchers to efficiently explore mutations, copy number variations, expression\ndifferences, and associated clinical information for specific genes [29]",
      "Using data from cBioPortal [30], we analyzed the\nmRNA expression levels of the target genes across different pathological stages of prostate cancer",
      "7 Correlation between NEURL4 expression and immune cell infiltration levels in Prostate cancer analyzed\n3.9 Clinical pathological staging analysis\nUsing the cBioPortal platform, the mRNA expression levels of ADM5, INPP5B, NEURL4, and TYK2 were systematically\nanalyzed across prostate cancer samples at different clinical stages (AJCC stages T2A to T4) (Dataset_4)",
      "Systematic mRNA expression analysis of ADM5, INPP5B, NEURL4, and TYK2 across prostate cancer stages (AJCC stages\nT2A\u2013T4) using cBioPortal revealed significant stage-specific differences",
      "Additionally, we extend our appreciation to The Human Protein Atlas\nand cBioPortal for their invaluable support in protein function analysis and data management, which significantly contributed to our study",
      "cBioPortal for Cancer Genomics: https://w ww.c biopo rtal.o rg/",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:32.275318",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40397285.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.915893077850342,
      "cbioportal_papers": 0.00037097930908203125,
      "pdf_extraction_pass2": 8.971327066421509,
      "cbioportal_papers_pass2": 0.00037384033203125,
      "used_full_extraction": true,
      "pdf_extraction": 17.88722014427185,
      "platform_mentions": 0.0033600330352783203,
      "data_citations": 0.00013685226440429688,
      "num_data_pmids_checked": 1
    }
  },
  "40391156": {
    "paper_id": "40391156",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Statistical analysis of DTL genetic alterations was performed\nusing cBioPortal (19) across pan-cancer cohorts",
      "The 3D protein Clinical specimens\nstructureandmutationhotspotsofDTLwerealsoanalyzedusing\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:34.660148",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40391156.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.225622177124023,
      "cbioportal_papers": 0.0003261566162109375,
      "pdf_extraction_pass2": 5.299149036407471,
      "cbioportal_papers_pass2": 0.0003292560577392578,
      "used_full_extraction": true,
      "pdf_extraction": 13.524771213531494,
      "platform_mentions": 0.0023751258850097656,
      "data_citations": 8.106231689453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40377094": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The rapid advancements of next-generation sequencing have led to an enormous expansion of genomic data, presenting challenges in identifying disease-causing variants and translating these findings into effective targeted therapeutic interventions. Accurate interpretation of variant pathogenicity and clinical significance is essential for precision medicine and biological research, as it enables the development of targeted therapies and enhances our understanding of disease mechanisms and pathways. However, an obstacle to the interpretation of variants in clinical practice is the need to manually query numerous databases and aggregate the results. Variant annotation pipelines aim to close this gap by automating the process of annotating variant data. Existing annotation pipelines, including ANNOVAR, SnpEff, and the Variant Effect Predictor (VEP) [1\u20133], primarily focus on the functional annotation of genetic variants. Several web-based tools, such as REEV and VarCards2 [4, 5], primarily support the biological interpretation of variants but do not focus on matching therapy suggestions or evaluating all variants at the level of a cell line or patient. On the other hand, there are platforms that have specialized in clinical interpretation, such as PanDrugs2 and MTB-Report [6, 7], suggesting potential treatments for pathogenic variants. For clinical use with cancer patients, some platforms provide solutions for variant interpretation in preparation for a molecular tumor board (MTB), such as MTB Portal, cBioPortal or PredictONCO [8\u201310], or commercial solutions, such as VarSome [11] or Illumina Connected Insights (ICI).",
      "Compared to other web-based variant interpretation tools, including wANNOVAR, VEP Web, REEV, and VarCards2, Onkopus provides personalized treatment options and the possibility of analyzing variants and potential therapies at patient level. Compared to commercial variant interpretation platforms such as ICI, Onkopus provides a similarly detailed overview and analysis of a patient\u2019s molecular profile. Both offer interactive platforms for visualizing and exploring selected variants and their actionability. Since ICI is directly connected to the Illumina cloud containing sequencing data, it also includes sequencing-specific metrics, like sequencing quality and depth, coverage, or tumor mutational burden. In a clinical context, these features could also be included in Onkopus, if the framework is integrated in the clinical infrastructure. As additional features, Onkopus provides molecular and protein structural specific characteristics and is published as open source software. It aims to follow current trends in the changing field of MTBs. cBioPortal provides a comprehensive platform for cohort analysis. Customized for MTBs, it can also be used for the preparation of MTBs. Similar to Onkopus, cBioPortal includes information from external sources and relevant links to them. However, while cBioPortal is designed for cohort analysis, Onkopus focuses on finding relevant treatments for individual patients. A combination of both tools will cover both aspects of data processing. In addition, Onkopus provides more options for converting variant data to other reference genomes via LiftOver (GRCh37, GRCh38, and T2T-CHM13)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.22234392166137695,
    "data_pmids_checked": 0,
    "paper_id": "40377094",
    "extraction_date": "2025-12-19T19:47:34.882599",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40377094.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40376539": {
    "cbioportal_paper_citations": [
      "This study performed bioinformatics analyses using publicly available databases, including a training cohort and an independent validation cohort. The training cohort was derived from the Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) dataset, comprising transcriptomic sequencing data and clinicopathological features from 421 PCa tissue samples and 52 normal prostate tissue samples (https://portal.gdc.cancer.gov). In the TCGA-PRAD dataset, all PCa patients underwent RP and were followed up under standardized protocols to record BCR status and recurrence times. To ensure the stability and reliability of the results, this study included the Memorial Sloan Kettering Cancer Center (MSKCC) dataset as an independent validation cohort (21). The MSKCC dataset, accessed through the cBioPortal database (https://www.cbioportal.org/), contains gene expression profiling data and clinical features from 131 PCa patients treated with RP (21,22). PCa patients in the validation cohort also received standardized postoperative follow-up, with clinical endpoints and times systematically documented."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26544944": [
        "PCa is a highly heterogeneous malignancy, with heterogeneity manifesting at multiple levels, particularly in molecular characteristics. Current molecular subtypes of PCa primarily rely on genomic and epigenetic features, and several studies have explored the feasibility of molecular subtyping in localized PCa. The TCGA Research Network conducted a multi-omics analysis of 333 primary PCa samples, incorporating whole-exome sequencing, transcriptomics, and epigenetic profiling (61). Through comprehensive and systematic analyses, the study identified seven major molecular subtypes of PCa, each characterized by distinct genomic features and potential biological mechanisms. Based on different oncogenic drivers, 74% of PCa cases were classified into one of the following seven molecular subtypes: ERG fusion, ETV1 fusion, ETV4 fusion, FLI1 fusion, SPOP mutation, FOXA1 mutation, and IDH1 mutation. However, 26% of PCa cases could not be accurately categorized into these subtypes. Despite its comprehensiveness, this molecular subtyping approach did not establish a correlation between molecular subtypes and patient prognosis, thereby limiting its clinical applicability. In another study, Zhao et al. applied the PAM50 assay to analyze 3,782 PCa samples to establish molecular subtypes (62). The results demonstrated that PAM50 could classify PCa samples into three molecular subtypes: Luminal A, Luminal B, and Basal. Survival analysis revealed that patients with the Luminal B subtype had poorer prognosis compared to those with the Luminal A or Basal subtypes. Regarding the risk of postoperative BCR, the 10-year BCR-free rate was 29% for Luminal B patients, compared to 41% for Luminal A patients and 39% for Basal patients. Multivariate analysis, adjusting for clinicopathological features such as age, PSA levels, Gleason score, surgical margin status, ECE, SVI, and lymph node involvement, demonstrated that BRFS was significantly better for basal and luminal A subtypes compared to luminal B. Further analysis revealed that only luminal B patients exhibited a significant response to postoperative androgen deprivation therapy (ADT). Thus, this study not only established molecular subtypes for PCa patients but also correlated these subtypes with patient prognosis, providing a foundation for stratified treatment strategies. By integrating molecular subtypes with clinical outcomes, this approach offered a framework for tailoring therapeutic interventions based on molecular characteristics. Given the critical role of tryptophan metabolism in malignancies, we constructed tryptophan metabolism-related molecular subtypes for PCa patients based on key TMRGs. Through clustering analysis, PCa patients were classified into two molecular subtypes. Unlike traditional molecular subtypes, such as basal or luminal subtypes, our classification was driven by TMRGs, which introduced a unique metabolic perspective for molecular subtypes. Survival analysis revealed that PCa patients in Cluster 2 had a significantly lower risk of postoperative BCR after RP compared to those in Cluster 1. Furthermore, multivariate Cox regression analysis demonstrated that the tryptophan metabolism-related molecular subtype was an independent predictor of postoperative BCR in PCa patients. Building on these findings, this study developed a nomogram incorporating tryptophan metabolism-related molecular subtypes to more accurately predict postoperative BRFS in PCa patients. Clinicopathological correlation analysis indicated that Cluster 2 patients had a significantly lower proportion of cases with high ISUP grade group and positive surgical margins compared to Cluster 1. These findings suggested a significant association between tryptophan metabolism-related molecular subtypes and the clinicopathological characteristics of PCa patients. Additionally, they partially explained the improved postoperative BRFS observed in Cluster 2, which might be attributed to the co-occurrence of favorable clinicopathological features within this molecular subtype."
      ],
      "20579941": [
        "This study performed bioinformatics analyses using publicly available databases, including a training cohort and an independent validation cohort. The training cohort was derived from the Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) dataset, comprising transcriptomic sequencing data and clinicopathological features from 421 PCa tissue samples and 52 normal prostate tissue samples (https://portal.gdc.cancer.gov). In the TCGA-PRAD dataset, all PCa patients underwent RP and were followed up under standardized protocols to record BCR status and recurrence times. To ensure the stability and reliability of the results, this study included the Memorial Sloan Kettering Cancer Center (MSKCC) dataset as an independent validation cohort (21). The MSKCC dataset, accessed through the cBioPortal database (https://www.cbioportal.org/), contains gene expression profiling data and clinical features from 131 PCa patients treated with RP (21,22). PCa patients in the validation cohort also received standardized postoperative follow-up, with clinical endpoints and times systematically documented."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6422719955444336,
    "data_pmids_checked": 2,
    "paper_id": "40376539",
    "extraction_date": "2025-12-19T19:47:35.524981",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40376539.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40429857": {
    "paper_id": "40429857",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:39.158428",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40429857.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 24.71136212348938,
      "cbioportal_papers": 0.00036597251892089844,
      "pdf_extraction_pass2": 31.24471092224121,
      "cbioportal_papers_pass2": 0.0003399848937988281,
      "used_full_extraction": true,
      "pdf_extraction": 55.95607304573059,
      "platform_mentions": 0.0026350021362304688,
      "data_citations": 0.0002391338348388672,
      "num_data_pmids_checked": 2
    }
  },
  "40398419": {
    "paper_id": "40398419",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "the American Association for Cancer Research Project2 7 was down-\nWe next tested whether the docking of O6BG to the\nloaded on 04/06/2023 via cBioPortal for Cancer Genomics (https://\nwww.aacr.org/professionals/research/aacr-project-genie/)2 8,29 for 1T38-Cys145 MGMT structure would be similar to that\nanalyzing the MGMT variants identified in all cancer types",
      "Integrative analysis of complex cancer genomics beta-YAC mice after ex vivo and in vivo hematopoietic stem\nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:42.632119",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40398419.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 15.545440912246704,
      "cbioportal_papers": 0.0003979206085205078,
      "pdf_extraction_pass2": 13.849838018417358,
      "cbioportal_papers_pass2": 0.00040602684020996094,
      "used_full_extraction": true,
      "pdf_extraction": 29.395278930664062,
      "platform_mentions": 0.0036869049072265625,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40386777": {
    "paper_id": "40386777",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.5 Genetic alteration analysis Thesecancerssharecommonfeaturesinthetumormicroenvironment\nandimmuneresponse,makingthemidealforinvestigatingtheroleof\nThecBioPortalplatform(https://www.cbioportal.org/,accessed LRFN4 in immune cell infiltration and tumor progression.Key\non September 3, 2024) was used to investigate LRFN4\u2019s genetic immune cell subsets such as CD8+ T cells and cancer-associated\nalterations in a pan-cancer cohort",
      "Despite the unavailability of certain data, such as rectum 3.7 Pan-cancer correlations between\nadenocarcinoma (READ) on the cBioPortal platform (36), the LRFN4 and immune genes\nprevalence of LRFN4 alterations in digestive system malignancies\nwasevaluated,showinganoverallincidenceof3%(Supplementary Co-expression analyses of LRFN4 and ICP genes were\nFigureS1A)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:46.560392",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40386777.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.798140048980713,
      "cbioportal_papers": 0.0002999305725097656,
      "pdf_extraction_pass2": 8.744389057159424,
      "cbioportal_papers_pass2": 0.0003132820129394531,
      "used_full_extraction": true,
      "pdf_extraction": 16.542529106140137,
      "platform_mentions": 0.030221939086914062,
      "data_citations": 0.0001087188720703125,
      "num_data_pmids_checked": 1
    }
  },
  "40369172": {
    "paper_id": "40369172",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "MSK dataset used for com-\nclone, GeneTech), Ki-67 (MIB-1, GeneTech) and SOX10 parison is available on the cBioPortal (Cerami et al. 2012;\n(EP268, ZSGB-Biotech, Beijing, China)",
      "(2013) Integrative analysis of complex cancer genomics and clini-\ncal profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:52.722043",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40369172.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.643921852111816,
      "cbioportal_papers": 0.00022101402282714844,
      "pdf_extraction_pass2": 5.896501064300537,
      "cbioportal_papers_pass2": 0.00021314620971679688,
      "used_full_extraction": true,
      "pdf_extraction": 13.540422916412354,
      "platform_mentions": 0.0018341541290283203,
      "data_citations": 7.200241088867188e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40365337": {
    "cbioportal_paper_citations": [
      "cBioPortal for Cancer Genomics (https://www.cbioportal.org/) integrates a multitude of data types, including somatic mutations, DNA copy number alterations, mRNA and miRNA expression, DNA methylation, and protein abundance, providing multi-dimensional visualisation (16). Our analysis incorporated data from TCGA (Firehose Legacy dataset), focusing on two cohorts: LGG (530 cases) and GBM (619 cases). The OncoPrint and Cancer Type Summary modules were employed to investigate the types and frequencies of LSM2 gene mutations in glioma. Additionally, the Survival module was utilised to assess the prognostic value of genetic alterations."
    ],
    "cbioportal_platform_mentions": [
      "Analysis of TCGA data via cBioPortal revealed a low mutation frequency of LSM2 in gliomas (0% in LGG, 5% in GBM, predominantly amplifications/deletions) ( Figures 4A, B ). Kaplan-Meier survival analysis showed no significant association between LSM2 alterations and patient survival (p=0.375, Figure 4C ), suggesting that genetic alterations may not be the primary driver of LSM2\u2019s role in glioma progression."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.3454439640045166,
    "data_pmids_checked": 1,
    "paper_id": "40365337",
    "extraction_date": "2025-12-19T19:47:54.116100",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40365337.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40386053": {
    "paper_id": "40386053",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Risk \ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46 = \ufffd\ud835\udc36\ud835\udc36\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc36\ud835\udc36\ud835\udc36\ud835\udc36\ud835\udc36\ud835\udc36\ud835\udc46\ud835\udc46\ud835\udc36\ud835\udc36\ud835\udc46\ud835\udc46\ud835\udc36\ud835\udc36\ud835\udc36\ud835\udc36 (\ud835\udc54\ud835\udc54\ud835\udc46\ud835\udc46\ud835\udc36\ud835\udc36\ud835\udc46\ud835\udc46\ud835\udc56\ud835\udc56) Moreover, we obtained TMB and MSI data from the\n\ud835\udc56\ud835\udc56\ncBioPortal database (https://www.cbioportal.org/)\n\u2217\ud835\udc5a\ud835\udc5a\ud835\udc5a\ud835\udc5a\ud835\udc5a\ud835\udc5a\ud835\udc5a\ud835\udc5a \ud835\udc38\ud835\udc38\ud835\udc38\ud835\udc38\ud835\udc38\ud835\udc38\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc46\ud835\udc38\ud835\udc38\ud835\udc38\ud835\udc38\ud835\udc36\ud835\udc36\ud835\udc46\ud835\udc46\ud835\udc36\ud835\udc36 (\ud835\udc54\ud835\udc54\ud835\udc46\ud835\udc46\ud835\udc36\ud835\udc36\ud835\udc46\ud835\udc46\ud835\udc56\ud835\udc56)\nhttps://www.medsci.org\n\nInt",
      "genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:47:57.668690",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40386053.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 13.462025165557861,
      "cbioportal_papers": 0.00031304359436035156,
      "pdf_extraction_pass2": 11.926483869552612,
      "cbioportal_papers_pass2": 0.0003199577331542969,
      "used_full_extraction": true,
      "pdf_extraction": 25.388509035110474,
      "platform_mentions": 0.004044055938720703,
      "data_citations": 1.3828277587890625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40374855": {
    "paper_id": "40374855",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Recent advancements in bioinformatics have significantly contributed to scientific progress by integrating\ndata repositories, open-access databases, such as the Cancer Genome Atlas (TCGA), Genotype-Tissue\nExpression (GTEx), Gene Expression Omnibus (GEO), cBioPortal, and advanced computational tools18\u201322",
      "cBioPortal analysis of the MEX3 family genes in HCC\nThe cBioPortal platform was employed to analyze genetic alterations in MEX3 family genes using data from the\nTCGA dataset26",
      "Gene names- MEX3A, MEX3B, MEX3C and MEX3D-\nwere entered into the designated search field, and genetic alteration data were extracted from the \u201cOncoPrint\u201d\nand \u201cCancer Types Summary\u201d modules in cBioPortal",
      "Using the cBioPortal online tool,\nwe analyzed genetic alterations, including mutations and copy number variations, of MEX3 family in HCC",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:02.036581",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40374855.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 14.01752495765686,
      "cbioportal_papers": 0.0003960132598876953,
      "pdf_extraction_pass2": 12.475712060928345,
      "cbioportal_papers_pass2": 0.00041675567626953125,
      "used_full_extraction": true,
      "pdf_extraction": 26.493237018585205,
      "platform_mentions": 0.0036499500274658203,
      "data_citations": 0.0001468658447265625,
      "num_data_pmids_checked": 1
    }
  },
  "40368937": {
    "paper_id": "40368937",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Control cohort 2 contains data from TCGA\nduplicationinMSH2cDNAatposition2727andtomakehPGK-3xFLAG- (Studyaccessionnumberphs000178;https://portal.gdc.cancer.gov),St\nMSH2c.2727dup-UbC-mNeonGreen and hPGK-MSH2-Clover con- Jude Children\u2019s Research Hospital https://www.cbioportal.org/study/\nstructs,whichwereinsertedinapLL3.7mlentiviralvector.Lentivirus summary?id=all_stjude_2015, and the Hospital for Sick Kids https://\nwasproducedbytransfectingHEK293Tcellswiththelentiviraltransfer www.cbioportal.org/study/summary?id=mbl_sickkids_2016"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:03.222572",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40368937.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.536130905151367,
      "cbioportal_papers": 0.00037026405334472656,
      "pdf_extraction_pass2": 8.08581805229187,
      "cbioportal_papers_pass2": 0.00035190582275390625,
      "used_full_extraction": true,
      "pdf_extraction": 16.621948957443237,
      "platform_mentions": 0.003428936004638672,
      "data_citations": 0.0002472400665283203,
      "num_data_pmids_checked": 2
    }
  },
  "40419484": {
    "paper_id": "40419484",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:05.571997",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40419484.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 32.05846571922302,
      "cbioportal_papers": 0.00043201446533203125,
      "pdf_extraction_pass2": 35.90144896507263,
      "cbioportal_papers_pass2": 0.0004401206970214844,
      "used_full_extraction": true,
      "pdf_extraction": 67.95991468429565,
      "platform_mentions": 0.0033197402954101562,
      "data_citations": 0.0004949569702148438,
      "num_data_pmids_checked": 3
    }
  },
  "40347939": {
    "cbioportal_paper_citations": [
      "Among DAWT patients, who do not usually receive actD-based therapy regimens, the relationship between proteasome expression and outcome was less evident; proteasome-medium patients fared worse than proteasome-low patients, but proteasome-high patients were not significantly different from proteasome-medium or proteasome-low8,52,53 patients (Figure 5D). Together, these data suggest that proteasome subunit levels may underlie some of the clinical differences between DAWT and FHWT and that high proteasome subunit levels correlate with poorer prognosis in rFHWT. Proteasome levels could be prognostic in some subgroups, and proteasome inhibition could benefit some of these patients.",
      "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesMouse monoclonal anti-TubulinCell Signaling TechnologyCat# 3873; RRID:AB_1904178Mouse monoclonal anti-GAPDHCell Signaling TechnologyCat# 97166; RRID:AB_2756824Rabbit monoclonal anti-Caspase-7Cell Signaling TechnologyCat# 12827; RRID:AB_2687912Rabbit monoclonal anti-cleaved Caspase-7Cell Signaling TechnologyCat# 8438; RRID:AB_11178377Rabbit monoclonal anti-Cyclin D2Cell Signaling TechnologyCat# 3741; RRID:AB_2070685Rabbit monoclonal anti-CDT1Cell Signaling TechnologyCat# 8064; RRID:AB_10896851Rabbit monoclonal anti-Cyclin E1Cell Signaling TechnologyCat# 20808; RRID:AB_2783554Rabbit monoclonal anti-PSMB5Cell Signaling TechnologyCat# 12919; RRID:AB_2798061Rabbit polyclonal anti-PSMD1SigmaCat# SAB2104781; RRID:AB_10668741Rabbit monoclonal anti-Cyclin A2Cell Signaling TechnologyCat# 91500; RRID:AB_3096041)Rabbit monoclonal anti-PARPCell Signaling TechnologyCat# 9532; RRID:AB_659884Rabbit monoclonal anti-cleaved PARPCell Signaling TechnologyCat# 5625; RRID:AB_10699459Rabbit monoclonal anti-POMPCell Signaling TechnologyCat# 15141; RRID:AB_2798726Rabbit polyclonal anti-PSMA6Cell Signaling TechnologyCat# 2459; RRID:AB_2268879Rabbit polyclonal anti-PSMB1InvitrogenCat# PA5-49648; RRID: AB_2635102Rabbit polyclonal anti-PSMB2ProteintechCat# 15154-1-AP; RRID:AB_2300322Rabbit monoclonal anti-RPL5Cell Signaling TechnologyCat# 51345; RRID:AB_2799391Rabbit polyclonal anti-RPL7AbcamCat# ab72550, RRID:AB_1270391Rabbit monoclonal anti-RPL11Cell Signaling TechnologyCat# 18163; RRID:AB_2798794Rabbit polyclonal anti-RPL26Cell Signaling TechnologyCat# 2065; RRID:AB_2146242Rabbit polyclonal anti-total AKTCell Signaling TechnologyCat# 9272; RRID:AB_329827Rabbit monoclonal anti-Phospho-AKT (Ser473)Cell Signaling TechnologyCat# 4060; RRID:AB_2315049Rabbit polyclonal anti-total 4E-BP1Cell Signaling TechnologyCat# 9452; RRID:AB_331692Rabbit monoclonal anti-phospho-4E-BP1 (Thr37/46)Cell Signaling TechnologyCat# 2855; RRID:AB_560835Rabbit monoclonal anti-total P70-S6K1Cell Signaling TechnologyCat# 34475; RRID:AB_2943679Rabbit polyclonal anti-phospho- P70-S6K1 (Thr389)InvitrogenCat# 710095; RRID:AB_2532559Horse Anti-Mouse IgG HRPCell Signaling TechnologyCat# 7076; RRID:AB_330924Goat Anti-Rabbit IgG HRPCell Signaling TechnologyCat# 7074; RRID:AB_2099233Rabbit Polyclonal Anti-Ki67AbcamCat# ab15580; RRID:AB_443209ImmPRESS\u00ae HRP Goat Anti-Rabbit IgG Polymer Detection Kit, PeroxidaseVector Laboratories Inc.Cat# MP-7451; RRID:AB_2631198Biological samplesPatient-derived Xenograft KT-53Murphy et al.51https://doi.org/10.1038/s41467-019-13646-9Chemicals, peptides, and recombinant proteinsClick-iT\u00ae AHAInvitrogenCat# C10102AZDye 680 AlkyneVector Laboratories Inc.Cat# CCT-1514Click-iT\u2122 Plus OPP Alexa Fluor\u2122 594 Protein Synthesis Assay KitInvitrogenCat# C10457Actinomycin DSigmaCat # A1410BortezomibSigmaCat# 5043140001RapamycinSelleckchemCat# S1039FxCycle\u2122 PI/RNase Staining SolutionInvitrogenCat# F10797MG-132SelleckchemCat# S2619Critical commercial assaysClick-&-Go\u00ae Click Chemistry Reaction Buffer KitVector Laboratories Inc.Cat# CCT-1001Click-iT\u2122 Plus OPP Alexa Fluor\u2122 594 Protein Synthesis Assay KitInvitrogenCat# C10457Low Input RiboMinus\u2122 Eukaryote System v2InvitrogenCat# A15027NEBNext\u00ae Small RNA Library Prep Set for Illumina\u00aeNew England BiolabsCat# E7330TruSeq Stranded Total RNA-seq Sample Prep KitIlluminaCat# 20020596Proteasome-Glo\u2122 Chymotrypsin-like AssayPromegaCat# G8621Click-iT\u2122 Plus EdU Pacific Blue\u2122 Flow Cytometry Assay KitInvitrogenCat# C10636Click-iT\u2122 Plus TUNEL Assay kitInvitrogenCat# C10617Deposited dataRaw sequence data, analyses, and resources of WiT49 ribo-seqThis paperNCBI GEO GSE270330Raw Sequence data, analyses of WiT49 CRISPR knockout library screenThis paperNCBI GEO GSE270330RPPA validated antibodiesHoff et al.101https://doi.org/10.1007/978-981-32-9755-5_8RPPA dataThis paperTable S4Human reference genome NCBI build 38, GRCh38Genome Reference Consortiumhttps://www.ncbi.nlm.nih.gov/datasets/genome/GCF_000001405.26/GENCODE v26The GENCODE Projecthttps://www.gencodegenes.org/human/release_26.htmlMSigDB v7.1Liberzon et al.102https://doi.org/10.1016/j.cels.2015.12.004Human Brunello CRISPR knockout pooled library (Brunello) reference sequencesDoench et al.103supplementary table 21, https://doi.org/10.1038/nbt.3437Wilms Tumor RNA-seq counts, mutational data, and clinical annotationGadd et al.8https://doi.org/10.1038/ng.3940Experimental models: Cell linesHuman: WiT49 cellsDr. Sharon Plon LaboratoryRRID: CVCL_0583Human: 17.94 cellsXimbioCat# 153333; RRID: CVCL_D704Experimental models: Organisms/strainsMouse: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJThe Jackson LaboratoryRRID: IMSR_JAX:005557OligonucleotidesPlease See Table S7Recombinant DNAHuman Brunello CRISPR knockout pooled library (Brunello)Doench et al.103Addgene Pooled Library 73178Software and algorithmsFijiSchindelin et al.99https://fiji.scHISAT2Kim et al.104https://doi.org/10.1038/s41587-019-0201-4StringTiePertea et al.105https://doi.org/10.1038/nbt.3122DESeq2 (v1.40.2)Love et al.106https://doi.org/10.1186/s13059-014-0550-8Fgsea (v.1.26.0)Korotkevich et al.107https://doi.org/10.1101/060012MAGeCKFlute R packageWang et al.108https://doi.org/10.1038/s41596-018-0113-7Synergyfinder+Zheng et al.109https://synergyfinder.org/cBioportalCerami et al.52; Gao et al.53https://www.cbioportal.orgFlowJo (v.10)BD Life Scienceshttps://www.flowjo.com",
      "We compared outcomes for these patients according to expression of proteasome enzymatic subunits in cBioportal.52,53 Specifically, we obtained RNA-seq RPKM z-scores for PSMB5, PSMB6, and PSMB7, compared to tumors that are diploid for that gene. For patients with multiple samples, the primary tumor sample was used. Log rank tests were used to compare survival curves."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1501479148864746,
    "data_pmids_checked": 0,
    "paper_id": "40347939",
    "extraction_date": "2025-12-19T19:48:05.744379",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40347939.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40345706": {
    "cbioportal_paper_citations": [
      "The melanoma patient cohort undergoing anti-PD-1 \u00b1 anti-CTLA-4 treatment has been described previously.9 Pretreatment RNA sequencing (RNA-Seq) data was available for analysis from 41 patients treated with anti-PD-1 monotherapy and 32 patients treated with combination therapy. RNA-Seq data and clinical data from The Cancer Genome Atlas (TCGA) were downloaded for 472 cutaneous melanoma samples from cBioPortal10 (study ID \u201cskcm_tcga\u201d) using the R package cgds11 and GENI.12 The vast majority of included tumor samples were reported as cutaneous melanoma, not otherwise specified (414). A small number of other histological subtypes were included in the analyzed TCGA dataset: nodular (20), epithelioid (8), amelanotic (7), superficial spreading (4), desmoplastic (3), acral-lentiginous (2), lentigo maligna (2) and spindle cell (2). Excluding patients with missing data for survival or MLKL expression resulted in 458 patients for analysis. For the multivariate Cox regression analysis, which included Union for International Cancer Control (UICC) stage as a covariate, complete data was available for 424 patients."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.135788917541504,
    "data_pmids_checked": 0,
    "paper_id": "40345706",
    "extraction_date": "2025-12-19T19:48:06.880297",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40345706.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40362343": {
    "paper_id": "40362343",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Using data retrieved from cBioPortal (accessed on\n4February2025),thefrequencyofRASalterationswasanalyzedacrossglioblastomaandlower-\n4 February 2025), the frequency of RAS alterations was analyzed across glioblastoma and lower-\ngradegliomas.Theobservedalterations,includingamplification,deletion,mutation,andmultiple\ngrade gliomas",
      "DataonalterationsinKRAS,NRASandHRASingliomaswerequeriedviacBioPortal\n(https://www.cbioportal.org/,accessedon4February2025)[111,112],usingTheCancer\nGenomeAtlasProgram\u2019s(TCGA)FirehoseLegacystudyforthedatasetsnamed\u201cGlioblas-\ntoma Multiforme\u201d and \u201cBrain Lower Grade Glioma\u201d, containing 604 and 530 samples,\nrespectively"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:13.788440",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40362343.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.261820077896118,
      "cbioportal_papers": 0.0003209114074707031,
      "pdf_extraction_pass2": 6.841511249542236,
      "cbioportal_papers_pass2": 0.00033593177795410156,
      "used_full_extraction": true,
      "pdf_extraction": 16.103331327438354,
      "platform_mentions": 0.0038118362426757812,
      "data_citations": 1.1920928955078125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40362524": {
    "paper_id": "40362524",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Two cBioportal breast cancer datasets, the Invasive\nBreast Carcinoma (TCGA, PanCancer Atlas) and Firehose Legacy, which also includes\ninvasivebreastcarcinomasamples,bothshowedsignificantcorrelationbetweenlowP2Y2\nexpressionandasmallerpercentagechanceofdisease-freesurvival(Figure6A,B)[34,35]",
      "Two cBioportal breast cancer datasets, the Invasive\nBreast Carcinoma (TCGA, PanCancer Atlas) and Firehose Legacy, which also includes in-\nvasive breast carcinoma samples, both showed significant correlation between low P2Y2\nexpression and a smaller percentage chance of disease-free survival (Figure 6A,B) [34,35]",
      "(A) Data from cBioPortal: PanCancer Atlas patients, including all subtypes of breast cancer,\nshowthatpatienttumorswithlowerP2Y2mRNAexpressionhavepoorerdisease-freesurvival\n(\ns\np\nh\n=\now\n4",
      "Bioinformatics\nTheonlinecBioPortal(RRID:SCR_014555)database(https://www.cbioportal.org/\n(accessedon7July2022))wasusedtotestwhetherP2Y2mRNAexpressionhadaneffect\nondisease-freesurvivalintwodifferentbreastcancerdatasets",
      "DataAvailabilityStatement:DataareprovidedwithinthemanuscriptorSupplementaryInformation\nfiles.Thedatasetsgeneratedduringand/oranalyzedduringthecurrentstudyareavailablefromthe\ncorrespondingauthoronreasonablerequest.Thedatasetsgeneratedduringand/oranalyzedduring\nthecurrentstudyareavailableinthecBioPortal(RRID:SCR_014555)orKMPlot(RRID:SCR_018753)\nrepository(seemethodsforfurtherinformation).[https://www.cbioportal.org/(accessedon7July\n2022)][https://kmplot.com/analysis/(accessedon7July2022)]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:13.915248",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40362524.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.504513025283813,
      "cbioportal_papers": 0.0003528594970703125,
      "pdf_extraction_pass2": 9.235989093780518,
      "cbioportal_papers_pass2": 0.019451141357421875,
      "used_full_extraction": true,
      "pdf_extraction": 19.74050211906433,
      "platform_mentions": 0.0036957263946533203,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40333987": {
    "cbioportal_paper_citations": [
      "(A) Schematic of pairwise correlation analysis of METABRIC patient data (80\u201382) ranking correlated genes with EYA3 and looking at enrichment of correlated genes within Hallmark gene sets. (B) Gene expression for the METABRIC dataset (80\u201382) was downloaded from cBioPortal, and CCL2 mRNA expression was compared against EYA3 mRNA expression for each sample. (C) Using the GSVA R package, ssGSEA was used to calculate the NF-\u03baB score using the Hallmark gene set collection, HALLMARK_TNFA_SIGNALING_VIA_NFKB (116, 117), for each sample in the METABRIC dataset and compared to CCL2 mRNA expression. (D) CCL2 and EYA3 mRNA expression was evaluated in varying genetic subsets in the METABRIC dataset.",
      "For pairwise-correlation GSEA, we accessed patient RNA expression data from the METABRIC patient cohort (80, 81) via access through cBioPortal (117, 118) as z scores of gene expression and performed a pairwise Pearson correlation between EYA3 and all other genes in the dataset using R (4.0.1) and R Studio (v.1.2.5033) and subsequently ranked genes based on their correlation with EYA3 expression. We used the ranked list as input for preranked GSEA (v4.0.3) using the Hallmarks Molecular Signature Database (h.all.v7.1) and identified pathways enriched with genes correlated with EYA3 expression in patient breast tumors. We plotted the significantly up- and down-regulated pathways using the ggplot2 package."
    ],
    "cbioportal_platform_mentions": [
      "Gene expression and survival data for the METABRIC dataset (80\u201382) were downloaded from cBioPortal (30 May 2024). Gene expression for EYA3 was used to stratify the overall cohort into quartiles. Individuals from the top and bottom quartiles were compared for OS using the survival (v3.5-8) and survminer (v0.4.9) R packages. OS was analyzed with patients living the past 10 years right censored; the log-rank test was used to calculate statistical significance.",
      "For EYA3 mRNA correlations, gene expression data for the METABRIC dataset (80\u201382) were downloaded from cBioPortal (30 May 2024). Using the GSVA (v1.48.3) R package, ssGSEA was used to calculate the NF-\u03baB score using the Hallmarks gene set collection (v2023.2), HALLMARK_TNFA_SIGNALING_VIA_NFKB (119, 120). Patients were stratified by the 3-Gene classifier subtype (80, 81) on cBioPortal. Data were plotted in GraphPad prism, and Spearman correlation was calculated for each correlation. EYA3 and CCL2 mRNA data from The Metastatic Breast Cancer Project were analyzed on cBioPortal."
    ],
    "data_publication_citations": {
      "30867590": [
        "We previously demonstrated that EYA3 promotes primary tumor growth in BC via regulating a MYC\u2013PDL1 axis and suppressing the adaptive immune response to the tumor (25). However, whether EYA3 may also regulate spontaneous metastasis, which is the leading cause of BC-related deaths (79), and thus substantially affect the prognosis of women with BC, remained unknown. To address this question, we first analyzed recurrence-free survival and OS in the METABRIC patient dataset for patients with high versus low EYA3 (80\u201382) and found that patients with high EYA3 expression (top quartile) exhibited decreased survival compared to those with low EYA3 expression (bottom quartile) (Fig. 1A and fig. S1A). We then stratified for patients with TNBC and observed a trend toward decreased recurrence-free survival in patients with high EYA3 expression (fig. S1B). However, this trend was not statistically significant, likely due to a smaller sample size when stratifying for only patients with TNBC.",
        "(A) Schematic of pairwise correlation analysis of METABRIC patient data (80\u201382) ranking correlated genes with EYA3 and looking at enrichment of correlated genes within Hallmark gene sets. (B) Gene expression for the METABRIC dataset (80\u201382) was downloaded from cBioPortal, and CCL2 mRNA expression was compared against EYA3 mRNA expression for each sample. (C) Using the GSVA R package, ssGSEA was used to calculate the NF-\u03baB score using the Hallmark gene set collection, HALLMARK_TNFA_SIGNALING_VIA_NFKB (116, 117), for each sample in the METABRIC dataset and compared to CCL2 mRNA expression. (D) CCL2 and EYA3 mRNA expression was evaluated in varying genetic subsets in the METABRIC dataset.",
        "Gene expression and survival data for the METABRIC dataset (80\u201382) were downloaded from cBioPortal (30 May 2024). Gene expression for EYA3 was used to stratify the overall cohort into quartiles. Individuals from the top and bottom quartiles were compared for OS using the survival (v3.5-8) and survminer (v0.4.9) R packages. OS was analyzed with patients living the past 10 years right censored; the log-rank test was used to calculate statistical significance.",
        "For EYA3 mRNA correlations, gene expression data for the METABRIC dataset (80\u201382) were downloaded from cBioPortal (30 May 2024). Using the GSVA (v1.48.3) R package, ssGSEA was used to calculate the NF-\u03baB score using the Hallmarks gene set collection (v2023.2), HALLMARK_TNFA_SIGNALING_VIA_NFKB (119, 120). Patients were stratified by the 3-Gene classifier subtype (80, 81) on cBioPortal. Data were plotted in GraphPad prism, and Spearman correlation was calculated for each correlation. EYA3 and CCL2 mRNA data from The Metastatic Breast Cancer Project were analyzed on cBioPortal."
      ],
      "27161491": [
        "For pairwise-correlation GSEA, we accessed patient RNA expression data from the METABRIC patient cohort (80, 81) via access through cBioPortal (117, 118) as z scores of gene expression and performed a pairwise Pearson correlation between EYA3 and all other genes in the dataset using R (4.0.1) and R Studio (v.1.2.5033) and subsequently ranked genes based on their correlation with EYA3 expression. We used the ranked list as input for preranked GSEA (v4.0.3) using the Hallmarks Molecular Signature Database (h.all.v7.1) and identified pathways enriched with genes correlated with EYA3 expression in patient breast tumors. We plotted the significantly up- and down-regulated pathways using the ggplot2 package.",
        "For EYA3 mRNA correlations, gene expression data for the METABRIC dataset (80\u201382) were downloaded from cBioPortal (30 May 2024). Using the GSVA (v1.48.3) R package, ssGSEA was used to calculate the NF-\u03baB score using the Hallmarks gene set collection (v2023.2), HALLMARK_TNFA_SIGNALING_VIA_NFKB (119, 120). Patients were stratified by the 3-Gene classifier subtype (80, 81) on cBioPortal. Data were plotted in GraphPad prism, and Spearman correlation was calculated for each correlation. EYA3 and CCL2 mRNA data from The Metastatic Breast Cancer Project were analyzed on cBioPortal."
      ],
      "22522925": [
        "We previously demonstrated that EYA3 promotes primary tumor growth in BC via regulating a MYC\u2013PDL1 axis and suppressing the adaptive immune response to the tumor (25). However, whether EYA3 may also regulate spontaneous metastasis, which is the leading cause of BC-related deaths (79), and thus substantially affect the prognosis of women with BC, remained unknown. To address this question, we first analyzed recurrence-free survival and OS in the METABRIC patient dataset for patients with high versus low EYA3 (80\u201382) and found that patients with high EYA3 expression (top quartile) exhibited decreased survival compared to those with low EYA3 expression (bottom quartile) (Fig. 1A and fig. S1A). We then stratified for patients with TNBC and observed a trend toward decreased recurrence-free survival in patients with high EYA3 expression (fig. S1B). However, this trend was not statistically significant, likely due to a smaller sample size when stratifying for only patients with TNBC.",
        "(A) Schematic of pairwise correlation analysis of METABRIC patient data (80\u201382) ranking correlated genes with EYA3 and looking at enrichment of correlated genes within Hallmark gene sets. (B) Gene expression for the METABRIC dataset (80\u201382) was downloaded from cBioPortal, and CCL2 mRNA expression was compared against EYA3 mRNA expression for each sample. (C) Using the GSVA R package, ssGSEA was used to calculate the NF-\u03baB score using the Hallmark gene set collection, HALLMARK_TNFA_SIGNALING_VIA_NFKB (116, 117), for each sample in the METABRIC dataset and compared to CCL2 mRNA expression. (D) CCL2 and EYA3 mRNA expression was evaluated in varying genetic subsets in the METABRIC dataset.",
        "Gene expression and survival data for the METABRIC dataset (80\u201382) were downloaded from cBioPortal (30 May 2024). Gene expression for EYA3 was used to stratify the overall cohort into quartiles. Individuals from the top and bottom quartiles were compared for OS using the survival (v3.5-8) and survminer (v0.4.9) R packages. OS was analyzed with patients living the past 10 years right censored; the log-rank test was used to calculate statistical significance.",
        "For pairwise-correlation GSEA, we accessed patient RNA expression data from the METABRIC patient cohort (80, 81) via access through cBioPortal (117, 118) as z scores of gene expression and performed a pairwise Pearson correlation between EYA3 and all other genes in the dataset using R (4.0.1) and R Studio (v.1.2.5033) and subsequently ranked genes based on their correlation with EYA3 expression. We used the ranked list as input for preranked GSEA (v4.0.3) using the Hallmarks Molecular Signature Database (h.all.v7.1) and identified pathways enriched with genes correlated with EYA3 expression in patient breast tumors. We plotted the significantly up- and down-regulated pathways using the ggplot2 package.",
        "For EYA3 mRNA correlations, gene expression data for the METABRIC dataset (80\u201382) were downloaded from cBioPortal (30 May 2024). Using the GSVA (v1.48.3) R package, ssGSEA was used to calculate the NF-\u03baB score using the Hallmarks gene set collection (v2023.2), HALLMARK_TNFA_SIGNALING_VIA_NFKB (119, 120). Patients were stratified by the 3-Gene classifier subtype (80, 81) on cBioPortal. Data were plotted in GraphPad prism, and Spearman correlation was calculated for each correlation. EYA3 and CCL2 mRNA data from The Metastatic Breast Cancer Project were analyzed on cBioPortal."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.36820292472839355,
    "data_pmids_checked": 3,
    "paper_id": "40333987",
    "extraction_date": "2025-12-19T19:48:14.291752",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40333987.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40333905": {
    "cbioportal_paper_citations": [
      "The data for this work was obtained from the TCGA Data Project (https://www.cancer.gov/ccg/research/genome-sequencing/tcga). The TCGA Data Project provides extensive information on genetic changes, gene expression, DNA methylation, and clinical outcomes for various types of cancer. The download was conducted through the Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/) [9]. Three studies on HNSCC were chosen from cBioPortal (http://www.cbioportal.org). These studies include the TCGA Firehose Legacy, TCGA Nature 2015, and TCGA Pan Cancer Atlas datasets. These investigations incorporated data from 530, 279, and 523 samples, respectively. The genomic profile changes that were examined mutations incloud putative copy number alterations (CNAs), and structural variants. Moreover, the survival study was analyzed for an altered group, with overlapping samples excluded. In addition, the cBioPortal was utilized to obtain a list of the top 50 genes that exhibit the highest frequency of alterations in HNSCC, including TP53 mutations [10]."
    ],
    "cbioportal_platform_mentions": [
      "The analysis results for 1332 cases using cBioPortal revealed that 70% of patients with HNSCC have genomic mutations in the TP53 gene. The group with this alteration has a significant correlation with both the disease\u2019s presence (P = 0.0349) and its progression (P = 0.0102). The significant correlation with progression-free status may indicate that these alterations could be biomarkers for predicting disease progression or response to treatment. Therefore, understanding the alterations associated with the disease can lead to the development of targeted therapies aimed at these specific changes. The results revealed that mutant TP53 increased the expression levels of TP53, but showed no significant association with patient survival. Therefore, these mutations can disrupt the normal function of TP53, leading to uncontrolled cell proliferation and tumor development. Moreover, the findings revealed a decrease in the expression of hsa-mir-133b in both mutant and non-mutant TP53 proteins. This decrease was found to have a significant association with patient survival. The reduced expression of miR-133b in TP53-related cancers has a significant impact on survival due to its role as a tumor-suppressor miRNA. In cancer, miR-133b is downregulated, which affects processes critical to cancer progression. This specific miRNA normally targets genes involved in cell proliferation, migration, and invasion, such as Sox9, c-MET, and WAVE2. When miR-133b expression is low, these targets are less regulated, allowing cancer cells to grow, invade, and metastasize more freely. Furthermore, miR-133b\u2019s downregulation is associated with higher tumor grade and poor prognosis in breast cancer, suggesting its levels could serve as a potential prognostic marker [24]. In a previous study, it was shown that hsa-mir-133b is a promising biomarker for oral squamous cell carcinoma [25].",
      "As stated in the Methods section of the manuscript, we have already detailed the entire preprocessing process for the TCGA datasets. This includes data collection from the TCGA Data Portal and cBioPortal, followed by gene expression analysis using the UALCAN tool and the TCGA-assembler pipeline (106-121). Regarding batch correction and statistical analysis, we did not perform any specific statistical analysis in this study. The analysis focused on exploring gene expression and mutation data, including TP53 and miRNA expression, without conducting statistical testing. We have clarified these points in the Methods section."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2155299186706543,
    "data_pmids_checked": 0,
    "paper_id": "40333905",
    "extraction_date": "2025-12-19T19:48:14.542311",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40333905.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40358846": {
    "paper_id": "40358846",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal database\nwas used to evaluate genetic mutation profiles",
      "2.3 Genetic alteration analysis\nThe cBioPortal platform integrates extensive tumor genome data from large-scale projects such as TCGA and the International\nCancer Genome Consortium (ICGC)",
      "Epigenetic modification, gene expression profiles, and\nproteomic data are among the multidimensional cancer genomics data that were explored and analyzed using the cBioPortal\ndatabase [22]",
      "Therefore, the frequency and various forms of SENPs in 372 HCC samples were assessed using the cBioPortal",
      "The red boxplots represent\nLIHC tissues\nVol.:(0123456789)\n\nAnalysis\nDiscover Oncology (2025) 16:752 | https://doi.org/10.1007/s12672-025-02598-w\n3.3 Genetic alterations in SENPs in HCC\nThe genetic landscape of SENPs in HCC has been studied by analyzing 372 HCC samples using the cBioPortal database",
      "B Frequency data of genetic alteration in SENP family genes in LIHC using cBioPortal\nVol.:(0123456789)\n\nAnalysis\nDiscover Oncology (2025) 16:752 | https://doi.org/10.1007/s12672-025-02598-w\nFig",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:17.247867",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40358846.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.335583448410034,
      "cbioportal_papers": 0.00024199485778808594,
      "pdf_extraction_pass2": 6.673130035400391,
      "cbioportal_papers_pass2": 0.00022101402282714844,
      "used_full_extraction": true,
      "pdf_extraction": 14.008713483810425,
      "platform_mentions": 0.0019850730895996094,
      "data_citations": 5.7220458984375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40340757": {
    "paper_id": "40340757",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genes mutated in the Oncopig HCC model were also found to be mutated in HCC\npatients based on comparison to the cBioportal database",
      "A nearly identical high impact variant (premature stop codon) was\nfound in the clinical cBioportal database 6 amino acids downstream after accounting\nfor homology in the proteins across species",
      "In addition, ATM was found to be mutated\nin Oncopig HCC at a residue 11 amino acids downstream of a mutation observed in\ncBioPortal after accounting for homology",
      "A p.Ala927 Asp mutation in PTCH1, which plays a role in sonic hedgehog signaling\n[45], was observed in Oncopig HCC 7 amino acids upstream of another Ala residue\nmutated in the online cBioPortal human HCC database after accounting for homology",
      "The cBioPortal online database [68,\n69], which has compiled clinical genomic studies for HCC, was queried to identify muta-\ntions in the Oncopig HCC model that are clinically seen in patients",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics\nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:19.027568",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40340757.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.520559072494507,
      "cbioportal_papers": 0.00030303001403808594,
      "pdf_extraction_pass2": 5.6059410572052,
      "cbioportal_papers_pass2": 0.00030517578125,
      "used_full_extraction": true,
      "pdf_extraction": 12.126500129699707,
      "platform_mentions": 0.0026979446411132812,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40361399": {
    "paper_id": "40361399",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Proportionality between Cldn1 and AKR1C2, -C3, and -B1 has also been shown in pub-\nlicdatabases(FigureS2A:cBioPortal;https://www.cbioportal.org/(accessedon24July\n2023)) [37,38]",
      "Theresultsareinpartbased\nupondatageneratedbytheTCGAResearchNetwork:https://www.cancer.gov/tcga(accessedon\n1February2025),KMPlotter: https://pancreas.kmplot.com/(accessedon1February2025),and\ncBioPortal:https://www.cbioportal.org/(accessedon24July2023)[80\u201384]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:22.205706",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40361399.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.97635293006897,
      "cbioportal_papers": 0.00033283233642578125,
      "pdf_extraction_pass2": 11.173970937728882,
      "cbioportal_papers_pass2": 0.0003681182861328125,
      "used_full_extraction": true,
      "pdf_extraction": 20.15032386779785,
      "platform_mentions": 0.003696918487548828,
      "data_citations": 0.0006239414215087891,
      "num_data_pmids_checked": 5
    }
  },
  "40319192": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "22722839": [
        "Large-scale genome sequencing studies indicate that mutations in FOXA1 are common in prostate cancer, particularly among Chinese patients, and may act as drivers of the disease34\u201337. FOXA1 influences tumor progression in multiple aspects, including malignant transformation, drug resistance, metastasis, and an immunosuppressive microenvironment38\u201341. Traditionally, FOXA1 is associated with defining tissue-specific enhancers and reprogramming AR transcriptional networks42,43. However, it also exerts effects independent of AR, involving epithelial-mesenchymal transition (EMT), castration resistance, immune suppression, and neuroendocrine prostate cancer transformation39,44\u201346. Directly targeting FOXA1 for therapeutic purposes faces significant challenges, making it crucial to understand its regulatory network47\u201350.",
        "We next investigated the cause of elevated NSUN2 expression. Since transcriptional regulation is a primary driver of gene expression, we searched for transcription factors associated with NSUN2 expression in prostate cancer using public databases. A strong association was identified between NSUN2 expression and FOXA1, a transcription factor known to assist AR in binding target genes and driving prostate cancer progression35\u201337,91. FOXA1 mutations, frequently observed in prostate cancer, are linked to the malignant phenotype92. However, extensive study has demonstrated that FOXA1 can function in an AR-independent manner91. EMT is inhibited by FOXA1 in a way that is independent of AR39. Immunological response to malignancy, interferon signaling gene expression, and STAT2 DNA-binding activity were all inhibited by FOXA1\u2019s interaction with the STAT2 DNA-binding domain93. FOXA1 has also been reported to repress NR3C1 (glucocorticoid receptor gene) via the corepressor TLE394. These findings suggest that FOXA1\u2019s full spectrum of functions is still not fully understood. We demonstrated that FOXA1 regulates NSUN2 expression through transcriptional control, as confirmed by ChIP and luciferase assay."
      ],
      "32220891": [
        "Although RNA methylation has been increasingly acknowledged as a critical factor in tumorigenesis, most studies have concentrated on N6-methyladenosine (m6A) modification75\u201380. Conversely, 5-methylcytosine (m5C), a second RNA methylation modification, has not received as extensive investigation. To identify potential targets involved in m5C modification, we constructed a geneset of methyl-transferases, identifying NSUN2 as a candidate by integrating gene expression data with prognostic information. Recent studies have highlighted NSUN2\u2019s role across cancers, including gastric cancer81, esophageal squamous cell carcinoma82,83, pancreatic cancer84, hepatocellular carcinoma85, bladder cancer86. Notably, NSUN2 plays roles in biological processes such as RNA methylation and mRNA stabilization. It was recently discovered that glucose functions as a cofactor, facilitating the activation of NSUN2. This process preserves m5C RNA methylation globally and stabilizes TREX2, leading to tumorigenesis and failure of anti-PD-L1 immunotherapy87. However, the specific mRNAs modified by NSUN2 in prostate cancer remain unclear. According to a bioinformatics analysis, prostate cancer patients exhibiting elevated NSUN2 expression levels demonstrate a poorer prognosis88. Despite this, NSUN2\u2019s role in PCa and its potential regulatory mechanisms have not been elucidated. In this study, we validated NSUN2\u2019s role in CRPC using C4-2 and 22Rv1 cell lines, both of which are representative models of CRPC. Our results showed that, in CRPC, NSUN2 strengthens proliferation and migration in vitro, consistent with findings from other cancer types22,26,89,90."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.8621611595153809,
    "data_pmids_checked": 6,
    "paper_id": "40319192",
    "extraction_date": "2025-12-19T19:48:23.075254",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40319192.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40317966": {
    "cbioportal_paper_citations": [
      "Mutated KRAS activates a complex cascade of downstream signaling pathways, including the RAF/MAPK and PI3K pathways, leading to cell proliferation and eventually tumor formation [52]. This study revealed that genes in the RTK/RAS/MAPK pathway and the PI3K pathway were frequently altered in 46% and 23% of the KRAS wild\u2010type PDACs, respectively. Among the genes of the RAS pathway, BRAF was the most affected gene (20%), of which non\u2010V600E mutations were more common than V600E mutations were. These results are in line with past studies of KRAS wild\u2010type PDACs showing that genes in the RTK/RAS/MAPK pathway are commonly altered (38%\u201360%), with the most frequent alterations observed in BRAF (10.8%\u201325%) [9, 16, 22, 24, 29]. Recently, Varghese et al reported a clinical and genomic study of 2,336 PDAC cases, including 127 KRAS wild\u2010type PDACs analyzed by a clinical sequencing assay (MSK\u2010IMPACT), whose information is available in an open database (cBioPortal) [29, 53]. Although the ethnicity composition of this cohort differed from that of our cohort (in their cohort, East Asian patients constituted 4.8% of the cohort, while this population constituted 100% of the cohort in this study), their results are similar to ours, showing that 60% of KRAS wild\u2010type PDACs had genetic alterations in genes of the RTK/RAS/MAPK pathway. BRAF was frequently mutated (17%), and the p.V600E mutation constituted a minor component in BRAF\u2010mutated PDACs (n = 3/22, 14%). Together, the results of our study and other reports suggest that RAS pathway activation is important for the tumorigenesis of PDAC with wild\u2010type KRAS."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "25855536": [
        "Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer, with a 5\u2010year relative survival of 3% for patients diagnosed with metastatic disease in Japan [1, 2]. Multiple large\u2010scale genomic studies of PDAC have revealed that the PDAC genome is characterized by frequent and recurrent mutations in KRAS, TP53, CDKN2A, and SMAD4 and a \u2018long tail\u2019 of recurrently but infrequently mutated genes [3, 4, 5, 6, 7]. Although most genetic alterations are not targetable, a small proportion of PDACs are now known to have targetable molecular alterations, such as germline mutations in homologous recombination repair genes (14%\u201317%), mismatch repair deficiency (dMMR)/high microsatellite instability (MSI\u2010H) (0.5%\u20132%), and KRAS p.G12C (1%) [3, 4, 8, 9, 10, 11]."
      ],
      "39753968": [
        "Recently, multiple studies have highlighted the importance of PDACs with wild\u2010type KRAS. This rare set of PDACs (5%\u201310%) was shown to have potentially actionable alterations more frequently than KRAS\u2010mutated PDACs, including BRAF mutations [12, 13, 14, 15], fusions of receptor tyrosine kinases (RTKs) (FGFR2, ALK, BRAF, NTRK1/2/3, NRG1, RET, and ROS1) [9, 16, 17, 18, 19, 20, 21, 22, 23], and dMMR/MSI\u2010H, resulting in high tumor mutational burden (TMB) [10, 16, 17, 24, 25]. Overall, these studies suggest that KRAS wild\u2010type PDAC is an ideal target for molecular characterization for personalized medicine. In addition, multiple clinical studies have investigated the prognostic significance of KRAS mutational status, with some studies reporting that patients with KRAS wild\u2010type PDAC have better clinical outcomes than those with KRAS\u2010mutant PDAC [16, 22, 26, 27, 28, 29]. These results suggest that, although PDACs with wild\u2010type KRAS may represent a heterogeneous group of ductal carcinomas, these carcinomas may have distinct clinicopathological features.",
        "Here, we studied the clinicopathological features of 75 patients with KRAS wild\u2010type PDACs, one of the largest cohorts in the literature, providing detailed clinicopathologic, therapeutic, and outcome information at a single institution. We showed that KRAS wild\u2010type PDACs occurred at younger ages than KRAS\u2010mutated PDACs did, consistent with the findings of several previous studies [18, 29, 50]. However, wild\u2010type KRAS status was not a significant prognostic factor in metastatic PDACs. We previously studied the prognostic significance of the KRAS mutation status in patients with unresectable PDAC that was diagnosed between 2004 and 2009 and concluded that PDAC patients with wild\u2010type KRAS had better clinical outcomes than those with mutated KRAS [28]. The chemotherapy regimens that were used in these cases differed greatly from those used for the present cohort, as they occurred before the current regimens (Gem\u2010nab\u2010PTX and FOLFILINOX) were approved as the standard of care for patients with advanced PDAC; this might have affected the outcomes of both subgroups.",
        "Mutated KRAS activates a complex cascade of downstream signaling pathways, including the RAF/MAPK and PI3K pathways, leading to cell proliferation and eventually tumor formation [52]. This study revealed that genes in the RTK/RAS/MAPK pathway and the PI3K pathway were frequently altered in 46% and 23% of the KRAS wild\u2010type PDACs, respectively. Among the genes of the RAS pathway, BRAF was the most affected gene (20%), of which non\u2010V600E mutations were more common than V600E mutations were. These results are in line with past studies of KRAS wild\u2010type PDACs showing that genes in the RTK/RAS/MAPK pathway are commonly altered (38%\u201360%), with the most frequent alterations observed in BRAF (10.8%\u201325%) [9, 16, 22, 24, 29]. Recently, Varghese et al reported a clinical and genomic study of 2,336 PDAC cases, including 127 KRAS wild\u2010type PDACs analyzed by a clinical sequencing assay (MSK\u2010IMPACT), whose information is available in an open database (cBioPortal) [29, 53]. Although the ethnicity composition of this cohort differed from that of our cohort (in their cohort, East Asian patients constituted 4.8% of the cohort, while this population constituted 100% of the cohort in this study), their results are similar to ours, showing that 60% of KRAS wild\u2010type PDACs had genetic alterations in genes of the RTK/RAS/MAPK pathway. BRAF was frequently mutated (17%), and the p.V600E mutation constituted a minor component in BRAF\u2010mutated PDACs (n = 3/22, 14%). Together, the results of our study and other reports suggest that RAS pathway activation is important for the tumorigenesis of PDAC with wild\u2010type KRAS."
      ],
      "23103869": [
        "Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer, with a 5\u2010year relative survival of 3% for patients diagnosed with metastatic disease in Japan [1, 2]. Multiple large\u2010scale genomic studies of PDAC have revealed that the PDAC genome is characterized by frequent and recurrent mutations in KRAS, TP53, CDKN2A, and SMAD4 and a \u2018long tail\u2019 of recurrently but infrequently mutated genes [3, 4, 5, 6, 7]. Although most genetic alterations are not targetable, a small proportion of PDACs are now known to have targetable molecular alterations, such as germline mutations in homologous recombination repair genes (14%\u201317%), mismatch repair deficiency (dMMR)/high microsatellite instability (MSI\u2010H) (0.5%\u20132%), and KRAS p.G12C (1%) [3, 4, 8, 9, 10, 11]."
      ],
      "39214094": [
        "Recently, multiple studies have highlighted the importance of PDACs with wild\u2010type KRAS. This rare set of PDACs (5%\u201310%) was shown to have potentially actionable alterations more frequently than KRAS\u2010mutated PDACs, including BRAF mutations [12, 13, 14, 15], fusions of receptor tyrosine kinases (RTKs) (FGFR2, ALK, BRAF, NTRK1/2/3, NRG1, RET, and ROS1) [9, 16, 17, 18, 19, 20, 21, 22, 23], and dMMR/MSI\u2010H, resulting in high tumor mutational burden (TMB) [10, 16, 17, 24, 25]. Overall, these studies suggest that KRAS wild\u2010type PDAC is an ideal target for molecular characterization for personalized medicine. In addition, multiple clinical studies have investigated the prognostic significance of KRAS mutational status, with some studies reporting that patients with KRAS wild\u2010type PDAC have better clinical outcomes than those with KRAS\u2010mutant PDAC [16, 22, 26, 27, 28, 29]. These results suggest that, although PDACs with wild\u2010type KRAS may represent a heterogeneous group of ductal carcinomas, these carcinomas may have distinct clinicopathological features."
      ],
      "26909576": [
        "Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer, with a 5\u2010year relative survival of 3% for patients diagnosed with metastatic disease in Japan [1, 2]. Multiple large\u2010scale genomic studies of PDAC have revealed that the PDAC genome is characterized by frequent and recurrent mutations in KRAS, TP53, CDKN2A, and SMAD4 and a \u2018long tail\u2019 of recurrently but infrequently mutated genes [3, 4, 5, 6, 7]. Although most genetic alterations are not targetable, a small proportion of PDACs are now known to have targetable molecular alterations, such as germline mutations in homologous recombination repair genes (14%\u201317%), mismatch repair deficiency (dMMR)/high microsatellite instability (MSI\u2010H) (0.5%\u20132%), and KRAS p.G12C (1%) [3, 4, 8, 9, 10, 11]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 5,
    "extraction_method": "jats_xml",
    "extraction_time": 1.4963419437408447,
    "data_pmids_checked": 6,
    "paper_id": "40317966",
    "extraction_date": "2025-12-19T19:48:24.590088",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40317966.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40335819": {
    "paper_id": "40335819",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genetic\nalterations were analyzed using the cBioPortal platform, while immune infiltration was examined through ssGSEA and\nSpearman correlation analysis",
      "2.2 cBioPortal analysis of TNFAIP8 family genes in AML\nThe cBioPortal platform (https://w ww.c biopo rtal.o rg/) was employed to analyze genetic alterations in TNFAIP8 family\ngenes within the TCGA dataset [15, 16]",
      "The gene names were entered into relevant fields,\nand alterations were retrieved using the\"OncoPrint\"and\"Cancer Types Summary\"tools available on cBioPortal",
      "An investigation was conducted\nusing the cBioPortal online platform to explore alterations, such as mutations and copy number changes, within the\nTNFAIP8 family in AML",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:27.531659",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40335819.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.484249830245972,
      "cbioportal_papers": 0.00027108192443847656,
      "pdf_extraction_pass2": 7.22847318649292,
      "cbioportal_papers_pass2": 0.0002689361572265625,
      "used_full_extraction": true,
      "pdf_extraction": 13.712723016738892,
      "platform_mentions": 0.0022547245025634766,
      "data_citations": 9.679794311523438e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40315846": {
    "cbioportal_paper_citations": [
      "Bulk RNAseq was downloaded from the cPedBio data portal.67,68 Samples were filtered to retain HGN patients <25 yo. Histone mutation status was assessed by identifying H3F3A mutations in WES data available for all patients."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29489754": [
        "Pediatric high-grade gliomas (pHGGs) are the most common malignant brain tumors in children and young adults with limited treatment options and dismal prognosis. Therapeutic strategies, previously mostly adapted from adult glioma treatments, overlooked critical biological disparities across ages, including variations in driver mutations, mutational burden, and tumor cell states of distinct developmental origins, all together impacting the immune microenvironment.1,2,3 Advancements in understanding the latter and its interconnectivity of individual cell types through multiomic profiling have provided valuable insights in adult glioma and became instrumental for the prediction of treatment responses.4,5,6,7",
        "pHGGs are reported to exhibit an immunologically \u201ccold\u201d phenotype, i.e., presenting a low infiltration of immune cells, presumed to be a result of low mutational burden and reduced tumor antigen presentation.1,21,22 We first confirmed this phenotype by performing spatial transcriptomics on sections of four selected pHGG samples from our cohort (Figures 1B and S1A) with a combined pre-designed and custom-designed gene expression-targeting panel, including markers for human brain tumor and immune cells. Within each sample section, we detected <0.5% T cells and approximately 16% myeloid cells, confirming the \u201cimmunologically cold\u201d phenotype typically observed in pHGG.",
        "Our spatial transcriptomic data revealed an overall small proportion of tumor-associated T cells below 0.5% across all pHGG consistent with prior findings.1,15 Using our method for cell enrichment from fresh surgical tumor specimen, we were able to significantly enhance our ability to study these underrepresented T cells at the single-cell level using transcriptomic analysis. In order to identify specific programs, which represent underlying cell states and subtypes within the T cell population, we derived de novo NMF T cell programs from our pHGG patient cohort as well as from previously published adult HGG-associated T cells5 (Figure S3A). Interestingly, we did not observe T cell clusters exclusively found in pediatric samples, suggesting a broad similarity between pediatric and adult cohorts at the T cell transcriptional level (Figure S3B). We next annotated pediatric tumor-associated T cell programs as follows: cytotoxic (markers: GNLY and GZMB), predysfunctional (markers: GZMK and HLA-DRA), cycling (markers: UBE2C and RRM2), interferon (IFN) response (markers: IFIT1 and IFIT3), memory (markers: CCR7 and selectin-L [SELL]), effector memory (markers: LMNA and NFKBIA), and activated effector memory (markers: TIMP1 and CRIP1) (Figure 3A; Tables S2 and S3). Within adult HGG-associated T cells, we identified two additional programs: Treg (regulatory T cells, markers: FOXP3 and CTLA4) and a stress-induced program (stress, markers: HSPA6 and HSPA1), but no IFN response program (Figures S3C and S3A). While Tregs, stress, and IFN response T cell programs were identified de novo only in adult or pediatric T cells, respectively, the low cell counts likely prevented program detection using NMF. To address this, we re-scored all adult and pediatric T cells for the nine programs and used these annotations as cell program assignments for downstream analysis. This resulted in the identification of 32 pediatric Tregs and 93 pediatric stress T cells, confirming that low cell count likely prevented program detection via NMF (Figures S3A\u2013S3D).Figure 3T cell subpopulations in pHGG and their ligand-receptor interactome(A) Heatmap depicting the relative expression of the top marker genes for each T cell program, after merging the pediatric/adult shared programs. TPM values were pseudobulked by program (left) and CD4/CD8 annotation (top), log transformed, and centered by gene.(B) Uniform manifold approximation and projection plots of CD4+ and CD8+ T cells identified via SS2 in this pHGG cohort, colored by their identified T cell program.(C and D) Proportion of each T cell subpopulation, represented by the respective expression program, in our pHGG cohort.(E) Kaplan-Meier survival analysis based on bulk RNA-seq data obtained from the CBTN. The sequencing data were deconvoluted to predict the proportion of CD4+ T cells, CD8+ T cells, myeloid cell, and tumor cell states from our analysis, using Cibersort.37 Samples were split into \u201chigh\u201d proportion and \u201clow\u201d (top/bottom quantiles) and run to determine effects on survival. See Table S5 for survival analysis results for all programs.(F and G) Ligand-receptor interactions of indicated cell types and subpopulations, as in Figure 2G. Thickness of the connecting lines represents the proportion among all identified potential interactions."
      ],
      "31792460": [
        "We next aimed at gaining more insight into immunotherapy resistance in glioma. In contrast to both pediatric and adult gliomas, melanoma tumors have historically shown promising response to ICI, including anti-PD-1-targeted therapies.51 We therefore sought to compare tumor-infiltrating CD8+ T cell states between glioma and melanoma. We integrated glioma CD8+ T cells from both adult and pediatric cohorts with a published melanoma CD8+ T cell SS2 dataset25 to enable a more direct comparison. We re-scored all cells for dysfunctional, cytotoxic, predysfunctional program-associated, and naive gene sets,27 revealing high concordance of these cell states across both tumor types (Figures S5F and S5G). Melanoma CD8+ T cells expressed dysfunctional markers markedly higher than glioma T cells (CTLA4, TIGIT, HAVCR2, and PDCD1; Figure 5H), suggesting increased susceptibility to ICI immunotherapy. In alignment with this finding, melanoma CD8+ T cells also contained a higher proportion of dysfunctional T cell subpopulation (Figure 5I). In contrast, we found elevated cytotoxic marker expression in glioma CD8+ T cells as well as a higher cytotoxic T cell subpopulation compared to melanoma CD8+ T cells (Figures 5H and 5I). In addition, melanoma samples did not reveal a significant increase in tumor-infiltrating Treg proportions within the CD4+ T cell population upon immune checkpoint blockade (Figure 5J)."
      ],
      "35649412": [
        "In regard to our findings of therapy-induced differences of immune cell states and proportions, a previous study demonstrated that immune cell populations can be significantly affected following chemo-/radiotherapy in adult HGGs, showing an overall decrease in T and B cells, but an increase in tumor-infiltrating Tregs among CD4+ T cells.46 In accordance with these results, we observed alterations in the pHGG immune microenvironment after chemo-/radiotherapy. Specifically, we observed that proportions of inflammatory TAMs and microglia were significantly reduced after chemo-/radiotherapy, while other myeloid subpopulations remained unchanged (Figure 5A). This indicates a potential targeted impact on brain-resident myeloid cell types, as reported for adult glioma.56,57 The depletion or inhibition of these immune cell populations may benefit the anti-inflammatory tumor environment, which could impact overall anti-tumor immune responses and treatment outcomes. Further studies will be needed to elucidate the specific mechanisms underlying this observation and to determine the functional consequences of this myeloid cell subpopulation shift on tumor progression and treatment response."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4433426856994629,
    "data_pmids_checked": 3,
    "paper_id": "40315846",
    "extraction_date": "2025-12-19T19:48:27.976922",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40315846.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40311680": {
    "cbioportal_paper_citations": [
      "From TCGA, we extracted the preprocessed and normalized level of 3 RNA-seq (version 2) data for different cancer datasets available at the Broad GDAC Firehose portal (downloaded January 2017 https://gdac.broadinstitute.org/) (35). For each sample, we downloaded RNA-Seq with Expectation Maximization gene normalized data (identifier: illuminahiseq_rnaseqv2- RSEM_genes_normalized). RNA-Seq expression level read counts were normalized using FPKMUQ (Fragments per Kilo-base of transcript per Million mapped reads upper quartile normalization). This dataset is referred to as the TCGA-dataset throughout this manuscript. In addition, we collected preprocessed segmented somatic CNA data for each of the cancer datasets (identifier: genome_wide_snp_6 segmented_scna_minus_germline_cnv_hg19), which was generated with the Affymetrix Genome-Wide Human SNP Array 6.0. In short, the copy number segmentation pipeline implemented by TCGA and applied to Affymetrix SNP Array 6.0 uses a fully open-source tool Birdsuite and the DNAcopy R-package to perform a circular binary segmentation analysis. Circular binary segmentation translates noisy intensity measurements into chromosomal regions of equal copy number. The final output files are segmented into genomic regions with the estimated copy number for each region. Next, the copy number values are transformed into segment mean values, which are equal to log2(copy number/2) https://docs.gdc.cancer.gov/Data/PDF/Data_UG.pdf, (71, 72, 73).",
      "For the estimation of immune cell composition, the R package Microenvironment Cell Populations-counter (MCP-counter) was used (74). MCP-counter is a transcriptome-based deconvolution method to estimate the abundance scores of immune cell populations from RNA-seq data. RNA-seq data and breast cancer molecular subtype annotations in the TCGA and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer cohorts were obtained from the cBioPortal to perform the MCP-counter analysis (https://www.cbioportal.org/) (71, 72). For METABRIC, the gene name STING1 was used for STING mRNA analysis. For TCGA, TMEM173 was used for STING mRNA analysis."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "22522925": [
        "To analyze whether the observed inverse relation between STING and MYC was also observed in patient samples, we investigated MYC and STING mRNA levels across multiple cancer subtypes, using the TCGA cohort (35). In agreement with our observations in cell line models, MYC mRNA expression was inversely correlated with STING mRNA expression across various cancer types, including breast cancer, and most prominently in gastric adenocarcinoma (Fig. 2A, Table S1). When analyzing the different breast cancer subtypes in the TCGA dataset, MYC amplification showed a statistically significant association with decreased STING mRNA levels in ER+/HER2\u2212 breast cancers (Fig. 2B, Table S1). Although a trend in inverse correlation between MYC amplification and STING mRNA expression was also observed in other breast cancer subtypes within the TCGA cohort, these did not show statistical significance, likely due to the limited number of samples per breast cancer subtype in our analysis (Fig. 2C). Yet, TNBCs showed the highest percentage of MYC amplification (Fig. 2C). To extend our analysis to a second cohort, we analyzed the METABRIC dataset (36). MYC and STING mRNA levels were inversely correlated, especially in basal-like breast cancers (Fig. 2D), a molecularly defined breast cancer subtype which encompasses the majority of TNBCs. Importantly, MYC mRNA expression was also correlated with decreased immune cell abundance, particularly T cells, B cells, and NK cells, in the tumor microenvironment of HER2+ and basal-like breast cancers (Fig. 2D). In line with expectations, STING mRNA was positively correlated with immune cell presence in the tumor microenvironment (Fig. 2E). Similar results were obtained when mRNA levels of MYC and STING were correlated to immune cell composition in TCGA breast cancer samples (Fig. 2, F and G). Because 1) STING downregulation was observed in multiple TNBC cell line models (Fig. 1, A\u2013C), 2) MYC amplification is most frequently observed in TNBCs among breast cancer subtypes, and 3) because the strongest inverse relation between MYC expression and immune cell composition was observed in basal-like breast cancers, we further focused on TNBC models.Figure 2MYC mRNA expression is inversely correlated with STING mRNA and with immune cell composition.A, TCGA dataset analysis showing the correlation between MYC copy number and STING mRNA levels across various cancer types. B, separate analysis of different breast cancer subtypes within the \"Breast carcinoma\" group of TCGA, with indicated numbers of samples per subgroup. p values were calculated using the Mann\u2013Whitney U test. C, the percentage of samples with MYC amplification per subgroup are indicated. D, correlation analysis between MYC mRNA expression and STING mRNA expression and immune cell composition in the METABRIC cohort. E, correlation analysis between STING mRNA expression and immune cell composition in the METABRIC cohort. F, correlation analysis between MYC mRNA expression and STING mRNA expression and immune cell composition in the TCGA breast cancer cohort. G, correlation analysis between STING mRNA expression and immune cell composition in the TCGA breast cancer cohort."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.36049795150756836,
    "data_pmids_checked": 1,
    "paper_id": "40311680",
    "extraction_date": "2025-12-19T19:48:28.363410",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40311680.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40305907": {
    "cbioportal_paper_citations": [
      "We obtained gene expression data of 3083 luminal samples from 11 BC datasets (CAL,27 DFHCC,28 GSE58644,29 MAINZ,30 METABRIC,31 NKI,32 TCGA,21 TRANSBIG,33 UNT,34 UPP,35 and VDX36) using the MetaGxBreast R package (version 1.18.0),37 together with their clinical information (Supplementary Tables S1 and S2, respectively, available at https://doi.org/10.1016/j.esmoop.2025.105080). The microarray gene expression data from each study were downloaded and integrated into a unified database. Batch effect correction according to the study was done using the removeBatchEffect function in the limma R package (version 3.54.1).38 This database was used to construct the recurrence risk models as described in the Supplementary Material, available at https://doi.org/10.1016/j.esmoop.2025.105080. PAM50 classification, mutation, and CNA data were available for 1780 patients with luminal BC sourced from the TCGA and METABRIC datasets and were downloaded via the cBioPortal.39,40 PAM50 classification for the remaining samples in the MetaGxBreast studies was carried out using the genefu R package (version 2.30.0).41",
      "Affymetrix 6.0 SNP array segment data file (seg) for luminal patients in the TCGA PanCanAtlas study was obtained from the cBioPortal.39,40 The GISTIC 2.0 software (Broad Institute, Cambridge, MA)42, 43, 44 accessed through the GenePattern portal,45 was employed to analyze the segment data separately for each risk group against the reference genome GRCh37 (hg19), with a confidence level of 0.75 as suggested in the software documentation. To identify reported CNAs, we compared the resulting peak locations with focal amplifications or deletions found in the TCGA21 and BIG-1-9846 studies (38 amplification peaks and 71 deletion peaks, Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2025.105080). To determine the frequency of TCGA and BIG reported structural variations in different risk groups, we used BEDTools47 to find the intersection between GISTIC result frequency and the examined peaks. Fisher\u2019s exact test was applied to assess the statistical significance of the differences in the number of samples with specific CNA between the high- and low-risk groups. CNA frequencies were converted into categorical sample counts before carrying out the test."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26451490": [
        "In this study, we investigated the association between specific genetic alterations with genomic prognostic scores and the likelihood of recurrence in patients with luminal BC. Utilizing publicly available data from 11 BC studies, we developed three transcriptome-based predictive models based on widely used clinical tests: Oncotype DX\u00ae, MammaPrint\u00ae, and PAM50-ROR. These models were employed to categorize TCGA21,64,65 and METABRIC31,66,67 patients with luminal BC into high- and low-recurrence-risk groups, revealing significant differences in recurrence rates between these groups."
      ],
      "24798001": [
        "When comparing our results with the existing literature,68, 69, 70 our chosen cut-offs effectively distinguished between high- and low-risk patients, as evidenced by higher HRs in the high-risk groups across all models. This consistency underscores the robustness of our classification approach in predicting recurrence. Historically, mutations in genes like TP5371,72 and RB1,73,74 and CNAs such as amplifications in cytoband 14q21.1 including the FOXA1 gene75,76 and deletions in cytoband 17p13.3 including the gene RPH3AL,77,78 have been linked to poor prognosis in BC. Our study corroborated these findings and identified additional genomic aberrations associated with high relapse risk, including mutations in PTPN22 and MEN1 and deletions in regions such as 10q26 and 22q11.1. Conversely, mutations in genes such as PIK3CA79,80 and MAP3K180,81 were associated with low risk of recurrence. Notably, our observation that PIK3CA mutations were enriched in low-risk luminal samples suggests that they may serve as a protective marker for overall survival, consistent with previous studies.79,82 Our analysis also highlighted the coexistence of certain mutations (e.g. TP53-KMT2C, TP53-USH2A) that were more prevalent in high-risk groups, suggesting additive effects that could exacerbate disease progression. Similarly, mutations such as PIK3CA-CBFB and PIK3CA-CDH1, and amplification in 19q13.43, were linked to low risk, indicating a complex interplay of genetic factors that mitigate recurrence."
      ],
      "23000897": [
        "Luminal BC constitutes \u223c60%-70% of BC diagnoses and is associated with increased patient survival rates and reduced relapse compared with other BC subtypes. Gene expression signatures allow for distinguishing between luminal A and B tumors. Luminal A tumors exhibit high expression of progesterone receptors (PR) and estrogen-related genes, and low expression of proliferation genes like Ki67. Conversely, luminal B tumors are characterized by low expression of estrogen receptor (ER) and PR and high expression of genes related to cell cycle, proliferation, and growth factor receptors. Luminal B tumors are more aggressive, with a higher 5-year recurrence rate compared with luminal A tumors.3,12, 13, 14 Overall, luminal tumors have a slower growth rate than ER-negative tumors, resulting in a better patient prognosis. In recent years various genomic prognostic tests have emerged to predict prognosis and treatment options for patients with BC. These include Oncotype DX\u00ae, MammaPrint\u00ae, PAM50, Endopredict, Breast Cancer Index, and others, all based solely on the gene expression profiles of tumors.3,8,15,16 The development of BC involves the accumulation of various genetic changes, encompassing germline mutations,17, 18, 19 driver mutations,20 and copy number alterations (CNAs).21,22 Advancements in next-generation sequencing technologies, which provide insights into gene sequences and CNAs, have enabled the integration of such data into routine clinical practices for individuals with cancer.23,24",
        "We obtained gene expression data of 3083 luminal samples from 11 BC datasets (CAL,27 DFHCC,28 GSE58644,29 MAINZ,30 METABRIC,31 NKI,32 TCGA,21 TRANSBIG,33 UNT,34 UPP,35 and VDX36) using the MetaGxBreast R package (version 1.18.0),37 together with their clinical information (Supplementary Tables S1 and S2, respectively, available at https://doi.org/10.1016/j.esmoop.2025.105080). The microarray gene expression data from each study were downloaded and integrated into a unified database. Batch effect correction according to the study was done using the removeBatchEffect function in the limma R package (version 3.54.1).38 This database was used to construct the recurrence risk models as described in the Supplementary Material, available at https://doi.org/10.1016/j.esmoop.2025.105080. PAM50 classification, mutation, and CNA data were available for 1780 patients with luminal BC sourced from the TCGA and METABRIC datasets and were downloaded via the cBioPortal.39,40 PAM50 classification for the remaining samples in the MetaGxBreast studies was carried out using the genefu R package (version 2.30.0).41",
        "Affymetrix 6.0 SNP array segment data file (seg) for luminal patients in the TCGA PanCanAtlas study was obtained from the cBioPortal.39,40 The GISTIC 2.0 software (Broad Institute, Cambridge, MA)42, 43, 44 accessed through the GenePattern portal,45 was employed to analyze the segment data separately for each risk group against the reference genome GRCh37 (hg19), with a confidence level of 0.75 as suggested in the software documentation. To identify reported CNAs, we compared the resulting peak locations with focal amplifications or deletions found in the TCGA21 and BIG-1-9846 studies (38 amplification peaks and 71 deletion peaks, Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2025.105080). To determine the frequency of TCGA and BIG reported structural variations in different risk groups, we used BEDTools47 to find the intersection between GISTIC result frequency and the examined peaks. Fisher\u2019s exact test was applied to assess the statistical significance of the differences in the number of samples with specific CNA between the high- and low-risk groups. CNA frequencies were converted into categorical sample counts before carrying out the test.",
        "We conducted an enrichment analysis to investigate the association between different mutations and recurrence risk groups. We used four published curated lists of cancer driver genes including one pan-cancer list58 and three BC lists.20,21,59 (Supplementary Table S5, available at https://doi.org/10.1016/j.esmoop.2025.105080). Our findings revealed that mutations in PIK3CA, MAP3K1, CDH1, KMT2C, CBFB, and AKT1 were enriched in the low-risk groups, while mutations in TP53, RB1, and PTPN22 were enriched in the high-risk groups (FDR < 0.05, detailed statistical values in Supplementary Table S5, available at https://doi.org/10.1016/j.esmoop.2025.105080, Figure 2A).Figure 2Mutations enrichment according to risk groups. (A) Enrichment and frequency of individual mutations within each risk group. The color range indicates whether the mutation is underrepresented (blue) or enriched (red). For each gene in every model, in every risk group, we counted the number of times it was significantly (FDR < 0.05) enriched or underrepresented across the lists that gene was included in (repetitiveness column). (B) Enrichment of co-occurring mutations in each risk group was determined by Fisher\u2019s exact test with FDR < 0.05. The red and green colors indicate significant enrichment in the high-risk group and in the low-risk group, respectively (in at least one out of the three modules. As the color intensity deepens, the enrichment becomes significant in more models). The number displayed in the gray tiles represents the total mutation count in a single gene across all patients. (C) Bar graph representing frequency ratio between high- and low-risk groups across different models of the selected 12 known cancer driver mutations with at least threefold frequency ratio between risk groups in one or more of the models. The color indicates the significance obtained from Fisher\u2019s exact test between the risk groups, with FDR < 0.05 (dark pink), P values <0.05 (blue), and not-significant (green). (D) The frequency of BRCA2 mutations in low- and high-risk groups as classified by the patients\u2019 Oncotype DX score (Oncotype DX score <11 is defined as low-risk and >26 is considered high-risk). FDR, false discovery rate.",
        "To identify CNAs associated with the different risk groups, we reanalyzed the segment data file of TCGA patients using GISTIC 2.0.42 Specifically, we focused on previously published CNAs associated with patients with luminal BC by the TCGA network21 and the BIG-1-98 clinical trial.46",
        "We found varying degrees of overlap between the previously described CNAs and the alterations we identified for the different risk groups. Specifically, we identified amplification peaks in a specific region of 14q21.1, which includes the genes FOXA1, NKX2-1, and NFKBIA, previously associated with patients with luminal B BC.21 These alterations were consistently identified in the high-risk groups across all three models (chr14:37968637-38182419), while no amplification peaks were detected in the low-risk groups for these genomic locations (FDR < 0.0001 across all models, detailed statistical values in Supplementary Table S8, available at https://doi.org/10.1016/j.esmoop.2025.105080, Figure 3A). Conversely, across all the models, the amplification peak in cytoband 19q13.43, linked to luminal A tumors,21 showed partial overlap (chr19: 58398957-58475548) with amplification peaks only in the low-risk groups (FDR < 0.05 across all models, detailed statistical values in Supplementary Table S8, available at https://doi.org/10.1016/j.esmoop.2025.105080, Figure 3B). Similarly, we identified specific patterns of deletion regions unique to either the high- or low-risk group (Supplementary Figure S5, available at https://doi.org/10.1016/j.esmoop.2025.105080).Figure 3Copy number alterations associated with the different risk groups. (A, B) Overlapping of amplification peaks identified in the different risk groups with previously published CNAs associated with luminal BC across all models. (A) Cytoband 14q21.1 peak associated with high-risk groups. (B) Cytoband 19q13.43 is associated with the low-risk group. (C) Cytoband 11q13 contains different amplification regions, one is amplified exclusively in high-risk groups (highlighted in red square), and the other is amplified exclusively in low-risk groups (highlighted in green square). (D-E) Bar graphs representing the frequency ratio of amplification (D) and deletion (E) peaks between high- and low-risk groups across different models. Peaks were selected if they have at least a threefold frequency ratio between risk groups in one or more of the models. The color indicates the significance obtained from Fisher's exact test between the risk groups, with FDR < 0.05 (dark pink), and P values <0.05 (blue). CNAs, copy number alterations; FDR, false discovery rate.",
        "Next, we detected CNA regions known to be associated with luminal BC (as reported by TCGA and BIG-1-9821,46) that displayed at least a threefold difference in frequencies between the high- and low-risk groups. Using the Oncotype-like score model, we identified 11 amplification peaks meeting this criterion, whereas using the PAM50-model revealed only four amplification peaks with such distinction. However, no amplification peaks meeting this cut-off were detected with the MammaPrint-like score model. Two amplification peaks, 3p25.1 and 14q21.1, were consistently identified in both the Oncotype-like score and PAM50-models (Fisher\u2019s exact test, FDR < 0.05 across all models, detailed statistical values in Supplementary Table S9, available at https://doi.org/10.1016/j.esmoop.2025.105080, Figure 3D).",
        "Conducting a GISTIC analysis on these patients\u2019 groups identified several distinct CNAs exclusive to the high- or low-risk categories. For instance, the amplification peak at cytoband 14q21.1, previously associated with luminal B BC21 and identified in Figure 3A as associated with high-risk, was linked to the high-risk group. On the other hand, the amplification peak at cytoband 19q13.43, previously associated with luminal A BC21 and shown in Figure 3B as associated with low-risk, was specifically associated with the low-risk group. We also identified the deletion peak at cytoband 17p13.3, previously associated with luminal B BC21 overlapped with peaks found solely in the high-risk groups (FDR < 0.0001, Supplementary Table S8, and Figure S5, available at https://doi.org/10.1016/j.esmoop.2025.105080).",
        "In this study, we investigated the association between specific genetic alterations with genomic prognostic scores and the likelihood of recurrence in patients with luminal BC. Utilizing publicly available data from 11 BC studies, we developed three transcriptome-based predictive models based on widely used clinical tests: Oncotype DX\u00ae, MammaPrint\u00ae, and PAM50-ROR. These models were employed to categorize TCGA21,64,65 and METABRIC31,66,67 patients with luminal BC into high- and low-recurrence-risk groups, revealing significant differences in recurrence rates between these groups."
      ],
      "30867590": [
        "In this study, we investigated the association between specific genetic alterations with genomic prognostic scores and the likelihood of recurrence in patients with luminal BC. Utilizing publicly available data from 11 BC studies, we developed three transcriptome-based predictive models based on widely used clinical tests: Oncotype DX\u00ae, MammaPrint\u00ae, and PAM50-ROR. These models were employed to categorize TCGA21,64,65 and METABRIC31,66,67 patients with luminal BC into high- and low-recurrence-risk groups, revealing significant differences in recurrence rates between these groups."
      ],
      "22522925": [
        "We obtained gene expression data of 3083 luminal samples from 11 BC datasets (CAL,27 DFHCC,28 GSE58644,29 MAINZ,30 METABRIC,31 NKI,32 TCGA,21 TRANSBIG,33 UNT,34 UPP,35 and VDX36) using the MetaGxBreast R package (version 1.18.0),37 together with their clinical information (Supplementary Tables S1 and S2, respectively, available at https://doi.org/10.1016/j.esmoop.2025.105080). The microarray gene expression data from each study were downloaded and integrated into a unified database. Batch effect correction according to the study was done using the removeBatchEffect function in the limma R package (version 3.54.1).38 This database was used to construct the recurrence risk models as described in the Supplementary Material, available at https://doi.org/10.1016/j.esmoop.2025.105080. PAM50 classification, mutation, and CNA data were available for 1780 patients with luminal BC sourced from the TCGA and METABRIC datasets and were downloaded via the cBioPortal.39,40 PAM50 classification for the remaining samples in the MetaGxBreast studies was carried out using the genefu R package (version 2.30.0).41",
        "In this study, we investigated the association between specific genetic alterations with genomic prognostic scores and the likelihood of recurrence in patients with luminal BC. Utilizing publicly available data from 11 BC studies, we developed three transcriptome-based predictive models based on widely used clinical tests: Oncotype DX\u00ae, MammaPrint\u00ae, and PAM50-ROR. These models were employed to categorize TCGA21,64,65 and METABRIC31,66,67 patients with luminal BC into high- and low-recurrence-risk groups, revealing significant differences in recurrence rates between these groups."
      ],
      "29625055": [
        "In this study, we investigated the association between specific genetic alterations with genomic prognostic scores and the likelihood of recurrence in patients with luminal BC. Utilizing publicly available data from 11 BC studies, we developed three transcriptome-based predictive models based on widely used clinical tests: Oncotype DX\u00ae, MammaPrint\u00ae, and PAM50-ROR. These models were employed to categorize TCGA21,64,65 and METABRIC31,66,67 patients with luminal BC into high- and low-recurrence-risk groups, revealing significant differences in recurrence rates between these groups."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 6,
    "extraction_method": "jats_xml",
    "extraction_time": 1.4978160858154297,
    "data_pmids_checked": 7,
    "paper_id": "40305907",
    "extraction_date": "2025-12-19T19:48:29.865049",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40305907.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40325849": {
    "paper_id": "40325849",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Lipofectamine3000 (Invitrogen, of STAD tumors was determined from \u201ctumor type\u201d analy-\nCA, USA) was used for all transfections according to the manu- sis available from the cBioPortal for Cancer Genomics (www",
      "Dogrusoz, et al., \u201cIntegrative Analysis of\nComplex Cancer Genomics and Clinical Profiles Using the cBioPortal,\u201d 60"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:30.321739",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40325849.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.298728942871094,
      "cbioportal_papers": 0.0003261566162109375,
      "pdf_extraction_pass2": 5.771183967590332,
      "cbioportal_papers_pass2": 0.000324249267578125,
      "used_full_extraction": true,
      "pdf_extraction": 13.069912910461426,
      "platform_mentions": 0.0030908584594726562,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40302186": {
    "cbioportal_paper_citations": [
      "First, we batch calculated the SMD of each gene expression level in the mRNA dataset of PAAD from 32 datasets across 16 platforms worldwide to screen for differentially expressed genes (DEGs) of PAAD (SMD 95% confidence interval does not include 0, p < 0.05). Next, cBioPortal (date: October 8, 2023) was selected to analyse PAAD data from the TCGA to screen for co\u2010expressed genes of SAE1 (|Spearman's correlation| > 0.3, p < 0.05) [20]. The intersection of DEGs and SAE1 co\u2010expressed genes yields the intersection of genes. Afterwards, we performed gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis (date: October 10, 2023) on these intersecting genes to evaluate the potential biological functions of abnormal SAE1 in PAAD. In addition, STRING v12.0 was used to explore potential SUMO\u2010modified substrates regulated by SAE1 and involved in the progression of PAAD [21]."
    ],
    "cbioportal_platform_mentions": [
      "This study draws useful research ideas and methods from the excellent literature achievements of predecessors and then accurately screens the potential regulatory factors related to SAE1 transcription in PAAD with the help of the Citrome Data Browser database [31, 32, 33]. We analysed the possibility of SAE1 interacting with transcription regulatory factors based on the ChIP\u2010seq data. This study also predicts the potential binding sites of transcription regulatory factors to SAE1 in PAAD based on data from the JASPAR database [34]. We also comprehensively analysed the abnormal expression patterns of SAE1 transcription regulatory factors in PAAD based on the collected and organised mRNA expression profiles of PAAD tissue. The correlation between SAE1 and transcriptional regulatory factor expression levels was also evaluated to further analyse the transcriptional regulatory patterns of SAE1 abnormalities in PAAD. In addition, we also used UALCAN, cBioPortal and UCSC Xena databases to explore SAE1 gene alterations and methylation modifications in PAAD [35, 36]."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.056285858154296875,
    "data_pmids_checked": 0,
    "paper_id": "40302186",
    "extraction_date": "2025-12-19T19:48:30.398965",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40302186.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40332161": {
    "paper_id": "40332161",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "ThecBioCancerGenomicsPortal(cBioportal,http://www.cbioportal.org,lastaccessed\non 19 January 2025), a genomics site developed and maintained by MSKCC and other\nacademic institutions, was used to interrogate sub-sets of cases with different levels of\nexpressioninTRPchannelsofinterestinthethreeselectedgenomiccohorts[69,70]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:32.410814",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40332161.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.311097145080566,
      "cbioportal_papers": 0.00032901763916015625,
      "pdf_extraction_pass2": 8.550235033035278,
      "cbioportal_papers_pass2": 0.000308990478515625,
      "used_full_extraction": true,
      "pdf_extraction": 17.861332178115845,
      "platform_mentions": 0.0032029151916503906,
      "data_citations": 0.00033783912658691406,
      "num_data_pmids_checked": 3
    }
  },
  "40317079": {
    "paper_id": "40317079",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gene expression patterns were analyzed using The Can- The decreased expression of IL6R\u03b1 in CD109 KO A431\ncer Genome Atlas (TCGA-Pan Cancer Atlas) head and and CD109 KO SCC9 cells was associated with an abro-\nneck squamous cell carcinoma datasets from cBioPortal gation in IL-6-mediated phosphorylation of STAT3 (Tyr\nfor Cancer Genomics (https:// www",
      "expression analysis of 523 HNSCC patients data avail- We show that loss of CD109 leads to a significant\nable at the cBioPortal for Cancer Genomics/TCGA decrease in cell surface and total IL6R\u03b1 protein levels,\ndatabase (see Methods) reveal that CD109 mRNA leading to loss of stemness in SCC cells",
      "(D) CD109 mRNA expression also correlates with IL6R\u03b1 and NRF2 expression in 523 HNSCC patients from the TCGA Pancancer Atlas\ndatabase (cBioPortal, https:// www",
      "tumor samples, and correlation studies of publicly avail- It was recently reported that CD109 interacts with\nable HNSCC patient data for mRNA (cBioportal for Can- GP130, a component of the IL-6 receptor complex, in\ncer Genomics) and proteomic (LinkedOmics) expression glioblastoma cells [10]",
      "cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:41.537469",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40317079.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.325127124786377,
      "cbioportal_papers": 0.0003421306610107422,
      "pdf_extraction_pass2": 8.588680982589722,
      "cbioportal_papers_pass2": 0.0004067420959472656,
      "used_full_extraction": true,
      "pdf_extraction": 16.9138081073761,
      "platform_mentions": 0.0037300586700439453,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40301866": {
    "paper_id": "40301866",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Furthermore, the cBioPortal database was used to analyze the SLC16A3\ngenomic alterations",
      "Furthermore, any alterations in the SLC16A3\nThe incidence of cancer has seen a rapid increase in gene were analyzed via the cBioPortal",
      "In addition, SLC16A3\nThe SLC16A3 gene alternations in TCGA pan-cancer expression in paired samples was much higher in most\ndatasets were examined using the cBioPortal database tumor types in comparison to healthy tissues",
      "Neverthe-\n[33] (http://www.cbioportal.org/), which is a web portal less, no considerable variance was noted in the SLC16A3\nfor analyzing cancer genomics",
      "In addition, a previ- this gap, a pan-cancer study of SLC16A3 gene altera-\nous study revealed that Lonidamine, as a small molecule tions was conducted through the cBioPortal database",
      "2017;114:206\u2013 genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:43.563145",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40301866.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.4601891040802,
      "cbioportal_papers": 0.00024199485778808594,
      "pdf_extraction_pass2": 6.70001220703125,
      "cbioportal_papers_pass2": 0.00023603439331054688,
      "used_full_extraction": true,
      "pdf_extraction": 13.16020131111145,
      "platform_mentions": 0.003322124481201172,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40303483": {
    "paper_id": "40303483",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "To achieve this, we performed integrative bioinformatics analysis using various publicly\navailable databases, including GENT2, TCGA, UALCAN, cBioPortal, Kaplan-Meier plotter, The ROC plotter,\nGDSC, TISIDB, and TIMER",
      "The transport function of NSTs is tissues 2 (GENT2), cBioPortal, and The University of\nessential for glycosylation modifications and Alabama at Birmingham cancer data analysis portal\nbiological development",
      "In addition, we\ndata of the TCGA COAD (colon adenocarcinoma)\nused the CRC dataset (TCGA, Firehose Legacy) from\nproject, processed through the STAR workflow, was\ncBioPortal to perform Spearman correlation analysis\nobtained from the TCGA database (https://portal",
      "cBioPortal (http://cbioportal.org) [22]",
      "To explore the mutation landscape of the\nResults\nSLC35A family in CRC, we utilized the cBioPortal tool\nTranscriptional expression levels of SLC35A (Figure 3A)",
      "(D) Regression\nanalysis between SLC35A2 and MYC-associated genes (MYC, CDK4, PLK1 and PES1) in CRC performed by cBioPortal",
      "Therefore, we analyzed the correlation\ngenes, we performed a correlation analysis on clinical between SLC35A2 expression and the\nsample data from cBioPortal",
      "KY Tsai, PL Wei, cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:44.389054",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40303483.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.8533852100372314,
      "cbioportal_papers": 0.0003199577331542969,
      "pdf_extraction_pass2": 8.665796041488647,
      "cbioportal_papers_pass2": 0.0003199577331542969,
      "used_full_extraction": true,
      "pdf_extraction": 14.519181251525879,
      "platform_mentions": 0.003865957260131836,
      "data_citations": 0.00011420249938964844,
      "num_data_pmids_checked": 1
    }
  },
  "40322197": {
    "paper_id": "40322197",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:47.032019",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40322197.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 14.732318878173828,
      "cbioportal_papers": 0.0002760887145996094,
      "pdf_extraction_pass2": 13.268772840499878,
      "cbioportal_papers_pass2": 0.0002770423889160156,
      "used_full_extraction": true,
      "pdf_extraction": 28.001091718673706,
      "platform_mentions": 0.0024199485778808594,
      "data_citations": 9.870529174804688e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40297138": {
    "cbioportal_paper_citations": [
      "The second validation strategy to determine the relevance of the genes/proteins prioritized in our analysis involved evaluating the frequency of genomic alterations in a cohort of thyroid cancer human patients. These findings were then compared with a set of genes and proteins not associated with cancer with an OncoScore <20 (Piazza et al., 2017). To achieve this, we retrieved genomic, transcriptomic, and proteomic alteration data from the PanCancer Atlas, which is part of The Cancer Genome Atlas (TCGA) consortium (Hoadley et al., 2018; Huang et al., 2018; Armend\u00e1riz-Castillo et al., 2020). Genomic alterations, including driver mutations, structural variants, copy number variants (CNVs), mRNA upregulation, mRNA downregulation, protein upregulation, and protein downregulation, were analyzed in a cohort of 496 thyroid cancer patients. According to the Genomics Data Commons of the National Cancer Institute (https://portal.gdc.cancer.gov/) and cBioPortal (http://www.cbioportal.org/) (Cerami et al., 2012; Gao et al., 2013), driver mutations were identified through whole-exome sequencing. mRNA upregulation and downregulation were analyzed using RNA sequencing V2 RSEM, where tumor sample expression Z-scores were compared with the distribution of log-transformed mRNA expression in adjacent normal samples (Li and Dewey, 2011). CNV amplifications and deep deletions were identified using GISTIC2.0 (Mermel et al., 2011). Protein upregulation and downregulation were measured using reverse-phase protein arrays, with tumor sample expression Z-scores compared against adjacent normal samples. Finally, a Bonferroni correction (P < 0.001) was applied to perform a multiple comparison test. This test assessed alteration frequencies across three groups: all thyroid cancer driver genes and proteins, the prioritized thyroid cancer driver genes and proteins, and non-cancer driver genes and proteins.",
      "Three validation strategies confirmed the therapeutic relevance of the 30 prioritized thyroid cancer driver genes/proteins. The first utilized CRISPR-based functional genomics through loss-of-function screens from the DepMap project (Tsherniak et al., 2017). This approach identified significant dependencies on key genes/proteins such as KRAS, NRAS, PABPC1, PPP2R1A, STAG2, and BRAF in thyroid cancer cell lines, underscoring their potential as critical therapeutic targets. The second strategy analyzed genomic alteration frequencies in a cohort of 496 thyroid cancer patients from the TCGA PanCancer Atlas, demonstrating significantly higher alteration frequencies in prioritized genes/proteins compared to non-cancer-associated genes/proteins, further validating their clinical utility (Cerami et al., 2012; Gao et al., 2013). The third strategy assessed ligandability using canSAR, identifying 16 proteins with very high ligandability scores and 14 with high scores. These findings reinforce the suitability of these proteins as druggable targets, enhancing the specificity and efficacy of therapies while reducing drug development costs (Gingrich et al., 2024)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625048": [
        "The second validation strategy to determine the relevance of the genes/proteins prioritized in our analysis involved evaluating the frequency of genomic alterations in a cohort of thyroid cancer human patients. These findings were then compared with a set of genes and proteins not associated with cancer with an OncoScore <20 (Piazza et al., 2017). To achieve this, we retrieved genomic, transcriptomic, and proteomic alteration data from the PanCancer Atlas, which is part of The Cancer Genome Atlas (TCGA) consortium (Hoadley et al., 2018; Huang et al., 2018; Armend\u00e1riz-Castillo et al., 2020). Genomic alterations, including driver mutations, structural variants, copy number variants (CNVs), mRNA upregulation, mRNA downregulation, protein upregulation, and protein downregulation, were analyzed in a cohort of 496 thyroid cancer patients. According to the Genomics Data Commons of the National Cancer Institute (https://portal.gdc.cancer.gov/) and cBioPortal (http://www.cbioportal.org/) (Cerami et al., 2012; Gao et al., 2013), driver mutations were identified through whole-exome sequencing. mRNA upregulation and downregulation were analyzed using RNA sequencing V2 RSEM, where tumor sample expression Z-scores were compared with the distribution of log-transformed mRNA expression in adjacent normal samples (Li and Dewey, 2011). CNV amplifications and deep deletions were identified using GISTIC2.0 (Mermel et al., 2011). Protein upregulation and downregulation were measured using reverse-phase protein arrays, with tumor sample expression Z-scores compared against adjacent normal samples. Finally, a Bonferroni correction (P < 0.001) was applied to perform a multiple comparison test. This test assessed alteration frequencies across three groups: all thyroid cancer driver genes and proteins, the prioritized thyroid cancer driver genes and proteins, and non-cancer driver genes and proteins."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2769908905029297,
    "data_pmids_checked": 1,
    "paper_id": "40297138",
    "extraction_date": "2025-12-19T19:48:47.309110",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40297138.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40292313": {
    "cbioportal_paper_citations": [
      "From a therapeutic perspective, analysis of available data in cancer patients has previously shown that ITGB4 expression is correlated with patient prognosis and survival across numerous types of cancer.29 ITGB4 shows significantly increased transcription in tumors in 23 of the 33 cancer types with available TCGA data. Increased expression of ITGB4 is associated with poor prognosis (shorter overall survival or disease-free survival) for the majority of cancer types (20 of the 33). Skin cancer patients showed the highest frequencies of mutations in ITGB4 of all the cancer types examined. However, not enough data exists to evaluate the connection between ITGB4 expression and metastasis in melanoma patients. Only a few patient samples available in the cBioPortal (v.6.0.23)44,45 have RNA-seq data collected along with metastatic status, and none have ITGB4 protein expression measured. Our results suggest that future study is warranted to quantify ITGB4 expression status in metastatic melanoma in patients. Beyond a single protein, however, our results indicate that there are likely to be RNA and 3D genome signatures within subpopulations of cells in a tumor that indicate a cell\u2019s initial propensity to undergo migration. Such invasive gene expression signatures have previously been discussed,46,47 but our study clarifies pre-existing 3D genome signatures and how these may further change during the process of cell migration. Our results also show that a whole suite of cellular and genomic changes accompany ITGB4 status, and knocking down ITGB4 only modestly reduces migration. Thus, our results also caution against using a single factor like ITGB4 as a prognostic marker or therapeutic target."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5340979099273682,
    "data_pmids_checked": 0,
    "paper_id": "40292313",
    "extraction_date": "2025-12-19T19:48:47.878678",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40292313.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40301468": {
    "paper_id": "40301468",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In addition, genetic variations including Copy\nNumber Variations (CNVs), Somatic Mutations (SMs) and Genomic Structural Variations (SVs) of the selected\nsamples, were obtained from TCGA PanCancer Atlas study using cBioPortal (Supplementary Information 1\u2014\nSupplementary Video 2)",
      "Patient dataset matching was ensured by comparing sample IDs between GDC and\ncBioPortal",
      "(A) Acquisition of patient-specific multi-omics data including genetic alterations, expression profiles, and\nsample sheet from TCGA PanCancer Atlas via GDC (Genomics Data Common) and cBioPortal, ensuring\nconsistency in patient datasets by comparing sample IDs between GDC and cBioPortal",
      "For obtaining\nthe genomic data including copy number variations (CNVs), somatic mutations (SMs), and genomic structural\nvariants (SVs), the same TCGA project was queried in cBioPortal",
      "Patient data matching was ensured by\ncomparing sample IDs between GDC and cBioPortal",
      "Note that patient\ninformation can be employed from other programs and projects as well such as TARGET (Therapeutically\nApplicable Research to Generate Effective Treatments) program and GENIE-MSK (Genomics, Evidence,\nNeoplasia, Information and Exchange at Memorial Sloan Kettering Cancer Center) project which are available at\nGDC and cBioPortal",
      "Patient dataset matching is ensured by comparing sample IDs\nbetween GDC and cBioPortal",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:56.002133",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40301468.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 12.581197023391724,
      "cbioportal_papers": 0.00047588348388671875,
      "pdf_extraction_pass2": 11.003606796264648,
      "cbioportal_papers_pass2": 0.0005311965942382812,
      "used_full_extraction": true,
      "pdf_extraction": 23.584803819656372,
      "platform_mentions": 0.004786252975463867,
      "data_citations": 1.2874603271484375e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40301429": {
    "paper_id": "40301429",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Variants of the PBK/\nTOPK gene and their prognostic implications were explored using cBioPortal",
      "PBK/TOPK mutations in breast cancer were analyzed using the cBioPortal database31 ( h t t p : / /w w w",
      "Furthermore, the\nsignificance of PBK/TOPK gene mutations in the prognostic outcomes of breast cancer was assessed by Kaplan\u2013\nMeier survival curves in cBioPortal",
      "Analysis of PBK/TOPK gene changes in breast cancer using cBioPortal\nBy adding the PBK/TOPK gene into the cBioPortal database, we obtained the OncoPrint gene alteration\nschematic, which showed changes in the queried genes in 49 (5%) of the 996 breast cancer samples with\nmutation and DNA copy alterations data (Fig",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:57.055739",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40301429.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.530601978302002,
      "cbioportal_papers": 0.0003628730773925781,
      "pdf_extraction_pass2": 6.960257053375244,
      "cbioportal_papers_pass2": 0.0003211498260498047,
      "used_full_extraction": true,
      "pdf_extraction": 15.490859031677246,
      "platform_mentions": 0.0028901100158691406,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40299444": {
    "paper_id": "40299444",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:48:58.754797",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40299444.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.87211799621582,
      "cbioportal_papers": 0.00022411346435546875,
      "pdf_extraction_pass2": 6.316976070404053,
      "cbioportal_papers_pass2": 0.0002262592315673828,
      "used_full_extraction": true,
      "pdf_extraction": 15.189094066619873,
      "platform_mentions": 0.0017809867858886719,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40299340": {
    "paper_id": "40299340",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "GenomicAlterationandMutationalBurden\ncBioPortal\u2019sCancerTypeSummarymodule[17]analyzedEOGTmutations,amplifi-\ncations,anddeletions"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:01.932395",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40299340.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.383004903793335,
      "cbioportal_papers": 0.00039315223693847656,
      "pdf_extraction_pass2": 10.128129959106445,
      "cbioportal_papers_pass2": 0.00047588348388671875,
      "used_full_extraction": true,
      "pdf_extraction": 17.51113486289978,
      "platform_mentions": 0.01010894775390625,
      "data_citations": 0.0001552104949951172,
      "num_data_pmids_checked": 1
    }
  },
  "40282424": {
    "paper_id": "40282424",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gene alterations and survival outcomes in TCGA-PAAD were examined through cBio-\nPortal(http://www.cbioportal.org)[15]",
      "Genes2025,16,463 8of16\n(B)GeneticalterationsofselectedSLCtargetsareshownalongsidesurvivalplots,illustratingOSand\nDSSforpatients.Statisticalsignificancewasassessedusingthelog-ranktest.(C)UsingAlphaFold2,\nthe3DstructuresofSLCtransporterswerepredictedandvisuallyrepresentedwithcolorcodingbased\nonpredictedlocaldistancedifferencetestscores:blueforveryhighconfidenceabove90,lightblue\nforhighconfidencebetween70and90,yellowforlowconfidencebetween50and70,andredforvery\nlowconfidencebelow50,providingadetailedvisualizationofstructuralreliability.AlphaMissense\nwasemployedtocategorizespecificaminoacidmutationsaslikelypathogenic,benign,oruncertain,\nutilizingproteinstructuralcontextandevolutionaryconstraintsforclassification.(D)Survivalcurves\nillustratetheassociationbetweenelevated(red)andreduced(black)expressionlevelsofSLCgenes\nwithOSandDSS,includinghazardratiosandp-valuestohighlighttheirprognosticrelevance.Data\nsources:(A)mRNAexpressiondatawereobtainedfromTCGAandGTEx,andproteinexpression\ndatafromtheHumanProteinAtlas(HPA)IHCdataset.(B)Geneticalterationsweresourcedfrom\ncBioPortal(TCGA-PAADcohort).(C)ProteinstructuralpredictionswereretrievedfromAlphaFold,\nwithmutationimpactclassificationperformedusingAlphaMissense"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:02.548445",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40282424.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.0986647605896,
      "cbioportal_papers": 0.0002589225769042969,
      "pdf_extraction_pass2": 6.568039894104004,
      "cbioportal_papers_pass2": 0.00026488304138183594,
      "used_full_extraction": true,
      "pdf_extraction": 14.666704654693604,
      "platform_mentions": 0.002344846725463867,
      "data_citations": 7.3909759521484375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40267151": {
    "cbioportal_paper_citations": [
      "To analyze genetic alterations in the GTF2E2 gene, we utilized the cBioPortal as our primary data source, referencing studies from the TCGA PanCancer Atlas [24,25]. We examined the frequency of somatic mutations and detailed genomic characteristics of GTF2E2 mutations across different cancer types. This analysis involved using the \u201cCancer Type Summary,\u201d \u201cMutations,\u201d and \u201cmRNA vs. Study\u201d modules on the portal, allowing us to identify specific mutation sites within the gene."
    ],
    "cbioportal_platform_mentions": [
      "In our study, we utilized the cBioPortal tool to examine genetic alterations in the expression of the gene GTF2E2 across a spectrum of cancers, based on data from 32 studies within the TCGA PanCancer Atlas, comprising 10,967 samples. Our analysis identified 64 mutation sites in the GTF2E2 gene sequence, ranging from amino acid 0\u2013291. These included 41 missense mutations, 14 truncating mutations, two splicing mutations, and seven structural variations or fusions. The mutation R194H/C emerged as the most common (Fig 11A). The predominant types of mutations observed were deep deletions, missense mutations, and gene amplifications. GTF2E2 mutations appeared most frequently in cancers of the PRAD, UCEC, BLCA, LIHC, COAD, OV, UCS, and BRCA (Fig 11B). Additionally, a shallow deletion in GTF2E2 mRNA expression was generally prevalent across the studied cancer types, except in LAML and THYM (Fig 11C).",
      "In our study, we analyzed GTF2E2 mutations across 32 cancers using the cBioPortal platform, finding low mutation frequencies overall. However, the mutations were most prevalent in prostate, uterine, and bladder cancers (PRAD, UCEC, and BLCA, respectively), highlighting a potential link between GTF2E2 mutations and tumors of the urinogenital system. To further explore the biological functions of GTF2E2, we constructed a PPI network, identifying 10 central hub genes. Subsequent analysis showed a significant correlation between the expression of GTF2E2 and these hub genes across various cancers, suggesting their interconnected roles in oncological processes."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.05050015449523926,
    "data_pmids_checked": 0,
    "paper_id": "40267151",
    "extraction_date": "2025-12-19T19:49:02.580275",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40267151.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40260977": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutations, structural variants, and gene amplifications in AXL, SRC, and c\u2010MET were investigated using the cBioPortal webserver [22] for ccRCC (n = 531) and pRCC (n = 290) cohorts from the TCGA, Firehose Legacy dataset (available at: https://www.cbioportal.org).",
      "Figure S1. Alteration frequency of mutation, amplification and deep deletion events in AXL, SRC, and c\u2010MET genes across ccRCC and pRCC cohorts of TCGA (Firehose Legacy) in the cBioPortal database"
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.06624579429626465,
    "data_pmids_checked": 0,
    "paper_id": "40260977",
    "extraction_date": "2025-12-19T19:49:02.661265",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40260977.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40259515": {
    "cbioportal_paper_citations": [
      "Technological advances in high\u2010throughput sequencing have accelerated cancer genomic studies. Completion of the Human Genome Project laid the foundation for these studies [13]. The Cancer Genome Atlas (TCGA) project is one of the most prominent achievements and provided a comprehensive map of genomic alterations as well as genome\u2010wide profiles of gene expression and epigenetic modifications for many cancer types [14]. The results are publicly available [15, 16], allowing researchers to exploit them according to their interests, including rare cancer types such as thymic tumors [17, 18, 19].",
      "Nevertheless, the number of genetic mutations significantly differs among cancers [15, 16, 47]. Additionally, some cancers have an extremely low mutation rate and even lack recurrent variants in genome\u2010wide sequencing analyses [47, 48, 49]. Ependymomas, a common childhood brain tumor, often lack recurrent variants but can exhibit a CpG island methylation phenotype with poor prognoses [50, 51]. Thus, further studies are warranted to address the causal role of epigenetic abnormalities that are independent of genetic aberrations in cancer initiation and progression."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26168399": [
        "Genome\u2010wide studies have also contributed to our understanding of cancer etiology. An example is the discovery of the causal relationship between an unappreciated virus, Merkel cell polyomavirus, and Merkel cell carcinoma [23]. Additionally, it was found that mutational signatures can predict putative etiologies for cancer development, such as tobacco smoking, ultraviolet exposure, and mismatch repair deficiency [24, 25, 26, 27]."
      ],
      "22367537": [
        "Nevertheless, the number of genetic mutations significantly differs among cancers [15, 16, 47]. Additionally, some cancers have an extremely low mutation rate and even lack recurrent variants in genome\u2010wide sequencing analyses [47, 48, 49]. Ependymomas, a common childhood brain tumor, often lack recurrent variants but can exhibit a CpG island methylation phenotype with poor prognoses [50, 51]. Thus, further studies are warranted to address the causal role of epigenetic abnormalities that are independent of genetic aberrations in cancer initiation and progression."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.17314410209655762,
    "data_pmids_checked": 2,
    "paper_id": "40259515",
    "extraction_date": "2025-12-19T19:49:02.840731",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40259515.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40257906": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Currently, numerous databases have been established to support gene expression analysis, gene-related correlations, and access to medical imaging data. An influential database in this regard is The Cancer Genome Atlas (TCGA), which contains a wide range of genomic information and gene expression data [12]. To further investigate gene correlations, the cBioPortal platform offers intuitive visualization tools, while the Gene Expression Profiling Interactive Analysis (GEPIA) tool allows for comprehensive gene expression analysis [13, 14]. Additionally, several specialized databases have been developed to explore diverse types of gene correlations, including gene\u2013gene interactions, gene\u2013protein associations, gene\u2013viral infection relationships, and networks for gene co-expression and metabolite co-accumulation [15\u201319]. Furthermore, The Cancer Imaging Archive (TCIA) serves as a critical resource by providing public access to a wide range of cancer-related medical images. Despite these advancements, most existing databases primarily focus on providing clinical factors, sequencing data, medical images, gene expression analysis, and gene-related correlations, leaving significant gaps in the integration of multi-modal data."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.105072021484375,
    "data_pmids_checked": 0,
    "paper_id": "40257906",
    "extraction_date": "2025-12-19T19:49:02.945905",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40257906.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40281485": {
    "paper_id": "40281485",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal database was used to explore the alteration\nfeatures of MEF2s in PAAD",
      "of MEF2s in PAAD by the cBioPortal database (http:// This study also used the European Bioinformatics Insti-\nwww",
      "High expression of MEF2C was associated with worse PAAD through the cBioPortal database",
      "A-B cBioPortal generated a schematic\ndiagram of MEF2s family mutations in PAAD",
      "C cBioPortal analyzed the relationship between MEF2s family gene mutations and prognostic value\nin PAAD\n\nZ hai et al. BMC Cancer (2025) 25:775 Page 9 of 16\nFig",
      "Studies also indicated that subtle changes RFS Relapse-free survival\nin methylation could trigger widespread alterations in DFS Disease-free survival\nHR Hazard ratio\nhistone modification patterns, including the loss of active\nCI Confidence intervals\nchromatin markers such as H3 K9ac and H3 K4 me3, and CBioPortal C Bio Cancer Genomics Portal\nthe establishment of repressive markers like H3 K27 me3, TIMER Tumor Immune Estimation Resource\nCNV Copy number variation\nthereby reinforcing a repressive chromatin environment\nTME tumor microenvironment\n[58]",
      "Class IIa HDACs repressive activities on MEF2-depedent transcrip-\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:07.644350",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40281485.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.123064041137695,
      "cbioportal_papers": 0.00028896331787109375,
      "pdf_extraction_pass2": 6.513573169708252,
      "cbioportal_papers_pass2": 0.0002789497375488281,
      "used_full_extraction": true,
      "pdf_extraction": 11.636637210845947,
      "platform_mentions": 0.0026199817657470703,
      "data_citations": 0.00010013580322265625,
      "num_data_pmids_checked": 1
    }
  },
  "40255484": {
    "cbioportal_paper_citations": [
      "We sourced RNA-Seq transcriptomic data from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov), comprising 535 tumor samples and 59 normal samples, for HNSC patients (Colaprico et al., 2016). Concurrently, the corresponding clinical data were retrieved from the UCSC Xena database (http://genome.ucsc.edu). A total of 289 genes associated with lactic acid metabolism (LMRGs) were collected from the GeneCards database (Stelzer et al., 2016) and Molecular Signatures Database (MSigDB) (Liberzon et al., 2015). To compare the differences in tumor immune therapy between high-risk score and low-risk score groups, we employed the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm (http://tide.dfci.harvard.edu) based on the Cox regression risk score. The copy number variation (CNV) segments underwent GISTIC 2.0 analysis using the Hiplot website (https://hiplot-academic.com/advance/gistic2). For the visualization of the protein-protein interaction (PPI) network and selecting hub genes, we utilized the Cytoscape software and the String website (Gao et al., 2013).",
      "The expression profiles of key genes were interrogated through the application of the Cox regression model. From the Cox multifactorial model, the top 20 differentially expressed genes (DEGs) associated with high and low-risk score groups were selected for further analysis. The GOSemSim package computed the top 20 DEGs linked to risk stratification in the Cox multifactorial model. Subsequently, the protein-protein interaction (PPI) network for these top 20 DEGs was constructed utilizing the String website, while the mRNA-miRNA interaction network was established using the MiRDB database (Gao et al., 2013)."
    ],
    "cbioportal_platform_mentions": [
      "We analyzed gene mutations in five key genes (COX8A, LDHB, NDUFA1, NDUFA4, NDUFB3) using samples from the TCGA-HNSC dataset and the cBioPortal database. The findings (Figure 3A) showed that NDUFB3 had the highest total mutation count, accounting for 2.4% of the total samples in the TCGA-HNSC dataset, mainly presenting as significant amplification. We also observed a significantly high correlation (p < 0.01) for all pairwise combinations of the 5 key genes (Figure 3B)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.0731351375579834,
    "data_pmids_checked": 0,
    "paper_id": "40255484",
    "extraction_date": "2025-12-19T19:49:07.717608",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40255484.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40277780": {
    "paper_id": "40277780",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DataAvailabilityStatement:Theoriginalcontributionspresentedinthisstudyareincludedinthis\narticle.Dataminedfrompubliclyavailabledatasetscanberetrievedfrominterrogatingthereferenced\ndatasetsat\u201cwww.cBioPortal.org(lastaccessedon3June2024).DatafromtheOrien-AvatarDatabase\narenotpubliclyavailableandrelevantdataarepresentedinthisarticle"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:11.463358",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40277780.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.315353155136108,
      "cbioportal_papers": 0.000324249267578125,
      "pdf_extraction_pass2": 5.388556003570557,
      "cbioportal_papers_pass2": 0.00033092498779296875,
      "used_full_extraction": true,
      "pdf_extraction": 12.703909158706665,
      "platform_mentions": 0.003432750701904297,
      "data_citations": 0.0003609657287597656,
      "num_data_pmids_checked": 3
    }
  },
  "40257604": {
    "paper_id": "40257604",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.4 Gene alterations\nWe utilized cBioPortal [25] to analyze the gene alteration status of Piezo1 and Piezo2 in the context of gastric cancer",
      "The OncoPrint feature in cBioPortal (TCGA provisional) was used to visually represent the genetic alterations, includ-\ning gene amplification, deep deletion, mRNA upregulation, and mRNA downregulation, observed in both Piezo1 and\nPiezo2 in individuals with gastric cancer [26]",
      "Additionally, the impact of Piezo1 and Piezo2 gene alterations on the\noverall survival and disease-free survival of gastric cancer patients was assessed using Kaplan\u2013Meier survival curves,\nwhich are also available in cBioPortal [27]",
      "3.5 Genomic alterations in PIEZO1 and PIEZO2 in gastric cancer\nAccording to the OncoPrint diagram from cBioPortal data, alterations in PIEZO1 and PIEZO2 genes were detected in\n2.6% and 7% of the sequenced cases, respectively",
      "The data that underpins the findings of this study can be retrieved from publicly available resources, such as the TCGA, TNMPLOT,\nGEPIA, TIMER, cBioPortal, STRING, CPADS, and BEST databases",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal",
      "Wu P, Heins ZJ, Muller JT, et al. Integration and analysis of CPTAC proteomics data in the context of cancer genomics in the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:13.074995",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40257604.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.444123983383179,
      "cbioportal_papers": 0.000186920166015625,
      "pdf_extraction_pass2": 4.655817985534668,
      "cbioportal_papers_pass2": 0.00017881393432617188,
      "used_full_extraction": true,
      "pdf_extraction": 10.099941968917847,
      "platform_mentions": 0.0016908645629882812,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40247060": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We used cBioPortal database to analyze PRC1 copy number variation (CNV) and DNA methylation levels in WT29. The TargetScan database was used to predict microRNAs that can bind to the 3\u2019UTR region of the PRC1 gene30. Concurrently, the microRNA sequencing data was downloaded from the TARGET-WT database, and we performed differential analysis to detect differentially expressed microRNAs between tumor and normal tissues (\u2018limma\u2019 package). Intersection analysis via Venn diagrams revealed miRNAs that both target PRC1 and exhibit differential expression in WT. On this basis, we analyzed the correlation between these microRNAs and PRC1 expression using the Pearson method. We selected the miRNA most likely to target PRC1 and verified it by RT-qPCR and WB experiments in cells. The miRNA mimic, inhibitor, and corresponding negative controls (mimic-NC and inhibitor-NC) were purchased from RiboBio (Guangdong, China). The sequences of these oligonucleotides are shown in Supplementary Table 3.",
      "Genomic structural variations that result in a change in the number of copies of a DNA sequence (DNA dosage) are often called copy number variations (CNVs)39. Specifically, it is a duplication or deletion event that affects a large number of base pairs40. CNV is one of the important reasons for abnormal gene expression in tumor41, so we analyzed the changes of PRC1 at genome level. Through the analysis of cBioPortal database, it was found that PRC1 genomic mutations were present in 7% of WT samples, and amplification was present in half of samples with high mRNA levels (Fig. 7A). PRC1 mRNA expression levels in gene amplification and gain samples were significantly higher than diploid and shallow deletion samples (Fig. 7B). These indicate that CNV of PRC1 may play an important role in the occurrence and development of WT by regulating its mRNA expression level.",
      "Epigenetics is the study of heritable traits or a stable change of cell function that occur without altering the DNA sequence42. Epigenetic factors can also lead to cancer43. DNA methylation is one of the most common epigenetic modifications and it frequently occurs in repeated sequences to suppress the expression and mobility of \u2018transposable elements\u201944. We analyzed the correlation between methylation level and PRC1 expression through cBioPortal database, and the results showed that there was no significant correlation (Spearman: r = -0.31; Pearson: r = -0.23) (Fig. 7C).",
      "Fig. 7Mechanism of upregulation of PRC1 expression in WT. (A) Analysis of PRC1 copy number variations (CNVs) in WT using the cBioPortal database. (B) Comparison of PRC1 mRNA expression levels in WT samples with shallow deletion, diploid, gain, and amplification using the cBioPortal database. (C) Correlation analysis between PRC1 expression and DNA methylation levels using the cBioPortal database (Spearman: r = -0.31; Pearson: r = -0.23; both p < 0.05). (D) Volcano plot showing differentially expressed miRNAs between normal tissues and Wilms tumor tissues in TARGET database (FDR < 0.05, |log2FC| < 0.5). (E) Venn plot showing intersection of the 49 down-regulated miRNAs in WT with 356 PRC1-binding miRNAs predicted by TargetScan database, yielding 12 candidate miRNAs that may contribute to PRC1 upregulation in WT. (F) (a) Violin plots showing the comparison of mRNA expression levels of the selected 9 miRNAs in WT and normal tissues in the TARGET database; (b) Pearson correlation analysis between hsa-miR-143-3p and PRC1 expression in WT. (G) (a, b) The protein expression levels of PRC1 detected by western blotting (p < 0.05); (c) The mRNA expression levels of PRC1 detected by RT-qPCR (p > 0.05).",
      "Mechanism of upregulation of PRC1 expression in WT. (A) Analysis of PRC1 copy number variations (CNVs) in WT using the cBioPortal database. (B) Comparison of PRC1 mRNA expression levels in WT samples with shallow deletion, diploid, gain, and amplification using the cBioPortal database. (C) Correlation analysis between PRC1 expression and DNA methylation levels using the cBioPortal database (Spearman: r = -0.31; Pearson: r = -0.23; both p < 0.05). (D) Volcano plot showing differentially expressed miRNAs between normal tissues and Wilms tumor tissues in TARGET database (FDR < 0.05, |log2FC| < 0.5). (E) Venn plot showing intersection of the 49 down-regulated miRNAs in WT with 356 PRC1-binding miRNAs predicted by TargetScan database, yielding 12 candidate miRNAs that may contribute to PRC1 upregulation in WT. (F) (a) Violin plots showing the comparison of mRNA expression levels of the selected 9 miRNAs in WT and normal tissues in the TARGET database; (b) Pearson correlation analysis between hsa-miR-143-3p and PRC1 expression in WT. (G) (a, b) The protein expression levels of PRC1 detected by western blotting (p < 0.05); (c) The mRNA expression levels of PRC1 detected by RT-qPCR (p > 0.05)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.14829683303833008,
    "data_pmids_checked": 0,
    "paper_id": "40247060",
    "extraction_date": "2025-12-19T19:49:13.236574",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40247060.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40278313": {
    "paper_id": "40278313",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Moreover, we used cBioPortal, GeneMANIA, Enrichr database,\nandMetaCoretodeterminethegeneticalterations,geneinteractions,geneontology,and\nsignalingpathwaysconnectedtoGNPDA1andSLC25A16inpatientswithbreastcancer",
      "cBioPortalandGeneMANIAAnalysisofTwoPotentialGenes\nA multidimensional cancer genome data set is accessible through the cBio Cancer\nGenomicsPortal(http://cbioportal.org,accessedon2August2022)",
      "Genetic Alteration, Gene Interaction, and Neighbor Gene Network of Two Potential Genes in\nwebtoPoalt,iaenhtes awtimtha Bpredaesmt Coannsctrear tedthesignificancescoresofDNAmethylationwhichpre-\ndictexpressionlevelsofGNPDA1andSLC25A16inpatientswithbreastcancer(FigureS2\nUsing the cBioPortal online tool (https://bit.ly/3OVsxFd, accessed on 2 December\nand Table S3)",
      "Genetic alteration, neighbor gene network, and interaction analysis of the two potential genes\nin patients with breast cancer (cBioPortal and GeneMANIA)",
      "Abbreviations\nThefollowingabbreviationsareusedinthismanuscript:\nFHBC FamilyHistoryOfBreastCancer\nmiRNA microRNA\nDEM DifferentiallyMethylated\nDEmiRNA DifferentialExpressedmicroRNA\nLIMMA LinearModelsForMicroarray\nDESeq2 DifferentialGeneExpressionAnalysisOfRNA-Seq2\nGEO GeneExpressionOmnibus\nmRNA MessengerRNA\ncBioPortal cBioCancerGenomicsPortal\nKEGG KyotoEncyclopediaOfGenesAndGenomes\nPPIs Protein\u2013ProteinInteractions\nBMI BodyMassIndex\nFDR FalseDiscoveryRate\nBH Benjamini\u2013Hochberg\n\nJ.Pers.Med.2025,15,134 22of26\nReferences\n1"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:16.129241",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40278313.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.20148515701294,
      "cbioportal_papers": 0.0003757476806640625,
      "pdf_extraction_pass2": 9.841392040252686,
      "cbioportal_papers_pass2": 0.0004889965057373047,
      "used_full_extraction": true,
      "pdf_extraction": 19.042877197265625,
      "platform_mentions": 0.020453929901123047,
      "data_citations": 1.4066696166992188e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40241262": {
    "cbioportal_paper_citations": [
      "RNA sequencing data was obtained from cBioPortal for Cancer Genomics (https://www.cbioportal.org/), and the data was extracted from the Colon Adenocarcinoma cohort of The Cancer Genome Atlas (TCGA) project. Specific gene expression data were downloaded using the RNA Seq RPKM normalized data from cBioPortal [27, 28]. Data on Meflin expression in colon fibroblasts were retrieved from the NCBI Gene Expression Omnibus (GEO) database (accession no. GSE4682)."
    ],
    "cbioportal_platform_mentions": [
      "Finally, we assessed the correlation between Meflin and \u03b1\u2010SMA expression in fibroblasts and the p53 status of colorectal cancer cells using human clinical specimens. The association between the clinicopathological characteristics of the patients and lesions with p53 status was evaluated (Tables S3 and S4). The Meflin\u2010stained area in cancer stromal fibroblasts was significantly smaller in p53\u2010missense type than in p53\u2010wild type colorectal cancers. The \u03b1\u2010SMA staining was higher in p53\u2010missense type colorectal cancer than in p53 wild\u2010type colorectal cancer, but the difference was not significant (Figure 5). Furthermore, we analyzed the publicly available databases to validate the relationship between p53 status and stromal Meflin expression in human clinical specimens. In the Colon Adenocarcinoma cohort of the TCGA (TCGA\u2010COAD) project obtained via cBioPortal for Cancer Genomics, the mRNA expression of Meflin was significantly lower in samples with missense\u2010type p53 than in those with wild\u2010type p53 (Figure 6). In addition, mRNA expression datasets of fibroblasts extracted from fresh surgical specimens of colorectal carcinoma (CAF group) and normal colonic mucosa (normal colonic fibroblasts, NCF group) were retrieved from the NCBI GEO database (accession no. GSE46824). The datasets revealed that Meflin expression was significantly lower in the CAF group than in the NCF group (Figure S6), and this was the same as in the coculture experiment (Figure S4). These results indicate a relationship between p53\u2010deficient colon cancer cells and Meflin in fibroblasts in invasive colon cancer tissue."
    ],
    "data_publication_citations": {
      "22810696": [
        "RNA sequencing data was obtained from cBioPortal for Cancer Genomics (https://www.cbioportal.org/), and the data was extracted from the Colon Adenocarcinoma cohort of The Cancer Genome Atlas (TCGA) project. Specific gene expression data were downloaded using the RNA Seq RPKM normalized data from cBioPortal [27, 28]. Data on Meflin expression in colon fibroblasts were retrieved from the NCBI Gene Expression Omnibus (GEO) database (accession no. GSE4682)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.17235994338989258,
    "data_pmids_checked": 1,
    "paper_id": "40241262",
    "extraction_date": "2025-12-19T19:49:16.962427",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40241262.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40237399": {
    "cbioportal_paper_citations": [
      "The assessment of NLRP1 genetic alterations was conducted using cBioPortal (https://www.cbioportal.org/) [28]. Specifically, within the \u201cQuick Choose\u201d section, we opted for \u201cTCGA Pan\u2010Cancer Atlas Studies\u201d to scrutinize the genetic alteration characteristics of the NLRP1 gene in all TCGA cancers. Entering \u201cNLRP1\u201d into the \u201cQuery\u201d section, we set the molecular profiles to include \u201cmutations\u201d and \u201ccopy number alterations\u201d. The \u201cCancer Types Summary\u201d module provides us with the various NLRP1 genetic alteration types including mutation, amplification, deep deletion, and the existence of multiple alterations in various TCGA cancers. Moreover, we examined the types of NLRP1 gene mutations across various cancers using the \u201cmutations\u201d module. Furthermore, we obtained an overview of cancerous samples with NLRP1 mutations in each tumor type from the \u201cGene_Mutation\u201d module of the TIMER2.0 database."
    ],
    "cbioportal_platform_mentions": [
      "Using cBioPortal, we examined the genetic alterations of NLRP1 across 32 TCGA tumor types. Notably, the highest genetic alteration frequencies in the NLRP1 gene were observed in SKCM, UCEC, and ACC, with alteration frequencies of 14.86%, 10.02%, and 5.49%, respectively. Moreover, SKCM, ACC, and UCS tumor subjects exhibited the highest frequencies of NLRP1 mutations (13.96%), deep deletions (2.2%), and amplifications (3.51%), respectively. Several alterations were detected with frequencies < 1% (Figure 8A, Data S3). A total of 303 mutations were identified in the NLRP1 gene across TCGA tumor subjects, comprising 243 missenses, 44 truncating mutations, 15 splice site alterations, and 1 in\u2010frame mutation. These mutations were distributed throughout the NLRP1 gene, encompassing both domain and non\u2010domain sites (Figure 8B, Data S4). Additionally, we utilized TIMER2.0 to further scrutinize NLRP1 gene mutations across various human malignancies. The NLRP1 mutations were predominantly observed in patients with SKCM (61 out of 468 patients), UCEC (51 out of 531 patients), and COAD (22 out of 406 patients) (Figure 8C)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.12982797622680664,
    "data_pmids_checked": 0,
    "paper_id": "40237399",
    "extraction_date": "2025-12-19T19:49:17.092348",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40237399.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40236999": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Ovarian cancer-related genes were retrieved from the DISGENET web-based tool using \u2018Epithelial ovarian cancer\u2019 data (CUI: C0677886) (Pinero et al., 2015). The genes were selected based on a Gene Disease Association (GDA) score above 0.1. The selected genes\u2019 Protein-Protein Interaction (PPI) were then identified using STRING v12.0 database with default setting (Szklarczyk et al., 2015). The resulting networks were then ranked using the Cytohubba plugin from Cytoscape v3.10.0 to find the best target gene for ovarian cancer. The mutation and survival profile of the gene based on ovarian cancer studies were also profiled using the cBioPortal database\u200b (Gao et al., 2013).",
      "From the cBioPortal database (https://www.cbioportal.org/), the study used as a reference for determining the gene mutation profile of MYC in ovarian cancer originates from 7 different studies, comprising a total of 1949 samples and 1892 patients. Based on these multiple studies, the MYC alteration profile varies from 10 to 40 %, with an average of 32 % across all cases (Fig. 2). Nearly all alterations observed in the MYC gene are amplifications, with the remainder being mixed alterations consisting of amplifications along with mutations.Fig. 2The MYC Gene Alteration Profile in Multiple Ovarian Cancer Studies from the cBioPortal Database.",
      "The MYC Gene Alteration Profile in Multiple Ovarian Cancer Studies from the cBioPortal Database."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.04952812194824219,
    "data_pmids_checked": 0,
    "paper_id": "40236999",
    "extraction_date": "2025-12-19T19:49:17.141959",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40236999.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40265174": {
    "paper_id": "40265174",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:21.282975",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40265174.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.636464834213257,
      "cbioportal_papers": 0.00025582313537597656,
      "pdf_extraction_pass2": 10.054803848266602,
      "cbioportal_papers_pass2": 0.0002467632293701172,
      "used_full_extraction": true,
      "pdf_extraction": 18.69126868247986,
      "platform_mentions": 0.039819955825805664,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40233762": {
    "cbioportal_paper_citations": [
      "Data from the TCGA PanCancer atlas was downloaded from cBioPortal (cbioportal.org)43 separated by cancer type. Individual cancer type mRNA data was merged by gene name across cancer types. Genes were matched between the mitochondrial stress dataset and the TCGA mRNA data using the clusterProfiler package to convert between Ensembl gene ID and gene symbols. Stress scores were calculated on log2(x + 1) transformed mRNA counts. For mutational analysis, mutations were considered protein-altering if they were classified as frameshift insertions or deletions, in-frame insertions or deletions, missense mutations, nonsense mutations, nonstop mutations, mutations in splice regions or splice sites, or mutations at translation start sites. Survival analysis was performed using the Cox proportional hazards model and the Kaplan-Meier estimator, as implemented in the survival, condsurv, and ggsurvfit packages in R."
    ],
    "cbioportal_platform_mentions": [
      "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesAnti-ATF4ProteinTech10835-1-APAnti-CHOPCell SignalingCat# 2895; RRID: AB_2089254Anti-phospho-eIF2\u03b1Cell SignalingCat# 3398; RRID: AB_2096481Anti-eIF2\u03b1Cell SignalingCat# 5324; RRID: AB_10692650Anti-TubulinCell SignalingCat# 2125; RRID: AB_2619646Chemicals, peptides, and recombinant proteinsFibroblast Basal MediumATCCPCS-201-030Fibroblast Growth Kit-Low serumATCCPCS-201-041Trypsin-EDTA for Primary CellsATCCPCS-999-003Trypsin Neutralizing SolutionATCCPCS-999-004Penicillin-Streptomycin (10,000 U/mL)Gibco15140122RPMI 1640 Medium w/o Amino Acids, Sodium PhosphateUS BiologicalR8999-04A-25LAntimycin ASigma-AldrichA8674-50MGBPTESSigma-AldrichSML0601-5MGChloramphenicolSigma-AldrichC0378-25G2,4-DinitrophenolSigma-AldrichD198501-100GDoxycycline hyclateSigma-AldrichD9891-5G(+)-Etomoxir (sodium salt)Cayman Chemical11969Daporinad (FK866)Selleck ChemicalsS2799Metformin hydrochlorideSigma-AldrichPHR1084-500MGRotenoneSigma-AldrichR8875-1GTunicamycinSigma-AldrichT7765-5MGUK-5099Sigma-AldrichPZ0160-5MGSeahorse XF RPMI mediumAgilent103576\u2013100XF Mito Stress TestAgilent103015\u2013100Critical commercial assaysDirect-zol RNA MiniprepZymo ResearchR2050TruSeq Stranded mRNA Library PrepIllumina20020595Deposited dataGene expression from fibroblasts treated with mitochondrial inhibitorsThis paperGEO: GSE241261TCGA PanCancer AtlasLiu et al.21Accessed via http://www.cbioportal.orgExperimental models: Cell linesPrimary Dermal Fibroblast; Normal, Human, Adult (HDFa)ATCCPCS-201-012Software and algorithmsR (4.3.1)The R Project for Statistical Computinghttps://www.r-project.orgBioconductor (3.17)Bioconductor projecthttps://www.bioconductor.orgSalmon (1.4.0)Patro et al.36https://github.com/COMBINE-lab/salmonTximeta (1.24.0)Love et al.37https://bioconductor.org/packages/release/bioc/html/tximeta.htmlDESeq2 (1.40.2)Love et al.38https://bioconductor.org/packages/release/bioc/html/DESeq2.htmlpheatmap (1.0.12)Kolde et al.39https://github.com/raivokolde/pheatmapclusterProfiler (4.9.2)Yu et al.40http://bioconductor.org/packages/release/bioc/html/clusterProfiler.htmlmixOmics (6.24.0)Rohart et al.20https://www.bioconductor.org/packages/release/bioc/html/mixOmics.htmlTraceFinderThermoFisherhttps://www.thermofisher.com/us/en/home/industrial/mass-spectrometry/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-software/lc-ms-data-acquisition-software/tracefinder-software.htmlOriginal codeThis paperMendeley Data: https://doi.org/10.17632/4769fjr4yd.2"
    ],
    "data_publication_citations": {
      "29625055": [
        "We used SQUID to investigate mitochondrial stress signatures in The Cancer Genome Atlas (TCGA) PanCancer Atlas dataset due to its combination of patient data coupled with sample assays (including RNA sequencing [RNA-seq] and mutational analysis) across many cancer types.21 Stress signatures generated using PanCancer Atlas genes closely resembled the original stress signatures (Figure S6A). Given that the TCGA PanCancer Atlas contains patient mutation data, we investigated the role of specific mutations on mitochondrial stress scores. We decided to focus on IDH1 in glioma, as it has well-studied changes to cellular metabolism and epigenetic regulation through synthesis of the oncometabolite D-2HG.22,23,24,25 IDH1 mutations were strongly enriched in glioma samples, with nearly 80% of glioma samples having mutations in IDH1. Consistent with past studies, these IDH1 mutations largely occurred at R132 (Figure S6B).24,25,26,27",
        "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesAnti-ATF4ProteinTech10835-1-APAnti-CHOPCell SignalingCat# 2895; RRID: AB_2089254Anti-phospho-eIF2\u03b1Cell SignalingCat# 3398; RRID: AB_2096481Anti-eIF2\u03b1Cell SignalingCat# 5324; RRID: AB_10692650Anti-TubulinCell SignalingCat# 2125; RRID: AB_2619646Chemicals, peptides, and recombinant proteinsFibroblast Basal MediumATCCPCS-201-030Fibroblast Growth Kit-Low serumATCCPCS-201-041Trypsin-EDTA for Primary CellsATCCPCS-999-003Trypsin Neutralizing SolutionATCCPCS-999-004Penicillin-Streptomycin (10,000 U/mL)Gibco15140122RPMI 1640 Medium w/o Amino Acids, Sodium PhosphateUS BiologicalR8999-04A-25LAntimycin ASigma-AldrichA8674-50MGBPTESSigma-AldrichSML0601-5MGChloramphenicolSigma-AldrichC0378-25G2,4-DinitrophenolSigma-AldrichD198501-100GDoxycycline hyclateSigma-AldrichD9891-5G(+)-Etomoxir (sodium salt)Cayman Chemical11969Daporinad (FK866)Selleck ChemicalsS2799Metformin hydrochlorideSigma-AldrichPHR1084-500MGRotenoneSigma-AldrichR8875-1GTunicamycinSigma-AldrichT7765-5MGUK-5099Sigma-AldrichPZ0160-5MGSeahorse XF RPMI mediumAgilent103576\u2013100XF Mito Stress TestAgilent103015\u2013100Critical commercial assaysDirect-zol RNA MiniprepZymo ResearchR2050TruSeq Stranded mRNA Library PrepIllumina20020595Deposited dataGene expression from fibroblasts treated with mitochondrial inhibitorsThis paperGEO: GSE241261TCGA PanCancer AtlasLiu et al.21Accessed via http://www.cbioportal.orgExperimental models: Cell linesPrimary Dermal Fibroblast; Normal, Human, Adult (HDFa)ATCCPCS-201-012Software and algorithmsR (4.3.1)The R Project for Statistical Computinghttps://www.r-project.orgBioconductor (3.17)Bioconductor projecthttps://www.bioconductor.orgSalmon (1.4.0)Patro et al.36https://github.com/COMBINE-lab/salmonTximeta (1.24.0)Love et al.37https://bioconductor.org/packages/release/bioc/html/tximeta.htmlDESeq2 (1.40.2)Love et al.38https://bioconductor.org/packages/release/bioc/html/DESeq2.htmlpheatmap (1.0.12)Kolde et al.39https://github.com/raivokolde/pheatmapclusterProfiler (4.9.2)Yu et al.40http://bioconductor.org/packages/release/bioc/html/clusterProfiler.htmlmixOmics (6.24.0)Rohart et al.20https://www.bioconductor.org/packages/release/bioc/html/mixOmics.htmlTraceFinderThermoFisherhttps://www.thermofisher.com/us/en/home/industrial/mass-spectrometry/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-software/lc-ms-data-acquisition-software/tracefinder-software.htmlOriginal codeThis paperMendeley Data: https://doi.org/10.17632/4769fjr4yd.2"
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.34676694869995117,
    "data_pmids_checked": 1,
    "paper_id": "40233762",
    "extraction_date": "2025-12-19T19:49:21.629841",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40233762.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40254646": {
    "paper_id": "40254646",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Common platforms for analyzing genetic alterations include\nGene4Denovo, VarCards, MethSurv, and cBioPortal",
      "Among these, cBioPortal is distinguished by its significant\nadvantages in multi-dimensional data integration, visualization, survival analysis, and user-friendliness",
      "In this study, we employed cBioPortal to identify\nand analyze the mutation status of 28 DRGs in TCGA-AML patients",
      "(A) The genetic\nalterations of 28 DRGs in AML patients were evaluated using cBioPortal",
      "Genetic alterations\nin DRGs of AML patients from the TCGA database were analyzed using the cBioportal network analysis tool\n(http://www.cbioportal.org/)",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:22.554758",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40254646.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.147651672363281,
      "cbioportal_papers": 0.0002841949462890625,
      "pdf_extraction_pass2": 7.6638147830963135,
      "cbioportal_papers_pass2": 0.0002970695495605469,
      "used_full_extraction": true,
      "pdf_extraction": 14.811466455459595,
      "platform_mentions": 0.0036749839782714844,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40252157": {
    "paper_id": "40252157",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The gene mutations were\ninvestigated through the application the cBioPortal database [36, 37]",
      "cBioPortal: (https://w ww.c biopo rtal.o rg/r esult s/o ncopr int?c ancer_s tudy_\nlist = egc_tmucih_2015%2Cstad_oncosg_2018%2Cstad_pfizer_uhongkong%2Cstad_tcga%2Cstad_utokyo%2Cstad_uhongkong&Z_SCORE_\nTHRESHOLD = 2.0&RPPA_SCORE_THRESHOLD = 2.0&profileFilter = mutations%2Cgistic&case_set_id = all&gene_list = ADAMTSL2&geneset_\nlist = %20&tab_index = tab_visualize&Action = Submit)",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of com-\nplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:23.640336",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40252157.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.599725961685181,
      "cbioportal_papers": 0.0002009868621826172,
      "pdf_extraction_pass2": 6.556617975234985,
      "cbioportal_papers_pass2": 0.0002009868621826172,
      "used_full_extraction": true,
      "pdf_extraction": 12.156343936920166,
      "platform_mentions": 0.001875162124633789,
      "data_citations": 5.7220458984375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40225932": {
    "cbioportal_paper_citations": [
      "The lollipop plots were generated using MutationMapper [20, 21] and modified subsequently. The protein structure of human GAA is adapted from [22, 23]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.12989592552185059,
    "data_pmids_checked": 0,
    "paper_id": "40225932",
    "extraction_date": "2025-12-19T19:49:23.770330",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40225932.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40225915": {
    "cbioportal_paper_citations": [
      "Mapping of genetic findings on gene scheme was performed using MutationMapper from cBioPortal with additional further editing pictures [35]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.24753689765930176,
    "data_pmids_checked": 0,
    "paper_id": "40225915",
    "extraction_date": "2025-12-19T19:49:24.024251",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40225915.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40225790": {
    "cbioportal_paper_citations": [
      "To this end, there currently exists an ever-growing number of effective analysis and visualization tools for the interrogation of gene expression data from public cohort sources. These include online applications such as cBioPortal [20, 21], Xena [22], FireBrowse (http://firebrowse.org/), GEPIA [23, 24], TCGAnalyzeR [25], and Web-TCGA [26] as well as standalone applications like TCGAbiolinks [27, 28], the newly released CRUX [29] and TCGAplot [30], among others. While these applications are exceptionally valuable to the research community, widely adopted and used, there remain unexplored angles to utilize and draw inference from these sources. Of particular interest, differential expression analyses (DEA) between groups are available in many of these applications, most commonly enabling normal-tumor comparisons [31, 32] or comparisons between different cancer subtypes. However, more bespoke DEA comparisons are challenging and remain in the domain only for the bioinformatically proficient."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "30333627": [
        "This case study is analogous to the analysis we performed using the same approach on a cohort of 672 primary specimens from 562 unique AML patients from the BeatAML cohort [53]. Compared to the TCGA LAML cohort which has only 178 participants, the BeatAML cohort is much larger, providing better stratification of individuals (Supplementary Fig. S3B and Fig. 1A in [34]). Remarkably, our findings with the TCGA LAML cohort are consistent with our published data showing that AML patients with high IL3RA and low CSF2RB expression (i.e. high IL3RA:CSF2RB ratio) have enrichment of stemness programs. In addition, the same analysis using the GTEX Whole Blood cohort (Supplementary Fig. S3C\u2013F) returned similar results albeit with a clearly skewed expression ratio profile compared to the TCGA LAML cohort (Supplementary Fig. S3C). These results demonstrate the robustness of TRANSECT and significance of the differential gene expression results between the high vs low IL3RA:CSF2RB ratio strata across various patient cohorts."
      ],
      "26091043": [
        "Currently, there exists an unprecedented amount of publicly available RNA-seq expression profiling data both from targeted experiments stored in online repositories such as Gene Expression Omnibus [8] as well as collections of cohort data from groups of related and unrelated individuals accessed through repositories such as the Genotype-Tissue Expression database (GTEx) [9, 10] and the Cancer Genome Atlas (TCGA) [11]. These datasets, either independently or together with other forms of genomic and proteomic data, have led to many discoveries relating to human disease of biological and clinical significance [12\u201318]. Gene expression measurements in particular have been ascribed as the top-scoring most informative prognostic biomarkers for the average cancer type, accounting for 46% of all prognostic markers [19]. Thus, in-depth analysis of these resources has already and will undoubtedly continue to reveal novel insights into human health of biological and clinical relevance."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5080392360687256,
    "data_pmids_checked": 4,
    "paper_id": "40225790",
    "extraction_date": "2025-12-19T19:49:24.532408",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40225790.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40212597": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesRabbit polyclonal anti-ANXA4 (Annexin A4)Atlas AntibodiesCat# HPA007393; RRID:AB_1078168Mouse monoclonal anti-ANXA4 (Annexin A4) (clone: D-2)Santa Cruz BiotechnologyCat# sc-46693; RRID:AB_626679Rabbit polyclonal anti-ANXA3 (Annexin A3)Atlas AntibodiesCat# HPA013398; RRID:AB_1844861Rabbit polyclonal anti-ANXA2 (Annexin A2)Cell Signaling TechnologyCat# 8235; RRID:AB_11129437Mouse monoclonal anti-TUBA (alpha-Tubulin) (clone: DM1A)Sigma-AldrichCat# T9026: RRID:AB_477593Rabbit polyclonal anti-CLDN1 (Claudin 1)AbcamCat# ab15098; RRID:AB_301644Rabbit polyclonal anti-ELF3 (E74-like factor 3)Atlas AntibodiesCat# HPA003479; RRID:AB_1078756Mouse monoclonal anti-PAX8 (clone: MRQ-50)Ventana/Roche DiagnosticsCat# 760\u20134618; RRID:N/AMouse monoclonal anti-SMA (ACTA2) (clone: 1A4)Dako/Agilent TechnologiesCat# GA611; RRID:N/AMouse monoclonal anti-CD34Dako/Agilent TechnologiesCat# M7165; RRID:AB_2063006Mouse monoclonal anti-CK1/3 (AE1/AE3)Dako/Agilent TechnologiesCat# IR053; RRID:N/AGoat polyclonal anti-LuciferaseNovus Biological, Bio-Techne GmbHCat# NB 100\u20131677; RRID:AB_531129Fluorophore-conjugated donkey polyclonal anti-rabbitThermo Fisher ScientificCat# A-31572; RRID:AB_162543HRP-linked goat polyclonal anti-mouse antibodyDako/Agilent TechnologiesCat# P0447; RRID:AB_2617137HRP-linked goat polyclonal anti-rabbit antibodyCell SignalingCat# 7074; RRID:AB_2099233HRP-linked rabbit polyclonal anti-goat antibodyDako/Agilent TechnologiesCat# P0449; RRID:AB_2617143Bacterial and virus strainsNEB Stable Competent E. coli (High Efficiency)New England BiolabsCat# C3040H; RRID:N/ABiological samplesCPTAC-CCRCC CohortLi et al.27N/ATCGA Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy)Cancer Genome Atlas Research7https://www.cbioportal.org/TCGA Cancer Cell Line Encyclopedia (Broad, 2019)Ghandi et al.30https://www.cbioportal.org/All other biological samples and cohorts were generated in this study and described in detailThis studyN/AChemicals, peptides, and recombinant proteinsHoechst 33342, trihydrochloride, trihydrate (permeable)Thermo Fisher Scientific Inc.Cat# H3570Hoechst 33258, Pentahydrat (bis-Benzimid) (impermeable)Thermo Fisher Scientific Inc.Cat# H3569RPMI 1640 GlutaMAX\u2122Thermo Fisher Scientific Inc.Cat# 61870036DMEM GlutaMAX\u2122Thermo Fisher Scientific Inc.Cat# 31966-021Fetal Calve Serum (FCS)Merck KGaACat# S0615Recombinant human TGFb1Thermo Fisher Scientific Inc.Cat# PHG9214CellTracker\u2122 Green CMFDAThermo Fisher Scientific Inc.Cat# C7025Ionomycin (calcium salt)Cayman ChemicalCat# 11932Hanks' Balanced Salt Solution (HBSS) with Calcium, Magnesium, Glucosewithout Phenol red, SodiumpyruvateGibco/Thermo Fisher Scientific Inc.Cat# 14025092Hanks' Balanced Salt Solution (HBSS) with Glucosewithout Calcium, Magnesium, Phenol red, SodiumpyruvateGibco/Thermo Fisher Scientific Inc.Cat# 14175095Matrigel\u00ae Growth Factor Reduced (GFR) Basement Membrane Matrix, Phenol Red-free, LDEV-freeCorningCat# 356231Paraformaldehyde 32% Aqueous Solution EM GradeElectron Microscopy SciencesCat# 15714-SDulbecco\u2019s Phosphate-Buffered Saline (PBS)Gibco/Thermo Fisher Scientific Inc.Cat# 14190094Digitonin (non-ionic detergent)Sigma-AldrichCat# D141Alexa Fluor phalloidin 488Thermo Fisher Scientific Inc.Cat# A12379HematoxylinSigma-AldrichCat# 51275Critical commercial assaysBrdU Cell Proliferation ELISA Kit (colorimetric)abcamCat# ab126556Opal 6-Plex Manual Detection KitAkoya BiosciencesCat# NEL811001KTPierce BCA Protein Assay KitThermo Fisher Scientific Inc.Cat# 23225Pierce\u2122 ECL Western Blotting-SubstratThermo Fisher Scientific Inc.Cat# 32109Monarch Total RNA Miniprep KitNew England Biolabs Inc.Cat# T2010SMycoplasma PCR detection kitHiss Diagnostics GmbHCat# 25235Liquid DAB+ Substrate Chromogen SystemDako/Agilent TechnologiesCat# K3468Deposited dataRNA Sequencing dataNCBI Gene Expression OmnibusGSE267754Proteomics dataMassIVE repositoryMassiVE: MSV000094814CPTAC-CCRCCThe Cancer Imaging Archivehttps://www.cancerimagingarchive.net/collection/cptac-ccrcc/Experimental models: Cell linesA498ATCCCat# HTB-44786-OATCCCat# CRL-1932hRPTECATCCCat# PCS-400-010HEK293T/17ATCCCat# CRL-11268OligonucleotideshU6-F primer (5\u2032-GAGGGCCTATTTCCCATGATT-3\u2032)AddgeneN/Anon targeting:nt-sgRNA-1: 5\u2032- GCGGGCAGAACGACCCTGAC -3'Rogg et al.63N/Anon targeting:nt-sgRNA-2: 5\u2032- GAAGACGTGCTGGCGTCACC -3'Rogg et al.63N/AANXA4-sg1: TCTGCTGGCTATAGGTAAGC(TGG)This studyN/AANXA4-sg2: GGACGATGCTCTCGTGAGAC(AGG)This studyN/ARecombinant DNApLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-78: GCACACTTCAAGAGACTCTATHorizon Discovery Biosciences LimitedTRCN0000056278pLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-80: GCAGAAATTGACATGTTGGATHorizon Discovery Biosciences LimitedTRCN0000056280pLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-81: GCCTTGAAGATGACATTCGCTHorizon Discovery Biosciences LimitedTRCN0000056281Scramble pLKO.1 shRNA controlSarbassov et al.64Addgene plasmid #1864, RRID:Addgene_1864hELF3 (NM_004433) in pLenti C-Myc-DDK-P2A-PuroOriGene TechnologiesRC200631L3Luciferase in pLenti-C-Myc-DDK-P2A-PuroThis study; swap cloning from existing plasmids (Maier et al.65)N/AHuman ANXA4 (NM_001320698.2) in pcDNA3.1+/C-(K)-DYKGenScript BiotechOHu26294pWPXLd expression vectorDidier Trono Lab (unpublished)Addgene plasmid #12258, RRID:Addgene_12258Luciferase in pWPXLdThis study; swap cloning from existing plasmids (Maier et al.65)N/AANXA4 in pWPXLdThis study; swap cloning from existing plasmidN/ATLCV2-LoxPAdam Karpf Lab (unpublished)Addgene plasmid #127098, RRID:Addgene_127098Software and algorithmsCHOPCHOP version 3Labun et al.66https://chopchop.cbu.uib.no/Phenochart slide viewer version 2.2.0Akoya BiosciencesN/AinForm Tissue Analysis Software 3.0Akoya BiosciencesN/AFiji ImageJ v1.54fSchindelin et al.67https://imagej.net/software/fiji/Zen blue 3.0 softwareCarl Zeiss AGN/AQuPath version 0.4.3 and 0.5.1.Bankhead et al.68https://qupath.github.io/Incucyte Live Cell Analysis Software 2023ASartoriusN/AGalaxy EuropeGalaxy Community69https://usegalaxy.eu/GenePatternReich et al.70https://www.genepattern.orgGEPIA 2GEPIA 2\u20132018 Zhang\u2019s Lab.http://gepia.cancer-pku.cnChEA3Keenan et al.71https://maayanlab.cloud/chea3Matrisome DB version 1Shao et al.72https://matrisomedb.orgInnate DBBreuer et al.73https://www.innatedb.comEMTome DBVasaikar et al.74http://www.emtome.orgProteomicsKern et al.75N/AGraphPad Prism 8GraphPadN/ACellProfiler version 4.2.7Stirling et al.76https://cellprofiler.org/R version 4.4.1 (2024-06-14 ucrt)R Foundation for Statistical Computinghttps://www.R-project.org/R package growthcurverSprouffske et al.77https://CRAN.R-project.org/package=growthcurverOtherPhenoCycler Fusion microscopeAkoya BiosciencesN/AGlass-Beads (425\u2013600 \u03bcm, acid-washed)Sigma-AldrichCat# G8772-10GThincert Cell Culture Insert (pore-size: 8 \u03bcm, 24-well format)Greiner Bio-OneCat# 662638ibiTreat-8well-dishesIbidi GmbHCat# 80826Incucyte S3 Live-Cell Analysis SystemSartoriusN/AIbidi Culture-Insert 2 Well in \u03bc-Dish 35 mm, High ibiTreatIbidi GmbHCat# 81176Vortexer REAX topHeidolph Scientific Products GmbHCat# 541-10000-00Heracell\u2122 240i CO2 IncubatorThermo Fisher Scientific Inc.Cat# 51032875",
      "The cBioPortal for Cancer Genomics was used for analysis of the TCGA Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy) and Cancer Cell Line Encyclopedia (Broad, 2019) datasets.7,30,82 For survival analysis, best gene expression (FPKM) cut-offs for survival between patient groups in the TCGA cohort were previously calculated and used to define ANXA4 high and ANXA4 low ccRCCs accordingly.83 Kaplan-Meier survival analysis and caparison of clinical parameters between these two patient groups as well as calculation of statistical characteristics was performed using the cBioPortal for Cancer Genomics toolbox (Table S2). Comparison and statistically analysis of ANXA4 expression values between ccRCC tumor samples and normal tissue was performed via the GEPIA 2.0 platform (Gene Expression Profiling Interactive Analysis \u2013 based on available TCGA and GTEX data). In addition, mRNA co-expression analysis for EFL3 in the Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy) cohort was retrieved from the cBioPortal for Cancer Genomics platform. The Matrisome DB, Innate DB and EMTome DB resources were used for annotation of ELF3 co-expressed genes (see Table S11 for co-expression analysis of ELF3).72,73,74",
      "For analysis of renal cancer cell lines, the Cancer Cell Line Encyclopedia (Broad, 2019) was filtered for renal cancer cell lines and gene expression z-scores, VHL mutation profiles and segmented copy number (CN) data for chromosomal segments were retrieved. Loss of the chromosome 3p arm was estimated by underrepresentation of respective CN segments (mean log2 FC < -0.5 for 3p segments). See Table S3 for details. A correlation analysis was conducted for ANXA4, VHL, EPAS1 (HIF2alpha), and HIF1alpha using the entire Cancer Cell Line Encyclopedia (Broad, 2019). The statistical characteristics were calculated using the cBioPortal for Cancer Genomics tool.",
      "For statistical analysis and graphical depiction of experimental data, the GraphPad Prism 8 software was used. Scatterplots indicate respective individual units (replicates, samples) used for statistical testing while bars or single dots indicate mean values of replicates or samples, described accordingly in detail within respective figure legend. Error bars indicate the standard error of the mean (S.E.M.) or confidence interval (CI) as indicated. Statistical tests were conducted based on the respective experimental design and data distribution. Statistical analysis of Figures 1E, 1F, 1G, 1H, S3B, S3C, and S3D was performed using the cBioPortal platform as was described in the respective methods section. Unpaired Student\u2019s t test (Figures 2D, 2E, 2J, 4B, 5K, 6A, 6E, 8D, 8F, 8G, 8I, and 8K), ordinary one-way ANOVA combined with Tukey\u2019s multiple comparisons test (Figures 2K, 4C, 5G, 5N, 8B, S5A, S5B, and S5C), ordinary one-way ANOVA with Sidak\u2019s multiple comparisons test (Figures 4E and 4G), two-way ANOVA with Sidak\u2019s multiple comparisons test (Figure 4H), unpaired Student\u2019s t test followed by calculation of the false discovery rate (FDR) using the method of Benjamini, Krieger and Yekutieli (Figure 5D), unpaired t test with Welch\u2019s correction (Figures 5H, 5I, 5J, 5L, 6B, 6C, 6I, and 6J) and Pearsons correlation analysis (Figures 5M and 6D) were used for presented analyses. See Incucyte analysis in the methods for detail of growth cure analysis in Figures 2F, 2G, and 2H. Statistical analysis of transcriptome and proteome data as well as implementation of analyses from external databases is described in the respective methods sections. Statistical significance was defined as p < 0.05 and significance levels are indicated as \u2217p < 0.05, \u2217\u2217p < 0.01, \u2217\u2217\u2217p < 0.001, \u2217\u2217\u2217\u2217p < 0.0001 and non-significant (n. s.) in respective figure panels. The number of independent experiments and analyzed units are stated in the figure legends and/or respective methods section."
    ],
    "data_publication_citations": {
      "31068700": [
        "Given the pronounced expression pattern of ANXA4 in ccRCC tumor cells in situ, we searched for appropriate cellular model systems to delineate functional implications of ANXA4. Here, we globally analyzed renal carcinoma derived cell lines in the Cancer Cell Line Encyclopedia and mapped expression levels of annexin proteins to VHL-mutations or loss of the p-arm of chromosome 3 (Figures 2A; Figure S3A; Table S3).30 Loss of chromosome 3p (encompassing ccRCC driver genes such as VHL, PBRM1, SETD2, BAP1) or mutations of the VHL gene are pathognomonic features of ccRCC.3 In line with our tissue-based analysis (see Figure 1), ANXA4 showed a consistent elevation in expression levels in numerous kidney tumor cell lines. Correlation analysis to VHL, EPAS1 (HIF2\u03b1) and HIF1\u03b1 as well as VHL-mutation status and loss of chromosome 3p indicated a potential link between ANXA4 and pVHL/-HIF signaling (Figure 2A; Figures S3B\u2013S3D). To further corroborate these observations, we made use of two independent ccRCC cancer cell lines with natural pVHL-loss (A498 and 786-O). Proteomic analysis of respective cell lines with pVHL-loss or constitutive pVHL-reexpression demonstrated a pronounced dependence of ANXA4 protein levels on the presence of pVHL (Figure 2B \u2013 most prominently in the A498 cell line; Figures 3E and 3F; Table S4). For further functional analysis, we generated knockdown lines on these cellular backgrounds and respective overexpression on a non-cancerous renal proximal tubular epithelial cell (RPTEC) line (Figures 2C\u20132E; Figure S3G). Previous studies have reported that ANXA4 affects cellular functions such as proliferation.31,32 To investigate whether ANXA4 could affect the proliferative behavior of ccRCC, we employed respective cellular models and recorded growth dynamics using long-term live imaging (up to 120h). In contrast to previous reports,32,33 we did not observe any significant impact of ANXA4 protein on cellular proliferation neither in knockdown nor in overexpression conditions (Figures 2F\u20132H). To exclude insufficient knockdown efficiency, we further made use of CRISPR/Cas9 genome editing and generated complete ANXA4 knockout clones from two independent guide RNAs on the A498 cellular background (given the most prominent dependency of ANXA4 on pVHL-protein confirmed via western blot experiments \u2013 Figures 2I and 2I). Notably, the knockout of ANXA4 did not result in a compensatory upregulation of other annexin proteins such as ANXA2 or ANXA3 (Figure 2I). Interestingly, complete knockout of ANXA4 in A498 cells did not affect cell proliferation as measured by BrdU incorporation (Figure 2K). In summary, our studies revealed a (at least partial) pVHL dependence of ANXA4 gene expression in ccRCC cancer cell lines and further demonstrated that ANXA4 protein levels do not modulate the proliferation of representative ccRCC cell lines.Figure 2ANXA4 is upregulated in kidney cancer cell lines by loss of VHL(A) Heatmaps present the expression of VHL and annexin family genes in kidney cancer derived cell lines included in the Cancer Cell Line Encyclopedia database. Z-scores indicate gene expressions relative to the entire cancer cell line database as a reference. Estimated loss of the p-arm of chromosome 3 (chr3p), mutations of the VHL gene, and prediction of oncogenicity (OncoKB) are indicated (colored box \u2013 positive, white box \u2013 negative for these features; crossed out box \u2013 no data available). A498 and 786-O cell lines (red label) were selected for further analysis of ANXA4.(B) Proteome analysis of A498 and 786-O ctrl. and pVHL re-expression cell lines demonstrated the regulation of ANXA4 in a pVHL dependent manner (two replicates per cell line were analyzed). Heatmap shows relative log2 fold changes (FC) of pVHL-loss over re-expression for annexin family proteins and marker proteins for pVHL dependent regulation (crossed out box \u2013 no ratio could be calculated).(C\u2013E) Western blot analysis for ANXA4 in shRNA mediated A498 ANXA4 knockdown (KD) and 786-O ANXA4 KD or overexpression (oeANXA4) in RPTEC cell lines (TUBA was used as loading control). Scramble shRNAs or Luciferase (oeLUCI) were expressed as controls (ctrl.). Densitometry of western blots shows optical densities of three (D) or four (E) independent experiments. Arbitrary units (a.u.) were normalized to respective controls per experiment.(F\u2013H) Analysis of cell growth curves revealed no differences in ANXA4 KD cell lines and only slight differences in ANXA4 overexpressing (OE) RPTECs (one representative experiment out of several independent experiments is shown; dots indicate mean values and error bars S.E.M. per time point; growth curves indicate fitted growth rates (nonlinear regression) and dotted line indicates \u00b195% confidence intervals).(I and J) Western blot analysis for ANXA4 in ANXA4 knockout (KO) and pVHL re-expression A498 cells (ANXA2, ANXA3, and TUBA were used as reference). CRISPR/Cas9 generated Ctrl.-1&-2 and KO-1&-2 indicate monoclonal cell lines using independent non-targeting or ANXA4 specific guide RNAs per cell line. Densitometry of western blots confirmed the downregulation of ANXA4 following pVHL re-expression (VHL+) in A498 cells (four independent replicates normalized to respective controls per experiment were analyzed).(K) Cell proliferation analysis by BrdU incorporation in ANXA4 KO and Ctrl. cell lines (12 replicates per genotype out of 4 independent experiments and 3 replicates per experiment; a.u. \u2013 arbitrary units). Dot plots show analyzed replicates (error bars indicate mean and S.E.M.; n.s. \u2013 not significant; \u2217p < 0.05; \u2217\u2217p < 0.01 and \u2217\u2217\u2217\u2217 <0.0001).Figure 3Membrane stress regulates the subcellular localization of ANXA4(A\u2013J) Influx of Calcium ions induced by Ionomycin and membrane stress by hypoosmolar media or digitonin treatment initiates recruitment of ANXA4 to the nuclear membrane in A498 cells. Representative immunofluorescence images show the subcellular localization of ANXA4 (cells were co-stained by Phalloidin (F-Actin) and Hoechst (Nucleus)). Dashed boxes indicate regions of magnification. Dashed lines indicate positions of correlating line scans. Line scans (B, D, F, H, and J) show mean fluorescence intensities (MFI) as arbitrary units (a.u.) of ANXA4 and F-Actin (red arrows indicate cytoplasm membranes, and black arrows indicate nuclear membranes).",
        "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesRabbit polyclonal anti-ANXA4 (Annexin A4)Atlas AntibodiesCat# HPA007393; RRID:AB_1078168Mouse monoclonal anti-ANXA4 (Annexin A4) (clone: D-2)Santa Cruz BiotechnologyCat# sc-46693; RRID:AB_626679Rabbit polyclonal anti-ANXA3 (Annexin A3)Atlas AntibodiesCat# HPA013398; RRID:AB_1844861Rabbit polyclonal anti-ANXA2 (Annexin A2)Cell Signaling TechnologyCat# 8235; RRID:AB_11129437Mouse monoclonal anti-TUBA (alpha-Tubulin) (clone: DM1A)Sigma-AldrichCat# T9026: RRID:AB_477593Rabbit polyclonal anti-CLDN1 (Claudin 1)AbcamCat# ab15098; RRID:AB_301644Rabbit polyclonal anti-ELF3 (E74-like factor 3)Atlas AntibodiesCat# HPA003479; RRID:AB_1078756Mouse monoclonal anti-PAX8 (clone: MRQ-50)Ventana/Roche DiagnosticsCat# 760\u20134618; RRID:N/AMouse monoclonal anti-SMA (ACTA2) (clone: 1A4)Dako/Agilent TechnologiesCat# GA611; RRID:N/AMouse monoclonal anti-CD34Dako/Agilent TechnologiesCat# M7165; RRID:AB_2063006Mouse monoclonal anti-CK1/3 (AE1/AE3)Dako/Agilent TechnologiesCat# IR053; RRID:N/AGoat polyclonal anti-LuciferaseNovus Biological, Bio-Techne GmbHCat# NB 100\u20131677; RRID:AB_531129Fluorophore-conjugated donkey polyclonal anti-rabbitThermo Fisher ScientificCat# A-31572; RRID:AB_162543HRP-linked goat polyclonal anti-mouse antibodyDako/Agilent TechnologiesCat# P0447; RRID:AB_2617137HRP-linked goat polyclonal anti-rabbit antibodyCell SignalingCat# 7074; RRID:AB_2099233HRP-linked rabbit polyclonal anti-goat antibodyDako/Agilent TechnologiesCat# P0449; RRID:AB_2617143Bacterial and virus strainsNEB Stable Competent E. coli (High Efficiency)New England BiolabsCat# C3040H; RRID:N/ABiological samplesCPTAC-CCRCC CohortLi et al.27N/ATCGA Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy)Cancer Genome Atlas Research7https://www.cbioportal.org/TCGA Cancer Cell Line Encyclopedia (Broad, 2019)Ghandi et al.30https://www.cbioportal.org/All other biological samples and cohorts were generated in this study and described in detailThis studyN/AChemicals, peptides, and recombinant proteinsHoechst 33342, trihydrochloride, trihydrate (permeable)Thermo Fisher Scientific Inc.Cat# H3570Hoechst 33258, Pentahydrat (bis-Benzimid) (impermeable)Thermo Fisher Scientific Inc.Cat# H3569RPMI 1640 GlutaMAX\u2122Thermo Fisher Scientific Inc.Cat# 61870036DMEM GlutaMAX\u2122Thermo Fisher Scientific Inc.Cat# 31966-021Fetal Calve Serum (FCS)Merck KGaACat# S0615Recombinant human TGFb1Thermo Fisher Scientific Inc.Cat# PHG9214CellTracker\u2122 Green CMFDAThermo Fisher Scientific Inc.Cat# C7025Ionomycin (calcium salt)Cayman ChemicalCat# 11932Hanks' Balanced Salt Solution (HBSS) with Calcium, Magnesium, Glucosewithout Phenol red, SodiumpyruvateGibco/Thermo Fisher Scientific Inc.Cat# 14025092Hanks' Balanced Salt Solution (HBSS) with Glucosewithout Calcium, Magnesium, Phenol red, SodiumpyruvateGibco/Thermo Fisher Scientific Inc.Cat# 14175095Matrigel\u00ae Growth Factor Reduced (GFR) Basement Membrane Matrix, Phenol Red-free, LDEV-freeCorningCat# 356231Paraformaldehyde 32% Aqueous Solution EM GradeElectron Microscopy SciencesCat# 15714-SDulbecco\u2019s Phosphate-Buffered Saline (PBS)Gibco/Thermo Fisher Scientific Inc.Cat# 14190094Digitonin (non-ionic detergent)Sigma-AldrichCat# D141Alexa Fluor phalloidin 488Thermo Fisher Scientific Inc.Cat# A12379HematoxylinSigma-AldrichCat# 51275Critical commercial assaysBrdU Cell Proliferation ELISA Kit (colorimetric)abcamCat# ab126556Opal 6-Plex Manual Detection KitAkoya BiosciencesCat# NEL811001KTPierce BCA Protein Assay KitThermo Fisher Scientific Inc.Cat# 23225Pierce\u2122 ECL Western Blotting-SubstratThermo Fisher Scientific Inc.Cat# 32109Monarch Total RNA Miniprep KitNew England Biolabs Inc.Cat# T2010SMycoplasma PCR detection kitHiss Diagnostics GmbHCat# 25235Liquid DAB+ Substrate Chromogen SystemDako/Agilent TechnologiesCat# K3468Deposited dataRNA Sequencing dataNCBI Gene Expression OmnibusGSE267754Proteomics dataMassIVE repositoryMassiVE: MSV000094814CPTAC-CCRCCThe Cancer Imaging Archivehttps://www.cancerimagingarchive.net/collection/cptac-ccrcc/Experimental models: Cell linesA498ATCCCat# HTB-44786-OATCCCat# CRL-1932hRPTECATCCCat# PCS-400-010HEK293T/17ATCCCat# CRL-11268OligonucleotideshU6-F primer (5\u2032-GAGGGCCTATTTCCCATGATT-3\u2032)AddgeneN/Anon targeting:nt-sgRNA-1: 5\u2032- GCGGGCAGAACGACCCTGAC -3'Rogg et al.63N/Anon targeting:nt-sgRNA-2: 5\u2032- GAAGACGTGCTGGCGTCACC -3'Rogg et al.63N/AANXA4-sg1: TCTGCTGGCTATAGGTAAGC(TGG)This studyN/AANXA4-sg2: GGACGATGCTCTCGTGAGAC(AGG)This studyN/ARecombinant DNApLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-78: GCACACTTCAAGAGACTCTATHorizon Discovery Biosciences LimitedTRCN0000056278pLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-80: GCAGAAATTGACATGTTGGATHorizon Discovery Biosciences LimitedTRCN0000056280pLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-81: GCCTTGAAGATGACATTCGCTHorizon Discovery Biosciences LimitedTRCN0000056281Scramble pLKO.1 shRNA controlSarbassov et al.64Addgene plasmid #1864, RRID:Addgene_1864hELF3 (NM_004433) in pLenti C-Myc-DDK-P2A-PuroOriGene TechnologiesRC200631L3Luciferase in pLenti-C-Myc-DDK-P2A-PuroThis study; swap cloning from existing plasmids (Maier et al.65)N/AHuman ANXA4 (NM_001320698.2) in pcDNA3.1+/C-(K)-DYKGenScript BiotechOHu26294pWPXLd expression vectorDidier Trono Lab (unpublished)Addgene plasmid #12258, RRID:Addgene_12258Luciferase in pWPXLdThis study; swap cloning from existing plasmids (Maier et al.65)N/AANXA4 in pWPXLdThis study; swap cloning from existing plasmidN/ATLCV2-LoxPAdam Karpf Lab (unpublished)Addgene plasmid #127098, RRID:Addgene_127098Software and algorithmsCHOPCHOP version 3Labun et al.66https://chopchop.cbu.uib.no/Phenochart slide viewer version 2.2.0Akoya BiosciencesN/AinForm Tissue Analysis Software 3.0Akoya BiosciencesN/AFiji ImageJ v1.54fSchindelin et al.67https://imagej.net/software/fiji/Zen blue 3.0 softwareCarl Zeiss AGN/AQuPath version 0.4.3 and 0.5.1.Bankhead et al.68https://qupath.github.io/Incucyte Live Cell Analysis Software 2023ASartoriusN/AGalaxy EuropeGalaxy Community69https://usegalaxy.eu/GenePatternReich et al.70https://www.genepattern.orgGEPIA 2GEPIA 2\u20132018 Zhang\u2019s Lab.http://gepia.cancer-pku.cnChEA3Keenan et al.71https://maayanlab.cloud/chea3Matrisome DB version 1Shao et al.72https://matrisomedb.orgInnate DBBreuer et al.73https://www.innatedb.comEMTome DBVasaikar et al.74http://www.emtome.orgProteomicsKern et al.75N/AGraphPad Prism 8GraphPadN/ACellProfiler version 4.2.7Stirling et al.76https://cellprofiler.org/R version 4.4.1 (2024-06-14 ucrt)R Foundation for Statistical Computinghttps://www.R-project.org/R package growthcurverSprouffske et al.77https://CRAN.R-project.org/package=growthcurverOtherPhenoCycler Fusion microscopeAkoya BiosciencesN/AGlass-Beads (425\u2013600 \u03bcm, acid-washed)Sigma-AldrichCat# G8772-10GThincert Cell Culture Insert (pore-size: 8 \u03bcm, 24-well format)Greiner Bio-OneCat# 662638ibiTreat-8well-dishesIbidi GmbHCat# 80826Incucyte S3 Live-Cell Analysis SystemSartoriusN/AIbidi Culture-Insert 2 Well in \u03bc-Dish 35 mm, High ibiTreatIbidi GmbHCat# 81176Vortexer REAX topHeidolph Scientific Products GmbHCat# 541-10000-00Heracell\u2122 240i CO2 IncubatorThermo Fisher Scientific Inc.Cat# 51032875",
        "The cBioPortal for Cancer Genomics was used for analysis of the TCGA Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy) and Cancer Cell Line Encyclopedia (Broad, 2019) datasets.7,30,82 For survival analysis, best gene expression (FPKM) cut-offs for survival between patient groups in the TCGA cohort were previously calculated and used to define ANXA4 high and ANXA4 low ccRCCs accordingly.83 Kaplan-Meier survival analysis and caparison of clinical parameters between these two patient groups as well as calculation of statistical characteristics was performed using the cBioPortal for Cancer Genomics toolbox (Table S2). Comparison and statistically analysis of ANXA4 expression values between ccRCC tumor samples and normal tissue was performed via the GEPIA 2.0 platform (Gene Expression Profiling Interactive Analysis \u2013 based on available TCGA and GTEX data). In addition, mRNA co-expression analysis for EFL3 in the Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy) cohort was retrieved from the cBioPortal for Cancer Genomics platform. The Matrisome DB, Innate DB and EMTome DB resources were used for annotation of ELF3 co-expressed genes (see Table S11 for co-expression analysis of ELF3).72,73,74"
      ],
      "23792563": [
        "The prognosis, outcome, and related clinical management of ccRCC is to date, largely depending on histopathological tumor staging. With the advent of \u201comics\u201d technologies (e.g., whole exome sequencing, transcriptomics, proteomics) and immune checkpoint blockade-based therapy protocols the role of molecular subclasses and the tumor (immune) microenvironment, as well as the unmet need of precise biomarkers for these became evident.7,8,9 To develop more precise molecular classifications, previous studies identified favorable PBRM1-mutated subtypes in contrast to cases with more aggressive BAP1 mutations.9 While additional genomic biomarkers (e.g., ClearCode34, CCP Score) based on selected gene signatures have been developed to predict prognosis in ccRCC, broad clinical application is still not established.10 On the contrary, current standardized pathological assessment (based on WHO guidelines) of ccRCC also grades for certain morphological growth patterns such as rhabdoid or eosinophilic appearance, as these features correlate with increased aggressiveness and poor clinical outcome.11 ccRCC shows high levels of intratumoral heterogeneity in terms of morphological features, including pure solid tumor sheets, cystic degeneration, and stroma-enrichment ranging to (at least partial) papillary growth patterns.12,13,14 Interestingly, the growth of ccRCC follows a rather expansive than invasive mode, resulting in the compression induced atrophy of the adjacent renal parenchyma and formation of a pseudo-capsule at the tumor boundary.15 This mode of expansion presumably translates into increased mechanical forces on growing tumor nodules and requires a specialized as well as adaptive membrane composition in respective ccRCC cell populations.",
        "For global annotation and analysis of annexin family proteins, we employed available and independent proteomic datasets of ccRCC tumor tissue (including our own analysis on syndromic cases of ccRCC in the context of VHL-disease) as well as corresponding transcriptomic data for the CPTAC cohort.25,26,27 While the compared datasets differed in numbers of detected proteins and analyzed patient cases, a robust detection for the majority of annotated annexin proteins was observed (Figure 1A; Table S1). It is noteworthy that ANXA8 and ANXA10 were the only proteins for which a detection was not achieved based on reported cut-off parameters. When comparing ccRCC tumor tissue to adjacent normal renal parenchyma, ANXA4 protein showed the highest level of protein abundance (Figure 1A). Due to the bulk nature of conventional proteomic tissue analysis, we aimed for a more granular dissection in terms of the cellular distribution of ANXA4. For further delineation of cellular identities, we interrogated an available scRNA-Seq dataset on ccRCC tumor tissue via the CELL\u00d7GENE platform.28,29 Interestingly, certain annexin family members, such as ANXA2, which showed significant levels of enrichment in the bulk proteomic datasets, exhibited almost equal expression levels in tumor and endothelial cells (Figures 1B and S1A). In this context, ANXA4 showed the highest level of tumor cell specificity when directly compared to other annexin genes (Figures 1B and 1C). To further corroborate these observations derived from proteomic and scRNA-Seq studies on a (sub-) cellular level, we employed immunofluorescence and -histochemistry on ccRCC tumor tissue. In accordance with scRNA-Seq based cellular deconvolution, the presence of ANXA2 and ANXA3 was observed in tumor and endothelial cells, while ANXA4 was exclusively detected within tumor cells (Figures 1D and S2A\u2013S2D). In contrast to ANXA2 (and to a lesser extent also ANXA3) showing only a prominent membranous localization pattern, ANXA4 was also detected in the nucleus and nuclear membrane compartment of respective renal tumor cells in ccRCC, but also in renal oncocytoma and to a lower extent in papillary renal cell carcinomas (Figures 1D, S2E, and S2F). To estimate the potential influence of ANXA4 on relevant parameters in ccRCC patient populations, we employed the TCGA resource for correlative analysis.7 Remarkably, respective patient populations with low levels of ANXA4 were attributed a rather aggressive disease course reflected by reduced overall survival (Figure 1E; Table S2), while no significant differences in tumor stage were identified (Figure 1F). In line with decreased survival parameters, higher tumor grades and increased levels of positive lymph nodes correlated with respective ANXA4 low tumors (Figures 1G and 1H). Remarkably, RNA-based expression analysis indicated that the majority of respective ANXA4-low tumors still exhibited higher (or at least similar) expression levels when compared to non-tumorous renal parenchyma (Figures S1B and S1C). Together, our analysis demonstrated a selective expression pattern of ANXA4 in ccRCC tumor cells characterized by various subcellular localization patterns (membranous and nuclear membranes).Figure 1ANXA4 is upregulated in ccRCC, prognostic favorable and recruited to cytoplasm and nuclear membranes(A) Heatmap depicts the expression of the annexin family members in previously published transcriptome and proteome datasets of indicated ccRCC cohorts compared to normal adjacent tissue (FC \u2013 fold change; crossed out boxes \u2013 not detected).25,26,27(B) Dot plot shows the relative expression of annexin family genes in indicated cell populations derived from previously published scRNA-Seq analysis of seven ccRCCs.28(C) t-SNE (t-distributed stochastic neighbor embedding) blot of scRNA-Seq data indicates the expression of ANXA4 in ccRCC cancer cells (cells below the 70\u2013100% percentile range of continuous values for ANXA4 expression are gray labeled).(D) Multiplex immunofluorescence (mIF) analysis of ccRCCs for ANXA4 expression and localization. Cancer cells were stained by CK1/3 (Cytokeratin-1/-3) and nuclei of cancer cells by PAX8. Stromal cells were stained by smooth muscle actin (SMA (ACTA2)), endothelial cells by CD34, and nuclei by DAPI (dashed boxes indicate regions of magnified images). Yellow arrows indicate ANXA4 positive nuclear membranes, and yellow arrowheads highlight positive plasma membranes in cancer cells.(E) Survival analysis for ANXA4 comparing patients with high (N = 404; blue) and low (N = 124; red) expression in the ccRCC TCGA cohort (HR \u2013 hazard ratio of ANXA4 low to high expression; CI \u2013 \u00b195% confidence interval).(F\u2013H) Comparison of ANXA4 high (N = 404) and low (N = 124) expressing ccRCCs in the TCGA cohort for disease stage, histologic grade, and primary lymph node presentation (n.s. \u2013 not significant; \u2217p < 0.05; \u2217\u2217p < 0.01).",
        "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesRabbit polyclonal anti-ANXA4 (Annexin A4)Atlas AntibodiesCat# HPA007393; RRID:AB_1078168Mouse monoclonal anti-ANXA4 (Annexin A4) (clone: D-2)Santa Cruz BiotechnologyCat# sc-46693; RRID:AB_626679Rabbit polyclonal anti-ANXA3 (Annexin A3)Atlas AntibodiesCat# HPA013398; RRID:AB_1844861Rabbit polyclonal anti-ANXA2 (Annexin A2)Cell Signaling TechnologyCat# 8235; RRID:AB_11129437Mouse monoclonal anti-TUBA (alpha-Tubulin) (clone: DM1A)Sigma-AldrichCat# T9026: RRID:AB_477593Rabbit polyclonal anti-CLDN1 (Claudin 1)AbcamCat# ab15098; RRID:AB_301644Rabbit polyclonal anti-ELF3 (E74-like factor 3)Atlas AntibodiesCat# HPA003479; RRID:AB_1078756Mouse monoclonal anti-PAX8 (clone: MRQ-50)Ventana/Roche DiagnosticsCat# 760\u20134618; RRID:N/AMouse monoclonal anti-SMA (ACTA2) (clone: 1A4)Dako/Agilent TechnologiesCat# GA611; RRID:N/AMouse monoclonal anti-CD34Dako/Agilent TechnologiesCat# M7165; RRID:AB_2063006Mouse monoclonal anti-CK1/3 (AE1/AE3)Dako/Agilent TechnologiesCat# IR053; RRID:N/AGoat polyclonal anti-LuciferaseNovus Biological, Bio-Techne GmbHCat# NB 100\u20131677; RRID:AB_531129Fluorophore-conjugated donkey polyclonal anti-rabbitThermo Fisher ScientificCat# A-31572; RRID:AB_162543HRP-linked goat polyclonal anti-mouse antibodyDako/Agilent TechnologiesCat# P0447; RRID:AB_2617137HRP-linked goat polyclonal anti-rabbit antibodyCell SignalingCat# 7074; RRID:AB_2099233HRP-linked rabbit polyclonal anti-goat antibodyDako/Agilent TechnologiesCat# P0449; RRID:AB_2617143Bacterial and virus strainsNEB Stable Competent E. coli (High Efficiency)New England BiolabsCat# C3040H; RRID:N/ABiological samplesCPTAC-CCRCC CohortLi et al.27N/ATCGA Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy)Cancer Genome Atlas Research7https://www.cbioportal.org/TCGA Cancer Cell Line Encyclopedia (Broad, 2019)Ghandi et al.30https://www.cbioportal.org/All other biological samples and cohorts were generated in this study and described in detailThis studyN/AChemicals, peptides, and recombinant proteinsHoechst 33342, trihydrochloride, trihydrate (permeable)Thermo Fisher Scientific Inc.Cat# H3570Hoechst 33258, Pentahydrat (bis-Benzimid) (impermeable)Thermo Fisher Scientific Inc.Cat# H3569RPMI 1640 GlutaMAX\u2122Thermo Fisher Scientific Inc.Cat# 61870036DMEM GlutaMAX\u2122Thermo Fisher Scientific Inc.Cat# 31966-021Fetal Calve Serum (FCS)Merck KGaACat# S0615Recombinant human TGFb1Thermo Fisher Scientific Inc.Cat# PHG9214CellTracker\u2122 Green CMFDAThermo Fisher Scientific Inc.Cat# C7025Ionomycin (calcium salt)Cayman ChemicalCat# 11932Hanks' Balanced Salt Solution (HBSS) with Calcium, Magnesium, Glucosewithout Phenol red, SodiumpyruvateGibco/Thermo Fisher Scientific Inc.Cat# 14025092Hanks' Balanced Salt Solution (HBSS) with Glucosewithout Calcium, Magnesium, Phenol red, SodiumpyruvateGibco/Thermo Fisher Scientific Inc.Cat# 14175095Matrigel\u00ae Growth Factor Reduced (GFR) Basement Membrane Matrix, Phenol Red-free, LDEV-freeCorningCat# 356231Paraformaldehyde 32% Aqueous Solution EM GradeElectron Microscopy SciencesCat# 15714-SDulbecco\u2019s Phosphate-Buffered Saline (PBS)Gibco/Thermo Fisher Scientific Inc.Cat# 14190094Digitonin (non-ionic detergent)Sigma-AldrichCat# D141Alexa Fluor phalloidin 488Thermo Fisher Scientific Inc.Cat# A12379HematoxylinSigma-AldrichCat# 51275Critical commercial assaysBrdU Cell Proliferation ELISA Kit (colorimetric)abcamCat# ab126556Opal 6-Plex Manual Detection KitAkoya BiosciencesCat# NEL811001KTPierce BCA Protein Assay KitThermo Fisher Scientific Inc.Cat# 23225Pierce\u2122 ECL Western Blotting-SubstratThermo Fisher Scientific Inc.Cat# 32109Monarch Total RNA Miniprep KitNew England Biolabs Inc.Cat# T2010SMycoplasma PCR detection kitHiss Diagnostics GmbHCat# 25235Liquid DAB+ Substrate Chromogen SystemDako/Agilent TechnologiesCat# K3468Deposited dataRNA Sequencing dataNCBI Gene Expression OmnibusGSE267754Proteomics dataMassIVE repositoryMassiVE: MSV000094814CPTAC-CCRCCThe Cancer Imaging Archivehttps://www.cancerimagingarchive.net/collection/cptac-ccrcc/Experimental models: Cell linesA498ATCCCat# HTB-44786-OATCCCat# CRL-1932hRPTECATCCCat# PCS-400-010HEK293T/17ATCCCat# CRL-11268OligonucleotideshU6-F primer (5\u2032-GAGGGCCTATTTCCCATGATT-3\u2032)AddgeneN/Anon targeting:nt-sgRNA-1: 5\u2032- GCGGGCAGAACGACCCTGAC -3'Rogg et al.63N/Anon targeting:nt-sgRNA-2: 5\u2032- GAAGACGTGCTGGCGTCACC -3'Rogg et al.63N/AANXA4-sg1: TCTGCTGGCTATAGGTAAGC(TGG)This studyN/AANXA4-sg2: GGACGATGCTCTCGTGAGAC(AGG)This studyN/ARecombinant DNApLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-78: GCACACTTCAAGAGACTCTATHorizon Discovery Biosciences LimitedTRCN0000056278pLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-80: GCAGAAATTGACATGTTGGATHorizon Discovery Biosciences LimitedTRCN0000056280pLKO.1 lentiviral vector + ANXA4 shRNA:shRNA-81: GCCTTGAAGATGACATTCGCTHorizon Discovery Biosciences LimitedTRCN0000056281Scramble pLKO.1 shRNA controlSarbassov et al.64Addgene plasmid #1864, RRID:Addgene_1864hELF3 (NM_004433) in pLenti C-Myc-DDK-P2A-PuroOriGene TechnologiesRC200631L3Luciferase in pLenti-C-Myc-DDK-P2A-PuroThis study; swap cloning from existing plasmids (Maier et al.65)N/AHuman ANXA4 (NM_001320698.2) in pcDNA3.1+/C-(K)-DYKGenScript BiotechOHu26294pWPXLd expression vectorDidier Trono Lab (unpublished)Addgene plasmid #12258, RRID:Addgene_12258Luciferase in pWPXLdThis study; swap cloning from existing plasmids (Maier et al.65)N/AANXA4 in pWPXLdThis study; swap cloning from existing plasmidN/ATLCV2-LoxPAdam Karpf Lab (unpublished)Addgene plasmid #127098, RRID:Addgene_127098Software and algorithmsCHOPCHOP version 3Labun et al.66https://chopchop.cbu.uib.no/Phenochart slide viewer version 2.2.0Akoya BiosciencesN/AinForm Tissue Analysis Software 3.0Akoya BiosciencesN/AFiji ImageJ v1.54fSchindelin et al.67https://imagej.net/software/fiji/Zen blue 3.0 softwareCarl Zeiss AGN/AQuPath version 0.4.3 and 0.5.1.Bankhead et al.68https://qupath.github.io/Incucyte Live Cell Analysis Software 2023ASartoriusN/AGalaxy EuropeGalaxy Community69https://usegalaxy.eu/GenePatternReich et al.70https://www.genepattern.orgGEPIA 2GEPIA 2\u20132018 Zhang\u2019s Lab.http://gepia.cancer-pku.cnChEA3Keenan et al.71https://maayanlab.cloud/chea3Matrisome DB version 1Shao et al.72https://matrisomedb.orgInnate DBBreuer et al.73https://www.innatedb.comEMTome DBVasaikar et al.74http://www.emtome.orgProteomicsKern et al.75N/AGraphPad Prism 8GraphPadN/ACellProfiler version 4.2.7Stirling et al.76https://cellprofiler.org/R version 4.4.1 (2024-06-14 ucrt)R Foundation for Statistical Computinghttps://www.R-project.org/R package growthcurverSprouffske et al.77https://CRAN.R-project.org/package=growthcurverOtherPhenoCycler Fusion microscopeAkoya BiosciencesN/AGlass-Beads (425\u2013600 \u03bcm, acid-washed)Sigma-AldrichCat# G8772-10GThincert Cell Culture Insert (pore-size: 8 \u03bcm, 24-well format)Greiner Bio-OneCat# 662638ibiTreat-8well-dishesIbidi GmbHCat# 80826Incucyte S3 Live-Cell Analysis SystemSartoriusN/AIbidi Culture-Insert 2 Well in \u03bc-Dish 35 mm, High ibiTreatIbidi GmbHCat# 81176Vortexer REAX topHeidolph Scientific Products GmbHCat# 541-10000-00Heracell\u2122 240i CO2 IncubatorThermo Fisher Scientific Inc.Cat# 51032875",
        "The cBioPortal for Cancer Genomics was used for analysis of the TCGA Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy) and Cancer Cell Line Encyclopedia (Broad, 2019) datasets.7,30,82 For survival analysis, best gene expression (FPKM) cut-offs for survival between patient groups in the TCGA cohort were previously calculated and used to define ANXA4 high and ANXA4 low ccRCCs accordingly.83 Kaplan-Meier survival analysis and caparison of clinical parameters between these two patient groups as well as calculation of statistical characteristics was performed using the cBioPortal for Cancer Genomics toolbox (Table S2). Comparison and statistically analysis of ANXA4 expression values between ccRCC tumor samples and normal tissue was performed via the GEPIA 2.0 platform (Gene Expression Profiling Interactive Analysis \u2013 based on available TCGA and GTEX data). In addition, mRNA co-expression analysis for EFL3 in the Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy) cohort was retrieved from the cBioPortal for Cancer Genomics platform. The Matrisome DB, Innate DB and EMTome DB resources were used for annotation of ELF3 co-expressed genes (see Table S11 for co-expression analysis of ELF3).72,73,74"
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2931358814239502,
    "data_pmids_checked": 2,
    "paper_id": "40212597",
    "extraction_date": "2025-12-19T19:49:24.832602",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40212597.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40244529": {
    "paper_id": "40244529",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Vol:.(1234567890)\n\nDiscover Oncology (2025) 16:552 | https://doi.org/10.1007/s12672-025-02340-6\nAnalysis\n2.3 Gene alteration analysis\nUpon accessing the cBioPortal website (https://w ww.c biopo rtal.o rg/) [23], the study selected the \u201cTCGA Pan Cancer Atlas\nStudies\u201d within the \u201cQuick select\u201d section, utilizing the input \u201cDEFB1\u201d to conduct an inquiry into the genetic attributes\nassociated with DEFB1",
      "We applied the cBioPortal tool for the purpose of elucidating the mutation\ncharacteristics pertaining to DEFB1",
      "Data availability The datasets analyzed for this study can be found in the HPA, TCGA, GTEx, TIMER2.0, UALCAN, CCLE, GEPIA2, and cBioPortal\nweb resources, and requests to further access to datasets can be directed to wangli_tjch@tmu.edu.cn",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:36.959984",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40244529.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 11.162821054458618,
      "cbioportal_papers": 0.00018095970153808594,
      "pdf_extraction_pass2": 12.542012929916382,
      "cbioportal_papers_pass2": 0.00018906593322753906,
      "used_full_extraction": true,
      "pdf_extraction": 23.704833984375,
      "platform_mentions": 0.001712799072265625,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40210757": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.262948989868164,
    "data_pmids_checked": 2,
    "paper_id": "40210757",
    "extraction_date": "2025-12-19T19:49:38.223034",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40210757.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40232629": {
    "paper_id": "40232629",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.5 Analysis of mutations in genes\nWe used the cBioPortal to investigate genetic alterations in the PPP1R3G gene across all TCGA PanCancer Atlas studies\n[20]",
      "3.5 Genetic alteration of PPP1R3G\nWe analyzed the genetic alterations affecting PPP1R3G expression in various cancers using the cBioPortal for Cancer\nGenomics",
      "Vol:.(1234567890)\n\nDiscover Oncology (2025) 16:530 | https://doi.org/10.1007/s12672-025-02361-1\nAnalysis\nData analysis on the cBioPortal platform revealed mutations in PPP1R3G across 24 of 32 cancer types, exhibiting a\nvariety of alteration types including mutations, amplifications, and deep deletions",
      "Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:40.440593",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40232629.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.323149919509888,
      "cbioportal_papers": 0.00037097930908203125,
      "pdf_extraction_pass2": 10.465215921401978,
      "cbioportal_papers_pass2": 0.00037360191345214844,
      "used_full_extraction": true,
      "pdf_extraction": 18.788365840911865,
      "platform_mentions": 0.004510402679443359,
      "data_citations": 0.0001552104949951172,
      "num_data_pmids_checked": 1
    }
  },
  "40210889": {
    "paper_id": "40210889",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:45.394384",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40210889.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.439304113388062,
      "cbioportal_papers": 0.00023698806762695312,
      "pdf_extraction_pass2": 10.110395193099976,
      "cbioportal_papers_pass2": 0.0002319812774658203,
      "used_full_extraction": true,
      "pdf_extraction": 20.549699306488037,
      "platform_mentions": 0.002579927444458008,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40234830": {
    "paper_id": "40234830",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:50.037765",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40234830.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 14.52389407157898,
      "cbioportal_papers": 0.0003819465637207031,
      "pdf_extraction_pass2": 18.367241859436035,
      "cbioportal_papers_pass2": 0.00036072731018066406,
      "used_full_extraction": true,
      "pdf_extraction": 32.891135931015015,
      "platform_mentions": 0.0032258033752441406,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40204776": {
    "paper_id": "40204776",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The genetic analysis of the TCGA pan-cancer based on the\ncBioPortal showed that patients with ESCA had the highest frequency of genetic alterations in the PVRIG\n(8.79%) gene, followed by those with UCS (7.02%), UCEC (6.05%), CHOL (5.56%), and STAD (5.45%)",
      "PVRIG gene mutation and methylation analysis\nThe online database cBioPortal (http://www.cbioportal.org) provides comprehensive analyses of genomics data\nwithin the TCGA pan-cancer database40,41",
      "Therefore, the \u201cCancer Types Summary\u201d module in the cBioPortal\ndatabase was used to explore the copy number alteration (CNA), alteration frequency, and mutation types of\nthe PVRIG gene across the TCGA pan-cancer",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:49:59.427818",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40204776.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.261440992355347,
      "cbioportal_papers": 0.00031304359436035156,
      "pdf_extraction_pass2": 10.932448863983154,
      "cbioportal_papers_pass2": 0.0003159046173095703,
      "used_full_extraction": true,
      "pdf_extraction": 21.1938898563385,
      "platform_mentions": 0.0038290023803710938,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40197136": {
    "paper_id": "40197136",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "tionally, the gene expression profiles and clinical charac-\nThrough multi-omics exploration, the characteristics of teristics of the METABRIC dataset were acquired from\nthe tumor microenvironment will be revealed more com- cBioPortal [19] (https://www.cbioportal.org/)",
      "The limited availability Acknowledgements\nof imaging data may impact reliability and stability of the The authors would like to thank the GEO, cBioPortal and TCGA databases for\nthe availability of the data",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical\nVascular Reconstruction and Organ Function Repair, Tianjin Medical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:50:00.046332",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40197136.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.901455879211426,
      "cbioportal_papers": 0.00032401084899902344,
      "pdf_extraction_pass2": 9.699372053146362,
      "cbioportal_papers_pass2": 0.00031304359436035156,
      "used_full_extraction": true,
      "pdf_extraction": 19.600827932357788,
      "platform_mentions": 0.004083871841430664,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40186325": {
    "paper_id": "40186325",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutations Modification Cancer Reference (https://www.cbioportal.org/)\n1 K35R Ubiquitination Head and neck squamous cell carcinoma [125, 126]\n2 T77A Phosphorylation Colorectal adenocarcinoma 125, 126]\n3 S155L Phosphorylation Cervical squamous cell carcinoma & Bladder urothelial carcinoma [125, 126]\n4 S190L Phosphorylation Pancreatic adenocarcinoma [125, 126]\n5 K274N Ubiquitination Liver hepatocellular carcinoma [125, 126]\n6 K310N Ubiquitination Ovarian serous cystadenocarcinoma & Skin cutaneous melanoma [125, 126]\n7 S431L Phosphorylation Uterine corpus endometrial carcinoma [125, 126]\nspecific sites in TIP60 associated with cancer muta- various PTMs",
      "Gao J et al. Integrative Analysis of Complex Cancer Genomics and Clinical Springer Nature remains neutral with regard to jurisdictional claims in\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:50:20.055791",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40186325.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.683357000350952,
      "cbioportal_papers": 0.00039887428283691406,
      "pdf_extraction_pass2": 9.914073944091797,
      "cbioportal_papers_pass2": 0.000392913818359375,
      "used_full_extraction": true,
      "pdf_extraction": 20.59743094444275,
      "platform_mentions": 0.029565095901489258,
      "data_citations": 1.2636184692382812e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40185303": {
    "cbioportal_paper_citations": [
      "RNA sequencing data for head and neck squamous cell carcinoma (HNSC) were accessed through cBioPortal from The Cancer Genome Atlas (TCGA) Firehose Legacy cohort [20,21]. MK2 expression levels were analyzed based on gene-level transcript quantification, which was log-transformed as log2(x+1) and normalized using RSEM counts. Expression values were then correlated with available clinical data from TCGA, including disease stage, lymph node involvement, perineural invasion (PNI), extracapsular spread, angiolymphatic invasion, p16 (HPV) status, sex, race, and age. Statistical analyses were performed using unpaired t-tests for two-group comparisons and one-way ANOVA for multi-group analyses, with a significance threshold set at P < 0.05."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.13503289222717285,
    "data_pmids_checked": 0,
    "paper_id": "40185303",
    "extraction_date": "2025-12-19T19:50:20.234998",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40185303.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40182607": {
    "paper_id": "40182607",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Pro\u2011tumorigenic alterations\nlong non\u2011coding (lnc)RNAs such as H19 and MIR31HG\npromote proliferation and invasion via Wnt/\u03b2\u2011catenin and cBioPortal",
      "cBioPortal, an open\u2011access web resource used in cancer\nA new stratification for GBM was established by the 2021 research and molecular profiling, effectively meets this need\nWHO CNS5",
      "histone acetyltransferases such as p300/CBP enhances gene cBioportal offers an oncoprint feature that allows users\nactivity but drives gliomagenesis, while methylation by lysine to generate graphical representations of genomic alterations\nmethyltransferases and protein arginine methyltransferase 2 across specific genes within a sample where every row corre\u2011\nis linked to aggression and oncogenesis",
      "resistance in GBM by actively effluxing chemotherapeutic cBioPortal also provides an analysis of mutual exclusivity,\ndrugs like temozolomide, reducing their intracellular using Fisher's exact test to ascertain whether certain genetic\nconcentration and rendering them less effective",
      "These methods provided by\ncancer.gov/ccg/research/genome\u2011sequencing/cgci), leading to cBioportal aid in unraveling the complex genetic dynamics\ngroundbreaking changes in the cancer field (42)",
      "a genomic evaluation of key genes involved in GBM tumori\u2011 cBioPortal in GBM research enables the identification\ngenesis and progression was carried out, combining results of of key genomic alterations such as EGFR, PTEN and IDH1\nlaboratory research and bioinformatics tools",
      "provides a comprehensive view of GBM by identifying molec\u2011\nIn a study published in Nature, cBioPortal was used for the ular interactions, tumor subtypes and biomarkers",
      "cBioPortal also has several limitations",
      "While cBioPortal supports are crucial to GBM pathology",
      "ONCOLOGY LETTERS 29: 243, 2025 5\nTo predict variant effect, the program uses pathogenic vari\u2011 of the 592 GBM samples (TCGA, Pan Atlas\u2011GBM) for mutual\nants found in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar) exclusivity and co\u2011occurrence using cBioPortal demonstrated\nand the Human Gene Mutation Database (https://www.hgmd",
      "developed by cBioPortal indicated that 26 out of 126 mutations\nA significant advantage of MutationTaster2 (a new version are the highly oncogenic A289V/T/D and 16 mutations are\nof the tool) compared to other mutation\u2011predicting tools is the G598 V/A (67)",
      "A cBioPortal analysis of 592 GBM samples, receptor conformation (75), further limiting the effectiveness\nbased on the TCGA database, indicated that EGFR shows the of traditional TKIs in targeting EGFR",
      "Lollipop models for gene alterations generated by cBioportal",
      "A cBioPortal analysis of 592 BKM120, XL147 and XL765, have progressed to clinical trials\nGBM samples (TCGA, PanCancer Atlas\u2011GBM) suggested that for GBM (109)",
      "and Akt activation through an mTORC1\u2011mediated feed\u2011\nBased on the lollipop model produced by cBioPortal, five of back loop",
      "Stoyanov GS, Dzhenkov D, Ghenev P, Iliev B, Enchev Y and cBioPortal",
      "Cancer Genome Atlas Research Network: Comprehensive analysis of CPTAC proteomics data in the context of cancer\ngenomic characterization defines human glioblastoma genes and genomics in the cBioPortal",
      "Brlek P, Kafka A, Bukovac A and Pe\u0107ina\u2011\u0160laus N: Integrative\nNoushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, cBioPortal analysis revealed molecular mechanisms that regu\u2011\nBerman SH, et al: The somatic genomic landscape of glioblas\u2011 late EGFR\u2011PI3K\u2011AKT\u2011mTOR pathway in diffuse gliomas of the\ntoma",
      "Dhar C: Utilizing publicly available cancer clinicogenomic data on\nsubtypes of glioblastoma characterized by abnormalities in cBioPortal to compare epidermal growth factor receptor mutant\nPDGFRA, IDH1, EGFR, and NF1",
      "Cancer Discov 6: Challenges and experiences extending the cBioPortal for cancer\n532\u2011545, 2016"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:50:52.523514",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40182607.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 20,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 14.905999183654785,
      "cbioportal_papers": 0.0004849433898925781,
      "pdf_extraction_pass2": 17.376919984817505,
      "cbioportal_papers_pass2": 0.0004680156707763672,
      "used_full_extraction": true,
      "pdf_extraction": 32.28291916847229,
      "platform_mentions": 0.004131793975830078,
      "data_citations": 0.0003390312194824219,
      "num_data_pmids_checked": 2
    }
  },
  "40430531": {
    "paper_id": "40430531",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:00.414708",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40430531.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 101.87197613716125,
      "cbioportal_papers": 0.0005087852478027344,
      "pdf_extraction_pass2": 164.8350019454956,
      "cbioportal_papers_pass2": 0.0006902217864990234,
      "used_full_extraction": true,
      "pdf_extraction": 266.70697808265686,
      "platform_mentions": 0.005773067474365234,
      "data_citations": 1.8835067749023438e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40178992": {
    "cbioportal_paper_citations": [
      "From a surfaceome data set, a bioinformatics triage is typically performed such as that in Figure 2C. First, targets found to be significantly enriched in disease samples should be annotated and filtered for high-confidence surface proteins. One can correlate with transcriptomics data either experimentally or bioinformatically against broadly aggregated databases such as cBioPortal (cbioportal.org)110 or the Human Protein Atlas (proteinatlas.org). Lastly, to identify disease-associated target candidates the data can be cross-referenced for low expression in normal tissue determined experimentally using Western blot or against humans such as GTEx (gtexportal.org)111 or HubMAP\u2019s Human Reference Atlas (humanatlas.io).112"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 2.9230141639709473,
    "data_pmids_checked": 0,
    "paper_id": "40178992",
    "extraction_date": "2025-12-19T19:51:03.337824",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40178992.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40178903": {
    "cbioportal_paper_citations": [
      "Somatic mutations in A\u03b2 are relatively rare. We queried A\u03b2 somatic mutations across all 226 studies in cBioPortal (35, 36), representing over 100,000 patients. We found that 199 patients contain a somatic change in A\u03b2, with the vast majority being missense mutations (Figure 3A). The most recurrent somatic missense mutation is a change at R233, reported in 7 patients (Figure 3A and Supplemental Table 4). The R233C mutation was also discovered in the germline of a single estrogen receptor\u2013positive (ER+) breast cancer patient in the MI-ONCOSEQ cohort. Since this particular variant was found in both the somatic and germline settings, additional functional studies were performed to determine whether it resulted in LOF of A\u03b2. tHMECs and MCF7 cells overexpressing V5-tagged A\u03b2-R233C were generated (Figure 3, B and C). To determine whether the A\u03b2-R233C variant formed catalytically active complexes, coimmunoprecipitation (Co-IP) of exogenously expressed wild-type or mutant A\u03b2 was performed using an anti-V5 antibody. The phosphatase activity of the V5-bound complex was determined against the fluorescent substrate DiFMUP. The addition of okadaic acid, a potent catalytic site inhibitor of PP2A (37), was used as a negative control. In both cell lines, the R233C-bound complexes had markedly reduced catalytic activity (Figure 3, D and E, and Supplemental Figure 3A). To determine whether the introduction of the R233C cancer-derived point mutant was disrupting catalytic subunit binding, the V5-bound Co-IP was analyzed by Western blotting for the PP2Ac catalytic subunit. In both tHMECs and MCF7 cells, the R233C mutant resulted in over 90% loss of catalytic subunit binding (Figure 3, F and G, and Supplemental Figure 3B). Additionally, there was a substantial decrease in binding of multiple regulatory subunits (Figure 3, H and I, and Supplemental Figure 3C), consistent with the model of PP2A heterotrimer assembly, whereby the A-C dimer must form first in order for B regulatory subunits to bind. These functional studies suggest that in addition to germline truncating mutations, germline missense mutations in A\u03b2, such as R233C, may contribute to the loss of A\u03b2 tumor suppressive ability through loss of catalytic and regulatory subunit binding."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "28783718": [
        "Approximately 5%\u201310% of human cancer results from inherited germline mutations in tumor suppressor genes or oncogenes (28). Germline mutations in PP2A subunits A\u03b1, C\u03b1, B56\u03b2, B56\u03b3, and B56\u03b4 have been identified in patients with intellectual disability (29\u201331), but so far, germline mutations in PP2A family members have not been linked to cancer predisposition. In this study, we report multiple cancer patients with truncating, loss-of-function (LOF) (28) germline mutations in the A\u03b2 gene that were identified by the Michigan Oncology Sequencing Center (MI-ONCOSEQ) (32). Many of these patients have a family history of cancer, further suggesting an inherited component of the disease. Overexpression of the truncated forms of A\u03b2 revealed that the mutant A\u03b2 is likely targeted for proteasomal degradation. An additional missense variant, R233C identified in a breast cancer patient, was also characterized as a LOF change, as it prevents catalytic subunit binding. Analysis of A\u03b2 levels in multiple breast cancer cohorts revealed that heterozygous loss of the A\u03b2 gene and decreased mRNA expression are common events in breast cancer development, suggesting that monoallelic, germline, LOF variants in this gene may result in a predisposition to cancer.",
        "The MI-ONCOSEQ has somatic and germline sequencing data for over 4000 cancer patients (32). We queried this database for patients harboring LOF germline variants in tumor suppressive PP2A subunits. Eight patients in this cohort contain LOF (presumed deleterious) mutations in the gene PPP2R1B (A\u03b2), the \u03b2 isoform of the scaffold subunit (Table 1). Given that 3 of the patients had breast cancer, we also queried for A\u03b2 LOF germline variants in the breast cancer cohort of The Cancer Genome Atlas (TCGA), where we found an additional patient with the V115 frameshift mutation (Table 1). The locations of the identified mutations on the A\u03b2 protein relative to the sites of regulatory and catalytic subunit binding are shown in Figure 1A. The most C-terminal mutation is a splice donor LOF variant at the end of exon 12 (Figure 1A). The C-terminal end of the A\u03b2 protein (HEAT repeats 11\u201315, aa positions 412\u2013601) is the region that binds the PP2Ac catalytic subunit (33). As a result, these truncating mutations are predicted to lose PP2Ac binding. The identified mutations occur at a very low frequency in the general population (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.186288DS1), the most common being the V115 frameshift mutation that occurs in 1 in 550 individuals in the European population, while E6X and E331fs have never been previously reported in any population (34). To determine whether additional truncating mutations in A\u03b2 have been identified in the general population, we looked at all A\u03b2 germline variants annotated as LOF in gnomAD (34) (Supplemental Figure 1). All annotated A\u03b2 LOF variants other than V115fs are rare, with less than 0.01% allele frequency.",
        "MI-ONCOSEQ sample collection and analysis: The study was approved under the University of Michigan Institutional Review Board (IRB) protocols HUM00046018, HUM00067928, and HUM00056496. Patients who were 18 years or older provided written informed consent for molecular profiling of tumor and normal tissue. Processing of tumor/germline tissue and clinical sequencing methods have been previously described (32)."
      ],
      "27161491": [
        "Since cancer predisposition genes such as BRCA1/2 are often lost at the somatic level in tumors (38), even in patients without germline mutations, we looked at mRNA levels of A\u03b2 in normal breast tissue and from lymph node\u2013negative breast cancer patient samples in the tumor bank at Erasmus University Medical Center. A\u03b2 levels were significantly decreased in all breast cancer histological subtypes compared with normal adjacent breast tissue (Figure 4A). Additional clinical characteristics, where available, are represented in Supplemental Table 5. There were no significant associations between A\u03b2 expression levels and ER status, age at primary surgery, or menopause status. A\u03b2 was significantly lower in tumors lacking progesterone receptor (PR) and in tumors that were ERBB2 (HER2) negative. Furthermore, A\u03b2 expression was significantly decreased in poorly differentiated tumors (classified by pathologists as poor grade), and tumors with lower A\u03b2 were associated with reduced disease-free survival (Figure 4B and Supplemental Table 5). To determine whether A\u03b2 mRNA loss in tumors could be explained by A\u03b2 genomic deletion, we looked at publicly available databases for which A\u03b2 copy number and mRNA data were available. A pan-cancer analysis of A\u03b2 copy number in TCGA demonstrated that breast cancer has one of the highest levels of A\u03b2 heterozygous loss, with shallow deletions occurring in approximately 48% of breast cancers (Supplemental Figure 4A). Heterozygous loss of the A\u03b2 gene was significantly associated with decreased A\u03b2 mRNA (Supplemental Figure 4B). This is mirrored in another breast cancer cohort, the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (39), where heterozygous loss was seen in 40% of patients (Supplemental Figure 4C) and similarly, this results in significantly reduced A\u03b2 mRNA expression in this cohort (Supplemental Figure 4D). METABRIC is the largest publicly available cohort for which A\u03b2 copy number, mRNA, and patient survival data exist. Both heterozygous loss of A\u03b2 and lower A\u03b2 mRNA levels were significantly associated with reduced overall survival in this cohort (Supplemental Figure 4, E and F). The loss of A\u03b2 in breast cancer and its association with poor prognosis suggests a crucial tumor suppressive role for this gene in breast cancer, potentially affecting multiple stages in tumor development and recurrence."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.43563389778137207,
    "data_pmids_checked": 2,
    "paper_id": "40178903",
    "extraction_date": "2025-12-19T19:51:03.781453",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40178903.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40176181": {
    "cbioportal_paper_citations": [
      "The cBio Cancer Genomics Portal [18] was used to compare each candidate gene and MYC mRNA expression in ovarian serous cystadenocarcinoma (TCGA, Pan Cancer Atlas Studies) [19, 20]."
    ],
    "cbioportal_platform_mentions": [
      "A total of 4,065,162 reads were counted and 13,595 types of gRNAs were detected during NGS. Applying cBioPortal [18], the Pearson correlation coefficient analysis was used to assess mRNA expression in MYC and the other genes, which had \u2265 1000 reads (totally 86 genes) (Supp. Fig. S2). From these 86 genes, the following 14 genes with positive and statistically significant correlations with MYC were selected as candidates: CYP4V2, ORC4, RPGRIP1L, ADPRH, LGR6, PHB, ANP32D, STOML2, PCED1A, NEURL2, ABI1, TTC9C, FUZ, and HOOK2 (Fig. 1d, Table 2). Table 2Guide RNA sequences and read count of candidate genes in NGSgRNAGene NameSequenceCountsg015083CYP4V2CTGCGAGGTTGCTCTACGTG1492sg042467ORC4GACATTGTAGCGGGAGGTAC1370sg051675RPGRIP1LTTAGCACAGGAGAATTTCCC1353sg004415ASPHTCCAGTTTGTCTCGGTCCTT1290sg032538LGR6TATTTCTCACTTCCTACAAC1282sg044709PHBACTCCCAAAAGGCTATGCAG1242sg002934ANP32DTAATAGATTTTGGGTGTGTT1128sg058828STOML2CTGTTCACGCCGAAGATCCC1106sg043681PCED1ATTTAGAAAAATCCGTGGTTT1093sg039172NEURL2CAGAGGTGAGCTGGCACCGG1085sg000482ABI1TGGGCGCATGCGCTTTGGAC1049sg022687FUZCGCAGTCATCATCTTCAATC1037sg064502TTC9CGTGTCGCTGGTGGTTCACCT1014sg027117HOOK2TCCTCAAGATCCTTTTGAGA1009",
      "Seven genes, CYP4v2, ASPH, ANP32D, PCED1A, ABI1, FUZ, and HOOK2, showed significantly higher luciferase activity than the control (Fig. 2a). Next, we established cells overexpressing these four genes, which showed > twofold higher activity than the control, namely ABI1 (NM_001178116), PCED1A (NM_001271168), HOOK2 (NM_001100176), and CYP4v2 (NM_207352) (Supp. Fig. S3). Using these cells the dual-luciferase reporter assay showed that these genes activated significantly higher luciferase activity (Fig. 2b). Furthermore, luciferase activity was significantly reduced in cells in which these four genes were knocked down (Fig. 2c). Then, quantitative PCR was performed to examine the mRNA expression of MYC in overexpression and knockdown of these four genes in OVSAHO cells; however, no significant correlation with MYC expression was observed (Supp. Fig. S4).Fig. 2Dual-luciferase reporter assay results. All experiments were performed in biological and technical triplicates. a Dual-luciferase reporter assay of candidate genes. Fourteen genes with a positive correlation with MYC on cBioPortal were selected as candidate genes based on the NGS results. b Dual-luciferase reporter assay with overexpression of the four genes. c Dual-luciferase reporter assay with knockdown of the four genes. The mean values of three or more groups were compared using a one-way ANOVA with Dunnett\u2019s multiple comparison test. *p \u2264 0.05, ** p \u2264 0.01, *** p \u2264 0.001, and **** p \u2264 0.0001. Data are represented as the mean \u00b1 standard deviation",
      "Dual-luciferase reporter assay results. All experiments were performed in biological and technical triplicates. a Dual-luciferase reporter assay of candidate genes. Fourteen genes with a positive correlation with MYC on cBioPortal were selected as candidate genes based on the NGS results. b Dual-luciferase reporter assay with overexpression of the four genes. c Dual-luciferase reporter assay with knockdown of the four genes. The mean values of three or more groups were compared using a one-way ANOVA with Dunnett\u2019s multiple comparison test. *p \u2264 0.05, ** p \u2264 0.01, *** p \u2264 0.001, and **** p \u2264 0.0001. Data are represented as the mean \u00b1 standard deviation",
      "Supplementary Material 1. Supplementary Figure S1. Flow cytometry results of Dendra 2-positive rate in HEK293T and ovarian cancer cell lines OVSAHO, OVTOKO, OVISE and OVCAR3. Supplementary Material 2. Supplementary Figure S2. Pearson correlation coefficient analysis in cBioPortal at mRNA expression between MYC and the other identified genes. (a) CYP4V2, (b) ORC4 , (c) RPGRIP1L , (d) ASPH , (e) LGR6 , (f) PHB , (g) ANP32D , (h) STOML2 , (i) PCED1A , (j) NEURL2 , (k) ABI1 , (l) FUZ , (m) TTC9C , and (n) HOOK. Supplementary Material 3. Supplementary Figure S3. Western blotting with overexpression of the four genes. Supplementary Material 4. Supplementary Figure S4. qPCR results of MYC expression in OVSAHO cells. (a) Knockdown (b) Overexpression. Supplementary Material 5. Supplementary Figure S5. qPCR results of MYC expression in knockdown of the four genes. (a) OVTOKO (b) OVISE and (c) OVCAR3. Supplementary Material 6. Supplementary Figure S6. qPCR results of MYC expression in overexpression of the four genes (a) OVTOKO (b) OVISE and (c) OVCAR3.",
      "Supplementary Material 2. Supplementary Figure S2. Pearson correlation coefficient analysis in cBioPortal at mRNA expression between MYC and the other identified genes. (a) CYP4V2, (b) ORC4 , (c) RPGRIP1L , (d) ASPH , (e) LGR6 , (f) PHB , (g) ANP32D , (h) STOML2 , (i) PCED1A , (j) NEURL2 , (k) ABI1 , (l) FUZ , (m) TTC9C , and (n) HOOK."
    ],
    "data_publication_citations": {
      "21720365": [
        "MYC is a widely studied proto-oncogene that plays an essential role in the tumorigenesis of many human cancers [3, 4]. The Cancer Genome Atlas project analyzed molecular abnormalities in 489 high-grade serous ovarian carcinomas. Copy number analysis showed that MYC was frequently amplified in over 20% of tumors, which is the highest frequency among major malignant tumors [5]. Previous studies have suggested that MYC hyperactivation is associated with aggressive cancer outcomes [6], and MYC has been implicated in cisplatin drug resistance in ovarian cancer [7\u20139]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.12957096099853516,
    "data_pmids_checked": 1,
    "paper_id": "40176181",
    "extraction_date": "2025-12-19T19:51:03.911605",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40176181.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40171493": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1999051570892334,
    "data_pmids_checked": 0,
    "paper_id": "40171493",
    "extraction_date": "2025-12-19T19:51:04.111623",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40171493.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40229908": {
    "paper_id": "40229908",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The\nGBM datasets containing the miRNA and mRNA expression profiles as well as clinical information such as the OS and DFS\nwere directly downloaded from the cBioPortal (https:// www",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integra-\ntive analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:07.168626",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40229908.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 36.12537980079651,
      "cbioportal_papers": 0.0003750324249267578,
      "pdf_extraction_pass2": 68.42112183570862,
      "cbioportal_papers_pass2": 0.0005691051483154297,
      "used_full_extraction": true,
      "pdf_extraction": 104.54650163650513,
      "platform_mentions": 0.005407094955444336,
      "data_citations": 1.6927719116210938e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40181033": {
    "paper_id": "40181033",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Expression level, gene mutation, immune\ninfiltration, pathway enrichment, and prognostic value analysis of P2RX4 were performed based on\nmultiple publicly available databases such as TCGA, GTEx, GEO, TIMER2, cBioportal, and Metascape\ndatabases",
      "When utilizing the cBioPortal site (version 6.0.25, https://www.cbioportal.org/)21 for P2RX4 mutation analysis,\nwe investigated the genetic changes of P2RX4 by selecting the \u2018TCGA Pan Cancer Atlas Studies\u2019 and searching\nfor \u2018P2RX4\u2019 in the \u2018Query by Gene\u2019 section",
      "Mutational analysis of P2RX4\nThen, we utilized cBioPortal to explore the P2RX4 mutation frequency based on the TCGA database (10967\nsamples from 32 studies), and observed that DLBC had a considerably high mutation rate, with the P2RX4\nalteration frequency above 4% (Figs",
      "(A) P2RX4 mutation frequency in multiple TCGA pan-cancer studies\naccording to the cBioPortal database",
      "(B) General mutation count of P2RX4 in various TCGA cancer types\naccording to the cBioPortal database",
      "Second,\nwhile bioinformatics tools like TIMER2 and cBioPortal provide robust preliminary insights, in vivo models and\nmechanistic studies are required to confirm P2RX4\u2019s role in autophagy and immune infiltration",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:15.598752",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40181033.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 12.017063856124878,
      "cbioportal_papers": 0.00023484230041503906,
      "pdf_extraction_pass2": 11.047307014465332,
      "cbioportal_papers_pass2": 0.0002410411834716797,
      "used_full_extraction": true,
      "pdf_extraction": 23.06437087059021,
      "platform_mentions": 0.002897024154663086,
      "data_citations": 8.702278137207031e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40166329": {
    "cbioportal_paper_citations": [
      "Genetic alterations of MTAP, mostly in the form of homozygous co-deletion with its neighboring tumor suppressor gene CDKN2A, are common events in a variety of human cancers 75,76. These alterations have been shown to promote tumor progression and aggressiveness, while also suggesting the potential to exploit the resultant MTAP deficiency for treatments 42,45,47,77\u201379. Intriguingly, MTAP alterations occur only in a small subset of PCa 75,76, supporting the speculation that MTAP may be pro-tumorigenic in prostate cancers61. Several previous studies have explored MTAP inhibition for suppressing multiple cancer types, including lung, colon, prostate, and head and neck cancers, by leveraging MTDIA, a potent and specific transition state analogue inhibitor of MTAP 58\u201361. Results from this study suggest that MTAP-mediated purine salvage can serve as an important source of purine supply in prostate and other MTAP-intact cancer cells, particularly under conditions of purine shortage. While the roles of MTAP in methionine salvage and the polyamine pathway in PCa pathogenesis remain to be fully addressed, we speculate that MTAP may be pro-tumorigenic in certain contexts through its roles in purine salvage. This aligns with the idea of targeting the MTAP pathway for treating PCa 61. Additionally, similar observations regarding MTAP\u2019s role as a purine supply source were made in models of PCa and gliomas. This further supports the idea of exploiting purine blockade to treat cancers with homozygous MTAP deletion (i.e., approximately 50% of glioblastomas)45\u201347. Notably, MTAP functions as a purine supply source in cancer types with vastly different frequencies of homozygous MTAP deletion; glioblastoma exhibits the highest frequency, while PCa is among the lowest 75,76. It is possible that compared to PCa, glioblastoma cells more readily adapt to the loss of purine salvage and/or derive greater benefits from the immunosuppressive microenvironment that MTAP loss may create 42,64,80."
    ],
    "cbioportal_platform_mentions": [
      "The Cancer Genome Atlas (TCGA) Prostate Adenocarcinoma (TCGA-PRAD) and SU2C/PCF Dream Team datasets were retrieved from the cBioPortal (http://www.cbioportal.org/) for Cancer Genomics. According to the above datasets, comparative expression and survival analysis were performed with cBioPortal, Gene Expression Profiling Interactive Analysis (GEPIA) and Prostate Cancer Transcriptome Atlas (PCTA) bioinformatic tools."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3074507713317871,
    "data_pmids_checked": 0,
    "paper_id": "40166329",
    "extraction_date": "2025-12-19T19:51:15.906290",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40166329.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40166319": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The survival analysis was performed using the Kaplan-Meier (KM) log-rank test on all genes based on their gene expression levels, either high or low. Our study utilized disease-free survival (DFS) information of 500 PRAD patients in the \u201cProstate Adenocarcinoma (TCGA, Firehorse Legacy)\u201d dataset[14] with corresponding clinicopathologic information available on cBioPortal."
    ],
    "data_publication_citations": {
      "20579941": [
        "DEA serves as the first step in the DiCE, generating a large candidate gene pool that forms the foundation for subsequent phases. In this study, DEA is performed using lmFit and eBayes functions in limma-voom[8] for the microarray dataset (GSE21032)[9] or edgeR package[10] in R for the RNA-seq data of the TCGA prostate adenocarcinoma (PRAD) cohort[11]. To ensure the inclusion of genes with subtle changes, loose cutoffs are applied, allowing small FCs and less statistical significance with higher p-values.",
        "We applied DiCE to the GSE21032[9] dataset, comprising 131 primary and 19 metastatic PCa tumors. DEA by limma identified 7,757 candidate genes with a loose cutoff of p-value < 0.05 (Fig. 3A). A subset of 3,403 genes was identified as the most discriminative in Phase II using the IG filter, followed by reconstruction of the PPI network (Phase III) keeping 3,186 genes with modified node distances using (1 - |c.c.|) based on gene expression profiles in PCa metastatic and primary tumors, respectively. Topological differential analysis in Phase IV further narrowed the list to 347 DiCE-genes in Phase V (Fig. 3A), encompassing 47 genes identified through a meta-analysis of five studies[26] and hub genes (Fig. 3B)."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 1.2641351222991943,
    "data_pmids_checked": 1,
    "paper_id": "40166319",
    "extraction_date": "2025-12-19T19:51:17.244694",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40166319.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40171466": {
    "paper_id": "40171466",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Materials and methods\nRNA-Seq data of CRCs stored as Colorectal Adenocarcinoma (TCGA, PanCancer Atlas) was downloaded from TCGA repository at cBioportal\n[20]",
      "Data availability\nThe datasets generated and/or analysed during the current study are available on the cBioportal repository (cBioportal.org)",
      "Gao J, Aksoy BA, and Dogrusoz U, et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal\nSci Signal [Internet] 6 pl1 Date accessed: 01/10/24 https://doi.org/10.1126/scisignal.2004088\n22"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:19.637845",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40171466.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.454681873321533,
      "cbioportal_papers": 0.00023698806762695312,
      "pdf_extraction_pass2": 7.937635898590088,
      "cbioportal_papers_pass2": 0.0002181529998779297,
      "used_full_extraction": true,
      "pdf_extraction": 15.392317771911621,
      "platform_mentions": 0.07242298126220703,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40163752": {
    "paper_id": "40163752",
    "cbioportal_paper_citations": [
      "doi:10.1158/2159-8290.CD-12-0095\n[PubMed: 22588877]\n16",
      "doi:10.1126/\nscisignal.2004088 [PubMed: 23550210]\n17"
    ],
    "cbioportal_platform_mentions": [
      "Methods: Clinical and tumor ploidy data for 63 Hispanic White, 561 non-Hispanic White, and\n86 non-Hispanic Black patients were obtained from cBioPortal for Cancer Genomics (TARGET\n[Therapeutically Applicable Research to Generate Effective Treatments], 2018)",
      "Author\nManuscript\nAuthor\nManuscript\nAuthor\nManuscript\nAuthor\nManuscript\n\nPorter et al. Page 2\nDatos cl\u00ednicos sobre la ploid\u00eda tumoral fueron obtenidos de cBioPortal for Cancer Genomics\n(TARGET [por su abreviatura en ingl\u00e9s], 2018)",
      "Methods\nClinical and tumor ploidy data, which included data on both race and ethnicity,\nwere obtained for 63 Hispanic White patients, 561 non-Hispanic White patients, and\n86 non-Hispanic Black patients from the cBioPortal for Cancer Genomics (Pediatric\nNeuroblastoma, Therapeutically Applicable Research to Generate Effective Treatments\n[TARGET], 2018) on November 14, 2024 (14\u201316)",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:22.998793",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40163752.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.695480108261108,
      "cbioportal_papers": 0.0016331672668457031,
      "used_full_extraction": false,
      "pdf_extraction": 5.695480108261108,
      "platform_mentions": 0.0010941028594970703,
      "data_citations": 5.0067901611328125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40185723": {
    "paper_id": "40185723",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:28.915487",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40185723.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 44.473787784576416,
      "cbioportal_papers": 0.00044918060302734375,
      "pdf_extraction_pass2": 44.33917808532715,
      "cbioportal_papers_pass2": 0.0004830360412597656,
      "used_full_extraction": true,
      "pdf_extraction": 88.81296586990356,
      "platform_mentions": 0.003290891647338867,
      "data_citations": 0.012450218200683594,
      "num_data_pmids_checked": 3
    }
  },
  "40154000": {
    "paper_id": "40154000",
    "cbioportal_paper_citations": [
      "[PubMed: 23550210]\n9"
    ],
    "cbioportal_platform_mentions": [
      "Integrative analysis of complex cancer genomics and\nclinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {
      "21798893": [
        "[PubMed: 21798893]\n8"
      ],
      "25631445": [
        "[PubMed: 25631445]\n7"
      ]
    },
    "extraction_date": "2025-12-19T19:51:29.093516",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40154000.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 2,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.987060308456421,
      "cbioportal_papers": 0.0012738704681396484,
      "used_full_extraction": false,
      "pdf_extraction": 5.987060308456421,
      "platform_mentions": 0.0013930797576904297,
      "data_citations": 0.09873509407043457,
      "num_data_pmids_checked": 2
    }
  },
  "40153767": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4670112133026123,
    "data_pmids_checked": 0,
    "paper_id": "40153767",
    "extraction_date": "2025-12-19T19:51:29.390494",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40153767.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40152300": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We performed analysis with the cBioPortal database (https://www.cbioportal.org) to identify CASP10 genetic mutations in pan-cancer. 31 Tumor Mutational Burden (TMB) scores from the TCGA database were subjected to Spearman\u2019s correlation analysis to assess their association with CASP10. We also used the GSCALite database to analyze the SNV and CNV profiles of CASP10 in pan-cancer. 32 Additionally, the UALCAN database (http://ualcan.path.uab.edu/analysis.html) was employed to examine CASP10 methylation profiles across various cancers and their adjacent normal tissues. 30",
      "The cBioportal database indicated that CASP10 gene alterations were present in 2% (56/2583) of pan-cancer patients (Figure 6(a)). The predominant alteration patterns included mutation, amplification, deep deletion, and multiple alterations. Bone cancer exhibited the highest alteration frequency, followed by bladder and ovarian cancers (Figure 6(b)). The CASP10 gene featured 12 mutation sites within the 0\u2013521 amino acid region (Figure 6(c)). Additionally, a positive correlation between CASP10 expression and TMB was observed in 6 cancer types (Figure 6(d))."
    ],
    "data_publication_citations": {
      "30643254": [
        "Recent research highlights the importance of TMB as a predictor of immune checkpoint inhibitor (ICI) efficacy, with TMB-High (TMB-H) tumors demonstrating greater responsiveness to ICI therapy. 49 These tumors typically present multiple neoantigens that, upon immune system recognition, can trigger a robust anti-tumor immune response.50,51 Our study revealed a positive correlation between CASP10 expression and TMB in specific cancer types, leading us to hypothesize that patients with elevated CASP10 levels may experience improved survival outcomes following immunotherapy."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6504170894622803,
    "data_pmids_checked": 1,
    "paper_id": "40152300",
    "extraction_date": "2025-12-19T19:51:30.050698",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40152300.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40170854": {
    "paper_id": "40170854",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "All radiomic\nThediscoverycohortissourcedfromtheI-SPY2trial(43,44)(The features were categorized into seven classes (1): 306 First Order\nCancer Imaging Archive, https://www.cancerimagingarchive.net/ Features(2);14ShapeFeatures(3);408GrayLevelCo-occurrence\ncollection/ispy2/), while the validation cohorts originate from Matrix (GLCM) Features (4); 272 Gray Level Size Zone Matrix\nTCGA-BRCA (45) (cBioPortal (46, 47), https:// (GLSZM) Features (5); 272 Gray Level Run Length Matrix\nwww.cbioportal.org/),GSE161529(48)(TISCH2(49),tisch.comp- (GLRLM) Features (6); 85 Neighbouring Gray Tone Difference\ngenomics.org/gallery/), and Breast Cancer (METABRIC (50, 51), Matrix(NGTDM)Features(7);238GrayLevelDependenceMatrix\nwww.cbioportal.org)",
      "and microbiome information were standardized using data from\ncbioportal",
      "Through the cbioportal platform, we\nLCK were identified as major drug targets",
      "This\nThrough comparison on cbioportal, we found that TP53 resultindicatesthatinflammation-relatedsignalingpathwaysinthe\nmutations weremainly enriched in theCS2 subtype, GATA3 and CS2subtype are inhibited bymethylation atthe DNA level.Lowly\nMAP3K1weremainlyenrichedintheCS1subtype,whilePIK3CA methylated genes in the CS2 subtype were mainly enriched in\nand RICTOR were mainly enriched in the CS3 subtype signaling pathways such as PI3K-Akt signaling pathway and\n(Supplementary Figure S7A).We compared the Fraction Genome MAPK signaling pathway"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:37.341269",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40170854.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 15.506685972213745,
      "cbioportal_papers": 0.000576019287109375,
      "pdf_extraction_pass2": 14.64174509048462,
      "cbioportal_papers_pass2": 0.0008068084716796875,
      "used_full_extraction": true,
      "pdf_extraction": 30.148431062698364,
      "platform_mentions": 0.022082090377807617,
      "data_citations": 0.0005657672882080078,
      "num_data_pmids_checked": 2
    }
  },
  "40155682": {
    "paper_id": "40155682",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TMB and MSI data were sourced from the cBioPortal database69 ( ht t p s : / / w w w",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:44.665432",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40155682.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 13.979200839996338,
      "cbioportal_papers": 0.0002918243408203125,
      "pdf_extraction_pass2": 11.025975942611694,
      "cbioportal_papers_pass2": 0.0003001689910888672,
      "used_full_extraction": true,
      "pdf_extraction": 25.005176782608032,
      "platform_mentions": 0.0027620792388916016,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40153088": {
    "paper_id": "40153088",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We utilized UALCAN, Cbioportal, and STRING websites to analyze the expression and gene\nmutations of the PRDXs family in pan-cancer, as well as the correlation of PRDXs family members",
      "Vol:.(1234567890)\n\nDiscover Oncology (2025) 16:415 | https://doi.org/10.1007/s12672-025-01872-1\nResearch\n2.2 UALCAN and Cbioportal dataset analysis\nUALCAN provides easy access to publicly available cancer transcriptome data",
      "The public cBioPortal site (www.c biopo rtal.o rg) is hosted by\nthe Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center",
      "The cBioportal database has been rec-\nognized as a way to verify gene mutations [30\u201332]",
      "The online cBioPortal for\nCancer Genomics was used to provide mutations of PRDXs (including mutation, structural variant, amplification, deep\ndeletion and multiple alterations) and its expression in different studies [35]",
      "The Cbioportal Dataset showed PRDX2 and PRDX6 have higher\nalteration frequency than others among of PRDXs family in Pan-Cancer",
      "This study showed the expression and mutation of PRDXs family members in pan cancer using the UALCAN Dataset\nand Cbioportal Dataset",
      "This study utilized the Cbioportal Dataset to display the\nmutation status of PRDXs in pan cancer, but due to database limitations, OSCC was not included",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles\nusing the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:44.868856",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40153088.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.865415096282959,
      "cbioportal_papers": 0.00024175643920898438,
      "pdf_extraction_pass2": 6.8948681354522705,
      "cbioportal_papers_pass2": 0.00025010108947753906,
      "used_full_extraction": true,
      "pdf_extraction": 15.76028323173523,
      "platform_mentions": 0.002241849899291992,
      "data_citations": 9.012222290039062e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40149458": {
    "paper_id": "40149458",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Methods: Computationaltools,including\nPredictSNP1.0,I-Mutant2.0,MUpro,HOPE,MutPred2,Cscape,Cscape-Somatic,GEPIA2,\ncBioPortal,andSTRING,wereusedtoanalyze695nsSNPsinthePD1protein",
      "IdentificationofCancerandAssociationwithnsSNPs\nThecBioPortaldatabase(https://www.cbioportal.org/,accessedon5November2024)[60,61]\nisavailabletothepublicandprovidesfacilitiesforretrieving,viewing,andprocessingbig\ndataincancergenomics"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:51:56.047479",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40149458.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.081547737121582,
      "cbioportal_papers": 0.0003483295440673828,
      "pdf_extraction_pass2": 15.874635934829712,
      "cbioportal_papers_pass2": 0.0005509853363037109,
      "used_full_extraction": true,
      "pdf_extraction": 25.956183671951294,
      "platform_mentions": 0.014342069625854492,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40146476": {
    "paper_id": "40146476",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The correlation between immune related genes and CNV-driven genes in immunogenetic studies and TCGA-LIHC (The\nCancer Genome Atlas Liver Hepatocellular Carcinoma) data using The cBioPortal website [35, 36]",
      "3 Results\n3.1 Identification of immune related genes\u2014CNV\u2011driven genes VPS72\nWe investigated the relationship between immune-related genes (IRGs) and copy number variation (CNV)-driven genes\nin TCGA-LIHC data using the cBioPortal website",
      "E\u2013F low VPS72 and CD8A coexpression subtype had a better DFS than the high\nVPS72 and low CD8A expression in our data and in the TCGA-LIHC cohort\nVol:.(1234567890)\n\nDiscover Oncology (2025) 16:410 | https://doi.org/10.1007/s12672-025-02017-0\nResearch\nTable 2 Clinical characteristics of the patients with VPS72/CD8A subtypes in our IHC cohort\nCharacteristics High-CD8A Double-low sub- High-VPS72 sub- Double-high sub- Total (N = 139) P value\nsubgroup(N = 36) group (N = 34) group (N = 43) group (N = 26)\nGender 0.38\nFemale 7(5.04%) 3(2.16%) 4(2.88%) 5(3.60%) 19(13.67%)\nMan 29(20.86%) 31(22.30%) 39(28.06%) 21(15.11%) 120(86.33%)\nAge 0.59\n< 55 25(17.99%) 20(14.39%) 30(21.58%) 15(10.79%) 90(64.75%)\n> = 55 11(7.91%) 14(10.07%) 13(9.35%) 11(7.91%) 49(35.25%)\nVirus 0.11\nNo virus 0(0.0e + 0%) 2(1.47%) 1(0.74%) 0(0.0e + 0%) 3(2.21%)\nHepatitis B 34(25.00%) 27(19.85%) 40(29.41%) 26(19.12%) 127(93.38%)\nHepatitis C 1(0.74%) 4(2.94%) 1(0.74%) 0(0.0e + 0%) 6(4.41%)\nDifferentiated 0.08\nLow 1(0.72%) 1(0.72%) 1(0.72%) 0(0.0e + 0%) 3(2.17%)\nLow- Moderately 3(2.17%) 2(1.45%) 2(1.45%) 8(5.80%) 15(10.87%)\nModerately 26(18.84%) 28(20.29%) 34(24.64%) 13(9.42%) 101(73.19%)\nHigh- Moderately 4(2.90%) 2(1.45%) 4(2.90%) 5(3.62%) 15(10.87%)\nHigh 2(1.45%) 1(0.72%) 1(0.72%) 0(0.0e + 0%) 4(2.90%)\nTumor size 0.02\n\u2264 3 13(9.42%) 3(2.17%) 11(7.97%) 3(2.17%) 30(21.74%)\n> 3 23(16.67%) 31(22.46%) 32(23.19%) 22(15.94%) 108(78.26%)\nSingle tumor 0.58\nNo 14(10.07%) 8(5.76%) 13(9.35%) 8(5.76%) 43(30.94%)\nYes 22(15.83%) 26(18.71%) 30(21.58%) 18(12.95%) 96(69.06%)\nki-67 0.52\n< 10% 7(6.60%) 2(1.89%) 5(4.72%) 4(3.77%) 18(16.98%)\n10%\u221230% 15(14.15%) 14(13.21%) 11(10.38%) 12(11.32%) 52(49.06%)\n> 30% 7(6.60%) 12(11.32%) 11(10.38%) 6(5.66%) 36(33.96%)\nHBsAg 0.11\nno 0(0.0e + 0%) 7(11.11%) 1(1.59%) 0(0.0e + 0%) 8(12.70%)\n+ 10(15.87%) 10(15.87%) 6(9.52%) 4(6.35%) 30(47.62%)\n+ + 8(12.70%) 7(11.11%) 6(9.52%) 4(6.35%) 25(39.68%)\nAFP 0.65\nNo 6(12.77%) 8(17.02%) 12(25.53%) 7(14.89%) 33(70.21%)\nYES 2(4.26%) 4(8.51%) 3(6.38%) 5(10.64%) 14(29.79%)\nVascular invasion 0.55\nNO 24(17.27%) 24(17.27%) 26(18.71%) 14(10.07%) 88(63.31%)\nYES 12(8.63%) 10(7.19%) 17(12.23%) 12(8.63%) 51(36.69%)\nExtrahepatic metastasis 0.18\nNO 35(25.18%) 33(23.74%) 37(26.62%) 24(17.27%) 129(92.81%)\nYES 1(0.72%) 1(0.72%) 6(4.32%) 2(1.44%) 10(7.19%)\nTACE 0.09\nNO 35(25.18%) 32(23.02%) 37(26.62%) 26(18.71%) 130(93.53%)\nYES 1(0.72%) 2(1.44%) 6(4.32%) 0(0.0e + 0%) 9(6.47%)\nBCLC age 0.28\nA 18(13.43%) 14(10.45%) 14(10.45%) 6(4.48%) 52(38.81%)\nB 6(4.48%) 10(7.46%) 9(6.72%) 9(6.72%) 34(25.37%)\nC 11(8.21%) 9(6.72%) 18(13.43%) 10(7.46%) 48(35.82%)\nAFP\n< 400 26(19.70%) 20(15.15%) 24(18.18%) 14(10.61%) 84(63.64%) 0.59\n> = 400 10(7.58%) 13(9.85%) 14(10.61%) 11(8.33%) 48(36.36%)\nVol.:(0123456789)\n\nResearch\nDiscover Oncology (2025) 16:410 | https://doi.org/10.1007/s12672-025-02017-0\n3.8 Potential of Lo\u2011immune as an indicator of immunotherapy response in patients with HCC\nTo further analyze the differences in PD-1 and other immune checkpoints gene (SIGLEC15, TIGIT, CD274, HAVCR2,\nCTLA4, LAG3, and PDCD1LG2) between the Lo-Immune and Hi-Immune groups, we utilized CBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:01.614971",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40146476.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.93284296989441,
      "cbioportal_papers": 0.00026702880859375,
      "pdf_extraction_pass2": 7.797954082489014,
      "cbioportal_papers_pass2": 0.0002739429473876953,
      "used_full_extraction": true,
      "pdf_extraction": 16.730797052383423,
      "platform_mentions": 0.0023839473724365234,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40149008": {
    "paper_id": "40149008",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The loss of OBSCN expression can\ninduce cytoskeletal remodeling or promote epithelial- Genetic alteration analysis\nmesenchymal transition (EMT), and promote the growth, cBioPortal (https://www.cbioportal.org/) database was\nmigration, and metastasis of pancreatic or breast cancer utilized to evaluate the alteration frequency and mutation\nsite of OBSCN in pan-cancers [12]",
      "Genetic changes in OBSCN in pan-cancers were revealed\nthrough comprehensive analysis\nTranswell assay According to the cBioPortal website, OBSCN is mutated\nFirst, Transwell cell suspensions were prepared in serum- in 10% of all cancers (Supplementary Fig",
      "By using the cBioPortal website to ana-\ncrystal violet after incubated in 37 \u25e6C incubator for 48 h",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen\n1Department of Urology, Shuguang Hospital, Shanghai University of A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics\nTraditional Chinese Medicine, Shanghai, China and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:02.495968",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40149008.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.932675123214722,
      "cbioportal_papers": 0.0002498626708984375,
      "pdf_extraction_pass2": 8.870934009552002,
      "cbioportal_papers_pass2": 0.00025200843811035156,
      "used_full_extraction": true,
      "pdf_extraction": 17.803609132766724,
      "platform_mentions": 0.003056764602661133,
      "data_citations": 9.322166442871094e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40188208": {
    "paper_id": "40188208",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Minn,A.J.etal.Genesthatmediatebreastcancermetastasisto\nused in this study are available in the cBioPortal database (https:// lung.Nature436,518\u2013524(2005)",
      "www.cbioportal.org) under accession code MSK MetTropsim",
      "TCGA-COAD and TCGA-READ and cBioPortal under accession code Pan-canceranalysisofwholegenomes.Nature578,82\u201393(2020)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:06.192680",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40188208.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 68.74866986274719,
      "cbioportal_papers": 0.0005061626434326172,
      "pdf_extraction_pass2": 67.37143898010254,
      "cbioportal_papers_pass2": 0.0005178451538085938,
      "used_full_extraction": true,
      "pdf_extraction": 136.12010884284973,
      "platform_mentions": 0.005169868469238281,
      "data_citations": 0.0016829967498779297,
      "num_data_pmids_checked": 7
    }
  },
  "40141455": {
    "paper_id": "40141455",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(C)ComparativeanalysisofNCKAP1proteinexpressionbetweentumorandadjacentnormaltissues\nacross10cancertypesviadatafromtheUALCANdatabase.(D)SubcellularlocalizationofNCKAP1\nintumorcells,asdeterminedviatheHPAdatabase.Redfluorescenceindicatesmicrotubules,whereas\ngreenfluorescenceindicatesNCKAP1distribution.(E,F)GeneticalterationassessmentofNCKAP1\nvia cBioPortal",
      "To conduct an in-depth analysis of multidi-\nmensionalcancergenomicdata,weanalyzedTCGAPan-CancerAtlasStudies\u2014Cancer\nTypeswithincBioPortal(www.cbioportal.org)toretrievecomprehensiveinformationon\nthegeneticalterationsofNCKAP1[26,27],includingcomprehensiveinformationonthe\nfrequencyofalterations,typesofmutations,andcopynumbervariations(CNAs)across\nall cancer types withinthe TCGA dataset"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:12.478923",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40141455.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.738139152526855,
      "cbioportal_papers": 0.0002598762512207031,
      "pdf_extraction_pass2": 6.682798147201538,
      "cbioportal_papers_pass2": 0.0002770423889160156,
      "used_full_extraction": true,
      "pdf_extraction": 16.420937299728394,
      "platform_mentions": 0.002588987350463867,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40189705": {
    "paper_id": "40189705",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "downloaded from cBioPortal for analysis of CDX2 expression and APC/\nCTNNB1 mutational status [24, 25]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:12.665942",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40189705.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 75.11835169792175,
      "cbioportal_papers": 0.0003581047058105469,
      "pdf_extraction_pass2": 72.11219525337219,
      "cbioportal_papers_pass2": 0.0003540515899658203,
      "used_full_extraction": true,
      "pdf_extraction": 147.23054695129395,
      "platform_mentions": 0.0029058456420898438,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40136700": {
    "paper_id": "40136700",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The expression level in transcripts per million (TPM) was extracted from a\nsubset of 157 CLL patients using the cBioPortal [17,18]",
      "The Chronic Lymphocytic Leukemia (Broad,\nNature 2015) RNAseq dataset was analysed using the cBioPortal in regard to the\nexpression of class II HLA genes and the conventional LAG-3 ligands: FGL1, LGALS3"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:21.925457",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40136700.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 11.041329860687256,
      "cbioportal_papers": 0.00021886825561523438,
      "pdf_extraction_pass2": 9.21098017692566,
      "cbioportal_papers_pass2": 0.00021195411682128906,
      "used_full_extraction": true,
      "pdf_extraction": 20.252310037612915,
      "platform_mentions": 0.0017201900482177734,
      "data_citations": 7.581710815429688e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40128173": {
    "cbioportal_paper_citations": [
      "The MSK MetTropism cohort was accessed on the 9th of August, 2024 through cBioPortal; a web-based bioinformatics tool designed to retrieve and visualize large-scale genomic and transcriptomic data. 22 The MSK MetTropism cohort was assembled using clinical and genomic data from over 25 000 patients with metastatic diseases. 23 The LUAD MSK MetTropism cohort (n = 4064) was downloaded. Cohort demographics (age, gender, and ethnicity), metastatic patterns (adrenal gland, biliary tract, urinary tract, bone, bowel, breast, central nervous system, peripheral nervous system, male genital, female genital, distant lymph nodes, head and neck, intra-abdominal, kidney, liver, lung, mediastinal, ovary, pleura, and skin), microsatellite instability type, and somatic mutation profiles were included in the analysis. The OS data defined as the length of time from either the date of diagnosis or the start of treatment until the loss of follow-up or death of any cause were obtained as well. Manual inspection and curation of the data were performed to ensure data quality before statistical analysis. The LUAD MSK MetTropism cohort was subdivided based on the presence (n = 1591) or absence (n = 2473) of bone metastasis. The no lung metastases group contained patients with non- metastatic LUAD and metastatic LUAD with various metastases patterns."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "25079552": [
        "KEAP1 plays a crucial role in cellular homeostasis and its dysfunction is associated with aggressive tumor growth and resistance to chemotherapy, radiotherapy, and targeted agents.52,53 As the third most commonly mutated gene in LUAD, 54 exploring the predictive and prognostic value of KEAP1 and its associated pathways represents an ongoing field of study. 55 We have observed a poor prognostic signature of KEAP1 mutation as it is associated with bone metastases (OR = 1.385, 95% CI: 1.075-1.785, P = .012) and poor prognosis in bone metastases sub-cohort of LUAD (HR = 1.594, 95% CI: 1.332-1.908, P < .001). Exploring the TCGA database has revealed that KEAP1-mutated LUAD exhibits poor prognosis in comparison to non-mutated counterparts.56,57 Simon et al examined the prognostic impact of KEAP1 mutations in a cohort of 2276 LUAD patients, demonstrating a negative prognostic outcome; however, they did not identify these mutations as predictive biomarkers for immune checkpoint inhibitors. 58 Saleh et al. comprehensively analyzed 6297 patients with localized- and advanced-stage NSCLC reporting that KEAP1 mutations are associated with a worse prognosis but they did not recommend its utilization in molecular stratification to guide clinical decisions. 59 Multiple reports have consistently reported similar poor clinical impact of KEAP1 mutations in LUAD.60,61 Regarding the matter of bone metastases of LUAD, KEAP1 was among the most common oncogenic mutations found. 62 To the best of our knowledge, our study was the first report to demonstrate its predictive and prognostic potential of a bone metastases sub cohort of LUAD."
      ],
      "35120664": [
        "The MSK MetTropism cohort was accessed on the 9th of August, 2024 through cBioPortal; a web-based bioinformatics tool designed to retrieve and visualize large-scale genomic and transcriptomic data. 22 The MSK MetTropism cohort was assembled using clinical and genomic data from over 25 000 patients with metastatic diseases. 23 The LUAD MSK MetTropism cohort (n = 4064) was downloaded. Cohort demographics (age, gender, and ethnicity), metastatic patterns (adrenal gland, biliary tract, urinary tract, bone, bowel, breast, central nervous system, peripheral nervous system, male genital, female genital, distant lymph nodes, head and neck, intra-abdominal, kidney, liver, lung, mediastinal, ovary, pleura, and skin), microsatellite instability type, and somatic mutation profiles were included in the analysis. The OS data defined as the length of time from either the date of diagnosis or the start of treatment until the loss of follow-up or death of any cause were obtained as well. Manual inspection and curation of the data were performed to ensure data quality before statistical analysis. The LUAD MSK MetTropism cohort was subdivided based on the presence (n = 1591) or absence (n = 2473) of bone metastasis. The no lung metastases group contained patients with non- metastatic LUAD and metastatic LUAD with various metastases patterns."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 1.14933180809021,
    "data_pmids_checked": 2,
    "paper_id": "40128173",
    "extraction_date": "2025-12-19T19:52:23.077160",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40128173.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40124611": {
    "cbioportal_paper_citations": [
      "Genomic alterations, such as mutations, structural variations, amplifications, deep deletions, and multiple alterations, were obtained from the cBioPortal database (Gao et al., 2013; https://www.cbioportal.org/). Furthermore, the cBioPortal web tool was employed to visualize the rate of genomic alterations."
    ],
    "cbioportal_platform_mentions": [
      "To investigate the role of nuclear cap binding proteins (NCBPs) in cancers, we analyzed the genomic alteration profiles of NCBPs including NCBP1, NCBP2, NCBP3, NCBP2AS2 and NCBP2-AS1 and NCBP2L in pan-cancer (TCGA, Firehose Legacy) using cBioPortal database (https://www.cbioportal.org/). As shown in Fig. 1A, NCBP2 was found to be the most frequently altered of the six genes, with nearly 7% of alterations occurring in pan-cancer, while the remaining genes showed relatively low mutation rates. In addition, Kaplan\u2013Meier survival analysis revealed that patients with NCBP2 alteration exhibited a shorter OS and disease-free survival (DFS) compared with those without NCBP2 alterations (Figs. 1B & 1C). Then, we conducted a cancer type-based genetic alteration analysis of NCBP2 in the TCGA pan-cancer tumor samples. As shown in Fig. 1D, the general alteration frequency of NCBP2 was relatively high in the top five cancers, which had an alteration frequency of >20% with \u201cAmplification\u201d as the primary type, while the most frequent NCBP2 alteration was identified among LUSC patients (>40%). As a consequence, we further analyzed the relationship between the expression of NCBP2 and copy numbers in the top five cancers. According to our findings, compared with diploid samples, samples with NCBP2 amplification/gain/deletion exhibited highest/higher/lower mRNA expression level of NCBP2, respectively (Figs. S1A\u2013S1E), indicating that copy numbers of NCBP2 appeared to be associated with its mRNA expression."
    ],
    "data_publication_citations": {
      "31068700": [
        "The expression of NCBP2 in various cell lines was obtained from the Cancer Cell Line Encyclopedia (Ghandi et al., 2019) (CCLE; http://sites.broadinstitute.org/ccle/) database. The AUC value, which indicates cellular sensitivity to drugs of paired cell lines, was acquired from the Genomics of Drug Sensitivity in Cancer (GDSC) (Yang et al., 2013) database (https://www.cancerrxgene.org/celllines). Subsequently, Spearman correlation was used to estimate the relationship between drug sensitivity and NCBP2. A positive correlation suggests that cell lines exhibiting high NCBP2 expression were resistant to certain drugs, while a negative correlation suggests that cell lines with high NCBP2 expression were sensitive to specific drugs."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2842869758605957,
    "data_pmids_checked": 1,
    "paper_id": "40124611",
    "extraction_date": "2025-12-19T19:52:23.374219",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40124611.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40115748": {
    "cbioportal_paper_citations": [
      "Median RNA-seq RNA expression values and clinicopathological data from metastatic prostate adenocarcinoma tumors (SU2C/PCF Dream Team, PNAS 2019) were analyzed using cBioPortal [16, 17]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31061129": [
        "In the end, to determine whether soft or hard ECM stiffness gene signatures correlate with patient survival, we generated hard ECM stiffness gene set (\u201cplastic signature\u201d) from top 50 DEGs overexpressed in plastic samples compared to 0.5 kPa hydrogel samples. For 0.5 kPa hydrogel gene set (\u201c0.5 kPa signature\u201d), we selected top 50 most significantly overexpressed DEGs in 0.5 kPa hydrogel samples compared to plastic samples. First, we determined the expression levels of plastic signature genes in metastatic prostate adenocarcinoma patient dataset (SU2C [29, 30]). Data were organized based on tumor site."
      ],
      "28825054": [
        "In the end, to determine whether soft or hard ECM stiffness gene signatures correlate with patient survival, we generated hard ECM stiffness gene set (\u201cplastic signature\u201d) from top 50 DEGs overexpressed in plastic samples compared to 0.5 kPa hydrogel samples. For 0.5 kPa hydrogel gene set (\u201c0.5 kPa signature\u201d), we selected top 50 most significantly overexpressed DEGs in 0.5 kPa hydrogel samples compared to plastic samples. First, we determined the expression levels of plastic signature genes in metastatic prostate adenocarcinoma patient dataset (SU2C [29, 30]). Data were organized based on tumor site."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5698161125183105,
    "data_pmids_checked": 2,
    "paper_id": "40115748",
    "extraction_date": "2025-12-19T19:52:23.950420",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40115748.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40136626": {
    "paper_id": "40136626",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "StudySamples\nThis study was conducted using data extracted from the cBioPortal platform [16]\nhttps://www.cbioportal.org, accessed on 4 March 2025)",
      "The cBioPortal platform is a\npublicrepositorythatallowsforthevisualization,analysis,andinterpretationofcancer\ngenomicdataobtainedfromlarge-scalegeneticandgenomicstudies,includingdatafrom\nThe Cancer Genome Atlas (TCGA) and PanCancer Atlas",
      "Acknowledgments: Wethanktheindividualswhodonatedtheirsamples,thescientistswhode-\nveloped and maintain cBioPortal, and the teams responsible for sample collection and curation,\nwithdatafromBreastInvasiveCarcinoma(TCGA,PanCancerAtlas)availablethroughcBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:24.286766",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40136626.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.32154893875122,
      "cbioportal_papers": 0.0003609657287597656,
      "pdf_extraction_pass2": 8.766967058181763,
      "cbioportal_papers_pass2": 0.00041985511779785156,
      "used_full_extraction": true,
      "pdf_extraction": 18.088515996932983,
      "platform_mentions": 0.004332065582275391,
      "data_citations": 0.00028395652770996094,
      "num_data_pmids_checked": 2
    }
  },
  "40111122": {
    "cbioportal_paper_citations": [
      "The Fanconi anemia (FA) pathway is critical for the preservation of genomic integrity and prevention of tumorigenesis. Biallelic germline mutation of any one of the 22 genes known to comprise the pathway causes FA, a complex heritable disorder marked by congenital malformations and high incidence of cancer during childhood (1). FA is associated with a high risk of bone marrow (BM) failure which typically evolves into acute myeloid leukemia (AML). Strikingly, the risk of leukemia is increased 600-fold for individuals with FA (2). However, germline monoallelic mutations within FA genes are more frequent, a subset of which predispose to various types of malignancies (3\u20137). Most recognized among these carrier predispositions is the breast cancer susceptibility associated with pathogenic variants of BRCA1 and BRCA2 (8\u201310). Further affecting the general population, somatic disruptions of the FA pathway are found in 30% of all sporadic cancers and more than 14% of sporadic AMLs (1, 11). Thus, FA gene function is critical for the prevention of heritable and sporadic cancers, especially AML.",
      "Drug sensitivity (52) and mutation data were obtained from the Cancer Cell Line Encyclopedia (53) available through cBioPortal (RRID: SCR_014555; refs. 11, 54). IC50 (\u03bcmol/L) values of Fanconi pathway WT and mutant cancer cell lines (Supplementary Dataset S3) for PLK1 inhibitors BI-2536 and GW843682X (52) were compared via an unpaired Student t test after removing outliers."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31068700": [
        "Drug sensitivity (52) and mutation data were obtained from the Cancer Cell Line Encyclopedia (53) available through cBioPortal (RRID: SCR_014555; refs. 11, 54). IC50 (\u03bcmol/L) values of Fanconi pathway WT and mutant cancer cell lines (Supplementary Dataset S3) for PLK1 inhibitors BI-2536 and GW843682X (52) were compared via an unpaired Student t test after removing outliers.",
        "PLK1 is an essential kinase for mitotic progression (66), and its overexpression is a common feature in several human malignancies (31, 67). Importantly, the therapeutic efficacy of small-molecular inhibitors targeting PLK1 is an ongoing area of clinical evaluation for the treatment of a range of cancers (35, 36, 38, 40). Interestingly, our retrospective analysis of the DepMap database (68, 69) revealed significantly higher expression of PLK1 in cancers with FA pathway disruptions compared with cancers with intact FA pathway, suggesting that FA pathway disruption may lead to PLK1 \u201caddiction\u201d (Supplementary Fig. S1A and S1B). To broadly assess whether FA pathway mutations sensitize to PLK1 inhibitors, we utilized cancer cell line drug sensitivity data publicly available from the Cancer Cell Line Encyclopedia (RRID: SCR_013836; ref. 53). We observed significantly increased sensitivity to the PLK1 inhibitors GW843682X and BI-2536 in cancer cell lines with FA pathway mutations compared with those with WT FA genes (Supplementary Fig. S1C and S1D; Supplementary Datasets S2\u2013S5). The most striking difference was observed in FANCA-mutated cancer cell lines (Supplementary Fig. S1E and S1F)."
      ],
      "22460905": [
        "PLK1 is an essential kinase for mitotic progression (66), and its overexpression is a common feature in several human malignancies (31, 67). Importantly, the therapeutic efficacy of small-molecular inhibitors targeting PLK1 is an ongoing area of clinical evaluation for the treatment of a range of cancers (35, 36, 38, 40). Interestingly, our retrospective analysis of the DepMap database (68, 69) revealed significantly higher expression of PLK1 in cancers with FA pathway disruptions compared with cancers with intact FA pathway, suggesting that FA pathway disruption may lead to PLK1 \u201caddiction\u201d (Supplementary Fig. S1A and S1B). To broadly assess whether FA pathway mutations sensitize to PLK1 inhibitors, we utilized cancer cell line drug sensitivity data publicly available from the Cancer Cell Line Encyclopedia (RRID: SCR_013836; ref. 53). We observed significantly increased sensitivity to the PLK1 inhibitors GW843682X and BI-2536 in cancer cell lines with FA pathway mutations compared with those with WT FA genes (Supplementary Fig. S1C and S1D; Supplementary Datasets S2\u2013S5). The most striking difference was observed in FANCA-mutated cancer cell lines (Supplementary Fig. S1E and S1F)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 1.039264440536499,
    "data_pmids_checked": 2,
    "paper_id": "40111122",
    "extraction_date": "2025-12-19T19:52:25.326134",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40111122.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40134439": {
    "paper_id": "40134439",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "downloaded from cBioPortal (50, 51) to assess the expressions of\nNRP1 and NRP2 mRNA across 19 different cancer types"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:26.128305",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40134439.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.483639001846313,
      "cbioportal_papers": 0.00035500526428222656,
      "pdf_extraction_pass2": 5.161819934844971,
      "cbioportal_papers_pass2": 0.00035500526428222656,
      "used_full_extraction": true,
      "pdf_extraction": 13.645458936691284,
      "platform_mentions": 0.002699136734008789,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40136647": {
    "paper_id": "40136647",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "DatabaseAnalysis\nOncoPrint plot of genes coding for NuRD complex was generated using available\nonline database analysis platform cBioportal (https://www.cbioportal.org accessed on\n31March2023)usingtheBreastcancerMETABRICdatabase(InvasiveBreastCarcinoma:\n\nCells2025,14,398 10of25\nMETABRIC,Nature2012andNatCommun2016)",
      "CorrelationinexpressionofGATAD2B\nand OGT was analyzed using cBioportal platform, using the breast cancer METABRIC\ndatabase",
      "Database analysis (cBioportal, breast cancer:\nMETABRIC)showedsomealterationsinbreastcancersamplesfortheseNuRDcomplex\ncomponents"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:34.501584",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40136647.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 13.345102071762085,
      "cbioportal_papers": 0.00039076805114746094,
      "pdf_extraction_pass2": 18.64547109603882,
      "cbioportal_papers_pass2": 0.0005037784576416016,
      "used_full_extraction": true,
      "pdf_extraction": 31.990573167800903,
      "platform_mentions": 0.005243062973022461,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40104742": {
    "cbioportal_paper_citations": [
      "The RNA data of IL-17-related DEGs and clinical information of IBC from TCGA were combined according to the sample ID. To screen prognostic genes in TCGA, univariate COX regression analysis was performed using the \u201csurvival\u201d package (18). The \u201cglmnet\u201d and \u201csurvival\u201d packages were used to perform least absolute shrinkage and selection operator (LASSO) logistic regression analysis (ten-fold cross-validation) to further identify the IL-17-related core prognostic genes and construct a prognostic model based on the IL-17 score in TCGA (19). The IL-17 score of each patient was computed using the following formula: OR51E1 expression value \u00d7 corresponding coef + NDRG2 expression value \u00d7 corresponding coef + SQLE expression value \u00d7 corresponding coef + RGS2 expression value \u00d7 corresponding coef + TSPAN7 expression value \u00d7 corresponding coef. The Shapiro-Wilk normality test and Wilcoxon rank-sum test were used to perform a difference analysis between the two groups. Somatic mutations in IBC samples from TCGA were analyzed using cBioPortal, an online platform for TCGA data exploration (https://www.cbioportal.org/) (20). The \u201csurvminer\u201d and \u201csurvival\u201d packages were used to perform Kaplan-Meier (K-M) survival analysis (18). The \u201cfactoextra\u201d and \u201cFactoMineR\u201d packages were used to perform principal component analysis (PCA) (21). RNA data from METABRIC were used to validate the prognostic model constructed based on TCGA data using the same methodology described above."
    ],
    "cbioportal_platform_mentions": [
      "To explore the mutations in the five core genes, the mutation data of IBC patients from cBioPortal were analyzed (Figure 2E). Mutation was identified in 282 (29%) of the 963 samples, and most alterations were amplified. In addition, SQLE had the highest mutation frequency (up to 20%). LASSO regression was then used to construct a prognostic prediction model based on the IL-17-related core genes in patients with IBC. The IL-17 score of each patient was computed using the following formula: OR51E1 expression value \u00d7 (0.580110283) + NDRG2 expression value \u00d7 (\u22120.085565983) + SQLE expression value \u00d7 (0.123783519) + RGS2 expression value \u00d7 (\u22120.05800736) + TSPAN7 expression value \u00d7 (\u22120.092125426)."
    ],
    "data_publication_citations": {
      "29625055": [
        "The RNA data of IL-17-related DEGs and clinical information of IBC from TCGA were combined according to the sample ID. To screen prognostic genes in TCGA, univariate COX regression analysis was performed using the \u201csurvival\u201d package (18). The \u201cglmnet\u201d and \u201csurvival\u201d packages were used to perform least absolute shrinkage and selection operator (LASSO) logistic regression analysis (ten-fold cross-validation) to further identify the IL-17-related core prognostic genes and construct a prognostic model based on the IL-17 score in TCGA (19). The IL-17 score of each patient was computed using the following formula: OR51E1 expression value \u00d7 corresponding coef + NDRG2 expression value \u00d7 corresponding coef + SQLE expression value \u00d7 corresponding coef + RGS2 expression value \u00d7 corresponding coef + TSPAN7 expression value \u00d7 corresponding coef. The Shapiro-Wilk normality test and Wilcoxon rank-sum test were used to perform a difference analysis between the two groups. Somatic mutations in IBC samples from TCGA were analyzed using cBioPortal, an online platform for TCGA data exploration (https://www.cbioportal.org/) (20). The \u201csurvminer\u201d and \u201csurvival\u201d packages were used to perform Kaplan-Meier (K-M) survival analysis (18). The \u201cfactoextra\u201d and \u201cFactoMineR\u201d packages were used to perform principal component analysis (PCA) (21). RNA data from METABRIC were used to validate the prognostic model constructed based on TCGA data using the same methodology described above.",
        "The \u201csurvival\u201d package was used to perform univariate COX regression analysis (18). The \u201crms\u201d and \u201csurvival\u201d packages were used to construct the nomogram and perform calibration analysis (number of samples for each group calculated repeatedly was set to 300; the number of repetitions was set to 1,000) (18). The \u201ctimeROC\u201d package was employed for receiver operating characteristic (ROC) analysis (18). The K-M \u201csurvival\u201d package and stdca.R file were used to perform the decision curve analysis (DCA) (22)."
      ],
      "22522925": [
        "This study utilized primary data sourced from TCGA, including 1,109 IBC and 113 normal breast samples. IBC data from the Gene Expression Omnibus (GEO) database (GSE42568) (14) were utilized to assist in the screening of IL-17-related genes, and data from METABRIC (15) database were used for validation. Two gene sets related to IL-17 (GSE10240_CTRL_VS_IL17_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_DN and GSE10240_CTRL_VS_IL17_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_UP) were obtained from Molecular Signature Database v7.5.1 (MSigDB). The flowchart is illustrated in Figure 1. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 1.8495821952819824,
    "data_pmids_checked": 2,
    "paper_id": "40104742",
    "extraction_date": "2025-12-19T19:52:36.410539",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40104742.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40128178": {
    "paper_id": "40128178",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The genetic/genomic alternations of the capsuleof6-week-oldathymicnudemice.Miceweremonitoreddaily\nHippo/YAP signaling pathway in renal cell carcinoma (RCC) were and euthanized every three months to examine tumorigenesis.Kid-\nanalyzed using the cBioPortal for Cancer Genomics online tools neysfromeachgroupwereharvestedforpathohistologicalanalyzes",
      "(available at http://www.cbioportal.org)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:39.268416",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40128178.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 12.602729082107544,
      "cbioportal_papers": 0.00041794776916503906,
      "pdf_extraction_pass2": 13.94651174545288,
      "cbioportal_papers_pass2": 0.0004630088806152344,
      "used_full_extraction": true,
      "pdf_extraction": 26.549240827560425,
      "platform_mentions": 0.004925966262817383,
      "data_citations": 0.015789031982421875,
      "num_data_pmids_checked": 0
    }
  },
  "40108134": {
    "paper_id": "40108134",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:44.669753",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40108134.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.35436487197876,
      "cbioportal_papers": 0.00040411949157714844,
      "pdf_extraction_pass2": 11.955686807632446,
      "cbioportal_papers_pass2": 0.0005922317504882812,
      "used_full_extraction": true,
      "pdf_extraction": 19.310051679611206,
      "platform_mentions": 0.016440153121948242,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40100436": {
    "paper_id": "40100436",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:57.325425",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40100436.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.234754085540771,
      "cbioportal_papers": 0.00023889541625976562,
      "pdf_extraction_pass2": 10.606441974639893,
      "cbioportal_papers_pass2": 0.0002391338348388672,
      "used_full_extraction": true,
      "pdf_extraction": 20.841196060180664,
      "platform_mentions": 0.002203226089477539,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40097393": {
    "paper_id": "40097393",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "CAMIL regression model: This is the Contrastively Clustered\nSeg\nmask PMask and ii) a consistency loss L comparing the attention-basedmultipleinstancelearningmodelasdescribedby\nCons\nNatureCommunications|( 2025)1 6:2610 10\n\nArticle https://doi.org/10.1038/s41467-025-57717-6\nNahhas et al. 23 Default parameters were used except for two Dataavailability\nchangeswhichbothledtoimprovedperformance:i)AReNet50 H&EimagesforTCGAKIRCcanbedownloadedfromtheTCGAGDC\nencoderpretrainedonImagenetwasusedtoextractfeatureson portal, while the corresponding gene expression data is available\n20Ximages(asopposedtoRetCCLondownsampledimages)and from cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:52:57.383244",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40097393.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.13687801361084,
      "cbioportal_papers": 0.00031685829162597656,
      "pdf_extraction_pass2": 8.92421007156372,
      "cbioportal_papers_pass2": 0.0003180503845214844,
      "used_full_extraction": true,
      "pdf_extraction": 18.06108808517456,
      "platform_mentions": 0.0022611618041992188,
      "data_citations": 0.00011706352233886719,
      "num_data_pmids_checked": 1
    }
  },
  "40111633": {
    "paper_id": "40111633",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.8 Assessment of genetic alterations\nGenetic alterations were analyzed using cBioPortal (https://w ww.c biopo rtal.o rg) [61, 62], including Oncoprint and\npathway modification analyses from earlier studies [35, 63]",
      "The gene list was submitted to cBioPortal",
      "3.6 Genetic alterations\nNine candidate genes were entered into the cBioportal database for investigation in a breast cancer study",
      "5 Genetic alterations in EGFR, PLK1, MMP2, ACHE, ABCG2, PTGS2, KIT, CDK1, and BCL2L1, as analyzed using cBioportal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal",
      "Gao J, Lindsay J, Watt S, Bahceci I, Lukasse P, Abeshouse A, et al. The cBioPortal for cancer genomics and its application in precision\noncology"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:53:04.664893",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40111633.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 11.93806004524231,
      "cbioportal_papers": 0.0003631114959716797,
      "pdf_extraction_pass2": 28.771548748016357,
      "cbioportal_papers_pass2": 0.0003581047058105469,
      "used_full_extraction": true,
      "pdf_extraction": 40.70960879325867,
      "platform_mentions": 0.003477334976196289,
      "data_citations": 1.0967254638671875e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40085362": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis of genetic alterations in TRPM4 and SLC9A1 across cancers was performed using the cBioPortal platform, encompassing 32 studies and 10, 967 samples ( Figures 4A, B ). TRPM4 harbored 12 mutation sites, including 49 missense mutations, 8 in-frame mutations, with R80Q being the most frequent mutation type. SLC9A1 exhibited 9 mutation sites, predominantly missense mutations, along with truncations, splice variants, structural variants (SVs)/fusions, and A781TV as the most common mutation type. Mutations in TRPM4 and SLC9A1 were observed in 32 high-grade breast cancer tissues ( Figures 4C, D ). TRPM4 mutations may impair calcium ion permeability, leading to intracellular sodium/calcium imbalance and promoting tumor migration. Missense mutations in SLC9A1 could disrupt sodium-hydrogen exchange function, exacerbating tumor microenvironment acidification and enhancing chemotherapy resistance. Although somatic mutations in TRPM4 and SLC9A1 are relatively rare events in breast cancer overall ( Figures 4E, F ), the specific mutations that do occur may offer valuable functional insights. For instance, TRPM4 mutations could potentially impair its calcium ion permeability, which might contribute to intracellular sodium/calcium imbalance\u2014a phenomenon supported by our functional data in knockdown models ( Figures 5G, H ). Similarly, missense mutations in SLC9A1 could disrupt sodium-hydrogen exchange, a mechanism that might exacerbate microenvironment acidification. Interestingly, we observed that these mutations were even less frequent in invasive mixed mucinous carcinoma compared to invasive ductal carcinoma, suggesting a distinct genetic landscape. However, given their low prevalence, their contribution to the overall breast cancer population is likely limited. Therefore, the primary clinical relevance of TRPM4 and SLC9A1 in breast cancer is more robustly underscored by their frequent mRNA/protein overexpression and strong association with poor prognosis, as demonstrated throughout our study, rather than by their mutational status."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.11084103584289551,
    "data_pmids_checked": 0,
    "paper_id": "40085362",
    "extraction_date": "2025-12-19T19:53:04.799071",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40085362.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40091029": {
    "paper_id": "40091029",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The analysis of variants\nNSCLC cohorts and functional in vitro studies, we dem-\nwas performed using paired germline DNA from each\nonstrate the dominant effect of cancer cell TAP2 down-\ncase as a reference using the cBioPortal bioinformatic\nregulation in tumor immune evasion and immunotherapy\npipeline [10, 11]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y,\nJacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer\nEthics approval and consent to participate\ngenomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:53:08.932082",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40091029.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 12.573235988616943,
      "cbioportal_papers": 0.0004012584686279297,
      "pdf_extraction_pass2": 11.63725996017456,
      "cbioportal_papers_pass2": 0.0004930496215820312,
      "used_full_extraction": true,
      "pdf_extraction": 24.210495948791504,
      "platform_mentions": 0.0042266845703125,
      "data_citations": 7.3909759521484375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40081943": {
    "cbioportal_paper_citations": [
      "The expression level of RANKL (TNFSF11 gene) and its receptor RANK (TNFRSF11A gene) in 81 normal cell types from 31 published single-cell RNA sequencing datasets (30 different healthy human tissues and peripheral mononuclear cells (PBMCs) (online supplemental table 3)) was evaluated through the Human Protein Atlas interface (V.23.0, release date: June 19, 2023). Altogether, transcriptomics data from 689,601 human cells were analyzed. In parallel, both RANKL and RANK messenger RNA (mRNA) levels in the most prevalent cancer subtypes (9,699 cancer samples divided into 28 subtypes) as well as in the four major breast cancer subclasses (luminal A (n=499), luminal B (n=197), HER2+ (n=78) and TNBC (n=171)) were assessed using The Cancer Genome Atlas (TCGA) public datasets (Pan-Cancer Atlas) through the cBioPortal interface.30 31 At last, transcriptomic data from TNBC contained in the TCGA-breast cancer (BRCA) collection was retrieved and patients were split into groups based on TNFRSF11A and TNFSF11 z-score normalized gene expression (top 25% vs bottom 25%). Differentially expressed genes were assessed between the two groups, including log2FC and p values for each gene. Gene set enrichment analysis (GSEA) and visualization were performed on significantly differentially expressed genes (p<0.05) using clusterProfiler (V.4.0)32 33 and enrichplot (V.3.18) packages in R."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29622463": [
        "Statistical analysis was performed using GraphPad Prism V.8.3 software (San Diego, California, USA). (Welch-corrected) unpaired student\u2019s t-test and one-way analysis of variance (ANOVA) followed by Dunnett\u2019s or Bonferroni multiple comparison post hoc test were used to assess the statistical significance between two and more groups/conditions, respectively. Where indicated, one sample t-test was used to determine whether the mean from an individual group was different from a specific value. In the case of discrete variables (immunohistochemical scores, aneuploidy,37 Buffa hypoxia score,38 age at diagnosis, number of metastatic foci), a Mann-Whitney or Kruskal-Wallis ANOVA test followed by Dunn post hoc test was performed according to the number of groups. The comparison of tumor characteristics (tumor size, nodal status, tumor type, TP53 mutation, treatment modality) between independent groups was performed using a \u03c72 test. The Kaplan-Meier method was used to estimate both the progression-free and overall survivals based on TCGA-BRCA data. Survival curves were compared using a Log-rank (Mantel-Cox) test. The correlation between RANKL expression and the density of various immune cells within the tumor microenvironment was assessed using Spearman\u2019s rank correlation test. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.20595788955688477,
    "data_pmids_checked": 1,
    "paper_id": "40081943",
    "extraction_date": "2025-12-19T19:53:09.144594",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40081943.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40088344": {
    "paper_id": "40088344",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genetic alterations and 3D structures were evaluated through\ncBioPortal",
      "2.3 Genetic alteration analysis\nThe cBioPortal (http://w ww.c biopo rtal.o rg/) provided insights into TIPRL genetic variations, including mutation types,\nsite-specific mutations, and copy number alterations [16]",
      "Survival metrics such as OS, progression-free survival, DFS, and\ndisease-specific survival were compared between TIPRL-altered and unaltered tumors using cBioPortal\u2019s \"Comparison\"\nfeature",
      "TIPRL genetic mutation patterns across cancers were ana-\nlyzed using cBioPortal",
      "Amplifications of TIPRL are identified through the cBioPortal platform, which provides insights into genetic\nalterations, including copy number variations (CNVs)",
      "The survival analysis (OS, DFS,\nand progression-free survival) conducted in cBioPortal reveals that tumors with TIPRL amplifications tend to have poorer\nsurvival outcomes compared to tumors with normal or unaltered TIPRL expression",
      "Research\nusing cBioPortal and TCGA data has shown that TIPRL is subject to genetic alterations such as copy number variations (CNVs)\nin certain cancers",
      "cBioPortal data demonstrated that TIPRL is subject to\ngenetic alterations in some cancers, which may confound the relationship between TIPRL expression and clinical outcomes\nlike OS or DFS",
      "Integrative\nanalysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T19:53:13.723884",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40088344.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.249842166900635,
      "cbioportal_papers": 0.00027489662170410156,
      "pdf_extraction_pass2": 7.1265270709991455,
      "cbioportal_papers_pass2": 0.00027370452880859375,
      "used_full_extraction": true,
      "pdf_extraction": 16.37636923789978,
      "platform_mentions": 0.0022859573364257812,
      "data_citations": 5.245208740234375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40076569": {
    "paper_id": "40076569",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The146metastatic\nBC cases [13] were also obtained from cBioPortal, where gene expression data were re-\ntrieved.Adatasetcomprising1980patientsfromtheMETABRICdatabase[24\u201326]wasused\ntovalidatethepreviousresults.Moreover,wealsoobtainedandintegratedclinicalinforma-\ntionsuchasOSforalltheBCcases",
      "Finally,weconsidered150samplesfromTheMetastatic\nBreastCancerProject(https://mbcproject.org/,accessedon1January2022),alsoobtained\nfromcBioPortal(https://www.cbioportal.org/study/summary?id=brca_mbcproject_2022,\naccessedon1January2022)",
      "DataAvailabilityStatement:Thisstudyutilizedmulti-omicsdatafromTheCancerGenomeAtlas\n(TCGA),accessedviathecBioPortalandpubliclyavailablefromhttps://www.cbioportal.org/study/\nsummary?id=brca_tcga_pan_can_atlas_2018",
      "Metastatic breast cancer cases and validation data\nfromtheMETABRICdatabasewerealsodownloadedfromthecBioPortal,respectively,fromhttps:\n//www.cbioportal.org/study/summary?id=metastatic_solid_tumors_mich_2017andhttps://www",
      "cbioportal.org/study/summary?id=brca_metabric(accessedon1December2024)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:38:34.299362",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40076569.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.474985837936401,
      "cbioportal_papers": 0.000164031982421875,
      "pdf_extraction_pass2": 4.917446136474609,
      "cbioportal_papers_pass2": 0.00015473365783691406,
      "used_full_extraction": true,
      "pdf_extraction": 10.39243197441101,
      "platform_mentions": 0.0016930103302001953,
      "data_citations": 0.0002601146697998047,
      "num_data_pmids_checked": 5
    }
  },
  "40082829": {
    "paper_id": "40082829",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(https://p ortal.g dc.c ancer.g ov/) is not open, we analy-\nRecent studies using radiolabeled substrates have sis the condition of SNPs in OC via cBioportal data-\nunveiled the dynamic nature of lipid metabolism in can- base [16]",
      "1 A waterfall map of 20 genes that mutant in more than 50 samples derived from cBioPortal\nConstruction of PPI network of mutant genes associated CAOV3) and normal ovarian epithelial cell line IOSE80 and\nwith lipid metabolism found that they were all up-regulated in ovarian cancer cell\nTo further study the potential interaction between lines (Fig",
      "Terrand J, Bruban V, Zhou L, Gong W, El Asmar Z, May P, et al. LRP1\nthe cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:38:34.886032",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40082829.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.594311237335205,
      "cbioportal_papers": 0.0001819133758544922,
      "pdf_extraction_pass2": 5.385925054550171,
      "cbioportal_papers_pass2": 0.00017881393432617188,
      "used_full_extraction": true,
      "pdf_extraction": 10.980236291885376,
      "platform_mentions": 0.001622915267944336,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40078282": {
    "paper_id": "40078282",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "RawfileswereprocessedusingMaxQuant(Ver2.1.4)using1%\npeptideandproteinFDRsearchconstraints,allvaluesweredefault cBioPortal\nexcept for 20 ppm first search tolerance and 7 ppm main search\ntoleranceagainstthelatestversionoftheUniProtprotein.fastafile cBioportal (Cerami et al., 2012; Gao et al., 2013) was\nfor Homo sapiens (canonical and isoform, 20230316)",
      "cBioPortal.Sci.Signal269,pl1.doi:10.1126/scisignal.2004088 2021.752127\nGarc\u00eda-Heredia,S.E.M.V.,Lucena-Cacace,A.,Molina-Pinelo,S.,andCarnero,A"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:38:35.823311",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40078282.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.80366587638855,
      "cbioportal_papers": 0.00023794174194335938,
      "pdf_extraction_pass2": 6.113347768783569,
      "cbioportal_papers_pass2": 0.00023293495178222656,
      "used_full_extraction": true,
      "pdf_extraction": 11.91701364517212,
      "platform_mentions": 0.0018389225006103516,
      "data_citations": 5.7220458984375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40087771": {
    "paper_id": "40087771",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Anti-CD8 anti-\nCarcinoma (TCGA, PanCancer Atlas)) data and clini- bodies were administered at a dose of 60 \u00b5g per mouse,\ncal information were downloaded using the cBioPortal anti-NK1.1 antibodies at 100 \u00b5g per mouse, and anti-\n(API) in R (4.3.0) [28]",
      "Point mutations information of NLRP4 of NSCLC\n\nMeng et al. Biomarker Research (2025) 13:44 Page 8 of 26\npatients were collected from cBioPortal database ( h t t p s : Monocle2-based trajectory analysis\n/ / w w w"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:38:46.594813",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40087771.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.671641826629639,
      "cbioportal_papers": 0.0005009174346923828,
      "pdf_extraction_pass2": 11.987270832061768,
      "cbioportal_papers_pass2": 0.0005860328674316406,
      "used_full_extraction": true,
      "pdf_extraction": 22.658912658691406,
      "platform_mentions": 0.03095221519470215,
      "data_citations": 1.71661376953125e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40075453": {
    "paper_id": "40075453",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal web tool (http:// cbiop ortal",
      "E TAP2\nalteration frequency analysis in pan-cancer by using the data from cBioPortal database",
      "Gao J, et al. Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:38:48.250186",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40075453.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.6183459758758545,
      "cbioportal_papers": 0.0002911090850830078,
      "pdf_extraction_pass2": 7.292004108428955,
      "cbioportal_papers_pass2": 0.0003063678741455078,
      "used_full_extraction": true,
      "pdf_extraction": 13.91035008430481,
      "platform_mentions": 0.0026807785034179688,
      "data_citations": 0.00011301040649414062,
      "num_data_pmids_checked": 1
    }
  },
  "40075071": {
    "cbioportal_paper_citations": [
      "GraphPad Prism software v10.1 was used for statistical analysis. Unpaired Student\u2019s t test was used for comparison between the two groups. One-way ANOVA analysis was used to compare more than two groups, and correction for multiple comparisons was applied when needed. Spearman\u2019s rank correlation coefficient analysis was used to calculate the correlation between the expression levels of BCL2 family proteins/STAT3 and IC50s to BH3-mimetc drugs or the STAT3 inhibitor. The genomic mutation, copy number variation, and MSI status data of the GC cell lines were sourced from the TCGA PanCancer Atlas study [64] using the cBioPortal [65]. The Wilcoxon rank sum test [66] was used to assess the association between the response of gastric cancer cell lines to BH3-mimetic drugs and genetic alterations implicated in GC tumorigenesis and the Complex Heatmap package was used for data visualization [67]. Data are reported as mean \u00b1 SD of \u22653 independent experiments and threshold for significance was p < 0.05. *p < 0.05; **p < 0.01; ***p < 0.001."
    ],
    "cbioportal_platform_mentions": [
      "We and others have previously shown that only a subset of human GC cell lines is susceptible to BCLXL inhibition [12, 13], indicating that other pro-survival BCL2 proteins may play a role in maintaining GC cell survival. To investigate this, we assembled a larger panel of GC cell lines (n = 16) representing the four TCGA molecular subtypes of gastric cancer, including the Epstein-Barr Virus subtype (EBV+), microsatellite instability subtype (MSI), chromosomal instability subtype (CIN) and genomically stable subtype (GS) [28]. We firstly assessed their response to the well-characterized inhibitors of these proteins, including venetoclax to target BCL2 (referred to as BCL2i hereafter) [5], A1331852 to target BCLXL (referred to as BCLXLi hereafter) [29], and S63845 (in vitro assays) or S64315 (in vivo assays) to target MCL1 (both referred to as MCL1i hereafter) [30, 31] (Fig. 1A).Fig. 1A subset of human GC cell lines is susceptible to single inhibition of BCLXL or MCL1.A Summary of the BH3-mimetic compounds used in this study. B Sensitivity of human GC cell lines to BH3-mimetic compounds. The sensitivity of 16 GC cell lines representing the four TCGA molecular subtypes to the indicated BH3-mimetics was determined after culturing in 0\u201310 \u03bcM of the drugs for 24 h. A discrete heat map representation of the mean IC50s was shown. C Genetic deleting BCLXL induces cell death in 23132/87 cells. The viability of 23132/87 cells 72 h after addition of doxocycline (DOX) to induce the expression of sgRNAs to target BCL2, BCLXL, BCLW, MCL1, BCL2A1 or BCLB was determined with CellTiter-Glo assays. 2 sgRNAs were tested for each gene. Unpaired Student\u2019s t-test was used for statistical significance. D SNU-16 cells lose their viability when MCL1 is genetically ablated. Similar experiments to those in (C) were performed in SNU-16 cells. Anti-tumor activity of BCLXLi and MCL1i in vivo. BALB/c nude mice were inoculated s.c. with NCI-N87 (E) or SNU-668 (F) cells and treatment commenced 1 week later with BCLXLi (p.o.) or MCL1i (i.v.) as indicated. Tumor sizes were monitored every 3 days. Data shown represents the mean tumor volumes \u00b1 SD of 5 mice (E) and 7 mice (F) in each group. Statistical significance was calculated using the Two-way ANOVA analysis. G, H Correlation analysis of BCLXLi or MCL1i sensitivity and recurrent poor-risk genetic alterations in GC. All GC lines used in the study were ranked by increasing IC50s to BCLXLi (G) or MCL1i (H) treatment. The recurrent genetic alterations associated with poor prognosis in these cells were derived from the TCGA PanCancer Atlas study using the cBioPortal. Wilcoxon rank sum test was performed to determine the correlation between drug sensitivity and different genetic alterations. I Expression of BCL2 family proteins in the panel GC lines studied. J Spearman\u2019s correlation analysis of BCL2 family protein expression and response to MCL1i and BCLXLi treatments. Spearman\u2019s coefficient values with P value < 0.05 were shown in the plot. K Heatmap representation showing the impact of deleting BAX, BAK, or both on MCL1i and BCLXLi sensitivity. The mean IC50s \u00b1 SD of GC cell lines expressing sgRNAs targeting BAX, BAK or both to the indicated BH3-mimetic drugs were shown. Cell viability was determined using the CellTiter-Glo assay; data in (B\u2013D) and (K) represent the means \u00b1 SD of \u22653 independent experiments; blots in (I) are representatives of 2 independent experiments. P values < 0.05 were considered significant. *P < 0.05, **P < 0.01, ***P < 0.001.",
      "A Summary of the BH3-mimetic compounds used in this study. B Sensitivity of human GC cell lines to BH3-mimetic compounds. The sensitivity of 16 GC cell lines representing the four TCGA molecular subtypes to the indicated BH3-mimetics was determined after culturing in 0\u201310 \u03bcM of the drugs for 24 h. A discrete heat map representation of the mean IC50s was shown. C Genetic deleting BCLXL induces cell death in 23132/87 cells. The viability of 23132/87 cells 72 h after addition of doxocycline (DOX) to induce the expression of sgRNAs to target BCL2, BCLXL, BCLW, MCL1, BCL2A1 or BCLB was determined with CellTiter-Glo assays. 2 sgRNAs were tested for each gene. Unpaired Student\u2019s t-test was used for statistical significance. D SNU-16 cells lose their viability when MCL1 is genetically ablated. Similar experiments to those in (C) were performed in SNU-16 cells. Anti-tumor activity of BCLXLi and MCL1i in vivo. BALB/c nude mice were inoculated s.c. with NCI-N87 (E) or SNU-668 (F) cells and treatment commenced 1 week later with BCLXLi (p.o.) or MCL1i (i.v.) as indicated. Tumor sizes were monitored every 3 days. Data shown represents the mean tumor volumes \u00b1 SD of 5 mice (E) and 7 mice (F) in each group. Statistical significance was calculated using the Two-way ANOVA analysis. G, H Correlation analysis of BCLXLi or MCL1i sensitivity and recurrent poor-risk genetic alterations in GC. All GC lines used in the study were ranked by increasing IC50s to BCLXLi (G) or MCL1i (H) treatment. The recurrent genetic alterations associated with poor prognosis in these cells were derived from the TCGA PanCancer Atlas study using the cBioPortal. Wilcoxon rank sum test was performed to determine the correlation between drug sensitivity and different genetic alterations. I Expression of BCL2 family proteins in the panel GC lines studied. J Spearman\u2019s correlation analysis of BCL2 family protein expression and response to MCL1i and BCLXLi treatments. Spearman\u2019s coefficient values with P value < 0.05 were shown in the plot. K Heatmap representation showing the impact of deleting BAX, BAK, or both on MCL1i and BCLXLi sensitivity. The mean IC50s \u00b1 SD of GC cell lines expressing sgRNAs targeting BAX, BAK or both to the indicated BH3-mimetic drugs were shown. Cell viability was determined using the CellTiter-Glo assay; data in (B\u2013D) and (K) represent the means \u00b1 SD of \u22653 independent experiments; blots in (I) are representatives of 2 independent experiments. P values < 0.05 were considered significant. *P < 0.05, **P < 0.01, ***P < 0.001."
    ],
    "data_publication_citations": {
      "25079317": [
        "We and others have previously shown that only a subset of human GC cell lines is susceptible to BCLXL inhibition [12, 13], indicating that other pro-survival BCL2 proteins may play a role in maintaining GC cell survival. To investigate this, we assembled a larger panel of GC cell lines (n = 16) representing the four TCGA molecular subtypes of gastric cancer, including the Epstein-Barr Virus subtype (EBV+), microsatellite instability subtype (MSI), chromosomal instability subtype (CIN) and genomically stable subtype (GS) [28]. We firstly assessed their response to the well-characterized inhibitors of these proteins, including venetoclax to target BCL2 (referred to as BCL2i hereafter) [5], A1331852 to target BCLXL (referred to as BCLXLi hereafter) [29], and S63845 (in vitro assays) or S64315 (in vivo assays) to target MCL1 (both referred to as MCL1i hereafter) [30, 31] (Fig. 1A).Fig. 1A subset of human GC cell lines is susceptible to single inhibition of BCLXL or MCL1.A Summary of the BH3-mimetic compounds used in this study. B Sensitivity of human GC cell lines to BH3-mimetic compounds. The sensitivity of 16 GC cell lines representing the four TCGA molecular subtypes to the indicated BH3-mimetics was determined after culturing in 0\u201310 \u03bcM of the drugs for 24 h. A discrete heat map representation of the mean IC50s was shown. C Genetic deleting BCLXL induces cell death in 23132/87 cells. The viability of 23132/87 cells 72 h after addition of doxocycline (DOX) to induce the expression of sgRNAs to target BCL2, BCLXL, BCLW, MCL1, BCL2A1 or BCLB was determined with CellTiter-Glo assays. 2 sgRNAs were tested for each gene. Unpaired Student\u2019s t-test was used for statistical significance. D SNU-16 cells lose their viability when MCL1 is genetically ablated. Similar experiments to those in (C) were performed in SNU-16 cells. Anti-tumor activity of BCLXLi and MCL1i in vivo. BALB/c nude mice were inoculated s.c. with NCI-N87 (E) or SNU-668 (F) cells and treatment commenced 1 week later with BCLXLi (p.o.) or MCL1i (i.v.) as indicated. Tumor sizes were monitored every 3 days. Data shown represents the mean tumor volumes \u00b1 SD of 5 mice (E) and 7 mice (F) in each group. Statistical significance was calculated using the Two-way ANOVA analysis. G, H Correlation analysis of BCLXLi or MCL1i sensitivity and recurrent poor-risk genetic alterations in GC. All GC lines used in the study were ranked by increasing IC50s to BCLXLi (G) or MCL1i (H) treatment. The recurrent genetic alterations associated with poor prognosis in these cells were derived from the TCGA PanCancer Atlas study using the cBioPortal. Wilcoxon rank sum test was performed to determine the correlation between drug sensitivity and different genetic alterations. I Expression of BCL2 family proteins in the panel GC lines studied. J Spearman\u2019s correlation analysis of BCL2 family protein expression and response to MCL1i and BCLXLi treatments. Spearman\u2019s coefficient values with P value < 0.05 were shown in the plot. K Heatmap representation showing the impact of deleting BAX, BAK, or both on MCL1i and BCLXLi sensitivity. The mean IC50s \u00b1 SD of GC cell lines expressing sgRNAs targeting BAX, BAK or both to the indicated BH3-mimetic drugs were shown. Cell viability was determined using the CellTiter-Glo assay; data in (B\u2013D) and (K) represent the means \u00b1 SD of \u22653 independent experiments; blots in (I) are representatives of 2 independent experiments. P values < 0.05 were considered significant. *P < 0.05, **P < 0.01, ***P < 0.001."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 2.5521249771118164,
    "data_pmids_checked": 380,
    "paper_id": "40075071",
    "extraction_date": "2025-12-19T22:10:45.924191",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40075071.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40074873": {
    "paper_id": "40074873",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Leveraging public databases including TCGA, GTEx, HPA, cBioPortal, UALCAN, STRING, CancerSEA and TISIDB database,\nwe examined EXO1\u2019s expression, diagnostic potential, prognostic significance, mutational characteristics, functional roles,\nand immunological effects across different cancer types",
      "2.4 Analysis of EXO1 genetic alterations\nThe cBioPortal [21] (https://w ww.c biopo rtal.o rg/) is a crucial resource for the analysis, visualization, and interpretation of\nintricate cancer genomics data",
      "In our study, we leveraged cBioPortal to investigate the mutation prevalence, categories,\ncopy number variations (CNVs), and mutational hotspots associated with the EXO1 gene within diverse TCGA tumor\nprofiles",
      "3.5 Genetic alteration of EXO1\nUtilizing the cBioPortal database, we conducted a pan-cancer analysis of genomic alterations in EXO1, identifying altera-\ntions in 4% of patients across the TCGA dataset (Fig",
      "21 Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:38:52.670658",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40074873.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.511644840240479,
      "cbioportal_papers": 0.00024819374084472656,
      "pdf_extraction_pass2": 8.331442832946777,
      "cbioportal_papers_pass2": 0.0002620220184326172,
      "used_full_extraction": true,
      "pdf_extraction": 16.843087673187256,
      "platform_mentions": 0.002691030502319336,
      "data_citations": 1.2159347534179688e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40074754": {
    "paper_id": "40074754",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "It is worth several point mutations in TRAP1 drawing from three protein\nnoting that D260 and P381S mutations confer insensitivity to databases: ClinVar, COSMIC and CBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:00.575175",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40074754.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.842740297317505,
      "cbioportal_papers": 0.000331878662109375,
      "pdf_extraction_pass2": 7.098201036453247,
      "cbioportal_papers_pass2": 0.0003368854522705078,
      "used_full_extraction": true,
      "pdf_extraction": 13.940941333770752,
      "platform_mentions": 0.0027141571044921875,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40069402": {
    "paper_id": "40069402",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:00.982932",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40069402.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.691452741622925,
      "cbioportal_papers": 0.00030493736267089844,
      "pdf_extraction_pass2": 6.971339225769043,
      "cbioportal_papers_pass2": 0.0002849102020263672,
      "used_full_extraction": true,
      "pdf_extraction": 12.662791967391968,
      "platform_mentions": 0.025229930877685547,
      "data_citations": 0.00020384788513183594,
      "num_data_pmids_checked": 2
    }
  },
  "40057668": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.05398893356323242,
    "data_pmids_checked": 0,
    "paper_id": "40057668",
    "extraction_date": "2025-12-19T20:39:01.038099",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40057668.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40065301": {
    "paper_id": "40065301",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Although a signifi- suggest a crucial oncogenic role of SLC25A35 in HCC by\ncant negative correlation was found between the mRNA reprogramming mitochondrial metabolism and suggest\nexpression and DNA methylation levels of SLC25A35 SLC25A35 as a potential therapeutic target for the treat-\nin HCC by using the online cBioPortal-based [20] bio- ment of HCC",
      "and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:07.657117",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40065301.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.490506887435913,
      "cbioportal_papers": 0.00031113624572753906,
      "pdf_extraction_pass2": 7.385993003845215,
      "cbioportal_papers_pass2": 0.00029397010803222656,
      "used_full_extraction": true,
      "pdf_extraction": 17.876499891281128,
      "platform_mentions": 0.0027980804443359375,
      "data_citations": 5.7220458984375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40055996": {
    "cbioportal_paper_citations": [
      "Protein changes found in PTEN were collected from the NGS and the FoundationOne reports. These protein changes were mapped against Genome Reference Consortium Human Build 36 to determine the location of the mutations. MutationMapper software from cBioPortal was utilized to characterize the mutation and create Lollipop diagrams [29, 30]. The software utilizes OncoKB [31], CIViC [32], My Cancer Genome [33], Cancer Hotspots [34], and 3D Cancer Hotspots [35] to annotate each mutation that is connected to any of these resources. Mutations identified in the current study were compared against other datasets publicly available through cBioPortal with thyroid specimens: Papillary Thyroid Carcinoma [36], Poorly Differentiated and Anaplastic Thyroid Cancers [37], Thyroid Carcinoma (TCGA, Firehouse legacy), and Thyroid Carcinoma (TCGA, PanCancer Atlas) datasets."
    ],
    "cbioportal_platform_mentions": [
      "Across the four datasets on cBioPortal previously mentioned there were 1629 cancerous thyroid specimens that resulted in 18 PTEN mutations. Three mutations in the Poorly Differentiated and Anaplastic Thyroid Cancers dataset were found in our cohort of indeterminate PTEN nodules. One of these mutations was at amino acid 287 resulting in truncation. In our dataset, this was correlated to benign pathology, whereas in the Poorly Differentiated and Anaplastic Thyroid Cancers dataset it was correlated to a PDTC specimen also harboring mutations in TP53, DNMT3A, and PPP2R1A. Similarly, one of our benign specimens harbored a nonsense mutation at 335 resulting in truncation. This same mutation was found in two specimens of ATC harboring 26 mutations in 1 specimen and 54 mutations in the other. The third mutation that matched our cohort was an isolated splice mutation at amino acid 70. In our dataset, this correlated to the PDTC final pathology and in the cBioPortal datasets it correlated to two anaplastic specimens. Thirty\u2010eight of the mutations were annotated with OncoKB's symbol for \u201cOncogenic/Likely Oncogenic/Predicted Oncogenic/Resistance\u201d [31]. Only two mutations were found in My Cancer Genome, N323Kfs*2 and R130*, both linked to ovarian carcinoma, but correlating with benign final pathology in our study.",
      "The most common type of mutation in our cohort was truncation (n = 29), followed by missense mutations (n = 6), splice mutations (n = 3), and an in\u2010frame mutation (n = 2). The most common specific mutation was found at amino acid 136 and accounts for four of the missense mutations. It correlated to three benign specimens and one PTC specimen. The specimen with PTC had an additional mutation at amino acid 211 causing truncation. This leads us to believe that an isolated missense mutation at 136 may have a more indolent behavior. The one specimen in our cohort that harbored a p.X70_splice mutation in PTEN was found to have PDTC on final pathology. Additionally, during our mutation dataset search on the cBioPortal, we found two other specimens that were found to have p.X70_splice mutations, both of which were found to be ATC. This suggests that this particular splice mutation may be associated with aggressive pathologic features. Unfortunately, the cBioPortal datasets that were used for comparison were made up of malignant, not indeterminate specimens, so we were not surprised by the limited overlap."
    ],
    "data_publication_citations": {
      "26878173": [
        "Protein changes found in PTEN were collected from the NGS and the FoundationOne reports. These protein changes were mapped against Genome Reference Consortium Human Build 36 to determine the location of the mutations. MutationMapper software from cBioPortal was utilized to characterize the mutation and create Lollipop diagrams [29, 30]. The software utilizes OncoKB [31], CIViC [32], My Cancer Genome [33], Cancer Hotspots [34], and 3D Cancer Hotspots [35] to annotate each mutation that is connected to any of these resources. Mutations identified in the current study were compared against other datasets publicly available through cBioPortal with thyroid specimens: Papillary Thyroid Carcinoma [36], Poorly Differentiated and Anaplastic Thyroid Cancers [37], Thyroid Carcinoma (TCGA, Firehouse legacy), and Thyroid Carcinoma (TCGA, PanCancer Atlas) datasets."
      ],
      "25417114": [
        "Protein changes found in PTEN were collected from the NGS and the FoundationOne reports. These protein changes were mapped against Genome Reference Consortium Human Build 36 to determine the location of the mutations. MutationMapper software from cBioPortal was utilized to characterize the mutation and create Lollipop diagrams [29, 30]. The software utilizes OncoKB [31], CIViC [32], My Cancer Genome [33], Cancer Hotspots [34], and 3D Cancer Hotspots [35] to annotate each mutation that is connected to any of these resources. Mutations identified in the current study were compared against other datasets publicly available through cBioPortal with thyroid specimens: Papillary Thyroid Carcinoma [36], Poorly Differentiated and Anaplastic Thyroid Cancers [37], Thyroid Carcinoma (TCGA, Firehouse legacy), and Thyroid Carcinoma (TCGA, PanCancer Atlas) datasets."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.429455041885376,
    "data_pmids_checked": 2,
    "paper_id": "40055996",
    "extraction_date": "2025-12-19T20:39:08.086674",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40055996.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40108111": {
    "paper_id": "40108111",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:17.985047",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40108111.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 25.57696795463562,
      "cbioportal_papers": 0.00029206275939941406,
      "pdf_extraction_pass2": 28.48288083076477,
      "cbioportal_papers_pass2": 0.00029587745666503906,
      "used_full_extraction": true,
      "pdf_extraction": 54.05984878540039,
      "platform_mentions": 0.0024340152740478516,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40064891": {
    "paper_id": "40064891",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "examine whether the presence of missense mutp53 in tumors To understand why SOR and VCR unexpectedly induced\nimpactstheoverallsurvivalofcancerpatientscomparedtop53null apoptosis more efficiently in mutp53-expressing cells than in\ntumors, we used the cBioPortal for Cancer Genomics to analyze p53nullcells,weperformedathoroughliteraturesearchtoidentify\navailableTCGAdatasets.Thesedatasets,collectedsincetheyear any shared characteristics of these drugs"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:19.969242",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40064891.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 14.216189861297607,
      "cbioportal_papers": 0.00038886070251464844,
      "pdf_extraction_pass2": 13.034485101699829,
      "cbioportal_papers_pass2": 0.0003609657287597656,
      "used_full_extraction": true,
      "pdf_extraction": 27.250674962997437,
      "platform_mentions": 0.008980035781860352,
      "data_citations": 5.245208740234375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40061138": {
    "paper_id": "40061138",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Interrogation of both TCGA cohort and colorectal cancer cell lines at the individual case and cell line\nlevel was performed online at the cBioPortal for Cancer Genomics platform (cBioportal, http://www",
      "cbioportal.org)",
      "cBioportal is a site containing genomic and associated clinical data from publicly available\nstudies, maintained by Memorial Sloan Kettering Cancer Center (MSKCC) and other academic institutions\n[29, 30]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:20.414027",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40061138.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 11.068882942199707,
      "cbioportal_papers": 0.0003120899200439453,
      "pdf_extraction_pass2": 8.765006065368652,
      "cbioportal_papers_pass2": 0.00033164024353027344,
      "used_full_extraction": true,
      "pdf_extraction": 19.83388900756836,
      "platform_mentions": 0.00368499755859375,
      "data_citations": 0.00044274330139160156,
      "num_data_pmids_checked": 4
    }
  },
  "40048040": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1811079978942871,
    "data_pmids_checked": 0,
    "paper_id": "40048040",
    "extraction_date": "2025-12-19T20:39:20.595284",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40048040.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40052583": {
    "paper_id": "40052583",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Cancer Center has created cBioPortal (http://www.cbioportal",
      "Sections were then The present study investigated the alteration frequency, muta\u2011\nincubated with 3, 3'\u2011diaminobenzidine solution for 5\u201110 min tion type, mutated site details and copy number alterations of\nat room temperature until the desired color intensity was SFXN1 in pan\u2011cancer using cBioPortal",
      "To probe the mutational\nSIGLEC15 and TIGIT in KICH, and between SFXN1 expres\u2011 landscape of SFXN1 across various cancer types, an extensive\nsion and CD274, CTLA4, HAVCR2, PDCD1LG2 and TIGIT search was conducted using cBioPortal",
      "tumorigenesis and its potential regulatory pathways, bioin\u2011\nformatics tools such as TCGA, UALCAN and cBioPortal\nGEO validation and the oncogenic role of SFXN1 in LUAD"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:27.795388",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40052583.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 11.425885915756226,
      "cbioportal_papers": 0.00033402442932128906,
      "pdf_extraction_pass2": 8.278578042984009,
      "cbioportal_papers_pass2": 0.0003361701965332031,
      "used_full_extraction": true,
      "pdf_extraction": 19.704463958740234,
      "platform_mentions": 0.0033931732177734375,
      "data_citations": 8.106231689453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40046063": {
    "cbioportal_paper_citations": [
      "cBioPortal database (37, 38) (http://cbioportal.org) was used to analyze the tumor mutation burden (TMB) data of BC patients in the TCGA-BRCA. The tumor immune dysfunction and exclusion indicator (TIDE) was used to estimate the patient response to immune checkpoint blockade (ICB). Higher TIDE scores corresponded to greater immune escape and a lower response rate to ICB. To evaluate the relationship between the prediction model and tumor-infiltrating immune cells (TICs), we used ssGSEA (39)to estimate the composition and abundance of TICs. In addition, the levels of TICs and stromal cells in the BC samples were quantitatively analyzed based on their gene expression profiles. The stromal score, immune score, ESTIMATE score, and tumor purity were obtained (40). The correlations between immune cells in different groups were calculated using the Spearman algorithm and visualized using the R package \u201cggplot2.\u201d"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.14229702949523926,
    "data_pmids_checked": 0,
    "paper_id": "40046063",
    "extraction_date": "2025-12-19T20:39:27.949567",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40046063.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40037357": {
    "cbioportal_paper_citations": [
      "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566",
      "Oncoplots representing CH and CH-Tum mutations were created for the 15 most frequently mutated genes using cBioPortal Oncoprinter v6.0.5.77,78"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "32059776": [
        "\u2022Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).\u2022This study does not report any original code. Scripts used to conduct study analyses are available online (Zenodo: https://doi.org/10.5281/zenodo.13737566). For CH variant filtering scripts, see the study by Vlasschaert et al.26\u2022Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.",
        "Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).",
        "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566"
      ],
      "34358469": [
        "\u2022Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).\u2022This study does not report any original code. Scripts used to conduct study analyses are available online (Zenodo: https://doi.org/10.5281/zenodo.13737566). For CH variant filtering scripts, see the study by Vlasschaert et al.26\u2022Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.",
        "Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).",
        "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566"
      ],
      "34534465": [
        "\u2022Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).\u2022This study does not report any original code. Scripts used to conduct study analyses are available online (Zenodo: https://doi.org/10.5281/zenodo.13737566). For CH variant filtering scripts, see the study by Vlasschaert et al.26\u2022Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.",
        "Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).",
        "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566"
      ],
      "33106634": [
        "Clonal hematopoiesis (CH) describes the clonal expansion of somatically mutated hematopoietic stem cells (HSCs) with a fitness advantage.1,2,3 CH is detected in the blood of 20%\u201330% of patients with solid cancers, which is considerably higher than in comparably aged, cancer-free individuals.4,5 CH driver mutations, including inactivation of the most common driver genes DNMT3A or TET2, are associated with systemic inflammation.1,6,7 Accordingly, CH is associated with excess morbidity and mortality attributable to numerous chronic diseases1,8,9,10,11,12; however, its impact on the tumor microenvironment (TME) and cancer outcomes remains unclear.13",
        "CH mutations are detectable in tumor-derived DNA sequencing.4,5,27 Since CH mutations are of hematopoietic origin, we posited that their identification in tumor sequencing reflects a greater degree of infiltration by CH-mutant leukocytes into the TME. We further hypothesized that this could identify cases where CH most potently impacts tumor biology. Following the identification of putative CH driver mutations in blood sequencing, we defined the detection of the same CH driver mutations in tumor sequencing, after accounting for potential tumor-derived and germline mutations, as CH-Tum (Figure 1A; STAR Methods). The prevalence of CH-Tum was 5.5% (n = 85), accounting for 30% of patients with CH (Figure 1B). Mutations in the remaining 70% of patients with CH solely found in peripheral blood are referred to as CH-PB (Figure 1A). Like CH, CH-Tum increased significantly with patient age (p = 7.9 \u00d7 10\u22125, rank-sum test; Figure S1B). Among those with CH, the presence of CH-Tum did not vary by cancer type after accounting for age (Figure 1B). In a multivariate model, we found that the detection of CH-Tum was associated with CH mutation VAF \u226510% in the peripheral blood (OR = 9.21 [4.58\u201318.6], logistic regression; Figure 1F) and degree of immune infiltration in the tumor sample as quantified by CIBERSORTx (OR = 6.69 [1.96\u201322.9], logistic regression; Figure 1G). Immune infiltrate scoring did not significantly differ based on peripheral blood VAF in CH-Tum or CH-PB (CH-Tum p = 0.19, CH-PB p = 0.2, rank-sum test; Figure S1E), but when separating between VAF \u226510% and <10%, immune infiltrate was significantly higher in CH-Tum relative to CH-PB in both conditions (VAF \u226510% p = 0.02, VAF <10% p = 0.002, rank-sum test; Figure S1F). This suggests that CH-Tum captures both tumor-immune infiltration and CH clone size, rather than acting as a surrogate for large CH clones in the blood. Like CH, CH-Tum was not associated with tumor stage at the time of diagnosis (OR = 1.41 [0.94\u20132.13], ordered logistic regression; Figure S1G).",
        "The prevalence of CH and CH-Tum in TCGA was lower than the CPTAC cohort and prior cancer cohorts profiled with targeted sequencing.4,5,27 Patients in CPTAC were significantly more likely to have CH, DNMT3A-CH, and TET2-CH, even after accounting for differences in patient age and gender (CH: OR = 1.93 [1.63\u20132.27]; DNMT3A-CH: OR = 2.45 [1.92\u20133.12]; TET2-CH: OR = 3.74 [2.60\u20135.38], logistic regression; Figures S1I\u2013S1K). Given the reported coverage gaps in exome capture kits used by the TCGA sequencing sites,28,29,30 we compared the depth of coverage in CPTAC and TCGA peripheral blood WES samples (Table S3). Across coding regions of CH driver genes considered in this study, CPTAC samples had a median average depth of 259x, which was significantly higher than the average depth in TCGA samples of 94x (p < 1 \u00d7 10\u2212308, rank-sum test; Figure S1L). This was present for DNMT3A (CPTAC median coverage = 215x, TCGA median coverage = 77x; p < 1 \u00d7 10\u2212308, rank-sum test; Figure S1M) and even more pronounced for TET2 (CPTAC median coverage = 312x, TCGA median coverage = 45x; p < 1 \u00d7 10\u2212308, rank-sum test; Figure S1N), with a number of TCGA samples receiving no coverage at all in these critical CH driver genes. Furthermore, although coverage depth did not differ based on CH status in CPTAC, inconsistencies in coverage within TCGA cohort led to the average depth being significantly higher in samples identified to have CH (CPTAC: p = 0.45; TCGA: p = 2 \u00d7 10\u221217, rank-sum test; Figures S1O and S1P). Noting these limitations, we largely excluded this cohort from subsequent analyses.",
        "CH-Tum has been previously identified in tumor sequencing reads as a potential contaminant confounding molecular tumor diagnostics.4,5,27 Rather than simply acting as diagnostic interference, the presence of CH-Tum has clinical and biological significance in solid cancers, associating with adverse clinical outcomes. Our finding that these effects are exclusive to CH-Tum, and not CH as a whole, provides evidence for a CH-driven effect on cancer outcomes by demonstrating dose dependency, while our treatment-naive study cohort also circumvents treatment-related confounding effects present in prior studies of CH in solid tumors.4,25 Detection of CH-Tum is feasible for clinical implementation with minor modification of existing paired tumor-blood sequencing practices. Although presented as a binary variable in this study due to technical limitations of WES, CH-Tum (versus CH-PB) likely exists on a spectrum, and future work will be required to delineate appropriate VAF thresholds that define the most clinically relevant levels of CH-mutant leukocyte infiltration in tumors. The relevance of tissue invasion by CH-mutant leukocytes may also extend beyond solid cancers; CH mutations were recently identified in atherosclerotic lesions,45,46 and future studies are required to determine whether the extent of mutant cell infiltration correlates with disease severity, providing a novel framework for understanding CH-related pathophysiology."
      ],
      "33212010": [
        "\u2022Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).\u2022This study does not report any original code. Scripts used to conduct study analyses are available online (Zenodo: https://doi.org/10.5281/zenodo.13737566). For CH variant filtering scripts, see the study by Vlasschaert et al.26\u2022Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.",
        "Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).",
        "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566"
      ],
      "29625055": [
        "\u2022Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).\u2022This study does not report any original code. Scripts used to conduct study analyses are available online (Zenodo: https://doi.org/10.5281/zenodo.13737566). For CH variant filtering scripts, see the study by Vlasschaert et al.26\u2022Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.",
        "Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).",
        "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566"
      ],
      "32649874": [
        "\u2022Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).\u2022This study does not report any original code. Scripts used to conduct study analyses are available online (Zenodo: https://doi.org/10.5281/zenodo.13737566). For CH variant filtering scripts, see the study by Vlasschaert et al.26\u2022Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.",
        "Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).",
        "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566"
      ],
      "31031003": [
        "\u2022Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).\u2022This study does not report any original code. Scripts used to conduct study analyses are available online (Zenodo: https://doi.org/10.5281/zenodo.13737566). For CH variant filtering scripts, see the study by Vlasschaert et al.26\u2022Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.",
        "Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).",
        "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566"
      ],
      "33577785": [
        "\u2022Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).\u2022This study does not report any original code. Scripts used to conduct study analyses are available online (Zenodo: https://doi.org/10.5281/zenodo.13737566). For CH variant filtering scripts, see the study by Vlasschaert et al.26\u2022Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.",
        "Clinical, genomic, and transcriptomic data from the CPTAC and TCGA cohorts were used to conduct this study and can be accessed via the NIH NCI genomic data commons portal (dbGaP: phs000892.v.6.p1, phs001287.v.18.p6, phs000178.v.11.p8). Processed proteomics data were acquired via the CPTAC software package described by Li et al.54 Additional patient and sample metadata were collected from several CPTAC and TCGA marker papers.39,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Additional supplemental data produced by this study are available online. (Zenodo: https://doi.org/10.5281/zenodo.13737566).",
        "REAGENT or RESOURCESOURCEIDENTIFIERDeposited dataCPTAC & TCGA Clonal Hematopoiesis Variant CallsThis paperTable S2CPTAC & TCGA Genomics & Transcriptomics Data (dbGaP: phs000892.v6.p1, phs001287.v18.p6, phs000178.v11.p8)NIH NCI Genomic Data Commonshttps://portal.gdc.cancer.gov/https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000892.v6.p1https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287.v18.p6https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000178.v11.p8CPTAC Proteomics & Phosphoproteomics DataLi et al.54https://doi.org/10.1016/j.ccell.2023.06.009CPTAC & TCGA Patient Clinical Information & Sample MetadataNIH NCI Genomic Data Commons; Petralia et al.39; Li et al.54; Wang et al.55; Vasaikar et al.56; Clark et al.57; Huang et al.58; Krug et al.59; Satpathy et al.60; Gillette et al.61; Cao et al.62; Dou et al.63; Zhang et al.64; Weinstein et al.65; Liu et al.66; Thorsson et al.67https://portal.gdc.cancer.gov/https://doi.org/10.1016/j.cell.2024.01.027https://doi.org/10.1016/j.ccell.2023.06.009https://doi.org/10.1016/j.ccell.2021.01.006https://doi.org/10.1016/j.cell.2019.03.030https://doi.org/10.1016/j.cell.2019.10.007https://doi.org/10.1016/j.cell.2020.10.036https://doi.org/10.1016/j.cell.2021.07.016https://doi.org/10.1016/j.cell.2020.06.013https://doi.org/10.1016/j.cell.2021.08.023https://doi.org/10.1016/j.cell.2020.01.026https://doi.org/10.1016/j.cell.2016.05.069https://doi.org/10.1038/ng.2764https://doi.org/10.1016/j.cell.2018.02.052https://doi.org/10.1016/j.immuni.2018.03.023cDNA Reference Transcriptome (Release 109)Ensemblhttps://ftp.ensembl.org/pub/LM22 Gene Signature MatrixNewman et al.68https://doi.org/10.1038/nmeth.3337HALLMARK Gene SetsLiberzon et al.69https://doi.org/10.1016/j.cels.2015.12.004https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp#HPredicted Anti-PD-1 ICI Response Gene SetsAyers et al.36; Benguigui et al.37; Zeng et al.38https://doi.org/10.1172/jci91190https://doi.org/10.1016/j.ccell.2023.12.005https://doi.org/10.1038/s41698-024-00703-wIL1A mRNA Expression Program Gene SetPark et al.31https://doi.org/10.1126/science.adn0327Glioma Stem Cell Gene SetsChen et al.43https://doi.org/10.1111/cns.13956Glioblastoma TAM Phenotype Gene SetsWang et al.44https://doi.org/10.1016/j.ccell.2024.03.013EnrichmentMap Gene SetsBader Labhttps://baderlab.org/GeneSetsPhosphoSitePlusHornbeck et al.70https://doi.org/10.1093/nar/gkr1122https://www.phosphosite.org/homeAction.actionNetworKINLinding et al.71https://doi.org/10.1093/nar/gkm902https://networkin.info/Kyoto Encyclopedia of Genes and Genomes (KEGG) PathwaysKanehisa & Goto72https://doi.org/10.1093/nar/28.1.27https://www.genome.jp/kegg/Reactome PathwaysCroft et al.73https://doi.org/10.1093/nar/gkq1018https://reactome.org/Software and algorithmsGenome Analysis Toolkit (GATK)-Mutect2 & DepthOfCoverage (v4.2.4.0)Van der Auwera and O\u2019Connor74https://gatk.broadinstitute.org/hc/en-us/articles/4413079262875-Mutect2https://gatk.broadinstitute.org/hc/en-us/articles/4413072451611-DepthOfCoverage-BETAPileup region custom scriptVlasschaert et al.26https://doi.org/10.1182/blood.2022018825https://github.com/weinstockj/pileup_regionANNOVARWang et al.75https://doi.org/10.1093/nar/gkq603https://annovar.openbioinformatics.org/en/latest/Integrated Genomics Viewer (v2.16.1)Robinson et al.76https://doi.org/10.1038/nbt.1754https://igv.org/cBioPortal Oncoprinter (v6.0.5)Cerami et al.77; Gao et al.78https://doi.org/10.1158/2159-8290.cd-12-0095https://doi.org/10.1126/scisignal.2004088https://www.cbioportal.org/oncoprintersurvival (v3.5-7)CRANhttps://cran.r-project.org/web/packages/survival/index.htmlsurvminer (v0.4.9)CRANhttps://cran.r-project.org/web/packages/survminer/index.htmlsamtools (v1.17)Li et al.79https://doi.org/10.1093/bioinformatics/btp352http://www.htslib.org/fastp (v0.23.1)Chen et al.80https://doi.org/10.1093/bioinformatics/bty560https://github.com/OpenGene/fastpkallisto (v0.46.1)Bray et al.81https://doi.org/10.1038/nbt.3519https://pachterlab.github.io/kallisto/MultiQC (v1.13)Ewels et al.82https://doi.org/10.1093/bioinformatics/btw354https://multiqc.info/DESeq2 (v1.26.0)Love et al.83https://doi.org/10.1186/s13059-014-0550-8https://bioconductor.org/packages/release/bioc/html/DESeq2.htmltximport (v1.28.0)Soneson et al.84https://doi.org/10.12688/f1000research.7563.2https://bioconductor.org/packages/release/bioc/html/tximport.htmlIHW (v1.14.0)Ignatiadis et al.85https://doi.org/10.1038/nmeth.3885https://bioconductor.org/packages/release/bioc/html/IHW.htmlashr (v2.2-63)Stephens86https://doi.org/10.1093/biostatistics/kxw041https://cran.r-project.org/web/packages/ashr/index.htmlEnhancedVolcano (v1.20.0)Bioconductorhttps://bioconductor.org/packages/release/bioc/html/EnhancedVolcano.htmlggvenn (v0.1.10)CRANhttps://cran.r-project.org/web/packages/ggvenn/index.htmlg:Profiler g:GOStKolberg et al.87https://doi.org/10.1093/nar/gkad347https://biit.cs.ut.ee/gprofiler/gostglmnet (v4.1-8)CRANhttps://cran.r-project.org/web/packages/glmnet/index.htmlCIBERSORTxNewman et al.68,88https://doi.org/10.1038/nmeth.3337https://doi.org/10.1038/s41587-019-0114-2https://cibersortx.stanford.edu/limma (v3.58.1)Ritchie et al.89https://doi.org/10.1093/nar/gkv007https://bioconductor.org/packages/release/bioc/html/limma.htmlGSEA (v4.3.2)Subramanian et al.90https://doi.org/10.1073/pnas.0506580102https://www.gsea-msigdb.org/gsea/index.jspEnrichment Map Pipeline Collection(EnrichmentMap v3.3.6, clusterMaker2 v2.3.4,AutoAnnotate v1.4.1)Reimand et al.91https://doi.org/10.1038/s41596-018-0103-9https://apps.cytoscape.org/apps/enrichmentmappipelinecollectionCytoscape (v3.10.1)Shannon et al.92https://doi.org/10.1101/gr.1239303https://cytoscape.org/KSEA App (v1.0)Wiredja et al.93https://doi.org/10.1093/bioinformatics/btx415https://casecpb.shinyapps.io/ksea/R (v4.3.1)The R Projecthttps://www.r-project.org/ggplot2 (v3.5.0)CRANhttps://cran.r-project.org/web/packages/ggplot2/index.htmlggridges (v0.5.6)CRANhttps://cran.r-project.org/web/packages/ggridges/index.htmlggbeeswarm (v0.7.2)CRANhttps://cran.r-project.org/web/packages/ggbeeswarm/index.htmlwec (v0.4-1)te Grotenhuis et al.94https://doi.org/10.1007/s00038-016-0901-1https://cran.r-project.org/web/packages/wec/index.htmlMASS (v7.3\u201360.0.1)CRANhttps://cran.r-project.org/web/packages/MASS/index.htmlglmmTMB (v1.1.9)CRANhttps://cran.r-project.org/web/packages/glmmTMB/index.htmlAnalysis ScriptsThis paperhttps://doi.org/10.5281/zenodo.13737566"
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 9,
    "extraction_method": "jats_xml",
    "extraction_time": 2.5576250553131104,
    "data_pmids_checked": 9,
    "paper_id": "40037357",
    "extraction_date": "2025-12-19T20:39:30.536412",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40037357.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40036568": {
    "cbioportal_paper_citations": [
      "Multimodal learning has been widely and successfully applied in natural language and vision domains, but its application in multimodal biomedical datasets presents significant challenges due to the diversity of data sources, ranging from molecular profiles to image examinations of human bodies, and may have a high rate of missing information in each modality [1] (Figure 3). Additionally, in specific modalities, the data acquisition and preprocessing procedures can be different, which hampers the standardization and interoperability of data across studies. Multiple dataset portals have been established to maintain the multimodal biomedical data, including The Cancer Genome Atlas (TCGA) [139], International Cancer Genome Consortium (ICGC) [140], Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [141], and The cBioPortal for Cancer Genomics (cBioPortal) [142] for cancer research, the Diabetes Remission Clinical Trial (DiRECT) [143] consortium for type 2 diabetes, the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) [144] dataset for AD, and other portals like UK Biobank [145] for general digital health records, but the data size of specific cancer types or diseases remains limited, which may impede neural network training."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "32025007": [
        "Multimodal learning has been widely and successfully applied in natural language and vision domains, but its application in multimodal biomedical datasets presents significant challenges due to the diversity of data sources, ranging from molecular profiles to image examinations of human bodies, and may have a high rate of missing information in each modality [1] (Figure 3). Additionally, in specific modalities, the data acquisition and preprocessing procedures can be different, which hampers the standardization and interoperability of data across studies. Multiple dataset portals have been established to maintain the multimodal biomedical data, including The Cancer Genome Atlas (TCGA) [139], International Cancer Genome Consortium (ICGC) [140], Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [141], and The cBioPortal for Cancer Genomics (cBioPortal) [142] for cancer research, the Diabetes Remission Clinical Trial (DiRECT) [143] consortium for type 2 diabetes, the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) [144] dataset for AD, and other portals like UK Biobank [145] for general digital health records, but the data size of specific cancer types or diseases remains limited, which may impede neural network training."
      ],
      "29625055": [
        "Multimodal learning has been widely and successfully applied in natural language and vision domains, but its application in multimodal biomedical datasets presents significant challenges due to the diversity of data sources, ranging from molecular profiles to image examinations of human bodies, and may have a high rate of missing information in each modality [1] (Figure 3). Additionally, in specific modalities, the data acquisition and preprocessing procedures can be different, which hampers the standardization and interoperability of data across studies. Multiple dataset portals have been established to maintain the multimodal biomedical data, including The Cancer Genome Atlas (TCGA) [139], International Cancer Genome Consortium (ICGC) [140], Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [141], and The cBioPortal for Cancer Genomics (cBioPortal) [142] for cancer research, the Diabetes Remission Clinical Trial (DiRECT) [143] consortium for type 2 diabetes, the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) [144] dataset for AD, and other portals like UK Biobank [145] for general digital health records, but the data size of specific cancer types or diseases remains limited, which may impede neural network training."
      ],
      "36038778": [
        "CT scans or MRI scans are commonly used non-invasive imaging techniques in clinical settings, which provide the structure information of the human body and are intensively used for the diagnosis of cancers, heart disease, and brain injuries. Deep learning methods have been developed for automatically extracting the morphological features of these images and for downstream tasks of lesion detection and segmentation, image enhancement and reconstruction, sample classification, and prognosis prediction [100]. The integration of radiomics and genomics has extended the clinical applications of these images, allowing for the prediction of molecular mutation status from images [101] and the combination of radiomics and genomics features for complementary learning of clinical samples. Vanguri et al. introduced the DyAM framework, which integrates CT images, PD-L1 immunohistochemistry (IHC), and genomic features for predicting clinical responses in non-small cell lung cancer (NSCLC) patients treated with cancer immunotherapy [102]. Boehm et al. comprehensively characterized the multimodal datasets of high-grade serous ovarian cancer and proposed that a combination of histopathological, radiologic, and genomic features can better predict the prognosis of patients and aid in risk stratification [103]. Applying deep learning methods to integrate high-dimensional multimodal data would further improve the current models and would be promising for future clinical applications."
      ],
      "22522925": [
        "Multimodal learning has been widely and successfully applied in natural language and vision domains, but its application in multimodal biomedical datasets presents significant challenges due to the diversity of data sources, ranging from molecular profiles to image examinations of human bodies, and may have a high rate of missing information in each modality [1] (Figure 3). Additionally, in specific modalities, the data acquisition and preprocessing procedures can be different, which hampers the standardization and interoperability of data across studies. Multiple dataset portals have been established to maintain the multimodal biomedical data, including The Cancer Genome Atlas (TCGA) [139], International Cancer Genome Consortium (ICGC) [140], Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [141], and The cBioPortal for Cancer Genomics (cBioPortal) [142] for cancer research, the Diabetes Remission Clinical Trial (DiRECT) [143] consortium for type 2 diabetes, the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) [144] dataset for AD, and other portals like UK Biobank [145] for general digital health records, but the data size of specific cancer types or diseases remains limited, which may impede neural network training."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 0.9175033569335938,
    "data_pmids_checked": 4,
    "paper_id": "40036568",
    "extraction_date": "2025-12-19T20:39:31.454008",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40036568.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40050422": {
    "paper_id": "40050422",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "5A), correlating with poor overall patient survival (Supple-\nthe PAAD dataset available in cBioPortal, we identified 19,848 mentary Fig"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:34.177600",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40050422.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.211315155029297,
      "cbioportal_papers": 0.00033593177795410156,
      "pdf_extraction_pass2": 6.9901509284973145,
      "cbioportal_papers_pass2": 0.00033402442932128906,
      "used_full_extraction": true,
      "pdf_extraction": 14.201466083526611,
      "platform_mentions": 0.002593994140625,
      "data_citations": 0.00011992454528808594,
      "num_data_pmids_checked": 1
    }
  },
  "40027644": {
    "cbioportal_paper_citations": [
      "We obtained individual-level data of colorectal and lung adenocarcinoma data from The Cancer Genome Atlas Program (TCGA) Pancancer Atlas through the cBioPortal repository[29], as described before[5, 7, 9, 10, 21]. The data were publicly available and de-identified, making this an exempt study (category 4) that did not require an Institutional Review Board IRB review."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.18897604942321777,
    "data_pmids_checked": 0,
    "paper_id": "40027644",
    "extraction_date": "2025-12-19T20:39:34.391151",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40027644.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40033050": {
    "cbioportal_paper_citations": [
      "Analyzing genomic data in the TCGA and other public repositories effectively requires programming skills and it is often challenging for the non-specialists. Multiple web-based applications have been developed to facilitate TCGA data analysis, including cBioPortal, Web-TCGA, UCSC Xena, and GEPIA2 (Cerami et al, 2012; Deng et al, 2016; Goldman et al, 2020; Tang et al, 2019). Although these visual analysis interfaces reduced the barriers to data utilization for many investigators in the field, there is still a need for a centralized platform that integrates multiple methods for customized analyses. In particular, no interactive tool to date is equipped with sophisticated functional genomic analysis capabilities that allow examining transcriptomics data from various sources including TCGA, landmark immunotherapy studies, and one\u2019s own research. To address this need and democratize the use of high-throughput data in the cancer research field, we introduce The Cancer Genome Explorer (TCGEx), an open-source web-based analysis platform written in R/Shiny that offers several modules for sophisticated custom analyses. Using this novel interface, we investigated the TCGA skin cutaneous melanoma (SKCM) data and identified gene expression patterns and mutational subtypes associated with differential survival. We also examined intratumoral immune signatures using TCGEx machine learning modules and revealed miRNAs associated with elevated interferon-gamma (IFN\u03b3) signaling. We validated these findings on independent data sets from immune checkpoint inhibition (ICI) trials and further identified a cytokine signature associated with positive responses to ICI across multiple types of cancers.",
      "TCGEx was created using the R programming language and Shiny framework and it runs on a publicly accessible GNU/Linux server. TCGEx is designed to work with preprocessed harmonized data allowing rapid and interactive analyses of TCGA projects, landmark ICI studies, and custom data sets. Preprocessed TCGA data for the pipeline were prepared by integrating RNA sequencing (RNAseq), microRNA sequencing (miRNAseq), reverse phase protein array (RPPA) proteomics data, and clinical metadata. To that end, \u201ctidy\u201d gene expression data frames were merged by the 16-digit TCGA sample barcodes followed by the addition of clinical metadata at the patient level by matching the 12-digit TCGA sample barcode. The latter data type contains dozens of features ranging from patient demographics to tumor subtypes and genetic aberrations, and it changes depending on the study. We further expanded the sample-level metadata by incorporating intratumoral immune cell signatures described by Thorsson et al (Thorsson et al, 2018). The ICI data sets were downloaded as is from cBioPortal and CRI-iAtlas repositories (Gao et al, 2013; Eddy et al, 2020), and prepared for the TCGEx pipeline. cBioPortal data sets had variable normalization methods including CPM, RPKM, and FPKM; whereas CRI-iAtlas data sets were quartile-normalized. These data sets were used directly as hosted in the source repositories, with a few minor adjustments to the variable names to implement in our platform (the code for preparing these data sets can be found on the TCGEx GitHub repository). TCGEx provides convenient access to the entire CRI-iAtlas data object (i.e., pan-cancer) and its subsets divided based on the specific study. In addition, the sample-level metadata from these repositories were used directly without altering variable names; thus selection of multiple data sets for integrative analyses will only keep the variables that are shared by these data sets. TCGEx analysis starts by selecting one or more cancer projects in the data selection module. After data selection, relevant data objects are loaded into the session and passed to individual analysis modules (Fig. 1). TCGEx offers the following user-friendly modules with graphical interfaces: (i) Kaplan\u2013Meier survival analysis; (ii) Cox proportional hazards survival analysis; (iii) feature-to-metadata exploratory graphing; (iv) feature-to-feature correlation graphing; (v) correlative features analysis; (vi) heatmap and hierarchical clustering; (vii) gene set enrichment analysis (GSEA); (viii) receiving operating characteristics (ROC) analysis; (ix) principal component analysis (PCA); and (x) lasso/ridge/elastic net machine learning analysis. Each module allows users to examine specific data subsets such as metastatic and/or primary tumor biopsies as well as healthy control samples. Furthermore, flexible options enable users to tailor the pipeline to their specific needs and generate informative publication-ready plots. The TCGEx Shiny app consists of modularized R scripts facilitating troubleshooting and incorporation of the code into other analysis pipelines. Thus, TCGEx aims to reduce barriers to high-throughput data analysis in cancer research by providing a scalable and user-friendly solution."
    ],
    "cbioportal_platform_mentions": [
      "This module provides the interface for selecting from 33 TCGA and 14 ICI data sets to be analyzed in TCGEx. Upon data selection, preprocessed data objects are loaded, and descriptive statistics are visualized to help users examine the age and sex distribution of the selected patients as well as the tissue origin of the biopsy samples. TCGA data objects were prepared by the sample-level merging of the log10(cpm+1) transformed RNAseq/miRNAseq data, normalized RPPA proteomic data, and clinical metadata. To facilitate downstream analyses, we removed genes where expression was zero or not available (NA) in 25% or more of the samples in the TCGA data set. ICI studies obtained from CRI-iAtlas repository were quartile-normalized while the data downloaded from cBioPortal were normalized through RPKM, FPKM, or TPM methods. For convenience and more control over the analyses, we added options for normalizing user-uploaded data sets and filtering lowly-expressed genes. Unlike some of the previously available tools for TCGA data analysis (Goldman et al, 2020; Tang et al, 2019), TCGEx allows users to select single or multiple data sets for integrative analyses. It is important to note that data sets normalized with different methods cannot be merged for integrated analyses. The data selection module prevents selection of incompatible data sets featured on TCGEx. Additionally, the same type of count data (such as TPM or FPKM) can be associated with technical variation depending on the software and the reference transcriptome used. Thus, although we took measures to minimize erroneous analyses, it is ultimately users\u2019 responsibility to ensure that the integration of data sets are appropriate. If multiple TCGA projects are selected, preprocessed data sets are aggregated keeping only the matched features and clinical metadata variables. In the end, the data selection module creates a tidy data frame containing normalized RNAseq/miRNAseq/RPPA data and clinical metadata; and feeds it to the other analysis modules."
    ],
    "data_publication_citations": {
      "26091043": [
        "TCGEx interface enables exploring the gene expression landscape in cancer and provides access to numerous functional genomics analysis pipelines. Its modular code structure allows interaction with preprocessed TCGA data as well as data from other sources (Fig. 1). Distinctive features of TCGEx complement the available tools in the field and provide access to new analysis capabilities (Table EV1). In this study, we have used this tool to investigate the transcriptomic landscape of human melanoma and other cancers with the goal of identifying gene expression patterns associated with antitumor immunity and immunotherapy response. To demonstrate the platform\u2019s capabilities and show how it can be adapted by users with different research hypotheses, we focus on two different classes of genes in particular, miRNAs and cytokine/cytokine receptor genes. All the figures herein are obtained from the TCGEx interface unless noted otherwise. Melanoma is an aggressive form of cancer that develops in pigment-producing cells of the skin, although it can rarely be observed in other organs including the eye and gastrointestinal tract as well. More than 320,000 new cutaneous melanoma cases are reported globally each year, and 55,000+ lives are lost because of this disease (Sung et al, 2021). UV exposure is a significant risk factor for the development of melanoma, and most cases are diagnosed at an advanced stage where the cancer cells have already metastasized to nearby lymph nodes or distant organs. Accordingly, the TCGA-SKCM study is composed of mainly metastatic tumor biopsies (368 metastatic, 103 primary tumors), as shown in the TCGEx data selection module (Fig. 2A). These samples originated from comparable numbers of male and female patients in various age groups (Fig. 2B). The landmark TCGA paper describing the genetic features of SKCM classified tumors into subtypes based on mutations in BRAF, NF1, and RAS genes (Cancer Genome Atlas Network, 2015). These subtypes are characterized by distinct sets of accompanying genomic aberrations including PTEN loss in BRAF-mutant tumors, KIT amplification in triple wild-type (WT) tumors, Akt3 amplification in RAS-mutant and wild-type tumors, and upregulation in ITGB8 in NF1-mutant tumors which are readily observed in transcriptomics data (Fig. 2C). The expression profiles of these genes were largely consistent between metastatic and primary tumors; however, the smaller sample size in the primary tumor group resulted in a greater variability in the data (Fig. EV1A). When these graphs are faceted by patient sex, some of these genes showed sex-dependent differences in their expression patterns (Fig. EV1B,C). Interestingly, BRAF-mutant melanomas expressed higher levels of transferrin (TF) which was recently shown to protect circulating tumor cells from oxidative stress leading to BRAF inhibitor resistance (Fig. EV1D) (Hong et al, 2021). On the other hand, NF1-mutant melanoma was distinctly marked by the high expression of hepatocyte-specific transcription factor ONECUT1 which was shown to be associated with tumor progression (Fig. EV1D) (Zhao et al, 2014). Our analyses also revealed that ZC3H13, a component of the RNA methyltransferase complex, is enriched in RAS-mutant melanoma; and triple-WT tumors selectively expressed FOXF2, a transcription factor that plays a complex role in regulating oncogenic signaling pathways (Fig. EV1D) (He et al, 2020). These findings suggest that distinct molecular mechanisms may be responsible for driving different tumor subtypes in melanoma and indicate possible intervention points.Figure 1TCGEx workflow overview.TCGEx pipeline begins with the user selection of preprocessed transcriptomics data from a single TCGA project or multiple projects for integrated analyses. The data selection module shows descriptive statistics including the sample types, sex, and age distribution of the patients in the selected project(s). The data are subsequently passed onto ten distinct modules for specialized analyses including survival modeling, gene set enrichment analysis (GSEA), principal component analysis (PCA), correlation calculation, and exploratory graphing in the form of scatter plots, boxplots, and heatmaps. In each module, the user can further focus on specific sample types such as primary and/or metastatic tumor samples, and some modules allow further subsetting in the analyses. Algorithmic and graphical parameters are easily changed through visual and responsive user interfaces. TCGEx modules are supported by interactive tutorials and provide options to export analysis results and graphical outputs for publication purposes. TCGEx is freely available on the web as well as through a docker image. All the subsequent figures in this manuscript are generated using the TCGEx modules.Figure 2Analysis of mutational subsets in skin cutaneous melanoma.(A) The TCGA-SKCM project consists of mostly metastatic samples. Analyses described herein are performed on both metastatic and primary tumors. (B) Comparable numbers of male and female individuals from a range of age groups are included in the SKCM patient cohort. (C) Expression profiles of PTEN, ITGB8, AKT3, and KIT can distinguish mutational subtypes of SKCM (BRAF mutants n = 146, NF1 mutants n = 27, RAS mutants n = 91, Triple WT n = 44), suggesting different molecular signaling landscapes exist in disease subsets (Cancer Genome Atlas Network, 2015). Statistical comparisons are performed using the t test, although users have the option to select nonparametric Wilcoxon test here as well. The box represents the interquartile range (IQR), spanning from the 25th percentile (lower bound) to the 75th percentile (upper bound). The horizontal line within the box indicates the median (50th percentile). Whiskers extend to the smallest and largest values within 1.5 \u00d7 IQR from the lower (Q1) and upper (Q3) quartiles, respectively. The P values are adjusted for multiple comparisons (****P < 0.0001; **P < 0.01, *P < 0.05, nsP > 0.05). (D) Kaplan\u2013Meier survival analysis revealed that BRAF-mutant SKCM has the most favorable clinical outcome. Ten-year survival curves are shown where dashed lines indicate the median survival time points in each group. The risk table provided below the survival curve denotes the number of surviving patients (i.e., at-risk patients) at different follow-up times. The log-rank P value shown on the graph tests the null hypothesis that none of the groups are different from one another. (E) Survival modeling using only BRAF- and RAS-mutant melanoma patients suggests that males in the RAS-mutant group have poorer survival outcomes compared to BRAF-mutant males and females in general. TCGEx provides users with flexible options to change the color scheme and the range of time axis in the graphs.",
        "(A) The TCGA-SKCM project consists of mostly metastatic samples. Analyses described herein are performed on both metastatic and primary tumors. (B) Comparable numbers of male and female individuals from a range of age groups are included in the SKCM patient cohort. (C) Expression profiles of PTEN, ITGB8, AKT3, and KIT can distinguish mutational subtypes of SKCM (BRAF mutants n = 146, NF1 mutants n = 27, RAS mutants n = 91, Triple WT n = 44), suggesting different molecular signaling landscapes exist in disease subsets (Cancer Genome Atlas Network, 2015). Statistical comparisons are performed using the t test, although users have the option to select nonparametric Wilcoxon test here as well. The box represents the interquartile range (IQR), spanning from the 25th percentile (lower bound) to the 75th percentile (upper bound). The horizontal line within the box indicates the median (50th percentile). Whiskers extend to the smallest and largest values within 1.5 \u00d7 IQR from the lower (Q1) and upper (Q3) quartiles, respectively. The P values are adjusted for multiple comparisons (****P < 0.0001; **P < 0.01, *P < 0.05, nsP > 0.05). (D) Kaplan\u2013Meier survival analysis revealed that BRAF-mutant SKCM has the most favorable clinical outcome. Ten-year survival curves are shown where dashed lines indicate the median survival time points in each group. The risk table provided below the survival curve denotes the number of surviving patients (i.e., at-risk patients) at different follow-up times. The log-rank P value shown on the graph tests the null hypothesis that none of the groups are different from one another. (E) Survival modeling using only BRAF- and RAS-mutant melanoma patients suggests that males in the RAS-mutant group have poorer survival outcomes compared to BRAF-mutant males and females in general. TCGEx provides users with flexible options to change the color scheme and the range of time axis in the graphs.",
        "BRAF-mutant melanoma constitutes about 50% of the cases in the TCGA cohort followed by RAS-mutant (~30%), NF1-mutant, and triple-WT tumors (~10% each). Of these four groups, BRAF-mutant melanoma has the most favorable prognosis (Fig. 2D), although this may be confounded by the younger age of the patients in this group (Cancer Genome Atlas Network, 2015). While melanoma incidence is comparable between both sexes, females were reported to have a reduced risk of mortality (Morgese et al, 2020). Examination of the TCGA-SKCM cohort as a whole did not show a significant survival difference between the two groups; however, a slightly increased risk was observed for the males (Appendix Fig. S1a,b). Notably, when we examined only BRAF and NRAS-mutant tumors, males were associated with poorer survival outcomes, especially in the NRAS-mutant subgroup (Fig. 2E). These analyses conducted on the entire SKCM cohort were repeated separately for metastatic and primary tumors, and possibly due to low sample numbers, clear survival differences were not observed between mutational subtypes in primary tumors (Appendix Fig. S1c\u2013f). Taken together our findings suggest that sex-specific factors may differentially influence the prognosis in different mutation subtypes.",
        "In addition to defining potential genetic drivers in melanoma, the TCGA-SKCM manuscript also identified three distinct tumor subsets based on gene expression profiles immune, keratin, and MITF-low groups (Cancer Genome Atlas Network, 2015). The immune subset was characterized by the higher expression of immune cell-specific genes (Fig. 3A), while the keratin and MITF-low subsets were characterized by the high and low expression of epithelial genes, respectively, in the absence of a clear immune infiltration signature. Of these three groups, the immune-enriched subset exhibits the most favorable survival outcome as analyzed in the RNAseq and the RPPA data (Fig. 3B; Appendix Fig. S2a\u2013d), which is consistent with the positive role of inflammation in SKCM reported previously (Thorsson et al, 2018). IFN\u03b3 is a key inflammatory cytokine released from T and NK cells to eliminate tumor cells. IFN\u03b3 exerts its multifaceted functions within the TME by signaling through IFN\u03b3-receptors (IFNGR) and regulating dozens of downstream genes in tumor cells and the neighboring immune cells (Parker et al, 2016). We examined IFN\u03b3 response gene expression signature in SKCM subsets and observed higher levels of most of these transcripts in the immune subset (Fig. 3C) (Liberzon et al, 2011), and as expected, these trends were paralleled by the elevated IFN\u03b3 transcript levels and CD8 + T-cell signatures within the TME. We next wanted to investigate the relationship between the intratumoral CD8 + T-cell score and the T-cell receptor (TCR) diversity (Thorsson et al, 2018). This is of interest because multiple studies have suggested that the clonally expanded T cells within melanoma are associated with a spectrum of dysfunctional phenotypes (Tirosh et al, 2016; Li et al, 2019). Increasing CD8 + T-cell signature within the TCGA-SKCM tumors positively correlated with the overall TCR diversity, suggesting a polyclonal T-cell infiltrate and the presence of T-cell clones with different antigenic specificities (Fig. 3D) (van der Leun et al, 2020). Notably, the increased TCR diversity correlated with higher levels of cytotoxic effector molecule perforin (PRF1) and decreasing genetic signatures of M2 macrophages that are known to exert pro-tumorigenic functions (Fig. 3E) (Thorsson et al, 2018). Taken together, TCGEx can be utilized to explore multifaceted data types in TCGA including the tumor-specific subtypes and the intratumoral immune landscape.Figure 3Analysis of the melanoma intratumoral immune landscape.(A) The immune-enriched melanoma subset previously defined based on multi-gene expression profiles (Cancer Genome Atlas Network, 2015) is characterized by higher levels of PTPRC (CD45, a pan-leukocyte marker) and CD3E (a T-cell marker) transcripts (Immune n = 163, Keratin n = 101, MITF-low n = 58). The box represents the interquartile range (IQR), spanning from the 25th percentile (lower bound) to the 75th percentile (upper bound). The horizontal line within the box indicates the median (50th percentile). Whiskers extend to the smallest and largest values within 1.5 \u00d7 IQR from the lower (Q1) and upper (Q3) quartiles, respectively. T test P values are adjusted for multiple comparisons (P < 0.0001, \u201c****\u201d). (B) Immune subset of the SKCM is associated with an improved survival outcome compared to keratin and MITF-low subsets. (C) Heatmap visualization of the top 25% variably expressed genes from the MSigDB Hallmark IFN\u03b3 response gene set (Liberzon et al, 2011) in primary and metastatic melanoma is shown (50 out of 200 genes are plotted). The annotation rows on top of the heatmap were prepared by categorizing IFN\u03b3 transcript level and CIBERSORT CD8 + T-cell score (Newman et al, 2015) at their median values. Melanoma subsets defined previously based on genome-wide expression patterns are also shown. CPM-normalized and log-transformed transcript counts are scaled by row to better show expression differences in data subsets. The default TCGEx parameters were used for hierarchical clustering (Euclidean distance and Ward.D2 clustering algorithm for both genes and samples). (D) Increasing intratumoral CD8 + T-cell signature is associated with a higher TCR diversity suggesting a polyclonal T-cell infiltrate. The Pearson correlation test was used for statistical analysis. (E) The higher TCR diversity in melanoma tumors correlates with increased levels of T-cell effector genes including perforin (PRF1) and IFN\u03b3 and decreased pro-tumorigenic M2 macrophage signatures (Thorsson et al, 2018). Statistical analysis was performed using the Pearson correlation test, and the corresponding P values are shown.",
        "(A) The immune-enriched melanoma subset previously defined based on multi-gene expression profiles (Cancer Genome Atlas Network, 2015) is characterized by higher levels of PTPRC (CD45, a pan-leukocyte marker) and CD3E (a T-cell marker) transcripts (Immune n = 163, Keratin n = 101, MITF-low n = 58). The box represents the interquartile range (IQR), spanning from the 25th percentile (lower bound) to the 75th percentile (upper bound). The horizontal line within the box indicates the median (50th percentile). Whiskers extend to the smallest and largest values within 1.5 \u00d7 IQR from the lower (Q1) and upper (Q3) quartiles, respectively. T test P values are adjusted for multiple comparisons (P < 0.0001, \u201c****\u201d). (B) Immune subset of the SKCM is associated with an improved survival outcome compared to keratin and MITF-low subsets. (C) Heatmap visualization of the top 25% variably expressed genes from the MSigDB Hallmark IFN\u03b3 response gene set (Liberzon et al, 2011) in primary and metastatic melanoma is shown (50 out of 200 genes are plotted). The annotation rows on top of the heatmap were prepared by categorizing IFN\u03b3 transcript level and CIBERSORT CD8 + T-cell score (Newman et al, 2015) at their median values. Melanoma subsets defined previously based on genome-wide expression patterns are also shown. CPM-normalized and log-transformed transcript counts are scaled by row to better show expression differences in data subsets. The default TCGEx parameters were used for hierarchical clustering (Euclidean distance and Ward.D2 clustering algorithm for both genes and samples). (D) Increasing intratumoral CD8 + T-cell signature is associated with a higher TCR diversity suggesting a polyclonal T-cell infiltrate. The Pearson correlation test was used for statistical analysis. (E) The higher TCR diversity in melanoma tumors correlates with increased levels of T-cell effector genes including perforin (PRF1) and IFN\u03b3 and decreased pro-tumorigenic M2 macrophage signatures (Thorsson et al, 2018). Statistical analysis was performed using the Pearson correlation test, and the corresponding P values are shown.",
        "In this module, users can explore the relationship between gene expression and categorical clinical meta-variables. Categorical variables vary according to tumor type, and they include disease pathological stage, patient sex and race, tumor molecular subtype (Berger et al, 2018; Cancer Genome Atlas Network, 2015), genome-wide methylation state (Cancer Genome Atlas Network, 2015), oncogenic signaling (OncoSign) cluster type (Ciriello et al, 2013), genetic aberrations (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020), genomic instability levels (Muzny et al, 2012), intratumoral lymphocyte scores (Cancer Genome Atlas Network, 2015), and numerous other metadata features (Dataset EV1). This module allows selecting specific categories to generate gene expression plots to emphasize differences in data subsets. To offer more flexibility in the analyses, we also added an optional faceting variable which can further break data into subcategories. This way, for instance, it becomes possible to plot the expression of a given gene in various mutation subsets in male and female patients separately. To facilitate publication-ready plotting, the program allows the user to select journal-specific color palettes, toggle individual data points on/off, and define specific statistical comparisons to highlight. Here, users can select the t test or Wilcoxon test for pairwise comparisons between data sub-groups. Thus, this module helps researchers explore gene expression in clinically meaningful data subsets."
      ],
      "29033130": [
        "TCGEx features ten analysis modules that can be flexibly adapted to various study contexts. Integrative analyses by aggregating data from multiple projects are also possible to investigate commonalities and differences among cancers. TCGEx\u2019s comprehensive computational pipeline utilizes preprocessed data from the TCGA repository that was prepared by combining transcriptomics data with clinical metadata and intratumoral immune signatures described by the leading studies in the field (Thorsson et al, 2018). Additionally, TCGEx features transcriptomic data from multiple landmark ICI studies (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Zhao et al, 2019; Cloughesy et al, 2019; Miao et al, 2018; Liu et al, 2019; Kim et al, 2018; Rosenberg et al, 2016; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016) and it allows users to upload and analyze their own data sets. We provide step-by-step in-app tutorials to increase user-friendliness and help researchers implement TCGEx into their workflows and generate publication-ready plots. TCGEx is publicly available without requiring user registration at https://tcgex.iyte.edu.tr web server as well as through a docker image to facilitate local execution and open-source program development (https://hub.docker.com/r/atakanekiz/tcgex). The source code of TCGEx is accessible at https://github.com/atakanekiz/TCGEx.",
        "Next, we wanted to validate the associations between miRNAs and intratumoral IFN\u03b3 signature in independent data sets obtained from melanoma biopsies prior to ICI therapy (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). No miRNA sequencing has been done in these clinical trials yet, but the miRNA host gene expression is available in the RNAseq data. We observed that the expression of the mature miRNAs and their host genes show a strong positive correlation in the TCGA data (Appendix Fig. S3), and thus we focused on the miRNA host genes in the ICI data sets as a surrogate for mature miRNA expression. Using quartile-normalized integrated data from 5 different melanoma ICI studies (313 total samples prior to treatment with anti-CTLA4 or anti-PD1), we constructed lasso regression against the averaged IFN\u03b3 signature genes as the response variable and 45 miRNA genes that are expressed in at least 25% of the samples as the predictor variables (Fig. 5A). This model predicted 11 miRNAs with positive coefficients, including MIR155HG, and 2 miRNAs with negative coefficients at the maximum penalization within 1 standard error of the minimum cross-validation error (Fig. 5B,C). We showed that MIR155HG expression is positively correlated with the cytotoxic lymphocyte markers CD8A, IFNG, and PRF1 across melanoma ICI data sets (Fig. 5D). As expected, the GSEA analysis revealed an enrichment of IFN\u03b3 signaling in MIR155HG-high samples (Fig. 5E). After validating MIR155HG\u2019s association with intratumoral immunity in melanoma ICI data, we performed similar analyses on pre-treatment Pan-ICI data prepared by integrating 10 quartile-normalized ICI studies (5 melanoma, 3 kidney, 1 stomach, and 1 bladder cancer studies adding up to 938 samples prior to treatment with anti-CTLA4, anti-PD1 or anti-PD-L1 inhibitors) (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Miao et al, 2018; Kim et al, 2018; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016; Liu et al, 2019). Lasso modeling against averaged IFN\u03b3-responsive genes revealed 15 (including MIR155HG), and 7 miRNA genes with positive and negative coefficients, respectively (Fig. 5F\u2013H) which were mostly consistent with the melanoma-specific analyses. When the genome-wide expression patterns of the pan-ICI pre-treatment data were examined, we noted that MIR155HG-high subset was associated with an enrichment of IFN\u03b3-responsive gene set (Fig. 5I) as well as other pathways associated with the immune response (Fig. 5J). Taken together, machine learning-based analysis of melanoma and other tumor biopsies revealed the miRNAs associated with antitumor immunity and further supported the connection between intratumoral IFN\u03b3 signaling and MIR155HG. We provide step-by-step instructions to reproduce Figs. 4 and 5 to assist users in performing similar analyses (Appendix). As these data originate from bulk methods, it is not possible to ascertain the gene expression to specific cell types within the TME, however, there is literature supporting the immunoregulatory roles of MIR155HG in both tumor cells and the infiltrating immune cells (Curti et al, 2022; Hsin et al, 2018). To examine which cell types within the melanoma TME could express MIR155HG and other ML-identified miRNAs, we turned to publicly available single-cell RNA data hosted on the Broad Institute Single Cell Portal (Tarhan et al, 2023). We examined three data sets featuring immune cells and malignant cells from primary and metastatic melanoma biopsies (Tirosh et al, 2016; Jerby-Arnon et al, 2018; Teijeira et al, 2019). Not all miRNAs were found in these data sets possibly due to low-expression levels, and the detected miRNAs showed variable expression patterns across malignant and immune cell clusters (Fig. EV3A,C,D,G\u2013I). While some miRNAs were broadly expressed (e.g., MIR17HG, MIR210HG, and MIRLET7BHG), MIR155HG expression was selective to the infiltrating T cells (Fig. EV3B,E,J). In particular, the highest MIR155HG expression was observed in CD8+ cytotoxic T lymphocytes that are cycling or exhausted (Fig. EV3G,H,K). Notably, melanoma tumor cells expressed low amounts of MIR155HG (Fig. EV3D,J), suggesting miRNAs not only indicate the presence of immune cells within the TME but can also mark their activation state.Figure 5Investigating the associations between miRNAs and immunity markers in cancer immunotherapy studies.(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method.",
        "(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method."
      ],
      "22810696": [
        "The Cancer Genome Atlas (TCGA) launched in 2006 is among the most ambitious projects to better understand and tackle human cancer (Blum et al, 2018). As of this writing, more than 11,000 tumor samples and matched healthy tissues have been characterized at the molecular level across 33 different cancer types as part of this initiative. TCGA studies employ a variety of experimental approaches including RNA and microRNA (miRNA) sequencing, whole-exome sequencing, and genotyping and methylation arrays to generate 2.5+ petabytes of publicly available data. Landmark studies from the TCGA network described common genetic aberrations in cancer such as TP53 loss (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020) as well as other cancer-specific changes including BRCA1/2 mutations in breast and ovarian tumors (Bell et al, 2011; Koboldt et al, 2012) and APC mutations in colorectal carcinoma (Muzny et al, 2012). Furthermore, transcriptomic profiling has led to the characterization of immune signatures within the tumor microenvironment (TME). Follow-up studies have revealed that the genomic and transcriptomic features of tumors determine whether they will respond to targeted therapies and immunotherapeutics (Van Allen et al, 2015; Hugo et al, 2015; Ayers et al, 2017; Auslander et al, 2018), suggesting that a better understanding of the heterogeneity within the TME is essential for improved therapeutics and clinical outcomes.",
        "In this module, users can explore the relationship between gene expression and categorical clinical meta-variables. Categorical variables vary according to tumor type, and they include disease pathological stage, patient sex and race, tumor molecular subtype (Berger et al, 2018; Cancer Genome Atlas Network, 2015), genome-wide methylation state (Cancer Genome Atlas Network, 2015), oncogenic signaling (OncoSign) cluster type (Ciriello et al, 2013), genetic aberrations (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020), genomic instability levels (Muzny et al, 2012), intratumoral lymphocyte scores (Cancer Genome Atlas Network, 2015), and numerous other metadata features (Dataset EV1). This module allows selecting specific categories to generate gene expression plots to emphasize differences in data subsets. To offer more flexibility in the analyses, we also added an optional faceting variable which can further break data into subcategories. This way, for instance, it becomes possible to plot the expression of a given gene in various mutation subsets in male and female patients separately. To facilitate publication-ready plotting, the program allows the user to select journal-specific color palettes, toggle individual data points on/off, and define specific statistical comparisons to highlight. Here, users can select the t test or Wilcoxon test for pairwise comparisons between data sub-groups. Thus, this module helps researchers explore gene expression in clinically meaningful data subsets."
      ],
      "23000897": [
        "The Cancer Genome Atlas (TCGA) launched in 2006 is among the most ambitious projects to better understand and tackle human cancer (Blum et al, 2018). As of this writing, more than 11,000 tumor samples and matched healthy tissues have been characterized at the molecular level across 33 different cancer types as part of this initiative. TCGA studies employ a variety of experimental approaches including RNA and microRNA (miRNA) sequencing, whole-exome sequencing, and genotyping and methylation arrays to generate 2.5+ petabytes of publicly available data. Landmark studies from the TCGA network described common genetic aberrations in cancer such as TP53 loss (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020) as well as other cancer-specific changes including BRCA1/2 mutations in breast and ovarian tumors (Bell et al, 2011; Koboldt et al, 2012) and APC mutations in colorectal carcinoma (Muzny et al, 2012). Furthermore, transcriptomic profiling has led to the characterization of immune signatures within the tumor microenvironment (TME). Follow-up studies have revealed that the genomic and transcriptomic features of tumors determine whether they will respond to targeted therapies and immunotherapeutics (Van Allen et al, 2015; Hugo et al, 2015; Ayers et al, 2017; Auslander et al, 2018), suggesting that a better understanding of the heterogeneity within the TME is essential for improved therapeutics and clinical outcomes."
      ],
      "31792460": [
        "TCGEx features ten analysis modules that can be flexibly adapted to various study contexts. Integrative analyses by aggregating data from multiple projects are also possible to investigate commonalities and differences among cancers. TCGEx\u2019s comprehensive computational pipeline utilizes preprocessed data from the TCGA repository that was prepared by combining transcriptomics data with clinical metadata and intratumoral immune signatures described by the leading studies in the field (Thorsson et al, 2018). Additionally, TCGEx features transcriptomic data from multiple landmark ICI studies (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Zhao et al, 2019; Cloughesy et al, 2019; Miao et al, 2018; Liu et al, 2019; Kim et al, 2018; Rosenberg et al, 2016; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016) and it allows users to upload and analyze their own data sets. We provide step-by-step in-app tutorials to increase user-friendliness and help researchers implement TCGEx into their workflows and generate publication-ready plots. TCGEx is publicly available without requiring user registration at https://tcgex.iyte.edu.tr web server as well as through a docker image to facilitate local execution and open-source program development (https://hub.docker.com/r/atakanekiz/tcgex). The source code of TCGEx is accessible at https://github.com/atakanekiz/TCGEx.",
        "Next, we wanted to validate the associations between miRNAs and intratumoral IFN\u03b3 signature in independent data sets obtained from melanoma biopsies prior to ICI therapy (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). No miRNA sequencing has been done in these clinical trials yet, but the miRNA host gene expression is available in the RNAseq data. We observed that the expression of the mature miRNAs and their host genes show a strong positive correlation in the TCGA data (Appendix Fig. S3), and thus we focused on the miRNA host genes in the ICI data sets as a surrogate for mature miRNA expression. Using quartile-normalized integrated data from 5 different melanoma ICI studies (313 total samples prior to treatment with anti-CTLA4 or anti-PD1), we constructed lasso regression against the averaged IFN\u03b3 signature genes as the response variable and 45 miRNA genes that are expressed in at least 25% of the samples as the predictor variables (Fig. 5A). This model predicted 11 miRNAs with positive coefficients, including MIR155HG, and 2 miRNAs with negative coefficients at the maximum penalization within 1 standard error of the minimum cross-validation error (Fig. 5B,C). We showed that MIR155HG expression is positively correlated with the cytotoxic lymphocyte markers CD8A, IFNG, and PRF1 across melanoma ICI data sets (Fig. 5D). As expected, the GSEA analysis revealed an enrichment of IFN\u03b3 signaling in MIR155HG-high samples (Fig. 5E). After validating MIR155HG\u2019s association with intratumoral immunity in melanoma ICI data, we performed similar analyses on pre-treatment Pan-ICI data prepared by integrating 10 quartile-normalized ICI studies (5 melanoma, 3 kidney, 1 stomach, and 1 bladder cancer studies adding up to 938 samples prior to treatment with anti-CTLA4, anti-PD1 or anti-PD-L1 inhibitors) (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Miao et al, 2018; Kim et al, 2018; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016; Liu et al, 2019). Lasso modeling against averaged IFN\u03b3-responsive genes revealed 15 (including MIR155HG), and 7 miRNA genes with positive and negative coefficients, respectively (Fig. 5F\u2013H) which were mostly consistent with the melanoma-specific analyses. When the genome-wide expression patterns of the pan-ICI pre-treatment data were examined, we noted that MIR155HG-high subset was associated with an enrichment of IFN\u03b3-responsive gene set (Fig. 5I) as well as other pathways associated with the immune response (Fig. 5J). Taken together, machine learning-based analysis of melanoma and other tumor biopsies revealed the miRNAs associated with antitumor immunity and further supported the connection between intratumoral IFN\u03b3 signaling and MIR155HG. We provide step-by-step instructions to reproduce Figs. 4 and 5 to assist users in performing similar analyses (Appendix). As these data originate from bulk methods, it is not possible to ascertain the gene expression to specific cell types within the TME, however, there is literature supporting the immunoregulatory roles of MIR155HG in both tumor cells and the infiltrating immune cells (Curti et al, 2022; Hsin et al, 2018). To examine which cell types within the melanoma TME could express MIR155HG and other ML-identified miRNAs, we turned to publicly available single-cell RNA data hosted on the Broad Institute Single Cell Portal (Tarhan et al, 2023). We examined three data sets featuring immune cells and malignant cells from primary and metastatic melanoma biopsies (Tirosh et al, 2016; Jerby-Arnon et al, 2018; Teijeira et al, 2019). Not all miRNAs were found in these data sets possibly due to low-expression levels, and the detected miRNAs showed variable expression patterns across malignant and immune cell clusters (Fig. EV3A,C,D,G\u2013I). While some miRNAs were broadly expressed (e.g., MIR17HG, MIR210HG, and MIRLET7BHG), MIR155HG expression was selective to the infiltrating T cells (Fig. EV3B,E,J). In particular, the highest MIR155HG expression was observed in CD8+ cytotoxic T lymphocytes that are cycling or exhausted (Fig. EV3G,H,K). Notably, melanoma tumor cells expressed low amounts of MIR155HG (Fig. EV3D,J), suggesting miRNAs not only indicate the presence of immune cells within the TME but can also mark their activation state.Figure 5Investigating the associations between miRNAs and immunity markers in cancer immunotherapy studies.(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method.",
        "(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method."
      ],
      "29867230": [
        "TCGEx features ten analysis modules that can be flexibly adapted to various study contexts. Integrative analyses by aggregating data from multiple projects are also possible to investigate commonalities and differences among cancers. TCGEx\u2019s comprehensive computational pipeline utilizes preprocessed data from the TCGA repository that was prepared by combining transcriptomics data with clinical metadata and intratumoral immune signatures described by the leading studies in the field (Thorsson et al, 2018). Additionally, TCGEx features transcriptomic data from multiple landmark ICI studies (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Zhao et al, 2019; Cloughesy et al, 2019; Miao et al, 2018; Liu et al, 2019; Kim et al, 2018; Rosenberg et al, 2016; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016) and it allows users to upload and analyze their own data sets. We provide step-by-step in-app tutorials to increase user-friendliness and help researchers implement TCGEx into their workflows and generate publication-ready plots. TCGEx is publicly available without requiring user registration at https://tcgex.iyte.edu.tr web server as well as through a docker image to facilitate local execution and open-source program development (https://hub.docker.com/r/atakanekiz/tcgex). The source code of TCGEx is accessible at https://github.com/atakanekiz/TCGEx.",
        "Next, we wanted to validate the associations between miRNAs and intratumoral IFN\u03b3 signature in independent data sets obtained from melanoma biopsies prior to ICI therapy (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). No miRNA sequencing has been done in these clinical trials yet, but the miRNA host gene expression is available in the RNAseq data. We observed that the expression of the mature miRNAs and their host genes show a strong positive correlation in the TCGA data (Appendix Fig. S3), and thus we focused on the miRNA host genes in the ICI data sets as a surrogate for mature miRNA expression. Using quartile-normalized integrated data from 5 different melanoma ICI studies (313 total samples prior to treatment with anti-CTLA4 or anti-PD1), we constructed lasso regression against the averaged IFN\u03b3 signature genes as the response variable and 45 miRNA genes that are expressed in at least 25% of the samples as the predictor variables (Fig. 5A). This model predicted 11 miRNAs with positive coefficients, including MIR155HG, and 2 miRNAs with negative coefficients at the maximum penalization within 1 standard error of the minimum cross-validation error (Fig. 5B,C). We showed that MIR155HG expression is positively correlated with the cytotoxic lymphocyte markers CD8A, IFNG, and PRF1 across melanoma ICI data sets (Fig. 5D). As expected, the GSEA analysis revealed an enrichment of IFN\u03b3 signaling in MIR155HG-high samples (Fig. 5E). After validating MIR155HG\u2019s association with intratumoral immunity in melanoma ICI data, we performed similar analyses on pre-treatment Pan-ICI data prepared by integrating 10 quartile-normalized ICI studies (5 melanoma, 3 kidney, 1 stomach, and 1 bladder cancer studies adding up to 938 samples prior to treatment with anti-CTLA4, anti-PD1 or anti-PD-L1 inhibitors) (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Miao et al, 2018; Kim et al, 2018; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016; Liu et al, 2019). Lasso modeling against averaged IFN\u03b3-responsive genes revealed 15 (including MIR155HG), and 7 miRNA genes with positive and negative coefficients, respectively (Fig. 5F\u2013H) which were mostly consistent with the melanoma-specific analyses. When the genome-wide expression patterns of the pan-ICI pre-treatment data were examined, we noted that MIR155HG-high subset was associated with an enrichment of IFN\u03b3-responsive gene set (Fig. 5I) as well as other pathways associated with the immune response (Fig. 5J). Taken together, machine learning-based analysis of melanoma and other tumor biopsies revealed the miRNAs associated with antitumor immunity and further supported the connection between intratumoral IFN\u03b3 signaling and MIR155HG. We provide step-by-step instructions to reproduce Figs. 4 and 5 to assist users in performing similar analyses (Appendix). As these data originate from bulk methods, it is not possible to ascertain the gene expression to specific cell types within the TME, however, there is literature supporting the immunoregulatory roles of MIR155HG in both tumor cells and the infiltrating immune cells (Curti et al, 2022; Hsin et al, 2018). To examine which cell types within the melanoma TME could express MIR155HG and other ML-identified miRNAs, we turned to publicly available single-cell RNA data hosted on the Broad Institute Single Cell Portal (Tarhan et al, 2023). We examined three data sets featuring immune cells and malignant cells from primary and metastatic melanoma biopsies (Tirosh et al, 2016; Jerby-Arnon et al, 2018; Teijeira et al, 2019). Not all miRNAs were found in these data sets possibly due to low-expression levels, and the detected miRNAs showed variable expression patterns across malignant and immune cell clusters (Fig. EV3A,C,D,G\u2013I). While some miRNAs were broadly expressed (e.g., MIR17HG, MIR210HG, and MIRLET7BHG), MIR155HG expression was selective to the infiltrating T cells (Fig. EV3B,E,J). In particular, the highest MIR155HG expression was observed in CD8+ cytotoxic T lymphocytes that are cycling or exhausted (Fig. EV3G,H,K). Notably, melanoma tumor cells expressed low amounts of MIR155HG (Fig. EV3D,J), suggesting miRNAs not only indicate the presence of immune cells within the TME but can also mark their activation state.Figure 5Investigating the associations between miRNAs and immunity markers in cancer immunotherapy studies.(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method."
      ],
      "30742119": [
        "TCGEx features ten analysis modules that can be flexibly adapted to various study contexts. Integrative analyses by aggregating data from multiple projects are also possible to investigate commonalities and differences among cancers. TCGEx\u2019s comprehensive computational pipeline utilizes preprocessed data from the TCGA repository that was prepared by combining transcriptomics data with clinical metadata and intratumoral immune signatures described by the leading studies in the field (Thorsson et al, 2018). Additionally, TCGEx features transcriptomic data from multiple landmark ICI studies (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Zhao et al, 2019; Cloughesy et al, 2019; Miao et al, 2018; Liu et al, 2019; Kim et al, 2018; Rosenberg et al, 2016; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016) and it allows users to upload and analyze their own data sets. We provide step-by-step in-app tutorials to increase user-friendliness and help researchers implement TCGEx into their workflows and generate publication-ready plots. TCGEx is publicly available without requiring user registration at https://tcgex.iyte.edu.tr web server as well as through a docker image to facilitate local execution and open-source program development (https://hub.docker.com/r/atakanekiz/tcgex). The source code of TCGEx is accessible at https://github.com/atakanekiz/TCGEx."
      ],
      "32025007": [
        "The Cancer Genome Atlas (TCGA) launched in 2006 is among the most ambitious projects to better understand and tackle human cancer (Blum et al, 2018). As of this writing, more than 11,000 tumor samples and matched healthy tissues have been characterized at the molecular level across 33 different cancer types as part of this initiative. TCGA studies employ a variety of experimental approaches including RNA and microRNA (miRNA) sequencing, whole-exome sequencing, and genotyping and methylation arrays to generate 2.5+ petabytes of publicly available data. Landmark studies from the TCGA network described common genetic aberrations in cancer such as TP53 loss (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020) as well as other cancer-specific changes including BRCA1/2 mutations in breast and ovarian tumors (Bell et al, 2011; Koboldt et al, 2012) and APC mutations in colorectal carcinoma (Muzny et al, 2012). Furthermore, transcriptomic profiling has led to the characterization of immune signatures within the tumor microenvironment (TME). Follow-up studies have revealed that the genomic and transcriptomic features of tumors determine whether they will respond to targeted therapies and immunotherapeutics (Van Allen et al, 2015; Hugo et al, 2015; Ayers et al, 2017; Auslander et al, 2018), suggesting that a better understanding of the heterogeneity within the TME is essential for improved therapeutics and clinical outcomes.",
        "In this module, users can explore the relationship between gene expression and categorical clinical meta-variables. Categorical variables vary according to tumor type, and they include disease pathological stage, patient sex and race, tumor molecular subtype (Berger et al, 2018; Cancer Genome Atlas Network, 2015), genome-wide methylation state (Cancer Genome Atlas Network, 2015), oncogenic signaling (OncoSign) cluster type (Ciriello et al, 2013), genetic aberrations (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020), genomic instability levels (Muzny et al, 2012), intratumoral lymphocyte scores (Cancer Genome Atlas Network, 2015), and numerous other metadata features (Dataset EV1). This module allows selecting specific categories to generate gene expression plots to emphasize differences in data subsets. To offer more flexibility in the analyses, we also added an optional faceting variable which can further break data into subcategories. This way, for instance, it becomes possible to plot the expression of a given gene in various mutation subsets in male and female patients separately. To facilitate publication-ready plotting, the program allows the user to select journal-specific color palettes, toggle individual data points on/off, and define specific statistical comparisons to highlight. Here, users can select the t test or Wilcoxon test for pairwise comparisons between data sub-groups. Thus, this module helps researchers explore gene expression in clinically meaningful data subsets."
      ],
      "29625055": [
        "Studying the association between gene expression and survival outcome is important for understanding key mechanisms of cancer progression (Liu et al, 2018). TCGEx features two distinct survival analysis methods: Kaplan\u2013Meier (KM) and Cox proportional hazards (CoxPH) modeling (Rich et al, 2010; Breslow, 1975). In both modules, categorical and continuous variables can be examined. Categorical meta-variables can differ between data sets, but it can include tumor grade, mutation types, and patient demographic information, among other features. Continuous variables such as gene expression and intratumoral immune cell signatures (Thorsson et al, 2018) can be directly modeled in CoxPH analysis or they can be categorized as \u201chigh\u201d, \u201cmid\u201d, and \u201clow\u201d at user-defined thresholds for KM analysis. If more than one cancer type is selected by the user, gene expression can be categorized across all the projects at a common threshold, or within each cancer type separately. In KM analysis involving categorical variables, the user can further determine data subsets to include in the analysis and further customize the pipeline. Both KM and CoxPH modules allow including covariates in the model to examine the association of multiple variables with the survival outcome simultaneously. Furthermore, the CoxPH module is designed to accept user-defined interaction terms to accommodate arbitrarily complex multivariable study designs. Survival analysis pipelines of TCGEx generate customizable plots and show various statistical details including log-rank P value for KM and CoxPH, and likelihood ratio test and Wald test p values along with hazard ratios for CoxPH. In addition, the proportionality assumption of the CoxPH model is checked using Schoenfeld residuals against time, and the user is prompted a message regarding the validity of the model. Taken together, TCGEx survival analysis modules provide flexible options for customizing analysis to specific needs and studying the relationship between gene expression and survival outcomes in cancer."
      ],
      "27939400": [
        "TCGEx features ten analysis modules that can be flexibly adapted to various study contexts. Integrative analyses by aggregating data from multiple projects are also possible to investigate commonalities and differences among cancers. TCGEx\u2019s comprehensive computational pipeline utilizes preprocessed data from the TCGA repository that was prepared by combining transcriptomics data with clinical metadata and intratumoral immune signatures described by the leading studies in the field (Thorsson et al, 2018). Additionally, TCGEx features transcriptomic data from multiple landmark ICI studies (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Zhao et al, 2019; Cloughesy et al, 2019; Miao et al, 2018; Liu et al, 2019; Kim et al, 2018; Rosenberg et al, 2016; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016) and it allows users to upload and analyze their own data sets. We provide step-by-step in-app tutorials to increase user-friendliness and help researchers implement TCGEx into their workflows and generate publication-ready plots. TCGEx is publicly available without requiring user registration at https://tcgex.iyte.edu.tr web server as well as through a docker image to facilitate local execution and open-source program development (https://hub.docker.com/r/atakanekiz/tcgex). The source code of TCGEx is accessible at https://github.com/atakanekiz/TCGEx.",
        "Next, we wanted to validate the associations between miRNAs and intratumoral IFN\u03b3 signature in independent data sets obtained from melanoma biopsies prior to ICI therapy (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). No miRNA sequencing has been done in these clinical trials yet, but the miRNA host gene expression is available in the RNAseq data. We observed that the expression of the mature miRNAs and their host genes show a strong positive correlation in the TCGA data (Appendix Fig. S3), and thus we focused on the miRNA host genes in the ICI data sets as a surrogate for mature miRNA expression. Using quartile-normalized integrated data from 5 different melanoma ICI studies (313 total samples prior to treatment with anti-CTLA4 or anti-PD1), we constructed lasso regression against the averaged IFN\u03b3 signature genes as the response variable and 45 miRNA genes that are expressed in at least 25% of the samples as the predictor variables (Fig. 5A). This model predicted 11 miRNAs with positive coefficients, including MIR155HG, and 2 miRNAs with negative coefficients at the maximum penalization within 1 standard error of the minimum cross-validation error (Fig. 5B,C). We showed that MIR155HG expression is positively correlated with the cytotoxic lymphocyte markers CD8A, IFNG, and PRF1 across melanoma ICI data sets (Fig. 5D). As expected, the GSEA analysis revealed an enrichment of IFN\u03b3 signaling in MIR155HG-high samples (Fig. 5E). After validating MIR155HG\u2019s association with intratumoral immunity in melanoma ICI data, we performed similar analyses on pre-treatment Pan-ICI data prepared by integrating 10 quartile-normalized ICI studies (5 melanoma, 3 kidney, 1 stomach, and 1 bladder cancer studies adding up to 938 samples prior to treatment with anti-CTLA4, anti-PD1 or anti-PD-L1 inhibitors) (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Miao et al, 2018; Kim et al, 2018; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016; Liu et al, 2019). Lasso modeling against averaged IFN\u03b3-responsive genes revealed 15 (including MIR155HG), and 7 miRNA genes with positive and negative coefficients, respectively (Fig. 5F\u2013H) which were mostly consistent with the melanoma-specific analyses. When the genome-wide expression patterns of the pan-ICI pre-treatment data were examined, we noted that MIR155HG-high subset was associated with an enrichment of IFN\u03b3-responsive gene set (Fig. 5I) as well as other pathways associated with the immune response (Fig. 5J). Taken together, machine learning-based analysis of melanoma and other tumor biopsies revealed the miRNAs associated with antitumor immunity and further supported the connection between intratumoral IFN\u03b3 signaling and MIR155HG. We provide step-by-step instructions to reproduce Figs. 4 and 5 to assist users in performing similar analyses (Appendix). As these data originate from bulk methods, it is not possible to ascertain the gene expression to specific cell types within the TME, however, there is literature supporting the immunoregulatory roles of MIR155HG in both tumor cells and the infiltrating immune cells (Curti et al, 2022; Hsin et al, 2018). To examine which cell types within the melanoma TME could express MIR155HG and other ML-identified miRNAs, we turned to publicly available single-cell RNA data hosted on the Broad Institute Single Cell Portal (Tarhan et al, 2023). We examined three data sets featuring immune cells and malignant cells from primary and metastatic melanoma biopsies (Tirosh et al, 2016; Jerby-Arnon et al, 2018; Teijeira et al, 2019). Not all miRNAs were found in these data sets possibly due to low-expression levels, and the detected miRNAs showed variable expression patterns across malignant and immune cell clusters (Fig. EV3A,C,D,G\u2013I). While some miRNAs were broadly expressed (e.g., MIR17HG, MIR210HG, and MIRLET7BHG), MIR155HG expression was selective to the infiltrating T cells (Fig. EV3B,E,J). In particular, the highest MIR155HG expression was observed in CD8+ cytotoxic T lymphocytes that are cycling or exhausted (Fig. EV3G,H,K). Notably, melanoma tumor cells expressed low amounts of MIR155HG (Fig. EV3D,J), suggesting miRNAs not only indicate the presence of immune cells within the TME but can also mark their activation state.Figure 5Investigating the associations between miRNAs and immunity markers in cancer immunotherapy studies.(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method."
      ],
      "26359337": [
        "The Cancer Genome Atlas (TCGA) launched in 2006 is among the most ambitious projects to better understand and tackle human cancer (Blum et al, 2018). As of this writing, more than 11,000 tumor samples and matched healthy tissues have been characterized at the molecular level across 33 different cancer types as part of this initiative. TCGA studies employ a variety of experimental approaches including RNA and microRNA (miRNA) sequencing, whole-exome sequencing, and genotyping and methylation arrays to generate 2.5+ petabytes of publicly available data. Landmark studies from the TCGA network described common genetic aberrations in cancer such as TP53 loss (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020) as well as other cancer-specific changes including BRCA1/2 mutations in breast and ovarian tumors (Bell et al, 2011; Koboldt et al, 2012) and APC mutations in colorectal carcinoma (Muzny et al, 2012). Furthermore, transcriptomic profiling has led to the characterization of immune signatures within the tumor microenvironment (TME). Follow-up studies have revealed that the genomic and transcriptomic features of tumors determine whether they will respond to targeted therapies and immunotherapeutics (Van Allen et al, 2015; Hugo et al, 2015; Ayers et al, 2017; Auslander et al, 2018), suggesting that a better understanding of the heterogeneity within the TME is essential for improved therapeutics and clinical outcomes.",
        "TCGEx features ten analysis modules that can be flexibly adapted to various study contexts. Integrative analyses by aggregating data from multiple projects are also possible to investigate commonalities and differences among cancers. TCGEx\u2019s comprehensive computational pipeline utilizes preprocessed data from the TCGA repository that was prepared by combining transcriptomics data with clinical metadata and intratumoral immune signatures described by the leading studies in the field (Thorsson et al, 2018). Additionally, TCGEx features transcriptomic data from multiple landmark ICI studies (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Zhao et al, 2019; Cloughesy et al, 2019; Miao et al, 2018; Liu et al, 2019; Kim et al, 2018; Rosenberg et al, 2016; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016) and it allows users to upload and analyze their own data sets. We provide step-by-step in-app tutorials to increase user-friendliness and help researchers implement TCGEx into their workflows and generate publication-ready plots. TCGEx is publicly available without requiring user registration at https://tcgex.iyte.edu.tr web server as well as through a docker image to facilitate local execution and open-source program development (https://hub.docker.com/r/atakanekiz/tcgex). The source code of TCGEx is accessible at https://github.com/atakanekiz/TCGEx.",
        "Next, we wanted to validate the associations between miRNAs and intratumoral IFN\u03b3 signature in independent data sets obtained from melanoma biopsies prior to ICI therapy (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). No miRNA sequencing has been done in these clinical trials yet, but the miRNA host gene expression is available in the RNAseq data. We observed that the expression of the mature miRNAs and their host genes show a strong positive correlation in the TCGA data (Appendix Fig. S3), and thus we focused on the miRNA host genes in the ICI data sets as a surrogate for mature miRNA expression. Using quartile-normalized integrated data from 5 different melanoma ICI studies (313 total samples prior to treatment with anti-CTLA4 or anti-PD1), we constructed lasso regression against the averaged IFN\u03b3 signature genes as the response variable and 45 miRNA genes that are expressed in at least 25% of the samples as the predictor variables (Fig. 5A). This model predicted 11 miRNAs with positive coefficients, including MIR155HG, and 2 miRNAs with negative coefficients at the maximum penalization within 1 standard error of the minimum cross-validation error (Fig. 5B,C). We showed that MIR155HG expression is positively correlated with the cytotoxic lymphocyte markers CD8A, IFNG, and PRF1 across melanoma ICI data sets (Fig. 5D). As expected, the GSEA analysis revealed an enrichment of IFN\u03b3 signaling in MIR155HG-high samples (Fig. 5E). After validating MIR155HG\u2019s association with intratumoral immunity in melanoma ICI data, we performed similar analyses on pre-treatment Pan-ICI data prepared by integrating 10 quartile-normalized ICI studies (5 melanoma, 3 kidney, 1 stomach, and 1 bladder cancer studies adding up to 938 samples prior to treatment with anti-CTLA4, anti-PD1 or anti-PD-L1 inhibitors) (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Miao et al, 2018; Kim et al, 2018; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016; Liu et al, 2019). Lasso modeling against averaged IFN\u03b3-responsive genes revealed 15 (including MIR155HG), and 7 miRNA genes with positive and negative coefficients, respectively (Fig. 5F\u2013H) which were mostly consistent with the melanoma-specific analyses. When the genome-wide expression patterns of the pan-ICI pre-treatment data were examined, we noted that MIR155HG-high subset was associated with an enrichment of IFN\u03b3-responsive gene set (Fig. 5I) as well as other pathways associated with the immune response (Fig. 5J). Taken together, machine learning-based analysis of melanoma and other tumor biopsies revealed the miRNAs associated with antitumor immunity and further supported the connection between intratumoral IFN\u03b3 signaling and MIR155HG. We provide step-by-step instructions to reproduce Figs. 4 and 5 to assist users in performing similar analyses (Appendix). As these data originate from bulk methods, it is not possible to ascertain the gene expression to specific cell types within the TME, however, there is literature supporting the immunoregulatory roles of MIR155HG in both tumor cells and the infiltrating immune cells (Curti et al, 2022; Hsin et al, 2018). To examine which cell types within the melanoma TME could express MIR155HG and other ML-identified miRNAs, we turned to publicly available single-cell RNA data hosted on the Broad Institute Single Cell Portal (Tarhan et al, 2023). We examined three data sets featuring immune cells and malignant cells from primary and metastatic melanoma biopsies (Tirosh et al, 2016; Jerby-Arnon et al, 2018; Teijeira et al, 2019). Not all miRNAs were found in these data sets possibly due to low-expression levels, and the detected miRNAs showed variable expression patterns across malignant and immune cell clusters (Fig. EV3A,C,D,G\u2013I). While some miRNAs were broadly expressed (e.g., MIR17HG, MIR210HG, and MIRLET7BHG), MIR155HG expression was selective to the infiltrating T cells (Fig. EV3B,E,J). In particular, the highest MIR155HG expression was observed in CD8+ cytotoxic T lymphocytes that are cycling or exhausted (Fig. EV3G,H,K). Notably, melanoma tumor cells expressed low amounts of MIR155HG (Fig. EV3D,J), suggesting miRNAs not only indicate the presence of immune cells within the TME but can also mark their activation state.Figure 5Investigating the associations between miRNAs and immunity markers in cancer immunotherapy studies.(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method.",
        "(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method.",
        "Pre-existing immune infiltration and particularly IFN\u03b3 signaling have been linked to better clinical outcomes in cancer and improved responses to immunotherapies (Van Allen et al, 2015; Ayers et al, 2017). After observing the association of MIR155HG with immune parameters within the TME, we next asked whether MIR155HG expression prior to ICI could stratify melanoma survival and therapy response. We separately categorized patients at the median MIR155HG for each of the five melanoma ICI data sets and, similar to what was observed for TCGA-SKCM, noted MIR155HG-high tumors showed an improved overall survival (Fig. 6A). When the patients were also segregated by immunotherapy response, we noted that the higher MIR155HG still marked better prognosis in non-responding patients, but not in the responding cohort (Fig. EV4A). We next wanted to examine the baseline differences at MIR155HG levels between responding and non-responding patients and noted that MIR155HG expression was elevated in one of the 5 melanoma ICI data sets prior to treatment with anti-PD1 or a combination of anti-CTLA4/anti-PD1 ICI (Fig. 6B) (Gide et al, 2019). Interestingly, ICI-responsive tumors tended to express higher levels of MIR155HG in this data set both prior to and during the immunotherapy although this was not statistically significant (Fig. EV4B). To understand whether miRNA expression can predict positive responses to ICI, we binarized therapy response (complete and partial responders vs progressive disease cases) and utilized binomial lasso regression in the pre-treatment combined melanoma data set. Our modeling revealed 11 and 17 miRNAs with positive and negative coefficients, respectively at the highest penalization level within 1 standard error of the maximum model AUC (Fig. EV4C\u2013E). Interestingly, some of the miRNAs associated with ICI response in this analysis (including MIR155HG, MIR23AHG and MIR181A1HG) were also observed when using lasso regression against IFN\u03b3 response as the response variable. As melanoma molecular subtype can impact prognosis and therapy response (J\u00f6nsson et al, 2010; Hilke et al, 2020); we performed chi-square analysis to examine the relationship between the mutational subtypes and the immunotherapy response in the CRI-iAtlas melanoma data sets featured on TCGEx. We found no statistically significant associations between therapy response (R/NR) and the mutational subsets (BRAF, NRAS, NF1, WT) (P = 0.2021) (Appendix Fig. S4a\u2013c). We then expanded the scope of the lasso regression and utilized the aggregated Pan-ICI data set as described above to investigate miRNAs as potential predictors of ICI response. This analysis returned only two miRNA genes with negative coefficients at the maximal penalization level (value of lambda within 1 standard deviation for the maximum cross-validated area under the roc curve [AUC]), however, relaxing the penalization level (value of lambda at the maximum cross-validated AUC) resulted in a total of 12 nonzero coefficients in the model (Fig. 6C\u2013E). MIR155HG was among the 3 miRNAs with positive coefficients in the model, although the overall model performance was not too high when only using miRNAs as predictors. Although MIR155HG was not found to be a powerful predictor of response in these analyses, it was consistently expressed across many data sets examined for this study. Thus, we used a recently reported online portal, Immuno-Oncology Signatures Explorer (IOSig) (Coleman et al, 2023), to assess the association of MIR155HG with ICI responsiveness in a larger cohort of ICI studies in comparison to other previously published response signatures (Dataset EV2; Table EV2). We noted that the single-gene MIR155HG signature was variably associated with ICI response, although an AUC between 0.7 and 0.8 was seen for 8 out of 30 pre-ICI treatment data sets where MIR155HG expression was detected (Fig. 6F; Dataset EV3). Notably, these studies involved various cancer types including melanoma, kidney, breast, and gastrointestinal cancers. However, due to variation across data sets and small sample sizes, it is not straightforward to identify tumor types where MIR155HG expression consistently predicts better responses (Appendix Fig. S4d). We validated IOSig platform\u2019s findings using Gide et al data set in the ROC module of TCGEx and showed that MIR155HG expression could distinguish responders (complete and partial response) from non-responders (stable or progressive disease), albeit more poorly compared to a previously published 6-gene IFN\u03b3 response signature shown to predict immunotherapy response (Fig. 6G) (Ayers et al, 2017). Of note, MIR155HG expression performed better in distinguishing responders to the anti-PD1/anti-CTLA4 combination therapy in this data suggesting differences in molecular pathways that are involved in the mechanisms of ICI therapeutics. Thus, our results suggest that, while MIR155HG rises among other miRNAs to differentiate some ICI responders, it does not constitute a strong signature to be generalized across data sets.Figure 6Investigating the associations between miRNAs and immunotherapy response.(A) The higher MIR155HG expression in tumors prior to immune checkpoint inhibition (ICI) corresponds to improved survival in metastatic melanoma. (B) Boxplot shows MIR155HG expression in tumors responding or refractive to ICI agents. MIR155HG expression is higher in responders in some but not all studies examined (Gide Pre-PD1 n = 41, Gide Pre-CTLA4 + PD1 n = 32, Hugo Pre-PD1 n = 26, Liu Pre-PD1 n = 121, Riaz Pre-PD1 n = 51, Van Allen Pre-CTLA4 n = 42). The box represents the interquartile range (IQR), spanning from the 25th percentile (lower bound) to the 75th percentile (upper bound). The horizontal line within the box indicates the median (50th percentile). Whiskers extend to the smallest and largest values within 1.5\u00d7 IQR from the lower (Q1) and upper (Q3) quartiles, respectively. (C\u2013E) Binomial lasso regression was applied to pre-treatment SKCM immunotherapy studies (n = 313). In these analyses, a positive response (partial or complete response) is binarized to \u201c1\u201d and no response (progressive disease) is binarized to \u201c0\u201d as the response variable, and miRNA host gene transcripts in the RNAseq data were used as predictors. Regularized coefficients at various levels of lambda (C) and the AUC of the model (D) are shown. Error bars represent the minimum cross-validation error and minimum cross-validation error + 1 standard error lines. Nonzero coefficients were extracted at the lambda value with the highest cross-validated AUC (E). (F) Performance of MIR155HG and various other gene signatures for predicting ICI response is assessed by the IOSig platform and summarized via the heatmap. The color-coded AUC estimates between 0 and 1 from 12 different cancer clinical trials are shown. The heatmap was generated in the R environment using the data exported from the IOSig platform. (G) The ROC module of TCGEx was used to assess the potential of MIR155HG and 6-gene IFN\u03b3 signatures in predicting response to immunotherapy (complete/partial response vs progressive disease) in a data set generated by Gide et al.",
        "Examining correlations among genes and continuous metadata features can help study co-regulation mechanisms (Van Allen et al, 2015) and miRNA-mRNA interactions (Van der Auwera et al, 2010). TCGEx offers two modules for correlation analysis which can generate sample-level scatter plots or correlation matrices and tables. Sample-level plots are generated by plotting two continuous variables against each other, where each point denotes a patient sample. Continuous variables for this analysis can include transcript counts in RNAseq/miRNAseq data, protein expression data, and numerical metadata such as mutation load or intratumoral immune cell scores (Thorsson et al, 2018). The correlation scatter plot is designed to be responsive, and it can show patient barcode, sex, and race upon hovering over individual data points. Furthermore, an optional faceting variable can be used to break data points into various subcategories and generate informative plots, as described in the previous modules. Users can visualize the best-fitting line and the linear regression equation on the graph to demonstrate the relationship between variables. In addition to these functionalities, we anticipated that it could be of interest to examine the top positive and negative correlators of a specific gene and plot a gene-to-gene correlation matrix. The second correlation analysis module of TCGEx enables these analyses by calculating pairwise Pearson and Spearman correlation coefficients and creating tabular and graphical outputs. Therefore, these pipelines facilitate examining the linear relationships between variables and help investigate potential genetic interactions."
      ],
      "29301960": [
        "TCGEx features ten analysis modules that can be flexibly adapted to various study contexts. Integrative analyses by aggregating data from multiple projects are also possible to investigate commonalities and differences among cancers. TCGEx\u2019s comprehensive computational pipeline utilizes preprocessed data from the TCGA repository that was prepared by combining transcriptomics data with clinical metadata and intratumoral immune signatures described by the leading studies in the field (Thorsson et al, 2018). Additionally, TCGEx features transcriptomic data from multiple landmark ICI studies (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Zhao et al, 2019; Cloughesy et al, 2019; Miao et al, 2018; Liu et al, 2019; Kim et al, 2018; Rosenberg et al, 2016; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016) and it allows users to upload and analyze their own data sets. We provide step-by-step in-app tutorials to increase user-friendliness and help researchers implement TCGEx into their workflows and generate publication-ready plots. TCGEx is publicly available without requiring user registration at https://tcgex.iyte.edu.tr web server as well as through a docker image to facilitate local execution and open-source program development (https://hub.docker.com/r/atakanekiz/tcgex). The source code of TCGEx is accessible at https://github.com/atakanekiz/TCGEx.",
        "Next, we wanted to validate the associations between miRNAs and intratumoral IFN\u03b3 signature in independent data sets obtained from melanoma biopsies prior to ICI therapy (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). No miRNA sequencing has been done in these clinical trials yet, but the miRNA host gene expression is available in the RNAseq data. We observed that the expression of the mature miRNAs and their host genes show a strong positive correlation in the TCGA data (Appendix Fig. S3), and thus we focused on the miRNA host genes in the ICI data sets as a surrogate for mature miRNA expression. Using quartile-normalized integrated data from 5 different melanoma ICI studies (313 total samples prior to treatment with anti-CTLA4 or anti-PD1), we constructed lasso regression against the averaged IFN\u03b3 signature genes as the response variable and 45 miRNA genes that are expressed in at least 25% of the samples as the predictor variables (Fig. 5A). This model predicted 11 miRNAs with positive coefficients, including MIR155HG, and 2 miRNAs with negative coefficients at the maximum penalization within 1 standard error of the minimum cross-validation error (Fig. 5B,C). We showed that MIR155HG expression is positively correlated with the cytotoxic lymphocyte markers CD8A, IFNG, and PRF1 across melanoma ICI data sets (Fig. 5D). As expected, the GSEA analysis revealed an enrichment of IFN\u03b3 signaling in MIR155HG-high samples (Fig. 5E). After validating MIR155HG\u2019s association with intratumoral immunity in melanoma ICI data, we performed similar analyses on pre-treatment Pan-ICI data prepared by integrating 10 quartile-normalized ICI studies (5 melanoma, 3 kidney, 1 stomach, and 1 bladder cancer studies adding up to 938 samples prior to treatment with anti-CTLA4, anti-PD1 or anti-PD-L1 inhibitors) (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Miao et al, 2018; Kim et al, 2018; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016; Liu et al, 2019). Lasso modeling against averaged IFN\u03b3-responsive genes revealed 15 (including MIR155HG), and 7 miRNA genes with positive and negative coefficients, respectively (Fig. 5F\u2013H) which were mostly consistent with the melanoma-specific analyses. When the genome-wide expression patterns of the pan-ICI pre-treatment data were examined, we noted that MIR155HG-high subset was associated with an enrichment of IFN\u03b3-responsive gene set (Fig. 5I) as well as other pathways associated with the immune response (Fig. 5J). Taken together, machine learning-based analysis of melanoma and other tumor biopsies revealed the miRNAs associated with antitumor immunity and further supported the connection between intratumoral IFN\u03b3 signaling and MIR155HG. We provide step-by-step instructions to reproduce Figs. 4 and 5 to assist users in performing similar analyses (Appendix). As these data originate from bulk methods, it is not possible to ascertain the gene expression to specific cell types within the TME, however, there is literature supporting the immunoregulatory roles of MIR155HG in both tumor cells and the infiltrating immune cells (Curti et al, 2022; Hsin et al, 2018). To examine which cell types within the melanoma TME could express MIR155HG and other ML-identified miRNAs, we turned to publicly available single-cell RNA data hosted on the Broad Institute Single Cell Portal (Tarhan et al, 2023). We examined three data sets featuring immune cells and malignant cells from primary and metastatic melanoma biopsies (Tirosh et al, 2016; Jerby-Arnon et al, 2018; Teijeira et al, 2019). Not all miRNAs were found in these data sets possibly due to low-expression levels, and the detected miRNAs showed variable expression patterns across malignant and immune cell clusters (Fig. EV3A,C,D,G\u2013I). While some miRNAs were broadly expressed (e.g., MIR17HG, MIR210HG, and MIRLET7BHG), MIR155HG expression was selective to the infiltrating T cells (Fig. EV3B,E,J). In particular, the highest MIR155HG expression was observed in CD8+ cytotoxic T lymphocytes that are cycling or exhausted (Fig. EV3G,H,K). Notably, melanoma tumor cells expressed low amounts of MIR155HG (Fig. EV3D,J), suggesting miRNAs not only indicate the presence of immune cells within the TME but can also mark their activation state.Figure 5Investigating the associations between miRNAs and immunity markers in cancer immunotherapy studies.(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method."
      ],
      "26997480": [
        "TCGEx features ten analysis modules that can be flexibly adapted to various study contexts. Integrative analyses by aggregating data from multiple projects are also possible to investigate commonalities and differences among cancers. TCGEx\u2019s comprehensive computational pipeline utilizes preprocessed data from the TCGA repository that was prepared by combining transcriptomics data with clinical metadata and intratumoral immune signatures described by the leading studies in the field (Thorsson et al, 2018). Additionally, TCGEx features transcriptomic data from multiple landmark ICI studies (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Zhao et al, 2019; Cloughesy et al, 2019; Miao et al, 2018; Liu et al, 2019; Kim et al, 2018; Rosenberg et al, 2016; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016) and it allows users to upload and analyze their own data sets. We provide step-by-step in-app tutorials to increase user-friendliness and help researchers implement TCGEx into their workflows and generate publication-ready plots. TCGEx is publicly available without requiring user registration at https://tcgex.iyte.edu.tr web server as well as through a docker image to facilitate local execution and open-source program development (https://hub.docker.com/r/atakanekiz/tcgex). The source code of TCGEx is accessible at https://github.com/atakanekiz/TCGEx.",
        "Next, we wanted to validate the associations between miRNAs and intratumoral IFN\u03b3 signature in independent data sets obtained from melanoma biopsies prior to ICI therapy (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). No miRNA sequencing has been done in these clinical trials yet, but the miRNA host gene expression is available in the RNAseq data. We observed that the expression of the mature miRNAs and their host genes show a strong positive correlation in the TCGA data (Appendix Fig. S3), and thus we focused on the miRNA host genes in the ICI data sets as a surrogate for mature miRNA expression. Using quartile-normalized integrated data from 5 different melanoma ICI studies (313 total samples prior to treatment with anti-CTLA4 or anti-PD1), we constructed lasso regression against the averaged IFN\u03b3 signature genes as the response variable and 45 miRNA genes that are expressed in at least 25% of the samples as the predictor variables (Fig. 5A). This model predicted 11 miRNAs with positive coefficients, including MIR155HG, and 2 miRNAs with negative coefficients at the maximum penalization within 1 standard error of the minimum cross-validation error (Fig. 5B,C). We showed that MIR155HG expression is positively correlated with the cytotoxic lymphocyte markers CD8A, IFNG, and PRF1 across melanoma ICI data sets (Fig. 5D). As expected, the GSEA analysis revealed an enrichment of IFN\u03b3 signaling in MIR155HG-high samples (Fig. 5E). After validating MIR155HG\u2019s association with intratumoral immunity in melanoma ICI data, we performed similar analyses on pre-treatment Pan-ICI data prepared by integrating 10 quartile-normalized ICI studies (5 melanoma, 3 kidney, 1 stomach, and 1 bladder cancer studies adding up to 938 samples prior to treatment with anti-CTLA4, anti-PD1 or anti-PD-L1 inhibitors) (Van Allen et al, 2015; Gide et al, 2019; Riaz et al, 2017; Hugo et al, 2016; Miao et al, 2018; Kim et al, 2018; Balar et al, 2017; McDermott et al, 2018; Choueiri et al, 2016; Liu et al, 2019). Lasso modeling against averaged IFN\u03b3-responsive genes revealed 15 (including MIR155HG), and 7 miRNA genes with positive and negative coefficients, respectively (Fig. 5F\u2013H) which were mostly consistent with the melanoma-specific analyses. When the genome-wide expression patterns of the pan-ICI pre-treatment data were examined, we noted that MIR155HG-high subset was associated with an enrichment of IFN\u03b3-responsive gene set (Fig. 5I) as well as other pathways associated with the immune response (Fig. 5J). Taken together, machine learning-based analysis of melanoma and other tumor biopsies revealed the miRNAs associated with antitumor immunity and further supported the connection between intratumoral IFN\u03b3 signaling and MIR155HG. We provide step-by-step instructions to reproduce Figs. 4 and 5 to assist users in performing similar analyses (Appendix). As these data originate from bulk methods, it is not possible to ascertain the gene expression to specific cell types within the TME, however, there is literature supporting the immunoregulatory roles of MIR155HG in both tumor cells and the infiltrating immune cells (Curti et al, 2022; Hsin et al, 2018). To examine which cell types within the melanoma TME could express MIR155HG and other ML-identified miRNAs, we turned to publicly available single-cell RNA data hosted on the Broad Institute Single Cell Portal (Tarhan et al, 2023). We examined three data sets featuring immune cells and malignant cells from primary and metastatic melanoma biopsies (Tirosh et al, 2016; Jerby-Arnon et al, 2018; Teijeira et al, 2019). Not all miRNAs were found in these data sets possibly due to low-expression levels, and the detected miRNAs showed variable expression patterns across malignant and immune cell clusters (Fig. EV3A,C,D,G\u2013I). While some miRNAs were broadly expressed (e.g., MIR17HG, MIR210HG, and MIRLET7BHG), MIR155HG expression was selective to the infiltrating T cells (Fig. EV3B,E,J). In particular, the highest MIR155HG expression was observed in CD8+ cytotoxic T lymphocytes that are cycling or exhausted (Fig. EV3G,H,K). Notably, melanoma tumor cells expressed low amounts of MIR155HG (Fig. EV3D,J), suggesting miRNAs not only indicate the presence of immune cells within the TME but can also mark their activation state.Figure 5Investigating the associations between miRNAs and immunity markers in cancer immunotherapy studies.(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method.",
        "(A\u2013C) Lasso regression was performed using the average expression of MSigDB Hallmark IFNg response gene set as the response variable and miRNA host genes as predictors in melanoma biopsies prior to immunotherapy (n = 313). The penalized coefficients (A) and the mean-squared cross-validation error of penalized models are shown (B). miRNA predictors with positive and negative coefficients at the lambda value corresponding to within 1 standard error of the minimum cross-validation error are listed (C). (D) Scatter plots show the relationship between MIR155HG and cytotoxic T lymphocyte-specific gene expression in melanoma ICI clinical trial data sets (Van Allen et al, 2015; Riaz et al, 2017; Hugo et al, 2016; Liu et al, 2019). Statistical analysis was performed using the Pearson correlation test, and the corresponding p values are shown. (E) Gene set enrichment analysis reveals higher expression of IFN\u03b3-responsive genes in MIR155HG-high melanoma biopsies prior to ICI therapy. Statistical significance was assessed using a permutation test. (F\u2013H) Lasso regression was performed using miRNA host genes as predictors and the average expression of MSigDB Hallmark IFN\u03b3 responsive genes as a response variable across pan-ICI data prepared by integrating ten different ICI studies comprising of 938 samples prior to treatment. Feature coefficients (F), mean-squared error of the penalized models (G), and the genes with nonzero coefficients (at minimum lambda + 1 standard error) are shown in immunotherapy biopsies (n = 938) (H). (I) MIR155HG-high biopsies demonstrate a significant enrichment of IFN\u03b3-response gene signature in the pan-ICI data set. Statistical significance was assessed using a permutation test. (J) The top differentially enriched pathways are shown for the MIR155HG-high and MIR155HG-low biopsies prior to ICI treatment. Statistical significance was assessed using a permutation test and, P values were adjusted for multiple comparisons using the Benjamini\u2013Hochberg method."
      ],
      "21720365": [
        "The Cancer Genome Atlas (TCGA) launched in 2006 is among the most ambitious projects to better understand and tackle human cancer (Blum et al, 2018). As of this writing, more than 11,000 tumor samples and matched healthy tissues have been characterized at the molecular level across 33 different cancer types as part of this initiative. TCGA studies employ a variety of experimental approaches including RNA and microRNA (miRNA) sequencing, whole-exome sequencing, and genotyping and methylation arrays to generate 2.5+ petabytes of publicly available data. Landmark studies from the TCGA network described common genetic aberrations in cancer such as TP53 loss (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020) as well as other cancer-specific changes including BRCA1/2 mutations in breast and ovarian tumors (Bell et al, 2011; Koboldt et al, 2012) and APC mutations in colorectal carcinoma (Muzny et al, 2012). Furthermore, transcriptomic profiling has led to the characterization of immune signatures within the tumor microenvironment (TME). Follow-up studies have revealed that the genomic and transcriptomic features of tumors determine whether they will respond to targeted therapies and immunotherapeutics (Van Allen et al, 2015; Hugo et al, 2015; Ayers et al, 2017; Auslander et al, 2018), suggesting that a better understanding of the heterogeneity within the TME is essential for improved therapeutics and clinical outcomes."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 14,
    "extraction_method": "jats_xml",
    "extraction_time": 3.5408949851989746,
    "data_pmids_checked": 14,
    "paper_id": "40033050",
    "extraction_date": "2025-12-19T20:39:35.014856",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40033050.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40027235": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Survival analysis: The cBioPortal for Cancer Genomics [46] was used to retrieve overall survival and relapse-free status data for primary breast cancer patients The effect of mutations in ESR1, PIK3CA, and TP53 genes on overall survival and relapse was studied using the dataset from TCGA and METABRIC cohorts. Early-stage primary breast cancer patients were included in the analysis. The samples were randomly selected from the data sets to have size-matched cohorts and avoid sampling bias to obtain statistically meaningful outcomes."
    ],
    "data_publication_citations": {
      "22522925": [
        "A multitude of preclinical and clinical studies have demonstrated that EBCs extensively undergo molecular and cellular evolution during therapy [[24], [25]]. New clones with acquired mutations may already start disseminating at the onset of therapy administration. Such clonal population could confer therapy resistance and provide growth advantages for tumor cells. For example, the ESR1 gene accumulates mutations leading to resistance to anti-estrogenic or aromatase inhibitor maintenance therapy. Profiling emerging mutations is limited via tissue biopsy due to sampling bias, and the heterogenous presence of tumor cells in affected tissue region. Timely detection of such de-novo or acquired variants through ctDNA analysis can offer precise therapy guidance for patients on maintenance therapy."
      ],
      "32025007": [
        "Since, our dataset showed enrichment of ESR1 variants, and its coexistence with PIK3CA and TP53 mutations from ctDNA as well as paired samples, we compared overall survival (OS) and relapse-free survival (RFS) from The Cancer Genome Atlas (TCGA) dataset of primary BC harbouring these mutations [35]. As observed in Fig. 6G, patients with ESR1 mutations alone showed dismal OS and RFS, suggesting that ESR1 variants could be an independent determinant for poor clinical outcomes in BC. The median OS for patients carrying ESR1 mutation was significantly lower (61 months) compared to the population without ESR1 mutation (OS undefined; \u2265150 months, P = 0.015). Further, the association of ESR1 mutation with PIK3CA and TP53 mutations is more pronounced in known metastatic BC patients [36]. Accordingly, survival analysis indicated dismal OS for patients carrying cooccurring ESR1, PIK3CA and TP53 variants. This suggests that coexisting ESR1, PIK3CA, and TP53 variants in primary tumor potentially progress and confer hormone therapy resistance. Indeed, we observed metastatic relapse in patients with coexisting PIK3CA and ESR1 as well as TP53 and ESR1 mutations respectively (representative cases, showing tumor recurrence and liver metastasis) within 24 months of initial curative intent standard of care (surgery followed by chemotherapy). Patients without standalone or concomitant ESR1 mutation showed improved relapse-free survival and no clinical sign of metastasis. Clinical follow up of all remaining patients is underway, and will be reported in due course."
      ],
      "30643254": [
        "OncoIndx enabled reliable interpretation of TMB, HRD, and LOH scores. The presence of mutations in one or multiple MMR or HRR genes is a measure of genomic instability [41]. We observed 30 % of patients carrying variants that could impact the MMR pathway. Among the patients with a high HRD score, 82 % carried at least one mutation in HRR pathway, showing a good correlation between HRR mutations and HRD score (P = 0.022, odds ratio = 10.2, FDR = 0.1). When compared based on HRD and TMB scores, we did not observe any significant association (P = 0.9), suggesting HRD and TMB to be independent of each other and define different biological processes. TMB and HRD score are important parameters for therapeutic consideration, as patients with HRR defective tumors can benefit from poly ADP ribose polymerase inhibitors (PARPi) [42]. Alongside PD/PD-L1 expression, TMB is an emergent biomarker for immunotherapy (ICI). Moreover, based on TMB scores multiple studies have reported improved ICI response in patients with progressive breast cancers [43]. Surprisingly, we observed about 25 % of patients associated with high TMB (bTMB high: 25 %; tTMB high 35 %) despite early stage of the disease. Since TMB utility for immunotherapy decisions is independent of the microsatellite status of the tumor [44], these patients can benefit from ICI decisions. The high TMB scores observed in this study could be due to the high rate of mutation accumulation in proliferating tumor cells that have not experienced any selection pressure considering treatment na\u00efve nature of the tumor. Additionally, the findings on TMB are from a small sample size, a clear limitation of the current study."
      ],
      "30205045": [
        "Since, our dataset showed enrichment of ESR1 variants, and its coexistence with PIK3CA and TP53 mutations from ctDNA as well as paired samples, we compared overall survival (OS) and relapse-free survival (RFS) from The Cancer Genome Atlas (TCGA) dataset of primary BC harbouring these mutations [35]. As observed in Fig. 6G, patients with ESR1 mutations alone showed dismal OS and RFS, suggesting that ESR1 variants could be an independent determinant for poor clinical outcomes in BC. The median OS for patients carrying ESR1 mutation was significantly lower (61 months) compared to the population without ESR1 mutation (OS undefined; \u2265150 months, P = 0.015). Further, the association of ESR1 mutation with PIK3CA and TP53 mutations is more pronounced in known metastatic BC patients [36]. Accordingly, survival analysis indicated dismal OS for patients carrying cooccurring ESR1, PIK3CA and TP53 variants. This suggests that coexisting ESR1, PIK3CA, and TP53 variants in primary tumor potentially progress and confer hormone therapy resistance. Indeed, we observed metastatic relapse in patients with coexisting PIK3CA and ESR1 as well as TP53 and ESR1 mutations respectively (representative cases, showing tumor recurrence and liver metastasis) within 24 months of initial curative intent standard of care (surgery followed by chemotherapy). Patients without standalone or concomitant ESR1 mutation showed improved relapse-free survival and no clinical sign of metastasis. Clinical follow up of all remaining patients is underway, and will be reported in due course.",
        "Further, we performed pathway enrichment analysis to further understand how the mutational landscape would affect the functional behaviour of tumor cells. Pathway analysis identified multiple significantly dysregulated KEGG-defined pathways [37,56]. Particularly, the enrichment of pathways governing drug resistance and migratory phenotype is of special interest, as they signify the aggressive disease and resistance to chemotherapy [36]. Although this study demonstrates enrichment of mutations predisposed to metastasis and therapy resistance in EBC, it is limited to a small set of patients with a single time point. Further, being a retrospective study, it did not include clinical measurables and hence is unable to directly relate the observed mutational landscape with the survival outcomes. Additionally, our study was limited to targeted genomic regions and did not consider non-coding variants, transcriptional and epigenetic dysregulations, and correlation with phenotypic markers."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6341288089752197,
    "data_pmids_checked": 5,
    "paper_id": "40027235",
    "extraction_date": "2025-12-19T20:39:35.025403",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40027235.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40025812": {
    "cbioportal_paper_citations": [
      "\u201cThe Cancer Genome Atlas\u201d GCT cohort was analyzed using cBioPortal. 30 , 31 \u201cShinyCell for R\u201d was used to analyze and illustrate single cell RNAseq data. 32 The \u201cSTRING\u201d algorithm was used to predict protein\u2013protein interactions. 33 The \u201cDAVID\u201d algorithm was used to predict molecular functions of gene sets. 34 \u201cVenny 2.1\u201d was used to generate Venn diagrams. \u201cshinyCircos\u2010V2.0\u201d and \u201cBoxPlotR\u201d were utilized to visualize ChIPseq data. 35 , 36 Enrichment of sequence motifs was graphically illustrated using \u201cImageGP.\u201d 37"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1323556900024414,
    "data_pmids_checked": 0,
    "paper_id": "40025812",
    "extraction_date": "2025-12-19T20:39:35.191159",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40025812.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40026293": {
    "cbioportal_paper_citations": [
      "Data for the METABRIC and TCGA datasets were retrieved from the cBioportal public databases (https://www.cbioportal.org/) [41, 42, 43]. Data for mutual exclusivity were retrieved and analysed from the mutual exclusivity section of cBioportal, querying for both CDH1 and AFDN. All other reported data were exported from the mutations section, querying for AFDN."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "27161491": [
        "Data for the METABRIC and TCGA datasets were retrieved from the cBioportal public databases (https://www.cbioportal.org/) [41, 42, 43]. Data for mutual exclusivity were retrieved and analysed from the mutual exclusivity section of cBioportal, querying for both CDH1 and AFDN. All other reported data were exported from the mutations section, querying for AFDN."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.21413516998291016,
    "data_pmids_checked": 1,
    "paper_id": "40026293",
    "extraction_date": "2025-12-19T20:39:35.237735",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40026293.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40057527": {
    "paper_id": "40057527",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "somaticallele-specificSCNAwerecollectedandretrieved,respectively,from\nCEU individuals in the 1000 Genomes Project collection and from the Dataavailability\nTCGAdataset(cbioportal.org)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:38.778675",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40057527.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 18.83366584777832,
      "cbioportal_papers": 0.0002989768981933594,
      "pdf_extraction_pass2": 18.90259885787964,
      "cbioportal_papers_pass2": 0.00030303001403808594,
      "used_full_extraction": true,
      "pdf_extraction": 37.73626470565796,
      "platform_mentions": 0.002774953842163086,
      "data_citations": 0.0007221698760986328,
      "num_data_pmids_checked": 7
    }
  },
  "40048017": {
    "paper_id": "40048017",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Cambridge, United Kingdom, 2010\n19 Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:42.830825",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40048017.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 12.38237190246582,
      "cbioportal_papers": 0.00041103363037109375,
      "pdf_extraction_pass2": 9.836074829101562,
      "cbioportal_papers_pass2": 0.0003349781036376953,
      "used_full_extraction": true,
      "pdf_extraction": 22.218446731567383,
      "platform_mentions": 0.015322685241699219,
      "data_citations": 0.00012803077697753906,
      "num_data_pmids_checked": 1
    }
  },
  "40019775": {
    "cbioportal_paper_citations": [
      "To probe the clinical impact of RICTOR expression and genomic amplification in patients with breast cancer, clinical breast cancer datasets curated by The Cancer Genome Atlas (TCGA; ref. 26) and METABRIC (27, 28) were queried for tumors harboring RICTOR gene amplification or RICTOR mRNA overexpression (defined as >2 SD above the mean RICTOR levels across the entire dataset), collectively defined herein as RICTOR alterations, using cBioPortal software (RRID: SCR_014555; ref. 29). Kaplan\u2013Meier survival curves were generated using cBioPortal software comparing overall survival (OS) of patients whose tumors harbor RICTOR alterations versus those without RICTOR alterations. Reverse phase protein array (RPPA) datasets of TCGA-curated invasive breast cancer were analyzed for Rictor protein overexpression and Rictor protein phosphorylation levels using cBioPortal software to determine whether Rictor protein overexpression correlates with patient survival and phosphorylation of mTORC2 substrates. RPPA analysis of TCGA breast invasive carcinoma was assessed by KmPlot software (RRID: SCR_018753), using software-directed selection of expression cutoff criteria. Clinical parameters embedded in datasets were used in KmPlot software to assess the correlation between Rictor protein phosphorylation analysis and OS within breast cancer clinical subtypes (ER+/HER2\u2212, ER+/HER2+, ER\u2212/HER2\u2212, and ER\u2212/HER2+).",
      "To understand the clinical relevance of Rictor/mTORC2 in malignant breast cancers, we assessed RICTOR gene alterations in publicly available datasets curated by TCGA (Cell, N = 817; ref. 26), METABRIC (N = 1904; ref. 27), and TCGA Firehose Legacy (N = 960; refs. 29, 33), finding RICTOR gene amplification or overexpression in 36.6% (N = 299), 14.5% (N = 277), and 33.6% (N = 323) of tumor samples, respectively (Fig. 1A). In each dataset, tumor RICTOR amplification/overexpression correlated with a decreased patient OS, consistent with previous reports correlating RICTOR mRNA expression with decreased survival in patients with breast cancer (25). Similarly, high Rictor protein expression assessed by RPPA correlated inversely with OS in invasive breast cancers (Fig. 1B), as did Rictor phosphorylation at T1135 (P-Rictor T1135; Supplementary Fig. S1A), a phospho-site correlating with, but not required for, oncogenic mTORC2 signaling (34). KmPlot software was used to assess Rictor T1135 phosphorylation within TCGA invasive breast tumors using RPPA data, further separating the tumors into groups based on clinical assessments of ER and HER2 expression: ER+/HER2+ (N = 196), ER+/HER2\u2212 (N = 284), ER\u2212/HER2+ (N = 38), and TNBC:ER\u2212HER2\u2212 (N = 103). P-Rictor T1135 correlated with decreased OS in three of four subgroups, with the greatest impact seen in TNBC:ER\u2212HER2\u2212 tumors (Fig. 1C). P-Rictor T1135 did not significantly correlate with decreased OS in the ER\u2212/HER2+ group. This could be due to the smaller population size of this group or may indicate that mTORC2 signaling does not affect survival in this clinical breast cancer subset. As Rictor is a key component of mTORC2, we assessed the RPPA dataset of invasive breast cancers (TCGA) to determine whether RICTOR gene expression or amplification correlates with increased mTORC2 signaling in clinical tumor specimens. Tumors with high RICTOR alteration harbored significantly higher P-Rictor T1135, P-Akt S473, and P-NDRG1, consistent with increased mTORC2 signaling in RICTOR-altered tumors (Fig. 1D). In contrast, mTORC1 effectors P-EIF4EBP1 and P-RPS6 exhibited diminished phosphorylation in RICTOR-altered breast tumors."
    ],
    "cbioportal_platform_mentions": [
      "To identify TNBC cell lines harboring PI3K/mTOR genomic alterations, cell lines curated by the Cancer Cell Line Encyclopedia (CCLE; ref. 30) were queried in cBioPortal software for TNBC characterization (defined as lacking ESR1 expression >1 SD above the groups average and/or ERBB2 gene amplification). The genomic copy number for selected gene data was analyzed for all cell lines.",
      "Rictor alterations correlate with increased mTORC2 signaling and decreased survival in invasive breast cancers. A\u2013C, Kaplan\u2013Meier curves illustrating the impact of (A) RICTOR alterations (gene amplification and/or mRNA expression >2 SDs above the dataset average) on OS in invasive breast cancer in three clinical gene expression datasets using cBioPortal software; (B) Rictor protein expression (software-defined best cutoff) on OS in TCGA invasive breast cancer RPPA datasets using KmPlot software; (C) Rictor phosphorylation at T1135 (software-defined best cutoff) on OS in TCGA invasive breast cancer RPPA datasets using KmPlot software. D, Invasive breast cancers (TCGA) were separated in RICTOR high (those with RICTOR gene amplification and/or mRNA expression >2 SD above the dataset average) or RICTOR low (all remaining tumors). Then RPPA data were assessed for phosphorylation of mTORC2 effectors Rictor (T1135), AKT (S473), and NDRG1 (T346) and for mTORC1 effectors EIF4EBP1 (T70) and RPS6 (S240/244). Each point represents a unique tumor sample. Midline is dataset average \u00b1 SD. An unpaired t test was used. E, Western blot analysis of serum-starved RICTOR-amplified and RICTOR-diploid cell lines treated with PP242 for 24 hours, then stimulated 30 minutes with insulin (10 ng/mL) and EGF (2 ng/mL). Antibodies used are indicated on the left."
    ],
    "data_publication_citations": {
      "26451490": [
        "To probe the clinical impact of RICTOR expression and genomic amplification in patients with breast cancer, clinical breast cancer datasets curated by The Cancer Genome Atlas (TCGA; ref. 26) and METABRIC (27, 28) were queried for tumors harboring RICTOR gene amplification or RICTOR mRNA overexpression (defined as >2 SD above the mean RICTOR levels across the entire dataset), collectively defined herein as RICTOR alterations, using cBioPortal software (RRID: SCR_014555; ref. 29). Kaplan\u2013Meier survival curves were generated using cBioPortal software comparing overall survival (OS) of patients whose tumors harbor RICTOR alterations versus those without RICTOR alterations. Reverse phase protein array (RPPA) datasets of TCGA-curated invasive breast cancer were analyzed for Rictor protein overexpression and Rictor protein phosphorylation levels using cBioPortal software to determine whether Rictor protein overexpression correlates with patient survival and phosphorylation of mTORC2 substrates. RPPA analysis of TCGA breast invasive carcinoma was assessed by KmPlot software (RRID: SCR_018753), using software-directed selection of expression cutoff criteria. Clinical parameters embedded in datasets were used in KmPlot software to assess the correlation between Rictor protein phosphorylation analysis and OS within breast cancer clinical subtypes (ER+/HER2\u2212, ER+/HER2+, ER\u2212/HER2\u2212, and ER\u2212/HER2+).",
        "To understand the clinical relevance of Rictor/mTORC2 in malignant breast cancers, we assessed RICTOR gene alterations in publicly available datasets curated by TCGA (Cell, N = 817; ref. 26), METABRIC (N = 1904; ref. 27), and TCGA Firehose Legacy (N = 960; refs. 29, 33), finding RICTOR gene amplification or overexpression in 36.6% (N = 299), 14.5% (N = 277), and 33.6% (N = 323) of tumor samples, respectively (Fig. 1A). In each dataset, tumor RICTOR amplification/overexpression correlated with a decreased patient OS, consistent with previous reports correlating RICTOR mRNA expression with decreased survival in patients with breast cancer (25). Similarly, high Rictor protein expression assessed by RPPA correlated inversely with OS in invasive breast cancers (Fig. 1B), as did Rictor phosphorylation at T1135 (P-Rictor T1135; Supplementary Fig. S1A), a phospho-site correlating with, but not required for, oncogenic mTORC2 signaling (34). KmPlot software was used to assess Rictor T1135 phosphorylation within TCGA invasive breast tumors using RPPA data, further separating the tumors into groups based on clinical assessments of ER and HER2 expression: ER+/HER2+ (N = 196), ER+/HER2\u2212 (N = 284), ER\u2212/HER2+ (N = 38), and TNBC:ER\u2212HER2\u2212 (N = 103). P-Rictor T1135 correlated with decreased OS in three of four subgroups, with the greatest impact seen in TNBC:ER\u2212HER2\u2212 tumors (Fig. 1C). P-Rictor T1135 did not significantly correlate with decreased OS in the ER\u2212/HER2+ group. This could be due to the smaller population size of this group or may indicate that mTORC2 signaling does not affect survival in this clinical breast cancer subset. As Rictor is a key component of mTORC2, we assessed the RPPA dataset of invasive breast cancers (TCGA) to determine whether RICTOR gene expression or amplification correlates with increased mTORC2 signaling in clinical tumor specimens. Tumors with high RICTOR alteration harbored significantly higher P-Rictor T1135, P-Akt S473, and P-NDRG1, consistent with increased mTORC2 signaling in RICTOR-altered tumors (Fig. 1D). In contrast, mTORC1 effectors P-EIF4EBP1 and P-RPS6 exhibited diminished phosphorylation in RICTOR-altered breast tumors."
      ],
      "27161491": [
        "To probe the clinical impact of RICTOR expression and genomic amplification in patients with breast cancer, clinical breast cancer datasets curated by The Cancer Genome Atlas (TCGA; ref. 26) and METABRIC (27, 28) were queried for tumors harboring RICTOR gene amplification or RICTOR mRNA overexpression (defined as >2 SD above the mean RICTOR levels across the entire dataset), collectively defined herein as RICTOR alterations, using cBioPortal software (RRID: SCR_014555; ref. 29). Kaplan\u2013Meier survival curves were generated using cBioPortal software comparing overall survival (OS) of patients whose tumors harbor RICTOR alterations versus those without RICTOR alterations. Reverse phase protein array (RPPA) datasets of TCGA-curated invasive breast cancer were analyzed for Rictor protein overexpression and Rictor protein phosphorylation levels using cBioPortal software to determine whether Rictor protein overexpression correlates with patient survival and phosphorylation of mTORC2 substrates. RPPA analysis of TCGA breast invasive carcinoma was assessed by KmPlot software (RRID: SCR_018753), using software-directed selection of expression cutoff criteria. Clinical parameters embedded in datasets were used in KmPlot software to assess the correlation between Rictor protein phosphorylation analysis and OS within breast cancer clinical subtypes (ER+/HER2\u2212, ER+/HER2+, ER\u2212/HER2\u2212, and ER\u2212/HER2+).",
        "To understand the clinical relevance of Rictor/mTORC2 in malignant breast cancers, we assessed RICTOR gene alterations in publicly available datasets curated by TCGA (Cell, N = 817; ref. 26), METABRIC (N = 1904; ref. 27), and TCGA Firehose Legacy (N = 960; refs. 29, 33), finding RICTOR gene amplification or overexpression in 36.6% (N = 299), 14.5% (N = 277), and 33.6% (N = 323) of tumor samples, respectively (Fig. 1A). In each dataset, tumor RICTOR amplification/overexpression correlated with a decreased patient OS, consistent with previous reports correlating RICTOR mRNA expression with decreased survival in patients with breast cancer (25). Similarly, high Rictor protein expression assessed by RPPA correlated inversely with OS in invasive breast cancers (Fig. 1B), as did Rictor phosphorylation at T1135 (P-Rictor T1135; Supplementary Fig. S1A), a phospho-site correlating with, but not required for, oncogenic mTORC2 signaling (34). KmPlot software was used to assess Rictor T1135 phosphorylation within TCGA invasive breast tumors using RPPA data, further separating the tumors into groups based on clinical assessments of ER and HER2 expression: ER+/HER2+ (N = 196), ER+/HER2\u2212 (N = 284), ER\u2212/HER2+ (N = 38), and TNBC:ER\u2212HER2\u2212 (N = 103). P-Rictor T1135 correlated with decreased OS in three of four subgroups, with the greatest impact seen in TNBC:ER\u2212HER2\u2212 tumors (Fig. 1C). P-Rictor T1135 did not significantly correlate with decreased OS in the ER\u2212/HER2+ group. This could be due to the smaller population size of this group or may indicate that mTORC2 signaling does not affect survival in this clinical breast cancer subset. As Rictor is a key component of mTORC2, we assessed the RPPA dataset of invasive breast cancers (TCGA) to determine whether RICTOR gene expression or amplification correlates with increased mTORC2 signaling in clinical tumor specimens. Tumors with high RICTOR alteration harbored significantly higher P-Rictor T1135, P-Akt S473, and P-NDRG1, consistent with increased mTORC2 signaling in RICTOR-altered tumors (Fig. 1D). In contrast, mTORC1 effectors P-EIF4EBP1 and P-RPS6 exhibited diminished phosphorylation in RICTOR-altered breast tumors."
      ],
      "23000897": [
        "Patients with premetastatic TNBC continue to lack molecularly targeted therapeutic options, making NAC and tumor resection surgery the clinical standard of care. Although TNBCs may be more sensitive to chemotherapies than other breast cancer subtypes, as few as 30% of patients with TNBC may experience a pathologic complete response following NAC (2, 46). Aberrant PI3K pathway alterations occur frequently in TNBCs, often as activating PIK3CA mutations or PTEN loss-of-function alterations(47). Interestingly, our CCLE analysis revealed that PI3K pathway alterations (PIK3CA mutations and/or PTEN loss) co-occurred in 90% of TNBC cases with RICTOR amplification. This further suggests that PI3K pathway alterations are a frequent molecular event in TNBC and that the respective contributions of RICTOR, PIK3CA, and PTEN to mTOR hyperactivation may drive tumor progression. Although data shown here are based on genomic analysis of immortalized cell lines and therefore may not reflect clinical TNBC populations, RICTOR amplification has been shown to co-occur with PI3K pathway alterations in TNBC and other cancers at a relatively high frequency (48, 49). Thus, there is intense clinical interest in PI3K pathway inhibition. Pan-PI3K inhibitors have achieved limited clinical success because of associated toxicities (50), but strategies to inhibit downstream effectors of this pathway, such as the mTOR complexes, have the potential to be more selective. Data shown here demonstrate that selective mTORC2 inhibition is a potential vulnerability within the pathway, particularly when sparing mTORC1 signaling."
      ],
      "31068700": [
        "To identify TNBC cell lines harboring PI3K/mTOR genomic alterations, cell lines curated by the Cancer Cell Line Encyclopedia (CCLE; ref. 30) were queried in cBioPortal software for TNBC characterization (defined as lacking ESR1 expression >1 SD above the groups average and/or ERBB2 gene amplification). The genomic copy number for selected gene data was analyzed for all cell lines."
      ],
      "22522925": [
        "To probe the clinical impact of RICTOR expression and genomic amplification in patients with breast cancer, clinical breast cancer datasets curated by The Cancer Genome Atlas (TCGA; ref. 26) and METABRIC (27, 28) were queried for tumors harboring RICTOR gene amplification or RICTOR mRNA overexpression (defined as >2 SD above the mean RICTOR levels across the entire dataset), collectively defined herein as RICTOR alterations, using cBioPortal software (RRID: SCR_014555; ref. 29). Kaplan\u2013Meier survival curves were generated using cBioPortal software comparing overall survival (OS) of patients whose tumors harbor RICTOR alterations versus those without RICTOR alterations. Reverse phase protein array (RPPA) datasets of TCGA-curated invasive breast cancer were analyzed for Rictor protein overexpression and Rictor protein phosphorylation levels using cBioPortal software to determine whether Rictor protein overexpression correlates with patient survival and phosphorylation of mTORC2 substrates. RPPA analysis of TCGA breast invasive carcinoma was assessed by KmPlot software (RRID: SCR_018753), using software-directed selection of expression cutoff criteria. Clinical parameters embedded in datasets were used in KmPlot software to assess the correlation between Rictor protein phosphorylation analysis and OS within breast cancer clinical subtypes (ER+/HER2\u2212, ER+/HER2+, ER\u2212/HER2\u2212, and ER\u2212/HER2+)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 5,
    "extraction_method": "jats_xml",
    "extraction_time": 0.8759560585021973,
    "data_pmids_checked": 5,
    "paper_id": "40019775",
    "extraction_date": "2025-12-19T20:39:43.720088",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40019775.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40021759": {
    "paper_id": "40021759",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Addi- CNVanalysis.InJanuary2022,TCGAcopy-numbervariationdatawere\ntionally,TumorMutationBurden(TMB)andFractionGenomeAltered retrievedusingthe\u201cTCGAbiolinks\u201dpackageinR.Segment_Meanvalues\nmetrics were sourced from cBioPortal for Cancer Genomics (https:// greaterthan0.3wereclassifiedasgains,whilevalueslessthan\u22120.3were\nwww.cbioportal.org/) during the same period49,50",
      "TMB and Fraction Genome Altered\npatchpredictionsacrosstheWSI.TheBoWapproach,ontheotherhand, metrics were obtained from cBioPortal (https://www.cbioportal.org/)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:47.628653",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40021759.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.442318916320801,
      "cbioportal_papers": 0.00034999847412109375,
      "pdf_extraction_pass2": 5.944822072982788,
      "cbioportal_papers_pass2": 0.00030994415283203125,
      "used_full_extraction": true,
      "pdf_extraction": 12.387140989303589,
      "platform_mentions": 0.0029120445251464844,
      "data_citations": 9.059906005859375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40018039": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The CNV module of the Gene Set Cancer Analysis (GSCA) (http://bioinfo.life.hust.edu.cn/GSCA) analyzed amplification/deletion and heterozygous/homozygous of m7GRGs in HNSCC and correlated m7GRG expression with CNV. 509 HNSCC patients somatic mutations were visualized using the maftools package (25), covering six mutation types. The impact of m7GRGs on HNSCC patient survival was assessed using 523 HNSCC samples from the cBioPortal (http://www.cbioportal.org/) (26).",
      "Using the GSCA database, an Oncoplot revealed the top 10 genes with SNVs among m7GRGs, with EIF4G1 (14%) and APAF1 (10%) having the highest mutation frequencies ( Figure 4A ). Missense mutations were the most common mutation type ( Figure 4B ). Single nucleotide polymorphisms (SNPs) were more frequent than insertions and deletions ( Figure 4C ), with C>T being the most common SNV type ( Figure 4D ). Analysis of the number of base changes per patient showed a median and maximum of 1 and 11 mutations, respectively ( Figure 4E ). A boxplot of each variant classification showed the frequency of occurrences ( Figure 4F ). Recalculating the top 10 mutated genes, considering multiple hits, yielded slightly different results ( Figure 4G ). There was a significant negative correlation between mRNA expression of m7GRGs and gene methylation levels ( Figure 4H ). Lower methylation levels were significantly associated with poorer prognosis in HNSCC patients ( Figure 4I ). Through the GSCA database, analysis of the CNV landscape of 45 m7GRGs in HNSCC showed high rates of heterozygous deletion/amplification ( Supplementary Figure S1A ). NCBP2, LSM1, PHAX, NSUN2, and NCBP3 had higher CNV rates compared to other genes ( Supplementary Figure S1B ). CNV analysis indicated both heterozygous amplification and heterozygous deletion of m7GRGs ( Supplementary Figure S1C ). Detailed mutation sites of EIF3D, EIF1, LARP1, and METTL1 included missense mutations, splice sites, nonsense mutations, and frameshift deletions ( Supplementary Figure S2A ). Supplementary Figure S2B provides a detailed distribution ratio of CNVs in m7GRGs in HNSCC. Subsequent analysis of HNSCC samples from the cBioPortal database revealed significant differences between the mutation group and the non-mutation group in mutation count (p = 0.0212, q = 0.145), TMB (nonsynonymous) (p = 0.0259, q = 0.145), genome alteration fraction (p = 0.0253, q = 0.145), and Ragnum hypoxia score (p = 0.0283, q = 0.145), especially in the PanCan Pathway Analysis (p = 5.54e-7, q = 2.547e-5) ( Figure 4J ). Survival analysis indicated that genetic alterations in m7GRGs were significantly associated with shorter OS (p = 0.0224, HR = 0.725 [0.539 - 0.976]) and DSS (p = 0.0414, HR = 0.689 [0.468 - 1.0144]) but not with PFS (p = 0.291, HR = 0.850 [0.622 - 1.162]) ( Figure 4K ). These results suggest that alterations in m7GRGs impact the prognosis of HNSCC patients."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.34775805473327637,
    "data_pmids_checked": 0,
    "paper_id": "40018039",
    "extraction_date": "2025-12-19T20:39:48.057940",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40018039.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40025017": {
    "paper_id": "40025017",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:51.478613",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40025017.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.315937995910645,
      "cbioportal_papers": 0.0003521442413330078,
      "pdf_extraction_pass2": 7.949739933013916,
      "cbioportal_papers_pass2": 0.00034809112548828125,
      "used_full_extraction": true,
      "pdf_extraction": 16.26567792892456,
      "platform_mentions": 0.0025038719177246094,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "40019690": {
    "paper_id": "40019690",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "platform on cbioportal.org [16]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:39:56.545350",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40019690.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.426194190979004,
      "cbioportal_papers": 0.00019669532775878906,
      "pdf_extraction_pass2": 6.396276950836182,
      "cbioportal_papers_pass2": 0.00019598007202148438,
      "used_full_extraction": true,
      "pdf_extraction": 12.822471141815186,
      "platform_mentions": 0.0021390914916992188,
      "data_citations": 7.295608520507812e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40008396": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Cases with incomplete clinical data in the TCGA database were excluded. According to COIL median expression values, patients were grouped into low- and high-expression groups. The correlation between COIL and overall survival (OS) was analyzed. In addition, an analysis of gene alterations and their association with survival time was conducted. The relationship between the gene changes of COIL and prognosis was analyzed by cBioportal.21 The selection condition of genomic profiles was set as \u201cEnter a Z-Score threshold \u00b12.0\u201d.",
      "The top 100 genes from cBioPortal and GEPIA were screened, and 41 of them were obtained by intersection (Figure 4A). These 41 COIL-related genes were assessed by KEGG and GO functional analysis. The results of KEGG analysis suggest that related genes may contribute to RNA transport regulation and spliceosome signal pathways (Figure 4B). GO enrichment analysis was also performed, including biological process (BP), cellular component (CC) and molecular function (MF). GO-CC analysis suggested that it was mainly enriched in the nucleus. For GO-BP, COIL-related genes were most enriched by covalent chromatin modification, oxidative phosphorylation, histone H4-K5, H4-K8, and H4-K16 acetylation. GO analysis results were visualized in Figure 4C. The PPI network was then performed in STRING database and visualized using Cytoscape software. Ten hub genes were screened according to MCC values. As shown in Figure 4D, the 10 hub genes are COIL, CBX1, MSH2, SUZ12, ATAD5, ZNF207, SUMO2, HNRNPU, SMARCE1, and KPNB1. Figure 4(A) Forty-one COIL-related genes were obtained through the intersection of cBioPortal and GEPIA databases. KEGG (B) or GO (C) analysis of these forty-one COIL-related genes was conducted. (D) A protein\u2013protein interaction network was established and visualized. (E) GSEA of COIL-related genes.",
      "(A) Forty-one COIL-related genes were obtained through the intersection of cBioPortal and GEPIA databases. KEGG (B) or GO (C) analysis of these forty-one COIL-related genes was conducted. (D) A protein\u2013protein interaction network was established and visualized. (E) GSEA of COIL-related genes."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.19216084480285645,
    "data_pmids_checked": 0,
    "paper_id": "40008396",
    "extraction_date": "2025-12-19T20:39:56.743574",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40008396.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40008192": {
    "cbioportal_paper_citations": [
      "We accessed the expression profiles of DNAJC12 mRNA in samples from 1108 patients with breast cancer through the Firehose Legacy TCGA dataset downloaded from cBioPortal (https://www.cbioportal.org/).20 -23 We included only samples with information regarding the PAM50 intrinsic subtype and DNAJC12 expression. Tumors classified as normal-like were excluded, and the resulting sample size was n = 808."
    ],
    "cbioportal_platform_mentions": [
      "Study flowchart. The analysis of DNAJC12 expression was performed through data mining using public databases containing mRNA expression data (https://ualcan.path.uab.edu/; https://www.cbioportal.org/; https://www.kmplot.com/; https://rocplot.org/) and by immunohistochemistry (IHC) on tissue microarrays (TMA) containing 292 primary breast tumors.",
      "Additionally, we downloaded the TCGA dataset from cBioPortal to explore the associations between DNAJC12 expression and clinicopathological characteristics of BC patients (Table 1). We found that the distribution of DNAJC12 expression levels significantly differs among groups when considering all 3 classical BC markers (ER P < .001; PR P < .001; and HER2 P = .010). As expected, DNAJC12 has higher expression levels on ER+ when median expression values are considered (P < .001), and the same holds for PR+ patients (P < .001). In this dataset, HER2+ patients had a lower expression of DNAJC12 when compared to HER2-patients (P = .007). DNAJC12 expression was also significantly different when comparing patients of different BC molecular subtypes. In this case, the luminal subtypes, positive for steroid hormone receptors ER/PR, had the highest median expression values, and HER2-enriched and TNBC patients had lower expression. Next, we investigated the association of the DNAJC12 mRNA expression and survival."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.38785576820373535,
    "data_pmids_checked": 0,
    "paper_id": "40008192",
    "extraction_date": "2025-12-19T20:39:57.157731",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40008192.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40007535": {
    "cbioportal_paper_citations": [
      "Clinical, genomic, and transcriptomic data from 206 primary sarcoma samples in The Cancer Genome Atlas (TCGA) were analyzed using CBioPortal v6.0.22 (35). The dataset \u2018Adult Soft Tissue Sarcomas\u2019 (36) was selected, and 174 soft tissue sarcoma samples were included in the survival analysis, excluding those without complete genomic and expression data, as well as uterine sarcoma and nerve sheath tumor samples. CBioPortal was additionally utilized to visualize data from the TCGA sarcoma cohort, retrieve patient clinical information, and access genomic and transcriptomic data."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29100075": [
        "Although initially STS were simply classified as \u2018non-immunogenic\u2019 tumors, studies have proved that this characterization does not apply to all (17). Indeed, different TME compositions have been found in STS patients, and some of them exhibited an elevated infiltration of immune cells and immune-related factors. Furthermore, the TME has also been associated with patient prognosis and could predict the patient\u2019s response to therapy (17, 18).",
        "Clinical, genomic, and transcriptomic data from 206 primary sarcoma samples in The Cancer Genome Atlas (TCGA) were analyzed using CBioPortal v6.0.22 (35). The dataset \u2018Adult Soft Tissue Sarcomas\u2019 (36) was selected, and 174 soft tissue sarcoma samples were included in the survival analysis, excluding those without complete genomic and expression data, as well as uterine sarcoma and nerve sheath tumor samples. CBioPortal was additionally utilized to visualize data from the TCGA sarcoma cohort, retrieve patient clinical information, and access genomic and transcriptomic data."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.7325198650360107,
    "data_pmids_checked": 1,
    "paper_id": "40007535",
    "extraction_date": "2025-12-19T20:39:57.972447",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40007535.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40004558": {
    "cbioportal_paper_citations": [
      "Figure 1 illustrates the workflow and results generated by the AF vs. EU DESeq2 analysis. The LncRNA Systems Biology Analyses are described in more detail in the Supplementary Materials [42,43,44,45,46,47,48,49,50,51,52,53,54]. Supplemental Table S2 outlines CbioPortal PC datasets queried. Figure S2B is a schematic of the workflow outlining downstream analyses of the top-ranking lncRNAs.",
      "The top-ranked lncRNAs were analyzed against PC datasets hosted on the cBioPortal platform, excluding AC098617.1 and AC005863.1 as they were not recognized transcripts within cBioPortal [63]. The analysis revealed co-occurrence among several lncRNAs, as summarized in Table 4. The alteration frequency of these lncRNAs across these prostate cancer datasets, highlighting alterations in expression, structural variant, mutation, and copy number alteration (CAN), are provided in Supplemental Figures S9\u2013S17."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625048": [
        "Figure 1 illustrates the workflow and results generated by the AF vs. EU DESeq2 analysis. The LncRNA Systems Biology Analyses are described in more detail in the Supplementary Materials [42,43,44,45,46,47,48,49,50,51,52,53,54]. Supplemental Table S2 outlines CbioPortal PC datasets queried. Figure S2B is a schematic of the workflow outlining downstream analyses of the top-ranking lncRNAs."
      ],
      "31061129": [
        "Figure 1 illustrates the workflow and results generated by the AF vs. EU DESeq2 analysis. The LncRNA Systems Biology Analyses are described in more detail in the Supplementary Materials [42,43,44,45,46,47,48,49,50,51,52,53,54]. Supplemental Table S2 outlines CbioPortal PC datasets queried. Figure S2B is a schematic of the workflow outlining downstream analyses of the top-ranking lncRNAs."
      ],
      "22722839": [
        "Figure 1 illustrates the workflow and results generated by the AF vs. EU DESeq2 analysis. The LncRNA Systems Biology Analyses are described in more detail in the Supplementary Materials [42,43,44,45,46,47,48,49,50,51,52,53,54]. Supplemental Table S2 outlines CbioPortal PC datasets queried. Figure S2B is a schematic of the workflow outlining downstream analyses of the top-ranking lncRNAs."
      ],
      "26544944": [
        "Figure 1 illustrates the workflow and results generated by the AF vs. EU DESeq2 analysis. The LncRNA Systems Biology Analyses are described in more detail in the Supplementary Materials [42,43,44,45,46,47,48,49,50,51,52,53,54]. Supplemental Table S2 outlines CbioPortal PC datasets queried. Figure S2B is a schematic of the workflow outlining downstream analyses of the top-ranking lncRNAs."
      ],
      "26928463": [
        "Figure 1 illustrates the workflow and results generated by the AF vs. EU DESeq2 analysis. The LncRNA Systems Biology Analyses are described in more detail in the Supplementary Materials [42,43,44,45,46,47,48,49,50,51,52,53,54]. Supplemental Table S2 outlines CbioPortal PC datasets queried. Figure S2B is a schematic of the workflow outlining downstream analyses of the top-ranking lncRNAs."
      ],
      "29610475": [
        "Figure 1 illustrates the workflow and results generated by the AF vs. EU DESeq2 analysis. The LncRNA Systems Biology Analyses are described in more detail in the Supplementary Materials [42,43,44,45,46,47,48,49,50,51,52,53,54]. Supplemental Table S2 outlines CbioPortal PC datasets queried. Figure S2B is a schematic of the workflow outlining downstream analyses of the top-ranking lncRNAs."
      ],
      "26000489": [
        "Figure 1 illustrates the workflow and results generated by the AF vs. EU DESeq2 analysis. The LncRNA Systems Biology Analyses are described in more detail in the Supplementary Materials [42,43,44,45,46,47,48,49,50,51,52,53,54]. Supplemental Table S2 outlines CbioPortal PC datasets queried. Figure S2B is a schematic of the workflow outlining downstream analyses of the top-ranking lncRNAs."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 7,
    "extraction_method": "jats_xml",
    "extraction_time": 2.791254997253418,
    "data_pmids_checked": 13,
    "paper_id": "40004558",
    "extraction_date": "2025-12-19T20:40:00.785087",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40004558.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40016583": {
    "paper_id": "40016583",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "https://d oi.o rg/\n(2013) Integrative analysis of complex cancer genomics and clini-\n10.1 371/j ourna l.p one.0 16662 6\ncal profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:00.898868",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40016583.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.8624749183654785,
      "cbioportal_papers": 0.00017833709716796875,
      "pdf_extraction_pass2": 5.947203874588013,
      "cbioportal_papers_pass2": 0.00017905235290527344,
      "used_full_extraction": true,
      "pdf_extraction": 12.809678792953491,
      "platform_mentions": 0.0014929771423339844,
      "data_citations": 7.081031799316406e-05,
      "num_data_pmids_checked": 1
    }
  },
  "40003901": {
    "cbioportal_paper_citations": [
      "Data from the TCGA-SKCM cohort [33] and 19 other TCGA cohorts as well as from the Pan-cancer Analysis of Advanced and Metastatic Tumors cohort from BCSGC (British Colombia Genome Sciences Centre) [34] were retrieved through https://cbioportal.org on 5 January 2024 [49,50]. Transcriptomic data from metastatic SKCM samples from the Posthumous Evaluation of Advanced Cancer environment (PEACE) study [25] were retrieved from Zenodo data repository https://zenodo.org/records/7673904 on 15 August 2024. Further details can be found in the Supplementary Materials and Methods."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26091043": [
        "In order to examine the degree of conservation of CRG expression between primary tumor samples and metastases, we compared bulk RNA-seq from SKCM metastatic samples with 20 types of primary tumors (including primary SKCM), using CRG expression (z score values of RNA-seq by expectation maximization (RSEM) expression), from The Cancer Genome Atlas (TCGA) [33] (Figure 1A).",
        "Data from the TCGA-SKCM cohort [33] and 19 other TCGA cohorts as well as from the Pan-cancer Analysis of Advanced and Metastatic Tumors cohort from BCSGC (British Colombia Genome Sciences Centre) [34] were retrieved through https://cbioportal.org on 5 January 2024 [49,50]. Transcriptomic data from metastatic SKCM samples from the Posthumous Evaluation of Advanced Cancer environment (PEACE) study [25] were retrieved from Zenodo data repository https://zenodo.org/records/7673904 on 15 August 2024. Further details can be found in the Supplementary Materials and Methods."
      ],
      "35121966": [
        "Independent validation of the association between high F3 expression and lung location of metastases was obtained from two independent studies with bulk RNA-seq data from metastases of SKCM (Figure 2D,E). In the BCGSC cohort (British Colombia Genomics Sciences Center, POG570) [34], we confirmed significantly higher expression of F3 in lung metastases of SKCM compared to all other metastatic locations of SKCM (p = 0.02, Figure 2D). Interestingly, lung metastases of breast carcinoma, non-small cell lung carcinoma, sarcoma/soft tissue tumors also ranked highest in F3 expression (Figure 2D). The transcriptomic characterization of multiple metastatic samples in posthumous SKCM patients PEACE study [25] offered the advantage of comparing multiple matched samples from a small number of patients. As shown in Figure 2E, in four SKCM patients with 38 samples analyzed, lung metastases systematically ranked as the highest expressors of F3 compared to other patient-matched metastatic locations (Figure 2E).",
        "Data from the TCGA-SKCM cohort [33] and 19 other TCGA cohorts as well as from the Pan-cancer Analysis of Advanced and Metastatic Tumors cohort from BCSGC (British Colombia Genome Sciences Centre) [34] were retrieved through https://cbioportal.org on 5 January 2024 [49,50]. Transcriptomic data from metastatic SKCM samples from the Posthumous Evaluation of Advanced Cancer environment (PEACE) study [25] were retrieved from Zenodo data repository https://zenodo.org/records/7673904 on 15 August 2024. Further details can be found in the Supplementary Materials and Methods."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2568929195404053,
    "data_pmids_checked": 2,
    "paper_id": "40003901",
    "extraction_date": "2025-12-19T20:40:01.110184",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40003901.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40001977": {
    "cbioportal_paper_citations": [
      "For gene alteration analysis, cBioPortal (www.cbioportal.org, accessed on 11 November 2024), a database providing TCGA-based cancer genomic data, was used [18]. A total of 398, 278, and 509 patient samples with mutation and Copy Number Alteration (CNA) data for OV, CESC, and UCEC were examined, respectively. Putative CNAs were obtained from Genomic Identification of Significant Targets in Cancer (GISTIC) [19]."
    ],
    "cbioportal_platform_mentions": [
      "Changes in SPOCK1 gene in TCGA and pan-cancer atlas datasets. (A) Patients with changes in SPOCK1 in OV cohort, \u201cno alterations\u201d continue until the 398th patient\u201d, (B) frequency of changes according to cancer types in OV cohort, (C) mutated regions in SPOCK1 gene in OV cohort, (D) patients with changes in SPOCK1 in CESC cohort, \u201cno alterations\u201d continue until the 278th patient, (E) frequency of changes according to cancer types in CESC cohort, (F) mutated regions in SPOCK1 gene in CESC cohort, (G) patients with alterations in SPOCK1 in the UCEC cohort, \u201cno alterations\u201d continue until the 509th patient, (H) frequency of alterations according to cancer type in the UCEC cohort, and (I) mutated regions in the SPOCK1 gene in the UCEC cohort. Kazal_2, kazal-type serine protease inhibitor domain (139\u2013180); SPARC_Ca_bdg, secreted protein acidic and rich in cysteine Ca binding region (196\u2013304); and thyroglobulin_1, thyroglobulin type-1 repeat (313\u2013376). Images obtained from the https://www.cbioportal.org/ web tool, accessed on 11 November 2024."
    ],
    "data_publication_citations": {
      "21720365": [
        "Cancer incidence and death rates are dramatically growing year after year. The World Health Organization (WHO) estimates that 20 million new cancer cases and 9.7 million cancer deaths will be reported in 2022 [1]. Although the most frequent malignancies are lung, colorectal, and breast, the prevalence of gynecological cancers among women is increasing year after year. The three most frequent gynecological cancers are cervical, endometrial, and ovarian cancer [2]. Low-stage gynecological malignancies can be treated with surgery, radiation, and chemotherapy [3,4,5]. Despite breakthroughs in clinical treatment, the survival rate for high-grade gynecological malignancies remains very low [6]. As a result, there is urgent need for new diagnostic markers and therapeutic target molecules that can effectively improve the prognosis of cancer."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2627871036529541,
    "data_pmids_checked": 1,
    "paper_id": "40001977",
    "extraction_date": "2025-12-19T20:40:01.394464",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/40001977.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40052110": {
    "paper_id": "40052110",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:06.265385",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40052110.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 22.68564462661743,
      "cbioportal_papers": 0.0004391670227050781,
      "pdf_extraction_pass2": 25.57928705215454,
      "cbioportal_papers_pass2": 0.0004968643188476562,
      "used_full_extraction": true,
      "pdf_extraction": 48.26493167877197,
      "platform_mentions": 0.003506898880004883,
      "data_citations": 1.1205673217773438e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40015991": {
    "paper_id": "40015991",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Continued\nReagentsandsoftware Source Identifier/reference RRID\nRNA-seqdata cBioPortal http://www.cbioportal.org SCR_014555\nMolecularsignatures mSigDB http://www.broadinstitute.org/\nmsigdb\nOther\nTCGAanalysisRscript N/A Riesenbergetal.2015\nextractionbufferbeforebeingcoatedwiththeprimaryan- Glo-Max 96 multidetector system (Promega)",
      "GeneexpressiondatafromtheCCLEandTCGAwere Weacknowledgefortheircollaborationthepatientsand\naccessed through cBioPortal (Cerami et al. 2012; Gao theHospitalLaPazInstituteforHealthResearchBiobank\netal.2013).Themovingaveragetrendlineofthebarplots (IdiPAZBiobank;PT20-0040,integratedintotheBiobanks\ninFigures1Fand2H,representingtheexpressionlevelof and Biomodel ISCII platform)",
      "Cancer\nGaoJ,AksoyBA,DogrusozU,DresdnerG,GrossB,SumerSO, Cell27:574\u2013588.doi:10.1016/j.ccell.2015.03.008\nSunY,JacobsenA,SinhaR,LarssonE,etal.2013.Integrative HodsonL,SkeaffCM,FieldingBA.2008.Fattyacidcomposition\nanalysisofcomplexcancergenomicsandclinicalprofilesus- ofadiposetissueandbloodin humansandits useasa bio-\ning the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:08.250591",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40015991.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.771254062652588,
      "cbioportal_papers": 0.0004048347473144531,
      "pdf_extraction_pass2": 8.947773933410645,
      "cbioportal_papers_pass2": 0.0007441043853759766,
      "used_full_extraction": true,
      "pdf_extraction": 16.719027996063232,
      "platform_mentions": 0.005630970001220703,
      "data_citations": 0.00020599365234375,
      "num_data_pmids_checked": 1
    }
  },
  "39999090": {
    "paper_id": "39999090",
    "cbioportal_paper_citations": [
      "https://doi.org/10.1158/2159-8290.CD-12-0095 PMID: 22588877\n38",
      "org/10.1126/scisignal.2004088 PMID: 23550210\n39"
    ],
    "cbioportal_platform_mentions": [
      "The transcriptomics dataset of HCC cases (n = 366) from TCGA were\nretrieved separately from the cBioPortal database [37,38]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:11.302724",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39999090.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.875259160995483,
      "cbioportal_papers": 0.0038988590240478516,
      "used_full_extraction": false,
      "pdf_extraction": 9.875259160995483,
      "platform_mentions": 0.0038101673126220703,
      "data_citations": 1.2874603271484375e-05,
      "num_data_pmids_checked": 0
    }
  },
  "40021663": {
    "paper_id": "40021663",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "tumor-specificretrotranspositioncountsasafunctionoftheaverage\nreadlength,depthofcoverage,averagebasequality,chimericread\nCategorizingtumorsasp53wildtype(WT)ormutant fraction,andclippedbasefractioninboththetumorsampleandthe\nCategoricaldesignationsofp53alterationwereobtainedthroughthe pairednormalsample.Theresidualsfromthismodelwerethenusedas\npublic repository cBioPortal (www.cbioportal.org, accessed 23 Feb- theadjustedL1RTestimates(SupplementaryFig.20b)",
      "Categorizingtumorsaswildtype(WT)ormutantfor Finally,weannotatedeachlocusbasedonwhetherthemeanTRT\nadditionalgenes valueacrosstumortypesfellwithinthelowesthistogrambin(fewer\nCategoricaldesignationsofalterationstatusforthe82mostfrequently than0.0018log2,QC-adjustedTRTspersample).Locithatsharedall\nmutated genes in TCGA were obtained through cBioPortal (www",
      "threeannotations(2clusterassignmentsfromtheRNAandTRTden-\ncbioportal.org,accessed23February2023)usingthesamequeryand drograms,andtheTRThistogram-basedannotation)wereassignedto\ncategorizationasabove.Thesample-levelannotationsforthedataset thesamecluster,resultinginthefinalsetof13clustersusedinFig.5\nusedinthisstudycanbefoundinSupplementaryData3.Thecomplete and Supplementary Fig",
      "cBioPortal), a series of Mann-Whitney U tests was performed"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:15.771955",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40021663.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 19.574713230133057,
      "cbioportal_papers": 0.00044274330139160156,
      "pdf_extraction_pass2": 17.413262128829956,
      "cbioportal_papers_pass2": 0.0004398822784423828,
      "used_full_extraction": true,
      "pdf_extraction": 36.98797535896301,
      "platform_mentions": 0.004141807556152344,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39992718": {
    "cbioportal_paper_citations": [
      "Our data support the idea that BRAFV600E suppresses cell migration and invasion via ERK-dependent feedback inhibition of RAC1 activation. We, therefore, hypothesize that secondary hits that restore migration are required for melanomagenesis. This can be accomplished by lesions that cause RAC1 activation to be insensitive to ERK-dependent feedback. RAC1 mutations or amplification (6%) and lesions in PTEN (20%) were identified in a set of 189 BRAFV600E human melanomas (TCGA; Fig. 6A; refs. 46, 47). Most RAC1 mutants identified are gain-of-function P29S mutants that rescue migration and the mesenchymal phenotype in a BRAFV600EPTENWT model (Fig. 4B and D). PTEN inhibits RAC1 activation by inhibiting PI3K signaling (48), and PTEN lesions have been associated with loss of protein expression."
    ],
    "cbioportal_platform_mentions": [
      "The data generated in this study are available from the corresponding author upon request. The Cancer Genome Atlas (TCGA) Firehose Legacy dataset analyzed in this study was obtained from cBioPortal for Cancer Genomics at https://www.cbioportal.org/study/summary?id=skcm_tcga.",
      "We assessed the migration of 16 BRAFV600E human melanoma lines. Five of these cell lines with PTENWT and RAC1WT (cbioportal) had significantly lower migration indices (Fig. 6E, i), RAC1-GTP, and pAKT levels (Fig. 6E, ii) compared with the other 11 lines that migrated faster. Seven of these lines were PTENnull; SK-MEL263 had wild-type PTEN and RAC1 amplification and elevated RAC1-GTP. Three outliers had moderate migratory ability compared with PTENnull cells. HT-144 was haploinsufficient for PTEN, with high pAKT but low RAC1-GTP. A375 and SK-MEL5 had wild-type PTEN, low pAKT levels, moderate RAC1-GTP levels, and migratory ability compared with PTENnull cells. In this cohort of cells, migration positively correlates with RAC1-GTP levels (Fig. 6E, ii). PTENnull YUMM lines have higher RAC1-GTP than PTENWT BRAFV600E lines (Fig. 6F)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.13642382621765137,
    "data_pmids_checked": 0,
    "paper_id": "39992718",
    "extraction_date": "2025-12-19T20:40:15.915973",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39992718.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39986611": {
    "cbioportal_paper_citations": [
      "In addition to promoting the TCA cycle, p53 enhances mitochondrial respiration. Cytochrome c oxidase subunit 2, a key component of electron transfer complex IV, is a transcriptional target of p53 and supports ATP production (Matoba et al., 2006, Qi et al., 2011). Notably, we confirmed mutant p53 tumors display higher levels of glycolytic genes (GLUT1, PFKB3, PGAM1, LDHA, MCT1, and PHGDH) and ME1, and lower levels of PARK2 (Fig. 2). Overall, extensive research highlights p53\u2019s role as a glycolysis suppressor, directing glucose into the TCA cycle for complete oxidation. This regulation helps cells meet energy demands while preventing tumor progression.Fig. 2The expression of p53 target metabolic genes in the p53-WT and p53-Mutant pan-cancer cohort. Gene expression data were obtained from TCGA PanCancer Atlas studies and analyzed using the cBioportal (https://www.cbioportal.org).(Cerami et al., 2012; Gao et al., 2013) Each dot represents a single study. FC, fold change (Mut/WT); RSEM, RNA Seq by expectation-maximization.Fig. 2",
      "The expression of p53 target metabolic genes in the p53-WT and p53-Mutant pan-cancer cohort. Gene expression data were obtained from TCGA PanCancer Atlas studies and analyzed using the cBioportal (https://www.cbioportal.org).(Cerami et al., 2012; Gao et al., 2013) Each dot represents a single study. FC, fold change (Mut/WT); RSEM, RNA Seq by expectation-maximization."
    ],
    "cbioportal_platform_mentions": [
      "K.Y.K created Figure 1 with feedback from all authors. K.M. analyzed data and generated Figure 2 using the cBioPortal. M.-S.L designed and supervised the study and wrote the manuscript with help from K.Y.K, H.S.S and K.M."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.18149209022521973,
    "data_pmids_checked": 0,
    "paper_id": "39986611",
    "extraction_date": "2025-12-19T20:40:16.117660",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39986611.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39985912": {
    "cbioportal_paper_citations": [
      "The Cancer Genomic Atlas (TCGA, RRDI: SCR_003193) [24] and Memorial Sloan Kettering - Metastatic Events and Tropisms (MSK-MET) [25] databases were used to calculate metastasis occurrence per patient and per organs respectively, in MSI CRC patients. Both datasets were downloaded through cBioportal [26] (RRID: SCR_014555). For the analysis of the MSK-MET database, we only considered patients associated with one primary tumor sample.",
      "REAGENT or RESOURCESOURCEIDENTIFIERChemicals, peptides, and recombinant proteinsD-Luciferin, Firefly, potassium saltCaliperCat# 119222TRIzol-LSThermo FisherCat# 10296010Critical commercial assaysAllPrep DNA/RNA Mini KitQiagenCat# 80204Agilent SureSelectXT Mouse All Exon KitN/ALot no 5190-4641#Optimal Dual-mode mRNA Library Prep KitYeasenCat# 12301ES98Whole Blood Cell StabilizerCytodelicsCat# mWBCS002-100Fixation BufferCytodelicsCat# WBFL002-1000Lysis BufferCytodelicsCat# WBFL002-1000Wash BufferCytodelicsCat# WBFL002-1000Deposited dataRaw and analyzed dataThis paperhttps://www.ebi.ac.uk/ena/browser/view/PRJEB85233Experimental models: Cell lines4T1-Luc2ATCCCat# CRL-2539-LUC2; RRID: CVCL_A4BMExperimental models: Organisms/strainsBALB/cOlaHsdEnvigoRRID: IMSR_ENV:HSD-162Software and algorithmsBWA-MEM v2.2.1Vasimuddin et al. [33]RRID: SCR_022192GATK v4.0.9.0Auwera et al. [34]RRID: SCR_001876FastQC v0.11.8N/ARRID: SCR_014583Samtools v1.9Li et al. [35]RRID: SCR_002105MutationalPatterns v3.12.0Blokzijl et al. [36]RRID: SCR_024247msisensor-pro v1.2.0Jia et al. [37]RRID: SCR_024765Fastp v0.23.2Chen et al. [38]RRID: SCR_016962STAR v2.7.1aDobin et al. [39]RRID: SCR_004463HTSeq-counts v2.0.2Anders et al. [40]RRID: SCR_011867EdgeR v4.0.16Chen et al. [41]RRID: SCR_012802complexHeatmap v2.18.0Gu et al. [42]RRID: SCR_017270cluster v2.1.6N/ARRID: SCR_013505WebGestalt 2019Liao et al. [43]RRID: SCR_006786GenePattern GSEAReich et al. [44]RRID: SCR_003201TRUST4Song et al. [29]N/ARIMAYang et al. [30]N/ApVACtools v4.0.6Hundal et al. [31]RRID: SCR_025435ggplot2 v3.5.0Wickham et al. [45]RRID: SCR_025435FlowJo v10.8.1N/ARRID: SCR_008520flowCore v3.20Hahne et al. [46]RRID: SCR_002205rstatix v0.7.2N/ARRID: SCR_021240OtherIn Vivo Imaging SystemPerkin-ElmerRRID: SCR_018621The Cancer Genomic AtlasWeinstein et al. [24]RRDI: SCR_003193Memorial Sloan Kettering - Metastatic Events and TropismsNguyen et al. [25]N/AcBioportalGao et al. [26]RRID: SCR_014555POLYTRON System PT 3100 DKinematicaCat# 441-0750Standard Dispersing Aggregate tipsKinematicaCat# PT-DA 07 / 2EC-F101Qubit ds DNAThermo FisherCat# Q32851Qubit RNAThermo FisherCat# Q332212100 BioanalyzerAgilentRRID: SCR_018043COSMICSondka et al. [27]RRID: SCR_002260Ensembl version 102Martin et al. [47]RRID: SCR_002344The cancer Meta ProgramGavish et al. [28]N/AMGI Jax informaticsN/ARRID: SCR_006460Molecular Signature DatabaseLiberzon et al. [48]RRID: SCR_016863Automacs Pro SeparatorMiltenyi BiotecRRID: SCR_018596CyTEK Aurora flow cytometerCytek BiosciencesRRID: SCR_019826"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "35120664": [
        "The Cancer Genomic Atlas (TCGA, RRDI: SCR_003193) [24] and Memorial Sloan Kettering - Metastatic Events and Tropisms (MSK-MET) [25] databases were used to calculate metastasis occurrence per patient and per organs respectively, in MSI CRC patients. Both datasets were downloaded through cBioportal [26] (RRID: SCR_014555). For the analysis of the MSK-MET database, we only considered patients associated with one primary tumor sample.",
        "REAGENT or RESOURCESOURCEIDENTIFIERChemicals, peptides, and recombinant proteinsD-Luciferin, Firefly, potassium saltCaliperCat# 119222TRIzol-LSThermo FisherCat# 10296010Critical commercial assaysAllPrep DNA/RNA Mini KitQiagenCat# 80204Agilent SureSelectXT Mouse All Exon KitN/ALot no 5190-4641#Optimal Dual-mode mRNA Library Prep KitYeasenCat# 12301ES98Whole Blood Cell StabilizerCytodelicsCat# mWBCS002-100Fixation BufferCytodelicsCat# WBFL002-1000Lysis BufferCytodelicsCat# WBFL002-1000Wash BufferCytodelicsCat# WBFL002-1000Deposited dataRaw and analyzed dataThis paperhttps://www.ebi.ac.uk/ena/browser/view/PRJEB85233Experimental models: Cell lines4T1-Luc2ATCCCat# CRL-2539-LUC2; RRID: CVCL_A4BMExperimental models: Organisms/strainsBALB/cOlaHsdEnvigoRRID: IMSR_ENV:HSD-162Software and algorithmsBWA-MEM v2.2.1Vasimuddin et al. [33]RRID: SCR_022192GATK v4.0.9.0Auwera et al. [34]RRID: SCR_001876FastQC v0.11.8N/ARRID: SCR_014583Samtools v1.9Li et al. [35]RRID: SCR_002105MutationalPatterns v3.12.0Blokzijl et al. [36]RRID: SCR_024247msisensor-pro v1.2.0Jia et al. [37]RRID: SCR_024765Fastp v0.23.2Chen et al. [38]RRID: SCR_016962STAR v2.7.1aDobin et al. [39]RRID: SCR_004463HTSeq-counts v2.0.2Anders et al. [40]RRID: SCR_011867EdgeR v4.0.16Chen et al. [41]RRID: SCR_012802complexHeatmap v2.18.0Gu et al. [42]RRID: SCR_017270cluster v2.1.6N/ARRID: SCR_013505WebGestalt 2019Liao et al. [43]RRID: SCR_006786GenePattern GSEAReich et al. [44]RRID: SCR_003201TRUST4Song et al. [29]N/ARIMAYang et al. [30]N/ApVACtools v4.0.6Hundal et al. [31]RRID: SCR_025435ggplot2 v3.5.0Wickham et al. [45]RRID: SCR_025435FlowJo v10.8.1N/ARRID: SCR_008520flowCore v3.20Hahne et al. [46]RRID: SCR_002205rstatix v0.7.2N/ARRID: SCR_021240OtherIn Vivo Imaging SystemPerkin-ElmerRRID: SCR_018621The Cancer Genomic AtlasWeinstein et al. [24]RRDI: SCR_003193Memorial Sloan Kettering - Metastatic Events and TropismsNguyen et al. [25]N/AcBioportalGao et al. [26]RRID: SCR_014555POLYTRON System PT 3100 DKinematicaCat# 441-0750Standard Dispersing Aggregate tipsKinematicaCat# PT-DA 07 / 2EC-F101Qubit ds DNAThermo FisherCat# Q32851Qubit RNAThermo FisherCat# Q332212100 BioanalyzerAgilentRRID: SCR_018043COSMICSondka et al. [27]RRID: SCR_002260Ensembl version 102Martin et al. [47]RRID: SCR_002344The cancer Meta ProgramGavish et al. [28]N/AMGI Jax informaticsN/ARRID: SCR_006460Molecular Signature DatabaseLiberzon et al. [48]RRID: SCR_016863Automacs Pro SeparatorMiltenyi BiotecRRID: SCR_018596CyTEK Aurora flow cytometerCytek BiosciencesRRID: SCR_019826"
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.608069896697998,
    "data_pmids_checked": 3,
    "paper_id": "39985912",
    "extraction_date": "2025-12-19T20:40:16.737201",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39985912.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39985100": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Using the TCGA database, we investigated RGS5 gene variation across tumor types (Fig. 4A). According to the cBioPortal website, we found that RGS5 mutations, primarily amplification, were more common in breast cancer (Fig. 4B). The GSCALite website provided us with the methylation levels of RGS5 in several tumor kinds, and we found that 10 tumor types had variable expression, particularly kidney and lung cancer (Fig. 4C). Additionally, we investigated the frequency of SNV mutations of the RGS5 gene in 16 different forms of cancer. The highest sample mutation frequency was found in UCEC patients (Fig. 4D). Furthermore, we examined the relationship between RGS5 and pan-cancer CNVs, including none, hete.amp, homo.amp, hete.del, and hete.del. The results suggested that the CNVs mutation of RGS5 was various in each type of cancer, and the main type of CNVs was hete.amp in most cancer types (Fig. 4E).Fig. 4The analysis of mutation landscape in pan-cancer. A Mutation landscapes of RGS5 for pan-cancer. B Mutation frequency of RGS5 for pan-cancer. C Methylation difference of RGS5 for pan-cancer. D The SNVs mutation type of RGS5 for pan-cancer. E The CNVs mutation type of RGS5 for pan-cancer"
    ],
    "data_publication_citations": {
      "29850653": [
        "With an emphasis on tumor mutation burden (TMB), microsatellite instability (MSI), neoantigen (NEO), and tumor purity, we used Pearson correlation analysis to investigate the connection between tumor genomic heterogeneity and RGS5 expression. The GDC website (https://portal.gdc.cancer.gov/) provided the data for these analyses, which were then processed using the R package \"maftools\" and the Mutect2 software [26, 27]. MSI scores from prior studies were utilized to calculate Pearson correlations with RGS5 expression [28]. By combining tumor methylation and mRNA expression profiles, we were able to derive a tumor stemness score that included both RNA expression-based stemness (RNAss) and DNA methylation-based stemness (DNAss) [29]. Furthermore, by combining mutation data and domain information, the gene mutation landscape was created, enabling us to evaluate mutation frequency across different tumor types [30]."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 1.457564115524292,
    "data_pmids_checked": 3,
    "paper_id": "39985100",
    "extraction_date": "2025-12-19T20:40:18.194859",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39985100.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39980836": {
    "cbioportal_paper_citations": [
      "The Cancer Genome Atlas (TCGA) PanCancer Atlas COADREAD cohort data were accessed via cbioportal.org [34\u201336]. Mutational data were compared between the 75 patients who were diagnosed aged \u226449 years vs the 517 patients who were diagnosed at age \u226550 years. For RNA-based analyses, patients with mismatch repair deficiency were excluded. Cohorts were built on age at diagnosis (<51 vs 51\u201360, 61\u201370, 71\u201380, 81+, 51+) and the differential expression data from each pairwise comparison were downloaded for further analysis.",
      "Differential gene expression between age-group cohorts in the TCGA PanCancer Atlas COADREAD cohorts was utilized [34, 35]. Gene-set enrichment analysis was run against the Hallmark Gene Sets by using GSEA software, through the Run GSEA PreRanked function [37]. Genes were ranked by significance of differential expression by using the formula \u2212log10(P-value) \u00d7 (sign of fold change). Heat maps were built in R version 4.3.0 by using the package ComplexHeatmap version 2.16 [38\u201340]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.0587770938873291,
    "data_pmids_checked": 0,
    "paper_id": "39980836",
    "extraction_date": "2025-12-19T20:40:18.272704",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39980836.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40002690": {
    "paper_id": "40002690",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "GenomicAnalysisofMIDNinCancers\nThe genetic alteration rate and types, mutation site information, and mutation co-\noccurrenceareanalyzedbasedonthecBioPortaldatabase(https://www.cbioportal.org\n(accessedon23October2023))[13]",
      "GenomicChangesinMIDNinCancers\nBased on the cBioportal database, we analyzed the genomic changes in MIDN in\ncancers",
      "Data Availability Statement: All data can be found in the GTEx (https://www.gtexportal.org),\nDepmap(https://depmap.org),GEPIA2(http://gepia2.cancer-pku.cn),Kaplan\u2013MeierPlotter(http:\n//kmplot.com),cBioPortal(https://www.cbioportal.org),GeneMANIA(http://genemania.org),\nSTRING(https://www.string-db.org),DAVID(https://david.ncifcrf.gov),OncoDB(https://oncodb"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:21.973288",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40002690.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 11.315351009368896,
      "cbioportal_papers": 0.0002529621124267578,
      "pdf_extraction_pass2": 9.72561526298523,
      "cbioportal_papers_pass2": 0.0002579689025878906,
      "used_full_extraction": true,
      "pdf_extraction": 21.040966272354126,
      "platform_mentions": 0.0027551651000976562,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39974905": {
    "cbioportal_paper_citations": [
      "Beyond its conceptual novelty, our work has potential therapeutic implications for mucosal inflammation and tumorigenesis. 5-KETE levels are elevated in the unaffected mucosa of patients with inflammatory bowel disease compared to inflamed mucosa from the same patients and samples from healthy controls, aligning with the idea that oxoeicosanoid signaling may protect the human intestine [21]. Our work suggests that OXER1 signaling may have antimutagenic effects by protecting host cells from ROS damage. Interestingly, a frequent frameshift mutation (S78Pfs*64 or S78Vfs*61) leading to a truncated, non-functional OXER1 has been reported in human gastrointesinal cancers [22]. The discovery of the redox-sensitive, 5-KETE-producing enzyme 5-HEDH in our companion paper (Ma et al., 2025) now opens the possibility to probe some physiological aspects of this vastly understudied redox signaling pathway also in rodents. Our current approach highlights the benefits of combining alternative model systems and human cell lines to illuminate \u201cblind spots\u201d of mouse genetics, while ensuring relevance to human biology. A better understanding of 5-KETE signaling should open up new avenues for mucoprotective therapies that protect barrier tissues against exessive oxidative stress."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.14188814163208008,
    "data_pmids_checked": 0,
    "paper_id": "39974905",
    "extraction_date": "2025-12-19T20:40:22.134221",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39974905.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39973042": {
    "cbioportal_paper_citations": [
      "Primary PCa and blood\u2010based transcriptomic datasets were systematically retrieved from established public databases, including the Genomic Data Commons (GDC) [25], cBioPortal [26], the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) [27], ArrayExpress [28] and PCaDB [29]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5787792205810547,
    "data_pmids_checked": 2,
    "paper_id": "39973042",
    "extraction_date": "2025-12-19T20:40:22.768576",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39973042.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39976130": {
    "paper_id": "39976130",
    "cbioportal_paper_citations": [
      "[PubMed: 22588877]\n39",
      "[PubMed: 23550210]\n40"
    ],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of\ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:24.145912",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39976130.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.867710828781128,
      "cbioportal_papers": 0.002668619155883789,
      "used_full_extraction": false,
      "pdf_extraction": 5.867710828781128,
      "platform_mentions": 0.0026280879974365234,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39994456": {
    "paper_id": "39994456",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Furthermore, we retrieved the METABRIC\nbreast cancer dataset via cBioPortal (https://www.cbioportal.org)35,36",
      "et al. Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:24.161083",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39994456.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.232420921325684,
      "cbioportal_papers": 0.0002841949462890625,
      "pdf_extraction_pass2": 7.65865683555603,
      "cbioportal_papers_pass2": 0.0002770423889160156,
      "used_full_extraction": true,
      "pdf_extraction": 15.891077756881714,
      "platform_mentions": 0.011791229248046875,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "39969205": {
    "cbioportal_paper_citations": [
      "A276P mutations were found in 19 tumors profiled in the TCGA database (Table 1). Overall, A276P/D/G mutations were reported in a relatively small number of tumors from diverse tissues [17, 18]. We expanded the heterozygous TP53+/A276P clone so that we could evaluate the phenotypic impact of this cancer-associated mutation."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1495189666748047,
    "data_pmids_checked": 0,
    "paper_id": "39969205",
    "extraction_date": "2025-12-19T20:40:24.322595",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39969205.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39969618": {
    "cbioportal_paper_citations": [
      "As of the year 2020, breast cancer has become the most common type of cancer [1]. Researchers in the field of breast cancer have focused a lot of attention on the possible link between estrogen receptors and the disease. Nearly 30 distinct tumor forms, including breast, ovarian, endometrial, and prostate cancers, have been found to exhibit tumoral ER, as reported in the literature [32, 33]. ER is widely expressed in breast tissue, and Estrogen regulation has a strong correlation with the onset of breast cancer [34]. The primary components of ER are ER\u03b1 and ER\u03b2. In the epithelium of a normal breast, the expression rate of ER\u03b1 is below 10%, whereas in breast cancers, it constitutes 50\u201380% [35]. ER\u03b1 knockout mice have been used in experiments to illustrate the function of ER\u03b1 in the development of mammary glands, specifically in the promotion of mammary tumor formation [36]. Within human breast cancers, there is a link between the expression of ER\u03b2 and the high levels of the cell proliferative marker Ki67 and cell cycle protein A [37]. Levels of ER\u03b2 are higher in normal breast tissue and decrease as the tumor progresses from a pre-invasive tumor to a neoplasm. Furthermore, ER\u03b2 expression correlates strongly with elevated progesterone receptor expression and breast tumor cell proliferation. Women who were treated with Tam experienced a significant decrease in the proliferation of tumor cells, which was attributed to the increased expression of ER\u03b2 protein [38]. According to these investigations, ER\u03b2 may have an oncogenic function, whereas its absence promotes breast cancer. While both ER\u03b2 and ER\u03b1 are upregulated in malignant breast tissue, the precise functions of ER\u03b2 in breast cancer are still undetermined."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.17184090614318848,
    "data_pmids_checked": 0,
    "paper_id": "39969618",
    "extraction_date": "2025-12-19T20:40:24.344954",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39969618.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39966556": {
    "cbioportal_paper_citations": [
      "Deletion of the whole or part(s) of the short arm of chromosome 17 (del17p) is a recurrent chromosomal aberration observed in many cancers [1\u20134]. del17p is particularly common in solid cancers such as pancreatic ductal adenocarcinomas and colorectal carcinomas where more than 60% of tumours have been reported to contain malignant cells bearing this copy number alteration (CNA) [1, 5\u20137]. Other cancers such as non-small cell lung cancer [8], prostate cancer [9], breast cancer [4] and squamous cell carcinoma of the cervix [10] also harbour this abnormality. Importantly, del17p is also observed in haemic cancers such as chronic lymphocytic leukaemia (CLL) [11], multiple myeloma (MM) [12], diffuse large B cell lymphoma (DLBCL) [13], mantle cell lymphoma (MCL) [14] and acute myeloid leukaemia (AML) [2], where it is associated with rapid progression, short survival and resistance to therapies [15, 16]. From a mechanistic point of view our understanding of the impacts of the loss of multiple genes is limited. The vast majority of studies investigating del17p in cancer have focussed on dysfunction of TP53 which is located at 17p13.1. Whilst the p53 protein encoded by TP53 has an important function in protecting cells from genomic and environmental insults, and in many cases is accompanied by nonsense and missense TP53 mutations that lead to functional loss of this protein [17], studies of CLL [16, 18], and other cancers [1, 8, 9, 12, 19], have shown that del17p is associated with adverse prognosis even in the absence of p53 dysfunction. It is only recently that we have begun to appreciate the wider impact of del17p on cancer cells. The purpose of this review is to assess the impact of del17p on cell behaviour and suggest new horizons for future research and therapies.",
      "In contrast to microdeletions, macro-deletions of 17p within malignant cells span a wider genomic region that varies widely between individual cancers. To understand the nature of this variability we used data available on the DepMap (https://depmap.org/portal/) [31, 32] and cBioPortal (https://www.cbioportal.org/) [17, 33] platforms to investigate the linkage of CNA among genes located on 17p. Figure 1A shows the relationship between copy numbers of TP53 (often used clinically as an indicator of 17p deletion) and of four other genes situated telomeric (POLR2A, PAFAH1B1) or centromeric (MAP2K4, LLGL1) to TP53. The high degree of concomitant loss, particularly of genes in the direct vicinity of TP53, strongly suggests co-deletion with TP53 and that such CNA occurs in a continuous fashion. This notion is illustrated in Fig. 1B where further analysis of this relationship across all cell lines available on the DepMap portal shows that CNAs of genes located telomeric to TP53 are more likely to show such concomitant loss than those that are centromeric. Furthermore, Fig. 1B also shows that the size of deletion is most likely to extend from GEMIN4 at the telomere to MAP2K4 close to the centromere. Application of this algorithm to cell lines derived from specific cancer types showed largely similar sizes of 17p loss with the exception of prostate adenocarcinoma where there was evidence for the occurrence of discreet microdeletions as opposed to the large-scale deletion observed associated with the other cancer cell lines (Fig. 1C). Large-scale deletion of 17p was also evident in AML and DLBCL using data obtained from primary patient samples within the cBioPortal platform (Fig. 1D), an observation made more evident by clustering the samples from individual patients. This showed that del17p is likely to encompass nearly the entire short arm in DLBCL, AML, breast, pancreatic and colorectal cancers (Fig. 1E). Importantly, this analysis also revealed the respective prevalence of del17p in patient samples from each of these tumours, revealing that this aneuploidy is more likely to be observed in solid than in haemic malignancies. With respect to prostate cancers, our findings were in keeping with those using cancer cell lines and del17p was manifested in about half of cases as microdeletions within 17p13.1 (Fig. 1E). Our findings are supported by studies reporting large deletions encompassing most of the entire arm of 17p in CLL [34], DLBCL [35], MM [36], AML [2] and some solid tumours [4\u20136, 9], typically using either SNP arrays or fluorescence in-situ hybridisation techniques such as chromosome painting. Key to the insight provided by the above analysis is that despite the much higher prevalence of del17p within solid tumours, our understanding of del17p and its impact on patient outcomes is mainly derived from studies of haemic malignancies.Fig. 1Analysis of deletion size associated with 17p aneuploidy in various cancers.A Dot plots showing copy number alteration (CNA) data of the four indicated genes (upper panel shows where they are located on chromosome 17p) plotted relative to TP53 CNA. The CNA data is derived from the cancer cell lines available on DepMap. B Graph showing the frequency of genes located on 17p that are co-deleted with TP53 in a continuous fashion, giving insight into the size of deletion that is most commonly observed in cells bearing del17p. The location of TP53 is indicated by the dotted red line, as are the positions of the genes illustrated in part A. The data used to construct this graph is taken from all cell lines available on DepMap. C Graphs showing the frequency of genes located on 17p that are co-deleted with TP53 in a continuous fashion using data (from DepMap) associated with cell lines derived from the indicated cancers. The location of TP53 is indicated by the dotted red line, as are the positions of the genes illustrated in part A. D Graphs showing the frequency of genes located on 17p that are co-deleted with TP53 in a continuous fashion using data (from cBioPortal) associated with primary cells derived from the indicated cancers. The location of TP53 is indicated by the dotted red line, as are the positions of the genes illustrated in part A. E Hierarchical cluster plots indicating 17p deletion size (x-axis) within cells from individual patients (y-axis) calculated from data recorded in cBioPortal for primary cells from the indicated cancers.",
      "A large question that looms over the study of del17p is whether it is the cause or consequence of genetic instability and/or p53 inactivation. This is because del17p is often associated with tumours with high chromosomal instability (CIN) and/or with p53 which has become dysfunctional, and because del17p is not always associated with aggressive tumour behaviour; a study of CLL patient outcomes where del17p is observed at diagnosis reported the presence of cases where disease progression was slow [37]. However, slow disease progression in this situation could be the result of association with good prognostic indicators such as mutated IGHV genes and/or to the presence of a low percentage of cells with del17p and/or whether TP53 was mutated as was reported by Yuan et al. [16] in a subsequent study of a larger cohort. This same study reported that presence of mutated TP53 together with del17p correlated with the poorest clinical outcomes, and this brings the question of whether dysfunction of p53 is a driver of 17p loss. Zenz et al. [38] published a detailed mutational profile of TP53 in CLL patient samples with and without del17p, noting that such mutation was present in 76% of cases. Such prevalence is consistent with other tumours such as AML and colorectal and pancreatic cancer (Fig. 2), but other malignancies, such as breast cancer and multiple myeloma, show considerably less, suggesting that association between mutated TP53 and del17p may be cancer dependent. In this respect, TP53 LOH may contribute to p53 inactivation due to haploinsufficiency. This effect has been shown in isogenic cell lines where monoallelic disruption of TP53 expression leads to lower p53 mRNA and protein levels to impact p53-mediated gene expression [39]. Furthermore, one study investigating the relevance of del17p in cell lines derived from MM showed that TP53 haploinsufficiency is associated with reduced p53 activation in response to etoposide or nutlin [40]. Regarding the effect of del17p in primary cancer cells, gene expression profiling revealed under-expression of p53 in CLL cells with a 17p deletion [41], but here it is important to note that p53 mRNA expression may be reduced by mechanisms other than TP53 LOH [17, 33]. Nevertheless, a recent study demonstrated that the introduction of gain-of-function missense mutations into p53, notably R175H and R273H, resulted in increased levels of aneuploidy in recipient cell lines compared to those which received nonsense mutations [42]. Importantly, del17p was not the most common deletion observed within this experimental system. However, studies of fibroblasts derived from patients with Li-Fraumeni syndrome (LFS), an inherited disorder where germ-line mutations in TP53 are of a similar nature to those reported by Redman-Rivera et al. do show LOH associated with the chromosome arm containing the wildtype allele of TP53 as part of observed increased genomic instability [43, 44]. Thus, dysfunctional p53 can drive 17p deletion, but it seems missense mutations are favoured, a notion supported by the cancers we studied for this review where TP53 with missense mutations are significantly represented in tumours with del17p (Fig. 2).Fig. 2Analysis of 17p deletion in relation to mutation of TP53.Data from cBioPortal on mutation within TP53 was analysed against the presence or absence of del17p for the indicated cancers (brca breast invasive carcinoma, coad colorectal adenocarcinoma, dlbc diffuse large B cell lymphoma, laml acute myeloid leukaemia, paad pancreatic adenocarcinoma, prad prostate adenocarcinoma) and illustrated according to A count within the total data set available, or as B a percentage within each variable (loss vs. intact 17p). TP53 mutation classification is indicated by the colour scheme.",
      "An important question here is whether haploinsufficiency of genes other than TP53 that are located on 17p is relevant for cancer biology. We previously investigated the gene expression profile of primary CLL cells obtained from patients with or without del17p and identified several genes in addition to TP53 that were under-expressed in cases with del17p including YWHAE, PRPF8, PAFAH1B1, and NUP88 [41]. Using a bioinformatics approach similar to the one reported by Li et al. [4] we examined TGCA data [17, 33] for genes located on 17p that are differentially expressed between samples with or without del17p obtained from patients with different types of cancer. An UpSet plot of this analysis revealed a panel of 76 genes, including the four we identified in CLL, that were consistently under-expressed, suggesting haploinsufficiency, in del17p samples from AML, colorectal, pancreatic, prostate and breast cancers (Fig. 4, Table 1). A significant feature of this panel is the inclusion of eighteen genes designated \u201ccommon essential\u201d as determined by CRISPR/Cas9 and siRNA screens of cancer cell lines [31, 32]. This designation relates to an absolute requirement of the protein produced by these genes for the survival of affected cells and, together with our observation of reduced expression of these genes in cells with del17p, suggests potential vulnerability. Indeed, haploinsufficiency with respect to expression of these genes has the potential of making cells bearing del17p less fit. This concept is largely unexplored with the exception of a study reporting the development of a tool, known as BISCUT, which was used to show correlation between cellular fitness and aneuploidy [61]. Although not relevant to del17p, this study identified WRN, a gene located on chromosome 8, as a haploinsufficient TSG able to drive tumour growth. This is important in the context of this review because 27 of 1217 recognised tumour suppressor genes (including TP53) are located on 17p at a significantly higher density than on other chromosome arms [62], and our analysis shows that 11 TSGs have lower expression in cells with del17p (Table 1). An additional notion to consider is that cells, including malignant cells, take cues from their environment that regulate their growth, a phenomenon known as cell competition (reviewed in Morata [63]). Here, cells with del17p may be outcompeted by other cancer cells that may be more fit in tumours that are heterogeneous, but this homoeostasis can rapidly change following interventions, such as when therapy is applied, leading to expansion and dominance of cell clones bearing del17p. The concept of cell competition could, therefore, be used to explain why del17p is not always associated with aggressive disease in CLL [37]. The proportion of malignant cells carrying del17p clone also plays a role where reports indicate that when this proportion is high, disease outcome in CLL [16] and MM [64] is poor and vice versa. The notion of increased vulnerability is supported by reports showing that reduced expression of POLR2A in del17p prostate and breast cancer cells is associated with enhanced sensitivity to the fungal toxin \u03b1-amanitin [4, 9]. Similarly, LOH and haploinsufficiency have been observed for the splicing factor PRPF8 in AML where reports indicate that reduced expression of this gene lead to increased proliferation of cells bearing del17p as well as increased sensitivity to the drug meayamycin which is an inhibitor of pre-mRNA splicing [65]. Mutation of RPA1 is reported to contribute to the development of lymphoid tumours in mice [66], while reduced expression of this gene is linked to enhanced cell sensitivity to PARP inhibitors such as olaparib [67]. Although not represented within our panel of downregulated genes, LOH and haploinsufficiency of MYBBP1A in pancreatic cancer cells is reported to increase the activity of PARP inhibitors through a mechanism involving the eviction of a minimal pool of chromatin-bound MYBB1A [68].Fig. 4Upset analysis of gene expression in primary malignant cells with del17p.Gene expression in primary malignant cells with or without del17p was compared (with DESeq2), focusing on genes located on 17p that were downregulated in del17p cells. Set size refers to the number of genes showing change in cells from the indicated cancers. Intersection size refers to the shared genes between the different cancers analysed. Cells from 5 cancers were compared; laml acute myeloid leukaemia, prad prostate adenocarcinoma, paad pancreatic adenocarcinoma, brca breast invasive carcinoma, coad colorectal adenocarcinoma. The data for analysis was taken from cBioPortal.Table 1Common genes affected by LOH and haploinsufficiency in cells with del17p.GeneEssential CRISPREssential RNAiTSGPosition on 17pChromosome bandGLOD475709717p13.3TIMM22YesNo99712917p13.3YWHAE134427517p13.3INPP5K149457717p13.3PITPNA151771817p13.3PRPF8YesYes165062917p13.3WDR81171652317p13.3SMYD4Yes177948517p13.3RPA1YesYesYes182970217p13.3DPH1Yes203011217p13.3SRR230337817p13.3SGSM2233749817p13.3METTL16YesNo240556217p13.3PAFAH1B1YesYesYes259318317p13.3CTNS363645917p13.2ITGAE371462817p13.2P2RX1389659217p13.2ATP2A3392387017p13.2ZZEF1400444517p13.2CYB5D2414316817p13.2UBE2G1426925917p13.2MED11YesYes473142817p13.2PSMB6YesYes479614417p13.2SLC25A11493713017p13.2SPAG7495922617p13.2NUP88YesYes535966817p13.2RPAINYesNo541964117p13.2C1QBP543277717p13.2DERL2547125417p13.2MIS12YesNo548628517p13.2KIAA0753657814717p13.1ACADVL721712517p13.1DVL2722534217p13.1PHF23Yes723502917p13.1GABARAPYes724000817p13.1CTDNEP1YesNo724359117p13.1ELP5YesNo725141617p13.1NEURL4731562817p13.1ACAP1733652917p13.1TMEM256740297517p13.1ZBTB4Yes745936617p13.1POLR2ANot doneYes748436617p13.1SENP3756191917p13.1MPDU1758352917p13.1FXR2759123017p13.1SAT2762623417p13.1TP53Yes766177917p13.1WRAP53768607117p13.1KDM6B783421717p13.1NAA38YesNo785668517p13.1KCNAB3792185917p13.1TRAPPC1YesNo793034517p13.1CNTROB793208117p13.1ALOXE3809590017p13.1VAMP2815914717p13.1PFAS824760817p13.1SLC25A35828776317p13.1KRBA2835690217p13.1RPL26YesNo837751617p13.1STX8925047117p13.1SCO11067247417p13.1ZNF181197743917p12MAP2K4Yes1202082917p12ELAC2YesNo1289492917p12COX101406949017p12ZSWIM71597656017p12TTC191599978417p12NCOR11602906517p11.2COPS3YesYes1724661617p11.2PEMT1750556317p11.2TOM1L2Yes1784351117p11.2ATPAF21797740917p11.2GID41803940817p11.2DRG21808789217p11.2ALKBH51818307817p11.2AKAP101990430217p11.2List of 76 common genes identified from the UpSet analysis presented in Fig. 4, reporting also on whether the gene was identified as \u201ccommon essential\u201d using either CRISPR or RNAi approaches (using the DepMap database) or as a Tumour Suppressor Gene (TSG). The position and cytoband of each gene on 17p is also provided."
    ],
    "cbioportal_platform_mentions": [
      "A Dot plots showing copy number alteration (CNA) data of the four indicated genes (upper panel shows where they are located on chromosome 17p) plotted relative to TP53 CNA. The CNA data is derived from the cancer cell lines available on DepMap. B Graph showing the frequency of genes located on 17p that are co-deleted with TP53 in a continuous fashion, giving insight into the size of deletion that is most commonly observed in cells bearing del17p. The location of TP53 is indicated by the dotted red line, as are the positions of the genes illustrated in part A. The data used to construct this graph is taken from all cell lines available on DepMap. C Graphs showing the frequency of genes located on 17p that are co-deleted with TP53 in a continuous fashion using data (from DepMap) associated with cell lines derived from the indicated cancers. The location of TP53 is indicated by the dotted red line, as are the positions of the genes illustrated in part A. D Graphs showing the frequency of genes located on 17p that are co-deleted with TP53 in a continuous fashion using data (from cBioPortal) associated with primary cells derived from the indicated cancers. The location of TP53 is indicated by the dotted red line, as are the positions of the genes illustrated in part A. E Hierarchical cluster plots indicating 17p deletion size (x-axis) within cells from individual patients (y-axis) calculated from data recorded in cBioPortal for primary cells from the indicated cancers.",
      "Data from cBioPortal on mutation within TP53 was analysed against the presence or absence of del17p for the indicated cancers (brca breast invasive carcinoma, coad colorectal adenocarcinoma, dlbc diffuse large B cell lymphoma, laml acute myeloid leukaemia, paad pancreatic adenocarcinoma, prad prostate adenocarcinoma) and illustrated according to A count within the total data set available, or as B a percentage within each variable (loss vs. intact 17p). TP53 mutation classification is indicated by the colour scheme.",
      "Gene expression in primary malignant cells with or without del17p was compared (with DESeq2), focusing on genes located on 17p that were downregulated in del17p cells. Set size refers to the number of genes showing change in cells from the indicated cancers. Intersection size refers to the shared genes between the different cancers analysed. Cells from 5 cancers were compared; laml acute myeloid leukaemia, prad prostate adenocarcinoma, paad pancreatic adenocarcinoma, brca breast invasive carcinoma, coad colorectal adenocarcinoma. The data for analysis was taken from cBioPortal.",
      "Loss of 17p could create vulnerabilities in cancer cells that are potentially exploitable. Such synthetic lethality could be particularly effective given the survival/growth advantage associated with del17p subclones and their enrichment following chemotherapy. Notably, thirteen genes deemed essential for cell replication/survival located in 17p (Fig. 2B) [31, 32] show lower expression when there is LOH and are potentially targetable with drugs. This review has already discussed how POLR2A LOH leads to lower expression of RNA polymerase II (RNAP2) in del17p prostate and breast cancer cells, and how this renders such cells more sensitive to the cytotoxic effects of the fungal toxin \u03b1-amanatin [4, 9]. This vulnerability could be therapeutically exploited through antibody-drug conjugates, which are ideal delivery conduits for compounds such as \u03b1-amanitin which are highly toxic. This approach is now being tested in recent reports on the development of an antibody-drug conjugate that combines an anti-B cell maturation antigen (BCMA) antibody with \u03b1-amanitin (HDP-101) for the treatment of MM with del17p [155, 156]. HDP-101 is currently undergoing phase I clinical evaluation where early reports indicate that it is well tolerated in the dosage cohorts tested and may have clinical benefit [157]. Another example of synthetic lethality associated with del17p is the enhanced cell sensitivity to PARP inhibitors associated with LOH and haploinsufficiency of PRPF8, RPA1 and MYBBP1A [67, 68]. Although not investigated in the specific context of 17p deletion, a recent report has described the targeting by proteasomal degradation of proline-, glutamic acid- and leucine-rich protein 1 (PELP1), an oestrogen receptor co-activator encoded at 17p13.2, in the treatment of ER+ breast cancer [158]. According to DepMap and cBioPortal, PELP1 LOH is associated with haploinsufficiency in many tumours, raising the possibility that del17p might confer increased sensitivity to the PELP1 degrader, SMIP34. PELP1 also functions as a glucocorticoid receptor co-repressor, potentially explaining the unexpected effectiveness of therapy containing high-dose methylprednisolone in del17p CLL [159, 160]. LOH of the proteasome 20S Subunit Beta 6 (PSMB6), located at 17p13.2, also results in haploinsufficiency, and in myeloma the STAT3 inhibitor, stattic, is reported to inhibit PSMB6 protein function to restore sensitivity to the proteasome inhibitor, bortezomib [161]. Finally, there is evidence to suggest that the metastatic behaviour of tumour cells might be influenced by arsenic trioxide which displaces zinc from CLIP170 resulting in disruption of the PAFAH1B1/NDEL1/dynein microtubule complex [162]. Cancer cells with del17p may be more sensitive to this compound due to low expression of PAFAH1B1 and NDEL1 resulting from LOH/haploinsufficiency of the corresponding genes at 17p13.3 and 17p13.1, respectively."
    ],
    "data_publication_citations": {
      "29713087": [
        "Deletion of the whole or part(s) of the short arm of chromosome 17 (del17p) is a recurrent chromosomal aberration observed in many cancers [1\u20134]. del17p is particularly common in solid cancers such as pancreatic ductal adenocarcinomas and colorectal carcinomas where more than 60% of tumours have been reported to contain malignant cells bearing this copy number alteration (CNA) [1, 5\u20137]. Other cancers such as non-small cell lung cancer [8], prostate cancer [9], breast cancer [4] and squamous cell carcinoma of the cervix [10] also harbour this abnormality. Importantly, del17p is also observed in haemic cancers such as chronic lymphocytic leukaemia (CLL) [11], multiple myeloma (MM) [12], diffuse large B cell lymphoma (DLBCL) [13], mantle cell lymphoma (MCL) [14] and acute myeloid leukaemia (AML) [2], where it is associated with rapid progression, short survival and resistance to therapies [15, 16]. From a mechanistic point of view our understanding of the impacts of the loss of multiple genes is limited. The vast majority of studies investigating del17p in cancer have focussed on dysfunction of TP53 which is located at 17p13.1. Whilst the p53 protein encoded by TP53 has an important function in protecting cells from genomic and environmental insults, and in many cases is accompanied by nonsense and missense TP53 mutations that lead to functional loss of this protein [17], studies of CLL [16, 18], and other cancers [1, 8, 9, 12, 19], have shown that del17p is associated with adverse prognosis even in the absence of p53 dysfunction. It is only recently that we have begun to appreciate the wider impact of del17p on cancer cells. The purpose of this review is to assess the impact of del17p on cell behaviour and suggest new horizons for future research and therapies."
      ]
    },
    "total_cbioportal_paper_citations": 4,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.267733097076416,
    "data_pmids_checked": 1,
    "paper_id": "39966556",
    "extraction_date": "2025-12-19T20:40:24.590416",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39966556.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39963143": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mutation frequency and specific mutation sites of ASCL1 in BC were examined using the cBioPortal database (18), while the Catalogue of Somatic Mutations in Cancer (COSMIC) database was employed to categorize mutation types in ASCL1 in BC (19).",
      "The frequency and types of ASCL1 mutations in primary breast cancer were examined using a dataset of 2051 samples with complete DNA sequencing data from the cBioPortal database (23, 24). Additionally, two metastatic BC datasets, including 481 patients from The Metastatic Breast Cancer Project and 216 patients from Lefebvre C et al. (25), totaling 697 patients, were analyzed for ASCL1 alteration types and frequencies in metastatic cases. In primary BC, the ASCL1 alteration frequency was found to be 0.4% (9/2051) ( Figure 2A ). In contrast, the frequency in metastatic BC was significantly higher at 5% (35/697), consisting of 14 cases of amplification, 19 cases of deep deletion, and 2 cases of missense mutations, with a statistically significant difference between primary and metastatic groups (P < 0.001) ( Figure 2B ). Mutation mapping further identified specific sites of missense mutations in ASCL1 in metastatic cases ( Figure 2C ). In addition, we further analyzed the mutation frequency and type of ASCL1 in BC using the COSMIC database. Among 2779 BC samples that were tested, 7 exhibited ASCL1 mutations. These included 2 synonymous substitutions, 1 in-frame insertion, 1 in-frame deletion, and 3 other mutation types ( Figure 2D ). Both synonymous substitutions involved C>T transitions ( Figure 2E ).",
      "Genetic alterations of ASCL1 in BC and their relationship to mutations in other key genes. (A, B) Oncoprint representation of ASCL1 genetic alterations in (A) primary BC and (B) metastatic BC, based on data from the cBioPortal database. (C) Diagram showing ASCL1 mutations across protein domains in metastatic BC, derived from cBioPortal data. (D, E) Types of (D) ASCL1 mutations and (E) specific substitution mutation of ASCL1 in BC from the COSMIC database. (F) Mutation landscape of key genes stratified by high and low ASCL1 expression in BC."
    ],
    "data_publication_citations": {
      "28027327": [
        "The frequency and types of ASCL1 mutations in primary breast cancer were examined using a dataset of 2051 samples with complete DNA sequencing data from the cBioPortal database (23, 24). Additionally, two metastatic BC datasets, including 481 patients from The Metastatic Breast Cancer Project and 216 patients from Lefebvre C et al. (25), totaling 697 patients, were analyzed for ASCL1 alteration types and frequencies in metastatic cases. In primary BC, the ASCL1 alteration frequency was found to be 0.4% (9/2051) ( Figure 2A ). In contrast, the frequency in metastatic BC was significantly higher at 5% (35/697), consisting of 14 cases of amplification, 19 cases of deep deletion, and 2 cases of missense mutations, with a statistically significant difference between primary and metastatic groups (P < 0.001) ( Figure 2B ). Mutation mapping further identified specific sites of missense mutations in ASCL1 in metastatic cases ( Figure 2C ). In addition, we further analyzed the mutation frequency and type of ASCL1 in BC using the COSMIC database. Among 2779 BC samples that were tested, 7 exhibited ASCL1 mutations. These included 2 synonymous substitutions, 1 in-frame insertion, 1 in-frame deletion, and 3 other mutation types ( Figure 2D ). Both synonymous substitutions involved C>T transitions ( Figure 2E )."
      ],
      "27161491": [
        "The frequency and types of ASCL1 mutations in primary breast cancer were examined using a dataset of 2051 samples with complete DNA sequencing data from the cBioPortal database (23, 24). Additionally, two metastatic BC datasets, including 481 patients from The Metastatic Breast Cancer Project and 216 patients from Lefebvre C et al. (25), totaling 697 patients, were analyzed for ASCL1 alteration types and frequencies in metastatic cases. In primary BC, the ASCL1 alteration frequency was found to be 0.4% (9/2051) ( Figure 2A ). In contrast, the frequency in metastatic BC was significantly higher at 5% (35/697), consisting of 14 cases of amplification, 19 cases of deep deletion, and 2 cases of missense mutations, with a statistically significant difference between primary and metastatic groups (P < 0.001) ( Figure 2B ). Mutation mapping further identified specific sites of missense mutations in ASCL1 in metastatic cases ( Figure 2C ). In addition, we further analyzed the mutation frequency and type of ASCL1 in BC using the COSMIC database. Among 2779 BC samples that were tested, 7 exhibited ASCL1 mutations. These included 2 synonymous substitutions, 1 in-frame insertion, 1 in-frame deletion, and 3 other mutation types ( Figure 2D ). Both synonymous substitutions involved C>T transitions ( Figure 2E )."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4271879196166992,
    "data_pmids_checked": 3,
    "paper_id": "39963143",
    "extraction_date": "2025-12-19T20:40:24.772207",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39963143.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39955536": {
    "cbioportal_paper_citations": [
      "Dysregulation or dysfunction of the cellular PCD pathway is closely related to the pathogenesis of many human diseases, including tumors [16]. At present, more than a dozen cell death pathways have been identified, among which the dysregulation of various PCD pathways, such as the apoptosis, pyroptosis and autophagy pathways, may be involved in the initiation, progression and response to chemotherapy in AML [48, 49]. However, these different types of PCD have not been systematically studied in AML patients. Here, we identified highly expressed PCD-related genes in AML and revealed that these overexpressed genes were enriched in many PCD pathways, such as the autophagy, apoptosis, necroptosis, and lysosome pathways, as well as in the cell senescence, cell cycle, and the PI3K-Akt, mTOR, P53 and AMPK signaling pathways. Previous studies have shown that the apoptosis-related genes MCL-1, BCL(x)L and BCL(w) drive the occurrence of leukemia [50\u201352]. The pyroptosis-related gene caspase-1 is highly expressed in AML and is associated with a lower OS rate [53, 54]. Changes in the autophagy-related genes ATGs are also related to the occurrence and development of AML [55]. Dramatic changes in the number and overall function of lysosomes, such as increased numbers, expansion of lysosomal compartments, and changes in sphingomyelin, are closely related to AML transformation [56, 57] and may lead to AML chemotherapy resistance [58]. In addition, the crosstalk between PI3K-Akt, mTOR, P53 and other signaling pathways can regulate some types of PCD. For example, P53 can inhibit the transcription of antiapoptotic genes such as BCL-xl and is often mutated in AML, which is related to poor prognosis [59]. Targeting the PI3K/mTOR pathway further inhibits MCL-1 translation and expression through dephosphorylation of GSK3\u03b1/\u03b2 [60] and can also increase the anti-AML activity of BCL-2 inhibitors [40]. Therefore, PCD-related features could help to predict OS and/or clinical outcome in AML patients."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "30333627": [
        "All the data sources are detailed in Supplementary Table S1, including identifiers and data processing. The expressed and clinical profiles of AML patients were obtained from TCGA (https://portal.gdc.cancer.gov/), GEO (https://www.ncbi.nlm.nih.gov/geo/) (GSE13159, GSE106291, and GSE146173), Beat AML [41, 42], and UCSC Xena (https://xena.ucsc.edu/). To provide more reliable expression analysis between AML patients and healthy controls (HCs), we downloaded a cohort from TCGA-TARGET-GTEx (Genotype-Tissue Expression Project) from the UCSC Xena project, which was processed together via the Toil method, normalized with RSEM TPM (transcripts per million) and log2 transformed. We first extracted the expression profiles of adult AML patients and HCs from this cohort to identify differentially expressed genes (DEGs), then, from GSE13159, used 74 HC samples, 73 of which were bone marrow (BM) samples, to further confirm the DEGs by intersection. The GDC TCGA-AML cohort was downloaded to scan PCD genes associated with AML prognosis and fit a predictive model (n = 150); then, we validated the predictive model in three other AML cohorts, GSE106291 (n = 250), GSE146173 (n = 246), and Beat AML (n = 440). The inclusion criteria for Beat AML patients were RNA-seq data available at initial diagnosis as well as complete survival information. A total of 1394 PCD-related genes (Table S2), excluding duplicate genes, were collected according to previous studies; these genes exhibited 13 types of PCD patterns [43, 44]."
      ],
      "27276561": [
        "In recent years, with increasing basic research, especially the use of large-scale genomic analysis, the development of AML diagnosis, risk stratification and targeted therapy has advanced. For example, FMS-like tyrosine kinase 3 (Flt3) mutations occur in approximately 30% of newly diagnosed AML patients (20-25% with FLT3-ITD and 5-10% with FLT3-TKD) [8] and are associated with an increased risk of relapse and worse survival. Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations occur in approximately 5-15% and 10-15% of newly diagnosed AMLs, respectively [9], and can cause DNA and histone hypermethylation, leading to the blockade of cell differentiation and the development of AML. In addition, the increased expression of BCL-2 in AML can lead to decreased sensitivity to chemotherapy and an increased recurrence rate [10]. Therefore, these genetic variants play key roles in diagnostic algorithms, risk stratification, and first-line therapy in AML patients and could lead to potential targets for drug development. For some high-risk relapsed/refractory (R/R) AML patients who are not eligible for allo-HSCT or intensive chemotherapy, targeted therapy can be administered to different molecularly defined subgroups. In recent years, the Food and Drug Administration (FDA) has approved gilteritinib, ivosidenib and enasidenib for the treatment of R/R AML patients with FLT3, IDH1 and IDH2 mutations, respectively, and these inhibitors have shown promising clinical efficacy as first-line treatments [11\u201313]. The combination of the selective BCL-2 inhibitor venetoclax and azacitidine has also been proven to effectively improve the objective response rate (ORR), CR rate and median overall survival (OS) of R/R AML patients [14]. However, the existing markers are far from meeting clinical needs, and properly evaluating and classifying AML patients to select the appropriate treatment plan is still a major problem. Therefore, further studies on potential biomarkers of AML are urgently needed to incorporate additional prognostic factors, such as the European Leukemia Network (ELN) and National Comprehensive Cancer Network (NCCN), into clinical guidelines to improve the risk stratification model [15] and provide potential targets and a theoretical basis for drug design and clinical treatment."
      ],
      "35868306": [
        "All the data sources are detailed in Supplementary Table S1, including identifiers and data processing. The expressed and clinical profiles of AML patients were obtained from TCGA (https://portal.gdc.cancer.gov/), GEO (https://www.ncbi.nlm.nih.gov/geo/) (GSE13159, GSE106291, and GSE146173), Beat AML [41, 42], and UCSC Xena (https://xena.ucsc.edu/). To provide more reliable expression analysis between AML patients and healthy controls (HCs), we downloaded a cohort from TCGA-TARGET-GTEx (Genotype-Tissue Expression Project) from the UCSC Xena project, which was processed together via the Toil method, normalized with RSEM TPM (transcripts per million) and log2 transformed. We first extracted the expression profiles of adult AML patients and HCs from this cohort to identify differentially expressed genes (DEGs), then, from GSE13159, used 74 HC samples, 73 of which were bone marrow (BM) samples, to further confirm the DEGs by intersection. The GDC TCGA-AML cohort was downloaded to scan PCD genes associated with AML prognosis and fit a predictive model (n = 150); then, we validated the predictive model in three other AML cohorts, GSE106291 (n = 250), GSE146173 (n = 246), and Beat AML (n = 440). The inclusion criteria for Beat AML patients were RNA-seq data available at initial diagnosis as well as complete survival information. A total of 1394 PCD-related genes (Table S2), excluding duplicate genes, were collected according to previous studies; these genes exhibited 13 types of PCD patterns [43, 44]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.7028331756591797,
    "data_pmids_checked": 4,
    "paper_id": "39955536",
    "extraction_date": "2025-12-19T20:40:25.306325",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39955536.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39955294": {
    "cbioportal_paper_citations": [
      "Public data repositories are highly valuable tools in the field of cancer research as omics-based datasets can be further analyzed and correlated with clinical parameters by the scientific community to formulate new hypotheses or to validate novel findings in independent cohorts. In glioma, the most extensively used datasets are from The Cancer Gene Atlas (TCGA, https://portal.gdc.cancer.gov/), Chinese Glioma Genome Data (http://www.cgga.org.cn/) and REMBRANDT (https://wiki.cancerimagingarchive.net/display/Public/REMBRANDT), alongside with current initiatives to organize and facilitate the mining of existing datasets such as cBioPortal7. To the best of our knowledge, there is no large collection of transcriptomics and epigenomics datasets derived from FFPE biomaterial that takes into consideration the intrinsic characteristics of fixed/embebbed nucleic acids to enable further validations in the same type of processed tissue. The majority of biopsies and surgical resections are stored as Formalin-fixed Paraffin-Embedded (FFPE) tissue specimens, the preferred procedure by Anatomical Pathology Departments for long-term and costly-effective biomaterial archiving that allows retrospective examinations. Thus, hospital FFPE collections are valued alternatives that compensate the general lack of fresh-frozen (FF) tissues. However, nucleic acids integrity is largely compromised by several factors derived from formaldehyde fixation, paraffin embebbing and duration of storage8,9; for example, the fixation process can induce base substitutions (prominently C > T/G > A)10\u201312 among other chemical modifications, such as addition of methylol groups that may promote adenine dimerization13."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.11363577842712402,
    "data_pmids_checked": 0,
    "paper_id": "39955294",
    "extraction_date": "2025-12-19T20:40:25.420626",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39955294.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39955388": {
    "cbioportal_paper_citations": [
      "Publicly available raw RNA-seq data of the TCGA (The Cancer Genome Atlas) KIRC (Kidney renal clear cell carcinoma) samples were downloaded and processed as previously described19 and used to generate gene expression heatmaps. cBioportal43,44 was used to investigate the expression of Y chromosome genes in relation to KDM5C mutation status."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "28481359": [
        "Clear cell renal cell carcinoma (ccRCC) represents 70\u201380% of all renal malignancies and is one of the ten most frequently occurring tumours in adults. ccRCC exhibits a unique mutation spectrum which suggests that it is an epigenetically-driven tumour. Eighty-two to ninety-two per cent of ccRCC primary tumours harbour biallelic inactivation of the von Hippel\u2013Lindau (VHL) tumour suppressor gene due to loss of one copy of chromosome 3p and inactivation of the second allele by mutation, deletion or hypermethylation1,2. Biallelic VHL inactivation is known to be the first event in the process of tumour formation in the majority of ccRCC cases1\u20135. The resulting activation of HIF-1\u03b1 and HIF-2\u03b1 transcription factors causes the transcriptional upregulation of several histone demethylases including KDM3A, KDM4B, KDM5C and KDM6B6\u201310, implicating various alterations in the methylation of histone H3 as an early event in the process of tumour formation following VHL inactivation. Indeed, human ccRCC tumours were shown to have a distinctive histone modification profile, being characterised amongst other modifications by decreased cellular levels of tri-methylation of lysine-27 of histone H3 (H3K27me3) and increased levels of acetylation of lysine-27 of histone H3 (H3K27ac)11, a histone modification that is typically associated with active gene transcription. Further investigations revealed that loss of VHL function caused accumulation of active chromatin marks including H3K27ac and mono-methylation of lysine-4 of histone H3 (H3K4me1) specifically at gene enhancers, due at least in part to the binding of stabilised HIF-2\u03b1 to these regions and the recruitment of the p300 histone acetylase12. Thus, as the earliest event in tumour formation, VHL mutation appears to induce alterations in cellular epigenetics via a number of HIF-\u03b1-dependent mechanisms. During ccRCC formation, cells accumulate additional mutations in other epigenetic regulatory genes1\u20135. These mutations include PBRM1, encoding a crucial subunit of the PBAF SWI/SNF chromatin remodelling complex, SETD2 encoding the histone H3 lysine-36 (H3K36) trimethylase, BAP1 encoding the histone H2A lysine-119 (H2AK119) deubiquitinase and KDM5C encoding a histone H3-lysine 4 (H3K4) di-/tri-methyl demethylase. KDM5C mutations were observed in 7% of single biopsies sampled from primary ccRCC1. However, sampling from multiple regions identified intra-tumoural clones with KDM5C mutations in 20% of primary ccRCCs4, a mutational frequency similar to the 18.4%13 and 24%14 mutational frequencies observed in two studies of ccRCC metastases. These genetic observations collectively argue that alterations in specific aspects of normal epigenetic regulation through post-translational regulation of histones are likely to be particularly important in the process of malignant transformation of normal renal epithelial cells and in the progression of ccRCC tumours."
      ],
      "23797736": [
        "Clear cell renal cell carcinoma (ccRCC) represents 70\u201380% of all renal malignancies and is one of the ten most frequently occurring tumours in adults. ccRCC exhibits a unique mutation spectrum which suggests that it is an epigenetically-driven tumour. Eighty-two to ninety-two per cent of ccRCC primary tumours harbour biallelic inactivation of the von Hippel\u2013Lindau (VHL) tumour suppressor gene due to loss of one copy of chromosome 3p and inactivation of the second allele by mutation, deletion or hypermethylation1,2. Biallelic VHL inactivation is known to be the first event in the process of tumour formation in the majority of ccRCC cases1\u20135. The resulting activation of HIF-1\u03b1 and HIF-2\u03b1 transcription factors causes the transcriptional upregulation of several histone demethylases including KDM3A, KDM4B, KDM5C and KDM6B6\u201310, implicating various alterations in the methylation of histone H3 as an early event in the process of tumour formation following VHL inactivation. Indeed, human ccRCC tumours were shown to have a distinctive histone modification profile, being characterised amongst other modifications by decreased cellular levels of tri-methylation of lysine-27 of histone H3 (H3K27me3) and increased levels of acetylation of lysine-27 of histone H3 (H3K27ac)11, a histone modification that is typically associated with active gene transcription. Further investigations revealed that loss of VHL function caused accumulation of active chromatin marks including H3K27ac and mono-methylation of lysine-4 of histone H3 (H3K4me1) specifically at gene enhancers, due at least in part to the binding of stabilised HIF-2\u03b1 to these regions and the recruitment of the p300 histone acetylase12. Thus, as the earliest event in tumour formation, VHL mutation appears to induce alterations in cellular epigenetics via a number of HIF-\u03b1-dependent mechanisms. During ccRCC formation, cells accumulate additional mutations in other epigenetic regulatory genes1\u20135. These mutations include PBRM1, encoding a crucial subunit of the PBAF SWI/SNF chromatin remodelling complex, SETD2 encoding the histone H3 lysine-36 (H3K36) trimethylase, BAP1 encoding the histone H2A lysine-119 (H2AK119) deubiquitinase and KDM5C encoding a histone H3-lysine 4 (H3K4) di-/tri-methyl demethylase. KDM5C mutations were observed in 7% of single biopsies sampled from primary ccRCC1. However, sampling from multiple regions identified intra-tumoural clones with KDM5C mutations in 20% of primary ccRCCs4, a mutational frequency similar to the 18.4%13 and 24%14 mutational frequencies observed in two studies of ccRCC metastases. These genetic observations collectively argue that alterations in specific aspects of normal epigenetic regulation through post-translational regulation of histones are likely to be particularly important in the process of malignant transformation of normal renal epithelial cells and in the progression of ccRCC tumours."
      ],
      "23792563": [
        "Clear cell renal cell carcinoma (ccRCC) represents 70\u201380% of all renal malignancies and is one of the ten most frequently occurring tumours in adults. ccRCC exhibits a unique mutation spectrum which suggests that it is an epigenetically-driven tumour. Eighty-two to ninety-two per cent of ccRCC primary tumours harbour biallelic inactivation of the von Hippel\u2013Lindau (VHL) tumour suppressor gene due to loss of one copy of chromosome 3p and inactivation of the second allele by mutation, deletion or hypermethylation1,2. Biallelic VHL inactivation is known to be the first event in the process of tumour formation in the majority of ccRCC cases1\u20135. The resulting activation of HIF-1\u03b1 and HIF-2\u03b1 transcription factors causes the transcriptional upregulation of several histone demethylases including KDM3A, KDM4B, KDM5C and KDM6B6\u201310, implicating various alterations in the methylation of histone H3 as an early event in the process of tumour formation following VHL inactivation. Indeed, human ccRCC tumours were shown to have a distinctive histone modification profile, being characterised amongst other modifications by decreased cellular levels of tri-methylation of lysine-27 of histone H3 (H3K27me3) and increased levels of acetylation of lysine-27 of histone H3 (H3K27ac)11, a histone modification that is typically associated with active gene transcription. Further investigations revealed that loss of VHL function caused accumulation of active chromatin marks including H3K27ac and mono-methylation of lysine-4 of histone H3 (H3K4me1) specifically at gene enhancers, due at least in part to the binding of stabilised HIF-2\u03b1 to these regions and the recruitment of the p300 histone acetylase12. Thus, as the earliest event in tumour formation, VHL mutation appears to induce alterations in cellular epigenetics via a number of HIF-\u03b1-dependent mechanisms. During ccRCC formation, cells accumulate additional mutations in other epigenetic regulatory genes1\u20135. These mutations include PBRM1, encoding a crucial subunit of the PBAF SWI/SNF chromatin remodelling complex, SETD2 encoding the histone H3 lysine-36 (H3K36) trimethylase, BAP1 encoding the histone H2A lysine-119 (H2AK119) deubiquitinase and KDM5C encoding a histone H3-lysine 4 (H3K4) di-/tri-methyl demethylase. KDM5C mutations were observed in 7% of single biopsies sampled from primary ccRCC1. However, sampling from multiple regions identified intra-tumoural clones with KDM5C mutations in 20% of primary ccRCCs4, a mutational frequency similar to the 18.4%13 and 24%14 mutational frequencies observed in two studies of ccRCC metastases. These genetic observations collectively argue that alterations in specific aspects of normal epigenetic regulation through post-translational regulation of histones are likely to be particularly important in the process of malignant transformation of normal renal epithelial cells and in the progression of ccRCC tumours.",
        "Nonetheless, the phenotypic data in 786-O cells are consistent with the observed genetics of human ccRCC which show that KDM5C mutation is almost always associated with a signature of low Y chromosome gene expression, suggestive of loss of the Y chromosome. By inference from 786-O cells, loss of the Y chromosome and KDM5D function may represent a barrier to further tumour evolution, which can be alleviated by KDM5C mutation, or vice versa. It will be important in future studies to investigate whether similar relationships between KDM5C and KDM5D mutations are observed in other male ccRCC cell lines that do not harbour KDM5C mutation and/or Y chromosome loss. It will also be interesting to determine whether complete loss of the Y chromosome is equivalent to KDM5D mutation, keeping in mind that the Y chromosome also harbours additional tumour suppressors such as KDM6C, the homologue of the EXITS tumour suppressor gene KDM6A which is mutated in rare cases of ccRCC1. We also note that the majority of ccRCC tumours with the Y chromosome loss gene expression signature do not harbour KDM5C mutations, arguing that there might be other mutations or cellular states that cooperate with the loss of the Y chromosome to permit or promote tumour evolution. However, our analyses of TCGA data revealed that there is no enrichment for other commonly recurrent ccRCC-specific gene mutations, including PBRM1, BAP1, SETD2, ARID1A, TP53, PTEN or MTOR in Y chromosome-deficient ccRCCs (data not shown)."
      ],
      "24487277": [
        "Clear cell renal cell carcinoma (ccRCC) represents 70\u201380% of all renal malignancies and is one of the ten most frequently occurring tumours in adults. ccRCC exhibits a unique mutation spectrum which suggests that it is an epigenetically-driven tumour. Eighty-two to ninety-two per cent of ccRCC primary tumours harbour biallelic inactivation of the von Hippel\u2013Lindau (VHL) tumour suppressor gene due to loss of one copy of chromosome 3p and inactivation of the second allele by mutation, deletion or hypermethylation1,2. Biallelic VHL inactivation is known to be the first event in the process of tumour formation in the majority of ccRCC cases1\u20135. The resulting activation of HIF-1\u03b1 and HIF-2\u03b1 transcription factors causes the transcriptional upregulation of several histone demethylases including KDM3A, KDM4B, KDM5C and KDM6B6\u201310, implicating various alterations in the methylation of histone H3 as an early event in the process of tumour formation following VHL inactivation. Indeed, human ccRCC tumours were shown to have a distinctive histone modification profile, being characterised amongst other modifications by decreased cellular levels of tri-methylation of lysine-27 of histone H3 (H3K27me3) and increased levels of acetylation of lysine-27 of histone H3 (H3K27ac)11, a histone modification that is typically associated with active gene transcription. Further investigations revealed that loss of VHL function caused accumulation of active chromatin marks including H3K27ac and mono-methylation of lysine-4 of histone H3 (H3K4me1) specifically at gene enhancers, due at least in part to the binding of stabilised HIF-2\u03b1 to these regions and the recruitment of the p300 histone acetylase12. Thus, as the earliest event in tumour formation, VHL mutation appears to induce alterations in cellular epigenetics via a number of HIF-\u03b1-dependent mechanisms. During ccRCC formation, cells accumulate additional mutations in other epigenetic regulatory genes1\u20135. These mutations include PBRM1, encoding a crucial subunit of the PBAF SWI/SNF chromatin remodelling complex, SETD2 encoding the histone H3 lysine-36 (H3K36) trimethylase, BAP1 encoding the histone H2A lysine-119 (H2AK119) deubiquitinase and KDM5C encoding a histone H3-lysine 4 (H3K4) di-/tri-methyl demethylase. KDM5C mutations were observed in 7% of single biopsies sampled from primary ccRCC1. However, sampling from multiple regions identified intra-tumoural clones with KDM5C mutations in 20% of primary ccRCCs4, a mutational frequency similar to the 18.4%13 and 24%14 mutational frequencies observed in two studies of ccRCC metastases. These genetic observations collectively argue that alterations in specific aspects of normal epigenetic regulation through post-translational regulation of histones are likely to be particularly important in the process of malignant transformation of normal renal epithelial cells and in the progression of ccRCC tumours."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 0.807081937789917,
    "data_pmids_checked": 4,
    "paper_id": "39955388",
    "extraction_date": "2025-12-19T20:40:25.579401",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39955388.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39951185": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2398369312286377,
    "data_pmids_checked": 0,
    "paper_id": "39951185",
    "extraction_date": "2025-12-19T20:40:25.693221",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39951185.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39948107": {
    "cbioportal_paper_citations": [
      "In this study, we have addressed the challenge of identifying oncogenes and tumor suppressors from the regions of SCNA by using an integrated approach. It is based on the fact that a driver gene may exhibit different forms of alteration. For example, KRAS is found to be amplified in 10.7%, over-expressed in 8.86%, and mutated in 0.6% of TCGA HGSOC patients (n = 316). Similarly, the tumor suppressor BRCA1 is mutated in 3% and methylated in 11% of HGSOC patients11. Hence to identify the driver genes in SCNA regions, we integrated the information from various factors such as frequency of amplification or deletion, size of the amplicon or deleted segment, the number of genes within the amplicon or deletion, level of expression in the tumor compared to normal (ovary), presence of mutation, the effect of gene alteration on overall survival. We have identified numerous known cancer driver genes and novel putative genes using this approach whose function remain undetermined in ovarian cancer. We validated the expression and function of two new potential driver genes, RNF144B, an amplified gene, and PPP2R2A, a homozygously deleted gene in HGSOC cell lines and tumors.",
      "RNF144B was ranked first with a score of 10/24 among other amplified genes with unknown functions in ovarian cancer (Table 1). RNF144B is located on chromosome 6q22.3, identified as the only gene in the amplicon (chr6:18466469\u201318508269) with a significant q-value of 4.0712e-16. Alteration of RNF144B was found in 52% of tumors, including amplification in 6.9% and gains in 43.35% (Fig. 1d). Among the fourteen members of the RBR (RING between RING) family, RNF144B, and RNF19A are altered at a higher frequency in HGSOC compared to the other members (Supplementary Fig. 1a). However, RNF19A was located within an arm-level amplification of 8q and was, therefore, not considered for further analysis. Other RBR family members such as RNF144A25 and PARK226 were shown to function as tumor suppressors. Patients with tumors exhibiting gain and amplification of RNF144B have a significantly higher expression at the RNA level compared to the diploid tumors (tumors without alteration in the relevant gene) (p < 0.0001)27 (Supplementary Fig. 2a).",
      "PPP2R2A emerged as the top-ranked novel deleted gene (score 11/24) out of the selected 18 genes (Table 2). Loss of Heterozygosity (LOH) and homozygous Deletion (HD) of PPP2R2A were observed in 70.8% of tumors (n = 316) (Fig. 1e). Homozygous deletion of PPP2R2A was observed in 4.74% of these tumors, which provided initial evidence that it could function as a tumor suppressor since homozygous deletions are very rare. The expression of PPP2R2A was significantly lower in tumors with a single allele or loss of both alleles compared with diploid tumors (p = < 0.0001) (Supplementary Fig. 3a)11. A similar trend of reduced expression was also observed in three independent ovarian cancer datasets (Supplementary Fig. 3b). Furthermore, we also found that among different subunits of the PP2A holoenzyme, the expression of PPP2R2A is absent at a higher frequency in this tumor type (Supplementary Fig. 1b).Table 2Scores for homozygously deleted genes in HGSOC.GenesChrFreq (DNA)Peak sizeNo of genesMutFreq (RNA)FCOSLitScorePPP2R2A8p21.21110700111MAP2K417p121010710111NF117q11.22111310110RB113q14.2212120019LPAR613q14.2212011018FBXO258p23.320104NA018WWOX16q23.1101031118CREBBP16p13.3113110018ERICH18p23.3201040007TDRP8p23.320103NA006ZNF5968p23.320103NA006MAPKBP115q15.1101021005RPL23AP538p23.310103NA005LRP1B2q22.1102100015CCSER14q22.110201NA015EVI2B17q11.2111011005Genes are arranged based on their assigned scores. The genes in the bold font are known tumor suppressors in HGSOC. Tumor suppressor genes in other tumor types are represented in italic font.Chr chromosome, Freq (DNA) frequency of homozygous deletion, Peak size size of the aberration, No.of Genes number of genes in the chromosomal aberration, Mut frequency of nonsense mutations, Freq (RNA) frequency of down-regulation, FC fold change compared to the normal ovary, OS overall survival, Lit: literature, NA not available. PPP2R2A which is underlined is selected for further analysis. Scoring for each gene is consistent with that outlined in Fig. 1b and the materials and methods section.",
      "To investigate the expression and clinicopathological significance of PPP2R2A in ovarian cancer, immunohistochemistry was performed on 100 HGSOC tumors and control samples from the ovary and fallopian tubes (n = 7 each). Prostate adenocarcinoma tissue was used as a positive control for IHC (Supplementary Fig. 4b). Immunoreactivity for PPP2R2A was observed in the cytoplasm of both normal and cancer cells (Fig. 6b). Ovarian and fallopian tube epithelial cells showed low to moderate cytoplasmic expression of PPP2R2A (score = 1&2). In contrast, the majority of HGSOC tissues exhibited low PPP2R2A expression. Out of 100 HGSOC samples, 72 tumors (72%) had no PPP2R2A immunoreactivity (score 0), and 10 tumors (10%) exhibited low expression (score 1) of this gene. The remaining, 18 cases had moderate (9%) and high expression (9%) of PPP2R2A (scores 2 & 3). Hence, from these results, it is clear that two-thirds of the HGSOC tumors had a loss of PPP2R2A expression (Fig. 6c). This data aligns with the loss of PPP2R2A in the TCGA HGSOC samples11. However, we did not find any correlation between the lack of PPP2R2A expression and overall survival (Supplementary Fig. 5b).",
      "The role of RNF144B, in the development of cancer, is emerging. This gene is significantly overexpressed in HNSCC18, endometrial cancer31, and chordoma32. Silencing of RNF144B results in decreased cell proliferation, colony formation, migration, invasion, and induced cell apoptosis in these tumor types18,31,32. Notably, the amplification of RNF144B is frequent in HGSOC (8.74%) next to uterine carcinosarcoma (12.5%) and is not frequently seen in other types of cancer based on the analysis of TCGA data11. In this study, using TCGA data we have shown that RNF144B is amplified and correlated with increased expression in HGSOC. Single allele gain was also noticed in a significant proportion of the tumors. Ectopic expression of RNF144B significantly increased cell proliferation, colony formation, and the migratory ability of the cells. E3 ubiquitin ligases function as oncogenes by targeting tumor suppressors such as p53, PTEN, and p21 for degradation18,33. Thus, it is reasonable to assume that RNF144B promotes ovarian tumorigenesis by targeting critical tumor suppressors. Further investigation into the selection of the substrates and the pathways could lead to the development of inhibitors. Several proteasomal inhibitors have shown success in targeting these E3 ubiquitin ligases and restoring the tumor suppressor function34. We also validated the overexpression of RNF144B in a significant proportion (50%) of HGSOC tumors using immunohistochemistry. Additionally, we, observed that the expression of RNF144B was significantly downregulated in tumors from patients who had received chemotherapy.",
      "Homozygous deletion (HD) and Loss of heterozygosity (LOH) of chromosomal regions are common and critical in tumor progression. Several chromosomal regions demonstrating a high frequency of LOH such as 17p, 17q, 22q, 18q, 8p, 6q, and 13q have been identified in ovarian cancer35,36. TCGA identified significant loss of heterozygosity and deletion of chromosomal region 8p21.2 in HGSOC tumors4. PPP2R2A is likely to be the candidate tumor suppressor in this chromosomal region as the neighboring gene BNIP3L is not linked with ovarian cancer37. Loss of expression of PPP2R2A has been frequently observed in several tumor types including prostate38, bladder39, lung19, thyroid40, and breast cancer41. In HGSOC tumors, PPP2R2A is frequently lost due to homozygous and heterozygous deletions. However, heterozygous deletions are significantly common occurring in 65.1%, compared to the homozygous deletions which are observed only in 4.7% of tumors27. Similar results have been observed in prostate tumors38. PPP2R2A has been shown to function as a haploinsufficient tumor suppressor in prostate cancer where complete loss of this gene has been shown to have deleterious consequences. Loss of one allele of PPP2R2A correlates with poor prognosis in patients with prostate cancer42. Given the prevalence of hemizygous loss of PPP2R2A in HGSOC, it is crucial to investigate whether PPP2R2A functions as a haploinsufficient tumor suppressor in this tumor type. Future studies involving selective deletion of a single allele of PPP2R2A in this tumor type may provide valuable insights. Silencing PPP2R2A has been shown to result in cell cycle arrest at the G1-S phase and affects cell proliferation, colony formation, and tumor growth19,41,43. In this study, we demonstrated that overexpression of PPP2R2A exerts an inhibitory effect on the growth of HGSOC cells. This is supported by our findings that PPP2R2A overexpression reduces cell proliferation, colony formation, migration, and invasion in ovarian cancer cells. These results supported the hypothesis that PPP2R2A functions as a tumor suppressor gene in HGSOC. A recent study using a non-tumorigenic model demonstrated that homozygous deletion of PPP2R2A caused embryonic lethality. Hence PPP2R2A is an essential gene both in embryonic development and tumorigenesis. PPP2R2A was identified to exert its tumor suppressor function by targeting several substrates for dephosphorylation. This includes PI3K/AKT, Cyclin-dependent kinase B-Cdk1 and 4, \u03b2-catenin, and C-Myc44,45. Therefore, it is worthwhile to comprehensively investigate the substrates and the signaling pathways associated with PPP2R2A. We next, investigated the association of PPP2R2A with response to PARP inhibitors. PPP2R2A has been implicated to play a role in the DNA repair pathway by dephosphorylating the DNA repair gene ATM. Silencing PPP2R2A results in a defective HR pathway and sensitizes the cells to PARP inhibitors19. We found that OVCAR5 cells, which express low levels of PPP2R2A, are sensitive to Niraparib compared to SKOV3 cells, which have high expression of PPP2R2A. Although this experiment was performed in only two cell lines as an initial experiment, it suggests that PPP2R2A expression may mediate sensitivity to PARP inhibitors Further investigation involving a large panel of ovarian cancer cell lines and tumors, with PPP2R2A depletion, is needed to confirm this observation. Given the emerging evidence of PP2A modulators as therapeutic agents, particularly in PARP inhibitor-resistant patients, PP2A and its associated pathways represent a promising target for future therapeutic strategies in HGSOC46. Finally, the immunohistochemical analysis revealed that the expression of PPP2R2A is lost in the majority of HGSOC tumors."
    ],
    "cbioportal_platform_mentions": [
      "TCGA data (Nature, 2011) for 316 HGSOC\u2019s were retrieved from different websites. The SCNA data was downloaded from FIREHOSE, Broad Institute https://gdac.broadinstitute.org). cBioportal http://www.cbioportal.org/publicportal/ was used to analyze mutation, SCNA, expression, and clinical data.",
      "Genetic alterations associated with patient survival outcomes are indicative of their biological significance15. A score of \u20321\u2032 was designated to genes whose aberrations had a significant impact (p\u22640.05) on overall survival (OS) if there was no significant correlation then it was \u20180\u2019. This analysis was performed using the cBioportal database, which employs the Kaplan-Meier statistics test to identify genes associated with the outcome. The patient cohort was divided into two groups; based on the presence or absence of alterations in amplification, mutation, or overexpression of a specific gene."
    ],
    "data_publication_citations": {
      "29489754": [
        "The Cancer Genome Atlas (TCGA) by NCI has comprehensively analyzed more than 500 ovarian tumor genomes at genetic, epigenetic, transcriptome, and protein levels4. The vast amount of data generated was deposited in the cancer genome portal (https://portal.gdc.cancer.gov/). The analysis of data from the TCGA of HGSOC has shown that p53 is mutated in nearly 100% of tumors. Most other genes are mutated at less than 5%. However, SCNA alterations were the most frequent in HGSOC compared to other tumors types4. SCNA-causing focal changes are less complex and may contain driver genes that recur in different tumor types5. SCNA results in loss of heterozygosity/deletion and gain/amplification of a gene or a chromosomal segment involving hundreds of genes. Though these affect numerous genes, only some of those genes are \u2018Drivers\u2019 provide a selective advantage, and assist tumor growth. Other genes that do not contribute to tumorigenesis are \u2018Passengers\u2019. Thus, the challenge is to identify the driver genes from passenger events6. If amplification (> 2N) or overexpression of a gene occurs within an SCNA, then it is likely to be an oncogene. In contrast, if deletion or loss of expression of a gene is detected then it is likely to be a tumor suppressor. Both these mechanisms significantly alter the expression of the gene. Previous strategies used to identify the driver gene were based on the frequency of CNA, mapping the minimal region of aberration and correlating the alteration with expression (positional cloning). Genes that are identified through these methods were further functionally validated either by silencing or by over-expressing in ovarian cancer cell lines. Oncogenes such as PAX8, ID4, GAB2, and BRD4 were identified through high throughput screening of more than a hundred genes7. However, this method is time-consuming, expensive, and requires additional validations to verify the relevance of a gene to cancer. Hence, several in-silico computational and statistical methods are being developed to identify driver genes from the regions of SCNA8\u201310."
      ],
      "21720365": [
        "The Cancer Genome Atlas (TCGA) by NCI has comprehensively analyzed more than 500 ovarian tumor genomes at genetic, epigenetic, transcriptome, and protein levels4. The vast amount of data generated was deposited in the cancer genome portal (https://portal.gdc.cancer.gov/). The analysis of data from the TCGA of HGSOC has shown that p53 is mutated in nearly 100% of tumors. Most other genes are mutated at less than 5%. However, SCNA alterations were the most frequent in HGSOC compared to other tumors types4. SCNA-causing focal changes are less complex and may contain driver genes that recur in different tumor types5. SCNA results in loss of heterozygosity/deletion and gain/amplification of a gene or a chromosomal segment involving hundreds of genes. Though these affect numerous genes, only some of those genes are \u2018Drivers\u2019 provide a selective advantage, and assist tumor growth. Other genes that do not contribute to tumorigenesis are \u2018Passengers\u2019. Thus, the challenge is to identify the driver genes from passenger events6. If amplification (> 2N) or overexpression of a gene occurs within an SCNA, then it is likely to be an oncogene. In contrast, if deletion or loss of expression of a gene is detected then it is likely to be a tumor suppressor. Both these mechanisms significantly alter the expression of the gene. Previous strategies used to identify the driver gene were based on the frequency of CNA, mapping the minimal region of aberration and correlating the alteration with expression (positional cloning). Genes that are identified through these methods were further functionally validated either by silencing or by over-expressing in ovarian cancer cell lines. Oncogenes such as PAX8, ID4, GAB2, and BRD4 were identified through high throughput screening of more than a hundred genes7. However, this method is time-consuming, expensive, and requires additional validations to verify the relevance of a gene to cancer. Hence, several in-silico computational and statistical methods are being developed to identify driver genes from the regions of SCNA8\u201310.",
        "Homozygous deletion (HD) and Loss of heterozygosity (LOH) of chromosomal regions are common and critical in tumor progression. Several chromosomal regions demonstrating a high frequency of LOH such as 17p, 17q, 22q, 18q, 8p, 6q, and 13q have been identified in ovarian cancer35,36. TCGA identified significant loss of heterozygosity and deletion of chromosomal region 8p21.2 in HGSOC tumors4. PPP2R2A is likely to be the candidate tumor suppressor in this chromosomal region as the neighboring gene BNIP3L is not linked with ovarian cancer37. Loss of expression of PPP2R2A has been frequently observed in several tumor types including prostate38, bladder39, lung19, thyroid40, and breast cancer41. In HGSOC tumors, PPP2R2A is frequently lost due to homozygous and heterozygous deletions. However, heterozygous deletions are significantly common occurring in 65.1%, compared to the homozygous deletions which are observed only in 4.7% of tumors27. Similar results have been observed in prostate tumors38. PPP2R2A has been shown to function as a haploinsufficient tumor suppressor in prostate cancer where complete loss of this gene has been shown to have deleterious consequences. Loss of one allele of PPP2R2A correlates with poor prognosis in patients with prostate cancer42. Given the prevalence of hemizygous loss of PPP2R2A in HGSOC, it is crucial to investigate whether PPP2R2A functions as a haploinsufficient tumor suppressor in this tumor type. Future studies involving selective deletion of a single allele of PPP2R2A in this tumor type may provide valuable insights. Silencing PPP2R2A has been shown to result in cell cycle arrest at the G1-S phase and affects cell proliferation, colony formation, and tumor growth19,41,43. In this study, we demonstrated that overexpression of PPP2R2A exerts an inhibitory effect on the growth of HGSOC cells. This is supported by our findings that PPP2R2A overexpression reduces cell proliferation, colony formation, migration, and invasion in ovarian cancer cells. These results supported the hypothesis that PPP2R2A functions as a tumor suppressor gene in HGSOC. A recent study using a non-tumorigenic model demonstrated that homozygous deletion of PPP2R2A caused embryonic lethality. Hence PPP2R2A is an essential gene both in embryonic development and tumorigenesis. PPP2R2A was identified to exert its tumor suppressor function by targeting several substrates for dephosphorylation. This includes PI3K/AKT, Cyclin-dependent kinase B-Cdk1 and 4, \u03b2-catenin, and C-Myc44,45. Therefore, it is worthwhile to comprehensively investigate the substrates and the signaling pathways associated with PPP2R2A. We next, investigated the association of PPP2R2A with response to PARP inhibitors. PPP2R2A has been implicated to play a role in the DNA repair pathway by dephosphorylating the DNA repair gene ATM. Silencing PPP2R2A results in a defective HR pathway and sensitizes the cells to PARP inhibitors19. We found that OVCAR5 cells, which express low levels of PPP2R2A, are sensitive to Niraparib compared to SKOV3 cells, which have high expression of PPP2R2A. Although this experiment was performed in only two cell lines as an initial experiment, it suggests that PPP2R2A expression may mediate sensitivity to PARP inhibitors Further investigation involving a large panel of ovarian cancer cell lines and tumors, with PPP2R2A depletion, is needed to confirm this observation. Given the emerging evidence of PP2A modulators as therapeutic agents, particularly in PARP inhibitor-resistant patients, PP2A and its associated pathways represent a promising target for future therapeutic strategies in HGSOC46. Finally, the immunohistochemical analysis revealed that the expression of PPP2R2A is lost in the majority of HGSOC tumors."
      ]
    },
    "total_cbioportal_paper_citations": 6,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.890552282333374,
    "data_pmids_checked": 2,
    "paper_id": "39948107",
    "extraction_date": "2025-12-19T20:40:26.583882",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39948107.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39948437": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "24798001": [
        "Cell fate loss has a crucial role in liver disease, including liver cancer18,19. High expression of the hepatocyte candidates (PROX1, KLF15, ONECUT2 and ZNF771) correlated with better prognosis in patients with HCC (Fig. 1e and Extended Data Fig. 1h). However, only Prox1, Onecut2 and Klf15 showed lifelong expression in the liver (Fig. 1b,f). To test whether they promote hepatocyte identity, we overexpressed them in mouse embryonic fibroblasts (MEFs) during reprogramming toward hepatocytes20 (Fig. 1g). PROX1 increased hepatocyte-like cell induction greater than tenfold, as measured by TJP1 protein expression, elevated albumin secretion per cell 17-fold, and boosted expression of hepatocyte-specific markers (Fig. 1h,i and Extended Data Fig. 1i\u2013l). In mice, PROX1 promotes liver development21, but both tumor-promoting and suppressor roles have been reported in liver cancer models22,23. Hence, we assessed whether PROX1 is dysregulated in patients with HCC and found lower expression in tumor samples than in normal tissues24 (Fig. 2a). Immunohistology confirmed reduced PROX1 levels in HCC compared to adjacent tissue (Fig. 2b and Extended Data Fig. 2a). Furthermore, in patients with HCC, high PROX1 expression or chromosomal amplifications including PROX1 were both associated with increased survival25\u201332 (Fig. 2c,d). These findings suggest that PROX1 has a tumor-suppressive role in HCC.Fig. 2PROX1 suppresses liver cancer formation and progression.a, PROX1 expression in tumors from patients with HCC and paired normal tissue24. b, PROX1 protein in patients with HCC liver tumors and adjacent nontumor tissues (n = 15). c, Survival of patients with HCC stratified by PROX1 expression levels (40% high-expression cutoff)32. d, Survival of patients with HCC ranked by PROX1 amplification status25\u201331. e, Confluency of Hep3B cancer cells upon PROX1 shRNA-KD or OE for 7 days normalized to uninduced controls (n = 3). f, Differential ATAC\u2013seq accessibility in Hep3B cells upon PROX1 OE for 2 days (n = 3; adjusted P < 0.05). g, Prox1 and hepatocyte signature expression across 7,793 single cells in healthy (day 0) and MYC-induced mouse HCC model (day 28)35. h, Mouse livers following HDTVI-mediated Myc OE and Trp53 KO with constitutive Prox1 OE (n = 5). i, Percentage of GFP+ tumors in mice treated as in h (n = 4). j, Survival of mice treated as in h following constitutive Prox1 OE (n = 5) or doxycycline-inducible late Prox1 OE (n = 4) at day 14 compared to control (n = 5 for constitutive OE and n = 3 for late OE). k, HDTVI-induced liver tumors following Kras(G12D) OE and Trp53 KO with constitutive Prox1 OE (OE; n = 4). l, Percentage of GFP+ tumors in mice treated as in k (n = 4). m, Survival of mice treated as in k following constitutive Prox1 OE or control (n = 4). Scale bar = 10 mm (h,k). Bar graphs and scatter plots show mean, error bars = s.d., boxplots show median and IQR and whiskers = 1.5\u00d7 IQR from specified replicates. Unpaired two-tailed t test (a,b,i,l), log-rank test (c,d,j,m) and two-tailed one-sample t test (e). P values are displayed. ROI, region of interest; HR, hazard ratio; KO, knockout; KD, knockdown; OE, overexpression; IQR, interquartile range.Source data",
        "a, PROX1 expression in tumors from patients with HCC and paired normal tissue24. b, PROX1 protein in patients with HCC liver tumors and adjacent nontumor tissues (n = 15). c, Survival of patients with HCC stratified by PROX1 expression levels (40% high-expression cutoff)32. d, Survival of patients with HCC ranked by PROX1 amplification status25\u201331. e, Confluency of Hep3B cancer cells upon PROX1 shRNA-KD or OE for 7 days normalized to uninduced controls (n = 3). f, Differential ATAC\u2013seq accessibility in Hep3B cells upon PROX1 OE for 2 days (n = 3; adjusted P < 0.05). g, Prox1 and hepatocyte signature expression across 7,793 single cells in healthy (day 0) and MYC-induced mouse HCC model (day 28)35. h, Mouse livers following HDTVI-mediated Myc OE and Trp53 KO with constitutive Prox1 OE (n = 5). i, Percentage of GFP+ tumors in mice treated as in h (n = 4). j, Survival of mice treated as in h following constitutive Prox1 OE (n = 5) or doxycycline-inducible late Prox1 OE (n = 4) at day 14 compared to control (n = 5 for constitutive OE and n = 3 for late OE). k, HDTVI-induced liver tumors following Kras(G12D) OE and Trp53 KO with constitutive Prox1 OE (OE; n = 4). l, Percentage of GFP+ tumors in mice treated as in k (n = 4). m, Survival of mice treated as in k following constitutive Prox1 OE or control (n = 4). Scale bar = 10 mm (h,k). Bar graphs and scatter plots show mean, error bars = s.d., boxplots show median and IQR and whiskers = 1.5\u00d7 IQR from specified replicates. Unpaired two-tailed t test (a,b,i,l), log-rank test (c,d,j,m) and two-tailed one-sample t test (e). P values are displayed. ROI, region of interest; HR, hazard ratio; KO, knockout; KD, knockdown; OE, overexpression; IQR, interquartile range."
      ],
      "31130341": [
        "Cell fate loss has a crucial role in liver disease, including liver cancer18,19. High expression of the hepatocyte candidates (PROX1, KLF15, ONECUT2 and ZNF771) correlated with better prognosis in patients with HCC (Fig. 1e and Extended Data Fig. 1h). However, only Prox1, Onecut2 and Klf15 showed lifelong expression in the liver (Fig. 1b,f). To test whether they promote hepatocyte identity, we overexpressed them in mouse embryonic fibroblasts (MEFs) during reprogramming toward hepatocytes20 (Fig. 1g). PROX1 increased hepatocyte-like cell induction greater than tenfold, as measured by TJP1 protein expression, elevated albumin secretion per cell 17-fold, and boosted expression of hepatocyte-specific markers (Fig. 1h,i and Extended Data Fig. 1i\u2013l). In mice, PROX1 promotes liver development21, but both tumor-promoting and suppressor roles have been reported in liver cancer models22,23. Hence, we assessed whether PROX1 is dysregulated in patients with HCC and found lower expression in tumor samples than in normal tissues24 (Fig. 2a). Immunohistology confirmed reduced PROX1 levels in HCC compared to adjacent tissue (Fig. 2b and Extended Data Fig. 2a). Furthermore, in patients with HCC, high PROX1 expression or chromosomal amplifications including PROX1 were both associated with increased survival25\u201332 (Fig. 2c,d). These findings suggest that PROX1 has a tumor-suppressive role in HCC.Fig. 2PROX1 suppresses liver cancer formation and progression.a, PROX1 expression in tumors from patients with HCC and paired normal tissue24. b, PROX1 protein in patients with HCC liver tumors and adjacent nontumor tissues (n = 15). c, Survival of patients with HCC stratified by PROX1 expression levels (40% high-expression cutoff)32. d, Survival of patients with HCC ranked by PROX1 amplification status25\u201331. e, Confluency of Hep3B cancer cells upon PROX1 shRNA-KD or OE for 7 days normalized to uninduced controls (n = 3). f, Differential ATAC\u2013seq accessibility in Hep3B cells upon PROX1 OE for 2 days (n = 3; adjusted P < 0.05). g, Prox1 and hepatocyte signature expression across 7,793 single cells in healthy (day 0) and MYC-induced mouse HCC model (day 28)35. h, Mouse livers following HDTVI-mediated Myc OE and Trp53 KO with constitutive Prox1 OE (n = 5). i, Percentage of GFP+ tumors in mice treated as in h (n = 4). j, Survival of mice treated as in h following constitutive Prox1 OE (n = 5) or doxycycline-inducible late Prox1 OE (n = 4) at day 14 compared to control (n = 5 for constitutive OE and n = 3 for late OE). k, HDTVI-induced liver tumors following Kras(G12D) OE and Trp53 KO with constitutive Prox1 OE (OE; n = 4). l, Percentage of GFP+ tumors in mice treated as in k (n = 4). m, Survival of mice treated as in k following constitutive Prox1 OE or control (n = 4). Scale bar = 10 mm (h,k). Bar graphs and scatter plots show mean, error bars = s.d., boxplots show median and IQR and whiskers = 1.5\u00d7 IQR from specified replicates. Unpaired two-tailed t test (a,b,i,l), log-rank test (c,d,j,m) and two-tailed one-sample t test (e). P values are displayed. ROI, region of interest; HR, hazard ratio; KO, knockout; KD, knockdown; OE, overexpression; IQR, interquartile range.Source data",
        "a, PROX1 expression in tumors from patients with HCC and paired normal tissue24. b, PROX1 protein in patients with HCC liver tumors and adjacent nontumor tissues (n = 15). c, Survival of patients with HCC stratified by PROX1 expression levels (40% high-expression cutoff)32. d, Survival of patients with HCC ranked by PROX1 amplification status25\u201331. e, Confluency of Hep3B cancer cells upon PROX1 shRNA-KD or OE for 7 days normalized to uninduced controls (n = 3). f, Differential ATAC\u2013seq accessibility in Hep3B cells upon PROX1 OE for 2 days (n = 3; adjusted P < 0.05). g, Prox1 and hepatocyte signature expression across 7,793 single cells in healthy (day 0) and MYC-induced mouse HCC model (day 28)35. h, Mouse livers following HDTVI-mediated Myc OE and Trp53 KO with constitutive Prox1 OE (n = 5). i, Percentage of GFP+ tumors in mice treated as in h (n = 4). j, Survival of mice treated as in h following constitutive Prox1 OE (n = 5) or doxycycline-inducible late Prox1 OE (n = 4) at day 14 compared to control (n = 5 for constitutive OE and n = 3 for late OE). k, HDTVI-induced liver tumors following Kras(G12D) OE and Trp53 KO with constitutive Prox1 OE (OE; n = 4). l, Percentage of GFP+ tumors in mice treated as in k (n = 4). m, Survival of mice treated as in k following constitutive Prox1 OE or control (n = 4). Scale bar = 10 mm (h,k). Bar graphs and scatter plots show mean, error bars = s.d., boxplots show median and IQR and whiskers = 1.5\u00d7 IQR from specified replicates. Unpaired two-tailed t test (a,b,i,l), log-rank test (c,d,j,m) and two-tailed one-sample t test (e). P values are displayed. ROI, region of interest; HR, hazard ratio; KO, knockout; KD, knockdown; OE, overexpression; IQR, interquartile range."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 1.3473830223083496,
    "data_pmids_checked": 4,
    "paper_id": "39948437",
    "extraction_date": "2025-12-19T20:40:26.954722",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39948437.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39944324": {
    "cbioportal_paper_citations": [
      "The DNA methylation level of SOX2 was analyzed through the methylation panel from TCGA module using the UALCAN [17,18]. There are more than 30 tumors are available to do the related analyses. The cBio Cancer Genomics Portal (cBioPortal) website (https://www.cbioportal.org/) [19,20] was explored to analyze the genetic alteration of SOX2 through the \u201cquick search\u201d panel and \u201cTCGA Pan Cancer Atlas Studies\u201d choice. The \u201ccancer types summary\u201d panel shows the information of genetic alteration, including alteration frequency, mutation type, and copy number alteration (CNA) across all TCGA tumors."
    ],
    "cbioportal_platform_mentions": [
      "Genetic alterations in SOX2 were analyzed using the cBioportal web tool, with 10,953 samples out of 10,967 samples from the TCGA database across different cancers examined. In TCGA pan-cancer panel, the most frequent DNA alteration is amplification. Amplifications of SOX2 were mainly observed in LUSC (39.43 %), OV (17.81 %), and ESCA (16.48 %) patients (Fig. 3A). In addition, SOX2 mutations in malignancies were sparsely distributed along the domain of SOX2 without hot spot mutation site (Fig. 3). The most frequent mutations were E84\u2217/Gfs\u221719/K and G54 R/W (Fig. 3) which were predicted to be missense mutations (putative driver).Fig. 3Genetic variation and aberration of SOX2 in different tumors. (A) Genetic aberration of SOX2 in tumors using cBioPortal \u2013TCGA pan-cancer panel. This data includes 10953 patients/10967 samples in TCGA studies. (B) The most frequent mutation was E84 and G54 R/W in TCGA cohort. The yellow highlighted spots are mutations. (C) SOX2 mutations were distributed along HMG_box domain without hot spot mutation site in TCGA cohort using cBioPortal.Fig. 3",
      "Genetic variation and aberration of SOX2 in different tumors. (A) Genetic aberration of SOX2 in tumors using cBioPortal \u2013TCGA pan-cancer panel. This data includes 10953 patients/10967 samples in TCGA studies. (B) The most frequent mutation was E84 and G54 R/W in TCGA cohort. The yellow highlighted spots are mutations. (C) SOX2 mutations were distributed along HMG_box domain without hot spot mutation site in TCGA cohort using cBioPortal."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.21132278442382812,
    "data_pmids_checked": 0,
    "paper_id": "39944324",
    "extraction_date": "2025-12-19T20:40:27.171421",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39944324.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39943991": {
    "cbioportal_paper_citations": [
      "Several existing tools facilitate the visualization of expression at the individual gene level. For example, TCGAplot (15) and GEPIA (16) provide visualizations for single genes and their correlations to immune-related genes, but they lack capabilities for visualizing gene pairs or implementing expression thresholds for prioritization. Likewise, cBioPortal (17) offers visualizations for individual targets alongside disease stratification across various clinical parameters, but it does not accommodate the visualization of gene pairs, pathways, or user-defined groups. Devis (18), GENAVi (19), and SEQUIN (20) focus on RNASeq data processing and visualization of differentially expressed genes, yet they do not support the exploration of multiple genes or pathways for target prioritization and patient stratification. Thus, there exists a need for a novel tool that provides the functionalities absent in existing platforms. Such a tool would be indispensable for advancing the field of targeted antibody therapies by facilitating a deeper understanding of inter-gene relationships and pathway dynamics."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29033130": [
        "To demonstrate the application of VIBE on real-world data, we employed a publicly available melanoma dataset (GSE91061) to identify potential antibody therapy targets for patients who progressed on Nivolumab (26). This dataset includes 51 samples collected before Nivolumab treatment and 58 samples taken after treatment from 65 patients, complete with clinical outcome information (complete or partial responders (CR/PR), progressive disease (PD), and stable disease (SD)). The authors identified 2,670 differentially expressed genes (DEGs) between pre- and on-therapy samples of responders and non-responders (26). 81 DEGs associated with stromal, tumor, and host-immunity pathways were highlighted as being of the most significance. Of these DEGs, we focused on 31 genes known to be expressed on the cell surface (27, 28), identifying these as potential antibody therapy targets. Additionally, we manually curated a list of genes indicative of the presence of CD3 cells, CD8 cells, Tregs (29), T cell activation (30), T cell infiltration (31), T cell exhaustion (29), and T cell cytotoxicity [Tc1, Tc2, Tc3 and Tc4] (32) each evaluated individually ( Supplementary Table 1 )."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.26840996742248535,
    "data_pmids_checked": 1,
    "paper_id": "39943991",
    "extraction_date": "2025-12-19T20:40:27.453557",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39943991.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39941813": {
    "cbioportal_paper_citations": [
      "The KEAP1-NRF2 (Kelch-like ECH-associated protein 1\u2013nuclear factor erythroid 2-related factor 2) signaling pathway is the main regulator of the oxidative and electrophilic stress response in the cell [4]. NRF2 is a transcription factor that regulates the expression of more than 200 cytoprotective genes, encoding proteins involved in Phase I (drug oxidation, reduction, and hydrolysis), Phase II (drug conjugation), and Phase III (drug transport) detoxification, glutathione (GST)- and thioredoxin (TXN)-based antioxidant systems, carbohydrate metabolism and NADPH regeneration, lipid metabolism (fatty acid oxidation and lipases), heme and iron metabolism, transcription, and proteasome and autophagy regulation [5,6]. The protein levels of NRF2 in the cells in basal conditions are kept low through the action of its interactor KEAP1, which binds it in the Cul3-RBX1 E3 ligase complex, in which NRF2 is ubiquitinated and subsequently degraded in the 26S proteasome [7,8,9]. The ubiquitination of NRF2 is blocked in conditions of oxidative or electrophilic stress through the modification of reactive cysteines in KEAP1, which changes the conformation of the KEAP1-Cul3-RBX1 complex, putting NRF2 in an unfavorable position for ubiquitination. This results in the translocation of newly synthesized NRF2 to the nucleus and the activation of the transcription of cytoprotective genes regulated by NRF2 [10,11,12] (Figure 1). While NRF2 has a protective role in normal cells, including the prevention of the initiation of carcinogenesis, once cancer is already initiated, NRF2 reveals its dark side by protecting cancer cells from chemo- and radiotherapy, resulting in an increased activity of NRF2, which is linked to poorer prognosis in several types of cancer. Consequently, the KEAP1-NRF2 signaling pathway is the subject of intensive research, as it represents an attractive target for the treatment of oxidative stress-related diseases and conditions [13,14,15]. Specific somatic mutations in KEAP1 or NRF2 that lead to the constitutive activation of the NRF2 pathway have been identified in a variety of cancer types, including lung, head and neck, and esophageal cancers [16,17]. According to the cBioPortal cancer genomic database, in a curated set of non-redundant studies, KEAP1 gene mutations are found in around 3% of samples; the highest percentage of KEAP1 mutations is found in lung cancer (13\u201316%), lung adenocarcinoma (15%), and non-small-cell lung cancer (NSCL, 13%). Mutations in the NFE2L2 (NRF2) gene were found in around 2% of studies and the highest percentage of mutations was found in endometrial carcinoma (12%) and lung adenocarcinoma (11%). Mutations in the KEAP1 gene are spread through the entire coding region, while NRF2 mutations are most frequently found in the Neh2 region, which contains ETGE and DLGex sites for binding to KEAP1 (https://www.cbioportal.org/; accessed on 20 January 2025) [18]. These mutations confer a growth advantage to cancer cells and lead to chemoresistance [19]. Moreover, NRF2 activation promotes metabolic reprogramming in cancer cells, thereby enhancing survival and proliferation [20]. The dual role of NRF2 in cancer, acting as a tumor suppressor in normal cells and an oncogene in cancer cells, emphasizes the complexity of targeting this pathway for cancer therapy [21]. KEAP1 mutations have been associated with poor prognosis in non-small-cell lung cancer, further underscoring the need to better understand KEAP1 functions beyond NRF2 regulation [22]. Apart from mutations in KEAP1, NRF2, and CUL3, NRF2 overactivation in cancer is also caused by epigenetic silencing of KEAP1, NFE2L2 gene amplification, alternative splicing of NFE2L2 mRNA, increase in NRF2 expression by oncoproteins, KEAP1 cysteine modifications by oncometabolites, and binding of competitive protein interactors to KEAP1 or NRF2 [23]. As mentioned previously, the therapeutic targeting of NRF2 in cancer might involve both the inhibition and induction of NRF2, based on its activity in the cancer tissues. Strategies for the assessment of NRF2 status include the identification of single nucleotide polymorphisms (SNPs) in the NRF2 gene, like rs6721961, which correlates with NRF2 activity, and measuring the expression of NRF2-controlled genes in cancer biopsies [3]. Challenges in the therapeutic targeting of NRF2 in cancer are numerous because of the crosstalk between NRF2 and many other cellular pathways, some of which are going to be described further in the subsequent sections. While there are a lot of NRF2 inducers, some of which are already approved for the treatment of multiple sclerosis (dimethyl fumarate) and Friedrich ataxia (omaveloxolone), there are no specific inhibitors of NRF2 thus far. However, there are several strategies for the development of compounds that could inhibit NRF2 in cancer, including inhibitors of the NRF2-sMAF interaction and compounds with indirect impact on NRF2, including PI3K inhibitors and inhibitors of glutaminase (GLS) and glucose-6-phosphate dehydrogenase (G6PD) [14]. An additional challenge in the development of targeted therapies for the modulation of the KEAP1-NRF2 pathway is the appearance of resistance to therapy. Strategies dealing with this challenge are being developed, including the use of CRISPR-Cas9 screen targeting the druggable genome to discover proteins that are indispensable for the growth of cancer cells. One such study discovered the dependency of highly aggressive human lung adenocarcinomas, harboring KEAP1 mutations that overactivate NRF2, on solute carrier family 33 member 1 (SLC33A1), an endomembrane-associated protein involved in autophagy regulation, which can be used to develop targeted therapies for this type of cancer [24]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "22960745": [
        "The KEAP1-NRF2 (Kelch-like ECH-associated protein 1\u2013nuclear factor erythroid 2-related factor 2) signaling pathway is the main regulator of the oxidative and electrophilic stress response in the cell [4]. NRF2 is a transcription factor that regulates the expression of more than 200 cytoprotective genes, encoding proteins involved in Phase I (drug oxidation, reduction, and hydrolysis), Phase II (drug conjugation), and Phase III (drug transport) detoxification, glutathione (GST)- and thioredoxin (TXN)-based antioxidant systems, carbohydrate metabolism and NADPH regeneration, lipid metabolism (fatty acid oxidation and lipases), heme and iron metabolism, transcription, and proteasome and autophagy regulation [5,6]. The protein levels of NRF2 in the cells in basal conditions are kept low through the action of its interactor KEAP1, which binds it in the Cul3-RBX1 E3 ligase complex, in which NRF2 is ubiquitinated and subsequently degraded in the 26S proteasome [7,8,9]. The ubiquitination of NRF2 is blocked in conditions of oxidative or electrophilic stress through the modification of reactive cysteines in KEAP1, which changes the conformation of the KEAP1-Cul3-RBX1 complex, putting NRF2 in an unfavorable position for ubiquitination. This results in the translocation of newly synthesized NRF2 to the nucleus and the activation of the transcription of cytoprotective genes regulated by NRF2 [10,11,12] (Figure 1). While NRF2 has a protective role in normal cells, including the prevention of the initiation of carcinogenesis, once cancer is already initiated, NRF2 reveals its dark side by protecting cancer cells from chemo- and radiotherapy, resulting in an increased activity of NRF2, which is linked to poorer prognosis in several types of cancer. Consequently, the KEAP1-NRF2 signaling pathway is the subject of intensive research, as it represents an attractive target for the treatment of oxidative stress-related diseases and conditions [13,14,15]. Specific somatic mutations in KEAP1 or NRF2 that lead to the constitutive activation of the NRF2 pathway have been identified in a variety of cancer types, including lung, head and neck, and esophageal cancers [16,17]. According to the cBioPortal cancer genomic database, in a curated set of non-redundant studies, KEAP1 gene mutations are found in around 3% of samples; the highest percentage of KEAP1 mutations is found in lung cancer (13\u201316%), lung adenocarcinoma (15%), and non-small-cell lung cancer (NSCL, 13%). Mutations in the NFE2L2 (NRF2) gene were found in around 2% of studies and the highest percentage of mutations was found in endometrial carcinoma (12%) and lung adenocarcinoma (11%). Mutations in the KEAP1 gene are spread through the entire coding region, while NRF2 mutations are most frequently found in the Neh2 region, which contains ETGE and DLGex sites for binding to KEAP1 (https://www.cbioportal.org/; accessed on 20 January 2025) [18]. These mutations confer a growth advantage to cancer cells and lead to chemoresistance [19]. Moreover, NRF2 activation promotes metabolic reprogramming in cancer cells, thereby enhancing survival and proliferation [20]. The dual role of NRF2 in cancer, acting as a tumor suppressor in normal cells and an oncogene in cancer cells, emphasizes the complexity of targeting this pathway for cancer therapy [21]. KEAP1 mutations have been associated with poor prognosis in non-small-cell lung cancer, further underscoring the need to better understand KEAP1 functions beyond NRF2 regulation [22]. Apart from mutations in KEAP1, NRF2, and CUL3, NRF2 overactivation in cancer is also caused by epigenetic silencing of KEAP1, NFE2L2 gene amplification, alternative splicing of NFE2L2 mRNA, increase in NRF2 expression by oncoproteins, KEAP1 cysteine modifications by oncometabolites, and binding of competitive protein interactors to KEAP1 or NRF2 [23]. As mentioned previously, the therapeutic targeting of NRF2 in cancer might involve both the inhibition and induction of NRF2, based on its activity in the cancer tissues. Strategies for the assessment of NRF2 status include the identification of single nucleotide polymorphisms (SNPs) in the NRF2 gene, like rs6721961, which correlates with NRF2 activity, and measuring the expression of NRF2-controlled genes in cancer biopsies [3]. Challenges in the therapeutic targeting of NRF2 in cancer are numerous because of the crosstalk between NRF2 and many other cellular pathways, some of which are going to be described further in the subsequent sections. While there are a lot of NRF2 inducers, some of which are already approved for the treatment of multiple sclerosis (dimethyl fumarate) and Friedrich ataxia (omaveloxolone), there are no specific inhibitors of NRF2 thus far. However, there are several strategies for the development of compounds that could inhibit NRF2 in cancer, including inhibitors of the NRF2-sMAF interaction and compounds with indirect impact on NRF2, including PI3K inhibitors and inhibitors of glutaminase (GLS) and glucose-6-phosphate dehydrogenase (G6PD) [14]. An additional challenge in the development of targeted therapies for the modulation of the KEAP1-NRF2 pathway is the appearance of resistance to therapy. Strategies dealing with this challenge are being developed, including the use of CRISPR-Cas9 screen targeting the druggable genome to discover proteins that are indispensable for the growth of cancer cells. One such study discovered the dependency of highly aggressive human lung adenocarcinomas, harboring KEAP1 mutations that overactivate NRF2, on solute carrier family 33 member 1 (SLC33A1), an endomembrane-associated protein involved in autophagy regulation, which can be used to develop targeted therapies for this type of cancer [24]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4166581630706787,
    "data_pmids_checked": 1,
    "paper_id": "39941813",
    "extraction_date": "2025-12-19T20:40:27.880140",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39941813.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39934677": {
    "cbioportal_paper_citations": [
      "RNA expression data were downloaded from TCGA (https://portal.gdc.cancer.gov/) on 10/05/2024, GTEx (https://www.gtexportal.org/home/) and GEO (https://www.ncbi.nlm.nih.gov/). We assessed TNMD messenger ribonucleic acid (mRNA) levels in 31 normal and 33 tumor tissues using a log2(value + 1) transformation. Using the \u201cstats\u201d and \u201ccar\u201d packages, we compared TNMD expression between cancer and normal tissues, visualized with \u201cggplot2,\u201d and applied the Wilcoxon rank sum test (p < 0.05). A summary of TNMD RNA and protein expression was obtained from the Human Protein Atlas (HPA) (https://www.proteinatlas.org/). cBioPortal (https://www.cbioportal.org/) analyzed the genetic alteration frequency, mutation type, and mutation site for TNMD [24]. We downloaded mRNA profiles of patients with CRC from GEO (GSE81986 [25]: the microarray data were generated using the GPL570, Affymetrix Human Genome U133 Plus 2.0 Array, containing 33 samples. GSE35452 [26]: the microarray data were generated using the GPL570, Affymetrix Human Genome U133 Plus 2.0 Array, containing 46 samples. GSE179351 [27]: the sequencing data were obtained using GPL18573 Illumina NextSeq 500, containing 54 samples), using GSE81986 as the validation dataset."
    ],
    "cbioportal_platform_mentions": [
      "To elucidate the expression patterns of TNMD across various cancers, we analyzed TNMD mRNA levels in tumor tissues and adjacent normal samples, utilizing data from TCGA and the GTEx project. TNMD was significantly upregulated in several cancers, including GBM, low-LGG, COAD, READ, LIHC, PAAD, TGCT, UCS, LAML, ACC, and THYM. Conversely, it exhibited markedly lower expression in cancers, including BLCA, BRCA, CESC, CHOL, ESCA, HNSC, KICH, KIRC, KIRP, LUAD, LUSC, OV, PRAD, SKCM, STAD, THCA, and UCEC (Fig. 1a). Further investigations revealed that TNMD mRNA expression levels were highest in UCS, READ, COAD, SARC, and KIRC among all TCGA tumors (Fig. 1b). Utilizing resources from the HPA, we identified distinctive TNMD mRNA expression patterns across various cancer cell lines, with the highest levels detected in uterine cancer, testis cancer, and uncategorized cell lines (Fig. 1c). TNMD protein expression also varied significantly across tumor types, showing the most pronounced levels in CRC, lymphoma, thyroid cancer, liver cancer, and pancreatic cancer (Fig. 1d). Moreover, an analysis using the cBioPortal online tool revealed that the primary genetic alterations in TNMD across diverse TCGA cancer samples included missense mutations, amplifications, and deep deletions, with mutations being the most frequent DNA alteration observed (Table. 1), (Fig. 1e)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3123326301574707,
    "data_pmids_checked": 1,
    "paper_id": "39934677",
    "extraction_date": "2025-12-19T20:40:28.198830",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39934677.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39931207": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Neratinib is a potentially overlooked treatment option for A/MBC, especially after progression on the standard-of-care (SOC) and could be utilized in combination with other therapeutics (11\u201314, 58, 59). Neratinib is even under investigation with T-DXd in advanced refractory gastric cancer patients (60). The initial phase I/II trials investigating neratinib and trastuzumab combination documented their tolerability and encouraging clinical activity, with durable responses up to 10-year observed in some patients (14). In phase III NALA trial, for example, neratinib plus capecitabine resulted in significantly prolonged PFS compared to lapatinib plus capecitabine in HER2+ MBC previously treated with at least two HER2-directed regimens (59), of whom almost all or more than half received trastuzumab or T-DM1, respectively. Furthermore, phase II NSABP FB-10 trial yielded an ORR of 63% upon neratinib plus T-DM1 in the HER2+ MBC (13, 61). ERBB2 amplification in study entry biopsies, ERBB2 RNA levels, and loss of detectable ctDNA and ERBB2 amplification in the ctDNA were identified as biomarkers of response. Our case is consistent with the first two biomarkers, although we do not have any data on ctDNA. Similar to T-DXd and unlike anti-HER2 agents, neratinib monotherapy could be also effective in HER2-low cases (62), explaining near-complete response in our patient despite HER2 IHC 0 with ERBB2 mRNA OE. Moreover, whereas p95HER2 was associated with trastuzumab resistance (63), two complete responders in the NSABP FB-10 trial had high total HER2 and p95HER2 levels in the baseline tissue. The p95HER2 is also likely to limit T-DXd activity (64), which could be one of the reasons driving resistance in our patient. Resistance to HER2-targeted therapies in HR+/HER2+ tumors following an initial response could be also caused by ER overexpression and/or activation (65, 66), potentially due to extensive bidirectional crosstalk between ER and HER2 signaling. Very recently, DESTINY-Breast08 reported remarkable outcomes in chemotherapy-na\u00efve patients with HER2-low, HR+ MBC upon T-DXd combine with anastrozole or fulvestrant. Similarly, neratinib resulted in longer DFS only in HR+/HER2+ patients, almost all of whom also received ET, in the phase 3 ExteNET trial (12). Finally, the SUMMIT phase II trial in the patients with HR+/HER2\u2212, HER2-mutant MBC not only supported a synergistic activity of neratinib with fulvestrant plus trastuzumab but also proved requirement for neratinib as there were no responses with fulvestrant or fulvestrant plus trastuzumab (67). HER2 mRNA expression did not significantly differ between partial response (PR), stable disease (SD), or progressive disease (PD) subgroups, although the sample numbers are quite low. Neratinib-containing regimen was even active in ERBB3 co-alterations (overexpressed in our case), implicating that HER2:HER3 heterodimer activity could be blocked in these tumors. Briefly, HER2 ADCs (with different platforms or payloads) or TKIs with ET combination could be tested in future clinical trials in the HR+ patients upon progression on T-DXd (17). These trials could be designed to not only assess the mutational profile but also other omics data such as transcriptome profiling by RNA sequencing, relevant serum/plasma biomarkers and cancer-specific clinical parameters. For example, the DG01 trial presented subgroup analyses regarding HER2 IHC, HER2 mRNA expression, plasma HER2 copy number/amplification and gain-of-function (GOF) mutations, and serum HER2 extracellular domain (ECD) (23). The DCRC01 also included HER2/CEP17 ratio, HER2 ISH signals, and HER2 H-score (24). The future trials of the T-DXd could be designed to analyze the efficacy by multiple HER2-related parameters utilized in this trial to define their relative importance as well as the outcomes for discordant cases (such as HER2 amplification and OE with IHC-negative status in our case). Unlike detailed analysis on the HER2, the DG01 performed subgroup analyses for only MET, EGFR, FGFR2, PIK3CA, and KRAS/NRAS based on their mutational status. Other DESTINY trials, such as Breast04 (ESR1, PIK3CA, and CDK4/6i resistance genes) (68), CRC01 (RAS, PIK3CA, and HER2) ( 24), and Lung01 (EGFR, KRAS/NRAS, and BRAF) ( 69), similarly focused on the mutational status of few genes. Accordingly, the alterations in genes with potential association to the T-DXd resistance in our case (GATA3, NOTCH2, CKS1B, and MCL1) could be highly relevant for multiple cancer types, primarily for breast, bladder, and gynecologic cancers as well as lung adenocarcinoma, lung squamous cell carcinoma, cholangiocarcinoma, and hepatocellular carcinoma [cBioPortal (70)]. However, these analyses should ideally be expanded to incorporate individual mRNA\u2013, gene expression signature\u2013, and even pathway activity scoring\u2013based analyses while still considering alteration status, although the genes selected for mutational subgroup analysis in the DESTINY trials make sense given their frequency and clinical relevance on the studied cancer type. According to the results from potential studies outlined above, T-DXd combinations with HER2 TKIs (such as neratinib) and other drugs could be tested as the next step. It is important to note that these combinations should be assessed on the basis of precision oncology principles to match the right treatment with the right patient, maximize the clinical activity, and minimize the drug and financial toxicity through dose modifications and regimen scheduling."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.13759183883666992,
    "data_pmids_checked": 0,
    "paper_id": "39931207",
    "extraction_date": "2025-12-19T20:40:28.355286",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39931207.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39928200": {
    "cbioportal_paper_citations": [
      "Through the online cBioPortal database (http://www.cbioportal.org/), we obtained alterations in DPH2 states in various types of cancer patients [37]. The frequency and type of mutations, as well as copy number alterations (CNA), were assessed in TCGA malignancies utilizing the \u201cCancer Types of Summar\u201d module. Additionally, the association between DPH2 expression and copy number variation (CNV) in 26 cancers was investigated using datasets obtained from the UCSC database and the GDC database and processed through the GISTIC software [38]."
    ],
    "cbioportal_platform_mentions": [
      "Genomic mutations play a significant role in tumorigenesis. We examined mutations in DPH2 in different tumor tissues using the cBioportal database. Our findings revealed that amplification and mutation were the predominant types of genetic variation, with the highest frequency of DPH2 genetic alteration observed in OV patients and the type of mutation was found to be a major factor in CHOL patients (Fig. 12A). Figure 12B depicts the types, locations and numbers of DPH2 genetic alterations, with missense alterations being the most prevalent. E213K/Q was caused by a frame shift mutations that translate from E (glutamic acid) to K (lysine) or Q (glutamine) at the site of 213 in the DPH2 protein, was identified in 2 cases of BLCA and 1 case of OV. Additionally, we investigated the relationship between DPH2 expression and CNV states in 26 cancers and observed significant differences in 18 cancers (Fig. 12C). Remarkably, the loss of DPH2 in the genome occurred infrequently, increasing the copy number of DPH2 in the tumors, aligning with the high expression of DPH2 in the vast majority of tumors, which were high expression in the vast majority of tumors. Figure 12D illustrates the association between DPH2 copy number and mRNA expression through a dot plot. Our analysis revealed that samples with DPH2 deletion exhibited lower mRNA expression levels compared to those with DPH2 amplification. In addition, there was a significant positive correlation between DPH2 mRNA expression and copy number in TCGA pan-cancer samples (Fig. 12E).Fig. 12Mutational characterization of DPH2 in pan-cancer. A Types and frequency of genetic alterations of DPH2 in various cancers. B Mutation site of DPH2. C The relationship between DPH2 expression and CNV states in 26 cancers. D, E Dot plot and correlation plot of the relationship between DPH2 copy number and mRNA expression. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001"
    ],
    "data_publication_citations": {
      "29850653": [
        "TMB refers to the total number of somatic gene coding errors, base substitutions, and insertions or deletions detected per megabase [33, 34]. Patient outcomes [35] are associated with mismatch repair deficiency, the underlying cause of MSI. TMB and MSI scores were calculated from TCGA and previously published results [36]. To generate the results, we used the R packages \u201cFmsb\u201d, \u201climma\u201d and \u201cdplyr\u201d."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2742881774902344,
    "data_pmids_checked": 1,
    "paper_id": "39928200",
    "extraction_date": "2025-12-19T20:40:28.629680",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39928200.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39919252": {
    "cbioportal_paper_citations": [
      "MTAP deletions occur in 10\u201315% of human cancers, providing one of the largest precision oncology patient populations.10\u221212 As MTAP is the only enzyme that catabolizes MTA (methylthioadenosine), an intermediate in the methionine salvage pathway, there is an accumulation of MTA in cells with MTAP deletion, and it acts as a weak, endogenous inhibitor of PRMT5 by binding competitively with SAM.13,14 MTA-cooperative PRMT5 inhibitors, i.e., compounds that can bind in the substrate binding pocket preferentially when MTA is in the SAM cofactor pocket, including clinical-stage compounds TNG908, TNG462, MRTX1719 (BMS-986504), and AMG 193 (Figure 1),15\u221218 differ from the first-generation inhibitors because they leverage the elevated levels of MTA in MTAP-deleted (MTAP-null) cells to bind to and inhibit the PRMT5\u2022MTA complex and selectively kill MTAP-null cells while sparing normal tissue, resulting in a broader therapeutic index."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6159090995788574,
    "data_pmids_checked": 0,
    "paper_id": "39919252",
    "extraction_date": "2025-12-19T20:40:29.282098",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39919252.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39910129": {
    "cbioportal_paper_citations": [
      "The TCGA mutation data of STAD patients was downloaded from the cBioportal database (https://www.cbioportal.org/)27,28. The R package \u201cmaftools\u201d was then used to identify the differences in somatic mutation data between the low-risk and high-risk subgroups and plotted in the form of waterfall charts."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.11058521270751953,
    "data_pmids_checked": 0,
    "paper_id": "39910129",
    "extraction_date": "2025-12-19T20:40:29.392786",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39910129.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39907408": {
    "cbioportal_paper_citations": [
      "The RNA-sequencing data and corresponding clinical information for 44 normal and 497 HNSCC samples were collected from The Cancer Genome Atlas database (TCGA). Based on extensive genome sequencing, 33 cancer types are currently represented in TCGA database, which is the largest available database of information on cancer genetics, and transcriptomic, genomic, proteomic, epigenetic, and other omics data. We compared the expression of ZC3H12A, ZC3H12B, ZC3H12C, and ZC3H12D in normal and tumor samples from TCGA database. In Supplementary Table S1, the ZC3H12D expression and complete clinical information of 497 patients with HNSCC are listed. The dataset GSE30784, GSE127165, and GSE12452 were retrieved from the Gene Expression Omnibus (GEO) database. The GSE30784 dataset includes data from 45 normal samples and 167 oral squamous cell carcinoma (OSCC) samples, and the GSE127165 dataset includes data from 57 laryngeal squamous cell carcinoma (LSCC) samples and 57 paired adjacent normal samples. The GSE12452 dataset includes data from 31 nasopharyngeal carcinoma (NPC) samples and 10 normal samples. Head and neck squamous cell carcinoma (HNSCC) consists primarily of cancers of the oral cavity, larynx, and pharynx (13). We assessed the differential expression of ZC3H12D between OSCC, LSCC, pharyngeal carcinoma, and normal tissues by the datasets from the GEO and TCGA databases. The Human Protein Atlas (HPA) was employed to obtain the ZC3H12D expression data that were obtained by immunohistochemical staining studies (14). Using the UALCAN database, a comprehensive analysis of ZC3H12D expression in various clinical subgroups classified according to tumor grade, individual cancer stage, age, race, gender, TP53 mutation status, nodal metastasis status, and HPV infection status was performed (15). The AlphaFold protein structure database was utilized to predict the protein structure of ZC3H12D (16). ZC3H12D chromosomal location was visualized with the \u201cRCircos\u201d package in R. The genetic alteration features as well as mutation sites of ZC3H12D were identified utilizing the cBioPortal database (17)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.12564802169799805,
    "data_pmids_checked": 0,
    "paper_id": "39907408",
    "extraction_date": "2025-12-19T20:40:29.604601",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39907408.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39897128": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1367480754852295,
    "data_pmids_checked": 0,
    "paper_id": "39897128",
    "extraction_date": "2025-12-19T20:40:29.780486",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39897128.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39897037": {
    "cbioportal_paper_citations": [
      "The functions of FTO in the development of cancers remain unclear. FTO has been reported to repress the growth of cancers in the colon, liver, and stomach, while it has also been reported to promote cancer cell proliferation 34-40. Compared with that in paired normal tissues, FTO was downregulated in breast carcinoma (BRCA), cervical carcinoma (CESC), COAD, lung carcinoma (LUAD and LUSC), and uterine cancer (UCEC and UCS) tissues but upregulated in esophageal carcinoma (ESCA), pancreatic adenocarcinoma (PAAD), and stomach adenocarcinoma (STAD) tissues, according to TCGA pancancer RNA-seq datasets 40-42. These phenomena suggest that the impact of the FTO gene on cancer development may be cancer specific. We did not observe a significant difference in FTO mRNA levels between COAD and paired normal tissues from 105 patients by qRT\u2012PCR. Although FTO-KO (or FTO-OE) inhibited (or enhanced) colon cancer cell proliferation, unexpectedly, we found that TTC7B-OE, which upregulates FTO expression, inhibited cell proliferation in an FTO-dependent manner. Our in vivo experiment fully confirmed these in vitro results. Both FTO-KO and TTC7B-OE significantly inhibited the growth of LoVo cells in nude mice, and the loss of FTO abolished the effect of TTC7B-OE, suggesting a dominant effect of TTC7B over FTO on colon cancer cell proliferation. In other words, the effect of FTO on cell proliferation may be weaker than that of TTC7B alone or in combination. FTO is a potential therapeutic target for cancer, and several small-molecule FTO inhibitors are under development 43, 44. Our findings described above suggest that TTC7B and RXRA may be closely associated with the sensitivity of colon cancer cells to FTO inhibitors because of their crucial regulation of FTO expression."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.10972213745117188,
    "data_pmids_checked": 0,
    "paper_id": "39897037",
    "extraction_date": "2025-12-19T20:40:29.922807",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39897037.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39896470": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "25631445": [
        "TP53 mutations (86\u201393% patients) and CDKN2A mutations/deletions (73\u201378% patients) are the most common drivers in UASCC (17,18) (Fig. 1A). Importantly, loss of these two drivers occurs early during the neoplastic evolution. For example, the most common genomically inactivated genes in oral leukoplakia samples (precursor lesions to HNSCC) are TP53 and CDKN2A (19,20). Thus, to model early neoplastic transformation of UASCC, we generated normal organoid lines from oral/esophageal epithelial cells, followed by the knockout of TP53/CDKN2A using the CRISPR/Cas9 genome editing (Fig. 1B)."
      ],
      "28052061": [
        "TP53 mutations (86\u201393% patients) and CDKN2A mutations/deletions (73\u201378% patients) are the most common drivers in UASCC (17,18) (Fig. 1A). Importantly, loss of these two drivers occurs early during the neoplastic evolution. For example, the most common genomically inactivated genes in oral leukoplakia samples (precursor lesions to HNSCC) are TP53 and CDKN2A (19,20). Thus, to model early neoplastic transformation of UASCC, we generated normal organoid lines from oral/esophageal epithelial cells, followed by the knockout of TP53/CDKN2A using the CRISPR/Cas9 genome editing (Fig. 1B)."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 1.158294916152954,
    "data_pmids_checked": 3,
    "paper_id": "39896470",
    "extraction_date": "2025-12-19T20:40:31.086492",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39896470.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39865078": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "32025007": [
        "We performed whole-genome sequencing (WGS) of matched tumor and normal tissues from 14 Japanese patients with HPV+ OPSCC. We analyzed these alongside WGS datasets of 18 and 19 patients with HPV+ head and neck squamous cell carcinoma (HNSCC) in the Pan-Cancer Analysis of Whole Genomes (PCAWG)8 and Ohio cohorts5, respectively, to provide a comprehensive analysis of HPV integration events and somatic mutations. This study reveals intratumor heterogeneity of HPV integration and its association with focal genomic instability and APOBEC signatures; minimal impact of smoking on somatic mutations; the involvement of haploinsufficient ataxia-telangiectasia mutated (ATM); and early PIK3CA gain during carcinogenesis in HPV+ HNSCC."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4538459777832031,
    "data_pmids_checked": 2,
    "paper_id": "39865078",
    "extraction_date": "2025-12-19T20:40:31.607322",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39865078.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39994636": {
    "paper_id": "39994636",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "and neck cancer (HNSC) Firehose Legacy cohort was\nobtained using cBioPortal [82, 83]",
      "Gao, J., et al., Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:31.671309",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39994636.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 12.136415958404541,
      "cbioportal_papers": 0.00041985511779785156,
      "pdf_extraction_pass2": 13.263682126998901,
      "cbioportal_papers_pass2": 0.0005018711090087891,
      "used_full_extraction": true,
      "pdf_extraction": 25.400098085403442,
      "platform_mentions": 0.004698038101196289,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "39970333": {
    "paper_id": "39970333",
    "cbioportal_paper_citations": [
      "Cancer Discov\n2012;2:401\u20134 [PubMed: 22588877]\n34"
    ],
    "cbioportal_platform_mentions": [
      "TCGA and GEPIA2\nTCGA data was accessed and visualized using cBioPortal (RRID:SCR_014555) and\nGEPIA2 (RRID:SCR_018294) (33\u201335)",
      "TCGA data used in this study were\naccessed via GEPIA2 and cBioPortal, and included SKCM, READ, and COAD datasets\nas well as ACC, BLCA, BRCA, CESC, CHOL, ESCA, HNSC, KICH, KIRC, LIHC, LUAD,\nLUSC, MESO, OV, PAAD, PCPG, PRAD, SARC, STAD, TGCT, THCA, THYM, UCEC,\nUCS, and UVM",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of\ncomplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {
      "26997480": [
        "Cell\n2016;165:35\u201344 [PubMed: 26997480]\n32"
      ]
    },
    "extraction_date": "2025-12-19T20:40:37.897024",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39970333.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.031495094299316,
      "cbioportal_papers": 0.0002040863037109375,
      "pdf_extraction_pass2": 10.030586957931519,
      "cbioportal_papers_pass2": 0.004208803176879883,
      "used_full_extraction": true,
      "pdf_extraction": 15.062082052230835,
      "platform_mentions": 0.0467221736907959,
      "data_citations": 0.015037059783935547,
      "num_data_pmids_checked": 1
    }
  },
  "39945320": {
    "paper_id": "39945320",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis of pan-cancer datasets from cBioPortal revealed\nteraction with histone H4, sumoylation, and mislocalization that there are five highly mutated H3 residues in the glob-\nof Cse4, and lack of lethality in a psh1 (cid:2) strain [ 27 ]",
      "Patient data from a curated set of nonredundant studies in cBioPortal were queried using a list of 17 H3\ncoding genes and visualized using MutationMapper tool of cBioPortal [ 53 , 54 ]",
      "tients (65 489 patient samples from cBioPortal) [ 30 , 32 ]",
      "an- exclusive centromere localization of the yeast Cse4 / CENP-A\nalyzed the pan-cancer datasets from cBioPortal",
      "https:// doi.org/ 10.7554/ eLife.27406 https:// doi.org/ 10.1158/ 2159- 8290.CD- 12- 0095\n36.Lowe BR, Yadav RK, Henry RA et al. Surprising phenotypic 54.Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of\ndiversity of cancer-associated mutations of gly 34 in the histone complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:45.747201",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39945320.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.977334022521973,
      "cbioportal_papers": 0.00035190582275390625,
      "pdf_extraction_pass2": 9.147258281707764,
      "cbioportal_papers_pass2": 0.000335693359375,
      "used_full_extraction": true,
      "pdf_extraction": 19.124592304229736,
      "platform_mentions": 0.0030660629272460938,
      "data_citations": 0.00013375282287597656,
      "num_data_pmids_checked": 1
    }
  },
  "39859304": {
    "paper_id": "39859304",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "InsilicoanalysisofMYCintheTCGAHNSCCdataset\n(n = 279, Nature 2015) was conducted using data obtained from the cBioPortal[27,28]\nfor Cancer Genomics (http://cbioportal.org, URL accessed on 8 September 2024)",
      "All data are from the TCGA database (279 samples), Nature 2015, accessed via\ncBioPortal.org[27,28]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:51.439178",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39859304.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.599548101425171,
      "cbioportal_papers": 0.00036215782165527344,
      "pdf_extraction_pass2": 11.163108825683594,
      "cbioportal_papers_pass2": 0.00040030479431152344,
      "used_full_extraction": true,
      "pdf_extraction": 19.762656927108765,
      "platform_mentions": 0.004117012023925781,
      "data_citations": 0.00015282630920410156,
      "num_data_pmids_checked": 1
    }
  },
  "39858603": {
    "paper_id": "39858603",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(B)\nGenomic alteration detection for FOXM1 across the TCGA Pan-Cancer Atlas (calculated by the\ncBioPortal OncoPrint algorithm)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:53.673439",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39858603.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.839807033538818,
      "cbioportal_papers": 0.0002601146697998047,
      "pdf_extraction_pass2": 7.910574197769165,
      "cbioportal_papers_pass2": 0.0002701282501220703,
      "used_full_extraction": true,
      "pdf_extraction": 15.750381231307983,
      "platform_mentions": 0.002229928970336914,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39854463": {
    "cbioportal_paper_citations": [
      "In line with the key role of the flexible NADK tails in regulating its enzyme activity, numerous mutations are observed in both the N- and C-terminal regions in cancer patients, as well as within the catalytic core (27, 28). However, further studies, including mutational analysis and investigations into their effects on tumorigenesis, are necessary to determine which mutations functionally alter NADK activity."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.15265583992004395,
    "data_pmids_checked": 0,
    "paper_id": "39854463",
    "extraction_date": "2025-12-19T20:40:53.833156",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39854463.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39994444": {
    "paper_id": "39994444",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Together, these findings demon-\nstratethat,inadditiontoBRCA1-deficientcells,sensitivitytoPARP\nCancergenomics analysis inhibitioncausedbylossofATMfunctionoritskinaseactivitycan\ncBioPortal (https://www.cbioportal.org/) [41, 42] was used to access\nalso bealleviated by depletionof SETD1A",
      "This study uses publicly available anonymised data from cBioportal [41,42], and\n67"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:54.679277",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39994444.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 21.959028005599976,
      "cbioportal_papers": 0.00030803680419921875,
      "pdf_extraction_pass2": 21.40452289581299,
      "cbioportal_papers_pass2": 0.0003001689910888672,
      "used_full_extraction": true,
      "pdf_extraction": 43.363550901412964,
      "platform_mentions": 0.003139019012451172,
      "data_citations": 8.106231689453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39859340": {
    "paper_id": "39859340",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(A) Summary of alterations in CCLs in CRC based on samples from cBioPortal (n = 1510)",
      "Thedatabasesselected\u2014ONCOMINE,GEPIA,cBioPortal,UALCAN,GeneMANIA,Metas-\ncape,TRRUST,LinkedOmics,TIMER,andSangerBox\u2014offerrobustdatasetsessentialfor\nexploringthesefactors",
      "cBioPortal\ncBioPortal(www.cbioportal.org),avisualtoolforanalyzingcancergeneticdata[55],\nwasvisitedtoobtaininformationonCCLs\u2019geneticalterationinCRCandanalyzethese\nalterationstoexploretheirimpactonCRCdevelopment"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:40:59.113114",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39859340.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 13.7478928565979,
      "cbioportal_papers": 0.0002617835998535156,
      "pdf_extraction_pass2": 13.742600917816162,
      "cbioportal_papers_pass2": 0.0002448558807373047,
      "used_full_extraction": true,
      "pdf_extraction": 27.490493774414062,
      "platform_mentions": 0.0026187896728515625,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39850523": {
    "cbioportal_paper_citations": [
      "Two publicly available datasets were collected from online sources and analyzed in this study. As the testing cohort, we used the Pan Cancer Clinical Data Resource [40] and the cBio Cancer Genomic Portal [41] to obtain data on tumor gene expression and clinical data from TCGA cohort, which consists of over 11,000 patient samples, similarly to how we have previously reported [16, 17]. Among them, 1,069 patients with ER-positive/HER2-negative BC by pathological determination were analyzed. Nottingham histological grade of primary breast tumors of TCGA was assessed from pathology reports as shown previously [42]. The validation cohort used that has gene expression and correlating clinical data was the SCAN-B (n = 3,273), which was accessed using the cBio portal system that our group has previously described [18, 19]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625055": [
        "Two publicly available datasets were collected from online sources and analyzed in this study. As the testing cohort, we used the Pan Cancer Clinical Data Resource [40] and the cBio Cancer Genomic Portal [41] to obtain data on tumor gene expression and clinical data from TCGA cohort, which consists of over 11,000 patient samples, similarly to how we have previously reported [16, 17]. Among them, 1,069 patients with ER-positive/HER2-negative BC by pathological determination were analyzed. Nottingham histological grade of primary breast tumors of TCGA was assessed from pathology reports as shown previously [42]. The validation cohort used that has gene expression and correlating clinical data was the SCAN-B (n = 3,273), which was accessed using the cBio portal system that our group has previously described [18, 19]."
      ],
      "23000897": [
        "All RNA sequence data utilized in this study were normalized and annotated to gene symbols from transcriptomics by the time of initial publication and followed by log2 conversion [18, 43]. Threshold values for defining \u201chigh\u201d and \u201clow\u201d ARC expression were the median ARC gene expression in each cohort. All patient information included in both cohorts was de-identified; therefore, Institutional Review Board approval was not required for this study."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2945687770843506,
    "data_pmids_checked": 2,
    "paper_id": "39850523",
    "extraction_date": "2025-12-19T20:40:59.408842",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39850523.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39850522": {
    "cbioportal_paper_citations": [
      "A total of 7,336 BC patients from eight publicly available independent cohorts were analyzed, ISPY2 (GSE173839, n = 105), Sweden Cancerome Analysis Network - Breast (SCAN-B) (GSE96058, n = 3,069), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (n = 1,903), The Cancer Genome Atlas (TCGA) (n = 1,073), GSE25066 (n = 508), GSE20194 (n = 278), GSE163882 (n = 222), and GSE34138 (n = 178). The cohorts analyzed in this study were selected based on their robust sample sizes, and association of clinical parameters and full transcriptome including VEGFA gene expression, which are critical for ensuring comprehensive and statistically reliable analyses. TCGA, METABRIC, and SCAN-B are the largest cohorts representing diverse patient demographics (TCGA is from the USA, METABRIC is from the UK and Canada, and SCAN-B is from Sweden) that we were able to access. Cohorts GSE20194, GSE34138, GSE163882, GSE25066, and ISPY2, were chosen for their detailed drug response data associated with full transcriptome, allowing the assessment of VEGFA expression in relation to therapeutic outcomes. High and low VEGFA gene expression groups were divided based on the calculated median. The TCGA cohort data [19] and the METABRIC cohort data [20] were downloaded from cBioportal as described by Gao et al [21]. The SCAN-B cohort data [22] were downloaded using the R package GEOquery from the NCBI Gene Expression Omnibus database. To analyze the relationship between VEGFA gene expression and drug response, the following primary BC cohorts were analyzed: GSE20194, GSE34138, GSE163882, GSE25066, and ISPY2 [23-27]. These cohorts were also downloaded from the NCBI Gene Expression Omnibus database using the R package GEOquery."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "22522925": [
        "A total of 7,336 BC patients from eight publicly available independent cohorts were analyzed, ISPY2 (GSE173839, n = 105), Sweden Cancerome Analysis Network - Breast (SCAN-B) (GSE96058, n = 3,069), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (n = 1,903), The Cancer Genome Atlas (TCGA) (n = 1,073), GSE25066 (n = 508), GSE20194 (n = 278), GSE163882 (n = 222), and GSE34138 (n = 178). The cohorts analyzed in this study were selected based on their robust sample sizes, and association of clinical parameters and full transcriptome including VEGFA gene expression, which are critical for ensuring comprehensive and statistically reliable analyses. TCGA, METABRIC, and SCAN-B are the largest cohorts representing diverse patient demographics (TCGA is from the USA, METABRIC is from the UK and Canada, and SCAN-B is from Sweden) that we were able to access. Cohorts GSE20194, GSE34138, GSE163882, GSE25066, and ISPY2, were chosen for their detailed drug response data associated with full transcriptome, allowing the assessment of VEGFA expression in relation to therapeutic outcomes. High and low VEGFA gene expression groups were divided based on the calculated median. The TCGA cohort data [19] and the METABRIC cohort data [20] were downloaded from cBioportal as described by Gao et al [21]. The SCAN-B cohort data [22] were downloaded using the R package GEOquery from the NCBI Gene Expression Omnibus database. To analyze the relationship between VEGFA gene expression and drug response, the following primary BC cohorts were analyzed: GSE20194, GSE34138, GSE163882, GSE25066, and ISPY2 [23-27]. These cohorts were also downloaded from the NCBI Gene Expression Omnibus database using the R package GEOquery."
      ],
      "23000897": [
        "A total of 7,336 BC patients from eight publicly available independent cohorts were analyzed, ISPY2 (GSE173839, n = 105), Sweden Cancerome Analysis Network - Breast (SCAN-B) (GSE96058, n = 3,069), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (n = 1,903), The Cancer Genome Atlas (TCGA) (n = 1,073), GSE25066 (n = 508), GSE20194 (n = 278), GSE163882 (n = 222), and GSE34138 (n = 178). The cohorts analyzed in this study were selected based on their robust sample sizes, and association of clinical parameters and full transcriptome including VEGFA gene expression, which are critical for ensuring comprehensive and statistically reliable analyses. TCGA, METABRIC, and SCAN-B are the largest cohorts representing diverse patient demographics (TCGA is from the USA, METABRIC is from the UK and Canada, and SCAN-B is from Sweden) that we were able to access. Cohorts GSE20194, GSE34138, GSE163882, GSE25066, and ISPY2, were chosen for their detailed drug response data associated with full transcriptome, allowing the assessment of VEGFA expression in relation to therapeutic outcomes. High and low VEGFA gene expression groups were divided based on the calculated median. The TCGA cohort data [19] and the METABRIC cohort data [20] were downloaded from cBioportal as described by Gao et al [21]. The SCAN-B cohort data [22] were downloaded using the R package GEOquery from the NCBI Gene Expression Omnibus database. To analyze the relationship between VEGFA gene expression and drug response, the following primary BC cohorts were analyzed: GSE20194, GSE34138, GSE163882, GSE25066, and ISPY2 [23-27]. These cohorts were also downloaded from the NCBI Gene Expression Omnibus database using the R package GEOquery."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 1.137378215789795,
    "data_pmids_checked": 2,
    "paper_id": "39850522",
    "extraction_date": "2025-12-19T20:41:00.546325",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39850522.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39856778": {
    "paper_id": "39856778",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In addition, most of the HGSOC patients with HGSOC were downloaded from the GDC\npatients relapse because they develop resistance to tax- portal and from the cBioportal (TCGA-OV Pan-Cancer)\nane-based chemotherapy",
      "By employ- samples as spatial prognostic information of the samples\ning the gene expression data from cBioportal, GSEApy (Fig",
      "and to provide insights into the morphological and\nAvailability of data and materials\nimmunological mechanism by which immunological fea- The TCGA data included in this study were downloaded from the GDC portal\ntures in tumor tissue link to the malignant phenotype of and cBioportal",
      "using the cBioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:02.534604",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39856778.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.150317907333374,
      "cbioportal_papers": 0.0002181529998779297,
      "pdf_extraction_pass2": 4.861173152923584,
      "cbioportal_papers_pass2": 0.00021600723266601562,
      "used_full_extraction": true,
      "pdf_extraction": 11.011491060256958,
      "platform_mentions": 0.030877113342285156,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39851465": {
    "paper_id": "39851465",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "ThecomparisonofSERPINA1expressionwithclinicopathologicalfeaturesinBCwas\nperformedusingcBioPortal[27](https://www.cbioportal.org,accessedon18October2024),\nspecificallythroughthe\u201cBreastInvasiveCarcinomafromTCGA\u2014PanCancerAtlas\u201dstudy"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:12.823160",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39851465.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.504539966583252,
      "cbioportal_papers": 0.0002760887145996094,
      "pdf_extraction_pass2": 9.481870174407959,
      "cbioportal_papers_pass2": 0.00027108192443847656,
      "used_full_extraction": true,
      "pdf_extraction": 18.98641014099121,
      "platform_mentions": 0.0028600692749023438,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39839837": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Publicly available data sets from TCGA and cBioPortal were analysed for the presence of structural variants involving NTRK1/2/3 gene loci. From three studies analyzing soft tissue sarcomas, well-differentiated and dedifferentiated liposarcoma cases were further analyzed to interrogate the frequencies of NTRK1/2/3 genes and MDM2 and CDK4 genes. From the 2551 cases presented in these three studies 265 unique well-differentiated or dedifferentiated liposarcoma samples were included for the analysis using cBioPortal [25\u201329].",
      "265 samples consisting of 38 well-differentiated and 227 dedifferentiated liposarcoma cases were retrieved from cBioPortal. Amplification of the NTRK1/2/3 genes were seen in 23/265 (8.6%) of the reported cases without preselection using pan-TRK immunohistochemistry for NTRK1/2/3. From these, 9/265 (3.3%), 11/265 (4.1%) and 3/265 (1.1%) cases showed amplification of the NTRK1, NTRK2 and NTRK3 genes, respectively. In all cases a mutually exclusive amplification pattern was observed. Only two cases (1 NTRK1 and 1 NTRK3) with amplification were seen in well-differentiated liposarcoma samples. Single nucleotide variants (SNVs) of the NTRK1/2/3 genes were reported in three cases, NTRK1 G619R, NTRK2 S180G and NTRK3 D167H. Intriguingly, the NTRK1 G619R was in a case with NTRK2 amplification, and the NTRK3 D167H was in a case with NTRK1 amplification.",
      "We found 18 cases with mutually exclusive amplification NTRK genomic loci. To our knowledge, the link between NTRK amplification and dedifferentiated liposarcoma was not investigated directly ever before. As 18/65 (27.6%) of the selected cases showed an amplification of in one of the NTRK genes, we further searched publicly available data derived from liposarcoma samples (both dedifferentiated and well-differentiated liposarcoma cases) from cBioPortal to estimate the frequency in an unbiased sample set. Amplification of the NTRK genes were observed 23/265 (8.6%) samples. This observed frequency is much lower than those observed in our study, however, here samples were analyzed without preselection for the presence of NTRK expression by IHC. Soft tissue sarcomas were screened for NTRK gene alterations other than fusions only in a few research [33\u201336]. NTRK amplifications were found in some tumors, like biliary tract cancers [37] and non-small cell lung cancer [38]."
    ],
    "data_publication_citations": {
      "20601955": [
        "Publicly available data sets from TCGA and cBioPortal were analysed for the presence of structural variants involving NTRK1/2/3 gene loci. From three studies analyzing soft tissue sarcomas, well-differentiated and dedifferentiated liposarcoma cases were further analyzed to interrogate the frequencies of NTRK1/2/3 genes and MDM2 and CDK4 genes. From the 2551 cases presented in these three studies 265 unique well-differentiated or dedifferentiated liposarcoma samples were included for the analysis using cBioPortal [25\u201329]."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.7225730419158936,
    "data_pmids_checked": 3,
    "paper_id": "39839837",
    "extraction_date": "2025-12-19T20:41:13.570316",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39839837.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39857430": {
    "paper_id": "39857430",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:13.609975",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39857430.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 11.758697986602783,
      "cbioportal_papers": 0.0003077983856201172,
      "pdf_extraction_pass2": 16.09989094734192,
      "cbioportal_papers_pass2": 0.00036597251892089844,
      "used_full_extraction": true,
      "pdf_extraction": 27.858588933944702,
      "platform_mentions": 0.002641916275024414,
      "data_citations": 0.0001289844512939453,
      "num_data_pmids_checked": 1
    }
  },
  "39849166": {
    "paper_id": "39849166",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:13.790861",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39849166.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.76697301864624,
      "cbioportal_papers": 0.0003719329833984375,
      "pdf_extraction_pass2": 6.443278074264526,
      "cbioportal_papers_pass2": 0.00037670135498046875,
      "used_full_extraction": true,
      "pdf_extraction": 13.210251092910767,
      "platform_mentions": 0.0029370784759521484,
      "data_citations": 0.00013709068298339844,
      "num_data_pmids_checked": 1
    }
  },
  "39835481": {
    "cbioportal_paper_citations": [
      "Gene expression data were downloaded from cBioPortal (31, 32). Cell-type deconvolution data were downloaded from Data4Cure (https://www.data4cure.com/)."
    ],
    "cbioportal_platform_mentions": [
      "The mouse sequence data generated in this study are publicly available in the Gene Expression Omnibus (RRID: SCR_005012) under accession number GSE281579. TCGA data analyzed in this study were obtained from cBioPortal. The human sequence data generated in this study are not publicly available because of patient privacy requirements but are available upon reasonable request to the corresponding author."
    ],
    "data_publication_citations": {
      "29867230": [
        "Based on previous findings, we hypothesized that MVD and TcellinfGEP are also associated with the response to combination treatment. However, testing this hypothesis has been difficult because of lack of broad availability of IHC-based MVD data. Obtaining tumor tissue with a sufficient mass for IHC analysis is not always practical, and gene signatures are complementarily used as surrogate markers of pathway activity and certain phenotypes. In addition, large public cancer datasets such as The Cancer Genome Atlas (TCGA; ref. 18) allow us to explore the relationship between gene signatures across various tumor types. Previously developed angiogenesis- and EC-related gene signatures contain genes that were highly expressed in ECs compared with other cell types (19, 20), downregulated by anti-VEGF therapies (21, 22), and co-expressed with well-known EC marker genes or angiogenesis-related genes (16, 23\u201325). However, gene signatures developed to reflect MVD from bulk RNA sequencing (RNA-seq) of tumor samples have been unavailable so far.",
        "To verify that the MVD gene score also correlates with MVD(IHC) in human samples, we performed RNA-seq and blood vessel staining with the human EC marker CD34 by IHC using commercially available FFPE samples of human tumors (Supplementary Table S2) and computed the MVD gene score and MVD(IHC). The MVD gene score and MVD(IHC) showed a significant correlation in human tumor samples (Fig. 2D; r = 0.57; P = 3.3 \u00d7 10\u22125), suggesting that the MVD gene score originally developed using the mouse tumor dataset also reflects MVD(IHC) in human samples. Furthermore, to examine the difference between MVD gene score and other angiogenesis-related gene signatures used in clinical biomarker analyses (16, 22, 25), we compared the correlation coefficient of each gene signature and MVD(IHC) in commercially available human FFPE tumor samples (Supplementary Fig. S3A) and the EC score estimated by cell-type deconvolution analysis using TCGA dataset (Supplementary Fig. S3B). The MVD gene score showed a stronger correlation with MVD(IHC) and the EC score than other angiogenesis-related gene signatures, indicating that the MVD gene score reflects microvessels rather than angiogenic activity itself.",
        "We compared the MVD gene score with other angiogenic gene signatures used in clinical biomarker analyses. The IMmotion150 angiogenic signature was derived from genes that had expression levels changed in response to a VEGF blockade in preclinical tumor models and biopsies from patients treated with anti-VEGF mAbs (22). The JAVELIN Renal 101 angiogenic signature was developed from one of the co-expression network modules enriched with angiogenesis-related genes and was associated with response to sunitinib (25). Merck\u2019s angiogenic signature was selected as genes co-expressed with known angiogenic genes, KDR, TIE1, TEK, and CD34, in public pan-cancer genomic datasets (16). Our MVD gene score focuses on the EC component of angiogenesis and its correlation with MVD, as measured by IHC. The MVD gene score is more appropriate to specifically reflect MVD instead of angiogenesis in general. The difference between the MVD signature developed in this study and previously developed angiogenic gene signatures was evident that the MVD signature had a stronger correlation with MVD(IHC) in human FFPE tumor tissue samples (Supplementary Fig. S3A) and the estimated ECs in TCGA tumor samples (Supplementary Fig. S3B)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2360248565673828,
    "data_pmids_checked": 1,
    "paper_id": "39835481",
    "extraction_date": "2025-12-19T20:41:13.871128",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39835481.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39850723": {
    "paper_id": "39850723",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The results were visualized\nwhich included the gene expression matrix for 22 types of using the cBioPortal database (http://www.cbioportal.org (27),\nimmune cells",
      "Then,\nthe mutation status of MK5\u2011AS1 and MK5 was explored using\nB cell CD19 0.16 0.0022 cBioPortal database, and the results showed that the incidence\nMS4A1 0.072 0.17 of MK5\u2011AS1 mutation was 6% (21/360) in HCC, and only two\nCD4+ T cell CD4 0.2 0.067 of the 360 patients had missense mutation in MK5, demon\u2011\nCD8+ T cell CD8A 0.11 0.013 strating that this mutation is fairly unlikely to be the major\nCD8B 0.12 0.02 reason of MK5\u2011AS1 upregulation (Fig",
      "Han P, Lei Y, Liu J, Liu J, Huang H, Tian D and Yan W: Cell\nof complex cancer genomics and clinical profiles using the adhesion molecule BVES functions as a suppressor of tumor\ncBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:15.155779",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39850723.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.995204210281372,
      "cbioportal_papers": 0.0003669261932373047,
      "pdf_extraction_pass2": 9.469768047332764,
      "cbioportal_papers_pass2": 0.0003821849822998047,
      "used_full_extraction": true,
      "pdf_extraction": 20.464972257614136,
      "platform_mentions": 0.00426793098449707,
      "data_citations": 0.0002779960632324219,
      "num_data_pmids_checked": 2
    }
  },
  "39847459": {
    "paper_id": "39847459",
    "cbioportal_paper_citations": [
      "Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. (2012) The cBio cancer\ngenomics portal: an open platform for exploring multidimensional cancer genomics data Cancer\nDiscov 2, 401\u2013404 10.1158/2159-8290.CD-12-0095 [PubMed: 22588877]\n41"
    ],
    "cbioportal_platform_mentions": [
      "Bioinformatics\nCbioPortal (39, 40) was used to assess genetic alterations for BLK, FGR, FYN, HCK, LCK,\nLYN, SRC, and YES1 in 171 basal-like breast cancer patients from The Cancer Genome\nAtlas (TCGA), PanCancer Atlas dataset (41, 42) and 199 basal breast cancer patients from\nthe Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset\n(43, 44)",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. (2013) Integrative analysis\nof complex cancer genomics and clinical profiles using the cBioPortal Sci Signal 6, pl1 10.1126/\nscisignal.2004088\n40"
    ],
    "data_publication_citations": {
      "23000897": [
        "(2012) Comprehensive molecular portraits of human breast tumours\nNature 490, 61\u201370 10.1038/nature11412 [PubMed: 23000897]\n43"
      ],
      "31068700": [
        "Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd et al. (2019)\nNext-generation characterization of the Cancer Cell Line Encyclopedia Nature 569, 503\u2013508\n10.1038/s41586-019-1186-3 [PubMed: 31068700]\n51"
      ],
      "27161491": [
        "Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA et al. (2016) The somatic\nmutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes Nat\nCommun 7, 11479 10.1038/ncomms11479 [PubMed: 27161491]\n44"
      ],
      "22522925": [
        "Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al. (2012) The genomic and\ntranscriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature 486, 346\u2013352\n10.1038/nature10983 [PubMed: 22522925]\n45"
      ]
    },
    "extraction_date": "2025-12-19T20:41:15.408637",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39847459.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 4,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 5.042827129364014,
      "cbioportal_papers": 0.00021791458129882812,
      "pdf_extraction_pass2": 7.780071973800659,
      "cbioportal_papers_pass2": 0.003068208694458008,
      "used_full_extraction": true,
      "pdf_extraction": 12.822899103164673,
      "platform_mentions": 0.003961801528930664,
      "data_citations": 0.017338037490844727,
      "num_data_pmids_checked": 4
    }
  },
  "39830266": {
    "cbioportal_paper_citations": [
      "Unexpectedly, all five recurrences in this cohort involved HPV types from phylogenetic clade \u03b17 (HPV18, HPV39, HPV45, HPV70) or \u03b15 (HPV69), with none involving clade \u03b19 types (HPV16, HPV35) (Figure 1A). Patients with cervical cancers containing clade \u03b17 HPV types have inferior survival versus those with clade \u03b1914,15. Therefore, HPV clade types were also assessed as an independent prognostic factor for recurrence for the larger cervical cancer dataset in The Cancer Genome Atlas (TCGA) using Kaplan-Meier analysis of clinical information and tumor tissue sequences (Tables 2 and 3, Figure 5). HPV types were determined using CTAT-Virus Integration Finder8 analysis of TCGA sequencing data, revealing 214 tumors (69.5%) with clade \u03b19 types, 83 (26.9%) with other clade types (\u03b15, \u03b16, \u03b17, or \u03b111) , and 11 (3.6%) being HPV-negative. Clinicopathologic variables known to be a priori prognostic factors were extracted from cBioPortal16 17, including age, histology, and stage at diagnosis, with N=297 patients having complete data. Comparisons of HPV clade \u03b19 with non-clade-\u03b19 (\u03b15/\u03b16/\u03b17/\u03b111) showed no significant baseline differences in these variables (Table 2). However, patients with non-\u03b19 clades exhibited inferior recurrence-free survival compared to those with HPV clade-\u03b19 tumors based on a log-rank test stratified for histology and stage (p=0.03). A multivariable Cox regression model including age (years), histology (squamous/adenocarcinoma) and stage (I, II, III, IV) (Table 3) was performed to account for these a priori variables, and women with HPV clades other than \u03b19 showed inferior recurrence-free survival in comparison to HPV clade-\u03b19 tumors (Hazard Ratio (HR)=2.48, 95% CI: 1.34\u20134.49, p=0.004) after adjusting for all variables (Figure 5). The effect of HPV clade on recurrence-free survival was second only to stage IV disease (HR: 4.40, 95% CI: 1.89\u201310.18, p=0.001) in this adjusted analysis (Table 3). In summary, these results show that non-\u03b19 clade HPV types are a risk factor for tumor recurrence following current standards of care.",
      "Identification of non-\u03b19 clade HPV types (at least \u03b15, \u03b16, \u03b17, and \u03b111) as a risk factor for recurrence in the TCGA/cBioPortal data16 17 and in the small retrospective study presented here establish that HPV clade type specifically affects cervical cancer recurrence per se following treatment as well as survival, and may reflect the same underlying molecular genetic properties of these HPV types. These effects contrast with the high prevalence of \u03b19 HPV16 (~50%) in cervical cancer and the correlation between HPV16 and progression of preinvasive, cervical intraepithelial neoplasia19 20. They also highlight a potential role for precise HPV typing in cervical cancer management using multiplexed HPV-typing by hybridization capture plus sequencing methods like HC+SEQ as used here to facilitate clade assignment. These approaches are technically comparable to clinically-utilized assays like exon capture, and inclusion of all known HPV types also enables broad diagnostic specificity plus tumorigenicity assessment of rare HPV types. Again, the potential for improved recurrence risk prediction emphasizes the need to develop improved upfront therapies for women at risk for cervical cancer relapse.",
      "To evaluate whether HPV type was associated with recurrence in the cervical cancer dataset of The Cancer Genome Atlas, we downloaded the RNA-sequencing, whole genome sequencing (WGS), and/or whole exome sequencing (WES) data for 302 cervical cancer samples from TCGA16. HPV typing was determined using CTAT-Virus Integration Finder developed by our group8. Sample HPV type was determined based on support with at least 50 mapped reads, >0.10 fraction genome coverage. Based on the inferred HPV type, samples were categorized into HPV clades \u03b19, and \u201c\u03b17 plus other\u201d as described above. RFS and demographic variables including age, histology, and stage at diagnosis were extracted from CBioportal17. Survival probabilities for RFS were estimated using the Kaplan-Meier method, and the log-rank test was used to compare RFS by HPV clade. Univariable and multivariable Cox proportional hazard regression analyses were also performed to assess further whether HPV clade was an independent risk factor for RFS. Previously reported risk factors related to RFS included in all models were age, stage, and histology. All analyses were performed using Stata version 18.0 (StataCorp, College Station, TX)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.02241039276123047,
    "data_pmids_checked": 0,
    "paper_id": "39830266",
    "extraction_date": "2025-12-19T20:41:15.446378",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39830266.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39833282": {
    "paper_id": "39833282",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Scientific Reports | (2025) 15:2477 | https://doi.org/10.1038/s41598-025-86185-7 2\n\nwww.nature.com/scientificreports/\nMaterials and methods\nFLT3 alteration frequency, mRNA expression level, and survival analysis\nThe cBioPortal (http://www.cbioportal.org/) for cancer genomics provides information regarding the integrative\nanalysis of complex cancer genomics and clinical profiles from 105 cancer studies in The Cancer Genome\nAtlas (TCGA) pipeline8,9",
      "FLT3 expression and the frequency of FLT3 alterations (including mutation, fusion,\namplification, deep deletion, and multiple alterations), as well as the prognostic value of FLT3 mutations in\ndifferent cancer types, were assessed using the TCGA Pan-Cancer Atlas (comprising 10,967 samples from 32\nstudies) following the online instructions of cBioPortal",
      "Scientific Reports | (2025) 15:2477 | https://doi.org/10.1038/s41598-025-86185-7 3\n\nwww.nature.com/scientificreports/\nResults\nGenetic alteration frequency and mRNA level of FLT3 in AML is higher than in solid\ncancers, and FLT3 alteration is associated with a poor prognosis only in AML\nThe data obtained from cBioPortal encompassed a combined study of 74,247 cancer samples",
      "Using the\ncBioPortal database, we evaluated the impact of FLT3 alterations on survival and found that patients with\nFLT3 alterations had a significantly shorter overall survival (OS) compared to those without FLT3 alterations\nacross pan-cancer types (p = 0.0311, Fig",
      "To further investigate the role of FLT3 in cancer, we assessed FLT3 mRNA expression across various cancer\ntypes using cBioPortal",
      "(A) FLT3 alterations (including mutations, deletions, and amplifications) were observed in pan\ncancer using the cBioPortal database",
      "(B) The role of an FLT3 alteration in OS was evaluated using the\ncBioPortal database",
      "(C) FLT3 expressions were observed in pan cancer using the cBioPortal database and the FLT3\nmRNA level was significantly higher in AML than in any other solid cancer",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:27.384704",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39833282.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.57939887046814,
      "cbioportal_papers": 0.0002551078796386719,
      "pdf_extraction_pass2": 6.91276478767395,
      "cbioportal_papers_pass2": 0.0002644062042236328,
      "used_full_extraction": true,
      "pdf_extraction": 13.49216365814209,
      "platform_mentions": 0.003216981887817383,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39821040": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.2282390594482422,
    "data_pmids_checked": 5,
    "paper_id": "39821040",
    "extraction_date": "2025-12-19T20:41:28.626913",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39821040.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39832113": {
    "paper_id": "39832113",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We employed a comprehensive suite of web platforms and software\ntools for data analysis, including R, Cytoscape, an integrated repository portal for tumor-immune system interactions\n(TISIDB), CBio Cancer Genomics Portal (cBioPortal), Search Tool for the Retrieval of Interaction Gene/Proteins (STRING),\nGene Set Cancer Analysis (GSCALite), and a cancer single-cell state atlas (CancerSEA)",
      "2.5 Genetic alteration analysis of CENPN\nWe conducted a search on cBioPortal [19] to obtain information regarding genetic alterations in the CENPN gene",
      "(A) ACC, (B) BRCA, (C) KIRP, (D) LGG, (E) LIHC, (F) OV\n3.6 Genetic alteration of CENPN\nThe genetic mutations in CENPN expression across various cancers were evaluated using the cBioPortal online tool",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles\nusing the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:30.486229",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39832113.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.529177904129028,
      "cbioportal_papers": 0.00025010108947753906,
      "pdf_extraction_pass2": 7.746056795120239,
      "cbioportal_papers_pass2": 0.00028061866760253906,
      "used_full_extraction": true,
      "pdf_extraction": 15.275234699249268,
      "platform_mentions": 0.009083032608032227,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39838298": {
    "paper_id": "39838298",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Alterations of biological systems with survival and mutation significance in\nHiSig analysis were checked in the METABRIC cohort using the CBioPortal OncoPrint\nfunction [26]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative\nanalysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:32.154508",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39838298.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.290771007537842,
      "cbioportal_papers": 0.00030803680419921875,
      "pdf_extraction_pass2": 9.29002594947815,
      "cbioportal_papers_pass2": 0.0002911090850830078,
      "used_full_extraction": true,
      "pdf_extraction": 18.58079695701599,
      "platform_mentions": 0.002604961395263672,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39816562": {
    "cbioportal_paper_citations": [
      "An evaluation of the correlation between BRI3BP mRNA expression and multiple variables, including patient age, tumor grade, tumor size, lymph vascular invasion (LVI), molecular subtypes, and patient outcomes, was performed using the METABRIC (n=1,980) and TCGA (n=854) cohorts (5,6). In the METABRIC cohort, the Illumina Totalprep RNA amplification kit (Ambion, Warrington, UK) was used to generate biotin-labeled cRNA from total RNA, which was then hybridized on the Illumina Human HT-12 v3 platform to evaluate mRNA expression. For TCGA, the Genomic Data Commons Data Portal and cBioPortal websites were used to extract the cohort data. The cohort was then assessed for RNASeqV2-derived mRNA expression data (13,14)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26451490": [
        "Previously, artificial neural network (ANN) methodology was used to identify principal genes in BC using two large transcriptomic cohorts of BC: The Cancer Genome Atlas (TCGA) (5) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (6). The BRI3 binding protein (BRI3BP) was found to be one of the top genes in invasive BC (7). BRI3BP may have an impact on mitochondrial viability and the structural dynamics of the endoplasmic reticulum (8). The mitochondrial protein known as BRI3BP binds to human cervical cancer oncogene (HCCR-1), which is overexpressed in many human tumors and may function as a negative regulator of the tumor protein p53 (p53) gene (9). The BRI3BP gene, also known as HCCR-binding protein 1 (HCCRBP-1), is a human cervical cancer oncogene (HCCR) that regulates p53. HCCRBP-1 works as a negative regulator of p53, promoting carcinogenesis in a range of human tissues by greatly raising protein kinase C (PKC) activity while decreasing pro-apoptotic PKC alpha and delta isoform levels. HCCRBP-1 reduces p21 promoter activity, perhaps via p53 stabilization, resulting in defective functioning (9). The oncogene HCCRBP-1 contributes to the development of human colorectal cancer and hepatocellular carcinoma (10,11). HCCRBP-1 has also been reported to be overexpressed in a range of human malignancies, such as leukemia, lymphoma, and carcinomas of the kidney, ovary, and stomach (12). Therefore, BRI3BP (also known as HCCRBP-1), an oncoprotein potentially involved in the development of many human cancers, is a prospective diagnostic and therapeutic target for human malignancies.",
        "An evaluation of the correlation between BRI3BP mRNA expression and multiple variables, including patient age, tumor grade, tumor size, lymph vascular invasion (LVI), molecular subtypes, and patient outcomes, was performed using the METABRIC (n=1,980) and TCGA (n=854) cohorts (5,6). In the METABRIC cohort, the Illumina Totalprep RNA amplification kit (Ambion, Warrington, UK) was used to generate biotin-labeled cRNA from total RNA, which was then hybridized on the Illumina Human HT-12 v3 platform to evaluate mRNA expression. For TCGA, the Genomic Data Commons Data Portal and cBioPortal websites were used to extract the cohort data. The cohort was then assessed for RNASeqV2-derived mRNA expression data (13,14)."
      ],
      "22522925": [
        "Previously, artificial neural network (ANN) methodology was used to identify principal genes in BC using two large transcriptomic cohorts of BC: The Cancer Genome Atlas (TCGA) (5) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (6). The BRI3 binding protein (BRI3BP) was found to be one of the top genes in invasive BC (7). BRI3BP may have an impact on mitochondrial viability and the structural dynamics of the endoplasmic reticulum (8). The mitochondrial protein known as BRI3BP binds to human cervical cancer oncogene (HCCR-1), which is overexpressed in many human tumors and may function as a negative regulator of the tumor protein p53 (p53) gene (9). The BRI3BP gene, also known as HCCR-binding protein 1 (HCCRBP-1), is a human cervical cancer oncogene (HCCR) that regulates p53. HCCRBP-1 works as a negative regulator of p53, promoting carcinogenesis in a range of human tissues by greatly raising protein kinase C (PKC) activity while decreasing pro-apoptotic PKC alpha and delta isoform levels. HCCRBP-1 reduces p21 promoter activity, perhaps via p53 stabilization, resulting in defective functioning (9). The oncogene HCCRBP-1 contributes to the development of human colorectal cancer and hepatocellular carcinoma (10,11). HCCRBP-1 has also been reported to be overexpressed in a range of human malignancies, such as leukemia, lymphoma, and carcinomas of the kidney, ovary, and stomach (12). Therefore, BRI3BP (also known as HCCRBP-1), an oncoprotein potentially involved in the development of many human cancers, is a prospective diagnostic and therapeutic target for human malignancies.",
        "An evaluation of the correlation between BRI3BP mRNA expression and multiple variables, including patient age, tumor grade, tumor size, lymph vascular invasion (LVI), molecular subtypes, and patient outcomes, was performed using the METABRIC (n=1,980) and TCGA (n=854) cohorts (5,6). In the METABRIC cohort, the Illumina Totalprep RNA amplification kit (Ambion, Warrington, UK) was used to generate biotin-labeled cRNA from total RNA, which was then hybridized on the Illumina Human HT-12 v3 platform to evaluate mRNA expression. For TCGA, the Genomic Data Commons Data Portal and cBioPortal websites were used to extract the cohort data. The cohort was then assessed for RNASeqV2-derived mRNA expression data (13,14)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3408932685852051,
    "data_pmids_checked": 2,
    "paper_id": "39816562",
    "extraction_date": "2025-12-19T20:41:32.530868",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39816562.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39821172": {
    "paper_id": "39821172",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "1 3\n\nJournal of Endocrinological Investigation (2025) 48:1149\u20131172 1151\nGenetic alteration analysis DIO2\u2011related gene enrichment analysis\nAfter logging into the cBioPortal web ( h t t p s : / / w w w",
      "Analysis of SARC Pathological we used cBioPortal online platform, that is a wide-ranging tool\nStage Plot was not possible due to lack of sufficient nor- to query the genetic alteration frequency, mutation types and\nmal tissue samples",
      "Although mutations of DIO2 genes have been reported\nrarely, the cBioPortal platform enabled to identify all the muta-\nSurvival analysis and prognostic value of DIO2 in tions for the DIO2 gene that have been annotated",
      "Indeed, we used the \u201cTCGA Pan-Cancer Atlas\nHR = 0.72, p-value = 0.016), READ (OS HR = 0.45) and UCEC Studies\u201d of cBioPortal online platform to explore the asso-\n(OS HR = 0.38) (Fig",
      "A Genetic muta- Correlation between DIO2 mutation status and Overall Survival, Dis-\ntions analysis of DIO2 in pan-cancer was conducted by cBioPortal ease-specific Survival, Disease-Free Survival and Progress Free Sur-\nonline platform (https://www.cbioportal.org) based on TCGA Dataset",
      "A cancer biomarker\ncauses the TH activation and that D2 induction is a reason can be generally defined as a tumoral feature that can be\nand not a consequence of a putative hypothyroidism in high objectively measured and easily quantified as an indicator\n1 3\n\nJournal of Endocrinological Investigation (2025) 48:1149\u20131172 1159\nTable 3 Genetic alterations of DIO2 through the TCGA PanCancer Atlas: a summary of the 98 mutations annotated in cBioPortal online platform\nStydy of origin Sample ID Protein change Mutation type Copy Allele frequency\nAdrenocortical Carcinoma TCGA-PK-A5HB-01 F19Sfs*23 FS del Diploid 0.15\nBrain Lower Grade Glioma TCGA-DB-A4XB-01 Q236E Missense Diploid 0.48\nBrain Lower Grade Glioma TCGA-DU-6392\u201301 A194T Missense Diploid 0.34\nBrain Lower Grade Glioma TCGA-DU-6392\u201301 V159I Missense Diploid 0.28\nOvarian Serous Cystadenocarcinoma TCGA-13\u20130885-01 Q186_Q197del IF del ShallowDel 0.21\nOvarian Serous Cystadenocarcinoma TCGA-31\u20131950-01 A226D Missense ShallowDel 0.07\nGlioblastoma Multiforme TCGA-15\u20131446-01 V210F Missense Diploid 0.04\nDiffuse Large B-Cell Lymphoma TCGA-FA-A4XK-01 R52W Missense Diploid 0.45\nLung Squamous Cell Carcinoma TCGA-56-A62T-01 G2D Missense Gain 0.28\nLung Squamous Cell Carcinoma TCGA-33\u20134586-01 R52L Missense ShallowDel 0.55\nLung Squamous Cell Carcinoma TCGA-34\u20137107-01 R229C Missense ShallowDel 0.31\nLung Squamous Cell Carcinoma TCGA-33-AASB-01 G243V Missense Diploid 0.20\nLung Squamous Cell Carcinoma TCGA-77\u20138143-01 S263I Missense Gain 0.58\nLung Squamous Cell Carcinoma TCGA-77\u20138144-01 V126F Missense Diploid 0.30\nBladder Urothelial Carcinoma TCGA-DK-A6AW-01 R255W Missense Diploid 0.39\nAcute Myeloid Leukemia TCGA-AB-2924\u201303 A190T Missense Diploid\nLiver Hepatocellular Carcinoma TCGA-DD-AAW0-01 P205T Missense Diploid 0.21\nProstate Adenocarcinoma TCGA-XK-AAIW-01 R53H Missense Diploid 0.53\nProstate Adenocarcinoma TCGA-KK-A59V-01 G49R Missense Diploid 0.19\nKidney Renal Clear Cell Carcinoma TCGA-AK-3456\u201301 R229C Missense Diploid 0.18\nKidney Renal Clear Cell Carcinoma TCGA-CW-5591\u201301 G224W Missense Diploid 0.24\nKidney Renal Clear Cell Carcinoma TCGA-A3-3319\u201301 N261Y Missense ShallowDel 0.53\nUterine Corpus Endometrial Carcinoma TCGA-DI-A0WH-01 F19Sfs*23 FS del Diploid 0.23\nUterine Corpus Endometrial Carcinoma TCGA-EY-A215-01 F19Sfs*23 FS del Diploid 0.34\nUterine Corpus Endometrial Carcinoma TCGA-FI-A2D0-01 R61H Missense Diploid 0.37\nUterine Corpus Endometrial Carcinoma TCGA-AP-A056-01 R53H Missense Diploid 0.36\nUterine Corpus Endometrial Carcinoma TCGA-BK-A26L-01 R61L Missense Gain 0.14\nUterine Corpus Endometrial Carcinoma TCGA-EO-A3AZ-01 R255W Missense Diploid 0.18\nUterine Corpus Endometrial Carcinoma TCGA-A5-A0G1-01 R209* Nonsense Diploid 0.21\nUterine Corpus Endometrial Carcinoma TCGA-A5-A0G1-01 R144C Missense Diploid 0.19\nUterine Corpus Endometrial Carcinoma TCGA-A5-A0G1-01 V89L Missense Diploid 0.16\nUterine Corpus Endometrial Carcinoma TCGA-A5-A1OF-01 K244N Missense Diploid 0.44\nUterine Corpus Endometrial Carcinoma TCGA-A5-A2K5-01 V6L Missense Diploid 0.35\nUterine Corpus Endometrial Carcinoma TCGA-AJ-A3EL-01 K237N Missense Diploid 0.22\nUterine Corpus Endometrial Carcinoma TCGA-AP-A1DK-01 R144H Missense Diploid 0.23\nUterine Corpus Endometrial Carcinoma TCGA-AX-A2HG-01 R144H Missense Diploid 0.30\nUterine Corpus Endometrial Carcinoma TCGA-AP-A1DV-01 E104D Missense Diploid 0.38\nUterine Corpus Endometrial Carcinoma TCGA-AX-A0J0-01 R265I Missense Diploid 0.46\nUterine Corpus Endometrial Carcinoma TCGA-AX-A0J0-01 L199R Missense Diploid 0.59\nUterine Corpus Endometrial Carcinoma TCGA-B5-A11E-01 V230A Missense Diploid 0.43\nUterine Corpus Endometrial Carcinoma TCGA-BS-A0UF-01 F247L Missense Diploid 0.37\nUterine Corpus Endometrial Carcinoma TCGA-D1-A103-01 Q196H Missense Diploid 0.25\nUterine Corpus Endometrial Carcinoma TCGA-D1-A163-01 A193T Missense Diploid 0.39\nUterine Corpus Endometrial Carcinoma TCGA-DI-A1BU-01 I3T Missense Diploid 0.36\nUterine Corpus Endometrial Carcinoma TCGA-E6-A1LX-01 Q13L Missense Diploid 0.16\nUterine Corpus Endometrial Carcinoma TCGA-FI-A2D0-01 S177Y Missense Diploid 0.37\nUterine Corpus Endometrial Carcinoma TCGA-FI-A2D0-01 R53C Missense Diploid 0.32\nLung Adenocarcinoma TCGA-17-Z015-01 R48H Missense 0.44\nLung Adenocarcinoma TCGA-05\u20134382-01 T47N Missense Diploid 0.36\nLung Adenocarcinoma TCGA-55\u20138094-01 R53P Missense ShallowDel 0.85\nLung Adenocarcinoma TCGA-86\u20138073-01 L41F Missense Diploid 0.12\nLung Adenocarcinoma TCGA-97-A4M7-01 R61L Missense Diploid 0.13\nLung Adenocarcinoma TCGA-17-Z031-01 V211E Missense 0.43\nLung Adenocarcinoma TCGA-44\u20132656-01 A171E Missense Diploid 0.21\nLung Adenocarcinoma TCGA-44\u20133918-01 T137K Missense Diploid 0.15\n1 3\n\n1160 Journal of Endocrinological Investigation (2025) 48:1149\u20131172\nT able 3 (continued)\nStydy of origin Sample ID Protein change Mutation type Copy Allele frequency\nLung Adenocarcinoma TCGA-44\u20136776-01 L4I Missense Diploid 0.32\nLung Adenocarcinoma TCGA-55\u20137913-01 K145* Nonsense Diploid 0.27\nLung Adenocarcinoma TCGA-55\u20138087-01 D162G Missense Diploid 0.08\nLung Adenocarcinoma TCGA-55\u20138506-01 Q188L Missense Gain 0.40\nLung Adenocarcinoma TCGA-73\u20134670-01 R144S Missense Diploid 0.38\nLung Adenocarcinoma TCGA-78\u20137539-01 E259* Nonsense Diploid 0.62\nLung Adenocarcinoma TCGA-86\u20138585-01 D162Y Missense Gain 0.36\nLung Adenocarcinoma TCGA-93\u20138067-01 V182L Missense Gain 0.22\nLung Adenocarcinoma TCGA-MP-A4TC-01 R201L Missense ShallowDel 0.22\nEsophageal Adenocarcinoma TCGA-LN-A49K-01 L15M Missense Gain 0.27\nEsophageal Adenocarcinoma TCGA-2H-A9GL-01 I221R Missense Gain 0.54\nEsophageal Adenocarcinoma TCGA-L5-A8NR-01 L124P Missense Diploid 0.56\nEsophageal Adenocarcinoma TCGA-LN-A49R-01 L146M Missense Diploid 0.52\nSkin Cutaneous Melanoma TCGA-D3-A5GN-06 S248F Missense ShallowDel 0.34\nSkin Cutaneous Melanoma TCGA-DA-A1HY-06 S248F Missense ShallowDel 0.52\nSkin Cutaneous Melanoma TCGA-EE-A2GM-06 R191Q Missense Gain 0.55\nSkin Cutaneous Melanoma TCGA-EB-A5SG-06 G109R Missense Diploid 0.20\nSkin Cutaneous Melanoma TCGA-EE-A2MJ-06 P206L Missense Gain 0.17\nSkin Cutaneous Melanoma TCGA-D3-A3CE-06 G224W Missense ShallowDel 0.15\nSkin Cutaneous Melanoma TCGA-D3-A8GI-06 E189K Missense ShallowDel 0.20\nSkin Cutaneous Melanoma TCGA-DA-A1I1-06 H165N Missense ShallowDel 0.08\nSkin Cutaneous Melanoma TCGA-EE-A29E-06 G49* Nonsense Diploid 0.11\nSkin Cutaneous Melanoma TCGA-EE-A2GK-06 F262L Missense Diploid 0.27\nStomach Adenocarcinoma TCGA-HU-A4H8-01 F19Sfs*23 FS del Diploid 0.23\nStomach Adenocarcinoma TCGA-BR-8676\u201301 V63I Missense Diploid 0.42\nStomach Adenocarcinoma TCGA-BR-6452\u201301 R52W Missense Diploid 0.13\nStomach Adenocarcinoma TCGA-BR-7707\u201301 G224R Missense Diploid 0.28\nStomach Adenocarcinoma TCGA-BR-8297\u201301 K237T Missense Diploid 0.08\nStomach Adenocarcinoma TCGA-BR-8363\u201301 N127T Missense Diploid 0.10\nBreast Invasive Carcinoma TCGA-E2-A15R-01 E148K Missense Diploid 0.41\nPancreatic Adenocarcinoma TCGA-IB-7651\u201301 R214H Missense Diploid 0.16\nColorectal Adenocarcinoma TCGA-A6-2686\u201301 F19Sfs*23 FS del Gain 0.18\nColorectal Adenocarcinoma TCGA-AG-3909\u201301 R214C Missense Diploid 0.13\nColorectal Adenocarcinoma TCGA-F5-6814\u201301 R61C Missense Diploid 0.57\nColorectal Adenocarcinoma TCGA-AA-A02R-01 P205L Missense Diploid 0.32\nColorectal Adenocarcinoma TCGA-AD-6889\u201301 P173L Missense Diploid 0.50\nColorectal Adenocarcinoma TCGA-AF-A56K-01 W257L Missense Diploid 0.15\nColorectal Adenocarcinoma TCGA-EI-6917\u201301 R191* Nonsense Diploid 0.23\nKidney Renal Papillary Cell Carcinoma TCGA-KV-A6GE-01 S203T Missense Diploid 0.05\nHead and Neck Squamous Cell Carcinoma TCGA-CN-5369\u201301 K65N Missense Diploid 0.09\nHead and Neck Squamous Cell Carcinoma TCGA-CN-A497-01 W170C Missense ShallowDel 0.39\nHead and Neck Squamous Cell Carcinoma TCGA-CQ-7063\u201301 H165Y Missense Diploid 0.22\nHead and Neck Squamous Cell Carcinoma TCGA-UF-A71D-01 V86M Missense ShallowDel 0.24\nof tumoral formation and/or progression",
      "Zeold A et al (2006) Characterization of the nuclear factor-\nics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:33.558836",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39821172.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.003201007843018,
      "cbioportal_papers": 0.018105030059814453,
      "pdf_extraction_pass2": 9.084758043289185,
      "cbioportal_papers_pass2": 0.0003437995910644531,
      "used_full_extraction": true,
      "pdf_extraction": 18.087959051132202,
      "platform_mentions": 0.0035810470581054688,
      "data_citations": 1.0728836059570312e-05,
      "num_data_pmids_checked": 0
    }
  },
  "39812592": {
    "cbioportal_paper_citations": [
      "We followed the SAGER guidelines regarding sex and gender equity in research. 23 For copy number analysis, we investigated the Memorial Sloan Kettering\u2014Metastatic Events and Tropisms (MSK\u2010MET) cohort 24 including 25 775 patients spanning 50 cancer types; and the Skin Cutaneous Melanoma (SKCM) cohort from The Cancer Genome Atlas (TCGA, Firehose Legacy, RRID:SCR_003193). In these cohorts, RECQL4 copy number alterations (CNA) and available clinical data were analysed. These data were taken from the cBioPortal for cancer genomics online database 25 , 26 (https://www.cbioportal.org/, RRID:SCR_014555). For transcript level analysis, we explored the SKCM TCGA Firehose Legacy cohort and four independent cohorts consisting of ICI\u2010treated melanoma patients as formerly published in Liu et al., 27 Hugo et al., 28 Gide et al. 29 and Riaz et al. 30 From these cohorts, we selected only the samples from pre\u2010treatment biopsies with cutaneous melanoma subtype. We extracted the clinico\u2010pathological and RECQL4, MYC and MKI67 expression in transcripts per million (TPM) mapped reads data from the PhenoTImE webtool 31 (https://doc.hornlab.org/shiny/cru337phenotime/). RNA sequencing (RNA\u2010seq) expression data from TCGA (RNASeqV2) was processed and normalised using RNA\u2010seq by Expectation\u2010Maximisation to generate TPM. Table 1 shows a summary of the analysed cohorts for RECQL4 CNA and gene expression levels."
    ],
    "cbioportal_platform_mentions": [
      "RECQL4 CNA data from the cBioPortal classified the copy number levels using the Genomic Identification of Significant Targets in Cancer version 2.0 algorithm (GISTIC2.0, RRID:SCR_000151). 32 According to the copy number, the samples were classified in four levels: (1) loss of heterozygosity (LOH), which indicates a shallow loss, probably a heterozygous deletion; (2) diploidy; (3) gain, which implies a low\u2010level gain of limited additional copies and generally of a broad segment; and (4) high\u2010level amplification (HIGH AMP), which indicates a gain of several additional copies and is generally focal. We mainly focused on the differences between the diploid and high amplification levels for the RECQL4 locus. Regarding transcript levels, we divided the samples in \u2018low\u2010\u2019 and \u2018high\u2010expression groups\u2019, individually for each cohort, by k\u2010means clustering using R language. We then merged the ICI\u2010treated cohorts and used these groups for the comparison of different clinical parameters and performance of survival analyses. In Table 2, details about the individual ICI\u2010treated cohorts are presented.",
      "We obtained the genomic data of the MSK\u2010MET cohort through cBioPortal. Fraction of genome altered (FGA) was defined as the fraction of the genome with absolute log2 copy ratios larger than .2, as previously described. 34 MSI type was categorised by the MSIsensor score (RRID:SCR_006418) according to Niu et al. 35 We calculated the tumour mutational burden (TMB) by dividing the total number of non\u2010synonymous mutations by the number of bases sequenced for each sample. We considered the samples with \u226510 mutations/megabase (mut/Mb) as high TMB."
    ],
    "data_publication_citations": {
      "31792460": [
        "We followed the SAGER guidelines regarding sex and gender equity in research. 23 For copy number analysis, we investigated the Memorial Sloan Kettering\u2014Metastatic Events and Tropisms (MSK\u2010MET) cohort 24 including 25 775 patients spanning 50 cancer types; and the Skin Cutaneous Melanoma (SKCM) cohort from The Cancer Genome Atlas (TCGA, Firehose Legacy, RRID:SCR_003193). In these cohorts, RECQL4 copy number alterations (CNA) and available clinical data were analysed. These data were taken from the cBioPortal for cancer genomics online database 25 , 26 (https://www.cbioportal.org/, RRID:SCR_014555). For transcript level analysis, we explored the SKCM TCGA Firehose Legacy cohort and four independent cohorts consisting of ICI\u2010treated melanoma patients as formerly published in Liu et al., 27 Hugo et al., 28 Gide et al. 29 and Riaz et al. 30 From these cohorts, we selected only the samples from pre\u2010treatment biopsies with cutaneous melanoma subtype. We extracted the clinico\u2010pathological and RECQL4, MYC and MKI67 expression in transcripts per million (TPM) mapped reads data from the PhenoTImE webtool 31 (https://doc.hornlab.org/shiny/cru337phenotime/). RNA sequencing (RNA\u2010seq) expression data from TCGA (RNASeqV2) was processed and normalised using RNA\u2010seq by Expectation\u2010Maximisation to generate TPM. Table 1 shows a summary of the analysed cohorts for RECQL4 CNA and gene expression levels.",
        "For gene set enrichment analysis (GSEA), we first derived the differentially expressed genes in diploid versus high\u2010amplified RECQL4 samples within the SKCM TCGA cohort. Next, we ranked the genes according to the logarithm of the fold change (FC) and the p\u2010value of the differential expression and performed a GSEA using the Hallmark Gene Set of the Molecular Signatures Database (MSigDB, RRID:SCR_022870). 36 GSEA was executed using \u2018fgsea\u2019 R package (RRID:SCR_020938). Normalised enrichment score (NES), p\u2010value and the false discovery rate (FDR) adjusted p\u2010value corrected by Benjamini\u2013Hochberg multiple test (q\u2010value) were calculated. In addition, we analysed enrichment in gene ontology (GO) terms defining biological processes using ShinyGO 0.76.2 webtool (RRID:SCR_019213). 37 The same procedures were repeated with Liu et al. 27 cohort as a validation of the results.",
        "When analysing tissue characteristics of the MSK\u2010MET cohort, 24 we identified a significantly increased level of tumour purity in tumours harbouring RECQL4 high amplifications (Figure 3A, p < .05), implicating a larger fraction of cancer cells in the tumour mass. In light of these findings, we postulated that recruitment of cells from the tumour microenvironment, including cells of the immune compartment, might be constrained under conditions of elevated RECQL4 copy number. To delineate the genes and pathways that are differentially regulated in tumours with RECQL4 CNA, we grouped samples of the TCGA SKCM cohort according to the RECQL4 CNA status (diploid and high\u2010amplified) and performed gene expression analyses. We detected a total of 2136 significantly differentially expressed genes, of which 490 were upregulated and 1646 were downregulated in the samples corresponding to RECLQ4 high amplification compared to diploids (Figure 3B). According to the GSEA, strong activation of pathways in samples presenting RECQL4 high amplification were related to cell proliferation, cell cycle and DNA damage repair (MYC targets variant 1 and variant 2, E2F targets, G2M checkpoint and DNA repair) (Figure 3C). These pathways are closely linked to RECQL4 intrinsic function. Besides, RECQL4 high\u2010amplified samples also had increased metabolic activity (oxidative phosphorylation). This may be due to the expression of RECQL4 in mitochondria, which is responsible for maintaining mitochondrial DNA integrity and coping with oxidative stress. 47 , 48 Of particular note, we observed a pronounced downregulation of key signalling pathways associated with the immune response in samples exhibiting high RECQL4 amplification. These included pathways involved in allograft rejection, IFN\u2010\u03b3 and \u2010\u03b1 responses, the complement cascade, global inflammatory response, tumour necrosis factor\u2010alpha signalling via nuclear factor kappa B, IL2\u2012STAT5 signalling and IL6\u2012JAK\u2012STAT3 signalling (Figure 3D\u2012K). Moreover, employing GO Biological Process annotation, we uncovered a significant downregulation in pathways associated with lymphocyte differentiation or activation within samples exhibiting RECQL4 high amplification (Figure 3L). Intriguingly, extending our analysis to a cohort of patients undergoing ICI treatment, consistent findings emerged. 27 A total of 2180 genes exhibited significant differential expression, with 132 upregulated and 2048 downregulated in RECQL4 high\u2010amplification samples compared to their diploid counterparts (Figure S1A). Further exploration through GSEA unveiled a confluence of downregulated pathways predominantly linked to immune responses (Figure S1B\u2012I), with notable attenuation observed in allograft rejection and the complement cascade, mirroring findings from the SKCM TCGA cohort. Additionally, the impairment in lymphocyte differentiation and activation was evident in the presence of RECQL4 amplifications (Figure S1J). These findings suggest that there is a global decline in immune response in the presence of RECQL4 high amplification that persists even under ICI treatment regimens."
      ],
      "26997480": [
        "We followed the SAGER guidelines regarding sex and gender equity in research. 23 For copy number analysis, we investigated the Memorial Sloan Kettering\u2014Metastatic Events and Tropisms (MSK\u2010MET) cohort 24 including 25 775 patients spanning 50 cancer types; and the Skin Cutaneous Melanoma (SKCM) cohort from The Cancer Genome Atlas (TCGA, Firehose Legacy, RRID:SCR_003193). In these cohorts, RECQL4 copy number alterations (CNA) and available clinical data were analysed. These data were taken from the cBioPortal for cancer genomics online database 25 , 26 (https://www.cbioportal.org/, RRID:SCR_014555). For transcript level analysis, we explored the SKCM TCGA Firehose Legacy cohort and four independent cohorts consisting of ICI\u2010treated melanoma patients as formerly published in Liu et al., 27 Hugo et al., 28 Gide et al. 29 and Riaz et al. 30 From these cohorts, we selected only the samples from pre\u2010treatment biopsies with cutaneous melanoma subtype. We extracted the clinico\u2010pathological and RECQL4, MYC and MKI67 expression in transcripts per million (TPM) mapped reads data from the PhenoTImE webtool 31 (https://doc.hornlab.org/shiny/cru337phenotime/). RNA sequencing (RNA\u2010seq) expression data from TCGA (RNASeqV2) was processed and normalised using RNA\u2010seq by Expectation\u2010Maximisation to generate TPM. Table 1 shows a summary of the analysed cohorts for RECQL4 CNA and gene expression levels."
      ],
      "29033130": [
        "We followed the SAGER guidelines regarding sex and gender equity in research. 23 For copy number analysis, we investigated the Memorial Sloan Kettering\u2014Metastatic Events and Tropisms (MSK\u2010MET) cohort 24 including 25 775 patients spanning 50 cancer types; and the Skin Cutaneous Melanoma (SKCM) cohort from The Cancer Genome Atlas (TCGA, Firehose Legacy, RRID:SCR_003193). In these cohorts, RECQL4 copy number alterations (CNA) and available clinical data were analysed. These data were taken from the cBioPortal for cancer genomics online database 25 , 26 (https://www.cbioportal.org/, RRID:SCR_014555). For transcript level analysis, we explored the SKCM TCGA Firehose Legacy cohort and four independent cohorts consisting of ICI\u2010treated melanoma patients as formerly published in Liu et al., 27 Hugo et al., 28 Gide et al. 29 and Riaz et al. 30 From these cohorts, we selected only the samples from pre\u2010treatment biopsies with cutaneous melanoma subtype. We extracted the clinico\u2010pathological and RECQL4, MYC and MKI67 expression in transcripts per million (TPM) mapped reads data from the PhenoTImE webtool 31 (https://doc.hornlab.org/shiny/cru337phenotime/). RNA sequencing (RNA\u2010seq) expression data from TCGA (RNASeqV2) was processed and normalised using RNA\u2010seq by Expectation\u2010Maximisation to generate TPM. Table 1 shows a summary of the analysed cohorts for RECQL4 CNA and gene expression levels.",
        "RECQL4 impacts survival and immune checkpoint inhibitor (ICI) response and is an independent prognostic factor in melanoma patients. (A) RECQL4 expression levels (log2 transcript per millions [TPM]) across cancer entities grouped according to sample type: tumour (red), healthy (blue) and metastatic (purple) tissues. (B) RECQL4 expression levels (log2 TPM+1) comparing melanoma tumour (Skin Cutaneous Melanoma cohort from The Cancer Genome Atlas [TCGA SKCM]) and normal skin tissues (Genotype\u2010Tissue Expression [GTEx]). (C) Disease\u2010free, (E) progression\u2010free and (D and F) overall survival fraction comparing RECQL4 low\u2010 and high\u2010expression groups. (G) RECQL4 expression levels (log counts per millions [CMP]) comparing responders and non\u2010responders. (H) RECQL4 expression levels (TPM) in samples obtained prior\u2010therapy (PRE) and early during treatment (EDT, 7\u221214 days following the initiation of immunotherapy) or on\u2010treatment (ON, 23\u221229 days following the initiation of immunotherapy). (I) Forest plot for multivariate Cox proportional hazards (CoxPH) model. Each variable is displayed in a row and the corresponding number (N) of samples, hazard ratio (HR) with 95% confidence intervals (CI, in brackets), and p\u2010values are indicated. p < .05 from a log rank test was considered significant and marked in bold. Cohorts: (A) pan\u2010cancer cohort from TCGA including 33 cancer types; (B) SKCM cohort from TCGA and healthy skin data from GTEx; (C and D) SKCM TCGA; (E\u2012G, I) ICI\u2010treated melanoma cohort; (H, left) Gide et al. 29 and (H, right) Riaz et al. 30 Statistics: (A and B) Wilcoxon rank sum test, p\u2010values as indicated (* p < .05; ** p < .01; *** p < .001; ns, p > .05). (C\u2012F) Log rank test, p < .05 was considered significant. (G and H) Wilcoxon rank sum test, p\u2010values as indicated. Abbreviations of the cancer types presented in (A) can be found at https://gdc.cancer.gov/resources\u2010tcga\u2010users/tcga\u2010code\u2010tables/tcga\u2010study\u2010abbreviations.",
        "Next, we investigated the potential correlation between RECQL4 expression and patient survival. High RECQL4 expression was associated with significantly shorter DFS (p = 1.76e\u201003) and OS (p = 3.52e\u201005) in the TCGA SKCM cohort (Figure 5C,D). Interestingly, high baseline RECQL4 expression was also predictive of shorter PFS (p = 2.07e\u201002) and OS (p = 2.79e\u201004) in melanoma patients receiving immune checkpoint\u2010targeted therapy (Figure 5E,F). We also clustered patients according to the Response Evaluation Criteria In Solid Tumours (RECIST) for their response to ICI therapy. Of note, biopsies from patients who did not respond to ICI treatment (non\u2010responder, RECISTv1.1 progressive disease) presented elevated RECQL4 expression level when compared to responders (RECISTv1.1 complete response or partial response) (Figure 5G, p = .03). Finally, we asked if the immune checkpoint blockade treatment per se is able to induce a shift in RECQL4 expression in melanoma patients. For that, we chose the Gide et al. 29 and Riaz et al. 30 cohorts, as they include RNA\u2010seq data from melanoma patient biopsies prior and on\u2010treatment/after ICI\u2010directed therapy. Both cohorts confirmed that there was no shift following therapy onset, underscoring the importance of baseline RECQL4 helicase levels (Figure 5H)."
      ],
      "35120664": [
        "We followed the SAGER guidelines regarding sex and gender equity in research. 23 For copy number analysis, we investigated the Memorial Sloan Kettering\u2014Metastatic Events and Tropisms (MSK\u2010MET) cohort 24 including 25 775 patients spanning 50 cancer types; and the Skin Cutaneous Melanoma (SKCM) cohort from The Cancer Genome Atlas (TCGA, Firehose Legacy, RRID:SCR_003193). In these cohorts, RECQL4 copy number alterations (CNA) and available clinical data were analysed. These data were taken from the cBioPortal for cancer genomics online database 25 , 26 (https://www.cbioportal.org/, RRID:SCR_014555). For transcript level analysis, we explored the SKCM TCGA Firehose Legacy cohort and four independent cohorts consisting of ICI\u2010treated melanoma patients as formerly published in Liu et al., 27 Hugo et al., 28 Gide et al. 29 and Riaz et al. 30 From these cohorts, we selected only the samples from pre\u2010treatment biopsies with cutaneous melanoma subtype. We extracted the clinico\u2010pathological and RECQL4, MYC and MKI67 expression in transcripts per million (TPM) mapped reads data from the PhenoTImE webtool 31 (https://doc.hornlab.org/shiny/cru337phenotime/). RNA sequencing (RNA\u2010seq) expression data from TCGA (RNASeqV2) was processed and normalised using RNA\u2010seq by Expectation\u2010Maximisation to generate TPM. Table 1 shows a summary of the analysed cohorts for RECQL4 CNA and gene expression levels.",
        "To investigate the impact of RECQL4 gene amplification in different cancer entities, we analysed the MSK\u2010MET cohort 24 where we detected a frequency of 3.07% (792 out of 25 775 cases) for RECQL4 high amplifications. The highest frequency of RECQL4 amplification was detected in ovarian cancer (10.14%; 120 of 1183 cases), melanoma (6.04%; 69 of 1142 cases), breast cancer (5.98%; 156 of 2609 cases), prostate cancer (3.68%; 80 of 2172 cases) and colorectal cancer (3.52%; 125 of 3548 cases) (Figure 1A). Moreover, patients presenting RECQL4 high amplification showed reduced OS compared to patients with lack of RECQL4 gene amplification (Figure 1B, p = 5.02e\u201006). Furthermore, we detected a greater prevalence of RECQL4 high amplification in metastatic lesions compared to primary tumours, but also a predisposition for RECQL4 high amplification (57%) in metastases of multiple tumour entities compared to the diploid status (39%) (Figure 1C, p = 7.11e\u201024). Next, we further explored the top five cancer cohorts with RECQL4 high amplification (Figure 1A). Except for ovarian cancer and melanoma, analyses of the individual cancer cohorts revealed the dominance of RECQL4 high amplification in metastatic samples over primary tumour tissues (Figure 1D, p < .05). In addition, we performed survival analyses in these cancer cohorts to investigate whether RECQL4 high amplification correlated with patient's prognosis. Interestingly, we observed that the presence of RECQL4 high amplification was associated with reduced OS in melanoma, breast cancer and prostate cancer (Figure 1E). Furthermore, high RECQL4 amplification was consistently associated with shorter OS across different melanoma histological subtypes (cutaneous, mucosal and uveal melanoma, Figure 1F).",
        "R ECQL4 high amplification impacts disease progression and survival. (A) RECQL4 high\u2010amplification frequency across different cancer entities in the Memorial Sloan Kettering\u2014Metastatic Events and Tropisms (MSK\u2010MET) total cohort. (B) Kaplan\u2012Meier analysis for overall survival of cancer patients according to RECQL4 copy number alteration (CNA). (C) Percentage of primary and metastatic tumour samples according to RECQL4 CNA status in the total cancer cohort and (D) in the individual cancer cohorts. (E) Kaplan\u2012Meier overall survival analysis according to RECQL4 CNA status in primary and metastatic tumour samples across cancer cohorts. (F) Kaplan\u2012Meier overall survival analysis according to RECQL4 CNA status in the different melanoma subtypes. Cohort: MSK\u2010MET. 24 Statistics: (B, E and F) log rank test and (C and D) two\u2010sided Fisher's exact test, p values as indicated; p < .05 was considered significant.",
        "RECQL4 high amplification is associated with higher fraction of genome altered (FGA), but reduced microsatellite instability (MSI) and tumour mutational burden (TMB). (A) FGA, (B) MSI type and (C) proportion of TMB high cases comparing diploid and high\u2010amplified samples for the RECQL4 locus in ovarian cancer, melanoma, breast, prostate and colorectal cancers. Cohort: Memorial Sloan Kettering\u2014Metastatic Events and Tropisms (MSK\u2010MET). 24 Statistics: (A) Wilcoxon rank sum test, (B) chi\u2010squared test and (C) two\u2010sided Fisher's exact test were used to compare differences between the RECQL4 diploid and high\u2010amplified group, p\u2010values as indicated; p < .05 was considered significant.",
        "When analysing tissue characteristics of the MSK\u2010MET cohort, 24 we identified a significantly increased level of tumour purity in tumours harbouring RECQL4 high amplifications (Figure 3A, p < .05), implicating a larger fraction of cancer cells in the tumour mass. In light of these findings, we postulated that recruitment of cells from the tumour microenvironment, including cells of the immune compartment, might be constrained under conditions of elevated RECQL4 copy number. To delineate the genes and pathways that are differentially regulated in tumours with RECQL4 CNA, we grouped samples of the TCGA SKCM cohort according to the RECQL4 CNA status (diploid and high\u2010amplified) and performed gene expression analyses. We detected a total of 2136 significantly differentially expressed genes, of which 490 were upregulated and 1646 were downregulated in the samples corresponding to RECLQ4 high amplification compared to diploids (Figure 3B). According to the GSEA, strong activation of pathways in samples presenting RECQL4 high amplification were related to cell proliferation, cell cycle and DNA damage repair (MYC targets variant 1 and variant 2, E2F targets, G2M checkpoint and DNA repair) (Figure 3C). These pathways are closely linked to RECQL4 intrinsic function. Besides, RECQL4 high\u2010amplified samples also had increased metabolic activity (oxidative phosphorylation). This may be due to the expression of RECQL4 in mitochondria, which is responsible for maintaining mitochondrial DNA integrity and coping with oxidative stress. 47 , 48 Of particular note, we observed a pronounced downregulation of key signalling pathways associated with the immune response in samples exhibiting high RECQL4 amplification. These included pathways involved in allograft rejection, IFN\u2010\u03b3 and \u2010\u03b1 responses, the complement cascade, global inflammatory response, tumour necrosis factor\u2010alpha signalling via nuclear factor kappa B, IL2\u2012STAT5 signalling and IL6\u2012JAK\u2012STAT3 signalling (Figure 3D\u2012K). Moreover, employing GO Biological Process annotation, we uncovered a significant downregulation in pathways associated with lymphocyte differentiation or activation within samples exhibiting RECQL4 high amplification (Figure 3L). Intriguingly, extending our analysis to a cohort of patients undergoing ICI treatment, consistent findings emerged. 27 A total of 2180 genes exhibited significant differential expression, with 132 upregulated and 2048 downregulated in RECQL4 high\u2010amplification samples compared to their diploid counterparts (Figure S1A). Further exploration through GSEA unveiled a confluence of downregulated pathways predominantly linked to immune responses (Figure S1B\u2012I), with notable attenuation observed in allograft rejection and the complement cascade, mirroring findings from the SKCM TCGA cohort. Additionally, the impairment in lymphocyte differentiation and activation was evident in the presence of RECQL4 amplifications (Figure S1J). These findings suggest that there is a global decline in immune response in the presence of RECQL4 high amplification that persists even under ICI treatment regimens.",
        "RECQL4 high amplifications drive signatures of immune\u2010modulation. (A) Tumour purity compared between RECQL4 diploid and high\u2010amplified samples in ovarian cancer, melanoma, breast, prostate and colorectal cancers. (B) Volcano plot showing the differentially expressed genes between RECQL4 diploid versus high\u2010amplified melanoma samples. Brown and green dots represent significant genes (upregulated: brown, n = 490; downregulated: green, n = 1646) in RECQL4 high\u2010amplified samples, compared to diploid samples. (C) Top 10 upregulated (brown) and downregulated (green) pathways of the Molecular Signatures Database (MSigDB) in the RECQL4 high\u2010amplified samples compared to the diploid samples. Gene set enrichment analysis (GSEA) for individual immune\u2010related pathways involved in (D) allograft rejection, (E) interferon\u2010gamma (IFN\u2010\u03b3) response, (F) the complement system, (G) inflammatory response, (H) nuclear factor kappa B (NF\u2010\u03baB)\u2010driven tumour necrosis factor\u2010alpha (TNF\u2010\u03b1) signalling, (I) IL2\u2012STAT5 signalling, (J) IL6\u2012JAK\u2012STAT3 signalling and (K) IFN\u2010\u03b1 response; presented in the order of significance. (L) Enriched gene ontology (GO) biological processes among the downregulated gene list from (B). The dot size denotes the number of genes and dot colour represents the \u2013log10 (q\u2010value). Cohorts: (A) Memorial Sloan Kettering\u2014Metastatic Events and Tropisms (MSK\u2010MET) 24 and (B\u2012L) Skin Cutaneous Melanoma cohort from The Cancer Genome Atlas (SKCM TCGA). Statistics: (A) Wilcoxon rank sum test and (B) Student's t\u2010test were used to compare differences between the RECQL4 diploid and high\u2010amplified groups. (C\u2012K) Pathway enrichment analyses results are presented by the normalised enrichment score (NES), p\u2010value (p\u2010val) and the false discovery rate (FDR) adjusted p\u2010value corrected by Benjamini\u2013Hochberg multiple test (q\u2010value, q\u2010val); q < .05 was considered significant."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 1.1404919624328613,
    "data_pmids_checked": 4,
    "paper_id": "39812592",
    "extraction_date": "2025-12-19T20:41:34.699433",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39812592.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39833905": {
    "paper_id": "39833905",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "For all the patients, the somatic\nMutation Annotation Format (MAF) file generated from exome sequencing data\nwas downloaded from cBioPortal [48] on 23rd November 2023",
      "These additional cancer\ndatasets were downloaded from cBioPortal on 28rd October 2024",
      "Results\nDatasets\nThe combined somatic mutation file (i.e., MAF) for 502 HNSC-TCGA patients\nwas obtained from cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer\ngenomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:36.779071",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39833905.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.907341003417969,
      "cbioportal_papers": 0.00027298927307128906,
      "pdf_extraction_pass2": 12.076194047927856,
      "cbioportal_papers_pass2": 0.00033402442932128906,
      "used_full_extraction": true,
      "pdf_extraction": 22.983535051345825,
      "platform_mentions": 0.003239870071411133,
      "data_citations": 0.0001227855682373047,
      "num_data_pmids_checked": 1
    }
  },
  "39820554": {
    "paper_id": "39820554",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Results\nSIRT7 mRNA expression is dysregulated in HNSCC, and it correlates with poor patient\noverall survival (OS)\nTo investigate SIRT7 expression in tissue samples from HNSCC patients, we analyzed data from several open-\naccess databases: cBioPortal (https://www.cbioportal.org), Genomic Data Commons Data Portal ( h t t p s: / / p o r t a l",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:49.088777",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39820554.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.246375799179077,
      "cbioportal_papers": 0.0003209114074707031,
      "pdf_extraction_pass2": 9.275562047958374,
      "cbioportal_papers_pass2": 0.00032520294189453125,
      "used_full_extraction": true,
      "pdf_extraction": 18.52193784713745,
      "platform_mentions": 0.004139900207519531,
      "data_citations": 0.00011801719665527344,
      "num_data_pmids_checked": 1
    }
  },
  "39805956": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.20778417587280273,
    "data_pmids_checked": 0,
    "paper_id": "39805956",
    "extraction_date": "2025-12-19T20:41:49.296681",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39805956.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39814910": {
    "paper_id": "39814910",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "PDBsum50 (https://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/\ncbioportal.org/study/clinicalData?id=brca_metabric)37\u201340",
      "cbioportal.org/study/clinicalData?id=brca_metabric; Breast cancer pro- 15"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:49.430911",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39814910.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.071592092514038,
      "cbioportal_papers": 0.0003819465637207031,
      "pdf_extraction_pass2": 7.797487020492554,
      "cbioportal_papers_pass2": 0.0004220008850097656,
      "used_full_extraction": true,
      "pdf_extraction": 16.869079113006592,
      "platform_mentions": 0.0036401748657226562,
      "data_citations": 0.0004029273986816406,
      "num_data_pmids_checked": 3
    }
  },
  "39803868": {
    "cbioportal_paper_citations": [
      "Data to characterize genomic alterations among patients with BTCs were derived from the American Association for Cancer Research (AACR) Genomics Evidence of Neoplasia Information Exchange (GENIE) data set v15.1 through cBioPortal [12]. The GENIE database was initially launched in 2017 and currently includes somatic genomic data from approximately 170 000 patients from 19 participating institutions [12]. All institutions employ NGS assays to detect somatic mutations, structural variants (e.g., fusions), and copy number alterations (e.g., amplifications or deletions) in formalin\u2010fixed paraffin\u2010embedded tumor samples using targeted panels of varying gene numbers [12]. Adult patients diagnosed with BTCs with available NGS data were identified and included in the analytic cohort. Data from the OncoKB database, provided by cBioPortal, were utilized to determine pathogenic gene alterations, as previously described [13, 14]. Germline mutations were excluded from the analysis. Genomic variations based on the anatomic location of BTCs (i.e., GBC, iCCA, and eCCA), as well as genomic co\u2010alterations involving important oncogenic pathways for each BTC subtype were examined."
    ],
    "cbioportal_platform_mentions": [
      "An additional pan\u2010cancer database from China [15], available through cBioPortal (https://www.cbioportal.org/study/summary?id=pan_origimed_2020), was utilized to identify patients with BTCs with available NGS data. Differences in genomic profiling between Western (i.e., patients in GENIE database) and Eastern populations (i.e., Chinese pan\u2010cancer database) with different subtypes of BTCs were evaluated.",
      "Data were expressed as median (interquartile range [IQR]) and frequency (%) for continuous and categorical variables, respectively. Differences in categorical variables were assessed with the chi\u2010squared or Fisher exact tests, while differences in continuous variables were assessed with the use of the Kruskal\u2013Wallis test. The prevalence of the most frequent genomic alterations among patients with BTCs was calculated after accounting for the number of samples tested for each gene (i.e., correct denominator). Differences in the prevalence of genomic alterations among patients with different types of BTCs were calculated. To adjust for multiple hypotheses across multiple gene pairs, p values were corrected by the Benjamini\u2010Hochberg method to determine false discovery rate\u2010corrected Q values. Patterns of co\u2010occurrence and mutual exclusivity for certain pairs of variant genes were evaluated utilizing the mutual exclusivity modules statistical method from cBioportal [17] calculating log2 odds ratio to assess the direction of associations. Triangled heatmaps were generated to visualize the genetic pair associations for each BTC type. Differences in OS were assessed with the Kaplan\u2013Meier method and the log\u2010rank test. The level of statistical significance was assessed at a = 0.05. All statistical analyses were performed with the online cBioPortal platform along with the addition of JMP v17 (SAS Institute Inc., Cary, NC) statistical software.",
      "The current study is the largest analysis of patients with BTCs from multiple academic institutions worldwide and the first comprehensive evaluation of co\u2010alterations for each subtype of BTCs to date. Genomic data from the AACR GENIE database were aggregated from multiple academic centers each utilizing different NGS assays with different gene panel sets and tumor content criteria [12]. The use of cBioPortal platform allowed us to retrieve the actual number of patients tested for each gene (i.e., correct denominator), and calculate mutational frequency of certain genes accurately [17]. However, the genomic databases utilized in the context of this study lacked detailed information regarding patient\u2010level characteristics including comorbidities, obesity, smoking, etiology of disease. Thus, the association of these factors with certain genomic profiles among Western vs. Eastern populations could not be assessed. Given the lack of detailed information on cancer stage and treatment characteristics, the prognostic impact of these factors among BTC individuals with certain genomic signatures could also not be assessed. In addition, due to the limited number of patients with KRAS\u2010mutant eCCA and HER2\u2010mutant GBC, the impact of co\u2010alterations among patients with these tumors could not be determined. Future prospective studies will be required to validate our findings and investigate the therapeutic potential of combination targeted therapies in different BTC subtypes."
    ],
    "data_publication_citations": {
      "28667006": [
        "Previous research has demonstrated that iCCA, eCCA, and GBC are biologically distinct entities [7, 18]. In a comprehensive analysis of whole exome and transcriptome sequencing of 260 patients with BTCs, Nakamura et al. identified IDH1 mutations in 20% of iCCA cases and FGFR2 fusions in 14% of cases [7]. Prior genomic analyses reported by Jusakul et al. demonstrated KRAS mutations in 37.8% of eCCA cases and ERBB2 amplifications in 11% of GBC cases [18]. These data were consistent with findings in the current study, which serve to highlight the varying prevalence of certain genetic mutations across BTC subtypes. Beyond the anatomic\u2010based variations in genomic profiles, the current study also demonstrated marked geographic variation in the genomic signatures of BTCs. While TP53 and TERT mutations were more commonly observed in Eastern populations across all BTC subtypes, a higher prevalence of IDH1, FGFR2, and BAP1 alterations were noted among Western populations. Although the reason behind these marked variations was likely multifactorial, differences in genomic profiles of Eastern vs. Western populations with BTCs might reflect differences in the etiology and pathogenesis of these diseases at different geographical locations [19, 20]. For example, in Southeast Asia, the liver fluke Opisthorchis viverrini is the leading cause of CCA, whereas in Western countries primary sclerosing cholangitis and nonalcoholic fatty liver disease (NAFLD) represent the main risk factors for the development of CCA [1]. Interestingly, prior research has demonstrated that TP53 and ARID1A mutations are highly enriched in fluke\u2010related CCAs, whereas BAP1 and IDH1/2 mutations are highly enriched in non\u2010fluke\u2010related CCAs [1]. These findings likely suggest potential regional environmental factors that influence trends related to different mutations. In turn, the data highlight the importance of considering geographic and ethnic backgrounds when developing targeted therapies for BTCs."
      ],
      "35120664": [
        "Another large clinical\u2010genomic pan\u2010cancer database [16] from the Memorial Sloan Kettering Cancer Center (MSKCC) was utilized to assess the impact of certain genomic profiles of BTCs on long\u2010term outcomes. Because all data originated from publicly available de\u2010identified databases, the present study was deemed exempt from the Institutional Review Board of the Ohio State University.",
        "The MSKCC MetTropism database [16] (Table S1) was further interrogated to identify individuals with IDH1\u2010mutant (n = 95 out of 407 iCCA samples), as well as FGFR2\u2010rearranged iCCA (n = 58 out of 407 iCCA samples). Patients with FGFR2\u2010rearranged iCCA harboring co\u2010alterations in the TP53 pathway or the PI3K pathway had worse OS compared with iCCA patients with FGFR2 fusions/rearrangements without these co\u2010alterations (FGFR2 fusion/TP53 pathway altered vs. FGFR2 fusion/TP53 pathway unaltered; median OS: 5.4 [95% CI: 4.3\u2010NA] vs. 26.6 [95% CI: 17.8\u2010NA] months, p = 0.031; FGFR2 fusion/PI3K pathway altered vs. FGFR2 fusion/PI3K pathway unaltered; median OS: 4.3 [95% CI: 1.9\u2010NA] vs. 26.6 [19.7\u2010NA] months, p < 0.001) (Figure 3A,B). In contrast, patients with both FGFR2 alterations and co\u2010alterations in cell cycle or RTK\u2010MAPK pathways had comparable outcomes with patients who did not have these co\u2010altered pathways (FGFR2 fusion/cell cycle pathway altered vs. FGFR2 fusion/cell cycle pathway unaltered; median OS: 19.7 [95% CI: 4.4\u2010NA] vs. 26.6 [95% CI: 17.2\u2010NA] months, p = 0.457; FGFR2 fusion/RTK\u2010MAPK pathway altered vs. FGFR2 fusion/RTK\u2010MAPK pathway unaltered; median OS: 17.8 [95%CI 8.5\u2010NA] vs. 25.2 [95%CI 15.4\u2010NA] months, p = 0.702, Figure 3C,D). Furthermore, patients with IDH1\u2010mutant iCCA and co\u2010alterations in the cell cycle pathway had shorter OS compared with individuals without these co\u2010alterations (median OS: 11.9 [95% CI: 8.08\u2010NA] vs. 19.4 [95% CI: 12.2\u201330.4] months, p = 0.036 (Figure 4A); co\u2010alterations in any other pathways were not associated with worse long\u2010term outcomes (Figure 4B\u2013D)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 1.1476080417633057,
    "data_pmids_checked": 3,
    "paper_id": "39803868",
    "extraction_date": "2025-12-19T20:41:50.578862",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39803868.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39820840": {
    "paper_id": "39820840",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "and Clinical Profiles Using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:50.609670",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39820840.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.946334838867188,
      "cbioportal_papers": 0.0005018711090087891,
      "pdf_extraction_pass2": 11.018694877624512,
      "cbioportal_papers_pass2": 0.0005590915679931641,
      "used_full_extraction": true,
      "pdf_extraction": 21.9650297164917,
      "platform_mentions": 0.01079702377319336,
      "data_citations": 0.00019311904907226562,
      "num_data_pmids_checked": 1
    }
  },
  "39802400": {
    "cbioportal_paper_citations": [
      "The Overall Survival plot was created using clinical datasets [[42], [43], [44], [45], [46]] deposited in the cBioPortal [47,48], covering a total of 3065 patients over a 30-year follow-up."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "30867590": [
        "The Overall Survival plot was created using clinical datasets [[42], [43], [44], [45], [46]] deposited in the cBioPortal [47,48], covering a total of 3065 patients over a 30-year follow-up."
      ],
      "22522925": [
        "The Overall Survival plot was created using clinical datasets [[42], [43], [44], [45], [46]] deposited in the cBioPortal [47,48], covering a total of 3065 patients over a 30-year follow-up."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.46375203132629395,
    "data_pmids_checked": 4,
    "paper_id": "39802400",
    "extraction_date": "2025-12-19T20:41:51.073508",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39802400.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39808498": {
    "paper_id": "39808498",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Mitchell D, et al. ALK1-Fc inhibits multiple cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:41:53.035857",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39808498.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.298527002334595,
      "cbioportal_papers": 0.0003681182861328125,
      "pdf_extraction_pass2": 7.934586048126221,
      "cbioportal_papers_pass2": 0.0003619194030761719,
      "used_full_extraction": true,
      "pdf_extraction": 16.233113050460815,
      "platform_mentions": 0.003437042236328125,
      "data_citations": 0.0002460479736328125,
      "num_data_pmids_checked": 2
    }
  },
  "39771050": {
    "cbioportal_paper_citations": [
      "The PER3 genome changes were analyzed using cBioPortal (https://www.cbioportal.org/; accessed on 11 January 2024) [19,20] in three datasets: Mayo Clinic, Clinical Cancer Research 2020; CPTAC, Cell 2021; and TCGA, Firehose Legacy. The prognostic significance of PER3 gene alterations was determined by K-M survival curve analysis and log-rank test. A p-value of less than 0.05 was used as the criterion for a significant difference."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625055": [
        "The clinical diagnosis of glioblastoma primarily depends on imaging measures, such as CT and MRI. In early diagnosis, diagnostic ROC curves are often used to determine the diagnostic value of a particular factor for the disease and to assess the predictive accuracy, which reflects the relationship between sensitivity and specificity. This study analyzed the diagnostic value of PER3 in GBM by selecting two molecular pathology indicators of GBM from the Glioma Diagnostic and Treatment Guidelines and analyzing the ROC curves together with PER3 as a diagnostic factor. BRAF has been reported to occur in various gliomas [43], and EGFR is one of the diagnostic indicators of grade 4 GBM of the WHO [44]. Both are potential targets for targeted therapy of GBM. Both PER3 and EGFR are potential targets for glioblastoma-targeted therapy. The area under the curve (AUC) is usually taken between 0.5 and 1, with a value closer to 1 indicating greater diagnostic predictiveness. Figure 9A shows that the AUC values of PER3, BEAF, and EGFR are all above 0.9. Additionally, the AUC values of PER3 for predicting the survival rate of GBM patients at both 5 and 7 years are greater than 0.7. These data further suggest that PER3 is a potential diagnostic and prognostic biomarker for GBM [45]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6466770172119141,
    "data_pmids_checked": 1,
    "paper_id": "39771050",
    "extraction_date": "2025-12-19T20:41:53.696166",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39771050.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39810024": {
    "paper_id": "39810024",
    "cbioportal_paper_citations": [
      "[PubMed: 23550210]\n37"
    ],
    "cbioportal_platform_mentions": [
      "Related links\nCancer Hotspots: https://www.cancerhotspots.org/#/home\ncBioPortal: https://www.cbioportal.org\nCIVIC: https://civicdb.org/welcome\nGenomic Data Commons: https://gdc.cancer.gov/\nInternational Cancer Genome Consortium (ICGC): https://dcc.icgc.org/\nOncoKB: https://www.oncokb.org/\nThe Cancer Genome Atlas (TCGA): https://www.cancer.gov/ccg/research/genome-sequencing/tcga\nAdditional information\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with\nthe author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the\nterms of such publishing agreement and applicable law",
      "1 was created using\ncBioPortal (https://www.cbioportal.org)36 based on the TCGA Pan-Cancer Atlas data",
      "Gao J et al. Integrative analysis of complex cancer genomics and clinical profiles using the\ncBioPortal",
      "The plots were created using cBioPortal based on The Cancer Genome Atlas\nPan-Cancer Atlas data"
    ],
    "data_publication_citations": {
      "22610119": [
        "[PubMed: 22610119]\n45"
      ],
      "29625049": [
        "[PubMed: 29625049]\n7"
      ],
      "29617662": [
        "[PubMed: 29617662]\n256"
      ],
      "29625050": [
        "[PubMed: 29625050]\n25"
      ],
      "26544944": [
        "[PubMed: 26544944]\n46"
      ],
      "32025007": [
        "[PubMed: 32025007]\n34"
      ]
    },
    "extraction_date": "2025-12-19T20:41:53.850085",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39810024.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 6,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.923274278640747,
      "cbioportal_papers": 0.0002696514129638672,
      "pdf_extraction_pass2": 12.124943256378174,
      "cbioportal_papers_pass2": 0.006567955017089844,
      "used_full_extraction": true,
      "pdf_extraction": 19.04821753501892,
      "platform_mentions": 0.009147882461547852,
      "data_citations": 0.05636906623840332,
      "num_data_pmids_checked": 6
    }
  },
  "39768811": {
    "paper_id": "39768811",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "TodeterminethemutationalfeaturesofDSCC1,\ncBioPortal was used in a previous study for comparative analysis"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:42:05.934119",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39768811.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.257791042327881,
      "cbioportal_papers": 0.00020885467529296875,
      "pdf_extraction_pass2": 5.9606781005859375,
      "cbioportal_papers_pass2": 0.00020885467529296875,
      "used_full_extraction": true,
      "pdf_extraction": 12.218469142913818,
      "platform_mentions": 0.001583099365234375,
      "data_citations": 0.0001480579376220703,
      "num_data_pmids_checked": 2
    }
  },
  "39766808": {
    "cbioportal_paper_citations": [
      "The cBioPortal for cancer genomics (http://www.cbioportal.org (accessed on 20 May 2024)) offers an extensive collection of information, including somatic mutations, copy number alterations, gene expression profiles, DNA methylation patterns, and protein enrichment data. This research investigated if changes in HTGPCRs influenced patient survival rates, using data from the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium 2020. Furthermore, the analysis examined variations in the copy number variation (CNV) of various cancer types as well as variations in single nucleotide variation (SNV) [26]."
    ],
    "cbioportal_platform_mentions": [
      "During our extensive exploration of the HTGPCR gene family in different types of cancers, we have identified notable genomic changes within its members. By utilizing the cBioPortal database, we conducted a thorough evaluation of mutations, copy number variations (CNVs), and single nucleotide variants (SNVs) within the HTGPCR family from a pan-cancer perspective. Our integrative analysis, which encompassed 2683 whole-cancer genomes and their corresponding normal tissues across 38 tumor types, revealed that the HTGPCR gene family was altered in 24.45% of the 2658 cases studied. The alterations were distributed among various HTGPCR genes, with HTR1A showing a 4% alteration rate, HTR1B at 2.2%, HTR1D at 1.3%, and so forth, culminating in HTR7 with a 1.8% alteration rate (Figure 4A,B)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2783772945404053,
    "data_pmids_checked": 0,
    "paper_id": "39766808",
    "extraction_date": "2025-12-19T20:42:06.232119",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39766808.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39766794": {
    "cbioportal_paper_citations": [
      "The survival maps and Kaplan\u2013Meier curves of overall survival (OS) and disease-free survival (DFS, also called relapse-free survival, RFS) of CD276 in pan-cancer from the TCGA and the GTEx databases were obtained from the \u201cSurvival Analysis\u201d module of the GEPIA2 web server (http://gepia2.cancer-pku.cn/#analysis) (accessed on 10 October 2023) [20]. The web-based tool Kaplan\u2013Meier plotter (http://kmplot.com/analysis/ (accessed on 10 October 2023) ) [22] was used to generate the OS for breast cancer, ovarian cancer, lung cancer, gastric cancer, and liver cancer from the GEO, EGA, and TCGA databases. Herein, cBioPortal (http://www.cbioportal.org/ (accessed on 10 October 2023)) [23,24] was used to explore the effect of CD276 mutation on the OS, DFS, disease-specific survival (DSS), and progression-free survival (PFS) of patients with skin cutaneous melanoma (SKCM), uterine corpus endometrial carcinoma (UCEC), or colorectal adenocarcinoma (COAD). The genomic alteration analysis of CD276 was conducted through the cBioPortal web resource (https://www.cbioportal.org/ (accessed on 10 October 2023)) [23,24]. In brief, we obtained the genomic alteration frequency and alteration type of CD276 in pan-cancer from the \u201cCancer Types Summary\u201d module. Via the \u201cMutations\u201d module, we analyzed the spatial distribution of each mutation site, the case number of the CD276 mutation, and the proportion of each cancer species in patients with CD276 mutation. Moreover, the 3D structure of CD276 was generated by the \u201cMutations\u201d module and the site with the most frequent mutation was marked.",
      "To explore the relationship between the expression of CD276 and the prognosis of patients, we employed the GEPIA2 web server [20] and the Kaplan\u2013Meier plotter [22] and found that increased expression of CD276 forecasted a shorter OS in patients with ACC, BRCA, BLCA, COAD, HNSC, LAML, LGG, LIHC, LUAD, MESO (Mesothelioma), gastric cancer, and ovarian cancer, and a shorter DFS in patients with ACC, GBM, LGG, and PAAD (Figure 2A,B and Figure S3A). However, DLBC (Diffuse Large B-Cell Lymphoma) showed an opposing trend compared to ACC, GBM, LGG, and PAAD, which warrants further investigation. To explore the genomic alteration of CD276 in pan-cancer, the cBioPortal web resource [23,24] was used. As shown in Figure 3A, patients with SKCM had the highest genomic alteration frequency, followed by MESO, UCEC, and KICH. The detailed spatial distribution and case number of each mutation site of CD276 are presented in Figure 3B. We found that R92C/H alteration within the V-set domain was the most common. The 3D structure of CD276 with R92 site labeling is displayed in Figure 3C. Among all patients with mutations in CD276, patients with UCEC, COAD, and SKCM accounted for the highest proportion (Figure 3D). Subsequently, we explored the impact of CD276 mutations on the OS, DFS, DSS, and PFS of patients with SKCM, UCEC, or COAD. The results showed that the survival time of patients with CD276 mutations tended to be prolonged, but there was no significant difference (Figure S3B). Collectively, the increased expression of CD276 in tumor tissue promotes tumor progression, and targeting CD276 might be able to prolong the survival time of patients."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.7281379699707031,
    "data_pmids_checked": 0,
    "paper_id": "39766794",
    "extraction_date": "2025-12-19T20:42:07.011691",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39766794.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39779746": {
    "paper_id": "39779746",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The hypoxia\nscore of KIRC was acquired from cBioPortal (https://www.cbioportal.org/)30",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:42:07.123958",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39779746.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.236027002334595,
      "cbioportal_papers": 0.00034809112548828125,
      "pdf_extraction_pass2": 9.219612836837769,
      "cbioportal_papers_pass2": 0.0003287792205810547,
      "used_full_extraction": true,
      "pdf_extraction": 16.455639839172363,
      "platform_mentions": 0.004155158996582031,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39766115": {
    "cbioportal_paper_citations": [
      "One final consideration in the molecular subtyping of VSCC is that HPV high-risk-negative p53abn VSCC may show both an immunohistochemical overexpression of p16 and a mutant-pattern p53 expression, which is so-called double positivity. The frequency of these cases ranges from 0% [22,52] to 4.2% [14] and 6.8% [53] and may be underestimated at this time. With regard to the mechanism of double positivity, p16 is frequently overexpressed in high-grade serous ovarian cancer, and <1% of these tumors harbor a CDKN2A mutation, so p16 overexpression is thought to be secondary to dysregulation and to underlying p53 and/or Rb mutations [54]. In VSCC, Yang et al. [14] reported a CDKN2A (frameshift) mutation in two out of five of their double-positive cases. Clearly, the reason for double-positive staining in VSCC requires further research, but the small number of cases reported to date suggests that the combination of p16 positivity and mutant-pattern p53 staining is usually seen in HPVi p53abn VSCC. The molecular subclassification of VSCC is summarized in Figure 5."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1940310001373291,
    "data_pmids_checked": 0,
    "paper_id": "39766115",
    "extraction_date": "2025-12-19T20:42:07.230594",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39766115.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39764216": {
    "cbioportal_paper_citations": [
      "The TCGA data of selected transcripts were downloaded from XenaBrowser University of California, Santa Cruz, cohort: TCGA Melanoma (SKCM), cBioportal (Gao et al., 2013[17]), UALCAN (Chandrashekar et al., 2017) and ENCORI (Li et al., 2014[40]) databases. Full patient characteristics are presented in Supplementary Table 1. All data from XenaBrowser were available online, with unrestricted access, and patient consent is not required. The use of the data does not violate the rights of any person or any institution (Kolenda et., 2024[35])."
    ],
    "cbioportal_platform_mentions": [
      "The datasets used during the current study are available online from XenaBrowser University of California, Santa Cruz, cohort: TCGA Melanoma (SKCM), cBioportal, UALCAN and ENCORI databases, or from the corresponding author on reasonable request."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.16446995735168457,
    "data_pmids_checked": 0,
    "paper_id": "39764216",
    "extraction_date": "2025-12-19T20:42:07.414124",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39764216.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39765187": {
    "cbioportal_paper_citations": [
      "Among patients with TMB-H mCRC, pembrolizumab efficacy significantly differed between MSI-H-TMB-H and MSS-TMB-H cases (Figure 1, Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2024.104108). Pembrolizumab also did not demonstrate superior efficacy relative to other non-ICI treatments in patients with MSS-TMB-H mCRC (Figure 2). To investigate mechanisms underlying this difference in pembrolizumab sensitivity, we subsequently analyzed the genomic profiles of CRCs. Between June 2019 and February 2024, a total of 6751 patients diagnosed with colorectal or appendiceal adenocarcinoma, with identified TMB value and MSI status through tissue-based CGP testing, were extracted from the C-CAT repository (Supplementary Figure S1C, available at https://doi.org/10.1016/j.esmoop.2024.104108). Among them, 14 cases with goblet cell carcinoid were excluded because this tumor type requires different chemotherapy agents than colorectal adenocarcinoma. The remaining 6737 patients were categorized into four groups based on MSI and TMB status: 6350 (94.3%) were MSS and TMB-low (TMB-L), 310 (4.6%) were MSS and TMB-H, 77 (1.1%) were MSI-H and TMB-H, and none (0%) were MSI-H and TMB-L (Supplementary Figure S1C, available at https://doi.org/10.1016/j.esmoop.2024.104108). The distribution of genomic alterations among the three groups is shown in Figure 4A. TMB values were significantly lower in MSS-TMB-H CRC compared with MSI-H-TMB-H CRC (median 11 muts/Mb versus 52 muts/Mb, P < 0.0001, Figure 4B). Among MSS-TMB-H CRCs, 295 cases (95%) had TMB values <20 muts/Mb, while only 8 cases (2.6%) had TMB >100 muts/Mb. Pathogenic variants of POLE referenced from OncoKB14 were detected in all eight of these hypermutated cases except one. We subsequently compared the frequency of pathogenic alterations among the three groups for the 71 genes that were commonly analyzed by both FoundationOne CDx and the NCC Oncopanel, and for which pathogenic alterations were detected in at least 3% of cases in one or more of the three groups. The list of the 71 genes and their frequencies of pathogenic alterations is shown in Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2024.104108. Comparing MSS-TMB-H with MSI-H-TMB-H, 38 of 71 genes (54%) were more frequently altered in MSI-H-TMB-H (Figure 4C). In contrast, only TP53, APC, and KRAS were frequently altered in MSS-TMB-H (Figure 4C). Comparing MSS-TMB-H with MSS-TMB-L, genes such as POLE, MSH2, BRCA1, and PBRM1 were more frequently altered in MSS-TMB-H (Figure 4D). Only 10 of 71 genes (14%) showed significant frequency differences, far fewer than in MSS-TMB-H versus MSI-H-TMB-H (Figure 4E). Hypermutated CRCs with pathogenic POLE mutations are considered a distinct subtype among MSS-TMB-H CRC.16 Similar analyses excluding seven pathogenic POLE-mutated cases yielded consistent findings, with 33 of 70 genes (47%) showing significant alteration-rate differences between MSS-TMB-H and MSI-H-TMB-H (Figure 4F and H), but we observed no significant differences in alteration frequency between MSS-TMB-H and MSS-TMB-L (0/70 genes; Figure 4G and H). Overall, MSS-TMB-H CRC exhibited significantly lower TMB values and fewer pathogenic alterations compared with MSI-H-TMB-H CRC. MSS-TMB-H and MSS-TMB-L CRCs displayed similar genomic profiles, particularly when pathogenic POLE-mutant cases were excluded.Figure 4Comprehensive analysis of genomic features in 6737 CRC cases. (A) OncoPrint representation of mutations, copy number alterations, and translocations in key driver genes across MSS-TMB-L, MSS-TMB-H, and MSI-H-TMB-H CRCs, generated via cBioPortal.34,35 (B) TMB distribution across the three groups stratified by TMB and MSI status. Red dots represent the cases with POLE pathogenic mutations. (C, D) Volcano plots showing differential gene alteration analysis of 71 genes in MSI-H-TMB-H CRC relative to MSS-TMB-H CRC (C), and in MSS-TMB-L CRC relative to MSS-TMB-H CRC (D). (E) Bar plots comparing frequencies of significantly altered genes (P < 0.05) among the 71 genes analyzed in Figure 4C and D. (F, G) Volcano plots of differential gene alteration analysis (excluding POLE mutations) of 70 genes in MSI-H-TMB-H CRC relative to MSS-TMB-H CRC (F), and in MSS-TMB-L CRC relative to MSS-TMB-H CRC (G). Seven patients with POLE pathogenic mutations were excluded. (H) Bar plots comparing frequencies of significantly altered genes (P < 0.05) among the 70 genes analyzed in Figure 4F and G. CRC, colorectal cancer; MSI-H, microsatellite instability-high; MSS, microsatellite-stable; TMB-H, tumor mutational burden-high; TMB-L, TMB-low.",
      "Comprehensive analysis of genomic features in 6737 CRC cases. (A) OncoPrint representation of mutations, copy number alterations, and translocations in key driver genes across MSS-TMB-L, MSS-TMB-H, and MSI-H-TMB-H CRCs, generated via cBioPortal.34,35 (B) TMB distribution across the three groups stratified by TMB and MSI status. Red dots represent the cases with POLE pathogenic mutations. (C, D) Volcano plots showing differential gene alteration analysis of 71 genes in MSI-H-TMB-H CRC relative to MSS-TMB-H CRC (C), and in MSS-TMB-L CRC relative to MSS-TMB-H CRC (D). (E) Bar plots comparing frequencies of significantly altered genes (P < 0.05) among the 71 genes analyzed in Figure 4C and D. (F, G) Volcano plots of differential gene alteration analysis (excluding POLE mutations) of 70 genes in MSI-H-TMB-H CRC relative to MSS-TMB-H CRC (F), and in MSS-TMB-L CRC relative to MSS-TMB-H CRC (G). Seven patients with POLE pathogenic mutations were excluded. (H) Bar plots comparing frequencies of significantly altered genes (P < 0.05) among the 70 genes analyzed in Figure 4F and G. CRC, colorectal cancer; MSI-H, microsatellite instability-high; MSS, microsatellite-stable; TMB-H, tumor mutational burden-high; TMB-L, TMB-low."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "28481359": [
        "Among patients with TMB-H mCRC, pembrolizumab efficacy significantly differed between MSI-H-TMB-H and MSS-TMB-H cases (Figure 1, Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2024.104108). Pembrolizumab also did not demonstrate superior efficacy relative to other non-ICI treatments in patients with MSS-TMB-H mCRC (Figure 2). To investigate mechanisms underlying this difference in pembrolizumab sensitivity, we subsequently analyzed the genomic profiles of CRCs. Between June 2019 and February 2024, a total of 6751 patients diagnosed with colorectal or appendiceal adenocarcinoma, with identified TMB value and MSI status through tissue-based CGP testing, were extracted from the C-CAT repository (Supplementary Figure S1C, available at https://doi.org/10.1016/j.esmoop.2024.104108). Among them, 14 cases with goblet cell carcinoid were excluded because this tumor type requires different chemotherapy agents than colorectal adenocarcinoma. The remaining 6737 patients were categorized into four groups based on MSI and TMB status: 6350 (94.3%) were MSS and TMB-low (TMB-L), 310 (4.6%) were MSS and TMB-H, 77 (1.1%) were MSI-H and TMB-H, and none (0%) were MSI-H and TMB-L (Supplementary Figure S1C, available at https://doi.org/10.1016/j.esmoop.2024.104108). The distribution of genomic alterations among the three groups is shown in Figure 4A. TMB values were significantly lower in MSS-TMB-H CRC compared with MSI-H-TMB-H CRC (median 11 muts/Mb versus 52 muts/Mb, P < 0.0001, Figure 4B). Among MSS-TMB-H CRCs, 295 cases (95%) had TMB values <20 muts/Mb, while only 8 cases (2.6%) had TMB >100 muts/Mb. Pathogenic variants of POLE referenced from OncoKB14 were detected in all eight of these hypermutated cases except one. We subsequently compared the frequency of pathogenic alterations among the three groups for the 71 genes that were commonly analyzed by both FoundationOne CDx and the NCC Oncopanel, and for which pathogenic alterations were detected in at least 3% of cases in one or more of the three groups. The list of the 71 genes and their frequencies of pathogenic alterations is shown in Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2024.104108. Comparing MSS-TMB-H with MSI-H-TMB-H, 38 of 71 genes (54%) were more frequently altered in MSI-H-TMB-H (Figure 4C). In contrast, only TP53, APC, and KRAS were frequently altered in MSS-TMB-H (Figure 4C). Comparing MSS-TMB-H with MSS-TMB-L, genes such as POLE, MSH2, BRCA1, and PBRM1 were more frequently altered in MSS-TMB-H (Figure 4D). Only 10 of 71 genes (14%) showed significant frequency differences, far fewer than in MSS-TMB-H versus MSI-H-TMB-H (Figure 4E). Hypermutated CRCs with pathogenic POLE mutations are considered a distinct subtype among MSS-TMB-H CRC.16 Similar analyses excluding seven pathogenic POLE-mutated cases yielded consistent findings, with 33 of 70 genes (47%) showing significant alteration-rate differences between MSS-TMB-H and MSI-H-TMB-H (Figure 4F and H), but we observed no significant differences in alteration frequency between MSS-TMB-H and MSS-TMB-L (0/70 genes; Figure 4G and H). Overall, MSS-TMB-H CRC exhibited significantly lower TMB values and fewer pathogenic alterations compared with MSI-H-TMB-H CRC. MSS-TMB-H and MSS-TMB-L CRCs displayed similar genomic profiles, particularly when pathogenic POLE-mutant cases were excluded.Figure 4Comprehensive analysis of genomic features in 6737 CRC cases. (A) OncoPrint representation of mutations, copy number alterations, and translocations in key driver genes across MSS-TMB-L, MSS-TMB-H, and MSI-H-TMB-H CRCs, generated via cBioPortal.34,35 (B) TMB distribution across the three groups stratified by TMB and MSI status. Red dots represent the cases with POLE pathogenic mutations. (C, D) Volcano plots showing differential gene alteration analysis of 71 genes in MSI-H-TMB-H CRC relative to MSS-TMB-H CRC (C), and in MSS-TMB-L CRC relative to MSS-TMB-H CRC (D). (E) Bar plots comparing frequencies of significantly altered genes (P < 0.05) among the 71 genes analyzed in Figure 4C and D. (F, G) Volcano plots of differential gene alteration analysis (excluding POLE mutations) of 70 genes in MSI-H-TMB-H CRC relative to MSS-TMB-H CRC (F), and in MSS-TMB-L CRC relative to MSS-TMB-H CRC (G). Seven patients with POLE pathogenic mutations were excluded. (H) Bar plots comparing frequencies of significantly altered genes (P < 0.05) among the 70 genes analyzed in Figure 4F and G. CRC, colorectal cancer; MSI-H, microsatellite instability-high; MSS, microsatellite-stable; TMB-H, tumor mutational burden-high; TMB-L, TMB-low."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3197970390319824,
    "data_pmids_checked": 1,
    "paper_id": "39765187",
    "extraction_date": "2025-12-19T20:42:07.462351",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39765187.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39762969": {
    "paper_id": "39762969",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2e): Originating from and popularized by\ncBioPortal, OncoPrint serves as a composable visualization to jointly visualize muta-\ntion events and expression profiles in patients",
      "The mutation dataset is accessible from cBioportal with the name of Breast Invasive Carcinoma\n(TCGA, PanCancer Atlas) [12]",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics\nand clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:42:13.301152",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39762969.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 2.364504098892212,
      "cbioportal_papers": 6.985664367675781e-05,
      "pdf_extraction_pass2": 3.4895408153533936,
      "cbioportal_papers_pass2": 6.794929504394531e-05,
      "used_full_extraction": true,
      "pdf_extraction": 5.8540449142456055,
      "platform_mentions": 0.03265118598937988,
      "data_citations": 5.245208740234375e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39768557": {
    "paper_id": "39768557",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "AllprimaryanalyseswereperformedbasedondatacontainedinthecBioportalfor\nCancerGenomicssite(www.cbioportal.org,accessedon11October2024)[26,27]",
      "cBioportal necessitates\nminimalbioinformaticsexpertiseforaccessandnavigation[26,27]",
      "Genomic\ntric TCGA cohort, as well as the studies of other cancer cohorts performed by TCGA, is\ncharacteristics of the entire TCGA (The Cancer Genome Atlas) gastric cohort and of the groups\nthat they have included whole exome sequencing, which allows analysis of genes that are\nwithnoCDX2induction(mRNAexpressionzscorerelativetoallsamples<\u22121)andCDX2induced\nnot typically included in the limited targeted sequencing used by other investigators and\n(mRNAexpressionzscorerelativetoallsamples>0;TableS3.MutationsinDNADamageResponse\nare publicly available in cBioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:42:16.714955",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39768557.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.332389116287231,
      "cbioportal_papers": 0.0003509521484375,
      "pdf_extraction_pass2": 13.526366233825684,
      "cbioportal_papers_pass2": 0.0003609657287597656,
      "used_full_extraction": true,
      "pdf_extraction": 22.858755350112915,
      "platform_mentions": 0.0037050247192382812,
      "data_citations": 0.00025391578674316406,
      "num_data_pmids_checked": 2
    }
  },
  "39761954": {
    "cbioportal_paper_citations": [
      "The mRNA expression profiles and corresponding clinicopathological information for 552 EC and 35 normal samples were downloaded from the Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/) database. The TIMER website (http://timer.cistrome.org/) was used to evaluate the differential expression of IGFBP2 in tumor and normal samples among 32 cancer types in the TCGA database [32]. Genetic alterations of IGFBP2 in these cancer types were analyzed via the cBioPortal website (www.cbioportal.org) [33]. Expression differences between TCGA\u2010EC and normal samples were analyzed using the \u201climma\u201d package in R software (version 4.3.1). The correlation between the clinical characteristics of EC patients and IGFBP2 expression was analyzed and visualized using the \u201cggplot2\u201d package. Survival analysis and visualization were performed using the \u201csurvival\u201d and \u201csurvminer\u201d packages in R software, with the quartile of IGFBP2 expression level as the cut\u2010off point. IGFBP2 and PKM2 protein levels in EC tissues from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database were analyzed through an online tool (http://ualcan.path.uab.edu/index.html)."
    ],
    "cbioportal_platform_mentions": [
      "Analysis of TCGA datasets via the cBioPortal database revealed that IGFBP2 was mutated and amplified in EC (Figure 1A). Examination of IGFBP2 expression across 33 cancer types in the TCGA cohort demonstrated that IGFBP2 was significantly differentially expressed in 23 cancer types (Figure 1B). IGFBP2 mRNA levels were significantly increased in the tumor tissues of EC patients and correlated with higher tumor grades (Figure 1C,D). Besides, IGFBP2 protein expression in EC tissues was evaluated and correlation with tumor stages in the CPTAC dataset (Figure 1E,F). Also, Kaplan\u2013Meier survival analysis revealed that high mRNA expression of IGFBP2 was closely related to poor clinical outcomes in EC patients (Figure 1G). Moreover, in tumor tissues and adjacent tissues of EC patients collected at our hospital, the mRNA and protein levels of IGFBP2 were significantly higher in tumor tissues than those in adjacent tissues (Figure 1H\u2013J and Figure S1). Further Chi\u2010square test analysis demonstrated that IGFBP2 expression levels were significantly associated with FIGO (Federation International of Gynecology and Obstetrics) stage and lymphatic metastasis in EC patients (Table 1).",
      "Clinical relevance of IGFBP2 in EC. (A) Genomic profiling of IGFBP2 across various human cancers determined using cBioPortal. (B) Analysis of IGFBP2 expression in normal and tumor tissues from the TCGA cohort, including 33 cancer types such as UCEC. (C) Higher IGFBP2 expression in EC tissues compared to normal tissues (TCGA database). (D) Correlation between IGFBP2 expression and tumor grade in EC patients (TCGA database). (E) Protein expression of IGFBP2 in EC and normal tissues analyzed using CPTAC database. (F) Protein expression of IGFBP2 in normal tissues and subgroups of patients with EC stratified based on tumor stage (CPTAC database). (G) The overall survival curves indicating that IGFBP2 predicts poor prognosis for EC (TCGA database). (H) Upregulation of IGFBP2 mRNA in EC tissues (n = 57) compared to adjacent normal tissues (n = 40) as measured by qRT\u2010PCR. (I) IGFBP2 expression levels in primary EC samples (n = 47) and normal tissues (n = 14) determined by IHC assay (magnification: \u00d7200, scale bar: 50 \u03bcm). (J) Western blot analysis of IGFBP2 protein expression in EC patients (n = 8). *p < 0.05; **p < 0.01; ***p < 0.001."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.26771092414855957,
    "data_pmids_checked": 0,
    "paper_id": "39761954",
    "extraction_date": "2025-12-19T20:42:17.002382",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39761954.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39761726": {
    "cbioportal_paper_citations": [
      "We first queried the Liver Hepatocellular Carcinoma (LIHC) dataset from TCGA to download RNA expression and copy number data using cBioportal.43,44 We calculated the frequency of copy-number amplification and mRNA up-regulation across all genes and generated the chromosome plots using the KaryoploteR package in R. We identified all 104 genes that were up-regulated in at least 40% of HCCs with a Z-score of \u22651.5. Next, we further filtered the gene list to include all genes with a copy-number amplification (defined as an amplification event with many copies44) in \u226510% of HCCs to identify 51 genes that were both amplified and up-regulated in HCC patients from the TCGA-LIHC dataset. We included Tert, Vegfa, and Ccnd1 as control genes with known roles in HCC. Then we designed a gRNA library with 5 gRNAs per gene and 20 NT control gRNAs for a 290-gRNA CRISPRa library (Supplementary Table 1). CRISPRa gRNA sequences were from Horlbeck et al.45 We designed oligonucleotides for the gRNA library as described previously.4 The CRISPRa oligo library (Agilent Technologies, Santa Clara, CA) was then amplified using primers AdaBioID-a-f and AdaBioIDa-R2 (Table 1) and purified (Qiagen Minelute #28004, Germantown, MD). The digested gRNA library was ligated with CRISPRa vectors, and the new plasmid libraries were purified from bacteria. To achieve robust gRNA coverage, we purified at least 1.2 million colonies for an estimated 300-fold coverage per gRNA. We used sanger sequencing to confirm gRNAs were cloned correctly."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.0047922134399414,
    "data_pmids_checked": 0,
    "paper_id": "39761726",
    "extraction_date": "2025-12-19T20:42:18.007326",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39761726.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39758250": {
    "cbioportal_paper_citations": [
      "In addition, genomic and/or transcriptomic data from three additional human cohorts of PCa patients were acquired. Specifically, cBioPortal46,47 was used to obtain data from TCGA (n = 545)48 and from the SU2C/Prostate Cancer Foundation (n = 266)37 cohorts, while GEO49 was used to obtain data from Roudier (GEO: GSE74367; n = 56)31 cohort. Moreover, proteomic data of human plasma samples were also obtained from the PeptideAtlas database (2023-04 build; n = 313).22"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625050": [
        "In addition, genomic and/or transcriptomic data from three additional human cohorts of PCa patients were acquired. Specifically, cBioPortal46,47 was used to obtain data from TCGA (n = 545)48 and from the SU2C/Prostate Cancer Foundation (n = 266)37 cohorts, while GEO49 was used to obtain data from Roudier (GEO: GSE74367; n = 56)31 cohort. Moreover, proteomic data of human plasma samples were also obtained from the PeptideAtlas database (2023-04 build; n = 313).22"
      ],
      "31061129": [
        "Apart from this overt diagnostic value, we have also reported that SRRM1 plasma levels are positively associated with the proportion of ADT-treated patients. Additionally, the circulating and mRNA levels of SRRM1 were positively correlated to the AR activity of PCa tissues, a key molecular determinant of PCa aggressiveness, and the clinical progression from localized HSPC to the highly aggressive CRPC.37,38,39 Furthermore, the expression of SRRM1 was positively correlated with a set of 49 genes (ADT resistance score) differentially expressed in response to hormone deprivation in vitro and was jointly associated with shorter time to biochemical recurrence in human PCa patients.30 Thus, these results suggest that SRRM1 might be implicated in the phenotypical progression from HSPC to CRPC. Consistent with this, we identified that patients with higher levels of SRRM1 progressed earlier to a CRPC phenotype, and that CRPC patients express more SRRM1 mRNA levels than HSPC patients. These results point to the promising value of plasma SRRM1 levels, not only as a diagnostic biomarker but also as a prognostic and predictive tool for ADT response. In this scenario, it is important to remark that the predictive value of PSA is inadequate to forecast the clinical response to hormonal blockade as shown by the CHAARTED trial, where 25% of the patients experienced clinical progression without PSA progression.4,5 In this regard, several alternative non-invasive biomarkers and multivariate nomograms have been proposed to fill this clinical gap, such as cell-free DNA determination,40 circulating tumor cells,7,41 or microRNA determination,42,43 among others. However, their impact on the patients has been limited due to their high cost and cumbersome translation to clinic in some cases, which may increase the relevance of plasma SRRM1\u2019s prognostic value for PCa patients as a cost-affordable alternative.",
        "In addition, genomic and/or transcriptomic data from three additional human cohorts of PCa patients were acquired. Specifically, cBioPortal46,47 was used to obtain data from TCGA (n = 545)48 and from the SU2C/Prostate Cancer Foundation (n = 266)37 cohorts, while GEO49 was used to obtain data from Roudier (GEO: GSE74367; n = 56)31 cohort. Moreover, proteomic data of human plasma samples were also obtained from the PeptideAtlas database (2023-04 build; n = 313).22"
      ],
      "22722839": [
        "Apart from this overt diagnostic value, we have also reported that SRRM1 plasma levels are positively associated with the proportion of ADT-treated patients. Additionally, the circulating and mRNA levels of SRRM1 were positively correlated to the AR activity of PCa tissues, a key molecular determinant of PCa aggressiveness, and the clinical progression from localized HSPC to the highly aggressive CRPC.37,38,39 Furthermore, the expression of SRRM1 was positively correlated with a set of 49 genes (ADT resistance score) differentially expressed in response to hormone deprivation in vitro and was jointly associated with shorter time to biochemical recurrence in human PCa patients.30 Thus, these results suggest that SRRM1 might be implicated in the phenotypical progression from HSPC to CRPC. Consistent with this, we identified that patients with higher levels of SRRM1 progressed earlier to a CRPC phenotype, and that CRPC patients express more SRRM1 mRNA levels than HSPC patients. These results point to the promising value of plasma SRRM1 levels, not only as a diagnostic biomarker but also as a prognostic and predictive tool for ADT response. In this scenario, it is important to remark that the predictive value of PSA is inadequate to forecast the clinical response to hormonal blockade as shown by the CHAARTED trial, where 25% of the patients experienced clinical progression without PSA progression.4,5 In this regard, several alternative non-invasive biomarkers and multivariate nomograms have been proposed to fill this clinical gap, such as cell-free DNA determination,40 circulating tumor cells,7,41 or microRNA determination,42,43 among others. However, their impact on the patients has been limited due to their high cost and cumbersome translation to clinic in some cases, which may increase the relevance of plasma SRRM1\u2019s prognostic value for PCa patients as a cost-affordable alternative."
      ],
      "26000489": [
        "Apart from this overt diagnostic value, we have also reported that SRRM1 plasma levels are positively associated with the proportion of ADT-treated patients. Additionally, the circulating and mRNA levels of SRRM1 were positively correlated to the AR activity of PCa tissues, a key molecular determinant of PCa aggressiveness, and the clinical progression from localized HSPC to the highly aggressive CRPC.37,38,39 Furthermore, the expression of SRRM1 was positively correlated with a set of 49 genes (ADT resistance score) differentially expressed in response to hormone deprivation in vitro and was jointly associated with shorter time to biochemical recurrence in human PCa patients.30 Thus, these results suggest that SRRM1 might be implicated in the phenotypical progression from HSPC to CRPC. Consistent with this, we identified that patients with higher levels of SRRM1 progressed earlier to a CRPC phenotype, and that CRPC patients express more SRRM1 mRNA levels than HSPC patients. These results point to the promising value of plasma SRRM1 levels, not only as a diagnostic biomarker but also as a prognostic and predictive tool for ADT response. In this scenario, it is important to remark that the predictive value of PSA is inadequate to forecast the clinical response to hormonal blockade as shown by the CHAARTED trial, where 25% of the patients experienced clinical progression without PSA progression.4,5 In this regard, several alternative non-invasive biomarkers and multivariate nomograms have been proposed to fill this clinical gap, such as cell-free DNA determination,40 circulating tumor cells,7,41 or microRNA determination,42,43 among others. However, their impact on the patients has been limited due to their high cost and cumbersome translation to clinic in some cases, which may increase the relevance of plasma SRRM1\u2019s prognostic value for PCa patients as a cost-affordable alternative."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6551110744476318,
    "data_pmids_checked": 4,
    "paper_id": "39758250",
    "extraction_date": "2025-12-19T20:42:18.679657",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39758250.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39756156": {
    "cbioportal_paper_citations": [
      "As CDKN2A loss is one of the most common genetic alterations in cancer and MTAP is located with close proximity on chromosome 9p, co-deletion of MTAP with CDKN2A occurs in 10\u201315 % of all human cancer and with greater frequency in tumor types such as glioblastoma, mesothelioma, pancreatic adenocarcinoma, NSCLC, and cholangiocarcinoma [15,16]. MTAP is a critical enzyme in the methionine salvage pathway, a process that recycles methionine from methylthioadenosine (MTA), the product of polyamine synthesis. MTAP loss causes the accumulation of its substrate, MTA, which is a SAM-competitive PRMT5 inhibitor [[1], [2], [3]]. We hypothesized that a compound that leverages the accumulation of MTA by binding to PRMT5 in an MTA-cooperative, substrate-competitive manner would achieve selective PRMT5 inhibition in MTAP-deleted cancer cells. A compound with this selectivity for tumor cells is expected to be well tolerated and efficacious with broad therapeutic potential both alone and in combination with other therapies.",
      "Homozygous deletion of the MTAP gene co-occurs with CDKN2A loss across histologies providing a large opportunity for precision oncology application (Fig. 1A). The most proximal consequence of MTAP loss is the accumulation of its substrate, methylthioadenosine (MTA) (Fig. 1B). In MTAP-isogenic cell lines generated by knocking out the endogenous MTAP gene using CRISPR-based technology, time-dependent accumulation of intracellular MTA occurred solely in MTAP-deleted cell lines and to a level consistent with a cell line with endogenous deletion of MTAP and CDKN2A (Fig. 1C, S1A-B, and S7A-B). As expected, exogenous MTA was rapidly metabolized by MTAP-proficient (MTAP WT) cells, whereas exogenous and endogenous MTA levels appeared to reach equilibrium in cells with MTAP loss (MTAP-null) cells suggesting bidirectional flux across the cell membrane (Fig. 1D). The MTA accumulation seen in MTAP-null cells was not an artifact of in vitro cell culture as a 7-fold increase in MTA was also detected in MTAP-null xenografts relative to isogenic MTAP WT xenografts (Figs. 1E and S1C). Consistent with previous reports, this accumulation was specific to MTA as alteration of intracellular SAM levels was not detected (Fig. 1E) [1,2,3]. The accumulation of MTA in MTAP-null cells was a direct consequence of MTAP loss as pharmacological inhibition of MTAP using the small molecule inhibitor, MT-DADMe-ImmA (MTDIA), in MTAP WT cells phenocopied MTAP loss by driving MTA accumulation relative to SAM (Fig. 1F) [25]. The accumulation of MTA competes with the PRMT5 activating cofactor, SAM, to form an inactive PRMT5\u00b7MTA complex [1,2]. PRMT5 inhibition can be monitored in cells by quantification of SDMA, which is the methyl mark conferred by type II PRMT family members of which PRMT5 is the primary type II PRMT. Evidence of basal PRMT5 inhibition in MTAP-null cells was observed both in vitro and in vivo with an average 2.5-fold reduction of SDMA-modified protein levels relative to MTAP WT isogenic controls (Fig. 1G-H).Fig. 1PRMT5 inhibition occurs with MTA accumulation caused by MTAP loss.(A) Cancer types with >5 % prevalence of MTAP and CDKN2A homozygous deletion according to TCGA PanCancer Atlas for all indications other than MPNST [15,16,26].(B) Methionine salvage pathway schematic.(C-D) Intracellular MTA levels in pancreatic (KP3 and KP4), heme (HAP1) and colorectal (HCT116) cell lines (C), or the HAP1 MTAP-isogenic cell line pair (D) following tissue culture for the indicated timepoints. sgCtrl = control, intron-targeting sgRNA, and sgMTAP = MTAP-targeting sgRNA. Data normalized to cell number. N = 2 data presented as mean \u00b1 SD.(E) Intracellular MTA and SAM levels in pancreatic (KP4) MTAP-isogenic xenograft tissue. Data presented as mean \u00b1 SD. **** refers to p-value <0.0001.(F) Intracellular MTA normalized to SAM levels in the NSCLC (SW1573) and heme (HAP1) MTAP-isogenic cell line pairs cultured for 48 h with the indicated concentration of MTDIA, an MTAP inhibitor. N = 2 data presented as mean \u00b1 SD.(G-H) SDMA levels in the heme (HAP1) or pancreatic (KP4) cell lines (n = 44 for each) (G) or xenografts (H). SDMA levels are normalized to DRAQ5 in (G) and presented as mean \u00b1 SD. H-scores from SDMA immunohistochemistry were calculated by manual pathology in (H). *** refers to a p-value <0.001.Fig 1:",
      "(A) Cancer types with >5 % prevalence of MTAP and CDKN2A homozygous deletion according to TCGA PanCancer Atlas for all indications other than MPNST [15,16,26].",
      "It has been reported that CDKN2A loss may sensitize cells to CDK4/6 inhibitors [30]. As nearly all MTAP-deleted tumors are also CDKN2A-deleted, we investigated the combination efficacy of TNG908 and CDK4/6 inhibitors. A clear combination benefit was evident in vivo in xenograft models regardless of single agent sensitivity to either abemaciclib or palbociclib. Whether this combination benefit is the result of inhibition of two parallel pathways or a mechanistic interaction between the CDK4/6-Rb and PRMT5 pathways remains unclear. Abemaciclib has been reported to be brain penetrant in clinical studies, suggesting that this combination may be particularly meaningful in MTAP-deleted, CDKN2A-deleted glioblastoma patients [37,38]. Furthermore, TCGA analysis of the tumor histologies with the highest prevalence of MTAP deletion suggests that, on the whole, other driver genetic alterations are neither enriched nor mutually exclusive with MTAP deletion [15,16]. Therefore, combination of TNG908 with other targeted agents that have orthogonal mechanisms of action may drive strong combination benefit with a broad therapeutic window due to non-overlapping toxicity."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "25240281": [
        "Homozygous deletion of the MTAP gene co-occurs with CDKN2A loss across histologies providing a large opportunity for precision oncology application (Fig. 1A). The most proximal consequence of MTAP loss is the accumulation of its substrate, methylthioadenosine (MTA) (Fig. 1B). In MTAP-isogenic cell lines generated by knocking out the endogenous MTAP gene using CRISPR-based technology, time-dependent accumulation of intracellular MTA occurred solely in MTAP-deleted cell lines and to a level consistent with a cell line with endogenous deletion of MTAP and CDKN2A (Fig. 1C, S1A-B, and S7A-B). As expected, exogenous MTA was rapidly metabolized by MTAP-proficient (MTAP WT) cells, whereas exogenous and endogenous MTA levels appeared to reach equilibrium in cells with MTAP loss (MTAP-null) cells suggesting bidirectional flux across the cell membrane (Fig. 1D). The MTA accumulation seen in MTAP-null cells was not an artifact of in vitro cell culture as a 7-fold increase in MTA was also detected in MTAP-null xenografts relative to isogenic MTAP WT xenografts (Figs. 1E and S1C). Consistent with previous reports, this accumulation was specific to MTA as alteration of intracellular SAM levels was not detected (Fig. 1E) [1,2,3]. The accumulation of MTA in MTAP-null cells was a direct consequence of MTAP loss as pharmacological inhibition of MTAP using the small molecule inhibitor, MT-DADMe-ImmA (MTDIA), in MTAP WT cells phenocopied MTAP loss by driving MTA accumulation relative to SAM (Fig. 1F) [25]. The accumulation of MTA competes with the PRMT5 activating cofactor, SAM, to form an inactive PRMT5\u00b7MTA complex [1,2]. PRMT5 inhibition can be monitored in cells by quantification of SDMA, which is the methyl mark conferred by type II PRMT family members of which PRMT5 is the primary type II PRMT. Evidence of basal PRMT5 inhibition in MTAP-null cells was observed both in vitro and in vivo with an average 2.5-fold reduction of SDMA-modified protein levels relative to MTAP WT isogenic controls (Fig. 1G-H).Fig. 1PRMT5 inhibition occurs with MTA accumulation caused by MTAP loss.(A) Cancer types with >5 % prevalence of MTAP and CDKN2A homozygous deletion according to TCGA PanCancer Atlas for all indications other than MPNST [15,16,26].(B) Methionine salvage pathway schematic.(C-D) Intracellular MTA levels in pancreatic (KP3 and KP4), heme (HAP1) and colorectal (HCT116) cell lines (C), or the HAP1 MTAP-isogenic cell line pair (D) following tissue culture for the indicated timepoints. sgCtrl = control, intron-targeting sgRNA, and sgMTAP = MTAP-targeting sgRNA. Data normalized to cell number. N = 2 data presented as mean \u00b1 SD.(E) Intracellular MTA and SAM levels in pancreatic (KP4) MTAP-isogenic xenograft tissue. Data presented as mean \u00b1 SD. **** refers to p-value <0.0001.(F) Intracellular MTA normalized to SAM levels in the NSCLC (SW1573) and heme (HAP1) MTAP-isogenic cell line pairs cultured for 48 h with the indicated concentration of MTDIA, an MTAP inhibitor. N = 2 data presented as mean \u00b1 SD.(G-H) SDMA levels in the heme (HAP1) or pancreatic (KP4) cell lines (n = 44 for each) (G) or xenografts (H). SDMA levels are normalized to DRAQ5 in (G) and presented as mean \u00b1 SD. H-scores from SDMA immunohistochemistry were calculated by manual pathology in (H). *** refers to a p-value <0.001.Fig 1:",
        "(A) Cancer types with >5 % prevalence of MTAP and CDKN2A homozygous deletion according to TCGA PanCancer Atlas for all indications other than MPNST [15,16,26]."
      ]
    },
    "total_cbioportal_paper_citations": 4,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4736521244049072,
    "data_pmids_checked": 1,
    "paper_id": "39756156",
    "extraction_date": "2025-12-19T20:42:19.153432",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39756156.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39762343": {
    "paper_id": "39762343",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:42:26.590795",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39762343.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.20018196105957,
      "cbioportal_papers": 0.0003559589385986328,
      "pdf_extraction_pass2": 9.916547060012817,
      "cbioportal_papers_pass2": 0.00038504600524902344,
      "used_full_extraction": true,
      "pdf_extraction": 19.116729021072388,
      "platform_mentions": 0.003113985061645508,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39753728": {
    "cbioportal_paper_citations": [
      "The cBioPortal database26 serves as a repository for the comprehensive compilation of data pertaining to mutation frequency, mutation types, specific mutation locations, and the three-dimensional (3D) structural attributes of prospective proteins across the entirety of TCGA cancer datasets."
    ],
    "cbioportal_platform_mentions": [
      "In this study, we conducted a comprehensive bioinformatics analysis of SMAD3-related data. Utilizing a range of databases including HPA, cBioPortal, UALCAN, GSCA, GEPIA, CancerSEA, TISMO, TISCH, and others, we assessed the expression levels of SMAD3 across various tissues and its associations with different cancer types. Furthermore, we delved into the prognostic significance, mutation patterns, and single-cell expression profiles of SMAD3. Our analysis extended to exploring the connections between SMAD3 and immune cell infiltration, immune-related genes, immune checkpoints, immunomodulatory genes, methylation patterns, tumor mutation burden (TMB), microsatellite instability (MSI), tumor stemness, and drug sensitivity. Additionally, we conducted functional enrichment analysis of genes related to SMAD3 to unveil the underlying molecular mechanisms contributing to diverse cancers. This study collectively sheds light on the potential of SMAD3 as a prognostic marker in various cancer contexts. Our in-depth in vitro experiments have provided substantial evidence regarding the atypical expression and biological roles of SMAD3 in Liver Hepatocellular Carcinoma (LIHC). The findings firmly establish SMAD3 as an independent and promising prognostic marker, underscoring its potential as a fresh therapeutic target for LIHC.",
      "Our analysis of genetic alterations across various cancers, conducted through the cBioPortal platform, allowed us to delve into the landscape of SMAD3 gene variations in pan-cancer. The results unveiled distinct patterns in different malignancies, with COAD exhibiting the highest frequency of SMAD3 variations at 6.40%, primarily in the form of mutations. Following COAD, the top five cancers with the highest variation frequencies were UCEC (5.48%), SKCM (3.83%), MESO (3.45%), and KICH (3.08%). Notably, MESO was unique in its pattern of variation, characterized by amplifications (Fig. 5A). In further exploration of these variations, we identified missense and truncating mutations as the primary mutation types affecting SMAD3, as depicted in Fig. 5B. These insights into the genetic alterations in SMAD3 shed light on its role in the context of different cancers.",
      "The similarities and differences between tumors can be shown by pan-cancer analysis, which can support to the theoretical framework guiding efforts in cancer prevention, the design of therapeutic targets, and the prospective screening of therapeutic drugs42. SMAD3 is central to the TGF-\u03b2 pathway and plays an important role in immune-inflammatory responses. Recent research suggests that SMAD3 is connected to the survival and prognosis of malignant tumors and plays a role in the etiology and advancement of colorectal cancer, lung cancer, breast cancer, bladder cancer, prostate cancer, cervical cancer, gastric cancer, and osteosarcoma12,14,15,43\u201346. We embarked on an exhaustive and all-encompassing analysis of 33 different global cancer types to discern the molecular characteristics of SMAD3. This analysis involved the utilization of diverse databases, including TCGA, GTEx, UALCAN, TIMER2.0, GSCA, and cBioportal. Our investigation aimed to elucidate SMAD3\u2019s role in tumor development and potential regulatory mechanisms, encompassing gene expression, prognosis, gene mutations, immunological infiltration, single-cell analysis, immune checkpoints, DNA methylation, RNA methylation, tumor mutation burden (TMB), microsatellite instability (MSI), tumor characteristics, and drug sensitivity."
    ],
    "data_publication_citations": {
      "29625055": [
        "Our data acquisition process entailed the retrieval of a meticulously standardized pan-cancer dataset originating from the UCSC database, specifically the TCGA TARGET GTEx dataset, which comprised a substantial cohort (PAN-CANCER N = 19131 G = 60499). Within this dataset, we meticulously extracted the gene expression data for SMAD3 from each sample. In addition, we secured a high-quality TCGA prognostic dataset, sourced from prior TCGA prognostic studies as published in Cell22. To complement this dataset, we incorporated the follow-up data obtained from TARGET through UCSC.our study encompassed the examination of various endpoints, including overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI), to scrutinize the association between SMAD3 expression and cancer prognosis. For this purpose, we harnessed the robust analytical tools of Kaplan-Meier survival analysis and Cox regression analysis to delve into the intricate relationship between SMAD3 and survival prognosis23 ."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.28786325454711914,
    "data_pmids_checked": 1,
    "paper_id": "39753728",
    "extraction_date": "2025-12-19T20:42:26.903056",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39753728.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39744441": {
    "cbioportal_paper_citations": [
      "cBioPortal (https://www.cbioportal.org/) is a comprehensive open resource for the exploration and visualization of large-scale cancer genomic databases, including The Cancer Genomic Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus databases, which provide information on mutations, copy number alterations, and clinical correlations 26. We used cBioPortal to explore the mutation data of TBK1 in UCEC, evaluate the prognostic value of TBK1 in patients with UCEC, and determine the correlation between TBK1 methylation and gene expression levels."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1255030632019043,
    "data_pmids_checked": 0,
    "paper_id": "39744441",
    "extraction_date": "2025-12-19T20:42:27.063244",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39744441.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39742369": {
    "cbioportal_paper_citations": [
      "The METABRIC dataset provides clinical and genomic data on breast tumors from five different hospitals and/or research centers in the United Kingdom and Canada [24]. It allows the utilization of the molecular profiles of breast tumors to analyze the association with clinical outcomes and to better understand the clinical heterogeneity of the disease [24]. The METABRIC dataset was obtained for 2509 patients with primary breast cancer and downloaded from the cBio cancer genomics portal (cBioPortal). The cBioPortal is an open-access resource for interactive exploration of multidimensional cancer genomics datasets [25]. The METABRIC dataset provides demographic and clinical data such as the age of the patient as diagnosis, menopausal status, Nottingham Prognostic Index (NPI), OS, tumor histological subtype, the number of positive lymph nodes, tumor size, the TNM-stage, grade, receptor status, and molecular subtype. The treatment modality received by patients (type of breast surgery, hormonal therapy, chemotherapy, and/or radiotherapy) is also indicated in the dataset."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.981652021408081,
    "data_pmids_checked": 0,
    "paper_id": "39742369",
    "extraction_date": "2025-12-19T20:42:28.082035",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39742369.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39755992": {
    "paper_id": "39755992",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The model was validated using the METABRIC cohort data from cBioPortal",
      "2 Material and methods\n2.1 Data acquisition and preprocessing\nThe TCGA-BRCA & Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) datasets related to breast\ncancer were obtained from two websites: cBioPortal (https:// www.c biop ortal",
      "Integra-\ntive analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:42:36.302666",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39755992.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.345493793487549,
      "cbioportal_papers": 0.0002930164337158203,
      "pdf_extraction_pass2": 7.787186861038208,
      "cbioportal_papers_pass2": 0.00028395652770996094,
      "used_full_extraction": true,
      "pdf_extraction": 17.132680654525757,
      "platform_mentions": 0.0024607181549072266,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39739214": {
    "paper_id": "39739214",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "In addition, we explored the association of CYFIP2 mutations with prognosis in\nthe cBioPortal (http://w ww.c biopo rtal.o rg/) database [15]",
      "E\u2013G The correlation of different mutation subgroups with OS, DFS and DSS\nwas explored through cBioPortal database\nsignaling pathway, calcium signaling pathway and chemokine signaling pathway",
      "Integra-\ntive analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:42:45.109882",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39739214.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.8329598903656,
      "cbioportal_papers": 0.0002620220184326172,
      "pdf_extraction_pass2": 8.178380966186523,
      "cbioportal_papers_pass2": 0.0002827644348144531,
      "used_full_extraction": true,
      "pdf_extraction": 17.011340856552124,
      "platform_mentions": 0.0024781227111816406,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39738287": {
    "paper_id": "39738287",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Genomic alterations and mutational landscape of DCLRE1B in different tumour types\nTo assess the pancancer frequency of genomic alterations in DCLRE1B, the cBioPortal website ( h t t p : / /w w w",
      "(B) The frequency of genomic alterations\nof DCLRE1B in pan-cancers based on the cBioPortal website",
      "et al. Integrative Analysis of Complex Cancer Genomics and Clinical profiles using the Cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:42:56.347675",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39738287.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.853450059890747,
      "cbioportal_papers": 0.00029015541076660156,
      "pdf_extraction_pass2": 10.162146091461182,
      "cbioportal_papers_pass2": 0.0002770423889160156,
      "used_full_extraction": true,
      "pdf_extraction": 20.01559615135193,
      "platform_mentions": 0.0031380653381347656,
      "data_citations": 8.821487426757812e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39737957": {
    "paper_id": "39737957",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "therelevanceoftargetingiNOSinMpBC,weanalyzedavailabletran-\nFurthermore, NO can uniquely activate multiple oncogenic sig- scriptomic data from The Cancer Genome Atlas (TCGA) cBioPortal\nnaling pathways, including those mediated by PI3K, extracellular CombinedDataset(n=179,290)(cbioportal.org),whichshowedthat\nsignal-regulated kinase, \u03b2-catenin, transforming growth factor beta \u2018MpBC\u2019wasthetopbreastcancersubtypeand4thhighestcancerto\n(TGF\u03b2),andhypoxia-induciblefactor(HIF)14,15.ConsideringthatMpBC harbor NOS2 genomic aberrations (Fig",
      "Data analyses conducted via cBioPortal\nLDAsoftware(https://bioinf.wehi.edu.au/software/elda/)",
      "(https://www.cbioportal.org/)andSTRINGutilizedpubliclyaccessible\nForflowcytometry,dissociatedtumorcellspost-treatment(two datasets"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:43:12.377877",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39737957.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 14.909406185150146,
      "cbioportal_papers": 0.0003941059112548828,
      "pdf_extraction_pass2": 12.331197023391724,
      "cbioportal_papers_pass2": 0.0003879070281982422,
      "used_full_extraction": true,
      "pdf_extraction": 27.24060320854187,
      "platform_mentions": 0.0035903453826904297,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39732849": {
    "paper_id": "39732849",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The cBioPortal for Cancer Genomics (https://www.cbioportal.org/) provided a convenient tool to analyze\nmultidimensional cancer genomics data36,37",
      "The OncoPrint\nmodule of the cBioPortal database displayed a concise and compact graphical summary of genomic alterations\nin the three ASXL family genes across 32 cancer types",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:43:13.401275",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39732849.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.043119192123413,
      "cbioportal_papers": 0.0002651214599609375,
      "pdf_extraction_pass2": 7.969228029251099,
      "cbioportal_papers_pass2": 0.00026607513427734375,
      "used_full_extraction": true,
      "pdf_extraction": 17.01234722137451,
      "platform_mentions": 0.0035741329193115234,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39720180": {
    "paper_id": "39720180",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "However, including noisy samples\u2014especially those\nFortheestrogenreceptor(ER)statusclassificationtask,weobtained with extreme values due to errors in sequencing technology or\nthe clinical information from cBioPortal (Gao et al., 2013), dataentry\u2014canskewtheresultsduringthesinglevariancefiltering\nFrontiersinGenetics 03 frontiersin.org\n\nLiuandPark 10.3389/fgene.2024.1488683\nstep.Thiscanleadtoanoveremphasisoncertainfeatures,causing iscrucialforcapturingtheintricatedependenciesandinteractions\nthe selection of unreliable or misleading data",
      "Genome-wide\nIntegrative analysis of complex cancer genomics and clinical profiles using the identificationandanalysisofepithelial-mesenchymaltransition-relatedRNA-binding\ncBioPortal.Sci.Signal.6(269),pl1.doi:10.1126/scisignal.2004088 proteinsandalternativesplicinginahumanbreastcancercellline.Sci.Rep.14(1),\n11753.doi:10.1038/s41598-024-62681-0\nGao, R., Zhou, D., Qiu, X., Zhang, J., Luo, D., Yang, X., et al. (2024)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:43:28.877847",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39720180.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.462058067321777,
      "cbioportal_papers": 0.0002770423889160156,
      "pdf_extraction_pass2": 6.997792959213257,
      "cbioportal_papers_pass2": 0.00028896331787109375,
      "used_full_extraction": true,
      "pdf_extraction": 15.459851026535034,
      "platform_mentions": 0.002140045166015625,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39717877": {
    "cbioportal_paper_citations": [
      "The cBioPortal is an open-access platform for visualizing and analyzing cancer genomics data. It provides a user-friendly interface for researchers to explore multidimensional cancer genomics datasets, access various cancer studies, perform interactive analyses, and visualize results through customizable plots and charts. The mutation profiling of the 3 DEGs viz., FST, VRK3, and SGK1 was analyzed using the cBioportal site. Over 504 samples were queried for the presence of gross genetic abnormalities or point mutations.21,22"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.30107593536376953,
    "data_pmids_checked": 0,
    "paper_id": "39717877",
    "extraction_date": "2025-12-19T20:43:29.217063",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39717877.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39730186": {
    "paper_id": "39730186",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Materials and Methods: A retrospective analysis of samples, showing moderate concordance with tissue\n937 CCA patients was performed using data from cBioPortal sequencing, and achieving 80% sensitivity and 93%\nspecificity",
      "(A) Overview of sample inclusion from the cBioPortal database",
      "937 patients with CCA were included in the present study,\nThus, the aims of the present study were as follows: i) to comprising 417 cases from the ICGC dataset, 382 cases from the\ndetermine the prevalence and distribution of KRAS mutations MSK datasets, 35 cases from TCGA dataset and 103 cases from the\nin CCA tumors by analyzing multiple CCA cohorts from the study by Zou et al. Data on the liver fluke-related status were also\ncBioPortal database; ii) to detect the 7 most clinically obtained from the ICGC and MSK cohorts",
      "Somatic KRAS mutation data and clinical OS was defined as the interval from the date of surgery to the time\ninformation on CCA tumors were retrieved from the cBioPortal of death or the last follow-up date, and RFS was defined as the\ndatabase (46), including 6 independent datasets (Figure 1A)",
      "Data was retrieved\nfrom the cBioPortal database",
      "This contrasts with the higher median and cBioPortal, which compiles information from multiple studies",
      "DOI: SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander\n10.3390/cancers12092434 C, Schultz N: Integrative analysis of complex cancer genomics\n36 Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:43:29.234075",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39730186.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.825483083724976,
      "cbioportal_papers": 0.00032591819763183594,
      "pdf_extraction_pass2": 8.026634931564331,
      "cbioportal_papers_pass2": 0.0003230571746826172,
      "used_full_extraction": true,
      "pdf_extraction": 16.852118015289307,
      "platform_mentions": 0.002708911895751953,
      "data_citations": 0.0005481243133544922,
      "num_data_pmids_checked": 5
    }
  },
  "39713797": {
    "cbioportal_paper_citations": [
      "The TCGA-KIRC dataset has been a cornerstone for renal cancer research, it includes comprehensive genomic, transcriptomic, pathology, and clinical data of 537 patients [15], which enables a multitude of studies to enhance our understanding of ccRCC. To assist the data analysis for researchers from or outside the field of bioinformatics, a set of tools were published, such as the cBioPortal [16], TCGA-Assembler [17], Firebrowse [18], and LinkedOmics [19]. These tools provide pre-preprocessed data, especially multi-omics data to help handle this vast amount of data. In this study, we focused on the treatment outcome prediction of ccRCC patients, including OS and DFS. Patients\u2019 clinical data, comprising demographic, diagnosis, treatment and follow-up data, multi-omics data, comprising pre-processed mRNA expression, miRNA expression (miRSeq), and DNA methylation data, and pathology data in the form of whole side image (WSI) are collected. The selection of modalities of multi-omics data is based on the reported prognostic performance in previous research and availability of data. The clinical data are from Genomic Data Commons Data Portal and cBioPortal, while the pre-processed multi-omics data is from TCGA Preprocessed Multi-Omics Cancer Benchmark Dataset [20]. OS is defined as the duration from initial diagnosis to last follow-up or patient death, and DFS is defined as the duration between initial diagnosis and last disease-free follow-up or cancer recurrence/progression. After excluding patients who miss any of the modalities of interest or have incomplete follow-up data of OS or DFS, we collected data of 226 ccRCC patients from TCGA-KIRC dataset in this study (67 patients have disease progression or recurrence at last follow-up and 38 patients are deceased). The clinical characteristics of the included patients are summarized in Tabel 1."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.38739609718322754,
    "data_pmids_checked": 0,
    "paper_id": "39713797",
    "extraction_date": "2025-12-19T20:43:29.604550",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39713797.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39711431": {
    "cbioportal_paper_citations": [
      "We selected patients from the GENIE cohort (v15.1-public; ref. 38) and focused our analysis on a subset of samples derived from Memorial Sloan Kettering, the largest American Association for Cancer Research (AACR) GENIE cohort. We further filtered for alterations listed as \u201csomatic\u201d and \u201cprofiled in all queried genes/profiles.\u201d After filtering, the subcohort was composed of 70,407 patients. KRAS-amplified samples were defined as having a genomic identification of significant targets in cancer (GISTIC), version 2.0 score of 2 according to AACR GENIE. Exact CN thresholds are not available from the AACR GENIE cohort."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31068700": [
        "The cancer cell lines used in PRISM screens were molecularly characterized through the Cancer Cell Line Encyclopedia (CCLE; ref. 31) and are made publicly available through the DepMap portal (https://depmap.org/portal/, accessed on June 06, 2023, DepMap Public version 22Q4). For the analysis of this study, we focused on gene mutations (OmicsSomaticMutations.csv), expression(OmicsExpressionProteinCodingGenesTPMLogp1.csv), and CN alterations (OmicsCNGene.csv). In this study, for CN alterations, unless otherwise specified, gene-level relative CN data were log2-transformed with a pseudocount of 1, log2 (CN ratio + 1). The CN ratio is a relative CN estimate and more specifically, relative to the ploidy of the cell line. Cell lines with an amplified WT KRAS gene (without mutations in KRAS) were grouped into cell lines with a relative CN of >2 or >7 of the KRAS gene."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6216881275177002,
    "data_pmids_checked": 1,
    "paper_id": "39711431",
    "extraction_date": "2025-12-19T20:43:29.888868",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39711431.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39709507": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "32042194": [
        "The hallmark of angiosarcoma involves the creation of distorted vascular spaces by malignant cells. These spaces harbor a diverse array of blood and immune components, where a controlled scavenging system is necessary for tumor maintenance. In this context, the ability of angiosarcoma cells to control the hemato-endothelial system emerges as pivotal to their pathogenic significance [12]. At the molecular level, recurrent mutations are found in TP53, and genes involved in phosphatidylinositol 3-kinase (PI3K) pathway such as PIK3CA, PIK3R1, and PTEN in both human angiosarcoma and canine hemangiosarcoma [13\u201317]. PIK3CA is a one of the most frequent cross-species oncogenic mutations, and approximately 20% of human patients and 30% of dogs exhibit PIK3CA mutations [13, 15\u201319]. The PI3K/AKT/mammalian target of rapamycin (mTOR) pathway is broadly activated in these vascular tumors [15, 20, 21]. PIK3CA mutations are known to functionally activate the PI3K pathway, promoting angiogenic signaling, cell survival, and proliferation [21\u201323]; thus, PI3K-\u03b1 has been regarded as an effective therapeutic target. Yet, the functional and molecular consequences of PIK3CA mutations remain incompletely known in vascular cancers.",
        "We first confirmed the occurrence of mutations in key genes involved in the PI3K pathway in human angiosarcomas and canine hemangiosarcomas. PI3K-related mutations were observed in approximately 37% of human angiosarcoma and up to 40% of canine hemangiosarcomas (Fig. S1A) [13, 15\u201317, 20]. PIK3CA mutations were identified in kinase domains in both species, activating the convergent PI3K/AKT pathway, despite their variable mutational signatures (Figs. 1A and S1B) [15]. To determine functional consequences of PIK3CA mutations, we established two homozygous PIK3CA H1047R mutant clones (C8 and C35) and a PIK3CA WT clone from DHSA-1426 hemangiosarcoma cells (Fig. 1B). Additionally, one homozygous PIK3CA H1047R mutant clone (hereafter referred to as COSB-H1047R) was generated from COSB hemangiosarcoma cells (Fig. S2). The two mutant DHSA-1426 cells showed increased phosphorylation of proteins downstream of PI3K (Fig. S3A). The COSB-H1047R exhibited only marginal increase of phosphorylation of S6K, indicating persistent activation of PI3K pathway without the PIK3CA hotspot mutations (Fig. S3B). Since PIK3CA H1047R mutation could change cell shape and polarity [31], we then examined the morphological appearance of the isogenic cells (Fig. 1C). The WT cells revealed virtually identical growth patterns to their parental DHSA-1426 cells, forming tube-like structures. In contrast, the mutant cells exhibited incomplete tubular structures and displayed a more pleomorphic appearance: the mutant C8 cells grew individually and contained noticeable subpopulations of small-sized round cells forming clumps, while the mutant C35 cells included an increased number of small round cells with a loss of shape. No significant change was found in the cell growth rates between the mutant and WT cells, although the mutant C8 cells appeared to grow slower than the others (Fig. 1D). We also observed distinct global transcriptomic profiles between the mutant and WT cells (Fig. 1E).Fig. 1Introduction of oncogenic PIK3CA mutation into hemangiosarcoma cells.A Representative histopathological images from canine hemangiosarcoma and human angiosarcoma patients. H&E staining (left); immunohistochemistry with AKT antibody (middle) and phosphor-AKT antibody (right). B A homogeneous PIK3CA H1047R mutation was confirmed by Sanger sequencing analysis of the PIK3CA gene in wildtype (WT) and two different PIK3CA H1047R knock-in clones from DHSA-1426 hemangiosarcoma cells. C Representative live cell morphology was obtained by capturing bright field images at 20\u00d7 (upper) and 10\u00d7 (lower) magnifications. D Growth rates of the WT and PIK3CA-mutant cells were visualized by plotting the absolute cell numbers at days two, three, and four after seeding the same number of cells at day zero. E Genetic variation among three cells was assessed by analyzing the principal components of gene expression profiles obtained from bulk RNA-seq.",
        "Emerging evidence demonstrates that the dynamics of molecular signals emitted from activating mutations determine cell fate [36, 48]. A semantic review has argued that signal intensity and duration likely play a deterministic role in activating mutations, as conceptualized by \u201cby-the-numbers scenarios\u201d [36]. This was exemplified by the rare co-occurrence of strong activating mutations in PIK3CA and PTEN, and the lack of correlation between RAS driver mutations and their downstream signaling activity. This view aligns with our previous observations in angiosarcomas, which suggest a cross-species mechanism [15]. Specifically, angiosarcomas exhibited largely mutually exclusive patterns of key driver mutations such as TP53, PIK3CA, and RAS across both human and canine species [13\u201317, 19, 49, 50]. Multiple fusion genes were also identified in these tumors, particularly those that co-occurred with driver mutations and were associated with the enrichment of an angiogenic molecular program [15]. Although they are likely non-pathogenic or passenger mutations, it is plausible that these fusions may modulate the signal strength of activating mutations, thereby contributing to the observed molecular convergence in angiosarcomas that sustains a high level of PI3K signaling [15]. In the present study, activation of PI3K signaling was noticeable in malignant cells without PIK3CA mutations; this signaling was augmented in DHSA-1426 cells with the mutations. Curiously but not surprisingly, no discernible increase in PI3K signaling was found in COSB cells with PIK3CA mutations. One possible explanation for this difference in pathway activation could be the distinct molecular features imprinted by their original tumor sites: DHSA-1426 was derived from a splenic tumor, and COSB originated from a subcutaneous tumor. Another non-mutually exclusive possibility is that the mutations are likely to reprogram the molecular nature of the cells provoking signaling that establishes distinct immune and metabolic signatures, as addressed in molecular subtypes of angiosarcomas in both humans and canines [14, 19, 51]."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3582441806793213,
    "data_pmids_checked": 1,
    "paper_id": "39709507",
    "extraction_date": "2025-12-19T20:43:29.962889",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39709507.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39697714": {
    "cbioportal_paper_citations": [
      "FMNL1 expression in normal and neoplastic hematopoietic cells was evaluated as previously described (14). Briefly, data from samples from patients with myeloid neoplasia and healthy donors were extracted from the GEO2R, Amazonia! database 2008 (15), cBioPortal (https://www.cbioportal.org) (16,17) and BloodSpot (https://www.fobinf.com/) platforms. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Functional genomics analysis was performed as previously described (14). In brief, the following tools were used for the analysis: Galaxy (https://usegalaxy.org/), ClusterVis (https://biit.cs.ut.ee/clustvis/), ShinyGo 0.77 database (http://bioinformatics.sdstate.edu/go/), GSEA v.4.0.15 [for gene set enrichment analysis (GSEA)]. Drug sensitivity prediction was performed as previously described (14) using the Beat AML study (18,19), Genomics of Drug Sensitivity in Cancer (GDSC) resource (https://www.cancerrxgene.org) (20), and Expression Atlas database (www.ebi.ac.uk/gxa/experiments/E-MTAB-2770). The molecular and biological processes associated with drug response associated with FMNL1 expression were identified using the GeneMANIA software (https://genemania.org/). A P value <0.05 and/or a false discovery rate (FDR) of 25% (q value <0.25) were considered statistically significant."
    ],
    "cbioportal_platform_mentions": [
      "\u2020, the clinical and laboratorial data of TCGA AML cohort were obtained from cBioPortal for Cancer Genomics (http://www.cbioportal.org); \u2021, gene expression values were dichotomized by ROC curve and C statistic; \u00a7, molecular risk was stratified according TCGA study; 3 AML patients were not classified; \u00b6, for statistical analyzes, Mann-Whitney test was used for measured factors, and Fisher\u2019s exact test or Chi-squared test was used for categorical factors. FMNL1, formin-like protein 1; TCGA, The Cancer Genome Atlas; AML, acute myeloid leukemia; ROC, receiver operating characteristic."
    ],
    "data_publication_citations": {
      "30333627": [
        "FMNL1 expression in normal and neoplastic hematopoietic cells was evaluated as previously described (14). Briefly, data from samples from patients with myeloid neoplasia and healthy donors were extracted from the GEO2R, Amazonia! database 2008 (15), cBioPortal (https://www.cbioportal.org) (16,17) and BloodSpot (https://www.fobinf.com/) platforms. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Functional genomics analysis was performed as previously described (14). In brief, the following tools were used for the analysis: Galaxy (https://usegalaxy.org/), ClusterVis (https://biit.cs.ut.ee/clustvis/), ShinyGo 0.77 database (http://bioinformatics.sdstate.edu/go/), GSEA v.4.0.15 [for gene set enrichment analysis (GSEA)]. Drug sensitivity prediction was performed as previously described (14) using the Beat AML study (18,19), Genomics of Drug Sensitivity in Cancer (GDSC) resource (https://www.cancerrxgene.org) (20), and Expression Atlas database (www.ebi.ac.uk/gxa/experiments/E-MTAB-2770). The molecular and biological processes associated with drug response associated with FMNL1 expression were identified using the GeneMANIA software (https://genemania.org/). A P value <0.05 and/or a false discovery rate (FDR) of 25% (q value <0.25) were considered statistically significant."
      ],
      "35868306": [
        "FMNL1 expression in normal and neoplastic hematopoietic cells was evaluated as previously described (14). Briefly, data from samples from patients with myeloid neoplasia and healthy donors were extracted from the GEO2R, Amazonia! database 2008 (15), cBioPortal (https://www.cbioportal.org) (16,17) and BloodSpot (https://www.fobinf.com/) platforms. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Functional genomics analysis was performed as previously described (14). In brief, the following tools were used for the analysis: Galaxy (https://usegalaxy.org/), ClusterVis (https://biit.cs.ut.ee/clustvis/), ShinyGo 0.77 database (http://bioinformatics.sdstate.edu/go/), GSEA v.4.0.15 [for gene set enrichment analysis (GSEA)]. Drug sensitivity prediction was performed as previously described (14) using the Beat AML study (18,19), Genomics of Drug Sensitivity in Cancer (GDSC) resource (https://www.cancerrxgene.org) (20), and Expression Atlas database (www.ebi.ac.uk/gxa/experiments/E-MTAB-2770). The molecular and biological processes associated with drug response associated with FMNL1 expression were identified using the GeneMANIA software (https://genemania.org/). A P value <0.05 and/or a false discovery rate (FDR) of 25% (q value <0.25) were considered statistically significant."
      ],
      "23634996": [
        "The parameters of overall survival (OS) and disease-free survival (DFS) for the AML cohort (n=173) (22) were previously defined (14). Statistical analyzes were carried out using SPSS Statistics for Windows, version 21.0 (SPSS, Chicago, IL, USA), Stata Statistic/Data Analysis 14.1 (Stata Corp., College Station, TX, USA), GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA) and R package Cutpointr (23,24). Kaplan-Meier curves were used to estimate survival, with comparisons made using the Cox regression and/or log-rank test. For continuous variables, statistical tests such as Student\u2019s t-test, Mann-Whitney, Kruskal-Wallis, or analysis of variance (ANOVA) were employed. For categorical variables, the Fisher\u2019s exact test or Chi-squared test was used. A P value of <0.05 was considered statistically significant."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.9725687503814697,
    "data_pmids_checked": 3,
    "paper_id": "39697714",
    "extraction_date": "2025-12-19T20:43:30.935570",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39697714.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39696405": {
    "paper_id": "39696405",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:43:46.874658",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39696405.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.689859867095947,
      "cbioportal_papers": 0.0001838207244873047,
      "pdf_extraction_pass2": 6.176220178604126,
      "cbioportal_papers_pass2": 0.00018095970153808594,
      "used_full_extraction": true,
      "pdf_extraction": 15.866080045700073,
      "platform_mentions": 0.00021314620971679688,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39707454": {
    "paper_id": "39707454",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Log-transformed mRNA z-Scores compared to the\nCell plating on deposited ECM expression distribution of all samples (Illumina HT-12 v3\nCells were cultured 2\u20133 days in 96 well plates to allow microarray) were obtained from the cBioPortal datahub\nECM deposition",
      "Integrative analysis of complex\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:43:59.439616",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39707454.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 13.216996908187866,
      "cbioportal_papers": 0.0004191398620605469,
      "pdf_extraction_pass2": 16.224400997161865,
      "cbioportal_papers_pass2": 0.00043892860412597656,
      "used_full_extraction": true,
      "pdf_extraction": 29.44139790534973,
      "platform_mentions": 0.04178881645202637,
      "data_citations": 0.0006017684936523438,
      "num_data_pmids_checked": 4
    }
  },
  "39692003": {
    "cbioportal_paper_citations": [
      "In our study, multiomics genomic characterization revealed a molecular profile of GBM, IDH\u2010wildtype, CNS WHO grade 4 in all cases. Key features included TERT promoter mutations (n = 5), a chromosome profile with +7/\u221210 (n = 4), and CDKN2A/B homozygous deletion (n = 4). DNA methylation profiling in 4 cases further demonstrated an epigenetic profile matching to or being suggestive of that of GBM. Also, the PTEN and NF1 mutations identified in cases 4, 5, and 6 have been recurrently described in GBM [34]. For the reported adult PLG cases, although some (n = 5) are morphologically diagnosed as GBM (Table S1), only one case had been molecularly tested and was found to harbor a TERT promoter mutation [15]. Although all our cases lack microvascular proliferation and most cases (five of six) lack necrosis, the molecular profiling of adult PLG, in line with GBM, underpins their aggressive nature and rapid progression. These molecular features are distinct from DLGNT, typically diagnosed in children with diffuse leptomeningeal enhancement [4], and characterized by chromosome 1p deletion and MAPK pathway alterations, most commonly the KIAA1549::BRAF fusion [3]. Although the behavior of DLGNT is quite variable, the course is generally significantly less rapid with longer survival."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3923807144165039,
    "data_pmids_checked": 0,
    "paper_id": "39692003",
    "extraction_date": "2025-12-19T20:43:59.861152",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39692003.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39687791": {
    "cbioportal_paper_citations": [
      "For the validation cohort, we utilized publicly accessible MRI and clinical information of GB patients. Datasets were as follows: TCGA-GBM with 262 GB patients,19,20 CPTAC-GBM with 62 GB patients,19,21 IvyGAP with 41 GB patients,19,22,23 and UPENN-GBM with 611 GB patients,24 all of which included available DICOM data. Two experienced neurosurgeons (I.S. and R.S.) reviewed the DICOM data, ensuring that only cases meeting the inclusion criteria for bGB were retained. Out of the 976 cases in the validation cohort, we selected cases with sufficient data regarding age, sex, extent of resection, IDH1 status, and MGMTp status. Data of TCGA-GBM and CPTAC-GBM were obtained from the cBio Cancer Genomics Portal (http://cbioportal.org)25,26 and GDC Data Portal (https://portal.gdc.cancer.gov/). Data of IvyGAP were obtained from the supplementary data.23 Data of UPENN-GBM24 were obtained from the publicly available repository of The Cancer Imaging Archive (TCIA)27 at: https://doi.org/10.7937/TCIA.709X-DN49. Some cases required to obtain idat files from GDC Data portal and assess the MGMTp status using DNA methylation-based classification of central nervous system tumors (https://www.molecularneuropathology.org/).28 Out of the total of 976 cases, 425 cases had complete data for the analysis of age, sex, surgery, IDH1, and MGMTp status, but not for KPS or exact EOR. For MGMTp status, cases categorized as \u201cintermediate\u201d were classified as \u201cmethylated.\u201d As we calculated the CC-rate using the K-cohort, we calculated the CC-rate using DICOM data obtained from selected cases in the Public-cohort."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.286391019821167,
    "data_pmids_checked": 0,
    "paper_id": "39687791",
    "extraction_date": "2025-12-19T20:44:00.147645",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39687791.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40149431": {
    "paper_id": "40149431",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Clinical,pathologic,andgenomicparametersoftheTCGAgastriccancercohortwere\nanalyzedusingthecBioportalforcancergenomicsplatform(www.cbioportal.org)[19,20]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:00.204343",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40149431.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 161.63702607154846,
      "cbioportal_papers": 0.00034689903259277344,
      "pdf_extraction_pass2": 174.6593201160431,
      "cbioportal_papers_pass2": 0.0003368854522705078,
      "used_full_extraction": true,
      "pdf_extraction": 336.29634618759155,
      "platform_mentions": 0.0034780502319335938,
      "data_citations": 0.00023293495178222656,
      "num_data_pmids_checked": 2
    }
  },
  "39687752": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.252532958984375,
    "data_pmids_checked": 0,
    "paper_id": "39687752",
    "extraction_date": "2025-12-19T20:44:00.401672",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39687752.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39779672": {
    "paper_id": "39779672",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Transgeneinduction gdc.cancer.gov/projects/TCGA-HNSC)]7 Additional clinical data for\nMicewereanesthetizedwithisofluraneand100\u00b5Loftamoxifensolu- thisprojectwasdownloadedfromcBioPortal(https://www.cbioportal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:00.447015",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39779672.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 57.480494022369385,
      "cbioportal_papers": 0.00049591064453125,
      "pdf_extraction_pass2": 71.88782501220703,
      "cbioportal_papers_pass2": 0.0004930496215820312,
      "used_full_extraction": true,
      "pdf_extraction": 129.36831903457642,
      "platform_mentions": 0.0036628246307373047,
      "data_citations": 0.0003440380096435547,
      "num_data_pmids_checked": 2
    }
  },
  "39684934": {
    "cbioportal_paper_citations": [
      "We performed mutational analysis using cBioportal [http://www.cbioportal.org] [42,43]. The results were reported in color-coded figures, which were based on an odds ratio of the presence of mutational frequency to the specific cancer type. The Cancer Cell Line Encyclopedia (CCLE\u2014https://portals.broadinstitute.org/ccle) [44] database was used to study the transcriptomic relationship between BRAF and ANXA7. Relative protein abundance was calculated for BRAF and ANXA7 using the MD Anderson cell line project (MCLP, https://bioinformatics.mdanderson.org/main/MCLP:Overview, accessed on 6 August 2024) [18]."
    ],
    "cbioportal_platform_mentions": [
      "To further investigate the regulatory role of the BRAF mutation (particularly V600E) on ANXA7 expression, we analyzed large-volume datasets from the curated databases cBioportal and CCLE. In about 60% of the thyroid cancer cases, BRAF mutations are present (Figure 3 and Figure S1 and Table S1 for cell lines). The BRAF gene is a proto-oncogene. The highest level of BRAF mutation is through the V600E mutation (cBioPortal). When the mRNA expression levels were viewed, both BRAF and ANXA7 had mid-range levels in thyroid cancer cases (Cancer Cell Line Encyclopedia, CCLE). However, when looking at the protein expression levels of these genes through reverse-phase protein array (RPPA), ANXA7 expression was lowest in thyroid cancer (MD Anderson Cell Line Project, Figure 2). Since it is the BRAF mutation and not the expression that leads to cancer, we decided to look more closely at ANXA7."
    ],
    "data_publication_citations": {
      "22460905": [
        "We performed mutational analysis using cBioportal [http://www.cbioportal.org] [42,43]. The results were reported in color-coded figures, which were based on an odds ratio of the presence of mutational frequency to the specific cancer type. The Cancer Cell Line Encyclopedia (CCLE\u2014https://portals.broadinstitute.org/ccle) [44] database was used to study the transcriptomic relationship between BRAF and ANXA7. Relative protein abundance was calculated for BRAF and ANXA7 using the MD Anderson cell line project (MCLP, https://bioinformatics.mdanderson.org/main/MCLP:Overview, accessed on 6 August 2024) [18]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.44326114654541016,
    "data_pmids_checked": 1,
    "paper_id": "39684934",
    "extraction_date": "2025-12-19T20:44:00.647710",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39684934.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39684518": {
    "cbioportal_paper_citations": [
      "A total of 19 microarray and RNA-seq datasets [23,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47] were obtained from the NCBI Gene Expression Omnibus (GEO) [48] and the Genomic Data Commons Data Portal [49]. IC50 values of anti-cancer drugs and RNA-seq data in Cancer Cell Line Encyclopedia (CCLE) datasets were obtained from the cBioPortal for Cancer Genomics [50,51]. Details of the datasets used in this study are summarized in Table 4."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31068700": [
        "A total of 19 microarray and RNA-seq datasets [23,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47] were obtained from the NCBI Gene Expression Omnibus (GEO) [48] and the Genomic Data Commons Data Portal [49]. IC50 values of anti-cancer drugs and RNA-seq data in Cancer Cell Line Encyclopedia (CCLE) datasets were obtained from the cBioPortal for Cancer Genomics [50,51]. Details of the datasets used in this study are summarized in Table 4."
      ],
      "29713087": [
        "A total of 19 microarray and RNA-seq datasets [23,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47] were obtained from the NCBI Gene Expression Omnibus (GEO) [48] and the Genomic Data Commons Data Portal [49]. IC50 values of anti-cancer drugs and RNA-seq data in Cancer Cell Line Encyclopedia (CCLE) datasets were obtained from the cBioPortal for Cancer Genomics [50,51]. Details of the datasets used in this study are summarized in Table 4."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.26525282859802246,
    "data_pmids_checked": 2,
    "paper_id": "39684518",
    "extraction_date": "2025-12-19T20:44:00.717818",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39684518.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "40369102": {
    "paper_id": "40369102",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "comparablewithasinglescalingparameter(Fig.S3).Fornewplatforms,the The TMB and FGA were retrieved from cBioPortal (https://www",
      "transferabilityhastobere-evaluated.Asecondlimitationofthecurrent cbioportal.org/study/summary?id=pancan_pcawg_2020)",
      "thisstudygeneralizesthepreviouslyfoundandvalidatedprognosticvalueof PublicdatafromtheCCLEwereretrievedfromcBioPortal(https://\nTBLasabiomarkerfordiseaserecurrenceinCRC24toseveralothercancer www.cbioportal.org/study/summary?id=ccle_broad_2019) and SV data\ntypes,therebyshowingthatTBLalongsideFGAandTMBhaspotentialasa fromthedepmapportal27.TheTMBandFGAwereretrievedfromcBio-\ngeneralbiomarkerfordiseaserecurrenceacrosscancertypes.Nevertheless, Portal.TheTBLwascalculatedbysummingthenumberofunbalancedSVs,\nfurtherexternalvalidationisneededtoverifyitsprognosticvalueinother i.e.,thedeletionsandduplications,pertumorsample",
      "Portal(https://cbioportal.org)",
      "Hanahan,D.&Weinberg,R.A.Hallmarksofcancer:thenext\narm level as provided by cBioPortal for the TCGA and GISTIC for the generation.Cell144,646\u2013674(2011)"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:00.729503",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/40369102.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 155.61505270004272,
      "cbioportal_papers": 0.0003008842468261719,
      "pdf_extraction_pass2": 181.20751571655273,
      "cbioportal_papers_pass2": 0.00030684471130371094,
      "used_full_extraction": true,
      "pdf_extraction": 336.82256841659546,
      "platform_mentions": 0.0026390552520751953,
      "data_citations": 0.0007140636444091797,
      "num_data_pmids_checked": 7
    }
  },
  "39682179": {
    "cbioportal_paper_citations": [
      "RAS signaling and mutations in cancers. (A) Schematic of RAS signaling in normal tissue (left panel) and cancers (right panel). RAS proteins are small GTPases that are used as signaling messengers to convey growth factor sensing by Receptor Tyrosine Kinase (RTK, e.g., EGFR epidermal growth factor receptor). Active RAS binds to GTP and activates downstream signaling kinases. Among the main ones is the BRAF-MEK-ERK pathway, which controls transcriptional activation of target genes involved in cell proliferation and survival. In cancers, RAS is very frequently mutated (see (B)); as such, it acquires auto-activation properties which unables it to hydrolyze GTP and as such maintains RAS in an active form. As such, RAS signaling is aberrantly \u2018switched-ON\u2019 in the absence of biological cues, namely growth factors. RAS mutations are leading to hyperproliferation, alterations in DNA replication dynamics, genomic instability and increased survival. Two main outcomes are then possible either in whatsoever normal cells: aberrant RAS activity leads to senescence (oncogene-induced senescence, OIS), or if secondary mutations are acquired that permit cells to escape senescence, they can further transform and take the direction to tumor growth. This figure has been created with Biorender.com (B). Frequencies of genomic alterations of K-RAS, N-RAS and H-RAS as retrieved from the cBioportal for Cancer Genomics database (www.cbioportal.org) (accessed on 3 April 2021) [8,9]. Data were retrieved from 185 non-redundant pan-cancers studies (TCGA and non-TCGA) with non-overlapping samples. A threshold of at least 50 cases/patients per study was used. Histograms are shown per each cancer type with studies with >10% or >5% of alteration frequency for K-RAS and H-RAS/N-RAS, respectively."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625050": [
        "It is important to note here that in addition to RAS genes, other members of the broad RAS signaling pathway can be mutated and behave similarly to increase oncogenic RAS signaling. It is the case with the EGFR (Epithelial Growth Factor Receptor), BRAF, ERK-MAP kinases, ERBB2, and so on and so forth. For instance, the broad RAS signaling pathway is mutated in 74% of lung adenocarcinomas in The Cancer Genome Atlas (TCGA) [12]. In addition to RAS mutations, identifying patients with RAS signaling alterations through monitoring the transcriptional signatures of RAS activity might be crucial. A novel transcriptional signature, RAS84, has been developed to identify cancers that are driven by RAS signaling by non-KRAS mutations [13]. This signature shows that ~80% of lung adenocarcinomas show activation of RAS signaling pathway independently of K-RAS mutation. Transcriptional signature RAS84 is mainly clonal, showing that oncogenic RAS activity is an early driver, at least in NSCLCs (lung adenocarcinomas) [13]. Previously described transcriptional signatures of oncogenic RAS activity, such as the \u2018K-RAS addiction\u2019 signature [14,15,16], have been outperformed by this novel RAS84 signature."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2314140796661377,
    "data_pmids_checked": 1,
    "paper_id": "39682179",
    "extraction_date": "2025-12-19T20:44:00.887728",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39682179.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39676597": {
    "cbioportal_paper_citations": [
      "Survival data and mRNA expression alterations of MBD2 in HNSCC were accessible via cBioportal (http://www.cbioportal.org) [18, 19]. The cBioPortal provides an open\u2010access resource for cancer genomics data, allowing researchers to explore the relationship between genetic alterations and clinical outcomes."
    ],
    "cbioportal_platform_mentions": [
      "Using UALCAN, we found that MBD2 mRNA is highly expressed in several cancers types, including cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD), uterine corpus endometrial carcinoma (UCEC), and HNSCC, compared to normal samples (Figure 1). To further assess MBD2 expression in HNSCC, we analyzed mRNA data from TCGA, which showed significantly higher MBD2 levels in 520 HNSCC samples compared to 44 adjacent normal samples (p = 0.011) (Figure 2A). Further, the same results were verified in HNSCC tissues and paired paracarcinoma tissues (p = 0.024) (Figure 2B). Survival data from cBioPortal indicated that altered MBD2 expression is negatively correlated with poor OS and DFS in HNSCC patients (Figure 2C,D).",
      "Relationship between MBD2 mRNA expression alterations and prognosis in HNSCC patients. MBD2 expression in HNSCC samples was remarkably higher than in adjacent normal samples from TCGA (A). MBD2 levels in HNSCC tissues were markedly elevated compared to paired paracarcinoma tissues from TCGA (B). Prognostic analysis using the cBioPortal database indicated that altered MBD2 expression correlates with poor OS (C) and DFS (D) in HNSCC patients. Data were presented as box\u2010and\u2010whisker plots. *p < 0.05."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.10730385780334473,
    "data_pmids_checked": 0,
    "paper_id": "39676597",
    "extraction_date": "2025-12-19T20:44:00.995123",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39676597.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39678373": {
    "cbioportal_paper_citations": [
      "HRD gene mutations, which are pivotal in this selection process, are detected in approximately 5% of testicular cancer cases. This emphasizes the necessity of biomarker-driven approaches to optimize treatment outcomes (Figure 3) (Gao et al., 2013)."
    ],
    "cbioportal_platform_mentions": [
      "The figure displays the frequency of mutations in homologous recombination repair (HRR) genes in testicular germ cell tumors (TGCTs). The data, obtained from cBioPortal, includes 11,250 samples from 10,635 patients. This combined study contains samples from three studies: MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017), Testicular Germ Cell Tumors (TCGA, PanCancer Atlas), and Testicular Germ Cell Cancer (TCGA, Firehose Legacy)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2597827911376953,
    "data_pmids_checked": 0,
    "paper_id": "39678373",
    "extraction_date": "2025-12-19T20:44:01.003793",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39678373.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39677720": {
    "cbioportal_paper_citations": [
      "The Cancer Genome Atlas (TCGA) Ovarian Serous PanCancer Atlas were accessed via the cBIOPortal (http://www.cbioportal.org)17 18HGSC tumor sc-RNA-seq data was analyzed via (https://lambrechtslab.sites.vib.be/19). Survival analyses (Kaplan\u2013Meier curves), protein expression (Z score) analyses, and mRNA expression (transcripts per million) were examined."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "21720365": [
        "The Cancer Genome Atlas (TCGA) Ovarian Serous PanCancer Atlas were accessed via the cBIOPortal (http://www.cbioportal.org)17 18HGSC tumor sc-RNA-seq data was analyzed via (https://lambrechtslab.sites.vib.be/19). Survival analyses (Kaplan\u2013Meier curves), protein expression (Z score) analyses, and mRNA expression (transcripts per million) were examined."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3103809356689453,
    "data_pmids_checked": 1,
    "paper_id": "39677720",
    "extraction_date": "2025-12-19T20:44:01.054333",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39677720.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39672307": {
    "cbioportal_paper_citations": [
      "Gene expression and survival data from The Cancer Genome Atlas (TCGA) [13] was downloaded from cbioportal (https://www.cbioportal.org/) [14]. Kaplan-Meier curves were constructed to investigate the relationship between gene expression and survival in individuals with cervical cancer."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.15383195877075195,
    "data_pmids_checked": 0,
    "paper_id": "39672307",
    "extraction_date": "2025-12-19T20:44:01.233344",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39672307.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39672812": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26544944": [
        "To elucidate how direct modulation of regulatory elements containing AREs shapes the chromatin states to regulate oncogenic and normal-specific signaling pathways, we first examined the genomic features of MACC H3K27ac peaks by classifying them into six categories based on their co-occupancy status and association with chromatin modifications. Using ChromHMM25 with six distinct histone marks (H3K4me1, H3K4me2, H3K4me3, H3K27me3, H3K36me3, H3K79me2) under androgen stimulation, we defined various chromatin states associated with MACCs (Fig. 5a), ranging from heterochromatin (E1) to active enhancers/promoters (E6; see Methods for detail). MACCs exhibited the expected dynamic changes in active enhancers/promoters at the E6 state, with either repressive or activating chromatin-modifying domains. The enrichment of the E5 state indicates significant chromatin remodeling at bivalent enhancers/promoters, consistent with AR\u2019s established role in regulating tumorigenesis/differentiation through bivalent enhancer26\u201328. We then focused on histone deacetylases (HDACs) and EZH2, given their common overexpression and bivalent transcriptional function in cancers26,29\u201331. By mapping the binding sites of these factors to MACC H3K27ac peaks, it was evident that only HDAC3, and not HDAC1/2 or EZH2, showed a dynamic response after androgen stimulation30 (Fig. 5b and Supplementary Fig. 9). Furthermore, HDAC3 binding sites were also associated with MACC peaks (Supplementary Fig. 10a) and were restricted to AR-bound chromatin enriched for AREs (Supplementary Fig. 10b), as other AR binding sites lacking an ARE showed no global difference in HDAC3 signal after androgen stimulation (Supplementary Fig. 10b). To determine HDAC3\u2019s effect on ARE-associated chromatin, we analyzed motif enrichment at HDAC3 binding sites (HDAC3 ChIP-seq)30 before and after androgen stimulation and found ARE motifs were significantly enriched (Fig. 5c and Supplementary Fig. 10c, d), unlike FOXA1 or HOXB13 motifs (Supplementary Fig. 10d). This suggests that HDAC3 plays a role in modulating the activation of those regulatory elements containing AREs in the prostate and HDAC3 activity could lead to alterations in the growth-suppressive phenotypes upon ARE activation. We then knocked out HDAC3 in our LNCaP ARE activation cells, which indeed intensified the growth-suppressive phenotypes upon ARE activation (Fig. 5d, e). To further confirm that HDAC3 restricts the ARE activation program, we applied transcriptional signatures from each specific MACC construct, AR- and cell cycle scores to RNA-seq profiles generated upon HDAC3 kockdown12. Disruption of HDAC3 expression correlated with a higher AR score and increased ARE activation activity, while cell cycle activity and ARE repression activity were diminished (Fig. 5f and Supplementary Fig. 10e, f). Accordingly, this resulted in impaired cell growth in LNCaP cells, in contrast to the promotion of cell growth observed with HDAC3 overexpression (Fig. 5g and Supplementary Fig. 10e), and a reduced response to androgen-mediated growth (Fig. 5h). We further explored the clinical relevance of these observations by employing gene set enrichment analysis on pathway hallmarks utilizing patient samples available in The Cancer Genome Atlas (TCGA)32. Patients (Supplementary Fig. 10g) were stratified into four groups based on their HDAC3 expression levels: Q1 (lowest HDAC3 expression), Q2, Q3, and Q4 (highest HDAC3 expression). Significantly, low HDAC3 expression correlated with elevated AR activity, as evidenced by enrichment in the canonical Androgen Response pathway and AR score (Fig. 5i, j and Supplementary Fig. 10h). Conversely, high HDAC3 expression was associated with an enrichment of cell cycle-related pathways (Fig. 5i, j and Supplementary Fig. 10h). Furthermore, higher levels of HDAC3 were indicative of poorer disease-free survival (DFS) (Fig. 5k). These data are consistent with the proposed regulatory function of HDAC3 in tempering the growth-inhibitory effects driven by ARE activation. Combined, we conclude that HDAC3 acts to dampen the growth-suppressive programs associated with ARE-enriched enhancers, highlighting its role in modulating AR-mediated transcriptional regulation.Fig. 5HDAC3 mitigates the growth-suppressive effect of AREs.a Combinatorial pattern of histone marks in a 6-state model using ChromHMM. The heatmap (Emission plot) displays the frequency of the six distinct histone modifications (H3K4me1\u2014active enhancer, H3K4me2, H3K4me3\u2014active promoter, H3K27me3\u2014repressive epigenetic mark, H3K36me3\u2014transcription mark, H3K79me2) under androgen stimulation along with MACCs in each state. b Signal of MACC H3K27ac (18 h) at all HDAC3 vehicle-treated (GSM717402) or HDAC3 DHT-treated (GSM717403) binding peaks. c Schematic of motif enrichment analysis from HDAC3 ChIP-seq before and after DHT stimulation. ARE motifs were enriched in the DHT condition at HDAC3 binding sites. d Immunoblot of HDAC3 expression in LNCaP activating MACC cells with control or two independent HDAC3 sgRNAs. The samples derive from the same experiment, but different gels for HDAC3 and Vinculin were processed in parallel. e Growth of HDAC3 knockout in LNCaP activating MACC cells with vehicle or increasing doses of tamoxifen. HDAC3 knockout amplified the growth-suppressive phenotypes upon ARE activation. The growth readout is presented in a heatmap format, n = 3. f Pathway analysis using gene expression profiling of HDAC3-knockdown RNA-seq data in LNCaP cells (GSE153585). g Growth of HDAC3 knockout or overexpression in LNCaP cells. The growth readout is presented in a heatmap format, n = 3. h Growth of LNCaP HDAC3 knockout cells after androgen deprivation and DHT stimulation. The growth readout is presented in a heatmap format, n = 3. i, j Pathway analysis using GSEA Hallmarks and gene signatures of Q4 vs. Q1 groups based on HDAC3 expression level in the TCGA cohort. k Kaplan\u2013Meier analysis of disease-free survival in the TCGA cohort, stratified into quartiles by HDAC3 expression level. Time = months. Statistical significance was determined using the log-rank test. For (d, e, g, h) experiments were conducted at least three times with consistent results. Source data are provided as a Source Data file. c Created with BioRender.com.",
        "We next asked whether the distinct AR target genes revealed by our strategy to directly modulate AREs were relevant in human prostate samples. We examined the relationship of transcriptional programs controlled by AREs to human PCa and normal prostate tissue samples. Unsupervised clustering of the transcriptomes of LNCaP cells with inducible expression of MACCs with human PCa and normal prostate samples32 revealed that all samples clustered with tumor samples except those with activation of AREs, whose transcriptional profile shifted toward normal prostate tissue (Fig. 6a and Supplementary Fig. 11a). Similar effects were observed in an independent cohort with matched cancer and normal tissue33 (Supplementary Fig. 11b, c). Gene expression signatures specific to ARE activation or repression were derived from the transcriptional responses of LNCaPs to different MACC constructs and applied to single-cell data from human PCa specimens34 showed enrichment of the signature of ARE activation primarily in normal luminal epithelial cells, while the signature of ARE repression was enriched in tumor luminal epithelium (Supplementary Fig. 11d\u2013g). We next examined the impact of these signatures on the prognosis in patients with PCa. In a cohort of over 169,000 patients with clinically localized PCa35 with available transcriptome profiles, the signature of ARE repression was associated with more aggressive tumors (Fig. 6b) and was highest in NCCN high and very high-risk disease (Fig. 6b), and higher Gleason grade, PSA (Supplementary Fig. 12a, b), and stage (Supplementary Tables 1 and 2), while ARE activation was associated with the opposite\u2014less aggressive cancers (Fig. 6b, Supplementary Fig. 12c\u2013e, and Supplementary Tables 3 and 4). ARE activation was associated with more luminal features, while the repressive signature was higher in tumors classified as basal subtype (Fig. 6b). In a cohort of 855 patients after radical prostatectomy36, high expression of the ARE repressive activation signature was associated with worse metastasis-free survival (Fig. 6c), while the ARE activated signature higher expression was associated with improved metastasis-free survival (Fig. 6d). Finally, in cohorts of patients with metastatic castration-resistant PCa37\u201340, the ARE activation signature was associated with improved overall survival (Fig. 6e and Supplementary Fig. 12f), maintenance of luminal character (Fig. 6f) and responsiveness to enzalutamide (Supplementary Fig. 12g). Together, these data support that in both clinically localized and advanced, treatment-resistant human PCa, genes controlled by AREs are associated with prognosis and luminal versus basal phenotypes.Fig. 6Distinct transcriptional programs revealed by modulating AREs are clinically relevant in human prostate cancer.a Unsupervised clustering of the transcriptomes of human prostate cancer and normal samples (TCGA), along with tamoxifen induced LNCaP MACC lines. b Association of ARE and activated signatures from LNCaP MACC lines with National Comprehensive Cancer Network (NCCN) risk category (top) and PAM50 luminal/basal classification (bottom) in clinically localized prostate cancer, n = 169,123 (n = number of patients; center: median; box: 25th to 75th percentile; shape: the distribution of the data, with the width indicating the kernel density estimate of the frequency). KS Kruskal\u2013Wallis, Int.Fav Favorable Intermediate risk, Int.Unfav Unfavorable Intermediate risk, also Supplementary Table 1 and 3. c Kaplan\u2013Meier analysis of metastasis-free survival in 855 men after radical prostatectomy, stratified into quartiles by ARE repressed signature expression level. Time = months. Statistical significance was determined using the log-rank test. d Kaplan\u2013Meier analysis of metastasis-free survival in 855 men after radical prostatectomy, stratified into quartiles by ARE activated signature expression level. Time = months. Statistical significance was determined using the log-rank test. e Kaplan\u2013Meier analysis of overall survival in 123 men with metastatic castrate resistant prostate cancer, stratified into quartiles by ARE activated signature expression level in biopsy specimens. Hazard ratio (HR) = 0.47 [0.26\u22120.83]. Statistical significance was determined using the log-rank test. f Correlation analysis of basal/luminal phenotype score (higher = more basal) by gene expression (Y-axis) with ARE activated signature expression level (X-axis). Rho = \u22120.81, Spearman\u2019s correlation. Statistical significance was evaluated using a two-sided Spearman\u2019s rank correlation test."
      ],
      "31061129": [
        "The CRPC cohort consisted of 123 biopsies from male metastatic castration-resistant prostate cancer (mCRPC) patients, derived from two studies37,38, with diverse clinical characteristics and treatment histories. Other mCRPC cohorts39,40 were also followed using the same strategies with the original published format. Baseline biopsy samples captured initial gene expression at first biopsy after mCRPC diagnosis. RNA-seq aligned with STAR provided gene expression data from gencode v.28, normalized to TPM, and log2 transformed. Z-scores standardized expression values per gene were calculated for ARE activating (VP64) and ARE repressed (KRAB) gene expression scores, summed log2 fold changes for positively and negatively expressed genes. The primary endpoint was overall survival from biopsy to death/last follow-up. Patients were stratified by quartiles of VP64 and KRAB scores. Kaplan\u2013Meier curves visualized survival analysis, and Cox proportional hazards regression evaluated gene expression\u2019s impact on survival as continuous variables per quartile. Basal/luminal gene expression score was calculated as previously described38 and was correlated with VP64 and KRAB scores, with Spearman analysis of correlation."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.266981840133667,
    "data_pmids_checked": 2,
    "paper_id": "39672812",
    "extraction_date": "2025-12-19T20:44:01.270865",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39672812.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39669561": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data from cBioportal (34, 35) were retrieved from metastatic melanoma cohorts to predict neoantigens using LRMAHpan. The cohort was constructed by sequencing the whole exomes of 38 pairs of pre-treatment melanoma tumors and normal tissues. This data includes mutation maps in MAF format for 38 cases and RPKM expression data obtained from mRNA analysis for 27 cases. Additionally, the dataset includes results of HLA class I and class II typing."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.0705709457397461,
    "data_pmids_checked": 0,
    "paper_id": "39669561",
    "extraction_date": "2025-12-19T20:44:01.304000",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39669561.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39669237": {
    "cbioportal_paper_citations": [
      "PIK3CA encodes the catalytic subunit of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) protein complex. PROS disorders represent clinically recognizable conditions, typically discerned at birth or during early childhood, and are associated with cutaneous, vascular, skeletal, and cerebral anomalies, as well as focal or segmental overgrowth of the body.30,31 PIK3CA variants associated with PROS overlap those reported as oncogenic variants found in multiple tumor types (COSMIC and cBioPortal Databases).32,33 A large number of PI3K/AKT pathway inhibitors are currently under clinical study, primarily in a cancer setting, but also in the setting of PROS. The co-existence of 2 clinically significant variants in PIK3CA and GNAQ has been seen in 3 cases in this study. A similar combination of variants has been reported in 2 patients in the literature. In 2018, 1 patient presenting with megalencephaly-capillary malformation was reported to carry both a PIK3CA p.Glu45Lys variant and a GNAQ p.Gln209His variant detected in DNA extracted from a congenital hemangioma.3 The other patient was a 58-year-old woman presenting with hepatic small vessel neoplasm. Both GNAQ p.Gln209His and PIK3CA p.His1047Arg variants were detected in an autopsy performed after a pulmonary embolism.34 The co-existence of 2 activating PIK3CA variants has been reported in at least 1 patient with lipoma, capillary malformation, and an ovarian cyst.13 To date, no genotype-phenotype correlation has been established regarding specific variants, or combination of variants, and severity of the disease."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.14253807067871094,
    "data_pmids_checked": 0,
    "paper_id": "39669237",
    "extraction_date": "2025-12-19T20:44:01.413501",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39669237.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39673574": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The gene panel investigated in the AU cohort was also investigated in the TCGA-COAD (Colon Adenocarcinoma) dataset for further validation. We extracted a total of 435 patients from the TCGA-COAD dataset available on cBioportal. (Gao et al. 2013; Mounir et al. 2019). This dataset was used in this study for genomics, transcriptomics, and other clinicopathological analysis. The mutation and copy number variation data were analyzed and visualized as previously described (Ahluwalia et al. 2022). The prognostic significance of individual genes was assessed in the TCGA dataset using univariate analysis, and the results were mapped based on individual p-values and z-scores. To analyze the distribution, we assessed four clinical endpoints: Progression Free Survival (PFS), Overall Survival (OS), DSS (Disease-Specific Survival), and DFS (Disease Free Survival). The top 3 genes, GTF3A, VEGFA, and PKM, were found to have the highest association with survival values and were subsequently selected for signature development. The Cox regression method was employed to calculate hazard ratios and p-values. Further, the gene signature was validated using four independent datasets, GSE14333 (n = 226 patients), GSE17536 (n = 177 patients), GSE28722 (n = 125), and GSE40967 (n = 574).",
      "The unprocessed count data was normalized using nCounter software (NanoString Technologies Inc.). In brief, the geometric mean of the negative and positive control samples was utilized to standardize the expression across all samples. Additional normalization was carried out using six internal control genes (ABCF1, GUSB, HPRT1, LDHA, POLR1B, and RPLO). The hierarchal clustering was performed using Ward\u2019s method to visualize the differential expression of genes in the AU cohort. The principal component analysis (PCA) was performed using the GEPIA portal (Tang et al. 2017). The p-values of the prognostic values of each gene were derived from cBioportal based on the z-score. Kaplan\u2013Meier analysis and a log-rank test were used to compare the survival distribution in the AU, TCGA, and GEO datasets. The immune cell infiltration was analyzed using the non-parametric Wilcoxon method. All the statistical analyses were performed using GraphPad Prism (version 9.2, GraphPad Software), R (version 4.2, R Foundation for Statistical Computing, Vienna, Austria) (http://www.R-project.org/), and SAS-JMP (version 16, SAS Institute). The p values of < 0.05 were considered statistically significant."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.38608527183532715,
    "data_pmids_checked": 2,
    "paper_id": "39673574",
    "extraction_date": "2025-12-19T20:44:01.427389",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39673574.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39668816": {
    "cbioportal_paper_citations": [
      "The characteristics of genomic alterations in DHX34 across the pan-cancer were analyzed utilizing the cBioPortal database (https://www.cbioportal.org) 25. This comprehensive analysis focused on investigating the genetic alteration rate, mutation types, and specific mutated site information of DHX34 in pan-cancer."
    ],
    "cbioportal_platform_mentions": [
      "To assess the mutation of DHX34 in pan-cancer, we conducted a comprehensive study using the cBioPortal database and found that DHX34 was altered in 5% (128/2565) of pan-cancer patients (Fig. 3A). Furthermore, our analysis of the mutation frequency of the DHX34 gene across various tumor types showed that cervical cancer (20%), esophagogastric cancer (15.34%), and bladder cancer (13.04%) had the highest alteration frequency, ranking among the top three. Notably, amplification was identified as the most prevalent type of DHX34 gene mutation (Fig. 3B). Analysis of the mutation sites of DHX34 in pan-cancer, revealed a total of 18 mutation sites, spanning the region between 0 and 1143 amino acids (Fig. 3C). Additionally, a positive correlation was observed between DHX34 expression and TMB across 12 tumor types, and MSI across10 tumor types (Fig. 3D, 3E), indicating that DHX34 significantly impacts both TMB and MSI."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.21532106399536133,
    "data_pmids_checked": 0,
    "paper_id": "39668816",
    "extraction_date": "2025-12-19T20:44:01.545856",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39668816.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39658088": {
    "cbioportal_paper_citations": [
      "RNA expression datasets in human tumors and cell lines were obtained from the open-access and open-source resource cBioPortal (Cerami et al, 2012; Gao et al, 2013). The human cutaneous melanoma transcriptomics dataset (SKCM) shown here was obtained from TCGA Research Network: http://www.cancer.gov/tcga (PanCancer Atlas). The human melanoma cell line transcriptomic dataset was obtained from the Cancer Cell Line Encyclopedia (CCLE, Broad, 2019) (Ghandi et al, 2019). Perturbation effects associated with CRISPR-Cas9 (Public 23Q4+Score, Gene effect: Chronos), RNAi (Achilles+DRIVE+Marcotte, Gene effect: DEMETER2), and inhibitors (PRISM Repurposing Primary Screen, Drug sensitivity/effect: Log2FC of cell count) in human melanoma cell lines were obtained from the DepMap Portal: https://depmap.org/portal. Spearman correlation coefficients (\u03c1) between genes of the SKCM dataset were obtained from cBioPortal. Spearman correlation coefficients between perturbation effects (DepMap) and transcript levels (CCLE) were calculated using Prism (GraphPad Software). Gene essentiality was determined using DepMap. The MitoCarta3.0 (Rath et al, 2021) dataset and associated MitoPathways3.0 were used to identify and classify mitochondrial proteins associated with transcriptomic data. Heat-maps were generated using Morpheus: https://software.broadinstitute.org/morpheus. For hierarchical clustering and dendrograms, the metric used was Euclidean distance, the linkage method was average, and clustering was performed on rows and columns."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31068700": [
        "RNA expression datasets in human tumors and cell lines were obtained from the open-access and open-source resource cBioPortal (Cerami et al, 2012; Gao et al, 2013). The human cutaneous melanoma transcriptomics dataset (SKCM) shown here was obtained from TCGA Research Network: http://www.cancer.gov/tcga (PanCancer Atlas). The human melanoma cell line transcriptomic dataset was obtained from the Cancer Cell Line Encyclopedia (CCLE, Broad, 2019) (Ghandi et al, 2019). Perturbation effects associated with CRISPR-Cas9 (Public 23Q4+Score, Gene effect: Chronos), RNAi (Achilles+DRIVE+Marcotte, Gene effect: DEMETER2), and inhibitors (PRISM Repurposing Primary Screen, Drug sensitivity/effect: Log2FC of cell count) in human melanoma cell lines were obtained from the DepMap Portal: https://depmap.org/portal. Spearman correlation coefficients (\u03c1) between genes of the SKCM dataset were obtained from cBioPortal. Spearman correlation coefficients between perturbation effects (DepMap) and transcript levels (CCLE) were calculated using Prism (GraphPad Software). Gene essentiality was determined using DepMap. The MitoCarta3.0 (Rath et al, 2021) dataset and associated MitoPathways3.0 were used to identify and classify mitochondrial proteins associated with transcriptomic data. Heat-maps were generated using Morpheus: https://software.broadinstitute.org/morpheus. For hierarchical clustering and dendrograms, the metric used was Euclidean distance, the linkage method was average, and clustering was performed on rows and columns."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4929189682006836,
    "data_pmids_checked": 1,
    "paper_id": "39658088",
    "extraction_date": "2025-12-19T20:44:02.169593",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39658088.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39649886": {
    "cbioportal_paper_citations": [
      "The Maximal Clique Centrality (MCC) algorithm, via the cytoHubba plugin in Cytoscape, identified hub genes. The online database cBioPortal (http://www.cbioportal.org) analyzed co-expression relationships between genes22. GEPIA (gepia.cancer-pku.cn) analyzed gene expression differences between GBM and normal tissues and performed survival analysis23."
    ],
    "cbioportal_platform_mentions": [
      "EIF4E scored highest in the MCC algorithm and had a high degree value. A co-expression relationship between EIF4E and PBK in GBM was revealed through the cBioPortal database (Fig. 4A). Western blot results showed a significant reduction in EIF4E expression after PBK knockdown in glioma cell line HS683 (Fig. 4B). The GEPIA database indicated EIF4E expression was significantly higher in GBM than in normal tissue (Fig. 4C). Survival analysis showed shorter overall survival and disease-free survival in glioma patients with high EIF4E expression (Fig. 4D, E).",
      "Association between EIF4E and PBK and patient survival. The co-expression relationship between EIF4E and PBK was performed by the cBioPortal online platform (A). The expression of EIF4E was downregulated after PBK knockdown in HS683 (B). GEPIA online platform was used to perform the expression of EIF4E in glioma and its effect on survival. EIF4E mRNA expression in GBM compared to normal brain tissues (C) in which normal samples are marked in gray and GBM samples are marked in red. High EIF4E expression decreases both overall survival (D) and disease-free survival (E)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.17634296417236328,
    "data_pmids_checked": 0,
    "paper_id": "39649886",
    "extraction_date": "2025-12-19T20:44:02.352306",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39649886.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39645166": {
    "cbioportal_paper_citations": [
      "Although limited, some studies have analyzed NSD1's mutational status in both HPV- and HPV + HNSCC subtypes. These studies found that NSD1 mutations characterize a subset of HPV- HNSCC but are absent in non-smoker HPV + HNSCC, consistent with the lower mutational burden typically observed in this subtype [63]. However, another study that did not account for smoking habits detected inactivating NSD1 mutations in a small number of HPV + HNSCC (Table 1) [64]. Notably, when analyzing the impact of NSD1 mutations on overall survival and disease-free progression, the authors found different effects based on HPV-status: NSD1 mutations were associated with worse survival in HPV- HNSCC, but with improved survival in HPV + tumors (Table 1) [64]. Although a larger cohort is needed to confirm these findings in HPV + HNSCC, these results suggest distinct roles for NSD1 mutations in different HNSCC subtypes.Table 1Genetic and expression alterations of the three NSD paralogues (NSD1, NSD2 and NSD3) in HPV + HNSCC and Cervical Cancers. Information about their role and/or their association with clinical and pathological characteristics are reported when available. Genetic alterations were extracted by the cBioPortal (TCGA, PanCancer Atlas). Information about gene expression and genetic alterations were also obtained from the referenced studies, when present. For HPV + Cervical cancers it was assumed that the 90\u201395 % of these tumors are HPV + [20,21,65,66]. NA = not available.Table 1Gene/ProteinHPV+HNSCCCervical CancerKind of AlterationRole and/or pathogenic associationRef.Kind of AlterationRole and/or pathogenic associationRef.NSD1Mutated:10 % n = 7/72NAcBioPortalMutated:6 % n = 19/297NAcBioPortal5 missense mutationNA10 missense mutationNA2 truncating mutationLikely oncogenic6 truncating mutationLikely oncogenicMutated:9 % n = 6/65No associated with any clinical characteristic/Worse survival and disease free survival(64)1 structural variant (NSD1-DPEP2 fusionLikely oncogenic1 amplificationLikely oncogenic1 deep deletionLikely oncogeni4 missense mutation3/4 probably pathogenic2 truncating mutationNAOverexpressed:YesBetter survival(65)Overexpressed:Not assessedNSD2Mutated:3 % n = 2/72NAcBioPortalMutated:3 % n = 10/297NAcBioPortal1 deep deletionNA4 missense mutationNA1 missense mutationNA1 splice mutationNA1 amplificationNA4 deep deletionNAOverexpressed:YesOncogenic and correlated with histological grade/Better survival(65, 68)Overexpressed:YesOncogenic/Associated with tumor stage, poor differentiation and lymph node metastasis(69\u201371)NSD3Mutated:1 % n = 1/72NAcBioPortalMutated:4 % n = 11/297NAcBioPortal1 deep deletionNA6 missense mutationNA3 amplificationNA2 deep deletionNAOverexpressed:YesBetter survival(65)Overexpressed:NA",
      "Genetic and expression alterations of the three NSD paralogues (NSD1, NSD2 and NSD3) in HPV + HNSCC and Cervical Cancers. Information about their role and/or their association with clinical and pathological characteristics are reported when available. Genetic alterations were extracted by the cBioPortal (TCGA, PanCancer Atlas). Information about gene expression and genetic alterations were also obtained from the referenced studies, when present. For HPV + Cervical cancers it was assumed that the 90\u201395 % of these tumors are HPV + [20,21,65,66]. NA = not available.",
      "While frequently overexpressed in both HNSCC and Cervical Cancers, NSD2 is reported to be rarely mutated in HNSCC. However, to the best of our knowledge, there is a lack of information regarding the mutational status specifically associated to the HPV- and HPV + subtypes. We have summarized the known altered status of the three NSD paralogue and their mutation frequency in the HPV+ subtypes with data extracted from the cBioportal (TCGA Pancancer) (http://www.cbioportal.org) (Table 1) [65,66]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 4.43689489364624,
    "data_pmids_checked": 0,
    "paper_id": "39645166",
    "extraction_date": "2025-12-19T20:44:06.806413",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39645166.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39640533": {
    "cbioportal_paper_citations": [
      "We downloaded GBM-associated RNAseq data in TPM format (n = 1323) from The Cancer Genome Atlas (TCGA) [13] and (GTEx), unified by the Toil process [14] using UCSC Xena (https: //xenabrowser.net/) [15] and analyzed as a test set (TCGA_GTEx- GBM). This test set was analyzed and the corresponding Counts format sequencing and clinical data were obtained through the TCGA official website (https: //portal.gdc.cancer.gov/). The specific clinical information is listed in Table S1. Microsatellite Instability (MSI), Mutation Count, Tumor Mutation Burden (TMB), and fractional genome altered (FGA) scores were obtained from the cBioPortal database [16]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.22515511512756348,
    "data_pmids_checked": 0,
    "paper_id": "39640533",
    "extraction_date": "2025-12-19T20:44:07.031667",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39640533.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39639242": {
    "cbioportal_paper_citations": [
      "The cBioPortal [33] online program (http://www.cbioportal.org/) is an open access resource for the interactive exploration of multidimensional cancer genome datasets. Our NTRK fusion-positive sample information was obtained from the Tumors with TRK fusions (MSK, Clin Cancer Res 2020) dataset in the cBioPortal, and the relevant clinical and sequencing data were downloaded from The Cancer Genome Atlas (TCGA) Data Portal (https://tcga-data.nci.nih.gov/tcga/). Moreover, cBioPortal was used to evaluate the coexpressed genes (CEGs) of NTRK1 and NTRK3. The CEGs of NTRKs derived from thyroid carcinoma (TCGA, Firehose Legacy) were used to determine the intersection with differentially expressed genes (DEGs), and the CEGs of NTRKs obtained from the pancancer analysis of whole genomes (ICGC/TCGA, Nature 2020) were used for enrichment analyses."
    ],
    "cbioportal_platform_mentions": [
      "From October 2012 to August 2022, we identified eight patients with NTRK fusion-positive cancer of five different types in our hospital. Our clinical data revealed that seven patients had evident invasive and metastatic capabilities at the time of initial diagnosis. Therefore, we questioned whether this invasiveness and metastasis were due to NTRK fusion or simply coincidental NTRK fusion. A subsequent literature analysis of NTRK fusion cancers revealed an association between NTRK fusions and enhanced tumor invasion and migration [17\u201320]. NTRK fusion-positive tumors exhibit pronounced invasiveness in terms of clinical, clinicopathological, and molecular characteristics, as well as in cellular and animal models [21, 22]. However, the underlying mechanisms remain unclear, prompting further investigation into the regulation of cancer invasion and metastasis by NTRK fusion. Owing to limited clinical data, we accessed public databases such as TCGA and cBioPortal for additional information. We identified a total of 32 patients harboring NTRK fusions across diverse cancer types. Among them, 12 were diagnosed with thyroid cancer (THCA), 4 with glioma, 3 with colon cancer, and no more than 3 with any other individual cancer type. Considering the paucity of available data, we opted to employ THCA data as an initial framework for investigating the correlation between NTRK fusion and tumor invasiveness.",
      "The comprehensive clinical details of the eight patients with positive NTRK fusion at our institution are presented in Table 1. Notably, with the exception of Patient 2, who exhibited no apparent invasion of adjacent tissues or lymph node involvement, all the other patients manifested varying degrees of local invasion, lymph node involvement, or distant metastasis, thereby demonstrating a high level of invasiveness and metastatic potential. Notably, Patient 1 presented with multiple metastatic sites at the time of initial diagnosis. Consequently, our objective was to investigate the associations between NTRK fusion and these aggressive characteristics. To address this question comprehensively, we extensively reviewed the literature on NTRK fusion cancers and reported a significant correlation between NTRK fusions and increased tumor invasiveness and migratory ability [17\u201320]. Pathology images of seven representative patients are provided in Supplementary Fig. 1. However, since patient 3 had their pathology examination conducted at an alternative medical establishment, there was a scarcity of accessible imaging data. We subsequently acquired the clinical (Supplementary Table 1) and genomic data of NTRK fusion patients from the TCGA Pancancer Atlas for further analysis. Owing to the incomplete clinicopathological characteristics of these NTRK fusion-positive patients (n = 30), only 22 patients with available data were included. The baseline staging characteristics of the 493 patients without NTRK fusion are summarized in Table 2. The association between NTRK fusion and clinical stage was examined via cBioPortal (Fig. 1A-B), revealing a significant correlation between NTRK fusion and advanced disease stage. Table 2Staging characteristics of patients with and without NTRK fusionCharacteristicsTHCAFusionP valuen49322T.stage, n (%) < 0.001T2160 (31.1%)6 (1.2%)T1a19 (3.7%)0 (0%)T3167 (32.4%)9 (1.7%)T1b78 (15.1%)2 (0.4%)T144 (8.5%)1 (0.2%)T49 (1.7%)0 (0%)T4a14 (2.7%)0 (0%)TX2 (0.4%)1 (0.2%)T2b0 (0%)2 (0.4%)T4b0 (0%)1 (0.2%)N.stage, n (%) < 0.001N0225 (43.7%)9 (1.7%)N1b71 (13.8%)4 (0.8%)N1a92 (17.9%)0 (0%)NX50 (9.7%)0 (0%)N155 (10.7%)7 (1.4%)N2c0 (0%)1 (0.2%)N20 (0%)1 (0.2%)M.stage, n (%)0.029M0274 (56%)10 (48%)MX209 (42%)9 (43%)M19 (1.8%)1 (4.8%)M1b0 (0%)1 (4.8%)Pathologic.stage, n (%) < 0.001Stage I276 (53.9%)9 (1.8%)Stage III112 (21.9%)0 (0%)Stage II51 (10%)2 (0.4%)Stage IVA44 (8.6%)4 (0.8%)Stage IVC6 (1.2%)0 (0%)Stage IV2 (0.4%)3 (0.6%)Stage IIB0 (0%)2 (0.4%)Stage IIA0 (0%)1 (0.2%)Fig. 1Clinical relevance of NTRK fusion (A, B) Statistical plot of clinical staging in the dataset titled Tumors with TRK fusions in cBioPortal (MSK, Clin Cancer Res 2020)",
      "Clinical relevance of NTRK fusion (A, B) Statistical plot of clinical staging in the dataset titled Tumors with TRK fusions in cBioPortal (MSK, Clin Cancer Res 2020)",
      "In light of the occurrence of NTRK gene fusions in various cancers, genes coexpressed with NTRK1 and NTRK3 were obtained from cBioPortal. The top 150 genes from these coexpressed gene sets, along with NTRK1 and NTRK3, were subsequently selected for Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO) enrichment analyses. (Fig. 2). Our enrichment analysis revealed that ntrk and its associated coexpressed genes significantly contribute to invasion-related pathways, including cell\u2012cell adhesion, extracellular matrix structural constituents conferring tensile strength, extracellular matrix structural constituents, and fibronectin binding. These findings strongly support our hypothesis, suggesting the active engagement of NTRK and its associated coexpressed genes in the processes of tumor invasion, migration, and metastasis.Fig. 2Functional annotation of NTRK and NTRK-coexpressed genes. A Top 10 CC, BP, and MF GO enrichment terms. B The top 10 enriched KEGG pathway terms. C Emapplot showing the relationships between enriched pathways",
      "Given that the thyroid cancer (THCA) dataset is relatively extensive, a comprehensive dataset was retrieved from the TCGA database to further examine the role of NTRK fusion proteins in tumorigenesis and development. In accordance with the clinical information of the samples, the data were subsequently categorized into three distinct groups: the NTRK fusion-positive group, the THCA group, and the normal group. Comparative analyses were conducted to discern disparities between the NTRK fusion-positive group and the other two groups. Figure 3A shows 175 DEGs in the NTRK fusion-positive group vs. the THCA group, and Fig. 3B shows 1622 DEGs in the NTRK fusion-positive group vs. the normal group. Moreover, we ranked the coexpressed genes (CEGs) of NTRK1 and NTRK3 in thyroid carcinoma (TCGA, Firehose Legacy) obtained from cBioPortal according to q values. The top 30 CEGs for each gene were subsequently selected for the analysis of genes intersecting with the other two groups of DEGs (Supplementary Table 2 and Fig. 3C). The expression of 10 intersecting genes\u2014ECM1, NOVA1, ADAMTS9, TMEM108, VSTM4, RMST, PRR29, PNMA8B, SSPP2 and CAPN3\u2014all of which are upregulated CEGs of NTRK3 that exhibit significant positive correlations and coexpression patterns with these genes among normal controls and fusion patients (Fig. 3D-F).Fig. 3Differentially expressed genes and their correlation and coexpression with NTRKs were screened. A. DEGs in the NTRK fusion group vs. the THCA group. B DEGs in the NTRK fusion group vs the normal group. C Venn diagram of the intersection of the CEGs of NTRK1 and NTRK3 with the previous two sets of DEGs. Heatmaps of the (D) correlation and (E\u2013F) coexpression of NTRK1 and NTRK3 with 10 intersecting genes (*P < 0.05)"
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.16172385215759277,
    "data_pmids_checked": 0,
    "paper_id": "39639242",
    "extraction_date": "2025-12-19T20:44:07.199776",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39639242.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39637905": {
    "paper_id": "39637905",
    "cbioportal_paper_citations": [
      "[PubMed: 23550210]\n15",
      "[PubMed:\n22588877]\n16"
    ],
    "cbioportal_platform_mentions": [
      "Pan-cancer cohort data can be accessed and analysed with cBioPortal,\nan open-access, open-source database,14,15 and Xena, a visualisation and analysis tool\nfor both public and private datasets.16 Both sites consolidate genomic and transcriptomic\ndatasets across several cohorts, are accessible for researchers, and assist in analysing and\npresenting genomic data",
      "Cancer Cell Line Encyclopedia data are also easily visualised using cBioPortal",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:14.206161",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39637905.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 6.964475870132446,
      "cbioportal_papers": 0.020016908645629883,
      "used_full_extraction": false,
      "pdf_extraction": 6.964475870132446,
      "platform_mentions": 0.002000093460083008,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39633507": {
    "cbioportal_paper_citations": [
      "Evidence increasingly shows that the TRPM family is abnormally expressed or dysfunctional in patients with several cancers, including melanoma, pancreatic, prostate, colorectal, breast, and brain cancer. This section explores the roles of TRPM channels in these cancers and summarizes their mutation frequency and the relationship between altered expression and clinicopathological features (Table 2). The mutation frequency of the TRPM family was derived from cBioPortal\u2019s analysis of TCGA pan-cancer atlas [19, 20]. Table 2The role of the TRPM family in various cancerTypes of CancerChannelMutation frequencyExpression levelClinicopathological featuresRef.MelanomaTRPM19%\u2193Increased invasion and metastasis phenotypes[21]TRPM215%\u2191Increased metastasis phenotypes[22]TRPM55%\u2191Associated with a poor prognosis for patients[23]Pancreatic CancerTRPM23%\u2191Positively correlated with tumor stage, increased proliferative, and invasive phenotypes[24, 25]TRPM72%\u2191Increased proliferation, migration and invasion phenotypes[26, 27]TRPM81%\u2191Positively correlated with the size and stage of primary tumor Increased migration and invasion phenotypes[28, 29]Prostate cancerTRPM21%\u2191Related to tumor grade and enhanced the proliferation phenotype[30, 31]TRPM42%\u2191Increased migration and invasion phenotypes[32]TRPM71%\u2191Increased migration and invasion phenotypes[33, 34]TRPM81%Remain controversial (possible staging dependency)[35\u201338]Breast cancerTRPM22%\u2191Increased proliferative phenotype[39]TRPM41%\u2191Significantly associated with poorer prognosis, as demonstrated by a higher lymph node status and a higher pathologic prognostic stage[40]TRPM72%\u2191Increased proliferation, invasion and spread phenotypes[41\u201343]TRPM82%\u2191Closely associated with proliferation parameters and promoted tumor cell migration[44, 45]Colorectal cancerTRPM26%\u2013TRPM42%Remain controversial (possible staging dependency)[46, 47]TRPM67%\u2193TRPM74%\u2191Positively correlated with tumor infiltration, lymph node metastasis, distant metastasis, and the clinical stage of colorectal cancer[48]TRPM85%\u2191Positively associated with tumor cell migration and invasive phenotypes, promoting liver metastasis.[49, 50]Brain cancerTRPM22%\u2191[51]TRPM33%\u2191Negatively correlated with the glioma grade[52]TRPM71%\u2191Increased proliferation, migration and invasion phenotypes[53]TRPM81%\u2191Increased proliferation, migration and invasion phenotypes[54, 55]: Up-regulated expression, : Down-regulated expression, : Unknown"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625048": [
        "Evidence increasingly shows that the TRPM family is abnormally expressed or dysfunctional in patients with several cancers, including melanoma, pancreatic, prostate, colorectal, breast, and brain cancer. This section explores the roles of TRPM channels in these cancers and summarizes their mutation frequency and the relationship between altered expression and clinicopathological features (Table 2). The mutation frequency of the TRPM family was derived from cBioPortal\u2019s analysis of TCGA pan-cancer atlas [19, 20]. Table 2The role of the TRPM family in various cancerTypes of CancerChannelMutation frequencyExpression levelClinicopathological featuresRef.MelanomaTRPM19%\u2193Increased invasion and metastasis phenotypes[21]TRPM215%\u2191Increased metastasis phenotypes[22]TRPM55%\u2191Associated with a poor prognosis for patients[23]Pancreatic CancerTRPM23%\u2191Positively correlated with tumor stage, increased proliferative, and invasive phenotypes[24, 25]TRPM72%\u2191Increased proliferation, migration and invasion phenotypes[26, 27]TRPM81%\u2191Positively correlated with the size and stage of primary tumor Increased migration and invasion phenotypes[28, 29]Prostate cancerTRPM21%\u2191Related to tumor grade and enhanced the proliferation phenotype[30, 31]TRPM42%\u2191Increased migration and invasion phenotypes[32]TRPM71%\u2191Increased migration and invasion phenotypes[33, 34]TRPM81%Remain controversial (possible staging dependency)[35\u201338]Breast cancerTRPM22%\u2191Increased proliferative phenotype[39]TRPM41%\u2191Significantly associated with poorer prognosis, as demonstrated by a higher lymph node status and a higher pathologic prognostic stage[40]TRPM72%\u2191Increased proliferation, invasion and spread phenotypes[41\u201343]TRPM82%\u2191Closely associated with proliferation parameters and promoted tumor cell migration[44, 45]Colorectal cancerTRPM26%\u2013TRPM42%Remain controversial (possible staging dependency)[46, 47]TRPM67%\u2193TRPM74%\u2191Positively correlated with tumor infiltration, lymph node metastasis, distant metastasis, and the clinical stage of colorectal cancer[48]TRPM85%\u2191Positively associated with tumor cell migration and invasive phenotypes, promoting liver metastasis.[49, 50]Brain cancerTRPM22%\u2191[51]TRPM33%\u2191Negatively correlated with the glioma grade[52]TRPM71%\u2191Increased proliferation, migration and invasion phenotypes[53]TRPM81%\u2191Increased proliferation, migration and invasion phenotypes[54, 55]: Up-regulated expression, : Down-regulated expression, : Unknown"
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3618009090423584,
    "data_pmids_checked": 1,
    "paper_id": "39633507",
    "extraction_date": "2025-12-19T20:44:14.610946",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39633507.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39630868": {
    "cbioportal_paper_citations": [
      "Tetratricopeptide repeat (TPR) domain 28 (TTC28) is a large protein (270,884 Da) containing 28 TPR domains, which makes studies on its functions very difficult. In fact, it has rarely been studied since it was identified in 2012 (20). TTC28 can interact with Aurora B (AURKB), which is essential for the progression of mitosis and cytokinesis (20). According to public datasets in The Cancer Genome Atlas (TCGA), TTC28 is a gene with recurrent somatic mutations and copy number variations in several kinds of human cancers (SI Appendix, Fig. S1 A and B) (21, 22). These changes in TTC28 have also been frequently detected in digestive system cancers included in non-TCGA studies, including esophageal squamous cell carcinoma (23), colorectal cancer (24), liver cancer (25), and gastric cancer (26). Furthermore, the mRNA expression of TTC28 is comprehensively down-regulated in many human cancers, according to analysis of TCGA transcriptome datasets with the gene expression profiling and interactive analyses (GEPIA) server (SI Appendix, Fig. S2A) (27). A low level of TTC28 expression was significantly associated with poor overall survival (OS) in patients with lung or ovarian cancer (SI Appendix, Fig. S2B), according to the KM plotter analysis (28). The TTC28 gene may be a target of TP53, a crucial gatekeeper of genome integrity (29). However, the biological functions of the TTC28 gene and the mechanisms underlying its downregulation in cancers remain to be studied."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "22810696": [
        "Tetratricopeptide repeat (TPR) domain 28 (TTC28) is a large protein (270,884 Da) containing 28 TPR domains, which makes studies on its functions very difficult. In fact, it has rarely been studied since it was identified in 2012 (20). TTC28 can interact with Aurora B (AURKB), which is essential for the progression of mitosis and cytokinesis (20). According to public datasets in The Cancer Genome Atlas (TCGA), TTC28 is a gene with recurrent somatic mutations and copy number variations in several kinds of human cancers (SI Appendix, Fig. S1 A and B) (21, 22). These changes in TTC28 have also been frequently detected in digestive system cancers included in non-TCGA studies, including esophageal squamous cell carcinoma (23), colorectal cancer (24), liver cancer (25), and gastric cancer (26). Furthermore, the mRNA expression of TTC28 is comprehensively down-regulated in many human cancers, according to analysis of TCGA transcriptome datasets with the gene expression profiling and interactive analyses (GEPIA) server (SI Appendix, Fig. S2A) (27). A low level of TTC28 expression was significantly associated with poor overall survival (OS) in patients with lung or ovarian cancer (SI Appendix, Fig. S2B), according to the KM plotter analysis (28). The TTC28 gene may be a target of TP53, a crucial gatekeeper of genome integrity (29). However, the biological functions of the TTC28 gene and the mechanisms underlying its downregulation in cancers remain to be studied."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 1.0724170207977295,
    "data_pmids_checked": 1,
    "paper_id": "39630868",
    "extraction_date": "2025-12-19T20:44:15.683474",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39630868.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39630301": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "PHLDA1 was evaluated as a prognostic marker in several types of cancer. PHLDA1 is a potential prognostic marker of patient survival in breast cancer (Nagai et al. 2007). Downregulation of PHLDA1 was associated with poor prognosis, more advanced clinical stage, and decreased overall survival (OS), as shown by the analysis of Kaplan\u2013Meier curves in breast cancer patients. Additionally, decreased expression of PHLDA1 in gastric adenocarcinoma correlates with decreased overall survival and increased tumor size, grade and metastasis (Zhao et al. 2015b). However, the multivariate analysis performed by the group did not indicate PHLDA1 as an independent prognostic factor. The prognostic significance of PHLDA was also found in non-small lung cancer, where low PHLDA1 mRNA expression was correlated with a worse OS in the Kaplan\u2013Meier analysis (Baldavira et al. 2021). In contrast, the group showed that mesothelioma patients with high PHLDA1 mRNA expression had poor OS (Baldavira et al. 2021). Moreover, expression of PHLDA1 as analyzed by immunohistochemistry in tissue microarray was associated with an advanced clinical stage and histological grade of oral squamous cell carcinomas and was postulated to be an independent prognostic factor by multivariate analysis (Coutinho-Camillo et al. 2013). Another study showed the high expression of PHLDA1/3 as assessed by immunohistochemical staining in pancreatic adenocarcinoma tissues and using the Human Protein Atlas database. The high expression of PHLDA1 was associated with decreased overall survival, relapse-free survival, and a poor prognosis in patients with pancreatic adenocarcinoma (Duan et al. 2022). Interestingly, the OS was even more shortened in patients with a high frequency of PHLDA1 mutations as determined using the cBioPortal database (Gao et al. 2013; Duan et al. 2022). Another finding showed that PHLDA1 protein levels exhibited a prognostic value in glioblastoma (Wang et al. 2022a). Thus, the OS and disease-free survival were markedly shortened in tumors with high PHLDA1 protein levels compared to low PHLDA1 levels. High PHLDA1 levels were also associated with a greater tendency of disease recurrence."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.305128812789917,
    "data_pmids_checked": 0,
    "paper_id": "39630301",
    "extraction_date": "2025-12-19T20:44:16.013558",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39630301.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39623404": {
    "cbioportal_paper_citations": [
      "TNBC clinical outcome data and corresponding mRNA expression levels of genes of interest were obtained from the Breast Cancer METABRIC, Nature 2012 & Nat Commun 2016 study via cBioPortal [22, 23]. To obtain a TNBC patient cohort, the 3-gene classifier subtype was set to ER-/HER2-. Furthermore, \u201cER status\u201d and \u201cER status by IHC\u201d were set to negative. HER2 status was set to negative and HER2 status gain measured by SNP6 were removed from the analysis. Finally, upon downloading clinical outcome data any progesterone positive cases were removed leaving a total of 187 patient samples for analysis. All patients in this analysis had Stage I-III disease. For all OS analyses, patients coded as \u201cdied of other causes\u201d were removed from analysis."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "36001024": [
        "The goal of this study was to identify novel immune markers of prognosis in TNBC, which still represents a critical unmet need. Currently, intratumoral PD-L1 expression remains the only clinically-approved marker to be used prospectively in ICI clinical trials for TNBC [16], which fails to recapitulate the high degree of tumor heterogeneity that TNBC patients exhibit. Other immune-based prognostic markers include microsatellite instability and high tumor mutational burden, but these are approved as tissue agnostic biomarkers and only represent a small proportion of TNBC cases [12]. Intratumoral and stromal TILs are still being evaluated for their prognostic utility, but challenges in standardization and reproducibility remain barriers to clinical integration [49]. Gene expression signatures and proteogenomic analyses are promising tools for disentangling issues presented by heterogeneity in TNBC, but require further investigation to validate their prognsotic value for therapeutic response [16, 50]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6293730735778809,
    "data_pmids_checked": 1,
    "paper_id": "39623404",
    "extraction_date": "2025-12-19T20:44:16.673647",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39623404.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39616986": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We excluded all germline mutations (present in at least one blood sample) and mutations found in > 10 % of the tumour samples (considered bona fide single nucleotide polymorphisms). The final set of somatic mutations underwent thorough review by researchers through a custom web application developed in-house. This review included an assessment of quality metrics, such as region coverage and the quality of reads supporting alternative alleles, validation of mutations and identification of potential inconsistencies in different runs of the same sample. These validated mutations were annotated using Varsome [20] and only variants predicted as Pathogenic, Likely Pathogenic and of Uncertain Significance were imported into a local instance of cBioPortal [21] and further annotated using ClinVar [22], COSMIC [23], and OncoKB [24].",
      "Patient characteristics are summarized in Table 1. Patients were predominantly ever smokers (50.4 %) and/or ever drinkers (56.8 %). Oral cavity was the most frequent cancer site. By reviewing the PubMed repository, we selected 20 published studies that reported sequencing data of HNSCC case series by using whole exome sequencing or targeted gene panels (Supplementary Table 2). Among the selected 20 case series, oral cavity samples were the most frequently sequenced and hypopharynx the least. Our case study largely recapitulated this distribution (Fig. 1A, Supplementary Figure 1A and Supplementary Table 3). Based on selected literature (Supplementary Table 2) and by interrogating publicly available HNSCC cancer gene dataset [21], we manually curated 15 genes that were either frequently mutated or impacted prognosis in HNSCC or appeared to be specific of the squamous cell lineage. These genes spanned from signal transduction (i.e., HRAS, PIK3CA, PTEN, AKT1), cell cycle regulation (i.e., CDKN2A, TP53), cell death (i.e., TP53, CASP8), cell differentiation (i.e., NOTCH1, FBXW7, FAT1, AJUBA) to chromatin organization (i.e., KMT2B, KMT2C, KMT2D, NSD1). We designed a custom targeting kit, which covered the complete coding sequence of the 15 genes to sequence genomic DNA purified from fresh frozen tumour samples. To identify candidate pathogenic somatic variants, we first excluded all the variants that we detected in at least one out of 20 matched blood samples, and then used a prediction score of pathogenicity based on current knowledge base (Supplementary Figure 1B-D and Supplementary Table 4\u20136) [20]. In order to verify our findings in an independent patient cohort, we used the HNSCC case study from The Cancer Genome Atlas (TCGA-HNSCC) using the cBioPortal web application [21]. Despite the differences in variant calling and filtering, the prevalence of mutations of the 15 selected genes across the present and the 20 published case series was quite consistent (Fig. 1B and Supplementary Table 7). In Pordenone's case series, the most frequently mutated gene was TP53; whereas, genes belonging to the PI3 K (i.e., AKT1, PIK3CA and PTEN) and NOTCH1 pathway were collectively altered in 12,8 % and 18 % of tumour samples, respectively (Fig. 1C and Supplementary Figure 2).Table 1Demographic and clinical characteristics of the Pordenone's case series.Table 1n(%)Sex Man87(69.6) Woman38(30.4)Age (years) <6045(36.0) 60\u20136942(33.6) \u22657035(28.0) Unknown3(2.4)Ever smoking No14(11.2) Yes63(50.4) Unknown48(38.4)Ever drinking No6(4.8) Yes71(56.8) Unknown48(38.4)Site Oral cavity67(53.6) Oropharynx36(28.8) Hypopharynx10(8.0) Larynx12(9.6)Clinical tumour size cT121(16.8) cT249(39.2) cT330(24.0) cT425(20.0)Clinical lymph nodes involvement cN061(48.8) cN139(21.2) cN225(20.0)Clinical stage I16(12.8) II27(21.6) III47(37.6) IV33(26.4) Unknown2(1.6)Grading Well differentiated16(12.8) Moderately differentiated67(53.6) Poorly differentiated32(25.6) Anaplastic/Undifferentiated1(0.8) Unknown9(7.2)Fig. 1Characteristics of revised and Pordenone's case series. A) Prevalence of the four anatomic sites across the revised (black dots) and Pordenone's (red dots) case series. Each dot represents a case series. Y-axis represents the prevalence of samples belonging to each anatomic site (X-axis) within the single case series. B) Prevalence of variants per each gene across the revised (black dots) and Pordenone's (red dots) case series. Each dot represents a case series. Y-axis represents the prevalence of samples carrying at least one variant in each gene (X-axis) within the single case series.Fig 1"
    ],
    "data_publication_citations": {
      "25631445": [
        "The site of origin of HNSCC is one of the most important prognostic factors, with tumours arising from the hypopharynx showing the worst prognosis (Fig. 2A and Supplementary Figure 3A). For this reason, we investigated whether the prevalence of somatic mutations of the 15 genes differed among anatomic sites. As anticipated, tumours originating from the oropharynx exhibited the lowest percentage of mutated samples; on the contrary, tumours arising from hypopharynx and larynx showed the greatest percentage of cases with at least one somatic mutation among the 15 selected genes both in our and TCGA's case studies (Fig. 2B, Supplementary Figure 3B). We also explored whether the differences across different sites of origin of HNSCC were gene-specific. As previously reported [26], TP53 mutations were mostly missense mutations and less frequent in the oropharynx (Fig. 2C, Supplementary Figure 3C and Supplementary Table 8\u20139). This reduction was quite prominent in the TCGA case series (Supplementary Figure 3C and Supplementary Table 9), probably due to the higher prevalence of HPV+ tumours in the TCGA dataset. We also confirmed in the Pordenone's case series that mutations in the CASP8 gene seem almost specifically confined within the oral cavity (Fig. 2C, Supplementary Figure 3C and Supplementary Table 8\u20139) [27]. Eventually, we noticed that somatic AJUBA mutations were enriched in tumours arising from the hypopharynx (Fig. 2C, Supplementary Figure 3C and Supplementary Table 5\u20136). In both case studies, AJUBA variants are typically truncating and they all remove the LIM C-terminal domains of the protein (Fig. 3A). Overall, Pordenone's and TCGA's case series showed a significant correlation (r-squared > 0,7) (Supplementary Figure 4A-D).Fig. 2The prevalence of mutations differs among the four anatomic sites within the Pordenone's case series. A) Kaplan Meier plot comparing anatomic sites of primary tumours and progression free survival. B) Prevalence of mutations of the 15 genes across four anatomic sites. Each dot represents a gene, which is mutated in at least one sample derived from the four anatomic sites. Y-axis represents the percentage of tumour samples carrying at least one mutation per each single gene. Genes that are not mutated are not shown C) Prevalence of tumour samples carrying mutations for each single gene across four anatomic sites. (Fisher exact test, * < 0,05; ** < 0,01).Fig 2Fig. 3Localization and type of variants of the AJUBA (A) and KMT2C (B) in the Pordenone's (top). Each image represents a lollipop plot that from top to bottom shows the protein cartoon with protein domains (coloured rectangles) and variants (green dots = missense mutations, black dots = truncating mutations, orange dots = variants affecting splice sites). Y-axis represents the number of samples carrying each variant. Below the protein cartoon, Cancer Hotspots knowledge base, OncoKB knowledge base, protein modifications (phosphorylation, acetylation and methylation), exon number and topology (i.e., Information of the subcellular location of the mature protein) are shown.Fig 3"
      ],
      "23619168": [
        "The site of origin of HNSCC is one of the most important prognostic factors, with tumours arising from the hypopharynx showing the worst prognosis (Fig. 2A and Supplementary Figure 3A). For this reason, we investigated whether the prevalence of somatic mutations of the 15 genes differed among anatomic sites. As anticipated, tumours originating from the oropharynx exhibited the lowest percentage of mutated samples; on the contrary, tumours arising from hypopharynx and larynx showed the greatest percentage of cases with at least one somatic mutation among the 15 selected genes both in our and TCGA's case studies (Fig. 2B, Supplementary Figure 3B). We also explored whether the differences across different sites of origin of HNSCC were gene-specific. As previously reported [26], TP53 mutations were mostly missense mutations and less frequent in the oropharynx (Fig. 2C, Supplementary Figure 3C and Supplementary Table 8\u20139). This reduction was quite prominent in the TCGA case series (Supplementary Figure 3C and Supplementary Table 9), probably due to the higher prevalence of HPV+ tumours in the TCGA dataset. We also confirmed in the Pordenone's case series that mutations in the CASP8 gene seem almost specifically confined within the oral cavity (Fig. 2C, Supplementary Figure 3C and Supplementary Table 8\u20139) [27]. Eventually, we noticed that somatic AJUBA mutations were enriched in tumours arising from the hypopharynx (Fig. 2C, Supplementary Figure 3C and Supplementary Table 5\u20136). In both case studies, AJUBA variants are typically truncating and they all remove the LIM C-terminal domains of the protein (Fig. 3A). Overall, Pordenone's and TCGA's case series showed a significant correlation (r-squared > 0,7) (Supplementary Figure 4A-D).Fig. 2The prevalence of mutations differs among the four anatomic sites within the Pordenone's case series. A) Kaplan Meier plot comparing anatomic sites of primary tumours and progression free survival. B) Prevalence of mutations of the 15 genes across four anatomic sites. Each dot represents a gene, which is mutated in at least one sample derived from the four anatomic sites. Y-axis represents the percentage of tumour samples carrying at least one mutation per each single gene. Genes that are not mutated are not shown C) Prevalence of tumour samples carrying mutations for each single gene across four anatomic sites. (Fisher exact test, * < 0,05; ** < 0,01).Fig 2Fig. 3Localization and type of variants of the AJUBA (A) and KMT2C (B) in the Pordenone's (top). Each image represents a lollipop plot that from top to bottom shows the protein cartoon with protein domains (coloured rectangles) and variants (green dots = missense mutations, black dots = truncating mutations, orange dots = variants affecting splice sites). Y-axis represents the number of samples carrying each variant. Below the protein cartoon, Cancer Hotspots knowledge base, OncoKB knowledge base, protein modifications (phosphorylation, acetylation and methylation), exon number and topology (i.e., Information of the subcellular location of the mature protein) are shown.Fig 3"
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 1.2967767715454102,
    "data_pmids_checked": 3,
    "paper_id": "39616986",
    "extraction_date": "2025-12-19T20:44:17.970525",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39616986.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39660330": {
    "paper_id": "39660330",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Nerves have been shown to infil-\ntrate the tumor microenvironment and actively The cBioPortal for Cancer Genomics (http://\nstimulate cancer cell growth and dissemination cbioportal.org) provides a Web resource for\n[8]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:19.698996",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39660330.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.27505612373352,
      "cbioportal_papers": 0.00015783309936523438,
      "pdf_extraction_pass2": 7.9789040088653564,
      "cbioportal_papers_pass2": 0.00015425682067871094,
      "used_full_extraction": true,
      "pdf_extraction": 18.253960132598877,
      "platform_mentions": 0.001734018325805664,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39695141": {
    "paper_id": "39695141",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "(http://www.cbioportal.org/faq#how-do-i-cite-the-cbioportal) data\nwere accessed"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:19.744393",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39695141.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 20.061546087265015,
      "cbioportal_papers": 0.0002219676971435547,
      "pdf_extraction_pass2": 12.805129051208496,
      "cbioportal_papers_pass2": 0.00023508071899414062,
      "used_full_extraction": true,
      "pdf_extraction": 32.86667513847351,
      "platform_mentions": 0.002421140670776367,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39615226": {
    "cbioportal_paper_citations": [
      "MLH1 has several proposed functions that we posited might be important for MLH1-PMS2 to suppress divergent RMDs, which informed our choice of testing four mutants. The first mutant was based on studies of MLH1 interactions with MSH2-MSH6 [11]. Specifically, we tested if mutating residues in MLH1 implicated in the interaction between the two heterodimers would affect the ability of MLH1 to suppress RMDs (MLH1 K57C, Q60L, Q62L, MLH1-KQQ) [40]. For the second mutant, we tested residues in MLH1 proposed to promote an interaction of the MLH1-PMS2 heterodimer with PCNA (MLH1 566QILIYDF>AILAYDA, MLH1\u2013566\u20133A) [41], although another study found that this mutant of MLH1 retained robust PCNA-activated nuclease activity [38]. The third mutant, MLH1-E34A, is proposed to disrupt the function of the ATPase domain [42]. Interestingly, the ATPase domain is a critical region of human MLH1, in that a majority of mutations leading to HNPCC kindreds are found in or around this region [43\u201345]. For the fourth MLH1 mutant, we tested residues in the unstructured linker domain of MLH1 (MLH1-R385A, D387A, MLH1-RADA), which is proposed to be required for endonuclease function and is also mutated in cancers [46,47]. To test these mutants, we generated mutant MLH1 expression vectors (Fig. 1B). We found that WT-MLH1 and the E34A mutant were able to suppress divergent RMDs, however the KQQ mutant, 566\u20133 A mutant, and RADA mutant all failed to suppress divergent RMDs (Fig. 2B). As mentioned above, two of the MLH1 mutants, KQQ and 566\u20133 A, were not expressed to the same level as the WT protein (Figs. 1D, 1E), which is consistent with studies that deficient MLH1 alleles are often expressed below WT levels [36]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1934049129486084,
    "data_pmids_checked": 0,
    "paper_id": "39615226",
    "extraction_date": "2025-12-19T20:44:19.922588",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39615226.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39612472": {
    "cbioportal_paper_citations": [
      "Information regarding the genetic alteration features of PTBP1 in pan-cancer was obtained from Cbioportal platforms (https://www.cbioportal.org/). Genetic alterations of PTBP1, including amplification, mutation, fusion, deep deletion, and multiple alterations, were all acquired from TCGA Pan-Cancer Atlas Studies by utilizing cBioPortal.20,21"
    ],
    "cbioportal_platform_mentions": [
      "Furthermore, we explored the frequency and types of PTBP1 genetic alterations in cancers. TCGA sequencing data from the cBioPortal database were analyzed to investigate PTBP1 gene alterations, including mutations, copy number aberrations, and structural variants such as gene fusions, in 10 967 samples from 32 studies covering the entire TCGA pan-cancer dataset. We observed 104 mutation sites between amino acids 0 and 531 (Figure 4A). In addition to mutations, we detected that 9% of sarcoma patients harbored amplification of PTBP1 (up to 6% of samples in the TCGA), which was the most common alteration (Figure 4B). Data from TCGA pan-carcinoma studies exhibited high mutation rates of PTBP1 in uterine corpus endometrial carcinoma (4%), melanoma (3%), and DLBC (2%) (Figure 4B). Gene fusions involving PTBP1, though infrequent, were observed in a few cancer types, including mesothelioma (around 1% frequency), prostate, and ovarian (Figure 4B).Figure 4.Mutation information of PTBP1 in different tumors of TCGA in the cBioPortal website. (A) Mutation site; (B) Mutation type.",
      "Mutation information of PTBP1 in different tumors of TCGA in the cBioPortal website. (A) Mutation site; (B) Mutation type."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.16698169708251953,
    "data_pmids_checked": 0,
    "paper_id": "39612472",
    "extraction_date": "2025-12-19T20:44:19.924685",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39612472.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39612413": {
    "cbioportal_paper_citations": [
      "cBioPortal[24,25] is a publicly accessible online source that facilitates the investigation, visualization, and examination of complex cancer genomics data. The \u201cTCGA pan-cancer analyses Atlas Studies\u201d were selected in the \u201cQuick Select\u201d option with the entry of \u201cEPHA2\u201d to investigate the genetic modifications. The investigation analyzed the modification frequencies, types of mutation, and copy number alterations (CNAs) in TCGA cancers documented in the \u201cCancer Types Summary\u201d module. The information on mutation sites was visualized in the 3D structure of the protein using the \u201cMutations\u201d module, while the \u201cComparison\u201d module was used to assess differences in survival outcomes in the presence and absence of EPHA2 gene mutations. Kaplan\u2013Meier curves and log-rank tests were used to analyze survival plots. All TCGA cancer expression data (TPM normalized) were obtained from UCSC XENA (xenbrowser.net). All Microsatellite instability (MSI) cancer data were acquired from https://www.science.org/doi/10.1126/science.aau0447. The Tumor mutation burden (TMB) data related to all types of cancers were acquired from https://gdc.cancer.gov/about-data/publications/panimmune. The calculation of MSI or TMB and the Pearson correlation analysis of EPHA2 gene expression were performed and visualized via Python package plotting, while lollipop plots were also generated. Additionally, radar plots were via ggradar package."
    ],
    "cbioportal_platform_mentions": [
      "The investigation involved the examination of EPHA2 genetic alteration status across various tumor samples using the cBioPortal. Figure 4A (Table S3, Supplemental Digital Content, http://links.lww.com/MD/O76) shows that Cholangio carcinoma exhibits the most notable frequencies of alterations in the EPHA2 (>15%). Specifically, the alteration types in EPHA2 include \u201cdeep deletion,\u201d which displayed approximately 5%, and \u201cmutation,\u201d accounting for 10% of the alterations identified. Further, in various cancer types, including UCEC, STAD, skin cutaneous melanoma (SKCM), BLCA, CESC, HNSC, ESCA, and COAD, the predominant CNA was the \u201cmutation\u201d type. The frequency of this type of CNA was approximately 7% in UCEC, 6% in STAD, 6% in SKCM, 5% in BLCA, 4% in CESC, 4% in HNSC, 3% in ESCA, and 3% in COAD. The \u201camplification\u201d variant of CNA was predominant in uterine carcinosarcoma, which displays a mutation frequency of 4%. In addition, all lymphoid neoplasm diffuse large B-cell lymphoma, adrenocortical carcinoma, acute myeloid leukemia, and LGG with genetic changes possessed mutations of EPHA2 with frequencies of 4%, 1%, 0.5%, and 0.5%, respectively. Notably, all PCPG and TGCT cases (2% and 1% frequencies) with genetic modifications possessed EPHA2 copy number deletion.",
      "Mutation of EPHA2 in various TCGA tumors. The mutation features of EPHA2 for the TCGA tumors using the cBioPortal tool. (A) A summary of the frequency of EPHA2 mutations for various tumors and mutation types. (B) Representation of the EPHA2 genetic mutation types, sites, and case numbers. A possible link between EPHA2 genetic mutation and OS, disease-specific survival, DFS, and PFS of LUAD (C), STAD (D), and UCEC (E) via cBioPortal tool. LUAD = lung adenocarcinoma, OS = overall survival, UCEC = uterine corpus endometrial carcinoma."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.09381508827209473,
    "data_pmids_checked": 0,
    "paper_id": "39612413",
    "extraction_date": "2025-12-19T20:44:20.016502",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39612413.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39609355": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "cBioPortal/MIRACUM-Pipe (Augsburg, Freiburg),",
      "After this preliminary evaluation, the case is subjected to further assessment within the precincts of the MTB. Biomaterial samples are collected, and their molecular characteristics assessed. An incisive analysis is conducted to ascertain the congruence between the genetic mutations specific to the individual patient and the potential therapeutic modalities. The analysis workflow consists of many steps, starting with sequencing, a preprocessing phase, alignment, variant calling and annotation, analysis, and finalizing report generation and export to an external support tool (cBioPortal) [16, 19]. This process can extend over a period of up to 3 months.",
      "The MTB in Augsburg uses the Knowledge Connector for collaborative case preparation and the identification of biomarkers and cBioPortal for data sharing for external partners. Further, both tools are currently in evaluation for future usage. The classification of the patients and the therapy recommendations follow the evidence level guideline set by the MASTER program (Table 2).",
      "A simple MTB workflow (see Fig. 1). consists of the following steps [41]:Eligibility screening.Registration of a patient in the MTB, directly or through the handling physician. Patient\u2019s personal and family history are shared with the MTB.A tumor biopsy is taken from the patient, and the DNA is extracted.An NGS method is used to identify characteristical modifications.Specific variants of the analyzed NGS data are called.Resulting information is interpreted and associated with potential treatments and clinical trials.A comprehensive clinical report containing all findings is created.MTB is held to discuss the case and suggest a specific treatment.The suggestion is exchanged with the handling physician and carried out.Follow-upFig. 1The classic MTB workflow. A patient is first registered directly or through a handling physician to an MTB. A biopsy is taken from the patient, from which the DNA is extracted and sequenced. Results are analyzed, annotated, and presented alongside patient\u2019s clinical data to the MTB board. A therapy is suggested to the handling physician. The presented tools and knowledge databases in Sects. 3 and 5 with their corresponding starting points in the workflow are shown in gray and light-blue respectively. The Knowledge Connector and the MIRACUM-Pipe aim to integrate the complete workflow, while the knowledge databases, cBioPortal, and the other tools are mainly used for interpretation and report generation, with the latter focusing on pipelines",
      "The classic MTB workflow. A patient is first registered directly or through a handling physician to an MTB. A biopsy is taken from the patient, from which the DNA is extracted and sequenced. Results are analyzed, annotated, and presented alongside patient\u2019s clinical data to the MTB board. A therapy is suggested to the handling physician. The presented tools and knowledge databases in Sects. 3 and 5 with their corresponding starting points in the workflow are shown in gray and light-blue respectively. The Knowledge Connector and the MIRACUM-Pipe aim to integrate the complete workflow, while the knowledge databases, cBioPortal, and the other tools are mainly used for interpretation and report generation, with the latter focusing on pipelines",
      "OncoKB is a curated database developed and maintained at the Memorial Sloan Kettering Cancer Center for Precision Oncology. It includes the biological and clinical implications of genetic variants in cancer as a clinical decision support system. Their annotations include therapeutic, diagnostic, and prognostic significance of somatic molecular alterations and, therefore, provide detailed information about biological and potential oncogenic effects of specific gene changes found in cancer cells. Furthermore, OncoKB supplies treatment implications based on the level of evidence of specific molecular alterations. All available information is organized hierarchically by gene, alteration, tumor type, and clinical significance and uses a newly developed classification system of evidence level. The levels of evidence are derived from US Food and Drug Administration (FDA) labeling, scientific literature, expert group recommendations, and National Comprehensive Cancer Network (NCCN) guidelines. OncoKB currently lists over 7500 genetic variants in over 800 cancer-associated genes from over 130 tumor types. Those resources are accessible through their openly accessible web resources, queries to their API, or integration into cBioPortal. OncoKB is available as a commercial, and open-source license for academic use [46].",
      "In the following section, we present eight tools used to support MTB discussions and therapy finding. The selection of the following tools highly depends on established processes, data sharing options and integration into the infrastructure. Table 4 also highlights the main information needed to use these tools, including input, output, processing method, and integrated knowledge databases.Table 4Overview of different MTB supporting tools. The table lists the most important information needed to use the various listed toolsToolInputProcessingKnowledge basesOutputURLRefs.cBioPortalCNV, expressions, clinical data etc. as meta and data files (TSV)MIRACUM-Pipe: processing of aligned omics data variant calling, annotation/ analysisOncoKBCiVICMyCancerGenomeVisualizationreportshttps://.cbioportal.org[70, 71]KCSNVs, indel, CNV, SV, gSmVs, Fusion, RNA, etc.NGS collaborationOncoKBCIViCEnsemblReactomeWord document with an MTB report\u2013[44, 72, 73]MTB ReportSNVs, CNV, gene fusions, cancer typeActionable variant filteringGDKDCIViCTARGETActionable variants, gene\u2013drug predictive associationshttps://mtb.bioinf.med.uni-goettingen.de/mtb-report/[74\u201378]MTBPSNVs, small indelsPredictive relevance analysis, variant annotationIn-house DBsClinVarBRCA-ExchangeOncoKBCIViCHTML reporthttps://mtbp.org[1, 35, 79]CancerVarCNV, exon variants, indelsMap variants to genome, annotate variants/genesOncoKBCIViCmetaKBVariant interpretation (clinical significance)https://cancervar.wglab.org[80]OpenCravatUnannotated VCF, TSV/CSV, dbSNP, 23andmeAnnotation, mappingClinVarPharmGKBCIViCMultiple extensionsVisualizationVCFhttps://www.opencravat.org[81]PCGRSNVs, indels, CNAsVariant/allele-specific annotation, functional, prediction of MSI status, mutational signature estimationDoCMDGIdbCIViCInteractive HTML reporthttps://sigven.github.io/pcgr[82]CNV copy number variation, SNV single nucleotide variants, VCF variant call format, can copy number alteration, TSV tab separated values, CSV comma separated values",
      "Using cBioPortal, an overview of genomic alterations in a number of patients and cancer types can be obtained, survival analyses can be performed, and group comparisons can be made. Own data can be analyzed with cBioPortal as well. cBioPortal uses OncoKB, CIViC, and MyCancerGenome to support decision-making participants in MTBs [70].",
      "cBioPortal for Cancer Genomics is a tool for multidimensional cancer genomics datasets and can be explored interactively. In addition, cBioPortal provides access to molecular profiles, clinical features from large-scale cancer genomics projects, and visualizations. This allows the previously mentioned large datasets to be used clinically. cBioPortal curates data directly from the TCGA Data Coordinating Center and from literature. In addition, researchers are asked to provide additional data in special cases. For consistent annotation, mutation calls are processed through an internal pipeline with prior knowledge on variants and clinical utility [70].",
      "MIRACUM-Pipe is a workflow developed to analyze and annotate NGS data used in an MTB. It uses different individual tools to perform quality control and alignment, call variants, estimate copy number variation, evaluate complex markers, and detect RNA fusion. It acts as a standardized solution to support the different steps of an MTB including additional modules for data import, clinical analyses, visualization, and report generation [71]. Using the current model, three types of analysis are supported: WES, targeted NGS (tNGS), and tumor-only analysis. The workflow is dockerized (MIRACUM-Pipe-Docker) and therefore allows for a fast deployment. The report generated using the pipeline can be imported into cBioPortal and visualized. The pipeline can also be adapted for more individualized usage by integrating or merging future databases, analysis tools and workflows [71]."
    ],
    "data_publication_citations": {
      "36593350": [
        "MTB Heidelberg (Germany) The MTB Heidelberg is considered one of the most advanced in Germany. Two interdisciplinary tumor conferences are held on a weekly basis with experts from various medical disciplines, including thoracic surgery, pneumology, thoracic oncology, pathology, radiology, and radiotherapy [21\u201325]. These MTBs discuss various oncological disorders, such as dermatological, gastrointestinal, gynecological, and neurological tumors and many others [24]. Notably, Heidelberg features state-of-the-art molecular pathology methodologies, including next-generation sequencing (NGS), multiplex analysis, and liquid biopsy, with the aim to identify distinctive molecular alterations within patient samples. The identification of rare and unique genetic anomalies, on a case-by-case basis, presents an opportunity to furnish specialized therapeutic interventions either within the framework of clinical trials or through the off-label application procedure [23, 24].",
        "At the National Center for Tumor Diseases (NCT) Heidelberg and Dresden, German Cancer Research Center (DKFZ), and the German Cancer Consortium (DKTK in Berlin, Essen/D\u00fcsseldorf, Frankfurt/Mainz, Freiburg, Munich, and T\u00fcbingen), the central program Molecularly Aided Stratification for Tumor Eradication Research (MASTER) was initiated. The main goal of this multidisciplinary platform is to stratify and classify patients with advanced rare cancers or incurable common tumors at early ages [22, 23]. An interdisciplinary team is involved, including physicians, biologists, study nurses, molecular oncologists, pathologists, documentalists, clinical, geneticists, investigators, and bioinformaticians. This team discusses registered patients\u2019 cases to identify novel treatment approaches based on whole-genome or exome sequencing (WGS/WES), RNA sequencing (RNA-seq) and DNA methylation profiling.",
        "NCT derives treatment recommendations for the MTB discussions based on the tumor entity and four evidence levels as described in Table 2 to associate molecular biomarkers in patients\u2019 samples to drug responses [23].Table 2This table shows the NCT evidence levels with m1 (in the same entity), m2 (in various entities), m3 (preclinical), and m4 (biological rationale).Evidence levelDescriptionLevel 1 (m1)Genetic variants with high evidence, mostly supported by clinical studies conducted in the same tumor entity. Variants that are recognized as relevant biomarkers for certain types of cancer through clinical studies or extensive scientific research. This information is usually anchored in national or international guidelinesLevel 2 (m2)Genetic variants with middle evidence. Variants that have been identified as potentially relevant in several studies but are not yet fully established in clinical practiceLevel 3 (m3)Genetic variants with lowest evidence. Variants that have been described as potentially relevant in individual studies or case reports but still require further research to confirm their clinical significanceLevel 4 (m4)In-depth molecular analysis of tumors, leading to the identification of new biomarkers and mutations that may be relevant for targeted therapies or experimental treatmentsMore information can be added to m1 and m2 evidence using suffixes (A: prospective study or meta-analysis, B: retrospective cohort or case-control study, and C: case study or single unusual responder) [23]",
        "More information can be added to m1 and m2 evidence using suffixes (A: prospective study or meta-analysis, B: retrospective cohort or case-control study, and C: case study or single unusual responder) [23]",
        "During an MTB discussion, each patient case is presented individually and conferred in 8\u201310 min. The clinical history and the molecular alterations of the patient are first presented respectively by the handling physician as well as a clinical bioinformatician. Following the guidelines of the MASTER program, a level of evidence is assigned, a set of treatment options is concluded by the corresponding molecular oncologist, and the called variants are finally evaluated and classified by clinical geneticists taking into consideration the patient\u2019s personal and family history. At the end of the discussion, a report is generated containing a summary of treatment recommendations, disease course and previous therapy, alongside all supporting and opposing evidence [23]."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 10,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2756781578063965,
    "data_pmids_checked": 1,
    "paper_id": "39609355",
    "extraction_date": "2025-12-19T20:44:20.200421",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39609355.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39608716": {
    "cbioportal_paper_citations": [
      "IGF-1R accumulation at the Golgi apparatus is promoted by cell adhesion-dependent phosphorylation of Tyr1250/1251 in the IGF-1R CT (32). Therefore, we next asked how cell adhesion molecules influence IGF-1R activity in cancer. Using cBioPortal (48), we first investigated the relationship between the IGF-1R and two core adhesion molecules known to associate with the IGF-1R, ITGB1 and ITGB3 (28, 29, 30, 31). Using the The Cancer Genome Atlas (TCGA) Pan Cancer Atlas\u2014Breast Invasive Carcinoma dataset (49) (n = 105), we found a moderate, positive correlation between IGF-1R and ITGB1 protein expression (Spearman = 0.49, p = 1.35 \u00d7 10\u22127), and a weak, positive correlation between IGF-1R and ITGB3 protein expression (Spearman = 0.33, p = 1.271 \u00d7 10\u22123) (Fig. 2A). Relative protein expression levels were measured by mass spectrometry carried out by the Clinical Proteomic Tumor Analysis Consortium and are represented as arbitrary units on a distribution. To further explore these relationships, a cohort of basal-like breast cancer patients (IGF1RvITGB1, n = 24; IGF1RvITGB3, n = 21) from the TCGA Pan Cancer Atlas\u2014Breast Invasive Carcinoma dataset was further analyzed (because this breast cancer subtype has similar features to TNBC (50)). Here, we observed a strong, positive correlation between IGF-1R and ITGB1 protein expression (Spearman = 0.7, p = 1.605 \u00d7 10\u22124); however, the weak, positive correlation between IGF-1R and ITGB3 protein expression was not statistically significant (Spearman = 0.33, p = 0.149) (Fig. 2B).Figure 2ITGB1 is highly expressed in migratory cancer cells and is required for IGF-1R turnover.A, correlation of ITGB1 (left) or ITGB3 (right) protein expression with IGF-1R expression using data from TCGA, PanCancer Atlas\u2014Breast Invasive Carcinoma dataset (n = 105). Relative protein expression levels were measured by mass spectrometry by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), represented as arbitrary units (A.U.) on a distribution. B, correlation of ITGB1 (left) or ITGB3 (right) protein expression with IGF-1R expression using data from TCGA, PanCancer Atlas\u2014Breast Invasive Carcinoma: Basal subtype datasets (IGF1RvITGB1, n = 24; IGF1RvITGB3, n = 21). Relative protein expression levels measured by mass spectrometry carried out by CPTAC\u2014represented as arbitrary units on a distribution. C, western blot showing ITGB1 expression in a panel of breast cancer cell lines. D\u2013G, western blot analysis of (D) MCF-7, (E) HeLa, (F) Hs578T, and (G) MDA-MB-231 cells transfected with either siNeg or siITGB1 siRNA. Cells were serum starved for 4 h and then stimulated with 50 ng/ml IGF-1 for either 10 min or 30 min. For (D\u2013G) densitometry quantification is presented as the average fold change \u00b1 SEM in IGF-1R protein levels relative to the unstimulated control sample (set to 1). Representative of n = 3 independent experiments. Significance was calculated using an unpaired, two-tailed Student\u2019s t test. Statistical significance was determined as p-value <0.05. Graded p-values are represented as follows: \u2217p < 0.05, \u2217\u2217p < 0.005, and \u2217\u2217\u2217p < 0.0005. IGF-1R, insulin-like growth factor 1 receptor; ITGB1, \u03b21-integrin; TCGA, The Cancer Genome Atlas.",
      "The results shown in Figure 2, A and B are, in whole, based upon data generated by TCGA Research Network, https://www.cancer.gov/tcga. Protein expression data were downloaded from the TCGA PanCancer Atlas\u2014Breast Invasive Carcinoma dataset (49), via cBioPortal (48). The IGF-1R, ITGB1, and ITGB3 protein expression data from this dataset that were used in this study were quantified by mass spectrometry by The National Cancer Institute\u2019s Clinical Proteomic Tumor Analysis Consortium."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625048": [
        "IGF-1R accumulation at the Golgi apparatus is promoted by cell adhesion-dependent phosphorylation of Tyr1250/1251 in the IGF-1R CT (32). Therefore, we next asked how cell adhesion molecules influence IGF-1R activity in cancer. Using cBioPortal (48), we first investigated the relationship between the IGF-1R and two core adhesion molecules known to associate with the IGF-1R, ITGB1 and ITGB3 (28, 29, 30, 31). Using the The Cancer Genome Atlas (TCGA) Pan Cancer Atlas\u2014Breast Invasive Carcinoma dataset (49) (n = 105), we found a moderate, positive correlation between IGF-1R and ITGB1 protein expression (Spearman = 0.49, p = 1.35 \u00d7 10\u22127), and a weak, positive correlation between IGF-1R and ITGB3 protein expression (Spearman = 0.33, p = 1.271 \u00d7 10\u22123) (Fig. 2A). Relative protein expression levels were measured by mass spectrometry carried out by the Clinical Proteomic Tumor Analysis Consortium and are represented as arbitrary units on a distribution. To further explore these relationships, a cohort of basal-like breast cancer patients (IGF1RvITGB1, n = 24; IGF1RvITGB3, n = 21) from the TCGA Pan Cancer Atlas\u2014Breast Invasive Carcinoma dataset was further analyzed (because this breast cancer subtype has similar features to TNBC (50)). Here, we observed a strong, positive correlation between IGF-1R and ITGB1 protein expression (Spearman = 0.7, p = 1.605 \u00d7 10\u22124); however, the weak, positive correlation between IGF-1R and ITGB3 protein expression was not statistically significant (Spearman = 0.33, p = 0.149) (Fig. 2B).Figure 2ITGB1 is highly expressed in migratory cancer cells and is required for IGF-1R turnover.A, correlation of ITGB1 (left) or ITGB3 (right) protein expression with IGF-1R expression using data from TCGA, PanCancer Atlas\u2014Breast Invasive Carcinoma dataset (n = 105). Relative protein expression levels were measured by mass spectrometry by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), represented as arbitrary units (A.U.) on a distribution. B, correlation of ITGB1 (left) or ITGB3 (right) protein expression with IGF-1R expression using data from TCGA, PanCancer Atlas\u2014Breast Invasive Carcinoma: Basal subtype datasets (IGF1RvITGB1, n = 24; IGF1RvITGB3, n = 21). Relative protein expression levels measured by mass spectrometry carried out by CPTAC\u2014represented as arbitrary units on a distribution. C, western blot showing ITGB1 expression in a panel of breast cancer cell lines. D\u2013G, western blot analysis of (D) MCF-7, (E) HeLa, (F) Hs578T, and (G) MDA-MB-231 cells transfected with either siNeg or siITGB1 siRNA. Cells were serum starved for 4 h and then stimulated with 50 ng/ml IGF-1 for either 10 min or 30 min. For (D\u2013G) densitometry quantification is presented as the average fold change \u00b1 SEM in IGF-1R protein levels relative to the unstimulated control sample (set to 1). Representative of n = 3 independent experiments. Significance was calculated using an unpaired, two-tailed Student\u2019s t test. Statistical significance was determined as p-value <0.05. Graded p-values are represented as follows: \u2217p < 0.05, \u2217\u2217p < 0.005, and \u2217\u2217\u2217p < 0.0005. IGF-1R, insulin-like growth factor 1 receptor; ITGB1, \u03b21-integrin; TCGA, The Cancer Genome Atlas.",
        "The results shown in Figure 2, A and B are, in whole, based upon data generated by TCGA Research Network, https://www.cancer.gov/tcga. Protein expression data were downloaded from the TCGA PanCancer Atlas\u2014Breast Invasive Carcinoma dataset (49), via cBioPortal (48). The IGF-1R, ITGB1, and ITGB3 protein expression data from this dataset that were used in this study were quantified by mass spectrometry by The National Cancer Institute\u2019s Clinical Proteomic Tumor Analysis Consortium."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.30564379692077637,
    "data_pmids_checked": 1,
    "paper_id": "39608716",
    "extraction_date": "2025-12-19T20:44:20.322252",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39608716.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39605688": {
    "cbioportal_paper_citations": [
      "A recurrent point mutation, EZH2Y641F (or Y646, depending on isoform), in the SET catalytic domain is observed in 15\u201320% of mature B-cell lymphomas such as follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) 11,12. Mouse models of the Ezh2Y641F mutation have shown that Ezh2 is required for Germinal Center (GC) formation, and that expression of the mutant Ezh2Y641F promotes GC hyperplasia and the development of B cell lymphoma 6,8,13\u201315. At the molecular level, Ezh2Y641 mutations were initially thought to be loss-of-function mutations 11, however, subsequent studies showed that they exhibit neomorphic activity, preferentially methylating mono- or di-methylated H3K27, but requiring the presence of wild-type EZH2 for initial mono-methylation steps 16,17. These observations are consistent with the fact that all EZH2Y641 mutations identified to date in human patients are heterozygous12. Globally, these mutations alter the distribution of H3K27me3, with increased deposition in some regions, decreased in others, and spreading of H3K27me3 past canonical boundaries 6,14,18. These findings suggest that EZH2Y641F mutations are not purely gain-of-function but likely neomorphic, and distinct from simple overexpression of wild-type EZH2."
    ],
    "cbioportal_platform_mentions": [
      "c. Correlation analyses of GBP1 with GBP4 (left), GBP4 with STAT1 (middle), and GBP2 with IRF1 (right) in DLBCL patients (TCGA DLBCL data, n=37, analyzed in cBioPortal)."
    ],
    "data_publication_citations": {
      "21796119": [
        "A recurrent point mutation, EZH2Y641F (or Y646, depending on isoform), in the SET catalytic domain is observed in 15\u201320% of mature B-cell lymphomas such as follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) 11,12. Mouse models of the Ezh2Y641F mutation have shown that Ezh2 is required for Germinal Center (GC) formation, and that expression of the mutant Ezh2Y641F promotes GC hyperplasia and the development of B cell lymphoma 6,8,13\u201315. At the molecular level, Ezh2Y641 mutations were initially thought to be loss-of-function mutations 11, however, subsequent studies showed that they exhibit neomorphic activity, preferentially methylating mono- or di-methylated H3K27, but requiring the presence of wild-type EZH2 for initial mono-methylation steps 16,17. These observations are consistent with the fact that all EZH2Y641 mutations identified to date in human patients are heterozygous12. Globally, these mutations alter the distribution of H3K27me3, with increased deposition in some regions, decreased in others, and spreading of H3K27me3 past canonical boundaries 6,14,18. These findings suggest that EZH2Y641F mutations are not purely gain-of-function but likely neomorphic, and distinct from simple overexpression of wild-type EZH2."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.19321417808532715,
    "data_pmids_checked": 1,
    "paper_id": "39605688",
    "extraction_date": "2025-12-19T20:44:20.393727",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39605688.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39602462": {
    "cbioportal_paper_citations": [
      "The Cancer Genome Atlas (TCGA) gene expression data were extracted from cBioPortal (http://www.cbioportal.org/; ref. 21). The correlation analysis between ACTG2, CCL21, WNT7A, MMP2 expression, and cytotoxic T lymphocyte (CTL) infiltration in cancer datasets was performed using the Tumor Immune Dysfunction and Exclusion system (http://tide.dfci.harvard.edu/faq/; ref. 22). The immune profiling analysis was conducted on 1,082 breast cancer samples from the TCGA-BRCA dataset using the single-sample gene set enrichment analysis (GSEA) method. This approach calculates an enrichment score for each immune-related gene set in individual samples, allowing for the characterization of immune cell infiltration and activity. The immune-related gene sets were obtained from published databases, covering a wide range of immune cell types and pathways. The single-sample GSEA scores were computed using the GSVA R package, which normalizes the expression data and assigns a relative score to each gene set. These scores represent the relative abundance or activity of specific immune cell populations and pathways across the samples (23)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.27950000762939453,
    "data_pmids_checked": 0,
    "paper_id": "39602462",
    "extraction_date": "2025-12-19T20:44:20.601841",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39602462.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39615893": {
    "cbioportal_paper_citations": [
      "To explore the prognostic effect of the ISAC, we downloaded data from the cBioPortal database for all patients with stage IV nsqNSCLC.27 28 After deduplication, a total of 1,012 patients with overall survival (OS) and mutational data were included for prognostic analysis (baseline characteristic: online supplemental table S4).232933"
    ],
    "cbioportal_platform_mentions": [
      "The coefficient of each mutational event was determined by a multivariable model (online supplemental methods, figure 2B and online supplemental table S8). As illustrated by calibration curves, the actual and ISAC-predicted 6/12 month PFS rates were highly consistent (figure 2C). The ISAC was irrelevant to age, sex, PD-L1 expression, and TMB (online supplemental table S9), but a high ISAC was linked with poor prognosis in the stage I\u2013III and stage IV nsqNSCLCs obtained from the cBioPortal database (online supplemental figure S2), suggesting the aggressiveness of high-ISAC nsqNSCLCs."
    ],
    "data_publication_citations": {
      "29596782": [
        "To explore the prognostic effect of the ISAC, we downloaded data from the cBioPortal database for all patients with stage IV nsqNSCLC.27 28 After deduplication, a total of 1,012 patients with overall survival (OS) and mutational data were included for prognostic analysis (baseline characteristic: online supplemental table S4).232933"
      ],
      "32015526": [
        "Since the MDACC cohort only contains mutational data of 70 genes, tumor mutational burden (TMB) was not calculated in this cohort and the genomic analysis in our study was limited to the key genes shared by all cohorts. The list of key genes and signaling pathways is shown in online supplemental table S3. This definition of pathways was derived from previous studies.2326",
        "To explore the prognostic effect of the ISAC, we downloaded data from the cBioPortal database for all patients with stage IV nsqNSCLC.27 28 After deduplication, a total of 1,012 patients with overall survival (OS) and mutational data were included for prognostic analysis (baseline characteristic: online supplemental table S4).232933"
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 2.599902868270874,
    "data_pmids_checked": 11,
    "paper_id": "39615893",
    "extraction_date": "2025-12-19T20:44:20.613775",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39615893.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39591374": {
    "cbioportal_paper_citations": [
      "C-BioPortal is a complex site, which can visualize, and analyze the cancer genomic [21]. The frequency of CCNE1 gene alteration, mutation type and alteration of copy number in tumors can be seen through \u201cCancer Types Summary\u201d section of the cBioPortal in TCGA. Setting \u201cTCGA Pan Cancer Atlas Study\u201d, we can query the genetic alteration signature of the CCNE 1 gene via the \u201cQuick select\u201d section. Additionally, we used the \u201cComparison\u201d section, analyzed data on the relationship among CCNE1 genetic alterations, OS, PFS, and DFS. The results are shown as log-rank P-values."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1336650848388672,
    "data_pmids_checked": 0,
    "paper_id": "39591374",
    "extraction_date": "2025-12-19T20:44:20.735591",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39591374.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39587886": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We curated two scRNA-seq human breast cancer datasets encompassing a total of 25 ER+ breast tumor samples. Processed scRNA-seq data from Wu et al.15 were obtained from the NCBI Gene Expression Omnibus (GEO) under accession number GSE176078, and raw count matrices by Bassez et al.16 were retrieved from https://lambrechtslab.sites.vib.be/en/single-cell. Gene expression and survival data for ER+ breast cancer patients (n = 1,498) were obtained from The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)22 through the cBioPortal for Cancer Genomics (http://cbioportal.org.) (http://cbioportal.org).23 The sample and data are summarized in Supplementary Table S1."
    ],
    "data_publication_citations": {
      "22522925": [
        "We curated two scRNA-seq human breast cancer datasets encompassing a total of 25 ER+ breast tumor samples. Processed scRNA-seq data from Wu et al.15 were obtained from the NCBI Gene Expression Omnibus (GEO) under accession number GSE176078, and raw count matrices by Bassez et al.16 were retrieved from https://lambrechtslab.sites.vib.be/en/single-cell. Gene expression and survival data for ER+ breast cancer patients (n = 1,498) were obtained from The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)22 through the cBioPortal for Cancer Genomics (http://cbioportal.org.) (http://cbioportal.org).23 The sample and data are summarized in Supplementary Table S1.",
        "To evaluate clinical relevance, we explored the association of these genes with outcomes in ER+ breast tumors using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset.22 The expression of RGL3 and S100A7 was not associated with overall survival outcomes (Hazard ratio = 0.95, log-rank test p-value = 0.614 for RGL3; Hazard ratio = 1.03, log-rank test p-value = 0.786 for S100A7) (Supplementary Figure S2). In contrast, high S100A11 expression was associated with poor survival outcomes in ER+ breast tumors, with a hazard ratio (HR) of 1.30 (Figure 2b, log-rank test p-value = 0.006). RGL3 and S100A7 showed no predictive value as potential therapeutic vulnerabilities; therefore, we decided not to pursue experimental investigation for RGL3 and S100A7. Instead, we focused on further exploring the association between secreted factor S100A11 and macrophage fraction."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3230600357055664,
    "data_pmids_checked": 1,
    "paper_id": "39587886",
    "extraction_date": "2025-12-19T20:44:20.937434",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39587886.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39591760": {
    "cbioportal_paper_citations": [
      "In pancreatic cancer, the expression of SETD2 is significantly decreased compared with normal tissues in around 10 % of the patients [90]. One hypothesis about the role of SETD2 in the initiation and metastasis in pancreatic cancer would be on implication in cell metabolism. Indeed, a loss of SETD2 has been shown to enhance glycolysis addiction through the upregulation of glucose transporter 1 (GLUT1) and to impair nucleoside synthesis by direct downregulation of the transcriptional level of transketolase in the pentose phosphate pathway. SETD2 deficiency in pancreatic cancer thus reprograms glycolytic metabolism to compensate for insufficient nucleoside synthesis [91]."
    ],
    "cbioportal_platform_mentions": [
      "In the different structures of SETD2 catalytic domain in complex with H3K36 peptide or nucleosome (mimicking the target lysine 36), the interaction of SETD2 with residue M36 is stabilized by four residues that form a hydrophobic cage around the target lysine (Y1579, M1607, F1664, Y1666). Among these residues, Y1666 is described as a mutation hotspots suggesting a major role of this residue although no studies have been conducted yet (Fig. 4). In addition, the other residues flanking H3K36M reinforce this recognition by hydrogen bonds and hydrophobic interactions. Histone H3 residues A29-V35, being small and uncharged, fit into a narrow electropositive pocket (formed by SETD2 residues F1589, Y1604, F1606, F1668), whereas histone H3 H39-Y41 residues form hydrogen bonds with residues E1636 and T1637 of SETD2, thanks to the trans configuration of residue H3P38. The H3P38 cis configuration, but also H3P38V mutations, are known to impair the interaction between SETD2 and H3 suggesting the importance of P38 for substrate binding [21].Fig. 4SETD2 mutation hotspots, mapping their position in the structure and the cancers in which they are involved. A: SETD2 catalytic domain (AWS \u2013 SET \u2013 post-SET) crystal structure (PDB 5JJY) [20] in blue cartoon. SETD2 mutation hotspots S1572, H1603, R1625, Y1666 are highlighted in red sticks. H3K36M peptide substrate is represented in orange cartoon and M36 residue is in sticks. SAH cofactor is represented in black sticks. Left panel: Overall structure. Right panel: Closed view of SETD2 mutation hotspots. B: Classification of cancers with SETD2 gene mutation hotspots as documented by cBioPortal for cancer genomics database.Fig 4",
      "SETD2 mutation hotspots, mapping their position in the structure and the cancers in which they are involved. A: SETD2 catalytic domain (AWS \u2013 SET \u2013 post-SET) crystal structure (PDB 5JJY) [20] in blue cartoon. SETD2 mutation hotspots S1572, H1603, R1625, Y1666 are highlighted in red sticks. H3K36M peptide substrate is represented in orange cartoon and M36 residue is in sticks. SAH cofactor is represented in black sticks. Left panel: Overall structure. Right panel: Closed view of SETD2 mutation hotspots. B: Classification of cancers with SETD2 gene mutation hotspots as documented by cBioPortal for cancer genomics database.",
      "The interaction between SETD2 and RNA pol II does not appear to affect SETD2 enzymatic catalysis, since overexpression of the R2510H oncogenic mutant has no impact on SETD2 methylation activity nor the stability of the enzyme [29]. Nevertheless, deletion of the SETD2 SRI domain results in an inability to recruit SETD2 to its target gene locus through binding to the CTD domain of RNA polymerase II. This hypothesis was confirmed by the study of the truncated mutation p.Gln2325*, which results in a global loss of H3K36me3 level [36]. In a same way, the SETD2-Nf1 fusion gene (Fig. 5), identified in a paediatric spindle cell tumour with the chromosomal translocation t(3;17)(p21;q12), results in deletion of the SETD2 SRI domain and a decrease in H3K36me3 level [37].Fig. 5SETD2 gene translocations. A: Translocations of the SETD2 gene and types of cancer in which they are involved. Non-exhaustive table compiled by cBioPortal for the Cancer Genomics Database.B: A case of SETD2 translocation described in a paediatric cell spider tumour with chromosomal translocation t(3;18)(p21;q12) and loss of the SETD2 SRI domain. SETD2 (1-2450) fuses with exon 3 of the NF1-020 transcript to form the SETD2-NF1 fusion protein[37].Fig 5",
      "SETD2 gene translocations. A: Translocations of the SETD2 gene and types of cancer in which they are involved. Non-exhaustive table compiled by cBioPortal for the Cancer Genomics Database.",
      "The most mutated catalytic residue R1625 is described as a hotspot mutation in the COSMIC and CBioPortal databases. Hackeer et al. deeply studied the R1625C missense mutation, located in the catalytic domain of SETD2, near the SAM cofactor binding site (Fig. 4). This mutation leads to an inactive enzyme, due to altered substrate binding, as demonstrated by in silico and peptide pull-down assays. In addition, the mutated protein is less stable than the WT form in SETD2 KO transfected cells. Accordingly, human cells expressing the SETD2 R1625C mutation show a decrease in the H3K36me3 epigenetic mark and defects in DNA repair [29]."
    ],
    "data_publication_citations": {
      "23792563": [
        "Among the different types of renal cancer, ccRCC is the major type with a high incidence rate and poor prognosis. The observed mutations of SETD2 were predominantly nonsense or missense mutations, frame shift and fusion, all leading to loss-of-function. In ccRCC several mutations of tumor suppressor genes and chromatin regulators have been identified near von Hippel-Lindau (VHL), including Polybromo1 (PBRM1), BRCA1 associated protein-1 (BAP1), and SETD2 [73]. Furthermore, SETD2 deficiency is associated with ccRCC recurrence and poor prognosis. Hence, SETD2 loss-of-function mutations were identified in 10 %\u223c20 % of primary ccRCC tumors, increasing to 30 %\u223c60 % of metastatic ccRCC tumors, H3K36me3 being reduced in distant metastases [74]. However, it is noteworthy that SETD2 mutations seem to be acquired and selected from pre-existing VHL- and/or PBRM1-mutated cells [75]. SETD2 has been associated with multiple defects in ccRCC including cryptic transcription [4], RNA splicing [76], DNA repair [77] or even autophagy [78]. All these mutations and molecular processes have recently been reviewed in an exhaustive way by Yu et al [79]."
      ],
      "29489754": [
        "SETD2 is associated with various cancers and is considered as one of the most frequently mutated genes in tumors [[13], [14], [15]]. Indeed, various mutations along the entire sequence of the protein have been reported. Most of these alterations are likely loss-of-function mutations that could affect the methyltransferase activity of the enzyme as well as its involvement in molecular assemblies (Fig. 2). As stated above, numerous tumors are associated with SETD2 genetic alterations, including clear-cell renal carcinomas which show the highest mutation frequency among SETD2-related cancers, but also leukemias and lymphomas, non-small-cell lung tumors, gastric tumors and gliomas. Although most mutations affecting SETD2 are monoallelic and may lead to haploinsufficiency, biallelic genetic defects in SETD2 and genetic translocations are found in different cancers [[16], [17], [18]].Fig. 2SETD2, a cancer driver gene. A: Identified cancer-associated mutations, as documented by the The Cancer Genome Atlas (TCGA) database, in the complete SETD2 enzyme and catalytic region (AWS, SET, post-SET). Missense mutations are shown in red, nonsense mutations in purple and frameshift mutations in blue. B: Overview of the distribution of mutations in SETD2 enzyme (left) and catalytic region (right), as described in the COSMIC (Catalogue Of Somatic Mutations In Cancer) database.Fig 2"
      ],
      "22980975": [
        "In lung cancer, inactivation of SETD2 and subsequent loss of H3K36me3 led to an acceleration of progression of both early and late-stage tumors. SETD2 is also inactivated at a higher frequency in metastatic sites compared with primary sites, which is linked to poor prognosis [92,93]. As previously discussed, in lung adenocarcinoma a loss of SETD2 favors cell proliferation, migration, invasion and EMT through regulation of the STAT1\u2013IL-8 signaling pathway [57]. Moreover, SETD2 has also been involved in a cisplatin-resistance mechanism in lung adenocarcinoma [94]."
      ],
      "23797736": [
        "Among the different types of renal cancer, ccRCC is the major type with a high incidence rate and poor prognosis. The observed mutations of SETD2 were predominantly nonsense or missense mutations, frame shift and fusion, all leading to loss-of-function. In ccRCC several mutations of tumor suppressor genes and chromatin regulators have been identified near von Hippel-Lindau (VHL), including Polybromo1 (PBRM1), BRCA1 associated protein-1 (BAP1), and SETD2 [73]. Furthermore, SETD2 deficiency is associated with ccRCC recurrence and poor prognosis. Hence, SETD2 loss-of-function mutations were identified in 10 %\u223c20 % of primary ccRCC tumors, increasing to 30 %\u223c60 % of metastatic ccRCC tumors, H3K36me3 being reduced in distant metastases [74]. However, it is noteworthy that SETD2 mutations seem to be acquired and selected from pre-existing VHL- and/or PBRM1-mutated cells [75]. SETD2 has been associated with multiple defects in ccRCC including cryptic transcription [4], RNA splicing [76], DNA repair [77] or even autophagy [78]. All these mutations and molecular processes have recently been reviewed in an exhaustive way by Yu et al [79]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 0.603848934173584,
    "data_pmids_checked": 5,
    "paper_id": "39591760",
    "extraction_date": "2025-12-19T20:44:21.022705",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39591760.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39575457": {
    "cbioportal_paper_citations": [
      "To assess mRNA expression within cohorts of specific pediatric brain tumor subtypes, we used the pediatric cBioportal tool11,12 to download mRNA expression data for the major histological types of pediatric brain cancer from the Open Pediatric Cancer (OpenPedCan) Project v12 dataset (data downloaded on September 28, 2023) and the v15 dataset (data downloaded on May 30, 2024, and August 12, 2024). These data consisted of tumor samples from 167 glioblastoma (GBM) samples from 159 patients, 12 brainstem glioma DIPGs from 12 patients, 411 DMG-H3K27M samples from 224 patients, 246 caudate (basal ganglia, GTEx), 255 nontumor brain cortex (GTEx), and 202 nontumor hypothalamus samples. RNA data were not available for all samples/patients. Specific to brainstem glioma DIPGs and DMG-H3K27M: 423 samples were analyzed from 235 patients (128 females, 102 males, and 5 unreported/unknown) with an average age of 8.1 years. Ages for other tumor subtypes, as well as other individual anonymous patient characteristics (gender, survival status, cancer type, patient ID, sample ID age, and race), are provided in Supplementary File. Normal brain tissue mRNA levels were taken from GTEx data already incorporated and normalized into Pediatric cBioportal. Mitochondrial Complex I gene expression scores were created by the sum of log2 z-score expression for 37 genes encoding Complex I proteins in the human genome. Hypoxia scores were created by using the sum of log2 z-score expression for the 50 genes described in the hypoxia Buffa metagene score.13 See Supplementary Table 1 for further details.",
      "Some tumors rely on OXPHOS for energy, and increased oxygen consumption can cause localized hypoxia. Tumors can increase OXPHOS flux by overexpressing genes involved in the process. Increased expression of these genes correlates with increased OXPHOS activity in vivo.14 We observed high OXPHOS rates in DIPG cells in vitro (Figure 1); therefore, we assessed OXPHOS gene expression in DIPG tumors and patient-derived cell lines. We were interested in electron transport chain (ETC) genes, where clinically approved drugs are known to target the protein product. We used datasets from the Childhood Cancer Model Atlas (CCMA),15 cBioPortal,11,12, and the Open Pediatric Cancer (OpenPedCan) Project v15 to extract mRNA abundance for cell lines and patients under multiple pediatric (\u226421 years old) brain tumor classifications (brainstem glioma [BSG] DIPG and DMG-H3K27M). One patient within the DMG-H3K27M classification was 29 years old. We also extracted data for adult GBMs (21-85 years old) for comparison. We used mRNA expression data from nontumor brain tissue samples (GTEx) and nonmalignant brain cell lines (CCMA). We used these data to create a mitochondrial Complex I expression score from the normalized log2 mRNA values of the 37 Complex I structural genes encoded in the human (nuclear) genome.14",
      "If DIPG tumors have increased OXPHOS in vivo, as demonstrated in our in vitro experiments, tumors would consume a significant amount of oxygen, creating hypoxic regions. Hypoxia is common in tumors like GBM,8 although the cause of hypoxia may vary between tumor types. While OXPHOS requires oxygen to function, the ETC continues to function optimally at oxygen concentrations as low as 0.5% v/v.16 While there are limited in vivo data on DIPG hypoxia, there are established methods for assessing tumor hypoxia, including the Buffa hypoxia signature, which comprises a list of 50 genes that are commonly overexpressed in hypoxic tumors when compared with surrounding nontumor tissue.13 Similar to the Complex I gene expression analyses, we used the same publicly available datasets11,12 to evaluate expression of the Buffa hypoxia metagene signature (50 genes that are prognostic of hypoxia in human tumors).13 To generate a hypoxia score, the data for all 50 genes were combined in a single score for each tumor sample extracted from cBioPortal11,12 and the Open Pediatric Cancer (OpenPedCan) Project v15, as described in the previous section and in Supplementary File. All 3 tumor subtypes had a significantly increased hypoxia score when compared with the caudate (Figure 2C). We also observed a strong correlation between the hypoxia metagene score and the Complex I gene expression score for individual tumors or normal brain tissue samples (Figure 2D). These data indicate that DIPG tumors with higher Complex I score show gene expression patterns consistent with a hypoxic tumor microenvironment, although the underlying tumor genetics may affect expression in varying ways."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2500011920928955,
    "data_pmids_checked": 0,
    "paper_id": "39575457",
    "extraction_date": "2025-12-19T20:44:21.314016",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39575457.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39576826": {
    "cbioportal_paper_citations": [
      "To identify somatic mutations of ALK5 in endometrial carcinomas, we used the cBioPortal for Cancer Genomics (https://cbioportal.org) [11, 12] to query publicly available mutation datasets using the search term \u201cTGFBR1\u201d. The queried datasets were previously generated by The Cancer Genome Atlas (TCGA) or Memorial Sloan-Kettering Cancer Center (MSKCC) and corresponded to the following cohorts: TCGA-Uterine Corpus Endometrial Carcinoma (PanCancer) [13], MSKCC-Advanced-Stage Endometrial Cancer [14], MSKCC-Endometrial Cancer MSI (MSK, 2022) [15], and TCGA-Uterine Carcinosarcoma (PanCancer) [16]. Publicly available clinicopathologic information for ALK5-mutated cases was also retrieved from the cBioPortal for Cancer Genomics.",
      "We used the cBioPortal for Cancer Genomics [11, 12] to query the ALK5 mutation status of tumors in the TCGA-UCEC and TCGA-UCS datasets [12, 15], after excluding the TCGA-UCEC ultramutated subgroup, and in the MSKCC clinical cohorts [13, 14]. Overall, 27 somatic mutations in ALK5 were identified among the 907 endometrial tumors queried (S1 Fig); 40.7% (11 of 27) of mutations, including the recurrent S241L-, R255C-, and R487G-ALK5 mutations, localized within the protein kinase domain, and 14.8% (4 of 27) were in the Activin types I and II receptor domain. The majority (81.5%, 22 of 27) of mutations were missense mutations; the remainder were splice-site (7.4%, 2 of 27), nonsense (7.4%, 2 of 27), or in-frame deletion (3.7%, 1 of 27) mutations."
    ],
    "cbioportal_platform_mentions": [
      "The mutations shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga\" and retrieved using the cBIOPortal for Cancer Genomics (https://cbioportal.org). ALK5 coding (c.) and ALK5 amino acid (p.) designations corresponding to CCDS6738."
    ],
    "data_publication_citations": {
      "35849120": [
        "To identify somatic mutations of ALK5 in endometrial carcinomas, we used the cBioPortal for Cancer Genomics (https://cbioportal.org) [11, 12] to query publicly available mutation datasets using the search term \u201cTGFBR1\u201d. The queried datasets were previously generated by The Cancer Genome Atlas (TCGA) or Memorial Sloan-Kettering Cancer Center (MSKCC) and corresponded to the following cohorts: TCGA-Uterine Corpus Endometrial Carcinoma (PanCancer) [13], MSKCC-Advanced-Stage Endometrial Cancer [14], MSKCC-Endometrial Cancer MSI (MSK, 2022) [15], and TCGA-Uterine Carcinosarcoma (PanCancer) [16]. Publicly available clinicopathologic information for ALK5-mutated cases was also retrieved from the cBioPortal for Cancer Genomics.",
        "We used the cBioPortal for Cancer Genomics [11, 12] to query the ALK5 mutation status of tumors in the TCGA-UCEC and TCGA-UCS datasets [12, 15], after excluding the TCGA-UCEC ultramutated subgroup, and in the MSKCC clinical cohorts [13, 14]. Overall, 27 somatic mutations in ALK5 were identified among the 907 endometrial tumors queried (S1 Fig); 40.7% (11 of 27) of mutations, including the recurrent S241L-, R255C-, and R487G-ALK5 mutations, localized within the protein kinase domain, and 14.8% (4 of 27) were in the Activin types I and II receptor domain. The majority (81.5%, 22 of 27) of mutations were missense mutations; the remainder were splice-site (7.4%, 2 of 27), nonsense (7.4%, 2 of 27), or in-frame deletion (3.7%, 1 of 27) mutations."
      ],
      "30068706": [
        "To identify somatic mutations of ALK5 in endometrial carcinomas, we used the cBioPortal for Cancer Genomics (https://cbioportal.org) [11, 12] to query publicly available mutation datasets using the search term \u201cTGFBR1\u201d. The queried datasets were previously generated by The Cancer Genome Atlas (TCGA) or Memorial Sloan-Kettering Cancer Center (MSKCC) and corresponded to the following cohorts: TCGA-Uterine Corpus Endometrial Carcinoma (PanCancer) [13], MSKCC-Advanced-Stage Endometrial Cancer [14], MSKCC-Endometrial Cancer MSI (MSK, 2022) [15], and TCGA-Uterine Carcinosarcoma (PanCancer) [16]. Publicly available clinicopathologic information for ALK5-mutated cases was also retrieved from the cBioPortal for Cancer Genomics.",
        "We used the cBioPortal for Cancer Genomics [11, 12] to query the ALK5 mutation status of tumors in the TCGA-UCEC and TCGA-UCS datasets [12, 15], after excluding the TCGA-UCEC ultramutated subgroup, and in the MSKCC clinical cohorts [13, 14]. Overall, 27 somatic mutations in ALK5 were identified among the 907 endometrial tumors queried (S1 Fig); 40.7% (11 of 27) of mutations, including the recurrent S241L-, R255C-, and R487G-ALK5 mutations, localized within the protein kinase domain, and 14.8% (4 of 27) were in the Activin types I and II receptor domain. The majority (81.5%, 22 of 27) of mutations were missense mutations; the remainder were splice-site (7.4%, 2 of 27), nonsense (7.4%, 2 of 27), or in-frame deletion (3.7%, 1 of 27) mutations."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5438709259033203,
    "data_pmids_checked": 2,
    "paper_id": "39576826",
    "extraction_date": "2025-12-19T20:44:21.487437",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39576826.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39570650": {
    "cbioportal_paper_citations": [
      "mRNA expression data for the comparison of ENPP2 expression in primary tumors and normal tissue in all cancers, and the additional matched normal tissue data, comes from combined cohort of TCGA (The Cancer Genome Atlas), TARGET (Therapeutically Applicable Research to Generate Effective Treatments) and GTEx (The Genotype-Tissue Expression) samples, available through the UCSC (University of California, Santa Cruz) Xena Browser (https://xenabrowser.net/) (21). The gene expression data across cancer cell lines comes from the Cancer Cell Line Encyclopedia (CCLE) from the Broad Institute and Novartis, updated 2019 (22,23) and was accessed through cBioPortal (RRID:SCR_014555) (24,25). The pancreatic scRNA-seq dataset from (26) was obtained from zenodo (https://zenodo.org/record/6024273). Seurat (27)was used to query the scRNA-seq dataset. Ucell (28) was used for scRNA-seq dataset scoring and ESTIMATE gene-set validation. Expressing cells defined as cells with non-zero gene expression value.",
      "ESTIMATE (Estimation of Stromal and Immune cell in Malignant Tumor tissues using Expression data) scores of tumor purity were downloaded from https://bioinformatics.mdanderson.org/estimate/ for every available cancer type for the RNA-Seq-V2 platform. cBioPortal (RRID:SCR_014555) was used for handling and downloading TCGA data (24,25). Of the 184 samples in the Pancreatic Adenocarcinoma (TCGA, PanCancer Atlas) dataset, 31 were annotated as non-PDAC (i.e., Pancreatic Adenocarcinoma, other subtype, or Pancreatic Carcinoma) and were removed from the analysis. Similar measures were not taken for the other cancer types studied. TME rich samples were defined as samples with both highest quartile stromal and highest quartile immune scores, and tumor rich samples were defined as samples with both lowest quartile stromal and lowest quartile immune scores (within each cancer type). These groups were compared using cBioPortal. The RSEM (Batch normalized from Illumina HiSeq_RNASeqV2) (log2) data was downloaded for ENPP2 and ACTA2 mRNA expression."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31068700": [
        "mRNA expression data for the comparison of ENPP2 expression in primary tumors and normal tissue in all cancers, and the additional matched normal tissue data, comes from combined cohort of TCGA (The Cancer Genome Atlas), TARGET (Therapeutically Applicable Research to Generate Effective Treatments) and GTEx (The Genotype-Tissue Expression) samples, available through the UCSC (University of California, Santa Cruz) Xena Browser (https://xenabrowser.net/) (21). The gene expression data across cancer cell lines comes from the Cancer Cell Line Encyclopedia (CCLE) from the Broad Institute and Novartis, updated 2019 (22,23) and was accessed through cBioPortal (RRID:SCR_014555) (24,25). The pancreatic scRNA-seq dataset from (26) was obtained from zenodo (https://zenodo.org/record/6024273). Seurat (27)was used to query the scRNA-seq dataset. Ucell (28) was used for scRNA-seq dataset scoring and ESTIMATE gene-set validation. Expressing cells defined as cells with non-zero gene expression value."
      ],
      "22460905": [
        "mRNA expression data for the comparison of ENPP2 expression in primary tumors and normal tissue in all cancers, and the additional matched normal tissue data, comes from combined cohort of TCGA (The Cancer Genome Atlas), TARGET (Therapeutically Applicable Research to Generate Effective Treatments) and GTEx (The Genotype-Tissue Expression) samples, available through the UCSC (University of California, Santa Cruz) Xena Browser (https://xenabrowser.net/) (21). The gene expression data across cancer cell lines comes from the Cancer Cell Line Encyclopedia (CCLE) from the Broad Institute and Novartis, updated 2019 (22,23) and was accessed through cBioPortal (RRID:SCR_014555) (24,25). The pancreatic scRNA-seq dataset from (26) was obtained from zenodo (https://zenodo.org/record/6024273). Seurat (27)was used to query the scRNA-seq dataset. Ucell (28) was used for scRNA-seq dataset scoring and ESTIMATE gene-set validation. Expressing cells defined as cells with non-zero gene expression value."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4165918827056885,
    "data_pmids_checked": 2,
    "paper_id": "39570650",
    "extraction_date": "2025-12-19T20:44:21.808368",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39570650.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39663776": {
    "paper_id": "39663776",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Materials and Methods: GEPIA and cBioPortal were used to analyze selenoprotein expression and mutations and copy number variations",
      "Gere\u00e7 ve Y\u00f6ntemler: Selenoprotein ekspresyonunu, mutasyonlar\u0131n\u0131 ve kopya say\u0131s\u0131 varyasyonlar\u0131n\u0131 analiz etmek i\u00e7in GEPIA ve cBioPortal kullan\u0131ld\u0131",
      "endometrial cancer, and uterine carcinosarcoma datasets from\nMultiple studies have demonstrated that selenium levels are the cBioPortal (http://www.cbioportal.org/) database were used\ngenerally low in most patients with gynecological malignancies to perform mutation and copy number variation analyses of\nand are closely associated with poor prognosis",
      "Mutations and copy number variations of selenoprotein (cBioPortal)",
      "using the cBioPortal",
      "Mutations and copy number variations of selenoprotein in cervical cancer, endometrial cancer and uterine\ncarcinosarcoma (cBioPortal)\n256\n\nHou et al. Role of selenoproteins in ovarian cancer Turk J Obstet Gynecol 2024;21:242-65\nSupplementary Figure 5"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:31.169176",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39663776.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 6,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 16.518869161605835,
      "cbioportal_papers": 0.00024890899658203125,
      "pdf_extraction_pass2": 13.232896089553833,
      "cbioportal_papers_pass2": 0.0002849102020263672,
      "used_full_extraction": true,
      "pdf_extraction": 29.751765251159668,
      "platform_mentions": 0.003198862075805664,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39567394": {
    "cbioportal_paper_citations": [
      "Liver hepatocellular carcinoma (LIHC) RNA-Seq data used in this study were obtained from the Cancer Genome Atlas (TCGA) (project ID: TCGA-LIHC1). Only primary tumor samples were employed to eliminate any bias or distortion in the data. The total number of primary tumor samples was 377. Data Commons Bioconductor package2 was used to download the raw transcriptome profiling data. cBio Cancer Genomics Portal3 [48, 49], an open resource for analyzing cancer genomics datasets, was used to categorize samples according to the HIF-1A expression. Only 372 samples were available for retrieval. A z-score threshold of \u00b1 2.0 was set to calculate the standard deviations from the mean expression of HIF-1A in all samples as a reference population. The samples were categorized into five subgroups, where 14 samples have high HIF-1A expression, eight samples have low HIF-1A expression, two samples have mutated HIF-1A gene, 16 samples are not profiled either in mutation, putative copy, fusion, or mRNA expression, and 332 samples have unaltered expression as illustrated in Online Resource 1. To study the effect of HIF-1A on the cancer-related properties in HCC patients, only the Highly Expressed (H_E) versus the Not Altered (N_A) groups were included in further data (Online Resource 2). Low HIF-1A expression cases were eliminated since they display genetic profiles different from those of the not altered cases [50, 51]. The final number of utilized samples was 346 after filtration. Principal component analysis (PCA) plots have been utilized, using plotPCA from DESeq24 package (V \u20181.32.0\u2019) [52], to evaluate the impact of differences in demographic factors such as age group, gender, ethnicity, and race between H_E and N_A on the gene expression profile as a source of variation. The age of 60 was used to split patients into two age groups. The results were visualized using \u201cggplot2\u201d (V \u20183.5.1\u2019)5 R package [53]."
    ],
    "cbioportal_platform_mentions": [
      "Below is the link to the electronic supplementary material.Supplementary file1 (XLSX 329 KB) Online Resources .xlsx: it contains the following sheets: Sheet 1: it contains article title, journal name, author names, affiliation and e-mail address of the corresponding author. Online Resource 1: It contains the retrieved 372 samples CBioPortal. The samples were labeled with one of five groups according to HIF-1A expression as follows: high HIF-1A expression, low HIF-1A expression, mutated HIF-1A gene, not profiled, and unaltered expression. Online Resource 2: Samples that were retrieved via CBioPortal. The samples were divided into two labels according to HIF-1A expression: Highly expressed and Not Altered. The table includes the demographic data for each patient including age, ethnicity, gender, and race. Online Resource 3: The identified 1852 DEGs between H_E and N_A groups were with a cutoff of |log2FC| > 2 and adjusted P-value < 0.01. Online Resource 4: It includes 582 proteins of the protein-protein interaction network with their degree values. Online Resource 5: A total of 327 enriched pathways were identified utilizing G: Profiler with False Discovery Rate (FDR) < 0.01Supplementary file2 (PDF 408 KB) S_Figure 1_Protein Protein Interaction Network.pdf: A protein-protein interaction network with 1136 proteins connected by 1713 edges was constructed. Nodes with zero degrees were excluded from the network diagram",
      "Supplementary file1 (XLSX 329 KB) Online Resources .xlsx: it contains the following sheets: Sheet 1: it contains article title, journal name, author names, affiliation and e-mail address of the corresponding author. Online Resource 1: It contains the retrieved 372 samples CBioPortal. The samples were labeled with one of five groups according to HIF-1A expression as follows: high HIF-1A expression, low HIF-1A expression, mutated HIF-1A gene, not profiled, and unaltered expression. Online Resource 2: Samples that were retrieved via CBioPortal. The samples were divided into two labels according to HIF-1A expression: Highly expressed and Not Altered. The table includes the demographic data for each patient including age, ethnicity, gender, and race. Online Resource 3: The identified 1852 DEGs between H_E and N_A groups were with a cutoff of |log2FC| > 2 and adjusted P-value < 0.01. Online Resource 4: It includes 582 proteins of the protein-protein interaction network with their degree values. Online Resource 5: A total of 327 enriched pathways were identified utilizing G: Profiler with False Discovery Rate (FDR) < 0.01"
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.0049808025360107,
    "data_pmids_checked": 0,
    "paper_id": "39567394",
    "extraction_date": "2025-12-19T20:44:32.271127",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39567394.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39562405": {
    "cbioportal_paper_citations": [
      "The cBioPortal website (http://www.cbioportal.org) was utilized to access, download, analyze, and visualize cancer genomics data, including somatic mutation, DNA copy number alteration (CNA), and DNA methylation data [14]. Selection of the \u201cTCGA Pan Cancer Atlas Study\u201d and GNL2 genetic alteration search were conducted at the site [15]. Mutation frequency, type, and CNA data for all TCGA cancers were obtained from the website\u2019s \u201cCancer Type Summary\u201d module. GNL2 mutation positions were visualized in a 3D protein structure schematic using the site\u2019s \u201cmutation\u201d tool. SCNA and mutation analysis considered heterozygosity and purity of amplifications and deletions, with over 5% frequency deemed high-frequency SCNAs. The association between SCNAs and expression was evaluated through Spearman\u2019s correlation between the expression values and the copy number fragment values of each gene. The library R package \u201cChAMPdata\u201d was used to annotate methylation probes of each gene, and differential methylation in tumor and normal samples was tested using the Wilcoxon rank test. Significantly hypomethylated or hypermethylated genes were identified with a P value cut-off of 0.05. Spearman\u2019s correlation between GNL2 transcript expression and promoter DNA methylation beta values was also calculated and considered significant if P < 0.05."
    ],
    "cbioportal_platform_mentions": [
      "Mutliomics data, including genetic variant, somatic copy number alteration (SCNA), mRNA expression, and DNA methylation data, from tumors and normal tissues in the TCGA pan-cancer cohort were examined. The 2D and 3D structures of the GNL2 mutation sites were also systematically analyzed (Fig. 3A, B). The cBioPortal database indicated that the frequency of GNL2 genetic alterations was generally low in almost all cancers, with mutations being the most common type of genetic alteration and amplification predominating in OV (Fig. 3C). SCNA plays a key role in regulating gene expression (Fig. 3D). The percentage of SCNA in GNL2 in cancer was further investigated. Generally, SCNAs appeared at a high frequency in most cancer types (more than 5% of all samples) and at a lower frequency only in a very small number of tumors (Fig. 3E). The effect of SCNA on GNL2 mRNA expression was assessed by calculating Spearman\u2019s correlation between gene expression and copy number in the masked copy number segment of TCGA. The results revealed a significant correlation between GNL2 mRNA expression and SCNA in most tumors (Fig. 3F), suggesting that GNL2 copy number abnormalities, which are common in most cancers, affect gene expression. Abnormal DNA methylation is associated with tumorigenesis. We analyzed the average \u03b2-values of methylation sites in promoter, super-enhancer, and CpG island regions in the GNL2 pan-cancer genome. We performed differential comparisons between cancer and normal tissues as well as correlation analyses with GNL2 expression. GNL2 showed a complex methylation pattern in a pan-cancer cohort (Fig. 3G, H), with most tumor tissues being hypomethylated compared with normal tissues. Despite the differences in the methylation pattern of GNL2, a negative correlation between GNL2 mRNA expression and DNA methylation was generally observed, indicating the complexity and cancer specificity of GNL2 gene expression regulation.",
      "Fig. 3Genetic alterations of GNL2 in cancers. A Representation of GNL2 genetic alteration sites and the corresponding case counts across pan-cancer data from cBioPortal. B 3D structure of GNL2 mutation sites. C Analysis displaying the frequency of GNL2 mutations in different tumor types. D Relationship between GNL2 mRNA expression and genetic alterations. E Histogram shows the frequency of somatic copy number alterations for GNL2 in each cancer type. F The Spearman\u2019s correlation depicting the relationship between somatic copy number alterations and GNL2 expression levels. G Heatmap shows the differential methylation patterns (promoter, CpG, super enhancer) of GNL2 in cancers; hypermethylated and hypomethylated GNL2s are marked in red and blue, respectively (Wilcoxon rank-sum test). H Spearman\u2019s correlation assessing the relationship between GNL2 transcriptional expression and the differential methylation patterns (promoter, CpG, super enhancer). Red and blue represent positive and negative correlations, respectively",
      "Genetic alterations of GNL2 in cancers. A Representation of GNL2 genetic alteration sites and the corresponding case counts across pan-cancer data from cBioPortal. B 3D structure of GNL2 mutation sites. C Analysis displaying the frequency of GNL2 mutations in different tumor types. D Relationship between GNL2 mRNA expression and genetic alterations. E Histogram shows the frequency of somatic copy number alterations for GNL2 in each cancer type. F The Spearman\u2019s correlation depicting the relationship between somatic copy number alterations and GNL2 expression levels. G Heatmap shows the differential methylation patterns (promoter, CpG, super enhancer) of GNL2 in cancers; hypermethylated and hypomethylated GNL2s are marked in red and blue, respectively (Wilcoxon rank-sum test). H Spearman\u2019s correlation assessing the relationship between GNL2 transcriptional expression and the differential methylation patterns (promoter, CpG, super enhancer). Red and blue represent positive and negative correlations, respectively"
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.18161916732788086,
    "data_pmids_checked": 0,
    "paper_id": "39562405",
    "extraction_date": "2025-12-19T20:44:32.452856",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39562405.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39561007": {
    "cbioportal_paper_citations": [
      "TCGA PanCancer Atlas data were accessed from the cBioPortal (63, 64) and analyzed using the web browser and in R. For PanCancer analysis, RNASeqV2 RSEM processed and normalized data were used (which corresponds to the rsem.genes.normalized_results file from TCGA). For RCC-specific analysis, mRNA expression Z scores were used, with the reference population set to normal samples. See the cBioPortal User Guide for more information on the RNA data available. For IL18BP analysis with ccRCC, patient samples were dichotomized based on the median mRNA Z score."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.22492599487304688,
    "data_pmids_checked": 0,
    "paper_id": "39561007",
    "extraction_date": "2025-12-19T20:44:32.728169",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39561007.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39554490": {
    "cbioportal_paper_citations": [
      "Variant calls were initially filtered based on individual variant caller quality tags (i.e. FILTER == PASS). These variant calls were merged with calls from the GDC\u2019s internal mutation calling pipeline consisting of four variant callers: MuSE, MuTect2, VarScan2 and Pindel. Variants were further filtered to those that had variant allele frequency \u22650.2 and mutant allele read count (t_alt_count) \u22652 followed by manual review using the Integrative Genomics Viewer (IGV) to further assess read support strength and evidence of any other confounding factors such as alignment at low-complexity regions and variant bases captured only by ends of reads (31). Current variant calls for BAP1 were then compared to historical calls generated for TCGA in the MC3 dataset and characterized by their somatic MAF variant classification (32). Chromosomal start locations of mutations were plotted, together with variant classification information, on a lollipop plot created using cBioPortal\u2019s MutationMapper web tool (33,34). Protein-level domain annotations and visualization were approximated using data from UniProt (35).",
      "Prevalence and characterization of BAP1 mutations in TCGA pan-cancer tumor types. (A) Example de novo realignment with ABRA2 to the hg38 reference genome for a 63-bp indel detected in an LIHC tumor sample (TCGA-FV-A3I0) with visualization in IGV. (B) Schematic of the variant calling workflow and combination with TCGA variant calls. (C) Distribution of BAP1 somatic variant types (total = 257 variants). Additional new mutations detected in the present workflow combined with updated TCGA GDC variant calls and prior TCGA MC3 mutation calls are indicated as upper and lower segments of bars, respectively. (D) Frequency of BAP1 mutant tumors by TCGA tumor type. (E) Lollipop plot of BAP1 somatic variant locations across the length of the gene, created using the cBioPortal MutationMapper (33,34). Bottom: protein-level schematic of the major domains of interest, approximated using data from (35). UCH: ubiquitin carboxy-terminal hydrolase; BARD1: BARD1 binding domain; HBM: HCF binding motif; BRCA1: BRCA1 binding domain; NLS: nuclear localization signal."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29622463": [
        "Estimates of focal gene-level copy number for BAP1 and other genes were downloaded from the GDC, which used the hg38 ABSOLUTE LiftOver workflow to provide per-gene integer value estimations of gene copy numbers for each sample (36,37). Samples with gene-level copy number of <2 corresponded to copy number loss. Segment widths of samples with copy number loss were computed from segment start and end loci from masked copy number segment files from the GDC, which provided estimates of genomic windows of segments containing the BAP1 gene locus using the DNAcopy workflow. Plots of segments in relation to the chromosome were generated using plotgardener (version 1.10.2) (38)."
      ],
      "29625055": [
        "Curated survival data from (49) were downloaded from the TCGA PanCanAtlas Publications webpage (see the \u2018Data availability\u2019 section). Late-stage tumors classified as any stage 4 were excluded from downstream analyses. Tumors classified as any stage 0\u20132 were reclassified as low stage and tumors classified as any stage 3 were reclassified as high stage. We implemented a maximum progression-free interval (PFI) cutoff based on median within-tumor-type follow-up times to account for large differences in patient follow-up. Tumors were stratified based on mutant-like versus wildtype-like classification. Kaplan\u2013Meier plots and corresponding risk tables were generated using the survival (version 3.7-0) and ggsurvfit (version 1.1.0).",
        "To further verify that our BAP1 activity signature effectively captures a transcriptional profile shift associated with BAP1 loss, we leveraged two external datasets of BAP1 knockout in human liver organoids. In the first dataset (GSE215785), common fibrolamellar carcinoma mutant backgrounds were generated, including BAP1 single-knockout and BAP1/PRKAR2A double-knockout organoids (50). Both single- and double-knockout organoids had significantly lower BAP1 activity scores relative to wildtype (pairwise t-test with Bonferroni correction P= 8.3e\u221211 and P= 1.5e\u221212, respectively; Figure 3E), but no difference was observed in the samples with the classic DNAJB1\u2013PRKACA fusion or PRKACA knockout, which is the known major driver of that subset of liver cancer. In the second dataset (GSE129457), BAP1 knockout organoid models were generated both with and without BAP1 re-expression (51). Consistent with GSE215785 data in Figure 3E, we also observed reduced BAP1 activity scores among BAP1 knockout organoids relative to wildtype (pairwise t-test P= 0.015; Figure 3F). Re-expression of BAP1 in the knockout organoid led to increased activity scores relative to knockout (Figure 3F). We used curated survival data from the TCGA Clinical Data Resource to perform tumor-specific survival analyses stratified by BAP1 activity class and noted improved progression-free survival outcomes for wildtype-like UVM and KIRC tumors (Supplementary Figure S6) (49). We did not have adequate long-term follow-up and were otherwise underpowered to detect differential survival for other tumor types."
      ],
      "29596782": [
        "Variant calls were initially filtered based on individual variant caller quality tags (i.e. FILTER == PASS). These variant calls were merged with calls from the GDC\u2019s internal mutation calling pipeline consisting of four variant callers: MuSE, MuTect2, VarScan2 and Pindel. Variants were further filtered to those that had variant allele frequency \u22650.2 and mutant allele read count (t_alt_count) \u22652 followed by manual review using the Integrative Genomics Viewer (IGV) to further assess read support strength and evidence of any other confounding factors such as alignment at low-complexity regions and variant bases captured only by ends of reads (31). Current variant calls for BAP1 were then compared to historical calls generated for TCGA in the MC3 dataset and characterized by their somatic MAF variant classification (32). Chromosomal start locations of mutations were plotted, together with variant classification information, on a lollipop plot created using cBioPortal\u2019s MutationMapper web tool (33,34). Protein-level domain annotations and visualization were approximated using data from UniProt (35).",
        "We compared somatic variants (257/265 total variants) to an earlier iteration of variant calling used to generate the TCGA MC3 dataset, which included alignment to the hg19 genome and seven callers: MuTect, Varscan2, Indelocator, Pindel, SomaticSniper, RADIA and MuSE (32). This earlier pipeline resulted in the detection of 251 variants from 224 individuals, of which 190 variants from 170 individuals similarly passed simple call quality filtering, none of which were \u226540 bp (Supplementary Figure S1 and Supplementary Table S2B and D). Our approach yielded an additional 77 unique somatic variant calls, representing a 41% increase over the prior MC3 calls (Figure 1C). All MC3 variants and mutant samples were captured in the new approach, except one variant, a 5 bp deletion in KIRP sample TCGA-2Z-A9JD (Supplementary Tables S2C and D). However, our realignment approach detected two single-nucleotide variants (deletion and missense) in the similar region, suggesting a potential difference in hg19 versus hg38 alignment and downstream variant calling.",
        "Here we report a 41% increase in detection of BAP1 somatic mutations across TCGA compared to prior mutation calls (32) by using a de novo local realigner and merging variant calls from six individual callers across two pipelines. While long-read sequencing technology has become more accessible and has improved detection of larger indels, historical datasets such as TCGA with short-read sequencing will continue to benefit from reanalysis as genome builds and gene models evolve and newer and improved tools capable of detecting additional variants are developed. Importantly, we were able to identify additional indels \u226540 bp that previously were undetected. While long-read sequencing technology has become more accessible and has improved detection of larger indels, historical datasets such as TCGA with short-read sequencing will continue to benefit from reanalysis using newer and improved tools capable of detecting additional variants. Our work also makes available an efficient variant calling pipeline that can be easily and readily applied to other cancer genes while substantially reducing file storage requirements and increasing computational speed through use of BAM slices and parallelization."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 1.1292791366577148,
    "data_pmids_checked": 4,
    "paper_id": "39554490",
    "extraction_date": "2025-12-19T20:44:33.863442",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39554490.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39550372": {
    "cbioportal_paper_citations": [
      "Several lines of evidence suggest a critical role for the G167 residue in IKK\u03b1 structure and function. IKK\u03b1G167 is well-conserved among different organisms (Fig. 1D) and is part of an evolutionarily constrained region of the protein37. The corresponding residue is also conserved in the activation loop of other IKK and IKK-related kinases (IKK\u03b2, IKK\u03b5, and TBK1) (Fig. 1E). Nonetheless, IKK\u03b1G167R has not been previously described in publicly available genome variant databases TOPMed38 or gnomAD v439 (Fig. 1F). Additionally, IKK\u03b1G167R has not been reported as a somatic mutation in cancer genomics databases COSMIC40 and cBioPortal41. G167 is located within the activation segment of the kinase domain of IKK\u03b1, away from the previously reported variants (IKK\u03b1Q422X and IKK\u03b1Y580C) (Fig. 1G). In silico prediction tools, including CADD42, PolyPhen-243, DEOGEN244, MutationTaster202145 and MutPred246 all predicted that IKK\u03b1G167R is deleterious. Furthermore, Missense3D47, CUPSAT48 and MutPred246 predicted structural abnormalities resulting from IKK\u03b1G167R (Tables S4\u2013S6). Importantly, IKK\u03b1G167 is part of a conserved DF/LG motif present in kinases that coordinates magnesium binding near an ATP-binding site15. Analysis of IKK\u03b1G167R structure using iCn3D49 based on IKK\u03b1WT structure (PDB: 5EBZ)15 suggested that R167, unlike G167, forms new molecular interactions with the ATP-binding residue K44 (Fig. 1H, I), implicating the modulation of the kinase function of the mutant IKK\u03b1."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "34272401": [
        "Due to its distinct roles in various pathways, cell types, and sub-cellular locations, non-synonymous variants in different domains of IKK\u03b1 can offer valuable insights into understanding the multifunctional nature of IKK\u03b1 and its impact on human physiology. In this regard, human IKK\u03b1 deficiency resulting from a nonsense variant (IKK\u03b1Q422X) has been associated with skeletal and skin abnormalities during embryonic development, leading to lethality32,33. Conversely, a homozygous missense variant in the helix-loop-helix (HLH) domain of IKK\u03b1 (IKK\u03b1Y580C), which does not affect its kinase activity but disrupts its interaction with NIK, does not lead to embryonic lethality but instead causes immune and skeletal abnormalities, accompanied by growth retardation, in the affected individual34. Moreover, somatic inactivating mutations of IKK\u03b1 have been reported in human malignancies, indicating its role as a tumour suppressor in lung adenocarcinoma and cutaneous squamous cell carcinoma35,36. However, the phenotypic consequences of homozygous missense variants directly impairing the kinase function of human IKK\u03b1 have not been reported thus far, and therefore, the impact of kinase inactive IKK\u03b1 on human physiology remains unknown."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.45758891105651855,
    "data_pmids_checked": 1,
    "paper_id": "39550372",
    "extraction_date": "2025-12-19T20:44:34.388554",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39550372.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39548546": {
    "cbioportal_paper_citations": [
      "In order to explore the role of HECTD2 in gastric cancer, the cBioPortal for cancer genomics (http://www.cbioportal.org) was used to get genes that are positively correlated with HECTD2 in gastric cancer, then screen for gene sets with a correlation coefficient greater than or equal to 0.3 [23, 24]. Then, we employed Metascape (http://metascape.org) [25] to perform enrichment analysis on HECTD2 related genes obtained from cBioPortal."
    ],
    "cbioportal_platform_mentions": [
      "Next, we explore the way in which HECTD2 plays its role in gastric cancer, and use the LinkedOmics online database to explore the potential mechanism of HECTD2. Firstly, we select the dataset of gastric cancer, construct the co-expression network of HECTD2, and use the heat map to display the first 50 genes that are positively or negatively related to HECTD2 (Fig. 3A, B). Next, the biological process categories of GO of HECTD2 co-expression genes were determined by gene set enrichment analysis (GSEA). The results showed that HECTD2 and its co-expression genes were mainly involved in \"cell\u2013cell adhesion via plasma-membrane adhesion molecules\" (Fig. 3C). Then, we carried out the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis, and the results showed that the co-expressed genes were in \"cell adhesion molecules\" and \u201cfocal adhesion\u201d (Fig. 3D). These results suggest that HECTD2 may promote cancer progression by regulating the adhesion and interstitial remodeling of tumor cells. In addition, we downloaded the TCGA gastric cancer dataset from cBioPortal (http://www.cbioportal.org/) online dataset and the genes with positive correlation with HECTD2, screened the genes with correlation coefficient greater than 0.3, and conducted pathway enrichment analysis by using Metascape (http://metascape.org/). The results showed that the enriched pathways were also concentrated in \"cell junction organization\" \"cell\u2013cell adhesion\" (Fig. 3E). Based on these results, we speculate that HECTD2 is mainly involved in the metastasis process of gastric cancer. Therefore, we further analyze the expression of HECTD2 in different subtypes and different pathways of gastric cancer, and found that the expression of HECTD2 gene was the lowest in the MSI subtype of gastric cancer (Fig. 4A). The results of pathway enrichment showed that EMT and PI3K/AKT pathway were significantly activated in patients with high expression of HECTD2 (Fig. 4D, E), while cell cycle and apoptosis were inhibited in patients with high expression, indicating that tumor cell apoptosis pathway (Fig. 4B, C) was inhibited in patients with high expression, and normal apoptosis was inhibited.Fig. 3HECTD2 participates in metastasis of gastric cancer. Download the HECTD2 related gene set from the TCGA-STAD dataset. A The top 50 genes with a positive correlation with HECTD2 genes are visualized in a heatmap. B The top 50 genes with a negative correlation with HECTD2 genes are visualized in a heatmap. C The GO enrichment of the BP terms of HECTD2 co-expressed genes. D The KEGG enrichment of the BP terms of HECTD2 co-expressed genes. E The GO enrichment of the BP terms of HECTD2 co-expressed genesFig. 4HECTD2 participates in metastasis of gastric cancer. A RNA expression level of HECTD2 in different subtypes of gastric cancer. B\u2013D RNA expression level of HECTD2 in cell cycle (B), apoptosis (C) and EMT (D) pathway of gastric cancer. E RNA expression level of HECTD2 in PI3K/AKT pathway. (**p < 0.01,***p < 0.001,****p < 0.0001)"
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.23224329948425293,
    "data_pmids_checked": 0,
    "paper_id": "39548546",
    "extraction_date": "2025-12-19T20:44:34.652217",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39548546.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39546381": {
    "cbioportal_paper_citations": [
      "The experiments on our proposed framework were run on The Cancer Genome Atlas (TCGA) breast cancer (BRCA) dataset (The Cancer Genome Atlas Network 2012). The two omics profiles used here are RNA-seq mRNA expression and miRNA expression, downloaded from the UCSC Xena Hub (Goldman et al. 2020). The dataset contains miRNA expression data for 830 patients. The dataset has mRNA expression data for 1218 patients, including the 830 patients present in the miRNA expression data. There are 20 530 genes with log 2(x+1) transformed RSEM normalized expression values in the mRNA data and 2238 miRNAs with log 2(x+1) transformed RPM feature values in the miRNA data. The clinical information for the breast cancer dataset was obtained from cBioPortal (Gao et al. 2013). For phenotype prediction, we predict the Estrogen Receptor and Triple Negative (TN) status of the breast cancer patients. There are 332 Estrogen Receptor positive (ER+) and 80 Estrogen Receptor negative (ER\u2212) samples in the clinical information data. For the TN phenotype, the dataset has 65 TN and 347 non-TN samples."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "23000897": [
        "The experiments on our proposed framework were run on The Cancer Genome Atlas (TCGA) breast cancer (BRCA) dataset (The Cancer Genome Atlas Network 2012). The two omics profiles used here are RNA-seq mRNA expression and miRNA expression, downloaded from the UCSC Xena Hub (Goldman et al. 2020). The dataset contains miRNA expression data for 830 patients. The dataset has mRNA expression data for 1218 patients, including the 830 patients present in the miRNA expression data. There are 20 530 genes with log 2(x+1) transformed RSEM normalized expression values in the mRNA data and 2238 miRNAs with log 2(x+1) transformed RPM feature values in the miRNA data. The clinical information for the breast cancer dataset was obtained from cBioPortal (Gao et al. 2013). For phenotype prediction, we predict the Estrogen Receptor and Triple Negative (TN) status of the breast cancer patients. There are 332 Estrogen Receptor positive (ER+) and 80 Estrogen Receptor negative (ER\u2212) samples in the clinical information data. For the TN phenotype, the dataset has 65 TN and 347 non-TN samples."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.274137020111084,
    "data_pmids_checked": 1,
    "paper_id": "39546381",
    "extraction_date": "2025-12-19T20:44:34.932763",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39546381.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39583311": {
    "paper_id": "39583311",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "A nota- To expound the biological significance of CALU in ccRCC,\nble increase in CALU expression was observed in ccRCC we used the cBioPortal database to explore the CALU co-\nrelative to NKT (Fig",
      "a Significant co- obtained from the cBioPortal database",
      "c-d Heatmap shows the top\nexpressed genes with a positive regulatory relationship with CALU 50 genes sharing a positive/negative correlation with CALU in\nobtained from the cBioPortal database",
      "Nucleic Acids Res\nplex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:39.136371",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39583311.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.001386880874634,
      "cbioportal_papers": 0.00019478797912597656,
      "pdf_extraction_pass2": 9.391304969787598,
      "cbioportal_papers_pass2": 0.00018906593322753906,
      "used_full_extraction": true,
      "pdf_extraction": 18.39269185066223,
      "platform_mentions": 0.0017049312591552734,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39544254": {
    "cbioportal_paper_citations": [
      "Understanding the molecular mechanism of a cancer variant has clear implications to treatment. For example, KRAS is frequently mutated in several cancers and the G12C mutation locks KRAS into an active oncogenic state. Functional profiling of mutant KRAS led to the development of a new class of inhibitors that were recently FDA approved for patients with KRAS G12C mutations (Ostrem et al., 2013; Lito et al., 2016; Janes et al., 2018; Canon et al., 2019). This example stresses the need to 1) map cancer variants and 2) understand their mechanisms. There are different kinds of cancer variants, and they can be grouped based on the technologies used to identify them.\u2022 Somatic mutation identified by sequencing studies: Somatic mutations are variants found by comparing the tumor and non-tumor samples from the same patient, including point mutations, copy number variants and structural variants. In this review, we focus on the point mutations category. Most of the somatic mutations are acquired. The Cancer Genome Atlas (TCGA) has mapped many coding somatic mutations in cancer with whole exome sequencing, focusing on protein coding regions of the genome (Weinstein et al., 2013; Bailey et al., 2018; Ding et al., 2018). The KRAS G12C example mentioned above is one example of a coding somatic mutation. Recently, the International Cancer Genome Consortium (ICGC) broadly applied whole genome sequencing (WGS) to identify millions of somatic mutations in non-coding regions, which span >95% of the human genome (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Rheinbay et al., 2020). In addition, sequencing studies can also identify germline variants with cancer relevance (Huang et al., 2018). Excellent online resources such as COSMIC, the cBio cancer genome portal, and CNCDatabase now catalog these sequenced variants (Cerami et al., 2012; Tate et al., 2019; Liu et al., 2021).\u2022 Single nucleotide polymorphisms (SNPs) identified by Genome-wide association studies (GWAS): By comparing the allelic frequency in large populations of patients and controls using genotyping arrays, GWAS have identified many inherited cancer-associated SNPs, including breast cancer, ovarian cancer and prostate cancer (Turnbull et al., 2010; Michailidou et al., 2013; Michailidou et al., 2015; Michailidou et al., 2017; Milne et al., 2017; Zhang et al., 2020). Like somatic mutations, many GWAS SNPs are also enriched in non-coding parts of the genome (Corradin and Scacheri, 2014). Public resources for cancer-relevant GWAS SNPs include the GWAS Catalog and PLCO (Ruan et al., 2022; Sollis et al., 2023).",
      "\u2022 Somatic mutation identified by sequencing studies: Somatic mutations are variants found by comparing the tumor and non-tumor samples from the same patient, including point mutations, copy number variants and structural variants. In this review, we focus on the point mutations category. Most of the somatic mutations are acquired. The Cancer Genome Atlas (TCGA) has mapped many coding somatic mutations in cancer with whole exome sequencing, focusing on protein coding regions of the genome (Weinstein et al., 2013; Bailey et al., 2018; Ding et al., 2018). The KRAS G12C example mentioned above is one example of a coding somatic mutation. Recently, the International Cancer Genome Consortium (ICGC) broadly applied whole genome sequencing (WGS) to identify millions of somatic mutations in non-coding regions, which span >95% of the human genome (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Rheinbay et al., 2020). In addition, sequencing studies can also identify germline variants with cancer relevance (Huang et al., 2018). Excellent online resources such as COSMIC, the cBio cancer genome portal, and CNCDatabase now catalog these sequenced variants (Cerami et al., 2012; Tate et al., 2019; Liu et al., 2021)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "32025007": [
        "Understanding the molecular mechanism of a cancer variant has clear implications to treatment. For example, KRAS is frequently mutated in several cancers and the G12C mutation locks KRAS into an active oncogenic state. Functional profiling of mutant KRAS led to the development of a new class of inhibitors that were recently FDA approved for patients with KRAS G12C mutations (Ostrem et al., 2013; Lito et al., 2016; Janes et al., 2018; Canon et al., 2019). This example stresses the need to 1) map cancer variants and 2) understand their mechanisms. There are different kinds of cancer variants, and they can be grouped based on the technologies used to identify them.\u2022 Somatic mutation identified by sequencing studies: Somatic mutations are variants found by comparing the tumor and non-tumor samples from the same patient, including point mutations, copy number variants and structural variants. In this review, we focus on the point mutations category. Most of the somatic mutations are acquired. The Cancer Genome Atlas (TCGA) has mapped many coding somatic mutations in cancer with whole exome sequencing, focusing on protein coding regions of the genome (Weinstein et al., 2013; Bailey et al., 2018; Ding et al., 2018). The KRAS G12C example mentioned above is one example of a coding somatic mutation. Recently, the International Cancer Genome Consortium (ICGC) broadly applied whole genome sequencing (WGS) to identify millions of somatic mutations in non-coding regions, which span >95% of the human genome (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Rheinbay et al., 2020). In addition, sequencing studies can also identify germline variants with cancer relevance (Huang et al., 2018). Excellent online resources such as COSMIC, the cBio cancer genome portal, and CNCDatabase now catalog these sequenced variants (Cerami et al., 2012; Tate et al., 2019; Liu et al., 2021).\u2022 Single nucleotide polymorphisms (SNPs) identified by Genome-wide association studies (GWAS): By comparing the allelic frequency in large populations of patients and controls using genotyping arrays, GWAS have identified many inherited cancer-associated SNPs, including breast cancer, ovarian cancer and prostate cancer (Turnbull et al., 2010; Michailidou et al., 2013; Michailidou et al., 2015; Michailidou et al., 2017; Milne et al., 2017; Zhang et al., 2020). Like somatic mutations, many GWAS SNPs are also enriched in non-coding parts of the genome (Corradin and Scacheri, 2014). Public resources for cancer-relevant GWAS SNPs include the GWAS Catalog and PLCO (Ruan et al., 2022; Sollis et al., 2023).",
        "\u2022 Somatic mutation identified by sequencing studies: Somatic mutations are variants found by comparing the tumor and non-tumor samples from the same patient, including point mutations, copy number variants and structural variants. In this review, we focus on the point mutations category. Most of the somatic mutations are acquired. The Cancer Genome Atlas (TCGA) has mapped many coding somatic mutations in cancer with whole exome sequencing, focusing on protein coding regions of the genome (Weinstein et al., 2013; Bailey et al., 2018; Ding et al., 2018). The KRAS G12C example mentioned above is one example of a coding somatic mutation. Recently, the International Cancer Genome Consortium (ICGC) broadly applied whole genome sequencing (WGS) to identify millions of somatic mutations in non-coding regions, which span >95% of the human genome (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Rheinbay et al., 2020). In addition, sequencing studies can also identify germline variants with cancer relevance (Huang et al., 2018). Excellent online resources such as COSMIC, the cBio cancer genome portal, and CNCDatabase now catalog these sequenced variants (Cerami et al., 2012; Tate et al., 2019; Liu et al., 2021).",
        "While numerous cancer-associated variants have been identified by different studies (Table 1), elucidating the role of the majority, especially those in non-coding regions, remains a challenge. Unlike coding variants with predictable effects on amino acids, non-coding variants pose unique challenges. First, non-coding variants impact diverse elements in the genome with unique functions. Thus, non-coding variants can influence cancer development through different mechanisms, for example by altering the activity of regulatory elements, modifying gene splicing, and altering miRNA function (described in the next section). Second, the number of non-coding variants far surpasses that of coding variants (Figure 1 (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020)). Problematically, many non-coding variants could be passengers rather than drivers. Functionally distinguishing the two possibilities is of utmost importance and will require new approaches for systematic functional analysis. Third, while many non-coding variants influence disease by modifying the expression of cancer genes, the assignment of variants to cancer genes may not be straightforward. For example, non-coding variants often localize to intergenic regions, which complicates efforts to understand how they link to cancer-relevant genes, pathways, and phenotypes. Addressing these challenges to a functional understanding of non-coding variants will be important to personalized medicine in cancer.",
        "Distribution of somatic variants in the genome (source: PCAWG) (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020)."
      ],
      "29625049": [
        "Understanding the molecular mechanism of a cancer variant has clear implications to treatment. For example, KRAS is frequently mutated in several cancers and the G12C mutation locks KRAS into an active oncogenic state. Functional profiling of mutant KRAS led to the development of a new class of inhibitors that were recently FDA approved for patients with KRAS G12C mutations (Ostrem et al., 2013; Lito et al., 2016; Janes et al., 2018; Canon et al., 2019). This example stresses the need to 1) map cancer variants and 2) understand their mechanisms. There are different kinds of cancer variants, and they can be grouped based on the technologies used to identify them.\u2022 Somatic mutation identified by sequencing studies: Somatic mutations are variants found by comparing the tumor and non-tumor samples from the same patient, including point mutations, copy number variants and structural variants. In this review, we focus on the point mutations category. Most of the somatic mutations are acquired. The Cancer Genome Atlas (TCGA) has mapped many coding somatic mutations in cancer with whole exome sequencing, focusing on protein coding regions of the genome (Weinstein et al., 2013; Bailey et al., 2018; Ding et al., 2018). The KRAS G12C example mentioned above is one example of a coding somatic mutation. Recently, the International Cancer Genome Consortium (ICGC) broadly applied whole genome sequencing (WGS) to identify millions of somatic mutations in non-coding regions, which span >95% of the human genome (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Rheinbay et al., 2020). In addition, sequencing studies can also identify germline variants with cancer relevance (Huang et al., 2018). Excellent online resources such as COSMIC, the cBio cancer genome portal, and CNCDatabase now catalog these sequenced variants (Cerami et al., 2012; Tate et al., 2019; Liu et al., 2021).\u2022 Single nucleotide polymorphisms (SNPs) identified by Genome-wide association studies (GWAS): By comparing the allelic frequency in large populations of patients and controls using genotyping arrays, GWAS have identified many inherited cancer-associated SNPs, including breast cancer, ovarian cancer and prostate cancer (Turnbull et al., 2010; Michailidou et al., 2013; Michailidou et al., 2015; Michailidou et al., 2017; Milne et al., 2017; Zhang et al., 2020). Like somatic mutations, many GWAS SNPs are also enriched in non-coding parts of the genome (Corradin and Scacheri, 2014). Public resources for cancer-relevant GWAS SNPs include the GWAS Catalog and PLCO (Ruan et al., 2022; Sollis et al., 2023).",
        "\u2022 Somatic mutation identified by sequencing studies: Somatic mutations are variants found by comparing the tumor and non-tumor samples from the same patient, including point mutations, copy number variants and structural variants. In this review, we focus on the point mutations category. Most of the somatic mutations are acquired. The Cancer Genome Atlas (TCGA) has mapped many coding somatic mutations in cancer with whole exome sequencing, focusing on protein coding regions of the genome (Weinstein et al., 2013; Bailey et al., 2018; Ding et al., 2018). The KRAS G12C example mentioned above is one example of a coding somatic mutation. Recently, the International Cancer Genome Consortium (ICGC) broadly applied whole genome sequencing (WGS) to identify millions of somatic mutations in non-coding regions, which span >95% of the human genome (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Rheinbay et al., 2020). In addition, sequencing studies can also identify germline variants with cancer relevance (Huang et al., 2018). Excellent online resources such as COSMIC, the cBio cancer genome portal, and CNCDatabase now catalog these sequenced variants (Cerami et al., 2012; Tate et al., 2019; Liu et al., 2021)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.14916682243347168,
    "data_pmids_checked": 2,
    "paper_id": "39544254",
    "extraction_date": "2025-12-19T20:44:39.312102",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39544254.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39684309": {
    "paper_id": "39684309",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Analysis of MGP Gene Mutations and Copy Number Variations in Cancer\nInt.J.Mol.Sci.2024,25,12597MGP gene alterations were studied using the cBioPortal database u1t1iloifz19ing the TCGA\nPanCancer Atlas set (Figure 8 and Table 2)",
      "cbioportal.org/;accessedon15November2024)[56,57]"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:46.313656",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39684309.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 23.93552279472351,
      "cbioportal_papers": 0.0003781318664550781,
      "pdf_extraction_pass2": 21.914088010787964,
      "cbioportal_papers_pass2": 0.00039505958557128906,
      "used_full_extraction": true,
      "pdf_extraction": 45.849610805511475,
      "platform_mentions": 0.003957986831665039,
      "data_citations": 5.9604644775390625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39543336": {
    "cbioportal_paper_citations": [
      "The cBioPortal was used to perform genetic alteration analysis of ACER1 in HNSCC and alteration-related prognosis28. The mutation types and substitutional mutation types of ACER1 in HNSCC were studied using the COSMIC database29. Correlation analysis of ACER1 expression and DNA methylation levels in HNSCC was carried out using the UALCAN database and the TCGA dataset. Promoter methylation levels of ACER1 in HNSCC were determined based on sample types, cancer stages, tumor grades, lymph node metastasis, TP53 mutation status, tobacco smoking history, and patients\u2019 gender, race and age."
    ],
    "cbioportal_platform_mentions": [
      "Extant research suggests that genetic alterations are closely associated with tumorigenesis and have an impact on cancer prognoses36. We investigated the alteration frequency of ACER1 in 504 HNSCC samples using the cBioPortal database. Our analysis shows that ACER1 altered in 0.99% of samples, including mutation, amplification and deep deletion, with alteration frequencies of 0.4% (2/504), 0.2% (1/504) and 0.4% (2/504) respectively. In exploring the mutation sites of ACER1, we found two missense mutation types occurring in ceramidase S118F and R258Q (Fig. 4A). Further analysis revealed that the most common copy number variations are shallow deletion and diploid in HNSCC patients (Fig. 4B). Between the altered and unaltered groups, the difference in OS probability is not significant, with an overall median of 56.44 months (p = 0.904, Fig. 4C). The results show that overall alteration of ACER1 is not the cause of worse outcomes led by low ACER1 expression. Subsequently, using the COSMIC database to detect mutation types and substitutional mutation types of ACER1 in HNSCC, we found that missense and synonymous substitutions occurred in 38.64% and 12.68% of cases, respectively (Fig. 4D). Substitution mutations occurred mainly in C > T (33.15%) and G > A (32.02%) (Fig. 4E).",
      "Fig. 4Genetic alteration of ACER1 in HNSCC. (A) Summary of alteration types, corresponding frequencies and mutation sites of ACER1 in the cBioPortal database. (B) ACER1 copy number variations in HNSCC. (C) Survival analysis of ACER1 altered and unaltered groups. (D, E) Mutation types and substitutional mutation types of ACER1 using the COSMIC database.",
      "Genetic alteration of ACER1 in HNSCC. (A) Summary of alteration types, corresponding frequencies and mutation sites of ACER1 in the cBioPortal database. (B) ACER1 copy number variations in HNSCC. (C) Survival analysis of ACER1 altered and unaltered groups. (D, E) Mutation types and substitutional mutation types of ACER1 using the COSMIC database."
    ],
    "data_publication_citations": {
      "22802077": [
        "Correlation between ACER1 expression and anticancer drug sensitivity was performed using the CellMiner database30,31. The \u201cimpute\u201d, \u201climma\u201d and \u201cggpubr\u201d packages in R were used for data processing and graphing. Finally, the Wilcoxon test of these drugs was conducted to predict the level of response to the drug in HNSCC patients, and the difference was statistically significant at p < 0.05."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.45634984970092773,
    "data_pmids_checked": 1,
    "paper_id": "39543336",
    "extraction_date": "2025-12-19T20:44:46.784455",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39543336.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39540676": {
    "cbioportal_paper_citations": [
      "To evaluate the prevalence and genomic profile of EGFR\u2010amplified BTC, we reviewed the previously reported tissue\u2010genome sequence datasets of 707 BTC samples (51 samples of cholangiocarcinoma [Firehose Legacy, TCGA], 412 samples of intrahepatic cholangiocarcinoma, and 244 samples of gallbladder cancer), available at c\u2010BioPortal (https://www.cbioportal.org/) [9, 10, 11, 12]. EGFR amplification was identified in 15/707 samples (2.12%), and the most common co\u2010existing pathogenic gene alterations included TP53 (47%) and CDKN2A (33%) (Figure 2A,B).",
      "Genomic features of EGFR\u2010amplified biliary tract cancer in the dataset of 707 previously reported cancers, available at c\u2010BioPortal (https://www.cbioportal.org/) [9, 10, 11, 12]. (A) Proportion of EGFR\u2010amplified cases. (B) Oncoprot of 15 EGFR\u2010amplified cases. Gene alterations were annotated using OncoKB (https://www.oncokb.org)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "33765338": [
        "To evaluate the prevalence and genomic profile of EGFR\u2010amplified BTC, we reviewed the previously reported tissue\u2010genome sequence datasets of 707 BTC samples (51 samples of cholangiocarcinoma [Firehose Legacy, TCGA], 412 samples of intrahepatic cholangiocarcinoma, and 244 samples of gallbladder cancer), available at c\u2010BioPortal (https://www.cbioportal.org/) [9, 10, 11, 12]. EGFR amplification was identified in 15/707 samples (2.12%), and the most common co\u2010existing pathogenic gene alterations included TP53 (47%) and CDKN2A (33%) (Figure 2A,B).",
        "Genomic features of EGFR\u2010amplified biliary tract cancer in the dataset of 707 previously reported cancers, available at c\u2010BioPortal (https://www.cbioportal.org/) [9, 10, 11, 12]. (A) Proportion of EGFR\u2010amplified cases. (B) Oncoprot of 15 EGFR\u2010amplified cases. Gene alterations were annotated using OncoKB (https://www.oncokb.org)."
      ],
      "36228155": [
        "To evaluate the prevalence and genomic profile of EGFR\u2010amplified BTC, we reviewed the previously reported tissue\u2010genome sequence datasets of 707 BTC samples (51 samples of cholangiocarcinoma [Firehose Legacy, TCGA], 412 samples of intrahepatic cholangiocarcinoma, and 244 samples of gallbladder cancer), available at c\u2010BioPortal (https://www.cbioportal.org/) [9, 10, 11, 12]. EGFR amplification was identified in 15/707 samples (2.12%), and the most common co\u2010existing pathogenic gene alterations included TP53 (47%) and CDKN2A (33%) (Figure 2A,B).",
        "Genomic features of EGFR\u2010amplified biliary tract cancer in the dataset of 707 previously reported cancers, available at c\u2010BioPortal (https://www.cbioportal.org/) [9, 10, 11, 12]. (A) Proportion of EGFR\u2010amplified cases. (B) Oncoprot of 15 EGFR\u2010amplified cases. Gene alterations were annotated using OncoKB (https://www.oncokb.org)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4948599338531494,
    "data_pmids_checked": 2,
    "paper_id": "39540676",
    "extraction_date": "2025-12-19T20:44:47.362748",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39540676.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39536285": {
    "cbioportal_paper_citations": [
      "The cohort included 188 cases of TP53-mutated myeloid disease, including 6 cases of clonal cytopenia of undetermined significance (CCUS), 80 cases of MDS or MDS/AML (<20% blasts), and 102 cases of AML. Patients were divided into groups based on bone marrow (BM) blast percentage, because the diagnosis of MDS or MDS/AML varied between the WHO5 and ICC for some cases. The clinicopathologic features of the entire cohort are shown in Table 2. Overall, there was an increased depth of cytopenias with progression of BM blast count. Except for cases of CCUS, there were very high rates of complex and MKs across disease categories. A total of 234 TP53 mutations were identified (Figure 2A), most of which were missense mutations (173, 74%), predominantly located in the DNA binding domain. In 118 of 188 (63%) cases, there were no additional gene mutations present beyond the TP53 mutation(s). For patients with <20% blasts, 52 of 80 (65%) received hypomethylating agent therapy. Of patients with AML, \u223c40% of patients received intensive induction chemotherapy, hypomethylating agent therapy, and venetoclax-based therapy at some point during their disease course. Overall, only 23 of 188 (12%) patients underwent stem cell transplant. All patients with CCUS were alive at last follow-up. Patients with <10% blasts showed significantly prolonged OS (median, 10.2 months) compared with patients with \u226510% blasts (P > .001), whereas there was no significant difference in OS between patients with 10% to <20% blasts (median, 6.9 months) and patients with \u226520% blasts (median, 3.0 months; Figure 3A). In total, 51 cases occurred in the setting of prior cytotoxic chemotherapy, including 33 of 80 cases of MDS or MDS/AML, and 18 of 102 cases of AML. There was no significant difference in OS between patients with and without a prior history of cytotoxic chemotherapy exposure for patients with <10% blasts, 10% to <20% blasts, or \u226520% blasts (supplemental Figure 1).Table 2.Clinicopathologic features of the cohortCharacteristicTotal cohort (N = 188)CCUS (n = 6)MDS and MDS/AML (n = 80)AML (n = 102)0% to <10% blasts (n = 61)10% to <20% blasts (n = 19)\u226520% blastsAge at dx (y), median (range)68.5 (28.0-88.0)69.5 (56.5-79.1)68.5 (38.0-84.0)71.1 (38.5-81.0)68.3 (28.0-88.0)Sex, male, n (%)98 (52)3 (50)27 (44)13 (68)55 (54)CBC at dx, median (range) ANC, \u00d7103/\u03bcL0.8 (0-16.1)2.7 (0.5-4.6)1.4 (0.1-11.5)1.2 (0.3-2.5)0.6 (0.0-16.1) Hb, g/dL8.4 (5.5-14.1)10.6 (7.3-13.2)8.8 (5.6-13.8)8.4 (6.6-12.3)8.3 (5.5-14.1) Plt, \u00d7103/\u03bcL48 (7-347)123 (81-232)62 (7-347)51 (8-114)36 (7-228)BM blast %, median (range)23 (0-100)2 (0.5-2.5)3 (0-9.5)15 (10-17.5)35 (20.8-100)Karyotype Complex, n (%)161 (86)0 (0)47 (77)19 (100)95 (93) Monosomal, n (%)154 (82)0 (0)46 (75)17 (90)91 (89) Del 17/17p, n (%)56 (30)0 (0)12 (20)4 (21)40 (40)Mutations by NGS 1 TP53 mutation, n (%)145 (77)6 (100)43 (70)15 (79)80 (78) \u22652 TP53 mutations, n (%)43 (23)0 (0)18 (30)4 (21)21 (21) Highest TP53 VAF, median (range)41 (1.1-97)8.9 (4.5-14.0)35 (4-97)41 (4-89)46.5 (1.1-93.0) 0 additional mutations, n (%)118 (63)4 (67)42 (67)16 (84)56 (55) 1 additional mutation, n (%)38 (20)2 (33)11 (18)1 (5)24 (24) \u22652 additional mutations, n (%)32 (17)0 (0)8 (13)2 (11)22 (22)Therapy Intensive induction, n (%)40 (21)0 (0)1 (2)1 (5)38 (37) HMA, n (%)106 (56)0 (0)39 (64)15 (79)52 (51) Venetoclax, n (%)70 (37)0 (0)12 (20)7 (37)51 (50) Stem cell transplant, n (%)23 (12)0 (0)11 (18)2 (11)10 (10)ANC, absolute neutrophil count; CBC, complete blood count; dx, diagnosis; Hb, hemoglobin; HMA, hypomethylating agent; NGS, next-generation sequencing; Plt, platelets.Figure 2.Distribution of TP53 mutations. Lolliplot figures showing the types and distribution of TP53 mutations in the entire cohort (A) and in cases of MDS with <10% blasts classified as MDS-TP53 by both classifications or by the ICC alone (B). SV, structural variant. Figure panels were generated using cBioPortal, as previously described.29,30Figure 3.OS in TP53-mutated myeloid disease. (A) OS of the entire cohort based on diagnosis and blast percentage. (B) OS for cases of MDS with <10% blasts classified as MDS-TP53 by both classifications vs cases of MDS with <10% blasts classified as MDS-TP53 by the ICC only (P=NS). (C-D) OS in patients with AML-TP53 compared to patients with AML-MR with wild-type TP53, both overall (C) and censored at the time of stem cell transplant (D).",
      "Distribution of TP53 mutations. Lolliplot figures showing the types and distribution of TP53 mutations in the entire cohort (A) and in cases of MDS with <10% blasts classified as MDS-TP53 by both classifications or by the ICC alone (B). SV, structural variant. Figure panels were generated using cBioPortal, as previously described.29,30",
      "Among the cases with \u226520% blasts (n = 102), 2 were classified as AML with NPM1 mutation by both ICC and WHO5. Additionally, 4 cases harbored TP53 mutations at a VAF of <10% and were classified by WHO5 as AML-MR, based on defining cytogenetic abnormalities or gene mutations, and per ICC as AML with MR gene mutations (n = 2) or AML with MR cytogenetic abnormalities (n = 2). The remaining 96 cases were classified as AML-TP53 by ICC. Per the WHO5, 1 of 96 was classified as AML defined by differentiation; the rest met criteria for AML-MR by WHO5, based on cytogenetic abnormalities (n = 92) or a prior history of MDS (n = 3). However, when compared with a separate cohort of AML-MR with wild-type TP53 (n = 45), cases classified as AML-TP53 by ICC showed significantly higher rates of complex and MKs and harbored significantly fewer uniquely mutated genes (Table 5; Figure 4). Patients with AML-TP53 were also less likely to undergo stem cell transplant. Finally, patients with AML-TP53 demonstrated worse OS than patients with AML-MR lacking TP53 mutations, both as a whole (median OS, 3.3 months vs 7.7 months, respectively) and when censoring at stem cell transplant (median OS, 3.3 months vs 7.5 months, respectively; Figure 3C-D). Furthermore, specifically among patients with a complex karyotype, patients with AML-TP53 showed significantly worse OS (n = 92; median OS, 3.3 months) than patients with AML-MR (n = 11; median OS, 6.5 months; P = .046). Finally, we evaluated whether clone size (TP53 VAF) had any impact on OS in our AML-TP53 cohort. Using VAF thresholds of 30%, 40%, 50%, and 60%, we found no impact on OS at any threshold (data not shown).Table 5.Clinicopathologic features of TP53-mutated AML and AML-MR with wild-type TP53CharacteristicAML-TP53 by ICC (n = 96)AML-MR (n = 45)P valueAge at dx (y), median (range)68.8 (28-88)68.9 (41-91)NSCK, n (%)92 (99)12 (27)<.0001MK, n (%)89 (97)12 (27)<.0001No. of unique genes mutated, median (range)1 (1-4)3 (0-6)<.0001Intensive induction, n (%)35 (36)24 (53)NSSCT, n (%)9 (10)10 (23)NSAbbreviations are explained in Tables 1 and 2.Figure 4.Distribution of mutations in AML-TP53 and AML-MR. Mutations and cytogenetic abnormalities are shown for patients with AML-TP53 and AML-MR with wild-type TP53, with each row representing a gene and each column representing a patient. The number (percent) of patients in each group harboring different types of mutations is shown at the right. chrom, chromatin modifier; mut, mutation; TF, transcription factor; TK, tyrosine kinase. Figure generated using cBioPortal, as previously described.29,30",
      "Distribution of mutations in AML-TP53 and AML-MR. Mutations and cytogenetic abnormalities are shown for patients with AML-TP53 and AML-MR with wild-type TP53, with each row representing a gene and each column representing a patient. The number (percent) of patients in each group harboring different types of mutations is shown at the right. chrom, chromatin modifier; mut, mutation; TF, transcription factor; TK, tyrosine kinase. Figure generated using cBioPortal, as previously described.29,30"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "23634996": [
        "The TP53 tumor suppressor gene, located on chromosome 17p, encodes a transcription factor that functions as a master regulator of the cell, affecting proliferation, DNA stability and repair, cell cycle arrest, and apoptosis, among many other processes.1 TP53 mutations are present in \u223c10% of myeloid neoplasms as a whole,2, 3, 4, 5, 6, 7 and are enriched in patients with secondary and therapy-related disease.8,9 TP53 mutations are associated with particularly adverse outcomes in myeloid disease, and patients with acute myeloid leukemia (AML) with a TP53 mutation at an allele frequency of \u226510% are classified as adverse risk by the European LeukemiaNet guidelines.10 In both myelodysplastic syndrome (MDS) and AML, TP53 mutations are associated with therapeutic resistance, increased rates of relapse, and significantly shorter survival.2, 3, 4, 5,11, 12, 13, 14, 15, 16, 17 In patients with MDS with <10% blasts, these poor outcomes have been shown to be associated specifically with biallelic TP53 inactivation, whereas such patients with MDS with monoallelic TP53 alteration showed similar survival outcomes to patients with wild-type TP53.4,11,14 Conversely, in cohorts of patients with \u226510% blasts, studies have shown that both monoallelic and biallelic TP53 mutations predict poor outcome, without significant differences between patients with MDS with excess blasts (10% to <20% blasts) and AML (\u226520% blasts).2,3,11,15, 16, 17, 18"
      ]
    },
    "total_cbioportal_paper_citations": 4,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3229241371154785,
    "data_pmids_checked": 1,
    "paper_id": "39536285",
    "extraction_date": "2025-12-19T20:44:47.718060",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39536285.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39567612": {
    "paper_id": "39567612",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Through integrated analyses of diverse databases, including\nTIMER2.0, UALCAN, OncoDB, cBioPortal, LinkedOmics, STRING, htfTarget, mirTarBase, circBank,\nand DGIdb, we explored eFGFs\u2019 gene expression, DNA methylation, prognostic significance, genetic\nalterations, gene regulatory networks, functional analysis, and drug interactions in COAD patients",
      "Alteration frequency of endocrine FGFs in COAD study based on cBioPortal database",
      "Data are derived from the Mutations tab of the cBioPortal database",
      "Scientific Reports | (2024) 14:28754 | https://doi.org/10.1038/s41598-024-79341-y 14\n\nwww.nature.com/scientificreports/\nExamination of genetic alterations in endocrine FGF genes across COAD studies\nCancer genomic data for multidimensional in silico analysis are easily accessible through cBioPortal ( ht t p s : / / w w\nw",
      "OncoPrint of cBioPortal displays\nmutation types and their corresponding proportions of queried genes in selected studies",
      "Throughout the analysis on the cBioPortal server, the parameter values were left at\ntheir default settings",
      "The datasets presented in\nthis study can be found in online repositories: https://cistrome.shinyapps.io/timer https://ualcan.path.uab.edu\nhttp://oncodb.org https://www.cbioportal.org http://www.linkedomics.org https://maayanlab.cloud/Enrichr\nhttps://www.smpdb.ca/ http://bioinfo.life.hust.edu.cn/hTFtarget# https://mirtarbase.cuhk.edu.cn h t t p: / / w w w",
      "et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:50.346394",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39567612.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 15.117319107055664,
      "cbioportal_papers": 0.0003330707550048828,
      "pdf_extraction_pass2": 13.736677885055542,
      "cbioportal_papers_pass2": 0.0003561973571777344,
      "used_full_extraction": true,
      "pdf_extraction": 28.853996992111206,
      "platform_mentions": 0.004091024398803711,
      "data_citations": 1.0013580322265625e-05,
      "num_data_pmids_checked": 0
    }
  },
  "39567540": {
    "paper_id": "39567540",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "SampleswerecollectedinTRIzolreagent(ThermoFisher,Darmstadt, IntheIGF1releaseexperiment5\u00d7103WTorANXA2-deficientMSC\nGermany).Chloroform (1/5thofTRIzolvolume)wasaddedtoallow wereembeddedinamatrigelsolution(1.5mg/ml)withorwithoutPLG\nNatureCommunications|( 2024)1 5:10059 16\n\nArticle https://doi.org/10.1038/s41467-024-54361-4\n(Sigma-Aldrich,Darmstadt,Germany)(1ng/ml),EACA(Sigma-Aldrich, Dataavailability\nDarmstadt, Germany) (12.5mM), ANXA2 antibody (Santa Cruz, Hei- RNAsequencingandmicroarraydataareavailableatGeneExpression\ndelberg,Germany)(60\u03bcg/ml),ANXA2/S100A10heterotetramerinhi- Omnibus(GEO)underaccessionnumbersGSE205762andGSE205872,\nbitor (A2ti) (MedChemExpress, Sollentuna, Sweden) (50 \u03bcM) or respectively.Dataontheexpressionofgenesinhumansamplesand\naprotinin(Sigma-Aldrich,Darmstadt,Germany)(60nM)andplatedin survivalofpatientswithB-ALLwereobtainedfromthepubliclyavail-\na48-wellplate.IGF1(12ng/ml)waseitheraddedtothesolutionorthe abledatasetTCGA(TARGETphaseII),accessedthroughthecBioPortal\nmatrigel.Afterpolymerizationofthematrigel(4\u20138)\u00d7104primaryGFP portal(https://www.cbioportal.org)andthroughtheBloodSpotportal\n(BCR-ABL1)+ BP1+ cells sorted from the BM of mice with BCR-ABL1- (https://www.fobinf.com/).Supplementaryinformationisavailablefor\ninducedB-ALLwereaddedtoeachcondition.Cellwerecounted48h this paper"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:44:57.329871",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39567540.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 16.286874055862427,
      "cbioportal_papers": 0.00048279762268066406,
      "pdf_extraction_pass2": 19.20513606071472,
      "cbioportal_papers_pass2": 0.0004949569702148438,
      "used_full_extraction": true,
      "pdf_extraction": 35.49201011657715,
      "platform_mentions": 0.004658937454223633,
      "data_citations": 7.867813110351562e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39519243": {
    "cbioportal_paper_citations": [
      "Clinical data for the UVM and NBL cases were obtained from cBioPortal.org [32,33]. We filtered NBL cases to those marked by the presence of MYCN amplification. For each cancer, we analyzed the association of various parameters representing the cases, such as the average proportion of disorder-promoting AA residues or the average ANCHOR2 score, with OS. Note, each parameter was calculated as the average of the total set of values (e.g., ANCHOR2 values) for the collection of the many blood-sourced TRB CDR3 or V-CDR3-J AA sequences obtained for any individual case. Cases were then split into two groups based on quantification of the case average for the parameter being assessed, i.e., upper vs. lower 50th percentile, and Kaplan\u2013Meier (KM) survival analyses were performed with the Python package \u201clifelines\u201d [26]. Statistical comparison of OS plots was conducted with the \u201clifelines\u201d package\u2019s implementation of the log-rank test. See Supplementary Materials Tables S6\u2013S8 for the KM input data."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3839890956878662,
    "data_pmids_checked": 0,
    "paper_id": "39519243",
    "extraction_date": "2025-12-19T20:44:57.731486",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39519243.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39504368": {
    "cbioportal_paper_citations": [
      "For the analyses conducted using the METABRIC dataset (28\u201330), expression and clinical data were downloaded from cBioPortal (68, 69) (www.cbioportal.org). Analyses were carried out using R (62) (v.4.1.0), using the singscore package (v.3.17) (70, 71). Briefly, human homologs of genes that were significantly altered in all fission KO 4T1 cell lines (mitochondrial fission KO) or in all KOs and Leflu-treated 4T1 (mitochondrial elongation) were used to compute a score for each patient based on the expression of these genes. Using the maxstat package (v.0.7-25) (72), the best cutoff was calculated to separate individuals with low (Fragmented) versus high (Fused) score. Kaplan-Meier curves were generated with the survival (73) (v.3.2-11) and survminer (74) (v.0.4.9) packages."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "30867590": [
        "To assess the clinical relevance of these findings, we derived a fission KO gene expression signature using the differentially expressed genes common to all 4T1 fission KO models identified in the transcriptomic data (Fig. 2A and fig. S2). We then computed fission KO signature scores for all patients comprised in the METABRIC dataset (28\u201330), and the cohort was divided into two groups according to their scores. The high-scoring group exhibited significantly improved survival (Fig. 4G), in agreement with our data demonstrating that disrupting mitochondrial fission limits breast cancer metastasis and progression. We performed survival analyses by breast cancer subtype and discovered that high fission KO signature scores correlated with significantly improved outcome in most subtypes, including the basal-like and HER2-positive breast cancer subtypes (fig. S6K), which are commonly associated with poor prognosis. In addition, we analyzed the time to distant recurrence as a measure of metastatic progression. Patients within the high-scoring group displayed a significant delay in distant recurrence (Fig. 4H). Collectively, these results suggest that limited mitochondrial fission is associated with improved outcome in patients with breast cancer.",
        "For the analyses conducted using the METABRIC dataset (28\u201330), expression and clinical data were downloaded from cBioPortal (68, 69) (www.cbioportal.org). Analyses were carried out using R (62) (v.4.1.0), using the singscore package (v.3.17) (70, 71). Briefly, human homologs of genes that were significantly altered in all fission KO 4T1 cell lines (mitochondrial fission KO) or in all KOs and Leflu-treated 4T1 (mitochondrial elongation) were used to compute a score for each patient based on the expression of these genes. Using the maxstat package (v.0.7-25) (72), the best cutoff was calculated to separate individuals with low (Fragmented) versus high (Fused) score. Kaplan-Meier curves were generated with the survival (73) (v.3.2-11) and survminer (74) (v.0.4.9) packages."
      ],
      "22522925": [
        "To assess the clinical relevance of these findings, we derived a fission KO gene expression signature using the differentially expressed genes common to all 4T1 fission KO models identified in the transcriptomic data (Fig. 2A and fig. S2). We then computed fission KO signature scores for all patients comprised in the METABRIC dataset (28\u201330), and the cohort was divided into two groups according to their scores. The high-scoring group exhibited significantly improved survival (Fig. 4G), in agreement with our data demonstrating that disrupting mitochondrial fission limits breast cancer metastasis and progression. We performed survival analyses by breast cancer subtype and discovered that high fission KO signature scores correlated with significantly improved outcome in most subtypes, including the basal-like and HER2-positive breast cancer subtypes (fig. S6K), which are commonly associated with poor prognosis. In addition, we analyzed the time to distant recurrence as a measure of metastatic progression. Patients within the high-scoring group displayed a significant delay in distant recurrence (Fig. 4H). Collectively, these results suggest that limited mitochondrial fission is associated with improved outcome in patients with breast cancer.",
        "For the analyses conducted using the METABRIC dataset (28\u201330), expression and clinical data were downloaded from cBioPortal (68, 69) (www.cbioportal.org). Analyses were carried out using R (62) (v.4.1.0), using the singscore package (v.3.17) (70, 71). Briefly, human homologs of genes that were significantly altered in all fission KO 4T1 cell lines (mitochondrial fission KO) or in all KOs and Leflu-treated 4T1 (mitochondrial elongation) were used to compute a score for each patient based on the expression of these genes. Using the maxstat package (v.0.7-25) (72), the best cutoff was calculated to separate individuals with low (Fragmented) versus high (Fused) score. Kaplan-Meier curves were generated with the survival (73) (v.3.2-11) and survminer (74) (v.0.4.9) packages."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 2.3822500705718994,
    "data_pmids_checked": 3,
    "paper_id": "39504368",
    "extraction_date": "2025-12-19T20:45:00.113836",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39504368.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39502478": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.30190110206604004,
    "data_pmids_checked": 0,
    "paper_id": "39502478",
    "extraction_date": "2025-12-19T20:45:00.415852",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39502478.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39544745": {
    "paper_id": "39544745",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "The\ndata were estimated through mass spectrome-\nthree-dimensional structure of TYMS was\ntry-based proteomics, defining \u201clow specificity\u201d\nobtained using the cBioPortal web tool [28]",
      "Genetic alteration features, alteration frequen-\ncy, mutation type, and mutated site information\nWestern blot\nfor TYMS were collected from the cBioPortal\nweb"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:45:00.966243",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39544745.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.553951025009155,
      "cbioportal_papers": 0.00021004676818847656,
      "pdf_extraction_pass2": 15.81495714187622,
      "cbioportal_papers_pass2": 0.00028705596923828125,
      "used_full_extraction": true,
      "pdf_extraction": 25.368908166885376,
      "platform_mentions": 0.0024080276489257812,
      "data_citations": 4.76837158203125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39483155": {
    "cbioportal_paper_citations": [
      "Alterations in the ENO1 genome were assessed using the cBioPortal tool30,31 and the prognostic effect of these alterations was assessed by KM survival analysis using the KM-plotter and the Genotype-2-Outcome (G-2-O) tools. 32",
      "Data from cBioPortal30,31 showed that genomic alterations in the ENO1 gene were detected in 0.2% of BCs and they mainly involved copy number alterations (CNAs; gene amplifications and deletions). The BC cohorts and the data are presented in Figure 5A and Supplementary Table 1. Interestingly, analysis of the metastatic BC cohorts (Figure 5B) showed 7% genomic alterations (gene amplifications, deletions missense, and truncating mutations) potentially highlighting that alterations in the ENO1 gene are acquired during treatment and could be related to disease progression and metastasis. The metagene signatures associated with ENO1 alterations predicted a poor clinical outcome for all types of alterations (mutations, amplification, and deletion; Figure 5C)."
    ],
    "cbioportal_platform_mentions": [
      "ENO1 genomic alterations and survival. Genomic alterations in the ENO1 gene were detected in (A) 0.2% of the primary BCs cohorts, mainly involving CNAs (gene amplifications and deletions) and in (B) 7% of the metastatic BC cohorts, mainly gene amplifications, deletions missense, and truncating mutations. (C) The metagene signatures associated with ENO1 alterations predicted a poor clinical outcome for all types of alterations (P < .001). BC cohorts and number of cases from cBioPortal are shown in Supplementary Table 1."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.33695220947265625,
    "data_pmids_checked": 0,
    "paper_id": "39483155",
    "extraction_date": "2025-12-19T20:45:01.310039",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39483155.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39482716": {
    "cbioportal_paper_citations": [
      "Clinical data for the TCGA-Prostate Adenocarcinoma (PRAD) cohort (https://portal.gdc.cancer.gov/projects/TCGA-PRAD) [28], including disease-free survival, were downloaded from the cBioPortal [29, 30] database. Raw expression counts were downloaded from TCGA with the TCGAbiolinks R package (version 2.25.3). Patients with mutation in TP53 gene (Supplementary Table 4, Additional File 1) were removed from subsequent analysis for Fig. 6b-c. Raw counts were transformed with the variance stabilizing transformation (VST). Survival analysis of TCGA-PRAD cohort was performed with the survminer R package [31] (version 0.4.9). Patients were divided into IL6SThigh/low expression groups based on the maximally selected rank statistics which provides a single value cutpoint that corresponds to the most significant relation with disease-free survival. Differential expression analysis between IL6SThigh and IL6STlow group was performed with DESeq2 (version 1.36.0). Alteration data including frequency of specific mutations and correlation analysis were obtained from the cBioPortal [29, 30] database. Immune scores for TCGA-PRAD cohort from the ESTIMATE method [32] were downloaded from https://bioinformatics.mdanderson.org/estimate/. Using the Mann\u2013Whitney test, we assessed whether there was a statistically significant difference in the immune scores between IL6SThigh and IL6STlow."
    ],
    "cbioportal_platform_mentions": [
      "Based on our mouse data, we hypothesized that high IL6ST expression in PCa patients would correlate with favorable clinical outcomes. To investigate the relationship between IL6ST mRNA expression levels and PCa, we examined the TCGA-PRAD cohort [28] comprising primary PCa patients and found a significant decrease in IL6ST mRNA expression in prostate tumor tissue compared to adjacent healthy tissue (Fig. 3a). We divided patients into IL6ST high and low expression groups using the maximally selected rank statistics method, which identifies the cutpoint with the most significant relation with disease-free survival. Stratifying patients based on their IL6ST mRNA demonstrated that high IL6ST expression is linked to a greater probability of disease-free survival compared to low IL6ST expression (Fig. 3b). In the TCGA-PRAD cohort, 7.2% of patients with prostate adenocarcinoma have alterations in the IL6ST gene, with 6.3% accounting for deep deletions and 0.9% for missense mutations of unknown significance (Fig. 3c). We therefore hypothesized that mutations leading to altered IL6ST expression could impact the initiation and/or progression of PCa. To test the validity of our findings, we analyzed four additional data sets from the Oncomine platform [42]. The results support a significant decrease in IL6ST mRNA expression in PCa compared to normal prostate glands, highlighting the potential impact of IL6ST alterations on PCa (Fig. 3d). We also observed a significant reduction in IL6ST expression relative to the primary PCa site during PCa progression in recurrent and advanced PCa and metastasis (Supplementary Fig. 3a, Additional File 5). Using the SurvExpress Analysis webtool [43], we next examined the MSKCC Prostate GSE21032 data set by Taylor et al. [44] in terms of survival, as it provides not only data on primary but also metastatic PCa. We assessed risk groups by a median split of samples based on their prognostic index and observed high expression of IL6ST in low-risk PCa patients and vice versa (Supplementary Fig. 3b, Additional File 5). In support of our previous findings from the TCGA-PRAD cohort, correlating biochemical recurrence-free survival time with IL6ST mRNA expression levels, we detected a significantly higher probability of biochemical recurrence-free survival associated with high as compared to low IL6ST levels (Supplementary Fig. 3c, Additional File 5). To further validate our findings in an independent dataset, we analyzed the SMD GSE40727 [45] cohort using the SurvExpress Analysis web tool. Survival analysis of patients expressing high and low levels of IL6ST, grouped according to the optimal risk split, showed a tendency for better biochemical recurrence-free survival probability in the IL6SThigh group compared to the IL6STlow group (Supplementary Fig. 3d-e, Additional File 5). These findings corroborate a tumor suppressive role of IL6ST expression in PCa. Interestingly, IL6ST mRNA expression positively correlated with STAT3 expression in PCa patients in both the TCGA-PRAD cohort and Taylor data set (MSKCC Prostate GSE21032), providing further evidence of the interconnected signaling between IL6ST and STAT3 in PCa (Fig. 3e and Supplementary Fig. 3f, Additional File 5). To examine the IL6ST/STAT3 signaling activation in the TCGA-PRAD data set, we correlated IL6ST (Supplementary Fig. 3g, Additional File 5) and STAT3 (Supplementary Fig. 3h, Additional File 5) mRNA expression levels with three STAT3 target signatures assessed by single sample gene set variation analysis (ssGSVA). All three STAT3 target gene sets were positively correlated to IL6ST and STAT3 mRNA expression levels indicating a tight association of high IL6ST and STAT3 expression and active STAT3 signaling. Together, these human patient data suggest that IL6ST expression could serve as a useful read-out to stratify PCa cases into low- and high-risk groups.Fig. 3High IL6ST expression is significantly associated with low-risk groups and better recurrence-free survival in human PCa. a IL6ST gene expression in adjacent (n = 52) and PCa (n = 497) tissue in TCGA-PRAD data set. Statistical analysis of the two risk groups was determined by using the Mann\u2013Whitney test. b Kaplan\u2013Meier plot showing time of disease-free survival in months for IL6STlow and IL6SThigh risk groups of the TCGA-PRAD data set. Groups were assessed based on the maximally selected rank statistics. blue: high IL6ST expressing group, red: low IL6ST expressing group. The blue and red numbers above horizontal axis represent the number of patients. c Proportion of IL6ST alterations in the TCGA-PRAD data set. Mutation types: deep deletion (n = 21; red), truncating mutations (n = 2; black) and multiple alterations (n = 1; grey). One patient has simultaneous mutations. The data originate from cBioPortal. d IL6ST mRNA expression levels of four different data sets of PCa patient samples compared to healthy prostate sample control. Normalized data and statistical analyses were extracted from the Oncomine Platform. The respective prostate data set and n-numbers are indicated. Representation: boxes as interquartile range, horizontal line as the mean, whiskers as lower and upper limits. e Spearman-correlation analysis of IL6ST and STAT3 expression in TCGA-PRAD data set using cBioPortal analysis tool",
      "High IL6ST expression is significantly associated with low-risk groups and better recurrence-free survival in human PCa. a IL6ST gene expression in adjacent (n = 52) and PCa (n = 497) tissue in TCGA-PRAD data set. Statistical analysis of the two risk groups was determined by using the Mann\u2013Whitney test. b Kaplan\u2013Meier plot showing time of disease-free survival in months for IL6STlow and IL6SThigh risk groups of the TCGA-PRAD data set. Groups were assessed based on the maximally selected rank statistics. blue: high IL6ST expressing group, red: low IL6ST expressing group. The blue and red numbers above horizontal axis represent the number of patients. c Proportion of IL6ST alterations in the TCGA-PRAD data set. Mutation types: deep deletion (n = 21; red), truncating mutations (n = 2; black) and multiple alterations (n = 1; grey). One patient has simultaneous mutations. The data originate from cBioPortal. d IL6ST mRNA expression levels of four different data sets of PCa patient samples compared to healthy prostate sample control. Normalized data and statistical analyses were extracted from the Oncomine Platform. The respective prostate data set and n-numbers are indicated. Representation: boxes as interquartile range, horizontal line as the mean, whiskers as lower and upper limits. e Spearman-correlation analysis of IL6ST and STAT3 expression in TCGA-PRAD data set using cBioPortal analysis tool"
    ],
    "data_publication_citations": {
      "26544944": [
        "Clinical data for the TCGA-Prostate Adenocarcinoma (PRAD) cohort (https://portal.gdc.cancer.gov/projects/TCGA-PRAD) [28], including disease-free survival, were downloaded from the cBioPortal [29, 30] database. Raw expression counts were downloaded from TCGA with the TCGAbiolinks R package (version 2.25.3). Patients with mutation in TP53 gene (Supplementary Table 4, Additional File 1) were removed from subsequent analysis for Fig. 6b-c. Raw counts were transformed with the variance stabilizing transformation (VST). Survival analysis of TCGA-PRAD cohort was performed with the survminer R package [31] (version 0.4.9). Patients were divided into IL6SThigh/low expression groups based on the maximally selected rank statistics which provides a single value cutpoint that corresponds to the most significant relation with disease-free survival. Differential expression analysis between IL6SThigh and IL6STlow group was performed with DESeq2 (version 1.36.0). Alteration data including frequency of specific mutations and correlation analysis were obtained from the cBioPortal [29, 30] database. Immune scores for TCGA-PRAD cohort from the ESTIMATE method [32] were downloaded from https://bioinformatics.mdanderson.org/estimate/. Using the Mann\u2013Whitney test, we assessed whether there was a statistically significant difference in the immune scores between IL6SThigh and IL6STlow.",
        "Based on our mouse data, we hypothesized that high IL6ST expression in PCa patients would correlate with favorable clinical outcomes. To investigate the relationship between IL6ST mRNA expression levels and PCa, we examined the TCGA-PRAD cohort [28] comprising primary PCa patients and found a significant decrease in IL6ST mRNA expression in prostate tumor tissue compared to adjacent healthy tissue (Fig. 3a). We divided patients into IL6ST high and low expression groups using the maximally selected rank statistics method, which identifies the cutpoint with the most significant relation with disease-free survival. Stratifying patients based on their IL6ST mRNA demonstrated that high IL6ST expression is linked to a greater probability of disease-free survival compared to low IL6ST expression (Fig. 3b). In the TCGA-PRAD cohort, 7.2% of patients with prostate adenocarcinoma have alterations in the IL6ST gene, with 6.3% accounting for deep deletions and 0.9% for missense mutations of unknown significance (Fig. 3c). We therefore hypothesized that mutations leading to altered IL6ST expression could impact the initiation and/or progression of PCa. To test the validity of our findings, we analyzed four additional data sets from the Oncomine platform [42]. The results support a significant decrease in IL6ST mRNA expression in PCa compared to normal prostate glands, highlighting the potential impact of IL6ST alterations on PCa (Fig. 3d). We also observed a significant reduction in IL6ST expression relative to the primary PCa site during PCa progression in recurrent and advanced PCa and metastasis (Supplementary Fig. 3a, Additional File 5). Using the SurvExpress Analysis webtool [43], we next examined the MSKCC Prostate GSE21032 data set by Taylor et al. [44] in terms of survival, as it provides not only data on primary but also metastatic PCa. We assessed risk groups by a median split of samples based on their prognostic index and observed high expression of IL6ST in low-risk PCa patients and vice versa (Supplementary Fig. 3b, Additional File 5). In support of our previous findings from the TCGA-PRAD cohort, correlating biochemical recurrence-free survival time with IL6ST mRNA expression levels, we detected a significantly higher probability of biochemical recurrence-free survival associated with high as compared to low IL6ST levels (Supplementary Fig. 3c, Additional File 5). To further validate our findings in an independent dataset, we analyzed the SMD GSE40727 [45] cohort using the SurvExpress Analysis web tool. Survival analysis of patients expressing high and low levels of IL6ST, grouped according to the optimal risk split, showed a tendency for better biochemical recurrence-free survival probability in the IL6SThigh group compared to the IL6STlow group (Supplementary Fig. 3d-e, Additional File 5). These findings corroborate a tumor suppressive role of IL6ST expression in PCa. Interestingly, IL6ST mRNA expression positively correlated with STAT3 expression in PCa patients in both the TCGA-PRAD cohort and Taylor data set (MSKCC Prostate GSE21032), providing further evidence of the interconnected signaling between IL6ST and STAT3 in PCa (Fig. 3e and Supplementary Fig. 3f, Additional File 5). To examine the IL6ST/STAT3 signaling activation in the TCGA-PRAD data set, we correlated IL6ST (Supplementary Fig. 3g, Additional File 5) and STAT3 (Supplementary Fig. 3h, Additional File 5) mRNA expression levels with three STAT3 target signatures assessed by single sample gene set variation analysis (ssGSVA). All three STAT3 target gene sets were positively correlated to IL6ST and STAT3 mRNA expression levels indicating a tight association of high IL6ST and STAT3 expression and active STAT3 signaling. Together, these human patient data suggest that IL6ST expression could serve as a useful read-out to stratify PCa cases into low- and high-risk groups.Fig. 3High IL6ST expression is significantly associated with low-risk groups and better recurrence-free survival in human PCa. a IL6ST gene expression in adjacent (n = 52) and PCa (n = 497) tissue in TCGA-PRAD data set. Statistical analysis of the two risk groups was determined by using the Mann\u2013Whitney test. b Kaplan\u2013Meier plot showing time of disease-free survival in months for IL6STlow and IL6SThigh risk groups of the TCGA-PRAD data set. Groups were assessed based on the maximally selected rank statistics. blue: high IL6ST expressing group, red: low IL6ST expressing group. The blue and red numbers above horizontal axis represent the number of patients. c Proportion of IL6ST alterations in the TCGA-PRAD data set. Mutation types: deep deletion (n = 21; red), truncating mutations (n = 2; black) and multiple alterations (n = 1; grey). One patient has simultaneous mutations. The data originate from cBioPortal. d IL6ST mRNA expression levels of four different data sets of PCa patient samples compared to healthy prostate sample control. Normalized data and statistical analyses were extracted from the Oncomine Platform. The respective prostate data set and n-numbers are indicated. Representation: boxes as interquartile range, horizontal line as the mean, whiskers as lower and upper limits. e Spearman-correlation analysis of IL6ST and STAT3 expression in TCGA-PRAD data set using cBioPortal analysis tool"
      ],
      "20579941": [
        "Based on our mouse data, we hypothesized that high IL6ST expression in PCa patients would correlate with favorable clinical outcomes. To investigate the relationship between IL6ST mRNA expression levels and PCa, we examined the TCGA-PRAD cohort [28] comprising primary PCa patients and found a significant decrease in IL6ST mRNA expression in prostate tumor tissue compared to adjacent healthy tissue (Fig. 3a). We divided patients into IL6ST high and low expression groups using the maximally selected rank statistics method, which identifies the cutpoint with the most significant relation with disease-free survival. Stratifying patients based on their IL6ST mRNA demonstrated that high IL6ST expression is linked to a greater probability of disease-free survival compared to low IL6ST expression (Fig. 3b). In the TCGA-PRAD cohort, 7.2% of patients with prostate adenocarcinoma have alterations in the IL6ST gene, with 6.3% accounting for deep deletions and 0.9% for missense mutations of unknown significance (Fig. 3c). We therefore hypothesized that mutations leading to altered IL6ST expression could impact the initiation and/or progression of PCa. To test the validity of our findings, we analyzed four additional data sets from the Oncomine platform [42]. The results support a significant decrease in IL6ST mRNA expression in PCa compared to normal prostate glands, highlighting the potential impact of IL6ST alterations on PCa (Fig. 3d). We also observed a significant reduction in IL6ST expression relative to the primary PCa site during PCa progression in recurrent and advanced PCa and metastasis (Supplementary Fig. 3a, Additional File 5). Using the SurvExpress Analysis webtool [43], we next examined the MSKCC Prostate GSE21032 data set by Taylor et al. [44] in terms of survival, as it provides not only data on primary but also metastatic PCa. We assessed risk groups by a median split of samples based on their prognostic index and observed high expression of IL6ST in low-risk PCa patients and vice versa (Supplementary Fig. 3b, Additional File 5). In support of our previous findings from the TCGA-PRAD cohort, correlating biochemical recurrence-free survival time with IL6ST mRNA expression levels, we detected a significantly higher probability of biochemical recurrence-free survival associated with high as compared to low IL6ST levels (Supplementary Fig. 3c, Additional File 5). To further validate our findings in an independent dataset, we analyzed the SMD GSE40727 [45] cohort using the SurvExpress Analysis web tool. Survival analysis of patients expressing high and low levels of IL6ST, grouped according to the optimal risk split, showed a tendency for better biochemical recurrence-free survival probability in the IL6SThigh group compared to the IL6STlow group (Supplementary Fig. 3d-e, Additional File 5). These findings corroborate a tumor suppressive role of IL6ST expression in PCa. Interestingly, IL6ST mRNA expression positively correlated with STAT3 expression in PCa patients in both the TCGA-PRAD cohort and Taylor data set (MSKCC Prostate GSE21032), providing further evidence of the interconnected signaling between IL6ST and STAT3 in PCa (Fig. 3e and Supplementary Fig. 3f, Additional File 5). To examine the IL6ST/STAT3 signaling activation in the TCGA-PRAD data set, we correlated IL6ST (Supplementary Fig. 3g, Additional File 5) and STAT3 (Supplementary Fig. 3h, Additional File 5) mRNA expression levels with three STAT3 target signatures assessed by single sample gene set variation analysis (ssGSVA). All three STAT3 target gene sets were positively correlated to IL6ST and STAT3 mRNA expression levels indicating a tight association of high IL6ST and STAT3 expression and active STAT3 signaling. Together, these human patient data suggest that IL6ST expression could serve as a useful read-out to stratify PCa cases into low- and high-risk groups.Fig. 3High IL6ST expression is significantly associated with low-risk groups and better recurrence-free survival in human PCa. a IL6ST gene expression in adjacent (n = 52) and PCa (n = 497) tissue in TCGA-PRAD data set. Statistical analysis of the two risk groups was determined by using the Mann\u2013Whitney test. b Kaplan\u2013Meier plot showing time of disease-free survival in months for IL6STlow and IL6SThigh risk groups of the TCGA-PRAD data set. Groups were assessed based on the maximally selected rank statistics. blue: high IL6ST expressing group, red: low IL6ST expressing group. The blue and red numbers above horizontal axis represent the number of patients. c Proportion of IL6ST alterations in the TCGA-PRAD data set. Mutation types: deep deletion (n = 21; red), truncating mutations (n = 2; black) and multiple alterations (n = 1; grey). One patient has simultaneous mutations. The data originate from cBioPortal. d IL6ST mRNA expression levels of four different data sets of PCa patient samples compared to healthy prostate sample control. Normalized data and statistical analyses were extracted from the Oncomine Platform. The respective prostate data set and n-numbers are indicated. Representation: boxes as interquartile range, horizontal line as the mean, whiskers as lower and upper limits. e Spearman-correlation analysis of IL6ST and STAT3 expression in TCGA-PRAD data set using cBioPortal analysis tool"
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5216031074523926,
    "data_pmids_checked": 2,
    "paper_id": "39482716",
    "extraction_date": "2025-12-19T20:45:01.831745",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39482716.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39479535": {
    "cbioportal_paper_citations": [
      "This study retrospectively analysed the genomic data of 448 colon, 90 rectal and 441 gastric cancers from the cancer genomic atlas (TCGA) PanCancer cases (Liu et al., 2018, Ebili et al., 2021), which are domiciled in the Genome Data Commons (GDC) and cBioPortal database (Liu et al., 2018, Ebili et al., 2021, Gao et al., 2013, Cerami et al., 2012).",
      "Open-access data, comprising level 3 RNASeq, methylation and microRNA data of the aforementioned cancer cohorts, were retrieved from the GDC and cBioPortal repositories (Gao et al., 2013, Cerami et al., 2012)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.36607789993286133,
    "data_pmids_checked": 0,
    "paper_id": "39479535",
    "extraction_date": "2025-12-19T20:45:02.197917",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39479535.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39473974": {
    "cbioportal_paper_citations": [
      "The results here are in whole or part based upon data generated by the TCGA Research Network, which are available in a public repository from the TCGA cBioPortal (http://www.cbioportal.org/index.do).37,38 Data are analyzed and downloaded on Select Cancer Study from 186 samples of Pancreatic Adenocarcinoma (TCGA, Provisional) and Select Genomic Profiles from mRNA Expression z-Scores (RNA Seq V2 RSEM)."
    ],
    "cbioportal_platform_mentions": [
      "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesInVivoMAb anti-mouse OX40 (CD134)Bio X cellCat#BE0031InVivoMAb anti-mouse PD-1 (CD279)Bio X cellCat#BE0146Purified Rat Anti-Mouse CD8aBD PharmingenTMCat#553027; RRID: AB_394565Biotin Rat Anti-Mouse Granzyme B Monoclonal AntibodyeBioscienceCat#13-8822-82; RRID: AB_1603282Mast Cell Tryptase (G-12)Santa CruzCat#Sc-32474; RRID: AB_2206484Purified Rat Anti-Mouse IL-10BD PharmingenCat#554464; RRID: AB_398557Biological samplesPancreatic disease patients samplesUT MD Anderson Cancer Centerwww.mdanderson.orgChemicals, peptides, and recombinant proteinscromolynSigmaCat#C0399masitinibSigmaCat#SML3594D-LuciferinCaliper Life SciencesCat#122796Toluidine blueVWRCat#0672-25GCritical commercial assaysRT2 SYBR@ Green Master MixesSABiosciencesCat#330502First Strand KitsSABiosciencesCat#330401RT2 ProfilerTM PCR Array Mouse Allergy & AsthmaSABiosciencesCat#PAMM-067ZD-12RT2 ProfilerTM PCR Array Mouse Toll-Like ReceptorSABiosciencesCat#PAMM-018ZD-12Trichome-Masson KitSigma-AldrichCat#HT15Experimental models: Cell linesPanc02 mouse pancreatic cancer cell linehttps://doi.org/10.1158/0008-5472.CAN-12-4479NAKPC mouse pancreatic cancer cell linehttps://doi.org/10.1158/0008-5472.CAN-12-4479NAExperimental models: Organisms/strainsC57BL/6 wild type miceThe Jackson LaboratoryCat#000664C57BL/6 albino mice (B6(Cg)-Tyrc-2J/J)The Jackson LaboratoryCat#000058mast cell-deficient mice (KitW-sh/W-sh)The Jackson LaboratoryCat#012861IL-10\u2013deficient mice (B6.129P2-IL10tmiCgn/J)The Jackson LaboratoryCat#002251PGE2-deficient mice (B6.129[FVB]-Ptgs2tm2.1(ptgs1)Fn/J)The Jackson LaboratoryCat#008104cLGL-KRasG12V/Ela-CreER micehttps://doi.org/10.1053/j.gastro.2009.05.052NAKPC-GEMM (KrasG12D/+; Trp53R172H/+; Pdx-1-Cre)Frederick National Laboratory for Cancer Research (NCI, Maryland, USAhttps://doi.org/10.1016/j.ccr.2005.04.023NAKC-GEMM (KrasG12D/+; Pdx-1-Cre)Frederick National Laboratory for Cancer Research (NCI, Maryland, USAhttps://doi.org/10.1016/S1535-6108(03)00309-XNASoftware and algorithmsImageJhttps://wsr.imagej.net/notes.htmlVersion 1.52p 22 June 2019Living ImageIVIS Spectrum in https://store.caliperls.com3.1 SoftwareTCGA cBioPortalhttp://www.cbioportal.org/index.doNAPrismhttps://www.graphpad.comNART2 Profiler PCR Array Data Analysishttp://pcrdataanalysis.sabiosciences.comNAscTIME Portalhttp://sctime.sklehabc.comNASingle cell RNA sequencing datahttp://sctime.sklehabc.com/#/visual/11/CRA001160?species=%5B%22Homo%20sapiens%22%5D&addpath&compare=trueANA"
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.4784798622131348,
    "data_pmids_checked": 0,
    "paper_id": "39473974",
    "extraction_date": "2025-12-19T20:45:03.676500",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39473974.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39472976": {
    "cbioportal_paper_citations": [
      "The cBioportal website (cbioportal.org) was used to analyze The Cancer Genome Atlas (TCGA)\u2014Firehose Legacy and the National Cancer Institute\u2019s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Glioblastoma cohorts [21\u201324]. We excluded 7 and 15 samples, respectively, from the TCGA and CPTAC cohorts that harbored pathogenic IDH1/2 alterations detected on NGS.",
      "NF1 alterations were mutually exclusive with alterations in EGFR (log2OR \u20132.3, p-adj < 0.001), MDM2 (log2OR \u20132.5, p-adj = 0.05), PDGFRA, and CDK4 (Fig. 1B, Supplementary Table 2). Alterations in NF1 co-occurred with alterations in PIK3R1 (log2OR 1.6, p-adj = 0.03). After adjusting for multiple hypotheses, only the associations between NF1 and EGFR, PIK3R1, and MDM2 remained statistically significant, supporting prior observations [8]. Mutual exclusivity of NF1 and EGFR alterations in IDH-wildtype glioblastoma was further substantiated using two publicly available resources, TCGA and CPTAC, totaling 368 genomically-characterized glioblastomas after excluding samples with pathogenic IDH1/2 alterations (Supplementary Table 3\u20134) [21\u201324].",
      "We evaluated how NF1 alterations were associated with overall survival. In our institutional cohort of 542 glioblastomas, we observed that neither truncating NF1 alterations in the entire cohort nor NF1 genomic loss in the TMA cohort alone were significantly associated with decreased overall survival (Fig. 1H). This was supported by the TCGA dataset where neither NF1 alterations nor mRNA expression was associated with a difference in overall survival (Supplementary Fig. 2A-B). Our findings contrasted with the CPTAC dataset where NF1 alterations were associated with decreased overall survival, though this was not true for NF1 mRNA or protein expression (Supplementary Fig. 2C-E) [23, 24]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "24120142": [
        "The cBioportal website (cbioportal.org) was used to analyze The Cancer Genome Atlas (TCGA)\u2014Firehose Legacy and the National Cancer Institute\u2019s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Glioblastoma cohorts [21\u201324]. We excluded 7 and 15 samples, respectively, from the TCGA and CPTAC cohorts that harbored pathogenic IDH1/2 alterations detected on NGS.",
        "NF1 alterations were mutually exclusive with alterations in EGFR (log2OR \u20132.3, p-adj < 0.001), MDM2 (log2OR \u20132.5, p-adj = 0.05), PDGFRA, and CDK4 (Fig. 1B, Supplementary Table 2). Alterations in NF1 co-occurred with alterations in PIK3R1 (log2OR 1.6, p-adj = 0.03). After adjusting for multiple hypotheses, only the associations between NF1 and EGFR, PIK3R1, and MDM2 remained statistically significant, supporting prior observations [8]. Mutual exclusivity of NF1 and EGFR alterations in IDH-wildtype glioblastoma was further substantiated using two publicly available resources, TCGA and CPTAC, totaling 368 genomically-characterized glioblastomas after excluding samples with pathogenic IDH1/2 alterations (Supplementary Table 3\u20134) [21\u201324].",
        "To identify whether pathogenic alterations in NF1 are associated with changes in mRNA or protein expression, we interrogated the TCGA and CPTAC glioblastoma cohorts [21, 22]. We observed significantly decreased average NF1 mRNA expression (p < 0.001 for each cohort) in tumors with known pathogenic NF1 alterations, though a subset had intact expression levels (Fig. 1E, F). We next evaluated whether NF1 mRNA expression correlated with protein expression. In 89 glioblastoma samples with both protein and mRNA, mRNA expression levels strongly correlated with protein expression (Spearman = 0.69, p < 0.001) as quantified by mass spectrometry (Fig. 1G).",
        "We next evaluated potential protein correlates for NF1 loss as identified via immunostaining or NGS. We assessed the expression of proteins known to be correlated with MAPK signaling (phospho-ERK, phospho-S6) or with NF1 status (p16, podoplanin) [29, 30]. We also evaluated proteins associated with proliferation and loss of cell cycle regulation in glioblastoma (p53, Ki-67) [30]. Expression of these proteins did not correlate with NFC or iNF-07E staining. We next asked whether IHC would be associated with NF1 genomic status and found positive phospho-ERK immunostaining to be associated with NF1 genomic loss (p = 0.045, Supplementary Table 5), supporting prior observations of a similar correlation in mesenchymal GBM [21]. Unsupervised hierarchical clustering by these seven proteins of interest did not identify distinct clusters corresponding with NF1 immunostaining (Supplementary Fig. 4). We evaluated for co-occurring or mutually exclusive gene alterations and found no statistically significant associations with NF1-deficiency by IHC staining."
      ]
    },
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5209989547729492,
    "data_pmids_checked": 1,
    "paper_id": "39472976",
    "extraction_date": "2025-12-19T20:45:04.199198",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39472976.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39472973": {
    "cbioportal_paper_citations": [
      "The mutation status of TSPAN6 was determined using cBioPortal for Cancer Genomics [18, 19]. To further explore the mutation types of TSPAN6 in gliomas, the COSMIC database was used [20]."
    ],
    "cbioportal_platform_mentions": [
      "Using data from TCGA database, we investigated the expression levels of TSPAN6 in tumor and normal tissues across various cancer types. As shown in Fig. 1a, TSPAN6 expression was significantly higher in tumor tissues of gastric cancer, endometrial cancer, lung adenocarcinoma, and esophageal cancer. Through comparative analysis, we observed that glioma tissues had markedly higher levels of TSPAN6 expression than normal tissues (Fig. 1B), consistent with the validation provided by the GSE4290 dataset (Fig. 1C). Furthermore, the UALCAN database demonstrated significantly elevated levels of TSPAN6 protein in pleomorphic glioblastoma tissues than in normal tissues (Fig. 1D). We analyzed TSPAN6 gene mutations using the cBioPortal database and found that \u201camplification\u201d was predominant in TCGA pan-cancer dataset. Among the 514 LGG patients, TSPAN6 gene mutations were detected in 1.56% of the cases, including both \u201camplification\u201d and \u201cmutations\u201d (Supplementary Figure 1).Fig. 1Upregulation of TSPAN6 expression in glioma and its association with adverse clinical pathological features of glioma patients. A Expression levels of TSPAN6 in different types of human malignancies from the TIMER database. B Expression levels of TSPAN6 in normal tissue and tumor tissue of glioma patients. C Expression of TSPAN6 in tumors and normal tissues from the GEO database GSE4290 dataset. D Protein expression levels of TSPAN6 in GBM and normal tissues from the UALCAN database. E\u2013I Correlation of TSPAN6 high expression with glioma clinical pathological features [WHO grade (E), IDH status (F), 1p/19q co-deletion (G), pathological subtype (H), and age (I)]"
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.22232866287231445,
    "data_pmids_checked": 0,
    "paper_id": "39472973",
    "extraction_date": "2025-12-19T20:45:04.421656",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39472973.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39543755": {
    "paper_id": "39543755",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "e d u ) , the cBio Cancer Genomics P o status of each site was analyzed using the Pyro Q-CpG\nr t a l (cBioPortal) [13, 14] (http://www.cbioportal.org/), software",
      "(A) The methylation level of 18 DNA methylation sites was com-\npared between tumors and normal tissues based on TCGA database; (B) Bioinformatics analysis showed a negative correlation between INHBA methyla-\ntion (HM450) and mRNA expression using TCGA database (The image was generated online using cBioPortal",
      "Spagnol LW, Polettini J, Silveira DA, et al. P16 gene promoter methylation is\ngenomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:45:04.533859",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39543755.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 11.870950937271118,
      "cbioportal_papers": 0.00024819374084472656,
      "pdf_extraction_pass2": 13.34700083732605,
      "cbioportal_papers_pass2": 0.00024509429931640625,
      "used_full_extraction": true,
      "pdf_extraction": 25.217951774597168,
      "platform_mentions": 0.003119945526123047,
      "data_citations": 6.198883056640625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39469643": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gene Set Cancer Analysis (GSCA) (http://bioinfo.life.hust.edu.cn/GSCA/#/) integrated expression, mutation, drug sensitivity, and clinical data from four public sources for 33 cancer types. Somatic mutations in SARC patients were downloaded and visualized using the maftools package in R, covering seven mutation types: Missense_Mutation, Multi_Hit, Frame_Shift_Del. We analyzed the correlation between URG mRNA expression and CNV/methylation, and their impact on survival outcomes, including Disease Free Interval (DFI), Disease Specific Survival (DSS), Overall Survival (OS), and Progression Free Survival (PFS). The cBioPortal (http://www.cbioportal.org/index) (27) was used to visualize genetic alterations and their effects on survival outcomes.",
      "Using the GSCA database, the percentage map of single nucleotide variants (SNVs) was analyzed, revealing a high mutation frequency for FLNA. Oncoplot displayed SNVs for the top 7 genes among URGs, with APOBEC3G, CBLB, HSPA5, IRF3, NEDD4, TRIM5, and VIM each showing a 14% mutation frequency ( Figure 5A ). Missense mutations were the most common type ( Figure 5B ). Single nucleotide polymorphisms (SNPs) were more frequent than deletions ( Figure 5C ), with C>T being the most common SNV type ( Figure 5D ). The median number of mutations per patient was found to be 1 ( Figure 5E ). A box plot showed the number of occurrences for each variant classification ( Figure 5F ). By recalculating the number of mutations and considering multiple hits, the top 7 mutated genes were identified ( Figure 5G ). Correlation analysis of URGs CNV and mRNA expression from the GSCA database indicated a significant positive correlation, while gene methylation levels showed a negative correlation with mRNA expression ( Figure 5H ). Figure 5I showed that for some URGs, CNV and methylation levels were significantly associated with poor prognosis in SARC patients. Survival analysis from the cBioPortal database indicated that genetic alterations in URGs were significantly associated with shorter OS (p=0.010), PFS (p=0.0448), DFS (p=0.0275), and DSS (p=7.565e-4) ( Figure 5J )."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4780306816101074,
    "data_pmids_checked": 0,
    "paper_id": "39469643",
    "extraction_date": "2025-12-19T20:45:04.899802",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39469643.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39464069": {
    "cbioportal_paper_citations": [
      "mRNA expression data from invasive lobular breast cancer (ILC), mixed ductal-lobular breast cancer (mDLC), and breast cancer of no special type (NST) from The Cancer Genome Atlas (TCGA, RRID:SCR_003193) pan-cancer clinical data resource26, METABRIC27, and the Sweden Cancerome Analysis Network - Breast (SCAN-B)28,29 shown in Figure S1A were accessed via Gene Expression eXPLORER (GEXPLORER) at https://leeoesterreich.org/resources on 6/4/2024. mRNA expression data and associated clinicopathological data from ILC and IDC/NST from TCGA shown in Figure 4C were accessed via cBioPortal30,31 (RRID:SCR_014555) on 6/13/2024. Enrichr was used for gene set enrichment analysis32\u201334. GLUD1 peptide counts from ER rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) in ILC cell lines shown in Figure 6A were graphed from Supplemental File 6 of Sottnik et al35."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26451490": [
        "ILC (Invasive Lobular Carcinoma) is a special histological subtype of breast cancer that accounts for 10\u201315% of cases diagnosed annually1,2. ILC has unique genetic, transcriptomic, and biological features as compared to the more common invasive ductal breast cancer, or breast cancer of no special type (IDC/NST). Nearly all ILC is estrogen receptor-positive (ER+), and characterized by mutational inactivation of CDH1, the gene encoding E-cadherin3, which is associated with the diffuse growth pattern of ILC tumors. Additionally, ILC metastasizes to the lung, bone, and brain like other ER+ breast malignancies, but it also has a propensity to spread to the digestive tract, ovaries, and the peritoneal cavity1,2. Complicating this atypical dissemination pattern, advanced or metastatic ILC may not be as easily detected by positron emission tomography using the glucose analog tracer 18F-fluorodeoxyglucose (i.e. [18F]FDG-PET)4, as several clinical studies have shown ILC has limited FDG avidity. While these observations complicate care of patients with metastatic ILC, they also suggest that ILC has a distinct metabolic phenotype among breast cancers that is less reliant on glucose uptake and metabolism."
      ],
      "27161491": [
        "mRNA expression data from invasive lobular breast cancer (ILC), mixed ductal-lobular breast cancer (mDLC), and breast cancer of no special type (NST) from The Cancer Genome Atlas (TCGA, RRID:SCR_003193) pan-cancer clinical data resource26, METABRIC27, and the Sweden Cancerome Analysis Network - Breast (SCAN-B)28,29 shown in Figure S1A were accessed via Gene Expression eXPLORER (GEXPLORER) at https://leeoesterreich.org/resources on 6/4/2024. mRNA expression data and associated clinicopathological data from ILC and IDC/NST from TCGA shown in Figure 4C were accessed via cBioPortal30,31 (RRID:SCR_014555) on 6/13/2024. Enrichr was used for gene set enrichment analysis32\u201334. GLUD1 peptide counts from ER rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) in ILC cell lines shown in Figure 6A were graphed from Supplemental File 6 of Sottnik et al35."
      ],
      "29625055": [
        "mRNA expression data from invasive lobular breast cancer (ILC), mixed ductal-lobular breast cancer (mDLC), and breast cancer of no special type (NST) from The Cancer Genome Atlas (TCGA, RRID:SCR_003193) pan-cancer clinical data resource26, METABRIC27, and the Sweden Cancerome Analysis Network - Breast (SCAN-B)28,29 shown in Figure S1A were accessed via Gene Expression eXPLORER (GEXPLORER) at https://leeoesterreich.org/resources on 6/4/2024. mRNA expression data and associated clinicopathological data from ILC and IDC/NST from TCGA shown in Figure 4C were accessed via cBioPortal30,31 (RRID:SCR_014555) on 6/13/2024. Enrichr was used for gene set enrichment analysis32\u201334. GLUD1 peptide counts from ER rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) in ILC cell lines shown in Figure 6A were graphed from Supplemental File 6 of Sottnik et al35.",
        "We used three well-characterized public datasets26\u201329 to compare mRNA expression of the four target proteins in our multiplex IHC panel in ILC, IDC/NST, and (where reported) mixed mDLC (Figure S1A). SLC7A11 and SLC3A2 expression are both significantly greater in IDC/NST compared to ILC in multiple datasets. This may in part be due to the fact that these analyses do not stratify by hormone receptor status, and xCT is often overexpressed in triple negative breast cancer43, which is more prevalent in IDC/NST. By contrast, GPX4 expression is significantly greater in ILC vs. IDC/NST in the METABRIC dataset, while GLUD1 expression is significantly greater in ILC vs. IDC/NST in both the METABRIC and SCAN-B datasets. Prior studies in models of mammary epithelial cells show GLUD1 expression is elevated under quiescent and slower growth conditions44, which is generally consistent with ILC\u2019s more indolent nature."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.44773197174072266,
    "data_pmids_checked": 3,
    "paper_id": "39464069",
    "extraction_date": "2025-12-19T20:45:05.347651",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39464069.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39496981": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 4.959265947341919,
    "data_pmids_checked": 16,
    "paper_id": "39496981",
    "extraction_date": "2025-12-19T20:45:05.375234",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39496981.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39458904": {
    "cbioportal_paper_citations": [
      "This study retrospectively analyzed the clinicopathological and genomic data of the cancer genome atlas (TCGA) colon, rectal, and gastric cancer cohorts [41,42,43,44]. All the data were retrieved from the Genome Data Commons (GDC) and cBioPortal for Cancer Genomics databases. Transcript quantification was accomplished with RNASeq (mRNA) and miRNASeq (miRNA). Methylation beta values were generated using a methylation array on the Illumina Human Methylation 450 platform, while the masked copy number segment data were generated using the Affymetrix SNP 6.0 genotyping array."
    ],
    "cbioportal_platform_mentions": [
      "The clinico-genomic data of the GI cancer cohorts were retrieved from the GDC and CBioPortal databases using Linux-based scripts and codes that were written in the Windows-based Ubuntu 20.04 environment. Linux-based codes and scripts were also utilized to prepare the gene expression datasets in accordance with the Molecular Signature Database (MSigDB) [45,46] and DESeq2 Gene Enrichment Analyses requirements (https://cloud.genepattern.org/, accessed on 25 July 2024) [47], whereas Excel spreadsheet was utilized in the generation of the phenotype and derivative gene set files (see below), following which these were converted to cls and grp files, respectively. The gastric cancer cohort comprised 441 primary cases with clinicopathological (including prognostic data), RNASeq, chromosomal copy number segment, methylation, and somatic mutation data. The following data were available for this cohort: clinicopathological (between 380 and 441 of 441 cases for each clinicopathological indices; Table 1); mRNA expression (415/441 cases); chromosomal copy number segment (441/441 cases); methylation (between 393 and 440 of 441 cases for individual methylation loci); microRNA expression (441/441 cases) data."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.16330766677856445,
    "data_pmids_checked": 0,
    "paper_id": "39458904",
    "extraction_date": "2025-12-19T20:45:05.511064",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39458904.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39456638": {
    "cbioportal_paper_citations": [
      "We found mutations in codon 12 of KRAS in 77.3% of patients, which is aligned with what has been reported in the literature [30] using more advanced methods like next-generation sequencing (NGS) or ddPCR. However, ARMS\u2013HRMA is significantly quicker (capable of determining KRAS mutation status in just six hours), and much more affordable, than NGS, making it easier to apply in clinical practice. In our cohort, KRAS mutation frequency distribution is in line with what is described in other studies, where G12D is the most frequent, followed by G12V and G12R [31,32,33]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625050": [
        "We found mutations in codon 12 of KRAS in 77.3% of patients, which is aligned with what has been reported in the literature [30] using more advanced methods like next-generation sequencing (NGS) or ddPCR. However, ARMS\u2013HRMA is significantly quicker (capable of determining KRAS mutation status in just six hours), and much more affordable, than NGS, making it easier to apply in clinical practice. In our cohort, KRAS mutation frequency distribution is in line with what is described in other studies, where G12D is the most frequent, followed by G12V and G12R [31,32,33]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2017531394958496,
    "data_pmids_checked": 1,
    "paper_id": "39456638",
    "extraction_date": "2025-12-19T20:45:05.577080",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39456638.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39452477": {
    "cbioportal_paper_citations": [
      "The interrogation of participating series at the individual case level from the two selected cohorts was performed online on the cBioPortal for Cancer Genomics platform (cBioportal, http://www.cbioportal.org). cBioportal is a site containing genomic and associated clinical data from publicly available studies, maintained by the Memorial Sloan Kettering Cancer Center (MSKCC) and other academic institutions [19,20]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "37202560": [
        "Two publicly available genomic series, the colorectal cancer series from The Cancer Genome Atlas (TCGA) and the cohort from Sidra-LUMC AC-ICAM, which provide data on mRNA expressions, were selected for evaluation [12,13]. Groups of cancers with different levels of CDX2 mRNA expression were constructed and compared for their clinical and genomic characteristics, as well as molecular alterations of interest. The CDX2-suppressed group was defined with a cut-off of mRNA expression z-score relative to normal samples (log RNA Seq V2) of less than \u22122. The non-CDX2-suppressed group included samples with mRNA expression z-scores relative to normal samples (log RNA Seq V2) above 0.",
        "Both TCGA and Sidra-LUMC AC-ICAM employed a whole-exome next-generation sequencing platform for their genomic analyses. The two studies provided data on mutations, copy number alterations, and structural variants. In TCGA, single-nucleotide mutation calling was conducted with inputs from various pipelines [14]. Copy number alterations were analyzed with the GISTIC (Genomic Identification of Significant Targets in Cancer) algorithm [15]. In the Sidra-LUMC AC-ICAM study, mutation calling was performed with the mutect (v.1.1.7) algorithm [13,16]."
      ],
      "29596782": [
        "Both TCGA and Sidra-LUMC AC-ICAM employed a whole-exome next-generation sequencing platform for their genomic analyses. The two studies provided data on mutations, copy number alterations, and structural variants. In TCGA, single-nucleotide mutation calling was conducted with inputs from various pipelines [14]. Copy number alterations were analyzed with the GISTIC (Genomic Identification of Significant Targets in Cancer) algorithm [15]. In the Sidra-LUMC AC-ICAM study, mutation calling was performed with the mutect (v.1.1.7) algorithm [13,16]."
      ],
      "22810696": [
        "Two publicly available genomic series, the colorectal cancer series from The Cancer Genome Atlas (TCGA) and the cohort from Sidra-LUMC AC-ICAM, which provide data on mRNA expressions, were selected for evaluation [12,13]. Groups of cancers with different levels of CDX2 mRNA expression were constructed and compared for their clinical and genomic characteristics, as well as molecular alterations of interest. The CDX2-suppressed group was defined with a cut-off of mRNA expression z-score relative to normal samples (log RNA Seq V2) of less than \u22122. The non-CDX2-suppressed group included samples with mRNA expression z-scores relative to normal samples (log RNA Seq V2) above 0."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6863870620727539,
    "data_pmids_checked": 3,
    "paper_id": "39452477",
    "extraction_date": "2025-12-19T20:45:06.316313",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39452477.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39443725": {
    "cbioportal_paper_citations": [
      "Here, we identified the DUB Ubiquitin Specific Protease 10 (USP10) as a direct binder of \u03b2-Catenin. The protein interaction between the DUB and the WNT effector only occurs in cells which have lost all AAR domains within APC, mutations present in around 30% of all CRC patients [25, 26]. USP10 is crucial in the tumorigenic signalling of \u03b2-Catenin and its abundance strongly enhanced WNT target gene expression and is required to maintain a stemness-like expression profile, in CRC and murine tumour organoids, respectively. Moreover, this mechanisms is evolutionarily conserved as elimination of USP10 suppressed the gut progenitor hyperproliferation phenotype and reduced survival in a homozygous Apc (ApcQ8/Q8) truncated D.melanogaster model [27]. Controlling USP10 abundance suppressed patient organoid growth and WNT and EMT signalling, while upregulating the unfolded stress response. Loss of USP10 reduced NOTUM signalling [28, 29], a prerequisite for competitive tumour cell growth, and prevented tumour engraftment and growth in vivo.",
      "Since USP10 was not implicated in intestinal homeostasis and \u03b2-Catenin signalling, next, we determined expression level of USP10 by interrogating publicly available patient data of colorectal cancer [25]. While USP10 was rarely mutated in CRC, it was predominantly upregulated, along with CTNNB1, when compared to adjacent wild-type tissue (Fig. 1d and Supplementary Fig. S1c), and USP10 and CTNNB1 demonstrated a significant degree of correlation of expression in CRC samples (Fig. 1e, nT = 275, nWT = 349, Spearman coefficient R = 0.79). Remarkably, elevated expression of USP10 in CRC is a strong indicator of overall poor patient survival in CRC (Fig. 1f), especially in the molecular subtypes CMS2-4 (Fig. S1e). Prompted by this observation, we next studied USP10 and \u03b2-Catenin levels by Immunohistochemistry (IHC) of tissue micro arrays (TMA) of CRC patients comprising non-transformed and tumour tissue. Not only was a difference in tissue architecture observed in CRC tissue samples, but USP10 and \u03b2-Catenin indeed showed a significant upregulation in CRC when compared to the adjacent tissue (Fig. 1g). Elevated protein abundance was furthermore analysed by using human samples from CRC resection surgeries, subjected to immunoblotting against endogenous USP10, \u03b2-Catenin and MYC. Non-transformed, adjacent tissue served as control. USP10, \u03b2-Catenin and the oncogene MYC were increased in tumour-samples compared to matched non-transformed tissue samples (Fig. 1h).",
      "Colorectal cancer is mostly driven by deregulated WNT signalling, resulting in hyper-activation of the proto-oncoprotein \u03b2-Catenin and constant transcription of its target genes [11]. This is predominantly initiated via loss of function mutations within the tumour suppressor gene APC; around 80% of all CRC patients harbour these mutations [4, 26]. It is noteworthy that truncation mutations vary regarding localisation and the therefore resulting remaining domains within the APC protein [7]. Recent studies have reported that tumour progression, loss-of-heterozygosity, and deregulation of WNT signalling are indeed affected by the length of the remaining tumour suppressor [42]. Furthermore, aberrant WNT signalling, caused by APC truncation, is a prerequisite for the establishing of a super competitor cell phenotype, manifesting CRC onset [28, 29, 33]. Despite our growing understanding of the underlying genetic causalities of colorectal cancer, the identification of mechanisms at the basis of this phenomenon and identification of suitable therapeutic targets presents a challenge that yet needs to be overcome [43]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.04114103317260742,
    "data_pmids_checked": 0,
    "paper_id": "39443725",
    "extraction_date": "2025-12-19T20:45:06.357544",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39443725.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39442954": {
    "cbioportal_paper_citations": [
      "To compare protein expression between tumor samples and matching healthy tissues of a given patient, corresponding cores were jointly analyzed and staining intensities were categorized as low (<5% positive cells), medium (5\u201320% positive cells), or high (>20% positive cells) (Figure 1A). Patients with higher or lower staining intensity categories in tumors compared to benign samples were defined to exhibit protein up\u2010 or downregulation, respectively. Only cases, for which \u22652 benign or malignant cores were available, were included in the analysis. For visualization and mutual exclusivity analysis, the online software Oncoprinter was used. 14 , 15 To assess a potential clinical significance of SMARCD1 and SMARCD3, all cores representing tumor tissue of a given patient were jointly analyzed and the percentage of positive cells or staining intensities (low: 5% positive cells; medium: 5\u201320% positive cells, high: >20% positive cells) were correlated with clinical parameters. Depending on the nature of the clinical variables (categorical or metric), Chi\u2010squared tests or Pearson correlation analyses were performed using SPSS Statistics (IBM). Associations of clinical parameters with progression\u2010free survival (PFS) were assessed using the Kaplan\u2013Meier method and Log\u2010Rank (Mantel\u2013Cox) tests using the same software. All tests were two\u2010sided. Statistical significance was considered at p < 0.05."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2336750030517578,
    "data_pmids_checked": 0,
    "paper_id": "39442954",
    "extraction_date": "2025-12-19T20:45:06.654074",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39442954.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39438406": {
    "cbioportal_paper_citations": [
      "Specimens were collected from 26 patients with histologically confirmed breast cancer diagnoses. According to the American Joint Committee on Cancer tumor node metastasis staging system, patients were categorized into two groups: lymphatic metastatic (n = 14) or non-lymphatic metastatic (n = 12). Clinical experiments adhered to the principles outlined in the Declaration of Helsinki and were approved by the Ethics Committee of Fujian Medical University (2022KYB149). Transcriptome profiles of normal tissues (n = 292) and tumor tissues from patients sourced from The Cancer Genome Atlas (TCGA) database (n = 1092), along with survival information, were obtained from Cbioportal and the Sanger database as descripted (Gao et al. 2013)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.29800891876220703,
    "data_pmids_checked": 0,
    "paper_id": "39438406",
    "extraction_date": "2025-12-19T20:45:06.952173",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39438406.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39455281": {
    "cbioportal_paper_citations": [
      "TP63 and SOX2 amplifications in human SCCs. Data were compiled from publicly available TCGA data on cBioPortal squamous cell carcinoma samples (Cerami et al. 2012; Gao et al. 2013). nsamples = 1833 as follows: nsamples = 297 cervical, nsamples = 227 esophagus, nsamples = 632 head and neck, nsamples = 511 lung, nsamples = 151 skin, nsamples = 15 vaginal.",
      "About 10% of SCCs have activating mutations in RAS (Fig. 1C). SCCs of the skin and head and neck are particularly enriched for HRAS mutations, whereas most other SCCs are enriched for KRAS mutations. Of the non-SCCs harboring RAS mutations, KRAS (adenocarcinomas of the pancreas and lung) > NRAS (melanomas) > HRAS (salivary duct carcinoma) (Cerami et al. 2012; Gao et al. 2013; Lin et al. 2014; Pickering et al. 2014; Song et al. 2014; Li et al. 2015; Sanchez-Vega et al. 2018; Chang and Shain 2021). With the exception of melanoma, RAS mutations in nonepithelial cancers tend to be rare (Zehir et al. 2017)."
    ],
    "cbioportal_platform_mentions": [
      "In SCCs, TERT, PIK3CA, and matrix metalloproteinases (MMPs) are common oncogenes, whereas KMT2D and CDKN2A are common tumor suppressors (Fig. 1A,B). Although these genes have been reviewed extensively elsewhere, we highlight salient features in SCCs. In terms of oncogenes, TERT promoter mutations are frequent in SCCs (Fig. 1A,B; Scott et al. 2014), resulting in increased telomerase activity, extended telomeres and additional functions (Stewart et al. 2002). Phosphoinositide 3-kinases (PI3Ks) comprise four classes of receptors. Class I is heterodimeric with regulatory and catalytic subunits. It activates AKT and is negatively regulated by PTEN. The p110a regulatory isoform encoded by PIK3CA is often mutated in human SCCs and is functionally important, as shown in mice (Fig. 1A,B; Loganathan et al. 2020). However, wild-type PI3K can also be hyperactivated, for example, by leptin receptor, through interaction with the tumor microenvironment, and this too can drive SCCs (Loganathan et al. 2020; Yuan et al. 2022). Analogously, MMP gene amplifications are common in \u223c15% of SCCs (or \u223c5% individually for MMP1, MMP3, MMP7, MMP8, MMP10, MMP12, MMP13, MMP20, and MMP27) (TCGA data via cBioPortal) and correlate with invasion (Sato et al. 1994; Wright et al. 1994; Wirtz et al. 2011). However, mechanical forces from the tumor itself and the tumor microenvironment can also markedly affect basement membrane breakdown (Fiore et al. 2020). Thus, as we discuss further below, SCCs, like most cancers, are not simply genetic disorders, but ones in which cross-talk between the cancer and its microenvironment can be instrumental drivers."
    ],
    "data_publication_citations": {
      "28481359": [
        "About 10% of SCCs have activating mutations in RAS (Fig. 1C). SCCs of the skin and head and neck are particularly enriched for HRAS mutations, whereas most other SCCs are enriched for KRAS mutations. Of the non-SCCs harboring RAS mutations, KRAS (adenocarcinomas of the pancreas and lung) > NRAS (melanomas) > HRAS (salivary duct carcinoma) (Cerami et al. 2012; Gao et al. 2013; Lin et al. 2014; Pickering et al. 2014; Song et al. 2014; Li et al. 2015; Sanchez-Vega et al. 2018; Chang and Shain 2021). With the exception of melanoma, RAS mutations in nonepithelial cancers tend to be rare (Zehir et al. 2017)."
      ],
      "22960745": [
        "In addition to RAS, activating mutations in TERT and PIK3CA are frequent across human SCCs (or upstream receptors that lead to RAS signaling, such as FGFR1 amplification) (Fig. 1; The Cancer Genome Atlas Research Network 2012; Campbell et al. 2018). Gene amplifications leading to elevated levels of key lineage-defining transcription factors such as TP63 and SOX2 have also been reported (Fig. 2), as have loss of function and/or dominant-negative mutations in TP53, KMT2D, NOTCH1, CDKN2A, and FAT1 (Hippo signaling) (Martin et al. 2018; Pastushenko et al. 2021), which are among the most highly mutated genes shared across many albeit not all SCCs (Fig. 1A,B). NOTCH and TP53 mutations, for instance, are more than five times more frequent in cutaneous SCCs than in cervical SCCs, whereas TP63 mutations are more frequent in cervical than in esophageal or vulval SCCs. Even more perplexingly, SOX2 amplifications are common in lung SCCs but rare if at all in cutaneous SCCs, and yet loss of Sox2 in mice is critical for both cutaneous and lung SCCs (Boumahdi et al. 2014; Mukhopadhyay et al. 2014)."
      ],
      "34272401": [
        "Interestingly, in some settings, skin is resistant to mutations in some canonical cancer genes (Ying et al. 2018). Although these resistance mechanisms are not universal across tissues or in all scenarios in skin (Van Keymeulen et al. 2015; Chang and Shain 2021), they highlight the importance of understanding how cell competition, cancer genes, and tissue biology interact to drive tumorigenesis. Although a deeper understanding of the molecular underpinnings of cell competition and clonal expansion is now needed, these findings underscore the importance of both dominant mutations and the microenvironment in governing the transition to malignancy and invasion.",
        "About 10% of SCCs have activating mutations in RAS (Fig. 1C). SCCs of the skin and head and neck are particularly enriched for HRAS mutations, whereas most other SCCs are enriched for KRAS mutations. Of the non-SCCs harboring RAS mutations, KRAS (adenocarcinomas of the pancreas and lung) > NRAS (melanomas) > HRAS (salivary duct carcinoma) (Cerami et al. 2012; Gao et al. 2013; Lin et al. 2014; Pickering et al. 2014; Song et al. 2014; Li et al. 2015; Sanchez-Vega et al. 2018; Chang and Shain 2021). With the exception of melanoma, RAS mutations in nonepithelial cancers tend to be rare (Zehir et al. 2017)."
      ],
      "25589618": [
        "About 10% of SCCs have activating mutations in RAS (Fig. 1C). SCCs of the skin and head and neck are particularly enriched for HRAS mutations, whereas most other SCCs are enriched for KRAS mutations. Of the non-SCCs harboring RAS mutations, KRAS (adenocarcinomas of the pancreas and lung) > NRAS (melanomas) > HRAS (salivary duct carcinoma) (Cerami et al. 2012; Gao et al. 2013; Lin et al. 2014; Pickering et al. 2014; Song et al. 2014; Li et al. 2015; Sanchez-Vega et al. 2018; Chang and Shain 2021). With the exception of melanoma, RAS mutations in nonepithelial cancers tend to be rare (Zehir et al. 2017).",
        "As more sequencing data across human cancers are being amassed, genetic changes that might facilitate immune evasion are also beginning to emerge, and with them come new challenges. One way is through loss of HLA class I or, alternatively, restriction of the neoantigens presented by the tumor. Recent studies show that lung SCCs, even compared with adenocarcinoma counterparts, have a high propensity to downregulate antigen-presenting machinery genes or key components of its structure, such as B2M (Li et al. 2015; Rosenthal et al. 2019). There is also a high rate of HLA class I loss of heterozygosity (LOH), which can limit T-cell-mediated destruction by preventing presentation of a diverse array of neoantigens on the tumor surface (McGranahan et al. 2017). Notably, downregulation of HLA class I has also been linked to poor outcomes in cervical SCCs, and HLA LOH is prevalent in esophageal SCCs (Mehta et al. 2008; Cui et al. 2023). These findings indicate that immune evasion through dampening of antigen presentation on the cancer cells may be a critical if not universal step in SCC pathogenesis. Therefore, methods to reverse this downregulation through epigenetic targets or to activate immune cells through non-MHC class I-dependent mechanisms may be effective strategies to explore in SCCs."
      ],
      "29625050": [
        "About 10% of SCCs have activating mutations in RAS (Fig. 1C). SCCs of the skin and head and neck are particularly enriched for HRAS mutations, whereas most other SCCs are enriched for KRAS mutations. Of the non-SCCs harboring RAS mutations, KRAS (adenocarcinomas of the pancreas and lung) > NRAS (melanomas) > HRAS (salivary duct carcinoma) (Cerami et al. 2012; Gao et al. 2013; Lin et al. 2014; Pickering et al. 2014; Song et al. 2014; Li et al. 2015; Sanchez-Vega et al. 2018; Chang and Shain 2021). With the exception of melanoma, RAS mutations in nonepithelial cancers tend to be rare (Zehir et al. 2017)."
      ],
      "21798893": [
        "In the skin epidermis, NOTCH plays a critical role in driving epidermal differentiation and suppressing basal cell fates (Blanpain et al. 2006; Watt et al. 2008; Zanconato et al. 2015). NOTCH1\u20134 are frequently mutated in skin SCCs and HNSCCs (Agrawal et al. 2011; Stransky et al. 2011; Wang et al. 2011; Gao et al. 2014; Pickering et al. 2014; Rampias et al. 2014; Song et al. 2014; South et al. 2014), where they function as tumor suppressors (Nicolas et al. 2003; Nowell and Radtke 2017). For example, Notch1 deletion results in spontaneous tumors or accelerated tumorigenesis following a mutagen (DMBA) and inflammatory insult (TPA) (Nicolas et al. 2003). This is in part because NOTCH mutations lead to aberrant immune signaling and inflammation in the skin, contributing to tumorigenesis (Demehri et al. 2008, 2009, 2012; Dumortier et al. 2010; Di Piazza et al. 2012; Murthy et al. 2012), as observed in other models (Perez-Moreno et al. 2008)."
      ],
      "21798897": [
        "In the skin epidermis, NOTCH plays a critical role in driving epidermal differentiation and suppressing basal cell fates (Blanpain et al. 2006; Watt et al. 2008; Zanconato et al. 2015). NOTCH1\u20134 are frequently mutated in skin SCCs and HNSCCs (Agrawal et al. 2011; Stransky et al. 2011; Wang et al. 2011; Gao et al. 2014; Pickering et al. 2014; Rampias et al. 2014; Song et al. 2014; South et al. 2014), where they function as tumor suppressors (Nicolas et al. 2003; Nowell and Radtke 2017). For example, Notch1 deletion results in spontaneous tumors or accelerated tumorigenesis following a mutagen (DMBA) and inflammatory insult (TPA) (Nicolas et al. 2003). This is in part because NOTCH mutations lead to aberrant immune signaling and inflammation in the skin, contributing to tumorigenesis (Demehri et al. 2008, 2009, 2012; Dumortier et al. 2010; Di Piazza et al. 2012; Murthy et al. 2012), as observed in other models (Perez-Moreno et al. 2008)."
      ],
      "24670651": [
        "About 10% of SCCs have activating mutations in RAS (Fig. 1C). SCCs of the skin and head and neck are particularly enriched for HRAS mutations, whereas most other SCCs are enriched for KRAS mutations. Of the non-SCCs harboring RAS mutations, KRAS (adenocarcinomas of the pancreas and lung) > NRAS (melanomas) > HRAS (salivary duct carcinoma) (Cerami et al. 2012; Gao et al. 2013; Lin et al. 2014; Pickering et al. 2014; Song et al. 2014; Li et al. 2015; Sanchez-Vega et al. 2018; Chang and Shain 2021). With the exception of melanoma, RAS mutations in nonepithelial cancers tend to be rare (Zehir et al. 2017).",
        "In the skin epidermis, NOTCH plays a critical role in driving epidermal differentiation and suppressing basal cell fates (Blanpain et al. 2006; Watt et al. 2008; Zanconato et al. 2015). NOTCH1\u20134 are frequently mutated in skin SCCs and HNSCCs (Agrawal et al. 2011; Stransky et al. 2011; Wang et al. 2011; Gao et al. 2014; Pickering et al. 2014; Rampias et al. 2014; Song et al. 2014; South et al. 2014), where they function as tumor suppressors (Nicolas et al. 2003; Nowell and Radtke 2017). For example, Notch1 deletion results in spontaneous tumors or accelerated tumorigenesis following a mutagen (DMBA) and inflammatory insult (TPA) (Nicolas et al. 2003). This is in part because NOTCH mutations lead to aberrant immune signaling and inflammation in the skin, contributing to tumorigenesis (Demehri et al. 2008, 2009, 2012; Dumortier et al. 2010; Di Piazza et al. 2012; Murthy et al. 2012), as observed in other models (Perez-Moreno et al. 2008)."
      ],
      "24686850": [
        "About 10% of SCCs have activating mutations in RAS (Fig. 1C). SCCs of the skin and head and neck are particularly enriched for HRAS mutations, whereas most other SCCs are enriched for KRAS mutations. Of the non-SCCs harboring RAS mutations, KRAS (adenocarcinomas of the pancreas and lung) > NRAS (melanomas) > HRAS (salivary duct carcinoma) (Cerami et al. 2012; Gao et al. 2013; Lin et al. 2014; Pickering et al. 2014; Song et al. 2014; Li et al. 2015; Sanchez-Vega et al. 2018; Chang and Shain 2021). With the exception of melanoma, RAS mutations in nonepithelial cancers tend to be rare (Zehir et al. 2017)."
      ],
      "25303977": [
        "About 10% of SCCs have activating mutations in RAS (Fig. 1C). SCCs of the skin and head and neck are particularly enriched for HRAS mutations, whereas most other SCCs are enriched for KRAS mutations. Of the non-SCCs harboring RAS mutations, KRAS (adenocarcinomas of the pancreas and lung) > NRAS (melanomas) > HRAS (salivary duct carcinoma) (Cerami et al. 2012; Gao et al. 2013; Lin et al. 2014; Pickering et al. 2014; Song et al. 2014; Li et al. 2015; Sanchez-Vega et al. 2018; Chang and Shain 2021). With the exception of melanoma, RAS mutations in nonepithelial cancers tend to be rare (Zehir et al. 2017).",
        "In the skin epidermis, NOTCH plays a critical role in driving epidermal differentiation and suppressing basal cell fates (Blanpain et al. 2006; Watt et al. 2008; Zanconato et al. 2015). NOTCH1\u20134 are frequently mutated in skin SCCs and HNSCCs (Agrawal et al. 2011; Stransky et al. 2011; Wang et al. 2011; Gao et al. 2014; Pickering et al. 2014; Rampias et al. 2014; Song et al. 2014; South et al. 2014), where they function as tumor suppressors (Nicolas et al. 2003; Nowell and Radtke 2017). For example, Notch1 deletion results in spontaneous tumors or accelerated tumorigenesis following a mutagen (DMBA) and inflammatory insult (TPA) (Nicolas et al. 2003). This is in part because NOTCH mutations lead to aberrant immune signaling and inflammation in the skin, contributing to tumorigenesis (Demehri et al. 2008, 2009, 2012; Dumortier et al. 2010; Di Piazza et al. 2012; Murthy et al. 2012), as observed in other models (Perez-Moreno et al. 2008)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 10,
    "extraction_method": "jats_xml",
    "extraction_time": 3.3773279190063477,
    "data_pmids_checked": 10,
    "paper_id": "39455281",
    "extraction_date": "2025-12-19T20:45:08.904549",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39455281.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39430818": {
    "cbioportal_paper_citations": [
      "All cases were from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) database. Data are listed in the cBioCancer Genomics Portal (cBioPortal, http://www.cbioportal.org), a database for analyzing large-scale genomics (33). We compared the clinical characteristics of patients between the BUB1 mRNA expression altered group and the non-altered group in the METABRIC study."
    ],
    "cbioportal_platform_mentions": [
      "We identified genes co-expressed with BUB1 using the cBioPortal database. Database for Annotation, Visualization, and Integrated Discovery (DAVID, https://david.ncifcrf.gov) was used to identify significant clusters of genes and pathways in resulting dataset (29). We used an online tool (https://www.bioinformatics.com.cn) to analyze Gene Ontology (GO) covering cellular component (CC), biological process (BP), molecular function (MF), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. LinkedOmics (http://www.linkedomics.org) database contains multi-omics data and clinical data for 32 cancer types and more than 11,000 patients from The Cancer Genome Atlas (TCGA, www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) (30). We used the website to construct a heat map showing the genes and miRNAs correlated with BUB1 in BRCA. Further, Linkedomics was utilized to perform Pearson correlation analysis of miRNAs and Cox proportional hazard (CoxPH) test of BUB1.",
      "The top 200 genes co-expressed with BUB1 obtained from the cBioPortal had an average Spearman\u2019s correlation coefficient of 0.778. We then performed functional and pathway enrichment analyses based on these genes using the DAVID database. For BP, these genes were mainly enriched in processes such as cell division, mitotic sister chromatid segregation, and chromosome segregation (Figure 4A). For CC, these genes were mainly enriched in components such as nucleoplasm, kinetochore, and nucleus (Figure 4B). For MF, these genes were mainly enriched in ATP binding, protein binding, and microtubule binding (Figure 4C). KEGG pathway analysis suggested that they were mainly enriched in cell cycle, oocyte meiosis, and DNA replication (Figure 4D)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3244650363922119,
    "data_pmids_checked": 0,
    "paper_id": "39430818",
    "extraction_date": "2025-12-19T20:45:09.236609",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39430818.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39436262": {
    "cbioportal_paper_citations": [
      "cBioPortal was used to analyze genomic aberrations in all 26 genes encoding human integrins (hereinafter referred to as integrin genes) across 32 cancer types (Figure 1A) [16]. Aggregately, the integrin family as a group of cell adhesion molecules represented a frequently altered pathway in 32 cancers. On average, 33.5% of the tumors contained at least one alteration in one integrin gene, with skin cutaneous melanoma (SKCM, 70.0%) and thyroid carcinoma (THCA, 6.0%) having the highest and lowest mutation frequencies, respectively (Figure 1B; Table S2). Detailed analysis of distinct alteration types revealed several interesting patterns. First, mutations occurred most often, followed by amplification, in a majority of cancers, especially in SKCM (58.1%) (Figure 1B; Table S2), consistent with a high mutation burden for SKCM among human cancers [17]. Second, amplification was observed more frequently in five female-specific cancers [uterine carcinosarcoma (UCS), ovarian serous adenocarcinoma (OV), breast invasive carcinoma (BRCA), uterine corpus endometrial carcinoma (UCEC), and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC)] than in two male-specific cancers [prostate adenocarcinoma (PRAD) and testicular germ cell tumor (TCGT)] (Figure 1C), while no significant difference was found between these two groups for mutation (t-test, P = 0.089) and deletion (t-test, P = 0.58). Moreover, the frequency of amplification was not notably different among the remaining non-sex-biased 25 cancers (Figure 1D). These results strongly supported that amplification in integrin genes may be associated with sex hormone sensitive cancer types. Third, deletion occurred predominantly in PRAD (10.5%), stomach adenocarcinoma (STAD, 7.3%), and esophageal carcinoma (ESCA, 7.1%), indicating the tumor suppressive role and loss-of-expression of integrin genes in these cancer types (also see below). Fourth, despite the overall high alteration rate of integrin genes, most individual integrin genes had a low mutation frequency, with an average alteration rate of 3% (Figure 1E). Interestingly, we found that several integrin genes were co-mutated. For example, ITGAD, ITGAL, ITGAX, and ITGAM were co-amplified owing to their same location at Chr16p11.2 (P < 0.001) (Figure 1F). Copy number variants (CNVs) at the Chr16p11 region has been associated with neurodevelopmental disorders and invasive BRCA [18]. Similarly, owing to distinct genomic locations, ITGA1 and ITGA2 both resided at Chr5q11.2 were co-altered (P < 0.001) but mutually exclusive to ITGA3, which is located at Chr17q21.33 (Figure 1F). Integrin proteins function through heterodimers and are generally grouped into four categories (Figure 1A) based on their ligand types [1,4]. ITGAD, ITGAL, ITGAX, and ITGAM all dimerize with ITGAB2 to form leukocyte-specific receptors. Therefore, the co-amplification of these four \u03b1 integrins indicates a functional similarity and/or redundancy and highlights their important roles in modulating tumor immunity. Although all coupled with ITGB1, ITGA3 functions as a laminin receptor, whereas ITGA1 and ITGA2 function as collagen receptors. A mutually exclusive mutation pattern between ITGA3 and ITGA1/2 suggested their different roles in cancer development. Fifth, a detailed comparison of the mutational landscape of individual integrin genes across 32 cancers revealed that they altered in both a tumor-specific and gene-specific manner (Figure S1A). For example, in terms of the mutation rate, ITGA10 (6%) and ITGB7 (1.3%) are the highest and lowest altered ones, respectively (Figure 1E). In terms of alteration types, ITGA10 had high amplification rates in hepatocellular carcinoma (LIHC, 9.7%), BRCA (9.2%), and bladder urothelial carcinoma (BLCA, 9.0%), whereas it predominantly mutated in SKCM (7.8%). In terms of cancer types, ITGA10 and ITGA5 represented the most frequently amplified genes in cholangiocarcinoma (CHOL), whereas other integrin genes were rarely amplified (Figure S1A). Moreover, integrin genes are frequently, but rarely, depleted in PRAD and CHOL, respectively. In total, these results indicated that integrin genes are frequently mutated in cancer. Importantly, the genomic alteration landscape of the integrin family was overtly heterogeneous at multiple layers, suggesting the diversity in the mechanisms through which integrins influence cancer development.",
      "Expression data of mRNA and miRNA, DNA methylation data, and clinical data for TCGA samples were downloaded from the University of California Santa Cruz (UCSC) Xena (https://xenabrowser.net/). Mutation data for TCGA samples were collected from cBioPortal [16]. Expression profiles for validation of the correlation between integrin genes and TFs (Figure S3K and L) were downloaded from the Gene Expression Omnibus (GEO: GSE157548) and the CGGA database (http://www.cgga.org.cn/). Transcriptomic and clinical data for validation of integrinScore prognostic value (Figure S5B) were downloaded from the International Cancer Genome Consortium (ICGC) Data Portal (https://dcc.icgc.org/). Expression data for metastatic cancer were collected from the MET500 cohort (https://met500.med.umich.edu/). Expression and clinical data for immunotherapy were downloaded from GEO or collected from the Tumor Immunotherapy Gene Expression Resource portal (http://tiger.canceromics.org/). Known subtypes or classifications of human cancers were collected from original publications as described in the Results section."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "30742119": [
        "The intrinsic link between integrinScore and the immune landscape provided a rationale for assessing whether integrinScore can serve as a tool to predict patients\u2019 response to ICB therapy. In three independent SKCM cohorts treated with anti-PD1 [51], adoptive T cell therapy [52], or combined therapy [53], patients were stratified by integrinScore, and we found that patients in the integrinScore-low group had significantly longer survival time (Figure 7D) and more beneficial responses to ICB. The percentage of responders in integrinScore-high group was 33.3% vs. 42.6%, 0 vs. 47.6%, and 44.6% vs. 76.9% compared with that in integrinScore-low group in anti-PD1, adoptive T cell, and combined therapy cohort, respectively (Figure S7F). Similar findings were observed in other three independent cohorts: a LUAD cohort treated with anti-PD1/PD-L1 (n = 28) (Figure 7E, Figure S7G) [54], a GBM cohort treated with anti-PD1 (n = 34) (Figure 7E) [55], and a KIRC cohort treated with anti-PD1 (n = 311) (Figure 7E) [56]. Although the differences in response rates between integrinScore-high and integrinScore-low groups were not statistically significant in some cohorts owing to a limited number of cases, the rate of beneficial response in the integrinScore-low group consistently tended to be higher in these cohorts (Figure S7F and G). Collectively, these results suggest that integrinScore, which integrates the interplay between integrins and the immune environment, is a potential biomarker for predicting the response of patients to various immunotherapies."
      ],
      "26909576": [
        "A dense fibrotic stroma is the definitive feature of pancreatic adenocarcinoma (PAAD), which serves as a barrier to capturing the intrinsic molecular features of epithelial cancer cells. In Moffitt\u2019s study, a blind source separation method was utilized to classify PAAD tumors into basal and classical subtypes, in which basal subtype molecularly resembled basal breast tumors [45]. Consistently, basal PAAD was found to have worse outcomes and higher integrinScores (Figure 5G). Bailey et al. used mRNA expression profiles to categorize PAAD into four subtypes, with the squamous subtype exhibiting the worst outcome [46]. Here, we found that squamous tumors had the highest integrinScore (Figure 5G). Immunogenically, squamous tumors were characterized by the activation of CD4+ regulatory T cells and inhibition of antigen-presenting cells, leading to immunosuppression in the TME [46]. This phenotype was also reflected by the higher proportion of tumors in the D and F subtypes (Figure S5I)."
      ],
      "29625055": [
        "We computed integrinScore for each sample in a way used in our recent study [38]. Briefly, we first performed survival analysis for integrin genes across 32 cancer types. We utilized two kinds of outcomes (OS and PFS) in a cancer-dependent manner for survival analysis, as recommended previously [71]. The oncogenic integrin gene was identified as when patients had higher gene expression, their survival time was significantly shorter; while the protective integrin gene was identified by the opposite trend. Then, the expression levels of 26 integrin genes for each sample were extracted and normalized. And the integrinScore was calculated based on a linear combination of normalized expression values of the 26 integrin genes, of which oncogenic and protective integrin genes contributed positively and negatively to integrinScore, respectively: integrinScore=\u03a3(oncogenic integrin genes)-\u03a3(protective integrin genes)"
      ],
      "26824661": [
        "To assess the clinical utility of integrinScore, we focused on individual cancer types. A strong correlation was observed between integrinScore and several known molecular subtypes in the majority of the TCGA cancers (Figure 5D\u2013G, Figure S5F\u2013W). In ACC tumors, steroid hormones rendered a hostile environment to immune infiltrating cells and thus promoted tumor progression [40]. Consistently, we found that tumors with lower steroid levels tended to have lower integrinScore (Figure 5D). A previous study reported that a subgroup of ACC tumors (noisy group) characterized by a significantly higher number of chromosomal breaks caused by frequent arm-level CNVs possessed worse prognosis [40]. Here, we found that tumors in the noisy group had a higher integrinScore (Figure 5D). In LGG, Ceccarelli et al. categorized more than 1100 diffuse gliomas into distinct molecular subtypes by multidimensional omics [41]. They reported that the PanGlioma_RNA cluster LGr4 and PanGlioma_DNA_methylation cluster LGm4/5/6 contained a large proportion of high-grade tumors with a poor prognosis. Consistently, higher integrinScore values were seen in LGr4 and LGm4/5/6 tumors (Figure 5E). In addition, classical (CL) and mesenchymal (ME) tumors, which have worse outcomes, had higher integrinScores than neural (NE) and pro-neural (PN) ones (Figure S5F, left). Combination of integrinScore with the CL or ME subtype further stratified and thus identified a subgroup of aggressive tumors (Figure S5F, right). Analysis of data from advanced glioblastoma multiforme (GBM) yielded similar results (Figure S5G)."
      ],
      "31792460": [
        "The intrinsic link between integrinScore and the immune landscape provided a rationale for assessing whether integrinScore can serve as a tool to predict patients\u2019 response to ICB therapy. In three independent SKCM cohorts treated with anti-PD1 [51], adoptive T cell therapy [52], or combined therapy [53], patients were stratified by integrinScore, and we found that patients in the integrinScore-low group had significantly longer survival time (Figure 7D) and more beneficial responses to ICB. The percentage of responders in integrinScore-high group was 33.3% vs. 42.6%, 0 vs. 47.6%, and 44.6% vs. 76.9% compared with that in integrinScore-low group in anti-PD1, adoptive T cell, and combined therapy cohort, respectively (Figure S7F). Similar findings were observed in other three independent cohorts: a LUAD cohort treated with anti-PD1/PD-L1 (n = 28) (Figure 7E, Figure S7G) [54], a GBM cohort treated with anti-PD1 (n = 34) (Figure 7E) [55], and a KIRC cohort treated with anti-PD1 (n = 311) (Figure 7E) [56]. Although the differences in response rates between integrinScore-high and integrinScore-low groups were not statistically significant in some cohorts owing to a limited number of cases, the rate of beneficial response in the integrinScore-low group consistently tended to be higher in these cohorts (Figure S7F and G). Collectively, these results suggest that integrinScore, which integrates the interplay between integrins and the immune environment, is a potential biomarker for predicting the response of patients to various immunotherapies."
      ],
      "28783718": [
        "Intriguingly, TME-related (except immune cells) and metastasis-related signatures, including integrin signaling, showed similar enrichment patterns across cancers (Figure 6B), indicating that the role of integrins in TME remodeling may promote metastasis [5,6]. EMT endows cancer cells with morphological plasticity, which facilitates their migration through barriers, consequently leading to invasion and metastasis [47]. EMT signatures predominantly positively enriched in integrinScore-high tumors across cancers (Figure 6B, Figure S6B). Notably, in bulk RNA sequencing (RNA-seq) data, these EMT signatures should be reflected largely by the stromal compartment within the TME, but not necessarily by epithelial cancer cells. Indeed, we examined the correlation between integrinScore and the mRNA expression of many known EMT markers and revealed a preferential positive correlation between integrinScore and mesenchymal markers in the majority of cancer types (Figure S6D). Especially, this correlation was more significant in adenocarcinomas including STAD, COADREAD, PRAD, and PAAD, indicating intrinsic similarities in metastasis among adenocarcinomas originating from different organs. On the contrary, a negative correlation was observed between mesenchymal markers and integrinScore in DLBC, SKCM, and KIRC, which was consistent with the negative enrichment of EMT signatures in the integrinScore-high groups in these cancers (Figure 6B). The strong correlation between integrinScore and TME/metastasis signatures indicates that integrinScore could be used to predict metastasis (Figure 6B, Figure S6D). To strengthen this idea, we integrated TCGA cohorts (mainly containing localized primary tumors) with the MET500 dataset (containing transcriptomes of 500 metastatic samples from 22 organs) [48]. Pairwise comparison revealed that, in most cancer types, integrinScores were significantly higher in metastatic vs. primary tumor samples (Figure 6C). Notably, primary SKCM samples had higher integrinScores than metastatic samples, which may be attributed to the source of most SKCM samples being metastatic lymph nodes. Similar integrinScores were observed between primary and metastatic samples in CHOL and thymoma (THYM), which was consistent with the generally insignificant enrichment of EMT/metastasis signatures in integrinScore-high vs. integrinScore-low groups in these cancers (Figure 6B)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 6,
    "extraction_method": "jats_xml",
    "extraction_time": 3.0755419731140137,
    "data_pmids_checked": 6,
    "paper_id": "39436262",
    "extraction_date": "2025-12-19T20:45:10.027815",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39436262.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39421870": {
    "cbioportal_paper_citations": [
      "We first analyzed DNA sequencing data from 76,639 pan-cancer samples available in public databases (23, 24). By querying 31 DDR/FA-relevant genes, we found that ATM had the highest mutation rate (5%), followed by BRCA2/FANCD1 (4%), with the remaining 29 genes showing lower mutation rates (2%, 1%, or less; Figure 1).",
      "This study utilized publicly available DNA sequence datasets to analyze the mutation rates of 31 genes involved in DDR/FA signaling (including ATM, ATR, BLM, HRR6, RAD18, FANCA, FANCB, FANCC, BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, BRIP1, FANCL, FANCM, PALB2, RAD51C, SLX4, ERCC4, RAD51, BRCA1, UBE2T, XRCC2, MAD2L2, RFWD3, FAAP20, FAAP24, FAAP100, and CENPX). These analyses were conducted using the c-BioPortal platform (24, 50), which facilitated the determination of mutation rates and the frequency of altered DDR/FA signaling across a variety of human cancers."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3833019733428955,
    "data_pmids_checked": 0,
    "paper_id": "39421870",
    "extraction_date": "2025-12-19T20:45:10.411221",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39421870.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39427051": {
    "cbioportal_paper_citations": [
      "The Pan-Can immunotherapy data was sourced from processed mutation and clinical data using the Memorial Sloan Kettering Cancer Center (MSKCC) project available through cBioPortal [39]. This dataset includes genomic and survival information from 1,661 tumour-normal pairs, covering a diverse range of cancer types. All samples within this collection were sequenced using the MSK-IMPACT assay.",
      "The drug sensitivity data was obtained from the CREAMMIST database [42]. The survival data for TCGA was downloaded from cBioportal under TGCA PanCan Altlas Studies [39, 43]. The boxplot visualisations are generated with ggplots [44] and ggpubr [45] package. The survival analysis is conduct by survival and ggsurvfit R packages."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "30643254": [
        "We analysed the mutation data from patients who underwent immunotherapy based on the MSK-IMPACT study from 11 different cancer types [17]. Within each caner type, using the 80th percentile of TMB, we assigned patients into TMB -high and -low groups and compared their overall survival (OS) (Fig. 1b). We further stratified patients within each of TMB-High and -Low groups based on their status\u2014alive/censored or deceased. We defined nbTMB for each patient sample by quantifying the numbers of mutations co-localised with non-B forming regions [19]. When comparing median nbTMBp across groups, the TMB-high group had a lower nbTMBp overall, relative to the TMB-low group (Fig. 1c). Within each TMB classified group, median nbTMBp was significantly higher in deceased patients, irrespective of their high/low status (Fig. 1c). A gene-level analysis of immune response signatures [20] revealed an 86% overlap between mutations co-localised with non-B motifs and immune checkpoint inhibitor-outcome-linked genes (n = 98) (Fig. 1d)."
      ],
      "31068700": [
        "We next explore the use of nbTMBp as a marker of altered cisplatin drug sensitivity in ovarian cancer. Cisplatin resistance is a major hurdle in effectively treating ovarian cancer [21]. Although cisplatin is commonly used for ovarian cancer treatment, drug resistance often arises due to a faulty apoptotic process, reducing treatment effectiveness [22\u201326]. Among the 57 ovarian cell lines with mutation profiles [27], ~40% have TMB greater than ten and a median fraction of genome altered (FGA) of ~50%, which supports the potential role of genomic instability in treatment resistance. Investigating how cells signal in response to chemotherapy from the non-B DNA perspective of genomic instability may shed light on treatment outcomes.",
        "The mutation data was extracted from two major repositories: the Cancer Cell Line Encyclopaedia (CCLE) and The Cancer Genome Atlas (TCGA) [33]. Both sources offer a comprehensive view of mutational landscapes. The mutation data for patient samples and cell lines are separately downloaded from UCSC Xena [34]. The specific dataset used for our analysis was identified as CCLE_DepMap_18Q2_maf_20180502. It contains somatic mutations include Single Nucleotide Polymorphisms and small INDELs (insertions/deletions). Mutational calls have been merged, focusing on the coding region and filtering out germline mutations. For patient mutation data, the somatic mutation dataset from TCGA is labelled as \u2018mc3.v0.2.8.PUBLIC.maf.gz\u2019 [35]. The genome assembly for both datasets is hg19 build. Early-stage pancreatic cancer TCGA patients were defined by Stage I or II pancreatic adenocarcinoma with a predicted tumour purity [36] of at least 25% and no history of neuroendocrine diagnoses, prior treatments, or non-pancreatic origins [37]."
      ],
      "29596782": [
        "The mutation data was extracted from two major repositories: the Cancer Cell Line Encyclopaedia (CCLE) and The Cancer Genome Atlas (TCGA) [33]. Both sources offer a comprehensive view of mutational landscapes. The mutation data for patient samples and cell lines are separately downloaded from UCSC Xena [34]. The specific dataset used for our analysis was identified as CCLE_DepMap_18Q2_maf_20180502. It contains somatic mutations include Single Nucleotide Polymorphisms and small INDELs (insertions/deletions). Mutational calls have been merged, focusing on the coding region and filtering out germline mutations. For patient mutation data, the somatic mutation dataset from TCGA is labelled as \u2018mc3.v0.2.8.PUBLIC.maf.gz\u2019 [35]. The genome assembly for both datasets is hg19 build. Early-stage pancreatic cancer TCGA patients were defined by Stage I or II pancreatic adenocarcinoma with a predicted tumour purity [36] of at least 25% and no history of neuroendocrine diagnoses, prior treatments, or non-pancreatic origins [37]."
      ],
      "26909576": [
        "According to the pathway analysis on gene signatures of sample clusters (see Methods), the high mlTNB-DR burden patients had mutation signatures enriched in MAPK and Notch signalling pathways, as compared to the other clusters enriched with double-stranded break and mismatch repair (cluster 1-IR), hedgehog and WNT signalling (cluster 2-STR) and interleukin-4 signalling (cluster 6-MR) pathways (Fig. 2d). There was a lack of significant association between mlTNB clusters with age, race, sex, PAAD subtypes [29, 30], KRAS mutation status and tumour purity. Additionally, there was no significant association between the non-B DNA clusters with markers of genomic instability, TMB, FGA, and MSI-score (measured by MANIS score) [31], whose distributions were similar across clusters and on average, were low in value (Fig. 2e). Specifically, the median TMB was 1.43, the median FGA, 0.13 and the median MSI-score was 0.28 across all groups. In the shortest PFS (high mlTNB-ZDNA, cluster 5-ZDNA) (Fig. 2f), chromosome 7 had the highest prevalence of non-B mutation co-localisation, while the longest PFS (high mlTNB-DR, cluster 3-DR) patient group non-B mutation co-localisation resided mainly on chromosome 5 (Fig. 2g). Our results lend support to the further study of mlTNB as a differentiating marker of survival in PAAD patients that may further inform on their heterogeneous response to treatment."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 1.654263973236084,
    "data_pmids_checked": 4,
    "paper_id": "39427051",
    "extraction_date": "2025-12-19T20:45:10.939465",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39427051.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39417978": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4188199043273926,
    "data_pmids_checked": 1,
    "paper_id": "39417978",
    "extraction_date": "2025-12-19T20:45:11.381449",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39417978.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39417716": {
    "cbioportal_paper_citations": [
      "N-glycan matrix-assisted laser desorption/ionization\u2013MSI (MALDI-MSI) was performed on FFPE tissue slides using a standardized protocol (33) used recently for analysis of prostate cancer (31) and multitumor TMA (37) FFPE tissues. Antigen retrieval of dewaxed slides was done in citraconic anhydride buffer, pH 3, for 30 minutes in a decloaking chamber at 95\u00b0C. PNGase F PRIME enzyme at 0.1 \u00b5g/\u00b5L was applied at 10 psi and 45\u00b0C using an M5 sprayer (HTX Technologies; ref. 33). The slides were incubated in prewarmed humidity chambers for 2 hours at 37\u00b0C for release of N-glycans. After 2 hours of PNGaseF digestion, the M5 sprayer was used to apply 7 mg/mL \u03b1-cyano-4-hydroxycinnamic acid (CHCA) matrix in 50% ACN/0.1% trifluoroacetic acid at 10 psi and 79\u00b0C (33). The prepared slides were desiccated at room temperature until analysis. For detection of released N-glycans, a Solarix dual-source 7T MALDI-Fourier transform ion cyclotron resonance (FTICR) mass spectrometer and a timsTOF Flex MALDI-quadrupole time-of-flight (QTOF) mass spectrometer were used (Bruker Corporation), operated in positive ion mode, as previously described (37, 38). Data were collected with a laser spot size of 20 to 25 \u00b5m, 300 laser shots per pixel, 40 \u00b5m raster, and mass ranges of 700 to 4,000 m/z. For each tissue, all acquired spectra were imported to SCiLS Lab software (Bruker Corporation) for processing and visualization. N-glycan spectra were normalized to total ion count. Spectra were annotated by matching glycan peak m/z values to an established in-house N-glycan database (31, 32, 38). Structural assignments and glycan compositions were made using multiple prior characterizations by reversed-phase LC/MS-MS, MALDI-TOF-MS/MS, and alternate enzymatic release experiments (37\u201339).",
      "Two independent datasets were used for validation of the MALDI imaging data. Clinical\u2013pathologic data and genomic data were downloaded from the cBioPortal for cancer genomics (http://www.cbioportal.org/; refs. 40, 41). First, a dataset of 494 primary prostate cancers (genomics data for 489 cancers) was obtained from the \u201cProstate Adenocarcinoma PanCancer Atlas\u201d dataset from The Cancer Genome Atlas (refs. 42, 43). Second, a dataset of 444 CRPC specimens from 429 patients was obtained from the \u201cMetastatic Prostate Adenocarcinoma SU2C/PCF Dream Team\u201d dataset (44). Copy-number alteration (CNA) data were obtained as amplification (AMP), gain (GAIN), shallow deletion (HETLOSS), and deep deletion (HOMDEL) for all 11 FUTs (FUT1\u2013FUT11) involved in N-glycan fucosylation. Tumor samples were selected if they had a gain or amplification for any of the 11 FUT genes. For analyses involving histology and location of metastatic tumors, tumors with increased copy number for any of the 11 FUT genes were further filtered by subtracting out any tumor that had a shallow or deep deletion for any of the FUT genes (N = 74). These data were further restricted to include only those FUT enzymes (FUT1, FUT3, FUT4, FUT5, FUT6, and FUT9) that can synthesize Ley antigen (N = 50). These tumors were then compared with tumors that were diploid for all the 11 FUT genes (N = 43). Similarly, RNA expression for FUT1 to FUT11 was obtained in fragments per kilobase of transcripts per million mapped reads format from the metastatic prostate adenocarcinoma dataset as above and matched with exposure to the androgen receptor signaling inhibitors (ARSI) abiraterone and enzalutamide (na\u00efve or exposed; N = 195) as well as AR CNAs (N = 208)."
    ],
    "cbioportal_platform_mentions": [
      "The genomic data generated in this study are publicly available at http://www.cbioportal.org/. MALDI data generated in this study are available upon request from the corresponding author."
    ],
    "data_publication_citations": {
      "26544944": [
        "Two independent datasets were used for validation of the MALDI imaging data. Clinical\u2013pathologic data and genomic data were downloaded from the cBioPortal for cancer genomics (http://www.cbioportal.org/; refs. 40, 41). First, a dataset of 494 primary prostate cancers (genomics data for 489 cancers) was obtained from the \u201cProstate Adenocarcinoma PanCancer Atlas\u201d dataset from The Cancer Genome Atlas (refs. 42, 43). Second, a dataset of 444 CRPC specimens from 429 patients was obtained from the \u201cMetastatic Prostate Adenocarcinoma SU2C/PCF Dream Team\u201d dataset (44). Copy-number alteration (CNA) data were obtained as amplification (AMP), gain (GAIN), shallow deletion (HETLOSS), and deep deletion (HOMDEL) for all 11 FUTs (FUT1\u2013FUT11) involved in N-glycan fucosylation. Tumor samples were selected if they had a gain or amplification for any of the 11 FUT genes. For analyses involving histology and location of metastatic tumors, tumors with increased copy number for any of the 11 FUT genes were further filtered by subtracting out any tumor that had a shallow or deep deletion for any of the FUT genes (N = 74). These data were further restricted to include only those FUT enzymes (FUT1, FUT3, FUT4, FUT5, FUT6, and FUT9) that can synthesize Ley antigen (N = 50). These tumors were then compared with tumors that were diploid for all the 11 FUT genes (N = 43). Similarly, RNA expression for FUT1 to FUT11 was obtained in fragments per kilobase of transcripts per million mapped reads format from the metastatic prostate adenocarcinoma dataset as above and matched with exposure to the androgen receptor signaling inhibitors (ARSI) abiraterone and enzalutamide (na\u00efve or exposed; N = 195) as well as AR CNAs (N = 208)."
      ],
      "31061129": [
        "Two independent datasets were used for validation of the MALDI imaging data. Clinical\u2013pathologic data and genomic data were downloaded from the cBioPortal for cancer genomics (http://www.cbioportal.org/; refs. 40, 41). First, a dataset of 494 primary prostate cancers (genomics data for 489 cancers) was obtained from the \u201cProstate Adenocarcinoma PanCancer Atlas\u201d dataset from The Cancer Genome Atlas (refs. 42, 43). Second, a dataset of 444 CRPC specimens from 429 patients was obtained from the \u201cMetastatic Prostate Adenocarcinoma SU2C/PCF Dream Team\u201d dataset (44). Copy-number alteration (CNA) data were obtained as amplification (AMP), gain (GAIN), shallow deletion (HETLOSS), and deep deletion (HOMDEL) for all 11 FUTs (FUT1\u2013FUT11) involved in N-glycan fucosylation. Tumor samples were selected if they had a gain or amplification for any of the 11 FUT genes. For analyses involving histology and location of metastatic tumors, tumors with increased copy number for any of the 11 FUT genes were further filtered by subtracting out any tumor that had a shallow or deep deletion for any of the FUT genes (N = 74). These data were further restricted to include only those FUT enzymes (FUT1, FUT3, FUT4, FUT5, FUT6, and FUT9) that can synthesize Ley antigen (N = 50). These tumors were then compared with tumors that were diploid for all the 11 FUT genes (N = 43). Similarly, RNA expression for FUT1 to FUT11 was obtained in fragments per kilobase of transcripts per million mapped reads format from the metastatic prostate adenocarcinoma dataset as above and matched with exposure to the androgen receptor signaling inhibitors (ARSI) abiraterone and enzalutamide (na\u00efve or exposed; N = 195) as well as AR CNAs (N = 208)."
      ],
      "29625048": [
        "Two independent datasets were used for validation of the MALDI imaging data. Clinical\u2013pathologic data and genomic data were downloaded from the cBioPortal for cancer genomics (http://www.cbioportal.org/; refs. 40, 41). First, a dataset of 494 primary prostate cancers (genomics data for 489 cancers) was obtained from the \u201cProstate Adenocarcinoma PanCancer Atlas\u201d dataset from The Cancer Genome Atlas (refs. 42, 43). Second, a dataset of 444 CRPC specimens from 429 patients was obtained from the \u201cMetastatic Prostate Adenocarcinoma SU2C/PCF Dream Team\u201d dataset (44). Copy-number alteration (CNA) data were obtained as amplification (AMP), gain (GAIN), shallow deletion (HETLOSS), and deep deletion (HOMDEL) for all 11 FUTs (FUT1\u2013FUT11) involved in N-glycan fucosylation. Tumor samples were selected if they had a gain or amplification for any of the 11 FUT genes. For analyses involving histology and location of metastatic tumors, tumors with increased copy number for any of the 11 FUT genes were further filtered by subtracting out any tumor that had a shallow or deep deletion for any of the FUT genes (N = 74). These data were further restricted to include only those FUT enzymes (FUT1, FUT3, FUT4, FUT5, FUT6, and FUT9) that can synthesize Ley antigen (N = 50). These tumors were then compared with tumors that were diploid for all the 11 FUT genes (N = 43). Similarly, RNA expression for FUT1 to FUT11 was obtained in fragments per kilobase of transcripts per million mapped reads format from the metastatic prostate adenocarcinoma dataset as above and matched with exposure to the androgen receptor signaling inhibitors (ARSI) abiraterone and enzalutamide (na\u00efve or exposed; N = 195) as well as AR CNAs (N = 208).",
        "Because there are 11 FUTs that fucosylated N-glycans, we investigated the presence of CNAs in genes encoding these enzymes in primary prostate tumors compared with metastatic prostate tumors using previously published datasets (42\u201344). We discovered that although there were significant enrichments in deletions of FUT3 to FUT7 (P < 0.001), there were more robust and significant enrichments in copy number of all 11 FUT genes (P < 0.0001; Fig. 4E). We further interrogated the metastatic prostate cancer dataset to identify if enrichments of the FUT genes were enriched in small-cell/neuroendocrine versus adenocarcinoma histology. Interestingly, not only was there significant (P < 0.05) enrichment of FUT copy number in metastatic tumors with small-cell/neuroendocrine histology (Fig. 4F) but the difference was more significant (P < 0.01) when copy number was restricted to the FUT with Ley synthetic ability (Fig. 4G)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 1.0433111190795898,
    "data_pmids_checked": 3,
    "paper_id": "39417716",
    "extraction_date": "2025-12-19T20:45:12.424866",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39417716.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39413736": {
    "cbioportal_paper_citations": [
      "Subsequent heatmap analysis indicated that 6 of the 10 genes were consistently overexpressed (TFPI2, IL1B, SAA1, and SAA2) or underexpressed (BTG2 and FGFBP1) in metastases, relative to primaries, in both in vivo PDO metastasis models and PDOs directly derived from human tumors (Figure 3C). We next performed in-depth analyses using 2 LUAD datasets: The Cancer Genome Atlas (TCGA)24,25 and the National Cancer Center Research Institute (Japan; NCCRI).26,27 BTG2 was the only gene with consistent prognostic value (Figures 3D, S3E, and S3F). Using another LUAD dataset (GSE18549),28 we validated that only BTG2 mRNA is decreased in LUAD that has metastasized to the brain, compared with LUAD that has metastasized to other organs (Figure 3E). BTG2 is a putative cell-cycle regulator with broad expression across most epithelial but few neuronal tissues. This observation suggests that downregulation of BTG2 may contribute to brain metastasis. To examine this hypothesis, we knocked down BTG2 in LUAD H460 cells (Figure 3F), which rarely develop early (<2 weeks after injection) brain metastasis in our model. After intracardiac injection of control and BTG2KD cells, we observed that, although the total tumor burden was similar between the groups (Figures 3G, 3H, and S3G), mice injected with BTG2KD cells had higher rates of brain metastasis, compared with mice injected with control cells (Figure 3I). Similar results were observed in an experiment in which we reinjected H460 BTG2KD cells isolated from mouse brain metastatic sites (Figures S3H and S3I), which suggests that BTG2KD promotes brain metastases. These findings illustrate another use of our in vivo PDO metastasis model: identification and further characterization of genes related to LUAD metastasis in specific organs.",
      "We used two publicly available LUAD datasets: TCGA (cbioportal.org)24,25 and NCCRI (NCBI Gene Expression Omnibus GSE31210).26,27 For survival analyses, we examined the expression of 12 genes of the putative brain metastasis markers. Survival was assessed using the Kaplan-Meier method and compared between high and low mRNA groups of individual genes using the log rank test. Cutoffs for each gene were determined by maximally selected rank statistics using the package maxstat in R (version 3.6.1, R Core Development Team, Vienna, Austria)."
    ],
    "cbioportal_platform_mentions": [
      "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD107a-PEBioLegendCat# 328607 RRID:AB-1186062IFN\u03b3-APCBioLegendCat# 506510 RRID:AB_315443CD137-PerCP/Cy5.5BioLegendCat# 309814 RRID:AB_2205686CD3-AF594BioLegendCat# 300446 RRID:AB_2563236CD8-PE-Cy7BioLegendCat# 300914 RRID:AB_314118CD45RO-BV650BioLegendCat# 304232 RRID:AB_2563462SOX2AbcamCat# ab92494; RRID:AB_10585428Ki-67AbcamCat# ab15580 RRID:AB_443209ALDH1A1AbcamCat# ab52492 RRID:AB_867566BTG2AbcamCat# ab85051 RRID: AB_1861407FGFR1ProteintechCat# 60325-1-IG RRID:AB_2881435p-ERKCell SignalingCat# 4370 RRID:AB_2315112ERKCell SignalingCat# 4695 RRID:AB_390779EpCAMThermo FisherCat# MA5-12153 RRID:AB_10982998ACTINSanta CruzCat# sc-8432 RRID:AB_626630Donkey anti-Mouse IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor\u2122 594Thermo FisherCat# A-21203RRID: AB_2535789Bacterial and virus strainsLentivirus, CAG-Luciferase (firefly) (GFP-Puro)GenTargetCat# LVP570Biological samplesHuman tumor tissue specimensThis studyN/AHuman non-cancerous adjacent tissueThis studyN/AHuman lung cancer metastatic samplesThis studyN/AHuman pleural effusion samplesThis studyN/AHuman peripheral blood monocytes (PBMCs)This studyN/AChemicals, peptides, and recombinant proteins10% paraffinSigma-AldrichCat# HT501128Collagenase BRocheCat# 11088815001DNase IMilliporeCat# 691823MatrigelCorningCat# 354234TrypLEThermo FisherCat# 12605010Ficoll-PaqueMilliporeCat# GE17-1440-02CisplatinSelleckchemCat# S1166VinorelbineSelleckchemCat# S4259NivolumabSelleckchemCat# A2002GolgiSTOPBDCat# 554724GolgiPLUGBDCat# 555029NucView488 DyeBiotiumCat# 30029-TCell Recovery SolutionCorningCat# 354253VivoGlo LuciferinPromegaCat# P1041AMG-510 (Sotoracib)SelleckchemCat# S8830Advanced DMEM/F12Thermo FisherCat# 12634028HEPESThermo FisherCat# 15630080GlutamaxThermo FisherCat# 35050061N-acetyl-L-cysteineMillipore SigmaCat# A9165-5GPrimocinInvivoGenCat# ant-pm-1N2ThermoFisherCat# 17502001B-27 supplement (50X), minus vitamin AThermoFisherCat# 12587001NogginR & DCat# 6057-NGFGFR & DCat# 233-FBCHIR 99021TocrisCat# 4423/50EGFPeproTechCat# AF-100-15Y-27632 dihydrochlorideAbmole BioscienceCat# M1817SB 431542R & DCat# 1614/10RPMI 1640Thermo FisherCat# 42402016Mounting mediumThermo FisherCat# P36934Penicillin/streptomycinThermo FisherCat# 10378016Human serumSigma-AldrichCat# H4522IL-2PeproTechCat# 200-02UltraGlutamine ILonzaCat# BE17-605E/U1Fetal Bovine SerumThermo FisherCat# 26140079Critical commercial assaysHRP/DAB IHC Detection KitAbcamCat# ab236466DNeasy Blood & Tissue KitQiagenCat# 69504NEBNext Ultra II End Repair/dA-Tailing ModuleNew England BiolabCat# E7595RNeasy Plus Mini kitQiagenCat# 74136CellTiter-Glo Luminescent Cell Viability assayPromegaCat# G7571Human CD8+ T cell Isolation KitMiltenyi BiotecCat# 130-096-495Deposited dataRNA-seqThis studyGene Expression Omnibus (GSE276387)TCGA lung adenocarcinoma cohortThe cBioPortal for Cancer GenomicsCbioportal.orgNCCRI lung adenocarcinoma cohortGene Expression OmnibusGSE31210BTG2 mRNA in lung adenocarcinoma metastasizing to brainGene Expression OmnibusGSE18549Experimental models: Cell linesNCI-H460ATCCCat# HTB-177 RRID:CVCL_0459Experimental models: Organisms/strainsNOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mouseThe Jackson LaboratoryStrain #:005557 RRID:IMSR_JAX:005557OligonucleotidesFGFR1 sgRNA: CTGGTCTTAGGCAAACCCCTThis studyN/AHLA-A FW: 5\u2032-ggccctgacccagacct-3\u2032This studyN/AHLA-A RV: 5\u2032-gcccctcctgctctatcca-3\u2032This studyN/ACD137 FW: 5\u2032-cactctgttgctggtcctcaa-3\u2032This studyN/ACD137 RV: 5\u2032-ggacagggactgcaaatctga-3\u2032This studyN/ACD47 FW: 5\u2032-tggtagcggcgctgttg-3\u2032This studyN/ACD47 RV: 5\u2032-tcagtagtgttttgtgcctcca-3\u2032This studyN/ACD274 FW: 5\u2032-ttcatgacctactggcatttgct-3\u2032This studyN/ACD274 RV: 5\u2032-agtgcagccaggtctaattgtt-3\u2032This studyN/APrimers for Sanger sequencing (See Table S5)This studyN/ARecombinant DNALcV2HygroGolden et al.54Addgene plasmid #91977; RRID:Addgene_91977Predesigned shRNA BTG2Millipore SigmaTRCN0000231595Software and algorithmsPrism version 10.2.3 (347)GraphpadGraphpad.comR 3.6.1R Core Development Teamr-project.orgBurrows-Wheeler Aligner, version 0.7.8BWA-MEMbio-bwa.sourceforge.netLiving Image Software, version 4.2PerkinElmerresources.perkinelmer.com"
    ],
    "data_publication_citations": {
      "28481359": [
        "We initiated a PDO program using human LUAD specimens, including surgically resected primary tumors (n = 32), metastatic tumors (n = 12), and MPEs (n = 5) (Table S1). We chose a bespoke Sanger sequencing screen (Figure S1B) on the basis of the results of MSK-IMPACT11 to identify PDOs. The success rate of generation of PDOs from metastatic tumors and MPEs was 92% and 100%, respectively. However, similar to others,10,12 the success rate of generation of PDOs from primary LUAD was only 31% (10/32) (Figure 1A). We identified clinicopathologic features positively associated with the successful establishment of PDOs from primary LUAD, including tumor content >30%, predominant solid (SOL) histologic subtype, poor differentiation, tumor maximum standardized uptake value \u22655 on fluorodeoxyglucose-positron emission tomography, and SOL tumor morphologic appearance on computed tomography (Figures 1B and S1C\u2013S1E).Figure 1Establishment and characterization of PDOs(A) Bars showing the success rate of generation of PDOs from different LUAD biospecimens. \u201cYes,\u201d preservation of the major mutations of the parental tumor; \u201cNo,\u201d major mutations in parental tumor are not preserved in the PDOs.(B) Bars indicating the success of generation of PDOs from the primary LUAD tumor with indicated clinicopathologic features. SUVmax, maximum standardized uptake value; \u201cYes\u201d and \u201cNo,\u201d as in (A).(C) H&E (rows 1 and 3), phase contrast (row 2), and Ki-67 (row 4) immunostaining of the primary tumor, noncancerous tissue, and matched PDOs.(D) Immunostaining of Sox2 in PDOs and their parental tumors.(E) Correlation heatmap of variant allele fractions across PDOs and their parental primary tumors.(F) Proportion of substitution context across PDOs and their parental primary tumors.(G) Correlation heatmap of the transcriptomic profiles across PDOs and their parental primary tumors."
      ],
      "37084736": [
        "To mimic LUAD systemic metastases,16 we used an intracardiac injection in vivo metastatic model17 to examine the metastatic capacity of PDOs (Figure 2A). PDO_6 and PDO_23 were derived from pathologic stage IA primary LUADs with predominant SOL histologic subtype (Figure S3A). Surveillance in vivo imaging system (IVIS) demonstrated the development of metastasis in 7 of 11 mice injected with PDO_6 (64%) and in 4 of 8 mice injected with PDO_23 (50%) (Figures 2B\u20132D). Interestingly, we observed distinct organotropism between 2 PDOs. Liver metastases were observed in almost all PDO_6 mice that developed metastases. However, metastases did not appear to exhibit an organotropic preference in PDO_23 mice that developed metastases (Figure 2C). Results of H&E and immunohistochemistry (IHC) staining showed that MDOs recapitulated the features of their parental PDOs, including morphologic appearance, proliferation, and stemness (Figure 2E). In summary, the aforementioned findings serve as strong evidence that PDOs form metastases and can be used to study the biology of LUAD metastasis.Figure 2Establishment of our in vivo PDO metastasis model(A) Schematic representation of the generation of our in vivo PDO metastasis model: (1) collection and dissociation of surgical LUAD specimens, (2) generation and characterization of PDOs, (3) labeling with luciferase-green fluorescence protein (GFP) (PDO_GL), (4) introduction into mice by intracardiac injection, (5) formation of metastatic site(s), (6) isolation of metastatic tumor and regeneration of organoids (MDOs), and (7) characterization of MDOs.(B) Bioluminescent images of mice injected with indicated PDOs.(C) Table showing organs in which metastases formed in mice after intracardiac injection of PDOs at 5 months. GB, gallbladder; LN, lymph node.(D) Representative H&E staining from healthy mice or mice with intracardiac injection of PDOs.(E) H&E and immunohistochemical staining of PDO_GL and MDOs."
      ],
      "25079552": [
        "Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide.1 The high mortality of NSCLC is primarily related to the development of metastatic disease.2 Lung adenocarcinoma (LUAD), the most common histologic type of NSCLC, has a high tumor mutation burden and well-annotated oncogenic drivers, some of which are targetable.3,4 An important advance in modeling human cancer during the last decade has been the development of patient-derived organoids (PDOs). Compared with immortalized cancer cells, PDOs are superior in recapitulating the histologic, genetic, and transcriptomic characteristics of the original tumors. These features make PDOs a promising tool for drug development, drug screening, and precision medicine.5,6 Recently, investigators have used organoids from human bronchial cells and NSCLC to study lung development and cancer phenotypes and to assess in vitro therapeutic vulnerabilities and resistance.7,8,9 Although lung cancer patient-derived xenografts (PDXs) have been shown to predict response to therapy and to help discern mechanisms of drug resistance, LUAD PDX tumors rarely metastasize; thus, such models afford only limited assessment of the biology of metastases. There remains a gap in our knowledge of whether an in vivo PDO platform could potentially help to elucidate the biology of metastases and dissect mechanisms of drug resistance and immune-priming strategies in LUAD."
      ],
      "29625057": [
        "To confirm that PDOs retain the genomic landscapes of their parental tumors, WGS was performed in PDO_6 and PDO_23 sample sets (Table S2), including (1) PDOs with short-term (early, <2 months) and long-term (late, >6 months) culturing, (2) their parental tumors, and (3) their matched adjacent noncancerous tissues. Comparisons of variant allele fractions (Figure 1E), the distributional profile of single-nucleotide variants (SNVs) (Figure 1F), and junction copy-number14 changes (Figure S2C) showed strong concordances between PDOs and their parental tumors. RNA-seq revealed that the transcriptomic profile of the PDO is highly correlated with that of its parental tumor (Figure 1G). Additional gene set enrichment analyses identified a signature of genes distinctly expressed in PDOs, compared with their parental tumors, including negative enrichment for gene sets corresponding to cell adhesion and extracellular matrix-receptor interaction and positive enrichment for gene sets corresponding to cell cycle and multiple metabolic-related pathways (Figures S2D\u2013S2E). These differences may be related to different microenvironments between PDOs in culture and their parental tumors.15 Collectively, these data demonstrate that our PDO system faithfully recapitulates and maintains the histologic, genomic, and transcriptomic profiles present in parental tumors."
      ],
      "32025007": [
        "To obtain the contributions of the 67 COSMIC single-base substitution signatures (release 3; https://cancer.sanger.ac.uk/cosmic/signatures/SBS/),58 \u201cdeconstructSigs\u201d was used with the high-quality somatic SNV calls as input.59"
      ],
      "32791233": [
        "SOL\u2014and micropapillary (MIP)\u2014predominant histologic subtypes are categorized as high architecture grades of LUAD and are associated with poor prognosis; SOL subtype is strongly associated with the development of distant metastatic disease.38,39 Interestingly, compared with the 100% success rate for generation of PDOs from SOL-predominant primary tumors, no PDOs were generated from MIP-predominant tumors (Figure 1B). This may be related to the very small sample size (n = 3) of MIP-predominant tumors. In addition, we found that MIP-predominant tumors have fewer alterations in the oncogenic Hippo and TP53 pathways and fewer mutations in the TP53 gene, compared with SOL-predominant tumors, in our LUAD cohort.40 Both of these pathways confer stemness in cancer cells41,42 and may contribute to the success of PDO generation."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 6,
    "extraction_method": "jats_xml",
    "extraction_time": 3.0897350311279297,
    "data_pmids_checked": 6,
    "paper_id": "39413736",
    "extraction_date": "2025-12-19T20:45:15.532409",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39413736.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39533328": {
    "paper_id": "39533328",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Addi-\ntumorigenesis in a clinical cohort, we next extracted data tionally, we observed higher cell death after ERK or\nfrom cBioPortal to examine relative differences between AKT inhibition in KRASG12C or KRASG12D cells, respec-\nK RASG12C and KRASG12D NSCLC (Supplementary Fig- tively (Fig",
      "profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:45:16.694362",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39533328.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 14.369143962860107,
      "cbioportal_papers": 0.00034308433532714844,
      "pdf_extraction_pass2": 11.954941034317017,
      "cbioportal_papers_pass2": 0.0003399848937988281,
      "used_full_extraction": true,
      "pdf_extraction": 26.324084997177124,
      "platform_mentions": 0.0033521652221679688,
      "data_citations": 0.0003490447998046875,
      "num_data_pmids_checked": 3
    }
  },
  "39409874": {
    "cbioportal_paper_citations": [
      "The frequencies of occurrence (>2%) of amplifications and deletions of the genes of the NanoString CNV panel were observed in a cohort of patients with ovary serous carcinoma (568 samples) [65], where 23 and 4 genes, respectively, accounted for 31% of all genes in the panel (27 of 87 genes). Thus, it can be concluded that this NanoString CNV panel is suitable for detecting CNVs in ovarian cancer samples. Our study\u2019s statistical analysis revealed that seven target genes (MET, HMGA2, KDR, C8orf4 (TCIM), PAX9, CDK6, CCND2) (a gene panel No. 2) exhibited the highest consistency between the results of CNV detection by different methods (DNA microarray, NanoString CNV, and ddPCR analysis). The biological features of these genes as well as their potential prognostic value in ovarian cancer are discussed in Appendix F, which includes a text subsection, Table A8, Figure A1, and the following literature references [43,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87]."
    ],
    "cbioportal_platform_mentions": [
      "In tumor samples, the CNVs of other genes were irregularly distributed. For the TCGA serous cystadenocarcinoma ovarian dataset (n=617), cBioPortal data show that 5.9% of CDKN2A genes and 5.7% of PTEN genes have copy number variations. Given that the mutant TP53 gene (which codes for the tumor suppressor p53) is found in about 87% of all ovarian cancer samples, it is likely that the CDKN2A and PTEN genes are also changed. For instance, we found that deep deletions of the CDKN2A gene correlate with TP53 mutational signatures and worse survival in breast cancer subjects [60]. Thus, we attempted to search for the potential associations between the most frequent CNVs of CDKN2A, PTEN, CCND2, and PTPRD genes with clinical data (Table A1 and Table A2, Appendix A). For this, a relatively \u2018homogeneous\u2019 subset of nine HGSC samples (SN30, SN32, SN36, SN38, SN44, SN46, SN50, SN54, SN56), having a similar tumor stage, TNM classification (T3N0(1)M0(1)), as well as Ki-67 and p53 IHC-staining patterns (Table A1 and Table A2, Appendix A), were analyzed. Notably, deletions of the CDKN2A and PTEN genes were observed in 3 patients (SN38, SN50, and SN54) with late stage cancer (IVb) and metastasis (T3NxM1), which may warrant further investigation. Apparently, the small sample size did not allow us to find more associations between the number of detected CNVs of target genes and other clinical data; for example, the number of CNVs in stage IIIc ovarian cancer cases ranged from 0 to 4. This was similar to the number of CNVs seen in samples from stages Ia and IIa (Figure 4), which were 2 and 3. Further, there was no correlation (Spearman\u2019s rank correlation coefficient = 0.16, p-value > 0.1) between the total number of CNVs of all nine genes under consideration (Figure 4) and the ages of 12 subjects with HGSC."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2377300262451172,
    "data_pmids_checked": 0,
    "paper_id": "39409874",
    "extraction_date": "2025-12-19T20:45:16.933389",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39409874.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39411658": {
    "cbioportal_paper_citations": [
      "Alteration data of tumor samples were downloaded from the Tumor Cancer Genome Atlas (TCGA). TCGA samples for which copy number alteration, mutation and gene expression data were all available, or for which only expression and copy number alteration data could be retrieved, were included, resulting in 6956 and 9327 samples, respectively, across 31 cancer types (Supplementary Table S1). Data for 15 m6A factors were obtained for these samples using the cBioPortal R package, cgdsr (v1.3.0) (45,46). GISTIC 2.0 (47) profiles were selected for copy number alterations, rna_seq_v2_mrna_median_Zscores profiles were chosen for gene expression, and all the mutations were considered. In addition, data were retrieved for the genes annotated as oncogenes and/or tumor suppressors in OncoKB (541 cancer drivers, https://www.oncokb.org/). For TCGA samples, tumor stages, grades, and molecular subtypes were retrieved from the cgdsr and TCGAbiolinks R packages (v2.12.6) (48). Tumor samples mRNA expression levels (TPM transcript per kilobase million) were obtained from Xena RSEM Toil Recomputed data (https://xena.ucsc.edu) (49).",
      "To investigate the pan-cancer profile of the factors comprising the m6A machinery, we selected the core 15 m6A writer, eraser and reader genes (writers: METTL3, METTL14, VIRMA, WTAP, ZC3H13, HAKAI and RBM15/15B; readers: YTHDC1/2, YTHDF1/2/3; erasers: ALKBH5 and FTO) and analyzed their variation in terms of mutations, differential expressions, and copy number alterations (CNAs) in 6956 TGCA cancer samples belonging to 31 tumor types (Figure 1A, Supplementary Table S1). We assumed differential expression significant only for absolute z-scores >2, and retained CNAs only at high gene copy levels, which are supposed to represent amplifications and homozygous deletions (45,46). Indeed, the pattern of CNAs at low gene copy levels, presumed to represent gains and heterozygous deletions, was rather widespread (Supplementary Figure S1A) (63). The majority of samples (70.6%) scored to be altered for either mutation, expression, or CNA in at least one of the selected m6A core factors, with altered expression (63.9%) being predominant (Figure 1B). Altered samples belong to all tumor types considered, although to different extents (Supplementary Figure S1B, Supplementary Tables S2\u2013S4), and the majority are altered for only one of the 15 m6A core factors (42.8%) (Supplementary Figure S1C). While writers and readers are more altered than erasers, accounting for about three times as many samples with at least one altered gene (Figure 1C), the average normalized frequency of alteration is the same (10%, 12% and 9%, respectively). Looking at the individual factors, the percentage of alterations ranges from 21.4% for VIRMA to 6.1% for RBM15 (Figure 1C, Supplementary Tables S2\u2013S4)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "32025007": [
        "We next focused on the individual occurrences of mutations, differential expression and CNAs, to gain insight into their functional involvement in tumorigenesis. The total number of point mutations in the 15 m6A core factor genes was only 758, predominantly missense (76%), with an average mutation frequency of 0.7%, lower than in the 541 cancer driver genes (1.1%) (Supplementary Figure S1D). Moreover, by investigating the mutation landscape of the 15 m6A factors using available classifications of cancer driver genes, we found that none were classified as cancer drivers or weak drivers (64\u201367), apart from RBM15, which emerged as a driver specifically in head and neck squamous cell carcinoma (HNSC) and lung adenocarcinoma (LUAD) (66). RBM15 has been reported as a potential cancer gene also for its involvement in the RBM15-MKL1 fusion in AML (68,69). Analysis of the differential expression of the 15 m6A core factors (9327 TCGA samples, Figure 1A) revealed that most factors (11/15) are more frequently upregulated than downregulated (paired Wilcoxon test P-value = 0.003) (Figure 1D). Notably, the core factors show a higher mean upregulation when compared to 15 randomly selected genes and to 15 randomly selected oncogenes (1000 iterations bootstrap, P-value < 10\u22123 and P-value = 0.005, respectively; n = 286 oncogenes). VIRMA, YTHDF1 and YTHDF3 are the most commonly upregulated genes, representing 18%, 19% and 13% of the altered tumor samples, respectively, and those with the highest upregulated-to-downregulated ratio, together with RBM15 and HAKAI. In contrast, YTHDF2 is the most frequently downregulated factor (5% of tumor samples; Figure 1D). Upregulation is also predominant at the level of single tumor types (19/31 tumors examined, paired Wilcox test adjusted P-value < 0.05), with VIRMA, YTHDF1, and YTHDF3 remaining the most upregulated genes (Figure 1D). Indeed, VIRMA, YTHDF1 and YTHDF3 are upregulated in at least 10% of samples in 21, 19 and 19 tumors, respectively, out of 31 tumor types. Finally, by analyzing the CNAs of the 15 m6A factors, we observed no significant difference between amplification and deep deletion frequencies at the pan-cancer and single tumor type level (pan-cancer: paired Wilcoxon test P-value = 0.5; 31/31 tumors examined: paired Wilcoxon test adjusted P-value > 0.05) (Figure 1E). Among all, VIRMA, YTHDF1, and YTHDF3 are the most frequently amplified genes, with 6%, 3% and 3% of tumor samples altered, respectively (Figure 1E)."
      ],
      "29625055": [
        "TCGA survival outcome data were obtained from the standardized datasets published by Liu et al. (60). The progression-free interval (PFI) endpoint was used in the pan-cancer analysis and samples without PFI survival time reported were filtered out. For single tumor survival analysis, the overall survival (OS) was used when more endpoint possibilities were available; otherwise, suggested endpoints between PFI and disease-specific survival (DSS) were applied. The PCPG samples were removed as no suitable endpoints were available, as suggested by Liu et al. (60)."
      ],
      "26824661": [
        "Since this type of genomic imbalance is characteristic of chromosomal instability (CIN), a well-known and transversal tumor phenotype, we assessed the prevalence of this feature among the tumor samples enriched for dysregulated YTHDF1-3 and VIRMA expression. As expected, we observed a high frequency of samples harboring this specific phenotype (Figure 3B). For example, the majority of COAD/READ and STAD altered samples belong to the CIN subtype, characterized by frequent amplification events in 20q (YTHDF1) and 8q (YTHDF3/VIRMA) (70\u201373). Similarly, 8q amplification is common in OV, UCS, LIHC, and UVM altered samples, the latter mostly belonging to subtypes 3 and 4, characterized by 8q whole-arm gain (74\u201377). Although the 8q amplification event has not been yet reported in TGCT, the altered samples belong to the seminoma subtype, where a positive correlation of VIRMA and YTHDF3 expression has been found (78,79). Finally, 1p (YTHDF2) loss is a feature of both LGG and PCPG, with LGG altered samples belonging to the IDHmut-codel subtype (characterized by IDH gene mutation and 1p/19q co-deletion (80)), and PCPG altered samples belonging to the kinase signaling subtype (81)."
      ],
      "28162975": [
        "Since this type of genomic imbalance is characteristic of chromosomal instability (CIN), a well-known and transversal tumor phenotype, we assessed the prevalence of this feature among the tumor samples enriched for dysregulated YTHDF1-3 and VIRMA expression. As expected, we observed a high frequency of samples harboring this specific phenotype (Figure 3B). For example, the majority of COAD/READ and STAD altered samples belong to the CIN subtype, characterized by frequent amplification events in 20q (YTHDF1) and 8q (YTHDF3/VIRMA) (70\u201373). Similarly, 8q amplification is common in OV, UCS, LIHC, and UVM altered samples, the latter mostly belonging to subtypes 3 and 4, characterized by 8q whole-arm gain (74\u201377). Although the 8q amplification event has not been yet reported in TGCT, the altered samples belong to the seminoma subtype, where a positive correlation of VIRMA and YTHDF3 expression has been found (78,79). Finally, 1p (YTHDF2) loss is a feature of both LGG and PCPG, with LGG altered samples belonging to the IDHmut-codel subtype (characterized by IDH gene mutation and 1p/19q co-deletion (80)), and PCPG altered samples belonging to the kinase signaling subtype (81)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 2.0406908988952637,
    "data_pmids_checked": 5,
    "paper_id": "39411658",
    "extraction_date": "2025-12-19T20:45:17.573231",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39411658.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39408773": {
    "cbioportal_paper_citations": [
      "The gene expression profiles of EC were acquired from the Genomic Data Commons (GDC) Portal, version 32, accessible at https://portal.gdc.cancer.gov/, (accessed on 1 March 2024) using the R package TCGAbiolinks [38]. Simultaneously, structured clinical data were obtained from cBioPortal [39]. The gene expression data were downloaded in raw counts format, and these counts were generated through the STAR pipeline [40]. Sample inclusion criteria encompassed samples that contained pertinent information regarding subtype, demographic, and survival details. To identify key genes associated with the Sonic Hedgehog pathway, we extracted relevant data from the Kyoto Encyclopedia of Genes and Genomes (KEGG) [41]. The extracted genes relevant to SHH signaling included IHH, DHH, SHH GLI1, GLI2, GLI3, SMO, SUFU, and PTCH1."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "23636398": [
        "Endometrial cancer (EC) is one of the most common malignancies of female genitalia and second, after cervical cancer, worldwide [1]. Rising EC incidence and mortality rate are major concerns for women, particularly in countries experiencing socioeconomic transitions [2]. The majority of EC patients are elderly women (postmenopausal), particularly those who are in their sixth and seventh decades of life [3]. For over three decades, EC has typically been distinguished into type I and type II [4]. These two classifications differ in terms of epidemiology, histology, prognosis, and treatment [5,6]. Type I ECs are more prevalent, accounting for 80% of diagnosed EC cases, offer favourable prognosis with a 5-year overall survival (OS) rate of 81.3%, and have a recurrence risk of less than 20% [6,7]. Type II ECs are majorly diagnosed at a relatively advanced stage, associated with intermediate-to-poor prognosis with a 5-year OS rate of 55%, and have a high recurrence risk. In recent years, the rapid growth of array- and sequencing-based technologies, coupled with significant advancements in bioinformatics, has revolutionized the landscape of medical research [8]. These developments have enabled researchers to explore the intricacies of the human genome and unlock invaluable insights for understanding and treating complex diseases [9,10,11,12,13,14]. Based on array- and sequencing-based technology, EC has been further classified into four distinct molecular-based subgroups: (i) polymerase \u03b5 (POLE) ultra-mutated, (ii) microsatellite instability (MSI) hyper-mutated, (iii) copy-number low (CN LOW), and (iv) copy-number high (CN HIGH) [15,16]. Among these subgroups, POLE mutated shows the best prognosis, followed by MSI, copy-number low, and copy-number high, which has the poorest prognosis [17]. The recent molecular and genomic classification of EC has significantly improved its prognosis and led to the approval of new systemic therapies, as well as the development of precision medicine, resulting in therapeutic advancements and continual adjustments in EC patients\u2019 management. Despite these advances, poorer outcomes are still associated with high-grade, metastatic, and recurrent EC."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.7425351142883301,
    "data_pmids_checked": 1,
    "paper_id": "39408773",
    "extraction_date": "2025-12-19T20:45:17.676009",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39408773.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39466792": {
    "paper_id": "39466792",
    "cbioportal_paper_citations": [
      "CeramiE,GaoJ,DogrusozU,GrossBE,SumerSO,AksoyBA,etal.ThecBiocancergenomicsportal:\nanopenplatformforexploringmultidimensionalcancergenomicsdata.CancerDiscov.2012; 2:401\u2013\n404.https://doi.org/10.1158/2159-8290.CD-12-0095PMID:22588877\n36",
      "org/10.1126/scisignal.2004088PMID:23550210\n37"
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:45:19.190085",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39466792.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 14.652570009231567,
      "cbioportal_papers": 0.001912832260131836,
      "used_full_extraction": false,
      "pdf_extraction": 14.652570009231567,
      "platform_mentions": 0.0015561580657958984,
      "data_citations": 7.152557373046875e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39408636": {
    "cbioportal_paper_citations": [
      "In light of the association between ALDH1B1-mediated lung tumor formation, chemoresistance and CSC phenotype, our study focused on elucidating the contribution of ALDH1B1 to the pathophysiological mechanisms underlying human lung adenocarcinoma. For this purpose, we employed a gene overexpression strategy utilizing the human lung adenocarcinoma (A549) cell line and data analysis of lung adenocarcinoma clinical samples [11,12]. This enabled us to examine the impact of ALDH1B1 overexpression on various aspects, including (i) cell parameters of morphology, proliferation and colony formation efficiency, (ii) chemoresistance, (iii) gene expression profile of EMT-related markers and CSC signaling pathway-associated molecules and (iv) cell migration. Our research contributes to our understanding of the role of ALDH1B1 in malignancies, highlighting its potential as an important biomarker in human lung adenocarcinoma.",
      "Clinical data from 507 lung adenocarcinoma patient samples were obtained from The Cancer Genome Atlas (TCGA) database via cBioportal.org (accessed on 1 February 2022) [11,12]. These data were utilized to investigate the correlation between ALDH1B1 and genes associated with CSC-related pathways. TCGA provides comprehensive data on cancer tissues, encompassing RNA-seq, mass spectroscopy, miRNA mutation, methylation and other types of data across 33 tumor types. The analysis focused on RNA-seq data from 507 lung cancer clinical samples and the Spearman\u2019s correlation analysis was conducted on all available log2(x + 1) transformed RNA-seq data. Correlation heat maps were generated using R language and the corrplot package."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.6165640354156494,
    "data_pmids_checked": 0,
    "paper_id": "39408636",
    "extraction_date": "2025-12-19T20:45:19.227413",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39408636.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39402558": {
    "cbioportal_paper_citations": [
      "Integrated atlases for select species, tissues, or diseases related to allergies are highly useful as consensus reference maps and for enhancing downstream analyses. For instance, in oncology research, interactive databases such as cBioPortal [16], GEPIA2 [17], OncoDB [18], and UCSCXenaShiny [19] have become invaluable tools for analyzing cancer multiomic data. Since 2013, approximately 16,000 publications have cited these resources, leveraging their capabilities to validate research findings. These web applications facilitate a wide range of analyses, from routine transcriptomic data analysis\u2014including differential gene expression, pathway enrichment, correlation, and Kaplan\u2013Meier survival analyses\u2014to more advanced techniques such as single-cell RNA sequencing, methylomic, and genomic data analyses. Moreover, these platforms excel in delivering high-quality visualizations, making them essential for both basic and translational cancer research. However, in the realm of allergic diseases, a comparable comprehensive platform is currently absent. Therefore, there is an urgent imperative to develop a robust platform dedicated to exploring gene-disease associations specifically tailored for immune alterations in allergic disease."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1441941261291504,
    "data_pmids_checked": 0,
    "paper_id": "39402558",
    "extraction_date": "2025-12-19T20:45:19.310426",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39402558.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39401325": {
    "cbioportal_paper_citations": [
      "At least \u226550 ng DNA was extracted from 40 \u00b5m of formalin-fixed, paraffin-embedded (FFPE) sections. FoundationOne CDx hybrid capture-based sequencing using adaptor ligation-based libraries was utilized, with mean coverage depth >600\u00d7. Base substitutions, insertions, deletions (short variants; SV), rearrangements, and copy number changes were assessed.26-28 To help visualize the sequencing data results, an oncoprint plot was generated with the online tools of the cbio portal as described by Gao et al and Cerami et al.29,30 Tumor mutational burden was determined on 0.8-1.2 Mb of sequenced DNA using a mutation burden estimation algorithm that, based on the genomic alterations detected.31 Assessment of microsatellite instability was performed from DNA sequencing, as previously described.32 The next-generation sequencing-based \u201cmicrosatellite instability score\u201d was translated into microsatellite instability high, microsatellite instability intermediate, or microsatellite stable by unsupervised clustering of specimens for which microsatellite instability status was previously assessed via gold standard methods.32 PD-L1 expression was determined on subsets of the tumors using the DAKO 22C3 assay with low positive tumor cell scoring defined as 1%-49% staining and high positive tumor cell scoring defined as \u226550% staining."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1724841594696045,
    "data_pmids_checked": 0,
    "paper_id": "39401325",
    "extraction_date": "2025-12-19T20:45:19.369578",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39401325.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39394443": {
    "cbioportal_paper_citations": [
      "Molecular docking was performed using the Schrodinger Glide software (Schr\u00f6dinger Release 2024-3: Glide, Schr\u00f6dinger, LLC, New York, NY, 2024.) Molecular dynamics was performed by Schrodinger Desmond software (Schr\u00f6dinger Release 2024-3: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2024. Maestro-Desmond Interoperability Tools, Schr\u00f6dinger, New York, NY, 2024.) Network construction was done through Cytoscape_v3.9.1. The Human Protein Atlas (HPA) database (The Human Protein Atlas) was used to investigate the association between the key gene expression and overall survival of BC patients18. cBioportal (cBioPortal for Cancer Genomics) was used to assess the mutation frequency of BC genes in patients19,20.",
      "Further, the Human Protein Atlas was explored to check the 5-year survival of Breast cancer patients with varied expression of the key genes- ESR1, CYP19A1, and EGFR18. The five-year survival rate for patients with high CYP19A1 expression was 76%, compared to 83% for those with low expression, with a p-value of 0.094. Similarly, for ESR1, the survival rates were 80% and 82% respectively, with a p-value of 0.083. For EGFR, the rates were 85% and 80% with a p-value of 0.026. Interestingly, a positive correlation in their expression was observed with poor survival of BC patients (Fig. 5c\u2013e). However, EGFR showed an opposite trend, which could be because of its conflicting role in BC47. Additionally, we checked the mutation frequency of the target gene in BC patients using the program and tools made available online at cBioportal (cBioPortal for Cancer Genomics)19,20. Interestingly, out of 135 putative targets, 134 genes were found mutated in breast cancer patients (Fig. 5f). Further, the mutation frequency of key genes was identified in breast cancer patients, and as shown in Table 3, 7.3% mutation frequency was observed for ESR1, 1.5% for EGFR and 0.30% for CYP19A1. Overall, the published manuscripts43\u201346 and database results highlight the critical role of these genes in breast cancer progression and prognosis, underscoring the importance of developing therapeutic strategies that target them.",
      "Additionally, cBioportal was explored and out of 135 putative targets identified, 134 were found to be prone to a mutation in BC patients, where 7.3% mutation frequency was observed for ESR1, 1.5% for EGFR, and 0.30% for CYP19A1. Also, the tendency of mutations to co-occur was observed for ESR1-EGFR (pvalue = 0.041), ESR1-CYP19A1 (pvalue = 0.155), and most significantly for EGFR-CYP19A1 (pvalue = 0.007)19,20. All these results implicate the important role of putative targets of marker compounds present in Krishnadi Churna in BC."
    ],
    "cbioportal_platform_mentions": [
      "Fig. 5(a) Venn Diagram depicting the key genes identified among the putative targets of herbal phytoconstituents. (b) Identified Hub gene network of herbal phytoconstituents for different algorithms of CytoHubba. Survival Plot with high and low expression of (c) ESR1, (d) CYP19A1, (e) EGFR in BC patients from Human Protein Atlas online database. (f) Venn Diagram depicting mutation status of target genes in BC from cBioportal.",
      "(a) Venn Diagram depicting the key genes identified among the putative targets of herbal phytoconstituents. (b) Identified Hub gene network of herbal phytoconstituents for different algorithms of CytoHubba. Survival Plot with high and low expression of (c) ESR1, (d) CYP19A1, (e) EGFR in BC patients from Human Protein Atlas online database. (f) Venn Diagram depicting mutation status of target genes in BC from cBioportal."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1511077880859375,
    "data_pmids_checked": 0,
    "paper_id": "39394443",
    "extraction_date": "2025-12-19T20:45:19.461626",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39394443.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39392932": {
    "paper_id": "39392932",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Three tumours were characterized by a well-circum-\noPortal (http://www.cbioportal.org/oncoprinter) was used scribed nodular growth pattern",
      "Atypical intradermal smooth muscle 27 Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of com-\nneoplasms: clinicopathologic analysis of 84 cases and a reap- plex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:45:47.331555",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39392932.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 13.837897777557373,
      "cbioportal_papers": 0.00022292137145996094,
      "pdf_extraction_pass2": 14.120594024658203,
      "cbioportal_papers_pass2": 0.00023818016052246094,
      "used_full_extraction": true,
      "pdf_extraction": 27.958491802215576,
      "platform_mentions": 0.002613067626953125,
      "data_citations": 0.0002338886260986328,
      "num_data_pmids_checked": 3
    }
  },
  "39421181": {
    "paper_id": "39421181",
    "cbioportal_paper_citations": [
      "Gao J, Aksoy BA, and Dogrusoz U, et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal\nSci Signal 6(269) pl1 https://doi.org/10.1126/scisignal.2004088 PMID: 23550210 PMCID: 4160307\n16"
    ],
    "cbioportal_platform_mentions": [
      "The HER2 mutation lollipop diagram was generated using the MutationMapper visualiza-\ntion tools available at the cBioPortal site (https://www.cbioportal.org/) [15]",
      "(Continued)\nRegion Histology type Sample size HER2 mutations HER2 amplification References\nPrevalence Detection Prevalence Detection\nmethod\u2020 method\nGreece NSCLC 502 1.8% all NGS all 1% RT-PCR [62]\n2% adenocarcinoma\nSwitzerland Adenocarcinoma 469 1.9% NGS all - [63]\nItaly Adenocarcinoma 537 3% RT-PCR or NGS 1.9% FISH [64]\nNetherlands NSCLC 3,342 1.2% NGS cohort ex - [65]\n18\u201320\nInternational NSCLC 1,934 4.3% NGS all - [66]\ncBioportal\nBrazil NSCLC 513 4.9% alterations NGS all - [67]\nBrazil NSCLC 722 0.8% NGS (ex 20 ins - [68]\nonly)\nGermany NSCLC 378 - - 2% FISH [69]\nGermany NSCLC 526 - - 3.2% NSCLC, FISH [70]\n6.3% in\nadenocarcinoma\nFrance NSCLC 250 - - 9% FISH [71]\nJapan NSCLC 270 - - 3% NSCLC FISH [72]\nKorea Adenocarcinoma 321 - - 14.3% SISH [73]\nChina NSCLC 7,643 - - 2.8% NGS [74]\nRussia NSCLC 218 - - 6% NSCLC FISH [75]\nPoland NSCLC 239 - - 1% MLPA [76]\n\u2020Note: Detection method specified as PCR utilised PCR for amplification of nucleic acid and subsequent sequencing using conventional techniques,\ne.g. Sanger sequencing\namp: amplified; DISH: dual in situ hybridisation; ex: exon; FISH: fluorescent in situ hybridisation; HER2: human epidermal growth factor receptor 2;\nins: insertion; LCC: large cell carcinoma; MALDI-TOF: matrix-assisted laser desorption ionisation-time of flight; MLPA: multiplex ligation-dependent\nprobe amplification; mut: mutation; N/A: not available; NGS: next-generation sequencing; NSCLC: non-small cell lung cancer; PCR: polymerase\nchain reaction; RT-PCR: reverse transcription polymerase chain reaction; SCC: squamous cell carcinoma; SISH: silver in situ hybridisation; USA:\nUnited States of America\nReferences\n1"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:45:48.159841",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39421181.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 17.08267092704773,
      "cbioportal_papers": 0.00029730796813964844,
      "pdf_extraction_pass2": 20.57923197746277,
      "cbioportal_papers_pass2": 0.008707046508789062,
      "used_full_extraction": true,
      "pdf_extraction": 37.6619029045105,
      "platform_mentions": 0.02783799171447754,
      "data_citations": 1.3113021850585938e-05,
      "num_data_pmids_checked": 0
    }
  },
  "39385035": {
    "cbioportal_paper_citations": [
      "Paired WES, RNA-seq and clinical data from patients with LUAD from the TCGA PanCancer Atlas cohort were downloaded from the cBioPortal for Cancer Genomics repository59. Immune cell subsets were estimated using aggregated data from TIMER2.060, which provides standardized output from six different immune estimation methods. Neutrophil, macrophage and CD8+ T cell signature data were assessed with MCPCounter to obtain ratios per sample. QuanTIseq was used to compare T cell and nonregulatory CD4 levels across mutation groups. Overall immune infiltrate (ImmuneScore) and TH1 levels were estimated as gene signatures using XCell57. Comparisons across groups were performed using the Kruskal\u2013Wallis H test. Analyses were performed using R v.4.0.3."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "25765070": [
        "To further investigate the mechanisms that might underlie the resistance of STK11MUT and KEAP1MUT tumours to PD-(L)1i, we investigated the immune and genomic profiles of 8,592 patients with lung adenocarcinoma (LUAD) with these and other alterations (Foundation Medicine (FMI) cohort). STK11 and/or KEAP1 mutations were observed in 25.2% and 32.4% of the overall LUAD and KRAS-mutant LUAD populations, respectively (Fig. 1b). For other subsets of NSCLC that are poorly responsive to PD-(L)1i, such as tumours containing EGFR mutations or ALK fusions, a lower TMB and/or lower levels of PD-L1 are thought to contribute to their immunologically cold phenotype22\u201324. A high TMB, by contrast, has been associated with improved responsiveness to both PD-(L)1i and dual ICB25,26. We therefore investigated whether the lack of PD-(L)1i response could be due to a low TMB and/or low levels of PD-L1. Notably, we observed that, compared with tumours that were wild type for both genes (median TMB 5.22 mutations per Mb), tumours with mutations in STK11 or KEAP1 had a higher TMB. This was particularly notable for KEAP1MUT tumours (median TMB 13.05 mutations per Mb) (Fig. 1c), especially in the absence of concurrent KRAS mutations (Extended Data Table 2). Therefore, lower TMB does not seem to account for the reduced responsiveness of STK11MUT and KEAP1MUT NSCLC tumours to immunotherapy."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.8048179149627686,
    "data_pmids_checked": 1,
    "paper_id": "39385035",
    "extraction_date": "2025-12-19T20:45:48.226557",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39385035.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39379982": {
    "cbioportal_paper_citations": [
      "As our next step, we aimed to investigate whether HRD-related morphological features within a specific cancer type are able to predict HRD status in another cancer type. Thus, providing insight as to whether a shared set of morphological features across diverse cancer types could potentially allow a pan-cancer pathology-based prediction system for HRD status. To test this hypothesis, we applied our trained HRD classifiers in a cross-cancer experimental design. The HRD classification model was trained with the TCGA-BRCA cohort and deployed on all other cohorts obtained from the TCGA and CPTAC datasets. Surprisingly, the BRCA-based model was able to significantly predict genomic HRD from non-BRCA tissue in UCEC, PRAD, CRC, and LUAD. For three of those cohorts, the external deployment of a BRCA-based model resulted in higher prediction AUROCs than did the respective internal validation experiments, with AUROCs of 0.70 \u00b1 0.02, p < 0.001 in TCGA-UCEC; 0.84 \u00b1 0.07, p = 0.004 in TCGA-PRAD, 0.65 \u00b1 0.03, p = 0.04 in TCGA-CRC and 0.87 \u00b1 0.1, p = 0.05 in CPTAC-UCEC, respectively (Fig. 2B). For LUAD and OV, the AUROCs remained with 0.62 \u00b1 0.03 for TCGA-LUAD, 0.66 \u00b1 0.06 for CPTAC-LUAD and 0.61 \u00b1 0.03 in TCGA-OV in a similar range to the internal validation results (Additional File 4: Fig. 3A\u2013L). Together, these data show that a classifier trained on BRCA is able to predict HRD status from histology in other tumor types, suggesting a shared \u201cHRD morphology.\u201dFig. 3Molecular characterization of The Cancer Genome Atlas breast cancer (TCGA-BRCA) cohort. A Distribution of breast cancer subtypes for the homologous recombination deficiency high (HRD-H) and low (HRD-L) ground truth subgroups. B Distribution of the breast cancer subtypes for the HRD-H and HRD-L deep learning (DL) predicted subgroups. C Alteration frequency for several genes of the HRD-H and HRD-L ground truth subgroups. D Alteration frequency for several genes of the HRD-H and HRD-L within cohort internal results prediction subgroups. E Grouped boxplots comparing the homologous recombination deficiency high (HRD-H) prediction scores with the mutational status (mutated = MUT, wildtype = WT) for the somatic and germline alterations of the BRCA1/2 genes. The central line represents the median value, while the box ranges between the first and third quartiles (IQR), and the whiskers extend to the lowest and highest values within 1.5 times the IQR. The y-axis represents the deep learning (DL) HRD-H prediction values. An independent t-test was performed to calculate the p-values (*p > 0.05; **p \u2264 0.05; ***p \u2264 0.01). This figure was created using https://www.cbioportal.org/ [59, 60]",
      "Molecular characterization of The Cancer Genome Atlas breast cancer (TCGA-BRCA) cohort. A Distribution of breast cancer subtypes for the homologous recombination deficiency high (HRD-H) and low (HRD-L) ground truth subgroups. B Distribution of the breast cancer subtypes for the HRD-H and HRD-L deep learning (DL) predicted subgroups. C Alteration frequency for several genes of the HRD-H and HRD-L ground truth subgroups. D Alteration frequency for several genes of the HRD-H and HRD-L within cohort internal results prediction subgroups. E Grouped boxplots comparing the homologous recombination deficiency high (HRD-H) prediction scores with the mutational status (mutated = MUT, wildtype = WT) for the somatic and germline alterations of the BRCA1/2 genes. The central line represents the median value, while the box ranges between the first and third quartiles (IQR), and the whiskers extend to the lowest and highest values within 1.5 times the IQR. The y-axis represents the deep learning (DL) HRD-H prediction values. An independent t-test was performed to calculate the p-values (*p > 0.05; **p \u2264 0.05; ***p \u2264 0.01). This figure was created using https://www.cbioportal.org/ [59, 60]"
    ],
    "cbioportal_platform_mentions": [
      "Initially, data from 4735 patients for nine tumor types within The Cancer Genome Atlas (TCGA), and 474 patients from four tumor types from the Clinical Proteomic Tumor Analysis Consortium (CPTAC; Fig. 1C) were retrieved through https://www.cbioportal.org/. The tumor types included in this study were breast cancer (TCGA-BRCA, n = 1058), colorectal cancer (TCGA-CRC, n = 580), hepatocellular carcinoma (TCGA-LIHC, n = 364), lung adenocarcinoma (TCGA-LUAD, n = 536, CPTAC-LUAD, n = 111), lung squamous cell carcinoma (TCGA-LUSC, n = 497; CPTAC-LUSC, n = 109), ovarian serous cystadenocarcinoma (TCGA-OV, n = 520), pancreatic adenocarcinoma (TCGA-PAAD, n = 177; CPTAC-PAAD, n = 153), prostate adenocarcinoma (TCGA-PRAD, n = 488), and uterine corpus endometrial carcinoma (TCGA-UCEC, n = 515; CPTAC-UCEC, n = 101; Additional File 1: Fig. 1A, B). Image data and corresponding clinical data were available in TCGA-BRCA for n = 1005, TCGA-CRC for n = 496, TCGA-LIHC for n = 348, TCGA-LUAD for n = 460, CPTAC-LUAD for n = 106, TCGA-LUSC for n = 451, CPTAC-LUSC for n = 108, TCGA-OV for = 90, TCGA-PAAD for n = 173, CPTAC-PAAD for n = 139, TCGA-PRAD for n = 391, TCGA-UCEC for n = 467, and CPTAC-UCEC for n = 99, thus resulting in a total n = 4333 (TCGA n = 3881, CPTAC n = 452, Fig. 1C, Additional File 1: Fig. 1A, B) patients. Data from TCGA-BRCA corresponding to Riaz et al.\u2019s study [42], was retrieved for additional experiments on BRCA1/2 mutational status. Estrogen receptor data for the subgroup analysis were available only for n = 661 patients in the TCGA-BRCA cohort.",
      "In our study, we performed three main experiments (Fig. 1B). To assess the baseline predictability of HRD from routine histology, we first trained a classifier using five-fold-cross-validation within each of the nine tumor entities mentioned above in the TCGA cohorts (internal validation). This was achieved by randomly splitting each cohort at the patient level, creating non-overlapping training and test sets for model training. The splitting ratio was 60:20:20 for the training, validation, and test splits in all the experiments. Internal validation was performed in a fivefold cross-validated design, so that no data leakage from the training to the test set occurred. This process was repeated individually for each cancer type in the TCGA cohorts. A weighted cross-entropy loss function was used to assist the model with the imbalanced dataset. Secondly, we deployed the five-fold-cross models trained in the first experiments on the same tumor type from the CPTAC cohorts as an external validation. By utilizing this approach, we circumvented any potential claims of selecting the model with the highest AUROC in the external validation. Finally, we trained an HRD classifier on the TCGA-BRCA cohort, which had the highest number of patients, and deployed it on all other TCGA cohorts (CRC, LIHC, LUAD, LUSC, PRAD, PAAD, OV, UCEC) as well as on all CPTAC cohorts (LUAD, LUSC, PAAD, UCEC). In our study, we aimed to evaluate the performance of the models using the AUROC, which is commonly used for assessing the accuracy of binary classification tasks. Our primary statistical endpoint was the AUROC \u00b1 95% confidence interval (CI) and Area under the precision-recall curve (AUPRC; Additional File 2: Table 1). To further assess the performance of each model, we used a two-sided t-test to compare the patient-level prediction scores between the HRD-H and HRD-L patient groups as defined by the ground truth and reported the p-values, assuming a significance level of < 0.05 as statistically significant, without correction for multiple testing (Additional File 2: Table 1). As a final step to obtain a more in-depth understanding of the TCGA-BRCA cohort, we uploaded our custom HRD-H and HRD-L ground truths and predicted subgroups in cBioPortal to examine the characteristics of these patients in the TCGA-BRCA PanCancer Atlas cohorts.",
      "Additional File 1: Figure 1. Homologous recombination deficiency prevalences across the cohorts. (A) Overview of the total patient count (n=573) in the CPTAC cohort before merging the image data with the molecular data and afterward. (B) Overview of the total patient count (n=5,155) in the TCGA cohort before merging the image data with the molecular data and afterward. (C) Distribution of the homologous recombination deficiency high (HRD-H) and low (HRD-L) patient number among the different tumor types of The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC). Abbreviations: BRCA=breast invasive carcinoma; CRC=colorectal cancer; LIHC=liver hepatocellular carcinoma; LUAD=lung adenocarcinoma; LUSC=lung squamous cell carcinoma; OV=ovarian serous cystadenocarcinoma; PAAD=pancreatic adenocarcinoma; PRAD=prostate adenocarcinoma; UCEC=uterine corpus endometrial carcinoma.Additional File 2: Table 1. Raw statistical results. All raw experimental results related to Figure 2, including receiving operating curve (ROC) with 95% confidence interval (CI), Precision-Recall Curve (PRC) with 95% confidence interval (CI), p-values and Homologous recombination deficiency (HRD) high (HRD-H) and HRD-low (HRD-L) patient numbers based on the ground truth, for internal 5-fold cross-validation on The Cancer Genome Atlas (TCGA) external validation on Clinical Proteomic Tumor Analysis Consortium (CPTAC) for both attMIL and transformer-based approaches.. [Supplementary_Table_1_All_statistical_results.xlsx] in separate file.Additional File 3: Figure 2. Receiving operating curve for the Internal Validation and tumor-wise external validation. The Receiving operating curve (ROC) and p-value (*p > 0.05; **p \u2264 0.05; ***p \u2264 0.01) are shown for the five-fold internal cross-validation experiments for each of the models in The Cancer Genome Atlas (TCGA) for the Homologous recombination deficiency (HRD) binary score for (A) TCGA-BRCA, (B) TCGA-CRC, (C) TCGA-LIHC, (D) TCGA-LUAD, (E) TCGA-LUSC, (F) TCGA-PAAD, (G) TCGA-PRAD, (H) TCGA-OV, (I) TCGA-UCEC; Roc curves for the external validation on the Clinical Proteomic Tumor Analysis Consortium (CPTAC) for each previously trained model for (J) CPTAC-LUAD, (K) CPTAC-LUSC, (L) CPTAC-PAAD, (M) CPTAC-UCEC. Abbreviations: BRCA=breast invasive carcinoma; CRC=colorectal cancer; LIHC=liver hepatocellular carcinoma; LUAD=lung adenocarcinoma; LUSC=lung squamous cell carcinoma; OV=ovarian serous cystadenocarcinoma; PAAD=pancreatic adenocarcinoma; PRAD=prostate adenocarcinoma; UCEC=uterine corpus endometrial carcinoma.Additional File 4: Figure 3. Receiving operating curve for the cross-cancer external validation. The Receiving operating curve (ROC) p-value (*p > 0.05; **p \u2264 0.05; ***p \u2264 0.01) are shown for the cross-cancer external validation experiments for each model trained on The Cancer Genome Atlas (TCGA) breast cancer (BRCA) cohort for the Homologous recombination deficiency (HRD) binary score on (A) TCGA-CRC, (B) TCGA-LIHC, (C) TCGA-LUAD, (D) CPTAC-LUAD, (E) TCGA-LUSC, (F) CPTAC-LUSC, (G) TCGA-OV, (H) TCGA-PAAD, (I) CPTAC-PAAD, (J) TCGA-PRAD, (K) TCGA-UCEC, (L) CPTAC-UCEC. Abbreviations: BRCA=breast invasive carcinoma; CRC=colorectal cancer; LIHC=liver hepatocellular carcinoma; LUAD=lung adenocarcinoma; LUSC=lung squamous cell carcinoma; OV=ovarian serous cystadenocarcinoma; PAAD=pancreatic adenocarcinoma; PRAD=prostate adenocarcinoma; UCEC=uterine corpus endometrial carcinoma.Additional File 5: Figure 4. Subgroup analysis and overview the BRCA1 promotor methylations in TCGA-BRCA. The Receiving operating curve (ROC) and Precision Recall curve (PRC) are shown for the five-fold internal cross-validation experiment for each of the models in The Cancer Genome Atlas - breast cancer (TCGA-BRCA) cohort for the Homologous recombination deficiency (HRD) score. ROC curve is represented for the four different subgroups (A) estrogen receptor positive (ER+) and HER2+ (B) ER+ and HER2- (C) ER negative (ER-) and HER2+ (D) ER- and HER2-. The PRC curve is shown for (E) ER+/HER2+, (F) ER+/HER2-, (G) ER-/HER2+, (H) ER-/HER2-. (I) Sketched representation of the occurring promotor methylations (accessed with HM27 and HM450) in the BRCA1 gene for the ground truth Homologous recombination deficiency high (HRD-H) and low (HRD-L) subgroups.Additional File 6: Figure 5. Morphological features of Homologous recombination deficiency in breast and endometrial cancer. Whole Slide Image (WSI) and classification heatmap (ground truth: Homologous recombination deficiency high (HRD-H) and low (HRD-L) and prediction: HRD-H) with magnifications of two different regions. The model was trained on The cancer genome atlas (TCGA) breast invasive carcinoma (BRCA) cohort and deployed cross cancer wise. Top true positive predicted patients are shown for (A) TCGA-BRCA, (B) Clinical Proteomic Tumor Analysis Consortium (CPTAC) uterine corpus endometrial carcinoma (UCEC) and (C) TCGA-UCEC. Additional File 7: Figure 6. Morphological features of Homologous recombination deficiency in pancreatic and prostate adenocarcinoma. Whole Slide Image (WSI) and classification heatmap (ground truth: Homologous recombination deficiency high (HRD-H) and low (HRD-L) and prediction: HRD-H) with magnifications of two different regions. The model was trained on The cancer genome atlas (TCGA) breast invasive carcinoma (BRCA) cohort and deployed cross cancer wise. Top true positive predicted patients are shown for (A) TCGA pancreatic adenocarcinoma (PAAD), (B) Clinical Proteomic Tumor Analysis Consortium (CPTAC) pancreatic adenocarcinoma (PAAD) and (C) TCGA prostate adenocarcinoma (PRAD).Additional File 8: Figure 7. Comparison of Homologous recombination deficient and proficient tissue slides. Whole Slide Images (WSIs) comparing Homologous recombination deficient high (HRD-H) and low (HRD-L) patients in three different tumor types of The cancer genome atlas (TCGA). (A) TCGA. BRCA HRD-H, (B) TCGA- BRCA HRD-L, (C) TCGA - UCEC HRD-H, (D) TCGA-UCEC HRD-L, (E) TCGA-PRAD HRD-H, (F) TCGA-PRAD HRD-L. Abbreviation: breast invasive carcinoma (BRCA), uterine corpus endometrial carcinoma (UCEC), prostate adenocarcinoma (PRAD).Additional File 9: Table 2. Homologous recombination deficiency score Tables. Training data and calculated homologous recombination deficiency score (HRD) out of the three subscores loss of heterozygosity (LOH), telomeric allelic imbalance (TAI) and large-scale state transitions (LST) available as continuous (HRDsum) and binary (HRD_Binary) target with a chosen cut-off of HRD-L=42 for patients of The Cancer Genome Atlas (TCGA, Sheet1) and Clinical Proteomic Tumor Analysis Consortium (CPTAC, Sheet2). Additional File 10: Table 3. Weblink for customized Homologous recombination deficiency (HRD) subgroups. Weblink for accessing the clinical and molecular characteristics in both the ground truth and prediction Homologous recombination Deficiency (HRD) subgroups at www.cbioportal.org for The Cancer Genome Atlas breast cancer (TCGA-BRCA) Pan Cancer Atlas 2018 study and the TCGA-BRCA Firehose Legacy cohort.",
      "Additional File 10: Table 3. Weblink for customized Homologous recombination deficiency (HRD) subgroups. Weblink for accessing the clinical and molecular characteristics in both the ground truth and prediction Homologous recombination Deficiency (HRD) subgroups at www.cbioportal.org for The Cancer Genome Atlas breast cancer (TCGA-BRCA) Pan Cancer Atlas 2018 study and the TCGA-BRCA Firehose Legacy cohort."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1788182258605957,
    "data_pmids_checked": 0,
    "paper_id": "39379982",
    "extraction_date": "2025-12-19T20:45:48.338751",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39379982.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39375741": {
    "cbioportal_paper_citations": [
      "The retinoblastoma (RB) protein regulates the cell cycle through the arrest of the G1/S phase [16, 29]. RB proteins, when phosphorylated, do not bind to E2F, a transcription factor that promotes cell proliferation [29]. Conversely, when RB is not phosphorylated, the protein binds to E2F, thus inhibiting cell cycle progression into the S phase [29]. The RB pathway is altered in GB in many ways, including homozygous deletion, promoter methylation, or mutation of pathway component proteins (16). The tumor suppressor p53 protein that controls cell proliferation and cell cycle progression is also altered in GB [30]. The p53 protein contributes to preventing damaged cells from propagating through the cell cycle [31]. Typically, p53 is altered in GB through deletions of the CDKN2A/ARF locus [30, 32]. Gene deletions within CDKN2B and CDKN2C, which encode tumor suppressor genes CDK4 and CDK6, promote uncontrolled cancer cell proliferation [18, 33]. The JAK/STAT signaling pathway regulates tumorigenic functions like angiogenesis and anti-apoptosis along with mediating cell responses to growth factors or cytokines [34, 35]. JAK proteins, activated by cytokine stimulation, phosphorylate STAT proteins to initiate pathway activation [35]. The STAT component includes a collection of transcription factors in the cytoplasm that are activated by phosphorylation [34]. In GB, secretion of interleukin (IL)-6, IL-8, and growth factors activate the STAT proteins and increase tumor proliferation [34, 36]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.21803808212280273,
    "data_pmids_checked": 0,
    "paper_id": "39375741",
    "extraction_date": "2025-12-19T20:45:48.600281",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39375741.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39375639": {
    "cbioportal_paper_citations": [
      "Gene-gene interaction network was constructed via GeneMANIA [21] (http://genemania.org/). The cBioPortal database [22](https://www.cbioportal.org/) integrates data of somatic mutation, DNA copy number change, mRNA and miRNA expression, protein and phosphoprotein abundance, which can perform mutation correlation analysis and visualization. First, we log into the database to select the top 100 positively correlated genes of YKT6 based on Spearman\u2019s correlation. Then, STRING database (https://cn.string-db.org) [23] and Cytoscape (Version 3.9.0) [24] were utilized to build the PPI network and screen the top ten hub genes according to the degree scores."
    ],
    "cbioportal_platform_mentions": [
      "The YKT6-related gene-gene interaction network was created via Genemania (Fig. 8A). The cBioPortal database was used to obtain YKT6 related genes and the top 100 genes were selected based on the Spearman values (Supplementary Table 3). Subsequently, the STRING database was used to construct PPI network and the top ten hub genes were screened as follows: CDC20, PLK1, CDCA8, TPX2, KIF2C, KIF23, KIF4A, FOXM1, MCM7 and CDCA5 (Fig. 8B). Additionally, TCGA data and clinical information showed that the selected ten hub genes were all highly expressed in LUAD (Supplementary Fig. 2), with relation to poor prognosis of LUAD patients (Supplementary Fig. 3)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.18802523612976074,
    "data_pmids_checked": 0,
    "paper_id": "39375639",
    "extraction_date": "2025-12-19T20:45:48.850595",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39375639.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39375392": {
    "cbioportal_paper_citations": [
      "In total, we included 32 cancer types for this study. The expression profile of BCAT2 and clinical information of pan-cancer patients were sourced from The Cancer Genome Atlas (TCGA)29 and Genotype-Tissue Expression (GTEx)30 databases, utilizing the Genomic Data Commons platform (GDC)31 for data retrieval. The cBioPortal database32 was employed to analyze BCAT2 genetic alterations."
    ],
    "cbioportal_platform_mentions": [
      "Understanding that genetic alterations and epigenetic modifications can trigger abnormal gene expression, we began our analysis with BCAT2 alterations across different cancer types using the cBioPortal platform. Our findings revealed a notably high frequency of BCAT2 alterations in adrenocortical carcinoma (4.47%), primarily characterized by gene amplification. This was followed by patients with endometrial cancer exhibiting various alterations including amplification, deep deletion, multiple alterations, and mutations (Fig. 1A).Fig. 1The genetic alteration of BCAT2 in pan-cancer. (A) cBioPortal tool was used to evaluate the genetic alteration of BCAT2. (B) Lollipop diagram presented the alteration sites of BCAT2. (C) RSEM quantized the transcript of BCAT2.",
      "The genetic alteration of BCAT2 in pan-cancer. (A) cBioPortal tool was used to evaluate the genetic alteration of BCAT2. (B) Lollipop diagram presented the alteration sites of BCAT2. (C) RSEM quantized the transcript of BCAT2."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.13944292068481445,
    "data_pmids_checked": 0,
    "paper_id": "39375392",
    "extraction_date": "2025-12-19T20:45:48.990140",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39375392.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39388307": {
    "paper_id": "39388307",
    "cbioportal_paper_citations": [
      "Cancer Discov\n2012;2:401\u20134 [PubMed: 22588877]\n13",
      "Sci Signal 2013;6:pl1\n[PubMed: 23550210]\n14"
    ],
    "cbioportal_platform_mentions": [
      "Raw gene expression data from the TCGA (prostate cancer, Firehose Legacy)\nand SU2C patient datasets were mined from cBioportal (https://www.cbioportal.org/)\n(12,13)",
      "Comparing the SU2C (metastatic CRPC) vs. TCGA (CSPC) patient datasets (cbioportal.org)\n(12,13), we found normalized GUCY1A1 and GUCY1B1 expression was lower in the\nformer (Fig",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis\nof complex cancer genomics and clinical profiles using the cBioPortal",
      "(F) Comparison of GUCY1A1 and GUCY1B1 expression (normalized\nto their respective GAPDH values) from TCGA vs. SU2C patient datasets (cBioportal)"
    ],
    "data_publication_citations": {
      "22722839": [
        "Nature 2012;487:239\u201343 [PubMed:\n22722839]\n25"
      ]
    },
    "extraction_date": "2025-12-19T20:45:50.128621",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39388307.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 12.98122763633728,
      "cbioportal_papers": 0.00021028518676757812,
      "pdf_extraction_pass2": 17.61206293106079,
      "cbioportal_papers_pass2": 0.005522012710571289,
      "used_full_extraction": true,
      "pdf_extraction": 30.59329056739807,
      "platform_mentions": 0.02963995933532715,
      "data_citations": 0.02966785430908203,
      "num_data_pmids_checked": 1
    }
  },
  "39533394": {
    "paper_id": "39533394",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "According to the NCI\u2019s Cancer Stat Facts, the 5-year cBioportal \u2013 OS analysis\nsurvival rate of AML patients is approximately 32%",
      "Diverse methods are proposed to cBioPortal [38]",
      "K-M analyses were also (OHSU dataset, Cancer Cell, 2022) [38], cBioPortal\nrestricted to AML patients with IDH1, IDH2, NPM1, FLT3- tool was exploited to inspect the percent of circulating\nITD, FLT3-TKD and CEBPA mutations",
      "cBioPortal tool was then exploited to subunit beta (ETFB), carnitine palmitoyltransferase 1A\ninvestigate the frequency of genetic mutations including (CPT1A), phytanoyl-CoA 2-hydroxylase (PHYH), trans-\nmissense mutations, inframe mutations, and truncating locase of inner mitochondrial membrane 9 (TIMM9),\nmutations in both cohorts of AML patients",
      "cytochrome c oxidase subunit 7A2 (COX7A2), cytochrome\nc oxidase copper chaperone (COX11), cytochrome B5\nFunctional enrichment analysis of mitochondrial/OXPHOS reductase 3 (CYB5R3) and voltage dependent anion chan-\nco\u2011expressing genes in primary human AML biospecimens nel 2 (VDAC2) were significantly associated with poor OS\nGenome-wide transcriptomics datasets of AML patients in AML patients (log-rank P value < 0.05 and FDR = 1%)\nwere obtained from cBioportal database (OHSU, Cancer (Supplementary Table 1 and Fig",
      "It is worth men- biospecimens\ntioning that the current regimen and biospecimen type of We examined the genes which are co-expressed with mito-\nSLC25A12low cohort (69% bone marrow aspirate and 31% chondrial/OXPHOS genes using the cBioPortal tool [38, 41]",
      "Gene Ontology (GO) enrichment analysis of\nhigh expressing cohorts) and AML mutations using the NDUFA6 co-expressing genes showed the enrichment of\ncBioPortal tool [41]",
      "3 The percent of AML blasts in the peripheral blood as well as the bone marrow of AML patients with low and high expression levels\nof the indicated genes\nBased on the mRNA expression levels of the indicated genes (mRNA expression z\u2011scores relative to all samples \u2013 log RNA\u2011Seq RPKM) in AML\npatients (OHSU dataset, Cancer Cell, 2022) [38], cBioPortal tool was exploited to inspect the percent of circulating blasts as well as blasts in the bone\nmarrow biospecimens of AML patients with low (z score \u2264 \u20111) and high (z score \u2265 1) expression levels of the assessed genes",
      "Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, et al. Acute\nbiospecimens obtained from AML patients (BeatAML.2 cBioportal dataset myeloid leukemia with IDH1 or IDH2 mutation: requency and clinico\u2011\n(OHSU, Cancer Cell, 2022)",
      "Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemo\u2011 grative analysis of complex cancer genomics and clinical profiles using\ntherapy\u2011resistant human acute myeloid leukemia cells are not enriched the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:45:50.253896",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39533394.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 10,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 31.802039861679077,
      "cbioportal_papers": 0.0002853870391845703,
      "pdf_extraction_pass2": 30.72298765182495,
      "cbioportal_papers_pass2": 0.0003001689910888672,
      "used_full_extraction": true,
      "pdf_extraction": 62.52502751350403,
      "platform_mentions": 0.0026481151580810547,
      "data_citations": 0.00010704994201660156,
      "num_data_pmids_checked": 1
    }
  },
  "39363498": {
    "cbioportal_paper_citations": [
      "Next-generation sequencing libraries were constructed from up to 20 ng of extracted formalin-fixed, paraffin-embedded DNA using the Oncomine Comprehensive Assay Plus (Thermo Fisher Scientific), a commercially available AmpliSeq DNA panel targeting more than 500 genes commonly altered in human cancers or up to 20 ng of extracted formalin-fixed, paraffin-embedded RNA using the Ion AmpliSeq Transcriptome Human Gene Expression Kit (Thermo Fisher Scientific), a commercially available AmpliSeq RNA panel targeting more than 20 000 human RefSeq genes, templated using an Ion Chef System (Thermo Fisher Scientific) and sequenced using an Ion GeneStudio S5 Prime System (Thermo Fisher Scientific). All DNA libraries were sequenced to at least 500\u00d7 mean depth with more than 80% uniformity, and all RNA libraries had at least 6 million mapped reads. Next-generation sequencing reads were processed, aligned, and analyzed using Ion Torrent Suite software (Thermo Fisher Scientific), cloud-based standard Ion Reporter workflows (Thermo Fisher Scientific), and/or custom in-house bioinformatic pipelines18,19. Annotated variants were filtered using standard criteria and manually curated by an experienced molecular pathologist (A.M.U.). Prioritized variations were visualized using the OncoPrinter tool (cBioPortal)20,21. Raw RNA sequencing read counts were obtained from the coverageAnalysis plug-in for the Ion Torrent Suite and for all pancreatic ductal adenocarcinoma cases in The Cancer Genome Atlas (TCGA) pancreatic cancer cohort (ie, pancreatic adenocarcinoma) from the University of California, Santa Cruz Xena Cancer Browser website (xena.ucsc.edu)22 and normalized using the Trimmed Mean of the M-values approach. Differential expression analysis was performed using the edgeR package in R (R Foundation for Statistical Computing)23. Two samples from each of the UC and UC-OGC groups did not pass the accepted quality control measures and were excluded from final analysis."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1737077236175537,
    "data_pmids_checked": 0,
    "paper_id": "39363498",
    "extraction_date": "2025-12-19T20:45:50.348347",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39363498.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39363320": {
    "cbioportal_paper_citations": [
      "Oncoprint was drawn using the cBioPortal online tool [20, 21]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "36355783": [
        "Looking into details of the resistance mechanisms identified, our data suggests that 25.1% (n = 44/175) of patients treated with targeted therapies will develop a by-pass resistance mechanism. One of the challenges in clinical practice is the development of new therapeutic strategies to effectively treat these patients. One suggested approach is to combine drugs that are already used in monotherapy. Combinations of targeted therapies have already demonstrated significant success, such as the combination of a BRAF inhibitor and MEK inhibitor in BRAF:p.(Val600Glu) mutated melanoma [32]. The data obtained from our PDX models indicate the potential efficacy of combining a therapy targeting the original oncogenic driver with another therapy targeting the by-pass mechanism. Previous studies [12\u201314, 33\u201336] have also demonstrated the utility of PDX models in testing these combinations. However, the challenge in clinical practice will be to manage the toxicities encountered and determine synergistic doses with minimal side effects between the compounds. PDX models can assist in pharmacokinetic/pharmacodynamics studies to validate the minimum doses required to achieve a tumor effect. Our PDX models have shown a mean similarity of 75.3% in terms of pathogenic driver, aligning closely with the 75.0% observed in another comprehensive pan cancer study focused specifically on PDX models [9]. Our extensive collection of PDX models will serve as a valuable preclinical tool for identifying crucial mechanisms that drive acquired resistance to current targeted therapies. Moreover, they offer opportunities for developing innovative strategies to overcome or preempt treatment failure. Currently, other therapeutic strategies, such as bi-specific antibodies, will enable us to simultaneously target the original oncogenic driver and the by-pass resistance mechanism. For instance, the use of amivantamab, a bispecific antibody targeting EGFR and MET [37], offers a promising approach to address this new clinical need."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.28968000411987305,
    "data_pmids_checked": 1,
    "paper_id": "39363320",
    "extraction_date": "2025-12-19T20:45:50.552681",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39363320.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39395421": {
    "paper_id": "39395421",
    "cbioportal_paper_citations": [
      "[PubMed: 23550210]\n25",
      "[PubMed: 22588877]\n26"
    ],
    "cbioportal_platform_mentions": [
      "Integrative analysis of complex cancer genomics and clinical profiles\nusing the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:45:50.615920",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39395421.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.747578859329224,
      "cbioportal_papers": 0.00021600723266601562,
      "pdf_extraction_pass2": 20.619894981384277,
      "cbioportal_papers_pass2": 0.00539398193359375,
      "used_full_extraction": true,
      "pdf_extraction": 31.3674738407135,
      "platform_mentions": 0.00999593734741211,
      "data_citations": 6.9141387939453125e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39372214": {
    "cbioportal_paper_citations": [
      "Data analysis was conducted for this review from six pan-cancer, non-redundant publicly available databases to study Ras mutational frequency in a pan-cancer context. The datasets analysed here comprised the following: MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017), Metastatic Solid Cancers (UMich, Nature 2017), MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018), SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018), China Pan-cancer (OrigiMed, Nature 2022) and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020). Survival and mutation data was extracted from cBioPortal, with Ras mutation frequencies and Kaplan-Meier curves calculated using Microsoft Excel and GraphPad Prism (Figure 3) (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; Miao et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
      "Ras mutations in cancer. (A) Ras-mutated patients, stratified by mutated Ras isoform (KRAS N = 3,752, NRAS N = 517, HRAS N = 178), experience poorer overall survival compared to Ras wild-type patients (N = 6,379) (Log-Rank test, P < 0.0001). (B) KRAS is the most mutated isoform of the three. N = 24,001 (C) There is extreme heterogeneity in the Ras mutational landscape, with over 200 different mutations occurring in Ras isoforms, with these most commonly being at positions G12, G13, and Q61. The top five mutations occurring across all isoforms are denoted in the figure. N = 44,451. This is supported by Supplementary Table S1. (D) Mutations stratified by Ras isoform, with top five mutations shown per isoform. Different isoforms have different likelihoods for certain mutations occurring, with HRAS showing the most diversity. The top five most common mutations per isoform denoted on the figure. N = 44,451. This is supported by Supplementary Table S1. Data was analysed from six non-redundant, pan-cancer datasets, obtained through cBioPortal and analysed using GraphPad Prism V8.0.1 and Microsoft Excel (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
      "Occurrence and frequency of isoform mutations differ between different types of cancers. Multiple studies converge in finding pancreatic, colorectal and lung cancer most commonly express KRAS mutations (Prior et al., 2012). Over 77% of all pancreatic cancer patients were shown to have KRAS mutations, 42% of colorectal cancer cases have KRAS mutations, and approximately 30% of Non-Small Cell Lung Cancer (NSCLC) cases have KRAS mutations (Hu et al., 2021; Reita et al., 2022; Vaughn et al., 2011; Prior et al., 2012). In contrast, Ras mutations are found in less than 1% of central nervous system cancer cases (Prior et al., 2020). In addition, the incidence of mutations in different Ras isoforms differs between cancers. For example, KRAS mutants dominate the Ras mutational burden in pancreatic cancer and NSCLC, whereas NRAS is most mutated in melanoma and acute myeloid leukaemia. In contrast, HRAS is the most mutated isoform in head and neck cancer (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017; Prior et al., 2020)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "28481359": [
        "Data analysis was conducted for this review from six pan-cancer, non-redundant publicly available databases to study Ras mutational frequency in a pan-cancer context. The datasets analysed here comprised the following: MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017), Metastatic Solid Cancers (UMich, Nature 2017), MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018), SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018), China Pan-cancer (OrigiMed, Nature 2022) and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020). Survival and mutation data was extracted from cBioPortal, with Ras mutation frequencies and Kaplan-Meier curves calculated using Microsoft Excel and GraphPad Prism (Figure 3) (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; Miao et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Ras mutations in cancer. (A) Ras-mutated patients, stratified by mutated Ras isoform (KRAS N = 3,752, NRAS N = 517, HRAS N = 178), experience poorer overall survival compared to Ras wild-type patients (N = 6,379) (Log-Rank test, P < 0.0001). (B) KRAS is the most mutated isoform of the three. N = 24,001 (C) There is extreme heterogeneity in the Ras mutational landscape, with over 200 different mutations occurring in Ras isoforms, with these most commonly being at positions G12, G13, and Q61. The top five mutations occurring across all isoforms are denoted in the figure. N = 44,451. This is supported by Supplementary Table S1. (D) Mutations stratified by Ras isoform, with top five mutations shown per isoform. Different isoforms have different likelihoods for certain mutations occurring, with HRAS showing the most diversity. The top five most common mutations per isoform denoted on the figure. N = 44,451. This is supported by Supplementary Table S1. Data was analysed from six non-redundant, pan-cancer datasets, obtained through cBioPortal and analysed using GraphPad Prism V8.0.1 and Microsoft Excel (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Occurrence and frequency of isoform mutations differ between different types of cancers. Multiple studies converge in finding pancreatic, colorectal and lung cancer most commonly express KRAS mutations (Prior et al., 2012). Over 77% of all pancreatic cancer patients were shown to have KRAS mutations, 42% of colorectal cancer cases have KRAS mutations, and approximately 30% of Non-Small Cell Lung Cancer (NSCLC) cases have KRAS mutations (Hu et al., 2021; Reita et al., 2022; Vaughn et al., 2011; Prior et al., 2012). In contrast, Ras mutations are found in less than 1% of central nervous system cancer cases (Prior et al., 2020). In addition, the incidence of mutations in different Ras isoforms differs between cancers. For example, KRAS mutants dominate the Ras mutational burden in pancreatic cancer and NSCLC, whereas NRAS is most mutated in melanoma and acute myeloid leukaemia. In contrast, HRAS is the most mutated isoform in head and neck cancer (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017; Prior et al., 2020)."
      ],
      "30150660": [
        "Data analysis was conducted for this review from six pan-cancer, non-redundant publicly available databases to study Ras mutational frequency in a pan-cancer context. The datasets analysed here comprised the following: MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017), Metastatic Solid Cancers (UMich, Nature 2017), MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018), SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018), China Pan-cancer (OrigiMed, Nature 2022) and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020). Survival and mutation data was extracted from cBioPortal, with Ras mutation frequencies and Kaplan-Meier curves calculated using Microsoft Excel and GraphPad Prism (Figure 3) (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; Miao et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Ras mutations in cancer. (A) Ras-mutated patients, stratified by mutated Ras isoform (KRAS N = 3,752, NRAS N = 517, HRAS N = 178), experience poorer overall survival compared to Ras wild-type patients (N = 6,379) (Log-Rank test, P < 0.0001). (B) KRAS is the most mutated isoform of the three. N = 24,001 (C) There is extreme heterogeneity in the Ras mutational landscape, with over 200 different mutations occurring in Ras isoforms, with these most commonly being at positions G12, G13, and Q61. The top five mutations occurring across all isoforms are denoted in the figure. N = 44,451. This is supported by Supplementary Table S1. (D) Mutations stratified by Ras isoform, with top five mutations shown per isoform. Different isoforms have different likelihoods for certain mutations occurring, with HRAS showing the most diversity. The top five most common mutations per isoform denoted on the figure. N = 44,451. This is supported by Supplementary Table S1. Data was analysed from six non-redundant, pan-cancer datasets, obtained through cBioPortal and analysed using GraphPad Prism V8.0.1 and Microsoft Excel (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Occurrence and frequency of isoform mutations differ between different types of cancers. Multiple studies converge in finding pancreatic, colorectal and lung cancer most commonly express KRAS mutations (Prior et al., 2012). Over 77% of all pancreatic cancer patients were shown to have KRAS mutations, 42% of colorectal cancer cases have KRAS mutations, and approximately 30% of Non-Small Cell Lung Cancer (NSCLC) cases have KRAS mutations (Hu et al., 2021; Reita et al., 2022; Vaughn et al., 2011; Prior et al., 2012). In contrast, Ras mutations are found in less than 1% of central nervous system cancer cases (Prior et al., 2020). In addition, the incidence of mutations in different Ras isoforms differs between cancers. For example, KRAS mutants dominate the Ras mutational burden in pancreatic cancer and NSCLC, whereas NRAS is most mutated in melanoma and acute myeloid leukaemia. In contrast, HRAS is the most mutated isoform in head and neck cancer (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017; Prior et al., 2020)."
      ],
      "35871175": [
        "Data analysis was conducted for this review from six pan-cancer, non-redundant publicly available databases to study Ras mutational frequency in a pan-cancer context. The datasets analysed here comprised the following: MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017), Metastatic Solid Cancers (UMich, Nature 2017), MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018), SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018), China Pan-cancer (OrigiMed, Nature 2022) and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020). Survival and mutation data was extracted from cBioPortal, with Ras mutation frequencies and Kaplan-Meier curves calculated using Microsoft Excel and GraphPad Prism (Figure 3) (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; Miao et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Ras mutations in cancer. (A) Ras-mutated patients, stratified by mutated Ras isoform (KRAS N = 3,752, NRAS N = 517, HRAS N = 178), experience poorer overall survival compared to Ras wild-type patients (N = 6,379) (Log-Rank test, P < 0.0001). (B) KRAS is the most mutated isoform of the three. N = 24,001 (C) There is extreme heterogeneity in the Ras mutational landscape, with over 200 different mutations occurring in Ras isoforms, with these most commonly being at positions G12, G13, and Q61. The top five mutations occurring across all isoforms are denoted in the figure. N = 44,451. This is supported by Supplementary Table S1. (D) Mutations stratified by Ras isoform, with top five mutations shown per isoform. Different isoforms have different likelihoods for certain mutations occurring, with HRAS showing the most diversity. The top five most common mutations per isoform denoted on the figure. N = 44,451. This is supported by Supplementary Table S1. Data was analysed from six non-redundant, pan-cancer datasets, obtained through cBioPortal and analysed using GraphPad Prism V8.0.1 and Microsoft Excel (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Occurrence and frequency of isoform mutations differ between different types of cancers. Multiple studies converge in finding pancreatic, colorectal and lung cancer most commonly express KRAS mutations (Prior et al., 2012). Over 77% of all pancreatic cancer patients were shown to have KRAS mutations, 42% of colorectal cancer cases have KRAS mutations, and approximately 30% of Non-Small Cell Lung Cancer (NSCLC) cases have KRAS mutations (Hu et al., 2021; Reita et al., 2022; Vaughn et al., 2011; Prior et al., 2012). In contrast, Ras mutations are found in less than 1% of central nervous system cancer cases (Prior et al., 2020). In addition, the incidence of mutations in different Ras isoforms differs between cancers. For example, KRAS mutants dominate the Ras mutational burden in pancreatic cancer and NSCLC, whereas NRAS is most mutated in melanoma and acute myeloid leukaemia. In contrast, HRAS is the most mutated isoform in head and neck cancer (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017; Prior et al., 2020)."
      ],
      "32025007": [
        "Data analysis was conducted for this review from six pan-cancer, non-redundant publicly available databases to study Ras mutational frequency in a pan-cancer context. The datasets analysed here comprised the following: MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017), Metastatic Solid Cancers (UMich, Nature 2017), MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018), SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018), China Pan-cancer (OrigiMed, Nature 2022) and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020). Survival and mutation data was extracted from cBioPortal, with Ras mutation frequencies and Kaplan-Meier curves calculated using Microsoft Excel and GraphPad Prism (Figure 3) (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; Miao et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Ras mutations in cancer. (A) Ras-mutated patients, stratified by mutated Ras isoform (KRAS N = 3,752, NRAS N = 517, HRAS N = 178), experience poorer overall survival compared to Ras wild-type patients (N = 6,379) (Log-Rank test, P < 0.0001). (B) KRAS is the most mutated isoform of the three. N = 24,001 (C) There is extreme heterogeneity in the Ras mutational landscape, with over 200 different mutations occurring in Ras isoforms, with these most commonly being at positions G12, G13, and Q61. The top five mutations occurring across all isoforms are denoted in the figure. N = 44,451. This is supported by Supplementary Table S1. (D) Mutations stratified by Ras isoform, with top five mutations shown per isoform. Different isoforms have different likelihoods for certain mutations occurring, with HRAS showing the most diversity. The top five most common mutations per isoform denoted on the figure. N = 44,451. This is supported by Supplementary Table S1. Data was analysed from six non-redundant, pan-cancer datasets, obtained through cBioPortal and analysed using GraphPad Prism V8.0.1 and Microsoft Excel (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Occurrence and frequency of isoform mutations differ between different types of cancers. Multiple studies converge in finding pancreatic, colorectal and lung cancer most commonly express KRAS mutations (Prior et al., 2012). Over 77% of all pancreatic cancer patients were shown to have KRAS mutations, 42% of colorectal cancer cases have KRAS mutations, and approximately 30% of Non-Small Cell Lung Cancer (NSCLC) cases have KRAS mutations (Hu et al., 2021; Reita et al., 2022; Vaughn et al., 2011; Prior et al., 2012). In contrast, Ras mutations are found in less than 1% of central nervous system cancer cases (Prior et al., 2020). In addition, the incidence of mutations in different Ras isoforms differs between cancers. For example, KRAS mutants dominate the Ras mutational burden in pancreatic cancer and NSCLC, whereas NRAS is most mutated in melanoma and acute myeloid leukaemia. In contrast, HRAS is the most mutated isoform in head and neck cancer (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017; Prior et al., 2020)."
      ],
      "29420467": [
        "Data analysis was conducted for this review from six pan-cancer, non-redundant publicly available databases to study Ras mutational frequency in a pan-cancer context. The datasets analysed here comprised the following: MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017), Metastatic Solid Cancers (UMich, Nature 2017), MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018), SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018), China Pan-cancer (OrigiMed, Nature 2022) and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020). Survival and mutation data was extracted from cBioPortal, with Ras mutation frequencies and Kaplan-Meier curves calculated using Microsoft Excel and GraphPad Prism (Figure 3) (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; Miao et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Ras mutations in cancer. (A) Ras-mutated patients, stratified by mutated Ras isoform (KRAS N = 3,752, NRAS N = 517, HRAS N = 178), experience poorer overall survival compared to Ras wild-type patients (N = 6,379) (Log-Rank test, P < 0.0001). (B) KRAS is the most mutated isoform of the three. N = 24,001 (C) There is extreme heterogeneity in the Ras mutational landscape, with over 200 different mutations occurring in Ras isoforms, with these most commonly being at positions G12, G13, and Q61. The top five mutations occurring across all isoforms are denoted in the figure. N = 44,451. This is supported by Supplementary Table S1. (D) Mutations stratified by Ras isoform, with top five mutations shown per isoform. Different isoforms have different likelihoods for certain mutations occurring, with HRAS showing the most diversity. The top five most common mutations per isoform denoted on the figure. N = 44,451. This is supported by Supplementary Table S1. Data was analysed from six non-redundant, pan-cancer datasets, obtained through cBioPortal and analysed using GraphPad Prism V8.0.1 and Microsoft Excel (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Occurrence and frequency of isoform mutations differ between different types of cancers. Multiple studies converge in finding pancreatic, colorectal and lung cancer most commonly express KRAS mutations (Prior et al., 2012). Over 77% of all pancreatic cancer patients were shown to have KRAS mutations, 42% of colorectal cancer cases have KRAS mutations, and approximately 30% of Non-Small Cell Lung Cancer (NSCLC) cases have KRAS mutations (Hu et al., 2021; Reita et al., 2022; Vaughn et al., 2011; Prior et al., 2012). In contrast, Ras mutations are found in less than 1% of central nervous system cancer cases (Prior et al., 2020). In addition, the incidence of mutations in different Ras isoforms differs between cancers. For example, KRAS mutants dominate the Ras mutational burden in pancreatic cancer and NSCLC, whereas NRAS is most mutated in melanoma and acute myeloid leukaemia. In contrast, HRAS is the most mutated isoform in head and neck cancer (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017; Prior et al., 2020)."
      ],
      "28783718": [
        "Data analysis was conducted for this review from six pan-cancer, non-redundant publicly available databases to study Ras mutational frequency in a pan-cancer context. The datasets analysed here comprised the following: MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017), Metastatic Solid Cancers (UMich, Nature 2017), MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018), SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018), China Pan-cancer (OrigiMed, Nature 2022) and Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020). Survival and mutation data was extracted from cBioPortal, with Ras mutation frequencies and Kaplan-Meier curves calculated using Microsoft Excel and GraphPad Prism (Figure 3) (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; Miao et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Ras mutations in cancer. (A) Ras-mutated patients, stratified by mutated Ras isoform (KRAS N = 3,752, NRAS N = 517, HRAS N = 178), experience poorer overall survival compared to Ras wild-type patients (N = 6,379) (Log-Rank test, P < 0.0001). (B) KRAS is the most mutated isoform of the three. N = 24,001 (C) There is extreme heterogeneity in the Ras mutational landscape, with over 200 different mutations occurring in Ras isoforms, with these most commonly being at positions G12, G13, and Q61. The top five mutations occurring across all isoforms are denoted in the figure. N = 44,451. This is supported by Supplementary Table S1. (D) Mutations stratified by Ras isoform, with top five mutations shown per isoform. Different isoforms have different likelihoods for certain mutations occurring, with HRAS showing the most diversity. The top five most common mutations per isoform denoted on the figure. N = 44,451. This is supported by Supplementary Table S1. Data was analysed from six non-redundant, pan-cancer datasets, obtained through cBioPortal and analysed using GraphPad Prism V8.0.1 and Microsoft Excel (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017).",
        "Occurrence and frequency of isoform mutations differ between different types of cancers. Multiple studies converge in finding pancreatic, colorectal and lung cancer most commonly express KRAS mutations (Prior et al., 2012). Over 77% of all pancreatic cancer patients were shown to have KRAS mutations, 42% of colorectal cancer cases have KRAS mutations, and approximately 30% of Non-Small Cell Lung Cancer (NSCLC) cases have KRAS mutations (Hu et al., 2021; Reita et al., 2022; Vaughn et al., 2011; Prior et al., 2012). In contrast, Ras mutations are found in less than 1% of central nervous system cancer cases (Prior et al., 2020). In addition, the incidence of mutations in different Ras isoforms differs between cancers. For example, KRAS mutants dominate the Ras mutational burden in pancreatic cancer and NSCLC, whereas NRAS is most mutated in melanoma and acute myeloid leukaemia. In contrast, HRAS is the most mutated isoform in head and neck cancer (Cerami et al., 2012; Gao et al., 2013; Hyman et al., 2018; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Miao et al., 2018; Robinson et al., 2017; Wu et al., 2022; Zehir et al., 2017; Prior et al., 2020)."
      ]
    },
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 6,
    "extraction_method": "jats_xml",
    "extraction_time": 1.7341089248657227,
    "data_pmids_checked": 6,
    "paper_id": "39372214",
    "extraction_date": "2025-12-19T20:45:50.724345",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39372214.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39362600": {
    "cbioportal_paper_citations": [
      "The gene encoding LKB1, STK11 (for \u2018serine/threonine kinase 11\u2019), was found in the late 1990s to be mutated in the Peutz\u2013Jeghers cancer syndrome characterised by benign gastric hamartomatous polyps, earning LKB1 the title of tumour-suppressor [125]. As a target of LKB1, this provided the first indication that AMPK could similarly function as a tumour suppressor. Conceptually it made sense in light of AMPK's fundamental role in preventing cell proliferation, particularly at the level of mTORC1 inhibition, a bona fide driver of cancer. Genetic evidence supported this theory, with whole-body loss of \u03b11 or \u03b21 accelerating tumour burden in two different mouse models of lymphoma [126,127]. However, it has since become clear that AMPK's role in cancer is context specific. AMPK affords tumours a survival advantage when confronted with energetic disturbances caused by conditions like anchorage-independent growth and solid tumour formation, oxidative stress, glucose deprivation, and metastasis [[128], [129], [130], [131]]. Conversely, loss of AMPK function in energy-replete cancerous cells enhances their proliferation [128]. One argument is that AMPK might prevent the onset of cancer, hence formation of the tumour itself [4], explaining some of the anti-cancer properties of pharmacological agents like metformin [132]. A fascinating emerging topic is the behaviour of AMPK subunit isoforms in different cancers. Analysis of the TCGA PanCancer Atlas via the cBioPortal database revealed a high frequency of PRKAA2 gene missense mutations in human cancer, especially cutaneous melanoma, whereas PRKAA1 is frequently amplified, particularly in lung cancer (Figure 3A) [133,134]. The reader is referred to Supplementary Table 1 for the major cancers these genes are altered in and relationships with other relevant genetic alterations. That \u03b11 could function as a tumour promoter and \u03b12 a suppressor is paradoxical and something we suspect is related, in part, to their differential phosphorylation profiles.Figure 3\u03b11-and \u03b12-AMPK regulation and implications for cancer. A) Analysis of the TCGA PanCancer Atlas lung adenocarcinoma dataset reveals a significant co-occurrence of amplification of the PRKAA1 gene (encoding for the \u03b11 isoform) with putative TP53 (encoding for the p53 tumour suppressor) driver mutations and mutations of unknown significance to RYR2, which encodes for a Ca2+-release channel. B) We present a hypothetical schema by which \u03b11-AMPK could confer tumour promoter effects to compensate for mutations to p53, specifically in the context of apoptotic signalling. \u2776 Apoptotic stress triggers the nuclear entrapment of \u03b11-AMPK by caspase-3 cleavage of the \u03b11-NES. \u2777 Nuclear \u03b11-AMPK is then activated by CaMKK2, itself stimulated by intra-nuclear Ca2+ flux for which the source could be RYR2 and/or TRPV2 Ca2+-release channels embedded in the endoplasmic reticulum (ER) [150,332]. \u2778 Activated \u03b11-AMPK phosphorylates nuclear substrates implicated in cell survival (EXO1) and DNA-damage repair (53BP1), \u2779 induces gene transcription that causes cell cycle arrest (e.g., p21-mediated blockade of CDK2), and \u277a upregulates TFEB-dependent \u2018CLEAR\u2019 network genes. \u277b The latter results in mitochondrial biogenesis and autophagy to ensure ongoing cell survival and progression in the nutrient-poor tumour microenvironment. Although steps one, two and four have been shown to be \u03b11-AMPK-dependent, the \u03b1 isoform dependency of nuclear substrate phosphorylation and TFEB activation (steps three and five) requires confirmation. C-D) Postulated pro- and anti-metastatic functions of each \u03b1 isoform provides insight into differential regulation by CaMKK2 and LKB1. C) \u03b11-AMPK phospho-activates the catalytic subunit of PDH to enhance TCA cycle activity and support the energy requirements of metastatic cells. \u03b1-KG, a product of glutaminolysis and intermediate of the TCA cycle, activates AMPK through CaMKK2, causing resistance to cell death (anoikis) during metastatic detachment from the extracellular matrix. D) Nuclear \u03b12-AMPK may oppose metastasis by preventing the epithelial to mesenchymal transition (EMT) via direct (FOXO3/PHF2 phosphorylation) or indirect (p53 activation) modulation of the epigenome, which would require inhibition of the nuclear oncoprotein UHRF1. It appears that suppression of the EMT by agents like metformin are LKB1-dependent, thereby contributing to \u03b12 activation selectivity. E) mTORC1 regulates LKB1 phosphorylation of \u03b12-AMPK. Left panel: a close-up cartoon view of the R365 pocket is shown in the crystal structure of the active AMPK \u03b12\u03b22\u03b31 heterotrimer (PDB: 6B2E) colour coded according to Figure 1B. The two mTORC1 substrates \u03b12-S345 and \u03b12-S377 are located in the \u03b1-linker region of AMPK. Whilst \u03b12-S377 is not resolved, \u03b12-S345 can be seen bordering the nucleotide-sensing R365 pocket. Right panel: energy stress-induced inhibition of mTORC1 relieves \u03b12-S345 phosphorylation of AMPK, causing lysosomal targeting where it is activated by LKB1. \u03b12-AMPK is then further activated by AMP upon relocating to bioenergetic hubs like mitochondria. Where phosphorylation (\u24c5) events are depicted in B-E, red lines ending with a circle denote inhibition of the target and black arrows activation.Figure 3",
      "The oncogenicity of \u03b11 is obviously multifaceted, with one possible scenario depicting proliferative mTORC1 activity commensurate with \u03b11-mitigated cell survival. An analogous situation occurs in Birt-Hogg-Dub\u00e9 syndrome driven by germline mutations in the FLCN gene. Loss of FLCN relieves inhibitory mTORC1 phosphorylation of the transcription factor TFEB without interfering with phosphorylation of its other substrates (e.g., S6K1, 4E-BP1) [167]. The result is a constitutively active nuclear TFEB that in addition to transcribing autophagy and lysosomal genes, upregulates the expression of lysosomal mTORC1 scaffolds RagC and RagD, in turn hyperactivating mTORC1 to create a lethal balance between anabolic and catabolic pathways to support proliferative demands [167,168]. Stable expression of \u03b11 in \u03b11/2-dKO lung adenocarcinoma cells enhances cell proliferation during glucose-deprived but not glucose-replete conditions, in a manner requiring AMPK-dependent TFEB/TFE3 activation and transcription of lysosomal genes [169], which may involve AMPK inhibition of FLCN [170]. TFEB/TFE3 transcription factors are known to amplify p53-dependent transcriptional programs in response to DNA damage [171]. Because PRKAA1 is amplified alongside driver mutations in TP53 (encoding for p53) in lung cancer (Figure 3A; Supplementary Table 1) [133,134], suggests an oncogenic \u03b11-AMPK and TFEB/TFE3 axis might compensate for loss of p53 function. There is clearly a long way to go to understanding the function of different \u03b1 isoforms in cancer, and unlike activator specificity, no \u03b1 isoform-specific AMPK inhibitors are available.",
      "Analysis of the TCGA PanCancer database demonstrates amplification of PRKAB2 in a range of cancers (Supplementary Table 1), such as hepatocellular carcinoma and breast invasive carcinoma [133,134]. PRKAB2 is located on chromosome 1q21, and gains of 1q occur at a high frequency in cancer [[200], [201], [202]]. Amplification of 1q21 often associates with a metastatic phenotype and/or disease recurrence [201,203,204], and PRKAB2 co-amplifies with the oncogene CHD1L, which has documented anti-apoptotic and metastatic functions [205]. Provisional data from The Metastatic Breast Cancer Project (taken from 301 patients) demonstrates significant co-amplification of PRKAB2 and CHD1L (Figure 4B; Supplementary Table 1) [133,134]; their hypothetical collaborative effects are depicted schematically in Figure 4C. Caspases increase the diffusion limit of nuclear pores [206], allowing caspase-3 to accumulate in the nucleus upon apoptotic stress where it could cleave the \u03b11-NES [144]. Overall, \u03b11\u03b22-containing complexes may have the greatest oncogenic potency due to their propensity to localise to the nucleus and direct anti-apoptotic pathways (e.g., transcriptional induction of mitochondrial biogenesis). This may underpin a role for these AMPK complexes during metastasis and/or disease recurrence. That PRKAA1 and PRKAB2 are both amplified in lung adenocarcinoma, although without significant overlap (Supplementary Table 1), suggests elevated production of \u03b22 may increase the steady-state levels of nuclear AMPK, arming cancerous cells with reinforced defences against genotoxic stress and nutrient starvation. It is interesting to observe that a small pool of nuclear AMPK is targeted for poly-ADP-ribosylation by the polymerase PARP1 in response to nutrient starvation, triggering AMPK nuclear export and autophagy initiation [207]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.17711615562438965,
    "data_pmids_checked": 0,
    "paper_id": "39362600",
    "extraction_date": "2025-12-19T20:45:50.754666",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39362600.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39362877": {
    "cbioportal_paper_citations": [
      "Alterations of epigenetic marks have been observed in multiple physiological and pathological conditions, including autoimmune disorders, aging, and cancer24,25. UHRF1, a key epigenetic regulator, is well-documented to coordinate DNA methylation and histone modifications in the nucleus26. The PHD and SRA domains are critical for UHRF1 to maintain aberrant DNA methylation in colorectal cancer (CRC) cells27. Analysis of the TCGA database by TIMER 2.028\u201330 revealed that UHRF1 mRNA is markedly upregulated in multiple cancer types, including lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) (Fig. 1a). Supporting this finding, an independent analysis of LUAD cohort GSE3286731 demonstrated that UHRF1 mRNA levels are upregulated in tumors, when compared with adjacent nonmalignant tissues (Fig. 1b). Moreover, analysis of an online dataset comprising 17 independent cohorts with 1411 total number of patients32 revealed that high UHRF1 expression correlates with reduced survival rates in lung cancer patients (Fig. 1c). Notably, analysis of mass spectrometry data from the Gillett et al. cohort33 demonstrated increased UHRF1 protein expression in non-small cell lung cancer (NSCLC) tumor tissues (Fig. 1d). In addition, result of the Xu et al. cohort34 suggested that higher levels of UHRF1 protein expression are correlated with poor NSCLC patient prognosis (Fig. 1e), which is consistent with a previous report35. Together, these findings indicate that high expression of UHRF1 correlates with the progression of NSCLC and poor prognosis of those patients.Fig. 1UHRF1 is overexpressed in cancer and promotes tumor growth in syngenic mouse models.a UHRF1 expression in cancers versus normal tissues. TPM, transcripts per million. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; SKCM, skin cutaneous melanoma. b UHRF1 expression in GSE32867 dataset (n = 58). c Survival analysis of lung cancer patients stratified by UHRF1 mRNA expression (n = 376 low, 1035 high). d UHRF1 Protein expression in Gillett et al. cohort (n = 102). e Survival analysis based on UHRF1 protein expression in Xu et al. cohort (n = 56 low, 9 high). f, g Tumor photos for LG1233 with 1 \u00d7 105 (f) or 1 \u00d7 106 (g) cells injected into female C57BL/6 mice. h, i Tumor growth (h) and survival(i) curves for LG1233 cells injected into female C57BL/6 mice. n = 7 per group. j, l Tumor photo (j) and growth curves (l) for LLC-OVA cells injected into female C57BL/6 mice. n = 7 (shNT), 8 (shUhrf1). k, m Tumor photo (k) and growth curves (m) for LLC-OVA cells injected into male nude mice. n = 5 per group. Data are mean \u00b1 SEM (h, l, m). For box plots, the box limits show the 25th to 75th percentile, the centre line shows the median value and the whiskers show the minimum to maximum values. n indicates the number of biological replicates. P values were determined using two-sided Wilcoxon signed-rank test (a, b, d), log-rank test (c, e, i), two-way ANOVA test (h, l, m). Source data are provided as a Source Data file. Data in (h, i, l, m) were repeated independently at least twice with similar results."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "32649877": [
        "Alterations of epigenetic marks have been observed in multiple physiological and pathological conditions, including autoimmune disorders, aging, and cancer24,25. UHRF1, a key epigenetic regulator, is well-documented to coordinate DNA methylation and histone modifications in the nucleus26. The PHD and SRA domains are critical for UHRF1 to maintain aberrant DNA methylation in colorectal cancer (CRC) cells27. Analysis of the TCGA database by TIMER 2.028\u201330 revealed that UHRF1 mRNA is markedly upregulated in multiple cancer types, including lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) (Fig. 1a). Supporting this finding, an independent analysis of LUAD cohort GSE3286731 demonstrated that UHRF1 mRNA levels are upregulated in tumors, when compared with adjacent nonmalignant tissues (Fig. 1b). Moreover, analysis of an online dataset comprising 17 independent cohorts with 1411 total number of patients32 revealed that high UHRF1 expression correlates with reduced survival rates in lung cancer patients (Fig. 1c). Notably, analysis of mass spectrometry data from the Gillett et al. cohort33 demonstrated increased UHRF1 protein expression in non-small cell lung cancer (NSCLC) tumor tissues (Fig. 1d). In addition, result of the Xu et al. cohort34 suggested that higher levels of UHRF1 protein expression are correlated with poor NSCLC patient prognosis (Fig. 1e), which is consistent with a previous report35. Together, these findings indicate that high expression of UHRF1 correlates with the progression of NSCLC and poor prognosis of those patients.Fig. 1UHRF1 is overexpressed in cancer and promotes tumor growth in syngenic mouse models.a UHRF1 expression in cancers versus normal tissues. TPM, transcripts per million. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; SKCM, skin cutaneous melanoma. b UHRF1 expression in GSE32867 dataset (n = 58). c Survival analysis of lung cancer patients stratified by UHRF1 mRNA expression (n = 376 low, 1035 high). d UHRF1 Protein expression in Gillett et al. cohort (n = 102). e Survival analysis based on UHRF1 protein expression in Xu et al. cohort (n = 56 low, 9 high). f, g Tumor photos for LG1233 with 1 \u00d7 105 (f) or 1 \u00d7 106 (g) cells injected into female C57BL/6 mice. h, i Tumor growth (h) and survival(i) curves for LG1233 cells injected into female C57BL/6 mice. n = 7 per group. j, l Tumor photo (j) and growth curves (l) for LLC-OVA cells injected into female C57BL/6 mice. n = 7 (shNT), 8 (shUhrf1). k, m Tumor photo (k) and growth curves (m) for LLC-OVA cells injected into male nude mice. n = 5 per group. Data are mean \u00b1 SEM (h, l, m). For box plots, the box limits show the 25th to 75th percentile, the centre line shows the median value and the whiskers show the minimum to maximum values. n indicates the number of biological replicates. P values were determined using two-sided Wilcoxon signed-rank test (a, b, d), log-rank test (c, e, i), two-way ANOVA test (h, l, m). Source data are provided as a Source Data file. Data in (h, i, l, m) were repeated independently at least twice with similar results."
      ],
      "32649874": [
        "Alterations of epigenetic marks have been observed in multiple physiological and pathological conditions, including autoimmune disorders, aging, and cancer24,25. UHRF1, a key epigenetic regulator, is well-documented to coordinate DNA methylation and histone modifications in the nucleus26. The PHD and SRA domains are critical for UHRF1 to maintain aberrant DNA methylation in colorectal cancer (CRC) cells27. Analysis of the TCGA database by TIMER 2.028\u201330 revealed that UHRF1 mRNA is markedly upregulated in multiple cancer types, including lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) (Fig. 1a). Supporting this finding, an independent analysis of LUAD cohort GSE3286731 demonstrated that UHRF1 mRNA levels are upregulated in tumors, when compared with adjacent nonmalignant tissues (Fig. 1b). Moreover, analysis of an online dataset comprising 17 independent cohorts with 1411 total number of patients32 revealed that high UHRF1 expression correlates with reduced survival rates in lung cancer patients (Fig. 1c). Notably, analysis of mass spectrometry data from the Gillett et al. cohort33 demonstrated increased UHRF1 protein expression in non-small cell lung cancer (NSCLC) tumor tissues (Fig. 1d). In addition, result of the Xu et al. cohort34 suggested that higher levels of UHRF1 protein expression are correlated with poor NSCLC patient prognosis (Fig. 1e), which is consistent with a previous report35. Together, these findings indicate that high expression of UHRF1 correlates with the progression of NSCLC and poor prognosis of those patients.Fig. 1UHRF1 is overexpressed in cancer and promotes tumor growth in syngenic mouse models.a UHRF1 expression in cancers versus normal tissues. TPM, transcripts per million. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; SKCM, skin cutaneous melanoma. b UHRF1 expression in GSE32867 dataset (n = 58). c Survival analysis of lung cancer patients stratified by UHRF1 mRNA expression (n = 376 low, 1035 high). d UHRF1 Protein expression in Gillett et al. cohort (n = 102). e Survival analysis based on UHRF1 protein expression in Xu et al. cohort (n = 56 low, 9 high). f, g Tumor photos for LG1233 with 1 \u00d7 105 (f) or 1 \u00d7 106 (g) cells injected into female C57BL/6 mice. h, i Tumor growth (h) and survival(i) curves for LG1233 cells injected into female C57BL/6 mice. n = 7 per group. j, l Tumor photo (j) and growth curves (l) for LLC-OVA cells injected into female C57BL/6 mice. n = 7 (shNT), 8 (shUhrf1). k, m Tumor photo (k) and growth curves (m) for LLC-OVA cells injected into male nude mice. n = 5 per group. Data are mean \u00b1 SEM (h, l, m). For box plots, the box limits show the 25th to 75th percentile, the centre line shows the median value and the whiskers show the minimum to maximum values. n indicates the number of biological replicates. P values were determined using two-sided Wilcoxon signed-rank test (a, b, d), log-rank test (c, e, i), two-way ANOVA test (h, l, m). Source data are provided as a Source Data file. Data in (h, i, l, m) were repeated independently at least twice with similar results."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5998179912567139,
    "data_pmids_checked": 2,
    "paper_id": "39362877",
    "extraction_date": "2025-12-19T20:45:50.998946",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39362877.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39360160": {
    "cbioportal_paper_citations": [
      "The changes in the ARPC1B status of cancer patients are obtained from the online cBioPortal database of cancer genomics (http://www.cbioportal.org/).[33] The genome changes of ARPC1B include \u201camplification\u201d, \u201cdeep deletion\u201d, \u201cmissense mutation\u201d and \u201cstructural abnormality\u201d. In addition, we also analyzed the correlation between the copy number of ARPC1B and promoter methylation in each tumor, using the \u201cggplot2\u201d package for plotting."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2618989944458008,
    "data_pmids_checked": 0,
    "paper_id": "39360160",
    "extraction_date": "2025-12-19T20:45:51.004675",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39360160.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39358461": {
    "cbioportal_paper_citations": [
      "To determine the prevalence and potential clinical impact of EMI1 copy number losses in cancer, publicly available TCGA (The Cancer Genome Atlas) data from 10 common cancer types [33] were queried using cBioPortal [34, 35]. TCGA data reveal that EMI1 copy number losses (i.e., shallow deletions) occur frequently and correspond with increases in both the fraction of the genome altered and aneuploidy scores in CRC, suggesting reduced expression may induce CIN. Moreover, reduced expression is associated with significantly worse disease-specific and progression-free survival for CRC patients relative to those with normal (diploid) copy number status, suggesting it may have pathogenic implications. To functionally determine the impact reduced EMI1 expression has in CRC, EMI1 silencing and quantitative imaging microscopy (QuantIM) were performed in four karyotypically stable, colonic epithelial cell lines. Notably, reduced expression in all four lines induced significant increases in CIN phenotypes that included changes in nuclear areas, micronucleus formation and aberrant chromosome numbers. To determine the long-term impact reduced EMI1 expression has on CIN, clinically relevant, heterozygous knockout clones (EMI1+/\u2212) were generated and assessed every 2 weeks over a 10-week period. In agreement with the silencing experiments, heterozygous loss of EMI1 and reduced expression induced ongoing and dynamic changes in CIN phenotypes that coincide with increases in DNA double-strand breaks (DSBs) along with increases in proliferation rates and anchorage-independent growth that are consistent with reduced expression inducing cellular transformation. Collectively, our data show that reduced EMI1 expression induces CIN that promotes cellular transformation, which supports a potential pathogenic role for heterozygous loss of EMI1 in early CRC development.",
      "Publicly available gene copy number, mRNA expression and clinical data were extracted from the TCGA Pan-Cancer Atlas dataset [33] for 10 common cancer types (breast, cervical, CRC, glioblastoma, head & neck, liver, lung, ovarian, prostate and uterine) using cBioPortal [34, 35] and as detailed elsewhere [36]. EMI1 mRNA expression data from samples with deep and shallow deletions were imported onto Prism v9 (GraphPad, San Diego, CA, USA), where cases with shallow deletions and diploid status were statistically compared using a Mann\u2013Whitney (MW) test. The fraction of the genome altered and aneuploidy score data from CRC patients were also imported onto Prism, where statistical comparisons (MW tests) were performed between cases harbouring shallow deletions relative to diploid controls. Clinical outcomes data, namely disease-specific and progression-free survival, were extracted from TCGA data [33] and stratified based on EMI1 copy number status\u2014shallow deletion versus diploid cases. Kaplan-Meier (KM) survival curves were generated and statistically compared using log-rank tests with a p-value < 0.05 being considered statistically significant.",
      "To determine the clinical impact EMI1 copy number losses and reduced expression may have in cancer, bioinformatic analyses were performed using publicly available TCGA data [33\u201335]. First, the prevalence of EMI1 copy number losses, specifically deep (homozygous) and shallow (heterozygous) deletions, were assessed in 10 common cancer types. As shown in Fig. 1a, copy number losses occur in all 10 cancer types and range from 7% in uterine cancers to 59% in ovarian cancers. While shallow deletions are only present in ~12% of CRC cases, this equates to ~240,000 new diagnoses annually throughout the world. Furthermore, shallow deletions in CRC correspond with significant decreases in mRNA expression (Fig. 1b; protein abundance is not available), which are associated with increases in genome instability, namely the fraction of the genome altered and aneuploidy scores (i.e., sum of total altered chromosome arms; Fig. 1c) [34, 35, 45, 46]. Moreover, CRC patients with EMI1 shallow deletions have significantly worse clinical outcomes relative to diploid counterparts, including both disease-specific and progression-free survival (Fig. 1d). Collectively, these data support the possibility that reduced EMI1 expression induces CIN that promotes CRC pathogenesis and contributes to worse patient outcomes.Fig. 1EMI1 copy number losses are frequent in cancer and are associated with genome instability and worse patient outcomes in CRC.a Bar graph presenting the frequency of EMI1 copy number losses, including deep (homozygous) and shallow (heterozygous) deletions in ten cancer types (total cases) [33\u201335]. Note that ~12% of CRC cases exhibit EMI1 copy number losses. b Violin plot reveals EMI1 copy number losses correspond with a significant reduction in mRNA expression in CRC cases relative to diploid counterparts (MW test; ****p-value < 0.0001). Red bar identifies median, while dashed lines identify interquartile range. c CRC patients with EMI1 shallow deletions exhibit significant increases in the fraction of the genome altered (left) and aneuploidy scores (right) relative to diploid counterparts (MW test; ****p-value < 0.0001) [45, 46]. d Kaplan-Meier curves reveal significantly worse disease-specific (left) and progression-free survival (right) for CRC patients with EMI1 shallow deletions (loss) relative to diploid cases [33\u201335].",
      "a Bar graph presenting the frequency of EMI1 copy number losses, including deep (homozygous) and shallow (heterozygous) deletions in ten cancer types (total cases) [33\u201335]. Note that ~12% of CRC cases exhibit EMI1 copy number losses. b Violin plot reveals EMI1 copy number losses correspond with a significant reduction in mRNA expression in CRC cases relative to diploid counterparts (MW test; ****p-value < 0.0001). Red bar identifies median, while dashed lines identify interquartile range. c CRC patients with EMI1 shallow deletions exhibit significant increases in the fraction of the genome altered (left) and aneuploidy scores (right) relative to diploid counterparts (MW test; ****p-value < 0.0001) [45, 46]. d Kaplan-Meier curves reveal significantly worse disease-specific (left) and progression-free survival (right) for CRC patients with EMI1 shallow deletions (loss) relative to diploid cases [33\u201335]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625048": [
        "To determine the prevalence and potential clinical impact of EMI1 copy number losses in cancer, publicly available TCGA (The Cancer Genome Atlas) data from 10 common cancer types [33] were queried using cBioPortal [34, 35]. TCGA data reveal that EMI1 copy number losses (i.e., shallow deletions) occur frequently and correspond with increases in both the fraction of the genome altered and aneuploidy scores in CRC, suggesting reduced expression may induce CIN. Moreover, reduced expression is associated with significantly worse disease-specific and progression-free survival for CRC patients relative to those with normal (diploid) copy number status, suggesting it may have pathogenic implications. To functionally determine the impact reduced EMI1 expression has in CRC, EMI1 silencing and quantitative imaging microscopy (QuantIM) were performed in four karyotypically stable, colonic epithelial cell lines. Notably, reduced expression in all four lines induced significant increases in CIN phenotypes that included changes in nuclear areas, micronucleus formation and aberrant chromosome numbers. To determine the long-term impact reduced EMI1 expression has on CIN, clinically relevant, heterozygous knockout clones (EMI1+/\u2212) were generated and assessed every 2 weeks over a 10-week period. In agreement with the silencing experiments, heterozygous loss of EMI1 and reduced expression induced ongoing and dynamic changes in CIN phenotypes that coincide with increases in DNA double-strand breaks (DSBs) along with increases in proliferation rates and anchorage-independent growth that are consistent with reduced expression inducing cellular transformation. Collectively, our data show that reduced EMI1 expression induces CIN that promotes cellular transformation, which supports a potential pathogenic role for heterozygous loss of EMI1 in early CRC development.",
        "Publicly available gene copy number, mRNA expression and clinical data were extracted from the TCGA Pan-Cancer Atlas dataset [33] for 10 common cancer types (breast, cervical, CRC, glioblastoma, head & neck, liver, lung, ovarian, prostate and uterine) using cBioPortal [34, 35] and as detailed elsewhere [36]. EMI1 mRNA expression data from samples with deep and shallow deletions were imported onto Prism v9 (GraphPad, San Diego, CA, USA), where cases with shallow deletions and diploid status were statistically compared using a Mann\u2013Whitney (MW) test. The fraction of the genome altered and aneuploidy score data from CRC patients were also imported onto Prism, where statistical comparisons (MW tests) were performed between cases harbouring shallow deletions relative to diploid controls. Clinical outcomes data, namely disease-specific and progression-free survival, were extracted from TCGA data [33] and stratified based on EMI1 copy number status\u2014shallow deletion versus diploid cases. Kaplan-Meier (KM) survival curves were generated and statistically compared using log-rank tests with a p-value < 0.05 being considered statistically significant.",
        "To determine the clinical impact EMI1 copy number losses and reduced expression may have in cancer, bioinformatic analyses were performed using publicly available TCGA data [33\u201335]. First, the prevalence of EMI1 copy number losses, specifically deep (homozygous) and shallow (heterozygous) deletions, were assessed in 10 common cancer types. As shown in Fig. 1a, copy number losses occur in all 10 cancer types and range from 7% in uterine cancers to 59% in ovarian cancers. While shallow deletions are only present in ~12% of CRC cases, this equates to ~240,000 new diagnoses annually throughout the world. Furthermore, shallow deletions in CRC correspond with significant decreases in mRNA expression (Fig. 1b; protein abundance is not available), which are associated with increases in genome instability, namely the fraction of the genome altered and aneuploidy scores (i.e., sum of total altered chromosome arms; Fig. 1c) [34, 35, 45, 46]. Moreover, CRC patients with EMI1 shallow deletions have significantly worse clinical outcomes relative to diploid counterparts, including both disease-specific and progression-free survival (Fig. 1d). Collectively, these data support the possibility that reduced EMI1 expression induces CIN that promotes CRC pathogenesis and contributes to worse patient outcomes.Fig. 1EMI1 copy number losses are frequent in cancer and are associated with genome instability and worse patient outcomes in CRC.a Bar graph presenting the frequency of EMI1 copy number losses, including deep (homozygous) and shallow (heterozygous) deletions in ten cancer types (total cases) [33\u201335]. Note that ~12% of CRC cases exhibit EMI1 copy number losses. b Violin plot reveals EMI1 copy number losses correspond with a significant reduction in mRNA expression in CRC cases relative to diploid counterparts (MW test; ****p-value < 0.0001). Red bar identifies median, while dashed lines identify interquartile range. c CRC patients with EMI1 shallow deletions exhibit significant increases in the fraction of the genome altered (left) and aneuploidy scores (right) relative to diploid counterparts (MW test; ****p-value < 0.0001) [45, 46]. d Kaplan-Meier curves reveal significantly worse disease-specific (left) and progression-free survival (right) for CRC patients with EMI1 shallow deletions (loss) relative to diploid cases [33\u201335].",
        "a Bar graph presenting the frequency of EMI1 copy number losses, including deep (homozygous) and shallow (heterozygous) deletions in ten cancer types (total cases) [33\u201335]. Note that ~12% of CRC cases exhibit EMI1 copy number losses. b Violin plot reveals EMI1 copy number losses correspond with a significant reduction in mRNA expression in CRC cases relative to diploid counterparts (MW test; ****p-value < 0.0001). Red bar identifies median, while dashed lines identify interquartile range. c CRC patients with EMI1 shallow deletions exhibit significant increases in the fraction of the genome altered (left) and aneuploidy scores (right) relative to diploid counterparts (MW test; ****p-value < 0.0001) [45, 46]. d Kaplan-Meier curves reveal significantly worse disease-specific (left) and progression-free survival (right) for CRC patients with EMI1 shallow deletions (loss) relative to diploid cases [33\u201335]."
      ]
    },
    "total_cbioportal_paper_citations": 4,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.37181997299194336,
    "data_pmids_checked": 1,
    "paper_id": "39358461",
    "extraction_date": "2025-12-19T20:45:51.139690",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39358461.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39354061": {
    "cbioportal_paper_citations": [
      "We explored the effects of LAD1 mRNA expression levels in clinical samples of head and neck SCC from The Cancer Genome Atlas (TCGA) dataset (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) on cBioPortal38,39 (https://www.cbioportal.org/, accessed on 2023/01/24). We selected a dataset of head and neck SCCs (Pancancer Atlas; sample size 523). In genomic profiles, mRNA expression z-scores relative to diploid samples (RNA Seq V2 RSEM) were selected, and the z-score threshold was set to \u00b1 2.0. Of the dataset, 515 were included in the analysis."
    ],
    "cbioportal_platform_mentions": [
      "Fig. 7Expression levels of vimentin and LAD1 and histological differentiation of the public cancer dataset. (a) Representative immunofluorescent images of HSC-3 and dot plots of vimentin-positive cell ratio in HSC-2, HSC-3, and HSC-4 cells. (b) A confocal immunofluorescence image of the vertical section of HSC-4 cells cultured on the collagen gel for LAD1 (red) and vimentin (green) with nuclear staining (Hoechst, blue). (c) Fluorescent intensity plot of vimentin (green) and LAD1 (red) on the yellow arrow in panel (b). (d) The histological grades of LAD1-mRNA high and low expression groups in the head and neck squamous cell carcinoma dataset of the cancer genome atlas; scale bars: 200 \u03bcm (a) and 20 \u03bcm (b). Bars in the chart, means \u00b1 s.e.; *p < 0.05, **p < 0.01. G1, well-differentiated; G2, moderately-differentiated; G3, poorly-differentiated; G4, undifferentiated; GX, not assessed. In LAD1-knockdown cells, the ratio of vimentin-positive cells significantly increased, and HSC-3 cells showed a high vimentin-positive percentage in LAD1-knockdown conditions (a). In the section of HSC-4 cells cultured on collagen gel, stacked cells on the gel were positive for LAD1 (red); however, invading cells in the gel showed strong positivity for vimentin (green) (b). In the measurement of fluorescence intensity (c), the vimentin intensity (green line) gradually increased from the surface (asterisks) to the deeper parts (daggers). Reciprocally, the LAD1 intensity (red line) was higher in surface cells (asterisks) but lower in deeper cells (daggers). Public database analysis via cBioportal revealed a significant increased rate (p < 0.05) of well-differentiated histology (G1) in the LAD1-mRNA high-expressing squamous cell carcinoma group.",
      "Expression levels of vimentin and LAD1 and histological differentiation of the public cancer dataset. (a) Representative immunofluorescent images of HSC-3 and dot plots of vimentin-positive cell ratio in HSC-2, HSC-3, and HSC-4 cells. (b) A confocal immunofluorescence image of the vertical section of HSC-4 cells cultured on the collagen gel for LAD1 (red) and vimentin (green) with nuclear staining (Hoechst, blue). (c) Fluorescent intensity plot of vimentin (green) and LAD1 (red) on the yellow arrow in panel (b). (d) The histological grades of LAD1-mRNA high and low expression groups in the head and neck squamous cell carcinoma dataset of the cancer genome atlas; scale bars: 200 \u03bcm (a) and 20 \u03bcm (b). Bars in the chart, means \u00b1 s.e.; *p < 0.05, **p < 0.01. G1, well-differentiated; G2, moderately-differentiated; G3, poorly-differentiated; G4, undifferentiated; GX, not assessed. In LAD1-knockdown cells, the ratio of vimentin-positive cells significantly increased, and HSC-3 cells showed a high vimentin-positive percentage in LAD1-knockdown conditions (a). In the section of HSC-4 cells cultured on collagen gel, stacked cells on the gel were positive for LAD1 (red); however, invading cells in the gel showed strong positivity for vimentin (green) (b). In the measurement of fluorescence intensity (c), the vimentin intensity (green line) gradually increased from the surface (asterisks) to the deeper parts (daggers). Reciprocally, the LAD1 intensity (red line) was higher in surface cells (asterisks) but lower in deeper cells (daggers). Public database analysis via cBioportal revealed a significant increased rate (p < 0.05) of well-differentiated histology (G1) in the LAD1-mRNA high-expressing squamous cell carcinoma group.",
      "Analysis of the cancer genome atlas database on cBioPortal (https://www.cbioportal.org/) showed that well-differentiated histology was considerably predominant in the LAD1-high expression group of head and neck SCC, compared with the low expression group (Fig. 7d). These results indicate the histopathological differentiation, i.e. degree of epithelial differentiation, is associated with LAD1 expression level in the clinical cancer tissue samples.",
      "Experimental data were analyzed using a one-way analysis of variance and Dunnett\u2019s post-hoc comparisons, and Welch\u2019s t-test. Statistical analyses were performed using R (4.2.1 and 4.4.0). A p-value < 0.05 was considered statistically significant. In the public database analysis, the chi-square test was performed using cBioPortal (https://www.cbioportal.org/), and secondary residual analysis was performed using GraphPad Prism 6 (GraphPad Software, Inc., CA, USA)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1571669578552246,
    "data_pmids_checked": 0,
    "paper_id": "39354061",
    "extraction_date": "2025-12-19T20:45:51.161887",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39354061.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39353903": {
    "cbioportal_paper_citations": [
      "TNBC cells are characterized by Notch-dependant IL1\u03b2 expression and Notch-independent expression of caspase-18,9, both prerequisites for IL1\u03b2 maturation and the recruitment of pro-tumoral TAMs to the tumor microenvironment. Here we established in a large survey of breast cancer cell lines11 and primary tumors12,13 that ER and caspase-1 expression are inversely related (Fig. 1a, b; Fig. S1a, b). Proving a causal relationship between ER and caspase-1, siRNA-mediated down-regulation of ER\u03b1 in hormone receptor-positive breast cancer cell lines resulted in an increase of both caspase-1 mRNA and pro-caspase-1 protein (Fig. S1c). Also, pro-caspase-1 expression emerged with ER\u03b1 loss in TMX2-28 breast cancer cells, an ER-independent derivative of MCF7 isolated after prolonged tamoxifen treatment14 (Fig. S1d, e). Conversely, ER\u03b1 overexpression resulted in pro-caspase-1 downregulation in TNBC cells and a decrease in secreted IL1\u03b2 and IL18 in conditioned media (Fig. S1f) and, confirming the presence of functional caspase-1, a decrease in the ability of the media to promote macrophage migration (Fig. S1g).Fig. 1Caspase-1 expression is regulated by ETS1 and ER\u03b1.a mRNA expression of caspase-1 in 22 (13 Luminal and 9 BLBC cell lines) human breast cancer cell lines11 classified into two groups based on subtype (luminal vs BLBC), mean with box defining interquartile interval, 95% confidence interval (CI), two-tailed, unpaired t-test with Welch\u2019s correction for unequal variances; *: p = 0.032. b Association between caspase-1 and ER mRNA expression in 945 human breast cancer samples (TCGA PanCancer Atlas dataset12,13 quantified by RNAseq, divided by subtype (Spearman correlation for all subtypes, two-sided). c Immunoblot of ETS1 and pro-caspase-1 from MDA-MB231 TNBC lysates after ETS1 knockdown (KD). d Immunoblot of ER\u03b1, ETS1 and pro-caspase-1 from MDA-MB231 cells without (-) or with (+) ectopic ER\u03b1 expression or after sh-mediated caspase-1 KD. e Immunoblot of ER\u03b1, ETS1, and pro-caspase-1 in wild-type MCF7 cells, cells overexpressing ETS1 (ETS1+) without (siScr) and with ER\u03b1 siRNA KD (siER\u03b1), and in TMX2-28 cells. \u03b2-actin is included as a loading control. f RTqPCR analyses of ER\u03b1, ETS1, and caspase-1 in wild-type MCF7 cells, cells overexpressing ETS1 (ETS1+) without (siScr) and with ER\u03b1 siRNA KD (siER\u03b1), and in TMX2-28 cells. One-way ANOVA with Dunnett\u2019s multiple comparisons test, *: p = 0.0104, **: p = 0.0042, ***: p = 0.0003. Data are presented as mean values \u00b1 standard error of the mean (SEM). g Schematic of ChIP assay for ETS1 binding to the caspase-1 promoter. h ChIP assay from MCF7 cells after ectopic ETS1 expression and ER\u03b1 KD, ***: p = 0.0003. i ChIP assay from MDA-MB231 cells after ectopic ER\u03b1 expression, **: p = 0.0053. Caspase-1 promoter/ETS1 complexes are quantified by RTqPCR after immunoprecipitation with nonspecific (IgG) or with anti-ETS1 antiserum. Mean with SEM, two-tailed, unpaired t-test with equal variances. n = 3 biologically independent experiments for immunoblots where representative images are shown, RTqPCR and ChIP assays.",
      "a mRNA expression of caspase-1 in 22 (13 Luminal and 9 BLBC cell lines) human breast cancer cell lines11 classified into two groups based on subtype (luminal vs BLBC), mean with box defining interquartile interval, 95% confidence interval (CI), two-tailed, unpaired t-test with Welch\u2019s correction for unequal variances; *: p = 0.032. b Association between caspase-1 and ER mRNA expression in 945 human breast cancer samples (TCGA PanCancer Atlas dataset12,13 quantified by RNAseq, divided by subtype (Spearman correlation for all subtypes, two-sided). c Immunoblot of ETS1 and pro-caspase-1 from MDA-MB231 TNBC lysates after ETS1 knockdown (KD). d Immunoblot of ER\u03b1, ETS1 and pro-caspase-1 from MDA-MB231 cells without (-) or with (+) ectopic ER\u03b1 expression or after sh-mediated caspase-1 KD. e Immunoblot of ER\u03b1, ETS1, and pro-caspase-1 in wild-type MCF7 cells, cells overexpressing ETS1 (ETS1+) without (siScr) and with ER\u03b1 siRNA KD (siER\u03b1), and in TMX2-28 cells. \u03b2-actin is included as a loading control. f RTqPCR analyses of ER\u03b1, ETS1, and caspase-1 in wild-type MCF7 cells, cells overexpressing ETS1 (ETS1+) without (siScr) and with ER\u03b1 siRNA KD (siER\u03b1), and in TMX2-28 cells. One-way ANOVA with Dunnett\u2019s multiple comparisons test, *: p = 0.0104, **: p = 0.0042, ***: p = 0.0003. Data are presented as mean values \u00b1 standard error of the mean (SEM). g Schematic of ChIP assay for ETS1 binding to the caspase-1 promoter. h ChIP assay from MCF7 cells after ectopic ETS1 expression and ER\u03b1 KD, ***: p = 0.0003. i ChIP assay from MDA-MB231 cells after ectopic ER\u03b1 expression, **: p = 0.0053. Caspase-1 promoter/ETS1 complexes are quantified by RTqPCR after immunoprecipitation with nonspecific (IgG) or with anti-ETS1 antiserum. Mean with SEM, two-tailed, unpaired t-test with equal variances. n = 3 biologically independent experiments for immunoblots where representative images are shown, RTqPCR and ChIP assays.",
      "Microarray gene expression data from human breast cancer cell lines was downloaded from ref. 11. Human breast cancer tumor microarray (METABRIC) and RNAseq (TCGA PanCancer Atlas) gene expression and outcome data was obtained from cBioPortal12,13."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 3,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.11273002624511719,
    "data_pmids_checked": 0,
    "paper_id": "39353903",
    "extraction_date": "2025-12-19T20:45:51.252516",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39353903.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39361894": {
    "cbioportal_paper_citations": [
      "Loss of CDK12 causes dependency on the non-essential splicing regulator SRPK1. A) Schematic of core spliceosome along with regulators that we targeted in the combinatorial lethal screen. B) Heatmap of 22RV1 cell number after four-day treatment as indicated (n: 2\u20133; CDK12/13 inhibitor THZ531: 50 nM). C) CRISPR-mediated depletion of SRPK1, CLK1 and CLK4 has minimal effect on cell number (non-essential gene: 0; median of all pan-essential genes: \u22121). Data was accessed through the DepMap CRISPR-database (DepMap 21Q4 public+score, Chronos) (Meyers et al. 2017). D) SRPK1 is significantly overexpressed in the CDK12-mutant tumors when compared to CDK12-wild type tumors. Primary prostate cancer (PC): The TCGA dataset (Taylor et al. 2010) and castration-resistant prostate cancer (CRPC): The SU2C/PCF dream team-dataset (Abida et al. 2019); P-values are those reported in the cBioPortal (Cerami et al. 2012; Gao et al. 2013).",
      "The RNA-seq data of LNCaP cells treated with control or 500 nM THZ531 was downloaded from BioProject (Accession: PRJCA004744) (Lei et al. 2021). First, the raw fastq files were aligned to human genome Hg38 using STAR aligner (Dobin et al. 2013; Gondane and Itkonen 2023). To identify the alternatively spliced sites, we used rMATS v4.1.1 (Shen et al. 2014) and SUPPA (Alamancos et al. 2015). The essentiality and the expression level of spliceosome components in patient samples were assessed using the data available through the DepMap CRISPR-database (DepMap 21Q4 Public+Score, Chronos) (Meyers et al. 2017) and cBioPortal (Cerami et al. 2012; Gao et al. 2013), respectively. The volcano- and box-plots were made in R Studio."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26544944": [
        "Here, we discovered a combinatorial lethal interaction between the compromised CDK12 activity and the non-essential components of the spliceosome. This project was initiated based on two notions: defects in CDK12 define an aggressive subtype of PC (Cancer Genome Atlas Research 2015; Wu et al. 2018; Abida et al. 2019; Schweizer et al. 2020), and the combined inhibition of OGT and CDK9, a functionally related kinase to CDK12, induces cytotoxic effects (Itkonen et al. 2020). Development of the highly specific inhibitors against both OGT and the transcriptional kinases has enabled direct dissection of the crosstalk between phosphorylation and O-GlcNAcylation."
      ],
      "31061129": [
        "Loss of CDK12 causes dependency on the non-essential splicing regulator SRPK1. A) Schematic of core spliceosome along with regulators that we targeted in the combinatorial lethal screen. B) Heatmap of 22RV1 cell number after four-day treatment as indicated (n: 2\u20133; CDK12/13 inhibitor THZ531: 50 nM). C) CRISPR-mediated depletion of SRPK1, CLK1 and CLK4 has minimal effect on cell number (non-essential gene: 0; median of all pan-essential genes: \u22121). Data was accessed through the DepMap CRISPR-database (DepMap 21Q4 public+score, Chronos) (Meyers et al. 2017). D) SRPK1 is significantly overexpressed in the CDK12-mutant tumors when compared to CDK12-wild type tumors. Primary prostate cancer (PC): The TCGA dataset (Taylor et al. 2010) and castration-resistant prostate cancer (CRPC): The SU2C/PCF dream team-dataset (Abida et al. 2019); P-values are those reported in the cBioPortal (Cerami et al. 2012; Gao et al. 2013).",
        "Here, we discovered a combinatorial lethal interaction between the compromised CDK12 activity and the non-essential components of the spliceosome. This project was initiated based on two notions: defects in CDK12 define an aggressive subtype of PC (Cancer Genome Atlas Research 2015; Wu et al. 2018; Abida et al. 2019; Schweizer et al. 2020), and the combined inhibition of OGT and CDK9, a functionally related kinase to CDK12, induces cytotoxic effects (Itkonen et al. 2020). Development of the highly specific inhibitors against both OGT and the transcriptional kinases has enabled direct dissection of the crosstalk between phosphorylation and O-GlcNAcylation."
      ],
      "20579941": [
        "Loss of CDK12 causes dependency on the non-essential splicing regulator SRPK1. A) Schematic of core spliceosome along with regulators that we targeted in the combinatorial lethal screen. B) Heatmap of 22RV1 cell number after four-day treatment as indicated (n: 2\u20133; CDK12/13 inhibitor THZ531: 50 nM). C) CRISPR-mediated depletion of SRPK1, CLK1 and CLK4 has minimal effect on cell number (non-essential gene: 0; median of all pan-essential genes: \u22121). Data was accessed through the DepMap CRISPR-database (DepMap 21Q4 public+score, Chronos) (Meyers et al. 2017). D) SRPK1 is significantly overexpressed in the CDK12-mutant tumors when compared to CDK12-wild type tumors. Primary prostate cancer (PC): The TCGA dataset (Taylor et al. 2010) and castration-resistant prostate cancer (CRPC): The SU2C/PCF dream team-dataset (Abida et al. 2019); P-values are those reported in the cBioPortal (Cerami et al. 2012; Gao et al. 2013)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6845009326934814,
    "data_pmids_checked": 3,
    "paper_id": "39361894",
    "extraction_date": "2025-12-19T20:45:51.332337",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39361894.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39351232": {
    "cbioportal_paper_citations": [
      "The cBio Cancer Genomics Portal (cBioPortal, http://www.cbioportal.org/) provides data for more than 5,000 tumor samples from 20 cancer studies (28). The alteration frequency of SCD mutations in the genomic profiles was used to calculate Pearson\u2019s correlation coefficients across pan-cancer, along with the data on missense mutation sites in PRAD."
    ],
    "cbioportal_platform_mentions": [
      "Promoter methylation and genetic alterations of the SCD gene. Box plots evaluating SCD promoter methylation levels in PRAD among different groups of patients based on clinical parameters including patients\u2019 age (A), race (B), nodal metastasis status (C), TP53 mutation status (D) using the UALCAN database. Multiple groups were compared using one-way ANOVA followed by Bonferroni\u2019s multiple comparisons for every two groups. (E) Alterations summary of SCD in different tumors. (F) The most common SCD genetic mutation in PRAD analyzed by the cBioPortal database. * P <0.05; ** P <0.01; *** P <0.001.",
      "Furthermore, we investigated the genetic alteration characteristics of SCD in the TCGA cohort through the cBioPortal network. According to the results, the frequency of SCD alteration in PRAD patients was 2.43% in 494 cases ( Figure 3E ). Particularly, mutations in the FA desaturase domain containing the SCD active site, with L134V (Leucine converts to Valine) being the most common locus, were observed in PRAD ( Figure 3F ). Both the original (Leu) and the substituted (Val) residues are non-polar with hydrophobic side chains and have only a slight difference. Therefore, we speculate that the L134V mutation may increase PRAD risk by enhancing SCD function. However, further clinical patient data is required to confirm this relationship. These findings revealed that the abnormal expression of SCD in specific cancers may stem from genetic alterations and promoter hypermethylation, providing a deeper understanding of PRAD tumorigenesis and guiding potential treatment strategy."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2574191093444824,
    "data_pmids_checked": 1,
    "paper_id": "39351232",
    "extraction_date": "2025-12-19T20:45:51.510031",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39351232.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39351073": {
    "cbioportal_paper_citations": [
      "Analysis of 32 TGCA Pan-Cancer Atlas studies (10,967 samples) using the cBioPortal for Cancer Genomics54,55 revealed EP300 mutations with the approximate ratio of 10% in all cancer samples tested (1,083 samples). It increased to 23.2% in melanomas and genitourinary cancers (Figure 3A). Point mutations (37% of altered samples) and changes in gene expression without genetic alterations (high expression 31% and low expression 22%) represented the most frequently occurring cases (Figure 3B).Figure 3EP300 alterations in cancers(A) EP300 changes across cancer types and (B) quantitative summary of EP300 changes in cancers was generated in cBioPortal based on the TCGA Pan-Cancer dataset."
    ],
    "cbioportal_platform_mentions": [
      "(A) EP300 changes across cancer types and (B) quantitative summary of EP300 changes in cancers was generated in cBioPortal based on the TCGA Pan-Cancer dataset.",
      "Missense and truncating mutations occur most often among the somatic mutations and account for approximately 93% of all detected changes (Figure 4A). The majority of observed missense alterations that are spread along EP300 gene are assigned to passenger-type mutations (Figure 4B). These changes in cancer genomes are not considered significant in the initiation or progression of cancer since the selective growth advantage has not been observed.56 On the contrary, the driver mutations that provide a cancer cell with beneficial adaptative features, were mainly identified in the catalytic domain and bromodomain/PHD region (Figure 4C). Among them, the most frequent substitution D1399N/Y changed the conformation of histone acetyltransferase KAT domain in the p300 protein, thereby abolishing its autoacetylation activity that is essential for proper protein functioning.57 Other mutations in the KAT domain (Y1414C/D, H1451L, and P1502L) similarly disrupted the acetyltransferase function.58,59 Deletions within the PHD finger that regulates p300 catalytic activity, reduced the p300 efficacy in acetylating histones, but surprisingly retained the capability of the enzyme to acetylate non-histone proteins such as p53.33 Protein-truncating variants led to a shortening or complete protein loss of p300.60 However, truncated variants with an intact catalytic domain can still maintain their function. It has been shown that the TAZ2 domain cooperates with other HAT neighboring domains to maintain the HAT active site in a closed state. Truncating TAZ2 induces a conformational change that opens the active site for substrate acetylation and confers an overactivation of p300.35 Interestingly, EP300 mutations may co-exist with mutations in CBP. In the 32 studies analyzed, 329 cancer patients were characterized by simultaneous alteration in these two genes. Similarly to EP300, the mutations in CBP occurred most frequently in the KAT domain.Figure 4EP300 somatic mutations in cancers(A) Frequency of EP300 somatic mutations in cancers, (B) localization of all somatic mutations in EP300 gene, and (C) localization of driver mutations in EP300 structure; (B) and (C) were generated in cBioPortal based on the TCGA Pan-Cancer dataset.",
      "(A) Frequency of EP300 somatic mutations in cancers, (B) localization of all somatic mutations in EP300 gene, and (C) localization of driver mutations in EP300 structure; (B) and (C) were generated in cBioPortal based on the TCGA Pan-Cancer dataset.",
      "To compare the transcription status of EP300 and to identify the possible expression changes of EP300 in cancer, we compared selected features between the tumor and normal samples from the TCGA and GTEx databases using GEPIA 2.61 As shown in Figure 5A, the mRNA level of EP300 varied in numerous normal and cancerous tissues. Among all the cancers that were considered, thymoma, stomach adenocarcinoma, and acute myeloid leukemia were characterized by a substantial increase in expression of EP300, whereas a decline was found in uterine carcinosarcoma and adenoid cystic carcinoma. The yield of the EP300 transcript can be determined by the rate of RNA synthesis, but also by the alteration of gene copy numbers that were shown to affect the expression level of some specific genes in cancers, hence promoting the development and progression of the disease. The results of pan-cancer studies provided evidence for strong correlation and a positive linear influence of the copy number on the expression of the majority of genes considered.62 However, it was also noted that, due to transcriptional adaptive mechanisms, changes in the gene copy number at the genome level did not always translate proportionally into altered gene expression levels.63 The causative interdependence between mRNA (mRNA expression Z scores relative to normal samples) and the copy number of EP300 was also found in TGCA Pan-Cancer Atlas studies (10,967 samples) (Figures 5B and 5C), and suggest that genetic variation generated a direct effect on the gene transcriptional level.Figure 5EP300 expression in cancers(A) Comparison of EP300 expression in cancers and normal tissues. ACC, adrenocortical cancer; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower-grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THYM, thymoma; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma. (B) Association of EP300 expression with copy number alterations in cancers. (C) Expression of EP300 across cancer types, generated in cBioPortal based on TCGA Pan-Cancer datasets. The comparison in (A) was generated using GEPIA 2. (B) TCGA-Pan Cancer datasets available in cBioPortal was analyzed using GraphPad Prism 8.",
      "(A) Comparison of EP300 expression in cancers and normal tissues. ACC, adrenocortical cancer; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower-grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THYM, thymoma; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma. (B) Association of EP300 expression with copy number alterations in cancers. (C) Expression of EP300 across cancer types, generated in cBioPortal based on TCGA Pan-Cancer datasets. The comparison in (A) was generated using GEPIA 2. (B) TCGA-Pan Cancer datasets available in cBioPortal was analyzed using GraphPad Prism 8.",
      "The increase in the expression and copy number of EP300 is associated with several clinicopathological features that specify tumor stages and prognosis such as grading, metastases, and patient survival in some cancer types. Cancer grading is used to predict the clinical behavior of malignancies and establish appropriate therapies.64 The grade score (numerical: G1\u2013G4) increases with decreasing cellular differentiation: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; and G4, undifferentiated/anaplastic.65 The degree of resemblance between the tumor and its tissue of origin is assessed based on morphological criteria. A high degree of differentiation meaning that the neoplasia is morphologically similar to the native organ and forms neoplastic organoid structures, whereas tumors in low stages of differentiation gradually lose the capacity for structural organization and start to display reduced cohesiveness. The term anaplasia signifies tumor morphology where all similarity with the origin has been lost.66 Malignant neoplasms range from well differentiated to undifferentiated. In general, increasingly undifferentiated tumors are usually more aggressive.67 Evaluation of the EP300 expression at different stages of tumor dedifferentiation shows that expression increases in the tumor cells that are not fully differentiated but decreases in undifferentiated tumors (Figure 6A). Since EP300 regulates various key physiological functions, including cell proliferation, differentiation, and somatic cell reprogramming, higher EP300 abundance and intracellular overall activity may facilitate tumor initiation and progression at an early stage.30 P300 acetylates pluripotency-related transcription factors and enhances their transcription activity, thus promoting stemness acquisition. In cancer, EP300 was considered as an oncogene capable of supporting tumor growth and metastatic potential and facilitating cancer stemness.68 Deficiency of EP300 abolished the cancer stem cell phenotype by reducing tumor sphere formation in vitro and in a xenograft mouse model in vivo,69 meaning a higher activity of p300 may promote the initial malignant transformation. However, in line with the observed reinstatement of p300 levels in high-grade tumors, the decline of EP300 directly suppresses GATA6 expression, which interferes with the GATA6-regulated differentiation program and leads to a phenotypic transition from the classical subtype to the dedifferentiated basal-like/squamous subtype of pancreatic cancer.70 Although a late decrease in p300 expression may look surprising, accumulating mutations and chromosome aberrations are likely to lead to the inactivation of numerous genes, including EP300 and p300-fueled epigenetic reprogramming and the adaptation of cancer cells may be dispensable in advanced, high-grade tumors. One line of evidence suggests that strongly elevated miRNA targets mRNA of EP300 in advanced cancers.71Figure 6Association of EP300 expression with clinical parameters and outcomesThe link between EP300 expression and tumor histologic grade is shown in (A), with tumor stage in (B), lymph node stage in (C), and metastasis stage in (D). The disease-free survival and overall patient survival in relation to EP300 expression is shown in (E) and (F), respectively. TCGA-Pan Cancer datasets available in cBioPortal were analyzed using GraphPad Prism 8 (A\u2013D), and generated using GEPIA 2 (E and F).",
      "The link between EP300 expression and tumor histologic grade is shown in (A), with tumor stage in (B), lymph node stage in (C), and metastasis stage in (D). The disease-free survival and overall patient survival in relation to EP300 expression is shown in (E) and (F), respectively. TCGA-Pan Cancer datasets available in cBioPortal were analyzed using GraphPad Prism 8 (A\u2013D), and generated using GEPIA 2 (E and F)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 7,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.21135997772216797,
    "data_pmids_checked": 0,
    "paper_id": "39351073",
    "extraction_date": "2025-12-19T20:45:51.579580",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39351073.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39356765": {
    "cbioportal_paper_citations": [
      "In addition, transcriptomic and genomic data from TCGA (n = 545) (21), SU2C (n = 266) (25), MSKCC (n = 149) (22), Grasso (n = 88) (23), and Roudier (GSE74367; n = 56) (24) PCa cohorts were obtained from cBioPortal (65, 66) and Gene Expression Omnibus (67) repositories. PanCancer (n = 4915) gene and transcript expression levels were obtained from UCSC Xena repository (68). HIRA-201 and HIRA-203 PSI value was determined as ENST00000263208 (HIRA-201) and ENST00000452818 (HIRA-203) transcript levels normalized by HIRA (ENSG00000100084) mRNA levels."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625050": [
        "We first interrogated the mRNA levels of SRSF6 in two independent human cohorts available in our laboratory [prostatectomies (cohort 1) and biopsies (cohort 2); tables S1 and S2, respectively], comprising PCa and non-tumor prostate tissue samples. SRSF6 mRNA levels were higher in PCa samples versus non-tumor prostate tissue in both cohorts (Fig. 1A). Moreover, SRSF6 expression significantly distinguished between PCa and non-tumor prostate samples in both cohorts (Fig. 1B). Consistently, we found that SRSF6 was also up-regulated in PCa and its levels distinguished between PCa and non-tumor prostate tissues in three additional human external cohorts [The Cancer Genome Atlas (TCGA) (21), Memorial Sloan Kettering Cancer Center (MSKCC) (22), and Grasso (23) datasets (Fig. 1, C and D)]. Notably, SRSF6 levels were especially elevated in CRPC samples in the Grasso cohort and were significantly higher in CRPC samples compared to those in primary PCa samples from the Roudier (24) cohort (Fig. 1C). SRSF6 expression levels perfectly discriminated between primary PCa and CRPC samples in the Roudier cohort [area under the curve (AUC) = 1.0, P < 0.001; Fig. 1D]. Of note, whole-transcriptome analyses from TCGA and Stand Up to Cancer/Prostate Cancer Foundation (SU2C) cohorts revealed that SRSF6 was among the top 25% of most expressed transcripts in both primary and CRPC tumors, respectively (Fig. 1E). Then, to investigate putative genomic alterations associated with SRSF6 overexpression in PCa, we explored SRSF6 genomic copy number alteration (CNA) and its association with SRSF6 mRNA levels in the TCGA [primary PCa; (21)] and SU2C [CRPC; (25)] cohorts. Specifically, SRSF6 was amplified/copy gained in 7.8% and deep deleted in 2.5% of the PCa tumors from TCGA cohort (fig. S1A). Furthermore, SRSF6 was amplified/copy gained in 22.6% and deep deleted in 4.3% of the PCa tumors from SU2C cohort (fig. S1B). In both TCGA and SU2C cohorts, SRSF6 CNA exhibited a significant association with SRSF6 mRNA levels (Fig. 1F). Besides that, SRSF6 mRNA levels did not consistently associate with any molecular subtype or common genomic aberration of PCa (fig. S1, C and D).",
        "In addition, transcriptomic and genomic data from TCGA (n = 545) (21), SU2C (n = 266) (25), MSKCC (n = 149) (22), Grasso (n = 88) (23), and Roudier (GSE74367; n = 56) (24) PCa cohorts were obtained from cBioPortal (65, 66) and Gene Expression Omnibus (67) repositories. PanCancer (n = 4915) gene and transcript expression levels were obtained from UCSC Xena repository (68). HIRA-201 and HIRA-203 PSI value was determined as ENST00000263208 (HIRA-201) and ENST00000452818 (HIRA-203) transcript levels normalized by HIRA (ENSG00000100084) mRNA levels."
      ],
      "20579941": [
        "We first interrogated the mRNA levels of SRSF6 in two independent human cohorts available in our laboratory [prostatectomies (cohort 1) and biopsies (cohort 2); tables S1 and S2, respectively], comprising PCa and non-tumor prostate tissue samples. SRSF6 mRNA levels were higher in PCa samples versus non-tumor prostate tissue in both cohorts (Fig. 1A). Moreover, SRSF6 expression significantly distinguished between PCa and non-tumor prostate samples in both cohorts (Fig. 1B). Consistently, we found that SRSF6 was also up-regulated in PCa and its levels distinguished between PCa and non-tumor prostate tissues in three additional human external cohorts [The Cancer Genome Atlas (TCGA) (21), Memorial Sloan Kettering Cancer Center (MSKCC) (22), and Grasso (23) datasets (Fig. 1, C and D)]. Notably, SRSF6 levels were especially elevated in CRPC samples in the Grasso cohort and were significantly higher in CRPC samples compared to those in primary PCa samples from the Roudier (24) cohort (Fig. 1C). SRSF6 expression levels perfectly discriminated between primary PCa and CRPC samples in the Roudier cohort [area under the curve (AUC) = 1.0, P < 0.001; Fig. 1D]. Of note, whole-transcriptome analyses from TCGA and Stand Up to Cancer/Prostate Cancer Foundation (SU2C) cohorts revealed that SRSF6 was among the top 25% of most expressed transcripts in both primary and CRPC tumors, respectively (Fig. 1E). Then, to investigate putative genomic alterations associated with SRSF6 overexpression in PCa, we explored SRSF6 genomic copy number alteration (CNA) and its association with SRSF6 mRNA levels in the TCGA [primary PCa; (21)] and SU2C [CRPC; (25)] cohorts. Specifically, SRSF6 was amplified/copy gained in 7.8% and deep deleted in 2.5% of the PCa tumors from TCGA cohort (fig. S1A). Furthermore, SRSF6 was amplified/copy gained in 22.6% and deep deleted in 4.3% of the PCa tumors from SU2C cohort (fig. S1B). In both TCGA and SU2C cohorts, SRSF6 CNA exhibited a significant association with SRSF6 mRNA levels (Fig. 1F). Besides that, SRSF6 mRNA levels did not consistently associate with any molecular subtype or common genomic aberration of PCa (fig. S1, C and D).",
        "In addition, transcriptomic and genomic data from TCGA (n = 545) (21), SU2C (n = 266) (25), MSKCC (n = 149) (22), Grasso (n = 88) (23), and Roudier (GSE74367; n = 56) (24) PCa cohorts were obtained from cBioPortal (65, 66) and Gene Expression Omnibus (67) repositories. PanCancer (n = 4915) gene and transcript expression levels were obtained from UCSC Xena repository (68). HIRA-201 and HIRA-203 PSI value was determined as ENST00000263208 (HIRA-201) and ENST00000452818 (HIRA-203) transcript levels normalized by HIRA (ENSG00000100084) mRNA levels."
      ],
      "31061129": [
        "We first interrogated the mRNA levels of SRSF6 in two independent human cohorts available in our laboratory [prostatectomies (cohort 1) and biopsies (cohort 2); tables S1 and S2, respectively], comprising PCa and non-tumor prostate tissue samples. SRSF6 mRNA levels were higher in PCa samples versus non-tumor prostate tissue in both cohorts (Fig. 1A). Moreover, SRSF6 expression significantly distinguished between PCa and non-tumor prostate samples in both cohorts (Fig. 1B). Consistently, we found that SRSF6 was also up-regulated in PCa and its levels distinguished between PCa and non-tumor prostate tissues in three additional human external cohorts [The Cancer Genome Atlas (TCGA) (21), Memorial Sloan Kettering Cancer Center (MSKCC) (22), and Grasso (23) datasets (Fig. 1, C and D)]. Notably, SRSF6 levels were especially elevated in CRPC samples in the Grasso cohort and were significantly higher in CRPC samples compared to those in primary PCa samples from the Roudier (24) cohort (Fig. 1C). SRSF6 expression levels perfectly discriminated between primary PCa and CRPC samples in the Roudier cohort [area under the curve (AUC) = 1.0, P < 0.001; Fig. 1D]. Of note, whole-transcriptome analyses from TCGA and Stand Up to Cancer/Prostate Cancer Foundation (SU2C) cohorts revealed that SRSF6 was among the top 25% of most expressed transcripts in both primary and CRPC tumors, respectively (Fig. 1E). Then, to investigate putative genomic alterations associated with SRSF6 overexpression in PCa, we explored SRSF6 genomic copy number alteration (CNA) and its association with SRSF6 mRNA levels in the TCGA [primary PCa; (21)] and SU2C [CRPC; (25)] cohorts. Specifically, SRSF6 was amplified/copy gained in 7.8% and deep deleted in 2.5% of the PCa tumors from TCGA cohort (fig. S1A). Furthermore, SRSF6 was amplified/copy gained in 22.6% and deep deleted in 4.3% of the PCa tumors from SU2C cohort (fig. S1B). In both TCGA and SU2C cohorts, SRSF6 CNA exhibited a significant association with SRSF6 mRNA levels (Fig. 1F). Besides that, SRSF6 mRNA levels did not consistently associate with any molecular subtype or common genomic aberration of PCa (fig. S1, C and D).",
        "In addition, transcriptomic and genomic data from TCGA (n = 545) (21), SU2C (n = 266) (25), MSKCC (n = 149) (22), Grasso (n = 88) (23), and Roudier (GSE74367; n = 56) (24) PCa cohorts were obtained from cBioPortal (65, 66) and Gene Expression Omnibus (67) repositories. PanCancer (n = 4915) gene and transcript expression levels were obtained from UCSC Xena repository (68). HIRA-201 and HIRA-203 PSI value was determined as ENST00000263208 (HIRA-201) and ENST00000452818 (HIRA-203) transcript levels normalized by HIRA (ENSG00000100084) mRNA levels."
      ],
      "22722839": [
        "We first interrogated the mRNA levels of SRSF6 in two independent human cohorts available in our laboratory [prostatectomies (cohort 1) and biopsies (cohort 2); tables S1 and S2, respectively], comprising PCa and non-tumor prostate tissue samples. SRSF6 mRNA levels were higher in PCa samples versus non-tumor prostate tissue in both cohorts (Fig. 1A). Moreover, SRSF6 expression significantly distinguished between PCa and non-tumor prostate samples in both cohorts (Fig. 1B). Consistently, we found that SRSF6 was also up-regulated in PCa and its levels distinguished between PCa and non-tumor prostate tissues in three additional human external cohorts [The Cancer Genome Atlas (TCGA) (21), Memorial Sloan Kettering Cancer Center (MSKCC) (22), and Grasso (23) datasets (Fig. 1, C and D)]. Notably, SRSF6 levels were especially elevated in CRPC samples in the Grasso cohort and were significantly higher in CRPC samples compared to those in primary PCa samples from the Roudier (24) cohort (Fig. 1C). SRSF6 expression levels perfectly discriminated between primary PCa and CRPC samples in the Roudier cohort [area under the curve (AUC) = 1.0, P < 0.001; Fig. 1D]. Of note, whole-transcriptome analyses from TCGA and Stand Up to Cancer/Prostate Cancer Foundation (SU2C) cohorts revealed that SRSF6 was among the top 25% of most expressed transcripts in both primary and CRPC tumors, respectively (Fig. 1E). Then, to investigate putative genomic alterations associated with SRSF6 overexpression in PCa, we explored SRSF6 genomic copy number alteration (CNA) and its association with SRSF6 mRNA levels in the TCGA [primary PCa; (21)] and SU2C [CRPC; (25)] cohorts. Specifically, SRSF6 was amplified/copy gained in 7.8% and deep deleted in 2.5% of the PCa tumors from TCGA cohort (fig. S1A). Furthermore, SRSF6 was amplified/copy gained in 22.6% and deep deleted in 4.3% of the PCa tumors from SU2C cohort (fig. S1B). In both TCGA and SU2C cohorts, SRSF6 CNA exhibited a significant association with SRSF6 mRNA levels (Fig. 1F). Besides that, SRSF6 mRNA levels did not consistently associate with any molecular subtype or common genomic aberration of PCa (fig. S1, C and D).",
        "In addition, transcriptomic and genomic data from TCGA (n = 545) (21), SU2C (n = 266) (25), MSKCC (n = 149) (22), Grasso (n = 88) (23), and Roudier (GSE74367; n = 56) (24) PCa cohorts were obtained from cBioPortal (65, 66) and Gene Expression Omnibus (67) repositories. PanCancer (n = 4915) gene and transcript expression levels were obtained from UCSC Xena repository (68). HIRA-201 and HIRA-203 PSI value was determined as ENST00000263208 (HIRA-201) and ENST00000452818 (HIRA-203) transcript levels normalized by HIRA (ENSG00000100084) mRNA levels."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 3.1254189014434814,
    "data_pmids_checked": 4,
    "paper_id": "39356765",
    "extraction_date": "2025-12-19T20:45:54.148527",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39356765.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39349509": {
    "cbioportal_paper_citations": [
      "For the cancer-based algorithm, a training dataset of 709 driver and 910 passenger mutations and a testing dataset of 100 driver and 100 passenger mutations were curated from four databases, namely cBioPortal37,38, OncoKB39, IntOGen2, and GnomAD40 (Fig. 2b and S2). Curation was performed in accordance with the supervised learning method established in machine learning and in the development of other prediction tools21,24,35,36. cBioPortal is an open-source resource of gene mutations along with categorization. OncoKB categorizes driver mutations based on clinical data. IntOGen is a database that collates mutations in tumor genomes and label possible driver ones. GnomAD processes raw data from large-scale sequencing projects2. The ClinVar database was used to assess the clinical significance of mutations from the training and testing datasets. Mutations categorized as \u201cBenign\u201d were regarded as passenger mutations. The total numbers of drivers, passengers, deleterious and neutral mutations provided by each database are listed in Fig. S2a and S2b. Mutations obtained from the IntOGen database were only used for the training dataset, as the criteria for their inclusion in the database are solely based on bioinformatics analysis without clinical/experimental support (Fig. S2c)2. Mutations were selected from previously published cancer/driver genes16 for analyses using both algorithms, as well as mutations from known breast cancer genes for validation of cancer-based algorithm (Table S3). Mutations that were classified incorrectly by all prediction tools were excluded from the testing dataset. The full list of mutations used in the training and testing data for cancer-based algorithms can be found in Supplementary Tables 3 and 4 respectively."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 2.623284101486206,
    "data_pmids_checked": 0,
    "paper_id": "39349509",
    "extraction_date": "2025-12-19T20:45:54.237172",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39349509.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39352383": {
    "cbioportal_paper_citations": [
      "In addition to the qualifying mutations defined above, we listed all recurrent protein-coding mutations detected in pre-ARSI and post-ARSI tumors in Supplemental Tables 2 and 3, respectively. We found 4 genes with recurrent mutations before ARSI (AKT1, AR, CDK12, and SPATA31E1); the former 3 are known to mutate in PCa, and their mutations in our dataset are known to be pathogenic (AKT1 E17K and AR T878A) or consistent with the known mechanisms of pathogenicity (the CDK12 stop gain mutation causing loss of function). After ARSI, we found a total of 242 unique recurrent mutations (Supplemental Table 3), with KMT2C C988F being the most frequently mutated (detected in 3 post-ARSI samples, 2 from the same patient, DTB-176). This mutation is absent in primary PCa in The Cancer Genome Atlas (TCGA) (26) and is predicted to be benign as a germline mutation in ClinVar (27). Although KMT2C is frequently mutated in cancer, we believe further statistical and functional evidence is needed to clarify whether C988F is associated with ARSI resistance. All the other 241 mutations were mutated twice among the 45 post-ARSI samples.",
      "Paired analysis of metastatic biopsies from the same patients before and after treatment offers a unique advantage in identifying resistance mechanisms conserved among patients. We performed paired differential gene expression (DGE) analysis to focus on post-ARSI changes after accounting for patient-unique factors. Our genome-wide analysis identified SSTR1 as the most significant hit; its expression consistently decreased in most patients after disease progression on ARSIs (Figure 5, A\u2013C). SSTR1 encodes somatostatin receptor 1, a G protein\u2013coupled receptor (GPCR) on the plasma membrane that mediates antiproliferative, antimigratory, and antisecretory effects when activated by its endogenous ligand, somatostatin (56). Somatostatin is a peptide that functions as a neurotransmitter in the CNS and as a hormone regulating the endocrine system by binding to somatostatin receptors 1\u20135 (SSTR1\u2013SSTR5) (56). Given their antitumor effects, somatostatin analogs such as octreotide and lanreotide (both are potent SSTR2 agonists but notably spare SSTR1) have been approved to treat gastroenteropancreatic NE tumors and carcinoid syndrome (57, 58). Among different cancer types in TCGA, SSTR1 mRNA in primary PCa is higher than all the other cancer types except glioma (26, 59) (Supplemental Figure 19). Using a recently published single-cell RNA-Seq dataset of mCRPC biopsies (60), we found that SSTR1 expression was predominantly restricted to PCa cells and absent in the tumor immune microenvironment (60, 61) (Supplemental Figure 20).",
      "Paired analysis is uniquely powered to identify resistance mechanisms conserved among patients by accounting for the effect of patient-specific factors. We identified SSTR1 as the most significant gene and found its expression decreased in most ARSI-resistant tumors (Figure 5, A\u2013C). In line with the near-ubiquity of this observation in our dataset, SSTR1 downregulation occurred after ARSI treatment across the full phenotypic spectrum captured by the Beltran (9) or Tang (17) method. SSTR1 expression is high in primary, untreated PCa and appears to be restricted to cancer cells (26, 59, 60). Our findings suggest that SSTR1 expression may be a candidate predictive biomarker for response to second-line ARSIs (i.e., Figure 5D and Supplemental Figure 22, B and C) following disease progression on the first ARSI (82). With the increasing use of ARSIs upfront to treat PCa, whether patients should be rechallenged with a second ARSI at disease progression has become an important clinical question. In this clinical space with growing patient needs, a second ARSI may be preferred prior to cytotoxic drugs such as chemotherapy and radioligand therapy, given the ARSI\u2019s favorable side-effect profile. However, its efficacy is hard to predict and can be highly variable (82, 83), as there is currently no predictive biomarker to guide this important clinical decision\u2013making process. We provide preliminary data to support tumor SSTR1 expression as a promising candidate for such a biomarker. Larger studies, ideally using a randomized controlled design, are needed to further evaluate this finding.",
      "The ECDT dataset (63) was downloaded from cBioPortal (26, 59), including variant calls and fragments per kilobase of transcript per million mapped reads (FPKM) values. Because 2 different RNA-Seq methods (\u201ccapture\u201d and \u201cpolyA\u201d) were used in ECDT, we followed the example of cBioPortal (26, 59) and reported our reanalysis focusing on SSTR1 expression and AR mutations separately for the 2 methods. RNA-Seq data from the COMBAT-CRPC trial (67) were downloaded from the NCBI\u2019s Gene Expression Omnibus (GEO) database (GEO GSE229555). RNA-Seq data from the SPT preclinical study in enzalutamide-resistant PDX models (68) were downloaded from GEO (GEO GSE124704). cistromeDB (42, 43) and ReMap (45) were queried through their respective web interfaces."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31061129": [
        "To investigate the effect of DNA mutations on SSTR1 expression in mCRPC (as it is not trivially explained by SSTR1 copy number), we conducted a genome-wide association analysis using the 134 WCDT mCRPC samples with both WGS and matched RNA-Seq data available. We tested the association between SSTR1 mRNA and the burden of functional protein-coding mutations in each gene, using a linear regression model adjusting for tumor purity (62). Among the 6,277 evaluable genes (each with at least 1 functional protein-coding mutation), AR demonstrated the strongest association with SSTR1 mRNA (P = 1.44 \u00d7 10\u20134; Figure 6A). AR-mutated tumors had higher SSTR1 expression (Figure 6B), independent of the AR copy number (Supplemental Figure 24A). To assess the effect of individual AR mutations, we performed single-variant analysis and found that T878A and, to a lesser extent, L702H were associated with SSTR1 mRNA (Figure 6, C and D), whereas H875Y was not (Figure 6E). Interestingly, the positive association between AR mutations and SSTR1 expression was observed only in ARSI-exposed, but not ARSI-naive, tumors (Figure 6, F and G). Further analysis using multiple linear regression confirmed that both ARSI exposure status (exposed vs. naive) and AR mutation status (mutated vs. WT) independently predicted SSTR1 expression (\u03b2 = \u20131.62, P = 5.88 \u00d7 10\u20135 and \u03b2 = 2.53, P = 3.84 \u00d7 10\u20135, respectively), with a trend toward significant statistical interaction (P = 0.067), whereas tumor purity had no effect (P = 0.82). To validate our findings in an independent cohort, we evaluated the SU2C/PCF East Coast Dream Team (ECDT) dataset (63). Similarly, we found that AR mutations were significantly associated with high SSTR1 expression (Figure 6, H and I), with L702H and H875Y showing statistical significance in single variant analysis (Supplemental Figure 24, B\u2013I). Further, AR mutation status predicted SSTR1 expression only in ARSI-exposed, but not ARSI-naive, tumors in the ECDT dataset (Figure 6, J\u2013M). Collectively, these data suggest that SSTR1 expression is linked to AR signaling in mCRPC.",
        "The ECDT dataset (63) was downloaded from cBioPortal (26, 59), including variant calls and fragments per kilobase of transcript per million mapped reads (FPKM) values. Because 2 different RNA-Seq methods (\u201ccapture\u201d and \u201cpolyA\u201d) were used in ECDT, we followed the example of cBioPortal (26, 59) and reported our reanalysis focusing on SSTR1 expression and AR mutations separately for the 2 methods. RNA-Seq data from the COMBAT-CRPC trial (67) were downloaded from the NCBI\u2019s Gene Expression Omnibus (GEO) database (GEO GSE229555). RNA-Seq data from the SPT preclinical study in enzalutamide-resistant PDX models (68) were downloaded from GEO (GEO GSE124704). cistromeDB (42, 43) and ReMap (45) were queried through their respective web interfaces."
      ],
      "31068700": [
        "Intrigued by the above findings of SSTR1, we conducted experiments in PCa cells to further investigate the relationship between SSTR1 and AR signaling. We selected the enzalutamide-resistant 22Rv1 cells to represent ARSI-resistant mCRPC; 22Rv1 cells also have higher SSTR1 expression compared with several other PCa cell lines (69). We found that dihydrotestosterone (DHT) treatment did not seem to change SSTR1 mRNA expression at 48 hours (Supplemental Figure 27A). Next, we performed SSTR1 stable knockdown (using clustered, regularly interspaced palindromic repeats interference [CRISPRi]) and stable overexpression assays in 22Rv1 cells (Supplemental Figure 27, B and C) and found no obvious effect on AR mRNA of either silencing or overexpressing SSTR1 (Supplemental Figure 27D). Consistent with our hypothesis, knockdown of SSTR1 significantly augmented 22Rv1 cell proliferation (Supplemental Figure 27E), while inducing overexpression of SSTR1 had the opposite effect (Supplemental Figure 27F). In line with similar findings from a prior study (70), our results validate the antitumor effect of SSTR1 in mCRPC."
      ],
      "35617398": [
        "Studies of preclinical models and patient samples have revealed recurring mechanisms of resistance to androgen deprivation therapy (ADT) and ARSIs. These mechanisms can be broadly grouped by their relationships to the androgen receptor (AR), the primary driver and drug target of PCa (2). AR-dependent mechanisms typically originate in the PCa genome and manifest as amplifications of AR (4) and its upstream enhancer (5\u20137) and gain-of-function mutations in the ligand binding domain (8). Conversely, non-AR-mediated mechanisms appear to be more heterogeneous (2) and may manifest as treatment-emergent evolution into AR-indifferent phenotypes such as small-cell neuroendocrine (NE) (9\u201314) or AR-negative, NE-negative (double-negative) PCa (11, 15\u201317). Nonetheless, how PCa becomes resistant to ARSIs remains inadequately understood, partially due to the difficulty of obtaining serial tissue biopsies through the treatment course, which would enable a direct search for treatment-emergent changes by contrasting progressive with baseline tumors in individual patients (18). To circumvent the need for tissue biopsies, recent studies serially sampled circulating tumor DNA (ctDNA) from patients and identified AR alterations as the main genetic driver of ARSI resistance (19, 20). Although liquid biopsy is an invaluable, noninvasive diagnostic tool, it complements rather than supplants tissue biopsy for a comprehensive understanding of resistance mechanisms.",
        "To further assess the functional effect of these 4 candidate regions, we examined the publicly available dataset of chromosome conformation capture (3C) coupled with immunoprecipitation (HiChIP) of H3K27ac, a histone mark of active enhancers and promoters (39), generated from the LNCaP PCa cell line (40). We observed evidence for chromatin looping between C4 (chrX:67787800-67793300), but not C1\u2013C3, and the AR promoter (Figure 3B). The copy number of C4 significantly increased (P = 0.0013; Supplemental Figure 9) after ARSI therapy, similar to the copy number gains involving AR (Figure 2B) and its upstream enhancer (Figure 2C). Furthermore, we found that 18 of the 42 (42.9%) pre-ARSI tumors and 22 of the 45 (48.9%) post-ARSI tumors harbored TDs involving C4, respectively, and that 10 of the 45 (22.2%) post-ARSI tumors gained new TDs involving C4. Unlike C1\u2013C3, C4 seemed to lack a prominent AR ChIP-Seq signal but maintained FOXA1 binding in mCRPC (Figure 3A). To explore additional TFs that may interact with the DNA sequences within C4, we performed a GIGGLE enrichment analysis (41) using all ChIP-Seq profiles available via cistromeDB (42, 43). In line with ChIP-Seq data from patient samples (Figure 3A), the AR was found to be the top TF binding to C1\u2013C3 but not to C4 (Supplemental Figure 10). To nominate candidate TFs binding to C4 in an unbiased manner, we leveraged the recently published assay for transposase-accessible chromatin sequencing (ATAC-Seq) data from human CRPC organoids (17). We identified 3 and 4 ATAC-Seq peaks within C1\u2013C3 and C4, respectively, performed TF motif enrichment analysis for these peaks (44), and observed distinct TF binding profiles (Supplemental Figure 11). Whereas steroid receptors were predicted to bind to C1\u2013C3, a very different set of TFs were predicted to bind to C4, among which we found FOXA1 to be significantly coexpressed with AR (Supplemental Figure 12). To further examine FOXA1 binding in C4, we queried the ReMap database (45) and observed evidence of FOXA1 binding in multiple PCa cell lines, primary PCa, and mCRPC (Supplemental Figure 13). Given the reported involvement of FOXA2 in lineage plasticity and NE PCa (46) but the lack of FOXA2 signal in ReMap (45), we searched the ChIP Atlas database (47) and found 2 ChIP-Seq peaks located in C4 reported by a recent study (48). Altogether, our multiomics analyses pinpoint a noncoding DNA element downstream of AR that is amplified in mCRPC and may mediate ARSI resistance by potentially interacting with TFs including FOXA1 and possibly FOXA2, calling for further research to understand the significance and mechanisms of these findings.",
        "Inspired by the recent progress in understanding mCRPC heterogeneity using advanced sequencing technologies such as ATAC-Seq, we similarly calculated phenotypic scores for each tumor using the key TFs defining the 4 molecular subtypes of mCRPC reported by Tang et al. (17): AR-dependent (CRPC-AR), NE (CRPC-NEPC), Wnt-dependent (CRPC-Wnt), and stem cell-like (CRPC-SCL). Despite a lack of consistent changes achieving statistical significance when comparing the 31 RNA-Seq pairs for each subtype score, we observed tumors that had large post-ARSI numerical changes in these scores, indicating treatment-emergent transcriptional rewiring (Supplemental Figure 16, A\u2013D). Post-ARSI changes of these subtype scores were often uncorrelated (Supplemental Figure 16E), indicating that they tend to measure orthogonal features of the tumor transcriptional profile. To identify pairs with exceptional state transitions after ARSI, we performed a principal component analysis using the changes in the 4 subtype scores and identified 4 outliers (Supplemental Figure 16F), 3 of which (DTB-080-PRO, DTB-135-PRO, and HMF-019-2) were also identified as phenotypic converters using the Beltran AR/NE scoring system (Figure 4, B and C). Concordant with the transcriptional heterogeneity assessed using the Labrecque genes (11) for these 3 pairs (Figure 4C), we observed variable changes in Wnt, NEPC, and SCL scores despite a more consistent decrease in the AR score (Supplemental Figure 16, G\u2013I). The fourth outlier, HMF-012-3 (Supplemental Figure 16F), maintained a relatively high AR post-ARSI score (Supplemental Figure 16, G-I) but lower Wnt, NEPC, and SCL scores (Supplemental Figure 16, J\u2013L), suggesting increased AR addiction or transition to a resistance phenotype not yet well captured by these scores. These findings also agree with the notion that the transcriptional phenotypes of mCRPC tumors, particularly those that have been treated with multiple hormonal therapy agents, represent a continuum rather than discrete states (11).",
        "To further determine the transcriptional features of ARSI-resistant tumors, we conducted a genome-wide analysis to identify differentially expressed genes by comparing all post-ARSI (n = 40) versus pre-ARSI (n = 31) samples (unpaired analysis). LMO3 was found to be the most significantly upregulated gene after ARSI therapy (Figure 4D). LMO3 is a TF that regulates NE differentiation and 1 of the 22 Labrecque genes used to molecularly subtype mCRPC (11); consistently, LMO3 expression increased in the 3 tumors, gaining a high Beltran NE score following ARSI (Figure 4, B and C). A query of ReMap (45) showed ChIP-Seq signals of FOXA1 in the promoter of LMO3 in mCRPC (51) that were distinct from those in primary PCa (52), indicating the rewiring of FOXA1 cistrome as a potential upstream event (Supplemental Figure 17). SFRP5, encoding a soluble regulator of Wnt signaling (53), was also significantly upregulated after ARSI (Figure 4D), highlighting the known importance of Wnt signaling in ARSI resistance (2, 17). To search for biological pathways associated with ARSI resistance, we conducted unpaired ssGSEA (34) and identified FGFR pathways among the most significantly upregulated, most prominently FGFR3 (Figure 4E and Supplemental Figure 18A). Notably, all 5 tumors with a high NE score were ARSI-resistant (Figure 4B) and had a high transcriptional activity of the FGFR3 pathway (Figure 4F). Among all Reactome pathways, change in the FGFR2 pathway was the most anticorrelated with change in AR expression (Figure 4G and Supplemental Figure 18B). These findings are consistent with prior studies reporting that FGFR signaling supports lineage plasticity and AR-independent PCa (12, 54, 55).",
        "Transcriptional reprogramming and lineage plasticity are widely observed in mCRPC and are increasingly recognized as a critical resistance mechanism adopted by PCa and other cancer types (2, 12, 49). Our analyses revealed excessively variable expression of lineage-informative genes (e.g., the 22 Labrecque genes for mCRPC subtyping) (11) after ARSI therapy (Supplemental Figure 15). Such phenotypic diversification is remarkable, given the prevalent genetic alterations that monotonously converge on augmenting AR signaling, indicating additional mechanisms (such as non-AR genetic alterations or epigenetic mechanisms discussed earlier) in play. Similar to prior studies (13, 14), we identified tumor pairs showing a clear phenotypic switch from an AR-driven to an apparently AR-indifferent form, measured either by the Beltran scoring system (9) or the 4-subtype classification scheme recently reported by Tang et al. (17). We also found increased activity of FGFR pathways after ARSI therapy, particularly in tumors gaining a NE phenotype , corroborating recent reports (12, 54, 55).",
        "Paired analysis is uniquely powered to identify resistance mechanisms conserved among patients by accounting for the effect of patient-specific factors. We identified SSTR1 as the most significant gene and found its expression decreased in most ARSI-resistant tumors (Figure 5, A\u2013C). In line with the near-ubiquity of this observation in our dataset, SSTR1 downregulation occurred after ARSI treatment across the full phenotypic spectrum captured by the Beltran (9) or Tang (17) method. SSTR1 expression is high in primary, untreated PCa and appears to be restricted to cancer cells (26, 59, 60). Our findings suggest that SSTR1 expression may be a candidate predictive biomarker for response to second-line ARSIs (i.e., Figure 5D and Supplemental Figure 22, B and C) following disease progression on the first ARSI (82). With the increasing use of ARSIs upfront to treat PCa, whether patients should be rechallenged with a second ARSI at disease progression has become an important clinical question. In this clinical space with growing patient needs, a second ARSI may be preferred prior to cytotoxic drugs such as chemotherapy and radioligand therapy, given the ARSI\u2019s favorable side-effect profile. However, its efficacy is hard to predict and can be highly variable (82, 83), as there is currently no predictive biomarker to guide this important clinical decision\u2013making process. We provide preliminary data to support tumor SSTR1 expression as a promising candidate for such a biomarker. Larger studies, ideally using a randomized controlled design, are needed to further evaluate this finding."
      ],
      "29610475": [
        "The 2 well-recognized mechanisms of ARSI resistance are genetic alterations augmenting AR signaling (2, 5\u20137, 19, 20) and phenotypic evolution into apparently AR-indifferent tumors (9\u201311, 13, 14). Our unbiased analyses of paired biopsies confirm both mechanisms and further emphasize the prominent role of genetic alterations involving AR and its neighboring regulatory elements to counteract ARSI-induced selective pressure (Figure 2A). We did not find definitive evidence for non-AR genetic alterations driving ARSI resistance, and current literature reports similar observations through analysis of serial tissue (18) or ctDNA (20) specimens. Together, these observations suggest 2 hypotheses that are not mutually exclusive and can be tested in future research. First, non-AR genetic drivers of ARSI resistance may have a high genetic heterogeneity and follow a \u201clong tail\u201d distribution (77), and larger sample sizes are required to observe individual events at sufficient frequency for robust statistical inference. Second, epigenetic mechanisms (e.g., changes in DNA methylation, histone modifications, chromatin accessibility, and genome organization) may play a key role in ARSI resistance, and epigenomic profiling techniques may facilitate the identification of these mechanisms (31, 50, 78\u201380)."
      ],
      "26855148": [
        "Studies of preclinical models and patient samples have revealed recurring mechanisms of resistance to androgen deprivation therapy (ADT) and ARSIs. These mechanisms can be broadly grouped by their relationships to the androgen receptor (AR), the primary driver and drug target of PCa (2). AR-dependent mechanisms typically originate in the PCa genome and manifest as amplifications of AR (4) and its upstream enhancer (5\u20137) and gain-of-function mutations in the ligand binding domain (8). Conversely, non-AR-mediated mechanisms appear to be more heterogeneous (2) and may manifest as treatment-emergent evolution into AR-indifferent phenotypes such as small-cell neuroendocrine (NE) (9\u201314) or AR-negative, NE-negative (double-negative) PCa (11, 15\u201317). Nonetheless, how PCa becomes resistant to ARSIs remains inadequately understood, partially due to the difficulty of obtaining serial tissue biopsies through the treatment course, which would enable a direct search for treatment-emergent changes by contrasting progressive with baseline tumors in individual patients (18). To circumvent the need for tissue biopsies, recent studies serially sampled circulating tumor DNA (ctDNA) from patients and identified AR alterations as the main genetic driver of ARSI resistance (19, 20). Although liquid biopsy is an invaluable, noninvasive diagnostic tool, it complements rather than supplants tissue biopsy for a comprehensive understanding of resistance mechanisms.",
        "Despite the recurrent genetic alterations converging on augmenting AR function, mCRPC is well known to exhibit treatment-emergent transcriptional heterogeneity and lineage plasticity, the underlying mechanisms of which are only partially understood (9\u201311, 49). To assess the phenotypic evolution of mCRPC being treated with ARSIs, we first analyzed RNA-Seq data focusing on genes used to define molecular subtypes of mCRPC (9, 11). After correcting for the sample source (Supplemental Figure 14), we found that AR was among the top 50 most variably expressed genes (ranking 49/20810). Notably, tumors exhibiting both the highest and lowest levels of AR expression were predominantly those having progressed on ARSIs (Figure 4A). Indeed, AR expression became more variable after ARSI therapy (P = 1.52 \u00d7 10\u20134, F test). Furthermore, all 22 genes used for molecular subtyping of mCRPC by Labrecque et al. (11) showed increased variability of post-ARSI expression (Supplemental Figure 15). Tumors with higher AR expression tended to have more copies of AR and its upstream enhancer (Figure 2, E and F, and Figure 4A), whereas tumors with lower AR expression tended to lack such amplifications. Corroborating prior reports (13, 14), we used the Beltran AR/NE scoring system (9) and observed tumors that transitioned from a high AR/low NE state to a low AR/high NE state (3 of 31 RNA-Seq pairs; Figure 4, B and C). Among these 3 pairs, 1 (HMF-019) transitioned to a clear NE phenotype, supported by the highly expressed NE TFs (e.g., NKX2-1, ASCL1, and INSM1) and markers (e.g., CHGA; Figure 4C), while the other 2 (DTB-080 and DTB-135) had a lower NE score with correspondingly less prominent expression of NE-related genes after ARSI therapy (11, 50).",
        "The 2 well-recognized mechanisms of ARSI resistance are genetic alterations augmenting AR signaling (2, 5\u20137, 19, 20) and phenotypic evolution into apparently AR-indifferent tumors (9\u201311, 13, 14). Our unbiased analyses of paired biopsies confirm both mechanisms and further emphasize the prominent role of genetic alterations involving AR and its neighboring regulatory elements to counteract ARSI-induced selective pressure (Figure 2A). We did not find definitive evidence for non-AR genetic alterations driving ARSI resistance, and current literature reports similar observations through analysis of serial tissue (18) or ctDNA (20) specimens. Together, these observations suggest 2 hypotheses that are not mutually exclusive and can be tested in future research. First, non-AR genetic drivers of ARSI resistance may have a high genetic heterogeneity and follow a \u201clong tail\u201d distribution (77), and larger sample sizes are required to observe individual events at sufficient frequency for robust statistical inference. Second, epigenetic mechanisms (e.g., changes in DNA methylation, histone modifications, chromatin accessibility, and genome organization) may play a key role in ARSI resistance, and epigenomic profiling techniques may facilitate the identification of these mechanisms (31, 50, 78\u201380).",
        "Transcriptional reprogramming and lineage plasticity are widely observed in mCRPC and are increasingly recognized as a critical resistance mechanism adopted by PCa and other cancer types (2, 12, 49). Our analyses revealed excessively variable expression of lineage-informative genes (e.g., the 22 Labrecque genes for mCRPC subtyping) (11) after ARSI therapy (Supplemental Figure 15). Such phenotypic diversification is remarkable, given the prevalent genetic alterations that monotonously converge on augmenting AR signaling, indicating additional mechanisms (such as non-AR genetic alterations or epigenetic mechanisms discussed earlier) in play. Similar to prior studies (13, 14), we identified tumor pairs showing a clear phenotypic switch from an AR-driven to an apparently AR-indifferent form, measured either by the Beltran scoring system (9) or the 4-subtype classification scheme recently reported by Tang et al. (17). We also found increased activity of FGFR pathways after ARSI therapy, particularly in tumors gaining a NE phenotype , corroborating recent reports (12, 54, 55).",
        "Paired analysis is uniquely powered to identify resistance mechanisms conserved among patients by accounting for the effect of patient-specific factors. We identified SSTR1 as the most significant gene and found its expression decreased in most ARSI-resistant tumors (Figure 5, A\u2013C). In line with the near-ubiquity of this observation in our dataset, SSTR1 downregulation occurred after ARSI treatment across the full phenotypic spectrum captured by the Beltran (9) or Tang (17) method. SSTR1 expression is high in primary, untreated PCa and appears to be restricted to cancer cells (26, 59, 60). Our findings suggest that SSTR1 expression may be a candidate predictive biomarker for response to second-line ARSIs (i.e., Figure 5D and Supplemental Figure 22, B and C) following disease progression on the first ARSI (82). With the increasing use of ARSIs upfront to treat PCa, whether patients should be rechallenged with a second ARSI at disease progression has become an important clinical question. In this clinical space with growing patient needs, a second ARSI may be preferred prior to cytotoxic drugs such as chemotherapy and radioligand therapy, given the ARSI\u2019s favorable side-effect profile. However, its efficacy is hard to predict and can be highly variable (82, 83), as there is currently no predictive biomarker to guide this important clinical decision\u2013making process. We provide preliminary data to support tumor SSTR1 expression as a promising candidate for such a biomarker. Larger studies, ideally using a randomized controlled design, are needed to further evaluate this finding."
      ]
    },
    "total_cbioportal_paper_citations": 4,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 5,
    "extraction_method": "jats_xml",
    "extraction_time": 3.119992971420288,
    "data_pmids_checked": 5,
    "paper_id": "39352383",
    "extraction_date": "2025-12-19T20:45:54.281940",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39352383.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39335495": {
    "cbioportal_paper_citations": [
      "Kaplan\u2013Meier survival analysis was conducted using the \u201csurvival\u201d and \u201csurvminer\u201d packages in R, and the patients were classified based on high and low DNAJB6 expression groups and on the optimal cut-off value. The cBio Cancer Genomics Portal (https://www.cbioportal.org accessed on 8 August 2024) [21] was used to analyze mutations and copy number variations in DNAJB6 in 302 patients with LUAD."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.08575582504272461,
    "data_pmids_checked": 0,
    "paper_id": "39335495",
    "extraction_date": "2025-12-19T20:45:54.344314",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39335495.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39335130": {
    "cbioportal_paper_citations": [
      "TCGA PanCancer Atlas COADREAD cohort data [22,23] were accessed via cbioportal.org [24]. Marker-high expressing groups were defined by a Z-score cutoff of EXP > 1 for each marker (\u03b1SMA, FAP, MMP2, PDPN, TAGLN, and THY1). Overlap for groups was calculated using cbioportal.com. Differential gene expression for each group with five or greater CRCs vs. the remaining COADREAD dataset was accessed and downloaded for further analysis. Some upset plots were adapted from cbioportal.com.",
      "Gene Set Enrichment Analysis (GSEA) was performed using the differential gene expression between each selected intersecting or individual marker expressing group and the remaining cohort from the TCGA PanCancer Atlas COADREAD dataset [22,23]. GSEA was run against the Hallmark Gene Sets using GSEA software version 4.2.3 [25], using the Run GSEA PreRanked function. Genes were ranked by significance of differential expression using the formula \u2212log10(p value) \u00d7 (sign of fold change). Heatmaps were built in R version 4.3.0 [26] using the package ComplexHeatmap version 2.16 [27,28]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.12339591979980469,
    "data_pmids_checked": 0,
    "paper_id": "39335130",
    "extraction_date": "2025-12-19T20:45:54.512087",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39335130.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39335197": {
    "cbioportal_paper_citations": [
      "HNSC gene expression RNAseq and clinical information data, uniformly processed by the TOIL process to be free of computational batch effects, were downloaded from UCSC Xena (https://xenabrowser.net/datapages/?cohort=GDC TCGA Head and Neck Cancer (HNSC), accessed on 5 January 2024), including The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data available on the platform [14]. The raw data were analyzed using R (v.4.3.3, http://www.r-project.org, accessed on 4 May 2024). cBioportal (http://www.cbioportal.org/, accessed on 5 May 2024) was also used to analyze the mRNA expression and to identify gene alterations in TCGA-HNSC [15]. All the protein expression and immunohistochemical staining data were obtained from The Human Protein Atlas (HPA) database (http://www.proteinatlas.org, accessed on 12 January 2024). Matched immunohistochemistry images and information were then used to compare and analyze the immunohistochemistry results for SLC genes using the R package \u201cHPAanalyze\u201d [16]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "25631445": [
        "Head and neck squamous cell carcinoma (HNSC) is a highly aggressive malignancy, representing a significant challenge in oncology due to its complex molecular landscape [1]. Despite some association with risk factors like tobacco, alcohol, and human papillomavirus (HPV), the majority of HNSC cases are driven by intricate genetic and epigenetic alterations that disrupt normal cellular processes [2]. Recent genomic studies have uncovered a range of mutations, copy number variations, and epigenetic modifications that contribute to the initiation and progression of HNSC [3]. The genetic and epigenetic alterations of SLC transporters not only promote uncontrolled cell growth and invasion but also confer resistance to conventional therapies, highlighting the need for targeted therapeutic strategies [4,5,6]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.23261189460754395,
    "data_pmids_checked": 1,
    "paper_id": "39335197",
    "extraction_date": "2025-12-19T20:45:54.520769",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39335197.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39333441": {
    "cbioportal_paper_citations": [
      "cBioPortal is an open-access resource for investigating genomics data [29]. The database substantially provide high-quality access to molecular view and their clinical attributes, showing accessible interpretation of rich datasets into biologic progress and clinical application. An comprehensive analysis of ACTL6A and clinical features was performed using cBioPortal for Cancer Genomics (http://www.cbioportal.org/index.do). Alterations of the ACTL6A gene was analyzed across available samples (n = 10967) in 32 studies. The search parameters contained alterations from GISTIC, including amplifications, deep deletions and missense mutations.",
      "To find out the mechanisms increasing the expression of ACTL6A and associated genes, we performed genetic alteration analysis using data with 10,967 patients\u2019 information from cBioPortal website (www.cbioportal.org/) [29, 39]. We identified the frequency of all 11 genes mutation and copy number alteration in 32 cancer types from TCGA (Fig. 5A). High frequency (> 40%) of genetic alteration is observed in LUSC, ESCA, STAD, MESO and uterine cancer. Moreover, we found that amplification was the most common genetic alteration across cancers, especially in OV, LUSC and ESCA. To investigate if all 11 genes copy number was related with their expression, we compared copy number alteration of all 11 genes with their mRNA level in 32 TCGA cancer types. The results indicated a strongly positive correlation between the copy number alteration and mRNA expression in digestive system tumors (ESCA, STAD, CHOL, LIHC, COAD, READ, PAAD), urogenital tumors (KIRP, KIRC, BLCA, PRAD, OV, UCS, CESC, BRCA, UCEC, UVM, TGCT), central nervous system tumors (LGG, GBM) and other tumors (SARC, MESO, LUSC, HNSC, LUAD, SKCM, ACC, PCPG, DLBC) (Fig. 5B). Then, we further explored the amplification and deletion of all 11 genes in pan-cancer. Heterozygous amplification of ACTL6A, RUVBL1, TRRAP had higher ratio compared to heterozygous deletion in in digestive system tumors (CHOL, LIHC, ESCA, PAAD, READ, COAD, STAD), urogenital tumors (BLCA, KICH, KIRC, KIRP, BRCA, CESC, OV, UCEC, UCS, PRAD) and other tumors (ACC, DLBC, GBM, HNSC, LUAD, LUSC, MESO, SARC, SKCM, TGCT) (Fig. 5C). In addition, homozygous amplification of these genes was observed in several cancer types, such as OV, LUSC, ESCA, HNSC, CESC and so on. Homozygous deletion of SMARCC1 was found in DLBC and KIRC (Fig. 5D). These results confirmed that overexpression of ACTL6A and associated genes was related with amplification in digestive system tumors, urogenital tumors, central nervous system tumors and others."
    ],
    "cbioportal_platform_mentions": [
      "In this study, we comprehensively analyzed the expression and the prognostic landscape of ACTL6A in pan-cancer using database, including Oncomine, TCGA, PrognoScan, STRING, cBioPortal, JASPAR, PROMO, GSCALite and The Human Transcription Factors Database. The potential relationship between ACTL6A and immune infiltration levels was discovered using TIMER. We found that high expression of ACTL6A in tumor might be driven by its amplifications. Moreover, it was also regulated by transcription factors (TFs), including E2F1, YY1, CDX2 and HOXD10. In addition, it regulated immune cells infiltration and the expression of immune marker sets, which resulted in poorer prognosis in liver hepatocellular carcinoma (LIHC) and brain lower grade glioma (LGG)."
    ],
    "data_publication_citations": {
      "29301960": [
        "Previous studies has shown that ACTL6A prevented SWI/SNF complex from binding to promoters of KLF4 and other differentiation genes [6]. Moreover, SWI/SNF might suppress tumorigenesis and have effects on immune system [7\u20139]. Inactivation of SWI/SNF complex was correlated with tumor sensitivity to immune checkpoint blockade therapies [10, 49, 50]. So, we continue to explore the role of ACTL6A in immune system during progression of cancer. We found that ACTL6A expression was related with the levels of immune infiltrating cells in cancers. ACTL6A had positive correlation with infiltration levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and DCs in most cancers, specially LIHC and LGG (Fig. 8A, B and Supplementary Fig. 1). As is reported, CD8+ T cells with effective anti-tumor immunity [51] might be suppressed by Tregs, a subset of CD4+ T cells [52]. Furthermore, the expression of ACTL6A was significantly correlated with immune cell marker sets expression. We identified ACTL6A was weakly correlated with marker sets of M1 macrophages, such as NOS2, ROS1. Nevertheless, it had strong correlation with marker sets of M2 macrophages, such as CD163, VSIG4, MS4A4A, and marker sets of TAMs, such as CD68, IL10, CD80, in LIHC and LGG (Fig. 8C\u2013J; Table 2 and Supplementary Table 3). These findings have indicated that ACLT6A might play an important role in polarization of tumor-associated macrophages (TAMs), leading to increased M2 macrophages and suppression of anti-tumor immunity [53]. Previous studies has confirmed that dendritic cells (DCs) contributed to tumor metastasis via increasing Treg cells and reducing CD8+ T cell cytotoxicity [54]. ACTL6A was related with DCs infiltration and positive correlated marker sets of infiltrating DCs (Supplementary Table 3). In addition, we also found strong correlation between ACTL6A and Treg and T cell exhaustion marker sets, such as CCR8, STAT5B, TGFB1, IL2RA, PDCD1, LAG3, HAVCR2 (Supplementary Table 3). Besides, monocyte and neutrophils in specific TME were also thought to facilitate formation of the immunosuppressive tumor microenvironment [55, 56]. The positive correlation between ACTL6A and monocyte and neutrophils indicated the progression of tumor. All these results suggested that ACTL6A might promote immune escape, which led to poor prognosis in LIHC and LGG."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1620941162109375,
    "data_pmids_checked": 1,
    "paper_id": "39333441",
    "extraction_date": "2025-12-19T20:45:54.695788",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39333441.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39333272": {
    "cbioportal_paper_citations": [
      "We utilized the cBioPortal web (https://www.cbioportal.org/) to do genetic alteration analysis22. Firstly, we selected the \u201cCancer Types Summary\u201d module. Then entering \u201cATAD2\u201d for queries, the alteration frequency, mutation type, and copy number alteration (CNA) of ATAD2 in the TCGA database were obtained; Secondly, we chose the \u201cMutations\u201d module to show the mutated site as well as the three-dimensional structure. Finally, the \u201cComparison\u201d module was chosen to tell the differences in survival and disease progression between cancer cases with and without ATAD2 genetic alteration in the TCGA database. Kaplan\u2013Meier plots with log-rank P-value were used to demonstrate the above."
    ],
    "cbioportal_platform_mentions": [
      "Fig. 4ATAD2 alteration landscape. (A) ATAD2 alteration frequency in multiple TCGA pan-cancer studies. (B) Mutation diagram of ATAD2 in different cancer types across protein domains. (C) The mutation site R1072C* and R1072H* in the 3D structure of ATAD2. (D) The potential correlation between mutation status and overall, disease-specific, disease-free and progression-free survival of UCEC conduct by the cBioPortal tool. Radar plot of the correlation between ATAD2 expression and TMB (E) and MSI (F) in different cancers.",
      "ATAD2 alteration landscape. (A) ATAD2 alteration frequency in multiple TCGA pan-cancer studies. (B) Mutation diagram of ATAD2 in different cancer types across protein domains. (C) The mutation site R1072C* and R1072H* in the 3D structure of ATAD2. (D) The potential correlation between mutation status and overall, disease-specific, disease-free and progression-free survival of UCEC conduct by the cBioPortal tool. Radar plot of the correlation between ATAD2 expression and TMB (E) and MSI (F) in different cancers."
    ],
    "data_publication_citations": {
      "29850653": [
        "The Sangerbox tool (http://sangerbox.com)23 was used to investigate the correlation between ATAD2 expression and tumor mutational burden (TMB) or microsatellite instability (MSI) in different tumors of TCGA. Additionally, gene mutation landscapes were plotted for both high and low ATAD2 expression groups, allowing for a comparison of the mutation frequencies of individual genes between the two groups. Spearman\u2019s rank correlation test was performed, and the P-value and partial correlation (cor) value were obtained."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.23196983337402344,
    "data_pmids_checked": 1,
    "paper_id": "39333272",
    "extraction_date": "2025-12-19T20:45:54.765094",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39333272.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39327614": {
    "cbioportal_paper_citations": [
      "The downregulation of Slug and Snail protein levels following Dasatinib treatment was particularly intriguing as these transcription factors are well-characterized regulators of the mesenchymal phenotype, and could explain how SRC drives claudin-low TNBC cell survival. Using cBioPortal we explored the relationship between Snail (SNAI1) and Slug (SNAI2) expression and patient outcomes in the Metabric dataset [7]. In the invasive breast cancer subset, tumors with the highest expression of SNAI2 had a significantly poorer likelihood of progression-free survival (Supplementary Figure S2A), and high SNAI2-expressing tumors were enriched significantly in the claudin-low subtype (Supplementary Figure S2B). Overall, this suggested that Slug signaling may regulate the pathogenesis of poor-outcome breast cancers."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.17870688438415527,
    "data_pmids_checked": 0,
    "paper_id": "39327614",
    "extraction_date": "2025-12-19T20:45:54.957565",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39327614.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39320608": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1502840518951416,
    "data_pmids_checked": 0,
    "paper_id": "39320608",
    "extraction_date": "2025-12-19T20:45:55.139361",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39320608.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39318795": {
    "cbioportal_paper_citations": [
      "HIF1A expression level analysis in different CNV groups was performed using the cBioportal database [30,31] (https://www.cbioportal.org/). Additionally, correlation analysis between HIF1A CNV with mRNA level was conducted using LinkedOmics [32] (http://www.linkedomics.org/)."
    ],
    "cbioportal_platform_mentions": [
      "To explore the underlying causes of HIF1A upregulation in LUAD and LUSC, we investigated the CNV and promoter methylation of HIF1A, representing regulatory mechanisms operating at the genetic and epigenetic levels. As anticipated, analysis results from cBioPortal indicated that HIF1A expression levels were significantly higher in tumors with an increased copy number of HIF1A compared to those with HIF1A deletions in both LUAD and LUSC (Fig. 3A). Spearman correlation analysis using LinkedOmics further affirmed the positive correlation between HIF1A CNV and its expression level in the two subtypes (Fig. 3B). On the other hand, HIF1A promoter methylation demonstrated a decrease in LUAD and LUSC patients and exhibited a negative correlation with its expression (Fig. 3C and D), aligning with its established biological function.Fig. 3Analysis of CNV and promoter methylation of HIF1A in LUAD and LUSC. A. mRNA expression level of HIF1A regarding different CNV classifications in LUAD and LUSC samples. B. Correlation analysis of HIF1A CNV with HIF1A expression level using LinkedOmics. C. Promoter methylation of HIF1A in LUAD and LUSC compared to adjacent controls using UALCAN. D. Correlation analysis of HIF1A promoter methylation with HIF1A expression level using LinkedOmics. E-G. Promoter methylation level analysis of HIF1A by UALCAN in different groups of LUAD or LUSC patients divided by cancer stages, nodal metastasis statuses, and TP53 mutation. Statistical significance analysis results between the two groups in each graph of E-G are shown in Table S2.Fig. 3",
      "Publicly available datasets were analyzed in this study. This data can be found at https://portal.gdc.cancer.gov/, http://ualcan.path.uab.edu/, http://gepia.cancer-pku.cn/, http://bioinfo.life.hust.edu.cn/GSCA/, https://www.cbioportal.org/, http://www.linkedomics.org/, http://cis.hku.hk/TISIDB/, http://cis.hku.hk/TISIDB/, https://lce.biohpc.swmed.edu/lungcancer/, and http://genemania.org/. All data generated or analyzed during this study are included in this published article."
    ],
    "data_publication_citations": {
      "25079552": [
        "Lung cancer is one of the most predominant cancer types worldwide. A majority of patients progress to metastatic and malignant stages at the time of diagnosis, posing significant challenges in terms of both treatment and the prevention of reoccurrence [1]. Lung cancer can be categorized into two primary clinical groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [2]. NSCLC, in particular, accounts for over 80 % of all lung cancer cases, with its three major subtypes, namely lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and large cell lung carcinoma (LCLC), holding prominence within this category [[3], [4], [5]]. Among these subtypes, LUAD commonly originates from alveolar cells, is more frequent in non-smokers, has frequent genetic mutations, and responds well to targeted therapy [6,7]. LUAD emerges as the most frequent NSCLC, contributing to approximately 50 % of all lung cancer-related deaths [8]. By comparison, LUSC develops from squamous cells, is strongly linked to smoking, has fewer genetic mutations, and is treated primarily with traditional therapies such as surgery, radiation therapy, and chemotherapy [9]. The molecular mechanisms and tumor microenvironment contributing to the carcinogenesis of LUAD and LUSC also exhibit significant differences [[10], [11], [12], [13]]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4716830253601074,
    "data_pmids_checked": 1,
    "paper_id": "39318795",
    "extraction_date": "2025-12-19T20:45:55.611131",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39318795.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39318189": {
    "cbioportal_paper_citations": [
      "Messenger RNA (mRNA) gene expression profiles from the first two datasets in Table 1, NEPC_WCM_2016 [6] and PRAD_SU2C_2019 [14], were retrieved from cBioportal [23,24], followed by log2 transformation. Limma [25] was used to identify differentially expressed genes (DEGs) with the cutoffs of False Discovery Rate (FDR) < 0.05 and |log2FC| > 1 between NEPC and non-NEPC samples for two datasets, respectively, given the sample information from the above datasets. The average amplitude of log2FC from the comparisons in the two datasets were used as the input of the analysis of association of NEPC genes."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26855148": [
        "Prostate cancer (PCa) is the most common cancer among American men, with an estimated 288 300 new diagnoses projected for 2023 [1]. Treatments of PCa include surgery, radiotherapy, chemotherapy, hormone therapy, and immunotherapy. However, the development of castration-resistant prostate cancer (CRPC) during hormone therapy poses a significant challenge. CRPC is characterized by sustained high serum prostate-specific antigen (PSA) levels, ongoing disease progression, and potential metastasis to the new sites, leading to a poor prognosis [2\u20134]. Most CRPC tumors still depend on androgen receptor (AR) signaling, and therefore, the use of current androgen-signaling inhibitors (ASIs) such as enzalutamide (ENZ) and abiraterone can offer temporary relief from resistance [5]. However, a subset of the CRPC patients exhibited neuroendocrine (NE) phenotype with diminished or absent reliance on AR signaling and a dismal prognosis [6\u20138]. The most lethal subtype of this disease, however, has similar initial symptoms comparable to CRPC and hence lacks appropriate unique identification markers. NE PCa (NEPC) biopsy samples also often exhibit in mixed histology, posing formidable challenges on accurate diagnosis and appropriate treatments [9].",
        "Messenger RNA (mRNA) gene expression profiles from the first two datasets in Table 1, NEPC_WCM_2016 [6] and PRAD_SU2C_2019 [14], were retrieved from cBioportal [23,24], followed by log2 transformation. Limma [25] was used to identify differentially expressed genes (DEGs) with the cutoffs of False Discovery Rate (FDR) < 0.05 and |log2FC| > 1 between NEPC and non-NEPC samples for two datasets, respectively, given the sample information from the above datasets. The average amplitude of log2FC from the comparisons in the two datasets were used as the input of the analysis of association of NEPC genes.",
        "Glmnet [27] was used to generate a logistic regression model to classify NEPC and non-NEPC samples based on marker genes selected. Optimal parameters of the model are estimated using cross-validation incorporating elastic net penalty. Beltran et al. [6] and Abida et al. [14] data were randomly split into training sets including 28 NEPC and 183 non-NEPC samples and test sets (9 NEPC and 61 non-NEPC samples). A logistic regression model was built using cross-validation on the training set. The resulting model was tested on the test set and the other three independent GEO test sets (Table 2). The performance of prediction was evaluated based on the area under the precision\u2013recall curve (AUPRC).",
        "We searched the literature for published NEPC marker gene sets mentioned in the introduction, namely, Beltran2016 [6], Tsai2017 [34], Bluemn2017 [35], Cheng2019 [36], Labrecque2019 [37], Dong2020 [20], Ostano2020 [38], and Sarkar2022 [39], in addition to six marker genes commonly used for clinical diagnose of NEPC, CHGA, PSA, NCAM1, ENO2, AR, and KLK3, named as NEPC canonical marker genes [11] (Fig. 1). The majority of genes within distinct marker sets tend to be unique or specific to a particular gene expression dataset employed for identification. The maximum pairwise overlap was observed for 11 genes between Beltran2016 and Tsai2017. Even the six canonical NEPC markers were rediscovered in certain marker gene sets but not universally across all of them. This lack of consensus in NEPC markers suggests the intricate nature of biological processes associated with NEPC progression and potential biases when simply comparing gene expression differences for different datasets."
      ],
      "31061129": [
        "Messenger RNA (mRNA) gene expression profiles from the first two datasets in Table 1, NEPC_WCM_2016 [6] and PRAD_SU2C_2019 [14], were retrieved from cBioportal [23,24], followed by log2 transformation. Limma [25] was used to identify differentially expressed genes (DEGs) with the cutoffs of False Discovery Rate (FDR) < 0.05 and |log2FC| > 1 between NEPC and non-NEPC samples for two datasets, respectively, given the sample information from the above datasets. The average amplitude of log2FC from the comparisons in the two datasets were used as the input of the analysis of association of NEPC genes.",
        "Glmnet [27] was used to generate a logistic regression model to classify NEPC and non-NEPC samples based on marker genes selected. Optimal parameters of the model are estimated using cross-validation incorporating elastic net penalty. Beltran et al. [6] and Abida et al. [14] data were randomly split into training sets including 28 NEPC and 183 non-NEPC samples and test sets (9 NEPC and 61 non-NEPC samples). A logistic regression model was built using cross-validation on the training set. The resulting model was tested on the test set and the other three independent GEO test sets (Table 2). The performance of prediction was evaluated based on the area under the precision\u2013recall curve (AUPRC).",
        "Taking the dataset of PRAD_SU2C_2019 [14] as another example, we evaluated scores estimated by the CDHu40, Dong2020, and Bluemn2018, respectively, across all NE and non-NE samples (Fig. 6A\u2013C) to examine these scores with the clinical diagnoses. CDHu40 scores displayed a significant increase in NE samples in comparison to non-NE samples, aligning consistently with the NE phenotype diagnosed by clinicians. More strikingly, by using CDHu40 as a criterion, the higher CDHu40 score group reports much worse OS compared with the low CDHu40 score group, with a hazard ratio (HR) = 3.04 and a statistically significant P-value, P = .016 (Fig. 6D). The results are calculated using stratified Cox regression with pathological grade being adjusted as a stratification factor. However, no notable difference was observed for patients classified by higher or lower scores based on Bluemn2018 and Dong2020 (Fig. 6E and F) or generated by other marker sets (Supplementary Fig. S3)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6211392879486084,
    "data_pmids_checked": 2,
    "paper_id": "39318189",
    "extraction_date": "2025-12-19T20:45:56.287126",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39318189.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39318060": {
    "cbioportal_paper_citations": [
      "A mutation frequency analysis of NLRP1 in various tumour types was conducted utilizing the cBioPortal database (http://www.cbioportal.org/). 34 Concisely, the NLRP1 mutations in tumours and a possible relationship between genetic alteration in NLRP1 and survival prognosis were investigated. The Kaplan\u2013Meier plots were carried out to compare prognostic disparities among the altered and unaltered groups within NLRP1 mutations. The log\u2010rank test was used to assess the statistical significance with a p\u2010value less than 0.05 indicating statistical significance."
    ],
    "cbioportal_platform_mentions": [
      "Some gene mutations are common in some malignancies and are strong predictors of tumour prognosis. 41 , 42 According to the cBioPortal database, NLRP1 mutations are relatively common in SKCM (15%) and UCEC (10%) (Figure 12A). Specifically, there are 311 mutation sites in the NLRP1 (243 missense mutations, 44 truncation mutations, 1 in\u2010frame mutation, 15 shear mutations and 8 fusion mutations), with E739K being the most common mutation (Figure 12B). In addition, the association analysis between the gene alterations of NLRP1 and the clinical survival prognosis of pan\u2010cancer cases in the TCGA illustrates that the cases with the NLRP1 mutation has a good prognosis in OS (N = 10,803, p = 1.929e\u20103) and DSS (N = 10,258, p = 1.355e\u20103) (Figure 12C,D). Taking together, NLRP1 mutations can act as a predictor of tumour prognosis."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.32865309715270996,
    "data_pmids_checked": 0,
    "paper_id": "39318060",
    "extraction_date": "2025-12-19T20:45:56.651374",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39318060.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39315235": {
    "cbioportal_paper_citations": [
      "The cBio Cancer Genomics Portal (cBioPortal, http://www.cbioportal.org/) provides comprehensive data on over 5,000 tumor samples derived from 20 cancer studies [21,22]. These genomic profiles encompass mutations, putative copy number alterations identified through the genomic identification of significant targets in cancer (GISTIC), and mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM) with a threshold of \u00b12.0. In this study, we conducted an analysis of KIFC1 mutations within the TCGA-LIHC dataset (TCGA PanCancer Atlas) available in the cBioPortal database [23]. Subsequently, these mutations were categorized based on their condition and corresponding survival curves were generated."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "29625048": [
        "The cBio Cancer Genomics Portal (cBioPortal, http://www.cbioportal.org/) provides comprehensive data on over 5,000 tumor samples derived from 20 cancer studies [21,22]. These genomic profiles encompass mutations, putative copy number alterations identified through the genomic identification of significant targets in cancer (GISTIC), and mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM) with a threshold of \u00b12.0. In this study, we conducted an analysis of KIFC1 mutations within the TCGA-LIHC dataset (TCGA PanCancer Atlas) available in the cBioPortal database [23]. Subsequently, these mutations were categorized based on their condition and corresponding survival curves were generated."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.6003446578979492,
    "data_pmids_checked": 1,
    "paper_id": "39315235",
    "extraction_date": "2025-12-19T20:45:57.261830",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39315235.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39314258": {
    "cbioportal_paper_citations": [
      "Correlation of HIF1A expression and immune regulators TMB and MSI: The Tumor Mutational Burden (TMB) and Micro Satellite Instability (MSI) are 2 emerging promising, predictive biomarkers for immunotherapy in cancer treatment. 50 Correlation between altered HIF1A gene expression and mutation in BC and immune regulators TMB and MSI evaluation were conducted using the cBioPortal.30-33,50-53 TMB is considered high if it exceeds a predetermined threshold, this cut-off may widely vary based on differing factors, including tumor type and usually 10 muts/Mb cut-off where used when analyzing different solid tumors.53,54 In cases of high values, TMB is a predictive biomarker, potentially indicating a high rate of response to immunotherapy. 55 In BC patients\u2019 correlation between HIF1A altered expression and TMB, MSI was evaluated together with hypoxia score using cBioPortal.30-33,47,50-53 Spearman and Pearson correlation analysis was conducted to investigate the correlation between HIF1A expression in TCGA BC patients and TMB, MSI, a P-value < .05 indicated the statistical significance.",
      "Tumor Mutational Burden (TMB) and Micro Satellite Instability (MSI) testing represent 2 emerging immunotherapy biomarkers in cancer treatment.50-52,58 The regression analyses were performed to establish correlations between HIF1A fraction genome alteration in TCGA BC cases and the results were revealed using TMB and MSI score tests (Figure 11A and B). The analyzed data revealed a noteworthy correlation between varying HIF1A expression and TMB (Spearman: R .36, P-value 6.01e-34; Pearson: R .23, P-value 7.4e-14; Figure 11A) and MSI score (Spearman: R .61, P-value 5.76e-110; Pearson: R .46, P-value 1.22e-56) in BC cases (Figure 11B). Moreover, the bar plot analysis of the BC cases, for stratified data based on races, demonstrated that individuals of white (Caucasian) and black (African) ethnicities exhibited the most notable association with high TMB scores compared to Asians (Figure 11C). A linear correlation was also observed between the count of HIF1A mutations and TMB scores in TCGA BC patients (Spearman: R .98, P-value .00; Pearson: R 1.0, P-value .00) with the highest mutational burden present in Caucasians (Supplemental File 1: Figure S4). The findings indicated a robust connection between the HIF1A altered expression, and mutation with TMB in TCGA BC patients."
    ],
    "cbioportal_platform_mentions": [
      "In recent years, the availability of high-throughput multi-Omics data provided the opportunity to unfold the molecular basis of cancer by analyzing genetic alterations like copy number alterations, mutations, and epigenetic regulations in tumors. Now, genetic polymorphisms like Single Nucleotide polymorphisms (SNPs) are considered the most valuable biomarkers in association with human diseases and/or disorders and cancers.22-24 The human HIF1A gene has 35 SNPs. 4 From the literature, the involvement of the 2 SNPs rs11549465 (C/T), and rs11549467 (G/A) of the HIF1A gene was mostly reported in association with different diseases and cancer.22-24 These 2 SNPs (rs11549465 and re11549467) are located within the oxygen-dependent degradation (ODD) domain of exon 12 of the HIF1A gene.25,26 They are responsible for amino acid substitution from proline to serine (P582S, rs11549465) and alanine to threonine (A588T, rs11549467) respectively.25,26 Involvement of these 2 SNPs (P582S, A588T) was reported with increased levels of expression as well as transcriptional activity in the progression of different cancers including oral, colorectal, head and neck, renal, and hepatic cancer.3,27-29 Breast cancer biology is complex, and yet to fully comprehend. In recent years, the availability of TCGA (The Cancer Genome Atlas) datasets and resources like cBioportal allow us to integrate, validate and compare various levels of multi-omics information across different races and to understand complex diseases like cancer better and move a step forward toward precision medicine. 30",
      "This study aimed to systematically evaluate the expression, function, and prognostic value of the HIF1A gene in breast invasive carcinoma (BC), interrelate the link between hypoxia and breast cancer incidences among different races and subtypes, and also to assess the prognostic relevance of HIF1A expression in overall survival. The main target was to quantitatively measure hypoxia in Bangladeshi breast cancer patients and evaluate their clinical and demographic factors. In addition, integration of literature mining and case-control datasets from The Cancer Genome Atlas (TCGA) was employed to assess HIFA transcripts and their genetic modifications in BC. To evaluate hypoxia in BC, we compared the levels of HIF1A expression in breast cancer patients of different races (Caucasian, African, and Asian) through multi-omics approaches using cBioPortal.30-36 This study investigated the structure-function relationship of HIF1A and examined the impact of SNPs in association with hypoxia and BC. Enrichment analyses and integrated network construction were utilized to establish correlations among interactions and regulatory pathways associated with BC. Here, we targeted to evaluate the possibility of HIF1A, as a potential biomarker in BC screening, by interrelating breast cancer genomic data with clinical features. Thus, this study aims to comprehensively evaluate the significance of HIF1A in breast cancer, with the ultimate goal of enhancing screening, diagnosis, and treatment for Bangladeshi breast cancer patients.",
      "Breast cancer dataset selection and pre-processing: In this study, The Cancer Genome Atlas (TCGA) breast invasive carcinoma dataset (TCGA, PanCancer Atlas) containing 1084 samples was selected for further investigation. The multidimensional breast cancer genomics data of the selected study was retrieved using the cBio Cancer Genomics Portal (cBioportal; http://www.cbioportal.org).30-38 The inclusion criteria of the selected TCGA BC dataset were: a case-control study including females, availability of patients\u2019 ethnicity, clinical, and subtypes data. The 1084 patient/case dataset of the selected study was then screened based on altered/varied expression of the Hugo gene symbol HIF1A. The responsive dataset was further screened based on having genomic altered expressions (mutations, structural variants, and putative copy number alterations) from GISTIC (Genomic Identification of Significant Targets in Cancer) and only HIF1A mRNA expression samples with z-scores (threshold \u00b1 2.0) of tumor samples in comparison to adjacent normal samples (RNA Seq V2 RSEM), and protein expression in the cohort, measured by reverse-phase protein array (RPPA) with a z-score threshold of \u00b12, was retrieved. Only the responsive dataset with a minimum of 2-fold up or down-regulation values of the HIF1A expression, in comparison to controls, was then selected.30-38 Thus, finally, only 37% of the patients\u2019 data of the selected study (TCGA, PanCancer Atlas), which met all the screening criteria, were used for further genomic profiling and correlation analyses.",
      "Assessment of changes in Transcriptomic mRNA expression of HIF1A in BC: The HIF1A gene altered transcript (mRNA) expression, for breast cancer patients and normal samples were extracted and analyzed using cBioPortal (http://www.cbioportal.org) and ULCAN (https://ualcan.path.uab.edu/analysis.html) data portals.32-36,39 The multi-omics data of mutations, structural variants, fraction genome alterations, copy number variations, co-expressions, protein expression, comparison, enrichment, and survival analysis were extracted and analyzed using cBioPortal. The different mutation types of HIF1A in TCGA breast cancer samples were detected through the DepMap (https://depmap.org/portal/) portal. 40 The BC patients\u2019 data stratified based on race categories, and breast cancer subtypes of the HIF1A gene were extracted from cBioPortal. The correlation between the 2 variables was analyzed using Spearman\u2019s or Pearson\u2019s test and a P-value < .05 was considered significant. All analysis was conducted and evaluated strictly following the cBioPortal guidelines. The expression variations of HIF1A among different race categories and subtypes were analyzed using UALCAN data portal. The GTex portal (https://gtexportal.org/home/snp/) was used to determine the risk frequency of HIF1A polymorphisms in different tissues. 41 For the selected TCGA BC patient clinical data analysis, like patient\u2019s age, sex, tumor stage, breast cancer subtype, and race was evaluated using the OncoPrint in cBioPortal. Co-expression between the HIF1A gene in TCGA BC samples and tumor markers like ER (Estrogen receptor), PR (Progesterone Receptor), and HER2 (Human Epidermal growth factor Receptor 2) was conducted using the GTEx, GEPIA2 42 and cBioPortal. Pearson\u2019s and Spearman\u2019s correlation coefficients were calculated against all other genes and a P-value < .05 indicated the statistical significance. Also, mutual exclusivity analyses were performed for ER, and HIF1A, where Fisher\u2019s exact test was used to analyze whether alterations are significantly mutually exclusive or co-occurring between every pair of query genes, and a P-value < .05 was considered significant using cBioPortal.30-36 Gene Ontology (GO) enrichment and gene set enrichment analysis (GSEA) were performed to explore the relevant pathways involved with HIF1A in BC. The ClinOmics Trail database (https://clinomicstrail.bioinf.unisb.de/) was used to conduct enrichment analyses of the pathway activities by the HIF1A gene in the selected TCGA breast cancer dataset. 43 GO enrichment contains molecular function (MF), cellular component (CC), and biological process (BP). P < .05, and FDR < 0.25 are defined as significantly enriched. 43 In this study, the Kaplan-Meier (KM) plot, log-rank test, and Cox regression analysis were used for survival analyses. 44 The overall survival analysis was conducted based on the low and high HIF1A mRNA expression of breast cancer patients using KM-Plotter (https://kmplot.com/analysis/). 44 The KM Plotter was used for the validation of the HIF1A as a survival biomarker. The statistical significance between the survival curves was analyzed using the log-rank test, and a P-value < .05 was considered statistically significant. 44",
      "Analysis of HIF1A gene mutation and methylation level in TCGA BC: The DNA methylation pattern of the selected TCGA breast cancer patients was extracted and evaluated using cBioPortal (http://www.cbioportal.org).30-33 The mean methylation pattern of HIF1A in normal, as well as tumor samples of the selected TCGA Breast invasive carcinoma, was evaluated using different probes of TCGA-Wanderer (http://maplab.imppc.org/wanderer/). 45 TCGA-Wanderer provided the level 3 TCGA methylation arrays (450k Infinium chip) and expression data (Illumina HiSeq RNAseq, summarized by exons and genes) to analyze the HIF1A expression and levels of methylation of the breast cancer samples. 44 The adjusted P-value threshold < .05 indicated was considered statistically significant. Also, MethSurv (https://biit.cs.ut.ee/methsurv/) was used to perform multivariable survival analysis using methylation data of TCGA breast cancer. 46 The statistical significance of the survival curves was evaluated using the log-rank test, and a P-value < .05 was considered statistically significant.",
      "Correlation between hypoxia and HIF1A expression in TCGA BC patients: The differential expression of the HIF1A gene between cases compared to controls of the TCGA BC dataset was evaluated to measure hypoxia using 3 different score-based approaches: including Buffo hypoxia, Ragnum hypoxia, and Winter hypoxia47-49 from cBioportal, (http://www.cbioportal.org/). Pearson correlation coefficient was used for correlation analysis. A 2-sided P-value < .05 was considered as statistically significant. The levels of HIF1A expression in BC cases were further stratified based on race and BC subtype categories were evaluated using the Buffo hypoxic score. 47 Group differences analysis was performed using Wilcoxon test or Kruskal\u2013Wallis test, and expressed as means \u00b1 standard deviation (SD). Also, Pearson correlation analysis between HIF1A expression and methylation of the TCGA BC dataset was evaluated using Buffo hypoxia score using cBioPortal.30-33,47",
      "In this investigation, we scrutinized the TCGA BC dataset, comprising 1084 samples, to examine the altered genomic and transcriptomic expression levels of the HIF1A gene in individuals with BC compared to control samples using cBioportal33-36 (Figure 8). Our evaluation encompassed fraction genome alterations, copy number variations, mutation count, levels of methylation, and structure-function alterations. We also identified up and down-regulated genes associated with the differential expression of the HIF1A gene in TCGA BC patients. Additionally, we employed cBioPortal to assess clinical attributes and background data of BC patients for correlation with genomic data. Finally, the clinical outcomes of HIF1A-altered patients were examined through overall survival analysis. In summary, through integrated multi-omics analyses, this study encompassed the transcriptional landscape of the HIF1A gene\u2019s differential expression in the TCGA BC (PanCancer Atlas) dataset (Figure 8). We performed a comprehensive examination, evaluating the mutation of the HIF1A gene in breast cancer patients from TCGA. Utilizing the cBioPortal database, our analysis through Oncoprint genomics unveiled that the expression levels of HIF1A were modified in 37% (398 out of 1084) of PanCancer BC patients (Supplemental File 1, Figure S2). Moreover, we examined copy number variations and assessed the correlation between the fraction of genome alteration and mutation count. The predominant type of HIF1A mutation was amplification (Supplemental File 1, Figure S2). Additionally, we identified genes with the highest mean frequency per genomic or transcriptomic alteration were identified (Supplemental File 1, Table S2). The bar plot examined the data on altered HIF1A transcripts levels in BC samples (cases) compared to normal samples (controls), revealing a notable distinction in HIF1A expression levels in BC cases (P-value 4.32e-05; Figure 8A). Subsequently, differential mRNA expression data from TCGA BC samples (n = 908) were scrutinized and stratified them based on various race categories. This analysis aimed to assess the frequency of HIF1A gene alterations, encompassing copy number variations, deletions, amplifications, and mutations, and was conducted using cBioPortal (Figure 8B; Supplemental File 2). The scattered plot analysis revealed a robust correlation between the fraction of altered genome and mutation count in BC samples for the HIF1A gene across various races (Spearman: R .43, P-value 1.03e-42; Pearson: R .33, P-value 7.2e-25; Figure 8B). The analysis of mutation types conducted by DepMap 40 revealed that missense mutations were the predominant alterations observed in cell lines (Figure 8C). Additionally, when examining altered HIF1A expression in breast cancer cases through race category stratified analysis, the most substantial expression variations were found in Whites (Caucasians: P-value 3.9e-06), as opposed to other races such as Blacks (Africans, P-value 8.1e-01) or Asians (P-value 1.7e-03), compared to healthy controls. Moreover, a notable difference in HIF1A expression was observed between Blacks and Asians (P-value 6.2e-04; Supplemental File 1: Table T7, Figure S3). Furthermore, a noteworthy change in the expression of HIF1A was observed between individuals of Black and Asian descent (P-value 6.2e-04; Supplemental File 1, Table T7, Figure S3). The predominant alteration associated with all cancer types is the up-regulation of mRNA transcripts. Co-variation genes related to the differential expression of HIF1A in TCGA BC samples were obtained from cBioPortal. The volcano plot, depicting high or up-regulated (n = 192) and low or down-regulated (n = 206) genes, revealed significant regulatory alterations in breast cancer cases (n = 398; P-value < .05; Figure 8D). This study analyzed the multi-omics data of TCGA_BC to assess pathway activities using the ClinOmics data portal. 43 The activity patterns of pathways in tumor samples from TCGA BC were organized and pathway activities were calculated based on the scores of differential expression. A radar chart was generated, with each radar axis representing the activity of a selected pathway (Figure 8E). The results of the enrichment analysis revealed that the signaling pathways most significantly associated with HIF1A expression were MAPK (P-value .001), Wnt (P-value .001), Notch (P-value .001), PI3-Akt (P-value .002), TGF-beta (P-value .004), NFKB (P-value .006), and HIF-1 (P-value .03). These pathways are implicated in the regulation of motility, invasion, modulation, and plasticity of the breast cancer microenvironment (Figure 8E). Finally, a Kaplan-Meier regression analysis was performed to examine the correlation between the clinical outcome and the prognosis of BC patients. The Kaplan-Meier (KM) plots depicted the overall survival analysis of the TCGA BC patients, stratified by high and low levels of HIF1A expression, revealed noteworthy differences in survival time (Hazard Ratio [HR] = 1.58, 95% CI: [1.31-1.92]; log-rank P-value 1.9e-06; Figure 8F). This outcome suggests that BC patients with elevated HIF1A expression levels experienced significantly shorter survival times compared to those with lower levels of mRNA expression (Figure 8F).",
      "In this study, we evaluated the hypoxic condition in selected TCGA BC samples using 3 different scoring methods: Buffo hypoxia, Ragnum hypoxia, and Winter hypoxia,47-49 utilizing cBioPortal. The association between varied HIF1A expressions in BC cases was examined for each hypoxia score47-49 using Spearman and Pearson correlation coefficients. The analyzed data indicated a noteworthy correlation among the 3 hypoxia score systems (Buffo hypoxia score: Spearman: R .27, P-value 5.77e-20; Pearson: R .26, P-value 1.52e-18); (Ragnum hypoxia score: Spearman: R .30, P-value 1.45e-23, Pearson: R .28, P-value 1.41e-21); and (Winter hypoxia score: Spearman: R .26, P-value 1.03e-17, Pearson: R .26, P-value 9.76e-18 for; Figure 10A-C). Thus, the 3 scatter plots generated consistently demonstrated a robust correlation between the HIF1A gene\u2019s differential expressions and hypoxia in TCGA BC. An analysis examining the correlation between the HIF1A fraction of genome altered and the mutation count in TCGA BC was performed, and the evaluation based on Buffo hypoxia score revealed a significant association (Spearman: R .42, P-value 4.31e-44); (Pearson: R .32, P-value 2.04e-25; Figure 10D; Supplemental File 1: Table T9). Furthermore, a stratified correlation analysis was conducted to explore the relationship between hypoxia and HIF1A mRNA expression based on racial categories, utilizing the Buffo hypoxia score for evaluation. The bar graph data indicated that the highest genome alterations were observed among Black and Asian populations compared to those in the White race category (Figure 10E; Supplemental File 1: Table T9).",
      "The data stratification of BC subtypes revealed a higher number of cases with estrogen receptor-positive (ER+) status (n = 694) compared to those with estrogen receptor-negative (ER-) status (n = 249) in the selected TCGA BC dataset (Figure 12A; Supplemental File 2). A correlation analysis was performed between the mRNA expression of HIF1A and the ESRI gene through cBioPortal. The results demonstrated a significant negative correlation (Spearman: R \u2212.34, P-value 1.29e-30; Pearson: R \u2212.33, P-value 7.9e-29; Figure 12B). Violin plots were generated to examine HIF1A expression covariate-adjusted methylation profiles, stratified by ER status through IHC and race categories (Figure 12C and D). The \u03b2-value, representing DNA methylation levels, exhibited a notable increase in the ER+ group compared to the ER-group (Figure 12C). Moreover, after accounting for covariates categorized by race, the data indicated that individuals of White ethnicity displayed the highest \u03b2-value in methylation levels in comparison to samples from other racial categories (Figure 12D). Additionally, we conducted a comparison of HIF1A fraction genome alteration levels in BC cases between ER+ and ER- subtypes. This analysis was further assessed using Buffo hypoxia score and TMB (Figure 12E and F). The examined data revealed significant alterations (P-value < 1.0e-10) between ER+ and ER- groups. Within the ER-category (specifically within HER2 and TNBC subtypes), samples exhibited heightened levels of hypoxia (Figure 12E) and TMB score (Figure 12F). This study collectively implies that within the TCGA BC cases, a higher prevalence of ER+ instances was observed in Whites and revealed heightened levels of methylation. Notably, a negative correlation was observed between the expression of HIF1A and the estrogen receptor ER gene (ESR1). The subsequent findings from the study were aligned with this correlation, hypoxia demonstrating a higher incidence of HIF1A genomic alterations within the ER- BC cases compared to the ER+ group."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 9,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 1.5444798469543457,
    "data_pmids_checked": 6,
    "paper_id": "39314258",
    "extraction_date": "2025-12-19T20:45:58.859228",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39314258.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39314235": {
    "cbioportal_paper_citations": [
      "The MEN1 M1K mutation disrupts the initiator methionine residue of MEN1 mRNA. While there are 1012 unique mutations of the MEN1 gene reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) Database,1,2 this particular mutation has not been described. No MEN1 mutations occur in any liposarcoma included in the COSMIC database. cBioPortal3,4 was screened for soft tissue sarcomas harboring MEN1 alterations. The overall MEN1 mutation frequency was 0.4%, with seven putative driver alterations across five datasets including 3071 samples.5\u20138 One pleomorphic liposarcoma was found to harbor a MEN1 I85Sfs*33 frameshift mutation. 6 No MEN1 M1K mutations in any cancer type have been reported in the cBioPortal database."
    ],
    "cbioportal_platform_mentions": [
      "Soft tissue sarcomas are rarely associated with mutations of the MEN1 gene. One case of bone sarcoma was identified to harbor the MEN1 c.2T>A mutation reported here and co-occurred with a putative oncogenic mutation in EXT1. 11 Another case of soft tissue sarcoma in the setting of a different MEN1 gene mutation has been reported in the literature. 12 There are few MEN1 mutations in patients with soft tissue sarcoma reported in cBioPortal."
    ],
    "data_publication_citations": {
      "20601955": [
        "CCNE1 encodes the protein cyclin E158, and its amplification leads to overexpression of this oncogene involved in cell cycle regulation. CCNE1 amplification is found in 33% of pleomorphic liposarcomas and 2% of dedifferentiated liposarcomas. 7 Additionally, CCNE1 amplification has been identified as a driver alteration in uterine leiomyosarcoma and has been noted in a number of other solid malignancies, including adenocarcinomas. 9 Loss-of-function mutations of the TP53 tumor suppressor protein are common in advanced cancers and have been found in 17% of pleomorphic liposarcomas. 7 GNAS mutations are rarely associated with sarcoma."
      ],
      "29100075": [
        "The MEN1 M1K mutation disrupts the initiator methionine residue of MEN1 mRNA. While there are 1012 unique mutations of the MEN1 gene reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) Database,1,2 this particular mutation has not been described. No MEN1 mutations occur in any liposarcoma included in the COSMIC database. cBioPortal3,4 was screened for soft tissue sarcomas harboring MEN1 alterations. The overall MEN1 mutation frequency was 0.4%, with seven putative driver alterations across five datasets including 3071 samples.5\u20138 One pleomorphic liposarcoma was found to harbor a MEN1 I85Sfs*33 frameshift mutation. 6 No MEN1 M1K mutations in any cancer type have been reported in the cBioPortal database."
      ],
      "35705560": [
        "The MEN1 M1K mutation disrupts the initiator methionine residue of MEN1 mRNA. While there are 1012 unique mutations of the MEN1 gene reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) Database,1,2 this particular mutation has not been described. No MEN1 mutations occur in any liposarcoma included in the COSMIC database. cBioPortal3,4 was screened for soft tissue sarcomas harboring MEN1 alterations. The overall MEN1 mutation frequency was 0.4%, with seven putative driver alterations across five datasets including 3071 samples.5\u20138 One pleomorphic liposarcoma was found to harbor a MEN1 I85Sfs*33 frameshift mutation. 6 No MEN1 M1K mutations in any cancer type have been reported in the cBioPortal database."
      ],
      "29625048": [
        "The MEN1 M1K mutation disrupts the initiator methionine residue of MEN1 mRNA. While there are 1012 unique mutations of the MEN1 gene reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) Database,1,2 this particular mutation has not been described. No MEN1 mutations occur in any liposarcoma included in the COSMIC database. cBioPortal3,4 was screened for soft tissue sarcomas harboring MEN1 alterations. The overall MEN1 mutation frequency was 0.4%, with seven putative driver alterations across five datasets including 3071 samples.5\u20138 One pleomorphic liposarcoma was found to harbor a MEN1 I85Sfs*33 frameshift mutation. 6 No MEN1 M1K mutations in any cancer type have been reported in the cBioPortal database."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 3.100559711456299,
    "data_pmids_checked": 4,
    "paper_id": "39314235",
    "extraction_date": "2025-12-19T20:46:01.959887",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39314235.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39310930": {
    "cbioportal_paper_citations": [
      "We screened the co-expressed genes of MCM3 in PAAD based on cBioPortal [28, 29]. If a certain gene in PAAD had a |Spearman\u2019s correlation| > 0.3 and p < 0.05, the gene was classified as a co-expressed gene of MCM3 in PAAD."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3173079490661621,
    "data_pmids_checked": 0,
    "paper_id": "39310930",
    "extraction_date": "2025-12-19T20:46:02.350679",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39310930.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39309809": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We investigated the genetic alterations affecting IGFBP1 expression in tumors using the cBioPortal web application. Our study included 10,967 samples from all 32 studies in TCGA PanCancer Atlas. We identified 67 mutation sites between amino acids 0 and 259, with 12 truncating and 55 missense mutations. The most frequently observed mutation was R177Q (Fig. 7A). The three most common types of mutations are deep deletions, amplifications, and mutations. IGFBP1 mutations were predominantly found in STAD, UCEC, LUAD, ESCA, SKCM, HNSC, DLBL, LUSC, and BUCA (Fig. 7B). Among the 32 malignancies examined, BRCA, DLBC, ESCA, LUAD, MESO, PAAD, and SKCM exhibited significant deletions in IGFBP1 mRNA expression (Fig. 7C).Fig. 7Genetic Alterations in IGFBP1 (A) Schematic depicting mutations in IGFBP1 throughout several protein domains. (B) Bar graph displaying mutations in IGFBP1. (C) IGFBP1 mutation counts and types.Fig. 7",
      "In this study, we used cBioPortal (https://www.cbioportal.org/) for Cancer Genomics to examine genetic alterations in IGFBP1 [16]. Specifically, we utilized the \"mutations\" module to identify the locations of mutations, and the \"mRNA vs. study\" and \"cancer types summary and mutations\" modules facilitated the exploration of somatic mutation frequency and genomic details of IGFBP1 mutations across various cancer types."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.22551298141479492,
    "data_pmids_checked": 0,
    "paper_id": "39309809",
    "extraction_date": "2025-12-19T20:46:02.576291",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39309809.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39309469": {
    "cbioportal_paper_citations": [
      "WES of the tissue samples obtained from patient 4 revealed a heterozygous variant, c.96+1G>C in TP53 (Tier III). The NM_000546.6 (TP53):c.96+1G>C variant affects a splice\u2013donor sequence, potentially resulting in the retention of large segments of intronic DNA by the mRNA and non-functional proteins. The c.96+1G>C variant occurs in 2 samples in COSMIC. The c.96+1G>C variant has been previously classified as pathogenic in ClinVar. The c.96+1G>C variant is predicted to disrupt the existing donor splice site at this position by 3 of 4 splice site algorithms. There are 347 downstream pathogenic LoF variants, with the furthest variant being 395 residues downstream of the variant c.96+1G>C. The c.96+1G>C variant is a LoF variant in the gene TP53, which is intolerant of LoF variants, as indicated by the following supporting evidence: presence of 9 overlapping LoF regions in CiVIC, presence of the existing pathogenic LoF variant NM_000546.6:c.\u221229+1G>C and 415 others, and 18.76% of variants in TP53 are LoF in COSMIC. For these reasons, this variant has been classified as oncogenic. TP53 deletions occur in approximately <1% of cancers. Inactivation of TP53 plays an important role in neoplastic transformation in solid tumors and it has also been reported in hematological malignancies in association with the progression of disease [19,20,21]. Deletion of the TP53 tumor suppressor gene occurs in approximately 50% of all human cancers [22]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.20546293258666992,
    "data_pmids_checked": 0,
    "paper_id": "39309469",
    "extraction_date": "2025-12-19T20:46:02.781854",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39309469.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39309198": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "CBioPortal integrates genomic data from different databases, such as the International Cancer Genome Consortium (ICGC) and the Cancer Genome Atlas (TCGA), and offers an in-depth analysis [35]. Genomic alterations in hub genes, including copy-number deep deletion, amplification, and missense mutation, in ovarian cancer samples were acquired from the cBioPortal database."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4034888744354248,
    "data_pmids_checked": 0,
    "paper_id": "39309198",
    "extraction_date": "2025-12-19T20:46:03.216893",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39309198.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39308676": {
    "cbioportal_paper_citations": [
      "To explore the potential reason for MTF1 expression dysregulation in pan-cancer, copy number variation (CNV) and methylation analyses of the MTF1 gene were performed using the gene set cancer analysis (GSCA) website (http://bioinfo.life.hust.edu.cn/GSCA/#/) 16. We analyzed and demonstrated the differences in MTF1 methylation in different cancer species and the correlation between methylation and expression, as well as the profiles of MTF1 CNV and its correlation with gene expression. The relationship between methylation, CNV status, and the survival of patients was also assessed. More detailed CpG methylation site data of MTF1 in KIRC, LGG, head and neck squamous cell carcinoma (HNSC), and lung squamous cell carcinoma (LUSC) was downloaded from the MethSurv database (https://biit.cs.ut.ee/methsurv/) 17. The results were presented using the ggplot2 package through lollipop charts, pie charts, and radar charts. As for the analysis of the genetic mutation profiles of MTF1, we referred to TCGA Pan-Cancer Atlas Studies (including 10967 samples of 32 studies) on an online database cBioPortal (https://www.cbioportal.org/) 18, 19."
    ],
    "cbioportal_platform_mentions": [
      "Besides abnormal gene expression, gene mutation and structural variation could be involved in the development of disease by affecting the structure and function of gene products. A total of 10,967 patients with various kinds of cancers from 32 studies in the cBioPortal database were analyzed. Mutations, structural variants, and CNV of the MTF1 gene were found in 22 out of 30 kinds of tumors. Among them, mutation and amplification were the most important genetic changes (Fig. 6A). As shown in the results, the frequency of MTF1 alteration was the highest in ovarian epithelial tumors at a rate of 7.02%, which also had the highest frequency of amplification (6.68%). Endometrial cancer had the highest incidence of mutation (5.8%) and miscellaneous neuroepithelial tumors had the uppermost rate of deletion (3.23%). Further analysis revealed that a total of 143 mutations were in the MTF1 gene, among which arginine to glutamine transition was the most common at position 251 located in the zinc finger double domain (245-271) (Fig. 6B). The change in spatial conformation caused by a mutation at this site is shown in the 3D structure diagram (Fig. 6C)."
    ],
    "data_publication_citations": {
      "29625055": [
        "MTF1 encodes a widely expressed transcription factor that binds metal response elements (MRE) in the promoters of heavy-metal response genes and regulates their transcription and expression. Previous studies have confirmed that zinc could bind MTF1 and induce its translocation to the nucleus, triggering the expression of downstream genes 9. Two years ago, a new mechanism of regulatory cell death, named cuproptosis, was discovered by scientists. They found that the direct binding of copper to the lipoylated components of the tricarboxylic acid (TCA) cycle resulted in the aggregation of lipoylated proteins and the subsequent loss of iron-sulfur clusters, which led to proteotoxic stress and cell death 10-12. Moreover, cuproptosis is a novel therapeutic target for cancer 11, 13. In addition, the screening results suggested that MTF1 might be a resistance factor to cuproptosis 14. Given the critical role of regulatory cell death in cancer treatment resistance 15, the relationship between MTF1 and cuproptosis and the role of MTF1 in cancer and immunity need to be further clarified."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.5781979560852051,
    "data_pmids_checked": 1,
    "paper_id": "39308676",
    "extraction_date": "2025-12-19T20:46:03.795185",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39308676.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39308669": {
    "cbioportal_paper_citations": [
      "We explored evidence of LY6H gene mutations from the cBioPortal database with the goal of understanding LY6H changes in pancarcinoma. cBioPortal for Cancer Genomics (http://cbioportal.org) is a comprehensive online platform for the exploration, visualization and analysis of multi-dimensional cancer genomic data16."
    ],
    "cbioportal_platform_mentions": [
      "We utilized the cBioPortal database to conduct an analysis on the genetic alterations of LY6H across various cancer types. As visually depicted in Figure 12A, a predominant majority of cancer types exhibited amplifications as the primary form of genetic alteration. Notably, Diffuse Large B-Cell Lymphoma displayed a prevalence of both mutations and amplifications in gene changes. Furthermore, Ovarian Serous Cystadenocarcinoma demonstrated the highest frequency (exceeding 25%) of gene alterations. Our analysis also revealed that somatic mutations in LY6H were predominantly deletions (Figure 12B).",
      "Cancer has emerged as a critical determinant of human survival and quality of life, making it the focal point of current medical research. Consequently, the identification of an appropriate cancer treatment modality assumes paramount importance in extending human lifespan. Leveraging patient information from TCGA, GTEx, UALCAN, cBioportal, UCSC, CTD, cancerSEA databases, we conducted an extensive analysis on the differential expression of LY6H across 33 human cancers to explore its associations with diagnosis, prognosis, immune infiltration, methylation patterns, genetic alterations, tumor stemness characteristics and chemical substances. Our findings aim to identify potential broad-spectrum biomarkers for cancer diagnosis by highlighting the significant up-regulation of LY6H in various cancer types and its potential utility in early detection.",
      "From the results interpreted by the cBioPortal platform, we know that LY6H is mutated in most forms of tumors. Among them, Diffuse Large B-Cell Lymphoma and Ovarian Serous Cystadenocarcinoma have the highest incidence, suggesting that attention should be paid to the relationship between LY6H gene mutation and blood system and female reproductive system. In addition, our single-cell functional analysis revealed a significant positive correlation between LY6H gene expression and angiogenesis, as well as a negative correlation with apoptosis, cell cycle regulation, DNA damage response and repair mechanisms, epithelial-mesenchymal transformation (EMT), invasion, metastasis, and quiescence."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.28853416442871094,
    "data_pmids_checked": 0,
    "paper_id": "39308669",
    "extraction_date": "2025-12-19T20:46:04.083821",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39308669.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39304557": {
    "cbioportal_paper_citations": [
      "We used the cbiopportal (https://www.cbioportal.org) online website for mutation and CNA analysis of hub genes. Segmentation analysis and the GISTIC algorithm were used to identify mutations and CNA in 6 hub genes [27]. The genetic alterations data for these hub genes were subsequently downloaded."
    ],
    "cbioportal_platform_mentions": [
      "We used the cBioPortal online tool to analyze the mutation status of 6 hub genes in the TCGA-PRAD cohort. The most common genetic alteration among all hub genes is Deep Deletion in PCa (Supplementary Fig. 4a). The alterations in these genes include Deep Deletion, Missense Mutation, Missense Mutation, and Amplification, in which each hub gene undergoes Deep Deletion (Supplementary Fig. 4b). MYOF (5%) has the highest rate of genetic alteration among these hub genes (Supplementary Fig. 4b).",
      "In order to validate the accuracy of these hub genes as biomarkers for PCa diagnosis, we found that they were downregulated in tumor tissues in both the GEO and TCGA validation cohorts, which was further confirmed by qRT-PCR in vitro cell experiments. Meanwhile, we analyzed possible genetic alterations in these hub genes through cBioPortal and found that Deep Deletion has occurred in these genes, and Deep Deletion is the most common genetic alteration in these hub genes. And previous studies indicated that the occurrence of Deep Deletion in the genome may be an important cause of gene downregulation [45]. Therefore, we speculate that the downregulation of these hub genes is related to the occurrence of Deep Deletion of genes. The results of ROC curve analysis indicated that they had high value as biomarkers for PCa diagnosis, and the nomogram plot demonstrated their excellent efficacy in predicting PCa risk. Additionally, we found that the expression of these six genes was lower in PCa patients with higher T/N pathological stage and Gleason score, and patients with low expression of these genes may have poorer progression-free survival (PFS). Furthermore, these six genes were positively correlated with each other, and the GSEA revealed that they played inhibitory roles in pathways or functions related to PCa growth and metastasis, such as MYC targets V1/V2, E2F targets, G2M checkpoint, mitotic spindle, and DNA repair. Due to their downregulation in PCa, the inhibition of these pathways or functions may be weakened, thus promoting tumor initiation and progression. Based on previous reports and our research, these hub genes can be used as prognostic biomarkers for early diagnosis and disease progression of PCa and may be potential therapeutic targets for PCa."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.17071175575256348,
    "data_pmids_checked": 0,
    "paper_id": "39304557",
    "extraction_date": "2025-12-19T20:46:04.254637",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39304557.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39303028": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "22960745": [
        "One of the hallmarks of a successful ICI response is tumor immunogenicity, the degree to which a tumor is primed to provoke a reaction from the patient\u2019s immune system (39). We thus investigated whether patients with low AMB risk showed characteristic immune phenotypes, such as the presence of tumor-infiltrating lymphocytes (TILs). For this purpose, we analyzed 804 patients with NSCLC for which both tumor genomic alteration profiles and hematoxylin and eosin\u2013stained histology images had been generated by The Cancer Genome Atlas project (TCGA-LUAD and TCGA-LUSC) (40, 41). Histology images were processed using a previously developed deep learning system that leverages ResNet-34 (39). By this approach, individual cells are first identified in the image by type (cancer, stroma, or lymphocyte), then broader regions of the image are classified as \u201cinflamed\u201d (high density of intraepithelial TILs), \u201cexcluded\u201d (lymphocytes detected only within tumor stromal regions), or \u201cdesert\u201d (lymphocytes not detected) (Fig. 5A and Supplementary Text)."
      ],
      "25079552": [
        "One of the hallmarks of a successful ICI response is tumor immunogenicity, the degree to which a tumor is primed to provoke a reaction from the patient\u2019s immune system (39). We thus investigated whether patients with low AMB risk showed characteristic immune phenotypes, such as the presence of tumor-infiltrating lymphocytes (TILs). For this purpose, we analyzed 804 patients with NSCLC for which both tumor genomic alteration profiles and hematoxylin and eosin\u2013stained histology images had been generated by The Cancer Genome Atlas project (TCGA-LUAD and TCGA-LUSC) (40, 41). Histology images were processed using a previously developed deep learning system that leverages ResNet-34 (39). By this approach, individual cells are first identified in the image by type (cancer, stroma, or lymphocyte), then broader regions of the image are classified as \u201cinflamed\u201d (high density of intraepithelial TILs), \u201cexcluded\u201d (lymphocytes detected only within tumor stromal regions), or \u201cdesert\u201d (lymphocytes not detected) (Fig. 5A and Supplementary Text)."
      ],
      "30643254": [
        "We focused on ICI response prediction in NSCLC and bladder cancers (BLCA), as both tumor types have been approved for ICI treatment, and response data have been released as a single integrated cohort (NSCLC, n = 344; BLCA, n = 211) (Samstein cohort) (34). In this dataset, tumors were subjected to mutational profiling for 468 cancer-related genes comprising the MSK-IMPACT gene panel (Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets), with immunotherapy outcomes measured as overall patient survival. We found no statistical differences in mutation rates between patients with NSCLC and BLCA (P = 0.19; fig. S1A). Mutational analysis indicated that known genetic biomarkers of ICI response (22) were mutated infrequently in this cohort (e.g., 3% of tumors with JAK3 mutation; Fig. 2A), with the exceptions of TP53 (57.1%) and KRAS (23.6%). For validation, we obtained separate collections of ICI-treated NSCLC tumors from Hellmann et al. (35) (n = 68) and BLCA tumors from the IMvigor210 trial (11) (n = 78). In the independent validation cohorts, all tumors had been subjected to genome-wide mutational profiling, with immunotherapy outcomes reported as well as progression-free survival (PFS; Hellmann cohort) or overall survival (OS; IMvigor210).",
        "A panel of 468 genes (MSK-IMPACT) was used to assess the mutational impact on response to immunotherapy. We marked each gene as mutated (\u201c1\u201d) if it had (i) missense/nonsense mutations, (ii) frameshift insertions/deletions, (iii) splice site regions, or (iv) in-frame insertions/deletions in a patient tumor; otherwise, the gene was marked as unmutated (\u201c0\u201d). To calculate an AMB, we used the gene-to-assembly associations from the NeST hierarchy (33). The mutational burden of an assembly was calculated by counting the sum of the number of mutated genes observed in the genes of the assembly. For TMB, we used the reported TMB values for the Samstein (34), Hellmann (35), and IMvigor210 cohorts (11). For IMvigor210 patients, we only considered patients with BLCA and removed samples biopsied before chemotherapy treatment. For TCGA patients, we calculated the TMB using the Maftools R package (66).",
        "To measure the performance of the AMB model in the Samstein cohort (Fig. 3A), we conducted leave-one-out cross-validation. For this purpose, we designated the top 20% of patients with the lowest predicted risks as \u201cpredicted responders\u201d (34); the remaining 80% of patients were designated as \u201cpredicted nonresponders.\u201d We also used the Samstein cohort to conduct Monte Carlo cross-validation (Fig. 3B), whereby we partitioned 90 and 10% of the data into training and test datasets, respectively, for each of the 100 independent iterations. Performance in Monte Carlo cross-validation was measured using the CI. The CI measures, over all admissible patient pairs, the frequency with which the model predicts patient j to outlive i when j outlives i in observed data (69). The CI was defined asC=NC+0.5\u00d7NTNC+ND+NTwhere NC, ND, and NT correspond to the number of concordant pairs, discordant pairs, and tied pairs, respectively. CI scores were computed by using the lifelines package where censored information was included when computing CI scores. To measure performance in the validation cohorts (the Hellmann and IMvigor210 cohorts), we determined the optimal tree depth for AMB- and GMB-based models from the Samstein cohort by selecting the most frequently selected tree depth from the Monte Carlo cross-validation (data S1). The tree depths selected were 3 and max tree depths for AMB- and GMB-based models, respectively. To stratify patients into predicted responders and nonresponders in the validation ICI cohorts, we identified a cutoff score from the Samstein cohort. Cutoff scores were determined by the lowest 20% risk score in the Samstein cohort, corresponding to 19.60, 15.55, or 0.90 risk scores for AMB, GMB, or TMB models, respectively."
      ],
      "25765070": [
        "Tumor mutation burden (TMB), typically quantified as the number of nonsynonymous somatic mutations per megabase in the tumor genome, was an early biomarker associated with ICI response (13). Across tumor types, a general relationship was reported between high TMB and objective response rates to immunotherapy, with melanoma and colorectal cancers with microsatellite instability having some of the best outcomes (14). This and other reports (15) led to accelerated approval by the US Food and Drug Administration to treat high TMB tumors with pembrolizumab, an ICI therapy that blocks the programmed cell death protein 1 (PD-1) receptor on the surface of T cells (1)."
      ],
      "29657128": [
        "We focused on ICI response prediction in NSCLC and bladder cancers (BLCA), as both tumor types have been approved for ICI treatment, and response data have been released as a single integrated cohort (NSCLC, n = 344; BLCA, n = 211) (Samstein cohort) (34). In this dataset, tumors were subjected to mutational profiling for 468 cancer-related genes comprising the MSK-IMPACT gene panel (Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets), with immunotherapy outcomes measured as overall patient survival. We found no statistical differences in mutation rates between patients with NSCLC and BLCA (P = 0.19; fig. S1A). Mutational analysis indicated that known genetic biomarkers of ICI response (22) were mutated infrequently in this cohort (e.g., 3% of tumors with JAK3 mutation; Fig. 2A), with the exceptions of TP53 (57.1%) and KRAS (23.6%). For validation, we obtained separate collections of ICI-treated NSCLC tumors from Hellmann et al. (35) (n = 68) and BLCA tumors from the IMvigor210 trial (11) (n = 78). In the independent validation cohorts, all tumors had been subjected to genome-wide mutational profiling, with immunotherapy outcomes reported as well as progression-free survival (PFS; Hellmann cohort) or overall survival (OS; IMvigor210).",
        "To assess the generalizability of AMB risk predictions, we used the previously trained model to predict the response status of patients in the independent NSCLC Hellmann cohort (35) described above, without any additional optimization or parameter tuning (see Materials and Methods). From principal components analysis, we found that AMB profiles were well correlated between the Samstein and Hellmann or IMvigor210 cohorts, without evidence of batch effects (fig. S1, B and C). We examined if AMB risk could be used to predict this quantitative PFS outcome in the Hellmann cohort. We found that predicted responders exhibited substantially longer PFS than predicted nonresponders (high AMB risk, P = 3.74 \u00d7 10\u22124; Fig. 3D); this predictive performance was on par or better than TMB (Fig. 3E) or GMB (Fig. 3F). We also investigated predictive performance in a second independent cancer cohort (patients with IMvigor210 BLCA, described above). Here too, we found that predicted IMvigor210 responders showed longer OS compared to predicted nonresponders (P = 2.48 \u00d7 10\u22122; Fig. 3G), outperforming TMB (Fig. 3H) or GMB (Fig. 3I). Collectively, these results suggested that integrating the mutational burden within specific protein assemblies offers a promising strategy for understanding the response to ICIs.",
        "A panel of 468 genes (MSK-IMPACT) was used to assess the mutational impact on response to immunotherapy. We marked each gene as mutated (\u201c1\u201d) if it had (i) missense/nonsense mutations, (ii) frameshift insertions/deletions, (iii) splice site regions, or (iv) in-frame insertions/deletions in a patient tumor; otherwise, the gene was marked as unmutated (\u201c0\u201d). To calculate an AMB, we used the gene-to-assembly associations from the NeST hierarchy (33). The mutational burden of an assembly was calculated by counting the sum of the number of mutated genes observed in the genes of the assembly. For TMB, we used the reported TMB values for the Samstein (34), Hellmann (35), and IMvigor210 cohorts (11). For IMvigor210 patients, we only considered patients with BLCA and removed samples biopsied before chemotherapy treatment. For TCGA patients, we calculated the TMB using the Maftools R package (66)."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 5,
    "extraction_method": "jats_xml",
    "extraction_time": 1.2283210754394531,
    "data_pmids_checked": 5,
    "paper_id": "39303028",
    "extraction_date": "2025-12-19T20:46:05.483063",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39303028.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39375962": {
    "paper_id": "39375962",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "2.3.4 | Somatic Mutation Analysis: We used the web-based tool cBioPortal to obtain\ngene-level data on somatic mutation types and frequencies for human prostate cancer,\nincluding co-occurrence frequency data and copy number variation frequency data by\nvariant type (amplification or deletion) [26]",
      "By secondary analysis of human somatic\nmutation frequency data from the cBioPortal database, we investigated somatic mutation\nVet Comp Oncol",
      "Consequently, examination of\nthe curated cBioPortal human prostate cancer data revealed highly significant pairwise\nco-occurrence of somatic mutations among S100P, IFITM1, GPX3, AZGP1 and ISG15",
      "Gao J, Aksoy BA, Dogrusoz U, et al. , \u201cIntegrative Analysis of Complex Cancer Genomics and\nClinical Profiles Using the cBioPortal,\u201d Science Signaling 6, no",
      "(A) Somatic mutations co-occurrence using cBioPortal database in the five seed genes for\nthe network analysis"
    ],
    "data_publication_citations": {
      "26544944": [
        "[PubMed: 26544944]\nVet Comp Oncol"
      ],
      "26000489": [
        "[PubMed: 26000489]\n40"
      ]
    },
    "extraction_date": "2025-12-19T20:46:06.029995",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39375962.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 2,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.439707040786743,
      "cbioportal_papers": 0.0002276897430419922,
      "pdf_extraction_pass2": 10.31167221069336,
      "cbioportal_papers_pass2": 0.0002942085266113281,
      "used_full_extraction": true,
      "pdf_extraction": 17.751379251480103,
      "platform_mentions": 0.002393960952758789,
      "data_citations": 0.04290914535522461,
      "num_data_pmids_checked": 2
    }
  },
  "39300407": {
    "cbioportal_paper_citations": [
      "Expanded information regarding EZH2 mutations and patient survival time in breast cancer patients was downloaded from cBioPortal, an open access database that is available at http://www.cbioportal.org [23, 24]. Using the Breast Cancer dataset (MSK, Cancer Cell 2018), data from the targeted sequencing of tumor/normal sample pairs from 1,918 breast cancer patients were retrieved."
    ],
    "cbioportal_platform_mentions": [
      "However, the role of EZH2 mutation in breast cancer is unclear. Previous studies on EZH2 mutations have mostly focused on hematological tumors [11]. With the development of genomics and sequencing technology, targeted next-generation sequencing (targeted NGS) has become widely used for screening cancer biomarkers for precision medicine [12\u201314]. In this study, we evaluated EZH2 mutation as a biomarker associated with VM in breast cancer by comparing tissue and blood samples from VM and non-VM MBC patients through targeted NGS. We collected data on 1,392 patients with breast cancer from the cBioPortal datasets to further evaluate whether EZH2 mutation was an independent prognostic factor for VM in primary breast cancer patients via multivariate analysis. Subsequently, we explored the preliminary mechanism by which EZH2 mutation leads to increased cell invasion and metastasis in vitro.",
      "We collected complete follow-up data for 1,392 patients with early breast cancer (stage 1\u20133) from cBioPortal (dataset MSK, Cancer Cell 2018) to verify our results. The results also showed that the DFS time of patients with EZH2 mutations was significantly shorter than that of patients without EZH2 mutations (26.9 months vs. 52.7 months, log-rank p = 0.029) (Fig. 2C). Patients with EZH2 mutations had a significantly greater risk of developing visceral metastases (HR 3.1), and the VMFS was significantly shorter in the EZH2 mutation group (31.5 months vs. 109.7 months, log-rank p = 0.008) (Fig. 2D). With menopausal status, ER status, PR status, HER2 status, TNM stage of the primary disease, and EZH2 mutation status as prognostic indicators, multivariate Cox regression analysis revealed that ER negativity, stage III status, and EZH2 mutation status (HR 2.73, p = 0.026) were independent factors for the occurrence of VM after breast cancer surgery (Table 4).",
      "Fig. 2EZH2 mutation is associated with the development of visceral metastasis. (A) Patients carrying EZH2 mutations had a significantly shorter VMFS (22 months vs. 50 months, p = 0.005) than patients without EZH2 mutations. (B) Patients carrying EZH2 mutations had a significantly shorter VMFS (10 months vs. unreached, p = 0.001) than patients without EZH2 mutations in the TNBC subtype. (C) DFS time of patients with EZH2 mutations was significantly shorter than that of patients without EZH2 mutations (26.9 months vs. 52.7 months, p = 0.029) in 1,392 patients from cBioPortal. (D) VMFS was significantly shorter in the EZH2 mutation group than that of patients without EZH2 mutations (31.5 months vs. 109.7 months, log-rank p = 0.008) in 1,392 patients from cBioPortal",
      "EZH2 mutation is associated with the development of visceral metastasis. (A) Patients carrying EZH2 mutations had a significantly shorter VMFS (22 months vs. 50 months, p = 0.005) than patients without EZH2 mutations. (B) Patients carrying EZH2 mutations had a significantly shorter VMFS (10 months vs. unreached, p = 0.001) than patients without EZH2 mutations in the TNBC subtype. (C) DFS time of patients with EZH2 mutations was significantly shorter than that of patients without EZH2 mutations (26.9 months vs. 52.7 months, p = 0.029) in 1,392 patients from cBioPortal. (D) VMFS was significantly shorter in the EZH2 mutation group than that of patients without EZH2 mutations (31.5 months vs. 109.7 months, log-rank p = 0.008) in 1,392 patients from cBioPortal",
      "Risk factor for VM in primary breast cancer from cBioPortal",
      "We also analyzed the correlation between EZH2 mutations and BRCA1 and BRCA2 mutations in our cohort, and the results revealed no correlation between EZH2 mutations and BRCA1 mutations (OR = 1.78, 95% CI 0.26\u201311.98, p = 0.616) and no correlation between EZH2 mutations and BRCA2 mutations (OR = 2.91, 95% CI 0.51\u201316.59, p = 0.334) (Table S1). We also performed further analysis of the Breast Cancer dataset (MSK, Cancer Cell 2018, http://www.cbioportal.org). We found no correlation between EZH2 mutations and BRCA1 or BRCA2 mutations (p > 0.05) (Table S2).",
      "In this study, we found that EZH2 mutation was an independent prognostic factor for VM by targeted NGS, and the results were further verified through a dataset from cBioPortal. The function of EZH2 mutations depends on the type of cancer, for example, gain-of-function in lymphomas and loss-of-function in medulloblastoma and bladder and renal cancers [29, 30]. Previous studies on the role of EZH2 mutation in breast cancer are rare. EZH2 rs6950683 and rs3757441 SNPs (TC + CC genotype) have been shown to be related to the tumor size of TNBC patients under 60 years of age [31]. The EZH2K515R mutation is located in exon 13 of the EZH2 gene. This region is an important site for EZH2 to interact with its positive regulatory factor CDYL. Therefore, the EZH2K515R mutation may lead to important functional changes in EZH2. Our results indicate that, compared with EZH2WT, the EZH2K515R mutation eventually leads to VM and a poor prognosis in TNBC cells by enhancing proliferation and invasion and inhibiting apoptosis in vitro. The molecular mechanism may be that the EZH2K515R mutation silences the expression of certain genes by inducing H3K27me3, and further study is underway to shed light on the potential of EZH2 as a therapeutic target.",
      "Our analysis of patient cohort data and a dataset from cBioPortal revealed that EZH2 mutation is associated with the development of VM in breast cancer through the enhancement of proliferation, invasion, and antiapoptotic effects in vitro. However, further studies are needed to elucidate the complex mechanism underlying this phenomenon."
    ],
    "data_publication_citations": {
      "34544752": [
        "Statistical analysis of clinicopathologic data was performed using a two-tailed Student\u2019s t test for continuous variables and Fisher\u2019s exact test for categorical variables. P values < 0.05 were considered to indicate statistical significance. K\u2012M survival curves were used to analyze patient survival. Multivariate analysis was performed to identify factors related to PFS using a Cox proportional hazards model. The variables included menstrual status, primary stage, ER/PR status, HER2 status, and EZH2 mutation status. Variables with p < 0.05 in the univariate analysis were included in the multivariate analysis. All analyses were performed using SPSS 21.0 (IBM, Armonk, NY, USA) and visualized with GraphPad Prism 9.3.0 (GraphPad Software, Inc) and R software v4.0.3 (R Core Team). Based on the formula for investigating the sample size by population rate \u03c0, n= (U\u03b1/\u03b4)2(1-P) P, we set \u03b1 = 0.05, U\u03b1 = 1.96, and \u03b4 = 0.05, where P is the sample rate. According to previous studies, the frequency of EZH2 mutations in breast cancers is approximately 1\u20133% [20\u201322]. Thus, we estimated the sample size to be 44 patients, the dropout rate was 10%, and 49 patients were ultimately enrolled."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 8,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.9460759162902832,
    "data_pmids_checked": 3,
    "paper_id": "39300407",
    "extraction_date": "2025-12-19T20:46:07.064569",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39300407.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39350531": {
    "paper_id": "39350531",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex\ncancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:46:09.712558",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39350531.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 10.352978944778442,
      "cbioportal_papers": 8.106231689453125e-05,
      "pdf_extraction_pass2": 7.841490030288696,
      "cbioportal_papers_pass2": 8.392333984375e-05,
      "used_full_extraction": true,
      "pdf_extraction": 18.19446897506714,
      "platform_mentions": 0.0010008811950683594,
      "data_citations": 4.0531158447265625e-06,
      "num_data_pmids_checked": 0
    }
  },
  "39300912": {
    "cbioportal_paper_citations": [
      "Our CRISPR screen data suggests that HOXA9 is a potential mediator of enzalutamide resistance. We sought to extend these findings by analyzing publicly available genomic and transcriptomic datasets from prostate cancer patients using cBioPortal.32 We observed that increased HOXA9 copy number is correlated with shorter survival in castration resistant disease (Figure 3A), where median survival was reduced from 105 months to 42. Since HOXA9 is upregulated in enzalutamide resistant DKO cells, we investigated HOXA9 copy number in studies from hormone sensitive and castration resistant disease. HOXA9 was amplified, or exhibited single copy gain, in 39.3% of castration resistant cases compared with only 17.6% of patients in studies of hormone sensitive prostate cancer (Figure 3B). Furthermore, in the MSKCC/DFCI 2018 dataset tumor samples are categorized as biopsies from primary or metastatic sites.33 Genomic gain of HOXA9 was found in 40% of metastatic tumors compared with 17% in primary prostate tumors (Figure 3C), showing that increased HOXA9 copy number is associated with advanced prostate cancer. We analyzed the SU2C/PCF Dream Team 2019 study as it relates genomic, transcriptomic, and histologic data from castration resistant patients.28 Figure 3D shows that HOXA9 is genetically altered or mis-expressed in 10% of samples. Strikingly, HOXA9 amplifications and overexpression accounts for 95% of these alterations, further suggesting that HOXA9 has an oncogenic role in advanced prostate cancer. We next evaluated HOXA9 mRNA expression in samples with histologic neuroendocrine features and they are correlated with higher HOXA9 expression (Figure 3E). Furthermore, when categorized based on histopathologic classification, HOXA9 expression is highest in tumors with a mixed adenocarcinoma and neuroendocrine histology, compared with pure adenocarcinoma or small-cell features (Figure 3F). Since RB loss was key to discovering HOXA9 upregulation, we compared RB1 and HOXA9 expression in samples from this study. We found an inverse correlation between RB1 and HOXA9 expression (Figure 3G). Overall, these clinical genomic observations indicate that increased HOXA9 expression is associated with advanced prostate cancer and may be an important mediator in the cellular response to enzalutamide.",
      "For survival data, the MCTP 2012 dataset in the cBioPortal database was selected,61 and queried specifically for HOXA9 genomic amplification using default settings.32 Analysis of indicated hormone sensitive prostate cancer studies,33,62\u201364 including the TCGA firehose legacy (https://www.cancer.gov/tcga), and castration resistance prostate cancer datasets were also queried specifically for HOXA9 amplification or gain.28,61,65,66 For transcriptomic data from the SU2C/PCF Dream Team FPKM PolyA mRNA data was used for analysis.28"
    ],
    "cbioportal_platform_mentions": [
      "HOXA9 amplification and gain in prostate cancer clinical samples is associated poorer overall survival, an advanced diseased state and neuroendocrine features. (A) Kaplan\u2013Meier curve comparing overall survival of prostate cancer patients with or without HOXA9 genomic amplification within MCTP 2012 dataset in cBioPortal. Median overall survival for each cohort is shown. Log rank test performed. (B) Frequency of HOXA9 amplification + gains across hormone sensitive prostate cancer (HSPC) and castration resistant prostate cancer (CRPC) datasets from cBioPortal. Average frequency for cohorts is shown. Welch\u2019s unpaired t test performed. (C) Genomic alterations within primary and metastatic prostate tumor samples from the MSK/DFCI, Nature Genetics 2018 HSPC dataset. (D) Oncoprint for HOXA9 displaying genomic and transcriptomic alterations in CRPC tumor samples from the SU2C/PCF Dream Team, PNAS 2019 dataset. (E) Tukey plots of HOXA9 mRNA expression (FPKM Poly A) in tumor samples with or without NE features from CRPC dataset in D. Welch\u2019s one-tailed t test. (F) Tukey plots of HOXA9 mRNA expression across pathology classifications in CRPC dataset from D. Welch\u2019s one-tailed t tests. (G) Correlation between RB1 and HOXA9 mRNA expression in CRPC dataset from D. Simple linear regression line and Spearman coefficient are shown. Two-sided t test. Where applicable: ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, ns, not significant."
    ],
    "data_publication_citations": {
      "31061129": [
        "We undertook a two-way analysis (Figure 1B) in which gene enrichment or loss, both temporally and between treatment groups, allowed for inference of gene function in response to enzalutamide. This approach facilitated quality control of the screen workflow, as well as discovery of new genes that impacted the cellular response to enzalutamide. Genes enriched, or lost, at Tf in enzalutamide treatment compared with Tf DMSO control cells may indicate genes that confer enzalutamide sensitivity or resistance (Figure 1C). The loss of FOXA1 mutant cells in response to enzalutamide treatment in this experiment is consistent with its role as a driver of resistance in advanced prostate cancer.17,28,29 Similarly, the increased presence of RB1 and TP53 mutant cells is consistent with their loss of function in enzalutamide resistant disease.15,28 However, gene loss events that score as sensitive, may reflect essential roles in cell physiology irrespective of drug treatment. In addition, loss of function mutations in negative growth regulators may simply increase proliferation in prolonged culture creating a false enzalutamide resistance phenotype. Comparison of Tf DMSO with T0 DMSO (Figure 1D) was made to control for essential gene functions or roles in cell proliferation. Most nontargeting sgRNA controls directed against nonmammalian genes such a Luc, EGFP, and LacZ appear close to a log2 fold change of zero and often lack statistical significance (Figure 1D), consistent with a neutral effect on proliferation or survival over time. In the analysis of DMSO treated controls (Figure 1D), loss of the MCM5 gene confirms its essential role in the proliferation of these cells and suggests its loss in enzalutamide treatment (Figure 1C) is not related to drug action. As further support for our characterization of gene essentially, we identified all of the top 10 preferentially essential genes for LNCaP cells highlighted in the DepMap database, as de-enriched in our Tf DMSO vs T0 DMSO analysis (Supplementary Table 1).30 Analogously, TP53 depletion is enriched over time in control culture (Figure 1D), suggesting that cells deficient for p53 have a proliferative advantage that may contribute to its apparent resistance phenotype during enzalutamide selection (Figure 1C). RB1 deletion has little impact on overall proliferation over two months in control culture conditions (Figure 1D), indicating its loss in response to drug treatment (Figure 1C) represents a role in acquisition of enzalutamide resistance in this experiment. The accurate classification of these genes suggested our screen data is ideal for discovering new mechanisms of enzalutamide treatment resistance.",
        "Our CRISPR screen data suggests that HOXA9 is a potential mediator of enzalutamide resistance. We sought to extend these findings by analyzing publicly available genomic and transcriptomic datasets from prostate cancer patients using cBioPortal.32 We observed that increased HOXA9 copy number is correlated with shorter survival in castration resistant disease (Figure 3A), where median survival was reduced from 105 months to 42. Since HOXA9 is upregulated in enzalutamide resistant DKO cells, we investigated HOXA9 copy number in studies from hormone sensitive and castration resistant disease. HOXA9 was amplified, or exhibited single copy gain, in 39.3% of castration resistant cases compared with only 17.6% of patients in studies of hormone sensitive prostate cancer (Figure 3B). Furthermore, in the MSKCC/DFCI 2018 dataset tumor samples are categorized as biopsies from primary or metastatic sites.33 Genomic gain of HOXA9 was found in 40% of metastatic tumors compared with 17% in primary prostate tumors (Figure 3C), showing that increased HOXA9 copy number is associated with advanced prostate cancer. We analyzed the SU2C/PCF Dream Team 2019 study as it relates genomic, transcriptomic, and histologic data from castration resistant patients.28 Figure 3D shows that HOXA9 is genetically altered or mis-expressed in 10% of samples. Strikingly, HOXA9 amplifications and overexpression accounts for 95% of these alterations, further suggesting that HOXA9 has an oncogenic role in advanced prostate cancer. We next evaluated HOXA9 mRNA expression in samples with histologic neuroendocrine features and they are correlated with higher HOXA9 expression (Figure 3E). Furthermore, when categorized based on histopathologic classification, HOXA9 expression is highest in tumors with a mixed adenocarcinoma and neuroendocrine histology, compared with pure adenocarcinoma or small-cell features (Figure 3F). Since RB loss was key to discovering HOXA9 upregulation, we compared RB1 and HOXA9 expression in samples from this study. We found an inverse correlation between RB1 and HOXA9 expression (Figure 3G). Overall, these clinical genomic observations indicate that increased HOXA9 expression is associated with advanced prostate cancer and may be an important mediator in the cellular response to enzalutamide.",
        "For survival data, the MCTP 2012 dataset in the cBioPortal database was selected,61 and queried specifically for HOXA9 genomic amplification using default settings.32 Analysis of indicated hormone sensitive prostate cancer studies,33,62\u201364 including the TCGA firehose legacy (https://www.cancer.gov/tcga), and castration resistance prostate cancer datasets were also queried specifically for HOXA9 amplification or gain.28,61,65,66 For transcriptomic data from the SU2C/PCF Dream Team FPKM PolyA mRNA data was used for analysis.28"
      ],
      "22722839": [
        "For survival data, the MCTP 2012 dataset in the cBioPortal database was selected,61 and queried specifically for HOXA9 genomic amplification using default settings.32 Analysis of indicated hormone sensitive prostate cancer studies,33,62\u201364 including the TCGA firehose legacy (https://www.cancer.gov/tcga), and castration resistance prostate cancer datasets were also queried specifically for HOXA9 amplification or gain.28,61,65,66 For transcriptomic data from the SU2C/PCF Dream Team FPKM PolyA mRNA data was used for analysis.28"
      ],
      "20579941": [
        "For survival data, the MCTP 2012 dataset in the cBioPortal database was selected,61 and queried specifically for HOXA9 genomic amplification using default settings.32 Analysis of indicated hormone sensitive prostate cancer studies,33,62\u201364 including the TCGA firehose legacy (https://www.cancer.gov/tcga), and castration resistance prostate cancer datasets were also queried specifically for HOXA9 amplification or gain.28,61,65,66 For transcriptomic data from the SU2C/PCF Dream Team FPKM PolyA mRNA data was used for analysis.28"
      ],
      "29610475": [
        "Our CRISPR screen data suggests that HOXA9 is a potential mediator of enzalutamide resistance. We sought to extend these findings by analyzing publicly available genomic and transcriptomic datasets from prostate cancer patients using cBioPortal.32 We observed that increased HOXA9 copy number is correlated with shorter survival in castration resistant disease (Figure 3A), where median survival was reduced from 105 months to 42. Since HOXA9 is upregulated in enzalutamide resistant DKO cells, we investigated HOXA9 copy number in studies from hormone sensitive and castration resistant disease. HOXA9 was amplified, or exhibited single copy gain, in 39.3% of castration resistant cases compared with only 17.6% of patients in studies of hormone sensitive prostate cancer (Figure 3B). Furthermore, in the MSKCC/DFCI 2018 dataset tumor samples are categorized as biopsies from primary or metastatic sites.33 Genomic gain of HOXA9 was found in 40% of metastatic tumors compared with 17% in primary prostate tumors (Figure 3C), showing that increased HOXA9 copy number is associated with advanced prostate cancer. We analyzed the SU2C/PCF Dream Team 2019 study as it relates genomic, transcriptomic, and histologic data from castration resistant patients.28 Figure 3D shows that HOXA9 is genetically altered or mis-expressed in 10% of samples. Strikingly, HOXA9 amplifications and overexpression accounts for 95% of these alterations, further suggesting that HOXA9 has an oncogenic role in advanced prostate cancer. We next evaluated HOXA9 mRNA expression in samples with histologic neuroendocrine features and they are correlated with higher HOXA9 expression (Figure 3E). Furthermore, when categorized based on histopathologic classification, HOXA9 expression is highest in tumors with a mixed adenocarcinoma and neuroendocrine histology, compared with pure adenocarcinoma or small-cell features (Figure 3F). Since RB loss was key to discovering HOXA9 upregulation, we compared RB1 and HOXA9 expression in samples from this study. We found an inverse correlation between RB1 and HOXA9 expression (Figure 3G). Overall, these clinical genomic observations indicate that increased HOXA9 expression is associated with advanced prostate cancer and may be an important mediator in the cellular response to enzalutamide.",
        "For survival data, the MCTP 2012 dataset in the cBioPortal database was selected,61 and queried specifically for HOXA9 genomic amplification using default settings.32 Analysis of indicated hormone sensitive prostate cancer studies,33,62\u201364 including the TCGA firehose legacy (https://www.cancer.gov/tcga), and castration resistance prostate cancer datasets were also queried specifically for HOXA9 amplification or gain.28,61,65,66 For transcriptomic data from the SU2C/PCF Dream Team FPKM PolyA mRNA data was used for analysis.28"
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 4.395199298858643,
    "data_pmids_checked": 6,
    "paper_id": "39300912",
    "extraction_date": "2025-12-19T20:46:09.891757",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39300912.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39297878": {
    "cbioportal_paper_citations": [
      "Several software programs are available for this aim, from internally developed by OECI cancer centers to commercial ones [58, 61, 62]. Some of these tools have evolved into comprehensive data management frameworks that also enable radio- and pathological images to be shared and discussed. Since the focus remains on tracking cancer molecular evolution, the recent upgrades of the cBioPortal framework [63] must be cited. Other than the multicohort molecular analysis system that became one of the de facto standards thanks to his open-source framework, it recently expanded its features into a management system also including patient-level timelines and imaging analysis. Additionally, the molecular data infrastructure was empowered to also describe targeted sequencing panels against the classical Whole-Exome Sequencing coverage of TCGA cohorts [64]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.44841599464416504,
    "data_pmids_checked": 0,
    "paper_id": "39297878",
    "extraction_date": "2025-12-19T20:46:10.167749",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39297878.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39300140": {
    "cbioportal_paper_citations": [
      "All genomic data analyzed in this manuscript have already been published in the sources described below. Our use of de-identified and published clinical and genomic data complies with all relevant ethical regulations. Mutational, copy number, sample, and patient data were downloaded from the cBioPortal datahub (https://github.com/cBioPortal/datahub)112,113. Whole genome duplication determinations were sourced from the original cohort study (MSK-MET and PCAWG) or from subsequent analyses (TCGA)44,52,60. A sample was considered to have undergone WGD based on processing by FACETS (MSK-MET), consensus across 10 different methods (PCAWG), or ABSOLUTE (TCGA)60,114,115. Genetic ancestry determinations for the MSK-MET cohort were graciously provided by Kanika Arora, following the method from ref. 34. Racial data was determined by electronic health record review (MSK-MET) and by interview during enrollment where patients were asked to select from the racial categories defined by the U.S. Office of Management and Business and used by the U.S. Census Bureau (TCGA). Regional lymph node metastasis data were sourced from ref. 58. Mutagen signatures of environmental agents were obtained from the original study96,116. Sample size calculations were not possible as our analysis was limited by the availability of published copy number data from patient cancers."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "32025007": [
        "WGD events in cancer are associated with genomic instability and aggressive disease (Fig. 1A)52,57. We investigated the frequency of WGD events in cancers from different patient cohorts: MSK-MET (n = 13,071 patients), The Cancer Genome Atlas (TCGA) (n = 8060 patients), and the Pan-cancer Analysis of Whole Genomes (PCAWG) (n = 1963 patients)58\u201360. These three datasets represent the largest publicly-available tumor sequencing cohorts with both copy number alteration data and patient demographic information. Full demographics of included patients and cancer types can be found in Table S1. We compared the frequency of WGD events in cancers from self-reported Black and white patients in the MSK-MET and TCGA cohorts and between cancers from individuals with inferred African and European ancestry in the PCAWG cohort. We discovered that cancers from self-reported Black patients and patients with inferred African ancestry exhibited a significantly higher incidence of WGDs compared to cancers from self-reported white patients or patients with inferred European genetic ancestry (Fig. 1B-D). Notably, CNAs in each of these datasets were detected using different genomic technologies: SNP arrays, targeted gene sequencing, and whole-genome sequencing, for TCGA, MSK-MET, and PCAWG, respectively58\u201360. As these findings were consistent across all three cohorts, we anticipate that they are robust and independent of any platform-specific artifacts.Fig. 1WGDs are more common among self-reported Black cancer patients and those with inferred African genetic ancestry.A A schematic of the whole-genome duplication process. WGDs produce a cell with a doubled chromosome complement (typically 4N). WGD events are associated with metastasis and disease progression. Loss of the tumor suppressor TP53 promotes WGDs; other causes of WGDs are largely unknown. The frequency of WGDs in self-reported Black and white patients from three different cohorts: B MSK-MET, C TCGA, and D PCAWG. Note that in the PCAWG dataset, a patient\u2019s self-reported race was not available, and instead inferred genetic ancestry was used (African (AFR) vs European (EUR)). E The frequency of WGD events in self-reported Black and white patients with either breast cancer, endometrial cancer, or NSCLC, in the MSK-MET and TCGA cohorts. Source data are provided as a Source Data file. Statistical testing was performed via two-tailed Pearson\u2019s Chi-squared test. Statistical significance: NS p \u2265 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Figure 1A was created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license (https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en).",
        "All genomic data analyzed in this manuscript have already been published in the sources described below. Our use of de-identified and published clinical and genomic data complies with all relevant ethical regulations. Mutational, copy number, sample, and patient data were downloaded from the cBioPortal datahub (https://github.com/cBioPortal/datahub)112,113. Whole genome duplication determinations were sourced from the original cohort study (MSK-MET and PCAWG) or from subsequent analyses (TCGA)44,52,60. A sample was considered to have undergone WGD based on processing by FACETS (MSK-MET), consensus across 10 different methods (PCAWG), or ABSOLUTE (TCGA)60,114,115. Genetic ancestry determinations for the MSK-MET cohort were graciously provided by Kanika Arora, following the method from ref. 34. Racial data was determined by electronic health record review (MSK-MET) and by interview during enrollment where patients were asked to select from the racial categories defined by the U.S. Office of Management and Business and used by the U.S. Census Bureau (TCGA). Regional lymph node metastasis data were sourced from ref. 58. Mutagen signatures of environmental agents were obtained from the original study96,116. Sample size calculations were not possible as our analysis was limited by the availability of published copy number data from patient cancers."
      ],
      "29625055": [
        "Clinical data including tumor response for first course of treatment and tumor status at the end of the clinical observation period were sourced from TCGA. Tumor responses included for analysis included \u201cComplete Remission/Response\u201d, \u201cPartial Remission/Response\u201d, \u201cStable Disease\u201d, and \u201cProgressive Disease,\u201d the remaining responses were not included for analysis as these categories represented disputed, uncertain, or missing clinical responses. The frequency of progressive disease was calculated as the proportion of patients with \u201cProgressive Disease\u201d over total number of patients with included tumor responses by WGD status at a pan-cancer and cancer type level. For tumor status, patients with documented \u201cTUMOR_FREE\u201d or \u201cWITH_TUMOR\u201d were included for analysis, remaining patients with missing data were excluded. The frequency of patients with persistent disease at the end of TCGA\u2019s clinical observational period was calculated as the proportion of patients \u201cWITH TUMOR\u201d over total number of patients with documented tumor status by WGD status at a pan-cancer and cancer type level. The definitions of these variables were provided in ref. 136. Testing for association was done via two-tailed Pearson\u2019s Chi-squared test."
      ],
      "35120664": [
        "WGD events in cancer are associated with genomic instability and aggressive disease (Fig. 1A)52,57. We investigated the frequency of WGD events in cancers from different patient cohorts: MSK-MET (n = 13,071 patients), The Cancer Genome Atlas (TCGA) (n = 8060 patients), and the Pan-cancer Analysis of Whole Genomes (PCAWG) (n = 1963 patients)58\u201360. These three datasets represent the largest publicly-available tumor sequencing cohorts with both copy number alteration data and patient demographic information. Full demographics of included patients and cancer types can be found in Table S1. We compared the frequency of WGD events in cancers from self-reported Black and white patients in the MSK-MET and TCGA cohorts and between cancers from individuals with inferred African and European ancestry in the PCAWG cohort. We discovered that cancers from self-reported Black patients and patients with inferred African ancestry exhibited a significantly higher incidence of WGDs compared to cancers from self-reported white patients or patients with inferred European genetic ancestry (Fig. 1B-D). Notably, CNAs in each of these datasets were detected using different genomic technologies: SNP arrays, targeted gene sequencing, and whole-genome sequencing, for TCGA, MSK-MET, and PCAWG, respectively58\u201360. As these findings were consistent across all three cohorts, we anticipate that they are robust and independent of any platform-specific artifacts.Fig. 1WGDs are more common among self-reported Black cancer patients and those with inferred African genetic ancestry.A A schematic of the whole-genome duplication process. WGDs produce a cell with a doubled chromosome complement (typically 4N). WGD events are associated with metastasis and disease progression. Loss of the tumor suppressor TP53 promotes WGDs; other causes of WGDs are largely unknown. The frequency of WGDs in self-reported Black and white patients from three different cohorts: B MSK-MET, C TCGA, and D PCAWG. Note that in the PCAWG dataset, a patient\u2019s self-reported race was not available, and instead inferred genetic ancestry was used (African (AFR) vs European (EUR)). E The frequency of WGD events in self-reported Black and white patients with either breast cancer, endometrial cancer, or NSCLC, in the MSK-MET and TCGA cohorts. Source data are provided as a Source Data file. Statistical testing was performed via two-tailed Pearson\u2019s Chi-squared test. Statistical significance: NS p \u2265 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Figure 1A was created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license (https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en).",
        "Next, we looked at the interaction of self-reported race, WGD, and patient outcome. Consistent with known national trends, we found that self-reported Black cancer patients exhibited a significantly shorter overall survival time following diagnosis compared to self-reported white patients (Fig. 3A)8\u201310. Similarly, WGD events were also associated with worse patient outcomes in a Kaplan-Meier analysis (Fig. 3B). Interestingly, among the subset of patients with WGD-positive tumors, there was no significant difference in survival time between self-reported Black and white patients (Fig. 3C). However, within the WGD-negative patient subset, a significant difference in survival between self-reported Black and white patients was observed (Fig. 3D). These results are consistent with prior reports demonstrating that WGD events drive metastases and aggressive disease, and suggest that the increased incidence of WGD events in self-reported Black patients may be linked with worse overall survival46,58,73. We speculate that within WGD-negative patients, WGD events may be occurring post-diagnosis, or additional genetic and environmental factors may be contributing to these disparate outcomes.Fig. 3Pan-cancer survival analysis in self-reported Black and white cancer patients.A A Kaplan-Meier plot displaying survival of self-reported Black and white patients in the MSK-MET cohort. B A Kaplan-Meier plot displaying survival of cancer patients based on WGD status. C A Kaplan-Meier plot displaying survival of WGD-positive self-reported Black and white cancer patients. D A Kaplan-Meier plot displaying survival of WGD-negative self-reported Black and white cancer patients. Source data are provided as a Source Data file. Statistical testing was performed via logrank test (A\u2013D).",
        "All genomic data analyzed in this manuscript have already been published in the sources described below. Our use of de-identified and published clinical and genomic data complies with all relevant ethical regulations. Mutational, copy number, sample, and patient data were downloaded from the cBioPortal datahub (https://github.com/cBioPortal/datahub)112,113. Whole genome duplication determinations were sourced from the original cohort study (MSK-MET and PCAWG) or from subsequent analyses (TCGA)44,52,60. A sample was considered to have undergone WGD based on processing by FACETS (MSK-MET), consensus across 10 different methods (PCAWG), or ABSOLUTE (TCGA)60,114,115. Genetic ancestry determinations for the MSK-MET cohort were graciously provided by Kanika Arora, following the method from ref. 34. Racial data was determined by electronic health record review (MSK-MET) and by interview during enrollment where patients were asked to select from the racial categories defined by the U.S. Office of Management and Business and used by the U.S. Census Bureau (TCGA). Regional lymph node metastasis data were sourced from ref. 58. Mutagen signatures of environmental agents were obtained from the original study96,116. Sample size calculations were not possible as our analysis was limited by the availability of published copy number data from patient cancers.",
        "To be included in our analysis, genomic aberrations had to occur in \u2265200 patients across racial groups and \u22652% of patients within a racial group. We focused mutational analysis on nonsynonymous mutations and trichotomized copy number levels to neutral, loss, and gain. As the cohorts we analyzed do not use the same identifiers for cancer type, we considered all cancer types regardless of identifier in pan-cancer analyses, while standardizing across cohorts for comparisons by cancer type. Standardization was as follows: breast cancer were samples listed as BRCA (TCGA) or Breast Cancer (MSK-MET); endometrial cancer were samples listed as UCEC (TCGA), Endometrioid Adenocarcinoma (MSK-MET), Serous Carcinoma (MSK-MET); non-small cell lung cancer (NSCLC) were samples listed as LUAD (TCGA), LUSC (TCGA), or Non-Small Cell Lung Cancer (MSK-MET); prostate cancer were samples listed as PRAD (TCGA) or Prostate Cancer (MSK-MET). A positive determination for regional lymph node metastasis was made according to the presence of \u201cregional_lymph\u201d in the \u201cmet_site_mapped\u201d variable from ref. 58. The code used to perform this analysis is available at https://github.com/sheltzer-lab/wgd_disparities."
      ],
      "29622463": [
        "One common type of chromosomal alteration is a whole-genome duplication (WGD) event, in which a cell\u2019s chromosome complement doubles. The causes and consequences of WGDs are poorly understood. Mutations in TP53 have been consistently associated with WGDs in patient sequencing, and cell culture experiments have demonstrated that loss of TP53 facilitates the outgrowth of cells that have undergone a failed mitosis48,49. Environmental carcinogens like combustion products have been shown to cause point mutations, but a link between these pollutants and WGDs has not been previously demonstrated50,51. Other genetic and environmental drivers of WGD events remain obscure44,52,53. WGDs enhance tumor adaptability and increase metastatic dissemination, potentially by enhancing tumor heterogeneity and allowing cancers to sample a wider range of karyotypes52,54\u201356. Approximately 30% of tumors exhibit WGDs, but whether patient race or ethnicity is associated with these events is unknown52.",
        "The increase in WGD events in self-reported Black patients compared to self-reported white patients ranged from 11% in the TCGA cohort to 35% in the PCAWG cohort. Additionally, the overall rate of WGD events ranged from 26% in MSK-MET to 36% in TCGA. However, within cancer types that were shared across datasets, the frequency of WGD events was highly correlated (Fig. S1). For instance, thyroid cancers consistently displayed the lowest incidence of WGDs (0\u20134%) while ovarian cancers consistently displayed the highest incidence of WGDs (55\u201360%), in alignment with other reports44,52. The overall differences in WGD frequency between cohorts may reflect differences in the distribution of cancer types.",
        "All genomic data analyzed in this manuscript have already been published in the sources described below. Our use of de-identified and published clinical and genomic data complies with all relevant ethical regulations. Mutational, copy number, sample, and patient data were downloaded from the cBioPortal datahub (https://github.com/cBioPortal/datahub)112,113. Whole genome duplication determinations were sourced from the original cohort study (MSK-MET and PCAWG) or from subsequent analyses (TCGA)44,52,60. A sample was considered to have undergone WGD based on processing by FACETS (MSK-MET), consensus across 10 different methods (PCAWG), or ABSOLUTE (TCGA)60,114,115. Genetic ancestry determinations for the MSK-MET cohort were graciously provided by Kanika Arora, following the method from ref. 34. Racial data was determined by electronic health record review (MSK-MET) and by interview during enrollment where patients were asked to select from the racial categories defined by the U.S. Office of Management and Business and used by the U.S. Census Bureau (TCGA). Regional lymph node metastasis data were sourced from ref. 58. Mutagen signatures of environmental agents were obtained from the original study96,116. Sample size calculations were not possible as our analysis was limited by the availability of published copy number data from patient cancers."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 3.658294200897217,
    "data_pmids_checked": 4,
    "paper_id": "39300140",
    "extraction_date": "2025-12-19T20:46:10.770966",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39300140.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39290334": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "We examined the mutations and putative copy number alterations (CNA) of ANXAs in KIRC using cBioPortal (https://www.cbioportal.org/), an online database on 30 different cancers collected from The Cancer Genome Atlas [23]. A total of 317 KIRC cases with pathology reports were selected in our study. The online tools and data sources are provided by cBioPortal.",
      "Genetic variations of Annexins in 317 cases retrieved from four studies, including 35 cases from Dana-Farber Cancer Institute [29] (DFCI), 98 cases from Beijing Genomics Institute [30] (BGI), 78 cases from Cancer Research UK London Research Institute [31] (IRC), and 106 cases from the University of Tokyo [32] (Utokyo), were analysed using the cBioPortal database (Figure 6). We found varying degrees of genetic variation among the 12 ANXA family members, of which ANXA6 has the highest incidence of genetic variation. Most genetic variations in Annexins were amplifications, although ANXA3, ANXA4, and ANXA10 had higher probabilities of mutation events. Deep deletions were found in ANXA5 and ANXA10. In addition, no gene fusion events were found in the four datasets."
    ],
    "data_publication_citations": {
      "22138691": [
        "Genetic variations of Annexins in 317 cases retrieved from four studies, including 35 cases from Dana-Farber Cancer Institute [29] (DFCI), 98 cases from Beijing Genomics Institute [30] (BGI), 78 cases from Cancer Research UK London Research Institute [31] (IRC), and 106 cases from the University of Tokyo [32] (Utokyo), were analysed using the cBioPortal database (Figure 6). We found varying degrees of genetic variation among the 12 ANXA family members, of which ANXA6 has the highest incidence of genetic variation. Most genetic variations in Annexins were amplifications, although ANXA3, ANXA4, and ANXA10 had higher probabilities of mutation events. Deep deletions were found in ANXA5 and ANXA10. In addition, no gene fusion events were found in the four datasets."
      ],
      "29301960": [
        "Genetic variations of Annexins in 317 cases retrieved from four studies, including 35 cases from Dana-Farber Cancer Institute [29] (DFCI), 98 cases from Beijing Genomics Institute [30] (BGI), 78 cases from Cancer Research UK London Research Institute [31] (IRC), and 106 cases from the University of Tokyo [32] (Utokyo), were analysed using the cBioPortal database (Figure 6). We found varying degrees of genetic variation among the 12 ANXA family members, of which ANXA6 has the highest incidence of genetic variation. Most genetic variations in Annexins were amplifications, although ANXA3, ANXA4, and ANXA10 had higher probabilities of mutation events. Deep deletions were found in ANXA5 and ANXA10. In addition, no gene fusion events were found in the four datasets."
      ],
      "23797736": [
        "Genetic variations of Annexins in 317 cases retrieved from four studies, including 35 cases from Dana-Farber Cancer Institute [29] (DFCI), 98 cases from Beijing Genomics Institute [30] (BGI), 78 cases from Cancer Research UK London Research Institute [31] (IRC), and 106 cases from the University of Tokyo [32] (Utokyo), were analysed using the cBioPortal database (Figure 6). We found varying degrees of genetic variation among the 12 ANXA family members, of which ANXA6 has the highest incidence of genetic variation. Most genetic variations in Annexins were amplifications, although ANXA3, ANXA4, and ANXA10 had higher probabilities of mutation events. Deep deletions were found in ANXA5 and ANXA10. In addition, no gene fusion events were found in the four datasets."
      ],
      "24487277": [
        "Genetic variations of Annexins in 317 cases retrieved from four studies, including 35 cases from Dana-Farber Cancer Institute [29] (DFCI), 98 cases from Beijing Genomics Institute [30] (BGI), 78 cases from Cancer Research UK London Research Institute [31] (IRC), and 106 cases from the University of Tokyo [32] (Utokyo), were analysed using the cBioPortal database (Figure 6). We found varying degrees of genetic variation among the 12 ANXA family members, of which ANXA6 has the highest incidence of genetic variation. Most genetic variations in Annexins were amplifications, although ANXA3, ANXA4, and ANXA10 had higher probabilities of mutation events. Deep deletions were found in ANXA5 and ANXA10. In addition, no gene fusion events were found in the four datasets."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 1.4490251541137695,
    "data_pmids_checked": 4,
    "paper_id": "39290334",
    "extraction_date": "2025-12-19T20:46:11.616918",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39290334.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39286654": {
    "cbioportal_paper_citations": [
      "The cBio Cancer Genomics Portal (http://www.cbioportal.org)20 was utilized to integrate RNA-seq raw data obtained from databases like TCGA to compare genetic alterations in HNSC. From this analysis, microsatellite instability data and tumor mutation load data were extracted for TCGA-HNSC patients. Statistical significance was determined by a P-value threshold of <0.05."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.22216391563415527,
    "data_pmids_checked": 0,
    "paper_id": "39286654",
    "extraction_date": "2025-12-19T20:46:11.839188",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39286654.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39286065": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "UALCAN web portal (The University of ALabama at Birmingham CANcer data analysis Portal) (http://ualcan.path.uab.edu/index.html) was used to analyse the expression profile of different isoforms of CGB (CGB5 and CGB7) since it has already been reported that CGB5 and CGB7 are most prevalent forms of mRNA seen in breast cancer, among major subclasses and histological types in BRCA that utilizes the data deposited in TCGA. Transcripts per million (TPM) were used to depict the gene expression [21]. GEPIA2 (Gene Expression Profiling Interactive analysis: http://gepia2.cancer-pku.cn/) is a server that allows users to analyse the differential expression of genes in samples from TCGA and GTEx data sets. Here, we employed this tool to analyse the expression of different CGB isoforms in tumor and normal samples across different cancer types and also stage plots of CGB isoforms (CGB5 and CGB7) in BRCA were derived from GEPIA2. CGB isoform expression (log2(TPM + 1) was compared across various tumor types with match TCGA normal data and results were demonstrated as heat map [22]. Expression of CGB isoforms in different grades, histology, and major subtypes of breast cancer was analysed using GENT2 (Gene Expression database of Normal and Tumor tissues http://gent2.appex.kr/gent2/) [23]. TIMER2 (http://timer.cistrome.org/) was used to analyse the correlation of BRCA1 mutation with CGB expression across various cancer types [24]. Here, we have employed LinkedOmics (http://linkedomics.org/login.php) portal, which utilizes multiomics HiseqRNA data from TCGA, to analyse correlated genes with different CGB isoforms using the LinkFinder module. The LinkInterpreter module helps in analysing the different pathways associated with these genes. The LinkInterpreter module was used to generate a bar plot depicting the pathways associated with positively and negatively correlated genes of CGB5. Pearson test was used to analyse the correlation of genes with CGB5 [25]. We have used the String protein interaction network platform (https://string-db.org/) to analyse the interaction of BRCA1 with the positively and negatively correlated genes obtained from the LinkFinder module with the CGB5 gene. The correlation analysis of CGB5 and the mutated genes detected by NGS was analysed by cBioPortal (https://www.cbioportal.org/). Three data sets were mainly used for analysis: Breast Invasive Carcinoma TCGA Provisional (1108 patients), Breast Invasive Carcinoma TCGA Cell 2015, Breast Cancer Metabric Nature 2012 & Nat commun 2016 (2509 patient samples) [26].",
      "Tissue samples that showed positivity for \u03b2-hCG by IHC were subsequently analysed by NGS to identify BRCA1 mutation. As indicated in Supplementary Table 8, only genes exhibiting a Spearman correlation with a p value of less than 0.01 have been taken into consideration. Since only one out of 4 tissue samples showed BRCA1 mutation, we further analysed whether the mutated genes detected by NGS (Supplementary Table 7) in the remaining samples had any correlation with \u03b2-hCG by using TCGA data set analysis from cBioportal (Supplementary Table 8). TCGA data set analysis showed significant negative correlation between the BRCA1, BRCA2, and BARD1 with \u03b2-hCG, and a positive correlation with SMARCB1, any of these genes are mutated in the 4 tissue samples that showed expression of \u03b2-hCG. The BRCA1 gene is closely associated with BRCA2 and BARD1, all of which are important in DNA damage repair. BRCA1 and BRCA2 are involved in the HR pathway, BRCA1 mainly helps in signal mediation during DNA damage whereas BRCA2 are repair initiators also known as effectors [41]. BRCA1-BARD1 heterodimer plays an important role in DNA repair, this heterodimer formation also helps in the retention of BRCA1 in the nucleus masking its nuclear export signal (NES) [42]. SMARCB1 which showed a strong positive correlation with \u03b2-hCG in TCGA analysis is also linked with the BRCA1/2 pathway genes [43]. SMARCB1 seemed to have a negative correlation with BRCA1 (Spearman correlation- \u22120.17; p value 9.39e\u22127). SMARCB1 mutation that we have seen in the tissue is in intron 4 which is a heterozygous splice region intron variant, and does not directly change the encoded amino acid sequence of the SMARCB1 protein (ClinVar Variation ID 825362). These results confirm the negative correlation between BRCA1 and \u03b2-hCG."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.21206927299499512,
    "data_pmids_checked": 0,
    "paper_id": "39286065",
    "extraction_date": "2025-12-19T20:46:12.058015",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39286065.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39282311": {
    "cbioportal_paper_citations": [
      "Data from the MSK-MET study31 for 25,775 patients with annotations of distant metastases locations was downloaded from the publicly available cbioportal66. Each patient had annotations of one of 27 primary cancer types and the presence or absence of a metastasis in one of 21 distant anatomical sites. The original authors extracted this data from electronic health records and mapped it to a reference set of anatomical sites. We sum over all patients to build a 27 x 21, cancer type by metastatic site occurrence matrix. We then normalize the rows to turn these into frequencies. We interpret the negative log frequencies as a \u201crelative time to metastasis\u201d, and only score migrations from the primary site to other sites, because there is no data to indicate frequencies of seeding from metastatic sites to other metastatic sites, or back to the primary. We make this data available for users, with the option for users to instead input their own organotropism vector for each patient."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "28445112": [
        "Currently, Metient uses genetic distance and organotropism as its metastasis priors, as well as MACHINA\u2019s parsimony criteria, however, the Metient framework is designed to be easily extensible. New parsimony criteria can be added as long as they can be computed as matrix functions of the tree adjacency matrix and vertex labeling matrices. Adding a new prior simply requires writing a scoring function because Metient incorporates auto-differentiation to compute its gradient updates. For instance, the framework could be easily extended to incorporate mutational signatures as a prior, since metastases exhibit shifts in mutational signature composition53,54. Metient has some limitations. It scales well in compute time for larger clone trees or more samples but, because the loss landscape complexity increases substantially, in approximately 1% of cases in bulk-sequencing data and 5% of single-cell lineage tracing data, Metient became stuck in local minima. This problem was resolved when we ran Metient multiple times and with more samples, and we recommend this practice with larger reconstruction problems. One criteria to assess convergence is when the Pareto front remains unchanged. Other migration history algorithms are also highly sensitive to the complexity of the loss landscape, and convergence issues that they face are not necessarily resolved by rerunning the algorithm. Also, Metient is not designed to consider subclonal copy number alternations (CNAs) when correcting its estimated variant allele frequencies for CNAs. Using the descendant cell fraction (DCF)55 or phylogenetic cancer cell fraction (phyloCCF)56 as inputs to Metient could solve this. Alternatively, one could input which clones are in which samples directly into Metient instead of the allele frequencies that define subclones, as we did to run Metient on the lineage tracing data. Finally, we note that choice of clustering and tree inference algorithm used when inputting data into Metient can impact both the clonality and phyleticity classifications. In an attempt to most accurately compare our migration histories to previously reported results, where possible, we used the same clustering and trees inferred for the original datasets."
      ],
      "35120664": [
        "MACHINA resolves parsimony conflicts by prioritizing the minimization of migrations, comigrations, and seeding sites in a fixed hierarchical manner (i.e., wm>>wc>>ws). Other methods simplify further, focusing solely on minimizing migrations4,15,22. Such a rigid model can obscure important differences among cancers. For example, in ovarian cancer metastatic events are often polyclonal due to the dissemination of clusters of metastatic cells through peritoneal fluid, these trends would lead to more migrations relative to comigrations28\u201330. In contrast, multiple seeding sites might be more common in the estimated 23.4% of cancer cases have lymph node involvement31, particularly in cancer types like non-small cell lung cancer32 where this frequently increases up to 87%. It has been proposed that metastatic cells can make a \u201cpit stop\u201d at regional lymph nodes before disseminating to other distant sites33. Prescribing a single, cancer-independent parsimony model risks missing these clinically-relevant differences.",
        "Metient provides two metastasis priors. One, genetic distance, can be applied to any cohort. The other, organotropism, can be used when appropriate tissue-type information are available for the sequenced tumor samples. The genetic distance prior considers the genetic distance of migration edges in the labeled clone tree; here genetic distance is defined as the number of mutations gained in the child clone and not present in the parent clone. This prior favors histories with higher averaged genetic distances on migration edges (Figure 1d, Methods, Supplementary Information). Theoretical and empirical evidence supports this approach. Colonizing clones at metastatic sites typically undergo clonal expansions34, making their mutations more detectable than those in the source tumor, where private mutations often remain undetected due to insufficient clonal expansion. Furthermore, metastasizing cells face strong selection pressures, which are associated with elevated mutation rates35\u201337. These pressures, combined with the increased genomic instability observed in metastases35\u201337, result in higher tumor mutation burdens compared to primary tumors31,38,39. Analysis of our cohorts confirm this trend, with migration edges showing higher genetic distances than non-migration edges when the most parsimonious migration history was unambiguous (Supplementary Figure S2).",
        "Data from the MSK-MET study31 for 25,775 patients with annotations of distant metastases locations was downloaded from the publicly available cbioportal66. Each patient had annotations of one of 27 primary cancer types and the presence or absence of a metastasis in one of 21 distant anatomical sites. The original authors extracted this data from electronic health records and mapped it to a reference set of anatomical sites. We sum over all patients to build a 27 x 21, cancer type by metastatic site occurrence matrix. We then normalize the rows to turn these into frequencies. We interpret the negative log frequencies as a \u201crelative time to metastasis\u201d, and only score migrations from the primary site to other sites, because there is no data to indicate frequencies of seeding from metastatic sites to other metastatic sites, or back to the primary. We make this data available for users, with the option for users to instead input their own organotropism vector for each patient."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.9122438430786133,
    "data_pmids_checked": 2,
    "paper_id": "39282311",
    "extraction_date": "2025-12-19T20:46:13.022115",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39282311.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39332711": {
    "paper_id": "39332711",
    "cbioportal_paper_citations": [
      "10.1158/2159-8290.CD-12-0095 [PubMed: 22588877]\n25",
      "10.1126/scisignal.2004088 [PubMed:\n23550210]\n26"
    ],
    "cbioportal_platform_mentions": [
      "In addition, all 14\nundifferentiated melanoma cases were compared molecularly with a cohort of conventional\nmelanoma counterparts using the cBioPortal server internally maintained at Dana\u2013Farber\nCancer Institute (DFCI) to access archived available data from patients with conventional\ncutaneous melanoma previously sequenced via the same version of the DNA sequencing\nplatform (OncoPanel) and subjected to the same analysis pipeline as the undifferentiated\nmelanoma group",
      "Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical\nprofiles using the cBioPortal"
    ],
    "data_publication_citations": {
      "28481359": [
        "10.1038/\nnm.4333 [PubMed: 28481359]\n12"
      ],
      "22842228": [
        "10.1038/ng.2359 [PubMed: 22842228]\n41"
      ],
      "26091043": [
        "10.1016/j.cell.2015.05.044 [PubMed: 26091043]\n32"
      ],
      "25589618": [
        "10.1158/1078-0432.CCR-14-1773 [PubMed: 25589618]\n21"
      ],
      "34145282": [
        "10.1038/s41467-021-24109-5 [PubMed: 34145282]\n23"
      ],
      "22817889": [
        "10.1016/j.cell.2012.06.024 [PubMed: 22817889]\n40"
      ]
    },
    "extraction_date": "2025-12-19T20:46:13.386571",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39332711.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 6,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.027318000793457,
      "cbioportal_papers": 0.000225067138671875,
      "pdf_extraction_pass2": 9.605582237243652,
      "cbioportal_papers_pass2": 0.0032281875610351562,
      "used_full_extraction": true,
      "pdf_extraction": 18.63290023803711,
      "platform_mentions": 0.013489961624145508,
      "data_citations": 0.031980037689208984,
      "num_data_pmids_checked": 6
    }
  },
  "39281483": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "This research involved a comprehensive analysis of the mRNA and protein expression patterns of copper transporters in 33 kinds of cancer and normal tissue samples. Information from multiple databases was integrated to investigate the associations between these transporters and different variables such as tumor stages, prognosis, cancer-related pathways, genetic mutations, immune cell infiltration, and drug response. Preliminary verification was conducted through immunohistochemical experiments. The research design overview is illustrated in Fig. 1.Fig. 1Flowchart of the study design. By comprehensive use of datasets from TCGA, CCLE, GTEx, UALCAN, cBioPortal, GSCALite, HPA, STRING, GeneMANIA, we explored the association of copper transporters with tumor stages, prognosis, cancer-related signaling pathways, gene mutation, immune cell infiltration, and drug sensitivity in 33 tumors.Fig. 1",
      "Flowchart of the study design. By comprehensive use of datasets from TCGA, CCLE, GTEx, UALCAN, cBioPortal, GSCALite, HPA, STRING, GeneMANIA, we explored the association of copper transporters with tumor stages, prognosis, cancer-related signaling pathways, gene mutation, immune cell infiltration, and drug sensitivity in 33 tumors.",
      "The frequency of changes in copper transporters in different types of cancers was analyzed using the CBioPortal database (https://www.cbioportal.org/) [22]. The percentage of Copy Number Variation (CNV) and its correlation with mRNA expression in each cancer type were calculated. The single nucleotide variation (SNV) percentage was computed using dividing the Number of Mutated Samples by the Number of Cancer Samples.",
      "To explore the gene alteration status of copper transporters across pan-cancer, we utilized data from the CBioPortal database. Fig. 8A displays the primary gene modifications identified, including mutation, amplification, and deep deletion. The mutation rate of SLC31A1 was highest among patients with pancreatic, esophageal, and bone cancer. Likewise, patients with melanoma, bladder, and non-small cell lung cancer exhibited the highest mutation rate of ATP7A. Furthermore, the mutation rate of ATP7B was highest in colorectal, esophageal, and lung cancer.Fig. 8The alteration of copper transporters in pan-cancers.(A) The frequency of alterations categorized by different mutation types. (B)Distribution of copy number variations (CNV) across 33 cancers. (C)Relationship between copy number variations and messenger RNA levels. The statistical significance was depicted by the size of the data points, with bigger dots indicating greater significance. FDR denoted false discovery rate.Fig. 8"
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.379072904586792,
    "data_pmids_checked": 0,
    "paper_id": "39281483",
    "extraction_date": "2025-12-19T20:46:13.401285",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39281483.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39345749": {
    "paper_id": "39345749",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Tumor Analysis Consortium (CPTAC) breast cancer dataset\nFinally, we investigated the effects of HEBP2 expression on [15] via cBioportal [16]",
      "Two and non-TNBC tissues using the CPTAC dataset on the data-\ndifferent gRNA sequences (5'-AGTT ATG AGA TCC GAC AC base platform cBioPortal [15, 16]",
      "1 HEBP2 mRNA expression levels in TNBC and non-TNBC TNBC tissues from the cBioPortal platform (****p < 0.0001; Stu-\ntissues, and survival analysis of HEBP2 expression in patients with dent\u2019s t test)",
      "database analysis using the cBioPortal platform (Fig"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:46:13.436380",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39345749.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 9.066428184509277,
      "cbioportal_papers": 0.00019931793212890625,
      "pdf_extraction_pass2": 10.21904182434082,
      "cbioportal_papers_pass2": 0.0001971721649169922,
      "used_full_extraction": true,
      "pdf_extraction": 19.285470008850098,
      "platform_mentions": 0.001714944839477539,
      "data_citations": 7.200241088867188e-05,
      "num_data_pmids_checked": 1
    }
  },
  "39279957": {
    "cbioportal_paper_citations": [
      "To preliminarily validate the clinical relevance of the core targets identified from the STAD data, we examined the available data from public databases. The Human Protein Atlas (HPA) database (34) was queried to obtain representative immunohistochemical (IHC) images of the core target proteins in normal and STAD tissues, facilitating the evaluation of protein expression level differences. We used the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) database (35) to assess the transcriptome-level expression differences of core targets between the STAD and normal cohorts. Overall survival (OS) was defined as the period from surgical resection to death. To investigate the impact of proteins on the prognosis of patients with STAD, the association between core targets expression and OS was analyzed by categorizing high and low expression levels into two groups (with the median as the cutoff) using the STAD and normal cohorts. Kaplan-Meier survival curves were derived from the GEPIA2 database. Significant core targets were identified by their P values for OS and log2-transcript per million (TPM). The cBioPortal database (36) was utilized to illustrate the mutational landscape of significant core targets through oncoprint visualizations."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.308521032333374,
    "data_pmids_checked": 0,
    "paper_id": "39279957",
    "extraction_date": "2025-12-19T20:46:13.709883",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39279957.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39269442": {
    "cbioportal_paper_citations": [
      "Van Gogh-like 2 (Vangl2), a core planar cell polarity (PCP) component, mediates Wingless-type (Wnt)/PCP signaling, and controls homeostasis, development, and repair of organs (Bailly et al., 2018; Brunt et al., 2021; Hatakeyama et al., 2014). Vangl2 has four transmembrane domains with both carboxyl termini and amino oriented toward the cytoplasm, which is phosphorylated in the endoplasmic reticulum (ER) and then transported to the cell surface and becomes stabilized, while the unphosphorylated Vangl2 is unstable and internalized to degrade via the lysosomal pathway (Feng et al., 2021). The shuttle of Vangl2 between cytoplasm and cell membrane results in its multifunction, including adhesion, membrane protrusive activity, migration, and bridging proteins (Hatakeyama et al., 2014). Indeed, Vangl2 inhibited matrix metalloproteinase 2 (MMP2) activity and affected cell adhesion to extracellular matrix proteins (Jessen and Jessen, 2017). Vangl2 also modulates glomerular injury by promoting MMP9 (Papakrivopoulou et al., 2018). Moreover, the abnormal function of Vangl2 results in various diseases, such as cancer, kidney glomerular injury, idiopathic pulmonary fibrosis, and systemic dysplasia (Papakrivopoulou et al., 2018; Poobalasingam et al., 2017). Vangl2 is markedly downregulated in patients with emphysema (Poobalasingam et al., 2017), while which level was upregulated and amplified in breast, ovarian, and uterine carcinomas (Kandoth et al., 2013; Cerami et al., 2012; Gao et al., 2013). In addition, Vangl2 is bounded to p62 to promote breast cancer (Puvirajesinghe et al., 2016). Our previous study showed that Vangl2 prevents osteogenic differentiation in mesenchymal stem cells, resulting in osteogenic dysplasia (Gong et al., 2021). Vangl2-mediated downstream factors of Toll-like (TLR) or interleukin (IL)-1 receptor, such as myeloid differentiation factor 88 (MyD88) (Gong et al., 2021), suggesting that Vangl2 may play roles in immune-related diseases, including autoimmune diseases. However, the function of Vangl2 in inflammatory diseases remains uncovered."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "23636398": [
        "Van Gogh-like 2 (Vangl2), a core planar cell polarity (PCP) component, mediates Wingless-type (Wnt)/PCP signaling, and controls homeostasis, development, and repair of organs (Bailly et al., 2018; Brunt et al., 2021; Hatakeyama et al., 2014). Vangl2 has four transmembrane domains with both carboxyl termini and amino oriented toward the cytoplasm, which is phosphorylated in the endoplasmic reticulum (ER) and then transported to the cell surface and becomes stabilized, while the unphosphorylated Vangl2 is unstable and internalized to degrade via the lysosomal pathway (Feng et al., 2021). The shuttle of Vangl2 between cytoplasm and cell membrane results in its multifunction, including adhesion, membrane protrusive activity, migration, and bridging proteins (Hatakeyama et al., 2014). Indeed, Vangl2 inhibited matrix metalloproteinase 2 (MMP2) activity and affected cell adhesion to extracellular matrix proteins (Jessen and Jessen, 2017). Vangl2 also modulates glomerular injury by promoting MMP9 (Papakrivopoulou et al., 2018). Moreover, the abnormal function of Vangl2 results in various diseases, such as cancer, kidney glomerular injury, idiopathic pulmonary fibrosis, and systemic dysplasia (Papakrivopoulou et al., 2018; Poobalasingam et al., 2017). Vangl2 is markedly downregulated in patients with emphysema (Poobalasingam et al., 2017), while which level was upregulated and amplified in breast, ovarian, and uterine carcinomas (Kandoth et al., 2013; Cerami et al., 2012; Gao et al., 2013). In addition, Vangl2 is bounded to p62 to promote breast cancer (Puvirajesinghe et al., 2016). Our previous study showed that Vangl2 prevents osteogenic differentiation in mesenchymal stem cells, resulting in osteogenic dysplasia (Gong et al., 2021). Vangl2-mediated downstream factors of Toll-like (TLR) or interleukin (IL)-1 receptor, such as myeloid differentiation factor 88 (MyD88) (Gong et al., 2021), suggesting that Vangl2 may play roles in immune-related diseases, including autoimmune diseases. However, the function of Vangl2 in inflammatory diseases remains uncovered."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4055140018463135,
    "data_pmids_checked": 1,
    "paper_id": "39269442",
    "extraction_date": "2025-12-19T20:46:13.841977",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39269442.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39281045": {
    "cbioportal_paper_citations": [
      "Various datasets containing tabular data of biochemical and clinical information on cranial cancer patients74\u201378 have been retrieved from cBioPortal.79,80 Next to \u201cparticipant\u201d and \u201cstudy sample\u201d identifiers there are columns that specify the exact type of tumor and the current clinical state of the patient in the form of the patients\u2019 survival time since diagnosis as well as the status of alive or deceased and many more dataset-specific clinical information dependent on the study. For the classification, there are multiple columns which specify mutations, their count and type. These had been retrieved through the gene query of selected and top mutated genes: TP53, telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1), ATRX, PTEN, TTN, EGFR, MUC16, NF1, PIK3CA, CIC, RYR2, RB1, NOTCH1, PIK3R1, AHNAK2, AHNAK, LRP2, FLG2, OBSCN, and MUC12. These could then be downloaded from the download tab under the option of mutations as tab-delimited format. The file contains study and sample IDs next to gene status or specified mutations, which were integrated with the clinical information. In the case of tests for mixed and incomplete data, all studies have been combined. In the case of qualitative assessment of synthetic data from complete input data, only the dataset by the glass consortium 78 has been utilized."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "30675060": [
        "Various datasets containing tabular data of biochemical and clinical information on cranial cancer patients74\u201378 have been retrieved from cBioPortal.79,80 Next to \u201cparticipant\u201d and \u201cstudy sample\u201d identifiers there are columns that specify the exact type of tumor and the current clinical state of the patient in the form of the patients\u2019 survival time since diagnosis as well as the status of alive or deceased and many more dataset-specific clinical information dependent on the study. For the classification, there are multiple columns which specify mutations, their count and type. These had been retrieved through the gene query of selected and top mutated genes: TP53, telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1), ATRX, PTEN, TTN, EGFR, MUC16, NF1, PIK3CA, CIC, RYR2, RB1, NOTCH1, PIK3R1, AHNAK2, AHNAK, LRP2, FLG2, OBSCN, and MUC12. These could then be downloaded from the download tab under the option of mutations as tab-delimited format. The file contains study and sample IDs next to gene status or specified mutations, which were integrated with the clinical information. In the case of tests for mixed and incomplete data, all studies have been combined. In the case of qualitative assessment of synthetic data from complete input data, only the dataset by the glass consortium 78 has been utilized."
      ],
      "31748746": [
        "Various datasets containing tabular data of biochemical and clinical information on cranial cancer patients74\u201378 have been retrieved from cBioPortal.79,80 Next to \u201cparticipant\u201d and \u201cstudy sample\u201d identifiers there are columns that specify the exact type of tumor and the current clinical state of the patient in the form of the patients\u2019 survival time since diagnosis as well as the status of alive or deceased and many more dataset-specific clinical information dependent on the study. For the classification, there are multiple columns which specify mutations, their count and type. These had been retrieved through the gene query of selected and top mutated genes: TP53, telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1), ATRX, PTEN, TTN, EGFR, MUC16, NF1, PIK3CA, CIC, RYR2, RB1, NOTCH1, PIK3R1, AHNAK2, AHNAK, LRP2, FLG2, OBSCN, and MUC12. These could then be downloaded from the download tab under the option of mutations as tab-delimited format. The file contains study and sample IDs next to gene status or specified mutations, which were integrated with the clinical information. In the case of tests for mixed and incomplete data, all studies have been combined. In the case of qualitative assessment of synthetic data from complete input data, only the dataset by the glass consortium 78 has been utilized.",
        "Another exemplary correlation that has been described specifies TERT gene mutations to be associated with older ages.91-93 In this case, no significant difference is observed in the case of using the complete dataset as input, in sample nor synthetic data, as shown in Figure 3. This result is also due to the low frequency of occurring TERT mutations among samples of the corresponding dataset by the glass consortium, 78 including 14 out of 444 samples only, while for IDH1 the mutation frequency includes 174 out of the 444 samples. The combined data of multiple datasets includes studies with a higher mutation frequency of TERT resulting in significant differences in input and output data, shown in Figure 4."
      ],
      "26824661": [
        "Various datasets containing tabular data of biochemical and clinical information on cranial cancer patients74\u201378 have been retrieved from cBioPortal.79,80 Next to \u201cparticipant\u201d and \u201cstudy sample\u201d identifiers there are columns that specify the exact type of tumor and the current clinical state of the patient in the form of the patients\u2019 survival time since diagnosis as well as the status of alive or deceased and many more dataset-specific clinical information dependent on the study. For the classification, there are multiple columns which specify mutations, their count and type. These had been retrieved through the gene query of selected and top mutated genes: TP53, telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1), ATRX, PTEN, TTN, EGFR, MUC16, NF1, PIK3CA, CIC, RYR2, RB1, NOTCH1, PIK3R1, AHNAK2, AHNAK, LRP2, FLG2, OBSCN, and MUC12. These could then be downloaded from the download tab under the option of mutations as tab-delimited format. The file contains study and sample IDs next to gene status or specified mutations, which were integrated with the clinical information. In the case of tests for mixed and incomplete data, all studies have been combined. In the case of qualitative assessment of synthetic data from complete input data, only the dataset by the glass consortium 78 has been utilized."
      ],
      "31263031": [
        "Various datasets containing tabular data of biochemical and clinical information on cranial cancer patients74\u201378 have been retrieved from cBioPortal.79,80 Next to \u201cparticipant\u201d and \u201cstudy sample\u201d identifiers there are columns that specify the exact type of tumor and the current clinical state of the patient in the form of the patients\u2019 survival time since diagnosis as well as the status of alive or deceased and many more dataset-specific clinical information dependent on the study. For the classification, there are multiple columns which specify mutations, their count and type. These had been retrieved through the gene query of selected and top mutated genes: TP53, telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1), ATRX, PTEN, TTN, EGFR, MUC16, NF1, PIK3CA, CIC, RYR2, RB1, NOTCH1, PIK3R1, AHNAK2, AHNAK, LRP2, FLG2, OBSCN, and MUC12. These could then be downloaded from the download tab under the option of mutations as tab-delimited format. The file contains study and sample IDs next to gene status or specified mutations, which were integrated with the clinical information. In the case of tests for mixed and incomplete data, all studies have been combined. In the case of qualitative assessment of synthetic data from complete input data, only the dataset by the glass consortium 78 has been utilized."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 4,
    "extraction_method": "jats_xml",
    "extraction_time": 3.140669107437134,
    "data_pmids_checked": 5,
    "paper_id": "39281045",
    "extraction_date": "2025-12-19T20:46:16.527335",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39281045.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "41386881": {
    "cbioportal_paper_citations": [
      "We performed a mutational analysis of renal cell carcinoma using cBioPortal (https://www.cbioportal.org/),78, 79 a publicly available online platform. We queried the database to retrieve somatic mutations, uncovered key genetic alterations associated with renal cell carcinoma, and elucidated relationships with pancreatic metastasis. On the other hand, the dysregulation of gene expression due to mutations was analyzed utilizing the TIMER 2.0 database, which utilizes TCGA samples for data analysis.77"
    ],
    "cbioportal_platform_mentions": [
      "During mutational studies from the cBioPortal database, we identified a range of mutations in the MET, KRAS, and PIK3CD genes, including gene fusions, missense mutations, splice site mutations, and frameshift mutations (Table 6 and Fig. S8). Notably, our study highlighted the significance of three specific KRAS missense mutations: G12C, G12V, and G12D which were found to be common between renal cell carcinoma and pancreatic cancer. Apart from the common mutations, the specific mutations in renal cell carcinoma genes could subsequently progress to pancreatic metastasis. The presence of the common mutations in both diseases suggests that they may be crucial drivers of the tumorigenic process in both RCC and PC. Furthermore, mutations in MET cause dysregulation of CDC42, EPAS1, HGF, MET, PIK3CD, and TGFB3 gene expression in renal cancers (KIRC and KIRP). On the other hand, mutations in KRAS cause dysregulation of EPAS1, FLCN, HGF, KRAS, MET, and PIK3CD in pancreatic cancer (PAAD) (Fig. 12). MET is significantly upregulated in RCC, which is usual; however, surprisingly, MET is also significantly upregulated in pancreatic cancer, further strengthening our finding that MET has a hidden role in the pancreatic cancer pathway.Table 6Mutations involved in renal cell carcinoma development.METKRASPIK3CDMET-C8ORF34 FusionGene fusionG12CMissenseMutationX906_spliceSplice Site MutationC8ORF34-MET FusionV1070MMissense mutationV1070GD697YMissense MutationV1188LG12VI1077TR636WS1236RI639LG12DK705QL296PL1205VD820NV504LA59GI860SL806Wfs*3Frameshift MutationS717Ffs*3Frameshift mutationFig. 12Mutational impact of (A) MET and (B) KRAS on regulating gene expressions in RCC (KIRC and KIRP) and PC (PAAD), respectively. Red = upregulation of gene, blue = downregulation of gene, and grey = no changes in gene expression."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.37655210494995117,
    "data_pmids_checked": 0,
    "paper_id": "41386881",
    "extraction_date": "2025-12-19T20:46:16.915769",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/41386881.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39268701": {
    "cbioportal_paper_citations": [
      "To assess the ability of the DMS to classify driver, passenger, and resistance mutations, we first gathered all MET kinase domain mutations reported from clinical observations in cBioPortal (Cerami et al., 2012; Gao et al., 2013; Figure 6A). Next, we compared GOF mutations between the TPR-MET and TPR-MET\u0394Ex14 libraries by statistically filtering scores within each library and comparing scores within IL-3 and IL-3 withdrawal conditions. We structurally mapped scores that had low propagated error and were greater than 2 or 2.5 standard deviations from the mean of the WT-synonymous score for each library - the same filtering criteria used throughout this study - to assign GOF status (Figure 6\u2014figure supplement 1A\u2013E)."
    ],
    "cbioportal_platform_mentions": [
      "(A) Lollipop diagram of MET kinase domain mutations and frequencies annotated in cBioPortal. (B) Distributions of clinically-associated mutations (green, right y-axis scale) overlaid with all missense mutations (gray, left y-axis scale). (C\u2013D) Distributions of categorized cancer-associated mutations. Hamming distance distributions of clinical, validated MET cancer mutations and clinically unobserved, gain-of-function (GOF) mutations detected in the screen for both intracellular domain (ICD) backgrounds. (E) Cancer-associated mutations mapped onto a MET kinase domain structure, colored according to MET and MET\u0394Ex14 backgrounds, with Hamming distance represented by the ribbon thickness at each position (PDB 3R7O). (F) Reported resistance mutation distributions (teal, right y-axis scale) for MET and MET\u0394Ex14, overlaid with their respective missense distributions (gray, left y-axis scale). (G) Inhibitor resistance mutation positions shown on an active MET kinase domain structure in teal (PDB 3R7O).",
      "Figure 6\u2014figure supplement 2.Identification and analysis of clinically associated mutations across MET kinase domain libraries.(A\u2013B) Box plots showing the distribution of mutations and fitness scores at clinically-associated residue positions annotated in cBioPortal, and further categorized based on level of literature validation (clinically detected but not validated, validated, gain-of-function (GOF) within our screen but not clinically detected). (C) Scatter plots showing the fitness scores for each mutation per kinase domain position under IL-3 withdrawal selection for TPR-MET and TPR-MET\u0394Ex14, with the average fitness scores of the wild-type synonymous population of each displayed in a dashed line. Specific mutations that are \u2265+2 standard deviations (SD) from the wild-type synonymous mean are highlighted with standard error displayed (TPR-MET, blue; TPR-MET\u0394Ex14, orange; n = 3). (D) Structurally mapped mutations with fitness scores \u2265+2 SD form the respective wild-type synonymous mean for TPR-MET and TPR-MET\u0394Ex14, with clinically-associated mutations highlighted as spheres (PDB 2G15).",
      "(A\u2013B) Box plots showing the distribution of mutations and fitness scores at clinically-associated residue positions annotated in cBioPortal, and further categorized based on level of literature validation (clinically detected but not validated, validated, gain-of-function (GOF) within our screen but not clinically detected). (C) Scatter plots showing the fitness scores for each mutation per kinase domain position under IL-3 withdrawal selection for TPR-MET and TPR-MET\u0394Ex14, with the average fitness scores of the wild-type synonymous population of each displayed in a dashed line. Specific mutations that are \u2265+2 standard deviations (SD) from the wild-type synonymous mean are highlighted with standard error displayed (TPR-MET, blue; TPR-MET\u0394Ex14, orange; n = 3). (D) Structurally mapped mutations with fitness scores \u2265+2 SD form the respective wild-type synonymous mean for TPR-MET and TPR-MET\u0394Ex14, with clinically-associated mutations highlighted as spheres (PDB 2G15).",
      "Relative to the distribution of all missense mutations, the distribution of clinically observed mutations is shifted to higher fitness values for both TPR-MET and TPR-MET\u0394Ex14 screens (Figure 6B; Figure 6\u2014figure supplement 2A\u2013D). Most of these mutations have near WT-fitness levels, with a small number having GOF fitness effects (Figure 6B). Next, we further subdivided our observations based on annotations in cBioPortal as either \u2018clinical, validated\u2019 or \u2018clinical, not validated.\u2019 Notably, mutations in the \u2018clinical, not validated\u2019 category were outliers with lower fitness values, indicating that these are likely passenger mutations (Figure 6C and D; Figure 6\u2014figure supplement 2A\u2013D). These results validate that the DMS recapitulates known oncogenic MET kinase variants and suggest that the screen can be used to help classify driver vs. passenger mutations.",
      "Cancer-associated missense mutations for the MET kinase domain was obtained from cBioPortal (NCBI ID: NM_000245). Resistance mutations were obtained from literature references (Duplaquet et al., 2018; Fernandes et al., 2021; Saraon et al., 2021; Lu et al., 2017; Fujino et al., 2019)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 5,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.17439889907836914,
    "data_pmids_checked": 0,
    "paper_id": "39268701",
    "extraction_date": "2025-12-19T20:46:17.108314",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39268701.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39762215": {
    "paper_id": "39762215",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:46:17.327634",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39762215.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 106.62797403335571,
      "cbioportal_papers": 0.0004878044128417969,
      "pdf_extraction_pass2": 137.34033489227295,
      "cbioportal_papers_pass2": 0.0004611015319824219,
      "used_full_extraction": true,
      "pdf_extraction": 243.96830892562866,
      "platform_mentions": 0.0033910274505615234,
      "data_citations": 0.00031685829162597656,
      "num_data_pmids_checked": 2
    }
  },
  "39268081": {
    "cbioportal_paper_citations": [
      "To explore the prognostic power of TFs, we downloaded two gene expression datasets from cBioPortal (Gao et al., 2013) and GEO (GSE76427) for HCC patients, which contained clinical information. HCC patients from TCGA were treated as a training dataset, and HCC patients from GSE76427 were used as an independent validation dataset. A univariate Cox proportional hazards regression analysis was performed to evaluate the association between the critical TFs and patients\u2019 OS. Only TFs with p-value <0.05 were selected to further conduct variable selection according to stepwise Cox proportional hazards regression analysis. Finally, we created a risk-score formula based on TFs expression weighted by Cox regression coefficients. Risk score=\u2211iNcoefi\u00d7expri where N was the number of selected TFs, expri was the expression value of the ith gene, and coefi was the Cox regression coefficient of the ith gene in the univariate Cox regression analysis. Patients were divided into high-risk and low-risk group based on the median risk score. KM curves were performed to compare the OS and DFS between two groups. To evaluate whether risk score could be an independent prognostic factor, Multivariate Cox proportional hazards regression model was conducted with risk score, age, sex, height, weight, race as covariates."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "23792563": [
        "Hepatocellular carcinoma (HCC) is the third most lethal cancer in the world, with patients often experiencing post-surgical recurrence and metastasis, leading to poor survival outcomes (Wang et al., 2021). Tumor heterogeneity is the main cause of drug resistance and treatment failure (Dagogo-Jack and Shaw, 2018; Marusyk et al., 2020; Vasan et al., 2019), which encompasses the cellular diversity and dynamics both among tumors in different patients and within individual tumor. The tumor heterogeneity is manifested through genomic mutations, aberrations in epigenetic modifications, transcriptional alterations, and changes at the protein level (Sun and Yu, 2015). Additionally, extrinsic factors such as hypoxia, pH levels, and the interactions between tumor cells and other stromal components within the tumor microenvironment (TME) contribute to the diversity and dynamics in tumor genotypes and phenotypes (Sun and Yu, 2015). Previous studies, such as those conducted by TCGA and ICGC, have integrated multi-omics profiles to delineate the heterogeneous molecular features of cancers and explored the subtyping of cancers, guiding personalized therapeutic strategies (Cancer Genome Atlas Research, 2013). Tumor heterogeneity also underpins tumor evolution, as tumor cells continuously accumulate genetic and epigenetic variations, forming heterogeneous subclones which possess different survival fitness and undergo dynamic processes of subclonal selection and elimination under selective pressures such as nutrient availability and metabolism (Davis et al., 2017; Greaves and Maley, 2012). Therefore, understanding the complexity of subclonal structure within tumor is crucial for elucidating tumor biology, disease progression, and response to therapy."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.29761385917663574,
    "data_pmids_checked": 1,
    "paper_id": "39268081",
    "extraction_date": "2025-12-19T20:46:17.406052",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39268081.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39266536": {
    "cbioportal_paper_citations": [
      "To identify somatic hotspot mutations previously described (i.e., not to discover new mutations), we used the following somatic mutation databases for previous cancer genomics studies: the Cancer Genome Interpreter (CGI)38, Mutagene39,40, cBioPortal-TCGA-cervix (Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinomas)4,41,42, and CHASMplus43. A detailed description is in Supplemental Material. Based on these databases, we classified previously reported mutations as either known drivers in ICC (i.e., TIER1) or known drivers in other cancers (i.e., TIER2). Specifically, we assigned mutations to TIER1 (restricted classification) if they were mutations reported to be drivers in ICC by CGI or Mutagene, or an amino-acid (aa) change in \u22652 samples from the cBioPortal-TCGA-cervix database; or to TIER2 (expanded classification) if they were mutations reported to be drivers in other cancers by CGI or Mutagene, or mutations at the same aa position in \u22653 samples from the cBioPortal-TCGA-cervix. Therefore, a hotspot mutation is defined as a mutation previously observed in the aforementioned somatic mutation databases and classified as TIER1 or TIER2. Mutations were classified as being potentially induced by APOBEC3 if they were a C > T or C > G DNA change occurring at a 5\u2019TCW3\u2019 [W is A or T] trinucleotide motif12. All hotspot mutations were visually inspected by manually reviewing each hotspot nucleotide position in the aligned reads in IGV44 and excluded if they were present in repetitive regions of the genome, called by ambiguously mapped reads (mapping Quality=0), reads with low base quality (quality \u226420), or showed forward or reverse strand bias45."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1333470344543457,
    "data_pmids_checked": 0,
    "paper_id": "39266536",
    "extraction_date": "2025-12-19T20:46:17.539509",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39266536.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39805837": {
    "paper_id": "39805837",
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:46:18.519333",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39805837.pdf",
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 113.90505170822144,
      "cbioportal_papers": 0.00045013427734375,
      "pdf_extraction_pass2": 155.31304788589478,
      "cbioportal_papers_pass2": 0.0004572868347167969,
      "used_full_extraction": true,
      "pdf_extraction": 269.2180995941162,
      "platform_mentions": 0.0034487247467041016,
      "data_citations": 1.3113021850585938e-05,
      "num_data_pmids_checked": 0
    }
  },
  "39263148": {
    "cbioportal_paper_citations": [
      "Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using the \u201cclusterProfiler\u201d package. P < 0.05 was considered to be statistically significant. MRDEGs (n = 314) obtained from the TCGA database were used to establish the protein-protein interaction (PPI) network using the STRING database (v.11.0; http://string\u2010db.org) [24] and Cytoscape software (v.3.7.2). The mutations of the four prognostic MRDEGs in cervical cancer tissues in the TCGA database were analyzed using the cBioPortal database (http://www.cbioportal.org/) [25,26]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.10981369018554688,
    "data_pmids_checked": 0,
    "paper_id": "39263148",
    "extraction_date": "2025-12-19T20:46:18.648289",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39263148.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39289237": {
    "paper_id": "39289237",
    "cbioportal_paper_citations": [
      "doi: 10.1126/scisignal.2004088\n[PubMed: 23550210]\n10"
    ],
    "cbioportal_platform_mentions": [
      "TCGA survey\nThe publicly available data of TCGA head and neck cohort [4] on cBioPortal [9] were\nreviewed to retrieve clinicopathologic features, including HPV status, anatomic site and\nsubsite, T stage, N stage, DSS, and PFS",
      "The whole slide images of these 14 tumors on cBioPortal were subsequently reviewed\nto classify the tumor as non-keratinizing or keratinizing subtype and to collect additional\npathologic features",
      "Based on the publicly available TCGA data on\ncBioPortal [4, 9], the frequency of TP53 mutations was significantly lower in the HPV(+)-\nOCSCC (3/13, 23%) compared with HPV(\u2212)-OCSCC (220/278, 79%, Fisher\u2019s exact test,\np=0.001)",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha\nR, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer\ngenomics and clinical profiles using the cBioPortal Sci Signal 6:pl1"
    ],
    "data_publication_citations": {},
    "extraction_date": "2025-12-19T20:46:18.669362",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39289237.pdf",
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 7.882758855819702,
      "cbioportal_papers": 0.0015454292297363281,
      "used_full_extraction": false,
      "pdf_extraction": 7.882758855819702,
      "platform_mentions": 0.0015828609466552734,
      "data_citations": 7.605552673339844e-05,
      "num_data_pmids_checked": 1
    }
  },
  "39294048": {
    "paper_id": "39294048",
    "cbioportal_paper_citations": [
      "[PubMed: 22588877]\n[10]",
      "[PubMed: 23550210]\n[11]"
    ],
    "cbioportal_platform_mentions": [
      "Primary discovery analyses were then performed in The Cancer Genome Atlas\n(TCGA) obtained from cBioPortal (n=491).[9\u201311] We correlated hallmark cell pathways\n(n=50) with PSMA in TCGA using multivariable linear regressions adjusting for clinical\nvariables (Supplemental methods) and tumor purity (Supplemental figure 1b)",
      "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis\nof complex cancer genomics and clinical profiles using the cBioPortal"
    ],
    "data_publication_citations": {
      "26544944": [
        "[PubMed: 26544944]\n[12]"
      ]
    },
    "extraction_date": "2025-12-19T20:46:18.684306",
    "pdf_path": "/Users/debruiji/git/cbioportal-article-classification/data/pdfs/39294048.pdf",
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 1,
    "data_pmids_version": "2025-12-19T16:53:06.855279",
    "extraction_method": "pdf",
    "_timing": {
      "pdf_extraction_pass1": 8.786738872528076,
      "cbioportal_papers": 0.002257108688354492,
      "used_full_extraction": false,
      "pdf_extraction": 8.786738872528076,
      "platform_mentions": 0.0018439292907714844,
      "data_citations": 0.0015156269073486328,
      "num_data_pmids_checked": 1
    }
  },
  "39262487": {
    "cbioportal_paper_citations": [
      "A harmonized pan-cancer dataset was downloaded from the UCSC (http://xenabrowser.net/) datasets: TCGA Pan-Cancer, further extracted ENSG00000099998 (GGT5) gene expression data from each sample, log2(x+0.001) transformation was performed for each expression value. GGT5 expression in different tumors and the relationship between GGT5 and prognosis, immune infiltration, clinical stage were analyzed in Sangerbox (17) (http://www.sangerbox.com/tool). GSE27342, GSE29272 and GSE118916 expression profiles were obtained from the Gene Expression Omnibus (GEO) datasets (https://www.ncbi.nlm.nih.gov/geo/). RNAseq data and corresponding clinical information for GC were obtained from the Cancer Genome Atlas (TCGA) datasets (http://portal.gdc.com), and differential mRNA expression was investigated using the R software Limma package. The LinkedOmic datasets (18) (http://www.linkedomics.org) and cBioPortal (19,20) (https://www.cbioportal.org/) were used to conduct a correlation study between GGT5 and other GC genes. In order to further determine the potential function of GGT5, ClusterProfiler (21) package in R software was used to analyze the GGT5 Gene Ontology (GO) functions and enrich Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, as well as to use LinkedOmic datasets for gene set enrichment analysis (GSEA) analysis."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.16033625602722168,
    "data_pmids_checked": 0,
    "paper_id": "39262487",
    "extraction_date": "2025-12-19T20:46:18.869385",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39262487.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39262489": {
    "cbioportal_paper_citations": [
      "TCGA ovarian cohort (10) of 489 OC patients with clinical data and gene expression was retrieved from cBioPortal (http://www.cbioportal.org/) (11,12), including \u201cstaging\u201d, \u201cgrading\u201d, \u201coverall survival\u201d and \u201cprimary treatment outcome\u201d, in which a subgroup of 90 platinum resistant samples and 197 sensitive samples was included. Kaplan-Meier (KM) plotter (13) of 1,816 OC patients with survival data was retrieved for survival analysis, containing a subgroup of 1,656 patients of which the overall survival (OS) data were accessible, and 1,435 patients of whom the progression-free survival (PFS) data were available. The survival data of 1,816 OC patients with mRNA expressions were integrated from GEO (https://www.ncbi.nlm.nih.gov/geoprofiles/) (14,15) (GSE51373, GSE9891, GSE63885, GSE15622, GSE30161, GSE14764, GSE65986, GSE18520, GSE27651, GSE26712, GSE19829, GSE26193, GSE23554 and GSE3149) and the ovarian cohort of TCGA (10). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "21720365": [
        "TCGA ovarian cohort (10) of 489 OC patients with clinical data and gene expression was retrieved from cBioPortal (http://www.cbioportal.org/) (11,12), including \u201cstaging\u201d, \u201cgrading\u201d, \u201coverall survival\u201d and \u201cprimary treatment outcome\u201d, in which a subgroup of 90 platinum resistant samples and 197 sensitive samples was included. Kaplan-Meier (KM) plotter (13) of 1,816 OC patients with survival data was retrieved for survival analysis, containing a subgroup of 1,656 patients of which the overall survival (OS) data were accessible, and 1,435 patients of whom the progression-free survival (PFS) data were available. The survival data of 1,816 OC patients with mRNA expressions were integrated from GEO (https://www.ncbi.nlm.nih.gov/geoprofiles/) (14,15) (GSE51373, GSE9891, GSE63885, GSE15622, GSE30161, GSE14764, GSE65986, GSE18520, GSE27651, GSE26712, GSE19829, GSE26193, GSE23554 and GSE3149) and the ovarian cohort of TCGA (10). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4127657413482666,
    "data_pmids_checked": 1,
    "paper_id": "39262489",
    "extraction_date": "2025-12-19T20:46:19.061162",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39262489.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39259093": {
    "cbioportal_paper_citations": [
      "Access to multidimensional cancer genomics data, including somatic mutations, alterations in DNA copy number, mRNA and miRNA expression, DNA methylation, and protein abundance, is available through the online cBioPortal database (www.cbioportal.org).[26] The mutations of CCTs in LUAD patients and the association between CCTs mutation and LUAD patient survival were assessed using cBioPortal. Kaplan\u2013Meier analysis was designed to evaluate the relationship between CCTs mutation and OS or DFS in LUAD patients. Log-rank test was utilized, and P < .05 was considered to be statistically significant."
    ],
    "cbioportal_platform_mentions": [
      "The TIMER2.0 database was used to identify CCTs mutation status across various tumor types. All 8 CCTs showed the highest mutation rate in uterine corpus endometrial carcinoma (Fig. S2, Supplemental Digital Content, http://links.lww.com/MD/M701). CCTs mutations and copy number alterations were then investigated in LUAD using the cBioPortal database. The mutation rate for CCT2 (5%), CCT3 (7%), CCT5 (8%), and CCT6A (4%) was relatively higher in LUAD than that for TCP1 (1.5%), CCT4 (0.9%), CCT7 (0.7%), and CCT8 (1.2%) (Fig. 3A). It is noteworthy that gene amplification and alteration of CCTs were the most evident in LUAD among different tissue types of lung cancer (Fig. S3, Supplemental Digital Content, http://links.lww.com/MD/M702). Moreover, it was observed that LUAD patients harboring CCTs mutations had a shorter OS than those without mutations (Fig. 3B). However, DFS exhibited no difference between the 2 groups (Fig. 3B). Promoter methylation of CCTs in LUAD was also assessed. Data from the UALCAN database indicated that CCT4, CCT5, CCT6A, and CCT8 exhibited significantly higher promoter methylation in normal tissues than in tumor tissues (Fig. 3C), suggesting that low promoter methylation may be responsible for upregulating these CCTs in LUAD.",
      "Mutation and methylation of CCTs in LUAD. (A) Mutations of CCTs in LUAD according to cBioPortal database. (B) Correlation between CCTs mutation and survival of LUAD patients. (C) Methylation of CCTs in LUAD based on the UALCAN database. **P < .01, ***P < .001. CCTs = chaperonin-containing TCP-1 (T-complex protein 1) subunit genes, LUAD = lung adenocarcinoma.",
      "Due to its high incidence rate and mortality, LUAD presents a constant challenge to clinical physicians and researchers in terms of precise diagnosis and efficient therapy. Therefore, it is critical to investigate more precise and sensitive biomarkers for the early identification of LUAD and personalized treatment. In this study, a comprehensive analysis of CCTs in LUAD was conducted using TCGA and other public databases such as UALCAN, GEPIA 2.0, TIMER 2.0, PrognoScan, cBioPortal, GEO, and STRING. The TCGA database was established in 2006 and compiled gene expression and clinical data on 33 different tumor types, ranging from hematological to solid tumors and from mildly to severely aggressive tumors.[28] Considerable progress has been achieved using TCGA to identify novel oncogenic biomarkers and establish molecular subtypes.[29\u201331] Many other platforms, such as UALCAN and GEPIA 2.0, have been developed to identify CCT family genes that may serve as novel and useful biomarkers for the diagnosis of LUAD and targets for LUAD treatment.",
      "The authors would like to sincerely thank the TCGA for data sharing, as well as UALCAN, GEPIA2.0, TIMER2.0, PrognoScan, cBioPortal, GEO, and STRING for providing data processing and analysis."
    ],
    "data_publication_citations": {
      "22960745": [
        "Due to its high incidence rate and mortality, LUAD presents a constant challenge to clinical physicians and researchers in terms of precise diagnosis and efficient therapy. Therefore, it is critical to investigate more precise and sensitive biomarkers for the early identification of LUAD and personalized treatment. In this study, a comprehensive analysis of CCTs in LUAD was conducted using TCGA and other public databases such as UALCAN, GEPIA 2.0, TIMER 2.0, PrognoScan, cBioPortal, GEO, and STRING. The TCGA database was established in 2006 and compiled gene expression and clinical data on 33 different tumor types, ranging from hematological to solid tumors and from mildly to severely aggressive tumors.[28] Considerable progress has been achieved using TCGA to identify novel oncogenic biomarkers and establish molecular subtypes.[29\u201331] Many other platforms, such as UALCAN and GEPIA 2.0, have been developed to identify CCT family genes that may serve as novel and useful biomarkers for the diagnosis of LUAD and targets for LUAD treatment."
      ],
      "18772890": [
        "Due to its high incidence rate and mortality, LUAD presents a constant challenge to clinical physicians and researchers in terms of precise diagnosis and efficient therapy. Therefore, it is critical to investigate more precise and sensitive biomarkers for the early identification of LUAD and personalized treatment. In this study, a comprehensive analysis of CCTs in LUAD was conducted using TCGA and other public databases such as UALCAN, GEPIA 2.0, TIMER 2.0, PrognoScan, cBioPortal, GEO, and STRING. The TCGA database was established in 2006 and compiled gene expression and clinical data on 33 different tumor types, ranging from hematological to solid tumors and from mildly to severely aggressive tumors.[28] Considerable progress has been achieved using TCGA to identify novel oncogenic biomarkers and establish molecular subtypes.[29\u201331] Many other platforms, such as UALCAN and GEPIA 2.0, have been developed to identify CCT family genes that may serve as novel and useful biomarkers for the diagnosis of LUAD and targets for LUAD treatment."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3653280735015869,
    "data_pmids_checked": 2,
    "paper_id": "39259093",
    "extraction_date": "2025-12-19T20:46:19.434231",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39259093.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39259414": {
    "cbioportal_paper_citations": [
      "Published clinical variables, including overall survival and age for 84 primary oligodendroglioma tumors were downloaded from cBioPortal [15, 25, 37]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "31263031": [
        "Published clinical variables, including overall survival and age for 84 primary oligodendroglioma tumors were downloaded from cBioPortal [15, 25, 37].",
        "To study age and survival-associated molecular features of oligodendroglioma, we consulted 550 oligodendroglioma tumors from seven publicly available cohorts, including the TCGA, Chinese Glioma Genome Atlas (CGGA), Capper et al., Glioma Longitudinal AnalySiS Consortium (GLASS), Jonsson et al., Oligo Nation, and the EORTC 26951 Phase III clinical trial [7, 12, 13, 37, 41, 68, 77]. Patient age (N = 481), overall survival (N = 342), and bulk RNA-sequencing data (N = 232) from the TCGA, CGGA, and GLASS were used to nominate a molecular marker associated with an older, more aggressive subset of oligodendroglioma. The DNA methylation profile of this marker was subsequently analyzed in a group of 364 tumors from the TCGA, Capper et al., and GLASS cohorts and, along with RNA-sequencing data, subjected to association tests with features in 156 TCGA pathology reports and 27 pre-operative multimodal magnetic resonance imaging volumes. To isolate our analyses to neoplastic cells and interrogate proliferating phenotypes, we used single-nucleus RNA sequencing from 7817 nuclei and single-nucleus ATAC-sequencing data from 18,549 nuclei published by Blanco-Carmona et al. and Wang et al. [10, 82]. All data analyzed in this study are summarized in Supplemental Table 1.",
        "Contrary to most cancer types, the age distribution of oligodendroglioma patients has been reported to appear bimodal, possibly indicating that certain age ranges are associated with different tumor biology [17, 64]. Although we were unable to statistically judge whether oligodendroglioma patient age distributions were multimodal in our data (Hartigans' dip test), we did find many cohorts exhibited a non-Gaussian distribution. Unlike IDH-wildtype glioblastoma and IDH-mutant astrocytoma adult-type diffuse gliomas in the TCGA, patient age in TCGA oligodendrogliomas was not normally distributed (p < 0.04, Shapiro\u2013Wilk) (Supplemental Fig. 5). In addition to the TCGA, oligodendroglioma age was significantly or marginally significantly non-Gaussian distributed among primary tumors in cohorts published by Jonsson et al. (N = 84, p = 0.01, Shapiro\u2013Wilk), Capper et al. (N = 111, p = 0.048), the CGGA (N = 48, p = 0.06), the GLASS Consortium (N = 31, p = 0.08), and Oligo Nation (N = 34, p = 0.09) (Fig. 1a) [7, 13, 19, 37, 80, 91]. In addition, all non-TCGA datasets were enriched for younger, longer surviving patients compared to the TCGA, suggesting that older patients may be underrepresented and obscure a clearer bimodal distribution in these datasets (Fig. 1b). Given that age is prognostic and non-Gaussian distributed in oligodendroglioma, we hypothesized that a distinctive, aggressive subtype of oligodendroglioma that occurs at older ages may exist.Fig. 1Investigation of the non-Gaussian age distribution in oligodendroglioma identifies HOXD12 expression as age and survival associated. a The distribution of oligodendroglioma patient age was significantly and marginally significantly non-Gaussian in six independent oligodendroglioma cohorts. b Older age was associated with worse outcomes in cohorts with survival data. c Unbiased differential gene expression analysis between older and younger patients returned 16 significantly differentially expressed genes, including several genes in the HOX, GATA, and keratin gene families. d, e Of the four differentially expressed genes that also stratified TCGA oligodendroglioma survival, HOXD12 had the strongest association with poor outcomes. f In addition to the TCGA, older oligodendroglioma patients were also enriched for HOXD12-positive expression status in the CGGA. g HOXD12-positive expression status was prognostic in the CGGA, validating the results from the TCGA. h HOXD12-positive expression status was prognostic independent of patient age and CNS WHO grade in the TCGA and independent of CNS WHO grade in the CGGA. i Age distributions of TCGA and CGGA oligodendrogliomas when partitioned by HOXD12-positive and HOXD12-negative expression status"
      ],
      "31748746": [
        "The Synapse API was used to download gene expression TPM data (Primary N = 9; Total 19), DNA methylation beta values from the merged Illumina 450 K and EPIC platforms (beta.merged) (Primary N = 10; Total N = 24), as well as clinical variables age (N = 34), WHO grade (N = 34), and overall survival (N = 34) for oligodendroglioma tumors in the Glioma Longitudinal AnalySiS (GLASS) cohort (Data Release version 2021-11-16) [7, 19, 80]. GLASS tumors were determined to be oligodendrogliomas if the following conditions were met in the metadata for the patient\u2019s primary tumor: \"idh_status\" was \u201cIDHmut\u201d and \"codel_status\" was \"codel\" or \"idh_codel_subtype\" was \"IDHmut-codel.\" For our age and WHO grade analyses, we restricted our analyses to primary tumors whose \"idh_codel_subtype\" was \"IDHmut-codel.\" All GLASS samples that appear in the TCGA were excluded.",
        "To study age and survival-associated molecular features of oligodendroglioma, we consulted 550 oligodendroglioma tumors from seven publicly available cohorts, including the TCGA, Chinese Glioma Genome Atlas (CGGA), Capper et al., Glioma Longitudinal AnalySiS Consortium (GLASS), Jonsson et al., Oligo Nation, and the EORTC 26951 Phase III clinical trial [7, 12, 13, 37, 41, 68, 77]. Patient age (N = 481), overall survival (N = 342), and bulk RNA-sequencing data (N = 232) from the TCGA, CGGA, and GLASS were used to nominate a molecular marker associated with an older, more aggressive subset of oligodendroglioma. The DNA methylation profile of this marker was subsequently analyzed in a group of 364 tumors from the TCGA, Capper et al., and GLASS cohorts and, along with RNA-sequencing data, subjected to association tests with features in 156 TCGA pathology reports and 27 pre-operative multimodal magnetic resonance imaging volumes. To isolate our analyses to neoplastic cells and interrogate proliferating phenotypes, we used single-nucleus RNA sequencing from 7817 nuclei and single-nucleus ATAC-sequencing data from 18,549 nuclei published by Blanco-Carmona et al. and Wang et al. [10, 82]. All data analyzed in this study are summarized in Supplemental Table 1.",
        "Contrary to most cancer types, the age distribution of oligodendroglioma patients has been reported to appear bimodal, possibly indicating that certain age ranges are associated with different tumor biology [17, 64]. Although we were unable to statistically judge whether oligodendroglioma patient age distributions were multimodal in our data (Hartigans' dip test), we did find many cohorts exhibited a non-Gaussian distribution. Unlike IDH-wildtype glioblastoma and IDH-mutant astrocytoma adult-type diffuse gliomas in the TCGA, patient age in TCGA oligodendrogliomas was not normally distributed (p < 0.04, Shapiro\u2013Wilk) (Supplemental Fig. 5). In addition to the TCGA, oligodendroglioma age was significantly or marginally significantly non-Gaussian distributed among primary tumors in cohorts published by Jonsson et al. (N = 84, p = 0.01, Shapiro\u2013Wilk), Capper et al. (N = 111, p = 0.048), the CGGA (N = 48, p = 0.06), the GLASS Consortium (N = 31, p = 0.08), and Oligo Nation (N = 34, p = 0.09) (Fig. 1a) [7, 13, 19, 37, 80, 91]. In addition, all non-TCGA datasets were enriched for younger, longer surviving patients compared to the TCGA, suggesting that older patients may be underrepresented and obscure a clearer bimodal distribution in these datasets (Fig. 1b). Given that age is prognostic and non-Gaussian distributed in oligodendroglioma, we hypothesized that a distinctive, aggressive subtype of oligodendroglioma that occurs at older ages may exist.Fig. 1Investigation of the non-Gaussian age distribution in oligodendroglioma identifies HOXD12 expression as age and survival associated. a The distribution of oligodendroglioma patient age was significantly and marginally significantly non-Gaussian in six independent oligodendroglioma cohorts. b Older age was associated with worse outcomes in cohorts with survival data. c Unbiased differential gene expression analysis between older and younger patients returned 16 significantly differentially expressed genes, including several genes in the HOX, GATA, and keratin gene families. d, e Of the four differentially expressed genes that also stratified TCGA oligodendroglioma survival, HOXD12 had the strongest association with poor outcomes. f In addition to the TCGA, older oligodendroglioma patients were also enriched for HOXD12-positive expression status in the CGGA. g HOXD12-positive expression status was prognostic in the CGGA, validating the results from the TCGA. h HOXD12-positive expression status was prognostic independent of patient age and CNS WHO grade in the TCGA and independent of CNS WHO grade in the CGGA. i Age distributions of TCGA and CGGA oligodendrogliomas when partitioned by HOXD12-positive and HOXD12-negative expression status"
      ],
      "38117484": [
        "HOXD12 is a gene in the HOX gene family located on the HOXD locus on chromosome 2\u2014one of four HOX loci (HOXA, HOXB, HOXC, and HOXD) found on chromosomes 7, 17, 12, and 2, respectively. In healthy individuals, HOX genes are involved in embryonic brain development and are usually absent in the adult brain; however, abnormal HOX gene expression and regulation have been extensively documented in cancer [1, 8, 29, 59]. Numerous genes in the HOX gene family have been reported to be involved in tumors of the CNS (as reviewed by Gon\u00e7alves et al. [29]), particularly in glioblastoma [16, 20, 22, 27, 29, 40, 42], primarily as oncogenes. More recently, HOX genes in the HOXA and HOXD loci have been implicated in IDH-mutant adult-type diffuse glioma progression and aggression [46, 47]. A study by Mamatjan et al. analyzed HOX gene overexpression and hypermethylation and proposed a seven HOX gene signature (HOXA4, HOXA7, HOXA10, HOXA13, HOXD3, HOXD9, and HOXD10) that was shown to be prognostic in IDH mutant astrocytoma and oligodendrogliomas [47]. The gene HOXD13 has also been implicated in glioma progression in a ChIP-seq analyses of 14 IDH-mutant gliomas, but this phenotype was not validated in oligodendroglioma [46]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 3,
    "extraction_method": "jats_xml",
    "extraction_time": 0.7522330284118652,
    "data_pmids_checked": 4,
    "paper_id": "39259414",
    "extraction_date": "2025-12-19T20:46:19.633090",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39259414.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39258533": {
    "cbioportal_paper_citations": [
      "Genomic alterations affecting PD\u2010L1, such as copy number gains, may influence the expression levels of PD\u2010L1 across various cancer types [23]. The two cell subsets, high or low PD\u2010L1 protein expressors that we have identified, led us to assess the PD\u2010L1 gene status using FISH analysis, despite its limited clinical utility for diagnosing PD\u2010L1 in BC, as per previous knowledge [15]. Despite cells displaying trisomy or polysomy of chromosome 9, no gene amplifications or deletions were detected. Only the T24 cells exhibited a copy number gain of CD274 (Fig. S1B). This suggests that the observed differences in PD\u2010L1 expression likely are not due to genetic alterations. Representative FISH analysis images of high PD\u2010L1 expressor (HT\u20101197) and low PD\u2010L1 expressor cells (RT4) cells are shown in Fig. S1C. Subsequently, an exploration of the PD\u2010L1 gene status in tumor samples was undertaken. This assessment was performed in silico using cBioPortal [24], with data obtained from the TCGA PanCan 2018 and the MSK Our Urol 2017 public datasets. The results revealed that less than 5% of patients with BC exhibit PD\u2010L1 gene amplifications or mutations (Fig. S1D). Interestingly, a study found that CD274 amplifications may serve as potential biomarkers for ICI response in UC [25].",
      "The tumor microenvironment can influence therapy response, and interactions between tumor cells, fibroblasts, and immune cells could be pivotal [36]. Our results indicated that TAK\u2010228 affects PD\u2010L1 and in some cell lines HLA\u2010I, both key immune response mediators. With this in mind, we aimed to explore whether TAK\u2010228 could influence the effect of the pro\u2010inflammatory cytokine IFN\u03b3 on UC cells. Notably, IFN\u03b3 led to reduced cell viability at 6 days, although T24 exhibited lower sensitivity to the effect of IFN\u03b3 compared to CAL\u201029 cells (Fig. 4A). These differences might be due to distinct IFN\u03b3 receptor (IFNGR1) expression levels, as evident from cBioPortal database data indicating IFNGR1 mRNA expression differences between these cell lines (Fig. S4A) [24, 37]. Confirmed by western blot, CAL\u201029 cells exhibited higher IFNGR1 protein levels compared to T24 cells (Fig. S4B). Interestingly, the addition of TAK\u2010228 notably amplified the cytotoxic impact of IFN\u03b3 on cell viability in both cell types (Fig. 4B). Analyzing PD\u2010L1 and HLA\u2010I levels post\u2010TAK\u2010228 treatment with or without IFN\u03b3, we observed potentiated effects of TAK\u2010228 combined with IFN\u03b3 in both T24 and CAL\u201029 cells, leading to significantly elevated intracellular levels of these two proteins observed through the analysis of whole\u2010cell lysate using western blotting (Fig. 4C). Additionally, the combination of IFN\u03b3 and TAK\u2010228 substantially increased the levels of surface PD\u2010L1. However, at the same time point surface HLA\u2010I levels were similar with the combination (Fig. 4D). Intricate processes govern the synthesis, transport, and surface display of HLA molecules. In specific conditions or treatments, these molecules can accumulate intracellularly before appearing on the cell membrane [38]."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "24476821": [
        "We investigated deeper into the mechanisms behind the TAK\u2010228\u2010related enhanced PD\u2010L1 expression. The regulation of PD\u2010L1 is complicated, involving various aspects such as genetics, epigenetics, transcription, translation, and post\u2010translational factors [54, 55]. We focused our investigation on well\u2010established pathways associated with PD\u2010L1 stabilization, including the inhibition of S6 phosphorylation [27] and GSK3\u03b2 inactivation [28]. Additionally, we explored alternative mechanisms and discovered that TAK\u2010228 enhances PD\u2010L1 expression through increased mRNA levels and the release of EGF and IFN\u03b2. EGF, a vital growth factor, binds to EGFR on cancer cells, activating MAPK/ERK and PI3K/AKT pathways, ultimately promoting PD\u2010L1 gene transcription [31]. IFN\u03b2, part of the interferon cytokine family, activates JAK\u2013STAT signaling, upregulating PD\u2010L1 via interferon\u2010stimulated response elements (ISREs) in the gene promoter region [32]. Targeting these pathways could reduce PD\u2010L1 expression, making EGFR\u2010altered UC more susceptible to immune attacks [56]. Understanding interactions like EGF\u2010EGFR's influence on PD\u2010L1 is especially relevant given the ongoing clinical trials assessing the use of afatinib (EGFR\u2010TKI) in advanced BC (NCT02122172)."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.4005100727081299,
    "data_pmids_checked": 1,
    "paper_id": "39258533",
    "extraction_date": "2025-12-19T20:46:19.834844",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39258533.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39261602": {
    "cbioportal_paper_citations": [
      "RNA-seq and proteomic data from the Spanish CLL cohort (CLLE-ES; Supplementary Table 1B), generated within the International Cancer Genome Consortium (ICGC; http://platform.icgc-argo.org/), the Cancer Cell Line Encyclopedia (CCLE; https://sites.broadinstitute.org/ccle/), The Cancer Genome Atlas (TCGA; http://www.cbioportal.org/, Supplementary Table 1C and 7A, B), dbGaP (study accession phs001959.v1.p1), and ProteomeXchange (study accession PXD028936), were retrieved [25\u201334]. For analysis of BRD9 and histone chromatin binding, ChIP-sequencing (ChIP-seq) data was downloaded from the ENCODE database (https://www.encodeproject.org) for the chronic myeloid leukemia (CML) cell line K562 [35, 36]. Details are provided in Supplementary Information.",
      "Since exon 15 inclusion in BRD9 has been reported to lead to nonsense-mediated decay and lower transcript levels in UVM and MDS, we sought to investigate BRD9 gene expression levels in additional cancer types that harbor SF3B1 mutations [18]. In a re-analysis of the UVM cases from TCGA [27, 29, 33, 34], a significant 0.45-fold gene expression difference was found in SF3B1MUT compared to SF3B1WT cases (Wilcoxon rank-sum test, P < 0.001); however, no significant differences were seen in other cancer types (Supplementary Fig. 8, Supplementary Table 7A, B). Furthermore, no significant differences in BRD9 gene/protein expression between SF3B1MUT and SF3B1WT cases were identified in three independent gene expression and one proteomic dataset from CLL (Supplementary Fig. 9A\u2013J).",
      "Comparison between SF3B1MUT and SF3B1WT subset #2 cases revealed 55 and 22 significantly higher and lower expressed genes in SF3B1MUT cases, respectively (Fig. 5A, B; |log2FC | \u2265 0.58 and FDR < 0.01). Analysis of the chromosomal positions of differentially expressed genes identified four adjacent genes on chromosome 1, NOL9, TAS1R1, ZBTB48, and KLHL21, which were upregulated in SF3B1MUT subset #2 cases (Fig. 5C). In a similar comparison of RNA-seq data from ICGC CLLE-ES [30, 31] (Supplementary Fig. 10A, B) and TCGA CLL [29, 33, 34] (Supplementary Fig. 10C\u2013E), we observed an overlap between the 3 datasets, indicating upregulation of ZBTB48 and TAS1R1 in SF3B1MUT (Fig. 5D). By comparing the differentially expressed genes in SF3B1MUT subset #2 cases with published ATAC-sequencing data of SF3B1MUT CLL [47], the gene quartet also exhibited increased chromatin accessibility in SF3B1MUT CLL (Fig. 5E). ChIP-seq data of the CML cell line K562 indicated that BRD9, SMARCA4, and SMARCC2 can bind to the gene quartet (Fig. 5F). Furthermore, based on the high signal for H3K27ac, H3K4me3, H3K9ac, H3K79me2, and H3K36me3, and the low signal for H3K27me3 and H3K9me3, these genes appear transcriptionally active [35, 36].Fig. 5BRD9 binds a gene quartet on chromosome 1 and displays selective dependency in DepMap.A Volcano plot depicting differentially expressed genes between 18 SF3B1MUT and 17 SF3B1WT subset #2 cases with 22 downregulated and 55 upregulated genes ( | log2FC | \u2265 0.58 and FDR < 0.01). B Unsupervised clustermap illustrating the distinct clustering of SF3B1MUT and SF3B1WT subset #2 cases based on differential gene expression. The four neighboring genes, NOL9, TAS1R1, ZBTB48, and KLHL21, located on chromosome 1 are depicted in color. The Ward method and the Euclidean metric were employed. C Karyoplot of chromosome 1 displaying differentially expressed genes between SF3B1MUT and SF3B1WT subset #2 cases. Examination of chromosomal positions revealed four neighboring genes, NOL9, TAS1R1, ZBTB48, and KLHL21. D Venn diagram showing the overlap of genes with differential expression between SF3B1MUT and SF3B1WT cases in three independent datasets; subset #2 CLL, ICGC CLLE-ES [30, 31], and TCGA CLL [29, 33, 34]. For the differential gene expression analyses of the latter two datasets see Supplementary Fig. 10A\u2013E. ZBTB48 appeared upregulated in all three datasets, while TAS1R1 in subset #2 CLL and ICGC CLLE-ES. E Venn diagram showing the overlap of genes with higher expression levels in SF3B1MUT subset #2 cases and increased chromatin accessibility in SF3B1MUT CLL cases from Beekman et al. [47]. The overlap comprises NOL9, TAS1R1, ZBTB48, and KLHL21. F Coverage tracks from ChIP-seq data sourced from the ENCODE database [35, 36], based on the CML cell line K562, illustrating the binding of BRD9 and the ncBAF complex subunits SMARCA4 and SMARCC2 to the gene quartet region on chromosome 1. The promoters for these genes appear active based on the signal for H3K27ac, H3K4me3, H3K9ac, and H3K79me2, and transcriptionally active based on the H3K36me3 signal, whereas transcriptional repression is low based on the low signal for H3K27me3 and H3K9me3. G Gene essentiality map showing the relationship between efficacy and selectivity of genes in shinyDepMap [37, 38]. SF3B1 appears as a non-selective dependency with high efficacy, while BRD9 as a selective dependency with high efficacy. BRD9 is in the dependency region of PIK3R1, EZH2, and FBXW7. H Functional similarity clustering showing a chromatin remodeling dependency cluster connected to the BRD9 dependency signature in shinyDepMap. BRD9 clusters with SMARCD1, a BAF complex subunit, subunits of the Mediator complex, p300/CBP subunits, and subunits of the SAGA complex. I BRD9 dependency ranking of the 1086 DepMap (22Q2) cell lines. For CLL cell lines, gene effect scores are given within the parenthesis. WT: wildtype; MUT: mutated; FDR: false discovery rate; FC: fold change.",
      "A Volcano plot depicting differentially expressed genes between 18 SF3B1MUT and 17 SF3B1WT subset #2 cases with 22 downregulated and 55 upregulated genes ( | log2FC | \u2265 0.58 and FDR < 0.01). B Unsupervised clustermap illustrating the distinct clustering of SF3B1MUT and SF3B1WT subset #2 cases based on differential gene expression. The four neighboring genes, NOL9, TAS1R1, ZBTB48, and KLHL21, located on chromosome 1 are depicted in color. The Ward method and the Euclidean metric were employed. C Karyoplot of chromosome 1 displaying differentially expressed genes between SF3B1MUT and SF3B1WT subset #2 cases. Examination of chromosomal positions revealed four neighboring genes, NOL9, TAS1R1, ZBTB48, and KLHL21. D Venn diagram showing the overlap of genes with differential expression between SF3B1MUT and SF3B1WT cases in three independent datasets; subset #2 CLL, ICGC CLLE-ES [30, 31], and TCGA CLL [29, 33, 34]. For the differential gene expression analyses of the latter two datasets see Supplementary Fig. 10A\u2013E. ZBTB48 appeared upregulated in all three datasets, while TAS1R1 in subset #2 CLL and ICGC CLLE-ES. E Venn diagram showing the overlap of genes with higher expression levels in SF3B1MUT subset #2 cases and increased chromatin accessibility in SF3B1MUT CLL cases from Beekman et al. [47]. The overlap comprises NOL9, TAS1R1, ZBTB48, and KLHL21. F Coverage tracks from ChIP-seq data sourced from the ENCODE database [35, 36], based on the CML cell line K562, illustrating the binding of BRD9 and the ncBAF complex subunits SMARCA4 and SMARCC2 to the gene quartet region on chromosome 1. The promoters for these genes appear active based on the signal for H3K27ac, H3K4me3, H3K9ac, and H3K79me2, and transcriptionally active based on the H3K36me3 signal, whereas transcriptional repression is low based on the low signal for H3K27me3 and H3K9me3. G Gene essentiality map showing the relationship between efficacy and selectivity of genes in shinyDepMap [37, 38]. SF3B1 appears as a non-selective dependency with high efficacy, while BRD9 as a selective dependency with high efficacy. BRD9 is in the dependency region of PIK3R1, EZH2, and FBXW7. H Functional similarity clustering showing a chromatin remodeling dependency cluster connected to the BRD9 dependency signature in shinyDepMap. BRD9 clusters with SMARCD1, a BAF complex subunit, subunits of the Mediator complex, p300/CBP subunits, and subunits of the SAGA complex. I BRD9 dependency ranking of the 1086 DepMap (22Q2) cell lines. For CLL cell lines, gene effect scores are given within the parenthesis. WT: wildtype; MUT: mutated; FDR: false discovery rate; FC: fold change."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26466571": [
        "Since exon 15 inclusion in BRD9 has been reported to lead to nonsense-mediated decay and lower transcript levels in UVM and MDS, we sought to investigate BRD9 gene expression levels in additional cancer types that harbor SF3B1 mutations [18]. In a re-analysis of the UVM cases from TCGA [27, 29, 33, 34], a significant 0.45-fold gene expression difference was found in SF3B1MUT compared to SF3B1WT cases (Wilcoxon rank-sum test, P < 0.001); however, no significant differences were seen in other cancer types (Supplementary Fig. 8, Supplementary Table 7A, B). Furthermore, no significant differences in BRD9 gene/protein expression between SF3B1MUT and SF3B1WT cases were identified in three independent gene expression and one proteomic dataset from CLL (Supplementary Fig. 9A\u2013J).",
        "Comparison between SF3B1MUT and SF3B1WT subset #2 cases revealed 55 and 22 significantly higher and lower expressed genes in SF3B1MUT cases, respectively (Fig. 5A, B; |log2FC | \u2265 0.58 and FDR < 0.01). Analysis of the chromosomal positions of differentially expressed genes identified four adjacent genes on chromosome 1, NOL9, TAS1R1, ZBTB48, and KLHL21, which were upregulated in SF3B1MUT subset #2 cases (Fig. 5C). In a similar comparison of RNA-seq data from ICGC CLLE-ES [30, 31] (Supplementary Fig. 10A, B) and TCGA CLL [29, 33, 34] (Supplementary Fig. 10C\u2013E), we observed an overlap between the 3 datasets, indicating upregulation of ZBTB48 and TAS1R1 in SF3B1MUT (Fig. 5D). By comparing the differentially expressed genes in SF3B1MUT subset #2 cases with published ATAC-sequencing data of SF3B1MUT CLL [47], the gene quartet also exhibited increased chromatin accessibility in SF3B1MUT CLL (Fig. 5E). ChIP-seq data of the CML cell line K562 indicated that BRD9, SMARCA4, and SMARCC2 can bind to the gene quartet (Fig. 5F). Furthermore, based on the high signal for H3K27ac, H3K4me3, H3K9ac, H3K79me2, and H3K36me3, and the low signal for H3K27me3 and H3K9me3, these genes appear transcriptionally active [35, 36].Fig. 5BRD9 binds a gene quartet on chromosome 1 and displays selective dependency in DepMap.A Volcano plot depicting differentially expressed genes between 18 SF3B1MUT and 17 SF3B1WT subset #2 cases with 22 downregulated and 55 upregulated genes ( | log2FC | \u2265 0.58 and FDR < 0.01). B Unsupervised clustermap illustrating the distinct clustering of SF3B1MUT and SF3B1WT subset #2 cases based on differential gene expression. The four neighboring genes, NOL9, TAS1R1, ZBTB48, and KLHL21, located on chromosome 1 are depicted in color. The Ward method and the Euclidean metric were employed. C Karyoplot of chromosome 1 displaying differentially expressed genes between SF3B1MUT and SF3B1WT subset #2 cases. Examination of chromosomal positions revealed four neighboring genes, NOL9, TAS1R1, ZBTB48, and KLHL21. D Venn diagram showing the overlap of genes with differential expression between SF3B1MUT and SF3B1WT cases in three independent datasets; subset #2 CLL, ICGC CLLE-ES [30, 31], and TCGA CLL [29, 33, 34]. For the differential gene expression analyses of the latter two datasets see Supplementary Fig. 10A\u2013E. ZBTB48 appeared upregulated in all three datasets, while TAS1R1 in subset #2 CLL and ICGC CLLE-ES. E Venn diagram showing the overlap of genes with higher expression levels in SF3B1MUT subset #2 cases and increased chromatin accessibility in SF3B1MUT CLL cases from Beekman et al. [47]. The overlap comprises NOL9, TAS1R1, ZBTB48, and KLHL21. F Coverage tracks from ChIP-seq data sourced from the ENCODE database [35, 36], based on the CML cell line K562, illustrating the binding of BRD9 and the ncBAF complex subunits SMARCA4 and SMARCC2 to the gene quartet region on chromosome 1. The promoters for these genes appear active based on the signal for H3K27ac, H3K4me3, H3K9ac, and H3K79me2, and transcriptionally active based on the H3K36me3 signal, whereas transcriptional repression is low based on the low signal for H3K27me3 and H3K9me3. G Gene essentiality map showing the relationship between efficacy and selectivity of genes in shinyDepMap [37, 38]. SF3B1 appears as a non-selective dependency with high efficacy, while BRD9 as a selective dependency with high efficacy. BRD9 is in the dependency region of PIK3R1, EZH2, and FBXW7. H Functional similarity clustering showing a chromatin remodeling dependency cluster connected to the BRD9 dependency signature in shinyDepMap. BRD9 clusters with SMARCD1, a BAF complex subunit, subunits of the Mediator complex, p300/CBP subunits, and subunits of the SAGA complex. I BRD9 dependency ranking of the 1086 DepMap (22Q2) cell lines. For CLL cell lines, gene effect scores are given within the parenthesis. WT: wildtype; MUT: mutated; FDR: false discovery rate; FC: fold change.",
        "A Volcano plot depicting differentially expressed genes between 18 SF3B1MUT and 17 SF3B1WT subset #2 cases with 22 downregulated and 55 upregulated genes ( | log2FC | \u2265 0.58 and FDR < 0.01). B Unsupervised clustermap illustrating the distinct clustering of SF3B1MUT and SF3B1WT subset #2 cases based on differential gene expression. The four neighboring genes, NOL9, TAS1R1, ZBTB48, and KLHL21, located on chromosome 1 are depicted in color. The Ward method and the Euclidean metric were employed. C Karyoplot of chromosome 1 displaying differentially expressed genes between SF3B1MUT and SF3B1WT subset #2 cases. Examination of chromosomal positions revealed four neighboring genes, NOL9, TAS1R1, ZBTB48, and KLHL21. D Venn diagram showing the overlap of genes with differential expression between SF3B1MUT and SF3B1WT cases in three independent datasets; subset #2 CLL, ICGC CLLE-ES [30, 31], and TCGA CLL [29, 33, 34]. For the differential gene expression analyses of the latter two datasets see Supplementary Fig. 10A\u2013E. ZBTB48 appeared upregulated in all three datasets, while TAS1R1 in subset #2 CLL and ICGC CLLE-ES. E Venn diagram showing the overlap of genes with higher expression levels in SF3B1MUT subset #2 cases and increased chromatin accessibility in SF3B1MUT CLL cases from Beekman et al. [47]. The overlap comprises NOL9, TAS1R1, ZBTB48, and KLHL21. F Coverage tracks from ChIP-seq data sourced from the ENCODE database [35, 36], based on the CML cell line K562, illustrating the binding of BRD9 and the ncBAF complex subunits SMARCA4 and SMARCC2 to the gene quartet region on chromosome 1. The promoters for these genes appear active based on the signal for H3K27ac, H3K4me3, H3K9ac, and H3K79me2, and transcriptionally active based on the H3K36me3 signal, whereas transcriptional repression is low based on the low signal for H3K27me3 and H3K9me3. G Gene essentiality map showing the relationship between efficacy and selectivity of genes in shinyDepMap [37, 38]. SF3B1 appears as a non-selective dependency with high efficacy, while BRD9 as a selective dependency with high efficacy. BRD9 is in the dependency region of PIK3R1, EZH2, and FBXW7. H Functional similarity clustering showing a chromatin remodeling dependency cluster connected to the BRD9 dependency signature in shinyDepMap. BRD9 clusters with SMARCD1, a BAF complex subunit, subunits of the Mediator complex, p300/CBP subunits, and subunits of the SAGA complex. I BRD9 dependency ranking of the 1086 DepMap (22Q2) cell lines. For CLL cell lines, gene effect scores are given within the parenthesis. WT: wildtype; MUT: mutated; FDR: false discovery rate; FC: fold change."
      ],
      "26200345": [
        "The potential significance of the multiple identified ASEs in transcripts encoding ncBAF complex-related proteins was examined using nanopore-based long-read RNA-seq, which confirmed many of the ASEs identified in our short-read RNA-seq analysis. Furthermore, they were observed in extended analyses of independent cohorts, showing that aberrant splicing extends beyond subset #2 CLL. On these grounds, the ncBAF complex may be targeted at multiple levels in SF3B1MUT CLL beyond BRD9. In addition to these alterations, BAF complex subunits SMARCC1 and ARID1A are deleted or mutated in 2% of CLL cases each [51]."
      ],
      "23415222": [
        "Recurrent SF3B1 mutations have been reported in various cancer types, including chronic lymphocytic leukemia (CLL), and shown to induce altered splicing by alternative branch point usage or cryptic 3\u2032 splice site selection [2\u20134]. SF3B1 mutations in CLL, particularly within hotspot exons where the most frequent substitution is p.K700E [5], are associated with rapidly progressive disease [6, 7]. These mutations are enriched in patients belonging to stereotyped subset #2 (up to 45%) [8\u201310] and associated with poor response to chemoimmunotherapy and short overall survival [8, 11\u201314]. SF3B1 mutations are often found at a subclonal level and expand during disease progression [15]. Accordingly, the occurrence of SF3B1 mutations in early-stage CLL is about 5\u201310% and above 20% at advanced stages [5\u20137]. Mutated SF3B1 in CLL has been associated with dysregulated DNA damage response, telomere dysfunction, increased Notch signaling mediated through a splice variant of DVL2, and activation of NF-\u03baB signaling facilitated by alternative splicing of MAP3K7 [3, 16]. In a mouse model, isolated SF3B1 mutations led to cellular senescence, whereas mutated SF3B1 in combination with ATM loss yielded a CLL-like disease in elderly mice [17].",
        "The strength of the study lies in the initial study cohort, which consisted of a uniform patient subgroup, specifically subset #2 CLL. Our analysis identified a greater number of SE ASEs than previous studies [3, 50], potentially due to differences in study cohorts and the bioinformatics tools applied; relevant to mention in that regard, we utilized contemporary, actively maintained tools to identify ASEs. The observed ASEs occurred to varying degrees in SF3B1MUT cases, likely due to the heterozygous state of SF3B1 mutations, allowing both normal and perturbed splicing. This may also stem from varying VAFs, where different admixtures of SF3B1MUT cells exist within the cancer cell population [15]. Consistent with this, we observed a strong correlation between PSI values and SF3B1 VAF."
      ],
      "32025007": [
        "Since exon 15 inclusion in BRD9 has been reported to lead to nonsense-mediated decay and lower transcript levels in UVM and MDS, we sought to investigate BRD9 gene expression levels in additional cancer types that harbor SF3B1 mutations [18]. In a re-analysis of the UVM cases from TCGA [27, 29, 33, 34], a significant 0.45-fold gene expression difference was found in SF3B1MUT compared to SF3B1WT cases (Wilcoxon rank-sum test, P < 0.001); however, no significant differences were seen in other cancer types (Supplementary Fig. 8, Supplementary Table 7A, B). Furthermore, no significant differences in BRD9 gene/protein expression between SF3B1MUT and SF3B1WT cases were identified in three independent gene expression and one proteomic dataset from CLL (Supplementary Fig. 9A\u2013J)."
      ],
      "22460905": [
        "We investigated the observed ncBAF complex-related ASEs in the remaining 65 subset cases (Supplementary Table 1A and 3C, D) and identified similar splicing differences in SF3B1MUT versus SF3B1WT for ZEB1, BRD9, DCAF16, DLST, and SERBP1 (Supplementary Fig. 1C). Subsequent analysis of RNA-seq data from ICGC CLLE-ES [30, 31], including 8 SF3B1MUT and 66 SF3B1WT cases (Supplementary Table 1B), identified 85 significant ASEs in transcripts of 71 genes (Supplementary Fig. 5A\u2013G, Supplementary Table 6A, B). A significant overlap was observed between the genes targeted by SF3B1MUT-related ASEs in the ICGC CLLE-ES and subset #2 cases, including BRD9, DLST, and SERBP1. Furthermore, we analyzed a set of 1019 cancer cell lines from CCLE [28], including 4 SF3B1MUT cell lines, and detected significant exon usage differences within six of the ncBAF complex-related ASEs identified in the comparison of SF3B1MUT and SF3B1WT subset #2 cases (Supplementary Fig. 6). Finally, we noted a strong correlation between the RNA-seq-based SF3B1MUT variant allele frequency (VAF) and the PSI values for most of the ncBAF complex-related ASEs, both in our subset cases and the ICGC CLLE-ES cases (Supplementary Fig. 7A, B) [30, 31]."
      ]
    },
    "total_cbioportal_paper_citations": 4,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 5,
    "extraction_method": "jats_xml",
    "extraction_time": 1.2147431373596191,
    "data_pmids_checked": 6,
    "paper_id": "39261602",
    "extraction_date": "2025-12-19T20:46:19.911668",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39261602.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39256686": {
    "cbioportal_paper_citations": [
      "The patient data were downloaded from the TCGA Firehose Legacy database in cBioPortal (https://www.cbioportal.org/) [21, 22]. Patient samples were separated into 3 groups, complete remission (CR, response group, n = 130), progressive disease (PD, no response group, n = 7) and stable disease (SD, no response group, n = 12), in accordance with the primary therapy outcome success type. A heatmap was prepared from the top 30 differentially expressed lncRNAs and created by Heatmapper (http://www.heatmapper.ca/) [23] with the \u201cspearman\u201d clustering distance method and \u201caverage linkage\u201d clustering methods."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2645440101623535,
    "data_pmids_checked": 0,
    "paper_id": "39256686",
    "extraction_date": "2025-12-19T20:46:19.942327",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39256686.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39255317": {
    "cbioportal_paper_citations": [
      "Recent studies have linked elevated PRMT5 levels to a variety of human disorders, particularly cancers, including lung cancer, breast cancer, leukemia, lymphoma, gastric cancer, and colorectal cancer [60, 61]. The regulation of proliferation by PRMT5 and the direct interaction of PRMT5 with proteins that are frequently dysregulated or mutated in cancer indicate that PRMT5 functions as an oncogene [62]. Multiple transcription factors regulate PRMT5 expression, such as Myc and NF-\u039aB, which can upregulate PRMT5 in numerous B cells [63]. Similarly, our findings are in accord with recent studies indicating that LANA can upregulate PRMT5 through transcriptional activation in KSHV latent cells (Fig 2). These results indicate that PRMT5 may play a role in KSHV-related malignancies. Given the current absence of accessible strategies to target PRMT5, it is imperative to investigate PRMT5 inhibitors."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1603834629058838,
    "data_pmids_checked": 0,
    "paper_id": "39255317",
    "extraction_date": "2025-12-19T20:46:19.995325",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39255317.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39251846": {
    "cbioportal_paper_citations": [
      "The EMT scores of the breast cancer patient tumor samples from the Cancer Genome Atlas Breast Invasive Carcinoma (TCGA BRCA, Cell 2015) and METABRIC datasets were calculated using gene expression data accessed via cBioportal [100, 101] and applying the EMT score metric developed by Tan et al. [56]. Briefly, the score was calculated by evaluating cumulative distribution functions (CDFs) for epithelial and mesenchymal gene signatures within a given sample and consists of values for over 300 genes. The distance between these signatures was determined by measuring the maximum separation between their respective CDFs. This value serves as the test statistic for the subsequent two-sample test to calculate the EMT score. The resulting score falls within the range of \u22121 to +1, where a positive EMT score indicates a mesenchymal phenotype and a negative EMT score signifies an epithelial phenotype in the sample."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.1866602897644043,
    "data_pmids_checked": 0,
    "paper_id": "39251846",
    "extraction_date": "2025-12-19T20:46:20.170338",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39251846.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39251514": {
    "cbioportal_paper_citations": [],
    "cbioportal_platform_mentions": [
      "Data were derived from the American Association of Cancer Research (AACR) Project Genomics Evidence of Neoplasia Information Exchange (GENIE) dataset (v15.0, released 27 December 2023) through cBioPortal.11 The GENIE database was initially launched in 2017 and currently includes somatic genomic data of approximately 167,000 patients from 19 participating institutions.11",
      "Adult patients with a diagnosis of iCCA who had available NGS data were identified and included in the analytic cohort. Data from the OncoKB database, provided by cBioPortal, were used to determine pathogenic gene alterations, as previously described.12,13 Germline mutations were excluded from the analysis. Genomic variations based on race and sex of participants were examined. Because all data originated from a publicly available de-identified database, the current study was deemed exempt from the Institutional Review Board of the Ohio State University.",
      "Data are expressed as median (interquartile range [IQR]) for continuous variables and as frequency (%) for categorical variables. The prevalence of the most frequent genomic alterations (including somatic mutations, structural variants, and copy number alterations) among patients with iCCA was calculated. Differences in frequency of genomic alterations relative to race, sex, and primary versus metastatic tumors were examined with the use of chi-square or Fisher\u2019s exact tests. The significance levels of co-occurrence and mutual exclusivity for a pair of variant genes were calculated by the Mutual Exclusivity Modules statistical method from cBioportal.14",
      "One of the strengths of the current study was the analysis of a large number of patients with genomic data derived from multiple academic institutions. Nevertheless, certain limitations should be taken into consideration when the results are interpreted. Genomic data were aggregated from multiple academic centers, each using different NGS assays with different gene panel sets and tumor content criteria.11 The use of the cBioPortal platform, however, allowed us to retrieve the actual number of patients tested for each gene (i.e., correct denominator) and to calculate mutational frequency of certain genes accurately.14 In addition, the GENIE database lacked detailed information regarding patient-level characteristics including comorbidities, obesity, smoking, family history of cancer, thus the association of these with certain genomic profiles could not be assessed. Data on iCCA subtypes and microsatellite instability (MSI) status also were not available in the AACR GENIE database, so we were unable to investigate racial and sex genomic differences relative to iCCA subtypes and MSI status. Information on cancer stage, treatment characteristics, and survival were also not available, thus we were unable to assess the prognostic implications of certain genomic alterations among iCCA patients."
    ],
    "data_publication_citations": {
      "29848569": [
        "Molecular profiling of iCCA has allowed for a better understanding of the distinct genomic landscape characterized by various oncogenic drivers that contribute to the pathogenesis and progression of disease.8 Indeed, up to 50% of iCCA patients present with potentially actionable genomic alterations including IDH1 (~20%), ARID1A (~20%), BAP1 (~18%), TP53 (~20%), and FGFR2 (~15%) fusions.8 Among these, IDH1 mutations and FGFR2 fusions have been considered the most promising targets in iCCA treatment.5,8 Recently, FGFR and IDH1 inhibitors received Food and Drug Administration (FDA) approval and currently are recommended for iCCA patients with FGFR2 fusions/rearrangements and IDH1 mutations, respectively.4",
        "Despite the encouraging results from precision oncologic studies, enrollment of Black and other non-White patients has been relatively low,8,9 thereby limiting our comprehensive understanding of the genomic landscape of iCCA in diverse populations. In turn, racial variations in the genomic profiling of iCCA may exist, but have not been studied to date. In addition, racial and sex disparities in the incidence and outcomes of patients with iCCA have previously been reported,10 yet the contribution of genetic variations to disparate outcomes of iCCA remains unknown. To this end, the current study aimed to assess comprehensively the genomic profile of iCCA using a large dataset of iCCA patients who had next-generation sequencing (NGS) of their tumors. Specifically, we sought to assess genomic alterations based on race and sex that could be related to differences in response to treatment and prognosis among a diverse patient population with iCCA.",
        "During the past decade, significant advances have been realized in the molecular characterization of biliary tract cancers including iCCA.5,8,9 Next-generation sequencing technologies have identified genetic aberrations thought to contribute to tumorigenesis and cancer progression in iCCA.8,15 The literature suggests that up to 50% of iCCA patients may present with at least one potentially actionable genetic alteration.8 Although previous clinical trials enrolled and analyzed patients with biliary tract cancers (i.e., iCCA, extrahepatic cholangiocarcinomas, gallbladder cancers) all together,17,18 recent evidence suggests that iCCA has a distinct biologic profile compared with other tumors.8 In analyzing 195 patients with intra- and extra-hepatic cholangiocarcinomas, Lowery et al.8 demonstrated that mutations in IDH1 and TP53 as well as FGFR2 fusions were more commonly seen in iCCA, whereas KRAS, SMAD4, and STK11 alterations more frequently occurred in extrahepatic cholangiocarcinomas. The data suggested that iCCA is a biologically unique disease with distinct molecular targets compared with other biliary tract cancers.8 These findings can have important implications as biomarker-driven clinical trials have shown a clear survival benefit for patients with advanced biliary tract cancers who received matched molecular targeted agents.9",
        "To date, IDH1 inhibitor ivosidenib and FGFR2 inhibitors (i.e., pemigatinib, futibatinib) have received FDA approval for the treatment of patients with advanced, refractory metastatic cholangiocarcinoma with IDH mutations and FGFR2 fusions/rearrangements, respectively.4,5 Previously, FGFR2 translocations have been reported as mutually exclusive with IDH1 mutations,8 a finding confirmed by this study. The current study also demonstrated that FGFR2 alterations frequently co-occurred with both BAP1 mutations and CDKN2A deletions, whereas IDH1 mutations co-occurred with PBRM1 mutations. This finding requires further investigation because it might explain why not all patients with FGFR2 fusions and IDH1 mutations respond to FGFR2 and IDH1 inhibitor therapy, respectively. In light of recent advances in personalized treatments with combination therapies,27 these data suggest that a combination of targeted agents might be recommended to patients with molecularly complex cancers, including iCCA."
      ]
    },
    "total_cbioportal_paper_citations": 0,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3330960273742676,
    "data_pmids_checked": 1,
    "paper_id": "39251514",
    "extraction_date": "2025-12-19T20:46:20.341322",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39251514.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39248068": {
    "cbioportal_paper_citations": [
      "Hub genes were identified based on their connectivity with degrees of 10 or higher. To explore these genes and their associated co-expression networks, the cBioPortal online platform (http://www.cbioportal.org) was utilized [25, 26]. This analysis facilitated a deeper insight into the interplay and co-expression patterns among these central genes."
    ],
    "cbioportal_platform_mentions": [
      "The assessment of the impact of hub genes on overall survival and disease-free survival was conducted through Kaplan-Meier curve analyses within the cBioPortal. These analyses are crucial for understanding how variations in the expression of these genes might influence the prognosis and survival outcomes of glioblastoma patients.",
      "Particularly, RRM2 and KIF23, with the highest node degrees of 22, were closely associated with poorer overall survival rates, underscoring their potentially critical roles in glioblastoma oncogenesis. Data derived from cBioPortal revealed that genomic alterations in RRM2 significantly correlated with both overall survival (p=3.315e-3) and disease-free survival (p=5.423e-3). Conversely, alterations in KIF23 did not show a significant association with either overall survival (p=0.281) or disease-free survival (p=0.422), as demonstrated in Fig. (3).",
      "This study posits that the analysis of survival in cBioPortal, which hinges on the correlation between gene mutations and prognostic outcomes, might overlook instances where gene overexpression stems from amplification rather than mutation. Hence, the overexpression of RRM2 in glioblastoma could predominantly result from gene amplification, a hypothesis that warrants further investigation for validation. Analysis utilizing Oncomine indicated that RRM2 and KIF23 expression patterns are significantly associated with the initial treatment response, the methylation status of MGMT, and the recurrence status in glioblastoma, suggesting their potential as markers for treatment strategy and prognosis evaluation (Fig. 7)."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 3,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3087458610534668,
    "data_pmids_checked": 0,
    "paper_id": "39248068",
    "extraction_date": "2025-12-19T20:46:20.479191",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39248068.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39248018": {
    "cbioportal_paper_citations": [
      "Prior studies have suggested a potential association between activin and immunity, but the influence of activin within the EOC immune TME is not well characterized. 12 To test the relationship between INHBA expression and immune signatures, we analyzed a panel of genes encoding for specific tumor\u2010infiltrating lymphocyte (TIL) cell types (Figure 2A). When GSE143897 cohort was stratified by INHBA expression, INHBA level was positively correlated with CD3G, CD4, CD8A, FOXP3 and CD25 (Figure 2A (i\u2013v), although statistical significance was only reached for CD8A (p = 0.03) and FOXP3 (p = 0.02). Similarly, TCGA analysis demonstrated a positive association between increasing INHBA expression and lymphocytic gene profile, with CXCR4, FOXP3, CD25/IL2A, CD8, CD4 and CD3G expression being higher in high\u2010INHBA cohort as compared to the low\u2010INHBA cohort (Figure 2B,C). To further assess this correlation between INHBA and genes associated with T cell function, we tested INHBA z score levels as extracted from cBioportal 38 , 39 for ovarian tumors against tumor immunophenotypes as defined from 9174 tumors of 29 solid cancers. 40 We find that when comparing INHBA levels against the 16 immune population signatures, the most significant Pearson's correlation was seen with a Treg signature (Figure 2D). Hence together these data suggest that across patient cohorts, INHBA is correlated with lymphocytic gene expression, favoring a more immunomodulatory profile."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.2385118007659912,
    "data_pmids_checked": 0,
    "paper_id": "39248018",
    "extraction_date": "2025-12-19T20:46:20.597924",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39248018.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39252918": {
    "cbioportal_paper_citations": [
      "For genetic interaction analyses, we compared the co-mutation frequencies for each gene pair using Fisher\u2019s two-sided exact test. For visual clarity in the figures, we omitted gene pairs that did not meet the nominal significance threshold of p < 0.05. Data were reported in terms of log odds ratios (ORs). For analysis of mutational co-occurrence patterns in the MDS cohort39, we extracted data using the cBioPortal browser46,47 and used Fisher\u2019s two-sided exact test.",
      "To compare the mutation frequencies observed in our cohort at diagnosis to previously published datasets (TCGA-AML4 and OHSU-AML38), we extracted data using the cBioPortal browser.46,47 We included all genes that were mutated in \u2265 4% of our cohort for analysis. To compare mutation frequencies between cohorts, we calculated Spearman and Pearson correlation statistics."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "35868306": [
        "At the time of AML diagnosis, FLT3 (38%), NPM1 (32%), DNMT3A (32%), and TET2 (21%) were the most frequently mutated genes in our cohort (Figure 1A). The mutation frequencies of the top mutated genes (defined as mutated in \u2265 4% of diagnosis samples) were highly correlated with those observed in the TCGA4 and BeatAML38 cohorts (Supplementary Figure 1B\u2013C). Based on karyotype analysis, chromosome 8 gain (10%) and chromosome 16 inversion (5%) were the most frequent chromosomal abnormalities. Approximately half of the patient cohort underwent AML NGS profiling twice, while the remaining half had three or more NGS profiles (Figure 1B). In total, 65.3% of patients (n = 119) were sequenced at the time of first cytologic complete remission (CR1) and 41.8% (n = 76) at the time of first relapse (REL1) (Figure 1C).",
        "To compare the mutation frequencies observed in our cohort at diagnosis to previously published datasets (TCGA-AML4 and OHSU-AML38), we extracted data using the cBioPortal browser.46,47 We included all genes that were mutated in \u2265 4% of our cohort for analysis. To compare mutation frequencies between cohorts, we calculated Spearman and Pearson correlation statistics."
      ],
      "23634996": [
        "At the time of AML diagnosis, FLT3 (38%), NPM1 (32%), DNMT3A (32%), and TET2 (21%) were the most frequently mutated genes in our cohort (Figure 1A). The mutation frequencies of the top mutated genes (defined as mutated in \u2265 4% of diagnosis samples) were highly correlated with those observed in the TCGA4 and BeatAML38 cohorts (Supplementary Figure 1B\u2013C). Based on karyotype analysis, chromosome 8 gain (10%) and chromosome 16 inversion (5%) were the most frequent chromosomal abnormalities. Approximately half of the patient cohort underwent AML NGS profiling twice, while the remaining half had three or more NGS profiles (Figure 1B). In total, 65.3% of patients (n = 119) were sequenced at the time of first cytologic complete remission (CR1) and 41.8% (n = 76) at the time of first relapse (REL1) (Figure 1C).",
        "To our knowledge, no study to date has systematically compared the genomic profiles of DNMT3Amut and TET2mut AML as the disease evolves from initial diagnosis through remission and subsequent relapse. DNMT3A and TET2 are the most commonly mutated genes associated with CH7\u20139, and both of these genes encode key regulators of DNA methylation.43 As DNMT3A and TET2 mutations are among the earliest genetic alterations in AML, dysregulation of DNA methylation is presumably an important predisposing factor for the subsequent pathogenesis of AML. Curiously, however, DNMT3A and TET2 play diametrically opposing roles in DNA methylation: whereas DNMT3A catalyzes DNA methylation, TET2 demethylates DNA. It stands to reason, then, that the evolutionary fitness landscapes of malignancies arising from DNMT3Amut clones likely differ from those that derive from TET2mut clones. Our analyses illuminate the distinct genomic features of DNMT3Amut, TET2mut, and ASXL1mut AML. While DNMT3Amut AML is comparatively enriched in FLT3 and NPM1 mutations4, TET2mut and ASXL1mut AML are instead enriched in CBL and SRSF2 mutations. We further demonstrate that these differences persist through chemotherapy and are often conserved at diagnosis and relapse. As DNMT3A, TET2, and ASXL1 mutations represent the earliest genetic events in the pathogenesis of AML, our findings demonstrate how \u201cfounding\u201d preleukemic driver mutations can subsequently mold the evolutionary paths traversed in the course of AML evolution.",
        "To compare the mutation frequencies observed in our cohort at diagnosis to previously published datasets (TCGA-AML4 and OHSU-AML38), we extracted data using the cBioPortal browser.46,47 We included all genes that were mutated in \u2265 4% of our cohort for analysis. To compare mutation frequencies between cohorts, we calculated Spearman and Pearson correlation statistics."
      ]
    },
    "total_cbioportal_paper_citations": 2,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 2,
    "extraction_method": "jats_xml",
    "extraction_time": 0.7071759700775146,
    "data_pmids_checked": 2,
    "paper_id": "39252918",
    "extraction_date": "2025-12-19T20:46:20.641450",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39252918.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39239051": {
    "cbioportal_paper_citations": [
      "In order to estimate co-expression and mutation data, the cbioportal website (https://www.cbioportal.org/) was operated. cbioportal provides a web resource for exploring, visualizing, and analyzing multidimensional cancer genomic data. The portal transforms molecular profiling data from cancer tissues and cell lines into easily comprehensible genetic, epigenetic, gene expression, and proteomic events. Also, the current database can compare the obtained results with clinical evidence21. The P greater than 0.05 is also intended to evaluate the achieved data."
    ],
    "cbioportal_platform_mentions": [
      "Also, using Cbioportal mutation rate was extracted. Mutation rates (highest to lowest) include C9 (6%), C1s (5%), C3 (5%), CFB (5%), MASP1 (5%), C1r (4%), C2 (4%), C5 (4%), C6 (4%), C8A (4%), C8B (4%), C8G (4%), C1QA (3%), C1QC (3%), C7 (3%), MBL2 (3%), C1QB (2.9%), MASP2 (2.9%), CFD (2.8%), FCN2 (2.6%), FCN3 (2.6%), CFP (2%), FCN1(2%), C4A (1.6%), C4B (1.5%) (Fig. 1).",
      "Using the Cbioportal website, other co-expression genes with complement genes were extracted. By using the \u201cCalculate and draw custom Venn diagrams website\u201d (https://bioinformatics.psb.ugent.be/webtools/Venn/), shared genes were identified24. The string web tool also created the interaction network among extracted genes (Fig. 2)24,25."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 2,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.06912589073181152,
    "data_pmids_checked": 0,
    "paper_id": "39239051",
    "extraction_date": "2025-12-19T20:46:20.716688",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39239051.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39237877": {
    "cbioportal_paper_citations": [
      "Co-expression analysis was performed using cbioportal.com [36, 37]. The data for TP53, SOX10, and IRF1 were downloaded from the Skin Cutaneous Melanoma (TCGA, Firehose Legacy), comprising 488 samples. Genes showing statistically significantly co-expression (P < 0.01) were analyzed. Venn diagrams were generated by VennDiagram R library (VennDiagram: Generate High-Resolution Venn and Euler Plots. R package version 1.7.3.; https://CRAN.R-project.org/package=VennDiagram). Co-expressed genes were searched for pathway enrichment using KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway database [38] and visualized using ShinyGO 0.77 [39]. Analysis based on TP53 status was performed on the SKCM data pack (472 samples, listed as cohort GDC TCGA Melanoma) obtained from cbioportal [36, 37]. Samples were divided into three groups on the basis of TP53 status (without mutation, with mutation, and hot-spot mutation). These groups were compared with mRNA levels using DESeq2 [40] and dplyr R-packages (dplyr: A Grammar of Data Manipulation. R Package Version 0.4.3.http://CRAN.R-project.org/package=dplyr)."
    ],
    "cbioportal_platform_mentions": [
      "We searched for possible explanations in DepMap (https://depmap.org/portal/) including cbioportal (https://www.cbioportal.org/), with a focus on melanoma. According to CRISPR (DepMap Public 23Q2 + Score, Chronos), SOX10 is classified as an essential gene in melanoma (gene score effect less than \u22121). There is a notable correlation between TP53 damaging mutations and SOX10 as an essential gene in cancer (Fig. 4A). The correlation can be explained by a cell line bearing a TP53 damaging mutation, with it being less probable that SOX10 will be an essential gene. In other words, when TP53 is wt, cell lines need SOX10 to survive. These findings emphasize the significance of p53 status in influencing SOX10. Furthermore, we searched for genes that exhibit the highest degree of co-dependence with SOX10 using data from CRISPR (DepMap Public 23Q2 + Score, Chronos), and identified genes associated with p53 pathway signaling (Fig. 4B).Fig. 4Bioinformatic analysis of SOX10 dependencies on p53 pathway. A The dependence of 64 melanoma cell lines for SOX10 gene effect from CRISPR (DepMap Public 23Q2 + Score, Chronos) on the x-axis (0 is equivalent to a gene that is not essential, less than \u22121 corresponds to essential genes) to TP53 mutation status on the y-axis (0 is no mutation, 1 is other mutations, 2 is damaging mutation as defined by DepMap portal). A375, HT144, and RPMI7951 are highlighted. The table shows Pearson and Spearman correlation coefficients for all cell lines and for melanoma cell lines. B The co-dependent genes for SOX10 from CRISPR (DepMap Public 23Q2 + Score, Chronos), showing the top five genes and the p53-related genes among the top 100 co-dependent genes, with their Pearson correlation coefficients indicating the strength of co-dependency between SOX10 and the indicated genes. C Venn diagram showing genes significantly co-expressed between TP53 and SOX10 (in intersection). The mRNA data were downloaded from cbioportal.org. D KEGG pathway enrichment analysis of genes significantly co-expressed with TP53 and SOX10. Visualized by ShinyGo0.77",
      "Bioinformatic analysis of SOX10 dependencies on p53 pathway. A The dependence of 64 melanoma cell lines for SOX10 gene effect from CRISPR (DepMap Public 23Q2 + Score, Chronos) on the x-axis (0 is equivalent to a gene that is not essential, less than \u22121 corresponds to essential genes) to TP53 mutation status on the y-axis (0 is no mutation, 1 is other mutations, 2 is damaging mutation as defined by DepMap portal). A375, HT144, and RPMI7951 are highlighted. The table shows Pearson and Spearman correlation coefficients for all cell lines and for melanoma cell lines. B The co-dependent genes for SOX10 from CRISPR (DepMap Public 23Q2 + Score, Chronos), showing the top five genes and the p53-related genes among the top 100 co-dependent genes, with their Pearson correlation coefficients indicating the strength of co-dependency between SOX10 and the indicated genes. C Venn diagram showing genes significantly co-expressed between TP53 and SOX10 (in intersection). The mRNA data were downloaded from cbioportal.org. D KEGG pathway enrichment analysis of genes significantly co-expressed with TP53 and SOX10. Visualized by ShinyGo0.77",
      "Additional file 1: Figure S1 Gating strategy for analysis of NK cytotoxicity assay (BD FACSuite). (A) Initial P1 gate was set in FSC/SSC plot to deplete debris and larger clusters of cells. (B) Individual cells were selected in gate P3 omitting cell doublets. (C) CFSE+ (tumor) cells are distinguished from NK cells by fluorescence intensity in the FITC channel (gate P4) within the P3 population. (D) Positive events in the 7-AAD channel are considered as dead cells. P6 gate includes dead cells within P4 parent population (7-AAD+ events from the CFSE+ population). All gate settings were adjusted on the basis of single cell line samples (A375 only, NK-92 only) and unstained control samples. Figure S2 Representative cytometric plot of untreated A375 (black solid lines) and A375p53KO (red solid lines) or the same cells treated with 1 \u03bcM AMG-232 for 24 h (dotted lines). Dot plots corresponding to both variants are shown below. Figure S3 (A) Western blots of PD-L1 (55 kDa) and \u03b2-actin (42 kDa) as loading control for HT144 and RPMI7951 cells treated with/without treatment of 1 \u03bcM AMG-232 for 24 h. Relative PD-L1 densitometry measurements were normalized to \u03b2-actin are indicated. (B) Relative PD-L1 densitometry measurements from WB shown in (A) presented as the mean of replicates \u00b1 SD (n = 3). Figure S4 Western blots in A375 and A375p53KO cells with or without 1 \u03bcM AMG-232 for 24 h and additionally treated with 20 \u03bcM MG-132 or CHX (100 \u03bcg/ml) for the last 4 h or 2 h before harvesting, respectively. IRF1, PD-L1, SOX10, MDM2, p53, p21, and \u03b2-actin (as loading control) have apparent molecular weights of 55, 55, 55, 90, 53, 21, and 42 kDa, respectively. Figure S5 Western blots for the indicated proteins in A375, and A375p53KO cell lines with/without treatment of 1 \u03bcM AMG-232 for 24 h. STAT1, p-STAT1, NF\u03baB, p-NF\u03baB, JAK2, JAK1, and \u03b2-actin (as loading control) have apparent molecular weights of 80, 80, 120, 135, 65, 65, and 42 kDa, respectively. Figure 6 (A) Venn diagram showing genes significantly co-expressed between TP53, SOX10, and IRF1 (in intersection) and the division of genes from intersection based on positive (marked as + for given gene) or negative (marked as \u2212 for given gene) correlation. The mRNA data used in this analysis were downloaded from cbioportal.org. for melanoma panel TCGA Firehose legacy. (B) KEGG Pathway enrichment analysis of 464 significantly co-expressed genes for group: IRF1+, TP53\u2212 and SOX10\u2212 from previous Venn diagram visualized by ShinyGo0.77. (C) KEGG pathway enrichment analysis of 406 significantly co-expressed genes from group IRF1\u2212, TP53+, SOX10+ from previous Venn diagram visualized by ShinyGo0.77. Figure S7 (A) Western blots for the indicated proteins in melanoma cell lines bearing wt p53 or p53-null. PD-L1, IRF1, IRF4, SOX10, JAK1, JAK2, STAT1, p53, and \u03b2-actin (as loading control) have apparent molecular weights of 55, 55, 55, 55, 135, 120, 80, 53, and 42 kDa, respectively. (B) The differential mRNA expression analysis of selected genes between wt TP53 and TP53 hot-spot mutant patient samples. The data were extracted from cbioportal.org from SKCM data pack (number of samples 472) listed as cohort GDC TCGA Melanoma. Log2ratio shows the fold change between wt and hot-spot mutant group. (C) Co-expression analysis of TP53 mRNA for wt p53 patient samples and selected genes. Pearson correlation coefficient with corresponding P-value demonstrating correlation strength is shown. Significantly co-expressed genes are highlighted in bold. Table S1 Oncogenic mutations in selected melanoma cell lines according to DepMAp. Table S2 List of antibodies used for WB.",
      "Additional file 1: Figure S1 Gating strategy for analysis of NK cytotoxicity assay (BD FACSuite). (A) Initial P1 gate was set in FSC/SSC plot to deplete debris and larger clusters of cells. (B) Individual cells were selected in gate P3 omitting cell doublets. (C) CFSE+ (tumor) cells are distinguished from NK cells by fluorescence intensity in the FITC channel (gate P4) within the P3 population. (D) Positive events in the 7-AAD channel are considered as dead cells. P6 gate includes dead cells within P4 parent population (7-AAD+ events from the CFSE+ population). All gate settings were adjusted on the basis of single cell line samples (A375 only, NK-92 only) and unstained control samples. Figure S2 Representative cytometric plot of untreated A375 (black solid lines) and A375p53KO (red solid lines) or the same cells treated with 1 \u03bcM AMG-232 for 24 h (dotted lines). Dot plots corresponding to both variants are shown below. Figure S3 (A) Western blots of PD-L1 (55 kDa) and \u03b2-actin (42 kDa) as loading control for HT144 and RPMI7951 cells treated with/without treatment of 1 \u03bcM AMG-232 for 24 h. Relative PD-L1 densitometry measurements were normalized to \u03b2-actin are indicated. (B) Relative PD-L1 densitometry measurements from WB shown in (A) presented as the mean of replicates \u00b1 SD (n = 3). Figure S4 Western blots in A375 and A375p53KO cells with or without 1 \u03bcM AMG-232 for 24 h and additionally treated with 20 \u03bcM MG-132 or CHX (100 \u03bcg/ml) for the last 4 h or 2 h before harvesting, respectively. IRF1, PD-L1, SOX10, MDM2, p53, p21, and \u03b2-actin (as loading control) have apparent molecular weights of 55, 55, 55, 90, 53, 21, and 42 kDa, respectively. Figure S5 Western blots for the indicated proteins in A375, and A375p53KO cell lines with/without treatment of 1 \u03bcM AMG-232 for 24 h. STAT1, p-STAT1, NF\u03baB, p-NF\u03baB, JAK2, JAK1, and \u03b2-actin (as loading control) have apparent molecular weights of 80, 80, 120, 135, 65, 65, and 42 kDa, respectively. Figure 6 (A) Venn diagram showing genes significantly co-expressed between TP53, SOX10, and IRF1 (in intersection) and the division of genes from intersection based on positive (marked as + for given gene) or negative (marked as \u2212 for given gene) correlation. The mRNA data used in this analysis were downloaded from cbioportal.org. for melanoma panel TCGA Firehose legacy. (B) KEGG Pathway enrichment analysis of 464 significantly co-expressed genes for group: IRF1+, TP53\u2212 and SOX10\u2212 from previous Venn diagram visualized by ShinyGo0.77. (C) KEGG pathway enrichment analysis of 406 significantly co-expressed genes from group IRF1\u2212, TP53+, SOX10+ from previous Venn diagram visualized by ShinyGo0.77. Figure S7 (A) Western blots for the indicated proteins in melanoma cell lines bearing wt p53 or p53-null. PD-L1, IRF1, IRF4, SOX10, JAK1, JAK2, STAT1, p53, and \u03b2-actin (as loading control) have apparent molecular weights of 55, 55, 55, 55, 135, 120, 80, 53, and 42 kDa, respectively. (B) The differential mRNA expression analysis of selected genes between wt TP53 and TP53 hot-spot mutant patient samples. The data were extracted from cbioportal.org from SKCM data pack (number of samples 472) listed as cohort GDC TCGA Melanoma. Log2ratio shows the fold change between wt and hot-spot mutant group. (C) Co-expression analysis of TP53 mRNA for wt p53 patient samples and selected genes. Pearson correlation coefficient with corresponding P-value demonstrating correlation strength is shown. Significantly co-expressed genes are highlighted in bold. Table S1 Oncogenic mutations in selected melanoma cell lines according to DepMAp. Table S2 List of antibodies used for WB."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 4,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 4.424666881561279,
    "data_pmids_checked": 0,
    "paper_id": "39237877",
    "extraction_date": "2025-12-19T20:46:25.141446",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39237877.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39242811": {
    "cbioportal_paper_citations": [
      "We acquired publicly accessible datasets containing patients' clinicopathological information, mRNA expression of CXCL9/10/11, and CCL5, and ISG (the human gene set \u201cGOBP_RESPONSE_TO_TYPE_I_INTERFERON\u201d from MSigDB], as well as DNA methylation of MB21D1 (cGAS) and TMEM173 (STING) for stomach adenocarcinoma (TCGA STAD; n = 440) from cBioPortal (https://www.cbioportal.org)38. We compared mRNA expression levels of CXCL9/10/11 and CCL5, the average of STING signaling genes, and methylation levels of MB21D1 (cGAS) and TMEM173 (STING) (\u03b2-values) among EBV (+) GC (EBV; n = 30), MSI-H GC (MSI; n = 73), and other subtypes of GC with EBV (\u2212), including GS (n = 50) and CIN (n = 223). Cases with not available for the information of GC subtype (n = 57) and POLE mutation (n = 7) were excluded from this analysis. Z-scores were used for all gene expression analyses, unless otherwise indicated."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "25079317": [
        "Gastric cancer (GC) ranks as the third leading cause of cancer-related deaths worldwide1,2. Despite advancements in multidisciplinary treatments that have improved clinical outcomes, prognosis for patients with advanced GC remains poor, highlighting the need for further therapeutic strategies. The Cancer Genome Atlas (TCGA) proposed a molecular classification that categorizes GC into four distinct subtypes: microsatellite unstable/instability-high (MSI-H), Epstein-Barr virus-positive [EBV (+)], genomically stable (GS), and chromosomal instability (CIN) tumors3. MSI-H and EBV (+) GCs are recognized as tumors with an immune-active tumor microenvironment (TME)4. Loss of DNA mismatch repair (MMR; MMR deficient [dMMR]) leads to the MSI-H phenotype, accounting for 20\u201325% and 8\u201319% of all GC cases in Western and Asian countries, respectively5. In the sporadic setting, more than 50% of dMMR/MSI-H GC cases arise from hypermethylation of the promoter region of MutL homolog 1 (MLH1), the most critical MMR gene, while mutations in MMR genes, including MLH1 and mutS homolog 2, are obsereved in approximately 15% of dMMR/MSI-H GC cases6. dMMR/MSI-H GC is characterized by high tumor mutational burden, neoantigen load, dense infiltration of immune cells such as CD8+ T cells, and higher expression of programmed cell death ligand 1 (PD-L1) compared to MMR proficient (pMMR)/microsatellite stable (MSS)/EBV (\u2212) GC. Indeed, dMMR/MSI-H GC likely exhibits a better prognosis and a favorable response to immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 agents, compared to pMMR/MSS/EBV (\u2212) GC7\u201310. However, the regulatory mechanisms of the immune-active TME in dMMR/MSI-H GC remain incompletely understood."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 4.7828369140625,
    "data_pmids_checked": 1,
    "paper_id": "39242811",
    "extraction_date": "2025-12-19T20:46:25.305795",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39242811.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39235852": {
    "cbioportal_paper_citations": [
      "Statistical analysis and correlation tests were performed using SPSS software (version 20.0, IBM). The t-test was used for continuous variables such as age and tumor size, while the chi-square test or Fisher's exact test was used for classified variables such as gender and pathological type. P values <0.05 were considered statistically significant. A waterfall diagram of the gene mutation spectrum was generated using oncoprints with the visualization tool from cBioPortal (https://www.cbioportal.org/visualize) (21, 22)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26878173": [
        "Our study, as well as other evidence found in prior researches (32) indicate that the coexistence of mutations including BRAF, RAS, TERT, and TP53 generally predicts a poor prognosis for thyroid cancer. The prognostic value of the BRAFV600E mutation alone in PTC patients is still controversial. Numerous studies and meta-analyses have argued the association of the BRAFV600E mutation with high-risk clinical pathological features (8, 9, 11, 18). However, in a large multicenter retrospective study, this association was no longer statistically significant after adjustment for clinical and histopathological features of aggressive thyroid tumors. The BRAFV600E test did not increase the predictive value of PTC-related prognosis and mortality (12). In this study, BRAF positive patients have older age, smaller tumor size, lower vascular invasion, and higher tumor multifocality, showing no clear correlation between BRAF V600E and the prognosis of PTC patients.",
        "Previous studies have shown that mutation in the TERT promoter is associated with poor prognosis (34, 35). In our study, we have also confirmed that TERT mutated tumors exhibit more aggressive clinical features. TERT promoter mutation often co-exists with BRAF or RAS mutation in thyroid cancer. Patients with the coexistence of TERT promoter and BRAF mutations have significantly larger tumors, more extrathyroidal invasion, and more advanced TNM staging compared with patients with a BRAF mutations alone (10, 36). It is reported that the frequency of TERT promoter mutation is significantly increased in PDTC (40%) and ATC (50\u201370%) (32, 37, 38), and it tends to occur more often in senior patients. All these findings suggest that TERT promoter mutation may be an advanced molecular event which generates a synergistic effect with early molecular events to promote malignant transformation. Additional studies are thus urged to clarify the function and mechanism of TERT co-mutation events in the malignant progression of thyroid tumors.",
        "NGS sequencing of recurrent and aggressive thyroid tumors holds substantial clinical significance in guiding personalized targeted treatment approaches. However, extensive use of NGS will cause great waste, considering the majority of thyroid cancer can be controlled or even cured by surgery. PDTC and ATC, on the other hand, have poor prognoses and often in need of multiple treatment methods including surgery, targeted therapy, and immune therapy. NGS is undisputedly of great help in screening available targets for medication. In this study, TERT, BRAF, TP53, RAS, and EIF1AX mutations have a frequency of more than 10% in PDTC and ATC. Other genes that have been proven to be associated with tumor initiation or progression like PIK3CA, ATM, PTEN, and CREBBP are also present in PDTC and ATC with a mutation frequency higher than 5% (32). Therefore, NGS is essential for PDTC and ATC patients in seeking suitable targeted therapy."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3049659729003906,
    "data_pmids_checked": 1,
    "paper_id": "39235852",
    "extraction_date": "2025-12-19T20:46:25.446512",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39235852.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39235510": {
    "cbioportal_paper_citations": [
      "Epigenetic alterations contribute to oncogenesis through multiple mechanisms, from repression of tumor suppressor genes or activation of oncogenes to tumor cell-extrinsic mechanisms such as angiogenesis, invasion, and anti-tumor immunity [1\u20134]. Epigenetic regulators have thus become effective therapeutic targets in multiple solid tumors. One epigenetic complex that is frequently mutated in many solid tumors and directly implicated in anti-tumor immunity is the Polycomb Repressive Complex 2 and particularly its enzymatic subunit, Ezh2 [5, 6]. Ezh2 possesses histone methyltransferase activity and mediates methylation of histone 3 on lysine 27 (H3K27me). Genetic alterations in Ezh2 include both loss- and gain-of-function events, and it can function both as a tumor suppressor [7\u201311] and as an oncogene [12\u201316]. A unique point mutation in the methyltransferase domain of Ezh2 (SET domain) at tyrosine 641 (Y641) alters its methyltransferase activity and may confer neomorphic functions by promoting unconventional changes to the distribution of H3K27me3 across the genome [12, 17], with complicated effects on gene expression."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "26091043": [
        "Previously, we investigated the role of Ezh2Y641F mutations in melanoma and found a direct interaction of Ezh2Y641F with Stat3, with direct effects on tumor immunity [18]. We also identified several loci directly bound by both Ezh2 and Stat3 in melanoma cells. Here, we expanded that study to additional cell lines to gain a more comprehensive understanding of genes regulated by both Ezh2 and Stat3 in melanoma in a BrafV600E/PtenF/F background, with or without the Ezh2Y641F mutation. First, using Stat3 ChIP-seq, we confirmed enrichment of Stat3 binding motifs in Ezh2Y641F melanoma cells compared to Ezh2WT cells and identified enriched representation of motifs of other immune regulators, such as Stat1 and Irf1 (Fig. 1a). Gene Set Enrichment Analysis (GSEA) [38] of Stat3 peaks enriched in Ezh2Y641F mutant melanoma cells identified several oncogenic signatures. Interestingly, we also identified several gene expression signatures that implicate autophagy or related cellular processes (Fig. 1b). We next assessed whether autophagy regulators were differentially expressed in Ezh2WT vs. Ezh2Y641F melanoma [12]. We found that Atg7, an important autophagy regulator, was upregulated in Ezh2Y641F melanomas compared to Ezh2WT and its expression was downregulated upon treatment with a pharmacological Ezh2 inhibitor (Fig. 1c). Chromatin immunoprecipitation, followed by sequencing (ChIP-seq) analysis, identified several Stat3 and Ezh2 peaks at the Atg7 gene promoter and the first intron (Fig. 1e). To confirm the relevance of these data in human patients, we analyzed data from the ReMap Atlas of Regulatory Regions (a collection of all public ChIP-seq data for transcriptional regulators from GEO, ArrayExpress, and ENCODE databases) [39] for Ezh2 and Stat3 in various cell types and the ENCODE registry of candidate cis-regulatory elements [40]. We identified several cis-regulatory elements that coincide with mouse experimental Ezh2 and Stat3 binding sites (Fig. 1d), suggesting that our findings in mouse models are conserved and potentially relevant to human disease. Consistent with these observations, expression of Stat3 correlates with increased expression of Atg7 in human melanoma patient samples [41].Fig. 1Regulation of Atg7 expression by Ezh2 and Stat3. a Enriched motifs in Ezh2WT and Ezh2Y641F melanoma cells. b Gene Set Enrichment Analysis (GSEA) of Stat3 ChIP-seq peaks identifies several signatures associated with autophagy mechanisms (FDR < 0.05). c Transcript expression of Atg7 in Ezh2Y641F vs. Ezh2WT melanoma cells measured by RNA-sequencing, in the absence or presence of the Ezh2 inhibitor JQEZ5. d Human ChIP-seq data in various cell lines showing direct binding of both Stat3 (green) and Ezh2 (blue) at the Atg7 promoter and intronic regions that correspond to cis-regulatory elements. Image modified from UCSC Genome Browser. e ChIP-seq tracks for Ezh2 and Stat3 in Ezh2WT and Ezh2Y641F melanoma cells at the mouse Atg7 locus indicating binding at the Atg7 promoter and the first intron"
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.23634099960327148,
    "data_pmids_checked": 1,
    "paper_id": "39235510",
    "extraction_date": "2025-12-19T20:46:25.694687",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39235510.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39234458": {
    "cbioportal_paper_citations": [
      "cBioPortal (http://cbioportal.org) uses data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) to profile. It includes a wide range of data such as DNA copy numbers, DNA methylation, mRNA and microRNA expression levels, and nonsynonymous mutations [10,11]. In this study, the cBioPortal database was utilized to analyze genetic variations of ATM, BRAF, CSF1R, ERBB4, FGFR3, FLT3, JAK3, KDR, KIT, PIK3CA, SMAD4, SMARCB1, STK11, and TP53 in NSCLC patients was determined using the online cancer genomics platform cBioPortal."
    ],
    "cbioportal_platform_mentions": [
      "We analyzed the genetic variation of the selected genes based on the NSCLCG sample data from the TCGA database via the cBioPortal database. The results are presented in figure 5. As anticipated, TP53 was the gene with the most frequent alterations across all three datasets. It exhibited an overall alteration frequency of 58% in the samples analyzed from these datasets. STK11 is also frequently observed mutation in lung cancer (17%), contributing significantly to the molecular landscape of the disease."
    ],
    "data_publication_citations": {
      "22960745": [
        "TP53 was the most frequently mutated gene, and the highest number of mutations was found in nearly all patients (90%), probably due to the advanced stages used for the present analysis. According to the lung cancer genome database, this tumor suppressor gene is the most commonly mutated gene in human cancers [20]. Although TP53 is not currently a therapeutic target, it is a prognostic factor for treatment response. Recent studies indicate that TP53 mutations are linked to chemotherapy resistance, poorer therapeutic responses, and reduced OS in NSCLC patients, varying by disease stage and sequencing methods [21\u201323]. Additionally, the biological impact of TP53 mutations can differ based on tumor histology and smoking history [23,24]."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.34946727752685547,
    "data_pmids_checked": 1,
    "paper_id": "39234458",
    "extraction_date": "2025-12-19T20:46:26.096095",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39234458.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39232498": {
    "cbioportal_paper_citations": [
      "Statistical analyses were performed using GraphPad Prism software (version 9.0). Quantitative data are expressed as mean \u00b1 SEM. Spearman correlation analysis was used to examine the correlation between two factors. For the quantification of staining assays, the staining positive areas in multiple visual fields were quantified by the ImageJ software (v1.53) and averaged to produce an averaged value for each mouse, which was then combined to generate the mean value for all mice in each group. TCGA data were downloaded from the cBioPortal system.38,39 The Z score was calculated using the formula z = (x-\u03bc)/\u03c3, where x is the quantification value for each sample, \u03bc is the population mean for all samples, and \u03c3 is the population standard deviation of all samples. For the comparison of two groups, an unpaired t-test was used for comparison of the means. For comparison of more than 2 groups, one-way ANOVA with Tukey\u2019s multiple comparison test was used. Kaplan\u2013Meier plots were drawn for survival analysis and Log rank test was used to compare the survival distributions among experimental groups. A p value <0.05 was considered statistically significant. \u2217p < 0.05, \u2217\u2217p < 0.01, \u2217\u2217\u2217p < 0.001, \u2217\u2217\u2217\u2217p < 0.0001, ns: not significant."
    ],
    "cbioportal_platform_mentions": [
      "REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesRabbit CK19AbcamCat# ab52625, RRID: AB_2281020Rabbit Ki67AbcamCat# ab15580, RRID: AB_443209Goat Col1SouthernBiotechCat# 1310-01,RRID: AB_2753206Mouse \u03b1SMADAKOCat# M0851,RRID: AB_2223500Rabbit CD4AbcamCat# ab183685, RRID: AB_2686917Rabbit CD8Cell SignalingCat# 85336S,RRID: AB_2800052Rabbit Arginase 1AbcamCat# ab91279, RRID: AB_10674215Rabbit CD45Cell SignalingCat# 70257,RRID: AB_2799780Rat CK8SigmaCat# MABT329, RRID: AB_2891089Rabbit Cadherin 1Cell SignalingCat# 3195,RRID: AB_2291471Rabbit VimentinCell SignalingCat# 5741,RRID: AB_10695459Rabbit ZEB1Novus BiologicalCat# NBP1-05987, RRID: AB_1556166Rabbit phospho-ERK1/2Cell SignalingCat# 9101S,RRID: AB_331646Rabbit ERKCell SignalingCat# 9102,RRID: AB_330744Rabbit Cleaved Caspase-3Cell SignalingCat# 9664S,RRID: AB_2070042Rabbit p63AbcamCat# ab124762, RRID: AB_10971840Rabbit \u03b2-actinCell SignalingCat# 4970,RRID: AB_2223172Rabbit CK5Cell SignalingCat#71536T,RRID: AB_3101753Rabbit HSP90Cell SignalingCat# 4877T,RRID: AB_2233307Goat CD206R&D SystemsCat# AF2535,RRID: AB_2063012Rabbit CK5BioLegendCat# 905501,RRID: AB_2565050Mouse CK8AbcamCat# ab9023,RRID: AB_306948Rat Ly6GAbcamCat# ab25377,RRID: AB_470492Rabbit CD4Cell SignalingCat# 25229,RRID: AB_2798898Rat FoxP3eBioscienceCat# 4-4771-80,RRID: AB_529583Rat Granzyme BeBioscienceCat# 50-8898-82,RRID: AB_11219679Rat LAG3Bio X CellCat# BP0174,RRID: AB_10949602Rat PD-1Bio X CellCat# BE0273,RRID: AB_2687796Bacterial and virus strainspCMV5B-Smad4AddgeneCat# 11743Chemicals, peptides, and recombinant proteinsProtease inhibitorRocheCat# 4693116001Crystal violetSigmaCat# C0775Lipofectamine 2000InvitrogenCat# 11668027RNAiMAXInvitrogenCat# 13778-150MRTX1133SelleckCat# E1051GSK1120212SelleckCat# S2673VerteporfinSelleckCat# S1786GemcitabineLC LaboratoriesCat# G4199NiclosamideSelleckCat# S3030OlaparibSelleckCat# S1060JQ1SelleckCat# S7110MK-2206 2HClSelleckCat# S10787RHMedChemExpressCat# HY-U00444VS-4718SelleckCat# S7653RapamycinSelleckCat# S1039RSL3MedChemExpressCat# HY100218AErastinMedChemExpressCat# HY15763Collagenase IVGibcoCat# 17104019Dispase IIGibcoCat# 17105041Type I collagen solution from rat tailSigma-AldrichCat# C3867Critical commercial assaysDirect-zol RNA KitZymo ResearchCat# 11-331Reverse Transcription KitApplied BiosystemsCat# 4368814SYBR Green Master MixApplied BiosystemsCat# 4367659Cell Counting Kit-8AbcamCat# ab228554Chromium Single Cell 3\u2032 Reagent Kits (v2)10x GenomicsCat# PN-120237ABC-KitVectorCat# PK-6100Stable DABInvitrogenCat# 750118Alcian blue Stain KitAbcamCat# 150662Pierce BCA protein assay kitThermo FisherCat# 23208Picrosirius RedAbcamCat# 150681TruSeq Stranded mRNA Sample Prep KitIlluminaCat# 20020594Deposited dataKPPC and PPSSC cancer cell lines RNA-sequencingThis paperGEO: GSE268896KPPC and PPSSC pancreatic tumors Single-cell RNA-sequencingThis paperGEO: GSE268899TCGA pancreatic adenocarcinoma cohort survival and gene expression data (GDAC Firehose PAAD)Broad Institutehttp://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/PAAD/20160128/Experimental models: Cell linesPrimary mouse KPPC cancer cell lineThis paperN/APrimary mouse PPSSC cancer cell lineThis paperN/AExperimental models: Organisms/strainsMouse: LSL-KrasG12D/+;Trp53loxP/+;Pdx1-CreChen et al.32N/AMouse: LSL-KrasG12D/+;Trp5R172H/+;Pdx1-CreChen et al.32N/AMouse: Smad4loxP/loxPJackson Laboratory017462Mouse: Tgfbr2loxP/loxPJackson Laboratory012603OligonucleotidesSee Table S1SigmaN/ARecombinant DNApCMV5B-Smad4AddgeneCat# 11743Software and algorithmsPrism v10.0.0GraphPad Software Inc.http://www.graphpad.com/cBioportal v2.2.0MSK Center for Mol Onchttps://www.cbioportal.org/Seurat R package (3.5.3)Satija et al.34https://satijalab.org/seurat/DESeq2Anders and Huber35https://bioconductor.org/packages/release/bioc/html/DESeq2.htmlSTAR alignerDobin et al.36https://github.com/alexdobin/STARGene Set Enrichment Analysis (GSEA)Broad Institutehttp://software.broadinstitute.org/gsea/index.jsp"
    ],
    "data_publication_citations": {
      "26909576": [
        "Pancreatic cancer is a highly lethal malignant disease that remains refractory to therapies. Pancreatic cancer development is associated with the dominant occurrence of an oncogenic KRAS gene mutation in approximately 90% of cases.1 In addition, mutations and/or deficiencies of tumor suppressor genes, including TP53 (60%\u201370%), CDKN2A (30%\u201340%), and SMAD4 (30%\u201340%), are commonly noted.2,3 Approximately 10% of pancreatic cancer cases harbor wild-type KRAS (hereafter referred to as \u201cKRAS-WT\u201d), whereas the mechanism of KRAS-WT pancreatic cancer development remains less understood.4,5,6,7 Recent studies identified a variety of alternative driver mutations, deletions, or fusions in KRAS-WT pancreatic cancer, providing insights into the molecular mechanism and potential therapeutic strategies for KRAS-WT pancreatic cancer.8,9,10,11,12",
        "In our previous assays (Figures 1D\u20131F), we noticed that PPSSC tumors exhibited significantly different histology as compared to KPPC tumors. Further analyses revealed the cancer cells of PPSSC tumors harbor unique adenosquamous carcinoma phenotype, in contrast to the typical adenocarcinoma phenotype observed in cancer cells of KPPC tumors (Figure 2A). Primary cancer cell lines established from PPSSC tumors revealed significant upregulation of keratinization pathway genes associated with squamous differentiation as compared with cancer cell lines from KPPC tumors, based on the bulk RNA sequencing analysis on these cancer cell lines (Figures 2B and 2C). As expected, PPSSC cancer cells harbored significantly elevated levels of squamous genes including Trp63 (encoding p63), Krt5 (encoding CK5), Krt6a/b (encoding CK6), and other squamous signature genes (Figure 2D), consistent with previous definitions.5 Immunohistochemistry staining further validated that PPSSC tumors had significantly higher p63 level than KPPC tumors (Figure 2E). In addition, PPSSC tumors exhibited significantly higher CK5 level and lower CK8 level than KPPC tumors, further confirming the squamous phenotype of PPSSC tumors (Figure 2F). Our observations on the PPSSC tumor model are consistent with recent studies showing the squamous phenotype of a commonly used human pancreatic cancer cell line BxPC3, harboring TP53 mutation and SMAD4 loss in the background of KRAS-WT.16Figure 2Loss of p53 and SMAD4 induces pancreatic tumor formation with unique adenosquamous carcinoma features(A) Representative images of H&E staining on tumor sections from KPPC mice (2.5-month-old) and stage-matched PPSSC mice (8-month-old), in comparison with representative images of primary cancer cell lines established from KPPC and PPSSC tumors. Scale bar: 100 \u03bcm.(B) Top enriched biological process pathways by gene ontology analysis for the upregulated genes in PPSSC cancer cells, as compared to KPPC cancer cells.(C) Gene set enrichment analysis (GSEA) of RNA-seq data on KPPC and PPSSC cancer cell lines. Squamous pancreatic cancer signature genes were enriched in PPSSC cancer cells, as compared with KPPC cancer cells.(D) The expression levels of featured genes from squamous pancreatic cancer signature in KPPC and PPSSC cancer cells.(E) Representative images of immunohistochemistry staining of p63 on tumor sections from KPPC mice (2.5-month-old) and stage-matched PPSSC (8-month-old) mice (n = 5/group). Quantitative results were shown with Student\u2019s t test. Scale bar: 100 \u03bcm. \u2217\u2217\u2217p < 0.001.(F) Representative images of immunofluorescence staining for CK5 (red), CK8 (green), and nuclei/DAPI (blue) on tumor sections from KPPC mice (2.5-month-old) and PPSSC mice (8-month-old) (n = 5/group). Quantitative results were shown with Student\u2019s t test. Scale bar: 100 \u03bcm. \u2217\u2217\u2217p < 0.001.",
        "Recent studies have established that pancreatic cancer cases can be classified into multiple subtypes, such as the basal-like subtype and classical subtype.5,23,24,25 We examined the expression of 11 basal-like subtype signature genes and 11 classical subtype signature genes to compare the KPPC and PPSSC cancer cells. However, the expression profiles of basal-like subtype and classical subtype genes were not significantly different between KPPC and PPSSC cancer cells (Figures S5A and S5B).",
        "For RNA-seq, total RNA samples were used to prepare the DNA library and were sequenced on the Illumina Hiseq 2000/2500 platform using the paired-end sequencing method. The raw sequencing data was filtered and aligned to the mouse genome assembly GRCm39 using HISAT2. The Fastq reads were processed by quality control and adaptor trimming, alignment, check strandness and gene count. Different expression gene (DEG) analysis was performed using DESeq2. TPM normalized counts were calculated with the DGEobj.utils package. Functional categorization and pathway reconstitution from the RNA-seq data were conducted using gene set enrichment analysis (GSEA) following the guidelines on the GSEA website of Broad Institute (http://www.broadinstitute.org/gsea/index.jsp). The squamous signature gene set was based on a previous study.5"
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 1,
    "extraction_method": "jats_xml",
    "extraction_time": 0.3035929203033447,
    "data_pmids_checked": 1,
    "paper_id": "39232498",
    "extraction_date": "2025-12-19T20:46:26.430289",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39232498.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39235528": {
    "cbioportal_paper_citations": [
      "SETD1A, SETD1B, KMT2A-D, and TP53 gene mutations were analyzed from MSKCC targeted genomic database of either Foundation One Heme or MSK-IMPACT as well as publicly available sequencing data sets (references in Fig. S2 study of origin) using cBioPortal (https://www.cbioportal.org). Briefly, these datasets were queried by the gene named and analysis was performed as described in Cerami et al. (2012); Gao et al. (2013)."
    ],
    "cbioportal_platform_mentions": [],
    "data_publication_citations": {
      "23699601": [
        "We also explored mutations and copy number changes of related H3K4 histone methyltransferase genes, including KMT2A, KMT2B, KMT2C, KMT2D, and SETD1A (Fig. 2, B and C; and Table S3). As anticipated, KMT2D emerged as the most frequently altered (mutated or deleted) H3K4 histone methyl transferase gene with frequencies of 62% in FL and 30% in DLBCL. The second most frequently mutated family member was SETD1B, with mutations or deletions in 16% of DLBCLs (and 7% of FLs). Other H3K4 methyltransferase genes were rarely mutated in our analysis; KMT2C showed mutation frequency of 5%. These findings align with public TCGA data and reported cohorts (Fig. S2 E) (Chapuy et al., 2018; Lohr et al., 2012; Morin et al., 2013; Reddy et al., 2017; Sanchez-Vega et al., 2018). Notably, SETD1B mutations were consistently associated with KMT2D mutations in all groups. For instance, in the MSK series of 216 FLs, the frequency of SETD1B lesions in KMT2D mutant tumors (n = 134) was 9.7%, whereas the SETD1B mutation frequency in KMT2D wild-type FLs (n = 82) was only 1.2% (Fig. 2 B and Fig. S2 F), indicating a significant concordance between SETD1B and KMT2D in FL (P = 0.008). We observed a similar trend in DLBCL (P = 0.064) (Fig. 2 C and Fig. S2 G) without association with the specific DLBCL genetic subtype described in the National Cancer Institute DLBCL cohort (Schmitz et al., 2018)."
      ],
      "28985567": [
        "We also explored mutations and copy number changes of related H3K4 histone methyltransferase genes, including KMT2A, KMT2B, KMT2C, KMT2D, and SETD1A (Fig. 2, B and C; and Table S3). As anticipated, KMT2D emerged as the most frequently altered (mutated or deleted) H3K4 histone methyl transferase gene with frequencies of 62% in FL and 30% in DLBCL. The second most frequently mutated family member was SETD1B, with mutations or deletions in 16% of DLBCLs (and 7% of FLs). Other H3K4 methyltransferase genes were rarely mutated in our analysis; KMT2C showed mutation frequency of 5%. These findings align with public TCGA data and reported cohorts (Fig. S2 E) (Chapuy et al., 2018; Lohr et al., 2012; Morin et al., 2013; Reddy et al., 2017; Sanchez-Vega et al., 2018). Notably, SETD1B mutations were consistently associated with KMT2D mutations in all groups. For instance, in the MSK series of 216 FLs, the frequency of SETD1B lesions in KMT2D mutant tumors (n = 134) was 9.7%, whereas the SETD1B mutation frequency in KMT2D wild-type FLs (n = 82) was only 1.2% (Fig. 2 B and Fig. S2 F), indicating a significant concordance between SETD1B and KMT2D in FL (P = 0.008). We observed a similar trend in DLBCL (P = 0.064) (Fig. 2 C and Fig. S2 G) without association with the specific DLBCL genetic subtype described in the National Cancer Institute DLBCL cohort (Schmitz et al., 2018)."
      ],
      "22343534": [
        "We also explored mutations and copy number changes of related H3K4 histone methyltransferase genes, including KMT2A, KMT2B, KMT2C, KMT2D, and SETD1A (Fig. 2, B and C; and Table S3). As anticipated, KMT2D emerged as the most frequently altered (mutated or deleted) H3K4 histone methyl transferase gene with frequencies of 62% in FL and 30% in DLBCL. The second most frequently mutated family member was SETD1B, with mutations or deletions in 16% of DLBCLs (and 7% of FLs). Other H3K4 methyltransferase genes were rarely mutated in our analysis; KMT2C showed mutation frequency of 5%. These findings align with public TCGA data and reported cohorts (Fig. S2 E) (Chapuy et al., 2018; Lohr et al., 2012; Morin et al., 2013; Reddy et al., 2017; Sanchez-Vega et al., 2018). Notably, SETD1B mutations were consistently associated with KMT2D mutations in all groups. For instance, in the MSK series of 216 FLs, the frequency of SETD1B lesions in KMT2D mutant tumors (n = 134) was 9.7%, whereas the SETD1B mutation frequency in KMT2D wild-type FLs (n = 82) was only 1.2% (Fig. 2 B and Fig. S2 F), indicating a significant concordance between SETD1B and KMT2D in FL (P = 0.008). We observed a similar trend in DLBCL (P = 0.064) (Fig. 2 C and Fig. S2 G) without association with the specific DLBCL genetic subtype described in the National Cancer Institute DLBCL cohort (Schmitz et al., 2018)."
      ],
      "21796119": [
        "Mutations in genes that encode histone tail modifiers are among the most frequent genetic lesions in FL (Green et al., 2011; Jiang et al., 2017; Morin et al., 2011; Okosun et al., 2013; Ortega-Molina et al., 2015; Pasqualucci et al., 2011). The lysine-specific methyltransferase 2D (KMT2D) is mutated in 76\u201389% of FLs, leading to a defect in histone H3 lysine 4 mono- and di-methylation (H3K4me1/me2) (Araf et al., 2016; Bouska et al., 2017; Shilatifard, 2012). We previously reported that loss of kmt2d in different Bcl2 transgenic models triggers the development of germinal center (GC) lymphomas resembling human FLs, and we have linked this to the silencing of key regulators of growth signaling pathways such as B cell receptor signaling, NF-\u03baB, and JAK-STAT (Ortega-Molina et al., 2015; Zhang et al., 2015). SETD1B (KMT2G) is a related enzyme that catalyzes the trimethylation of histone H3 lysine 4 (H3K4me3). Among SET domain proteins of the complex of proteins associated with Set1 complex, only KMT2D, SETD1B (KMT2G), and KMT2C are mutational targets in lymphoma as documented in the International Cancer Genome Consortium database and reviewed in Bakhshi and Georgel (2020). The potential involvement of SETD1B mutations in lymphoma biology is somewhat surprising, given that conditional inactivation of SETD1B leads to lymphopenia and myeloid proliferation in mice (Schmidt et al., 2018), and SETD1B knockouts are embryonically lethal (Bledau et al., 2014). Mechanistically, the H3K4me3 mark is considered a marker of active promoters and has been linked to transcription initiation (Lauberth et al., 2013; Vermeulen and Timmers, 2010). A recent study emphasized the role of the H3K4me3 mark in the pause and release of RNA polymerase II and thereby the general process of transcription elongation (Wang et al., 2023a). Our results highlight a more selective role for SETD1B in the epigenetic regulation of cell death programs in B cell lymphomas that connect loss of SETD1B to lymphomagenesis and resistance to Venetoclax."
      ],
      "29625050": [
        "We investigated SETD1B mutations in large collections of human FLs (n = 216) and DLBCLs (n = 248) sourced from Memorial Sloan Kettering Cancer Center (MSKCC). We also included published data from various sources, and in total, we analyzed data from 1,759 FL and DLBCL samples. We identified 16 SETD1B missense mutations, 29 frameshift lesions, 3 nonsense mutations, and 2 splice mutations. A hotspot was apparent at position 8 where we observed 21 frameshift insertions that replaced a histidine (H) with a proline (P) and caused termination at amino acid 30 (H8Pfs*30) (Fig. 2 A). The SETD1B variant allele frequency (VAF < 0.5) across both MSK FL and MSK DLBCL studies suggests heterozygous or subclonal lesions (Fig. S2 A). SETD1B expression showed only a modest, not significant decrease between wild-type and mutant tumor samples (Fig. S2 B), while KMT2D analysis showed a stronger trend toward reduced expression (Fig. S2 C). The SIFT score (Sorting Intolerant from Tolerant) is a method to predict effects of amino acid changes on protein function (Ng and Henikoff, 2003). We observed SIFT scores close to \u201c0\u201d for SETD1B missense mutations listed in The Cancer Genome Atlas (TCGA) (Sanchez-Vega et al., 2018) study, which is consistent with a deleterious, loss-of-function effect (Fig. S2 D).",
        "Comprehensive analysis of SETD1B mutation frequency in lymphoma across multiple studies. (A) Estimated allele frequency in tumor patient samples from MSK DLBCL and MSK FL studies. (B and C) Dot plot representing the (B) SETD1B and (C) KMT2D mRNA expression levels in altered and non-altered DLBCL patient samples (TCGA, Pan Cancer Atlas, Sanchez-Vega et al., 2018). (D) Table representing SIFT scores for SETD1B missense mutations found in TCGA, PanCancer Atlas database (Sanchez-Vega et al., 2018). (E) Oncoprint representation of mutation status of KMT2 family genes in 1,295 samples from published DLBCL sequencing studies. Samples are arranged in columns with genes labeled along rows. Only samples with alterations are shown. (F and G) Pie charts showing the frequency of SETD1B mutations in a cohort of (F) FL and (G) DLBCL patients with wild-type or mutated KMT2D. Patients with KMT2D mutations have a higher likelihood of having mutations in SETD1B in both cohorts. (H) Oncoprint representation of mutation status of SETD1B and TP53 genes in 1,295 samples from published DLBCL sequencing studies (P = 0.55). P values were calculated with two-sided Fisher Exact test.",
        "We also explored mutations and copy number changes of related H3K4 histone methyltransferase genes, including KMT2A, KMT2B, KMT2C, KMT2D, and SETD1A (Fig. 2, B and C; and Table S3). As anticipated, KMT2D emerged as the most frequently altered (mutated or deleted) H3K4 histone methyl transferase gene with frequencies of 62% in FL and 30% in DLBCL. The second most frequently mutated family member was SETD1B, with mutations or deletions in 16% of DLBCLs (and 7% of FLs). Other H3K4 methyltransferase genes were rarely mutated in our analysis; KMT2C showed mutation frequency of 5%. These findings align with public TCGA data and reported cohorts (Fig. S2 E) (Chapuy et al., 2018; Lohr et al., 2012; Morin et al., 2013; Reddy et al., 2017; Sanchez-Vega et al., 2018). Notably, SETD1B mutations were consistently associated with KMT2D mutations in all groups. For instance, in the MSK series of 216 FLs, the frequency of SETD1B lesions in KMT2D mutant tumors (n = 134) was 9.7%, whereas the SETD1B mutation frequency in KMT2D wild-type FLs (n = 82) was only 1.2% (Fig. 2 B and Fig. S2 F), indicating a significant concordance between SETD1B and KMT2D in FL (P = 0.008). We observed a similar trend in DLBCL (P = 0.064) (Fig. 2 C and Fig. S2 G) without association with the specific DLBCL genetic subtype described in the National Cancer Institute DLBCL cohort (Schmitz et al., 2018)."
      ],
      "29713087": [
        "We also explored mutations and copy number changes of related H3K4 histone methyltransferase genes, including KMT2A, KMT2B, KMT2C, KMT2D, and SETD1A (Fig. 2, B and C; and Table S3). As anticipated, KMT2D emerged as the most frequently altered (mutated or deleted) H3K4 histone methyl transferase gene with frequencies of 62% in FL and 30% in DLBCL. The second most frequently mutated family member was SETD1B, with mutations or deletions in 16% of DLBCLs (and 7% of FLs). Other H3K4 methyltransferase genes were rarely mutated in our analysis; KMT2C showed mutation frequency of 5%. These findings align with public TCGA data and reported cohorts (Fig. S2 E) (Chapuy et al., 2018; Lohr et al., 2012; Morin et al., 2013; Reddy et al., 2017; Sanchez-Vega et al., 2018). Notably, SETD1B mutations were consistently associated with KMT2D mutations in all groups. For instance, in the MSK series of 216 FLs, the frequency of SETD1B lesions in KMT2D mutant tumors (n = 134) was 9.7%, whereas the SETD1B mutation frequency in KMT2D wild-type FLs (n = 82) was only 1.2% (Fig. 2 B and Fig. S2 F), indicating a significant concordance between SETD1B and KMT2D in FL (P = 0.008). We observed a similar trend in DLBCL (P = 0.064) (Fig. 2 C and Fig. S2 G) without association with the specific DLBCL genetic subtype described in the National Cancer Institute DLBCL cohort (Schmitz et al., 2018)."
      ]
    },
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 0,
    "total_data_pmids_cited": 6,
    "extraction_method": "jats_xml",
    "extraction_time": 1.2029120922088623,
    "data_pmids_checked": 6,
    "paper_id": "39235528",
    "extraction_date": "2025-12-19T20:46:26.572796",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39235528.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  },
  "39232081": {
    "cbioportal_paper_citations": [
      "Overall mutation landscape and mutation site visualization were analyzed by cBioPortal32 database (https://www.cbioportal.org/). Structure of TIMM9\u2013TIMM10 complex was obtained from RCSB PDB platform (https://www.pdbus.org/, pdb code: 7cgp, Missense mutations simulations were performed by PyMOL 4.6.0 software (https://pymol.org/2/) particularly, and concrete missense mutation sites were obtained from the result of cBioportal analysis. PDBePISA webtool (https://www.ebi.ac.uk/msd-srv/prot_int/) was utilized to calculate binding free energy changes before and after mutation simulation. 2-D visualization of the conformation that represented a binding energy reduction was performed by LigPlot 2.2 software33 (https://www.ebi.ac.uk/thornton-srv/software/LigPlus/download2.html). Multiwfn 3.834 (dev) software (http://sobereva.com/multiwfn/) was utilized to perform Independent Gradient Model (IGM) analysis to characterize the interaction strength between mutation site and molecular environment, calculating based on promolecular electron density approximation. \u201cCNV summary\u201d, \u201cCNV and Expression\u201d and \u201cCNV and Survival\u201d modules in GSCA23 platform were respectively used in plotting the CNV percentage landscape, correlations of CNV with TIMM9 and TIMM10 mRNA expressions, associations of CNV with prognosis outcomes of overall survival (OS), progression free survival (PFS) and disease-specific survival (DSS). Similarly, \u201cDifferential methylation\u201d, \u201cMethylation and Survival\u201d, \u201cMethylation and Expression\u201d modules in GSCA platform were individually analyzed for differential methylations of TIMM9 and correlations of TIMM9 and TIMM10 methylations with their expressions. The association between differential methylations of TIMM9 and prognosis outcomes in OS, PFS, and DSS was researched. The methylation level between normal group and tumor group was also analyzed by \u201cQuick Start\u201d module of Shiny Methylation Analysis Resource Tool35 (SMART, http://www.bioinfo-zs.com/smartapp/)."
    ],
    "cbioportal_platform_mentions": [
      "The cBioPortal database analysis revealed that TIMM9 has genomic alterations in the majority of types of cancers (Fig. 4A). We analyzed the mutation landscape (Fig. 4C) and collected data on missense mutations (Table S2). The structure of the TIMM9\u2013TIMM10 complex was obtained from the RCSB PDB database (pdb code: 7cgp, chain D: TIMM9, chain H: TIMM10). We performed in silico site-directed mutagenesis simulations using PyMOL 2.4.0 software (Fig. S5A) to obtain the structures after missense mutations. We calculated the binding energies of TIMM9 and TIMM10 using the PDBePISA platform and found that the binding energy of S49L was largely decreased (Table S2), indicating an improvement in binding capability (interface of TIMM9 with SER-49: \u2212 20.0 kcal/mol; interface of TIMM9 with LEU-49: \u2212 21.1 kcal/mol). S49L, a missense mutation, improves binding capability between TIMM9 and TIMM10. The 3D (Fig. 4B) and 2D (Fig. 4D) structures of WT and S49L were visualized. SER-49 only formed a van der Waals interaction with MET-65 of TIMM10, whereas LEU-49 formed one with ILE-61 and MET-65 of TIMM10. Independent Gradient Modeling (IGM) also confirmed that LEU-49 can form a stronger interaction with TIMM10 (Fig. 4E), indicating S49L may positively affects TIMM9-associated functions by forming a hydrophobic nucleus.Fig. 4TIMM9 exhibited genomic instabilities in tumors. (A) The visualization of genomic alterations in TIMM9. Red, blue, and green represent amplification, deep deletion, and mutation, respectively. (B) The site-directed mutagenesis simulation and structural exhibition of S49L missense mutation, in TIMM9. The original structure was obtained from PDB database (PDB code: 7cgp, green: TIMM9, cyan: TIMM10). (C) Landscape of concrete mutation sites in TIMM9 (green dots: missense mutations, brown dots: splice mutations). (D) 2-D visualization of molecular micro-environment of S49L. (E) Weak interactions around 49th residue of TIMM9 were analyzed using IGM method, the strength of interaction increases from green to blue. (F) CNV landscape of TIMM9 (Hete heterozygous, Homo homozygous, Amp amplification, Del deletion). (G) Correlation between CNV and expression of TIMM9 and TIMM10 in tumors. (H) Association between differentiation in CNV level and prognosis. (I) Differential methylation of TIMM9. **, ***, correspond to p < 0.01, p < 0.001, respectively. (J) Correlation between methylation and expression of TIMM9 and TIMM10 in tumors. (K) Association between methylation and prognosis. CNV copy number variation."
    ],
    "data_publication_citations": {},
    "total_cbioportal_paper_citations": 1,
    "total_cbioportal_platform_mentions": 1,
    "total_data_pmids_cited": 0,
    "extraction_method": "jats_xml",
    "extraction_time": 0.8313429355621338,
    "data_pmids_checked": 1,
    "paper_id": "39232081",
    "extraction_date": "2025-12-19T20:46:27.404637",
    "xml_path": "/Users/debruiji/git/cbioportal-article-classification/data/xml/39232081.xml",
    "data_pmids_version": "2025-12-19T16:53:06.855279"
  }
}